<SEC-DOCUMENT>0001558370-25-003985.txt : 20250328
<SEC-HEADER>0001558370-25-003985.hdr.sgml : 20250328
<ACCEPTANCE-DATETIME>20250328160538
ACCESSION NUMBER:		0001558370-25-003985
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		113
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250328
DATE AS OF CHANGE:		20250328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioXcel Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001720893
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				821386754
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38410
		FILM NUMBER:		25785937

	BUSINESS ADDRESS:	
		STREET 1:		555 LONG WHARF DRIVE
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511
		BUSINESS PHONE:		203-643-8060

	MAIL ADDRESS:	
		STREET 1:		555 LONG WHARF DRIVE
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>btai-20241231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.9.0.3 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 3/28/2025 7:21:33 PM -->
<!-- iXBRL Library version: 1.0.9062.16423 -->
<!-- iXBRL Service Job ID: 59017a13-ba05-4d83-acd0-83eacdcbb4c9 -->
<html xmlns:btai="http://www.bioxceltherapeutics.com/20241231" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title>BioXcel Therapeutics, Inc._December&#160;31, 2024</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" xs:nil="true" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_La-EaG7Cp0W0ee4WZ-arqQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" xs:nil="true" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_Ab0U0OpCdEqMgbG5X47l-Q"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:EntityCentralIndexKey" id="Tc_APWTfR0U6kedsQCr81AF0w_2_1">0001720893</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:DocumentFiscalYearFocus" id="Tc_qcvV8B_U40Oh2eivP8Vqow_4_1">2024</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:DocumentFiscalPeriodFocus" id="Tc_5UvOUen8ZEi_MVruR7keLg_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:AmendmentFlag" id="Tc_W7OMxTAtT0WBfpIeoX5x0g_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_hYGHwvMpfU6F1AX9KwsGtA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_JUhYODu6bUCF--FUwX6LDw">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden_VjkgfzRL90eELJLE8OO7cg">http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" xs:nil="true" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" name="us-gaap:PreferredStockValue" id="Hidden_IIpe6ROVE0uzyVQI76hytw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" xs:nil="true" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" name="us-gaap:PreferredStockValue" id="Hidden_QropzL8Q3USNg_pLCNbuTg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" name="us-gaap:CommonStockSharesIssued" id="Hidden_7DatXox1g0qQEKSaGo77iw">1871000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" id="Hidden__r-eL5w_Z0mc8eX5EelIrQ">3102000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_2_10_2025_To_2_10_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wNzSowqeUkChgrK7zHK_5A" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_MAC978-QcU6PY1cLIWQ4hg">0.0625</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_vDidZuvwFUuTvGIhGHCssg" name="us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" id="Hidden_q_7viYeZgU21L0rksnVcQQ">http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember</ix:nonNumeric><ix:nonNumeric contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_hsgX06rVV0aG4JHyHT8zVg" name="us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" id="Hidden_kFih0nmoC0-H7vISN9YfvQ">http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mnMmxsdqv0CnwoCMs9Wk3Q" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_O-R2_NsEcUirYc0hrciCHQ">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_A8ZHOdOBykqthS4c1Q8gUA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_ZV8mysUnJEKMO7_R1BXZ3w">P12M</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_a6pX1JmlWkyKm9cKj1tV7w">http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden_pNs2n3-e20CuK4JoOz4cQA">http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="btai-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_11_21_2024_To_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_QAwpylSU5UyaB8Q_rrtbYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_5_2023_To_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_3RWlGpXOtESBeWP1E_X8Xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-05</xbrli:startDate><xbrli:endDate>2023-12-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_3_2025_To_3_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_N0FLHzjjW0ebf_9f1FrfOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:PurchaseAgreementRegisteredSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-03</xbrli:startDate><xbrli:endDate>2025-03-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_25_2024_To_3_25_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_p4L6ETPqFEWoA9lBndZOtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-25</xbrli:startDate><xbrli:endDate>2024-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_mzi71qMtwUW4NC2oL1_1RQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_10_2025_To_2_10_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wNzSowqeUkChgrK7zHK_5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-10</xbrli:startDate><xbrli:endDate>2025-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mVjyx3cGLEy1gJnnx6T0VA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JBhziCHFEUu1-FicgIwmyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6eSNIlZJN0KWpLFkIG2zfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gi1gHYnNBk66zzB63nP9Xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2OE8-Puy-k62aulMwMTDvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QQDsQgcnEkyWGJT2fjUW4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_tv06eTkorUuLZsqZJC7L6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_GIUFHpY0_EqDv2ibJW6xSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xOcQ1mX8HUS3oomqLm_lMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_vq2yym5s9EyjbM2-H8oIkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_v9I1drvLSkCReDIKAPrJEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_StockPlan2017Member_L_iPsP7adEiG4elxGlZNHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:StockPlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_vDwwtKHeaUKjbZq0pfe-PA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_N0vp5VFCUkqtRrwPRBSFFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_tHUExHKUMUmrePF-CWMIfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_qoDjPOgKl02zcP5r7FAQuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_RvCrri81RU2aLpOi6LE4XQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_OpSGdiyFOEqI7cFehOL59A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BcKPgE027Eq07dZFNZcBVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dHuj7RaJ8EKL0Sny_5o-CQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xVBddGnbW0ybwujG6xab2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SRyiKYrKEE6xThkeoaB7WA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ida0xzaxyUGKvrdsH2Fr0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_S6eKsZBc2UGXa8jiNAbKrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_B1zotSn0RUq8Gi-caKB5-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_urjzmG69Fk6Da0LeQweFZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_p0pq-UOWxEu_wI0sw4gUPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_hTkGBWRuAUSz0YVpoWxPsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_A8ZHOdOBykqthS4c1Q8gUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_Sa7bc9y2BEeY9w4XybT9qQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_8_2024_To_5_8_2024_IhAulVfqfE-gUqz51YDtXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-08</xbrli:startDate><xbrli:endDate>2024-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_8_2023_To_8_8_2023_1AQEFh0qkU22JOe-2n46Ww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-08</xbrli:startDate><xbrli:endDate>2023-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_17_2024_To_9_17_2024_OiBFsSYoqEGoJgxld_C82A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-17</xbrli:startDate><xbrli:endDate>2024-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_17_2024_XxyLTPFqzUyn2yLJ69oiWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aq06NwagjEu8lcUy9jbLbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gdYMQB6xIEGwPzlcPnEPVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2022_Zfgyqm8oPECQksmotjQKJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember__lhd_4aX8kyoPoUbqHBE0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_MsiOU9Br5ESWVEwY_A5X2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_awYc1AER0EGr0NZ0NV2hSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_bGkvra2V9Ue26IMBxqrCww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_MJeawgIMDEyPxu7dj7F8aQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_3NEbuF2yQ0q1F_2-3706qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_kXPimCUV7keG3q0uOSWbGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_zmvJP9XWKUylAuis6tmJsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_27_2024_To_3_27_2024_1d4XGKCHW0m2lIKs8HPE9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-27</xbrli:startDate><xbrli:endDate>2024-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_g-3YkuAMa0WFmUst9waAug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_22_2024_To_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_qCNNy1whp0ivehAR5sAVYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-22</xbrli:startDate><xbrli:endDate>2024-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_27_2024_To_3_27_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_RvjnXZnJAEar_nFyvWCG8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-27</xbrli:startDate><xbrli:endDate>2024-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_AhSo6vKkHk2Ijnc-39vr0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_DmobgouGJEKpKx5umwnDTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_dCk4KHjYVECYOD1bNWMxhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_0Fa5GpoDykyuoxmj8TA-dQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_AF3B6HHa0kyLVVlQaBJT2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_CehH3SOYY0-qk9E4i9FXiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_vPHQPh73CEuoO2NrgO5-hQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_CDdL6odIhEyB7dtSsjWgHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_q1hbZmrNS0GGTI07xc-mMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_0gKxZS-bl0i0rf4ETalC4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_QcDNt3XBCU29K3TtzRineQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E9MLp3OJ8EufrFv1jvE6sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oXWwEn3ERUe7z06ZWkBHXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_11_2024_To_7_11_2024_srt_RangeAxis_srt_MinimumMember_l8F9i5yxlk2GrsHmZ41AHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-11</xbrli:startDate><xbrli:endDate>2024-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_11_2024_To_7_11_2024_srt_RangeAxis_srt_MaximumMember_MahkWQ1D0kWY8CGoanrcrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-11</xbrli:startDate><xbrli:endDate>2024-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_4_30_2022_AGdwF45rAUaEqJM-M8UB2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheDMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_KgqW-5X7r06gLp9NBzxFsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheCMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_KEur4f2KVkKKQYGXeBkN_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheBMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_6ZZ0nOytkkyfb35YWqDR_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_OgOR5W9P3kGRnS_l9vYR4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_25_2024_To_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_DqkDewrv3kmwfGEQUIsTbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-25</xbrli:startDate><xbrli:endDate>2024-11-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_5eL_-_utPUCNyy4fj-GOyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_p63njE8R7Eu_9LSZHS_XWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_N-lEdCI780-JkLi3BNV9Ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_25_2024_To_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_355-JNdbG0a2GsWONO9ZWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-25</xbrli:startDate><xbrli:endDate>2024-11-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_21_2024_To_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_KgwhcGdOLE6rb5LSOLdQQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_5_2023_To_12_5_2023_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_NN4G50mhQUiE2MWFIStQGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-05</xbrli:startDate><xbrli:endDate>2023-12-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Lm8AZQPL40KMLw_EFZsryQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_Mb79eA35SUKhSf2JoRymdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_j0QU6pzy1kWBLf65tC1seA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_4epNlYQKv0iKvwBrZlbiTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_sog3pKgdW0eiohkZeERd4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_3fPI5jL5i0amKn6Rp0WTxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_ZZb5ojV8nECXF6PGT2Sv6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OZo6Dpf0wkeLIC74MDokcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_B-Y0cXQAQ0Sb_-x7Pz9oew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_S1WaCx3EFEyAR8UWU9J9zA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_mCar_ZgvpEWSra0NQcz42g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_7e_v0kd2N0eBHM_SA31z7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_387uYLHD2EqiYkh3ZygEsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_LcJiex4QpE2YqESAdf6fpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_2mozctssp0KbH0y09FoRew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_SeVI2KEJJkaPytkbFhDmdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_OG-f8LWXVEuAP6w4PvNKlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_6A5TfvgGDkyeNTAS_CDIyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_RYPqtdbPfUOCOJbUwsxRdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_vnbH2b6cvk6tsJ16seh7xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_fnIGASQkZ0KT8yEsdC0CCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_0MsOXlyLLki32Y4tNC1zZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_btai_MeasurementInputProbabilityOfExerciseMember_R6UHsXs59kO6T0pv-5n4Pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">btai:MeasurementInputProbabilityOfExerciseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_btai_MeasurementInputEstimatedPremiumMember_Nx0QCxfhw0uGTxWALoXeBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">btai:MeasurementInputEstimatedPremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_V0NHkt3bfk2Ba2s21MfECQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrants2024StrikePriceNotAmendedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_OQu-LcOiKkqIepIPSq1fgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_qJT7c0kn9Eu2AFMTvKrocQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_nUBe9GYzxE-ZmBiqq4O37Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_k8T7cHsMIUGhoBLO_zrk7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_T8m7TXv_3kCCweETb2zyjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_u9-8OCpVJkG9nsYV-XtccA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_p6z9MJatyUSUOiTjIZSLJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_mLs5yiiHEkCXZbPPpDd3Ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_jgX2LEyonkeD7lRM74FyMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_cLng8ai8UkazAQbJGlFaNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_yGOW9iQj6UGPG-rEriM09Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_6kMEiu_1N06tYfLStTj0oQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_oLqCI4mI10aP6GWCCHFvVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_icjol4YP1kutdR0RMqnOew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_qc0Go_Cfk020vCx7lAeh0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_CGrKS2JtHkaQ1g9h6LmHqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_9G_zTSXx60uhtuDGxqBgBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_oWedOZ60s0mXTRW5Lcn6Tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_1xcAi6iP-EO-REO2QzswUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_c4v5KMKYk0ChF42pkKq26w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_hovoRwmQvEeyatpC8QBdeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Cs-w0dC4c0WGpoXT9tdaBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember__BmWodN8tEOta3SjGS5jbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_goRVwXyuWUydp4Kjx4bF3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_0FNSOQxNAE-0IkMjsa2iKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_TN6VQOKYb02WtCDp3elR3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_aidNv9HgNk2DhIo_TgvNhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_2DCibhs95kq8Jc8YpX7xJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vpbgA0Y3d02GV60wknoGug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ExafltryU0uKvGWyPhUsBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_WvQM_Cfj6UW7acmcXHo-pQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_iXjg5DQGe0ydE6a0tFygQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AtesnzW9Vk62r5o4Z5MLOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MeVvKC1qK0CFc5qbgrTI9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_HN9QZyHZZEqqvDSOhHwi6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_JBeXWTEcBki5v7foWKB49w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_XYejg84PY0-8-DI1vMLBvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_DdDbFFCDBE64P_O4BJl7kA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_nJRaa39oO02skohtFNO_CQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_HcAF3jq9Q06V5LIYvzVw4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AmN6FsQg1EitMV_BHxN7_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ecW8VPGztk2Gf79xQBkyNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_cPgf57S61Uyah5MXLI1evA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KTr0ds-yYES_mpozAK0KPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rgfcXxi9006PlNFx3qH35g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1mPU0Lx-nE-RmcrvYY9V3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5D28fXSYSUCIMdnKx2CzdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_vDidZuvwFUuTvGIhGHCssg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_qKlv5oEboUGlNN_gzIoC-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_8_2022_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_rBZ8Wee2aUaWKVAwuLAbJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_28_2022_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_na3LkfDiw0K2aagoP_bMuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_4QXVMUpriU-O3ONSCTxFLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_d7MaxUhhVECHSCm80cC1Ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_T8y78WMP4ECZ9sQKm-yKhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_xroiFJrnD0eA_jiPBHLdvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_07DuWNjS7E2tMACIgVlBjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_LmEJHhC5GEuhV4cvR-CyZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_I-pOhJgS20CdZAck10nsIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_2OCsk1QU00-KJSY3sMd-yQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_UmSoTOy6ZEqdvjDqQLaKEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_11_2024_M-RCVSP_HEGMyNg657_jKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-07-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_btai_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_W_hOEF0UGE6XdSlHUL5Rsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">btai:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_btai_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_5C4QWry9fk6gmoPexiMApw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">btai:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uVBBMguAlEqRZE6UprsHRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tk2nuQrdU0uVZYuijUkSUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WhUd_ZOlBUmqQn-nMAVDoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_nr25qN2kxkCVXTVDwzfXDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:PurchaseAgreementRegisteredSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_qU4qYdPWcke_ZGR8vt26Xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_T6cTQVW5iEu7v6aQO3r8Lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_tnK7lRA_PkmprsVLffcXvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_G-NzlEzfREKwJKc_rBs35Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_3zrIDKZAEUqRigs4dt4KAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024PrefundedAccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_aWycUKhL-06MF4rymZ6neQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024PrefundedAccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_LGUU816Yp0m2LKivHXs1uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_0htohoQg0EW5M9buTb1qzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_PrefundedWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_yKIZRxNDvEu7Hv10JhQ-7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:PrefundedWarrantsMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:PurchaseAgreementRegisteredSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_c4ZQpDZ5ekCFoY0FzRG6JA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:PurchaseAgreementRegisteredSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_tkaY4qbmDUqjsdxXtER_7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:PurchaseAgreementRegisteredSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_P_XszpuZj0GQUjB1hTtEgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_IntraCoastalCapitalMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_b02B55BM6EG9d7CRINubvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:IntraCoastalCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_HudsonBayCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_McrVOhYGbEC_tS_1BvXkKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:HudsonBayCapitalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_HeightsCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_gmwEIZ8DKkiPWDp5YfOhFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:HeightsCapitalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_ArmisticeCapitalMasterFundMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_mhbEOSMN9E-6fQNPjBHEBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:ArmisticeCapitalMasterFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_FRRTD6E8_UWc7CqpvzLbPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantShares2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_lI6dv2jX_EWXRmyQX2VxXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_sWnPUgoZNUaV48uFc0AzEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_UVB3pFbO506ugN_GMsELIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_WWey9zxoakaXp0S1ZYs4vg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_kfeh-8yR4k-MMGH2ApsgLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrants2024StrikePriceNotAmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_P_lWwiR8M0e2d17J1qElcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_Olx3FwfBuUyeg4UcTjGZjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_-Q7xp87Es0iyjocCWGGiMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_ULyHbDGAWkiYKXfDf_TeDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OriginalWarrantsMember_NyepRdGwwE65aulGXbIqFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OriginalWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_JyNR98gl_k-4MeLePLJWaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_ao0h5xCb-0is227s68HQKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_IrTiliqP_U6VjgDahhs3oQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_oiu1ThMdnUOs-KiwIduWmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_zFzFVctYTUm5PGuvO5mZ0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantShares2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_5ri5JcF8t06zRgfNuESzxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_7Rf_XFQB_kmb6iMCoS8NYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_W5J6mPqvkkqYc6G6pFfyUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_uPbZgXmXZUiSsb-dyLE4HA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_jhStatqo5EaSoSvdA9RW0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_waelNlOubE2wBVFPlyHhnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_Lzrt-ozGkUiBpO-gtGyjpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_8wNKxgPGRUu5CFwHgwGsEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_a-yRAQ6nhkmrbi3aQ6cBLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_uVcJZBaEUU2RieeIBXowxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_btai_BioxcelWarrantsAggregateMember_D-VgH0D5EkWR5T5lmAPfSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_lFtYhgCxvUaKZc-Y-rTpsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_ufIYMMNpvEWk__kIwMRFvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_1Vg-MGOfMUG52-OKD_lr3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_btai_BioxcelWarrantsAggregateMember_yQW7FSPMyU-tXyPdIkz20Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_OQGpm4OmO0GvGOO9BwRRtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_vlhYBLGO70Kx9W7BpuYnNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_QvezY-cudU6QqyNRbmjCmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_oEnUYj2nH0S7nHVXLQ4q4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0DAGDztWUkKwXUglANCasg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_ecd_IndividualAxis_btai_VimalMehtaMember_I0XJDPHFNECy_x1rSOZJ9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:VimalMehtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_ecd_IndividualAxis_btai_RichardSteinhartMember_4GcV7wKgb0qyo8g-DWuPiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:RichardSteinhartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_ecd_IndividualAxis_btai_JavierRodriguezMember_bkghpJl7jUGxwTp51yM2GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:JavierRodriguezMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_ecd_IndividualAxis_btai_FrankYoccaMember_1VVE1uh3REuAmq0XmRLywQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:FrankYoccaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_VimalMehtaMember_fZwn5BB5AEyBJNs2qszV2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:VimalMehtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_RichardSteinhartMember_6zb1jv50yke5UAZ2fdNlYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:RichardSteinhartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_JavierRodriguezMember_u3tdF-_eYkmI9WHxmSaiPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:JavierRodriguezMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_FrankYoccaMember_EjqW660Xi0ae7YJdz_f5pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:FrankYoccaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_12_31_2024_3PEv7wfJfUKxY2X6WXJQ_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ILN-_SN1KEyD2kZtjTgasA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_26_2025_l5KrQw1_MEy8y_GUvIg7oQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_vxYm8GIUnUOKESLLX6fb8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_M-TubXQul02zZZfaAcmBuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_28_2025_To_3_28_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_PrefundedWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_zbIxHgjTxE2SCgROmOBKRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:PrefundedWarrantsMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:PurchaseAgreementRegisteredSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-28</xbrli:startDate><xbrli:endDate>2025-03-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2025_To_2_28_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_KmnbJXUr7EyUFHylcIdSIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024PrefundedAccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_g6yAJhZGY0yVCcOg2tqiqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_Wv-fkHFxikOa4i1-EXoS9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_IRUWqt-XME6DBPhp1Szf3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-20</xbrli:startDate><xbrli:endDate>2020-05-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mnMmxsdqv0CnwoCMs9Wk3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_CrXc_wq4WE6253aRHA7iZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_pyA1UGmh10OZkxGv9jCGdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2023_To_11_30_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_EVFuPSms4EKLkPgGiKPLIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_31_2021_To_5_31_2021_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_7HqDJsFg10yEnahziR0XDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-31</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_V2jj_eDlt0q_u0vXSYoyKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_20_2024_To_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_4EZhC-NYEUGDlhcjArlf5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantShares2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-20</xbrli:startDate><xbrli:endDate>2024-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_Hql-Wv3mXkKp2hBGSh3usg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_cP_MaCBZ7UyPaY583or7dQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_w_gcoxE8C0GzioKd7L0Zdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_m9UZs2c2l0S2PukXjZUImg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_hoC3FYJ7zkS3zSkEUQbGEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_WgBqcPiqCk2sU5U9HArJCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_HHsV3q--b0-Hi4NmC1wOxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterFundingOfTrancheBLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_M-8oLHEl10ODoYzrqVk1qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:FromAndAfterFundingOfTrancheBLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_tXi0TB25sk2fARG5mILYWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_G6VSgb21CUeRJAKu7-undQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_X9rWZSSabEakPXkM8Eutyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_xR9vxlNSTk2dU3JYtP5BmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_FD1LiU8FskaLMx-wupgQpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_jyI3cFSKl0a4pfcKd3ZJiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-20</xbrli:startDate><xbrli:endDate>2024-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_8e8qqxErlUCxNND1J5ekRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-20</xbrli:startDate><xbrli:endDate>2024-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_5ZybN_dt3E6T6rIGI2RnCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-20</xbrli:startDate><xbrli:endDate>2024-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_12_2024_To_2_12_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_QkgOxhTM3EWQV2UEUZ202A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-12</xbrli:startDate><xbrli:endDate>2024-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_ots7YDarCkyspj_MFv5RgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_a4FuB-EA3US0t7LRQkJ_0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_12_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_1pH0cdjOhkqjWy9MM_KenA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_5_2023_To_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_54xfhc08YEGFKmDToW_EHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-05</xbrli:startDate><xbrli:endDate>2023-12-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_13_2023_To_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_9T8VX87-MkurojwuBrp51A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-13</xbrli:startDate><xbrli:endDate>2023-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_jWcBt1FrAUy7Aw7aYKtEBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-20</xbrli:startDate><xbrli:endDate>2020-05-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_hsgX06rVV0aG4JHyHT8zVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_WSKgB0WSZUCURjOJ6-sK0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_DBnAiitHfkaS-GOZJ2VMnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_V7ch7PHY70Gc6KcqC2X73Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_R53JeYIpIkKLogFP9f7n0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember__PljhQkwa0ehF3g8M7cQfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_t-V_k3tNdUCIUzhMpzNVHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_12_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_jnGiVGydjU-NmDn4wyec3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_r6Nt5rznFkuA80tgQ2K1yA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">btai:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">btai:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_SalesMilestonesMember_ivfM8IqGnEukjOEO4xau4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btai:SalesMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_DevelopmentMilestonesMember_jNVSm8QxO0KzJACAONNxDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btai:DevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_TfYSaq0lxkWKFNAMb3ByvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_c3NRP_HuykWiud2XxAIfdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IE4SFBMuyECxTHM_3bnLDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_30_2017_To_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__Rfp0WkOeUSwkyApqU9Aow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_eSrtMnrTnkmoVkWywMsDcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_WO_5QqewW0WCAmc5bwIHMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_Y_HWoZmdDBn0OhfgBS6ig-MA"><xbrli:measure>btai:Y</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_segment_u3k5mJIKoECDA2MsRZB6Gg"><xbrli:measure>btai:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_employee_g1iuox2T4U2nGaIKFGYE2w"><xbrli:measure>btai:employee</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_40b29d58_101e_482e_918c_5d73f686d258"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:DocumentType" id="Narr_CR6bYiZGZkejh6BYHUt_vw"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><a id="_a847c753_2275_4a3e_abe3_1baf8bd99860"></a><a id="Tc_-176TbuK4EShj3q17hiu_g_1_0"></a><a id="Tc_RPl_RNY1EEqYhe-Yu1IfoQ_2_1"></a><a id="Tc_DPz0nNfOsEKr7AMEF5fHLA_3_0"></a><a id="Tc_6X1FJQmtLUagjRnCtIgobg_4_0"></a><a id="Tc_yjx4RW5ef0ecKgBSr3q0iQ_5_1"></a><a id="Tc_HAXZO8txfEiZiyFGxmh5bQ_6_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:96.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Mark one)</b></p></td></tr><tr><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:DocumentAnnualReport" id="Tc_4v9eKKTRJkWt15xV8lUm-g_2_0"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annual Report Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">For the fiscal year ended </b><ix:nonNumeric format="ixt:date-monthname-day-year-en" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:DocumentPeriodEndDate" id="Narr_Rsp6rTnSGUyygdFZFfWxbw"><ix:nonNumeric format="ixt:date-monthname-day-en" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:CurrentFiscalYearEndDate" id="Narr_WEbOj44HhEOVsIof9-7ocA"><b style="font-size:7pt;font-weight:bold;">December&#160;31</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">, 2024</b></ix:nonNumeric></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">or</b></p></td></tr><tr><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:DocumentTransitionReport" id="Tc_mwQts6P_x0G44JMRohTffg_5_0"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Transition Report Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">For the transition period from              to             .</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-size:7pt;font-weight:bold;">Commission file number&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:EntityFileNumber" id="Narr_Hhe8aMgLsEmO9f-pprL07w"><b style="font-size:7pt;font-weight:bold;">001-38410</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:EntityRegistrantName" id="Narr_SQVjzB8MlUWfWXJbdZjCBQ"><b style="font-weight:bold;">BioXcel Therapeutics, Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">(Exact name of Registrant as specified in its charter)</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:EntityIncorporationStateCountryCode" id="Narr_5-Ta2br0DUS12kPc5bSh6g"><b style="font-size:7pt;font-weight:bold;">Delaware</b></ix:nonNumeric><span style="font-size:7pt;"><br/></span><span style="font-size:7pt;">(State or other jurisdiction of</span><span style="font-size:7pt;"><br/></span><span style="font-size:7pt;">incorporation or organization)</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:EntityTaxIdentificationNumber" id="Narr_EqfjrnE5JkuzYHK0WPprMg"><b style="font-size:7pt;font-weight:bold;">82-1386754</b></ix:nonNumeric><span style="font-size:7pt;"><br/></span><span style="font-size:7pt;">(I.R.S. Employer</span><span style="font-size:7pt;"><br/></span><span style="font-size:7pt;">Identification No.)</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:EntityAddressAddressLine1" id="Narr_3QprBY7kmUeUkTksH6bPUQ"><b style="font-size:7pt;font-weight:bold;">555 Long Wharf Drive</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:EntityAddressCityOrTown" id="Narr_hE7boxFu90-0xMq1xvEsFQ"><b style="font-size:7pt;font-weight:bold;">New Haven</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:EntityAddressStateOrProvince" id="Narr_WPDBBFxuhkyMMl6VOakFwg"><b style="font-size:7pt;font-weight:bold;">CT</b></ix:nonNumeric><span style="font-size:7pt;"><br/></span><span style="font-size:7pt;">(Address of principal executive offices)</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:EntityAddressPostalZipCode" id="Narr_BmiXigH__EmJkR1rP1JzOQ"><b style="font-size:7pt;font-weight:bold;">06511</b></ix:nonNumeric><span style="font-size:7pt;"><br/></span><span style="font-size:7pt;">(Zip Code)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Registrant&#8217;s telephone number, including area code:&#160;</span><b style="font-size:7pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:CityAreaCode" id="Narr_Lw0laxJT00-JlLDgGPa9MA"><b style="font-size:7pt;font-weight:bold;">475</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:LocalPhoneNumber" id="Narr_gyXRQY4OXE-PMEcUO_r8XQ"><b style="font-size:7pt;font-weight:bold;">238-6837</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><a id="_266d601b_6b44_470f_8a2c_8f44a0c673ed"></a><a id="Tc_Tu6iKwCaK0O2Xy-YtaRg5Q_1_0"></a><a id="Tc_nhcOwrLtL0WDTEjX6tMaIA_1_1"></a><a id="Tc_K9iJYL24-0q8Ko-cnBzjjA_1_2"></a><a id="Tc_bA3vqvghEEKGnBtPsW3-Ag_2_0"></a><a id="Tc_VDXl3K8oF0eK7sw2R0jA9w_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:43.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title of each class</span></p></td><td style="vertical-align:top;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:top;width:43.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Name of exchange on which registered</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:Security12bTitle" id="Narr_VGf5o9U3RUiRowP9ToY-vg"><b style="font-size:7pt;font-weight:bold;">Common Stock</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">, par value $0.001 per share</b></p></td><td style="vertical-align:top;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:TradingSymbol" id="Tc_r1Klw1ce9UGfRbz9A7Psgg_2_1"><b style="font-size:7pt;font-weight:bold;">BTAI</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:43.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:7pt;font-weight:bold;white-space:pre-wrap;">  </b><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:SecurityExchangeName" id="Narr_z_QB4zzLvkuivsEtLSsbrA"><b style="font-size:7pt;font-weight:bold;">Nasdaq</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;"> Capital Market</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act:&#160;<b style="font-weight:bold;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. &#160;Yes&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;white-space:pre-wrap;">  </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_FTU5wZcEKkmYVyPph2p74Q"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. &#160;Yes&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;white-space:pre-wrap;">  </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:EntityVoluntaryFilers" id="Narr_z_dd8c-Jk0OUJ7O6QPpmNg"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports) and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;</span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:EntityCurrentReportingStatus" id="Narr_fB__nzwTHkG0QgGSLQ5Qkw"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span><span style="font-size:7pt;white-space:pre-wrap;">  No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;</span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:EntityInteractiveDataCurrent" id="Narr_w3vN2-B2PEezZOhQm40S3g"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span><span style="font-size:7pt;white-space:pre-wrap;">  No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:26.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 0pt 10pt;">Large&#160;accelerated&#160;filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:21.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:18pt;margin:0pt;">Accelerated&#160;filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:24.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:EntityFilerCategory" id="Narr_jr5pE5ZbY0yb0254UkvkmA"><span style="font-size:7pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:7pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p></td><td style="vertical-align:top;width:27.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:18pt;margin:0pt;"><span style="font-size:7pt;">Smaller&#160;reporting&#160;company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:EntitySmallBusiness" id="Narr_qCpelrbQQUuU3pPF-4YROg"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:26.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 10pt;"><span style="font-size:7pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:21.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:27.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:18pt;margin:0pt;"><span style="font-size:7pt;">Emerging growth company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:EntityEmergingGrowthCompany" id="Narr_0NyfAe4HiE2eltyiXRWVbg"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. &#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:IcfrAuditorAttestationFlag" id="Narr_pC_eA2VbcUW1-Fq8DLn_aw"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><ix:nonNumeric format="ixt:fixed-false" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_-uNV0xlIO0mBQ9mRwC4i5g"><span style="font-size:7pt;">&#61551;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#61551;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). &#160;Yes&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:EntityShellCompany" id="Narr_J9RlO0ssaUekcgfx2bWQBQ"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric><span style="font-size:7pt;white-space:pre-wrap;">  No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt;">As of June 30, 2024, the last business day of the registrant's most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_6_30_2024_ILN-_SN1KEyD2kZtjTgasA" decimals="0" name="dei:EntityPublicFloat" id="Narr_moAhNTvvyk-fS6_yU3wEqg">41,276,960</ix:nonFraction> (based upon the closing sale price of the registrant&#8217;s common stock reported on the Nasdaq Capital Market on that date). This calculation excludes shares held by the registrant&#8217;s current directors and executive officers and stockholders that the registrant has concluded are affiliates of the registrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;">There were <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_3_26_2025_l5KrQw1_MEy8y_GUvIg7oQ" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_qQaaRzXd6kK2MgB6SXAGFg">5,486,038</ix:nonFraction> shares of our common stock outstanding at March 26, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt;">.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'\007b49\007ebf';line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_b1350d71_1bb7_45a8_85c8_56531976ed0e"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#FORWARDLOOKINGSTATEMENTS_331203"><span style="font-style:normal;font-weight:normal;">Forward Looking Statements</span></a></p></td><td style="vertical-align:bottom;width:10.13%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#SummaryRiskFactors"><span style="font-style:normal;font-weight:normal;">Summary Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTI_674733"><span style="font-style:normal;font-weight:normal;">Part&#160;I.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1Business_810543"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1Business_810543"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">8</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1ARiskFactors_143189"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1ARiskFactors_143189"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">53</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_512583"><span style="font-style:normal;font-weight:normal;">Item&#160;1B.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_512583"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">116</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1C"><span style="font-style:normal;font-weight:normal;">Item 1C</span></a>.</p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1C"><span style="font-style:normal;font-weight:normal;">Cybersecurity</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">116</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item2Properties_105398"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item2Properties_105398"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">118</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item3LegalProceedings_216198"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item3LegalProceedings_216198"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">118</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_460898"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_460898"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">118</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#PartII_326423"><span style="font-style:normal;font-weight:normal;">Part&#160;II.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">118</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item6Reserved_721061"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item6Reserved_721061"><span style="font-style:normal;font-weight:normal;">Reserved</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">119</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;7.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">120</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item&#160;7A.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">139</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item&#160;8.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">139</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item&#160;9.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">140</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item9AControlsandProcedures_710755"><span style="font-style:normal;font-weight:normal;">Item&#160;9A.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item9AControlsandProcedures_710755"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">140</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item9BOtherInformation_895714"><span style="font-style:normal;font-weight:normal;">Item&#160;9B</span></a>.</p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item9BOtherInformation_895714"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">140</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item9C"><span style="font-style:normal;font-weight:normal;">Item 9C.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item9C"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">141</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#PARTIII_44466"><span style="font-style:normal;font-weight:normal;">Part&#160;III.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Item&#160;10.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">142</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item_11"><span style="font-style:normal;font-weight:normal;">Item&#160;11.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item_11"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">149</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item_12"><span style="font-style:normal;font-weight:normal;">Item&#160;12.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item_12"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">155</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item_13"><span style="font-style:normal;font-weight:normal;">Item&#160;13.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item_13"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">157</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item_14"><span style="font-style:normal;font-weight:normal;">Item&#160;14.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item_14"><span style="font-style:normal;font-weight:normal;">Principal Accounting Fees and Services</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">161</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#PARTIV_900935"><span style="font-style:normal;font-weight:normal;">Part&#160;IV.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item15ExhibitsFinancialStatementSchedule"><span style="font-style:normal;font-weight:normal;">Item&#160;15.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item15ExhibitsFinancialStatementSchedule"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">162</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item16Form10KSummary_689937"><span style="font-style:normal;font-weight:normal;">Item&#160;16.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item16Form10KSummary_689937"><span style="font-style:normal;font-weight:normal;">Form&#160;10-K Summary</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">168</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#SIGNATURES_328256"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">169</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_ddf12b1f_8c59_4bdf_8aa6_657a76a76970"></a><a id="FORWARDLOOKINGSTATEMENTS_331203"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">This Annual Report on Form&#160;10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;designed,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All statements contained in this Annual Report on Form 10-K, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our sales strategy for IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to raise additional capital and continue as a going concern;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to stay listed on the Nasdaq Capital market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with covenants under our financing arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments relating to our SERENITY and TRANQUILITY programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of our total addressable markets and related underlying estimates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our plans relating to clinical trials and marketing applications for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our plans to research, develop and commercialize our current and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our plans to seek to enter into collaborations for the development and commercialization of certain product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential benefits of any future collaboration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of and results of discussions we have with regulators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rate and degree of market acceptance, clinical utility, number of prescribers and formulary wins of IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and any product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our commercialization, marketing and manufacturing capabilities and strategy, including the potential benefits from any advertising campaigns;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our participation in, and any potential benefits from, events, conferences, presentations and conventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our intellectual property position and strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates regarding expenses, future revenue, capital requirements and need for additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential investments in, or other strategic options for, our subsidiary, OnkosXcel Therapeutics, LLC (&#8220;OnkosXcel&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments relating to our competitors and our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of government laws and regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments related to legal proceedings and investigations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our relationship with BioXcel LLC.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">These forward-looking statements are based on management&#8217;s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, those listed under Part&#160;I, Item&#160;1A. &#8220;Risk Factors,&#8221; Part II, Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Annual Report on Form 10-K. These and other important factors discussed under the caption &#8220;Risk Factors&#8221; in our other filings with the Securities and Exchange Commission (&#8220;SEC&#8221;) could cause actual results to differ materially from those indicated by the forward-looking statements made in this filing. Given these uncertainties, you should not rely on these forward-looking statements as predictions of future events. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">As used in this Annual Report on Form 10-K, unless otherwise specified or the context otherwise requires, the terms &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; the &#8220;Company&#8221; or &#8220;BTI&#8221; refer to BioXcel Therapeutics, Inc., and &#8220;BioXcel, LLC&#8221; refers to the Company&#8217;s former parent company and stockholder, BioXcel LLC, and its predecessor, BioXcel Corporation.  All brand names or trademarks appearing in this Annual Report on Form 10-K are the property of their respective owners, including IGALMI</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, which is a trademark of BioXcel Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may use our website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors &amp; Media section of its website at <i style="font-style:italic;">www.bioxceltherapeutics</i><i style="font-style:italic;">.com</i>. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the &#8220;Email Alerts&#8221; option under the News / Events menu of the Investors &amp; Media section of our website at <i style="font-style:italic;">www.bioxceltherapeutics</i><i style="font-style:italic;">.com</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="SummaryRiskFactors"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SUMMARY RISK FACTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our business is subject to numerous risks and uncertainties, including those described in Part I, Item 1A. &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a limited operating history and have not generated substantial product revenues to date, which may make it difficult to evaluate the success of our business to date and to assess our future viability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred significant operating losses since inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts or otherwise seek strategic alternatives.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Nasdaq may delist our common stock from trading on its exchange, which could limit investors' ability to make transactions in our securities and subject us to additional trading restrictions.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have significant indebtedness and other contractual obligations that could impair our liquidity, restrict our ability to do business and thereby harm our business, results of operations and financial condition. We may not have sufficient cash flow from operations to satisfy our obligations under our financing facilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our strategic reprioritization and other workforce reductions in force may not achieve our intended outcome.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have limited experience in drug discovery and drug development.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Developments relating to our TRANQUILITY II Phase 3 trial may impact the timing of our development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer&#8217;s disease and may also subject us to additional risks and uncertainties, including regulatory, stockholder or other actions, loss of investor confidence and negative impacts on the trading price of our common stock.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In the near term, we are dependent on the success of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, and four of our product candidates, BXCL501, BXCL502, BXCL701 and BXCL702. If we are unable to complete the clinical development of or obtain marketing approval for our product candidates or successfully commercialize </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> or our product candidates, either alone or with a collaborator, or if we experience significant delays in doing so, our business could be substantially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Interim &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The regulatory approval processes of the United States (&#8220;U.S.&#8221;) Food and Drug Administration (&#8220;FDA&#8221;), and comparable foreign authorities are lengthy, time consuming, expensive and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical trials are expensive, difficult to design, difficult to conduct and involve an uncertain outcome.</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We depend on enrollment of patients in our clinical trials to continue development of our product candidates. If we are unable to enroll patients in our clinical trials, our research and development efforts could be adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our estimated number of episodes of agitation and our corresponding estimated total addressable market are subject to inherent challenges and uncertainties. If we have overestimated the number of episodes or the size of our total addressable market for our current and potential future products or product candidates, or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability may be harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The discovery and development of product candidates based on EvolverAI, BioXcel LLC&#8217;s proprietary pharmaceutical discovery and development engine, as well as our own AI platform is novel and unproven, and we do not know whether we will be able to develop any products of commercial value.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Regulators may limit our ability to develop or implement our proprietary AI algorithms and/or may eliminate or restrict the confidentiality of our proprietary technology, which could have an adverse effect on our business, results of operations, and financial condition.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Although the FDA has approved IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder, we will still face extensive and ongoing regulatory requirements and obligations for IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and for any product candidates for which we obtain approval.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Although we obtained FDA approval for IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, our products and product candidates may not be accepted by physicians or the medical community in general, and there may be insufficient insurance coverage and reimbursement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are found in violation of federal, state or foreign health care &#8220;fraud and abuse&#8221; laws, we may be required to pay significant fines and penalties, which may adversely affect our business, financial condition and results of operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We continue to depend on BioXcel LLC to provide us with certain services for our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are substantially dependent on third parties for the manufacture of our clinical supplies of our product candidates, and our commercial supplies of IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, and we intend to rely on third parties to produce commercial supplies of any other approved product candidate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely on third parties to conduct our preclinical and clinical trials. If these third parties do not successfully perform their contractual legal and regulatory duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Data breaches or cyber-attacks could disrupt our business, operations and information technology systems, and financial results, or result in the loss or exposure of confidential or sensitive Company information.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are and may in the future be subject to legal proceedings, claims and investigations in or outside the ordinary course of business. Such proceedings,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">claims and investigations could be costly and time-consuming to defend and could result in unfavorable outcomes, which may have a material adverse effect on our business, operating results and financial condition, and negatively affect the price of our common stock.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unfavorable global political or economic events and conditions could adversely affect our business, financial condition or results of operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face risks associated with the increased scrutiny relating to environmental, social and governance matters.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection.</span></td></tr></table><div style="margin-top:10pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TRADEMARKS, TRADE NAMES AND SERVICE MARKS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">This Annual Report includes our trademarks, trade names and service marks, including, without limitation, &#8220;IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>&#8221; and our logo, which are our property and are protected under applicable intellectual property laws. Solely for convenience, trademarks, trade names and service marks may appear in this Annual Report without the &#174;, TM and SM symbols, but such references are not intended to indicate, in any way, that we or the applicable owner forgo or will not assert, to the fullest extent permitted under applicable law, our rights or the rights of any applicable licensors to these trademarks, trade names and service marks. We do not intend our use or display of other parties&#8217; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INDUSTRY AND OTHER DATA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Unless otherwise indicated, information contained in this Annual Report concerning our industry and the markets in which we operate, including our general expectations, market position and market opportunity, is based on our management&#8217;s estimates and research, as well as industry and general publications and research, surveys and studies conducted by third parties. While we believe the information from these third-party publications, research, surveys and studies included in this Annual Report is reliable, we do not guarantee the accuracy or completeness of such information, and we have not independently verified this information. Management&#8217;s estimates are derived from publicly available information, their knowledge of our industry and their assumptions based on such information and knowledge, which we believe to be reasonable. This data involves a number of assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in this Annual Report under &#8220;Forward Looking Statements,&#8221; &#8220;Risk Factor Summary&#8221; and Part I, Item 1A &#8220;Risk Factors.&#8221; These and other factors could cause our future performance and market expectations to differ materially from our assumptions and estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_3d848956_d999_4a09_a3d5_20a0dff34ef5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><a id="PARTI_674733"></a><a id="_40488b07_190c_4332_87d9_f511ceca798b"></a><a id="Item1Business_810543"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;1. Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">BioXcel Therapeutics, Inc. (&#8220;BTI,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is a biopharmaceutical company utilizing artificial intelligence (&#8220;AI&#8221;) to develop transformative medicines in neuroscience and, through the Company&#8217;s wholly owned subsidiary, OnkosXcel Therapeutics LLC (&#8220;OnkosXcel&#8221;), immuno-oncology. We are focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients&#8217; lives. We employ various AI platforms to reduce therapeutic development costs and potentially accelerate development timelines. Our approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. We believe this differentiated approach has the potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Our most advanced neuroscience candidate is BXCL501. In indications other than those approved by the United States (&#8220;U.S.&#8221;) Food and Drug Administration (&#8220;FDA&#8221;) as IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, BXCL501 is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine (or &#8220;Dex&#8221;) in development for the treatment of agitation associated with psychiatric and neurological disorders. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On April 6, 2022, we announced that the FDA approved IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is approved to be self-administrated by patients under the supervision of a health care provider. On July 6, 2022, we announced that IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> was commercially available in doses of 120 and 180 micrograms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On September 5, 2024, we announced the initiation of our SERENITY At-Home trial, a double-blind, placebo-controlled study to evaluate the safety of a 120 mcg dose of BXCL501 in 200 patients for acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting. On November 12, 2024, we announced that the first patient had been randomized in the trial, and on March 27, 2025, that 24 clinical trial sites had been opened and 127 patients had been enrolled. Topline data results, which are expected in the second half of 2025, are intended to support a supplemental new drug application (&#8220;sNDA&#8221;) submission to potentially expand the label of IGALMI&#174; (dexmedetomidine) sublingual film in the at-home setting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We are continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer&#8217;s disease in the at-home setting and in care facilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As described further below, we have<span style="text-decoration-line:line-through;text-decoration-style:solid;"> </span>deprioritized the development of BXCL501 for certain other proposed indications, as a potential adjunctive treatment for major depressive disorder (&#8220;MDD&#8221;), as well as our BXCL701 program, except as noted under &#8220;Immuno-Oncology&#8221; below. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On September 5, 2024, we submitted to the FDA the proposed protocol for our TRANQUILITY In-Care Phase 3 trial designed to evaluate the efficacy and safety of a 60 mcg dose of BXCL501 for agitation associated with Alzheimer&#8217;s dementia. See further discussion in <i style="font-style:italic;">&#8220;Our Neuroscience Clinical Programs&#8221;</i> below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On October 15, 2024, we announced a U.S. Department of Defense grant to the University of North Carolina to fund a study of BXCL501 (sublingual dexmedetomidine) for treating Acute Stress Disorder (ASD). See further discussion in <i style="font-style:italic;">&#8220;Additional Neuroscience Opportunities&#8221;</i> below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator being developed by OnkosXcel as a potential therapy for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Nasdaq Notice</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On September 16, 2024, the Company received a letter from the Listing Qualifications Department (the &#8220;Staff&#8221;) of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On February 6, 2025, the Company announced that it would effect a 1-for-16 reverse stock split of its common stock. The reverse stock split became effective at 5:00 p.m. on February 7, 2025, and the company&#8217;s common stock began trading on a split-adjusted basis (above $1 per share) at the opening of the market on Monday, February 10, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">To regain compliance, the Company was required to maintain a minimum closing bid price of $1.00 per share for at least 12 consecutive trading days. This requirement was met on February 26, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">As previously reported, on September 20, 2024, we received a letter from the Nasdaq Staff notifying us that for the 30 consecutive business days prior to the date of the letter, the Company&#8217;s market value of listed securities (&#8220;MVLS&#8221;) closed below the minimum $35 million requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the &#8220;MVLS Requirement&#8221;). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company was granted a period of 180 calendar days, or until March 19, 2025, to regain compliance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">As anticipated, on March 20, 2025, the Company received another letter from the Staff stating that, as a result of the Company&#8217;s continued non-compliance with the MVLS Requirement, its securities would be delisted from Nasdaq unless the Company appealed the Staff&#8217;s delisting determination by requesting a hearing before the Nasdaq Hearings Panel (the &#8220;Panel&#8221;). The Company made timely request for a hearing before the Panel to appeal the Staff&#8217;s determination. The Company&#8217;s common stock will remain listed and eligible for trading on Nasdaq at least pending the ultimate conclusion of the hearing process; however, there can be no assurance that the Company will ultimately regain compliance and remain listed on Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">2024 Clinical Prioritization </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As discussed in Note 4, <i style="font-style:italic;">Restructuring</i> in the notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K, on May 8, 2024 the Company took additional actions as part of its continued efforts to preserve cash and prioritize investment in its core clinical programs. As part of these actions, the Company initiated a reduction of approximately 15% of the Company&#8217;s workforce. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">O<span style="background:#ffffff;">n September 17, 2024, the Company approved a plan for an additional reduction in its workforce by 15 employees (including all but one sales and marketing employee), or approximately 28% of the Company&#8217;s headcount (the &#8220;Clinical Prioritization&#8221;), in order to extend its cash runway and prioritize investment on the clinical development of its lead neuroscience asset, BXCL501. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Neuroscience</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Neuroscience Strategy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our goal is to become the leading AI-enabled neuroscience therapeutics company. We continue to evaluate all strategic options for our neuroscience assets, which could include licensing, partnering, and co-commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Novel Drug Re-Innovation Approach</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We aim to deploy and implement, throughout the drug development process, an AI ecosystem designed to rapidly identify medications related to our key focus areas of neuroscience and immuno-oncology. Our in-house, uniquely integrated AI-to-drug-development capability is complemented by the services and technology of BioXcel LLC, our former parent company. It includes a labeled properties graph (also referred to as a &#8220;knowledge graph&#8221;) that visually relates collected big data in the form of entities and their properties that include neuropsychiatric symptoms, brain circuits, drug targets, and existing drugs. We believe that understanding the relation between entities relevant to drug development may lead to novel potential uses for existing drugs. Predictive algorithms or queries of the knowledge </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">graph may uncover not only single drugs but potentially identify new combinations of drugs that we believe may be more effective in treating disorders than single agents. New combinations of drugs may lower tolerable doses of drugs and provide the basis for stronger intellectual property positions. Our AI team prioritizes the most valuable external opportunities in a data-driven manner. These opportunities may be found in new potential uses for launched drugs, in drugs that are part of pharmaceutical company pipelines no longer being pursued, or within academic efforts to develop new drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Traditional drug development is marred by low success rates, long drug development cycles, and exorbitant development costs that are increasing year over year. In addition, many serious diseases remain unaddressed due to limitations of the current drug discovery paradigm.  The pharmacological universe spans more than 27,000 active pharmaceutical agents, of which only approximately 4,000 are approved and marketed. Marketed drugs may not be exclusively effective in the indication for which they are approved but relevant to other indications, including rare diseases, and thus represent an untapped potential for addressing unmet medical needs and recouping research and development costs. Many of the remaining agents are active clinical candidates that are shelved or have failed for reasons other than toxicity, which offers the opportunity to re-innovate for other indications or patient segments. Such agents potentially represent an unrealized investment of billions of research and development dollars by the private and public sectors, while failing to remediate immeasurable patient suffering and sacrifice during clinical development. Also, these compounds may have known pharmaco-dynamic and pharmaco-kinetic properties, potentially allowing for a more data-driven selection of appropriate doses for development programs. Finally, with respect to neuropsychiatric indications, we prioritize those compounds with structural design features that we believe may contribute to high blood-brain barrier permeability, and therefore could increase the likelihood of compound penetration into the brain. Lack of brain penetration is a common cause for failure of many drugs developed for neuropsychiatric indications. In addition, we are prioritizing compounds with available human safety data, acceptable pharmacokinetic results, and data that support a high probability of achieving reasonable brain concentrations after dosing. The compounds in our pipeline have been identified using this proprietary platform.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">This drug re-innovation model has been exemplified by the successful development and commercialization of drugs such as Tecfidera<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (Biogen, Inc.), Thalomid<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (Celgene Corporation), and Viagra<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (Pfizer, Inc.). All of these drugs were identified by insights in biology and disease pathophysiology. The successful business models of biotech companies like Axsome Therapeutics, Inc. and Karuna Therapeutics, Inc. (acquired by Bristol Myers Squibb) are based on the re-innovation and combination of existing clinical candidates or marketed drugs to provide novel solutions for patients. Unfortunately, such discoveries have been severely limited in scope due to the lack of a genuinely integrated approach to mining big data and advanced analytics. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our AI-based discovery and development process is the foundation of our drug re-innovation model for identifying the next wave of potential medicines. Our therapeutic area experts have substantial experience across the drug discovery and development value chain. We believe that our method of finding potential product candidates gives us a higher probability of success because it combines AI expertise and intuition of human experience in drug development. We believe the combination of AI and drug discovery and development expertise facilitates the generation of therapeutic candidates and gives us a significant competitive advantage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:268.53pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our approach is illustrated below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="btai-20241231x10k001.jpg" alt="Graphic" style="display:inline-block;height:267.83pt;left:0%;padding-bottom:0.7pt;position:relative;top:0pt;width:476.11pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We continue to integrate and evolve our neuroscience and immuno-oncology AI machine learning and drug discovery and development platform. Our platform led to the identification of Dex, the rapid development of BXCL501, and its approval by the FDA as IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, as well as the advancement of BXCL501 for other potential indications. We are continuing to leverage our platform to identify and develop new neuroscience and immuno-oncology programs.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:246pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Neuroscience Clinical Programs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following is a summary of the status of our neuroscience clinical development programs as of the date of this Annual Report on Form 10-K: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="btai-20241231x10k002.jpg" alt="Graphic" style="display:inline-block;height:245.25pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As a selective adrenergic agent with a sublingual or buccal route of administration, BXCL501 is designed to be easy to administer and has shown a rapid onset of action in multiple clinical trials, including clinical trials studying patients with schizophrenia, bipolar disorders, and dementia. We believe the results from these studies suggest that BXCL501 has the potential to generate a calming effect without producing excessive sedation. We believe that BXCL501 is highly differentiated from antipsychotics currently used as a standard of care for the treatment of agitation that often produce unwanted side effects such as excessive sedation and extra-pyramidal motor effects. Managing patient agitation in neuropsychiatric and neurodegenerative disorders represents a significant challenge for physicians and caregivers. We believe that BXCL501 has the potential to address these challenges while providing an efficient treatment regimen for patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Agitation Overview and Market Opportunity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Agitation in patients with neuropsychiatric diseases is a serious medical condition. Agitation is characterized by feelings of unease, excessive talking, and/or unintentional and purposeless motions, such as wringing of the hands or pacing. People experiencing agitation may also express excitement, hostility, poor impulse control, tension, uncooperativeness, and occasional disruptive behavior, which may lead to aggression and violence. In many cases, people develop agitation when treatment for their underlying disorder is not working well. Stressful situations or traumatic events can also trigger agitation. Agitation can occur suddenly or slowly and vary in length, lasting for a few minutes or for an extended period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">With the agitation issues associated with schizophrenia and bipolar disease coupled with a fast-growing elderly population that is potentially likely to experience agitation associated with Alzheimer&#8217;s disease, the difficulties and expenses of acute treatment of agitation are expected to grow significantly. We estimate that in the United States, there are approximately 1.9 million patients diagnosed with Alzheimer&#8217;s disease-related dementia (&#8220;AAD&#8221;) and that those patients experience agitation at a rate of about six episodes per month, on average.  In addition, we estimate that there are approximately 1.6 million Americans diagnosed with schizophrenia or bipolar disorders and that those patients experience agitation at a rate of about three episodes per month, on average. We, therefore, believe there is significant </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">potential market opportunity for BXCL501 if approved for use in these patient populations in the at-home setting. The foregoing estimates of the incidence of each patient population and the number of agitation episodes experienced and potential market opportunity are based on management&#8217;s estimates and third-party data, which may be materially different from actual agitation episodes and actual treatable patients. For additional information regarding risks associated with these estimates, see Part I, Item 1A, Risk Factors </span><i style="font-style:italic;">&#8220;&#8212; Our estimated number of episodes of agitation and our corresponding estimated total addressable market are subject to inherent challenges and uncertainties. If we have overestimated the number of episodes or the size of our total addressable market for our current and potential future products or product candidates, or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability may be harmed.&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Treatments for Agitation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Antipsychotics, the current standard of care for acute treatment of agitation associated with schizophrenia and bipolar disorder, are also used off-label to treat agitation in dementia and other conditions. Side effects of these medications include movement disorders, including akathisia and extrapyramidal symptoms. One of the serious limitations of these drugs is that they can sedate the patient and do not permit verbal interaction with the hospital staff to continue. Intramuscular (&#8220;IM&#8221;)-delivered antipsychotics, such as haloperidol and olanzapine, are used extensively in this setting but are invasive and often require patient restraint. This type of treatment can dehumanize patients and cause trauma that could have long-term impact on them. Furthermore, these treatments include a black box warning for use in elderly patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">While sublingual tablet formulations utilizing antipsychotics have been developed, these formulations have long half-lives (21-24 hours) and significant side effects when given acutely or chronically. Oral agents such as benzodiazepines are also used but have a slow onset of action and are consequently ineffective in the acute treatment of agitation. Side effects of these agents include sedation, amnesia, confusion, and paradoxical responses. They can intensify cognitive slowing and worsen memory and motor impairment, contributing to an increased risk of falls and fractures. In addition, long-term use of benzodiazepines has been found to be habit-forming and can cause addiction or relapse to abuse substances. Nonadherence with oral agents can also be problematic as patients may attempt to spit out these medications. We believe that, based on the current method of administration of oral medicine for agitation, an orally dissolving, mucoadhesive film could offer compliance advantages by making it less likely that patients will avoid treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The sublingual or buccal route of administration is an accepted alternative to oral administration of drug delivery to the central nervous system when rapid onset or more controlled delivery is required. Currently, there are six products approved for film administration, including our product, IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>. For example, BioDelivery Sciences International, Inc., a commercial-stage specialty pharmaceutical company, has developed a buccal film formulation of buprenorphine for chronic pain management and buprenorphine and naloxone for opioid dependence. We developed BXCL501 as a differentiated sublingual film dosage form of Dex, which we believe may offer benefits such as ease of use and quick absorption for rapid therapeutic effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mechanism of Action: &#945;2a Adrenergic Receptor and NE Role in Acute Agitation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">BXCL501 is a sublingual formulation of Dex that is designed to be easily administered and have a rapid onset of action. Dex is approved in the U.S. for the sedation of initially intubated and mechanically ventilated patients during treatment in the intensive care unit (&#8220;ICU&#8221;). It is also used in the intensive care setting for sedation of non-intubated patients prior to and/or during surgical and other invasive procedures. Dex, launched in the U.S. as Precedex<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#8482;</sup> in 1999, is a selective &#945;2a adrenergic receptor agonist that has a strong safety record and has been studied in over 130 clinical trials to date. It has also been sold in the European Union (&#8220;EU&#8221;) and other countries under the trade name Dexdor<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> as a sedative for intensive care patients. Dex was approved by the European Commission for sedation of adult ICU patients requiring a sedation level no deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale 0 to -3). It has been used to prevent or treat hyperactive delirium resulting from anesthesia in </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">the ICU. Given these uses of the IV formulation of Dex, we believe Dex formulated in a sublingual film and at much lower doses allows for ease of administration in settings where rapid acute treatment of agitation is needed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">IGALMI</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-style:italic;font-weight:bold;"> Commercial Strategy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We continue to support IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the hospital setting through limited and focused commercial activity.&#160; In the third quarter of 2023, we revised our commercial strategy for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the institutional setting, reducing in-hospital commercialization expenses, suspending programs no longer deemed core to our business, and shifting focus to the development of BXCL501 for use in the at-home and care facilities in the treatment of acute agitation in schizophrenia and bipolar disorders, and in the treatment of acute agitation (non-daily) associated with dementia due to probable Alzheimer&#8217;s disease (collectively, the &#8220;Reprioritization&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Following the Reprioritization, a small Corporate Account Director team supported existing customers and targeted Integrated Delivery Networks (&#8220;IDNs&#8221;) with educational assistance and contracting opportunities, while our trade operation supported customers with drug supply.&#160; The goal of this approach was to help maintain current business and potentially broaden IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> utilization through volume contracting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">As part of the Clinical Prioritization announced on September 19, 2024, we made further workforce reductions including sales and marketing employees, as the Company announced it would maintain IGALMI&#8482;&#160;in the market with minimal commercial support. The Clinical Prioritization staff reductions may have future impacts on net revenue. Net revenues from IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> product sales for the years ended December 31, 2024 and 2023 were $2.3 million and $1.4 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are currently seeking potential commercial partners. Our continued commercialization efforts for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> are designed to build the foundation to launch additional potential follow-on indications. If IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> would be approved outside the U.S., we would consider launching the product through collaborations with third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">BXCL501 Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">In indications other than those approved by the FDA as IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, BXCL501 remains an investigational, proprietary, orally dissolving film formulation of Dex, a selective alpha-2 receptor agonist, targeting symptoms from stress-related behaviors such as agitation. BXCL501 is our most advanced neuroscience clinical program, being evaluated for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the acute treatment of agitation (non-daily) in patients with dementia due to probable Alzheimer&#8217;s disease in care facilities and at-home settings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">As a selective adrenergic agent with a sublingual or buccal route of administration, BXCL501 is designed to be easily administered and, compared to medications that may take days or weeks, has shown a relatively rapid onset of action in multiple clinical trials, including those studying patients with bipolar disorders, schizophrenia, and Alzheimer&#8217;s disease. We believe results from these studies suggest that BXCL501 has the potential to reduce agitation without producing excessive sedation. We also believe BXCL501 is highly differentiated from antipsychotics, which are currently used as first-line standard-of-care treatments despite often producing unwanted side effects such as excessive sedation or extra pyramidal motor effects. Managing patient agitation in neuropsychiatric and neurodegenerative disorders represents a significant challenge for physicians and caregivers. We believe BXCL501 has the potential to address these challenges while providing an efficient treatment regimen for patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We also believe that BXCL501, if approved for the respective indications, has the potential to become the standard of care for the acute treatment of agitation arising from diseases such as schizophrenia, bipolar disorder and Alzheimer&#8217;s disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, given the differentiated design of BXCL501 and its mechanism of action, we believe BXCL501 has the potential to address several diseases or conditions for which agitation is a symptom of the condition or underlying disease, including opioid withdrawal and post-traumatic stress disorder (&#8220;PTSD&#8221;), which are being evaluated in investigator-sponsored trials run by several leading academic research institutions.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">BXCL501 Clinical Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">SERENITY Program: Agitation Associated with Bipolar Disorders I and II or Schizophrenia (at-home setting)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">We initiated the clinical study of BXCL501 in patients with agitation associated with bipolar disorders or schizophrenia in SERENITY III, which consisted of two parts. The first part was comparable to our pivotal SERENITY I and II studies. Using similar inclusion and exclusion criterion under a well-controlled in-patient setting, acutely agitated patients with bipolar disorders or schizophrenia were randomized to self-administer either 60 mcg of BXCL501 or placebo in a double-blind placebo-controlled trial. The primary endpoint of Part I was efficacy, as measured by the change in PEC score change from baseline at two hours post-dose. The secondary objectives of Part I were safety and tolerability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On May 25, 2023, we reported topline results from Part I of the study. Although the trial did not meet its primary efficacy endpoint, we believe the efficacy results, observed with the 60 mcg dose, representing half of the lowest approved dose of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> for in-patient use (120 mcg), were promising. Specifically, greater than 50% of individuals were responders, defined as those patients who achieved a 40% or greater reduction in PEC score. Furthermore, this population responder rate was consistent and dose-proportionate to the same response rates observed in the larger SERENITY I and II trials. Although the primary efficacy endpoint as a group mean change in PEC score from baseline at 2 hours was not statistically significant at the primary endpoint at 2 hours (p=0.077), BXCL501 statistically separated from placebo at 4 hours (p=0.049). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Part II of the SERENITY III study was designed to evaluate the same dose tested in Part I, 60 mcg (with an optional additional 60 mcg dose), but in the at-home setting and focusing on safety only. However, because the trial did not meet its primary efficacy endpoint using this 60 mcg dose in Part I, we paused continuation of Part II of the study pending feedback from the FDA. We held a Type C meeting with the FDA on November 8, 2023 to discuss changes to Part II of our SERENITY III study. We proposed the evaluation of an 80 mcg dose based on previous clinical experience with this dose during our Phase 1b trial in schizophrenia patients with agitation, and pharmacokinetic and pharmacodynamic modeling suggesting that use of an 80 mcg dose of BXCL501 could provide an optimal balance between safety and efficacy for at-home use. Based on feedback from the FDA during the meeting, we made the decision to evaluate a 120 mcg dose in the at-home setting. The 120 mcg dose has already demonstrated efficacy based on the approval of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="white-space:pre-wrap;"> (when administered under the supervision of a healthcare provider, for a single agitation episode), so we sought further feedback from the FDA regarding the proposed design of this study amendment in a request for a follow-up meeting with the FDA, which was held on March 6, 2024.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Based on the FDA&#8217;s feedback in advance of and during the March 6, 2024 meeting, we moved forward evaluating the use of the 120 mcg dose of BXCL501 in the at-home setting, and amended Part 2 of the SERENITY III study. We now refer to this study as the SERENITY At-Home trial, with safety as the primary objective and efficacy measures as exploratory endpoints to support use in the at-home setting. This was the FDA&#8217;s recommendation in the November 8, 2023 FDA meeting, for the acute treatment of agitation in bipolar disorders or schizophrenia. We also plan to initiate a clinical study designed to enroll approximately 30 patient-informant dyads to evaluate the correlation between patient-and informant-reported efficacy measurement and the PEC scale, conducted by trained clinician raters as previously recommended by the FDA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is already approved at the 120 mcg dose based on efficacy data that we previously generated in treating a single episode of agitation. Consistent with the data generated to date, the label for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> currently includes a limitation on use (&#8220;LOU&#8221;), noting the lack of efficacy or safety data beyond 24 hours following the first dose. During our March 6, 2024 Type C meeting with the FDA, we discussed, among other things, whether evaluating the at-home use of BXCL501 120 mcg, with safety as the primary objective and efficacy measures as exploratory endpoints, if successful, could support the submission of an sNDA seeking expansion of the current label for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> 120 mcg to allow at-home use and labeling without the current LOU. Based on FDA feedback, we believe that our ability to seek labeling without the current LOU will depend, in part, on the number of agitation episodes we observe during our planned study period. On April 22, 2024, we announced our plans, subject to funding, to advance the SERENITY At-Home trial. On September 5, 2024, we announced the initiation of our SERENITY At-Home trial. The pivotal Phase 3 trial is designed to evaluate the safety of BXCL501 in the at home setting. On November 12, 2024, we announced that </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">the first patient had been randomized in the trial. On March 27, 2025, 24 clinical trial sites had been opened and 127 patients have been enrolled, representing 63% of the total required enrollment in the trial. Topline data results, which are expected in the second half of 2025, are intended to support a supplemental new drug application (&#8220;sNDA&#8221;) submission to potentially expand the label of IGALMI&#174; (dexmedetomidine) sublingual film. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">TRANQUILITY Program: Acute Agitation Associated with Dementia due to Probable Alzheimer&#8217;s Disease (AAD)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On June 29, 2023, we announced positive topline results from TRANQUILITY II, a randomized, double-blind, placebo-controlled, parallel group trial that evaluated the safety and efficacy of BXCL501 for the acute treatment of Alzheimer&#8217;s-related agitation in adults 65 years and older with mild to moderate dementia in assisted living facilities (&#8220;ALFs&#8221;) and residential care settings who required minimal assistance with activities of daily living. The trial dosed 149 patients. Randomized patients self-administered 40 mcg or 60 mcg of BXCL501 or placebo for agitation episodes that occurred over a 12-week period. The primary endpoint was the change from pre-dose in Positive and Negative Syndrome Scale-Excitatory Component (&#8220;PEC&#8221;) total score at 2 hours post-dose for the first treated episode of agitation. The key secondary efficacy endpoints were PEC change from pre-dose at 1 hour post-dose of study treatment for the first treated episode of agitation, and PEC change from pre-dose at 30 minutes post-dose of study treatment for the first treated episode of agitation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">The Phase 3 trial met its primary efficacy endpoint with the 60 mcg dose; a statistically significant and clinically meaningful 7.5 point reduction from baseline in PEC total score was observed at 2 hours versus 5.4 with placebo (p=0.0112). The 60 mcg dose also met the first key secondary endpoint of reducing agitation symptoms at 1 hour during the first episode of agitation (p=0.0185) but did not meet the other key secondary endpoint of change from baseline in PEC score at 30 minutes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Efficacy for this dose was supported by several secondary measures, including the Clinical Global Impressions &#8211; Improvement Scale (&#8220;CGI-I&#8221;) and Agitation-Calmness Evaluation Scale (&#8220;ACES&#8221;). Most patients (76%) responded to the first 60 mcg dose and were determined to be &#8220;Very Much&#8221; or &#8220;Much Improved&#8221; (CGI-I of 1 or 2, respectively) compared to 50% with placebo. The primary endpoint was not met for the 40 mcg dose, with a 5.7 point reduction from baseline in PEC score.    </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On June 29, 2023, we also announced that we had learned that an investigator in this study, who enrolled approximately 40% of the patients, engaged in misconduct. Since that time, we have taken steps to further investigate and evaluate the conduct of the TRANQUILITY II trial at this clinical site. Based on these steps to date, we believe that there have been no further instances of misconduct or fraud or other findings that adversely impact the data integrity or reliability of the eligibility, safety, and efficacy data obtained at the clinical trial site in question.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On March 3, 2025 we announced that the U.S. Food and Drug Administration (FDA) concluded that the inspection of a single site in its TRANQUILITY II Phase 3 trial was closed under 21 C.F.R.20.64(d)(3) and released the Establishment Inspection Report. The FDA designated &#8220;Voluntary Action Indicated&#8221; for the site. We believe this further supports the reliability of data from the TRANQUILITY II trial of BXCL501.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0.3pt 0pt 12pt 0pt;">In a Type B/Breakthrough Therapy designation meeting with the FDA on October 11, 2023, we reviewed our TRANQUILITY clinical trial program and discussed the data package required to support submission of an sNDA for the potential approval of BXCL501 for the acute treatment of agitation in patients with mild to moderate dementia due to probable Alzheimer&#8217;s disease in the ALF and at-home settings. Specifically, we sought feedback from the FDA as to whether our data package consisting of TRANQUILITY I and II, along with the clinical pharmacology and toxicology programs previously discussed with the FDA, would be sufficient to support an sNDA submission for the potential use of BXCL501 to treat agitation in patients with mild to moderate dementia due to probable Alzheimer&#8217;s disease in either the at-home or ALF setting, or, if not, what additional data would be required. Based on the FDA&#8217;s feedback in this meeting, we understand that the FDA will require additional efficacy data, including repeat efficacy data, and long-term safety data. We therefore requested another meeting with the FDA to further discuss the additional data that would be required to support an sNDA submission.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">On February 20, 2024, we held a Type B/Breakthrough Therapy designation meeting with the FDA. The original purpose of this meeting was to obtain feedback on the design of a proposed at-home study that did not include caregiver-collected efficacy endpoints, based on our belief that obtaining caregiver assessments of efficacy would be challenging. We believe there are no validated caregiver endpoints for assessing efficacy in Alzheimer&#8217;s disease patients in the at-home setting. As a result, we focused on requesting feedback from the FDA regarding our proposal for an at-home clinical study with safety as the primary objective, and to better understand what additional data would be required to submit an sNDA to support labeling for BXCL501 to include the acute treatment of agitation associated with dementia in probable Alzheimer&#8217;s disease or, in the alternative, in this population in the care setting only.  In its preliminary responses, the FDA reiterated its prior comments that we need to generate additional efficacy data, including repeat-dose efficacy data, to support an sNDA submission, as the FDA indicated that our proposed efficacy database, which currently includes the 70 patients who have been treated with 60 mcg of BXCL501 in TRANQUILITY I and TRANQUILITY II, would not contain substantial evidence of effectiveness absent additional data. The FDA advised that we generate the necessary efficacy data in care facilities prior to conducting any trials in the at-home setting. In addition, the FDA indicated the need to generate long-term safety data to support an sNDA submission, including from probable Alzheimer&#8217;s disease patients exposed to BXCL501, for up to one year. Based on the FDA&#8217;s feedback, we are currently planning to generate additional Phase 3 efficacy and safety data, in a variety of relevant care-facility settings and across severity of dementia, in our planned TRANQUILITY In-Care Phase 3 trial. In addition, we plan to discuss the details of the requirement for long-term safety data at a future meeting with the FDA. Also, although we announced in November 2023 that we were planning to conduct a Phase 3 trial in the at-home setting, with safety as the primary objective (TRANQUILITY At Home), given the priority to expand the database to generate additional efficacy and safety data in care facilities, and subject to funding, we are re-evaluating the timing for initiating TRANQUILITY At Home.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0.3pt 0pt 0pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;margin:0pt;">On September 5, 2024, we submitted to the FDA the proposed protocol for our TRANQUILITY In-Care Phase 3 trial designed to evaluate the efficacy and safety of a 60 mcg dose of BXCL501 for agitation associated with Alzheimer&#8217;s dementia. On November 12, 2024, we announced that we had received FDA feedback on the proposed protocol<b style="font-weight:bold;">.&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Adjunctive treatment in&#160;Major Depressive Disorder (&#8220;MDD&#8221;)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">We were previously evaluating BXCL501 as an adjunctive treatment for MDD. The initial clinical study in this program was a double-blind, placebo-controlled, multiple ascending dose (&#8220;MAD&#8221;) trial to evaluate the safety and tolerability of daily doses of BXCL501 in healthy volunteers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">As part of the Reprioritization announced on August 14, 2023, we paused our plan to develop a Phase 2 human proof-of-concept trial design to investigate BXCL501 as a potential adjunctive treatment and its potential accelerant effect in combination with first-line selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">Pediatric Study</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">In June 2021, we initiated a global clinical trial designed to evaluate the safety and efficacy of BXCL501 in the acute treatment of agitation associated with pediatric schizophrenia and bipolar disorders, in part to fulfill pediatric study requirements agreed to with the FDA in connection with the approval of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>. The trial protocol has been reviewed by the FDA, as well as by the European Medicines Agency, to fulfill potential commitments to study the effects of BXCL501 in pediatric patients ages 13 to 17 with schizophrenia and ages 10 to 17 with bipolar disorders. Enrollment of patients with schizophrenia, schizoaffective disorder, bipolar I, and bipolar II disorder is ongoing in this multisite, double-blind, placebo-controlled parallel group trial. Approximately 63% of the 150 total subjects have been enrolled in the U.S. and 95 of such subjects have completed the clinical trial. In July 2023, we stopped activities in the European region as enrollment and site recruitment was unproductive. Similar to our registration trials in schizophrenia and bipolar disorder (SERENITY I and II), the primary endpoint is the change from baseline PEC total score at two hours. The U.S. portion of this program remains active following the Reprioritization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">In October 2024, we submitted a request to the FDA for an extension and plan to submit an updated trial protocol to complete enrollment requirements for pediatric patients with <span style="white-space:pre-wrap;">schizophrenia or schizoaffective disorder.  The FDA granted a 3-year extension to complete the pediatric study.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">IGALMI</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><b style="font-weight:bold;"> Post-Marketing Requirement Study </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On June 25, 2024, we announced positive topline results from our post-marketing requirement study evaluating whether tolerance, tachyphylaxis, or withdrawal occur following repeat dosing of the 180 mcg (highest approved dose) of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>. This study was a single-arm, open-label study of 28 inpatient adults with frequent episodes of agitation associated with bipolar disorders or schizophrenia who self-administered 180 mcg dose of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> as needed over seven days. A total of 83 episodes were treated. The study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal, and IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> was generally well tolerated during the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Additional Neuroscience Opportunities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">BXCL501 Pipeline Opportunities for Franchise Expansion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Given the differentiated design of BXCL501 and its selective mechanism of action, we believe BXCL501 has the potential for broad applicability across several indications where agitation is a symptom of a condition or underlying disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Government-Supported Investigator-Sponsored Trial Programs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company has been awarded key opportunities for the development of BXCL501 in post-traumatic stress disorder (&#8220;PTSD&#8221;), alcohol use disorder (&#8220;AUD&#8221;), and opioid use disorder (&#8220;OUD&#8221;). These are being funded through Cooperative Agreements with the U.S. Department of Defense Congressionally Directed Medical Research Program and National Institute on Drug Abuse (&#8220;NIDA&#8221;).  Clinical and regulatory responsibilities are led by clinical researchers and regulatory staff at the Veterans Affairs Connecticut Healthcare System, Yale University Medical School, RTI International, Columbia University New York State Psychiatric Institute, and NIDA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 22.3pt;"><b style="font-weight:bold;background:#ffffff;">Opioid Use Disorder Program</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 22.3pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt;"><span style="background:#ffffff;">As previously announced, NIDA awarded a grant to Columbia University to fund clinical testing of BXCL501 as a potential treatment for opioid withdrawal in patients diagnosed with OUD. The original 160-patient, three-site, four-arm</span><span style="background:#ffffff;">&#160;</span><span style="color:#212121;">study is a randomized, double-blind, double-dummy inpatient study comparing BXCL501 (180 mcg and 240 mcg BID), lofexidine (as a positive control), and placebo. The study&#8217;s goal is to evaluate the safety and efficacy of BXCL501 relative to lofexidine and placebo in subjects with OUD.</span><span style="color:#212121;">&#160; A </span><span style="color:#212121;">majority of OUD patients participating in the study are anticipated to be exposed to</span><span style="background:#ffffff;"> fentanyl adulterated or associated with xylazine</span><span style="color:#212121;">. To date, a</span><span style="background:#ffffff;">ll three initial sites have recruited, enrolled, and dosed patients diagnosed with OUD who are physically dependent on opioids, including prescription opioids. The Company is supplying BXCL501 for the conduct of this study, which is sponsored by Columbia University</span><span style="color:#212121;">. We expect that the results from current study will be used to select a recommended dose of BXCL501 to compare to placebo in a later outpatient Phase 3 study sponsored by </span><span style="background:#ffffff;">NIDA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">On November 6, 2023, we announced that NIDA requested Columbia University, the trial coordinator, to add a fourth site to expedite trial completion.</span> <span style="background:#ffffff;">The patient screening and enrollment process for the fourth site commenced in March 2024, a potential mid-study readout anticipated in the first half of 2025. Subject to favorable results and available funding, we plan to seek FDA feedback on potential registrational paths.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;background:#ffffff;">Alcohol Use Disorder with Comorbid Post-traumatic Stress Disorder Program</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In December 2020, the Veterans Affairs Connecticut Healthcare System and Yale University Medical School were awarded a grant by the U.S. Department of Defense&#8217;s Congressionally Directed Medical Research Program with the overall objective to evaluate BXCL501 in patients who suffer from AUD with comorbid PTSD. The Company provided BXCL501 for the inpatient Alcohol Interaction Study, which has been completed. We understand Yale is currently seeking approval from its Institutional Review Board (&#8220;IRB&#8221;) and allowance from the FDA to proceed with a trial </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">evaluating the effects of up to 80 mcg BID of BXCL501 per day for 28 days on alcohol consumption, PTSD symptoms, cognitive function, memory, sleep, and mood in patients diagnosed with mild, moderate, or severe AUD and who meet Criterion A for comorbid PTSD. The new outpatient study has received funding approval from the Pharmacotherapies for Alcohol and Substance Use Disorders Alliance (funded through a Cooperative Agreement between the U.S. Department of Defense Congressionally Directed Medical Research Program and RTI International). Patient screening and enrollment began in the fourth quarter of 2024. We believe the results from this study may be used to inform a Phase 3 study intended to commence with support by the alliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">Acute Stress Disorder (ASD) Program</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">On October 15, 2024, we announced a U.S. Department of Defense grant to the University of North Carolina (&#8220;UNC&#8221;) to fund a study of BXCL501 for treating ASD. The award provides $2,800 to the UNC Institute for Trauma Recovery from September 15, 2024 through September 14, 2026 to evaluate the potential efficacy of BXCL501 to reduce ASD symptom severity and/or posttraumatic neuropsychiatric symptoms. The double-blind, placebo-controlled trial is expected to enroll 100 patients experiencing ASD resulting from motor vehicle collisions, beginning in the first half of 2025. We intend to supply BXCL501 for the trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">BXCL502 Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">We identified a second neuropsychiatric drug candidate, BXCL502 &#8722; Latrepirdine (Dimebon) &#8722; through our AI-based platform. We plan to evaluate BXCL502 initially as a monotherapy and possibly in combination with BXCL501 for the chronic treatment of agitation in patients with dementia and acute stress disorder. The active pharmaceutical ingredient (&#8220;API&#8221;) underlying BXCL502 affects serotonergic signaling in the brain. Our preclinical data suggests BXCL502 has the potential to treat stress-related neuropsychiatric symptoms in dementia and other stress-related disorders. In previously published third-party clinical trial data, daily administration of the API of BXCL502 demonstrated improvement in behaviors using a well-established, clinically validated symptom scale. Formulation and further clinical development planning for BXCL502 was paused as part of the Reprioritization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Other Product Candidates Leveraging the AI Platform</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Our AI platform is comprised of a series of customized and specific AI applications aimed at identifying, predicting efficacy and testing of late-stage assets with known mechanisms of action and associated pharmacology and safety data. We target neuropsychiatric and neurological rare disorders, where the compounds are either disease-modifying or symptom-mitigating. Compounds are tested in relevant models of disease and rank-ordered based on the potential to enter the clinic and ease of development. Disease areas of interest are stress related such as agitation, or neuropsychiatric symptoms associated with dementia and responsible for increased levels of healthcare burden.  For example, our pipeline concepts BXCL503 and BXCL504 putatively have the potential to address apathy and aggression in dementia, respectively.</span> These programs were also paused as part of the Reprioritization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Neuroscience Competition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. The neuroscience and rare disease segments of the industry are highly competitive. While we believe that our technology, development experience, and scientific knowledge provide competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical, and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Many of our competitors may have significantly greater financial resources, and expertise in research and development, manufacturing, preclinical studies, conducting clinical trials, obtaining regulatory approvals, and marketing approved medicines than we do. Mergers and acquisitions in the pharmaceutical, biotechnology, and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and in establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">complementary to or necessary for our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The key competitive factors affecting the success of our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, if any, the level of generic competition, and the availability of reimbursement from government and other third-party payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize medicines that are safer, more effective, more convenient, less expensive, or have fewer or less severe side effects than any medicines we may develop. Our competitors also may obtain FDA or other regulatory approval for their medicines more rapidly than us, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic medicines. There are many generic medicines currently on the market for certain indications that we are pursuing, and additional generics are expected to become available over the coming years. We expect that any of our therapeutic product candidates that are approved will be priced at a significant premium over competitive generic medicines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and any of our other product candidates that are approved, if any, will compete with the drugs discussed below, in addition to any other drugs currently in development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Drugs used for the acute treatment of agitation related to schizophrenia and bipolar disorder are antipsychotics frequently administered via IM injection that typically requires patient restraint. These include IM aripiprazole, olanzapine, ziprasidone, and haloperidol. Oral products include the sublingually administered atypical antipsychotic Asenapine, as well as benzodiazepines, lorazepam, and midazolam. The typical antipsychotic Adasuve<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (loxapine) from Alexza is delivered via inhalation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Neuroscience Manufacturing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We do not have manufacturing facilities. We currently rely on strategic manufacturing partners, in particular ARx, LLC (&#8220;ARx&#8221;), and expect to continue to rely on third parties for the manufacture of our product candidates for clinical research and our products for commercialization efforts. ARx has agreed to exclusively manufacture and supply our supply of film formulation of dexmedetomidine to be used for the commercial supply of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and for ongoing clinical trials of BXCL501, subject to certain alternative supply provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BXCL501 drug product is manufactured using commercially available components and packaging materials. The equipment employed for manufacturing and analysis is consistent with standard pharmaceutical production.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Neuroscience Commercialization</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We plan to retain worldwide commercialization rights for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and other approved product candidates, if any, but could consider collaboration opportunities to maximize returns or facilitate commercialization efforts in foreign jurisdictions. For additional information regarding our commercialization efforts for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, see above under &#8220;IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> Commercial Strategy.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As product candidates advance through our pipeline, our commercialization plans may change. Clinical data, the size of the development programs, the size of the target market, the required commercial infrastructure, and manufacturing needs may all influence global commercialization strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Neuroscience Intellectual Property</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Our policy is to protect and enhance the proprietary technologies, inventions, and improvements that are commercially important to our business by filing patent applications in the U.S. and other jurisdictions related to our proprietary technology, inventions, improvements, and product candidates. We also rely on trademarks, trade secrets, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">and know-how relating to our proprietary technologies and product candidates, continuing innovation, and in-licensing technology and products. This reliance is expected to develop, maintain, and strengthen our proprietary position for novel therapeutics and novel formulations of existing therapeutics across multiple therapeutic areas. We also plan to rely on data exclusivity, market exclusivity, and patent term extensions when available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">We have multiple patent families filed to protect our Neuroscience program, including BXCL501.  As of February 20, 2025, our neuroscience patent portfolio included five Patent Cooperation Treaty (&#8220;PCT&#8221;) applications not yet in national phase, 13 U.S. utility applications, 16 issued U.S. utility patents, 76 pending non-U.S. utility applications, 24 allowed or granted non-U.S. patents (including four in Japan), one pending U.S. design patent application, and 39 allowed or registered design patents (including two in Japan). Thirteen U.S. utility patents, directed to our proprietary sublingual film formulation of Dex and methods of treating agitation, are listed in the&#160;FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the &#8220;Orange Book&#8221;) for IGALMI</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> with expiration dates between 2037 and 2043. In the formulation family, we have granted or allowed patents in China, Europe, Eurasia, Japan, Mexico, and the U.S., and pending applications in the U.S., China, and other major markets. We expect that patents issued in this family will expire no earlier than 2039. We have also filed applications in additional patent families that are relevant to BXCL501. We have one granted European patent and applications pending in the U.S. and Japan directed to methods of treating insomnia using sublingual Dex. We expect that patents issued from these applications, will expire no earlier than 2035. We also have granted patents and pending applications filed in major markets, including the U.S., Europe, Japan, and China, directed to methods of treating agitation. We expect that patents issued from these applications, will expire between 2039 and 2043. We also have four PCT applications directed to treating mania, depression, stress and agitation. If patents are issued from those cases, we expect them to expire in 2043 or 2044. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">In August 2024, the Company received a Notice of Allowance from the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) for U.S. Patent Application No. 18/600,431 (the &#8220;&#8217;431 Application&#8221;). The &#8217;431 Application claims methods of treating agitation using an oromucosal formulation of dexmedetomidine. The &#8216;431 Application issued as U.S. Patent No. 12,138,247 (the &#8216;247 Patent) patent, issued on November 2024, and is expected to expire no earlier than January 12, 2043. The &#8217;247 Patent is listed in the Orange Book for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">The term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most countries, including the U.S., the patent term is 20 years from the earliest filing date of a non-provisional patent application. Depending upon the timing, duration, and specifics of FDA approval of our product candidates, a U.S. patent that we own or license may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (a.k.a., the &#8220;Hatch-Waxman Act&#8221;). The act permits a patent restoration term of up to five years as compensation for patent term lost during product development and the drug approval regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND, and the submission date of a new drug application (&#8220;NDA&#8221;), plus the time between the submission date of an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension, and the application for extension must be made prior to patent expiration. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of clinical trials and other factors involved in the submission of the relevant NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">The term of a patent can also be extended by PTA established in 35 U.S.C. 154(b). The intention of the PTA is to accommodate for delays caused by the USPTO during the prosecution of a US utility or plant patent application. Under PTA, the USPTO delay is divided into three types: type A (delays after 14 months from the filing date of the application until the USPTO issues a first Office Action and delays after four months from the filing of certain actions by the applicant until the USPTO responds to such actions); type B (delays after three years from the earliest effective filing date until a patent is granted); and type C (delays due to interferences, secrecy orders, and successful appeals). The total amount of PTA is calculated by adding the types A, B, and C delays, and then subtracting any delay that is overlapped among three types or that is attributable to the applicant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">The term of a patent can also be shortened by a terminal disclaimer. A terminal disclaimer is a statement filed by a patent owner in which the owner disclaims or dedicates to the public the terminal part of the term of a patent. Often, the terminal disclaimer is filed in cases where at least one claim of a pending application would have been obvious in light of at least one claim in an earlier-filed patent, (or non-statutory obviousness-type double patenting rejection).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The patent positions of companies such as ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of method of use patents or reformulation patents has emerged in the U.S. patent laws and their interpretation outside of the U.S. are also uncertain. Changes in either the patent laws or their interpretation in the U.S. and other countries may diminish our ability to protect our technology or product candidates and enforce the patent rights that we license, and also could affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell, or importing products that infringe our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our technology, inventions, and improvements. With respect to both licensed and company owned intellectual property, we cannot guarantee that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may file in the future, nor can we be sure that any patents that may be granted to us in the future will be commercially useful in protecting our products, the methods of use, or the manufacture of those products. In addition, if a pending patent application is granted, it is possible that only a subset of the claims that are currently contained in the pending patent application will be issued. Further, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Patent and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology, and the issued patents that we in-license and those that may issue in the future may be challenged, invalidated, or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for our product candidates. In addition, the scope of the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies outside the scope of the rights granted under any issued patents that we own or exclusively in license. For these reasons, we may face competition with respect to our product candidates. Moreover, because of the extensive time required for development, testing, and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized, any patent protection for such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides. For additional information regarding intellectual property regulations and risks, see below under &#8220;Immuno-Oncology Intellectual Property&#8221; and Part I, Item 1A, &#8220;Risk Factors - Risks Related to Our Intellectual Property.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Immuno-Oncology</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April 19, 2022, we announced the formation of a wholly owned subsidiary, OnkosXcel to develop potentially transformative medicines in oncology. OnkosXcel uses proprietary AI capabilities to drive the capital-efficient development of innovative anti-cancer therapeutics. On March 14, 2023, we announced that OnkosXcel had confidentially submitted a draft registration statement on Form S-1 with the SEC relating to the proposed initial public offering of its common stock following its conversion into a corporation. The Company is continuing to evaluate strategic options for OnkosXcel. With the Company&#8217;s Reprioritization announcement on August 14, 2023, further work on the immuno-oncology programs described below has generally been paused, except as noted below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our approach to drug discovery leverages the application and methodology of our proprietary AI-based research and development platform, complemented by EvolverAI, utilized in the successful development of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> with the aim of efficiently identifying and developing immuno-oncology product candidates. We believe that BXCL701 reflects the potential of this discovery approach in immuno-oncology. BXCL701 is an investigational, oral innate immune activator which demonstrated a 25% composite response rate in a Phase 2a clinical trial to treat patients with small cell neuroendocrine carcinoma (&#8220;SCNC&#8221;) phenotype metastatic castration-resistant prostate cancer (&#8220;mCRPC&#8221;). On February 12, 2024, the Company announced that the FDA has designated as a Fast Track development program the investigation of BXCL701 in combination with a checkpoint inhibitor for the treatment of patients with metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability. We have finalized a potential </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">registrational trial design in mCRPC patients with SCNC phenotype, however in light of our Clinical Prioritization, we have not met with the FDA to discuss this, nor plan at the current time to initiate this trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">mCRPC is often characterized as a &#8220;cold&#8221; tumor, which is a tumor with an immunosuppressive tumor microenvironment (&#8220;TME&#8221;) and poor immune cell infiltration. Currently approved checkpoint inhibitors (&#8220;CPIs&#8221;) that target programmed cell death 1 (&#8220;PD-1&#8221;) or cytotoxic T-lymphocyte-associated protein 4 (&#8220;CTLA-4") have failed to demonstrate meaningful single-agent activity against such difficult-to-treat tumor types, including mCRPC. BXCL701 is designed to promote an immune-induced inflammatory response in the TME primarily via inhibition of dipeptidyl peptidases (&#8220;DPP&#8221;) 8 and 9, which we believe can provide enhanced CPIs therapeutic utility. We believe BXCL701 can potentially provide significant benefits for the approximately 20% of the estimated 299,010 men who will be diagnosed with prostate cancer in the U.S. in 2024 and are expected to progress to the more aggressive mCRPC form of the disease, including approximately 20%, or 11,960, of those patients who will develop the SCNC phenotype, for which there are currently limited treatment options. Immune checkpoints represent a myriad of inhibitory pathways that act to regulate the duration and intensity of an antigen-induced immune response and factor prominently in mediating immune tolerance. They function as critical gatekeepers that prevent the indiscriminate attack of normal host cells by components of the immune system. Certain cancers co-opt these pathways and overexpress immune checkpoint molecules to camouflage themselves to avoid detection and destruction. CPIs, designed to harness the intrinsic power resident in the immune system, work by disabling the suppressive function of immune checkpoints, allowing the immune system to bypass such cancers&#8217; shield of immune tolerance. CPIs are expected to generate sales of more than $50 billion worldwide by 2025, up from sales of approximately $29 billion in 2020. While CPIs have proven to be a significant advancement in cancer therapy, those currently approved by the FDA do not produce meaningful results in a majority of patients, as the clinical benefit is generally viewed to be limited to between 13% and 30% of cancer patients, and the duration of response is relatively short.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe the limited efficacy of approved CPIs results primarily from their intervention at later stages of the immune response. As a result, other targets and pathways can be exploited by the tumor to create a TME that can evade the enhanced immunological response enabled by approved CPIs. While numerous agents designed to target the earlier stages of an immune response are in development for use in combination with CPIs, their activity is restricted to a single component of the immune response. In contrast, we have developed BXCL701 to simultaneously address multiple components of the immune response, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Cancer antigen presentation by dendritic cells</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: stimulation of dendritic cell trafficking to tumor draining lymph nodes.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Priming and activation of T cells</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: acceleration of tumor-induced priming of T cells and the formation of potent cytotoxic T lymphocytes (&#8220;CTLs&#8221;).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Infiltration of immune cells into the tumor</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: stimulation of release of chemokines that attract effector T cells but block regulatory T cells, and also induce NK cell and neutrophil migration.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Killing of tumor cells</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: induction of formation of CTLs and NK cells expressing tumor-killing perforins and granzymes, as well as the formation of memory T cells that can selectively kill returning tumor cells.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Accordingly, we believe BXCL701 may have utility in stimulating increased activation, proliferation, and infiltration of tumor cells by immune effector cells, enabling its potential application in combination with currently approved CPIs, across a range of solid tumors and hematological malignancies, to potentially:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Convert immunological cold tumors into ones sensitive to CPIs;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Enhance hot tumors&#8217; response rate and depth of response to CPIs; and</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Restore CPI sensitivity to tumors that were previously responsive.</i></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Central to our drug discovery initiatives are proprietary, AI-driven platform technologies we employ to identify novel therapeutic uses for approved therapeutics and candidates in clinical evaluation. The first and most advanced of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:210pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">our AI-driven discovery programs is our innate immune modulation program, which supported the pursuit of BXCL701 as a development candidate. We believe the application of this program provides us actionable insights into the inflammasome, a component of the innate immune system responsible for activation of the inflammatory response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Immuno-Oncology Programs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Below is a summary of the status of our immuno-oncology clinical development programs as of the date of this Annual Report on Form 10-K. We believe our product candidates, if successfully developed and approved, have the potential to become compelling treatment options for their respective indications. With our Reprioritization announced on August 14, 2023, further work on our immuno-oncology program has been paused, other than as noted below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="btai-20241231x10k003.jpg" alt="Graphic" style="display:inline-block;height:209.8pt;left:0%;padding-bottom:0.2pt;position:relative;top:0pt;width:481pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Immuno-Oncology Clinical Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Leveraging the insights enabled by the application and methodology of our proprietary AI-based platform complemented by EvolverAI, which was used to identify novel therapeutic uses for our approved therapeutics and product candidates in clinical evaluation, and our industry expertise, we are pursuing two proprietary discovery programs to advance our goal of developing anti-cancer therapeutics. The first program, which encompasses BXCL701 across a range of indications, is based on the application of innate immune modulation technology. This program has been constructed to embrace key distinguishing characteristics of the innate immune system and we believe it is supported by our development efforts. This approach has driven the development of BXCL701, which we are currently evaluating in a Phase 1b/2a clinical proof-of-concept trial as a potential treatment for mCRPC with either SCNC or adenocarcinoma phenotype. Fundamental to the innate immune modulation program is BXCL701&#8217;s potential to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Convert cold tumors into ones sensitive to CPIs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Enhance hot tumors&#8217; response rate and depth of response to CPIs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Restore CPI sensitivity to tumors which had previously been responsive.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BXCL701 as a Potential Treatment for mCRPC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Prostate cancer is the most common malignancy and the second-leading cause of cancer-related deaths in men in the U.S. According to the American Cancer Society, approximately 299,010 men will be diagnosed with, and 35,250 men will die of, prostate cancer in 2024. The majority of these cases are classified as adenocarcinomas and involve low risk, localized or regional disease for which the five-year survival rate ranges from 60% to 99%. However, an estimated 20% </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">of these newly diagnosed cases will progress to the more aggressive metastatic disease. The five-year survival rate for men with metastatic prostate cancer drops significantly, to approximately 30%. Approximately 20% of patients with mCRPC will develop the SCNC phenotype, which is characterized by poor prognosis and low survival rate with a five-year life expectancy of 14%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;">Prostate function requires the presence of various androgens, such as testosterone. Early cancerous prostate cells typically also require androgens to proliferate. Accordingly, aggressive forms of prostate cancer can initially be treated using androgen deprivation therapy (&#8220;ADT&#8221;). While ADT offers temporary therapeutic benefit, in almost all patients the treatment eventually loses efficacy, referred to as &#8220;castration resistance.&#8221; Cases of castration-resistant prostate cancer (&#8220;CRPC&#8221;) are generally treated with a second-generation androgen receptor (&#8220;AR&#8221;) inhibitor, such as XTANDI</span><sup style="font-family:'Symbol';font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">&#226;</sup><span style="font-size:10pt;"> (enzalutamide), or an androgen synthesis inhibitor, such as ZYTIGA</span><sup style="font-family:'Symbol';font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">&#226;</sup><span style="font-size:10pt;"> (abiraterone), which targets the enzyme CYP17 to block the production of testosterone. These therapeutics have widely become the standard of care, though only ZYTIGA has been approved to treat mCRPC, as well as metastatic high-risk castration-sensitive prostate cancer. XTANDI has been approved to treat CRPC and metastatic castration-sensitive prostate cancer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;">Virtually all patients who initially respond to ZYTIGA and XTANDI are expected to progress to even more aggressive forms of prostate cancer requiring further treatment. Patients whose disease has progressed after treatment with these second-generation targeted endocrine therapies are administered a docetaxel containing drug regimen that provides a survival benefit of only 10 months. The poly-ADP ribose polymerase (&#8220;PARP&#8221;) inhibitors LYNPARZA</span><sup style="font-family:'Symbol';font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">&#226;</sup><span style="font-size:10pt;"> (olaparib) and RUBRACA</span><sup style="font-family:'Symbol';font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">&#226;</sup><span style="font-size:10pt;"> (rucaparib) are approved for the treatment of mCRPC in patients whose disease has progressed after receiving XTANDI or ZYTIGA, but their approval is limited to instances of mCRPC linked to a BRCA gene mutation. As such, an unmet medical need remains for patients with mCRPC who are not eligible for PARP inhibitor treatment after treatment with the targeted endocrine therapy and docetaxel.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, a number of men, both newly diagnosed patients and men whose disease has progressed after second-generation targeted endocrine therapy, will develop an aggressive tumor that typically expresses very little AR and accordingly does not respond to therapeutics targeting the AR signaling pathway. Prostate cancer with this phenotype is referred to as SCNC, for which there is currently no effective treatment. The incidence of SCNC is increasing with the widespread use of AR inhibitor therapy. Treatment protocols for patients with SCNC typically involve cytotoxic chemotherapies despite their short duration of response and considerable toxicities. These patients represent an additional unmet medical need among men with prostate cancer. We believe BXCL701 may prove efficacious in addressing the unmet needs of both adenocarcinoma and SCNC prostate cancer phenotypes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">mCRPC is often characterized as a cold tumor, or a tumor with an immunosuppressive TME and poor immune cell infiltration. Currently approved CPIs, which target PD-1 and CTLA-4, have not demonstrated significant single-agent therapeutic activity. For instance, a Phase 2 investigator sponsored trial (&#8220;IST&#8221;) to assess the efficacy of the PD-L1 inhibitor avelumab, marketed by EMD Serono and Pfizer as BAVENCIO<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup><sup style="font-family:'Symbol';font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#226;</sup>, to treat mCRPC with SCNC phenotype, as well as aggressive variant prostate cancer with adenocarcinoma histology, generated an ORR of 6.7% (representing 1 of 15 patients who was known to be microsatellite instability-high, an established marker of response to CPIs).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe the limited efficacy of CPIs results primarily from their intervention at later stages of the immune response. As a result, other targets and pathways can be exploited by the tumor to create a TME that can evade the enhanced immunological response enabled by approved CPIs. BXCL701 is designed to act on multiple components of immune system functioning, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Cancer antigen presentation by dendritic cells</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: stimulation of dendritic cell trafficking to tumor draining lymph nodes.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Priming and activation of T cells</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: acceleration of tumor-induced priming of T cells and the formation of potent CTLs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Infiltration of immune cells into the tumor</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: stimulation of release of chemokines that attract effector T cells but block regulatory T cells and also induce NK cell and neutrophil migration.</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:273.65pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Killing of tumor cells</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: induction of formation of CTLs and NK cells expressing tumor-killing perforins and granzymes as well as the formation of memory T cells that can selectively kill returning tumor cells.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We believe BXCL701 may have utility in stimulating increased activation, proliferation, and infiltration of tumor cells by immune effector cells, enabling its potential use in combination with currently approved CPIs to treat cold tumors, such as mCRPC. We elected to pursue mCRPC as an indication for BXCL701 due to its enrichment for DPP mutations, which are especially prevalent in tumors with SCNC phenotype.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">BXCL701 has been evaluated in a Phase 1b/2a clinical proof-of-concept trial that we sponsored to investigate its potential efficacy when used in combination with pembrolizumab. Enrollment in this trial is complete, and the data are described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We received initial comments from the FDA on our proposed clinical development plan and received feedback regarding dose-optimization for use in future studies. However, the start of any such additional trial is paused following the Company&#8217;s Reprioritization. The Phase 1b portion of our Phase 1b/2 clinical trial was a dose escalation safety lead-in which employed a standard 3 x 3 trial design to determine the recommended Phase 2 dose (&#8220;RP2D&#8221;). During each 21-day treatment cycle, 200 mg of pembrolizumab were administered intravenously on day one, with BXCL701 taken twice daily on days one through 14, for a minimum of two cycles. The results of this Phase 1b trial, which were presented at The Society for Immunotherapy of Cancer&#8217;s 35th Anniversary Annual Meeting, allowed us to identify 0.3 mg, taken twice daily, as the RP2D.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="btai-20241231x10k004.jpg" alt="Graphic" style="display:inline-block;height:273.65pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Phase 2a portion of the trial was segregated into two 28-patient trial cohorts, one cohort consisting of mCRPC patients with SCNC phenotype and a second cohort consisting of mCRPC patients with adenocarcinoma phenotype. Initially, we focused on mCRPC with SCNC phenotype as the primary patient population for BXCL701, since DPP9 is amplified in approximately 17% of treatment-emergent mCRPC with SCNC phenotype, compared to 5% or less in the broader prostate cancer population. However, we also observed responses in mCRPC patients with adenocarcinoma phenotype who were microsatellite stable in the Phase 1b portion of the trial. On this basis, we widened our Phase 2a trial to include relapsed mCRPC patients with either SCNC or adenocarcinoma phenotype. Both cohorts employed a Simon two-stage trial design of 15 trial participants followed by 13 additional patients. The primary endpoint of the Phase 2a portion of this trial was a composite response rate, determined as either a RECIST 1.1 response (defined as a </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:264.65pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">reduction in RECIST score of 30% or more), and/or a reduction in prostate specific antigen (&#8220;PSA&#8221;) level of 50% or more, and/or a conversion in circulating tumor cells (&#8220;CTCs&#8221;) from 5 or more CTCs/7.5 milliliter (&#8220;ml&#8221;) to less than 5 CTCs/7.5 ml. Secondary endpoints included duration of response, progression-free survival, overall survival, changes in circulating cytokines, and certain disease-specific biomarkers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe the results observed in the Phase 2a trial of BXCL701 administered in combination with pembrolizumab support further development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We were particularly encouraged by the results observed in the cohort consisting of mCRPC patients with SCNC phenotype. Updated Phase 2a results for the SCNC cohort were presented at the 30<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Annual Prostate Cancer Foundation Scientific Retreat (PCF 2023). BXCL701 in combination with pembrolizumab demonstrated a 25% (seven out of 28 evaluable patients) composite response rate in mCRPC patients with SCNC phenotype, for whom there is no standard of care. As of a data cutoff of September 6, 2023, five of these responders were RECIST 1.1 responders (four confirmed responses and one unconfirmed response) with decreases in tumor size ranging from -45% to -67% and a median duration of response of 7.6 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="btai-20241231x10k005.jpg" alt="Graphic" style="display:inline-block;height:264.65pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">AEs consistent with cytokine activation, including fever, nausea, chills, fatigue, headache, and dizziness were observed during the trial and were generally mild to moderate. SAEs experienced by six trial participants - one patient hospitalized with Grade 1 orthostatic hypotension, one patient hospitalized with Grade 3 hypotension and acute kidney injury (&#8220;AKI&#8221;), which resolved, one patient with Grade 3 hypothyroidism which resolved, one patient with Grade 3 colitis, one patient with Grade 3 generalized oedema, and one patient hospitalized with Grade 4/5 tumor lysis syndrome/AKI, which resulted in fatality after the patient voluntarily discontinued dialysis - were reported as related or possibly related to BXCL701 or pembrolizumab, though there was no evidence that BXCL701 potentiated immune-related AEs associated with CPIs. The table below summarizes treatment-related AEs observed in the SCNC cohort as of December 19, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:260.15pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="btai-20241231x10k006.jpg" alt="Graphic" style="display:inline-block;height:260.15pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On October 10, 2023, we reported positive overall survival (OS) results from the Phase 2a portion of the trial in SCNC patients. BXCL701 in combination with pembrolizumab demonstrated a compelling median OS and 12-month survival rate. As of a data cutoff of September 6, 2023, evaluable patients with SCNC (n = 28) showed a median OS of 13.6 months (95% CI 10.9&#8211;NR), and a 12-month survival rate of 56.5%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On February 12, 2024 the Company announced that the FDA designated as a Fast Track development program the investigation of BXCL701 in combination with a checkpoint inhibitor for treatment of patients with metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Phase 2a trial has also been completed for the adenocarcinoma cohort. Updated results for this trial cohort were also presented at PCF 2023. BXCL701 in combination with pembrolizumab demonstrated a 21% (six out of 29 evaluable patients) composite response rate in mCRPC patients with adenocarcinoma phenotype, for whom there are limited treatment options. As of a cutoff date of September 6, 2023, five of these composite responders were RECIST 1.1 responders (four confirmed responses and one unconfirmed response) with decreases in tumor size ranging from -30% to -99% and a median duration of response to 19 months.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:269.2pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="btai-20241231x10k007.jpg" alt="Graphic" style="display:inline-block;height:269.2pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of the cutoff date of December 19, 2022, the majority of AEs experienced by patients in the adenocarcinoma cohort were low grade. AEs consistent with cytokine activation were observed, including fever, myalgia, nausea, chills, fatigue, dyspnea, headache and dizziness. SAEs experienced by five patients (12%) were reported as possibly related to BXCL701 or pembrolizumab: two reports of hypotension; one report of dizziness; one report of peripheral edema; one report of pyrexia; one report of Myasthenia Gravis; and one report of Cytokine Release Syndrome. Two patients (5%) discontinued therapy due to AEs. There was no evidence that BXCL701 potentiated immune-related AEs related to CPIs. The table below summarizes treatment-related AEs observed in the adenocarcinoma cohort.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:283.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="btai-20241231x10k008.jpg" alt="Graphic" style="display:inline-block;height:283.05pt;left:0%;padding-bottom:0.45pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On November 8, 2023, we reported positive OS results from the Phase 2a portion of the trial in patients with adenocarcinoma. As of a data cutoff of September 6, 2023, among evaluable patients with adenocarcinoma (n = 29) BXCL701 in combination with pembrolizumab demonstrated a median OS of 15.5 months (95% CI 9.6&#8211;NR), and a 12-month survival rate of 59.3%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BXCL701 as a Potential Treatment for Small Cell Lung Cancer (&#8220;SCLC&#8221;)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The American Cancer Society estimates that in 2024, about 35,187 cases of SCLC will be diagnosed in the U.S. Approximately 60-70% of these patients present with extensive disease, and first-line therapy for a majority of these patients involves the combination of a CPI with platinum-based chemotherapy or etoposide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We are encouraged by the therapeutic potential of BXCL701 for SCLC given the activity it has demonstrated in the ongoing SCNC clinical trial. We are preparing the protocol for a Phase 1b/2 trial design to be a dose-escalation safety lead-in to establish a RP2D. However, the start of any such trial is paused following the Reprioritization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BXCL701 as a Potential Treatment for Other Cancers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition to its potential use in combination with CPIs to treat mCRPC, an immunologically cold tumor, we are developing BXCL701 as a therapeutic for pancreatic cancer, and other solid tumors with greater, or &#8220;non-cold,&#8221; immunological activity that are nonetheless regarded as difficult-to-treat, and hematological malignancies. We believe the synergistic potential of BXCL701 and CPIs, when administered in combination, could increase cancer cell susceptibility to an enhanced immune response, potentially increasing the clinical benefit of CPIs, whose single-agent efficacy in treating these tumor types is generally viewed to be limited to between 13% and 30% of cancer patients and the duration of response to treatment is often short. As such, we envision the potential therapeutic benefit of BXCL701 increasing the sensitivity of cold tumors to CPI therapy, enabling the potential treatment of a range of cancers including pancreatic cancer, breast cancer, colorectal cancer, and ovarian cancer, as well as enhancing the depth of response to CPIs in other cancers. In addition, based on the preclinical observation that BXCL701 showed direct cytotoxic activity </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">against certain leukemic cells, we have initiated clinical development targeting relapsed or refractory acute myeloid leukemia (&#8220;AML&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pancreatic Cancer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The American Cancer Society estimated that in 2024, approximately 66,440 cases of pancreatic cancer were expected to be diagnosed in the U.S. We are supporting a Phase 2 investigator-sponsored trial (&#8220;IST&#8221;) sponsored by Georgetown Lombardi Comprehensive Cancer Center (&#8220;Georgetown Lombardi&#8221;), designed to evaluate the use of BXCL701 along with pembrolizumab to treat pancreatic cancer. Few therapeutic options are available for patients with this disease, which has a five-year survival rate of less than 10%, among the lowest of all cancers. Pancreatic cancer has among the highest levels of overexpression and amplification of DPPs. Preclinical models demonstrated synergy between DPP inhibition with BXCL701 and anti-PD-1 antibody in the pancreatic cancer tumor microenvironment. Based on these preclinical observations, Georgetown Lombardi has initiated a Phase 2 IST to assess the safety of BXCL701 when administered in combination with pembrolizumab (safety lead-in), as well as to estimate the 18-week progression-free survival rate (primary objective of the efficacy phase) in previously treated metastatic pancreatic ductal adenocarcinoma. This trial started in the third quarter of 2023. On February 6, 2024, we announced the completion of patient enrollment in the safety lead-in portion of the trial. As part of the trial&#8217;s safety lead-in, the first six patients have been enrolled and will be observed for a six-week safety window period. The trial is then expected to enroll approximately 39 patients in its efficacy phase in a Simon 2-stage single-arm, open-label design (19 patients in stage 1 and 20 patients in stage 2). Patients will be monitored radiographically and by tumor markers for response assessment. Tumor biopsies and blood samples will also be collected over the course of treatment to better understand the potential mechanism of action for the combination. The human proof of concept portion of the trial started in the first half of 2024. On April 24, 2024, we announced that an abstract entitled &#8220;Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC): Preliminary findings,&#8221; was selected for presentation at the poster session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting that took place in Chicago, Illinois from May 31 to June 4, 2024. Investigators reported that, as of the applicable cutoff date, one patient was progression-free at 18 weeks, three patients showed substantial reductions in serum CA19-9, a tumor marker that may correlate with increased T-cell infiltration, and one patient showed a best response of partial responses, out of six patients that had been treated with the combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Relapsed or Refractory AML</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The American Cancer Society estimated that in 2024, approximately 20,800 new cases of AML were expected to be diagnosed in the U.S. We are supporting a Phase 1b IST sponsored by the Dana-Farber Cancer Institute (&#8220;Dana-Farber&#8221;) designed to evaluate the use of BXCL701, along with the current standard of care to treat relapsed or refractory AML. We believe that pyroptosis triggered by BXCL701 may provide potent single agent cytotoxicity directed towards AML. We also believe that DPP9 copy number may provide an actionable biomarker, as high copy number has been observed to correlate with BXCL701 toxicity in human AML cell lines. DPP8/9 inhibition has been shown to be cytotoxic to THP-1 cells, monocytic cancer cells cultured from a patient with AML, but not other cell lines, suggesting a specific vulnerability of AML to these inhibitors which we believe can be exploited for therapeutic benefit. Based on these preclinical observations, Dana-Farber has initiated a Phase 1b trial to assess the safety of BXCL701 and to determine the maximum tolerated dose or the RP2D of BXCL701 as a single agent. This trial started in the first quarter of 2023. Subject to successful completion of this Phase 1b trial, we anticipate that Dana-Farber will conduct further studies to determine BXCL701's objective response rate in AML in combination with the standard of care.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Potential Anti-cancer Programs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We collaborated with the University of Texas MD Anderson Cancer Center in a Phase 2a IST to evaluate the potential efficacy of BXCL701 administered in combination with pembrolizumab in patients with advanced solid cancer. The design of this open label trial included two cohorts and incorporated a two-stage configuration, which allowed for an expansion of patient enrollment to a total of 17 patients in each cohort if a RECIST 1.1 complete response or partial response was observed in at least one of the initial nine patients. The first cohort enrolled patients who previously had not received CPI therapy, with a second cohort consisting of patients that were either refractory to CPI therapy or had relapsed while on CPI therapy, meaning that no further response to CPI treatment is anticipated among patients in the second cohort. Trial participants received 200 mg of pembrolizumab on day 1 of a 21-day cycle, with 0.2 mg of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">BXCL701 administered twice-daily (&#8220;BID&#8221;) on days 1 through 7 during the first cycle, the dose increasing to 0.3 mg BID on Days 8 through 14 during the first and the subsequent cycles. Evaluable trial participants were required to receive a minimum of two treatment cycles. A preliminary assessment of BXCL701 dosed in combination with a CPI, as of completion of the first stage, noted responses in one patient in each of the CPI na&#239;ve and CPI refractory/relapsed cohorts, including a partial response in CPI-na&#239;ve, microsatellite stable endometrial carcinoma, PD-L1 negative (CPS &lt;1) and a partial response in CPI-refractory uveal melanoma. These preliminary results were presented at the 2021 American Society of Clinical Oncology annual meeting (ASCO 2021). Patient enrollment in this trial was completed in the third quarter of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe BXCL701 may have potential application in breast cancer, as its use in combination with monoclonal antibody therapy generated encouraging in vivo data in a preclinical disease model where enhanced antibody-dependent cellular cytotoxicity was observed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The FDA has granted BXCL701 orphan drug designation for the treatment of AML, stage IIb to IV melanoma, pancreatic cancer, and soft tissue sarcoma. As we consider BXCL701&#8217;s therapeutic potential for additional indications that represent unmet medical needs, we intend to apply for additional orphan drug designations for BXCL701.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Biomarker Development Initiatives Intended to Complement BXCL701 Administration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We are also actively engaged in the identification and development of predictive biomarkers that we believe could be used in conjunction with BXCL701 to predict the likelihood of patient response to therapy across the range of targeted indications. Based on preliminary data from AML patients, we believe DPP9 copy number could correlate to BXCL701 response rate, with a greater likelihood of BXCL701 cytotoxicity in patients with increased DPP9 copy number. We are pursuing its use in our biomarker discovery activities as a potential companion diagnostic. At the Society for Immunotherapy of Cancer&#8217;s 38<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Annual Meeting (SITC 2023), we presented data from the Phase 2a trial in SCNC patients, which indicated DPP9 overexpression is a potential response-predictive biomarker of BXCL701 and pembrolizumab combination treatment in mCRPC patients with SCNC phenotype.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Immuno-Oncology Manufacturing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We rely on third party contract manufacturing organizations to support development and manufacture of product candidates for our clinical trials, and, if any of our current or future product candidates receives marketing approval, we expect to rely on such manufacturers to meet commercial demand. We expect this strategy will enable us to maintain a more efficient infrastructure, avoiding dependence on our own manufacturing facility and equipment, while simultaneously enabling us to focus our expertise on the clinical development and future commercialization of our products. Drug substance is produced by Aptuit (Oxford) Ltd, an Evotec Company, and drug product by Pharma Services (Patheon) by Thermo Fisher Scientific. We expect to enter into commercial supply agreements with these manufacturers prior to any potential approval of BXCL701.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BXCL701 drug product is manufactured via conventional pharmaceutical processing procedures, employing commercially available excipients and packaging materials. The procedure and equipment employed for manufacture and analysis are consistent with standard organic synthesis or pharmaceutical production, and are transferable to a range of manufacturing facilities, if needed. We have selected a larger third-party drug product manufacturer and will be executing technology transfer of drug product manufacture to a larger manufacturer. We also plan to maintain the current drug substance and product manufacturer as part of our supply chain strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Immuno-Oncology Competition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The biotechnology and pharmaceutical industries have made substantial investments in recent years into the rapid development of novel immunotherapies for the treatment of a range of pathologies, including infectious diseases and cancers, making this a highly competitive market. We believe BXCL701 is the only innate immune system activator in clinical development specifically addressing the cold tumor problem in immuno-oncology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We face substantial competition from multiple sources, including large and specialty pharmaceutical, biopharmaceutical and biotechnology companies, academic research institutions and governmental agencies, and public </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">and private research institutions. Our competitors compete with us on the level of the technologies employed, or on the level of development of product candidates. In addition, many small biotechnology companies have formed collaborations with large, established companies to (i) obtain support for their research, development, and commercialization of products or (ii) combine several treatment approaches to develop longer lasting or more efficacious treatments that may potentially directly compete with our current or future product candidates. We anticipate that we will continue to face increasing competition as new therapies and combinations thereof, technologies, and data emerge within the field of immunotherapy and, furthermore, within the treatment of infectious diseases and cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition to the current standard of care treatments for patients with infectious diseases or cancers, numerous commercial and academic preclinical studies and clinical trials are being undertaken by a large number of parties to assess novel technologies and product candidates in the field of immunotherapy. Results from these studies and trials have fueled increasing levels of interest in the field of immunotherapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Large pharmaceutical companies that have commercialized or are developing immunotherapies to treat cancer include AstraZeneca AB, Bristol-Myers Squibb Company, Merck &amp; Co., Inc., Novartis AG, Pfizer Inc., and F. Hoffmann-La Roche Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We face significant competition from pharmaceutical and biotechnology companies that target specific tumor-associated antigens using immune cells or other cytotoxic modalities. These generally include immune cell redirecting therapeutics such as T cell engagers, adoptive cellular therapies such as CAR-Ts, antibody drug conjugates, targeted radiopharmaceuticals, targeted immunotoxin, and targeted cancer vaccines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Clinical stage companies that compete with us directly on the level of the development of product candidates targeting the innate immune system include Amgen Inc., Mirati Therapeutics, Inc., Bristol- Myers Squibb Company, Ryvu Therapeutics, Merck &amp; Co., Inc., Replimune Group Inc., Nektar Therapeutics, Novartis AG, Xbiotech Inc., Stingthera, Inc., AstraZeneca AB, F. Hoffmann-La Roche Ltd and Aravive, Inc. Clinical stage companies that compete with us directly on the level of the development of product candidates targeting the mCRPC include Astellas Pharma Inc., Pfizer Inc., Bayer AG, Janssen, Sanofi S.A., Clovis Oncology, Inc., AstraZeneca AB, Merck &amp; Co., Inc., GSK plc, Tempest Therapeutics, Inc., Zenith Epigenetics Ltd. and Gossamer Bio, Inc. Clinical stage companies that compete with us directly on the level of the development of product candidates utilizing the therapeutic potential of synthetic lethality include Repare Therapeutics Inc., IDEAYA Biosciences, Inc. and Tango Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Many of our competitors, either alone or in combination with their respective strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, the regulatory approval process, and marketing than we do. Mergers and acquisition activity in the pharmaceutical, biopharmaceutical and biotechnology sector is likely to result in greater resource concentration among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through sizeable collaborative arrangements with established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our commercial opportunity could be reduced or eliminated if one or more of our competitors develop and commercialize products that are safer, more effective, better tolerated, or of greater convenience or economic benefit than our proposed product offerings. Our competitors also may be in a position to obtain FDA or other regulatory approval for their products more rapidly, resulting in a stronger or dominant market position before we are able to enter the market. The key competitive factors affecting the success of all of our programs are likely to be product safety, efficacy, convenience and treatment cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Immuno-Oncology Intellectual Property</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Intellectual property is of vital importance in our field and in biotechnology generally. We seek to protect and enhance proprietary technology, inventions, and improvements that are commercially important to the development of our business by seeking, maintaining, enforcing, and defending patent and other intellectual property rights, whether developed internally or licensed from third parties. We will also seek to rely on regulatory protection afforded through </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">inclusion in expedited development and review, data exclusivity, market exclusivity, and patent term extensions where available. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">As of February 20, 2025, we have multiple patent families filed to protect our immuno-oncology program, including our core patent family directed to methods of using BXCL701 with immune checkpoint inhibitors, which is granted in the U.S., Japan, Australia, Canada, Russia, China, India, Taiwan, South Africa, Mexico, New Zealand, Europe and United Arab Emirates.  Additional applications in this family are pending in major markets. Patents issued from this family are expected to expire no earlier than 2036. We have an additional patent issued in the U.S. directed to a method of selecting patients based on a biomarker and methods of treating certain cancers, with an expected expiration date no earlier than 2039.  A corresponding European Patent case directed to selecting patients is issued and is expected to expire no earlier than 2039.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Additional applications are directed to administering BXCL701 in combination with various other molecules, biomarkers, and dosing regimens. We also have three PCT applications directed to novel formulations of BXCL701, various dosing regimens, methods of use, combination therapies, and to methods of treating small cell lung cancer. We expect that any patents issuing from the PCT and provisional applications will expire no earlier than 2043 to 2044.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We expect to file additional patent applications in support of current and new immuno-oncology clinical candidates as well as new platform and core technologies. For additional information regarding intellectual property regulations and risks, see above under &#8220;&#8212;Neuroscience&#8212;Neuroscience Intellectual Property&#8221; and Part I, Item 1A, &#8220;Risk Factors - Risks Related to Our Intellectual Property.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Our Relationship with BioXcel LLC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March 21, 2025, BioXcel LLC holds an ownership interest of approximately 8.8% in the Company and our pipeline compounds were identified by applying our growing internal AI capabilities, along with BioXcel LLC&#8217;s EvolverAI, a proprietary pharmaceutical discovery and development engine, for drug re-innovation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We entered into the Amended and Restated Asset Contribution Agreement (the &#8220;Contribution Agreement&#8221;), pursuant to which BioXcel LLC, agreed to contribute BioXcel LLC&#8217;s rights, title and interest in BXCL501, BXCL701, BXCL502 and BXCL702, and all of the assets and liabilities associated in consideration for (i) 592,500 shares of our common stock, (ii) $1 million upon completion of an initial public offering, (iii) $500,000 upon the later of the 12-month anniversary of an initial public offering and the first dosing of a patient in the bridging bioavailability/bioequivalence study for the BXCL501 program, (iv) $500,000 upon the later of the 12 month anniversary of an initial public offering and the first dosing of a patient in the Phase 2 proof of concept open-label monotherapy or combination trial with Keytruda for the BXCL701 program and (v) a one-time payment of $5 million within 60 days after the achievement of $50 million in cumulative net sales of any product or combination of products resulting from the development and commercialization of any one of the contributed product candidates or a product derived therefrom. As of December 31, 2024, all of the foregoing have been paid except for (v).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We entered into a Separation and Shared Services Agreement with BioXcel LLC that took effect on June 30, 2017, as amended and restated thereafter (the &#8220;Services Agreement&#8221;), pursuant to which services provided by BioXcel LLC through its subsidiaries in India and the U.S. will continue indefinitely, as agreed upon by the parties. These services include certain intellectual property prosecution and management and research and development activities. The Company had an option, exercisable until December 31, 2024, to enter into a collaborative services agreement with BioXcel LLC pursuant to which BioXcel LLC shall perform product identification and related services for us utilizing EvolverAI, its proprietary pharmaceutical discovery and development engine. To maintain the ability to exercise the foregoing option, pursuant to an amendment to the Services Agreement effective as of April 19, 2022, the Company agreed to pay BioXcel LLC $18,000 per month from March 13, 2023 to December 31, 2024. This option was not exercised. However, BioXcel LLC continues to perform certain administrative services under the terms of the expired contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The parties were obligated to negotiate the collaborative services agreement in good faith and to incorporate reasonable market-based terms, including consideration for BioXcel LLC reflecting a low, single-digit royalty on net sales and reasonable development and commercialization milestone payments, provided that (i) development milestone </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">payments did not exceed $10 million in the aggregate and were not to be payable prior to proof of concept in humans and (ii) commercialization milestone payments were to be based on reaching annual net sales levels, were to be limited to 3% of the applicable net sales level, and were not exceed $30 million in the aggregate. However, subsequent to December 31, 2024 no development activity has been carried out by BioXcel LLC and none is contemplated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Service charges recorded under the Services Agreement were $1.3 million for each of the years ended December 31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Government Regulation and Product Approval</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Government authorities in the U.S., at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of drug products. A new drug must be approved by the FDA through the NDA process before it may be legally marketed in the U.S. We, along with any third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval of our products and product candidates. The process of obtaining regulatory approvals and the subsequent compliance with applicable U.S. federal, state, and local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">U.S. Drug Development Process</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In the U.S., the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), and its implementing regulations. The process required by the FDA before a drug may be marketed in the U.S. generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of preclinical laboratory tests, animal studies, and formulation studies in accordance with FDA&#8217;s Good Laboratory Practice requirements and other applicable regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent Institutional Review Board (&#8220;IRB&#8221;) or ethics committee at each clinical site before each clinical trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices (&#8220;GCPs&#8221;) to establish the safety and efficacy of the proposed drug for its intended use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparation of and submission to the FDA of an NDA after completion of all pivotal clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a determination by the FDA within 60 days of its receipt of an NDA to file the application for review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA advisory committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current Good Manufacturing Practice (&#8220;cGMP&#8221;) requirements to assure that the facilities, methods, and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity, and potential inspection of selected clinical investigation sites to assess compliance with GCPs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the NDA to permit commercial marketing of the product for specified indications for use in the U.S.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Prior to beginning the first clinical trial with a product candidate in the U.S., a sponsor must submit an IND to the FDA. An IND is a request for allowance from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before any clinical trials can begin. Submission of an IND may or may not result in FDA allowance to begin a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include among other things, the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. While the IND is active, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and its investigators for actual or suspected serious and adverse events, along with any findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs and findings from animal or in vitro testing suggesting a significant risk to humans, as well as any clinically important increased incidence of a suspected serious adverse reaction compared to that listed in the protocol or investigator brochure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether a study can move forward at designated check points, based on access to data from the study, and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other for other grounds, such as no demonstration of efficacy. The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1: The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 2: The product candidate is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule, and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 3: The product candidate is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product labeling.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be conducted after initial marketing approval and may be used to gain additional experience from the treatment of patients in the intended </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, during the development of a drug, sponsors are given opportunities to periodically meet with or seek feedback from the FDA. These interactions may be requested, for example, prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. These interactions can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach alignment on the next phase of development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">U.S. Review and Approval Process</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, including results from preclinical and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of the product, or from a number of alternative sources, including studies initiated by independent investigators. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once filed, the FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#8217;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act guidelines that are currently in effect, the FDA has a goal of ten months from the filing date to complete a standard review of an NDA for a drug that is a new molecular entity, and of ten months from the date of NDA receipt to complete a standard review of an NDA for a drug that is not a new molecular entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that review, evaluate and provide a recommendation as to whether the NDA should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities comply with cGMP and are adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCPs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">After the FDA evaluates an NDA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter (&#8220;CRL&#8221;). An approval letter authorizes commercial marketing and sale of the product with specific prescribing information for specific indications. A CRL usually describes the specific deficiencies in the NDA identified by the FDA </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">and may require additional clinical data, including additional clinical trials, or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a CRL is issued, the sponsor must resubmit the NDA or, address all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If regulatory approval of a product is granted, such approval will be granted for specific indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA with a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. The FDA may also require one or more post-market studies and additional surveillance programs to further assess and monitor the product&#8217;s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these post-marketing studies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, the Pediatric Research Equity Act (&#8220;PREA&#8221;), requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Expedited Development and Review Programs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">The FDA offers expedited development and review programs for qualifying product candidates. For example, the Fast Track program is intended to expedite or facilitate the process for reviewing product candidates that are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once an NDA is submitted, the NDA may be eligible for priority review. An NDA for a  Fast Track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough Therapy designation to expedite its development and review. A product candidate can receive Breakthrough Therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The Breakthrough Therapy designation includes the Fast Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Any application for a drug submitted to the FDA for approval, including a product candidate with a Fast Track designation and/or Breakthrough Therapy designation, may be eligible for other FDA review programs intended to expedite the FDA review and approval process, such as priority review. An NDA is eligible for priority review if the product candidate is designed to treat a serious or life-threatening disease or condition, and if approved, would provide a </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">significant improvement in safety or effectiveness compared to available alternatives for such disease or condition. For new-molecular-entity NDAs, priority review designation means the FDA&#8217;s goal is to take action on the application within six months of the 60-day filing date, or with respect to non-new-molecular-entity NDAs, within six months of the NDA receipt date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Additionally, depending on the design of the applicable clinical studies, product candidates studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled confirmatory clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit, and may require that such confirmatory studies be underway prior to granting accelerated approval. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required confirmatory studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires pre-approval of promotional materials as a condition for accelerated approval, which could adversely impact the timing of the commercial launch of the relevant product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Fast Track designation, Breakthrough Therapy designation, priority review, and accelerated approval do not change the standards for approval, but such designations may expedite the development or approval process. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions to qualify for such program or may decide that the time period for FDA review or approval will not be shortened.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Orphan Drug Designation and Exclusivity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 individuals in the U.S., or a patient population greater than 200,000 individuals in the U.S. and when there is no reasonable expectation that the cost of developing and making available the drug in the U.S. will be recovered from sales in the U.S. for that drug. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full NDA, to market the same drug for the same disease or condition for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research costs and a waiver of the NDA user fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the disease or condition for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the U.S. may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if a second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Post-approval Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Drug products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">events, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market, or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters, or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical holds on clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consent decrees, corporate integrity agreements, debarment or exclusion from federal health care programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mandated modification of promotional materials and labeling and the issuance of corrective information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases, and other communications containing warnings or other safety information about the product; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The FDA closely regulates the marketing, labeling, advertising, and promotion of drug products. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#8217;s labeling and that differ from those approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturers&#8217; communications on the subject of off-label use of their products. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA-approved labelling.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Hatch-Waxman Act</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Section 505 of the FDCA describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A Section 505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A 505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy but where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the applicant to rely, in part, on the FDA's prior findings of safety and efficacy for an existing product, or published literature, in support of its application. Section 505(j) establishes an abbreviated approval process for a generic version of approved drug products through the submission of an Abbreviated New Drug Application (&#8220;ANDA&#8221;). An ANDA provides for marketing of a generic drug product that has the same active ingredients, dosage form, strength, route of administration, labeling, performance characteristics and intended use, among other things, to a previously approved product. ANDAs are termed "abbreviated" because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and efficacy. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent to, or performs in the same manner as, the innovator drug through in vitro, in vivo, or other testing. The generic version must deliver the same amount of active ingredients into a subject's bloodstream in the same amount of time as the innovator drug and can often be substituted by pharmacists under prescriptions written for the reference listed drug. In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent with claims that cover the applicant's drug or a method of using the drug. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA's Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an ANDA or 505(b)(2) NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Upon submission of an ANDA or a 505(b)(2) NDA, an applicant must certify to the FDA that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on which such patent expires; or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except where the ANDA or 505(b)(2) NDA applicant challenges a listed patent through the last type of certification (a &#8220;paragraph IV certification&#8221;). If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have expired. If the ANDA or 505(b)(2) NDA applicant has provided a paragraph IV certification to the FDA, the applicant must send notice of the paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the paragraph IV certification. If the paragraph IV certification is challenged by an NDA holder or the patent owner(s) asserts a patent challenge to the paragraph IV certification, the FDA may not approve that application until the earlier of 30 months from the receipt of the notice of the paragraph IV certification, the expiration of the patent, when the infringement case concerning each such patent was favorably decided in the applicant's favor or settled, or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the 30-month stay. In instances where an ANDA or 505(b)(2) NDA applicant files a paragraph IV certification, the NDA holder or patent owner(s) regularly take action to trigger the 30-month stay, recognizing that the related patent litigation may take many months or years to resolve. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor's decision to initiate patent litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Hatch-Waxman Act establishes periods of non-patent regulatory exclusivity for certain approved drug products, during which the FDA cannot approve (or in some cases accept) an ANDA or 505(b)(2) application that relies on the branded reference drug. For example, the holder of an NDA, including a 505(b)(2) NDA, may obtain five years of non-patent data exclusivity upon approval of a new drug containing new chemical entities that have not been previously approved by the FDA. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the therapeutic activity of the drug substance. During the exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2) NDA submitted by another company that contains the previously approved active moiety. However, an ANDA or 505(b)(2) NDA may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The Hatch-Waxman Act also provides three years of non-patent exclusivity to the holder of an NDA (including a 505(b)(2) NDA) for a </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical studies (other than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted or sponsored by the applicant. This three-year exclusivity period protects against FDA approval of ANDAs and 505(b)(2) NDAs for the condition of the new drug's approval. As a general matter, the three-year exclusivity does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for generic versions of the original, unmodified drug product. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">FDA Approval and Regulation of Medical Devices and Companion Diagnostics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If safe and effective use of a therapeutic depends on an in vitro diagnostic, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves the therapeutic product. In August 2014, the FDA issued final guidance clarifying the requirements that apply to approval of therapeutic products and in vitro companion diagnostics. According to the guidance, if the FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic device is not approved or cleared for that indication. Approval or clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the FDCA, in vitro diagnostics, including companion diagnostics, are regulated as medical devices. In the U.S., the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, medical devices, including companion diagnostic tests, require marketing clearance or approval from the FDA prior to commercial distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The two primary types of FDA marketing authorization applicable to a medical device are premarket notification (&#8220;510(k) clearance&#8221;) and premarket approval (&#8220;PMA&#8221;). To obtain 510(k) clearance, a manufacturer must submit to the FDA a premarket notification submission demonstrating that the proposed device is &#8220;substantially equivalent&#8221; to a legally marketed predicate device. The FDA&#8217;s 510(k) clearance process usually takes from three to twelve months but may take longer. The FDA may require additional information, including clinical data, to make a determination regarding substantial equivalence. If the FDA agrees that the device is substantially equivalent to a predicate device currently on the market, it will grant 510(k) clearance to commercially market the device. If the FDA determines that the device is &#8220;not substantially equivalent&#8221; to a previously cleared device, the device is automatically designated as a Class III (i.e., high-risk) device. The device sponsor must then fulfill more rigorous PMA requirements or can request a risk-based classification determination for the device in accordance with the &#8220;de novo&#8221; process, which is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k) clearance or depending on the modification, approval of a PMA application or de novo classification. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k), de novo classification or a PMA in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#8217;s determination. If the FDA disagrees with a manufacturer&#8217;s determination, the FDA can require the manufacturer to cease marketing and/or request the recall of the modified device until it receives 510(k) clearance, approval of a PMA application, or issuance of a de novo classification. Also, in these circumstances, the manufacturer may be subject to significant regulatory fines or penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. In addition, PMAs for certain devices must generally include the results from extensive </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, a PMA application typically requires data regarding analytical and clinical validation studies. As part of the PMA review, the FDA will typically inspect the manufacturer&#8217;s facilities for compliance with the QSR which imposes elaborate testing, control, documentation and other quality assurance requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Approval of a PMA is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. If the FDA&#8217;s evaluation of the PMA application is favorable, the FDA typically issues an approvable letter requiring the applicant&#8217;s agreement to specific conditions, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution. Once granted, approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards are not maintained, or problems are identified following initial marketing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#8217;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which currently cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">In January 2024, the FDA announced that it intends to initiate the process to reclassify most in vitro diagnostic tests (&#8220;IVDs&#8221;) that are currently Class III into Class II, including companion diagnostics.  If such reclassification efforts occur, any companion diagnostics that are the subject of the down-classification may no longer require premarket approval, but rather may become subject to the generally less burdensome 510(k) clearance process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">International Regulations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition to regulations in the U.S., we are and will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials, marketing authorization, post-marketing requirements, and any commercial sales and distribution of our products. We must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of any products in those countries. The requirements and process governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary from country to country. Failure to comply with applicable foreign regulatory requirements, may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Non-Clinical Studies and Clinical Trials</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Similar to the U.S., the various phases of non-clinical and clinical research in the EU are subject to significant regulatory controls.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Non-clinical studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. Non-clinical (pharmaco-toxicological) studies must be conducted in compliance with the principles of good laboratory practice (&#8220;GLP&#8221;) as set forth in EU Directive 2004/10/EC (unless otherwise justified for certain particular </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">medicinal products, e.g., radio-pharmaceutical precursors for radio-labeling purposes). In particular, non-clinical studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Clinical trials of medicinal products in the EU must be conducted in accordance with EU and national regulations and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (&#8220;ICH&#8221;) guidelines on GCP as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.  If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU countries, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The regulatory landscape related to clinical trials in the EU has been subject to recent changes. The EU Clinical Trials Regulation (&#8220;CTR&#8221;) which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. Unlike directives, the CTR is directly applicable in all EU member states without the need for member states to further implement it into national law. The CTR notably harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, which contains a centralized EU portal and database.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">While the EU Clinical Trials Directive required a separate clinical trial application (&#8220;CTA&#8221;) to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, much like the FDA and IRB, respectively, the CTR introduces a centralized process and only requires the submission of a single application for multi-center trials. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. Clinical trials for which an application was submitted (i) prior to January 31, 2022 under the EU Clinical Trials Directive, or (ii) between January 31, 2022 and January 31, 2023 and for which the sponsor has opted for the application of the EU Clinical Trials Directive remain governed by said Directive until January 31, 2025. After this date, all clinical trials (including those which are ongoing) will become subject to the provisions of the CTR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">During the development of a medicinal product, the EMA and national regulators provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Scientific Advice Working Party of the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;). A fee is incurred with each scientific advice procedure. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical trials, and pharmacovigilance plans and risk-management programs. Advice is not legally binding to any future MA application (&#8220;MAA&#8221;) of the product concerned. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Marketing Authorization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In order to market our product candidates in the EU and many other foreign jurisdictions, we must obtain separate regulatory approvals. More concretely, in the EU, medicinal products candidates can only be placed on the market after obtaining a MA. To obtain regulatory approval of a product candidate in the EU, we must submit a MAA. The process for doing this depends, among other things, on the nature of the medicinal product. There are two types of MAs:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Centralized MA&#8221;: are issued by the European Commission through the centralized procedure based on the opinion of the EMA&#8217;s CHMP and are valid throughout the EU. The centralized procedure is compulsory for </span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">certain types of medicinal products such as (i) medicinal products derived from biotechnology processes, such as genetic engineering, (ii) medicinal products containing a new active substance indicated for the treatment of certain diseases, such as HIV or AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune and other immune dysfunctions and viral diseases, (iii) designated orphan medicinal products, and (iv) advanced therapy medicinal products (&#8220;ATMPs&#8221;) such as gene therapy, somatic cell therapy or tissue-engineered medicines. The centralized procedure is optional for product candidates containing a new active substance not yet authorized in the EU, or for product candidates that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;National MA&#8221;: are issued by the competent authorities of the EU member states, only cover their respective territory, and are available for product candidates not falling within the mandatory scope of the centralized MAs. Where a product has already been authorized for marketing in an EU member state, this national MA can be recognized in another member state through the mutual recognition procedure. If the product has not received a national MA in any member state at the time of application, it can be approved simultaneously in various member states through the decentralized procedure. Under the decentralized procedure, an identical dossier is submitted to the competent authorities of each of the member states in which the MA is sought, one of which is selected by the applicant as the reference member state.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the centralized procedure, the maximum timeframe for the evaluation of a MAA by the EMA is 210 days. This excludes so-called clock stops, during which additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. At the end of the review period, the CHMP provides an opinion to the European Commission. If this opinion is favorable, the European Commission may then adopt a decision to grant an MA. In exceptional cases, the CHMP might perform an accelerated review of a MAA in no more than 150 days (not including clock stops). Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the PRIME scheme, which provides incentives similar to the Breakthrough Therapy designation in the U.S. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to optimize their product development plans and speed up their evaluation to help them reach patients earlier. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated contact and rapporteur from the CHMP is appointed early in the PRIME scheme, facilitating increased understanding of the product at EMA&#8217;s committee level. An initial meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">MAs have an initial duration of five years. After these five years, the authorization may be renewed on the basis of a reevaluation of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the European Commission or the national competent authority decides on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Data and Marketing Exclusivity </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The EU also provides opportunities for market exclusivity. Upon receiving an MA, reference product generally receives eight years of data exclusivity and an additional two years of market exclusivity. If granted, the data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial MA of the reference product in the EU. The overall 10-year market exclusivity period can be extended to a maximum of 11 years if, during the first eight years of those 10 years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new chemical entity, and products may not qualify for data exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Orphan Medicinal Products</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those in the U.S. A medicinal product may be designated as orphan if (1)&#160;it is intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition; (2)&#160;either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b)&#160;the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment; and (3)&#160;there exists no satisfactory method of diagnosis, prevention, or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The application for orphan drug designation must be submitted before the MAA. Orphan designation entitles a party to incentives such as fee reductions or fee waivers, protocol assistance, and access to the Centralized MA process. Upon grant of a MA, orphan medicinal products are entitled to 10 years of market exclusivity for the approved therapeutic indication. During the 10-year market exclusivity period, the competent authorities cannot accept a MAA, or grant a MA, or accept an application to extend a MA, for the same indication, in respect of a similar medicinal product. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed pediatric investigation plan (&#8220;PIP&#8221;). No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, a MA may be granted to a similar product for the same indication at any time if (1) the second applicant can establish that its product, although similar, is safer, more effective, or otherwise clinically superior; (2) the applicant consents to a second orphan medicinal product application; or (3) the applicant cannot supply enough orphan medicinal product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Failure to comply with EU and member state laws that apply to the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil, or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines, and criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The aforementioned EU rules are generally applicable in the European Economic Area (&#8220;EEA&#8221;), which consists of the 27 EU member states plus Iceland, Liechtenstein, Norway, Switzerland and Turkey, as well as cooperating countries Albania, Bosnia and Herzegovina, Kosovo, Montenegro, North Macedonia, and Serbia.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Since the end of the Brexit transition period on January 1, 2021, Great Britain (England, Scotland and Wales) has not been directly subject to EU laws, however under the terms of the Ireland/Northern Ireland Protocol, EU laws generally apply to Northern Ireland. The EU laws that have been transposed into UK law through secondary legislation remain applicable in Great Britain, however new legislation such as the EU CTR is not applicable in Great Britain (&#8220;GB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Trade and Cooperation Agreement (&#8220;TCA&#8221;) became effective on January 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of Good Manufacturing Practice (&#8220;GMP&#8221;) inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Other Foreign Regulations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For other countries outside of Europe, such as countries in Eastern Europe, Latin America, or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary from country to country. In all cases, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Regulation of Companion Diagnostics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In the EU, in vitro diagnostic medical devices were regulated by Directive 98/79/EC, which regulated the placing on the market, the CE marking, the essential requirements, the conformity assessment procedures, the registration obligations for manufacturers and devices, as well as the vigilance procedure. In vitro diagnostic medical devices had to comply with the requirements provided for in the Directive, and with further requirements implemented at national level (as the case may be). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The regulation of companion diagnostics is subject to further requirements since in-vitro medical diagnostic devices Regulation (No 2017/746) (&#8220;IVDR&#8221;) became applicable on May 26, 2022. The IVDR applies since May 26, 2022, but there is a tiered system extending the grace period for many devices (depending on their risk classification) before they have to be fully compliant with the Regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;"> The IVDR introduced a new classification system for companion diagnostics, which are now specifically defined as diagnostic tests that support the safe and effective use of a specific medicinal product, by identifying patients that are suitable or unsuitable for treatment. Companion diagnostics will have to undergo a conformity assessment by a notified body. Before it can issue an EU certificate, the notified body must seek a scientific opinion from the EMA on the suitability of the companion diagnostic to the medicinal product concerned if the medicinal product falls exclusively within the scope of the centralized procedure process for the authorization of medicines, or the medicinal product is already authorized through the centralized procedure process, or an MAA for the medicinal product has been submitted through the centralized procedure process. For other substances, the notified body can seek the opinion from a national competent authority or the EMA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The aforementioned EU rules are generally applicable in the EEA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Pharmaceutical Coverage, Pricing and Reimbursement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Significant uncertainty exists as to the coverage and reimbursement status of drug products for which we obtain regulatory approval. In the U.S. and other countries, sales of products for which we receive regulatory approval for commercial sale will depend in part on the availability of reimbursement from third-party payors. Third-party payors include government health administrative authorities, managed care providers, private health insurers, and other organizations. The process for determining whether a payor will provide coverage for a drug product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the drug product. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">FDA-approved drugs for a particular indication. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Member states are free to restrict the range of pharmaceutical products for which their national health insurance systems provide reimbursement, and to control the prices and reimbursement levels of pharmaceutical products for human use. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result, new products are facing increasingly high barriers to entry. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The marketability of products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, an increasing emphasis on managed care in the U.S. has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is secured for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">To raise sufficient financial resources to commercialize our approved products and continue to advance our product candidates, we will need to address pricing pressures and potential third-party reimbursement coverage for our approved products and product candidates. In the U.S. and elsewhere, sales of pharmaceutical products depend in significant part on the availability of reimbursement to the consumer from third-party payors, such as government payors, like Medicare and Medicaid, and private insurance plans. Third-party payors are increasingly challenging the prices charged for medical products and services. It is and will continue to be time consuming and expensive for us or our strategic collaborators to go through the process of seeking reimbursement from Medicare and private payors. Our products may not be considered cost-effective, and coverage and reimbursement may not be available or sufficient to allow us to sell our products on a competitive and profitable basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Healthcare Reform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">We participate in the Medicaid Drug Rebate Program and other federal and state government pricing programs in the U.S., and we may participate in additional government pricing programs in the future.  The U.S. government and other governments have shown significant interest in pursuing health care reform, which has resulted in changes to these programs and impacts </span>IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and our product candidates that may be approved. For example, in March 2010, the Patient Protection and Affordable Care Act (&#8220;ACA&#8221;) was enacted and substantially changed the way health care is financed in the U.S. by both government and private insurers. Among other cost containment measures, the ACA established:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a Medicare Part D coverage gap discount program, in which pharmaceutical manufacturers who wish to have their drugs covered under Part D must offer discounts to eligible beneficiaries during their coverage gap period, or the &#8220;donut hole&#8221;; and</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new formula that increases the rebates a manufacturer must pay under the Medicaid Drug Rebate Program.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Since its enactment, there have been judicial, executive and congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in effect in its current form. In addition, we expect that federal, state, and local governments in the U.S. will continue to consider legislation to limit the growth of health care costs, including the cost of prescription drugs. Future legislation could limit payments for pharmaceuticals such as IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and the product candidates that we are developing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers, which will remain in effect through 2032, absent additional congressional action. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. More recently, in March 2021, Congress enacted the American Rescue Plan Act of 2021, which, among other things, eliminated the statutory Medicaid drug rebate cap, effective January 1, 2024. The rebate was previously capped at a drugs average manufacturer price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Most significantly, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) into law.  This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010.  Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025).  The IRA permits the Secretary of the Department of Health and Human Services (HHS) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations.  HHS has issued and will continue to issue guidance implementing the IRA, although the Medicare drug price negotiation program is currently subject to legal challenges.  While the impact of the IRA on the pharmaceutical industry and our business cannot yet be fully determined, it is likely to be significant.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, individual U.S. states have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Future legislation could limit payments for pharmaceuticals such as IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174; </sup>and the product candidates that we are developing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressures. The implementation of cost-containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Other Health Care Laws and Compliance Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For approved products, we may be subject to various federal, state, and foreign laws targeting fraud and abuse in the health care industry. Such laws include, without limitation, U.S. federal and state anti-kickback, fraud and abuse, false claims, consumer fraud, and transparency laws and regulations with respect to drug pricing and payments and other transfers of value made to physicians and other health care professionals, as well as similar foreign laws in jurisdictions outside the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal health care program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of this statute </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">or specific intent to violate it in order to have committed a violation. Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for health care items or services reimbursed by any source, not only the Medicare and Medicaid programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The federal False Claims Act imposes liability on any person who, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal health care program. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. The &#8220;qui tam&#8221; provisions of the False Claims Act allow a private individual to bring civil actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government, and to share in any monetary recovery. In addition, various states have enacted false claims laws analogous to the False Claims Act. Many of these state laws apply where a claim is submitted to any third-party payer and not merely a federal health care program. When an entity is determined to have violated the False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus significant civil penalties for each separate false claim.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Also, the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) created several federal crimes, including health care fraud, and false statements relating to health care matters. The health care fraud statute prohibits knowingly and willfully executing a scheme to defraud any health care benefit program, including private third-party payers. The false statements statute prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Physician Payment Sunshine Act (the &#8220;Sunshine Act&#8221;), which was enacted as part of the ACA, requires applicable manufacturers of drugs, devices, biologicals, or medical supplies covered under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, to report annually to the Secretary of the Department of Health and Human Services payments or other transfers of value made by that entity, or by a third-party as directed by that entity, to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), certain non-physician providers including physician assistants and nurse practitioners, and teaching hospitals, or to third parties on behalf of such providers, as well as ownership and investment interests held by physicians and their immediate family members during the course of the preceding calendar year. Failure to comply with the reporting requirements can result in significant civil monetary penalties for any payment or other transfer of value that is not reported. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Moreover, analogous state and foreign laws and regulations may be broader in scope than the provisions described above and may apply regardless of payor. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and relevant federal government compliance guidance; require drug manufacturers to report information related to payments and other transfers of value to physicians and other health care providers, many of which differ from each other in significant ways, thus further complicating compliance efforts; and restrict marketing practices or require disclosure of marketing expenditures and pricing information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Violations of any of these laws or any other governmental laws and regulations that may apply include, without limitation, significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded health care programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, diminished profits, and the curtailment or restructuring of our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Data Privacy &amp; Security</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Numerous state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of personal information, including health-related information. In the U.S., numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, including HIPAA, and federal and state consumer protection laws and regulations (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, certain state and non-U.S. laws, such as the California Consumer Privacy Act (&#8220;CCPA&#8221;), the California Privacy Rights Act (&#8220;CPRA&#8221;), and the EU General Data Protection Regulation (&#8220;GDPR&#8221;), govern the privacy and security of personal </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">information, including health-related information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation.  Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing. Additionally, our use of AI and machine learning may be subject to laws and evolving regulations regarding the use of AI or machine learning, controlling for data bias, and anti-discrimination.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Human Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Employees</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In August 2023, our Board of Directors approved the Reprioritization. Following a comprehensive review of the business, we determined to focus on high-potential agitation-market opportunities using our innovative, AI-based clinical drug development platforms. Our goal was to reduce more than 50% of our cash burn, as compared to our cash burn levels during the second quarter of 2023, to approximately $80 million on a go-forward annualized basis. As part of the Reprioritization, our Board of Directors approved a reduction of approximately 60% of our workforce, from approximately 190 to 80 employees. These actions also included a shift in commercial strategy for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the institutional setting, a reduction of in-hospital commercialization expenses, a suspension of programs no longer deemed core to our business, and a shift in focus to develop BXCL501 for use in the at-home setting in the treatment of agitation in schizophrenia, bipolar disorders, and in patients with mild to moderate dementia due to probable Alzheimer&#8217;s disease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">In May, 2024 the Company took additional actions as part of its continued efforts to preserve cash and prioritize investment in its core clinical programs. As part of these actions, the Company initiated a further reduction of approximately 15% of the Company&#8217;s then current workforce. The Company recorded total restructuring costs of $0.9 million for the three months ended June 30, 2024. These costs consisted of severance and benefit costs, all of which were paid during the three month period ended June 30, 2024. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">In September, 2024, the Company approved a plan for an additional reduction its workforce by 15 employees, or approximately 28% of the Company&#8217;s headcount (the &#8220;Clinical Prioritization&#8221;), in order to extend its cash runway and prioritize investment on the clinical development of its lead neuroscience asset, BXCL501. The Company recorded total restructuring costs of $1.6 million for the three months ended September 30, 2024. These costs also consisted of severance and benefit costs. The Company completed the Clinical Prioritization in October 2024, and commenced payments which are expected to be completed in the first quarter of 2025.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">We recorded restructuring costs of $2.4 million and $4.2 million in the years ended December 31, 2024 and 2023, respectively, including severance and benefit costs of $4.1 million and contract termination costs of $0.1 million, substantially all of which were paid in 2023. As of December 31, 2024 and 2023, respectively,  we had 37 and 74 full-time employees. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Culture</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe that the success of our human capital management investments is evidenced by our low employee turnover, despite the difficult restructuring actions recently taken, and is regularly reviewed by our Board of Directors as part of their oversight of our human capital strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employee Engagement, Talent Development &amp; Benefits</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees. We provide our employees with competitive salaries, bonuses, opportunities for equity ownership and other comparable benefits for our industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employee and Visitor Safety Protocols</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We follow health and safety guidelines to protect the well-being of our employees and visitors.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Diversity &amp; Inclusion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Much of our success is rooted in the diversity of our teams and our commitment to inclusion. We value diversity at all levels and continue to focus on extending our diversity and inclusion initiatives across our entire workforce. We believe that our business benefits from the different perspectives a diverse workforce brings, and we pride ourselves on having a strong, inclusive and positive culture based on our shared mission and values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Our Corporate Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company was incorporated as a Delaware corporation on March&#160;29, 2017. Our principal executive offices are located at 555 Long Wharf Drive, New Haven, CT 06511 and our telephone number is (475) 238-6837.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Available Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our website address is www.bioxceltherapeutics.com. The contents of, or information accessible through, our website are not part of this Annual Report on Form 10-K. We make our filings with the SEC, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments to those reports, available free of charge on our website as soon as reasonably practicable after we file such reports with, or furnish such reports to, the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may use our website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors &amp; Media sections of our website at www.bioxceltherapeutics.com. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the &#8220;Email Alerts&#8221; option under the News / Events menu of the Investors &amp; Media section of our website at www.bioxceltherapeutics.com.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The reference to our website address does not constitute incorporation by reference of the information contained on or available through our website, and you should not consider such information to be a part of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_d7a77e10_250e_4e87_90ce_8e9d9847f66d"></a><a id="Item1ARiskFactors_143189"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;1A. Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should carefully consider the risks described below, as well as general economic and business risks and the other information in this Annual Report on Form&#160;10-K. The occurrence of any of the events or circumstances described below or other adverse events could have a material adverse effect on our business, results of operations and financial condition and could cause the trading price of our common stock to decline. Additional risks or uncertainties not presently known to us or that we currently deem immaterial may also harm our business.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Financial Position and Need for Additional Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We have a limited operating history and have not generated substantial product revenues to date, which may make it difficult to evaluate the success of our business and to assess our future viability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We were incorporated in March 2017 and our operations to date have been largely focused on staffing our Company, raising capital, advancing the development of our product candidates, including conducting clinical and preclinical studies and establishing our commercial organization. We have only one product approved for commercial sale, and have limited experience in obtaining marketing approvals, manufacturing products on a commercial scale, and conducting sales and marketing activities necessary for successful commercialization. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully commercializing products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We expect our financial condition and operating results to continue to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. We are focused primarily on research and development while continuing to support IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> commercial activities. We may encounter unforeseen expenses, difficulties, complications and delays, and may not be successful in such a transition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We have incurred significant operating losses since inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Since our inception, we have incurred significant operating losses. Our net loss was $59.6 million and $179.1 million for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, we had a stockholders&#8217; deficit of approximately $93.1 million. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We have only one product candidate approved for marketing in the U.S., none in any other jurisdiction, and may never receive approval beyond the one product approved to date. It could be several years, if ever, before we have a commercialized product that generates significant revenues through sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or our product candidates, if approved. As a result, we are uncertain when or if we will achieve profitability and, if so, whether we will be able to sustain it. The net losses we incur may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses may increase in the long term as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluate the development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conduct preclinical studies and clinical trials for our current product candidates and any future product candidates that we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to develop, maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pursue regulatory approvals for our current and future product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop an appropriate sales, marketing, and distribution infrastructure to commercialize IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and any other product candidates for which we may obtain marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potentially hire additional clinical, commercial, regulatory, scientific and finance personnel; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur additional legal, accounting and other expenses in operating as a public company.</span></td></tr></table><div style="margin-top:10pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">To become and remain profitable, we must develop and commercialize more products or product candidates with significant market potential. This will require us to be successful in a range of challenging activities, including completing clinical trials of our product candidates, developing commercial scale manufacturing processes, obtaining marketing approval, manufacturing, marketing, and selling IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and any current and future product candidates for which we may obtain marketing approval, and satisfying any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate sufficient revenue to achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Although we have obtained U.S. FDA approval for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, because of the numerous risks and uncertainties associated with product development, we are unable to accurately predict the timing or amount of expenses or when, or if, we will obtain marketing approval to commercialize any additional product candidates. If we are required by the FDA, or other regulatory authorities such as the European Medicines Agency (&#8220;EMA&#8221;) to perform studies and trials in addition to those currently expected, or if there are any delays in the development, or in the completion of any planned or future preclinical studies or clinical trials of our current or future product candidates, our expenses could increase and profitability could be further delayed. For example, developments with respect to our TRANQUILITY program evaluating BXCL501 in patients with dementia due to probable Alzheimer&#8217;s disease may increase the likelihood that we experience such costs or delays, as discussed in the risk factor below entitled: &#8220;<i style="font-style:italic;">Developments relating to our TRANQUILITY II Phase 3 trial may impact the timing of our development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer&#8217;s disease</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our failure to become and remain profitable would decrease the value of our Company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our Company also could cause you to lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our strategic reprioritization and other workforce reductions may not achieve our intended outcome.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In August 2023, we announced a broad-based strategic reprioritization (the &#8220;Reprioritization&#8221;) and have taken further restructuring actions since then. As part of these efforts, we have taken actions to reduce certain operational and workforce expenses that are no longer deemed core to our ongoing operations in order to extend our cash runway and drive innovation and growth in high potential clinical development and value creating opportunities. These actions include a shift in commercial strategy for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="white-space:pre-wrap;"> in the institutional setting, a reduction of in-hospital commercialization expenses, a suspension of programs no longer determined to be core to ongoing operations, and a prioritization on at-home treatment setting opportunities for BXCL501. As part of this strategy, we reduced our workforce in 2023 by approximately 60%.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In May and September 2024, we initiated further workforce reductions, and we may undertake further similar cost-saving initiatives, which may include additional restructuring or workforce reductions. These types of cost-reduction activities can be complex and result in unintended consequences and costs, including decreased employee morale, loss of institutional knowledge and expertise and adversely impact our business. We completed these additional restructuring actions to further reduce the workforce by 50%, ending the year ended December 31, 2024 with 37 full-time employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The reduction in force may result in unintended consequences and costs, such as the loss of institutional knowledge and expertise, attrition beyond the intended number of employees, decreased morale among our remaining employees, and the risk that we may not achieve the anticipated benefits of the reduction in force. In addition, while positions have been eliminated, certain functions necessary to our operations remain, and we may be unsuccessful in distributing the duties and obligations of departed employees among our remaining employees. The reduction in workforce could also make it difficult for us to pursue, or prevent us from pursuing, new opportunities and initiatives due to insufficient personnel, or require us to incur additional and unanticipated costs to hire new personnel to pursue such opportunities or initiatives. The workforce reduction could also harm our reputation, making our ability to recruit skilled personnel difficult.  If we are unable to realize the anticipated benefits from the reduction in force, or if we experience significant adverse consequences from the reduction in force, our business, financial condition, and results of operations may be materially adversely affected.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">In addition, we may not realize the benefits of or there may be unanticipated costs associated with our Reprioritization. As a result of the Reprioritization, including our strategic refocus, we may not generate material revenues from IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the near term because our commercial force will be significantly reduced. If we are unable to commercialize IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in a different setting or unable to develop, receive marketing approval for and successfully commercialize BXCL501, BXCL701 and any of our other product candidates on our own or with any future collaborator, or experience delays because of any of these factors or otherwise, our business could be materially and substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">In addition, because we have limited financial and managerial resources, under our Reprioritization, we intend to focus on specific product candidates, indications and development programs. We may also conduct several clinical trials for our product candidates in parallel over the next several years, which may make our decision as to which product candidates to focus on more difficult. As a result, we may forgo or delay pursuit of opportunities with other product candidates or other indications that could have had greater commercial potential or likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through future collaborations, licenses and other similar arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. If we are not successful in increasing our efficiency as a result of this Reprioritization, our efforts to develop and commercialize our product candidates may be delayed or halted and our business could be materially adversely impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts or otherwise seek strategic alternatives. In addition, the failure to raise additional financing in accordance with the minimum capital raising requirements of our Credit Agreement (as defined herein) would trigger an event of default thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We will require additional future funding to support current and anticipated future expenses. We currently anticipate continuing to develop and conduct clinical trials with respect to our current and any future product candidates; seek to identify and develop additional product candidates; acquire or in-license other product candidates or technologies; seek regulatory approvals for our product candidates that successfully complete clinical trials, if any; establish sales, marketing, distribution and other commercial infrastructure to support the commercialization of products for which we may obtain marketing approval; require the manufacture of larger quantities of product candidates for clinical development and, potentially, commercialization; maintain, expand and protect our intellectual property portfolio; hire and retain limited additional personnel, such as clinical, quality control and scientific personnel; add operational, financial and management information systems and personnel, including personnel to support our product development and help us comply with our obligations as a public company; and add equipment and physical infrastructure to support our research and development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We have been and may continue to be required to expend significant funds to continue to commercialize IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the U.S. and advance the development of BXCL501, BXCL701, BXCL502 and our other product candidates. In addition, while we may seek one or more collaborators for future development of our current product candidates or any future product candidates that we may develop for one or more indications, we may not be able to enter into a collaboration for any of our product candidates for such indications on suitable terms, on a timely basis or at all. In any event, our existing cash will not be sufficient to fund all of the efforts that we plan to undertake or to fund the completion of development of our product candidates or our other preclinical programs. Accordingly, we will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources. We may also seek third-party investments in or other strategic options for our subsidiary, OnkosXcel. Further financing may not be available to us on acceptable terms, or at all. In addition, we are reliant on the financial institutions with which we hold our cash and cash equivalents. If such institutions were to close, we may not be able to recover all of our cash or cash equivalents held at such institutions. Moreover, market volatility, credit crises, adverse macroeconomic conditions, such as high interest or inflation rates, or other factors, as well as Company-specific factors such as the progress of our development pipeline, adverse clinical events or results, regulatory investigations, or ongoing or potential legal proceedings, could also adversely impact our ability to access capital as and </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">when needed. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Management believes that the Company&#8217;s cash and cash equivalents of $29.8 million as of December 31, 2024, together with approximately $14.0 million gross proceeds received from the registered direct offering in March 2025, will allow the Company to fund its operations and meet its liquidity requirements into the third quarter of 2025. However, there can be no assurance that we will be able to extend our cash runway by meeting the conditions for additional funding under the terms of our Credit Agreement (defined below) or otherwise. In addition, the failure to raise additional financing in accordance with the minimum capital raising requirements of our Credit Agreement would trigger an event of default thereunder. The Fifth Amendment to our Credit Agreement included a new capital raising covenant requiring that the Company receive (A) after the effective date of the Fifth Amendment and on or prior to November 27, 2024, at least $7.0 million in gross cash proceeds from the issuance of the Company&#8217;s common stock, warrants and/or pre- funded warrants (&#8220;Raise 1&#8221;), (B) after the effective date of the Fifth Amendment and on or before March 15, 2025 (provided that the Company was required to use its commercially reasonable efforts to satisfy the requirement by February 15, 2025), at least $18.0 million in net cash proceeds (including the proceeds of Raise 1) from (i) the issuance of the Company&#8217;s common stock, warrants and/or pre-funded warrants, (ii) non-refundable cash consideration from partnering transactions entered into after the effective date of the Fifth Amendment (so long as such partnering transactions would not require the Company or any of its subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made), (iii) the issuance of the Company&#8217;s subordinated debt (subject to terms set forth in the Fifth Amendment), and/or (iv) asset sales permitted pursuant to the Credit Agreement or consented to by the Lenders (such capital raise, &#8220;Raise 2&#8221;), and (C) after the effective date of the Fifth Amendment and on or prior to the earlier of (x) August 15, 2025 and (y) the date that is 30 days after the final data readout of the SERENITY At-Home Phase 3 trial, at least $29.0 million in net cash proceeds (&#8220;Raise 3&#8221;) (including the proceeds from Raise 1 and Raise 2) from the same permitted capital raising activities listed in the preceding clause (B).The Company has met the requirements of Raise 1 and Raise 2, but has not met the requirements of Raise 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the Fifth Amendment and the required capital raises described in the preceding paragraph, the Lenders agreed to modify the Credit Agreement&#8217;s minimum liquidity covenant to require minimum cash liquidity of $7.5 million (instead of $25.0 million) from and after the closing of Raise 1 until March 30, 2025. On March 31, 2025, the minimum liquidity amount will increase to $10.0 million, and on September 30, 2025, the minimum liquidity amount will further increase to $15.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Furthermore, our estimate as to how long we expect our existing cash to be able to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Our future funding requirements, both short-term and long-term, will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, timing, costs, and results of clinical trials of our product candidates, including any delays that have occurred or may occur due to the recent developments with the TRANQUILITY program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to enter into and the terms and timing of any collaborations, licensing agreements or other arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of seeking regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of commercialization activities for IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and for any of our product candidates that receive marketing approval, to the extent such costs are not the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">revenue received from commercial sales of IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and our current and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against intellectual property related claims;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of future product candidates that we pursue and their development requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in regulatory policies or laws that may affect our operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in physician acceptance or medical society recommendations that may affect commercial efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of acquiring potential new product candidates or technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of operating as a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which our operations continue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of legal proceedings and investigations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs associated with any adverse market conditions or other macroeconomic factors.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As we continue our research and development activities, we will require additional resources to continue as a going concern. We can provide no assurance that we will successfully obtain additional resources to improve our financial condition. If we are unable to obtain necessary additional capital, we could be compelled to pursue alternative options, including, without limitation, implementing further workforce reductions, reducing or ceasing product development programs and advancement of our clinical trials and product candidates, selling our assets or seeking other strategic alternatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have significant indebtedness and other contractual obligations that could impair our liquidity, restrict our ability to do business and thereby harm our business, results of operations and financial condition. We may not have sufficient cash flow from operations to satisfy our obligations under the Credit Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, we had aggregate principal indebtedness of $106.7 million outstanding under our Credit Agreement and Guaranty (as amended, the &#8220;Credit Agreement&#8221;) by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the &#8220;Lenders&#8221;), and Oaktree Fund Administration LLC (&#8220;OFA&#8221;) as administrative agent. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Restrictive covenants in the Credit Agreement place limits on our ability to conduct our business. The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness, and dividends and other distributions, subject to certain exceptions, including specific exceptions with respect to product commercialization and development activities. In addition, certain events, including receipt of a warning letter from the FDA, may constitute an event of default. We must also comply with certain covenants under the Credit Agreement, including a financial covenant that requires we maintain certain minimum cash liquidity amounts. In addition, certain events, including certain regulatory events and any &#8220;going concern&#8221; or similar qualification in a report of the Company&#8217;s independent registered public accountants relating to the Company&#8217;s annual financial statements (except for the years ended December 31, 2024 and 2023, respectively), constitute an event of default under the Credit Agreement. The report of our independent registered public accounting firm included in this Annual Report on Form 10-K contains a &#8220;going concern&#8221; explanatory paragraph. The Credit Agreement also includes other covenants relating to certain change of control events can also trigger an event of default under the Credit Agreement, including control by any entity or group of entities, other than BioXcel LLC and its affiliates, that acquires 35% or more of our voting capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our ability to make scheduled payments or payments to maintain compliance with covenants or to restructure or refinance these and other outstanding debt obligations depends on our financial and operating performance, including growth in revenue from IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and BXCL501, which will be affected by prevailing economic, industry and competitive conditions and by financial, business and other factors beyond our control. A failure to pay our debt, fixed costs and other obligations or a breach of our contractual obligations or other event of default could result in a variety of adverse consequences, including the acceleration of our obligations or the exercise of remedies by our creditors and lessors. In such a situation, it is unlikely that we would be able to cure our breach, fulfill our obligations, make required </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">payments or otherwise cover our fixed costs, which would have a material adverse effect on our business, results of operations and financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, historically we have relied on debt and equity financings as our primary sources of liquidity. If our future cash flows and capital resources are insufficient to fund our debt service obligations, we may be forced to reduce or delay expenditures, sell assets, seek additional capital or seek to restructure or refinance our indebtedness. Any refinancing or restructuring of our indebtedness could be at higher interest rates and may require us to comply with more onerous covenants. These alternative measures may not be successful and may not permit us to meet our scheduled or any accelerated debt service obligations. In the absence of such cash flows and resources, we could face substantial liquidity problems and might be required to sell material assets or pursue other strategic alternatives to attempt to meet our debt service obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">As of December 31, 2024, we had $29.8 million in cash and cash equivalents. Based on our existing cash, cash equivalents and lack of current availability under our funding facilities, we do not believe we have sufficient cash on hand to support current operations and service our debt obligations for at least one year from the date of issuance of the audited consolidated financial statements appearing in this Annual Report on Form 10-K. This condition raises substantial doubt about our ability to continue as a going concern for at least one year from the date that our financial statements for the year ended December 31, 2024 are issued. In order to mitigate the current and potential future liquidity issues, we have undertaken the Reprioritization and other restructuring actions, and may, among other things, seek to raise capital through the issuance of common stock, or by restructuring, refinancing, and/or amending the terms of the Credit Agreement (including with respect to regulatory related events of default that do not contain a cure period) or pursue other strategic alternatives.  However, such transactions may not be successful and we may not be able to raise additional equity and/or financing necessary to meet our obligations. Moreover, our Credit Agreement contains covenants that we may be unable to comply with and which could result in the acceleration of our debt service obligations, further reducing our capital resources and ability to fund our operations. As such, there can be no assurance that we will be able to continue as a going concern and we may be forced to delay, reduce or discontinue our product development programs or commercialization efforts in order to preserve cash. For additional cost-saving and other strategic initiatives we may be compelled to pursue, see the risk factor entitled, </span><i style="font-style:italic;">&#8220;We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts or otherwise seek strategic alternatives.&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We could be delisted from The Nasdaq Capital Market, which could seriously harm the liquidity of our stock and our ability to raise capital or complete a strategic transaction.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As previously reported, on September 20, 2024, we received a letter from Nasdaq Staff notifying us that for the 30 consecutive business days prior to the date of the letter, the Company&#8217;s market value of listed securities closed below the minimum $35 million requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company was granted a period of 180 calendar days, or until March 19, 2025, to regain compliance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As anticipated, on March 20, 2025, the Company received another letter from the Staff stating that, as a result of the Company&#8217;s continued non-compliance with the MVLS Requirement, its securities would be delisted from Nasdaq unless the Company appeals the Staff&#8217;s delisting determination by requesting a hearing before the Nasdaq Panel. The Company made timely request for a hearing before the Panel to appeal the Staff&#8217;s determination. The Company&#8217;s common stock will remain listed and eligible for trading on Nasdaq at least pending the ultimate conclusion of the hearing process; however, there can be no assurance that the Company will ultimately regain compliance and remain listed on Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If our common stock is delisted by Nasdaq, the price of our common stock may decline and our common stock may be eligible to be quoted on the OTC Bulletin Board, another over-the-counter quotation system, or on the pink sheets, which would negatively affect the liquidity of our common stock and an investor may find it more difficult to dispose of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">their common stock or obtain accurate quotations as to the market value of our common stock. Any such delisting action may materially adversely affect our ability to raise capital or pursue strategic transactions on acceptable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, if our common stock is delisted from the Nasdaq Capital Market and the trading price remains below $5.00 per share, trading in our common stock might also become subject to the requirements of certain rules&#160;promulgated under the Exchange Act, which require additional disclosure by broker-dealers in connection with any trade involving a stock defined as a &#8220;penny stock&#8221; (generally, any equity security not listed on a national securities exchange that has a market price of less than $5.00 per share, subject to certain exceptions).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We continue to actively monitor our performance with respect to the listing standards and will consider available options to resolve any deficiency and maintain compliance with the Nasdaq rules. There can be no assurance that we will be able to maintain compliance or, if we fall out of compliance, regain compliance with any deficiency, or if we implement an option that regains our compliance, maintain compliance thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to the Discovery and Development of Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We have limited experience in drug discovery and drug development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Prior to the acquisition of our product and product candidates, we were not involved in and had no control over their preclinical and clinical development. In addition, we are relying upon the parties we acquired our product candidates from to have conducted research and development in accordance with the applicable protocol, legal, regulatory and scientific standards, accurately reported the results of all clinical trials conducted prior to our acquisition of the applicable product candidate, and correctly collected and interpreted the data from these studies and trials. To the extent any of these activities did not occur, our expected development time and costs could increase, which could adversely affect our prospects for marketing approval of, and receiving any future revenue from, these product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Developments relating to our TRANQUILITY II Phase 3 trial may impact the timing of our development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer&#8217;s disease.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Following our discovery of principal investigator misconduct at one of the clinical sites in our TRANQUILITY II Phase 3 clinical trial, we initiated an investigation into the issues associated with the trial.  This principal investigator had previously been subject to a December 2022 FDA inspection of her clinical site in connection with the TRANQUILITY II clinical trial.  At the conclusion of this inspection, the FDA issued an FDA Form-483 identifying three inspectional observations. These observations related to the principal investigator&#8217;s failure to adhere to the informed consent form approved by the Institutional Review Board for a limited number of subjects whose records the FDA reviewed, maintain adequate case histories for certain patients whose records the FDA reviewed, and adhere to the investigational plan in certain instances. For example, the FDA cited the principal investigator&#8217;s delay in informing the sponsor&#8217;s medical monitor or pharmacovigilance safety vendor of an SAE, for one of the subjects, which report was made to our vendor outside of the 24 hour time period prescribed by the clinical trial protocol. The principal investigator for this clinical site responded to the FDA observations within the time period requested. The FDA concluded that the inspection of a single site in its TRANQUILITY II Phase 3 trial is closed under 21 C.F.R.20.64(d)(3) and released the Establishment Inspection Report. The FDA has designated &#8220;Voluntary Action Indicated&#8221; for the site.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In May 2023, it came to our attention that this same principal investigator in the TRANQUILITY II clinical trial may have fabricated email correspondence around the time of the FDA inspection, purporting to demonstrate that the investigator timely submitted to our pharmacovigilance safety vendor a report of an SAE from a different subject than the one cited in the FDA Form-483, and purporting to show that the vendor had confirmed receipt. Upon receipt of this information, we promptly initiated an investigation and received confirmation that the principal investigator fabricated the email correspondence related to the timing of the reporting of this SAE to our pharmacovigilance vendor to make it appear as though this SAE had been timely reported as required by the clinical trial protocol. This principal investigator has not participated in any other clinical trial sponsored or conducted by us. Both we and the principal investigator&#8217;s employer have reported this incident to the FDA. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Since that time, we have taken steps to further investigate and evaluate the conduct of the TRANQUILITY II trial at this clinical site. Based on these steps to date, we believe that there have been no further instances of misconduct or fraud or other findings that adversely impact the data integrity or reliability of the eligibility, safety, and efficacy data obtained at the clinical trial site in question.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">The primary efficacy endpoint in TRANQUILITY II was the change in PEC score, which is a measurement of agitation severity captured by trained raters during an agitation episode.  While change in PEC score has been used to support the approval of IGALMI</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="white-space:pre-wrap;"> for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults, it has not been used as a primary endpoint to support the approval of a drug candidate for the treatment of agitation associated with Alzheimer&#8217;s Disease.  Prior to initiating our TRANQUILITY II trial, we believe we reached alignment with FDA regarding the use of PEC scores as a primary endpoint to assess individual agitation episodes in dementia patients.  In the normal course, we have been in communication with the FDA regarding the data and information needed to further support the consistency of the measurement of PEC ratings, and we believe that we have generated sufficient data to demonstrate such consistency.  Following submission of certain data on PEC score from a separate study of raters assessing video vignettes, the FDA expressed certain concerns with respect to the reliability of PEC scores in that study. The FDA has requested that we provide additional information to support the consistency of the measurement of PEC ratings to assess the treatment of agitation associated with Alzheimer&#8217;s Disease. While we believe that we have generated sufficient data to demonstrate such consistency, and we plan to submit these data and analyses to the FDA, if the FDA disagrees, it may require that we provide more information to demonstrate reliability in the measurement of PEC scores and/or may require that we generate additional data to support the reliability of PEC score measurements in our TRANQUILITY II trial. There can be no assurances that any information or and data we provide to FDA will sufficiently demonstrate the consistency and reliability of the PEC-score data from our TRANQUILITY II trial, or that our PEC-score data will not represent a potential review issue in connection with any application we may submit to FDA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In addition, we are continuing to seek feedback from the FDA with respect to our TRANQUILITY program. For example, on February 20, 2024, we held a Type B/Breakthrough Therapy designation meeting with the FDA. The original purpose of this meeting was to obtain feedback on the design of a proposed at-home study that did not include caregiver-collected efficacy endpoints, based on our belief that obtaining caregiver assessments of efficacy would be challenging. We believe there are no validated caregiver endpoints for assessing efficacy in Alzheimer&#8217;s disease patients in the at-home setting. As a result, we focused on requesting feedback from the FDA regarding our proposal for an at-home clinical study with safety as the primary objective, and to better understand what additional data would be required to submit an sNDA to support labeling for BXCL501 to include the acute treatment of agitation associated with dementia in probable Alzheimer&#8217;s disease or, in the alternative, in this population in the care setting only. In its preliminary responses, the FDA reiterated its prior comments that we generate additional efficacy data, including repeat-dose efficacy data, to support an sNDA submission, as the FDA indicated that our proposed efficacy database, which currently includes the 70 patients who have been treated with 60 mcg of BXCL501 in TRANQUILITY I and TRANQUILITY II, would not contain substantial evidence of effectiveness absent additional data.  The FDA advised that we generate the necessary efficacy data in care facilities prior to conducting any trials in the at-home setting. In addition, the FDA indicated the need to generate long-term safety data to support an sNDA submission, including from probable Alzheimer&#8217;s disease patients exposed to BXCL501, for up to one year. We have received the final meeting minutes from the FDA, which we believe are consistent with the FDA&#8217;s preliminary responses and the subsequent meeting discussion. Based on the FDA&#8217;s feedback, we are currently planning to generate additional Phase 3 efficacy and safety data, in a variety of relevant care-facility settings and across severity of dementia, including through, among other things, conducting our planned TRANQULITY In-Care Phase 3 trial. In addition, we plan to discuss the details of the requirement for long-term safety data at a future meeting with the FDA. Also, although we announced in November 2023 that we were planning to conduct a Phase 3 trial in the at-home setting, with safety as the primary objective (TRANQUILITY At Home), given the priority to expand the database to generate additional efficacy and safety data in care facilities, we are re-evaluating the timing for initiating TRANQUILITY At Home. Conducting any new clinical trial can take significant time, funding and resources, and there are no assurances we could raise sufficient capital or have the liquidity and resources to conduct further clinical trials in our TRANQUILITY program, including our planned TRANQUILITY In-Care Trial. Any new clinical trials conducted in our target patient populations may have different safety or efficacy results from the topline data the Company previously announced for the TRANQUILITY II clinical trial. Further, any government investigation, disqualification, or debarment of, or proceeding or action against the principal investigator, or any government investigation, proceeding or action against us, could further delay development </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">and approval of BXCL501 for this indication, and otherwise have a material adverse effect on us, our financial condition (including triggering a potential event of default under our Credit Agreement), results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have limited clinical data supporting potential safety or efficacy of BXCL501 for use in the at-home setting in the acute treatment of agitation in patients with dementia due to probable Alzheimer&#8217;s disease.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In August 2023, we announced our intention to pursue the Reprioritization, including among other things, a shift in focus to primarily develop BXCL501 for use in expanded settings, including the at-home setting and care facilities, for the acute treatment of agitation in patients with dementia due to probable Alzheimer&#8217;s disease and the acute treatment of agitation in schizophrenia and bipolar patients in the at-home setting. Although we have conducted several clinical trials that evaluated BXCL501 in the institutional setting, and we are conducting the SERENITY At-Home Phase 3 trial evaluating the safety of BXCL501 for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting, but we have not conducted a clinical trial evaluating the at-home use of BXCL501 in the acute treatment of agitation in patients with dementia due to probable Alzheimer&#8217;s disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Although we will seek additional feedback from the FDA regarding the potential of its ongoing or completed clinical trials to support submission of one or more sNDAs and to support a label for use in the home, it is possible that the FDA may not consider our available data adequate to support such submissions. For example, on October 11, 2023, we received feedback from the FDA that TRANQUILITY I and TRANQUILITY II alone are not sufficient to support an sNDA submission for the use of BXCL501 to treat acute agitation (non-daily) in patients with dementia due to probable Alzheimer&#8217;s disease in either the at-home setting or care facilities, and the FDA indicated that we should, among other things, conduct a further clinical trial to evaluate safety and collect efficacy data of BXCL501 before we are able to submit an sNDA seeking approval of BXCL501 for use in such populations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For a description of recent developments relating to our TRANQUILITY program, please see the prior risk factor, &#8220;<i style="font-style:italic;">Developments relating to our TRANQUILITY II Phase 3 trial may impact the timing of our development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer&#8217;s disease.</i>&#8221; We cannot provide assurance that we will be able to seek or obtain approval of BXCL501 for treatment of agitation in patients with dementia due to probable Alzheimer&#8217;s disease in the at-home setting based on this updated development plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Although we continue to seek feedback from the FDA with respect to our TRANQUILITY program, the FDA may not agree that any trial designs we propose are sufficient to establish both the safety and efficacy of BXCL501 for the acute treatment of agitation associated with dementia due to probable Alzheimer&#8217;s disease in either a care setting or an at-home setting. For example, to assess safety, the FDA has indicated that we need to expose more patients to BXCL501 for a longer period of time and that an efficacy trial of a shorter duration, combined with the patients in its previous trials, would not support submissions of an sNDA. Further, to assess efficacy in the home setting, the FDA may determine that we cannot rely on our previous studies of BXCL501 for this proposed indication since those studies were conducted in assisted living facilities and they are not comparable to the at-home setting. The FDA may also require us to seek approval for BXCL501 for use in care facilities prior to seeking any approval for at-home use in the targeted AD patient population. In particular, we are planning to generate additional Phase 3 safety and efficacy data in a variety of relevant care-facility settings, but even if our planned clinical efforts are successful and even if we are able to obtain approval of BXCL501 for use in patients with dementia due to probable Alzheimer's disease, we cannot provide assurance that we will be able to seek or obtain approval of BXCL501 for the treatment of agitation in patients with dementia due to probable Alzheimer&#8217;s disease in the at-home setting based on this data and we will be required to generate additional data to evaluate the at-home use of BXCL501 in our targeted Alzheimer's dementia population before we are able to seek approval for such at-home use in this population, if ever. In addition, the FDA may determine that we cannot rely on the data from our prior TRANQUILITY II Phase 3 trial to support an sNDA as a result of potential data integrity issues at the trial site, as the FDA may not agree with our belief that data reliability and integrity remain intact. See Part II, Item 1A, &#8220;Risk Factors&#8212;Risks Related to the Discovery and Development of Product Candidates&#8212;<i style="font-style:italic;">Developments relating to its TRANQUILITY II Phase 3 trial may impact the timing of its development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer&#8217;s disease</i>&#8221; for additional information. If the FDA does not accept the data from our prior TRANQUILITY II Phase 3 trial, we could be required to conduct additional </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">clinical trials beyond those we currently contemplate, which would increase our costs and delay potential submission of an sNDA for BXCL501 which in turn would adversely affect our financial position and operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Accordingly, if the FDA reaches these conclusions or otherwise finds that our proposed clinical studies would not adequately evaluate the safety and efficacy of BXCL501 for the acute treatment of agitation associated with dementia due to probable Alzheimer&#8217;s disease in an at-home setting and/or care setting, we may need to evaluate more patients for a longer period of time to demonstrate the safety and efficacy of BXCL501.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">With respect to our SERENITY program, we also held a Type C Meeting with the FDA on March 6, 2024 to obtain further feedback on our proposed changes to the design of SERENITY III Part 2, including with respect to the trial endpoints, and to discuss the content and format of a potential sNDA submission to expand the label of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> 120 micrograms to the acute treatment of agitation associated with schizophrenia and bipolar disorders in the outpatient setting. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is already approved at the 120 mcg dose based on efficacy data that we previously generated in treating a single episode of agitation. Consistent with the data generated to date, the label for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> currently includes a limitation on use (&#8220;LOU&#8221;), noting the lack of efficacy or safety data beyond 24 hours following the first dose. During our March 6, 2024 Type C meeting with the FDA, we discussed, among other things, whether evaluating the at-home use of BXCL501 120 mcg, with safety as the primary objective and efficacy measures as exploratory endpoints, if successful, could support the submission of an sNDA seeking expansion of the current label for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> 120 mcg to allow at-home use and labeling without the current LOU. Based on current FDA feedback, we have amended the Part 2 of the SERENITY III protocol to evaluate the safety and efficacy of the 120 mg dose in the at-home setting, and now refer to this revised trial as the SERENITY At-Home trial. We believe that our ability to seek labeling without the current LOU will depend, in part, on the number of agitation episodes we observe during our planned study period. Even if our planned SERENITY At-home trial is successful in demonstrating safety in the at-home setting, and even if the IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> 120 mcg label is expanded to allow outpatient use, there is no guarantee that we will observe and/or treat a sufficient number of agitation episodes during the study period to support removal of the current LOU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Any modifications to our proposed trial designs, whether by us or by the FDA would delay our initiation of such proposed trials, increase the costs of any trial that we do conduct and delay any potential submission of an sNDAs for BXCL501. Requirements to conduct additional clinical trials evaluating BXCL501 in support of our planned sNDAs seeking approvals for BXCL501 for our targeted patient populations in at-home settings would increase our costs, and in either case, such modifications or requirements could have a material adverse effect on our prospects and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">In the near term, we are dependent on the success of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and the development of four of our product candidates, BXCL501, BXCL502, BXCL701 and BXCL702. If we are unable to complete the clinical development of or obtain marketing approval for our product candidates or successfully commercialize IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and our other product candidates, either alone or with a collaborator, or if we experience significant delays in doing so, our business could be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We currently have only one product that has received regulatory approval and may never be able to develop additional marketable product candidates. We are continuing to invest a significant portion of our efforts and financial resources in the commercialization of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and development of our four product candidates, BXCL501, BXCL502, BXCL701 and BXCL702, as well as other product candidates. In connection with the Reprioritization, we have significantly reduced the resources devoted to commercialization of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and it is possible that will have adverse consequences on the revenue that we are able to generate from IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the near term. As part of the Company&#8217;s Reprioritization, the IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> commercial team shifted focus to a hospital/Integrated Delivery Network (&#8220;IDN&#8221;) contracting strategy with a Corporate Account Director (CAD) team. The goal of the realigned CAD team is to work with large IDNs and drive sales utilizing a top-down approach. Over time, the revised commercial effort is expected to allow the Company to continue to make inroads into the institutional market in a more cost-efficient manner. However, we have limited experience in drug development and commercialization, and our prospects are substantially dependent on our ability, or that of any future collaborator, to develop, obtain marketing approval for and successfully commercialize product candidates in one or more additional disease indications.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The success of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and of BXCL501, BXCL701, BXCL502 and our other product candidates will depend on several factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of an investigational new drug application (&#8220;IND&#8221;) by the FDA or acceptance of comparable applications by foreign regulatory authorities allowing us to conduct clinical trials of our product candidates in the U.S. or in foreign jurisdictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation, progress, timing, costs and results of clinical trials of our product candidates and potential product candidates, including any delays caused by the developments relating to the TRANQUILITY program, and any additional trials we may need to conduct prior to seeking approvals for BXCL501 in at-home and/or care facilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstration of safety and efficacy of our product candidates to the satisfaction of the FDA, or any comparable foreign regulatory authority, and sufficient for marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and performance of our current and future collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the nature of any required post-marketing clinical trials or other commitments to applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of supply arrangements with third-party raw materials suppliers and manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of arrangements with third-party manufacturers to obtain finished drug product that is appropriately packaged for sale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adequate ongoing availability of raw materials and drug product for clinical development and any commercial sales;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent, trade secret protection and regulatory exclusivity, both in the U.S. and internationally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">protection of our rights in our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful launch of commercial sales following any marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a continued acceptable safety profile following any marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercial acceptance by patients, the medical community and third-party payors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to compete with other therapies.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Many of these factors are beyond our control, including the results of clinical trials, the time required for the FDA, or any comparable foreign regulatory authorities, to review any regulatory submissions we may make, potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts of any future collaborator. If we are unable to commercialize IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or develop, receive marketing approval for and successfully commercialize BXCL501, BXCL701 and our other product candidates, on our own or with any future collaborator, or experience delays because of any of these factors or otherwise, our business could be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interim &#8220;top-line&#8221; and preliminary data from our clinical trials, that we announce or publish from time to time, may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">From time to time, we may publicly disclose top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data. The results and related findings and conclusions based on such preliminary data are subject to change, and have in the past changed, following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the top-line or preliminary data we previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our Company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If the interim, top-line or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, expensive and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. It is not uncommon for companies in the biopharmaceutical industry to suffer significant setbacks in advanced clinical trials due to nonclinical findings made while clinical studies are underway and safety or efficacy observations made in clinical studies, including previously unreported adverse events. Our future clinical trial results may not be successful, and notwithstanding any potential promising results in earlier studies, we cannot be certain that we will not face similar setbacks. The historical failure rate for product candidates in our industry is high. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during a product candidate&#8217;s clinical development and may vary among jurisdictions. We obtained regulatory approval for our first product candidate for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder, which is in the early stages of commercialization. It is possible that none of our other product candidates, or any product candidates we may seek to develop in the future, will ever obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our current product candidates, or any that may be developed in the future, could fail to receive regulatory approval for many reasons, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, or comparable foreign regulatory authorities, may disagree with the design or implementation of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the satisfaction of the FDA, or comparable foreign regulatory authorities, that a product candidate is safe and effective for its proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of clinical trials may not meet the level of statistical significance required by the FDA, or comparable foreign regulatory authorities, for approval;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, or comparable foreign regulatory authorities, may disagree with our interpretation of data from preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the U.S. or elsewhere;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, or comparable foreign regulatory authorities, may disagree that our changes to branded reference drugs meet the criteria for the 505(b)(2) regulatory pathway or comparable foreign regulatory pathways;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, or comparable foreign regulatory authorities, may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies or regulations of the FDA, or comparable foreign regulatory authorities, may significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have limited experience in completing clinical trials of product candidates. Consequently, we may not have the necessary capabilities, including adequate staffing, to successfully manage the execution and completion of clinical trials we initiate in a way that leads to our obtaining marketing approval for our product candidates in a timely manner, or at all. This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, even if we were to obtain approval, regulatory authorities may approve our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate or may restrict its distribution. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have only submitted one NDA to the FDA and have not submitted any similar marketing applications to comparable foreign authorities, for any product candidate, and we cannot be certain that our product candidates currently in development, or any than may be developed in the future, will be successful in clinical trials or receive regulatory approval. Further, our product candidates currently in development, or any that may be developed in the future, may not receive regulatory approval even if we believe they are successful in clinical trials. If we do not receive regulatory approvals for additional product candidates, we may not be able to continue our operations. For any regulatory approvals to market one or more of our product candidates, our revenues will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets for patients that we are targeting for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or our other product candidates are not as significant as we estimate, we may not generate significant revenues from sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or such other product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We plan to seek regulatory approval to commercialize our product candidates in the U.S., the European Union (&#8220;EU&#8221;) and in additional foreign countries. While the scope of regulatory approval is similar in other countries, to obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates, and we cannot predict success in these jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the EU recently evolved. The EU Clinical Trials Regulation (&#8220;CTR&#8221;), which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the Clinical Trials Directive required a separate clinical trial application (&#8220;CTA&#8221;), to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application for multi-center trials. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. For clinical trials whose CTA was made under the Clinical Trials Directive before January 31, 2022, the Clinical Trials Directive will continue to apply on a transitional basis for three years. Additionally, sponsors could choose to submit a CTA under either the Clinical Trials Directive or the CTR until January 31, 2023 and, if authorized, those are governed by the Clinical Trials Directive until January 31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Clinical trials are expensive, time-consuming, difficult to design, difficult to conduct, and involve an uncertain outcome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Before obtaining marketing approval from the FDA, or other comparable foreign regulatory authorities, for the sale of our product candidates, we must complete preclinical development and extensive clinical trials to demonstrate the safety and efficacy of our product candidates, in accordance with applicable law and regulations. Failure can occur at any time during the clinical trial process. Although we are planning for certain clinical trials relating to BXCL501, BXCL701, BXCL502 and our other product candidates, there can be no assurance that the FDA, or other comparable foreign regulatory authorities, will accept our proposed trial designs as sufficient to establish the safety and/or efficacy of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may experience delays in our clinical trials and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including delays related to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, or comparable foreign regulatory authorities, disagreeing as to the design or implementation of our clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining regulatory allowances or authorizations to commence a trial or consensus with regulatory authorities on trial designs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reaching agreement on acceptable terms with prospective contract research organizations (&#8220;CROs&#8221;) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining institutional review board approval at each site, or independent ethics committee approval at any sites outside the U.S.;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">dependence on the needs and timing of third-party collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes to clinical trial protocols;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recruiting suitable patients to participate in a trial in a timely manner and in sufficient numbers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical sites deviating from trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing patient safety concerns that arise during the course of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">having patients complete a trial or return for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">imposition of a clinical hold by regulatory authorities, including as a result of unforeseen safety issues or side effects or failure of trial sites to adhere to regulatory requirements;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the occurrence of SAEs in trials of the same class of agents conducted by other companies or institutions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subjects choosing an alternative treatment for the indications for which we are developing our product candidates, or participating in competing trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adding a sufficient number of clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing sufficient quantities of a product candidate for use in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of adequate funding to continue the clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">selection of clinical end points that require prolonged periods of clinical observation or analysis of the resulting data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a facility manufacturing our product candidates or any of their components being ordered by the FDA, or comparable foreign regulatory authorities, to temporarily or permanently shut down due to violations of current good manufacturing practice (&#8220;cGMP&#8221;) regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes to our manufacturing process that may be necessary or desired;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, GCPs or other regulatory requirements; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">third-party contractors not performing data collection or analysis in a timely or accurate manner;  third-party contractors not complying with training and trial protocol; or third-party contractors becoming debarred or suspended or otherwise penalized by the FDA, such as in the case of the recent events relating to the TRANQUILITY II clinical trial, or other government or regulatory authorities, for violations of regulatory requirements, in which case, we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board (&#8220;DSMB&#8221;) for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we have agreements governing their committed activities, we have limited influence over their actual performance, which increases the risk that such CROs or trial sites may fail to perform in accordance with regulatory requirements, clinical trial protocols or with the agreements governing their services to us. For example, investigator misconduct affecting our TRANQUILITY II trial, which evaluated BXCL501 in patients with probable Alzheimer&#8217;s disease, may have a material adverse impact on our development program for BXCL501 in these patients, as described more fully in the risk factor above entitled: &#8220;<i style="font-style:italic;">Developments relating to our TRANQUILITY II Phase 3 trial may impact the timing of our development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer&#8217;s disease</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Further, conducting clinical trials in foreign countries, as we may do for our current and future product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol due to differences in health care services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries. For example, current geopolitical conflicts in Eastern Europe and the Middle East may adversely impact our ability to conduct trials in those regions and elsewhere.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We depend on enrollment and evaluation of patients in our clinical trials to continue development of our product candidates. If we are unable to enroll patients in our clinical trials, our research and development efforts could be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll and evaluate a sufficient number of patients who remain in the study until its conclusion. We may experience difficulties in patient enrollment or evaluation in our clinical trials for a variety of reasons. Patient enrollment and evaluation is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, the size of the patient population required for analysis of the trial&#8217;s primary endpoints, our ability to recruit clinical trial investigators with the appropriate competencies and experience, our ability to obtain and maintain patient consents, the risk that patients enrolled in clinical trials will drop out of the trials before evaluation or completion, the frequency of acute agitation symptoms in enrolled patients, the opportunity for evaluation of patients enrolled in our trials, and competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating. Many pharmaceutical companies are conducting clinical trials in patients with the disease indications that our product candidates are designed to target. As a result, we must compete with them for clinical sites, physicians and the limited number of patients who fulfill the stringent requirements for participation in clinical trials. Also, due to the confidential nature of clinical trials, we do not know how many of the eligible patients may be enrolled in competing studies and who are consequently not available to us for our clinical trials. Our clinical trials may be delayed or terminated due to the inability to enroll enough patients. The delay or inability to meet planned patient enrollment may result in increased costs and delay or termination of our trials, which could have a harmful effect on our ability to develop products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. The clinical evaluation of BXCL501, BXCL502, BXCL701, BXCL702 and our other product candidates in patients, in many cases, is ongoing and it is possible that there may be side effects associated with their use. Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. For example, in our Phase 2 clinical trial of BXCL701 for the treatment of emergent neuroendocrine prostate cancer, one patient experienced acidosis with a fatal outcome. Although the clinical investigator could not determine that the fatality was related to treatment with BXCL701, it is possible that BXCL701 could be tied to unacceptable side effects in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If we observe drug-related AEs or other unacceptable safety concerns in clinical trials, we, the FDA, the IRBs at the institutions in which our studies are conducted, or the DSMB could suspend or terminate our clinical trials or the FDA, or comparable foreign regulatory authorities, could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. For example, the FDA placed Point Therapeutics, Inc.&#8217;s IND for BXCL701 on clinical hold following an increase in observed mortality in patients receiving BXCL701 in a Phase 3 trial in patients with non-small cell lung cancer. Though we believe that this result was caused by, among other things, an imbalance in the disease severity of patients enrolled in the active arm of the clinical trial, there is no guarantee that excess mortality will not be observed in future clinical studies. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the clinical trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">medical personnel using our product candidates to understand the side effect profiles observed in our clinical trials and upon commercialization of any of our product candidates that may receive regulatory approval. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Additionally, if we or others later identify undesirable side effects caused by IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or any other product candidate that receives marketing approval, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw approvals of such products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to recall a product or change the way such a product is administered to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional restrictions may be imposed on the marketing or distribution of the particular product or the manufacturing processes for the product or any component thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to implement Risk Evaluation and Mitigation Strategies (&#8220;REMS&#8221;) or create a medication guide outlining the risks of such side effects for distribution to patients, or similar risk management measures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our product may become less competitive; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product or product candidate, if approved, and could significantly harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The discovery and development of product candidates based on EvolverAI, BioXcel LLC&#8217;s proprietary pharmaceutical discovery and development engine, and our artificial intelligence (&#8220;AI&#8221;) platform is novel and unproven, and we do not know whether we will be able to develop any products of commercial value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are leveraging our own AI platform and BioXcel LLC&#8217;s EvolverAI, a proprietary pharmaceutical discovery and development engine, to create a pipeline of neuroscience and immuno-oncology product candidates for patients whose diseases have not been adequately addressed to date by other approaches and to design and conduct efficient clinical trials with a higher likelihood of success. While we believe that applying our AI platform and BioXcel LLC&#8217;s EvolverAI to create medicines for defined patient populations may potentially enable drug research and clinical development that is more efficient than conventional drug research and development, our approach is novel. Although we obtained FDA approval for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, because our approach is novel, the cost and time needed to develop our product candidates is difficult to predict, and our efforts may not result in the discovery and development of commercially viable medicines. We may also be incorrect about the effects of our product and product candidates on the diseases of our defined patient populations, which may limit the utility of our approach or the perception of the utility of our approach. Furthermore, our estimates of our defined patient populations available for study and treatment may be lower than expected, which could adversely affect our ability to conduct clinical trials and may also adversely affect the size of any market for medicines we may successfully commercialize. Our approach may not result in time savings, higher success rates or reduced costs as we expect it to, and if not, we may not attract collaborators or develop new drugs as quickly or cost effectively as expected and therefore we may not be able to commercialize our approach as originally expected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Issues in the development and use of artificial intelligence, combined with an uncertain regulatory environment, may result in reputational harm, liability, or other adverse consequences to our business operations. As with many </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">technological innovations, artificial intelligence presents risks and challenges that could impact our business. We may adopt and integrate generative artificial intelligence tools into our systems for specific use cases reviewed by legal and information security. Our vendors may incorporate generative artificial intelligence tools into their offerings without disclosing this use to us, and the providers of these generative artificial intelligence tools may not meet existing or rapidly evolving regulatory or industry standards with respect to privacy and data protection and may inhibit our or our vendors&#8217; ability to maintain an adequate level of service and experience. If we, our vendors, or our third-party partners experience an actual or perceived breach or privacy or security incident because of the use of generative artificial intelligence, we may lose valuable intellectual property and confidential information and our&#160;reputation and the public perception of the effectiveness of our security measures could be harmed. Further, bad actors around the world use increasingly sophisticated methods, including the use of artificial intelligence, to engage in illegal activities involving the theft and misuse of personal information, confidential information, and intellectual property. Any of these outcomes could damage our reputation, result in the loss of valuable property and information, and adversely impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Additionally, our use of AI and machine learning may be subject to laws and evolving regulations regarding the use of AI or machine learning, controlling for data bias, and anti-discrimination, and we may not always be able to anticipate how to respond to these laws or regulations. Further, there is an increase in litigation in a number of jurisdictions, including the United States, relating to the use of AI, particularly generative AI. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s AI platform and BioXcel LLC&#8217;s EvolverAI may fail to help us discover and develop additional potential product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Any drug discovery that we are conducting using the Company&#8217;s AI platform and BioXcel LLC&#8217;s EvolverAI may not be successful in identifying compounds that have commercial value or therapeutic utility. The Company&#8217;s AI platform and BioXcel LLC&#8217;s EvolverAI may initially show promise in identifying potential product candidates, yet fail to yield viable additional product candidates for clinical development or potential commercialization for a number of reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">research programs to identify new product candidates will require substantial technical, financial and human resources, and we may be unsuccessful in our efforts to identify new product candidates. If we are unable to identify suitable additional compounds for preclinical and clinical development, our ability to develop product candidates and obtain product revenues in future periods could be compromised, which could result in significant harm to our financial position and adversely impact our stock price;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compounds found through the Company&#8217;s AI platform and BioXcel LLC&#8217;s EvolverAI may not demonstrate efficacy, safety or tolerability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to receive marketing approval and achieve market acceptance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitors may develop alternative therapies that render our potential product candidates non-competitive or less attractive; or</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a potential product candidate may not be capable of being produced at an acceptable cost.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulators may limit our ability to develop or implement our proprietary AI algorithms and/or may eliminate or restrict the confidentiality of our proprietary technology, which could have an adverse effect on our business, results of operations, and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our future success depends on our ability to continue to develop and implement our proprietary AI algorithms and models, and to maintain the confidentiality of this technology. Changes to existing regulations, their interpretation or implementation, or new regulations could impede our use of this technology or require that we disclose our proprietary technology to our competitors, which could impair our competitive position and result in an adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We obtained Fast Track designation for certain of our product candidates, and we may seek Fast Track designation for other indications or for our other product candidates, but we might not receive such designations, and even if we do, such designations may not actually lead to a faster development or regulatory review or approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If a product candidate is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical need for this condition, a product sponsor may apply for FDA Fast Track designation. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once an NDA is submitted, the product candidate may be eligible for priority review if the relevant criteria are met. An NDA for a Fast Track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. We obtained Fast Track designation for BXCL501 for the acute treatment of mild-to-moderate agitation associated with schizophrenia, bipolar disorder, and dementia, and we further obtained Fast Track designation for BXCL701, in combination with a checkpoint inhibitor, for the treatment of patients with metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability, and we may seek additional Fast Track designation for BXCL501 or BXCL701 or for one or more of our other product candidates, but we might not receive such designations from the FDA. However, even if we receive Fast Track designation, Fast Track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular timeframe. We may not experience a faster development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We obtained Breakthrough Therapy Designation for BXCL501 for the acute treatment of agitation associated with dementia, and we may seek additional Breakthrough Therapy designations for our product candidates if the clinical data support such a designation for one or more product candidates. A Breakthrough Therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Product candidates designated as Breakthrough Therapies by the FDA also receive the benefits associated with Fast Track designation, including the potential for rolling review of an NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">candidate may not result in a faster development process, review or approval compared to drugs considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the period for FDA review or approval will not be shortened.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the FDA does not conclude that our product candidates satisfy the requirements for the 505(b)(2) regulatory approval pathway, or if the requirements for approval of any of our product candidates under Section 505(b)(2) are not as we expect, the approval pathway for our product candidates will likely take significantly longer, cost significantly more and encounter significantly greater complications and risks than anticipated, and in any case may not be successful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We intend to seek FDA approval through the 505(b)(2) regulatory pathway for certain of our product candidates. The Hatch-Waxman Act added Section 505(b)(2) to the Federal Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;). Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies that were not conducted by or for the applicant. If the FDA does not allow us to pursue the 505(b)(2) regulatory pathway for our product candidates as anticipated, we may need to conduct additional clinical trials, provide additional data and information and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for our product candidates would likely substantially increase. Moreover, the inability to pursue the 505(b)(2) regulatory pathway could result in new competitive products reaching the market faster than our product candidates, which could materially adversely impact our competitive position and prospects. Even if we are allowed to pursue the 505(b)(2) regulatory pathway for a product candidate, we cannot assure you that we will receive the requisite or timely approvals for commercialization of such product candidate. In addition, we expect that our competitors will file citizens&#8217; petitions with the FDA in an attempt to persuade the FDA that our product candidates, or the clinical studies that support their approval, contain deficiencies. Such actions by our competitors could delay or even prevent the FDA from approving any NDA that we submit under Section 505(b)(2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are required by the FDA, or similar regulatory authorities, to obtain approval (or clearance, or certification) of a companion diagnostic device in connection with approval of one of our product candidates, and we do not obtain, or face delays in obtaining approval (or clearance, or certification) of a companion diagnostic device, we will not be able to commercialize the product candidate, and our ability to generate revenue will be materially impaired</span>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">According to FDA guidance, if the FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared for that indication. If a satisfactory companion diagnostic is not commercially available, we may be required to create or obtain one that would be subject to regulatory approval requirements. For example, we may decide to collaborate with patient diagnostic companies during our clinical trial enrollment process for BXCL701 to help identify patients with tumor gene alterations that we believe may be most likely to respond to treatment with BXCL701. The process of obtaining or creating such diagnostic is time consuming and costly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Companion diagnostics are developed in conjunction with clinical programs for the associated product and are subject to regulation as medical devices by the FDA and comparable foreign regulatory authorities, and, to date, the FDA has generally required premarket approval of companion diagnostics for cancer therapies. Generally, when a companion diagnostic is essential to the safe and effective use of a therapeutic product, the FDA requires that the companion diagnostic be approved before or concurrent with approval of the therapeutic product and before a product can be commercialized. The approval of a companion diagnostic as part of the therapeutic product&#8217;s labeling limits the use of the therapeutic product to only those patients who express the specific genetic alteration that the companion diagnostic was developed to detect. In January 2024, the FDA announced that it intends to initiate the process to reclassify most in vitro diagnostic tests (&#8220;IVDs&#8221;) that are currently Class III into Class II, including companion diagnostic IVDs.  If such reclassification efforts occur, any companion diagnostics that are the subject of the down-classification may no longer require premarket approval, but rather may be marketed pursuant to the generally less burdensome 510(k) clearance process.  However, there is no assurance that any companion diagnostic required for our pharmaceutical development programs will benefit from the reclassification, or that the reclassification, even if it does occur, will result in a shorter timeline to development or marketing of the companion diagnostic.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If the FDA, or a comparable foreign regulatory authority, requires approval (or certification or clearance) of a companion diagnostic for any of our product candidates, whether before or after the product candidate obtains marketing approval, we and/or third-party collaborators may encounter difficulties in developing and obtaining approval (or clearance, or certification) for these companion diagnostics. Any delay or failure by us or third-party collaborators to develop or obtain regulatory approval (or clearance, or certification) of a companion diagnostic could delay or prevent approval or continued marketing of our related product candidates. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process for the companion diagnostic or in transferring that process to commercial partners or negotiating insurance reimbursement plans, all of which may prevent us from completing our clinical trials or commercializing our product candidates, if approved, on a timely or profitable basis, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Approval, clearance or certification of companion diagnostics may be subject to further legislative or regulatory reforms notably in the EU. On May 25, 2017, the new In Vitro Medical Devices Regulation No. 2017/746 (&#8220;IVDR&#8221;) entered into force. The IVDR repeals and replaces the EU In Vitro Diagnostic Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EU member states, regulations are directly applicable (i.e., without the need for adoption of EU member states laws implementing them) in all EU member states and are intended to eliminate current differences in the regulation of medical devices among EU member states. The IVDR, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EU for medical devices and ensure a high level of safety and health while supporting innovation. The IVDR became effective in May 2022. However, on October 14, 2021, the European Commission proposed a &#8220;progressive&#8221; roll-out of the IVDR to prevent disruption in the supply of in vitro diagnostic medical devices. The European Parliament and Council adopted the proposed regulation on December 15, 2021. The IVDR has applied since May 26, 2022, but there is a tiered system extending the grace period for many devices (depending on their risk classification) before they have to be fully compliant with the regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The regulation of companion diagnostics in the EU is subject to further requirements since the IVDR became applicable as it introduced a new classification system for companion diagnostics. Companion diagnostics will have to undergo a conformity assessment by a notified body. Before it can issue an EU certificate, the notified body must seek a scientific opinion from the EMA on the suitability of the companion diagnostic to the medicinal product concerned if the medicinal product falls exclusively within the scope of the centralized procedure for the authorization of medicines, or the medicinal product is already authorized through the centralized procedure, or a marketing authorization (&#8220;MA&#8221;) application for the medicinal product has been submitted through the centralized procedure. For other substances, the notified body can seek the opinion from a national competent authority or the EMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">These modifications may make it more difficult and costly for us to obtain regulatory clearances, approvals or certifications for our companion diagnostics or to manufacture, market or distribute our products after clearance, approval or certification is obtained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Although the FDA has approved IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder, we will still face extensive and ongoing regulatory requirements and obligations for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and for any product candidates for which we obtain approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Any regulatory approvals that we may receive for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or any of our product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA-approved label for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> includes certain warnings and precautions regarding hypotension, orthostatic hypotension, bradycardia, somnolence, and QT interval prolongation. The FDA may also require a REMS to approve a product candidate, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, the manufacturing processes, labeling, packaging, distribution, AE reporting, storage, advertising, promotion, import, export and recordkeeping for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> are and will remain subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, and on-going compliance with cGMPs, and GCPs for any clinical trials that we conduct post-</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. If we or a regulatory authority discover previously unknown problems with a product, such as AEs of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, discovery of previously unknown AEs or other problems with our products, manufacturers or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on manufacturing such products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the labeling or marketing of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on product manufacturing, distribution or use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-marketing studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of the products from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution or disgorgement of profits or revenues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of marketing approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Further, the policies of the FDA and other regulatory authorities may change, and additional government regulations may be enacted that could impose extensive and ongoing regulatory requirements and obligations on any product candidate for which we obtain marketing approval. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the U.S. or abroad.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The FDA and other regulatory authorities strictly regulate marketing, labeling, advertising and promotion of prescription drugs. These regulations include standards and restrictions for direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving the internet and off-label promotion. Any regulatory approval that the FDA or any other regulatory authority may grant is limited to those specific diseases and indications for which a product is deemed to be safe and effective. For example, the FDA-approved label for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is currently limited to the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults to be self-administrated by patients under the supervision of a health care provider. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">While physicians in the U.S. may choose, and are generally permitted, to prescribe drugs for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, our ability to promote the products is narrowly limited to those indications that are specifically approved by the FDA. These &#8220;off-label&#8221; uses are common across medical specialties and may constitute an appropriate </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">treatment for some patients in varied circumstances. For example, other formulations of Dex, the active ingredient in IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, have been approved for uses beyond those authorized in IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> approved labeling, such as for use in sedation of surgical patients, and we are continuing to develop BXCL501 for potential use in patients with dementia, MDD, Alzheimer&#8217;s disease and other indications. We do not market or promote IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> for these uses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Regulatory authorities in the U.S. generally do not regulate the behavior of physicians in their choice of treatments. Regulatory authorities do, however, restrict communications by pharmaceutical companies on off-label use. If we are found to have promoted our products for any off-label uses, the U.S. federal government (and other foreign governments) could levy civil, criminal and/or administrative penalties, and seek fines against us. The FDA, or other regulatory authorities, could also require that we enter into a consent decree or a corporate integrity agreement, or seek a permanent injunction against us under which specified promotional conduct is monitored, changed or curtailed. If we cannot successfully manage the promotion of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Disruptions at the FDA and other government agencies caused by funding shortages or staffing reductions could prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The ability of the FDA and foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, the FDA&#8217;s or foreign regulatory authorities&#8217; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s or foreign regulatory authorities&#8217; ability to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result of some of these aforementioned issues. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies, such as the EMA, following its relocation to Amsterdam and corresponding staff changes, may also slow the time necessary for new drug or modifications to approved drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Additionally, recent actions by the United States federal government have caused concern in the industry that this may occur. For example, beginning on February 13, 2025, the Department of Health and Human Services began firing a large number of its probationary employees, a category that includes new federal employees and employees recently promoted or transferred to new positions or agencies. Larger&#160;layoffs&#160;may follow, according to a memorandum issued by the Office of Personnel Management on February 26, 2025. These terminations, if they withstand legal challenges, may significantly delay and impede our interactions with&#160;FDA. Similar results may stem from the recent confirmed resignations of some senior&#160;FDA&#160;employees with responsibility for regulation of drugs and biologics, as well as possible future&#160;layoffs&#160;and resignations. There are also reports that the United States federal government intends to request Congress to reduce&#160;FDA&#160;funding in upcoming budgets. Such funding cuts may also delay the development and approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may conduct certain of or portions of our clinical trials for our product candidates outside of the U.S. and the FDA may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We may choose to conduct one or more of our clinical trials or a portion of our clinical trials for our product candidates outside the U.S. The acceptance of study data from clinical trials conducted outside the U.S. or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the foreign </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">study data are not intended to serve as the sole basis for approval, if the clinical trial was not otherwise subject to an IND, the FDA will not accept the data as support for an application for marketing approval unless the study was conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an on-site inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and could result in current or future product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to extensive regulations outside the U.S. and may not obtain marketing approvals for products in Europe and other jurisdictions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition to regulations in the U.S., should we or our collaborators pursue marketing approvals for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and for BXCL501, BXCL502, BXCL701, BXCL702 and our other product candidates internationally, we and our collaborators will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we, or our collaborators, obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We expect to pursue marketing approvals for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and may pursue marketing approvals for BXCL501, BXCL502, BXCL701, BXCL702 and our other product candidates in Europe and other jurisdictions outside the U.S. with collaborative partners. The time and process required to obtain regulatory approvals and reimbursement in Europe and other jurisdictions may be different from those in the U.S. Also, regulatory approval in one jurisdiction does not ensure approvals in any other jurisdiction; however, negative regulatory decisions in any jurisdiction may have a negative impact on the regulatory process in other jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Following a national referendum and enactment of legislation by the government of the United Kingdom (&#8220;UK&#8221;), the UK formally withdrew from the EU on January 31, 2020 and ratified a trade and cooperation agreement governing its future relationship (commonly referred to as &#8220;Brexit&#8221;). The agreement, which was applied provisionally from January 1, 2021 and entered into force on May 1, 2021, addresses trade, economic arrangements, law enforcement, judicial cooperation and a governance framework including procedures for dispute resolution, among other things. Because the agreement merely sets forth a framework in many respects and requires complex additional bilateral negotiations between the UK and the EU as both parties continue to work on the rules for implementation, significant political and economic uncertainty remains about how the precise terms of the relationship between the parties will differ from the terms before withdrawal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Since January 1, 2021, the UK operates under a distinct regulatory regime to the EU. EU pharmaceutical laws only apply in respect of the UK to Northern Ireland (as set out in the Protocol on Ireland/Northern Ireland). EU laws which have been transposed into UK law through secondary legislation continue to be applicable as &#8220;retained EU law&#8221;. While the UK has indicated a general intention that new laws regarding the development, manufacture and commercialization of medicinal products in the UK will align closely with EU law, there are limited detailed proposals for future regulation of medicinal products. The trade and cooperation agreement includes specific provisions concerning medicinal products, which include the mutual recognition of cGMP, inspections of manufacturing facilities for medicinal products and cGMP documents issued (such mutual recognition can be rejected by either party in certain circumstances) but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations. For example, it is not clear to what extent the UK will adopt legislation aligned with, or similar to, the EU CTR which became applicable on January 31, 2022 and which significantly reforms the assessment and supervision processes for clinical trials throughout the EU. On January 17, 2022, the UK Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) launched an eight-week consultation on reframing the UK legislation for clinical trials which aimed to streamline clinical trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public involvement in clinical trials. The MHRA responded to the consultation on March 21, 2023 and confirmed that it would bring forward changes to the legislation. The final legal texts introduced by the UK Government will ultimately </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">determine the extent to which the UK clinical trials framework aligns with or diverges from the EU CTR. A decision by the UK not to closely align its regulations with the new approach that will be adopted in the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Therefore, there remains political and economic uncertainty regarding to what extent the regulation of medicinal products will differ between the UK and the EU in the future. Any divergences will increase the cost and complexity of running our business, including with respect to the conduct of clinical trials. Brexit also materially impacted the regulatory regime with respect to the approval of our product candidates. Great Britain is no longer covered by the EU&#8217;s procedures for the grant of MAs (Northern Ireland is covered by the centralized authorization procedure and can be covered under the decentralized or mutual recognition procedures). As of January 1, 2021, all existing centralized MAs were automatically converted into UK MAs effective in Great Britain and issued with a UK MA number on January 1, 2021 (unless MA holders opted out of this scheme). A separate MA is now required to market drugs in Great Britain. It is currently unclear whether the regulator in the UK, the MHRA, is sufficiently prepared to handle the increased volume of MA applications that it is likely to receive. Any delay in obtaining, or an inability to obtain, any regulatory approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in Great Britain and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in Great Britain for our product candidates, which could significantly and materially harm our business. Any of these factors could have a significant adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we are found in violation of federal, state or foreign health care &#8220;fraud and abuse&#8221; laws, we may be required to pay significant fines and penalties, including, without limitation, debarment, suspension or exclusion from participation in federal, state or similar health care programs, which may adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In the U.S., we are subject to various federal and state health care &#8220;fraud and abuse&#8221; laws, including anti- kickback laws, false claims laws and other laws intended to reduce fraud and abuse in federal and state health care programs, which could affect us, and our ability to successfully commercialize our products in the U.S. We may have to comply with similar laws and regulations outside the U.S. These laws include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce the referral of business, including the purchase, order or prescription of a particular drug for which payment may be made under a federal health care program, such as Medicare or Medicaid. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">false claims laws prohibit anyone from knowingly and willfully presenting or causing to be presented for payment to third-party payers, including government payers, claims for reimbursed drugs or services that are false or fraudulent, claims for items or services that were not provided as claimed, or claims for medically unnecessary items or services. Cases have been brought under false claims laws alleging that off-label promotion of pharmaceutical products or the provision of kickbacks has resulted in the submission of false claims to governmental health care programs. In addition, the government may assert that a claim, including items or services resulting from a violation of the federal Anti-Kickback Statute, constitutes a false or fraudulent claim for purposes of the false claims laws. Further, private individuals have the ability to bring actions on behalf of the government under the federal False Claims Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) prohibits persons or entities from knowingly and willfully executing a scheme to defraud any health care benefit program, including private payers, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services. Similar to the federal Anti- Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them to have committed a violation;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer of remuneration to a Medicare or state health care program beneficiary if the person knows, or should know, it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal physician sunshine requirements under the Patient Protection and Affordable Care Act (&#8220;ACA&#8221;), which requires certain manufacturers of drugs, devices, biologics, and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants, and certified nurse midwives), and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to health care providers and other potential referral sources; and state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other health care providers or marketing expenditures and pricing information; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to health care providers.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, the exclusion from participation in federal and state or foreign health care programs, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to market our products and adversely impact our financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may be unable to maintain sufficient clinical trial liability insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our inability to retain sufficient clinical trial liability insurance at an acceptable cost to protect against potential liability claims could prevent or inhibit our ability to conduct clinical trials for product candidates we develop. We may be unable to obtain appropriate levels of such insurance. Even if we do secure clinical trial liability insurance for our programs, we may not be able to achieve sufficient levels of such insurance. Any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that exceeds the limits of our insurance coverage. We have supplemented our clinical trial coverage with product liability coverage in connection with the commercial launch of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and expect that we would similarly supplement our coverage for any of our other product candidates that may receive regulatory approval, but we may be unable to obtain such increased coverage on acceptable terms or at all. If we are found liable in a clinical trial lawsuit or a product liability lawsuit in the future, we will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Commercialization of Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If our products do not gain market acceptance or if we fail to accurately forecast demand or manage our inventories, our business will suffer because we might not be able to fund future operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A number of factors may affect the market acceptance of our products or any other products or product candidates we develop or acquire, including, among others:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the price of our products relative to other products for the same or similar treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the perception by patients, physicians and other members of the health care community of the effectiveness, utility and safety of our products for their indicated applications and treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to fund our sales and marketing efforts; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effectiveness of our sales and marketing efforts, including our strategic refocus to hospital/IDNs as part of the Reprioritization.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If our products do not gain market acceptance, we may not be able to fund future operations, including developing, testing and obtaining regulatory approval for new product candidates and expanding our sales and marketing efforts for our approved products, which would cause our business to suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We plan to continue to commercialize IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder, to be self-administered by patients under the supervision of a healthcare provider, which is our only approved product to date. However, in connection with the Reprioritization, we significantly reduced the resources devoted to commercialization of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and it is possible that will have adverse consequences on the revenue that we are able to generate from IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>. Revenues for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> for the year ended December 31, 2024 were $2.3 million. If our commercial products do not gain market acceptance, we may not be able to fund future operations, including developing, testing and obtaining regulatory approval for an sNDA for other BXCL501 indications, including in the at-home setting for the acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer&#8217;s disease, or for other product candidates that it may develop. Our results of operations could be materially harmed if we are unable to successfully commercialize IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> for any currently or additionally approved indications or any future product candidates that we may have approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our results of operations could be materially harmed if we are unable to accurately forecast customer demand for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and manage our inventory. To ensure adequate inventory supply, we must forecast inventory needs and place orders with our suppliers based on our estimates of future demand for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>. Our ability to accurately forecast demand for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> could be negatively affected by many factors, including our failure to accurately manage our expansion strategy, product introductions by competitors, an increase or decrease in customer demand for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or for products of our competitors, our failure to accurately forecast customer acceptance of new products, unanticipated changes in general market conditions or regulatory matters, and weakening of economic conditions or consumer confidence in future economic conditions. Inventory levels in excess of customer demand may result in inventory write-downs or write-offs, which would cause our gross margin to be adversely affected and could impair the strength of our brand. Conversely, if we underestimate customer demand for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, our third-party contract manufacturer may not be able to deliver products to meet our requirements, and this could result in damage to our reputation and customer relationships. In addition, if we experience a significant increase in demand, additional supplies of raw materials or additional manufacturing capacity may not be available when required on terms that are acceptable to us, or at all, or suppliers or our third-party manufacturers may not be able to allocate sufficient capacity in order to meet our increased requirements, which could have an adverse effect on our ability to meet customer demand for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We seek to maintain sufficient levels of inventory to protect ourselves from supply interruptions. As a result, we are subject to the risk that a portion of our inventory will become obsolete or expire, which could have a material adverse effect on our earnings and cash flows due to the resulting costs associated with the inventory impairment charges and costs required to replace such inventory.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our estimated number of episodes of agitation and our corresponding estimated total addressable market are subject to inherent challenges and uncertainties. If we have overestimated the number of episodes or the size of our total addressable market for our current and potential future products or product candidates, or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability may be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:14pt 0pt 10pt 0pt;">We have based our potential market opportunity on a number of internal and third-party estimates and resources, including, without limitation, management&#8217;s estimates and research, as well as industry and general publications and research, surveys and studies conducted by third parties, which may be incorrect.&#160; Our estimated potential market opportunity is based on estimates of episodes of agitation across our indications, and these estimated episodes of agitation are also based on internal and third-party estimates and market resources using data self-reported by patients. The conditions supporting our assumptions or estimates and the market data supporting these assumptions and estimates may change at any time or otherwise be inaccurate, thereby reducing the predictive accuracy of these underlying factors.  Our total addressable market will ultimately depend upon, among other things, the number of actual treatable episodes, the diagnosis criteria included in the final label for each of our product candidates, if approved for sale for these indications, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients and treatable episodes in the United States and other major markets and elsewhere may turn out to be materially lower than expected, the number of treatable episodes may be significantly fewer than total episodes experienced, patients may not be otherwise amenable to treatment with our product candidates or new patients may become increasingly difficult to identify or gain access to, all of which would harm our results of operations and our business. For example, our estimates of the monthly average episodes for patients diagnosed with bipolar disorder and patients diagnosed with schizophrenia and, therefore, our estimated total addressable market are based on third-party market surveys which differ from an observational study in the EU of inhaled loxapine for the treatment of agitation in patients with schizophrenia or bipolar disorder conducted which found that only 40% of enrolled patients reported agitation episodes in the six-month study period. If third-party or internally generated data prove to be inaccurate or we make errors in our assumptions based on that data, our total addressable market may be meaningfully smaller than we have estimated, our future growth opportunities and sales growth may be impaired, any of which could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We obtained Orphan Drug Designation for BXCL701 for the treatment of pancreatic cancer, melanoma, acute myeloid leukemia and soft tissue sarcoma and we may seek Orphan Drug Designation for other indications or product candidates, and we may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for market exclusivity, and may not receive Orphan Drug Designation for other indications or for our other product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Regulatory authorities in some jurisdictions, including the U.S. and EU, may designate drugs intended for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the U.S., or a patient population greater than 200,000 individuals in the U.S. where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the U.S. In the EU, orphan drug designation is granted by the European Commission based on a scientific opinion of the EMA&#8217;s Committee for Orphan Medicinal Products. A medicinal product may be designated as orphan if its sponsor can establish that (i) the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (ii) either (a) such condition affects no more than 5 in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment; and (iii) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the medicinal product will be of significant benefit to those affected by the condition. The application for orphan designation must be submitted before the application for MA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the U.S., orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity. Orphan drug exclusivity in the U.S. provides that the FDA may not approve any other applications, including a full NDA, to market the same drug for the same disease or condition for </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">seven years. In limited circumstances, the applicable exclusivity period is 10 years in the EU. The EU exclusivity period can be reduced to six years if, at the end of the fifth year, it is established that a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In January 2021, the FDA granted Orphan Drug Designation to BXCL701 for the treatment of soft tissue sarcoma. In September 2019, the FDA granted Orphan Drug Designation to BXCL701 for the treatment of acute myeloid leukemia. Prior to 2019, the FDA granted Orphan Drug Designation to BXCL701 for the treatment of pancreatic cancer and melanoma. We may seek Orphan Drug Designations for BXCL701 in other diseases or conditions or for other product candidates. There can be no assurances that we will be able to obtain such designations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Even if we, or any future collaborators, obtain orphan drug designation for a product candidate, we, or they, may not be able to obtain or maintain orphan drug exclusivity for that product candidate. We may not be the first to obtain marketing approval of any product candidate for which we have obtained orphan drug designation for the orphan- designated indication due to the uncertainties associated with developing pharmaceutical products, and it is possible that another company also holding orphan drug designation for the same product candidate will receive marketing approval for the same disease or condition before we do. If that were to happen, our applications for that disease or condition may not be approved until the competing company&#8217;s period of exclusivity expires. In addition, exclusive marketing rights in the U.S. and abroad may be limited if we seek approval for an indication broader than the orphan-designated disease or condition or may be lost if the FDA or foreign regulatory authorities later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we, or any future collaborators, obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active ingredients may be approved for the same disease or condition. Even after an orphan drug is approved, the FDA or foreign regulatory authorities can subsequently approve the same drug with the same active ingredient for the same condition if the FDA or foreign regulatory authorities conclude that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care or the manufacturer of the product with orphan exclusivity is unable to maintain sufficient product quantity. Orphan drug designation neither shortens the development or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process and does not prevent competitors from obtaining approval of the same product candidate as ours for indications other than those in which we have been granted orphan drug designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we are unable to develop satisfactory sales and marketing capabilities, we may not succeed in commercializing IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or any product candidate for which we may obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have limited experience in marketing and selling drug products. We have not entered into arrangements for the sale and marketing of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, BXCL501, BXCL502, BXCL701, BXCL702 or any other product candidate. Typically, pharmaceutical companies would employ groups of sales representatives and associated sales and marketing staff numbering in the hundreds to thousands of individuals to call on the large number of physicians and hospitals. Following our Reprioritization, we may need to rebuild a commercial sales and marketing team if we seek to modify our commercial strategy for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or initiate commercial sales for any product candidate in the future, which will likely require significant cost. We may seek to collaborate with a third-party to market our drugs or may seek to market and sell our drugs by ourselves. If we seek to collaborate with a third-party, we cannot be sure that a collaborative agreement can be reached on terms acceptable to us. We may also need to hire additional personnel skilled in marketing and sales for our direct marketing and selling efforts. We cannot be sure that we will be able to acquire, or establish third-party relationships to provide, any or all of these marketing and sales capabilities. The maintenance and expansion of our direct sales force or establishment of a contract sales force, or a combination thereof, as applicable, to market our products is expensive and time-consuming and could delay any product launch. In addition, reputational harm from the Reprioritization may adversely impact our efforts to hire personnel skilled in marketing and sales. Further, we can give no assurances that we will be able to maintain a direct and/or contract sales force for any period of time or that our sales efforts will be sufficient to grow our revenues or that our sales efforts will ever lead to profits. A direct sales force has in the past subjected and may in the future subject us to higher fixed costs than those of companies that market competing products through independent third parties, due to the costs that we bear associated with employee benefits, training, and managing sales personnel. As a result, we could be at a competitive disadvantage. Additionally, these fixed costs may slow our ability to reduce costs if needed, which could have a material adverse effect on our business, financial condition, and results of operations.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We operate in a highly competitive and rapidly changing industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Biopharmaceutical product development is highly competitive and subject to rapid and significant technological advancements. Our success is highly dependent upon our ability to in-license, acquire, develop and obtain regulatory approval for new and innovative products on a cost-effective basis and to market them successfully. In doing so, we face and will continue to face intense competition from a variety of businesses, including large, fully integrated, well-established pharmaceutical companies who already possess a large share of the market, specialty pharmaceutical and biopharmaceutical companies, academic institutions, government agencies and other private and public research institutions in the U.S., the EU and other jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions in the biopharmaceutical industry could result in even more resources being concentrated among a small number of our competitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Competition may further increase as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing, on an exclusive basis, products that are more effective or less costly than any product candidate that we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Established biopharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, discovering, developing, receiving FDA approval for or commercializing drugs before we do, which would have an adverse impact on our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The availability of our competitors&#8217; products could limit the demand and the price we are able to charge for products and product candidates, if any, that we commercialize. The inability to compete with existing or subsequently introduced drugs would harm our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Although we obtained FDA approval for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, our products and product candidates may not be accepted by physicians or the medical community in general, and there may be insufficient insurance coverage and reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There can be no assurance that IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, or BXCL501, BXCL502, BXCL701, BXCL702 and our other product candidates or any other product candidate successfully developed by us, independently or with partners, if approved, will be accepted by physicians, hospitals and other health care facilities. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> competes, and BXCL501, BXCL502, BXCL701, BXCL702 and any future product candidates we develop will compete, with a number of products manufactured and marketed by major pharmaceutical and biotechnology companies. The degree of market acceptance of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and any drugs we develop depends on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our demonstration of the clinical efficacy and safety of our products and product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timing of market approval and commercial launch of our products and product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indication(s) for which our products and product candidates are approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product label and package insert requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advantages and disadvantages of our products and product candidates compared to existing therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continued interest in and growth of the market for anti-cancer or anti-agitation drugs;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strength of sales, marketing, and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product pricing in absolute terms and relative to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future changes in health care laws, regulations, and medical policies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability of coverage and reimbursement in select jurisdictions, and future changes to coverage and reimbursement policies of government and third-party payors.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or any product candidate for which we obtain regulatory approval. In the U.S. and other countries, sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and any other products for which we receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payors. Third-party payors include government health administrative authorities, such as Medicaid and Medicare, managed care providers, private health insurers and other organizations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Third-party payors are increasingly challenging the prices charged for medical products and services. It will be time consuming and expensive for us to go through the process of seeking coverage and reimbursement from Medicare and private payors. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and any other products for which we receive regulatory approval may not be considered cost-effective, and coverage and reimbursement may not be available or sufficient to allow us to sell our proposed products on a profitable basis. Further federal, state and foreign government proposals and health care reforms are likely which could limit the prices that can be charged for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>and the product candidates that we develop and may further limit our commercial opportunities. Our results of operations could be materially adversely affected by proposed health care reforms, by the Inflation Reduction Act and other drug pricing legislation in the U.S., by the possible effect of such current or future legislation on amounts that private insurers will pay and by other health care reforms that may be enacted or adopted in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Health care reform measures could hinder or prevent our product candidates&#8217; commercial success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The U.S. government and other governments have shown significant interest in pursuing health care reform. Any government-adopted reform measures could adversely impact the pricing of health care products and services in the U.S. or internationally and the amount of reimbursement available from governmental agencies or other third-party payors for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and the product candidates that we develop. The continuing efforts of the U.S. and foreign governments, insurance companies, managed care organizations and other payors of health care services to contain or reduce health care costs may adversely affect our ability to set prices for our products, which we believe are fair, and our ability to generate revenues and achieve and maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">New laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and decisions, that relate to health care availability, methods of delivery or payment for products and services, or sales, marketing or pricing, may limit our potential revenue, and we may need to revise our research and development programs. The pricing and reimbursement environment may change in the future and become more challenging due to several reasons, including policies advanced by the current executive administration in the U.S., new health care legislation or fiscal challenges faced by government health administration authorities. Specifically, in both the U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health care system in ways that could affect our ability to sell our products profitably.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For example, in the U.S., the ACA, which was enacted in 2010, has substantially changed the way health care is financed by both government health plans and private insurers, and significantly impacts the pharmaceutical industry. For example, the ACA imposed a non-deductible excise tax on pharmaceutical manufacturers or importers that sell branded prescription drugs to government programs. In addition, as part of the ACA&#8217;s provisions closing a funding gap that existed in the Medicare Part D prescription drug program, manufacturers are required to provide a discount on branded prescription drugs for drugs provided to certain beneficiaries who fall within the &#8220;donut hole.&#8221; Similarly, the ACA increased the level of Medicaid rebates payable by manufacturers of brand-name drugs from 15.1% to 23.1% of the average manufacturer price and required collection of rebates for drugs paid by Medicaid managed care organizations. The ACA also included changes to the Public Health Service&#8217;s 340B drug pricing program (the &#8220;340B program&#8221;) including expansion of the list of eligible covered entities that may purchase drugs under the program.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in effect in its current form. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, other legislative changes have been proposed and adopted in the U.S. since the ACA was enacted. These changes include the Budget Control Act of 2011, which resulted in aggregate reductions of Medicare payments to providers, which went into effect on April 1, 2013, and, due to subsequent legislative amendments to the statute, will remain in effect through 2032, unless additional Congressional action is taken. Furthermore, the American Taxpayer Relief Act of 2012, further reduced Medicare payments to several types of providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. More recently, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, beginning January 1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Most significantly, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) into law. This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010.  Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025).  The IRA permits the Secretary of the Department of Health and Human Services (&#8220;HHS&#8221;) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations.  HHS has issued and will continue to issue guidance implementing the IRA, although the Medicare drug price negotiation program is currently subject to legal challenges. While the impact of the IRA on the pharmaceutical industry and our business cannot yet be fully determined, it is likely to be significant.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The cost of prescription pharmaceuticals in the U.S. will likely continue to be the subject of considerable discussion. Members of Congress and the Biden Administration have indicated they will continue to pursue further legislative or administrative measures to control prescription drug costs. There have been several Congressional inquiries, as well as legislative and regulatory initiatives and executive orders designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. We cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Individual states in the U.S. continue to consider and have enacted legislation to limit the growth of health care costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation that may prevent or limit our ability to take price increases at certain rates or frequencies. Requirements under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered in taking such increases, wholesale acquisition cost information disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation could limit the price or payment for certain drugs, and a number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers who fail to comply with drug price transparency requirements, including the untimely, inaccurate, or incomplete reporting of drug pricing information. If we are found to have violated state law requirements, we may become subject to penalties or other enforcement mechanisms, which could have a material adverse effect on our business. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">It is likely that federal and state legislatures within the U.S. and foreign governments will continue to consider changes to existing health care legislation. We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified. The continuing efforts of governments, insurance companies, managed care organizations and other payors of health care services to contain or reduce costs of health care may adversely affect the demand for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and any other drug products for which we may obtain </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">regulatory approval, our ability to set a price that we believe is fair for our products, our ability to obtain adequate coverage and reimbursement approval for a product, our ability to generate revenues and achieve or maintain profitability, and the level of taxes that we are required to pay.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In the EU, similar developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved. In markets outside of the U.S. and EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On December 13, 2021, Regulation No 2021/2282 on Health Technology Assessment (&#8220;HTA&#8221;) amending Directive 2011/24/EU, was adopted. While the regulation entered into force in January 2022, it will only begin to apply from January 2025 onwards, with preparatory and implementation-related steps to take place in the interim. Once applicable, it will have a phased implementation depending on the concerned products. The regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products as well as certain high-risk medical devices, and provide the basis for cooperation at the EU level for joint clinical assessments in these areas. It will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the highest potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the U.S., we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We participate in the Medicaid Drug Rebate Program (&#8220;MDRP&#8221;) and other federal and state government pricing programs in the U.S., and we may participate in additional government pricing programs in the future. These programs generally require manufacturers to pay rebates or otherwise provide discounts to government payors in connection with drugs that are dispensed to beneficiaries of these programs. As a condition of having federal funds being made available for covered outpatient drugs under Medicaid and Medicare Part B, a manufacturer must enroll in the MDRP. Under this program, we must pay a rebate to state Medicaid programs for each unit of our covered outpatient drug dispensed to a Medicaid beneficiary and paid for by a state Medicaid program. Medicaid drug rebates are based on pricing data that we must report on a monthly and quarterly basis to CMS. For the MDRP, this data includes the average manufacturer price (&#8220;AMP&#8221;) for each drug and, in the case of an innovator product, like IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, the best price. If we become aware that our MDRP price reporting submission for a prior period was incorrect or has changed as a result of recalculation of the pricing data, we must resubmit the corrected data for up to three years after the data originally was due. Further, under the IRA, AMP figures we report will also be used to calculate a rebate on Medicare Part D utilization, triggered by price increases that outpace inflation. If we fail to provide information timely or are found to have knowingly submitted false information to the government, we may be subject to civil monetary penalties and other sanctions, including termination from the MDRP, which would result in payment not being available for our covered outpatient drugs under Medicaid or, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">if applicable, Medicare Part B. Failure to make necessary disclosures and/or to identify overpayments additionally could result in allegations against us under the Federal False Claims Act and other laws and regulations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Federal law requires that a manufacturer that participates in the MDRP also participate in the 340B program in order for federal funds to be available for the manufacturer&#8217;s drugs under Medicaid and Medicare Part B, and we participate in the 340B program. The 340B program is administered by the Health Resources and Services Administration (&#8220;HRSA&#8221;) and requires us to charge statutorily defined covered entities no more than the 340B &#8220;ceiling price&#8221; for our covered outpatient drugs used in an outpatient setting. These 340B program covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the AMP and rebate amount for the covered outpatient drug as calculated under the MDRP. In general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price calculation and discount requirement. We must report 340B ceiling prices to HRSA on a quarterly basis, and HRSA publishes them to 340B covered entities. HRSA has finalized regulations regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities for 340B eligible drugs. HRSA has also finalized an administrative dispute resolution process through which 340B covered entities may pursue claims against participating manufacturers for overcharges, and through which manufacturers may pursue claims against 340B covered entities for engaging in unlawful diversion or duplicate discounting of 340B drugs. In addition, legislation may be introduced that, if passed, would further expand the 340B program, such as adding further covered entities or requiring participating manufacturers to agree to provide 340B program discounted pricing on drugs used in an inpatient setting.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">In order to be eligible to have drug products paid for with federal funds under Medicaid and Medicare Part B and purchased by certain federal agencies and grantees, we also must participate in the U.S. Department of Veterans Affairs (&#8220;VA&#8221;) Federal Supply Schedule (&#8220;FSS&#8221;) pricing program. Under the VA/FSS program, we must report the Non-Federal Average Manufacturer Price (&#8220;Non-FAMP&#8221;) for our covered drugs to the VA and charge certain federal agencies no more than the Federal Ceiling Price, which is calculated based on Non-FAMP using a statutory formula. These four agencies are the VA, the U.S. Department of Defense, the U.S. Coast Guard, and the U.S. Public Health Service (including the Indian Health Service). We must also pay rebates on products purchased by military personnel and dependents through the TRICARE retail pharmacy program. If we fail to provide timely information or are found to have knowingly submitted false information, we may be subject to civil monetary penalties.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Individual states continue to consider and have enacted legislation to limit the growth of health care costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation that may prevent or limit our ability to take price increases at certain rates or frequencies. Requirements under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered in taking such increases, wholesale acquisition cost information disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation could limit the price or payment for certain drugs, and a number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers who fail to comply with drug price transparency requirements, including the untimely, inaccurate, or incomplete reporting of drug pricing information. If we are found to have violated state law requirements, we may become subject to penalties or other enforcement mechanisms, which could have a material adverse effect on our business.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Pricing and rebate calculations are complex, vary among products and programs, and are often subject to interpretation by manufacturers, governmental or regulatory agencies, and the courts. The terms, scope and complexity of these government pricing programs change frequently, as do interpretations of applicable requirements for pricing and rebate calculations. Responding to current and future changes may increase our costs and the complexity of compliance will be time-consuming. Any required refunds to the U.S. government or responding to a government investigation or enforcement action would be expensive and time consuming and could have a material adverse effect on our business, results of operations and financial condition. Price recalculations under the MDRP also may affect the ceiling price at which we may be required to offer products under the 340B program. Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we fail to submit required price data on a timely basis, or if we are found to have charged 340B program covered entities more than the statutorily mandated ceiling price. In the event that CMS were to terminate our Medicaid rebate agreement, pursuant to </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">which we participate in the MDRP, no federal payments would be available under Medicaid or Medicare for our covered outpatient drugs. We cannot assure you that price data submissions we make will not be found to be incomplete or incorrect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Relationship with BioXcel LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">BioXcel LLC has significant influence over the direction of our business, and the concentrated ownership of our common stock will prevent you and other stockholders from influencing significant decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2024, BioXcel LLC owned approximately 15.5% of the economic interest and voting power of our outstanding common stock and BioXcel LLC is controlled by BioXcel Holdings, Inc. Our Chief Executive Officer and member of our board of directors, Vimal Mehta, Ph.D., is the Chief Executive Officer, President, Treasurer and Secretary and a member of the board of managers of BioXcel LLC and Chief Executive Officer, President, Treasurer and Secretary and the sole member of the board of directors of BioXcel Holdings, Inc. See &#8220;<i style="font-style:italic;">The management of and beneficial ownership in BioXcel LLC by our executive officers and our directors may create, or may create the appearance of, conflicts of interest.</i>&#8221; below. Even though BioXcel LLC controls less than a majority of the voting power of our outstanding common stock, it may influence the outcome of such corporate actions so long as it owns a significant portion of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Approval of commercial terms between us and BioXcel LLC does not preclude the possibility of stockholder litigation, including but not limited to derivative litigation nominally against BioXcel LLC and against its directors and officers and also against us and our directors and officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The commercial terms of the Separation and Shared Services Agreement (as amended and/or restated and in effect as of the date hereof, the &#8220;Services Agreement&#8221;), and the Amended and Restated Asset Contribution Agreement (as amended and/or restated and in effect as of the date hereof, the &#8220;Contribution Agreement&#8221;), that we entered into with BioXcel LLC have not been negotiated by persons consisting solely of disinterested directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">No assurance can be given that any equity or debt holder of BioXcel LLC or the Company will not claim in a lawsuit that such terms in fact are not in the best interests of BioXcel LLC or the Company and its applicable equity holders, that the directors and officers of BioXcel LLC or the Company breached their fiduciary duties in connection with such agreements and that any disclosures by the Company to its stockholders regarding these agreements and the relationship between BioXcel LLC and us did not satisfy applicable requirements. In any such instance, we and our directors and officers may also be named as defendants and we would have to defend ourselves and our directors and officers. While we would seek indemnification from BioXcel LLC under the terms of these agreements against any damages or other costs, which could be substantial, no such indemnification has yet been agreed to or may be agreed to and be in effect. Further, any such litigation would be time-consuming and would divert focus and resources from the development of our product candidates and our business, including but not limited to possibly delaying our clinical trials due to our management having to spend time and attention on such litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We continue to depend on BioXcel LLC to provide us with certain services for our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We rely, in part, on BioXcel LLC and access to its EvolverAI, to complement our in-house, uniquely integrated AI-to-drug-development capability. EvolverAI is a research and development engine created and owned by BioXcel LLC, to identify, research and develop potential product candidates in neuroscience and immuno-oncology. We negotiated the Services Agreement with BioXcel LLC pursuant to which BioXcel LLC agreed to perform certain intellectual property prosecution and management and research and development activities for us utilizing its EvolverAI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Under the Services Agreement, we had an option, exercisable until December 31, 2024, to enter into a separate collaborative services agreement with BioXcel LLC pursuant to which BioXcel LLC shall perform product identification and related services for us utilizing its EvolverAI.  We agreed to pay BioXcel LLC $18,000 per month from March 13, 2023, to December 31, 2024 in exchange for this option. We agreed to negotiate any such collaborative services agreement in good faith and to incorporate reasonable market-based terms, including consideration for BioXcel LLC reflecting a low, single-digit royalty on net sales and reasonable development and commercialization milestone payments, provided that (i) development milestone payments shall not exceed $10 million in the aggregate and not be </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">payable prior to proof of concept in humans and (ii) commercialization milestone payments shall be based on reaching annual net sales levels, be limited to 3% of the applicable net sales level, and not exceed $30 million in the aggregate.  We did not exercise this option, which expired on December 31, 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, at the time of our initial public offering (&#8220;IPO&#8221;), BioXcel LLC granted us (i) a first right to negotiate exclusive rights to any additional product candidates in the fields of neuroscience and immuno-oncology that BioXcel LLC may identify on its own and not in connection with BioXcel LLC&#8217;s provision of services to us under the Services Agreement and (ii) an exclusivity agreement in the neuroscience and immuno-oncology fields whereby BioXcel LLC agreed not develop drugs, or engage in preclinical discovery for the purpose of developing drugs, in the neuroscience and immuno-oncology fields for or on behalf of a third party, utilizing EvolverAI or otherwise. This first right to negotiate and exclusivity period expired on March 12, 2023, and there is no assurance that we will extend the terms of the agreement. We are continuing to assess our ongoing business needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On September 19, 2023, the Company, Krishnan Nandabalan, Ph.D., InveniAI LLC (&#8220;Inveni&#8221;) and Invea Therapeutics, Inc. (&#8220;Invea&#8221;) and the other parties thereto entered into a non-compete agreement pursuant to which Dr. Nandabalan, Inveni and Invea agreed not to compete with the Company and its controlled affiliates in the fields of neuroscience and immuno-oncology for a period of five years from September 19, 2023 and not to solicit employees of the Company or its controlled affiliates for a period of two years from September 19, 2023. Inveni and Invea are subsidiaries of BioXcel LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If our rights under the Services Agreement were to become limited or if we are otherwise precluded from conducting research and development using EvolverAI, or if BioXcel LLC, Inveni or Invea do not fulfill their obligations under the agreements, such development could materially adversely affect our future operating results, financial condition, and prospects. Furthermore, certain individuals conducting services on our behalf are not our employees, and we cannot control whether they devote sufficient time, skill and resources to our ongoing development programs. We also cannot ensure that BioXcel LLC retains sufficient resources or personnel or otherwise to conduct its operations. BioXcel LLC may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting research and development activities, which could impede their ability to devote appropriate time to our research and development programs. BioXcel LLC is not currently restricted from using EvolverAI to perform drug discovery services for our direct competitors, and if we do not extend the exclusivity period in the neuroscience and immuno-oncology fields, this could harm our competitive position and adversely affect our future operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The management of and beneficial ownership in BioXcel LLC may create, or may create the appearance of, conflicts of interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Our Chief Executive Officer and member of our board of directors, Vimal Mehta, Ph.D., is the Chief Executive Officer, President, Treasurer and Secretary and a member of the board of managers of BioXcel LLC and Chief Executive Officer, President, Treasurer and Secretary and the sole member of the board of directors of BioXcel Holdings, Inc.  Additionally, as of December 31, 2024, Dr. Mehta, through his beneficial ownership of BioXcel LLC, beneficially owned approximately 15.5% of the Company. The management and ownership of BioXcel LLC by Dr. Mehta may create the appearance of conflicts of interest when Dr. Mehta is faced with decisions that could have different implications for BioXcel LLC than the decisions have for us, including decisions that relate to our Services Agreement and Contribution Agreement, as well as potential agreements relating to future product candidates and AI-related services or collaborations. Any perceived conflicts of interest resulting from investors questioning the independence of our management or the integrity of corporate governance procedures may materially affect our stock price and expose us to litigation risk.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Any disputes that arise between us and BioXcel LLC with respect to our past and ongoing relationships could harm our business operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Disputes may arise between BioXcel LLC and us in a number of areas relating to our past and ongoing relationships, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual property, technology and business matters, including failure to make required technology transfers and failure to comply with contractual provisions applicable to BioXcel LLC and us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">labor, tax, employee benefit, indemnification and other matters arising from the separation of BTI from BioXcel LLC;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distribution and supply obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee retention and recruiting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business combinations involving us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales or distributions by BioXcel LLC of all or any portion of its ownership interest in us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the nature, quality and pricing of services BioXcel LLC has agreed to provide us; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business opportunities that may be attractive to both BioXcel LLC and us.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We entered into the Services Agreement with BioXcel LLC related to the separation of our business operations from those of BioXcel LLC that contains certain limitations on BioXcel LLC&#8217;s ability to control various aspects of our business and operations, notwithstanding BioXcel LLC&#8217;s substantial ownership position. This agreement may be amended upon agreement between us and BioXcel LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">BioXcel LLC may experience challenges with the acquisition, development, enhancement, or deployment of technology necessary for EvolverAI. We may face similar challenges with other AI platforms that we utilize, including our own in-house proprietary platform.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BioXcel LLC operates in businesses that require sophisticated computer systems and software for data collection, data processing, cloud-based platforms, analytics, statistical projections and forecasting, mobile computing, social media analytics and other applications and technologies. BioXcel LLC seeks to address its technology risks by increasing its reliance on the use of innovations by cross-industry technology leaders and adapt these for their pharmaceutical, biotechnology, biopharmaceutical, diagnostic, medical device and contract research and manufacturing clients. Some of the technologies supporting the industries they serve are changing rapidly and we must continue to adapt to these changes in a timely and effective manner at an acceptable cost. They also must continue to deliver data to their clients in forms that are easy to use while simultaneously providing clear answers to complex questions. We also utilize our own in-house AI platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">There can be no guarantee that we or BioXcel LLC will be able to develop, acquire or integrate new technologies, that these new technologies will meet our and BioXcel LLC&#8217;s needs or achieve our expected goals, or that we will be able to do so as quickly or cost-effectively as our competitors. Significant technological change could render BioXcel LLC&#8217;s EvolverAI or other AI platforms that we utilize obsolete. BioXcel LLC&#8217;s and our continued success will depend on the ability to adapt to changing technologies, manage and process ever-increasing amounts of data and information and improve the performance, features and reliability of these services in response to changing client and industry demands. If EvolverAI or other AI and machine learning models that we use are incorrectly designed, do not operate properly, the data we use to train them is incomplete, inadequate or biased in some way, or if we do not have sufficient rights to use the data on which our AI and machine learning models rely, the performance of our products, services and businesses, as well as our reputation, could suffer or we could incur liability through the violation of laws, third-party privacy rights or contracts to which we are a party. BioXcel LLC or we may experience difficulties that could delay or prevent the successful design, development, testing, and introduction of advanced versions of EvolverAI, limiting our </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ability to identify new product candidates. New services, or enhancements to existing EvolverAI services, may not adequately meet our requirements. Any of these failures could have a material adverse effect on our operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Reliance on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We are substantially dependent on third parties for the manufacture of our clinical supplies of our product candidates and our commercial supplies of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and we intend to rely on third parties to produce commercial supplies of any other approved product candidate. Therefore, our development of our products could be stopped or delayed, and our commercialization of any future product could be stopped, delayed or made less profitable if third-party manufacturers fail to obtain approval of the FDA or comparable regulatory authorities or fail to provide us with drug product in sufficient quantities or at acceptable prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We entered into a commercial supply agreement with ARx, LLC (&#8220;ARx&#8221;) pursuant to which ARx has agreed to exclusively manufacture and supply us with all of our worldwide demand of film formulation of Dex to be used for the commercial supply of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and for ongoing clinical trials of our product candidate BXCL501, subject to certain alternative supply provisions. If ARx is unable or ceases to produce our supply of Dex in sufficient quantities as and when needed or if the ARx agreement becomes too costly, our business would be harmed because there can be no assurance that we will be able to identify or enter into agreements with alternative suppliers on a timely basis on acceptable terms, if at all. An interruption in our ability to sell our products to customers could occur if we encounter delays or difficulties in securing Dex, or if the quantity or quality supplied does not meet our specifications, or if we cannot then obtain an acceptable substitute. If any of these events occur, our business and operating results could be harmed. Our specified minimum annual payment could adversely affect our cash flows in the future, such as in times when we have sufficient inventory and would otherwise be able to use our cash for other purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The manufacture of biotechnology and pharmaceutical products is complex and requires significant expertise, capital investment, process controls and know-how. Common difficulties in biotechnology and pharmaceutical manufacturing may include: sourcing and producing raw materials, transferring technology from chemistry and development activities to production activities, validating initial production designs, scaling manufacturing techniques, improving costs and yields, establishing and maintaining quality controls and stability requirements, eliminating contaminations and operator errors, and maintaining compliance with regulatory requirements. We do not currently have nor do we plan to acquire the infrastructure or capability internally to produce an adequate supply of compounds to meet future requirements for clinical trials and commercialization of our products or to produce our products in accordance with cGMP prescribed by the FDA or similar foreign requirements. Drug manufacturing facilities are subject to inspection before the FDA or foreign regulatory authorities will issue an approval to market a new drug product, and ARx, the Patheon pharma services division of Thermo Fisher Scientific Inc., and any other manufacturers that we may use must adhere to the cGMP or similar foreign regulations prescribed by the FDA or foreign regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As such, these third-party manufacturers will be required to comply with cGMPs, and other applicable laws and regulations. We have no control over the ability of these third parties to comply with these requirements, or to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or any other applicable regulatory authorities do not approve the facilities of these third parties for the manufacture of our other product candidates or any products that we may successfully develop, or if it withdraws any such approval, or if our suppliers or contract manufacturers decide they no longer want to supply or manufacture for us, we may need to find alternative manufacturing facilities, in which case we might not be able to identify manufacturers for clinical or commercial supply on acceptable terms, or at all. Any of these factors would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates and adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We, ARx, the Patheon pharma services division of Thermo Fisher Scientific Inc., and/or our other third-party manufacturers may be adversely affected by developments outside of our control, and these developments may delay or prevent further manufacturing of our products. Adverse developments may include labor disputes, resource constraints, shipment delays, inventory shortages, lot failures, unexpected sources of contamination, lawsuits related to our manufacturing techniques, equipment used during manufacturing, or composition of matter, unstable political environments, acts of terrorism, war, natural disasters, and other natural and man-made disasters. If we, ARx, the Patheon pharma services division of Thermo Fisher Scientific Inc., or our other third-party manufacturers were to </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">encounter any of the above difficulties, or otherwise fail to comply with contractual obligations, our ability to provide any product for clinical trial or commercial purposes would be jeopardized. This may increase the costs associated with completing our clinical trials and commercial production. Further, production disruptions may cause us to terminate ongoing clinical trials and/or commence new clinical trials at additional expense. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications or pass safety inspections. If production difficulties cannot be solved with acceptable costs, expenses, and timeframes, we may be forced to abandon our clinical development and commercialization plans, which could have a material adverse effect on our business, prospects, financial condition, and the value of our securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We, or third-party manufacturers on whom we rely, including ARx, may be unable to successfully scale-up manufacturing of our product and product candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and commercializing any approved products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In order to conduct clinical trials of our product candidates and commercialize any approved product candidates, we, or our manufacturers, including ARx, and the Patheon pharma services division of Thermo Fisher Scientific Inc., will need to manufacture them in large quantities. We, or our manufacturers, may be unable to successfully increase the manufacturing capacity for any of our approved products or product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If we, or any of our manufacturers, are unable to successfully scale up the manufacture of our approved products or product candidates in sufficient quality and quantity, the development, testing, and clinical trials of that product candidate may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. If we are unable to obtain or maintain third-party manufacturing for commercial supply of our approved products, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our approved products or product candidates successfully.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our failure to find third-party collaborators to assist or share in the costs of product development could materially harm our business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our strategy for the development and commercialization of our proprietary products and product candidates may include the formation of collaborative arrangements with third parties. Collaborators have significant discretion in determining the efforts and resources they apply and may not perform their obligations as expected. Potential third-party collaborators include biopharmaceutical, pharmaceutical and biotechnology companies, academic institutions and other entities. Third-party collaborators may assist us in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">funding research, preclinical development, clinical trials and manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeking and obtaining regulatory approvals; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully commercializing IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> or product candidates.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If we are not able to establish collaboration agreements, we may be required to undertake product development and commercialization at our own expense. Such an undertaking may limit the number of product candidates that we will be able to develop, significantly increase our capital requirements and place additional strain on our internal resources. Our failure to enter into collaborations could materially harm our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, our dependence on licensing, collaboration and other agreements with third parties may subject us to a number of risks. These agreements may not be on terms that prove favorable to us and may require us to relinquish certain rights in our product candidates. To the extent we agree to work exclusively with one collaborator in a given area, our opportunities to collaborate with other entities could be curtailed. Lengthy negotiations with potential new collaborators may lead to delays in the research, development or commercialization of product candidates. The decision by our collaborators to pursue alternative technologies or the failure of our collaborators to develop or commercialize successfully any product candidate to which they have obtained rights from us could materially harm our business, financial condition and results of operations.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We rely on third parties to conduct our preclinical and clinical trials. If these third parties do not successfully perform their contractual legal and regulatory duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have relied upon and plan to continue to rely upon third-party medical institutions, clinical investigators, contract laboratories and other third-party CROs to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCPs, which are regulations and guidelines enforced by the FDA, the competent authorities of the European Economic Area (&#8220;EEA&#8221;) countries and comparable foreign regulatory authorities for all of our products in clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If regulatory authorities determine that we or any of our CROs failed to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP and similar foreign regulations. Any failure, whether by us or our CROs, to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, if any of our relationships with our third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether they devote sufficient time and resources to our on-going clinical, nonclinical and preclinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. For example, investigator misconduct during our TRANQUILITY II trial evaluating BXCL501 in patients with probable Alzheimer&#8217;s disease could require us to conduct additional clinical trials before we are able to seek or obtain approval for BXCL501 for use in this patient population, as described more fully in the risk factor above entitled: &#8220;<i style="font-style:italic;">Developments relating to our TRANQUILITY II Phase 3 trial may impact the timing of our development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer&#8217;s disease</i>.&#8221; As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. If the third parties conducting our GCP preclinical studies or our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical trial protocols or to GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties. Switching or adding CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Business and Industry</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Unfavorable global political or economic events and conditions could adversely affect our business, financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our business could be adversely affected by unstable economic and political conditions within the United States and foreign jurisdictions, including as a result of an economic downturn and geopolitical events, such as changes in U.S. federal policy that affect the geopolitical landscape. In addition, the global economy, including credit and financial markets, has recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, rising interest and inflation rates, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. A severe or prolonged economic downturn or recession and a continued increase in inflation rates or interest rates could result in a variety of risks to our business, and our ability to raise additional capital when needed on acceptable terms, if at all. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Increased inflation rates and related increases in interest rates can adversely affect us by increasing our costs, including labor and employee benefit costs. In addition, events such as pandemics, epidemics, or outbreaks of an infectious disease may materially and adversely impact our business if we or any of the third parties with whom we engage were to experience shutdowns or other business disruptions. Furthermore, geopolitical conflicts and war, such as the current military conflict between Russia and Ukraine and the war between Israel and Hamas, and other conflicts in the Middle East, could disrupt or otherwise adversely impact our operations and those of third parties upon which we rely. Related sanctions, export controls or other actions have and may in the future be initiated by nations including the U.S., the EU or Russia (e.g., potential cyberattacks, disruption of energy flows, etc.), which could adversely affect our business and/or our supply chain, our CROs, CMOs and other third parties with which we conduct business. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our future success may depend on our ability to attract and retain qualified personnel, including consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are dependent on the principal members of our management and scientific teams. Our success and the execution of our operating strategy, to the extent we continue operations, depend largely on the continued service of our employees. In addition to our employees, we have access to certain of BioXcel LLC&#8217;s employees and resources through the various agreements we have with BioXcel LLC. We have expanded our management team to include an operational ramp-up of additional technical staff required to achieve our business objectives. We will need to retain such employees, and may need to continue to expand our managerial, commercial, operational, technical, and scientific, financial, and other resources to manage our operations and clinical trials, continue our research and development activities, and any approved product candidates. Our management and scientific personnel, systems and facilities currently in place may not be adequate to support our future growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may utilize the services of third-party vendors to perform tasks including preclinical and clinical trial management, statistics and analysis, regulatory affairs, medical advisory, market research, formulation development, chemistry, manufacturing and control activities, other drug development functions, legal, auditing, financial advisory, and investor relations. Because we rely on numerous consultants to outsource many key functions of our business, we will need to be able to effectively manage these consultants to ensure that they successfully carry out their contractual obligations and meet expected deadlines. However, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for our product candidate or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all. If we are not able to recruit and retain qualified personnel, we may be unable to successfully implement the tasks necessary to further develop and commercialize our product candidate and, accordingly, may not achieve our research, development and commercialization goals.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We depend on our senior management team, and the loss of one or more of our executive officers or key employees or an inability to attract and retain highly skilled employees could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our success depends largely upon the continued services of our key executive officers, including Vimal Mehta, our Chief Executive Officer, President and a member of our Board, as well as the other principal members of our management, scientific, clinical teams and commercial readiness teams. We do not maintain &#8220;key person&#8221; insurance for any of these executive officers or any of our other key employees. We also rely on our leadership team in the areas of research and development, marketing, services and selling, general and administrative functions. From time to time, there may be changes in our executive management and leadership teams resulting from the hiring or departure of executives or other key employees, which could disrupt our business. The replacement of one or more of our executive officers or other key employees would likely involve significant time and costs and may significantly delay or prevent the achievement of our business objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">To continue to execute our business strategy, we also must attract and retain highly skilled personnel. We might not be successful in maintaining our unique culture and continuing to attract and retain qualified personnel. We have, from time to time, had difficulty hiring and retaining highly skilled personnel with appropriate qualifications, including as a result of the Reprioritization and related consequences for our reputation. We may experience such difficulties in the future, and any further restructuring or related reduction in force could exacerbate such difficulties. The pool of qualified personnel with experience working within the biopharmaceutical and biotechnology market is limited overall. In addition, many of the companies with which we compete for experienced personnel have greater resources than we have.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Furthermore, prior workforce reductions and any future similar cost-saving initiatives may make it difficult for us to maintain valuable aspects of our culture, retain institutional knowledge and expertise, to prevent a negative effect on employee morale or attrition beyond our planned reduction in headcount, and to attract competent personnel who are willing to embrace our culture in the future. Our executive officers and other employees are at-will employees, which means they may terminate their employment relationship with us at any time, and their knowledge of our business and industry would be extremely difficult to replace. We may not be able to retain the services of any members of our senior management or other key employees. If we do not succeed in retaining and motivating existing employees or attracting well-qualified employees in the future, our business, financial condition and results of operations could be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, in making employment decisions, particularly in the biotechnology and high-technology industries, job candidates often consider the value of the stock options or other equity instruments they are to receive in connection with their employment. Volatility in the price of our stock might, therefore, adversely affect our ability to attract or retain highly skilled personnel. Furthermore, the requirement to expense the fair value of stock options and other equity instruments might discourage us from granting the size or type of stock option or equity awards that job candidates require to join our Company. If we fail to attract new personnel or fail to retain and motivate our current personnel, our business and future growth prospects could be severely harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may acquire other companies or technologies, which could divert our management&#8217;s attention, result in dilution to our stockholders and otherwise disrupt our operations and adversely affect our operating results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may in the future seek to acquire or invest in businesses, applications and services or technologies that we believe could complement or expand our services, enhance our technical capabilities or otherwise offer growth opportunities. The pursuit of potential acquisitions may divert the attention of management and cause us to incur various expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, we do not have any experience in acquiring other businesses. If we acquire additional businesses, we may not be able to integrate the acquired personnel, operations and technologies successfully, or effectively manage the combined business following the acquisition. We also may not achieve the anticipated benefits from the acquired business due to a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to integrate or benefit from acquired technologies or services in a profitable manner;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated costs or liabilities associated with the acquisition;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty integrating the accounting systems, operations and personnel of the acquired business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties and additional expenses associated with supporting legacy products and hosting infrastructure of the acquired business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty converting the customers of the acquired business onto our platform and contract terms, including disparities in the revenue, licensing, support or professional services model of the acquired company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of management&#8217;s attention from other business concerns;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse effects to our existing business relationships with business partners and customers as a result of the acquisition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential loss of key employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">use of resources that are needed in other parts of our business; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">use of substantial portions of our available cash to consummate the acquisition.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, a significant portion of the purchase price of companies we acquire may be allocated to acquired goodwill and other intangible assets, which must be assessed for impairment at least annually. In the future, if our acquisitions do not yield expected returns, we may be required to take charges to our operating results based on this impairment assessment process, which could adversely affect our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Acquisitions could also result in dilutive issuances of equity securities or the incurrence of debt, which could adversely affect our operating results. In addition, if an acquired business fails to meet our expectations, our operating results, business and financial position may suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with any regulations applicable to us, to provide accurate information to regulatory authorities, to comply with manufacturing standards we have established, to comply with federal and state health care fraud and abuse laws and regulations, or to report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained during clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business Conduct and Ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Business interruptions could adversely affect future operations, revenues, and financial conditions, and may increase our costs and expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our operations, and those of our directors, advisors, contractors, consultants, CROs, and collaborators, could be adversely affected by earthquakes, floods, hurricanes, typhoons, extreme weather conditions, fires, water shortages, power failures, business systems failures, medical epidemics, and other natural and man-made disaster or business interruptions. Our phones, electronic devices and computer systems and those of our directors, advisors, contractors, consultants, CROs, and collaborators are vulnerable to damages, theft and accidental loss, negligence, unauthorized access, terrorism, war, electronic and telecommunications failures, and other natural and man- made disasters. Several of our employees conduct business outside of our headquarters and leased or owned facilities. These locations may be subject to additional security and other risk factors due to the limited control of our employees. If such an event as </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">described above were to occur in the future, it may cause interruptions in our operations, delay research and development programs, clinical trials, regulatory activities, manufacturing and quality assurance activities, sales and marketing activities, hiring, training of employees and persons within associated third parties, and other business activities. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Likewise, we will rely on third parties, including ARx, to manufacture IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and our product candidates and to conduct clinical trials, and similar events as those described in the prior paragraph relating to their business systems, equipment and facilities could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidate could be delayed or altogether terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Data breaches or cyber-attacks could disrupt our business operations and information technology systems or those of third parties on which we rely, adversely impact our financial results, or result in the loss or exposure of confidential or sensitive product candidate, clinical trial, employee, or Company information.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business, including our mobile and web-based applications, our e-commerce platform and our enterprise software. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information, clinical trial data, and personal information (collectively, &#8220;Confidential Information&#8221;) of customers and our employees and contractors. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such Confidential Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our information technology systems and those of third parties on which we rely have been and may in the future be attacked or breached by individuals or organizations intending to obtain our Confidential Information; harm or disrupt our business operations; or otherwise misappropriate information or Company funds. A security compromise of our information technology systems or business operations, or those of third parties on which we rely, could occur through a variety of methods such as from cyber-attacks and cyber-intrusions over the Internet, misconfigurations, &#8220;bugs&#8221; or other vulnerabilities, malware, computer viruses, email spoofing, attachments to e-mails, persons inside or outside our organization or persons with access to systems inside our organization. The risk of such intrusions, threats to data and information technology systems and breaches has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">While we maintain some of our own critical information technology systems, we also depend on third parties to provide important information technology services relating to several key business functions. Our measures to prevent, detect and mitigate these threats, including password protection, firewalls, backup servers, threat monitoring and periodic penetration testing, may not be successful in preventing a data breach or limiting the effects of a breach. Because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Furthermore, the security measures employed by third-party service providers may prove to be ineffective at preventing breaches of their systems. Any attack that results in disruptions to our operations, or the unauthorized release or loss of Confidential Information, could have a material adverse effect on our business reputation, increase our costs and expose us to material legal claims and liability (such as class actions) and result in regulatory investigations and enforcement actions, fines and penalties, negative reputational impacts that cause us to lose existing or future customers, and/or significant incident response, system restoration or remediation and future compliance costs. If the unauthorized release or loss of Confidential Information were to occur, our operations and financial results and our share price could be adversely affected. Although we maintain insurance for our business, the coverage under our policies may not be adequate to compensate us for all losses that may occur.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect in connection with clinical trials in the U.S. and abroad. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission, and breach reporting of individually identifiable health information. Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA. If we are determined to act as a covered entity or business associate under HIPAA and be directly regulated under HIPAA, any person acting on our behalf may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, the California Consumer Privacy Act, as amended by the California Privacy Rights Act (collectively, the &#8220;CCPA&#8221;), requires covered businesses that process the personal information of California residents to, among other things: provide certain disclosures to California residents regarding the business&#8217;s collection, use, and disclosure of their personal information; receive and respond to requests from California residents to access, delete, and correct their personal information, or to opt out of certain disclosures of their personal information, and enter into specific contractual provisions with service providers that process California resident personal information on the business&#8217;s behalf. If we are subject to or affected by HIPAA, the CCPA, or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In Europe, the General Data Protection Regulation (&#8220;GDPR&#8221;) went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the U.S., and the efficacy and longevity of current transfer mechanisms between the EEA, and the United States remains uncertain. On July 10, 2023, the European Commission adopted its Adequacy Decision in relation to the new EU-US Data Privacy Framework (&#8220;DPF&#8221;), rendering the DPF effective as a GDPR transfer mechanism to U.S. entities self-certified under the DPF. We expect the existing legal complexity and uncertainty regarding international personal data transfers to continue. In particular, we expect the DPF Adequacy Decision to be challenged and international transfers to the United States and to other jurisdictions more generally to continue to be subject to enhanced scrutiny by regulators. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Further, since January 1, 2021, companies have had to comply with the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR (i.e., fines up to the greater of &#163;17.5 million or 4% of global turnover). On October 12, 2023, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">the UK Extension to the DPF came into effect (as approved by the UK Government), as a data transfer mechanism from the UK to U.S. entities self-certified under the DPF.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Increased scrutiny of and evolving expectations for environmental, social and governance (&#8220;ESG&#8221;) initiatives may impose additional costs or otherwise adversely impact our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There has been an increased focus from investors, capital providers, shareholder advocacy groups, other market participants, customers, and other stakeholder groups regarding companies&#8217; ESG initiatives. While we may at times engage in voluntary initiatives (such as voluntary disclosures, certifications, or goals, among others) or commitments to improve the ESG profile of our Company and/or offerings, such initiatives or achievements of such commitments may be costly and may not have the desired effect. Additionally, some investors may use third-party or proprietary ESG ratings to guide their investment strategies and, in some cases, may choose not to invest in us if they believe our ESG practices are inadequate. The criteria by which companies&#8217; ESG practices are assessed are evolving, which could result in greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. Alternatively, if we elect not to or are unable to satisfy new criteria or do not meet the criteria, some investors may conclude that our policies with respect to ESG are inadequate and choose not to invest in us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If our ESG practices do not meet evolving investor or other stakeholder expectations and our standards, reputation, ability to attract or retain employees and desirability as an investment or business partner could be negatively impacted. Similarly, our failure or perceived failure to adequately pursue or fulfill any ESG goals and objectives or to satisfy various reporting standards, if any, could expose us to additional regulatory, social or other scrutiny, the imposition of unexpected costs, or damage to our reputation, which in turn could have a material adverse effect on our business and could cause the market value of our common stock to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our failure to successfully acquire, develop and market additional product candidates or approved drug products could impair our ability to grow.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As part of our growth strategy, we may evaluate, acquire, license, develop and/or market third-party products or product candidates and technologies. Our internal research capabilities are limited and we may be dependent upon pharmaceutical and biotechnology companies, academic scientists and other researchers to sell or license products or technology to us. The success of this strategy depends partly upon our ability to identify, select and acquire promising pharmaceutical product candidates and products. The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, future acquisitions may entail numerous operational and financial risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exposure to unknown liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disruption of our business and diversion of our management&#8217;s and technical personnel&#8217;s time and attention to develop acquired products or technologies;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">higher than expected acquisition and integration costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased amortization expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to retain key employees of any acquired businesses.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Any product candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to risks of failure typical of pharmaceutical product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot provide assurance that any products that we develop or approved products that we acquire will be manufactured profitably or achieve market acceptance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to use our net operating losses and tax credits to offset future taxable income and income tax liabilities may be limited.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">At December 31, 2024 the Company had approximately $432.6 million of gross federal and $443.5 million of gross state net operating loss carry-forwards. Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) in 2017 amended the net operating losses carryforward rules. Net operating losses generated after December 31, 2017, may be carried forward indefinitely, subject to certain limitations on their use. Net operating losses generated prior to 2018 may be carried forward for twenty years. If not utilized, these net operating losses will expire by 2037. State net operating losses have varying carryforward and applicable expiration periods. $430.0 million of the federal net operating losses were incurred after December 31, 2017, and will be carried forward indefinitely; the balance of the federal net operating losses are subject to expiration no later than 2037. The utilization of such net operating loss carry-forwards and realization of tax benefits in future years depends predominantly upon having taxable income. The Company has approximately $16.0 million of federal orphan drug credits and research and development credits which will begin to expire in 2037 if not utilized. The Company also has approximately $1.5 million of state research and development credits which will begin to expire in 2040 if not utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, under sections 382 and 383 of the Code, our federal net operating losses and tax credit carryforwards, such as research/development credits and orphan drug credits, may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders (or groups of stockholders) in excess of 50% over a rolling three-year period. Similar state provisions may also exist. These ownership changes may limit the amount of the net operating losses and tax credit carryforwards that can be utilized annually to offset future taxable income and income tax, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Entities are also required to evaluate, measure, recognize and disclose any uncertain federal or state income tax provisions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of December 31, 2024, there were no uncertain tax positions. The Company's U.S. federal and state net operating losses have occurred since its inception in 2017 and as such, tax years subject to potential tax examination could apply from that date because the utilization of net operating losses from prior years opens the relevant tax year to audit by The U.S. Internal Revenue Service (&#8220;IRS&#8221;) and/or state taxing authorities. The Company did not have any unrecognized tax benefits and has not accrued any interest or penalties for the 12 months ended December 31, 2024 and 2023.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection. If our patent position does not adequately protect our product candidates, others could compete against us more directly, which would harm our business, possibly materially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our commercial success will depend in part on obtaining, maintaining enforcing and defending our patents, trademarks, trade secrets and other intellectual property rights and proprietary technology for our current and future approved products and product candidates, the processes used to manufacture them and the methods for using them, as well as successfully defending these patents against third-party challenges. We are the owner of record of certain patents and patent applications pending in the U.S. and in certain foreign jurisdictions. Patents issued from non-provisional applications, which are typically filed from provisional patent applications or from PCT applications that enter the national phase. Neither provisional patent applications nor PCT applications issue directly as patents. We own PCT patent applications relating to our platform technologies covering methods of use and applications of the platform technologies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We cannot be certain that any future patents will issue with claims that cover our product candidates. Our ability to stop third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents, trademarks, trade secrets and other intellectual property rights and proprietary technology that cover these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The patent positions of biotechnology and pharmaceutical companies can be highly uncertain and involve complex legal and factual questions that have been the subject of much litigation in recent years and for which important legal principles remain unresolved. Therefore, the scope of any patent claims that we have or may obtain cannot be predicted with certainty. No consistent policy regarding the breadth of claims allowed in pharmaceutical patents has emerged to date in the U.S. or in foreign jurisdictions outside of the U.S. Changes in either the patent laws or interpretations of patent laws in the U.S. and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict which of our patent applications will issue, the breadth of claims that may be enforced in the patents that may be issued from the applications we currently, or may in the future, own or license from third parties, whether any of the issued patents will be found to be infringed, invalid or unenforceable or will be threatened or challenged by third parties, that any of our issued patents have, or that any of our currently pending or future patent applications that mature into issued patents will include, claims with a scope sufficient to protect our products and services. Further, if any patents we obtain or license are deemed invalid and unenforceable, our ability to commercialize or license our technology could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Others have filed, and in the future are likely to file, patent applications covering products and technologies that are similar, identical or competitive to ours or important to our business. We cannot be certain that any patent application owned by a third-party will not have priority over patent applications filed or in-licensed by us, or that we or our licensors will not be involved in interference, opposition, reexamination, review, reissue, post grant review or invalidity proceedings before U.S. or non-U.S. patent offices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to independently develop, make and commercialize compounds that are similar to, or are alternatives or duplicates of any of our product candidates, but that are not covered by the claims of our patents or are not infringing, misappropriating, or otherwise violating our other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we might not have been the first to make the inventions covered by our issued patents or pending patent applications that we license or may own in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or our future collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our pending patent applications or those that we may own in the future may not result in issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the claims of our issued patents or patent applications when issued may not cover our products or product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any patents that we obtain may not provide us with any competitive advantages;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop, manufacture and commercialize competitive products or product candidates for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop additional proprietary technologies that are patentable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may choose not to seek patent protection for some of our proprietary technology or product candidates to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such trade secrets or know-how;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any granted patents may be held invalid or unenforceable as a result of legal challenges by third parties; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may have an adverse effect on our business.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Periodic maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to the USPTO and foreign patent agencies in several stages or annually over the lifetime of our owned and in-licensed patents and patent applications. In addition, the USPTO and various foreign governmental patent agencies require compliance with various procedural, document submission, fee payment and other requirements during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical products or technology. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, it would have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we fail to comply with our obligations in the agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose rights that are important to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may be required to enter into intellectual property license agreements that are important to our business. These license agreements may impose various diligence, payment, and other obligations on us. For example, we may enter into exclusive license agreements with universities, research institutions, or peer industry third parties pursuant to which we may be required to use commercially reasonable efforts to engage in various development and commercialization activities with respect to licensed products and may need to satisfy specified milestone and royalty payment obligations. If we fail to comply with any obligations under our agreements with any of these licensors, we may be subject to termination of the license agreement in whole or in part; increased financial obligations to our licensors or loss of exclusivity in a particular field or territory, in which case our ability to develop or commercialize products covered by the license agreement will be impaired.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, disputes may arise regarding intellectual property subject to a license agreement, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations under the license agreement and what activities satisfy those obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if a third-party expresses interest in an area under a license that we are not pursuing, under the terms of certain of our license agreements, we may be required to sublicense rights in that area to a third-party, and that sublicense could harm our business; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected approved products or product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We or our licensors may be subject to claims that third parties have an interest in our patents, trade secrets, or other intellectual property that we regard as our own or our licensor&#8217;s, based on claims that the relevant agreements with employees or consultants obligating them to assign their intellectual property rights to us or our licensor are ineffective or in conflict with prior or competing contractual obligations to assign inventions and intellectual property rights to another employer, to a former employer, or to another person or entity. We may also be subject to claims that our former employees, contractors or collaborators, or other third parties have an ownership interest in our current or future patents, patent applications, or other intellectual property rights, including as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Although it is our policy to require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property rights that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We are not aware of any threatened or pending claims related to these matters, but in the future litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets, or other intellectual property, and it may be necessary or we may desire to obtain a license to a third party&#8217;s intellectual property rights to settle any such claim; however, there can be no assurance that we would be able to obtain such license on commercially reasonable terms, if at all. If we or our licensors fail in defending any such claims, in addition to paying monetary damages or a settlement payment, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. A court could prohibit us from using technologies, features or other intellectual property rights that are essential to our products or technologies, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of another person or entity, including another or former employers. An inability to incorporate technologies, features or other intellectual property rights that are important or essential to our products or product candidates could have a material adverse effect on our business, financial condition, results of operations, and competitive position, and may prevent us from developing, manufacturing and/or commercializing our </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">products or technologies. In addition, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to develop, manufacture and/or commercialize our products or services, which could materially and adversely affect our business, financial condition and results of operations. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">An NDA submitted under Section 505(b)(2) subjects us to the risk that we may be subject to a patent infringement lawsuit that would delay or prevent the review or approval of our product candidate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our product candidates have been or will be submitted to the FDA for approval under Section 505(b)(2) of the FDCA. Section 505(b)(2) permits the submission of an NDA where at least some of the information required for approval comes from studies that were not conducted by, or for, the applicant and on which the applicant has not obtained a right of reference. The 505(b)(2) application would enable us to reference published literature and/or the FDA&#8217;s previous findings of safety and effectiveness for a branded reference drug with the same active ingredient. For NDAs submitted under Section 505(b)(2) of the FDCA, the patent certification and related provisions of the Hatch-Waxman Act apply. In accordance with the Hatch-Waxman Act, such NDAs may be required to include paragraph IV certifications, that certify that any patents listed in the FDA&#8217;s Orange Book, with respect to any product referenced in the 505(b)(2) application, are invalid, unenforceable or will not be infringed by the manufacture, use or sale of the product that is the subject of the 505(b)(2) NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the Hatch-Waxman Act, the holder of patents that the 505(b)(2) application references may file a patent infringement lawsuit after receiving notice of the paragraph IV certification. Filing of a patent infringement lawsuit against the filer of the 505(b)(2) applicant within 45 days of the patent owner&#8217;s receipt of notice triggers a one-time, automatic, 30-month stay of the FDA&#8217;s ability to approve the 505(b)(2) NDA, unless patent litigation is resolved in the favor of the paragraph IV certification filer, or the patent expires before that time. Accordingly, we may invest a significant amount of time and expense in the development of one or more product candidates only to be subject to significant delay and patent litigation before such product candidates may be commercialized, if at all. In addition, a 505(b)(2) application will not be approved until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the branded reference drug product has expired. The FDA may also require us to perform one or more additional clinical studies or measurements to support the change from the branded reference drug, which could be time consuming and could substantially delay our achievement of regulatory approvals for such product candidates. The FDA may also reject our future 505(b)(2) submissions and require us to file such submissions under Section 505(b)(1) of the FDCA, which would require us to provide extensive data to establish safety and effectiveness of the drug product for the proposed use and could cause delay and be considerably more expensive and time consuming. These factors, among others, may limit our ability to successfully commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our intellectual property related to IGALMI</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-style:italic;font-weight:bold;"> BXCL501, BXCL502, BXCL701, BXCL702 or any future product candidates is not adequate or if we are not able to successfully enforce our intellectual property rights, the commercial value of our products or product candidates may be adversely affected and we may not be able to compete effectively in our market.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Third parties, including our competitors, may currently, or in the future, infringe, misappropriate or otherwise violate our issued patents or other intellectual property rights, and we may file lawsuits or initiate other proceedings to protect or enforce our patents or other intellectual property rights, which could be expensive, time-consuming and unsuccessful. We regularly monitor for unauthorized use of our intellectual property rights and, from time to time, analyze whether to seek enforce our rights against potential infringement, misappropriation or violation of our intellectual property rights. However, the steps we have taken, and are taking, to protect our proprietary rights may not be adequate to enforce our rights as against such infringement, misappropriation or violation of our intellectual property rights. In certain circumstances it may not be practicable or cost-effective for us to enforce our intellectual property rights fully, particularly in certain developing countries or where the initiation of a claim might harm our business relationships. We may also be hindered or prevented from enforcing our rights with respect to a government entity or instrumentality because of the doctrine of sovereign immunity. Our ability to enforce our patent or other intellectual </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">property rights depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products or technologies. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product or technologies. Thus, we may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Any inability to meaningfully enforce our intellectual property rights could harm our ability to compete and reduce demand for our products and product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Even where laws provide protection, costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and the outcome of such litigation would be uncertain. If we choose to commence a proceeding or litigation to prevent another party from infringing our patents, that party could counterclaim  that our patents are invalid or should not be enforced against them. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. There is a risk that the examiner or court will decide that our patents are invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the related inventions. There is also the risk that, even if the validity of our patents is upheld, the examiner or court may construe the patent&#8217;s claims or other intellectual property narrowly or refuse to stop the other party from using the technology at issue on the grounds that such other party&#8217;s activities do not infringe our rights to such patents. In addition, the U.S. Supreme Court has recently modified some tests used by the USPTO in granting patents over the past 20 years, which may decrease the likelihood that we will be able to obtain patents and increase the likelihood of challenge to any patents we obtain or license. Any proceedings or litigation to enforce our intellectual property rights or defend ourselves against claims of infringement of third-party intellectual property rights could be costly and divert the attention of managerial and scientific personnel, regardless of whether such litigation is ultimately resolved in our favor. We may not have sufficient resources to bring these actions to a successful conclusion. If a defendant were to prevail on its legal assertion of invalidity and/or unenforceability against our intellectual property related to a product or a product candidate, we could lose at least part, and perhaps all, of the patent protection on such product or product candidate. Such a loss of patent protection would have a material adverse impact on our business. Moreover, our competitors could counterclaim that we infringe their intellectual property, and some of our competitors have substantially greater intellectual property portfolios than we do. An adverse result in any litigation or administrative proceeding could put one or more of our patents or other intellectual property rights at risk of being invalidated or interpreted narrowly, which could adversely affect our competitive business position, financial condition and results of operations.  Moreover, if we are unable to successfully defend against claims that we have infringed the intellectual property rights of others, we may be prevented from using certain intellectual property and may be liable for damages, which in turn could materially adversely affect our business, financial condition or results of operations. Even if we are successful in any litigation, we may incur significant expense in connection with such proceedings, and the amount of any monetary damages may be inadequate to compensate us for damage as a result of the infringement and the proceedings. Further, a court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may not be an adequate remedy. Furthermore, the monetary cost of such litigation and the diversion of the attention of our management could outweigh any benefit we receive as a result of the proceedings. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our business. Any of the foregoing may cause us to incur substantial costs, and could place a significant strain on our financial resources, divert the attention of management from our core business and harm our reputation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Further, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearing, motions, or other interim developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, and/or third party claims seeking to invalidate our patents, which would be costly, time consuming and, if successfully asserted against us, may prevent or delay our product development efforts and stop us from commercializing or increase the costs of commercializing our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our commercial success will depend in part on our ability to develop, manufacture or commercialize our products and product candidates without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. There is considerable patent and other intellectual property litigation in the pharmaceutical and biotechnology industries, and companies in the industry have used intellectual property litigation to gain a competitive advantage. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our products, or the manufacture or use of our product candidates. In addition to infringement claims against us, third parties may also raise similar claims before administrative bodies in the United States or abroad. Such mechanisms include interference proceedings, post grant review, inter partes review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions. If third parties prepare and file patent applications in the United States that also claim technology similar or identical to ours, we may have to participate in interference or derivation proceedings in the USPTO to determine which party is entitled to a patent on the disputed invention. We may also become involved in similar opposition proceedings in the European Patent Office or similar offices in other jurisdictions regarding our intellectual property rights with respect to our products and technology. Since patent applications are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. Such administrative proceedings could result in revocation of or amendment to our patents in such a way that they no longer cover our products or product candidates. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity and/or unenforceability, we may lose at least part, and perhaps all, of the patent protection on our products or technologies. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations, and prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. The costs of these lawsuits could affect our results of operations and divert the attention of managerial and scientific personnel. Some of these third parties may be better capitalized and have more resources than us. There is a risk that a court would decide that we are infringing the third-party&#8217;s patents and would order us to stop the activities covered by the patents. In that event, we may not have a viable way around the patent and may need to halt commercialization of the relevant product candidate. In addition, there is a risk that a court will order us to pay the other party damages for having violated the other party&#8217;s patents. We also could be ordered to pay substantial damages, including treble damages and attorney&#8217;s fees if we are found to be willfully infringing a third party&#8217;s patents or other intellectual property rights. In addition, we may be obligated to indemnify our licensors and collaborators against certain intellectual property infringement claims brought by third parties, which could require us to expend additional resources. The pharmaceutical and biotechnology industries have produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third party patents are valid and enforceable, and infringed by the use of our products and/or technologies, which could have a negative impact on the commercial success of our current and any future products or technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the U.S., proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#8217;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, which may not be available, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We cannot be certain that others have not filed patent applications for technology covered by our pending applications, or that we were the first to invent the technology, because:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">some patent applications in the U.S. may be maintained in secrecy until the patents are issued;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent applications in the U.S. are typically not published until 18 months after the priority date; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publications in the scientific literature often lag behind actual discoveries.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours. Any such patent application may have priority over our patent applications, which could further require us to obtain rights to issued patents covering such technologies. If another party has filed U.S. patent applications on inventions similar to ours that claim priority to any applications filed prior to the priority dates of our applications, we may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the U.S. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar inventions prior to our own inventions, resulting in a loss of our U.S. patent position with respect to such inventions. Other countries have similar laws that permit secrecy of patent applications and may be entitled to priority over our applications in such jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to enforce our intellectual property rights throughout the world. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to life sciences. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain and enforce adequate intellectual property protection for our technology. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Finally, a Unitary Patent and Unified Patent Court (&#8220;UPC&#8221;) system was implemented in Europe on June 1, 2023. This new regime may present uncertainties for our ability to protect and enforce our patent rights against competitors in Europe. Under the UPC, all European patents, including those issued prior to ratification of the European Patent Package, by default automatically fall under the jurisdiction of the UPC. The UPC provides our competitors with a new forum to centrally revoke our European patents, and allows for the possibility of a competitor to obtain pan-European injunctions. It will be several years before we will understand the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by the UPC. Under the EU Patent Package, we will have the right to opt our patents out of the UPC over the first seven years of the court&#8217;s existence, but doing so may preclude us from realizing the benefits of the new unified court.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our competitive position may be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our trademarks could be challenged, invalidated, infringed, and circumvented by third parties, and our trademarks could also be diluted, declared generic or found to be infringing on other marks. If any of the foregoing occurs, we could be forced to re-brand our products or technologies, resulting in loss of brand recognition and requiring us to devote resources to advertising and marketing new brands, and suffer other competitive harm. Third parties may also adopt trademarks similar to ours, which could harm our brand identity and lead to market confusion. Further, there can be no assurance that competitors will not infringe on our trademarks or that we will have adequate resources to enforce our trademarks. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. Certain of our current or future trademarks may become so well known by the public that their use becomes generic and they lose trademark protection. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, operating results and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We rely on our trademarks, trade names and brand names, such as &#8220;IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>&#8221; and our logo, to distinguish our company and our products from our competitors and the products of our competitors, and have registered or applied to register many of these trademarks in the United States and certain countries outside the United States, however, we have not yet registered all of our trademarks in all of our current and potential markets. There can be no assurance that our trademark applications will be approved for registration. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in proceedings before the USPTO and comparable agencies in many foreign jurisdictions, third parties may also oppose our trademark applications and may seek to cancel trademark registrations or otherwise challenge our use of the trademarks. Opposition or cancellation proceedings may be filed against our trademark filings in these agencies, and such filings may not survive such proceedings. While we may be able to continue the use of our trademarks in the event registration is not available, particularly in the United States, where trademark rights are acquired based on use and not registration, third parties may be able to enjoin the continued use of our trademarks if such parties are able to successfully claim infringement in court. In addition, opposition or cancellation proceedings may be filed against our trademark applications and registrations and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would. Our trademarks or trade names may be infringed, circumvented, declared generic or determined to be violating or infringing on other marks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and products could be significantly diminished.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition to patent protection, we also rely on other intellectual property rights, including protection of copyright, trade secrets, know-how and/or other proprietary information to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect, and some courts are less willing or unwilling to protect trade secrets. To maintain the confidentiality of our trade secrets and proprietary information, we rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary information. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes and we may not enter into such agreements with all employees, consultants and third parties who have been involved in the development of our intellectual property rights. Although we generally require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed. In addition, despite the protections we do place on our intellectual property or other proprietary rights, monitoring unauthorized use and disclosure of our intellectual property rights by employees, consultants and other third parties who have access to such intellectual property or other proprietary rights is difficult, and we do not know whether the steps we have taken to protect our intellectual property or other proprietary rights will be adequate. Therefore, we may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by such employees, consultants, advisors or third parties, despite the existence generally of these confidentiality restrictions. These agreements may not effectively prevent disclosure of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. There can be no assurances that such employees, consultants, advisors or third parties will not breach their agreements with us, that we will have adequate remedies for any breach, or that our trade secrets will not otherwise become known or independently developed by third parties, including our competitors. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. The exposure of our trade secrets and other proprietary information would impair our competitive advantages and could have a material adverse effect on our business, financial condition and results of operations. In particular, a failure to protect our proprietary rights may allow competitors to copy our technology, which could adversely affect our pricing and market share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition to contractual measures, we try to protect the confidential nature of our proprietary information by maintaining physical security of our premises and electronic security of our information technology systems. Such security measures may not, for example, in the case of misappropriation of a trade secret by an employee, consultant or other third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee, consultant or other third party from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products or services that we consider proprietary. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. While we use commonly accepted security measures, trade secret violations are often a matter of state law in the United States, and the criteria for protection of trade secrets can vary among different jurisdictions. If the steps we have taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our intellectual property rights or confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, it could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Furthermore, any license agreements we enter into in the future may require us to notify, and in some cases license back to the licensor, certain additional proprietary information or intellectual property that we developed using the rights licensed to us under these agreements. Any such licenses back to the licensor could allow our licensors to use that proprietary information or intellectual property in a manner that could harm our business. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part of its transparency initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change in the future, if at all. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. Further, it is possible that others will independently develop the same or similar technology, products or services or otherwise obtain access to our unpatented technology, and in such cases, we could not assert any trade secret rights against such parties. If we fail to obtain or maintain trade secret protection, or if our competitors obtain our trade secrets or independently develop technology or products similar to ours, our competitive market position could be materially and adversely affected. In addition, some courts are less willing or unwilling to protect trade secrets and agreement terms that address non-competition are difficult to enforce in many jurisdictions and might not be enforceable in certain cases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may be subject to claims that our employees, consultants or independent contractors have misappropriated the intellectual property rights, including know-how or trade secrets of a third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We may be subject to claims that our employees or consultants have wrongfully used for our benefit or disclosed to us confidential information of third parties. As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors may have executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment or </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">engagement. Although we try to ensure that our employees, consultants and independent contractors do not use the intellectual property rights, proprietary information, know-how, or trade secrets of others in their work for us, and do not perform work for us that is in conflict with their obligations to another employer or any other entity, we may be subject to claims that we or our employees, consultants or independent contractors have, inadvertently or otherwise misappropriated the intellectual property, including know-how, trade secrets or other proprietary information of their former employers or clients. To the extent that our employees, consultants or contractors use intellectual property rights or proprietary information owned by others in their work for us, disputes may arise as to the rights in any related or resulting know-how and inventions. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we could lose valuable intellectual property rights or personnel, which could adversely impact our business. There is no guarantee of success in defending these claims, and even if we are successful, litigation could result in substantial costs and be a distraction to management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our intellectual property may not be sufficient to protect our products from competition, which may negatively affect our business as well as limit our partnership or acquisition appeal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may be subject to competition despite the existence of intellectual property we license or own. We can give no assurances that our intellectual property claims will be sufficient to prevent third parties from designing around patents we own or license and developing and commercializing competitive products. The existence of competitive products that avoid our intellectual property could materially adversely affect our operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Furthermore, limitations, or perceived limitations, in our intellectual property may limit the interest of third parties to partner, collaborate or otherwise transact with us, if third parties perceive a higher than acceptable risk to commercialization of our products or future products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our drug re-innovation approach involves the filing of patent applications covering new methods of use and/or new formulations of previously known, studied and/or marketed drugs. Although the protection afforded by our patent and patent applications may be significant with respect to BXCL501, BXCL502, BXCL701 and BXCL702, when looking at our patents&#8217; ability to block competition, the protection offered by our patents may be, to some extent, more limited than the protection provided by patents claiming the composition of matter of entirely new chemical structures previously unknown. If a competitor were able to successfully design around any method of use and formulation patents we may have in the future, our business and competitive advantage could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may elect to sue a third party, or otherwise make a claim, alleging infringement or other violation of patents, trademarks, trade dress, copyrights, trade secrets, domain names or other intellectual property rights that we either own or license from BioXcel LLC. If we do not prevail in enforcing our intellectual property rights in this type of litigation, we may be subject to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">paying monetary damages related to the legal expenses of the third party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facing additional competition that may have a significant adverse effect on our product pricing, market share, business operations, financial condition, and the commercial viability of our products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restructuring our company or delaying or terminating select business opportunities, including, but not limited to, research and development, clinical trial, and commercialization activities, due to a potential deterioration of our financial condition or market competitiveness.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A third-party may also challenge the validity, enforceability or scope of the intellectual property rights that we license or own; and the result of these challenges may narrow the scope or claims of or invalidate patents that are integral to our product candidates in the future. There can be no assurance that we will be able to successfully defend patents we own in an action against third parties due to the unpredictability of litigation and the high costs associated with intellectual property litigation, amongst other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Intellectual property rights and enforcement may be less extensive in jurisdictions outside of the U.S.; thus, we may not be able to protect our intellectual property and third parties may be able to market competitive products that may use some or all of our intellectual property.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Changes to patent law, including the Leahy-Smith America Invents Act of 2011 and the Patent Reform Act of 2009 and other future article of legislation, may substantially change the regulations and procedures surrounding patent applications, issuance of patents, and prosecution of patents. We can give no assurances that patents we own or license and can be successfully defended or will protect us against future intellectual property challenges, particularly as they pertain to changes in patent law and future patent law interpretations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:10pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;">In Europe, a new unitary patent system took effect on June 1, 2023, and may significantly impact European patents, including those granted before the introduction of the new system. Under the new system, Applicants can, upon grant of a patent, opt for that patent to become a Unitary Patent which will be subject to the jurisdiction of a new Unitary Patent Court (UPC).  Patents granted before the implementation of the new system can be opted out of UPC jurisdiction, remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC may be challenged in a single UPC-based revocation proceeding that, if successful, could invalidate the patent in all countries who are signatories to the UPC.&#160; Further, because the UPC is a new court system and there is little precedent for the court&#8217;s laws, there is increased uncertainty regarding the outcome of any patent litigation. We are unable to predict what impact the new patent regime may have on our ability to exclude competitors in the European market. In addition to changes in patent laws, geopolitical dynamics, including Russia&#8217;s incursion into Ukraine, and the imposition of tariffs and responses to tariffs, may impact our ability to obtain and enforce patents in particular jurisdictions.  If we are unable to obtain and enforce patents as needed in particular markets, our ability to exclude competitors in those markets may be reduced.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, enforcing and maintaining our intellectual property protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by the USPTO, courts and foreign government patent agencies, and our patent protection could be reduced or eliminated for non- compliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Owning our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The price of our common stock may fluctuate substantially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">You should consider an investment in our common stock to be risky, and you should invest in our common stock only if you can withstand a significant loss and wide fluctuations in the market value of your investment. Some factors that may cause the market price of our common stock to fluctuate, in addition to the other risks mentioned in this &#8220;Risk Factors&#8221; section, are:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sale of our common stock by our stockholders, executives, and directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">volatility and limitations in trading volumes of our shares of common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">speculative trading in and short sales of our stock, as well as trading phenomena such as the &#8220;short squeeze&#8221; and &#8220;short and distort&#8221; schemes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain financings to conduct and complete research and development activities including, but not limited to, our clinical trials, and other business activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">possible delays in the expected recognition of revenue due to lengthy and sometimes unpredictable sales timelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and success of introductions of new applications and services by us or our competitors or any other change in the competitive dynamics of our industry, including consolidation among competitors, customers or strategic partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">network outages or security breaches;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to attract new customers;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">customer renewal rates and the timing and terms of customer renewals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to secure resources and the necessary personnel to conduct clinical trials on our desired schedule;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commencement, enrollment or results of our clinical trials for our product candidates or any future clinical trials we may conduct;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the development status of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any delays or adverse developments or perceived adverse developments with respect to the FDA&#8217;s review of our preclinical and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any delay in our submission for studies or product approvals or adverse regulatory decisions, including failure to receive regulatory approval for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated safety concerns related to the use of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failures to meet external expectations or management guidance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in our capital structure or dividend policy, future issuances of securities, sales of large blocks of common stock by our stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our cash position;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements and events surrounding financing efforts, including debt and equity securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to enter into new markets or develop new products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reputational issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competition from existing technologies and products or new technologies and products that may emerge;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of acquisitions, partnerships, collaborations, joint ventures, new products, capital commitments, or other events by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in general economic, political and market conditions in or any of the regions in which we conduct our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in industry conditions or perceptions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in valuations of similar companies or groups of companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analyst research reports, recommendation and changes in recommendations, price targets, and withdrawals of coverage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">departures and additions of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes and litigations related to intellectual properties, proprietary rights, and contractual obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in applicable laws, rules, regulations, or accounting practices and other dynamics; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other events or factors, many of which may be out of our control.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, if the market for stocks in our industry or industries related to our industry, or the stock market in general, experiences a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, financial condition and results of operations. If any of the foregoing occurs, it could cause our </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">stock price to fall and may expose us to lawsuits that, even if unsuccessful, could be costly to defend and a distraction to management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Future sales and issuances of our common stock, including common stock that may be sold following exercise of outstanding warrants, would result in additional dilution of the percentage ownership of our stockholders and could adversely impact the share price of our common stock. </p><p style="font-family:'MS Mincho';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We expect that significant additional capital will be needed in the future to continue our planned operations, including, without limitation, funding our trials and studies, marketing and commercializing our products and funding our operations. Accordingly, we have sold, and in the future may sell, common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. To the extent we raise additional capital by issuing </span><span style="font-family:'Times New Roman','Times','serif';">additional shares of common stock or securities convertible or exchangeable for our common stock</span><span style="font-family:'Times New Roman','Times','serif';">, our stockholders may experience substantial dilution, and new investors could gain rights superior to our existing stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In March 2024, we issued and sold in a registered direct offering 190,913 shares of our common stock, accompanying warrants to purchase up to 538,728 shares of our common stock and pre-funded warrants to purchase up to 347,814 shares of our common stock. In November 2024, we issued and sold in a registered direct offering 350,000 shares of our common stock, accompanying warrants to purchase up to 912,500 shares of our common stock and pre-funded warrants to purchase up to 562,500 shares of our common stock, (see Note 11, <i style="font-style:italic;">Common Stock Financing Activities </i>in this Annual Report on Form 10-K for additional information). In addition, we issued additional warrants to purchase up to 312,506 shares of common stock in connection with the Fifth Amendment of our Credit Agreement (see Note 9, <i style="font-style:italic;">Debt and Credit Facilities</i><span style="white-space:pre-wrap;"> in this Annual Report on Form 10-K for additional information). In March 2025, we issued and sold in a registered direct offering 188,383 shares of common stock, pre-funded warrants to purchase up to 3,811,617 shares of our common stock, accompanying warrants to purchase up to 4 million shares, and option warrants to purchase an additional 4 million shares and 4 million warrants.  The number of shares of common stock underlying our outstanding warrants is significant in relation to our outstanding common stock (145% as of March 21, 2025), which could have a negative effect on the market price of our common stock and make it more difficult for us to raise funds through future equity offerings. In the event these warrants are exercised, our stockholders will experience additional dilution. To the extent outstanding stock options or warrants are exercised, there would be further dilution to our existing stockholders, which could impact the price of our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We do not intend to pay cash dividends on our shares of common stock so any returns will be limited to the value of our shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the increase, if any, of our share price. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">If we were deemed to be an investment company under the Investment Company Act of 1940, as amended (the &#8220;1940 Act&#8221;), applicable restrictions could make it impractical for us to continue our business as contemplated and could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under Sections 3(a)(1)(A) and (C) of the 1940 Act, a company generally will be deemed to be an &#8220;investment company&#8221; for purposes of the 1940 Act if (1) it is, or holds itself out as being, engaged primarily, or proposes to engage primarily, in the business of investing, reinvesting or trading in securities or (2) it engages, or proposes to engage, in the business of investing, reinvesting, owning, holding or trading in securities and it owns or proposes to acquire investment securities having a value exceeding 40% of the value of its total assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis. We do not believe that we are an &#8220;investment company,&#8221; as such term is defined in the 1940 Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Notwithstanding Sections 3(a)(1)(A) and (C) of the 1940 Act, we are a research and development company and comply with the safe harbor requirements of Rule 3a-8 of the 1940 Act. We intend to conduct our operations so that we will not be deemed an investment company. However, if we were to be deemed an investment company, restrictions imposed by the 1940 Act, including limitations on our capital structure and our ability to transact with affiliates, could </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">make it impractical for us to continue our business as contemplated and could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We are a &#8220;smaller reporting company&#8221; and are able to avail ourselves of reduced disclosure requirements applicable to smaller reporting companies, which could make our common stock less attractive to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are a smaller reporting company, and we will remain a smaller reporting company until we determine that either (1) our annual revenues are at least $100 million and our voting and non-voting common stock held by non-affiliates is at least $250 million measured on the last business day of our most recent second fiscal quarter, or (2) our voting and non-voting common stock held by non-affiliates is at least $700 million measured on the last business day of our most recent second fiscal quarter. Smaller reporting companies are able to provide simplified executive compensation disclosure, and have certain other reduced disclosure obligations, including, among other things, being required to provide only two years of audited financial statements and not being required to provide selected financial data, supplemental financial information or risk factors. In addition, as a non-accelerated filer, we are exempt from the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have elected to take advantage of certain of the reduced reporting obligations. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We are and may in the future be subject to legal proceedings, claims and investigations in or outside the ordinary course of business. Such proceedings, claims and investigations could be costly and time-consuming to defend and could result in unfavorable outcomes, which may have a material adverse effect on our business, operating results and financial condition, and negatively affect the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are, and may in the future become, subject to various legal proceedings, claims and investigations that arise in or outside the ordinary course of business. For example, on July 7, 2023, plaintiff Katelyn Martin filed a class action complaint against the Company and certain executives in the United States District Court for the District of Connecticut, captioned <i style="font-style:italic;">Martin v. BioXcel Therapeutics, et al.</i>, 3:23-cv-00915 (D. Conn). The case has since been renamed to <i style="font-style:italic;">Hills et al v. BioXcel Therapeutics, Inc. et al</i>. On October 4, 2023, pursuant to the Private Securities Litigation Reform Act, the court appointed two co-Lead Plaintiffs. The co-Lead Plaintiffs filed an amended complaint on December 5, 2023, alleging violations of Sections 10(b) and 20A of the Exchange Act and SEC Rule 10b-5 promulgated thereunder. On July 11, 2024, the Court dismissed the amended complaint without prejudice and, on August 1, 2024, co-Lead Plaintiffs filed a second amended complaint. The second amended complaint alleges that defendants made false or misleading statements regarding the TRANQUILITY II trial and the development of BXCL501 for an expanded indication related to the treatment of certain Alzheimer&#8217;s-related agitation. The Company moved to dismiss the second amended complaint on September 6, 2024. <span style="white-space:pre-wrap;background:#ffffff;">On February 24, 2025, while the Company&#8217;s motion to dismiss remained pending, Plaintiffs moved for leave to further amend their complaint.  The Company filed an opposition to the motion on March 17, 2025.  Plaintiffs&#8217; reply is due April 7, 2025.  </span><span style="white-space:pre-wrap;">  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On November 28, 2023, Plaintiffs Pratheesan Panancherry and Jeffrey Bastress filed a stockholder derivative complaint in the United States District Court for the District of Connecticut purportedly on behalf of the Company and against Vimal Mehta, Richard I. Steinhart, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption <i style="font-style:italic;">Panancherry et al v. Mehta et al</i>, 3:23-cv-1554. Following the initial action, Plaintiffs Maria Vomvolakis (3:24-cv-3) and Kelly Fowler (3:24-cv-203) each filed separate stockholder derivative complaints in the District of Connecticut raising similar claims as Panancherry and Bastress, including business torts and violations of the Exchange Act. The cases have been consolidated under the caption <i style="font-style:italic;">In re BioXcel Therapeutics, Inc. Stockholder Derivative Litigation</i>, 3:23-cv-1554 (D. Conn.). The consolidated action is currently stayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On January 11, 2024, Plaintiff Jeremy Smith filed a stockholder derivative complaint in the United States District Court for the United States District Court for the District of Delaware purportedly on behalf of the Company and against Vimal Mehta, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, Richard I. Steinhart, Robert Risinger, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption <i style="font-style:italic;">Smith v. </i></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Mehta et al</i>, 1:24-cv-00041. Following the initial action, Plaintiff Janice Korff filed a stockholder derivative complaint in the District of Delaware raising similar claims as Smith (1:24-cv-130), including business torts and violations of the Exchange Act. The cases have been consolidated under the caption <i style="font-style:italic;">In re BioXcel Therapeutics, Inc. Derivative Litigation,</i> 1:24-cv-00041 (D. Del.). The consolidated action is currently stayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company is also cooperating with a formal investigation of the Company and certain of its officers and directors by the SEC, relating to the Company&#8217;s public disclosures, including about product sales and the receipt of a Form 483 by an investigator at one of the Company&#8217;s clinical trial sites in the TRANQUILITY II study, and trading in the securities of the Company. The Company has produced documents, and current and former officers and employees of the Company have testified before the SEC. The above-captioned proceedings, as well as any investigation or proceeding that may be instituted by the SEC may result in substantial costs or liabilities, as well as a diversion of management&#8217;s attention and resources, which could harm our business, result in a decline in the market price of our common stock and impact our financing efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The potential costs and liabilities associated with legal proceedings, claims and investigations involving us or members of our leadership team is uncertain, and the results of such legal proceedings, claims and investigations cannot be predicted with certainty. Lawsuits and other administrative or legal proceedings that may arise can involve substantial costs, including the costs associated with investigation, litigation and possible settlement, judgment, penalty or fine. In addition, lawsuits and other legal proceedings may be time consuming to defend or prosecute and may require a commitment of management and personnel resources that will be diverted from our normal business operations. Also, our insurance coverage may be insufficient, our assets may be insufficient to cover any amounts that exceed our insurance coverage, and we may have to pay damage awards or otherwise may enter into settlement arrangements in connection with such claims. Moreover, we may be unable to continue to maintain our existing insurance at a reasonable cost, if at all, or to secure additional coverage, which may result in costs associated with lawsuits and other legal proceedings being uninsured. Any such payments or settlement arrangements in current or future litigation could have a material adverse effect on our business, operating results or financial condition. Even if the plaintiffs&#8217; claims are not successful, current or future litigation could result in substantial costs and significantly and adversely impact our reputation and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, operating results and financial condition, and negatively affect the price of our common stock. In addition, such lawsuits may make it more difficult to finance our operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Biotechnology and pharmaceutical companies with publicly traded stock or who obtain funding through the stock market often experience significant stock price volatility, based on events beyond their control, including outcomes of clinical trials, actions of regulators and product approvals. Such further litigation, may result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business and result in a decline in the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our certificate of incorporation, our bylaws, and Delaware law may have anti-takeover effects that could discourage, delay, or prevent a change in control, which may cause our stock price to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our amended and restated certificate of incorporation, our amended and restated bylaws and Delaware law could make it more difficult for a third party to acquire us, even if closing such a transaction would be beneficial to our stockholders. We are authorized to issue up to 10 million shares of preferred stock. This preferred stock may be issued in one or more series, the terms of which may be determined at the time of issuance by our board of directors without further action by stockholders. The terms of any series of preferred stock may include voting rights (including the right to vote as a series on particular matters), preferences as to dividend, liquidation, conversion and redemption rights and sinking fund provisions. No preferred stock is currently outstanding. The issuance of any preferred stock could materially adversely affect the rights of the holders of our common stock, and therefore, reduce the value of our common stock. In particular, specific rights granted to future holders of preferred stock could be used to restrict our ability to merge with, or sell our assets to, a third party and thereby preserve control by the present management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Provisions of our amended and restated certificate of incorporation and our amended and restated bylaws and Delaware law also could have the effect of discouraging potential acquisition proposals or making a tender offer or delaying or preventing a change in control, including changes a stockholder might consider favorable. Such provisions </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">may also prevent or frustrate attempts by our stockholders to replace or remove our management. In particular, the certificate of incorporation and bylaws and Delaware law, as applicable, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide the board of directors with the ability to alter the bylaws without stockholder approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">place limitations on the removal of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that vacancies on the board of directors may be filled by a majority of directors in office, although less than a quorum.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Financial reporting obligations of being a public company in the U.S. are expensive and time-consuming, and our management is required to devote substantial time to compliance matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As a publicly traded company we have incurred and will continue to incur significant legal, accounting and other expenses. The obligations of being a public company in the U.S. require significant expenditures and place significant demands on our management and other personnel, including costs resulting from public company reporting obligations under the Exchange Act and the rules and regulations regarding corporate governance practices, including those under the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, and the listing requirements of the stock exchange on which our securities are listed. These rules require the establishment and maintenance of effective disclosure and financial controls and procedures, internal control over financial reporting and changes in corporate governance practices, among many other complex rules that are often difficult to implement, monitor and maintain compliance with. Moreover, despite reforms made possible by the JOBS Act, the reporting requirements, rules, and regulations will make some activities more time-consuming and costly, particularly as we are no longer an &#8220;emerging growth company.&#8221; In addition, we expect these and similar rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain such insurance. Our continued compliance with applicable requirements and to keep pace with new regulations requires management and other personnel to devote a substantial amount of their time, otherwise we may fall out of compliance and risk becoming subject to litigation or being delisted, among other potential problems.</p><p style="font-family:'MS Mincho';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">General Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If securities or industry analysts do not publish research or reports, or publish unfavorable research or reports about our business, our stock price and trading volume may decline.</p><p style="font-family:'MS Mincho';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us, our business, our markets and our competitors. We do not control these analysts. If securities analysts do not cover our common stock, the lack of research coverage may adversely affect the market price of our common stock. Furthermore, if one or more of the analysts who do cover us downgrade our stock or if those analysts issue other unfavorable commentary about us or our business, which has occurred in the past, our stock price would likely decline. If one or more of these analysts cease coverage of us or fails to regularly publish reports on us, we could lose visibility in the market and interest in our stock could decrease, which in turn could cause our stock price or trading volume to decline and may also impair our ability to expand our business with existing customers and attract new customers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we fail to comply with the rules&#160;under the Sarbanes-Oxley Act related to accounting controls and procedures in the future, or, if we discover material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Section 404 of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness of our internal control over financial reporting. If we fail to comply with the rules under the Sarbanes-Oxley Act related to disclosure controls and procedures in the future, or, if we discover material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have discovered material weaknesses in the past. If future material weaknesses or significant deficiencies are discovered or if we otherwise fail to achieve and maintain the adequacy of our internal control, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act. Moreover, effective internal controls are necessary for us to produce reliable financial reports and are important to helping prevent financial fraud. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our common stock could drop significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Changes in tax laws or exposure to additional income tax liabilities could have a material impact on our business, results of operations, financial condition and cash flows.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The tax regimes we are subject to or operate under, including income and non-income taxes, are unsettled and may be subject to significant change. Changes in tax laws, regulations, or rulings, or changes in interpretations of existing laws and regulations, could materially adversely affect our business, financial condition, results of operations, and prospects. For example, the TCJA, the Coronavirus Aid, Relief and Economic Security Act, and the Inflation Reduction Act (the &#8220;IRA&#8221;) made many significant changes to the U.S. tax laws. Beginning in 2022, the TCJA requires taxpayers to capitalize and amortize certain research and development expenditures over five years if incurred in the U.S. and 15 years if incurred in foreign jurisdictions, rather than deducting them currently. Although there have been legislative proposals to repeal or defer the research and development expenditure capitalization requirement to later years, there can be no assurance that the provision will be repealed or otherwise modified. As another example, the IRA includes provisions that will impact the U.S. federal income taxation of certain corporations, including imposing a minimum tax on the book income of certain large corporations and a 1% excise tax on the value of certain corporate stock repurchases by publicly traded companies that would be imposed on the company repurchasing such stock. Regulatory or accounting guidance with respect to existing or future tax laws could materially affect our tax obligations and effective tax rate. It is uncertain if, and to what extent, various states will conform to current federal law or any newly enacted federal tax legislation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Additional indirect taxes in various jurisdictions could materially adversely affect our business, financial condition, results of operations, and prospects. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We currently collect and remit applicable indirect taxes in jurisdictions where we, through our employees or economic activity, have a presence and where we have determined, based on applicable legal precedents, that our activities are taxable. We do not currently collect and remit indirect taxes, including state and local excise, utility user, and ad valorem taxes, fees, and surcharges in jurisdictions where we believe we do not have sufficient &#8220;nexus.&#8221; Tax authorities may challenge our position that we do not have sufficient nexus in a taxing jurisdiction or that our activities are not taxable in such jurisdiction and may decide to audit our business and operations with respect to indirect taxes, which could result in significant tax liabilities (including related penalties and interest) for us or our customers, which could materially adversely affect our business, financial condition, results of operations, and prospects.</p><a id="_1b6150c8_2b76_47cb_8451_4adf9e915cb8"></a><a id="Item1BUnresolvedStaffComments_512583"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;1B.&#160;Unresolved Staff Comments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_567a1c17_90f2_43ce_8789_0c749779d3b8"></a><a id="Item1C"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item 1C. Cybersecurity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Cybersecurity Risk Management and Strategy</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="Tb_n2X5ZYsTDkqJ_gH8Ob196w" continuedAt="Tb_n2X5ZYsTDkqJ_gH8Ob196w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. Our cybersecurity risk management program includes a cybersecurity incident response plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We designed and assessed our program based on the National Institute of Standards and Technology Cybersecurity Framework. This does not imply that we meet any particular technical standards, specifications, or requirements, only </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_n2X5ZYsTDkqJ_gH8Ob196w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">that we used the National Institute of Standards and Technology Cybersecurity Framework as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="Tb_7zodwI12e0S5nPgzwFA9mA" escape="true">Our cybersecurity risk management program is <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="Narr_TRtM47qSUE6wxI0uytHF9A">integrated</ix:nonNumeric> into our overall enterprise risk management program, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our cybersecurity risk management program includes:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise information technology environment;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>a management team responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the use of <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="Narr_dPonRqmVE0Gz22iJ1-ZZUg">external service providers</ix:nonNumeric>, where appropriate, to assess, test or otherwise assist with aspects of our security controls;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>cybersecurity awareness training of our employees, incident response personnel, and senior management; </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>a <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" format="ixt:fixed-true" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="Narr_pVosgLZFLUuug5JsgPeZ5A">third-party risk management process</ix:nonNumeric> for service providers, suppliers, and vendors.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There can be no assurance that our cybersecurity risk management program and processes, including our policies, controls or procedures, will be fully implemented, complied with or effective in protecting our systems and information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="Narr_lbz4sC9AFE-d3-PHXchNsA">materially affected</ix:nonNumeric> or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. For more information, see the section titled &#8220;Risk Factors&#8212; Business interruptions could adversely affect future operations, revenues, and financial conditions, and may increase our costs and expenses.&#8221;</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Cybersecurity Governance</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="Tb_Bsq8NNhVuUiCRofGVV9C3g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Tb_19re0ChUEUCJ3xwXcfaC_g" escape="true">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="Narr_eqAkuSFejUWQxbjPZsjzAg">Audit Committee</ix:nonNumeric> (the &#8220;Committee&#8221;) oversight of cybersecurity and other information technology risks</ix:nonNumeric>. The Committee oversees management&#8217;s implementation of our cybersecurity risk management program. </p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Tb_2pBcIpVUukephPE604ywuA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="Tb_xGSNAbpM-kWm8LwGv5Ovzw" escape="true">The Committee receives periodic reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential</ix:nonNumeric>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Committee <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="Narr_AR8RH3v9nk-Tvv3VHfrLog">reports</ix:nonNumeric> to the full Board regarding its activities, including those related to cybersecurity. The full Board also receives briefings from management on our cyber risk management program. Board members receive presentations on cybersecurity topics from the internal Security Incident Management Team or external experts as part of the Board&#8217;s continuing education on topics that impact public companies.</p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="Tb_OYG9G6OuekqxgIhv_Yb0zA" continuedAt="Tb_OYG9G6OuekqxgIhv_Yb0zA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our Security Incident Management Team, which includes our <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="Tb_CFKtzp4YekG2xU7LJPrRzg" escape="true">Chief Financial Officer, the Executive Director of Information Technology, Chief Legal Officer and the Quality Assurance Director</ix:nonNumeric>, has approximately <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="Group_VxUQm0PYXE6A4oyt0eD8WQ" escape="true">30 combined years of risk management experience</ix:nonNumeric> and is responsible for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. Our Security Incident Management Team&#8217;s experience includes prior work experience in cybersecurity; financial management and controls, data quality assurance and liability and risk management.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_OYG9G6OuekqxgIhv_Yb0zA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the information technology environment.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_36de69ff_59e2_4f61_bcec_cebf62048ebe"></a><a id="Item2Properties_105398"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;2.&#160;Properties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our corporate headquarters are located at 555 Long Wharf Drive in New Haven, Connecticut. The Company occupies 18,285 square feet of space. The leases for this space expire in February 2026 and we have a renewal option for one additional five-year term. We believe that our existing facilities are suitable and adequate to meet our current needs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_653b2af3_8f0f_44b6_837d_c702369185c5"></a><a id="Item3LegalProceedings_216198"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;3. Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">From time to time, we may be subject to litigation and claims arising in the ordinary course of business. For information about our legal proceedings, see Note 18 to our audited financial statements included elsewhere in this Annual Report on Form 10-K which information is incorporated herein by reference.</p><p style="font-family:'MS Mincho';font-size:10pt;text-align:justify;text-indent:18pt;margin:10pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In addition, in February 2024, we became aware that the SEC had initiated a formal investigation involving the Company and certain of its directors and officers. This formal investigation relates to the Company&#8217;s public disclosures, including about product sales and the receipt of a Form 483 by an investigator at one of the Company&#8217;s clinical trial sites in the TRANQUILITY II study, and trading in the securities of the Company. We are cooperating fully with the investigation including producing documents, and current and former officers and employees of the Company have testified before the SEC. We cannot predict or determine whether any proceeding may be instituted by the SEC in connection with its investigation or the outcome of any proceeding that may be instituted, or the effects any such proceeding could have on the Company&#8217;s business or financing efforts.</span></p><a id="_d36813f3_e279_4751_9811_4d2eb74d3a80"></a><a id="Item4MineSafetyDisclosures_460898"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;4. Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Not applicable.</p><a id="PartII_326423"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Part&#160;II</p><a id="_666c8db8_bab9_4d29_9399_20298f814e7c"></a><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Market Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our common stock is traded on The Nasdaq Capital Market<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> under the symbol &#8220;BTAI.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March 21, 2025, there were 13 stockholders of record of our common stock. The actual number of holders of our common stock is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Dividend Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We have never paid or declared any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our common stock in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion of our business. Any future determination to pay dividends will be at the discretion of our board of directors and will depend upon a number of factors, including our results of operations, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors that our board of directors deems relevant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Equity Compensation Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The information required by Item&#160;5 of Form&#160;10-K regarding equity compensation plans is incorporated herein by reference to Item&#160;11. of Part&#160;III of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Unregistered Sales of Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There were no unregistered sales of equity securities by the Company during the three months ended December 31, 2024, that was not previously disclosed on a Current Report on Form 8-K or Quarterly Report on Form 10-Q.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="Item6Reserved_721061"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item 6. Reserved</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d8945f93_4645_4fe3_a29f_5234974e3d1a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_b8f31d08_5bd2_488a_81b3_39ed5a0c3838"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;7.&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes appearing elsewhere in this report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled &#8220;Risk Factors&#8221; included elsewhere in this Annual Report on Form 10-K. All dollar amounts in the below Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations are presented in U.S. dollars, and all dollar and share amounts are presented in thousands, unless otherwise noted or the context otherwise provides.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:10pt;margin:0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">BioXcel Therapeutics, Inc. (&#8220;BTI&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company utilizing artificial intelligence (&#8220;AI&#8221;) to develop transformative medicines in neuroscience and, through the Company&#8217;s wholly owned subsidiary, OnkosXcel Therapeutics LLC (&#8220;OnkosXcel&#8221;), immuno-oncology. We are focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients&#8217; lives. We employ various AI platforms to reduce therapeutic development costs and potentially accelerate development timelines. Our approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. We believe this differentiated approach has the potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Our most advanced neuroscience candidate is BXCL501. In indications other than those approved by the United States (&#8220;U.S.&#8221;) Food and Drug Administration (&#8220;FDA&#8221;) as IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, BXCL501 is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine (or &#8220;Dex&#8221;) in development for the treatment of agitation associated with psychiatric and neurological disorders. Our most advanced immuno-oncology asset, BXCL701, is an investigational oral innate immune activator being developed by OnkosXcel Therapeutics as a potential therapy for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On April 6, 2022, we announced that the FDA approved IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is approved to be self-administrated by patients under the supervision of a health care provider. On July 6, 2022, we announced that IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> was commercially available in doses of 120 and 180 micrograms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">We are continuing to develop BXCL501 for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer&#8217;s disease in the at-home setting and in care facilities. As described further below, we have recently deprioritized the development of BXCL501 for certain indications, including development of BXCL501 as a potential adjunctive treatment for major depressive disorder (&#8220;MDD&#8221;), as well as our BXCL701 program except as noted in Part, Item 1, &#8220;Business&#8221; under the heading &#8220;Immuno-Oncology.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In our SERENITY program, we are evaluating BXCL501 for use in the at-home setting for agitation associated with bipolar disorders or schizophrenia. We completed Part 1 of the SERENITY III trial and announced topline results on May 25, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We reviewed our SERENITY III program with the FDA in Type C meetings on November 8, 2023 and March 6, 2024. Based on the feedback received from the FDA to date, we are moving forward to evaluate at-home use of the 120 mcg dose of BXCL501, with safety as the primary objective and efficacy measures as exploratory endpoints to support continued efficacy in the at-home setting as recommended by the FDA in the November 8, 2023 meeting, for the acute treatment of agitation in bipolar disorders or schizophrenia. We also plan to initiate a clinical study designed to enroll approximately 30 patient-informant dyads to evaluate the correlation between patient-and informant-reported efficacy measurement and the PEC scale, conducted by trained clinician raters as previously recommended by the FDA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On September 5, 2024, we announced the initiation of patient enrollment in our SERENITY At-Home trial. The pivotal Phase 3 trial is designed to evaluate the safety of BXCL501 in the at home setting. On March 27, 2025, we announced that 24 clinical trial sites had been opened and 127 patients had been enrolled, representing 63% of the total required enrollment. Topline data results, which are expected in the second half of 2025, are intended to support a supplemental new drug application (sNDA) submission to potentially expand the label of IGALMI&#174; (dexmedetomidine) sublingual film. See further discussion in <i style="font-style:italic;">&#8220;Our Neuroscience Clinical Programs&#8221;</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">For our TRANQUILITY program, we have conducted clinical studies evaluating BXCL501 for the acute treatment of agitation associated with mild to moderate dementia in patients with probable Alzheimer&#8217;s disease, who reside in assisted living facilities (&#8220;ALFs&#8221;) and residential care settings and who required minimal assistance with activities of daily living. On June 29, 2023, we announced positive topline data from our TRANQUILITY II trial, as well as information regarding certain investigator misconduct and noncompliance at a clinical trial site. Since that time, we have taken steps to further investigate and evaluate the conduct of the TRANQUILITY II trial at this clinical site. Based on these steps to date, we believe that there have been no further instances of misconduct or fraud or other findings that adversely impact the data integrity or reliability of the eligibility, safety, and efficacy data obtained at the clinical trial site in question.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 3, 2025 we announced that the U.S. Food and Drug Administration (FDA) concluded that the inspection of a single site in its TRANQUILITY II Phase 3 trial was closed under 21 C.F.R.20.64(d)(3) and released the Establishment Inspection Report. The FDA designated &#8220;Voluntary Action Indicated&#8221; for the site.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We had previously been conducting the TRANQUILITY III clinical trial, which was designed to evaluate the potential for BXCL501 to treat acute agitation in patients with moderate to severe dementia associated with probable Alzheimer&#8217;s disease living in nursing homes and who require moderate to full assistance with activities of daily living. We paused enrollment in TRANQUILITY III due to the much higher-than-expected background frequency of episodes of agitation experienced by the first several patients enrolled in the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We held Type B/Breakthrough Therapy Designation meetings with the FDA on October 11, 2023 and on February 20, 2024 to obtain additional feedback on our plans for further development of BXCL501 for the treatment of agitation associated with dementia in patients with probable Alzheimer&#8217;s disease. We are currently planning to generate additional Phase 3 efficacy and safety data, in a variety of relevant care-facility settings and across severity of dementia using the Positive and Negative Syndrome Scale-Excitatory Component (&#8220;PEC&#8221;) as the primary efficacy measure. In addition, we plan to discuss the details of the requirement for long-term safety data at a future meeting with the FDA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On September 5, 2024, we submitted to the FDA the proposed protocol for our TRANQUILITY In-Care Phase 3 trial designed to evaluate the efficacy and safety of a 60 mcg dose of BXCL501 for agitation associated with Alzheimer&#8217;s dementia. On November 12, 2024, we announced that we had received feedback from the FDA on the proposed protocol. See further discussion in <i style="font-style:italic;">&#8220;Our Neuroscience Clinical Programs&#8221;</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On October 15, 2024, we announced a U.S. Department of Defense grant to the University of North Carolina to fund a study of BXCL501 (Sublingual Dexmedetomidine) for treating Acute Stress Disorder (ASD). See further discussion in <i style="font-style:italic;">&#8220;Additional Neuroscience Opportunities&#8221;</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">IGALMI</b><sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><b style="font-weight:bold;"> Commercialization Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We continue to support IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the hospital setting with minimal commercial support.&#160;On August 14, 2023, the Company announced it had implemented a shift in commercial strategy for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the institutional setting, a reduction of in-hospital commercialization expenses, a suspension of programs no longer deemed core to the Company&#8217;s business, and a shift to focus on the development of BXCL501 for use in the at-home and care facilities in the treatment of acute agitation in schizophrenia and bipolar disorders, and in the treatment of acute agitation (non-daily) associated with dementia due to probable Alzheimer&#8217;s disease (collectively, the &#8220;Reprioritization&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Following the Reprioritization, a small Corporate Account Director (&#8220;CAD&#8221;) team supported current customers and targeted Integrated Delivery Networks (&#8220;IDNs&#8221;) with educational support and contracting opportunities, while our trade operation supported customers with drug supply.&#160; The goal of this approach was to help maintain current business and potentially broaden IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> utilization through volume contracting. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">As part of the Clinical Prioritization in September 2024, further workforce reductions were made, including 9 additional marketing and sales employees. The Clinical Prioritization staff reductions may have future impacts on net revenue. Despite our reduction in commercial resources, net revenues from IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> product sales of $2,266 for the year ended December 31, 2024 were up 64% over net revenues from IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="white-space:pre-wrap;"> product sales of $1,380 for the year ended December 31, 2023.  We believe this positive growth reflects increasing market acceptance and interest in our product.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are currently seeking potential commercial partners. Our continued commercialization efforts for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> are designed to build the foundation to launch additional potential follow-on indications, if any. If IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> would be approved outside the U.S., we would consider launching the product through collaborations with third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Recent Developments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Nasdaq Delisting Notice</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As previously reported, on September 20, 2024, we received a letter from Nasdaq Staff notifying us that for the 30 consecutive business days prior to the date of the letter, the Company&#8217;s market value of listed securities closed below the minimum $35 million requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company was granted a period of 180 calendar days, or until March 19, 2025, to regain compliance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As anticipated, on March 20, 2025, the Company received another letter from the Staff stating that, as a result of the Company&#8217;s continued non-compliance with the MVLS Requirement, its securities would be delisted from Nasdaq unless the Company appeals the Staff&#8217;s delisting determination by requesting a hearing before the Nasdaq Panel. The Company made timely request for a hearing before the Panel to appeal the Staff&#8217;s determination. The Company&#8217;s common stock will remain listed and eligible for trading on Nasdaq at least pending the ultimate conclusion of the hearing process; however, there can be no assurance that the Company will ultimately regain compliance and remain listed on Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Credit Agreement Amendments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Fifth Amendment to Credit Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On November 21, 2024, we entered into the Fifth Amendment to our Credit Agreement &#160;(the &#8220;Fifth Amendment&#8221;), pursuant to which the Lenders agreed to, among other things, (i) waive the Credit Agreement&#8217;s covenant that the report and opinion the Company will receive from its independent registered public accounting firm with respect to the financial statements for the year ending December 31, 2024 will not contain a &#8220;going concern&#8221; or similar qualification, (ii) permanently waive the Credit Agreement&#8217;s minimum revenue covenant, and (iii) waive the Fourth Amendment&#8217;s requirement that the Company raise, after the effective date of the Fourth Amendment and on or before November 30, 2024, at least $50,000 in gross cash proceeds from the issuance of its common stock, warrants, and/or pre-funded warrants, and/or in cash and/or non-cash consideration from newly entered-into partnering transactions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Fifth Amendment included a new capital raising covenant requiring that the Company receive (A) after the effective date of the Fifth Amendment and on or prior to November 27, 2024, at least $7,000 in gross cash proceeds from the issuance of the Company&#8217;s common stock, warrants and/or pre-funded warrants(&#8220;Raise 1&#8221;), (B) after the effective date of the Fifth Amendment and on or before March 15, 2025 (provided that the Company will use its commercially reasonable efforts to satisfy the requirement by February 15, 2025), at least $18,000 in net cash proceeds (including the proceeds of Raise 1) from (i) the issuance of the Company&#8217;s common stock, warrants and/or pre-funded warrants, (ii) non-refundable cash consideration from partnering transactions entered into after the effective date of the Fifth Amendment (so long as such partnering transactions would not require the Company or any of its subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made), (iii) the issuance of the Company&#8217;s </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">subordinated debt (subject to terms set forth in the Fifth Amendment), and/or (iv) asset sales permitted pursuant to the Credit Agreement or consented to by the Lenders (such capital raise, &#8220;Raise 2&#8221;), and (C) after the effective date of the Fifth Amendment and on or prior to the earlier of (x) August 15, 2025 and (y) the date that is 30 days after the final data readout of the SERENITY At-Home Phase 3 trial, at least $29,000 in net cash proceeds (including the proceeds from Raise 1 and Raise 2) from the same permitted capital raising activities listed in the preceding clause (B). The Company met the requirements of Raise 1, discussed in Note 11, <i style="font-style:italic;">Common Stock Financing Activities</i>. The Company met the requirements of Raise 2, discussed in Note 20, <i style="font-style:italic;">Subsequent Events</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the Fifth Amendment and the required capital raises described in the preceding paragraph, the Lenders agreed to modify the Credit Agreement&#8217;s minimum liquidity covenant to require minimum cash liquidity of $7,500 (instead of $25,000) from and after the closing of Raise 1 until March 30, 2025. On March 31, 2025, the minimum liquidity amount will increase to $10,000, and on September 30, 2025, the minimum liquidity amount will further increase to $15,000. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the Fifth Amendment, the Company paid a one-time amortization payment of $2,500 principal amount, together with accrued and unpaid interest and a portion of the prepayment fee and other fees payable in December 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Fifth Amendment also modified the interest rate of the loans provided under the Credit Agreement from a floating rate of Term SOFR plus 7.50% per annum, to a fixed rate of 13% per annum, retroactive to and effective as of September 30, 2024. For the quarterly payment dates <span style="color:#202020;">ending December 31, 2024, March 31, 2025, and June 30, 2025, t</span>he Company has the ability to make interest payments of up to 10% per annum &#8220;in-kind&#8221; by capitalizing and adding such interest to the outstanding principal amount of the loans under the Credit Agreement<span style="color:#202020;">. </span>In addition, pursuant to the Fifth Amendment, the Company will be required to make quarterly amortization payments equal to 5.0% of the principal amount of funded loans, together with applicable prepayment fees, beginning on March 31, 2026. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#202020;">On the effective date of the Fifth Amendment and as a condition to effectiveness thereof, the Company&#8217;s wholly owned subsidiaries OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC (collectively, &#8220;OnkosXcel&#8221;), which previously provided unsecured guarantees of the Company&#8217;s obligations under the Credit Agreement, granted security interests in substantially all of their assets to support such obligations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#202020;">The Fifth Amendment amended the negative covenants under the Credit Agreement to remove flexibility the Company and its subsidiaries previously had thereunder to undertake various transactions, including, without limitation, with respect to potential dispositions of OnkosXcel or out-licenses by OnkosXcel of its intellectual property. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#202020;">Pursuant to the Fifth Amendment, the Company committed to appoint a new independent board director (subject to customary background checks, applicable law, confirmation of independence and Nasdaq rules), and to provide the independent director with various privileges and committee memberships on the board of directors of the Company (including the appointment of such director on committee to be formed to focus on capital raising and evaluate strategic options). The Company also agreed to engage an investment banker reasonably acceptable to OFA and the Lenders to assist the Company and its board of directors with evaluating and exploring strategic options. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#202020;">The Company also agreed to covenants requiring that the Company&#8217;s cash expenditures be monitored by the Lenders according to a board-approved budget provided to the Lenders prior to the signing of the Fifth Amendment, which cash budget will be updated on a bi-weekly basis going forward. The Company will not be permitted to make disbursements for any two-week period in excess of 115% of the aggregate budgeted amount of disbursements for the applicable period. Finally, pursuant to the Fifth Amendment, the Company is restricted from paying cash bonuses to its employees or executives during the fiscal years 2024 and 2025 without OFA&#8217;s consent or increasing the cash compensation for fiscal year 2025 for certain senior officers of the Company from their compensation for fiscal year 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><i style="color:#202020;font-style:italic;">Company Warrants and Registration Rights Agreement </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#202020;">In connection with the closing of the Fifth Amendment, the Company agreed to, substantially concurrently with the closing of Raise 1, grant new warrants to the Lenders to purchase an aggregate of 313 shares of common stock on the </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:246pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#202020;">closing date of the Fifth Amendment, at an exercise price of $0.16 per share (the &#8220;New Warrants&#8221;). The New Warrants will expire on the seventh anniversary of their issuance. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#202020;">In addition, the Company agreed to, substantially concurrently with the closing of Raise 1, amend and restate all warrants to purchase stock of the Company issued to the Lenders prior to the effective date of the Fifth Amendment, to revise the exercise price thereunder to an exercise price equal to the lower of (i) the price per share of the common stock of the Company issued in Raise 1 and (ii) arithmetic average of the volume-weighted average price of the Company&#8217;s common stock on the Nasdaq Capital Market during the 30 trading days preceding Raise 1 (such existing warrants, as amended and restated, the &#8220;Original Warrants&#8221;). The Original Warrants provide the Lenders with the right to purchase a total of 28 shares of common stock of the Company. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Sixth Amendment to Credit Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span><span style="color:#202020;">On March 4, 2025, we entered into the Sixth Amendment to our Credit Agreement (the &#8220;Sixth Amendment&#8221;), pursuant to which the Lenders agreed to, among other things, delay the date on which we are required to engage an investment banker (which date has been subsequently extended to April 30, 2025).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Our Neuroscience Clinical Programs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following is a summary of the status of our major clinical development programs as of the date of this Annual Report on Form 10-K:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="btai-20241231x10k002.jpg" alt="Graphic" style="display:inline-block;height:245.25pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For additional information regarding our pipeline candidates, see Part I, Item 1, &#8220;Business&#8221; in this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s consolidated financial statements are prepared in accordance with U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;).</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Components of Our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 18pt;"><b style="font-style:normal;font-weight:bold;">Product Revenue, Net</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Revenue relates to sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and reflect limited market access since commercial launch in July 2022. The revenues are net of rebates, chargebacks, discounts, and other adjustments. During the fourth quarter of 2022, we began contracting directly with intermediaries such as GPOs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 18pt;"><b style="font-style:normal;font-weight:bold;">Operating Costs and Expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Cost of Goods Sold</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold primarily relates to the costs of producing, packaging, and delivering our product to customers as well as costs related to excess or obsolete inventory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our research and development expenses reflect costs associated with the identification of our preclinical and clinical product candidates. Expenditures primarily consist of salary, benefits and non-cash stock-based compensation for our research and development personnel, costs incurred under agreements with contract research organizations and sites that conduct our non-clinical studies and clinical trials, costs of outside consultants engaged in research and development activities, travel expenses, the cost of acquiring, developing and manufacturing preclinical and clinical trial materials and lab supplies, and depreciation and other expenses. Payments to BioXcel LLC are also included in research and development expenses. Costs associated with third parties that provide non-clinical services such as toxicology, pharmacology, research and discovery, biomarker studies and similar services are included in the professional fees category of research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We expense research and development costs as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our research and development costs by program for the&#160;years ended December&#160;31, 2024 and 2023 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Direct external costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">BXCL501</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,397</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 46,661</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">BXCL701</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,058</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,050</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other research and development programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 771</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,142</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total direct external costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,226</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 57,853</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Internal personnel costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,047</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,675</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Sub-total direct costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 28,273</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 80,528</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indirect costs and overhead</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,162</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,798</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total research and development expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,435</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 84,326</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;">Selling, General and Administrative</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses primarily consist of salaries, benefits and non-cash stock-based compensation for our sales, executive and administrative personnel. Selling, general and administrative expenses also include legal expenses to pursue patent protection of our intellectual property and other corporate matters, professional fees for audit and tax services and insurance charges. We may also incur increased costs to comply with corporate governance, internal controls, investor relations and disclosures and similar requirements applicable to public companies.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As a result of our restructuring activities completed during 2024, we expect that our selling, general and administrative expenses will decline due to IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>&#8217;s restructured commercialization plan and reduced personnel costs. However, we may also experience increased selling, general and administrative expenses due to higher fees for outside consultants, attorneys, and accountants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Restructuring Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">2023 Strategic Reprioritization  </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On August 8, 2023, our Board of Directors approved a broad-based strategic reprioritization (the &#8220;Reprioritization&#8221;). We determined to take actions to reduce certain operational and workforce expenses no longer deemed core to ongoing operations to extend its cash runway and drive innovation and growth in high-potential clinical development and value-creating opportunities. These actions included a shift in commercial strategy for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the institutional setting as described, a reduction of in-hospital commercialization expenses, a de-prioritization of programs no longer determined to be core to ongoing operations, and a prioritization on at-home treatment setting opportunities for BXCL501, all as described in Part I, Item 1, &#8220;Business&#8221;. As part of this strategy, our Board of Directors approved a reduction of approximately 60% of our workforce. Annualized operating expenses were expected to be reduced by approximately $80,000. The Reprioritization was substantially completed by the end of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As a result of the Reprioritization, the Company recorded restructuring costs of $4,163 in the year ended December 31, 2023. These costs consisted of severance and benefit costs of $4,063 and contract termination costs of $100. The Company paid $3,998 of severance and benefit costs and $100 of contract termination costs during the year ended December 31, 2023. Remaining costs were paid during the first quarter of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">2024 Clinical Prioritization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As discussed in Note 4, <i style="font-style:italic;">Restructuring</i>, on May 8, 2024 the Company took additional actions as part of its continued efforts to preserve cash and prioritize investment in its core clinical programs. As part of these actions, the Company initiated a further reduction of approximately 15% of the Company&#8217;s then current workforce. The Company notified impacted employees on May 8, 2024 and recorded total restructuring costs of $856 for the three months ended June 30, 2024. These costs consisted of severance and benefit costs, all of which were paid during the three month period ended June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">On September 17, 2024, the Company approved a plan for an additional reduction in its workforce by 15 employees (including all but one marketing and sales employee), or approximately 28% of the Company&#8217;s headcount (the &#8220;Clinical Prioritization&#8221;), in order to extend its cash runway and prioritize investment on the clinical development of its lead neuroscience asset, BXCL501. The Company incurred aggregate charges in connection with the Clinical Prioritization of $1,586 which relate primarily to severance and benefits costs. Accordingly, the Company recorded a restructuring charge of $1,553 in the third quarter 2024, and $33 in the fourth quarter. The Company completed the Clinical Prioritization in October 2024, and paid $983 of the related costs during the fourth quarter of 2024. The remaining costs of approximately $603, is included in Accrued Expenses on the Consolidated Balance at December 31, 2024, and is expected to be paid in the first quarter of 2025.</span> <span style="background:#ffffff;">As a result of these actions, operating costs of $69,511 for the year ended December 31, 2024 decreased by approximately $103,651 compared to operating costs of $173,162 for the year ended December 31, 2023.</span> <span style="background:#ffffff;">Net cash used in operating activities of $72,027 for the year ended December 31, 2024 decreased by approximately $82,979, compared to Net cash used in operating activities of $155,006 for the year ended December 31, 2023. These achievements demonstrate the Company&#8217;s operational capability and commitment to be focused on limited objectives in the near term. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;">Other (Income) Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Other (income) expense primarily consists of interest costs associated with the Credit Agreement the Company entered into in April 2022, changes in fair value of derivative financial instruments, and interest income earned on cash and cash equivalents that were comprised primarily of money market funds. Interest expense may increase in the future if we meet required milestones, and we are able to draw down additional funds under the Credit Agreement.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A description of recently issued accounting pronouncements is set forth in Note&#160;3, Summary of Significant Accounting Policies to the consolidated financial statements included in this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Comparison of the&#160;Years Ended December&#160;31, 2024 and 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Product Revenue, Net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Commercial sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> launched in July 2022. Product revenue, net for the years ended December 31, 2024 and 2023 was $2,266 and $1,380, respectively, comprised of sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> reflecting an increase of 64%. As part of the Company&#8217;s Reprioritization in August 2023, the IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> commercial team shifted focus to a hospital/contracting strategy with a corporate account director team to work with large Integrated Delivery Networks and drive sales utilizing a top-down approach. As part of the Clinical Prioritization in September 2024, further workforce reductions were made. We are currently seeking potential commercial partners. Our continued commercialization efforts for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174; </sup>are designed to build the foundation to launch additional potential follow-on indications, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Cost of Goods Sold</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold for the years ended December 31, 2024 and 2023 were $2,143 and $1,260, respectively, which primarily related to the costs to produce, package and deliver IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> to customers, as well as costs related to excess or obsolete inventory. We entered into a commercial supply agreement with ARx, LLC (&#8220;ARx&#8221;) pursuant to which ARx has agreed to exclusively manufacture and supply us with all of our worldwide demand of film formulation of Dex to be used for the commercial supply of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>and for ongoing clinical trials of our product candidate BXCL501, subject to certain alternative supply provisions. The increase in Cost of goods sold for the year ended December 31, 2024 is primarily the result of increased sales and a $474 increase in the reserve for excess and obsolete inventory, compared to the prior year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;">Research and Development Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Research and development expenses for the&#160;years ended December&#160;31, 2024 and 2023 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,796</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,351</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6,555)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (40)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,251</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,324</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,073)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (64)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,067</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,590</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9,523)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (65)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical trials expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,384</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 35,094</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (25,710)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (73)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chemical, manufacturing and controls cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,927</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,687</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6,760)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (78)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,010</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,280</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,270)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (39)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,435</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 84,326</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (53,891)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (64)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The decrease of $53,891 for the year ended December 31, 2024, compared to the year ended December 31, 2023 is primarily attributable to the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">A decrease in clinical trials expense was a result of reduced costs associated with the wind down of the SERENITY III study to evaluate BXCL501 for at home use for the acute treatment of agitation related to schizophrenia and bipolar disorders.  In addition, the TRANQUILITY II study of BXCL501 for the potential treatment of agitation in patients with Alzheimer&#8217;s disease was completed in 2023, and the reduction of these costs were partially offset by the September 2024 launch of SERENITY-At Home trial.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A decrease in personnel and related costs related to the Clinical Prioritization.</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A decrease in Chemical, manufacturing and controls (&#8220;CMC&#8221;) costs due to lower CMC costs related to decreased clinical trial activities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A decrease in non-cash stock-based compensation due to higher award forfeitures in 2024.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Following IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>&#8217;s approval by the FDA, we capitalize costs related to commercial production of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> as inventory and expense those CMC costs related to clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Selling, General and Administrative Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses for the years ended December 31, 2024 and 2023 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">% Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,856</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 27,171</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (19,315)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (71)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,904</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,290</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (8,386)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (68)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 16,137</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 22,310</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (6,173)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (28)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,389</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,485</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (11,096)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (89)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,671</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,743</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (72)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,535</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,414</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,879)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (52)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total selling, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 34,492</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 83,413</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (48,921)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (59)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The decrease of $48,921 for the year ended December 31, 2024, relative to the year ended December 31, 2023 is primarily attributable to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A decrease in personnel costs due to the Clinical Prioritization, reducing 9 full-time employees.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Decreased professional fees, primarily related to lower legal costs in 2024 compared to 2023 for the investigation of our TRANQUILITY II study, and reductions in consulting and recruiting fees in 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Decreased other expenses as a result of lower headcount.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Decreased non-cash stock-based compensation costs due to increased award forfeitures in 2024 and lower headcount. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Decreased commercial and marketing research costs.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;">Restructuring Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Restructuring costs were $2,441 and $4,163 for the years ended December 31, 2024 and 2023, respectively. See &#8220;Components of Our Results of Operations - Restructuring Costs&#8221; above for a discussion of the Company&#8217;s Reprioritization and restructuring activities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;">Other (Income) Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Interest expense increased to $15,129 for the year ended December 31, 2024 compared to $13,314 for the year ended December 31, 2023, due to an increase in interest rates compared to the prior year and higher average debt balances during the year due to borrowings under the Credit Agreement. The expense was partially offset by interest income earned on cash and cash equivalents that were held primarily in short-term money market funds. Interest income decreased to $2,602 for the year ended December 31, 2024 compared to $5,649 for the year ended December 31, 2023, due to lower average cash balances during the year. Other (income) expense, net is primarily associated with changes in fair value of derivative financial instruments for the period, which relate to instruments associated with the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Inflation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Inflation generally affects us by increasing our labor costs and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations during the periods presented. For a discussion of inflationary risks to our future revenues under the Inflation Reduction Act, see &#8220;<i style="font-style:italic;">Health care reform measures could hinder or prevent our product candidates</i>&#8217; commercial success.&#8221; in Part I, Item 1A., &#8220;Risk Factors&#8221; elsewhere in this Annual Report on Form 10-K.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Reverse&#160;Stock&#160;Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On February 10, 2025, the Company effected a 1-for-16&#160;reverse&#160;stock&#160;split&#160;of its issued and outstanding common stock (the &#8220;Reverse Stock Split&#8221;). As a result of the&#160;Reverse&#160;Stock&#160;Split, each 16 shares of common stock issued and outstanding immediately prior to February 10, 2025&#160;were automatically converted into 1 share of common stock. The&#160;Reverse&#160;Stock&#160;Split&#160;did not change the par value of the common stock or the authorized number of shares of common stock. All outstanding convertible notes, stock options and RSUs entitling their holders to purchase or obtain or convert into shares of our common stock were adjusted, as required by the terms of these securities. All applicable common share and per share amounts have been retrospectively restated to show the effect of the reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2024, we had cash and cash equivalents of $29,854, working capital of $15,161 and stockholders&#8217; deficit of $93,101. Net cash used in operating activities was $72,027 and $155,006 for the years ended December 31, 2024 and 2023, respectively. We incurred losses of approximately $59,599 and $179,053 for the years ended December 31, 2024 and 2023, respectively. We will need to generate significant product revenues to achieve profitability. Our history of significant losses, negative cash flows from operations, potential near-term increased covenant-driven amortization payments or full repayment obligations under our Credit Agreement, the regulatory event of default triggers under the Credit Agreement, other funding requirement covenants under the Credit Agreement, limited liquidity resources currently on hand, and dependence on our ability to obtain additional financing to fund our operations after the current resources are exhausted, about which there can be no certainty, have resulted in management&#8217;s assessment that there is substantial doubt about our ability to continue as a going concern for a period of at least 12 months from the issuance date of the financial statements included in this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to support the Company&#8217;s cost structure and operating plan. Management&#8217;s plans to improve the Company&#8217;s liquidity and reduce its operating expenses and capital requirements include, among other things, pursuing one or more of the following steps to raise additional capital, none of which can be guaranteed or are entirely within the Company&#8217;s control:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>&#9679;<span style="display:inline-block;width:29.96pt;"></span>raise funding through the sale of the Company&#8217;s equity securities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>&#9679;<span style="display:inline-block;width:29.96pt;"></span>raise funding through third-party investments in or other strategic options for OnkosXcel;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>&#9679;<span style="display:inline-block;width:29.96pt;"></span>raise funding through debt financing and/or restructuring of its existing Credit Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>&#9679;<span style="display:inline-block;width:29.96pt;"></span>establish collaborations with potential partners to advance the Company&#8217;s product pipeline;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>&#9679;<span style="display:inline-block;width:29.96pt;"></span>establish collaborations with potential marketing partners;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>&#9679;<span style="display:inline-block;width:29.96pt;"></span>reduce overhead and headcount to focus on core priorities, and/or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>&#9679;<span style="display:inline-block;width:29.96pt;"></span>any combination of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">To date, we have continued research and development activities while managing our cash position. However, we require additional funding to continue as a going concern. There are no assurances that we will be successful in obtaining an adequate level of financing as and when needed to finance our operations on terms acceptable to us or at all, particularly when there is market uncertainty or an economic downturn or if other events make investment in our securities less appealing. If we are unable to secure adequate additional funding as and when needed on acceptable or commercially reasonable terms, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more product candidates. In addition, there are various macro-economic trends affecting the financing markets whose impact on our liquidity and future funding requirements are uncertain as of the filing date of this Annual Report on Form 10-K. We will need substantial additional funding, and if we are unable to raise capital when needed, we could be compelled to pursue alternative options, including, without limitation, implementing further workforce reductions, reducing or ceasing product development programs and advancement of our clinical trials and product candidates, selling our assets or seeking other strategic alternatives. See &#8220;Risks Related to Financial Position and </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Need for Additional Capital<i style="font-style:italic;"> &#8212; We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts or otherwise seek strategic alternatives.</i>&#8221; in Part I. Item 1A., &#8220;Risk Factors&#8221; elsewhere in this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Sources of Liquidity </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have primarily focused our efforts on raising capital and building the products in our pipeline, and, although we generate revenue from sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, we do not expect to generate positive cash flows from operations in the near term. Since our inception, our operations have been financed primarily from proceeds from the sale of equity securities, including our initial public offering, private placements of our common stock, registered offerings of our common stock, an Open Market Sale Agreement (as amended, supplemented and/or restated from time to time, the &#8220;Sale Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), and borrowings under our Credit Agreement (as described below). We have not yet established an ongoing source of revenue sufficient to cover our operating costs and will need to do so in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financing Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April 19, 2022, we entered into two financing agreements: the Credit Agreement and the RIFA. Pursuant to the Credit Agreement, the Lenders originally agreed to provide up to $135,000 in senior secured term loans to us. On April 28, 2022, we borrowed the first $70,000 tranche of loans under the Credit Agreement. Pursuant to the RIFA, the Purchasers agreed to provide us with up to $120,000 in financing for our near-term commercial activities of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, development and commercialization of BXCL501 and other general corporate purposes. On July 8, 2022, we drew down the first tranche of $30,000 under the RIFA. In connection with the Credit Agreement, we granted to the Lenders (i) warrants to purchase up to 17 shares of our common stock (the &#8220;Closing Date Warrants&#8221;), (ii) rights to purchase up to $5,000 of our common stock and (iii) warrants to purchase up to 175 individual ownership units (i.e., not in thousands) in OnkosXcel (the &#8220;OnkosXcel Warrants&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On November 13, 2023, we, the Lenders and OFA entered into a Waiver and First Amendment to Credit Agreement and Guaranty (the &#8220;First Amendment&#8221;) that provided for, among other things, a waiver and a modification to the covenant in the Credit Agreement regarding investments in OnkosXcel, pursuant to which we were permitted to invest up to a maximum of $30,000 at any time outstanding in OnkosXcel, increased from the $25,000 at any time outstanding. The First Amendment waived any defaults or events of default arising under the Credit Agreement due to a breach prior to the date of the First Amendment of the OnkosXcel investment covenant, or a breach of our obligation to notify OFA of such default, including our investment in an amount in excess of what was previously permitted under the OnkosXcel investment covenant. In connection with the First Amendment, we paid to the Lenders a fee of $180 (representing 0.25% of the loans outstanding under the Credit Agreement on the date of the First Amendment) and agreed to pay to the Lenders an exit fee equal to 0.25% of the loans under the Credit Agreement repaid upon maturity or prepayment of the loans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On December 5, 2023, we entered into the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement (the &#8220;Second Amendment&#8221;) with the Lenders and OFA, as administrative agent. The Second Amendment terminated the RIFA and converted the financing previously provided to us thereunder to term loans under the Credit Agreement. In addition, the Second Amendment replaced the Credit Agreement&#8217;s existing &#8220;Tranche B&#8221; and &#8220;Tranche C&#8221; term loan opportunities with three new tranches aggregating up to $100,000 in potential funding:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A $20,000 &#8220;Tranche B&#8221; term loan available upon satisfaction of the following conditions on or before December 31, 2024: (i) us raising an aggregate of at least $40,000 after the date of the First Amendment from (a) equity proceeds or (b) a bona fide contract with a governmental authority to use BXCL501 for opioid withdrawal, (ii) initiation of a new clinical trial in the TRANQUILITY program based on our meeting with the FDA held on October 11, 2023, and (iii) the total pro forma indebtedness outstanding under the Credit Agreement as a percentage of our trailing 30-day market capitalization being less than 30%;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A $30,000 &#8220;Tranche C&#8221; term loan available upon satisfaction of the following conditions on or before December 31, 2025: (i) either (a) receipt of approval from the FDA of an sNDA in respect of the use of BXCL501 for the acute treatment of agitation associated with dementia or (b) the receipt of approval from the FDA of an sNDA in respect of the use of BXCL501 for (x) the acute treatment of agitation associated with schizophrenia in adults and (y) the acute treatment of agitation associated with bipolar I or II disorder in adults, in each case, in the community/at home setting without the requirement for administration under the supervision of a healthcare provider, and (ii) the total pro forma indebtedness outstanding under the Credit Agreement as a percentage of our trailing 30-day market capitalization being less than 30%; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A $50,000 &#8220;Tranche D&#8221; term loan available upon satisfaction of the following conditions on or before December 31, 2025: (i) the conditions precedent to the borrowing of Tranche C (as described in the preceding bullet point) have been satisfied, and (ii) our total net revenue attributable to sales of BXCL501 (for the avoidance of doubt, including any revenues attributable to use of BXCL501 for opioid withdrawal) for the trailing twelve consecutive month period exceeding a specified amount.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Second Amendment also modified the interest rate of the loans provided under the Credit Agreement to be a floating rate per annum equal to the secured overnight financing rate (&#8220;SOFR&#8221;) (subject to a SOFR floor of 2.5% and a cap of 5.5%) plus 7.5%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Following the Second Amendment, we were required to comply with certain covenants under the Credit Agreement, including a financial covenant that requires we maintain a minimum cash liquidity amount of $15,000 (or higher upon certain events) and a modified minimum revenue requirement measured on a quarterly basis based on the revenue attributable to BXCL501 for the six consecutive month period ending on the last day of the relevant quarter (the &#8220;Revenue Covenant&#8221;), subject to cure payments of not less than $1,000 if we failed to meet the minimum revenue requirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the closing of the Second Amendment, we amended and restated the Closing Date Warrants granted to the Lenders on April 19, 2022 to purchase up to 17 shares of the Company&#8217;s common stock at an exercise price of $320.64 per share. Pursuant to the amendment and restatement of the Closing Date Warrants, dated December 5, 2023 (the &#8220;Amended and Restated Closing Date Warrants&#8221;), the exercise price of the Closing Date Warrants was reduced to $58.3232 per share, which represented the arithmetic average of the volume-weighted average price of the Company&#8217;s common stock on the Nasdaq Capital Market during the 30 trading days preceding the Second Amendment Effective Date. In addition, the Company granted new warrants to the Lenders to purchase up to 4 shares of the Company&#8217;s common stock (the &#8220;2023 Warrant Shares&#8221;) at an exercise price of $58.3232 per share (the &#8220;2023 Warrants&#8221;). The Amended and Restated Closing Date Warrants and the 2023 Warrants will expire on April 19, 2029 and may be net exercised at the holder&#8217;s election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On February 12, 2024 (the &#8220;Third Amendment Effective Date&#8221;), we entered into the Third Amendment to Credit Agreement and Guaranty (the &#8220;Third Amendment&#8221;), pursuant to which the Lenders agreed to waive the covenant that we shall not receive a report and opinion from our independent auditors that contains a &#8220;going concern&#8221; or like qualification or exception or emphasis of matter of going concern footnote with respect to our financial statements for the fiscal year ended December 31, 2023 and, as a result, such event shall not be an event of default. As a condition to the effectiveness of the Third Amendment, among other things, we shall have received at least $40,000 in gross proceeds from a registered public sale of the Company&#8217;s common stock, warrants and/or pre-funded warrants on or before February 20, 2024. We did not meet this condition and therefore the Third Amendment did not become effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On March 20, 2024, we entered into the Fourth Amendment to the Credit Agreement (&#8220;the Fourth Amendment&#8221;), pursuant to which the Lenders waived the Credit Agreement&#8217;s covenant that the report and opinion the Company received from its independent registered public accounting firm with respect to the financial statements for the year ending December 31, 2023 not contain a &#8220;going concern&#8221; or similar qualification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Fourth Amendment included covenants that we receive, (i) after the effective date of the Fourth Amendment and on or before April 15, 2024, at least $25,000 in gross proceeds from the issuance of our common stock, warrants and/or pre-funded warrants, and/or in non-refundable cash consideration from partnering transactions entered into after the effective date of the Fourth Amendment (so long as such partnering transactions would not require us or any of our </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made), and (ii) after the effective date of the Fourth Amendment and on or before November 30, 2024, at least $50,000 (for the avoidance of doubt, inclusive of amounts previously counted toward the preceding clause (i)) in gross proceeds from the issuance of our common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent (as defined in the Credit Agreement) in its sole discretion ) from partnering transactions entered into after the effective date of the Fourth Amendment. Failure to perform this covenant would constitute (A) a default under the Credit Agreement and (B) an event of default under the Credit Agreement, subject to a cure period, in the case of clause (i) of the preceding sentence, until May 15, 2024 (for the avoidance of doubt, failure to perform clause (ii) would constitute an immediate event of default under the Credit Agreement without any cure or grace period). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, the Fourth Amendment provided that if we had not, after the Effective Date and on or before September 30, 2024, received at least $40,000 in gross proceeds from the issuance of our common stock, warrants and/or pre-funded warrants, and/or cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the effective date of the Fourth Amendment, the &#8220;Minimum Liquidity Amount&#8221; (as defined in the Credit Agreement) that we are required to maintain at all times will increase to $25,000 from $15,000, unless and until we had received, after the effective date of the Fourth Amendment and on or before November 30, 2024, at least $50,000 in gross proceeds from the issuance of our common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the effective date of the Fourth Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the Fourth Amendment, on the effective date of the Fourth Amendment, we granted new warrants to the Lenders to purchase up to 6 shares of our common stock (the &#8220;2024 Warrant Shares&#8221;) at an exercise price of $49.1568 per share (the &#8220;2024 Warrants&#8221;), which represents a 10% premium over the arithmetic average of the volume-weighted average price of our common stock on the Nasdaq Capital Market during the 30 trading days preceding the Effective Date. The 2024 Warrants will expire on April 19, 2029 and may be net exercised at the holder&#8217;s election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On November 21, 2024, the Company entered into the Fifth Amendment to Credit Agreement and Guaranty and First Amendment to Fourth Amendment to Credit Agreement and Guaranty (the &#8220;Fifth Amendment&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the Fifth Amendment, the Lenders agreed to, among other things, (i) waive the Credit Agreement&#8217;s covenant that the report and opinion the Company will receive from its independent registered public accounting firm with respect to the financial statements for the year ending December 31, 2024 will not contain a &#8220;going concern&#8221; or similar qualification, (ii) permanently waive the Credit Agreement&#8217;s minimum revenue covenant, and (iii) waive the Fourth Amendment&#8217;s requirement that the Company raise, after the effective date of the Fourth Amendment and on or before November 30, 2024, at least $50,000 in gross cash proceeds from the issuance of its common stock, warrants, and/or pre-funded warrants, and/or in cash and/or non-cash consideration from newly entered-into partnering transactions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Fifth Amendment included a new capital raising covenant requiring that the Company receive (A) after the effective date of the Fifth Amendment and on or prior to November 27,2024, at least $7,000 in gross cash proceeds from the issuance of the Company&#8217;s common stock, warrants and/or pre-funded warrants(&#8220;Raise 1&#8221;), (B) after the effective date of the Fifth Amendment and on or before March 15, 2025 (provided that the Company was required to use its commercially reasonable efforts to satisfy the requirement by February 15, 2025), at least $18,000 in net cash proceeds (including the proceeds of Raise 1) from (i) the issuance of the Company&#8217;s common stock, warrants and/or pre-funded warrants, (ii) non-refundable cash consideration from partnering transactions entered into after the effective date of the Fifth Amendment (so long as such partnering transactions would not require the Company or any of its subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made), (iii) the issuance of the Company&#8217;s subordinated debt (subject to terms set forth in the Fifth Amendment), and/or (iv) asset sales permitted pursuant to the Credit Agreement or consented to by the Lenders (such capital raise, &#8220;Raise 2&#8221;), and (C) after the effective date of the Fifth Amendment and on or prior to the earlier of (x) August 15, 2025 and (y) the date that is 30 days after the final data readout of the SERENITY At-Home Phase 3 trial, at least $29,000 in net cash proceeds (including the proceeds from Raise 1 and Raise 2) from the same permitted capital raising activities listed in the preceding clause (B). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the Fifth Amendment and the required capital raises described in the preceding paragraph, the Lenders agreed to modify the Credit Agreement&#8217;s minimum liquidity covenant to require minimum cash liquidity of $7,500 (instead of $25,000) from and after the closing of Raise 1 until March 30, 2025. On March 31, 2025, the minimum liquidity amount will increase to $10,000 and on September 30, 2025, the minimum liquidity amount will further increase to $15,000. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the Fifth Amendment, the Company made the required one-time amortization payment of $2,500 principal amount, together with accrued and unpaid interest and a portion of the prepayment fee and other fees payable by December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Fifth Amendment also modified the interest rate of the loans provided under the Credit Agreement from a floating rate of Term SOFR plus 7.50% per annum, to a fixed rate of 13% per annum, retroactive to and effective as of September 30, 2024. For the quarterly payment dates <span style="color:#202020;">ending December 31, 2024, March 31, 2025, and June 30, 2025, t</span>he Company will have the ability to make interest payments of up to 10% per annum &#8220;in-kind&#8221; by capitalizing and adding such interest to the outstanding principal amount of the loans under the Credit Agreement<span style="color:#202020;">. </span>In addition, pursuant to the Fifth Amendment, the Company will be required to make quarterly amortization payments equal to 5.0% of the principal amount of funded loans, together with applicable prepayment fees, beginning on March 31, 2026. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#202020;">On the effective date of the Fifth Amendment and as a condition to effectiveness thereof, the Company&#8217;s wholly owned subsidiaries OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC (collectively, &#8220;OnkosXcel&#8221;), which previously provided unsecured guarantees of the Company&#8217;s obligations under the Credit Agreement, granted security interests in substantially all of their assets to support such obligations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#202020;">The Fifth Amendment amended the negative covenants under the Credit Agreement to remove flexibility the Company and its subsidiaries previously had thereunder to undertake various transactions, including, without limitation, with respect to potential dispositions of OnkosXcel or out-licenses by OnkosXcel of its intellectual property. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#202020;">Pursuant to the Fifth Amendment, the Company committed to appoint a new independent board director (subject to customary background checks, applicable law, confirmation of independence and Nasdaq rules), and to provide the independent director with various privileges and committee memberships on the board of directors of the Company (including the appointment of such director on committee to be formed to focus on capital raising and evaluate strategic options). The Company also agreed to engage an investment banker reasonably acceptable to OFA and the Lenders to assist the Company and its board of directors with evaluating and exploring strategic options. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#202020;">The Company also agreed to covenants requiring that the Company&#8217;s cash expenditures be monitored by the Lenders according to a board-approved budget provided to the Lenders prior to the signing of the Fifth Amendment, which cash budget will be updated on a bi-weekly basis going forward. The Company will not be permitted to make disbursements for any two-week period in excess of 115% of the aggregate budgeted amount of disbursements for the applicable period. Finally, pursuant to the Fifth Amendment, the Company is restricted from paying cash bonuses its employees or executives during the fiscal years 2024 and 2025 without OFA&#8217;s consent or increasing the cash compensation for fiscal year 2025for certain senior officers of the Company from their compensation for fiscal year 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#202020;">As of December 31, 2024, we had aggregate principal indebtedness of $106,722 outstanding under the Credit Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="color:#202020;font-weight:bold;">Company Warrants and Registration Rights Agreement </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Prior to the Fifth Amendment, pursuant to the Credit Agreement, the Lenders had the right to purchase shares of our common stock, so long as borrowings under the Credit Agreement are outstanding, for a purchase price of $5,000 at a price per share equal to a 10% premium to the volume-weighted average price of the common stock over the 30 trading days prior to the Lenders&#8217; election to proceed with such equity investment (the &#8220;Equity Investment Right&#8221;). The Equity Investment Right was terminated as part of the Fifth Amendment. Also, in connection with the closing of the Fifth Amendment, the Company agreed to, substantially concurrently with the closing of Raise 1, grant new warrants to the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Lenders to purchase an aggregate of 313 shares of common stock, at an exercise price of $0.16 per share (the &#8220;New Warrants&#8221;). The New Warrants will expire on the seventh anniversary of their issuance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#202020;">In addition, the Company agreed to, substantially concurrently with the closing of Raise 1, amend and restate all warrants to purchase stock of the Company issued to the Lenders prior to the effective date of the Fifth Amendment, to revise the exercise price thereunder to an exercise price equal to the lower of (i) the price per share of the common stock of the Company issued in Raise 1 and (ii) arithmetic average of the volume-weighted average price of the Company&#8217;s common stock on the Nasdaq Capital Market during the 30 trading days preceding Raise 1 (such existing warrants, as amended and restated, the &#8220;Original Warrants&#8221;). The Original Warrants provide the Lenders with the right to purchase a total of 28 shares of common stock of the Company. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#202020;">We entered into a registration rights agreement with the Lenders in connection with the original closing of the Credit Agreement, which has been amended and restated since in connection with each issuance of additional warrants to the Lenders, including most recently, in connection with the Fifth Amendment (as so amended and restated the &#8220;Amended and Restated Registration Rights Agreement&#8221;). Pursuant to the Amended and Restated Registration Rights Agreement, we have filed registration statements on Form S-3 to register the shares issuable upon exercise of the Original Warrants and the New Warrants for resale. The maximum shares of our common stock issuable under the Original Warrants and the New Warrants is 366.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As part of entering into the Credit Agreement, OnkosXcel, a wholly owned subsidiary of BTI, granted the OnkosXcel Warrants to the Lenders to purchase 175 individual limited liability company units. The strike price of the OnkosXcel Warrants is formulaic based on the value of OnkosXcel at the time of exercise and can only be exercised upon occurrence of an equity related liquidity event for OnkosXcel of at least $20,000. The exercise price per unit of the OnkosXcel Warrants will be set upon the earlier of the closing of the next sale (or series of related sales) by OnkosXcel of equity securities of OnkosXcel with aggregate proceeds of not less than $20,000 to unrelated third parties (the &#8220;Next Equity Financing&#8221;) at an exercise price per unit equal to a 10% premium over the price per unit of the equity securities sold by OnkosXcel in such Next Equity Financing or, in the event of a sale of OnkosXcel prior to the Next Equity Financing or an initial public offering constituting the Next Equity Financing, the lesser of (x) 75% of the fair value of the consideration to be paid for a unit upon the consummation of such transaction and (y) 150% of the valuation applicable to the initial profits units issued by OnkosXcel after the closing of the Credit Agreement. The OnkosXcel Warrants are transferable with approval from BTI, which cannot be unreasonably withheld, expire on April 19, 2029, and may be net exercised at the holder&#8217;s election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">See Note 9, <i style="font-style:italic;">Debt and Credit Facilities</i> and Note 20, <i style="font-style:italic;">Subsequent Events</i> in the notes to consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional information relating to the Credit Agreement and RIFA, including applicable interest rates, payment obligations and certain restrictive and financial covenants thereunder. As of December 31, 2024, we were in compliance with all restrictive and financial covenants under the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">ATM Program</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In May 2021, we entered into the Sale Agreement with Jefferies pursuant to which we could offer and sell shares of our common stock, having an aggregate offering price of up to $100,000, from time to time, through an &#8220;at the market offering&#8221; program under which Jefferies will act as sale agent. On November 1, 2023, we entered into an amendment to the Sale Agreement with Jefferies to increase the size of the &#8220;at the market offering&#8221; program; pursuant to the Sale Agreement, as amended, we can offer and sell shares of our common stock having an aggregate offering price of up to $150,000 (excluding any shares of common stock already sold in the &#8220;at the market offering&#8221; program prior to the date of the amendment), from time to time, through an &#8220;at the market offering&#8221; program under which Jefferies will act as sale agent. During the year ended December 31, 2024, we sold 240 shares under the Sale Agreement for net proceeds of $7,451. During the year ended December 31, 2023, we sold 88 shares under the Sale Agreement for net proceeds of $26,221. We terminated the Sales Agreement with Jefferies on March 26, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Cash Flows</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash (used in) provided by:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (72,027)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (155,006)</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (20)</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 36,660</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26,522</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;">Operating Activities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Net cash used in operating activities for the&#160;year ended December&#160;31, 2024 was $72,027 and was primarily attributable to our net loss of $59,599, a $20,180 increase in the change in fair value of our derivative liability, a $4,327 decrease in accounts payable, accrued expenses, due to related parties, and other current liabilities, and a $1,872 increase in prepaid expenses, other current assets and other assets, offset by $6,543 in payable in kind interest on our credit agreement and $6,156 in non-cash stock-based compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Net cash used in operating activities for the year ended December 31, 2023 was $155,006 and was primarily attributable to our net loss of $179,053 and a $3,219 decrease in accounts payable, accrued expenses, due to related parties, and other current liabilities, partially offset by a $2,888 decrease in prepaid expenses, other current assets and other assets, $18,614 in non-cash stock-based compensation, and a $4,369 increase in accrued and payable in kind interest.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;"> </span><span style="font-style:italic;">Investing Activities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Net cash used in investing activities for the years ended December 31, 2024 and 2023, respectively was $0 and $20 and was primarily attributable to leasehold improvements in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 22.5pt;"><span style="font-style:italic;">Financing Activities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Net cash provided by financing activities for the year ended December 31, 2024, was $36,660 and was primarily attributable to net proceeds of $39,214 from the sale of common stock under public offerings and the Sale Agreement with Jefferies, less a debt principal payment of $2,500.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Net cash provided by financing activities for the year ended December 31, 2023, was $26,522 and was primarily attributable to net proceeds of $26,221 from the sale of common stock under the Sale Agreement with Jefferies and net proceeds of $508 from the exercise of stock options.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Operating Capital and Capital Expenditure Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We expect to continue to incur significant and increasing operating losses at least for the next several years as we commercialize IGALMI</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-weight:normal;"> and as we expand our clinical trials of and seek marketing approval focused on BXCL501 while pursuing development of additional product candidates for BXCL502, BXCL701 and BXCL702. We expect to continue to incur net losses in the near term. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our planned clinical trials and our expenditures on other research and development activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect, and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development, and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. We anticipate that our expenses will increase substantially as we:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue our clinical development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conduct additional research and development with our product candidates;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to identify, acquire, license, develop and commercialize product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">integrate acquired technologies into a comprehensive regulatory and product development strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire scientific, clinical, quality control and administrative personnel and utilize professional services, including consultants, lawyers, and accountants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add operational, financial and management information systems and personnel, including personnel to support our drug development and commercial efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fully develop a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and any product candidates for which we may obtain regulatory approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to operate as a public company.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe that our existing cash and cash equivalents as of December 31, 2024 will not be sufficient to enable us to fund operating expenses and capital expenditure requirements for at least the next 12 months from the date of the issuance of the consolidated financial statements included in this Annual Report on Form 10-K, including funding our ongoing research and development and commercialization efforts. In particular, we believe that our cash and cash equivalents of $29,854 as of December 31, 2024 plus the approximately of $14,000 gross proceeds from our financing in March 2025 will allow us to fund our operations and meet our liquidity requirements into the third quarter of 2025, assuming we are able to comply with the covenants under our Credit Agreement. We expect that we will need to obtain substantial additional funding to fund our ongoing operations. To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, the ownership interests of our existing stockholders may be materially diluted, and the terms of these securities could include liquidation or other preferences that could adversely affect the rights of our existing stockholders. In addition, debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends, which could adversely impact our ability to conduct our business. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. If we are unable to raise capital when needed or on attractive terms, we could be forced to significantly delay, scale back or discontinue the development or commercialization of our product candidates, seek collaborators at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available, and relinquish or license, potentially on unfavorable terms, our rights to our product candidates that we otherwise would seek to develop or commercialize ourselves. To date, we have continued research and development activities while managing our cash position. However, we can provide no assurance that will be successful in obtaining additional necessary resources and, if we are unable to fund our operations, including our clinical trials, we may need to focus on advancing fewer of our product candidates or otherwise consider strategic alternatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Contractual Obligations and Commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">In July 2024, the Company signed an amendment to its commercial supply agreement that requires minimum annual payments for the first five years of the agreement ending in 2026 that in aggregate total $10,000.  The Company has met the minimum requirements for the first 3 years ending in 2024. The remaining minimum commitments for years 4 and 5 (2025 and 2026) is $2,000 each year. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In February 2022, we signed a distribution agreement with a third party to distribute product related to BXCL501 in the U.S. The distributor will be paid defined fees for its services under the agreement, which can be terminated by either party for cause. The distribution agreement can also be terminated by us without cause, subject to payment of agreed termination fees.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI leases office space for its corporate headquarters at 555 Long Wharf Drive, New Haven, Connecticut (the &#8220;HQ Lease&#8221;). The HQ Lease expires in February 2026. The Company has an option to renew the HQ Lease for one additional five-year term. Payments under the HQ Lease are fixed. The Company has approximately $456 of payments remaining under the HQ Lease. For additional details, see Note 13, <i style="font-style:italic;">Leases</i> in the notes to consolidated financial statements included in this Annual Report on Form 10-K for additional information relating to the Company&#8217;s leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, we are obligated to make quarterly interest payments under our Credit Agreement. For additional details, see Note 9, <i style="font-style:italic;">Debt and Credit Facilities</i> in the notes to consolidated financial statements included in this Annual Report on Form 10-K for additional information relating to the Company&#8217;s debt payment obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The preparation of our consolidated financial statements in conformity with U.S. GAAP requires management to exercise its judgment. We exercise considerable judgment with respect to establishing sound accounting policies and in making estimates and assumptions that affect the reported amounts of our assets and liabilities, our recognition of revenues and expenses, and disclosure of commitments and contingencies at the date of the consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On an ongoing basis, we evaluate our estimates and judgments. We base our estimates and judgments on a variety of factors including our historical experience, knowledge of our business and industry, current and expected economic conditions, the attributes of our products and the regulatory environment. We periodically re-evaluate our estimates and assumptions with respect to these judgments and modify our approach when circumstances indicate that modifications are necessary. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">While we believe that the factors we evaluate provide us with a meaningful basis for establishing and applying sound accounting policies, we cannot guarantee that the results will always be accurate. Since the determination of these estimates requires the exercise of judgment, actual results could differ from such estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We define critical accounting policies as those that are reflective of significant judgments and uncertainty and which may potentially result in materially different results under different assumptions and conditions. In applying these critical accounting policies, our management uses its judgment to determine the appropriate assumptions to be used in making certain estimates. These estimates are subject to an inherent degree of uncertainty. Our critical accounting policies are noted below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Stock Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company has granted stock options, restricted stock units and profit units to employees, directors, and consultants, as well as warrants to other third parties. For employee, director and consultant awards, the value of each grant is estimated on the date of grant using a Black-Scholes option-pricing model. The Black-Scholes pricing model incorporates the volatility of the price of BTI&#8217;s stock, the risk-free interest rate, the estimated life of the award, the closing market price of the Company&#8217;s stock and the exercise price of the award. Management bases the Company&#8217;s estimates of stock price volatility on the historical volatility of the Company&#8217;s common stock, as well as a peer group of comparable companies. However, these estimates are neither predictive nor indicative of the future performance of the Company&#8217;s stock. For purposes of the calculation, management assumed that no dividends would be paid during the life of the stock awards. The estimates utilized in the Black-Scholes calculation involve inherent uncertainties and the application of management judgment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Research and Development Expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As part of the process of preparing the Company&#8217;s consolidated financial statements, BTI&#8217;s management is required to estimate prepaid and accrued expenses, including research and development expenses. This process involves reviewing open contracts, communicating with personnel to identify services that have been performed on behalf of the Company and estimating the level of service performed and the associated cost incurred for the service when BTI has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company&#8217;s service providers invoice </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">BTI monthly for services performed or when contractual milestones are met. BTI management makes estimates of prepaid and/or accrued expenses, including research and development expenses, as of each reporting date in the Company&#8217;s consolidated financial statements based on facts and circumstances known to management at that time. BTI periodically confirms the accuracy of its estimates with the service providers and makes adjustments, if necessary. Examples of estimated accrued research and development expenses include fees paid to contract research organizations (&#8220;CROs&#8221;) in connection with clinical studies, amounts paid to contract manufacturing organizations, and fees paid to sites in connection with clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company bases its expenses related to clinical studies on management&#8217;s estimates of the services received and efforts expended pursuant to contracts with multiple CROs that conduct and manage clinical trial studies on our behalf. The financial terms of these agreements are subject to an initial negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to vendors exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing certain service fees, BTI management estimates the time period over which services will be performed, enrollment of patients, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from management&#8217;s estimate, management will adjust the accrual or prepaid accordingly. Although the Company does not expect management&#8217;s estimates to be materially different from amounts actually incurred, management&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in BTI reporting amounts that are too high or too low in any particular period.</p><a id="_5d7b0bf0_fe7f_4a6b_9080_99c563245c97"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;7A. Quantitative and Qualitative Disclosures about Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Foreign Exchange Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2024, we had $29,854 of cash and cash equivalents. Our cash and cash equivalents are primarily held in U.S. Government money market funds. We do not participate in any foreign currency hedging activities and have limited exposure to other derivative financial instruments, primarily resulting from the terms and conditions of the Credit Agreement. We did not recognize any significant exchange rate losses during the years ended December 31, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We do not believe that our cash and cash equivalents have significant risk of default or illiquidity. While we believe our cash and cash equivalents do not contain material market risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash at one or more financial institutions that exceed federally insured limits. In the event of a failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we will be able to access uninsured funds in a timely manner or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Interest Rate Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The loans under the Credit Agreement bear interest at a fixed rate of 13% payable quarterly. Consequently, we have material interest rate exposure due to our indebtedness if market rates drop in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Capital Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We currently do not have substantial product revenues and depend on funds raised through other sources. One source of funding includes future debt or equity offerings. Our ability to raise funds in this manner depends upon, among other things, capital market forces affecting our stock price, and on the state of the capital markets generally<span style="background:#ffffff;">.</span></p><a id="_7b761205_0f22_4797_9f17_8769abbfa338"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;8. Financial Statements and Supplementary Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The financial statements required pursuant to this item and the related report of our independent auditor are included in Item 15 of this report beginning on page F-1 and are incorporated under this Item by reference. Our independent auditor for the years ended December 31, 2024 and 2023 was <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:AuditorName" id="Narr_hQyi2u_3skOA9Gi47k-S2Q">Ernst &amp; Young LLP</ix:nonNumeric> (PCAOB ID: <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:AuditorFirmId" id="Narr_FgyQBiyiUUufa0LyhEQ33Q">42</ix:nonNumeric>), located in <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="dei:AuditorLocation" id="Narr_WIskErTylEiU0cW_IWL52g">Stamford, Connecticut</ix:nonNumeric>, USA.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_98088447_d78a_456e_9038_b4a28bc492ff"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_06840954_fa84_43fe_88b5_ea3db950e695"></a><a id="Item9AControlsandProcedures_710755"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9A. Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2024. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Based on the evaluation of our disclosure controls and procedures as of December 31, 2024, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Management&#8217;s Annual Report on Internal Controls Over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth in &#8220;Internal Control-Integrated Framework (2013)&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management concluded that, as of December 31, 2024, our internal control over financial reporting was effective.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Attestation Report of the Registered Public Accounting Firm</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm on internal control over financial reporting as we are a &#8220;smaller reporting company&#8221; and &#8220;non-accelerated filer&#8221; as defined under SEC rules.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Changes in Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended December 31, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><a id="_235c8e29_7fad_4f10_9169_b8e334afa623"></a><a id="Item9BOtherInformation_895714"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9B.&#160;Other Information</p><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_3PEv7wfJfUKxY2X6WXJQ_g" name="ecd:MtrlTermsOfTrdArrTextBlock" id="Tb_RvJWPy3V1Eq9CZTMwhskMA" continuedAt="Tb_RvJWPy3V1Eq9CZTMwhskMA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Insider Trading Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>On <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_VimalMehtaMember_fZwn5BB5AEyBJNs2qszV2g" name="ecd:TrdArrAdoptionDate" id="Narr_P5pdjdNi2UyJL_9mSu-I6A">December 14, 2024</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_VimalMehtaMember_fZwn5BB5AEyBJNs2qszV2g" name="ecd:TrdArrIndName" id="Narr_n9_s9iJZFUCwUtiIu95OEA">Vimal Mehta</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_VimalMehtaMember_fZwn5BB5AEyBJNs2qszV2g" name="ecd:TrdArrIndTitle" id="Narr_PpPCx8J0UU6TWo61dDgqvw">Chief Executive Officer</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_VimalMehtaMember_fZwn5BB5AEyBJNs2qszV2g" format="ixt:fixed-true" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_21BMKKD10kiiSNgiIZibKw">adopted</ix:nonNumeric> a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_ecd_IndividualAxis_btai_VimalMehtaMember_I0XJDPHFNECy_x1rSOZJ9g" decimals="0" format="ixt:num-dot-decimal" name="ecd:TrdArrSecuritiesAggAvailAmt" scale="0" id="Narr_d2sDwJu3oEOPdnz4_etApQ">2,184</ix:nonFraction> shares of the Company&#8217;s common stock to cover taxes due in connection with the vesting of restricted stock units until <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_VimalMehtaMember_fZwn5BB5AEyBJNs2qszV2g" name="ecd:TrdArrExpirationDate" id="Narr_2h9F-8cdyUy0ir2nAl3a_w">December 31, 2025</ix:nonNumeric>.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_RvJWPy3V1Eq9CZTMwhskMA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>On <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_RichardSteinhartMember_6zb1jv50yke5UAZ2fdNlYw" name="ecd:TrdArrAdoptionDate" id="Narr_7gwnkEjyw0a_KMeLf5An0A">December 14, 2024</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_RichardSteinhartMember_6zb1jv50yke5UAZ2fdNlYw" name="ecd:TrdArrIndName" id="Narr_dvg4QoNveEiRRCwh0-UUQw">Richard Steinhart</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_RichardSteinhartMember_6zb1jv50yke5UAZ2fdNlYw" name="ecd:TrdArrIndTitle" id="Narr_BXgH1I7HxEq1-5h_Vk2yQw">Chief Executive Officer</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_RichardSteinhartMember_6zb1jv50yke5UAZ2fdNlYw" format="ixt:fixed-true" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_QNbvNQ9XYUaegfm9OZNLUg">adopted</ix:nonNumeric> a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_ecd_IndividualAxis_btai_RichardSteinhartMember_4GcV7wKgb0qyo8g-DWuPiQ" decimals="0" format="ixt:num-dot-decimal" name="ecd:TrdArrSecuritiesAggAvailAmt" scale="0" id="Narr_1e2i9xeB5UmFz9IleBv6hg">1,563</ix:nonFraction> shares of the Company&#8217;s common stock to cover taxes due in connection with the vesting of restricted stock units until <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_RichardSteinhartMember_6zb1jv50yke5UAZ2fdNlYw" name="ecd:TrdArrExpirationDate" id="Narr_0Wg-TDQDIkqWfI7Py0dn_g">December 31, 2025</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>On <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_JavierRodriguezMember_u3tdF-_eYkmI9WHxmSaiPg" name="ecd:TrdArrAdoptionDate" id="Narr_RKa72M52hUujnMvYdpXpMg">December 14, 2024</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_JavierRodriguezMember_u3tdF-_eYkmI9WHxmSaiPg" name="ecd:TrdArrIndName" id="Narr_enqyZRIbyUW3NnHLwim0tQ">Javier Rodriguez</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_JavierRodriguezMember_u3tdF-_eYkmI9WHxmSaiPg" name="ecd:TrdArrIndTitle" id="Narr_s_VEeybnW0u9KWVgu3P79w">Senior Vice President, Chief Legal Officer</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_JavierRodriguezMember_u3tdF-_eYkmI9WHxmSaiPg" format="ixt:fixed-true" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_-NML_yPyEkOBeIjbf9syAg">adopted</ix:nonNumeric> a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_ecd_IndividualAxis_btai_JavierRodriguezMember_bkghpJl7jUGxwTp51yM2GA" decimals="0" format="ixt:num-dot-decimal" name="ecd:TrdArrSecuritiesAggAvailAmt" scale="0" id="Narr_C1S9GiD3PkOHr1X6JP24XA">1,563</ix:nonFraction> shares of the Company&#8217;s common stock to cover taxes due in connection with the vesting of restricted stock units until <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_JavierRodriguezMember_u3tdF-_eYkmI9WHxmSaiPg" name="ecd:TrdArrExpirationDate" id="Narr_YYNcOuBMUEe9QO9ng0Z-Tg">December 31, 2025</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>On <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_FrankYoccaMember_EjqW660Xi0ae7YJdz_f5pg" name="ecd:TrdArrAdoptionDate" id="Narr_ttBbrXKlqUO3lO3E58u5LQ">December 14, 2024</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_FrankYoccaMember_EjqW660Xi0ae7YJdz_f5pg" name="ecd:TrdArrIndName" id="Narr_ryD9M5mt-0Kl6h_1MYxq2g">Frank Yocca</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_FrankYoccaMember_EjqW660Xi0ae7YJdz_f5pg" name="ecd:TrdArrIndTitle" id="Narr_Nsn6AT2EF0qKySuJdWWYlg">Chief Scientific Officer</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_FrankYoccaMember_EjqW660Xi0ae7YJdz_f5pg" format="ixt:fixed-true" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_Cc3EVWYjbUmKmmFNkhg63g">adopted</ix:nonNumeric> a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_ecd_IndividualAxis_btai_FrankYoccaMember_1VVE1uh3REuAmq0XmRLywQ" decimals="0" format="ixt:num-dot-decimal" name="ecd:TrdArrSecuritiesAggAvailAmt" scale="0" id="Narr_8FoSLpOFU06FwlMUShVvKw">1,563</ix:nonFraction> shares of the Company&#8217;s common stock to cover taxes due in connection with the vesting of restricted stock units until <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_FrankYoccaMember_EjqW660Xi0ae7YJdz_f5pg" name="ecd:TrdArrExpirationDate" id="Narr_afqH43djXU-JPof2BHL4iQ">December 31, 2025</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Each of these plans were terminated effective March 17, 2025.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Open Market Sales Agreement Termination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On March 26, 2025, we and Jefferies terminated that certain Open Market Sales Agreement, dated May 10, 2021, as amended on November 1, 2023.</p><a id="_d1de64ef_035c_4d02_b23a_cb1b129b5b7f"></a><a id="Item9C"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a><a id="_324974cc_94af_4f92_b824_9f4d46180e93"></a><a id="PARTIII_44466"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item 10. Directors, Executive Officers, and Corporate Governance.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">INFORMATION ABOUT OUR DIRECTORS &amp; EXECUTIVE OFFICERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following information with respect to our Board of Directors (the &#8220;Board&#8221;) and executive officers is presented as of March 28, 2025:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:7.2pt;"><td style="vertical-align:top;width:35.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Age</b></p></td><td style="vertical-align:bottom;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:48.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position at BioXcel</b></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:35.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vimal Mehta, Ph.D.</p></td><td style="vertical-align:bottom;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">64</p></td><td style="vertical-align:bottom;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer and President, and Director</p></td><td style="vertical-align:bottom;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:35.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Richard Steinhart</p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">67</p></td><td style="vertical-align:bottom;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:35.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Frank Yocca, Ph.D.</p></td><td style="vertical-align:bottom;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">69</p></td><td style="vertical-align:bottom;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Scientific Officer</p></td><td style="vertical-align:bottom;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:35.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Javier Rodriguez</p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">53</p></td><td style="vertical-align:bottom;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President, Chief Legal Officer and Corporate Secretary</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:35.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Peter Mueller, Ph.D.</p></td><td style="vertical-align:bottom;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">68</p></td><td style="vertical-align:bottom;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman of the Board</p></td><td style="vertical-align:bottom;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:35.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June Bray</p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">71</p></td><td style="vertical-align:bottom;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:35.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sandeep Laumas, M.D.</p></td><td style="vertical-align:bottom;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">56</p></td><td style="vertical-align:bottom;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:35.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Miller</p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">67</p></td><td style="vertical-align:bottom;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:35.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Votruba, M.D.</p></td><td style="vertical-align:bottom;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">59</p></td><td style="vertical-align:bottom;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:35.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David Mack</p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">54</p></td><td style="vertical-align:bottom;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:35.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rajiv Patni, M.D.</p></td><td style="vertical-align:bottom;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">59</p></td><td style="vertical-align:bottom;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Business Experience and Background of Directors and Executive Officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Vimal Mehta, Ph.D.</span> co-founded the Company and has served as a member of our Board since April 2017 and as our Chief Executive Officer and President since May 2017. Dr. Mehta also served as our Corporate Secretary from May 2017 to February 2021. He is also the co-founder of BioXcel Corporation (now BioXcel LLC) and, following its inception in 2005 until March 2023, served as its Chairman of the Board and Chief Executive Officer. Dr. Mehta holds a Ph.D. in Chemistry from the University of Delhi, India and completed a Post-Doctoral Fellowship in Chemistry at the University of Montpellier, France. During the length of his career, Dr. Mehta has garnered a deep understanding of the biopharma and healthcare ecosystem and has been actively involved in diverse global value generating initiatives encompassing corporate strategy and planning, global business development, and corporate fundraising. As our co-founder, he has helped shape our strategic and business trajectory which the Board believes qualifies him to serve as a director of our Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Richard I. Steinhart</span> has served as our Senior Vice President and Chief Financial Officer since March 2018. From October 2017 to March 2018, Mr. Steinhart served as our Vice President and Chief Financial Officer. From October 2015 to June 2017, he was Vice President and CFO at Remedy Pharmaceuticals, Inc. From January 2014 to September 2015 Mr. Steinhart worked as a financial and strategic consultant to the biotechnology and medical device industries. From April 2006 through December 2013, Mr. Steinhart was employed by MELA Sciences, Inc., as their Vice President, Finance and Chief Financial Officer, Treasurer and Secretary from April 2006 to April 2012 and as Sr. Vice President, Finance and Chief Financial Officer from April 2012 to December 2013. From May 1992 until joining MELA Sciences, Mr. Steinhart was a Managing Director of Forest Street Capital/SAE Ventures, a boutique investment banking, venture capital, and management consulting firm focused on healthcare and technology companies. Prior to Forest Street Capital/SAE Ventures, he was Vice President and Chief Financial Officer of Emisphere Technologies, Inc. Mr. Steinhart&#8217;s other experience includes seven years at CW Group, Inc., a venture capital firm focused on medical technology and biopharmaceutical companies, where he was a General Partner and Chief Financial Officer. Mr. Steinhart is a member of the Board of Directors of Actinium Pharmaceuticals, Inc., a position he assumed in November 2013, and Atossa Genetics, Inc., where he began his service in March 2014. Mr. Steinhart serves as the Chairman of the Audit Committee at Actinium Pharmaceuticals, where he also sits on the Corporate Governance Committees. Mr. Steinhart serves as the Chairman of Atossa Genetics Audit Committee and is a member of its Audit Committee and Compensation Committee. He holds B.B.A. and M.B.A. degrees from Pace University and is a Certified Public Accountant (inactive). </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">142</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Frank D. Yocca, Ph.D.</span> has served as our Executive Vice President and Chief Scientific Officer since December 2023. From March 2018 to December 2023, he served as our Senior Vice President and Chief Medical Officer. From June 2017 to March 2018, Dr. Yocca served as our Vice President and Chief Scientific Officer. From April 2015 to April 2017, he was Senior Vice President, CNS R&amp;D of BioXcel. From 2005 to 2015, Dr. Yocca held multiple leadership roles at AstraZeneca plc, including Vice President, Strategy and Externalization, Neuroscience Virtual Innovative Medicine Unit (iMed) (2011-2015), Vice President and Head, Strategy Unit, CNS and Pain Innovative Medicine Unit (iMed) (2010 to 2011) and Vice President and Head, CNS Pain Discovery (2005 to 2010). Prior to this, he was Executive Director at the Bristol Myers Squibb Pharmaceutical Research Institute from 1984 to 2004 where he served concurrent leadership responsibilities within the Neuroscience Clinical Group for Early and Late Clinical Development Studies. Prior to this, Dr. Yocca served as Executive Director, Neuroscience Discovery from 1997 to 2003, where he was a collaborator in the development and implementation of corporate strategic plans and leader for the Neuroscience Biology Department in the discovery of psychiatry and Alzheimer&#8217;s clinical candidates. He was a core member of the Abilify Product Development and Commercialization Team from 1999 to 2002 and a core member of the Early and Late Discovery and Development Teams from 1984 to 2001. Dr. Yocca holds a B.S. in biochemistry from Manhattan College and an M.S. in pharmacology and a Ph.D. in neuropharmacology from St. John&#8217;s University. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Javier Rodriguez</span> has served as our Senior Vice President and Chief Legal Officer and Corporate Secretary since January 2021. Mr. Rodriguez has over 20 years of extensive strategic and legal experience within the biopharmaceutical industry and has broad leadership experience managing legal, compliance, corporate governance, intellectual property, data privacy, and government affairs professionals. Prior to joining BioXcel Therapeutics, he was Chief Legal Officer at Indivior PLC (LSE: INDV), a global pharmaceuticals company with operations in over 40 countries, from December 2014 to December 2020, where he oversaw all legal affairs, data privacy compliance, and corporate governance matters. Before taking on his role at Indivior, Mr. Rodriguez was General Counsel at Reckitt Benckiser Pharmaceuticals Inc. where he played a key leadership role in negotiating and successfully effectuating the demerger and spin-off of the organization in 2014, which included closing a $750 million secured term loan and $50 million revolving credit facility to fund on-going operations of the demerged entity. Earlier in his career, Mr. Rodriguez held roles of increasing responsibility at Reckitt Benckiser LLC, Bayer Healthcare Pharmaceuticals, Inc. and Berlex, Inc. He began his legal career in 2000 as a litigation associate at Thelen Reid &amp; Priest, LLP in New York City. He holds a B.S. in Civil Engineering from Rutgers University, a M.S.E. in Structural Engineering from the University of Michigan and a J.D. from the University of Pennsylvania.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Peter Mueller, Ph.D.</span> has served as a director of our Company since April 2017 and Chairman of the Board since August 2017. With over 30 years of global pharma and biotech experience, Dr. Mueller is currently the President of the Mueller Health Foundation, a private foundation tackling globally lethal infectious diseases such as tuberculosis by addressing latency and the ever-growing challenges of antimicrobial resistance. From 2014 to 2016, he was President of R&amp;D and Chief Scientific Officer of Axcella Health, a biotechnology company. From 2003 to 2014, Dr. Mueller served as Executive Vice President Global Research and Development &amp; Chief Scientific Officer for Vertex Pharmaceuticals, Incorporated, a biotechnology company. He was involved in the development of Incivek (2011), Kalydeco (2012), and Orkambi (2014). Prior to his tenure at Vertex, he served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc. overseeing global research programs (immunology, inflammation, cardiovascular diseases and gene therapy) and the development of all drug candidates of the company&#8217;s worldwide portfolio in North and South America, Canada and Japan, beginning in 1997. He was involved in the development of Spiriva, Combivent, Atrovent and Viramune. Dr. Mueller received both an undergraduate degree and a Ph.D. in Chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University. He is a member of various scientific and political societies and currently serves on the Board of the US-India Chamber of Commerce Biotech. He also serves as chairman of the Scientific Advisory Board of BioXcel LLC and is an advisor to the University of Iowa Center for Bioanalysis and Bioprocessing. We believe that Dr. Mueller&#8217;s extensive experience in the life sciences industry as a scientist and executive qualifies him to serve as a director of our Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">June Bray</span> has served as a director of our Company since March 2021. She previously served as Senior Vice President, Global Regulatory Affairs and Medical Writing of Allergan, Inc., a pharmaceutical company, from 2008 to 2020, where she was in charge of global regulatory strategies for development projects and lifecycle management for all therapeutic areas. From 2006 to 2008, Ms. Bray was Vice President, Regulatory Affairs at Organon &amp; Co. (prior to its </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">143</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">merger with Merck &amp; Co.), where she led departments responsible for regulatory activities for development and marketed products and, from 1980 to 2006, Ms. Bray served in various capacities at Berlex Laboratories, Inc., most recently as Vice President, Global Regulatory Affairs for Specialized Therapeutics/Oncology, a position she held from 2003 to 2006. Ms. Bray has served on the Board of Quince Therapeutics, Inc. since June 2022. Ms. Bray holds an M.B.A. from Fairleigh Dickinson University and a B.S. from the University of Rhode Island. We believe that Ms. Bray&#8217;s extensive experience in developing global regulatory strategies for product candidates qualifies her to serve as a director of our Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sandeep Laumas, M.D.</span> has served as a director of our Company since September 2017. Since June 2020, Dr. Laumas has served as Chief Business Officer and Chief Financial Officer of Instil Bio Inc. He served as a Director of BioXcel Corporation from May 2013 to August 2017. Dr. Laumas served as a director of 9 Meters BioPharma, Inc. (formerly Innovate Biopharmaceuticals Inc.), a biopharma company, from January 2014 to June 2021, including serving as the Executive Chairman from 2014 to April 2020, and as its Chief Executive Officer from February 2019 to April 2020. Dr. Laumas has served as a director of Unicycive Therapeutics Inc. since January 2018. He began his career at Goldman Sachs &amp; Co. in New York in the Investment Banking Division. Dr. Laumas then joined Balyasny Asset Management in New York and later moved to North Sound Capital as a Managing Director responsible for global healthcare investments. He has been investing in healthcare via investment vehicles, Bearing Circle Capital. Dr. Laumas has served as a director of Parkway Holdings Ltd. (IHH Healthcare) and SRL Ltd. Dr. Laumas received his A.B. in Chemistry from Cornell University in 1990, M.D. from Albany Medical College in 1995 with a research gap year at the Dana-Farber Cancer Institute and completed his medical internship in 1996 from the Yale University School of Medicine. Dr. Laumas has a novel industry perspective, particularly in both public and private investments and financial transactions in the healthcare arena, which we believe qualifies him to serve as a director of our Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Michael Miller</span> has served as a director of our Company since June 2022. He has served as an advisor to several biopharmaceutical companies, including Concarlo Therapeutics since June 2022 and Rigel Pharmaceuticals, Inc. since January 2022. Prior to that, he served as Executive Vice President, Commercial of Jazz Pharmaceuticals plc from March 2014 to August 2020. Since May 2018, Mr. Miller has served on the Board of Puma Biotechnology Inc., where he also serves on the Compensation Committee. Mr. Miller received his B.S. from the University of San Francisco and his M.B.A. from San Francisco State University. The Board believes that Mr. Miller&#8217;s extensive experience at commercial pharmaceutical and public companies will provide valuable contributions to the Board. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Michal Votruba, M.D.,</span> has served as a director of our Company since March 2019. Since 2013, Dr. Votruba has been a Director of the Gradus/RSJ Life Sciences Fund, the largest dedicated fund in Central Europe with a portfolio of companies in Europe and the United States. Dr. Votruba served as a director of Mynd Analytics, Inc., a telebehavioral health services company, from July 2015 to 2019, and served as a director of Telemynd, Inc., successor to Mynd Analytics, since 2019. Since 2010, he has served as a member of the board of PrimeCell Therapeutics as the Director of Global Business Development overseeing the expansion of the largest regenerative medicine company operating in Central Europe. In 2009, the Czech Academy of Sciences solicited Dr. Votruba&#8217;s expertise for the first successful privatization project of the Institute of Experimental Medicine in Prague: the newly created protocol established a precedent for future privatization projects in the Czech Republic. Dr. Votruba earned his M.D. from the Medical Faculty of Charles University in Prague in 1989. Shortly thereafter, he emigrated from Czechoslovakia and developed his professional career in Canada and the USA. Since 2005, Dr. Votruba combined his theoretical and clinical experience in the field of Competitive Intelligence serving the global pharmaceutical industry for eight years as an industry analyst advising senior leaders of companies including Amgen, Novartis, Eli Lilly, Allergan, EMD, Serono and Sanofi. Dr. Votruba brings valuable expertise to the Board as a clinical psychiatrist and broad experience in the international marketing of innovative medical technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">David Mack</span> has more than 25 years of experience as a lawyer, director, and investor. He served as a director of of our Company since November 2024. He has extensive experience in leading transactions as well as deep knowledge of complex restructuring and litigation. He has previously served (or serves) on the boards of TerraForm Global, Inc. (NSDQ: GLBL), Speedcast International Limited (ASX: SDA) and Intelsat S.A., among others. He started his career in Sydney as a lawyer with Mallesons Stephen Jaques and then worked for Linklaters LLP in London. In 2000, he moved to the US, where he worked at Simpson Thacher &amp; Bartlett, LLP followed by Perry Capital LLC. He has a BA and an LLB (Hons) from the University of Sydney. In connection with his appointment, Mr. Mack was also appointed to the Compensation Committee, effective with his commencement of service, as well as the newly formed Capital Raising </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">144</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Committee. We believe that Mr. Mack is qualified to serve as a director of our Company because of his extensive experience working on strategic transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dr. Rajiv</span><i style="font-style:italic;">&#160;</i><span style="font-style:italic;font-weight:bold;">Patni</span> Since September 2024, Dr. Patni has served as the Chief Executive Officer of Judo Bio, a biopharmaceutical development company focused on pioneering oligonucleotide medicines delivered to the kidney. He previously served as Chief Research and Development Officer at Reata Pharmaceuticals, a commercial-stage company acquired by Biogen and he is currently serving as a board member of Quince Therapeutics, Inc. (Nasdaq: QNCX). Previously, Dr. Patni also served as Chief Medical Officer at several public, commercial-stage biopharmaceutical companies - Global Blood Therapeutics, Portola Pharmaceuticals, and Adamas Pharmaceuticals, until their acquisitions by larger companies. Earlier in his career, Dr. Patni held roles of increasing responsibility at Pfizer, Roche, and Actelion. Dr. Patni received his M.D. from the Icahn School of Medicine at Mount Sinai in New York City as part of an accelerated B.S./M.D. program. He completed an internal medicine residency and adult cardiology fellowship at the Albert Einstein College of Medicine, also in New York City, where he continued as an attending physician-scientist before joining the biopharmaceutical industry. We believe that Dr. Patni&#8217;s extensive experience in biopharmaceutical product development will provide valuable contributions to the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Board and Committee Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">During fiscal 2024, our Board of Directors met 12 times, the audit committee met four times, the capital raise committee met four times, and the pricing committee met two times. In 2024, each of our incumbent directors attended at least 75% of the meetings of the Board and committees on which he or she then served as a member. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Executive sessions, which are meetings of the non-management members of the Board, are regularly scheduled throughout the year. In addition, at least twice per year, the independent directors meet in a private session that excludes management and any non-independent directors. The Chair of the Board presides at each of these meetings and, in his absence, the non-management and independent directors in attendance, as applicable, determine which member will preside at such session.</p><a id="_Toc187748832"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Board Leadership Structure</span><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our Corporate Governance Guidelines provide our Board with flexibility to combine or separate the positions of Chairperson of the Board and Chief Executive Officer in accordance with its determination that utilizing one or the other structure would be in the best interests of the Company and its stockholders. If the Chairperson of the Board is a member of management or does not otherwise qualify as independent, our Corporate Governance Guidelines provide for the appointment by the independent directors of a lead independent director (the &#8220;Lead Director&#8221;). The Lead Director&#8217;s responsibilities include, but are not limited to: presiding over all meetings of the Board at which the Chairperson of the Board is not present, including any executive sessions of the independent directors; approving Board meeting schedules and agendas; and acting as the liaison between the independent directors and the Chief Executive Officer and Chairperson of the Board. Our Corporate Governance Guidelines provide that, at such times as the Chairperson of the Board qualifies as independent, the Chairperson of the Board will serve as Lead Director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The positions of our Chair of the Board and our Chief Executive Officer are currently served by two separate persons. Dr. Mueller serves as Chairman of the Board, and Dr. Mehta serves as our Chief Executive Officer. In his capacity as the independent Board Chair, Dr. Mueller performs the functions of the Lead Director. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Board believes that our current leadership structure of Chief Executive Officer and Chair of the Board being held by two separate individuals is in the best interests of the Company and its stockholders and strikes the appropriate balance between the Chief Executive Officer and President&#8217;s responsibility for the strategic direction, day-to day-leadership and performance of our Company and the Chair of the Board&#8217;s responsibility to guide overall strategic direction of our Company and provide oversight of our corporate governance and guidance to our Chief Executive Officer and President and to set the agenda for and preside over Board meetings. We recognize that different leadership structures may be appropriate for companies in different situations and believe that no one structure is suitable for all companies. Accordingly, the Board will continue to periodically review our leadership structure and make such changes in the future as it deems appropriate and in the best interests of the Company and its stockholders. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">145</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_Toc187748834"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Board Committees</span><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Board has three standing committees: an audit committee, a compensation committee and a nominating and corporate governance committee, each of which has the composition and the responsibilities described below. In addition, from time to time, special committees may be established under the direction of our Board when necessary to address specific issues. Each of the audit committee, the compensation committee and the nominating and corporate governance committee operates under a written charter which are available in the &#8220;Governance&#8201;-&#8201;Governance Documents&#8221; section of the &#8220;Investors&#8221; page of our website located at <i style="font-style:italic;">www.bioxceltherapeutics.com</i>. </p><a id="_Toc187748835"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nominating and</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Corporate</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Audit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Compensation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Governance</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Committee</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Committee</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Committee</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June Bray</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Aptos Narrow';">&#8211;&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Aptos Narrow';">&#8211;&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:bottom;width:47.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sandeep Laumas, M.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chair</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:bottom;width:47.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Peter Mueller, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chair</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chair</p></td></tr><tr><td style="vertical-align:bottom;width:47.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Miller</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Aptos Narrow';">&#8211;&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Aptos Narrow';">&#8211;&#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michal Votruba, M.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Aptos Narrow';">&#8211;&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Aptos Narrow';">&#8211;&#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David Mack</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Aptos Narrow';">&#8211;&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Aptos Narrow';">&#8211;&#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rajiv Patni</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Aptos Narrow';">&#8211;&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Aptos Narrow';">&#8211;&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Aptos Narrow';">&#8211;&#8212;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Audit Committee</span><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our audit committee is responsible for, among other things: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">appointing, approving the compensation of, and assessing the independence of, our registered public accounting firm; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overseeing the work of our independent registered public accounting firm, including through the receipt and consideration of reports from such firm; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and discussing our annual and quarterly financial statements and related disclosures with management and our independent registered public accounting firm; </span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">considering whether to recommend to the Board that the Company&#8217;s audited financial statements be included in the Company&#8217;s Annual Report on Form 10-K; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">coordinating our Board&#8217;s oversight of our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discussing our risk assessment and risk management policies, and overseeing management of our financial risks, cybersecurity risks, information security risks, and, as necessary or advisable, such other material risks facing the Company; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">meeting independently with our internal auditors, if any, independent registered public accounting firm and management; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing on a periodic basis our investment policy; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and approving or ratifying any related person transactions; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pre-approving all audit and non-audit services provided to us by our independent auditor (other than those provided pursuant to appropriate preapproval policies established by the committee or exempt from such requirement under SEC rules); </span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">146</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or auditing matters, and for the confidential and anonymous submission by our employees of concerns regarding questionable accounting or auditing matters; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparing the audit committee report required by SEC rules. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The current members of our audit committee are Peter Mueller, Sandeep Laumas, Michael Miller and Michal Votruba, with Dr. Laumas serving as chair. All members of our audit committee meet the requirements for financial literacy under the applicable Nasdaq rules and regulations. Our Board has affirmatively determined that each member of our audit committee qualifies as &#8220;independent&#8221; under Nasdaq&#8217;s additional standards applicable to audit committee members and Rule 10A-3 of the Exchange Act applicable to audit committee members. In addition, our Board has determined that each of Dr. Laumas, Mr. Miller, Dr. Mueller, and Dr. Votruba qualifies as an &#8220;audit committee financial expert,&#8221; as such term is defined in Item 407(d)(5) of Regulation S-K. </p><a id="_Toc187748836"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Compensation Committee</span><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our compensation committee is responsible for, among other things: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and approving, or recommending for approval by the board of directors, the compensation of our Chief Executive Officer and our other executive officers; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and approving or make recommendations to the Board regarding the Company&#8217;s incentive compensation plans and equity-based plans and arrangements; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overseeing and administering our incentive compensation and equity-based plans and arrangement; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">periodically reviewing and making recommendations to our board of directors with respect to director compensation; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and discussing annually with management our &#8220;Compensation Discussion and Analysis,&#8221; to the extent required; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparing the annual compensation committee report required by SEC rules, to the extent required; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and discussing the results of the most recent stockholder advisory vote on executive compensation, and reviewing and recommending to our board of directors for approval the frequency with which we should conduct such votes, to the extent required; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overseeing the Company&#8217;s programs and policies as may be applicable, regarding talent management (including retention, development and training) and diversity and inclusion. </span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The current members of our compensation committee are Peter Mueller, Ph.D., David Mack and Sandeep Laumas, M.D., with Dr. Mueller serving as chair. Our Board has determined that each member of our compensation committee qualifies as &#8220;independent&#8221; under Nasdaq&#8217;s additional standards applicable to compensation committee members and is a &#8220;non-employee director&#8221; as defined in Section 16b-3 of the Exchange Act. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The compensation committee generally considers the Chief Executive Officer&#8217;s recommendations when making decisions regarding the compensation of non-employee directors and executive officers (other than the Chief Executive Officer). Pursuant to the compensation committee&#8217;s charter, the compensation committee has the authority to retain or obtain the advice of compensation consultants, legal counsel and other advisors to assist in carrying out its responsibilities. Before selecting any such consultant, counsel or advisor, the compensation committee reviews and considers the independence of such consultant, counsel or advisor in accordance with applicable Nasdaq rules. We must provide appropriate funding for payment of reasonable compensation to any advisor retained by the compensation committee. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">147</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_Toc187748837"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Compensation Consultants</span><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The compensation committee has the authority under its charter to retain outside consultants or advisors, as it deems necessary or advisable. In accordance with this authority, the compensation committee. </p><a id="_Toc187748838"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Nominating and Corporate Governance Committee</span><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our nominating and corporate governance committee is responsible for, among other things: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying individuals qualified to become members of our Board; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recommending to our Board the persons to be nominated for election as directors and to each committee of the Board; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing and recommending to our Board corporate governance guidelines, and reviewing and recommending to our board of directors proposed changes to our corporate governance guidelines from time to time; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and making recommendations to the Board in connection with a director&#8217;s notification of a change in employment or other circumstances; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overseeing a periodic evaluation of our Board. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The current members of our nominating and corporate governance committee are June Bray, Sandeep Laumas and Peter Mueller, with Peter Mueller serving as chair. Our Board has determined that each of Ms. Bray and Drs. Laumas and Mueller qualifies as &#8220;independent&#8221; under applicable Nasdaq rules applicable to nominating and corporate governance committee members. </p><a id="_Toc187748845"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Code of Business Conduct and Ethics</span><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have adopted a code of business conduct and ethics (the &#8220;Code of Conduct&#8221;) that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions. A copy of our Code of Business Conduct and Ethics is available under the &#8220;Governance&#8201;-&#8201;Governance Documents&#8221; section of the Investors page of our website located at <i style="font-style:italic;">www.bioxceltherapeutics.com</i>, or by writing to our Corporate Secretary at our offices at 555 Long Wharf Drive, New Haven, CT 06511. We intend to make any required disclosures regarding amendments to, or waivers of, provisions of our Code of Conduct on our website rather than by filing a Current Report on Form 8-K. </p><a id="_Toc187748847"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Insider Trading Policy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We maintain an <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="Narr_q6FBZWrm-k-GQ9utRDyoFQ">Insider Trading Compliance Policy</ix:nonNumeric><span style="white-space:pre-wrap;"> governing the purchase, sale, and other disposition of Company securities that is applicable to all of our directors, officers and employees. We believe our Insider Trading Compliance Policy and procedures are reasonably designed to promote compliance with insider trading laws.  A copy of our Insider Trading Compliance Policy is filed hereto as Exhibit 19.1.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The policy additionally prohibits our directors, officers and employees from purchasing financial instruments, such as prepaid variable forward contracts, equity swaps, collars, and exchange funds, or otherwise engaging in transactions that hedge or offset, or are designed to hedge or offset, any decrease in the market value of our equity securities. All such transactions involving our equity securities, whether such securities were granted as compensation or are otherwise held, directly or indirectly, are prohibited. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Compensation Recovery Policy (Clawback Policy)</span><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In 2023, we adopted a <a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837024003784/btai-20231231xex97d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">compensation</span></a> recovery, or &#8220;clawback,&#8221; policy (the &#8220;Clawback Policy&#8221;) in accordance with the Nasdaq listing standards and Exchange Act Rule 10D-1. The Clawback Policy provides for the mandatory recovery (subject to limited exceptions) from current and former officers of incentive-based compensation that was erroneously </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">148</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">received during the three years preceding the date that the Company is required to prepare an accounting restatement. The Clawback Policy is overseen and administered by the Compensation Committee. The full text of the Clawback Policy was included as Exhibit 97 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which was filed with the SEC on March 22, 2024. </p><a id="_Toc187748848"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Interested Persons&#8217; Communications with the Board</span><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">To help foster input and insight from the Company&#8217;s stockholders and other interested parties (collectively, &#8220;Interested Parties&#8221;), Interested Parties may communicate with, or otherwise make his or her concerns known directly to, the Chairperson of the Board, the lead director, if any, any chairperson of a Board committee, or the non-management or independent members of the Board, by addressing such communications to the intended recipient by name or position in care of: BioXcel Therapeutics, Inc., Attn: Chief Legal Officer, 555 Long Wharf Drive, New Haven, Connecticut 06511. The Chief Legal Officer will forward such communications to the appropriate party. </p><a id="Item_11"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;11. Executive Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following is a discussion of the compensation arrangements of our named executive officers (&#8220;NEOs&#8221;). As a smaller reporting company, we are not required to include a Compensation Discussion and Analysis section and have elected to comply with the scaled disclosure requirements applicable to smaller reporting companies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our NEOs include our principal executive officer and our two most highly compensated executive officers, other than our principal executive officer, for the fiscal year ended December 31, 2024. These NEOs and their positions are: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Vimal Mehta, Ph.D., our Chief Executive Officer and President; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Javier Rodriquez, our Senior Vice President, Chief Legal Officer and Secretary; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Richard Steinhart, our Senior Vice President and Chief Financial Officer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Summary Compensation Table</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following table shows information regarding the compensation of our NEOs for the years presented. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:23.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Non-Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incentive Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">All Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Salary</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Compensation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Compensation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name and Principal Position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)(1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)(1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)(2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Vimal Mehta, Ph.D.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,001,570</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 101,250</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,425</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,119,245</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Chief Executive Officer</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,001,569</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,097,600</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,615,928</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,050</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,731,147</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Javier Rodriguez</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 423,833</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 181,755</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 398,530</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,625</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,012,552</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Senior VP and Chief Legal Officer</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 423,833</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 191,588</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 498,272</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,250</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,121,943</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Richard Steinhart</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 409,872</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 181,755</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 398,339</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,128</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 998,216</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">SVP and Chief Commercial Officer</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">The amounts reported represent the grant date fair value of performance-based units, restricted stock units and stock options granted to our NEOs as computed in accordance with Accounting Standards Codification 718, Compensation&#8201;-&#8201;Stock Compensation (ASC 718). For all performance-based units, the amounts were calculated based on the probable outcome of the performance condition as of the grant date. The following are the values of the performance-based units as of the grant date assuming attainment of the maximum level of performance: Dr. Mehta ($300,000), Mr. Rodriguez ($84,000) and Mr. Steinhart</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">($84,000). Note that the amounts reported in these columns reflect the accounting cost for these awards and do not correspond to the actual economic value that may be received by our NEOs from the awards. We provided information regarding the assumptions used to calculate the value of the restricted stock units and stock options in Note 12 to our financial statements included herein. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(2)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">The amounts reported for 2024 represent reimbursement for healthcare benefits ($7,800) and ($4,128) for Dr. Mehta and Mr. Steinhart, respectively, and 401(k) matching contributions of ($8,625) for each named executive officer other than Mr. Steinhart. No bonus was paid for the year 2024. </span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">149</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_Toc187748852"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Narrative to Summary Compensation Table</b><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">2024 Salaries&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our NEOs receive a base salary to compensate them for services rendered to the Company. The base salary payable to each NEO is intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role and responsibilities. The base salaries of our NEOs are reviewed from time to time and adjusted when our Board or compensation committee determines an adjustment is appropriate. The compensation committee determined not to increase the salaries of the NEOs in 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">2024 Equity Awards&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">During 2024, we awarded stock options, time-based restricted stock units and performance-based restricted stock units (&#8220;PSUs&#8221;) to our NEOs as the long-term incentive component of our executive compensation program. We typically grant equity awards at such times as our Board determines appropriate. The following table sets forth the equity awards we granted to our NEOs during 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:37.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:56.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024 Equity Awards Granted (#)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PSUs</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vimal Mehta, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,250</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,625</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Javier Rodriguez</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,875</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 625</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,375</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Richard Steinhart</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,875</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 625</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,375</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The options were granted with exercise prices equal to the fair market value of our common stock on the date of grant. The stock options generally vest and becomes exercisable as to 50% of the total number of shares underlying the option on each of the first and second anniversaries of the date of grant and the remaining become fully vested on the second anniversary of the date of the grant, subject, in each case, to the holder&#8217;s continued service through the applicable vesting date. The time-based restricted stock units generally vest fully on the first anniversary of the date of the grant, subject, in each case, to the holder&#8217;s continued service through the applicable vesting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The PSUs granted to Dr. Mehta, Mr. Rodriquez and Mr. Steinhart are eligible to vest within thirty days of the first anniversary of the grant date the participants continued employment with the Company and based on the attainment of the following performance metrics, as determined by the Board: (i) a satisfactory completion of securing at least $25 million of additional funding for the Company (50% of the PSUs); (ii) successfully initiates trials for its Serenity and Tranquility programs and progress towards data readouts for such program trials (25% of the PSUs); (iii) significant progress towards achieving $5 million in IGALMI revenues (15% of the PSUs); and (iv) making progress towards securing a partnership deal (10% of the PSUs). The Board decided to grant PSUs during 2024 in order to further align the interests of Dr. Mehta, Mr. Rodriquez and Mr. Steinhart with the strategic clinical and operational objectives of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Refer to the &#8220;Outstanding Equity Awards at Year End&#8221; table below for additional information regarding the equity awards granted to our NEOs during 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">2024 Annual Bonuses&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We offer our NEOs the opportunity to earn discretionary annual cash bonuses to compensate them for attaining company and individual performance goals. Each NEO&#8217;s target bonus opportunity is expressed as a percentage of annual base salary. Pursuant to the Fifth Amendment to the Credit Agreement, we are restricted from paying cash bonuses to our employees or executives during the fiscal years 2024 and 2025 without OFA&#8217;s consent or increasing the cash compensation for fiscal year 2025 for certain senior officers of the Company from their compensation for fiscal year 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The performance goals for annual bonuses are reviewed and approved annually by the compensation committee. For 2024, the annual bonus metrics established by the compensation committee were based on the achievement of certain company performance goals, as well as an assessment of individual performance. In early 2025 the Board determined that it would use its discretion to not award annual bonuses for 2024 performance to the NEOs.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">150</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Elements of Compensation&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our NEOs are eligible to participate in our employee benefit plans and programs, which generally include medical, dental and vision benefits, and life, short-term, and long-term disability insurance to the same extent as our other full-time employees generally, subject to the terms and eligibility requirements of those plans. During 2024, we reimbursed Dr. Mehta for his healthcare premium payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We maintain a 401(k) defined contribution plan (the &#8220;401(k) Plan&#8221;), for the benefit of our employees who satisfy certain eligibility requirements. Our NEOs are eligible to participate in the 401(k) Plan on the same terms as other full-time employees. In 2024, we matched employee contributions to the 401(k) Plan up to 50% of the first 5% of eligible compensation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The amounts paid pursuant to these arrangements are set forth in the Summary Compensation Table in the column entitled &#8220;All Other Compensation.&#8221; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In response to&#160;Item&#160;402(x)(1) of&#160;Regulation S-K, the Company does not currently grant new awards of stock options, stock appreciation rights, or similar option-like instruments within four business days before or one business day after the release of a Form 10-Q, 10-K, or 8-K that discloses material nonpublic information (MNPI). Accordingly, the Company has no specific policy or practice on the timing of awards of such options in relation to the disclosure of MNPI by the Company.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">151</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_Toc187748853"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Outstanding Equity Awards at Year End</b><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth all outstanding equity awards held by each of the NEOs as of December 31, 2024. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Incentive</b></p></td></tr><tr><td style="vertical-align:bottom;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Plan</b></p></td></tr><tr><td style="vertical-align:bottom;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Incentive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Awards:</b></p></td></tr><tr><td style="vertical-align:bottom;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Market or</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Awards:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Payout</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Value of</b></p></td></tr><tr><td style="vertical-align:bottom;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Market</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Unearned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Unearned</b></p></td></tr><tr><td style="vertical-align:bottom;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Value of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Shares,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Shares,</b></p></td></tr><tr><td style="vertical-align:bottom;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Shares or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Shares or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Units of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Units or</b></p></td></tr><tr><td style="vertical-align:bottom;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Units of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Units or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Other</b></p></td></tr><tr><td style="vertical-align:bottom;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Rights</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Rights</b></p></td></tr><tr><td style="vertical-align:bottom;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Underlying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Underlying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">That</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">That</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">That</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">That</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Vesting</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Unexercised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Unexercised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Have Not</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Have Not</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Have Not</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Have Not</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Commencement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Options (#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Options (#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Expiration</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Vested</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Vested</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Vested</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Vested</b></p></td></tr><tr><td style="vertical-align:bottom;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Unexercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">($)(1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">($)(1)</b></p></td></tr><tr><td style="vertical-align:bottom;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Vimal Mehta, Ph.D.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">08/23/2017</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 18,376</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 6.56</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">08/23/2027</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">05/23/2019</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 11,732</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 160.64</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">05/23/2029</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">05/26/2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 15,625</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 735.84</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">05/26/2030</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/25/2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 14,647</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 978</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 658.72</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/25/2031</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/14/2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 7,170</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 3,268</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 244.96</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/14/2032</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/14/2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 816</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 4,882</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/15/2023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 4,588</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 5,913</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 313.60</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/14/2033</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/15/2023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 1,969</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 11,779</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">07/22/2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 6,250</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 19.20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">07/22/2034</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">07/22/2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 15,625</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 93,475</span></p></td></tr><tr><td style="vertical-align:bottom;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Javier Rodriquez</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">02/22/2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 1,917</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 84</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 878.40</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">02/22/2031</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">08/16/2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 523</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 103</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 381.44</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">08/16/2031</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/14/2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 1,427</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 659</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 244.96</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/14/2032</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/14/2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 163</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 975</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/15/2023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 869</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 1,132</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 313.60</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/15/2033</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/15/2023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 317</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 1,896</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">07/22/2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 1,875</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 19.20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">07/22/2034</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">07/22/2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(8)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 625</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 3,739</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">07/22/2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 4,375</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 26,173</span></p></td></tr><tr><td style="vertical-align:bottom;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Richard Steinhart</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">10/02/2017</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 5,010</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 88.80</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">10/02/2027</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/12/2018</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 2,016</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 176.00</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/12/2028</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">05/26/2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 3,438</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 735.84</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">05/25/2030</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/25/2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 1,172</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 79</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 658.72</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/25/2031</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/14/2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 1,430</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 655</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 244.96</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/14/2032</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/14/2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 163</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 975</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/15/2023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 869</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 1,132</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 313.60</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/15/2033</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">03/15/2023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 317</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 1,896</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">07/22/2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 1,875</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 19.20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">07/22/2034</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">07/22/2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(8)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 625</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 3,739</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;">07/22/2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 4,375</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;"> 26,173</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">The amounts shown are based on the closing price of our common stock on December 31, 2024 of $5.9840 per share. For the restricted stock units in Employee Holdings, the amount shown is based on the fair market value of such awards as of December 31, 2024. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(2)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">The unvested portion of the option vests in substantially equal monthly installments until the fourth anniversary of the vesting commencement date. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(3)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">The option vests as to 25% of the shares on the first anniversary of the vesting commencement date and in substantially equal monthly installments thereafter until the fourth anniversary of the vesting commencement date. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(4)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">The RSUs vest in substantially equal quarterly installments until the fourth anniversary of the vesting commencement date </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(5)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">The RSUs vest as to 25% of the shares on the first anniversary of the vesting commencement date and in substantially equal quarterly installments thereafter until the fourth anniversary of the vesting commencement date. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(6)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">The PSUs are eligible to vest on the first anniversary of the vesting commencement date based on the Board&#8217;s determination that certain Company performance metrics have been attained. See &#8220;</span><i style="font-size:8pt;font-style:italic;">Equity Compensation</i><span style="font-size:8pt;">&#8221; above for a description of these metrics. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(7)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;white-space:pre-wrap;">The option vests as to 50% of the shares on each of the first and second anniversaries of the grant date.  </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(8)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;white-space:pre-wrap;">The RSUs vest on the first anniversary of the grant date.  </span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">152</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_Toc187748854"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Employment Arrangements</b><b style="font-weight:bold;">&#160;- 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">We have entered into employment agreements with each of our NEOs that set forth the terms and conditions of each executive&#8217;s employment with us. All descriptions of the employment agreements herein describe the agreements in effect as of December 31, 2024, and do not reflect subsequent amendments.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Each employment agreement establishes an annual base salary and target bonus opportunity for each NEO. The amounts in effect during 2024 are described above under the headings &#8220;2024 Salaries&#8221; and &#8220;2024 Annual Bonuses.&#8221; The NEOs are eligible to participate in our employee benefit plans and programs for which the NEO is eligible, subject to the terms and conditions of such plans and programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">During 2024, in the event that an NEO was terminated by us without cause, or by the executive for good reason, subject to the NEO&#8217;s timely execution and non-revocation of a release of claims in our favor, the executive would have been eligible to receive (i) a pro-rated portion of the executive&#8217;s annual bonus for the year of termination; (ii) base salary continuation for 24 months for Dr. Mehta, 6 months for Mr. Rodriguez and Mr. Steinhart; and (iii) reimbursement for COBRA premium payments for the applicable severance period. In addition, Dr. Mehta would be entitled to vesting of 50% of any unvested equity awards held by him immediately prior to his termination. The Company must provide an NEO 30 days&#8217; notice in the event we terminate such NEO without cause. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The employment agreements also provide that, in the event an NEO&#8217;s employment is terminated by us without cause or by the NEO for good reason, in either case, within 6 months prior to or 12 months after a change in control, then, subject to the NEO&#8217;s timely execution and non-revocation of a release of claims in our favor, the NEO will be entitled to a lump sum payment equal to 6 months of base salary (or 24 months of base salary for Dr. Mehta), which payment is in addition to the severance payments and benefits described above. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The employment agreements generally define &#8220;cause&#8221; as, subject to certain notice and cure rights, the NEO&#8217;s (i) material breach or material default of the employment agreement or any other agreement between us and the NEO, or repeated failure to follow the direction of the Company or our Board, as applicable; (ii) gross negligence, willful misfeasance or breach of fiduciary duty to us or our affiliates; (iii) commission of an act or omission involving fraud, embezzlement, misappropriation or dishonesty in connection with NEO&#8217;s duties to us or our affiliates, or, for Mr. Rodriguez or Mr. Steinhart, that is otherwise likely to be materially injurious to the business or reputation of the Company or our affiliates; or (iv) conviction of, indictment for, or pleading guilty or nolo contendere to, any felony or other crime involving fraud or moral turpitude. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The employment agreements generally define &#8220;good reason&#8221; as, subject to certain notice and cure rights, the occurrence of any of the following (without the NEO&#8217;s express written consent): (i) a significant reduction of the NEO&#8217;s duties, position or responsibilities, or the removal of the NEO from such position, duties or responsibilities; (ii) for Dr. Mehta and Mr. Rodriguez only, the relocation of the NEO by more than 25 miles; or (iii) any action or inaction that constitutes a material breach by us or any of our successors of its obligations to the NEO under the employment agreement (or for Dr. Mehta, any other agreement between us and Dr. Mehta). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The employment agreements also contain covenants prohibiting the NEOs from competing with us or soliciting our suppliers, employees or customers during employment and for a period of one year following termination.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">153</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Non-Employee Director Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The non-employee members of our Board are eligible to receive compensation for their service on our Board. Under our director compensation program, during 2024 each non-employee director was eligible to receive an option to purchase 1,875 shares of common stock upon such director&#8217;s initial election or appointment to the Board. Additionally, each non-employee director who has been serving as a non-employee director for at least six months as of the date of any annual meeting of stockholders and will continue to serve as a non-employee director immediately following such meeting, was eligible to receive an option to purchase 1,062 shares of common stock on the date of such annual meeting. The options granted to our non-employee directors have an exercise price equal to the fair market value of our common stock on the date of grant and expire not later than ten years after the date of grant. The stock options granted upon a director&#8217;s initial election or appointment vest in three substantially equal annual installments following the date of grant. The stock options granted annually to directors vest in a single installment on the earlier of the day before the next annual meeting or the first anniversary of the date of grant. In addition, all unvested stock options vest in full upon the occurrence of a change in control. For the appointment of David Mack in 2024, we provided a separate grant of RSUs and a separate cash arrangement in lieu of the stock option award and cash payments typically granted to new directors, as described below in the &#8220;Director Compensation Table&#8221;. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, our non-employee directors were eligible to receive cash retainers for service on our Board and committees of our Board during 2024 as set forth in the table below. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Base Board Fee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 60,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chair of Board or Lead Independent Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 35,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chair of Audit Committee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chair of Compensation Committee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chair of Nominating and Corporate Governance Committee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Member of Audit Committee (non-Chair)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Member of Compensation Committee (non-Chair)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,500</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Member of Nominating and Corporate Governance Committee (non-Chair)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,000</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Director fees under the program are payable in arrears in four equal quarterly installments not later than the fifteenth day following the final day of each calendar quarter, <i style="font-style:italic;">provided</i> that the amount of each payment will be prorated for any portion of a quarter that a director is not serving on our board. </p><a id="_Toc187748857"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We also reimburse all of our non-employee directors for all reasonable and customary business expenses in accordance with company policy. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">154</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Director Compensation Table</span><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth information for the year ended December 31, 2024 regarding the compensation awarded to, earned by or paid to our non-employee directors: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fees Earned or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid in Cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Peter Mueller, Ph.D.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 130,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,410</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 150,410</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sandeep Laumas, M.D.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 92,500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,410</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 112,910</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michal Votruba, M.D.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 70,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,410</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 90,410</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June Bray<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 65,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,410</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 85,410</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Miller<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 70,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,410</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 90,410</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David Mack<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(8)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 185,619</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 215,619</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">The amounts reported represent the grant date fair value of stock options granted to our non-employee directors as computed in accordance with ASC 718. Note that the amounts reported in this column reflect the accounting cost for these stock options and do not correspond to the actual economic value that may be received by the recipients from the options. We provide information regarding the assumptions used to calculate the value of the option awards in Note 12 to our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-size:8pt;">(2)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-size:8pt;">As of December 31, 2024, Dr. Mueller held options to purchase an aggregate of 16,667 shares of our common stock, of which 15,604 shares of common stock were exercisable. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-size:8pt;">(3)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-size:8pt;">As of December 31, 2024, Dr. Laumas held options to purchase an aggregate of 14,028 shares of our common stock, of which 12,965 shares of common stock were exercisable. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-size:8pt;">(4)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-size:8pt;">As of December 31, 2024, Dr. Votruba held options to purchase an aggregate of 6,265 shares of our common stock, of which 5,202 shares of common stock were exercisable. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-size:8pt;">(5)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-size:8pt;">As of December 31, 2024, Ms. Bray held options to purchase an aggregate of 5,013 shares of our common stock, of which 3,950 shares of common stock were exercisable. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-size:8pt;">(6)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-size:8pt;">As of December 31, 2024, Mr. Miller held options to purchase an aggregate of 4,001 shares of our common stock, of which 2,938 shares of common stock were exercisable. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-size:8pt;">(7)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-size:8pt;">As of December 31, 2024, Mr. Mack held 16,932 unvested restricted stock units.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">(8) &#160; &#160;As of December 31, 2024, Mr. Mack earned $30,000 in board fees for services provided since joining the Board in November 2024.</p><a id="Item_12"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table sets forth information relating to the beneficial ownership of our common stock as of March 21, 2025 by: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding shares of common stock; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of our directors; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of our named executive officers for 2024; and </span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all of our current directors and executive officers as a group. </span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC. Under these rules, a person is deemed to be a &#8220;beneficial&#8221; owner of a security if that person has or shares voting power or investment power, which includes the power to dispose of or to direct the disposition of such security. Except as indicated in the footnotes below, we believe, based on the information furnished to us, that the individuals and entities named in the table below have sole voting and investment power with respect to all shares of common stock beneficially owned by them, subject to any applicable community property laws. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">155</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The percentage of shares beneficially owned is computed on the basis of 5,468,038 shares of our common stock outstanding as of March 21, 2025. Shares of our common stock that a person has the right to acquire within 60 days of March 21, 2025 are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all directors and executive officers as a group. Unless otherwise indicated below, the address for each beneficial owner listed is c/o 555 Long Wharf Drive, New Haven, CT 06511. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage of Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name of Beneficial Owner</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficially Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficially Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Holders of more than 5%:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">BioXcel LLC<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 480,343</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8.78</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Armistice Capital Master Fund Ltd.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,385,083</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9.99</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Named executive officers and directors:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vimal Mehta, Ph.D.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 573,619</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Javier Rodriguez<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,903</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Richard Steinhart<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21,437</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">June Bray<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,950</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Sandeep Laumas, M.D.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,965</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Michael Miller<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(8)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,312</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Peter Mueller, Ph.D.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(9)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23,091</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Michal Votruba, M.D.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(10)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,725</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">David Mack<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(11)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,158</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Rajiv Patni<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(12)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 938</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">All executive officers and directors as a group</span> (11 individuals)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(13)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 692,185</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">*&#160;Represents less than 1%. </p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Based solely on a Schedule 13D filed with the SEC on June 6, 2024. BioXcel LLC and BioXcel Holdings, Inc. have shared voting power and shared dispositive power over 480,343 shares of our common stock. Dr. Mehta and affiliated trusts are significant stockholders of BioXcel Holdings, Inc. BioXcel LLC is majority owned and controlled by BioXcel Holdings, Inc. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. Mr. Mehta is an executive officer and the sole member of the board of directors of BioXcel Holdings, Inc. and an executive officer and one of two managers on the board of managers of BioXcel LLC and BioXcel Holdings, Inc. As such, each of Mr. Mehta and BioXcel Holdings, Inc. may be deemed to beneficially own the Common Stock held of record by BioXcel LLC. The address of BioXcel LLC and BioXcel Holdings, Inc. is 2614 Boston Post Road Suite 33B, Guilford, CT 06437. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(2)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;white-space:pre-wrap;">Based on information known to us, Armistice Capital Master Fund Ltd. owns warrants to purchase 1,385,083 shares of our common stock that are exercisable within 60 days of March 21, 2025. The warrants to purchase shares of common stock are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (&#8220;Master Fund&#8221;), and may be deemed to be beneficially owned by: (i) Armistice Capital, LLC (&#8220;Armistice Capital&#8221;), as the investment manager of Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. Armistice Capital has sole voting and dispositive control of the shares reported herein. The address for the stockholder is 510 Madison Avenue, 7th Floor, New York, New York 10022.  Warrants held by Armistice Capital are subject to a beneficial ownership limitation of 4.99% or 9.99%, which such limitation restricts the stockholder from exercising that portion of the warrants, as applicable, that would result in the stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(3)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Represents for Dr. Mehta: (i) 4,236 shares of common stock (of which 125 shares are owned jointly with Dr. Mehta&#8217;s spouse); (ii) options to purchase 89,050 shares of our common stock that can be exercised within 60 days of March 21, 2025; and (iii) 480,343 shares of common stock held by BioXcel LLC as to which Dr. Mehta may be deemed to have beneficial ownership as described under footnote (1) above. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(4)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Represents for Mr. Steinhart: (i) 1,373 shares of common stock and (ii) options to purchase 20,064 shares of our common stock that can be exercised within 60 days of March 21, 2025.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(5)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Represents for Mr. Rodriguez: (i) 1,591 shares of common stock and (ii) options to purchase 5,312 shares of our common stock that can be exercised within 60 days of March 21, 2025. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(6)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Represents for Ms. Bray: options to purchase 3,950 shares of our common stock that can be exercised within 60 days of March 21, 2025. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(7)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Represents for Dr. Laumas: options to purchase 12,965 shares of our common stock that can be exercised within 60 days of March 21, 2025. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(8)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Represents for Mr. Miller: options to purchase 2,312 shares of our common stock that can be exercised within 60 days of March 21, 2025. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(9)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Represents for Dr. Mueller: (i) 7,487 shares of common stock held by Dr. Mueller (including shares of our common stock held by the Peter Mueller 2018 Irrevocable Family Trust, as to which Dr. Mueller serves as trustee); and (iii) options to purchase 15,604 shares of our common stock that can be exercised within 60 days of March 21, 2025. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(10)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Represents for Dr. Votruba: 11,523 shares of our common stock held by RSJ Investments SICAV a.s. (&#8220;RSJ/Gradus&#8221;) and over which Dr. Votruba, an asset manager at RSJ/Gradus, has voting and/or dispositive power. Also includes options to purchase 5,202 shares of our common stock that can be exercised within 60 days of March 21, 2025, which options Dr. Votruba was granted in respect of his service on our Board but as to which he assigned to RSJ/Gradus pursuant to the policies of RSJ/Gradus regarding stock ownership by employees. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(11)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Represents for Mr. Mack: 3,386 restricted stock units that vest within 60 days of March 21, 2025. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(12)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Represents for Mr. Patni: options to purchase 938 shares of our common stock that vest within 60 days of March 21, 2025. </span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">156</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(13)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Includes options to purchase 173,611 shares of our common stock that can be exercised within 60 days of March 21, 2025 and 3,386 RSUs that vest within 60 days of March 21, 2025. </span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Securities Authorized for Issuance Under Equity Compensation Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table provides certain information with respect to the Company&#8217;s equity compensation plans in effect as of December 31, 2024: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.13908768%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of securities</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining available</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for future issuance</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">to be issued upon</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">under equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise price of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">compensation plans</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">outstanding options,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">outstanding options,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(excluding securities</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">warrants and rights</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">warrants and rights</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">reflected in column (a))</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:46.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Plan Category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(a)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(b)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(c)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity compensation plans approved by security holders<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 407,477</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 265.36</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 117,044</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity compensation plans not approved by security holders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 407,477</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 265.36</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 117,044</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Consists of the BioXcel Therapeutics, Inc. 2017 Incentive Award Plan (the &#8220;2017 Plan&#8221;), the BioXcel Therapeutics, Inc. 2020 Incentive Award Plan (the &#8220;2020 Plan&#8221;) and the BioXcel Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the &#8220;2020 ESPP&#8221;). </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(2)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Includes 119,781 outstanding options to purchase shares under the 2017 Plan, 69,506 performance-based units, 26,898 restricted stock units and 191,292 outstanding options to purchase shares under the 2020 Plan. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(3)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">As of December 31, 2024, the weighted-average exercise price of outstanding options under the 2017 Plan was $59.74 and the weighted-average exercise price of outstanding options under the 2020 Plan was $394.11. The weighted average exercise price of outstanding awards does not take into account the shares issuable upon vesting of outstanding performance-based units and restricted stock units which have no exercise price. </span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(4)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Includes 41,748 shares available for future issuance under the 2020 Plan and 75,296 shares available for issuance under the 2020 ESPP. Following the effective date of the 2020 Plan, we ceased making grants under the 2017 Plan. To the extent outstanding awards under the 2017 Plan are forfeited or lapse unexercised, the shares of common stock subject to such awards will be available for issuance under the 2020 Plan. The 2020 Plan provides for an annual increase to the number of shares available for issuance thereunder on the first day of each calendar year beginning on January 1, 2021 and ending on and including January 1, 2030, by an amount equal to the lesser of (i) 4% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by our board of directors (but no more than 625,000 shares may be issued upon the exercise of incentive stock options). The 2020 ESPP provides for an annual increase to the number of shares available for issuance thereunder on the first day of each calendar year beginning on January 1, 2021 and ending on and including January 1, 2030, by an amount equal to the lesser of (i) 1% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as is determined by our board of directors, provided that no more than 31,250 shares of our common stock may be issued under the component of the 2020 ESPP that is intended to qualified under Section 423 of the Code. As of the date of this proxy statement, we have not commenced offering periods under the 2020 ESPP. </span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_Toc187748864"></a><a id="Item_13"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item 13. Certain Relationships and Related Transactions, and Director Independence</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Certain Relationships and Related Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">March 2024 Registered Direct Offering</span><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 27, 2024, we completed a registered direct offering, which resulted in the issuance and sale of (i) 190,913 shares of our common stock, (ii) pre-funded warrants to purchase up to 347,814 shares of our common stock at an exercise price of $0.016 per share and (iii) accompanying warrants to purchase up to 538,728 shares of our common stock at an exercise price of $51.20 per share. The combined offering price of the common stock and accompanying warrants was $46.416 per share and share underlying each accompanying warrant, and the combined offering price of the Armistice pre-funded warrants and accompanying warrants was $46.40 per share underlying each pre-funded warrant and accompanying warrant. The Armistice pre-funded warrants and the accompanying warrants are exercisable at any time after the date of issuance, however, the accompanying warrants will expire on the fifth anniversary of the date of issuance. A holder of Armistice pre-funded warrants will not be entitled to exercise any portion of such Armistice pre-funded warrants which, upon giving effect to such exercise, would cause (i) the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed 9.99% of the number of shares of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">157</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">our common stock outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of our securities beneficially owned by the holder (together with its affiliates) to exceed 9.99% of the combined voting power of all of our securities then outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Armistice Pre-Funded Warrants. A holder of Accompanying Warrants will not be entitled to exercise any portion of such Accompanying Warrants which, upon giving effect to such exercise, would cause (i) the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed 4.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of our securities beneficially owned by the holder (together with its affiliates) to exceed 4.99% of the combined voting power of all of our securities then outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Accompanying Warrants. In each case, such percentages may be increased by a holder of Armistice Warrants to any other percentage not in excess of 19.99% upon at least 61 days&#8217; prior notice from the holder to us. We received net proceeds of approximately $24.9 million from this offering, after deducting offering expenses. The following table sets forth the aggregate number of shares of our common stock and shares of common stock underlying the Armistice Warrants acquired in the offering by holders of more than 5% of our common stock, including entities that became holders of more than 5% of our common stock as a result of the registered direct offering. On November 21, 2024, the exercise price of warrants to purchase 538,728 shares of common stock issued in March 2024 Registered Direct Offering described here was reduced to $9.136 per share.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Underlying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Underlying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pre-Funded</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accompanying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Participants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Holders of More than 5 %</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Armistice Capital Master Fund Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 190,913</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 347,814</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 538,728</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,999,999.01</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Additional details regarding certain of these stockholders and their equity holdings are provided in this Proxy Statement under the caption &#8220;Stock Ownership&#8201;-&#8201;Security Ownership of Certain Beneficial Owners and Management.&#8221;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">158</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_Toc187748865"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">November 2024 Offering&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On November 25, 2024, we completed an offering, which resulted in the issuance and sale to Armistice of (i) 283,854 shares of our common stock, (ii) pre-funded warrants to purchase up to 562,500 shares of our common stock at an exercise price of $0.016 per share and (iii) accompanying warrants to purchase up to 846,355 shares of our common stock at an exercise price of $7.68 per share. The combined offering price of the common stock and accompanying warrants was $7.68 per share and share underlying each accompanying warrant, and the combined offering price of the Armistice pre-funded warrants and accompanying warrants was $7.664 per share underlying each pre-funded warrant and accompanying warrant. The Armistice pre-funded warrants and the accompanying warrants are exercisable at any time after the date of issuance, however, the accompanying warrants will expire on the fifth anniversary of the date of issuance. A holder of Armistice pre-funded warrants will not be entitled to exercise any portion of such Armistice pre-funded warrants which, upon giving effect to such exercise, would cause (i) the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of our securities beneficially owned by the holder (together with its affiliates) to exceed 9.99% of the combined voting power of all of our securities then outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Armistice pre-funded warrants. A holder of accompanying warrants will not be entitled to exercise any portion of such accompanying warrants which, upon giving effect to such exercise, would cause (i) the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed 4.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of our securities beneficially owned by the holder (together with its affiliates) to exceed 4.99% of the combined voting power of all of our securities then outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the accompanying warrants. In each case, such percentages may be increased by a holder of Armistice Warrants to any other percentage not in excess of 19.99% upon at least 61 days&#8217; prior notice from the holder to us. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">BioXcel LLC</span><span style="font-style:italic;font-weight:bold;">&#160;</span></p><a id="_Toc187748866"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BioXcel LLC owned approximately 8.8% of the shares of our outstanding common stock as of March 21, 2025. BioXcel LLC is the successor in interest to BioXcel Corporation, our former parent. BioXcel LLC is a subsidiary of, and majority owned and controlled by BioXcel Holdings, Inc. Vimal Mehta and affiliated trusts are significant stockholders of BioXcel Holdings, Inc. Dr. Mehta is also an executive officer and the sole member of the board of managers of BioXcel Holdings, Inc. and an executive officer and one of two managers of BioXcel LLC and BioXcel Holdings, Inc. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amended and Restated Asset Contribution Agreement with BioXcel LLC</span><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We entered into an asset contribution agreement, effective June 30, 2017, with BioXcel LLC (formerly BioXcel Corporation), as amended and restated on November 7, 2017, pursuant to which BioXcel LLC contributed to us, and we acquired from BioXcel LLC, all of BioXcel LLC&#8217;s rights, title and interest in and to BXCL501, BXCL701, BXCL502 and BXCL702 (collectively, the &#8220;Candidates&#8221;) and all of the assets and liabilities associated with the Candidates, in consideration for (i) 592,500 shares of our common stock, (ii) $1 million upon completion of our initial public offering (&#8220;IPO&#8221;), (iii) $500,000 upon the later of the 12 month anniversary of our IPO and the first dosing of a patient in the bridging bioavailability/bioequivalence study for the BXCL501 program, (iv) $500,000 upon the later of the 12 month anniversary of our IPO and the first dosing of a patient in the Phase 2 Proof of Concept open label monotherapy or combination trial with Keytruda for the BXCL701 program and (v) a one-time payment of $5 million within 60 days after the achievement of $50 million in cumulative net sales of any product or combination of products resulting from the development and commercialization of any one of the Candidates or a product derived therefrom. There were no such payments during the years ended December 31, 2023 or 2024 pursuant to such provisions in the Contribution Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, pursuant to the Contribution Agreement, BioXcel LLC granted us a first right to negotiate exclusive rights to any additional product candidates in the fields of neuroscience and immuno-oncology (the &#8220;Option Field&#8221;) that BioXcel LLC may identify on its own, excluding the Candidates, and not in connection with BioXcel LLC&#8217;s provision of services to us under the Services Agreement as defined and described below. This first right to negotiate an exclusivity period expired on March 12, 2023. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">159</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_Toc187748867"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amended and Restated Separation and Shared Services Agreement</span><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We entered into a separation and shared services agreement, dated June 30, 2017, or the Effective Date, with BioXcel LLC (formerly BioXcel Corporation), as amended and restated thereafter, pursuant to which services provided by BioXcel LLC through its subsidiaries in India and the United States will continue indefinitely, as agreed upon by the parties. These services are primarily for drug discovery, chemical, manufacturing and controls cost and general and administrative support. Service charges recorded under this agreement were $1.3 million for each of the years ended December 31, 2024 and 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the Services Agreement, the Company has an option, exercisable through December 31, 2024, to enter into a collaborative services agreement with BioXcel LLC pursuant to which BioXcel LLC shall perform product identification and related services for us utilizing EvolverAI. The Company agreed to pay BioXcel LLC $18,000 per month, prorated for any partial month, as applicable, for the period beginning March 13, 2023 and ending December 31, 2024 as consideration for the option. The parties are obligated to negotiate the collaborative services agreement in good faith and to incorporate reasonable market-based terms, including consideration for BioXcel LLC reflecting a low, single-digit royalty on net sales and reasonable development and commercialization milestone payments, <i style="font-style:italic;">provided</i> that (i) development milestones shall not exceed $10 million in the aggregate and not be payable prior to proof of concept in humans and (ii) commercialization milestones shall be based on reaching annual net sales levels, be limited to 3% of the applicable net sales level, and not exceed $30 million in the aggregate. </p><a id="_Toc187748870"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">InveniAI</span><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On September 19, 2023, we, Krishnan Nandabalan, Ph.D., a former member of our Board, InveniAI and Invea Therapeutics, Inc., a wholly-owned subsidiary of BioXcel LLC (&#8220;Invea&#8221;) and the other parties thereto entered into a non-compete agreement pursuant to which Dr. Nandabalan, InveniAI and Invea agreed not to compete with us and our controlled affiliates in the fields of neuroscience and immuno-oncology for a period of five years from September 19, 2023 and not to solicit employees of the Company or its controlled affiliates for a period of two years from September 19, 2023. </p><a id="_Toc187748871"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Director and Officer Indemnification and Insurance</b><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have agreed to indemnify each of our directors and executive officers against certain liabilities, costs and expenses, and have purchased directors&#8217; and officers&#8217; liability insurance.</p><a id="_Toc187748833"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Director Independence</b><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under our Corporate Governance Guidelines and Nasdaq rules, a director is independent if he or she does not have a material or other disqualifying relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities as a director. In addition, the director must meet the bright-line tests for independence set forth by the Nasdaq rules. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our Board has undertaken a review of its composition, the composition of its committees and the independence of our directors and considered whether any director has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our Board of Directors has determined that none of Ms. Bray, Mr. Miller, Mr. Mack or Drs. Laumas, Mueller, Patni or Votruba, representing seven of our eight current directors, has a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors qualifies as &#8220;independent&#8221; as that term is defined under the Nasdaq rules. In making these determinations, our Board considered the relationships that each non-employee director has with us and all other facts and circumstances our Board deemed relevant in determining their independence, including the director&#8217;s beneficial ownership of our common stock and the relationships of our non-employee directors with certain of our significant stockholders.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">160</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Item_14"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;14. Principal Accounting Fees and Services</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Audit Committee retained Ernst &amp; Young LLP to audit the Company&#8217;s consolidated financial statements for the years ended December 31, 2024 and December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The table below sets forth the aggregate fees billed to us for services related to the fiscal year ended December 31, 2024 and 2023 by Ernst &amp; Young LLP. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Audit Fees<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 946,270</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 903,500</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Audit-Related Fees<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">All Other Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 946,270</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 919,500</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:1pt;">&#8203;</span><span style="font-size:8pt;">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Audit fees consisted of audit services performed in connection with the audit of the Company&#8217;s consolidated financial statements, the reviews of the Company&#8217;s interim condensed consolidated financial statements, and related services that are normally provided in connection with registration statements. Included in the 2024 and 2023 audit fees are $155,000 and $105,000, respectively, billed in connection with our follow-on offerings. 2024 and 2023 audit fees also include fees related to the audit and review of the registration statements of the Company&#8217;s subsidiary, OnkosXcel Therapeutics LLC, of $0 and $65,000, respectively.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="font-size:8pt;">(2)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="font-size:8pt;">Audit-related fees consisted of out-of-pocket costs for the annual audit.</span><span style="font-size:1pt;">&#8203;</span></p></td></tr></table><a id="_Toc187748822"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Pre-Approval Policies and Procedures</b><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Consistent with SEC policies and guidelines regarding audit independence, the audit committee is responsible for the pre-approval of all audit and permissible non-audit services provided by our independent registered public accounting firm on a case-by-case basis. Our audit committee has established a policy regarding approval of all audit and permissible non-audit services provided by our principal accountants. No non-audit services were performed by our independent registered public accounting firm during the years ended December 31, 2024 and 2023. Our audit committee pre-approves these services by category and service. Our audit committee has pre-approved all of the above-described services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-size:1pt;font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">161</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_f57ce2e3_54b9_4597_93c2_5894b108e083"></a><a id="PARTIV_900935"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;IV</p><a id="Item15ExhibitsFinancialStatementSchedule"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;15. Exhibits, Financial Statement Schedules</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The following documents are filed as part of this report:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statements:</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:91.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Audit_Report"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID: 00042)</p></td><td style="vertical-align:bottom;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-1</p></td></tr><tr><td style="vertical-align:bottom;width:91.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#BALANCESHEETS_688394"><span style="font-style:normal;font-weight:normal;">Consolidated</span><span style="font-style:normal;font-weight:normal;"> Balance Sheets</span><span style="font-style:normal;font-weight:normal;"> as of December 31, 2024 and 2023</span></a></p></td><td style="vertical-align:bottom;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-3</p></td></tr><tr><td style="vertical-align:bottom;width:91.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#STATEMENTSOFOPERATIONS_773604"><span style="font-style:normal;font-weight:normal;">Consolidated </span><span style="font-style:normal;font-weight:normal;">Statements of Operations</span><span style="font-style:normal;font-weight:normal;"> for the Years Ended December 31, 2024 and 2023</span></a></p></td><td style="vertical-align:bottom;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:bottom;width:91.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY_"><span style="font-style:normal;font-weight:normal;">Consolidated </span><span style="font-style:normal;font-weight:normal;">Statements of Changes in Stockholders&#8217; Equity</span><span style="font-style:normal;font-weight:normal;"> for the Years Ended December 31, 2024 and 2023</span></a></p></td><td style="vertical-align:bottom;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:bottom;width:91.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#STATEMENTSOFCASHFLOWS_770795"><span style="font-style:normal;font-weight:normal;">Consolidated </span><span style="font-style:normal;font-weight:normal;">Statements of Cash Flows</span><span style="font-style:normal;font-weight:normal;"> </span><span style="font-style:normal;font-weight:normal;">for the Years Ended December 31, 2024 and 2023</span></a></p></td><td style="vertical-align:bottom;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:bottom;width:91.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#NOTESTOFINANCIALSTATEMENTS_564668"><span style="font-style:normal;font-weight:normal;">Notes to C</span><span style="font-style:normal;font-weight:normal;">onsolidated </span><span style="font-style:normal;font-weight:normal;">Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statement Schedules:</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Exhibits.</span></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="4" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:36.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.91%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed/</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Furnished</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000110465918016770/a18-8090_1ex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation</span></a> </p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/10/2021</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465924070503/tm249625d6_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Amended and Restated Certificate of Incorporation</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">06/12/2024</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.3</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465925009906/tm255604d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Amended and Restated Certificate of Incorporation</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/06/2025</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.4</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000110465918016770/a18-8090_1ex3d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws</span></a> </p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/13/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20241231xex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of the Registrant&#8217;s Securities Registered Under Section 12 of the Exchange Act</span></a> </p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000104746918001032/a2234645zex-4_2.htm#Exhibit:http://www.sec.gov/Archives/edgar/data/1720893/000104746918001032/a2234645zex-4_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen Stock Certificate evidencing the shares of common stock</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-222990</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/26/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.3</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465923123807/tm2332261d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Amended and Restated Warrant Agreement, dated December 5, 2023</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/06/2023</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.4</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465923123807/tm2332261d1_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant Agreement, dated December 5, 2023</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/06/2023</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.5</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20241231xex4d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Amended and Restated Warrant Agreement, dated November 25, 2024</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.6</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465924038441/tm249625d2_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Pre-Funded Warrant, dated March 25, 2024</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/25/2024</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">162</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="4" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:36.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.91%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed/</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Furnished</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.7</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465924038441/tm249625d2_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Accompanying Warrant, dated March 25, 2024</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/25/2024</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.8</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465924121582/tm2428677d2_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Fifth Amendment Warrant, dated November 21, 2024</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/21/2024</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.9</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465924122587/tm2428677d4_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Pre-Funded Warrant, dated November 21, 2024</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/25/2024</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.10</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465924122587/tm2428677d4_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant, dated November 21, 2024</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/25/2024</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.11</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465925002583/tm251419d2_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Amended and Restated Fourth Amendment Warrant, dated November 25, 2024</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-3</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-284224</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">01/10/2025</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.12</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837024003784/btai-20231231xex4d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Registration Rights Agreement, between the Company and the parties thereto, dated March 20, 2024.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.6</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/22/2024</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.13</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465924121582/tm2428677d2_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Third Amended and Restated Registration Rights Agreement, between the Company and the parties thereto, dated November 25, 2024</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/21/2024</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1+</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837020002196/btai-20191231ex102ae7793.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> Amended and Restated Separation and Shared Services Agreement, dated </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">March 6, 2020</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, by and between BioXcel Corporation and BioXcel Therapeutics,&#160;Inc.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">10.2      </span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/09/2020</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"/></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2#</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837021002916/btai-20201231ex1034633bc.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">F</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">irst</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Second Amended and Restated Separation and Shared Services Agreement, dated March 3, 2021, by and between BioXcel LLC and BioXcel Therapeutics Inc</span></a>.</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/12/2021</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837023008597/btai-20230331xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Second Amended and Restated Separation and Shared Services Agreement, dated March 3, 2021, by and between BioXcel LLC and BioXcel Therapeutics Inc.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/09/2022</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4#</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000104746918000756/a2234454zex-10_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Asset Contribution Agreement, effective November&#160;7, 2017, by and between BioXcel LLC and BioXcel Therapeutics,&#160;Inc.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-222990</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/12/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">163</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="4" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:36.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.91%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed/</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Furnished</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.5</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000110465918053383/a18-21149_1ex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease Agreement, dated as of August 20, 2018, by and between Fusco Harbour Associates, LLC, as Landlord, and BioXcel Therapeutics, Inc., as Tenant</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/23/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.6</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837020013632/btai-20200930ex1018d184a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment, dated August 19, 2020, to Lease Agreement, dated as of August 20, 2018, by and between Fusco Harbour Associates, LLC, as Landlord, and BioXcel Therapeutics, Inc., as Tenant</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/12/2020</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.7<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000104746918000756/a2234454zex-10_3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2017 Equity Incentive Plan</span></a> </p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-222990</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/12/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.8<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000104746918000756/a2234454zex-10_4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Incentive Stock Option Agreement under the 2017 Equity Incentive Plan</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-222990</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/12/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.9<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000104746918000756/a2234454zex-10_5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Non-Statutory Stock Option Agreement under the 2017 Equity Incentive Plan</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-222990</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.5</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/12/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837020010611/btai-20200630ex101dd8d33.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">BioXcel Therapeutics, Inc. 2020 Incentive Award Plan and forms of award agreements thereunder</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/14/2020</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.11<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465920064759/tm2020394d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">BioXcel Therapeutics, Inc. 2020 Employee Stock Purchase Plan</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/14/2020</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.12<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000104746918000756/a2234454zex-10_6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnification Agreement with directors and executive officers</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-222990</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.6</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/12/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.13<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000110465918016770/a18-8090_1ex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated March 7, 2018 by and between BioXcel Therapeutics,&#160;Inc. and Vimal Mehta</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/13/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.13.1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465925001869/tm252221d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Employment Agreement, dated January 7, 2025 by and between BioXcel Therapeutics, Inc. and Vimal Mehta</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">01/08/2025</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.14<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000104746918000756/a2234454zex-10_11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated February&#160;12, 2018, by and between BioXcel Therapeutics,&#160;Inc. and Frank Yocca</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-222990</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.11</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/12/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.14.1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465925001869/tm252221d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Employment Agreement, dated January 7, 2025 by and between BioXcel Therapeutics, Inc. and Frank Yocca</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">01/08/2025</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">164</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="4" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:36.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.91%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed/</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Furnished</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.15<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000104746918000756/a2234454zex-10_12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, effective October&#160;2, 2017, by and between BioXcel Therapeutics,&#160;Inc. and Richard Steinhart</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-222990</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.12</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/12/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.15.1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465925001869/tm252221d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Employment Agreement, dated January 7, 2025 by and between BioXcel Therapeutics, Inc. and Richard Steinhart</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">01/08/2025</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.16<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000110465918038902/a18-14962_1ex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated June 1, 2018, by and between BioXcel Therapeutics, Inc. and Dr. Vincent O&#8217;Neill, M.D.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">06/07/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.17<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0001720893/000155837021002916/btai-20201231ex101943a8b.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement between Javier Rodriguez and BioXcel Therapeutics, Inc., dated February 15, 2021.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.19</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/12/2021</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"/></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.18<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465924107327/tm2425903d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Separation Agreement between Matthew Wiley and BioXcel Therapeutics, Inc., dated October 3, 2024.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/09/2024</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.18.1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465924107327/tm2425903d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consulting Agreement between Matthew Wiley and BioXcel Therapeutics, Inc. dated October 8, 2024</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/09/2024</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.19@</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837023008597/btai-20230331xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement BioXcel Therapeutics, Inc. and Vincent O&#8217;Neill, M.D. dated July 1, 2022</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/08/2023</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.20<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837022013353/btai-20220630xex10d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Non-Employee Director Compensation Program</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/11/2022</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.21</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837022007805/btai-20220331xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">BioXcel Trademark License Agreement, between the Company and BioXcel LLC</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/09/2022</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22+&amp;</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837022013353/btai-20220630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Credit Agreement and Guaranty, by and among BioXcel Therapeutic, Inc., Oaktree Fund Administration, LLC, the Subsidiary Guarantors from time to time party thereto and the Lenders from time to time party thereto, dated April 19, 2022</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/11/2022</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22.1+&amp;</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837023018917/btai-20230930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Waiver and First Amendment to Credit Agreement and Guaranty, by and between the Company, the lenders party thereto and Oaktree Fund Administration LLC dated November 13, 2023.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/14/2023</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22.2&amp;</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465924012333/tm244487d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement dated </span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/08/2024</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">165</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="4" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:36.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.91%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed/</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Furnished</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"/><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465924012333/tm244487d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">December 5, 2023, to the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto, and Oaktree Fund Administration LLC, as administrative agent (as amended)</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"/><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"/><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"/><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"/><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"/><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"/></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22.3&amp;</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465924014028/tm244487d3_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Credit Agreement and Guaranty dated February 12, 2024, to the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto, and Oaktree Fund Administration LLC, as administrative agent (as amended)</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/12/2024</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22.4</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837024003784/btai-20231231xex10d224.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Credit Agreement and Guaranty, dated March 20, 2024, to the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto, and Oaktree Fund Administration LLC, as administrative agent (as amended)</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22.4</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/22/2024</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22.5+&amp;</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465924121582/tm2428677d2_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment to Credit Agreement and Guaranty, dated November 21, 2024, to the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto, and Oaktree Fund Administration LLC, as administrative agent (as amended)</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/21/2024</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22.6</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20241231xex10d226.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Sixth Amendment to Credit Agreement and Guaranty, dated March 4, 2025, to the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto, and Oaktree Fund Administration LLC, as administrative agent (as amended)</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">166</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="4" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:36.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.91%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed/</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Furnished</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.23+&amp;</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837022013353/btai-20220630xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Commercial Supply Agreement, between ARx, LLC and BioXcel Therapeutics, Inc., dated April 1, 2022</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/11/2022</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.23.1+&amp;</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837024010967/btai-20240630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1 to Commercial Supply Agreement, between Arx, LLC and BioXcel Therapeutics, Inc. dated July 11, 2024</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/06/2024</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.24@</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465922092973/tm2223745d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC Management Incentive Plan</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/19/2022</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.25@</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465922092973/tm2223745d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Profits Interest Award Agreement under the Management Incentive Plan</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/19/2022</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.26@</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837023008597/btai-20230331xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of RSU Agreement pursuant to the OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC Management Incentive Plan.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/08/2023</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.27+</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465923103556/tm2326812d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Non-Compete Agreement, by and among the Company, Dr. Krishnan Nandabalan, InveniAI LLC, Invea Therapeutics, Inc. and the other parties thereto, dated September 19, 2023.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">09/25/2023</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">19.1</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20241231xex19d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Insider Trading Policy</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21.1</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20241231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of BioXcel Therapeutics, Inc.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23.1</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20241231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Ernst &amp; Young LLP </span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.1</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20241231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.2</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20241231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.1</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20241231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">**</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">167</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="4" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:36.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.91%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed/</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Furnished</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.2</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20241231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">**</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">97.1</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837024003784/btai-20231231xex97d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Policy for Recovery of Erroneously Awarded Compensation</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">97.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/22/2024</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.INS</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline eXtensible Business Reporting Language (XBRL) Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.SCH</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.CAL</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.DEF</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.LAB</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.PRE</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="white-space:pre-wrap;">@    Indicates a management contract or any compensatory plan, contract or arrangement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="white-space:pre-wrap;">+     Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="white-space:pre-wrap;">#     Confidential treatment has been granted for portions omitted from this exhibit and those portions have been separately filed with the Securities and Exchange Commission.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="white-space:pre-wrap;">&amp;    Annexes, schedules, and certain exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant hereby agrees to furnish supplementally a copy of any omitted annex, schedule or exhibit to the SEC upon request.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="white-space:pre-wrap;">*     Filed herewith.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="white-space:pre-wrap;">**   Furnished herewith.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Item16Form10KSummary_689937"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;16. Form&#160;10-K Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">None</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">168</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_765e4ba4_e2f6_42b5_a556_8f30227761ea"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="SIGNATURES_328256"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">BioXcel Therapeutics,&#160;Inc.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dated: March 28, 2025</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">By:</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">/s/ Vimal Mehta</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Vimal Mehta, Ph.D.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dated: March 28, 2025</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">By:</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">/s/ Richard Steinhart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Richard Steinhart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><i style="font-style:italic;">(Principal Financial Officer)</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times';font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times';font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:36pt;margin:0pt;"><span style="font-family:'Times';">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times';font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:38%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:20.05%;margin:0pt;padding:0pt;"></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></th></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;">/s/&#160;Vimal Mehta</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Vimal Mehta, Ph.D.</p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Chief Executive Officer and Director <i style="font-style:italic;">(Principal Executive Officer)</i></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">March 28, 2025</p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;">/s/&#160;Richard Steinhart</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Richard Steinhart</p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Chief Financial Officer <i style="font-style:italic;">(Principal Financial Officer and Principal Accounting Officer)</i></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">March 28, 2025</p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;">/s/&#160;Peter Mueller</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Peter Mueller, Ph.D.</p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Chairman of the Board of Directors</p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">March 28, 2025</p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;">/s/&#160;June Bray</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">June Bray</p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">March 28, 2025</p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;">/s/&#160;Sandeep Laumas</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Sandeep Laumas, M.D.</p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">March 28, 2025</p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;">/s/&#160;Michael Miller</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Michael Miller</p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">March 28, 2025</p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;">/s/ Michal Votruba</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Michal Votruba</p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">March 28, 2025</p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;">/s/ David Mack</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">David Mack</p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">March 28, 2025</p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;">/s/ Rajiv Patni</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Rajiv Patni</p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">March 28, 2025</p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'\007b49\007ebf';line-height:0pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">169</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_7fc6f566_c489_46f8_a1c3_4e714bc00893"></a><a id="Audit_Report"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 4.69pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the Stockholders and the Board of Directors of BioXcel Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have audited the accompanying consolidated balance sheets of BioXcel Therapeutics, Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations, changes in stockholders' (deficit) equity and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">The Company&#8217;s Ability to Continue as a Going Concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has suffered recurring losses from operations, has used significant cash in operations and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management's evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Critical Audit Matter</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the Audit Committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgment. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosure to which it relates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="padding-left:4.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.1%;"><tr style="height:1pt;"><td style="vertical-align:top;width:14.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:82.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">As of December 31, 2023, research and development expenses and accrued research and development expenses includes clinical trial expenses and related accrued clinical trial expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.5pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:14.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Description of the Matter</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">How We Addressed the Matter in Our Audit</i></p></td><td style="vertical-align:top;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Clinical trial expense and related accrued clinical trial expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">As discussed in Note 3 to the consolidated financial statements, at the end of the reporting period, the Company estimates the progress toward completion of the research or development objectives, and depending on the amount and timing of payments to the service providers may record net prepaid or accrued expense for associated research and development costs. As of December 31, 2024, research and development expenses and accrued research and development expenses includes clinical trial expenses and related accrued clinical trial expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">Auditing the Company&#8217;s clinical trial expenses and related accrued clinical trial expenses was complex because the evidence is accumulated from multiple third-party service providers and in certain circumstances, the nature and amount of services that have been rendered during the reporting period does not correspond to the timing and pattern of vendor invoicing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.5pt 12pt 0pt;">To test the clinical trial expenses and accrued clinical trial expenses, our audit procedures included, among others, evaluating the significant assumptions used by management to estimate the clinical trial expenses and testing the accuracy and completeness of the underlying data. To test the significant assumptions, we inspected the Company's contracts with third-party service providers, corroborated the progress of clinical trials and other research and development projects with the Company&#8217;s internal personnel that oversee these activities, and obtained information directly from third-party service providers which included the third parties&#8217; estimates of clinical trial costs incurred to date. We also examined invoices received from vendors and cash disbursements made to third-party service providers subsequent to December 31, 2024 to assess the completeness of the recorded accruals.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Ernst &amp; Young LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stamford, Connecticut</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 28, 2025</p><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'\007b49\007ebf';line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_79cc4a13_af47_4708_be6a_709b42d06d0f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BIOXCEL THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="BALANCESHEETS_688394"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(amounts in thousands, except per share amounts)</b></p><a id="_5ca8df52_6219_44d8_bcae_a98041ff4c46"></a><a id="Tc_8rsUG9QKjE-eTocFcwdH4g_3_2"></a><a id="Tc_P42F07v1cUmyf2pwdPqyZQ_3_5"></a><a id="Tc_srLEievBP0eYQNb_7mTY3Q_4_2"></a><a id="Tc_6_jbRPY_BkqOQOdy4pbQgQ_4_5"></a><a id="Tc_OHelcZNYuUKhwXsk9YvZWg_5_0"></a><a id="Tc_EB7CIe5RgkOqZ3OL2k9QHQ_6_0"></a><a id="Tc_P3AvLeQiuEGRekFwQXGGig_7_0"></a><a id="Tc_QVBAvEJ1BUSRv6WD7U55-w_7_2"></a><a id="Tc_4REoc3qgy0OKsnMN11ChgQ_7_5"></a><a id="Tc_qJGdbVNkT0mQxL1LdRvMGg_8_0"></a><a id="Tc_scdibU-0p0S8SortBMn5_Q_9_0"></a><a id="Tc_Sv2qXJ9Q8UmX72CWvHjW4Q_10_0"></a><a id="Tc_iWsJOhNdpEqHY0sFWU8cBg_11_0"></a><a id="Tc_ZAX_wL-QD0-QI0D34LPatw_12_0"></a><a id="Tc_dGbqSlSmgkCsVq8jDLP2bQ_13_0"></a><a id="Tc_iw0NM44xA0ihpmXi0pknVA_14_0"></a><a id="Tc_z55Ghv06r0-T-J9W7-bbHg_15_0"></a><a id="Tc_ZgtfHey-fEysAggAfnaoYg_16_0"></a><a id="Tc_QXCPvaXHvk6H6Z6bCpVTqQ_16_2"></a><a id="Tc_pU-ADqQxakys3Y_JHceITQ_16_5"></a><a id="Tc_FGY8YHQY8EiDy_bKrYimLA_18_0"></a><a id="Tc_Z8cMqLlb0EKNRXGdqX5pNg_19_0"></a><a id="Tc_U_LSaRtNNU6Msx31ZLV0JQ_20_0"></a><a id="Tc_irth3zWEfE6SmwyqO7h6iQ_20_2"></a><a id="Tc_93YV86AYLEGTjMS5Kqr_GQ_20_5"></a><a id="Tc_fztGAwU0iU2hitlRQJf7Yw_21_0"></a><a id="Tc_3TX9_x4_9UCAPArD5iyFWw_22_0"></a><a id="Tc_WpNIM5IdJUuLrHeoZ5BdZQ_23_0"></a><a id="Tc_FI6QkFeOC0iT-lV7ehARkA_23_3"></a><a id="Tc_gXQCyEmgZUWQHsGvhSH1cg_24_0"></a><a id="Tc_k3B7OiAmSUuIc1ofA6d1vw_25_0"></a><a id="Tc_84eSgGFwLEKBiGa4la-1uw_26_0"></a><a id="Tc_kfye7kIxn0Cvrrwqp_LqWw_27_0"></a><a id="Tc_Lh6ifTlUgUKgEsH3MybP3Q_28_0"></a><a id="Tc_6CpAZu0MOEmRaZFRm3vLaA_29_0"></a><a id="Tc_iY5jgtSi0U61fUvLiGW8JQ_31_0"></a><a id="Tc_M9krWZVB1USEYNmfz9qiBA_32_0"></a><a id="Tc_oI0MMUbo4kq2Xsbdq8z7nA_33_0"></a><a id="_5a5b6730_efdc_4e82_a030_06f6c9b1b6c8"></a><a id="_5a5b6730_efdc_4e82_a030_06f6c9b1b6c8_2"></a><a id="_5a5b6730_efdc_4e82_a030_06f6c9b1b6c8_3"></a><a id="Tc_SnMxc1asD0qn057PjALvjg_34_0"></a><a id="Tc_Y_el7sYfBUmwDd9OUUhlcg_35_0"></a><a id="Tc_WcQsAK94q0ajIoW3Kj5l7Q_36_0"></a><a id="Tc_Fpb6LA7wIUW2eFu_scb30g_37_0"></a><a id="Tc_Fj5MO-hEHk2FeK6WLRbFIg_38_0"></a><a id="Tc_kYD5NOxs2EasuAtj2rB3gw_38_2"></a><a id="Tc_HKU4BL0HzkuSZi-TEev4Zw_38_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_wDn2n51etUCuJWcCE7bwKg_7_3">29,854</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_FSmgQEacqke9UyNi1dAcuQ_7_6">65,221</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts receivable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="Tc_Wx9NwN8rF0OZip_LKgp_6Q_8_3">131</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="Tc_uyXKu9k-pkSevF-Ya5QSiA_8_6">71</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_LOcWeBrW8EqEozjr55xzcg_9_3">679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_hVGxeXTqiUW7EsDMYXQTyw_9_6">1,991</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_rCulIDayAUWL_LZqP_L_Lw_10_3">5,290</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_3kgTo6RGWk2srVHEl9bUFA_10_6">2,782</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_rlVnUiS360CV3c3UynfY9Q_11_3">1,440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_90UrBx45n0G_dVOiyE130A_11_6">2,078</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_1qpoyPuONUyVuvs-IlVZKA_12_3">37,394</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc__BPlloRcPUqXr_U9JMScgQ_12_6">72,143</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_it7Gq6xR8EelYrC8YjtflA_13_3">475</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_7B5L_Z6zZ0evrlgk6ZafDA_13_6">784</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_3fqTos16AkShygwKGWbqeA_14_3">382</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_knExMRmLwEmOSvuiyuzexA_14_6">688</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_a4Nvjl0zwUmHzBegLOwR0g_15_3">87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_66WfEgjV4U6HYPxxlTx-Qg_15_6">87</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_Ak8G1e7wF0OnwPMX5p2CKQ_16_3">38,338</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_oN9dOpdZ9U-yKrMJ_KEJsQ_16_6">73,702</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_M9EZhUGI7EGoEYh2RQ1rhw_20_3">15,990</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_T7t-sPc5HUWEpwhP_wBy_A_20_6">13,654</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_gW0MlG0dpku8PG7qj7Bm_Q_21_3">5,762</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_B-jXinGCUUCtA7n5OdQSMQ_21_6">12,424</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Due to related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_CehH3SOYY0-qk9E4i9FXiA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_Y9KbOoBe4UKs18BF05kvsA_22_3">107</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_q1hbZmrNS0GGTI07xc-mMg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_nTM2_0iEMk6tkKJt5TK1aQ_22_6">107</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_WT6xCQEwkUm3adPP662_LQ_23_6">736</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_vPHQPh73CEuoO2NrgO5-hQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_8jNHqh_QsEOMP2NMaiMn-A_24_3">374</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_0gKxZS-bl0i0rf4ETalC4w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc__A_Wpg8Z6U-yQp0mKmwtHg_24_6">346</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_Bvs0e8AtU0aI4sAwDDcNaQ_25_3">22,233</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_o8YeDKvTckqgXgrfyj4X0g_25_6">27,267</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term portion of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_QLFF2wejAEq9-fHWVB9_pA_26_3">65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_QXrBmpsdkEy49sDM5A4Eiw_26_6">440</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_mtOjvaJIeEmRYYJZQp2Ugw_27_3">6,633</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_zmhR0sY2RkW22ToMvgpTkA_27_6">1,905</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_7Fef2iOPaUCgr6cdHaW-QA_28_3">102,508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_TGihjN5oFkGwdE-CEiwY6g_28_6">100,598</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="white-space:pre-wrap;">     Total liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_7-NCwgwh5UiehLH6RloZHQ_29_3">131,439</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_W8yCHc-3402bRCmq8a49cA_29_6">130,210</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments and contingencies (Note 18)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders' (deficit) equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_OM4CuqL8ikCbAvhml4yNag"><ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_5pjbbjdRr0q4R906uHT_ug">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="Narr_ns6kTW8Np0SnRLs3uAGG8w"><ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="Narr_ZDqiMS5orUWGHE-9bUXsIA">10,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="Narr_1eDx_R2FqkyW760eg-hyhQ"><ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="Narr_ta8J35HBvEas5ZRSIS3wGw">no</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31,&#160;2024 and December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_IIpe6ROVE0uzyVQI76hytw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_QropzL8Q3USNg_pLCNbuTg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_L8SVXDQMiEu3Ljd3oPB1Ag"><ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_cRvaO1GLjE24LkkIE3eaeA">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="Narr_sKbPyXzogkyVd7gZzPPcBw">200,000</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="Narr_ZtUwwVU34UGFWdaZWhcAAQ">100,000</ix:nonFraction> shares authorized as of December&#160;31,&#160;2024 and December&#160;31,&#160;2023, respectively; <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="Narr_lncJZ73D80ORtzNo6R1_lA">3,102</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="Narr_blGOn7ldWkOh1D_bDn7RbQ">1,871</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_7DatXox1g0qQEKSaGo77iw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden__r-eL5w_Z0mc8eX5EelIrQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> as of December&#160;31,&#160;2024 and December&#160;31,&#160;2023, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_9O3mcoILSEeWpfc2TPljhA_34_3">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_xNLfVhXcQUqUeEOD4nHJTg_34_6">30</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additional paid-in-capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_6l12LPTL_Uip9dXQdiGK3A_35_3">557,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_6MY8CRBKU0WefHN4siuY4w_35_6">534,060</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_DRbft5OeD0alWbLcfGbohg_36_3">650,197</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_FKEaSLwTiUKm7GWP8gMnFg_36_6">590,598</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total stockholders' (deficit) equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_uNAR3RTpuUS5ahbe2TeSJA_37_3">93,101</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_LSPYQF50eEqq9nl2o2l1lw_37_6">56,508</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total liabilities and stockholders' (deficit) equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_VoT4_AnPRUy2PXAzWrT0lw_38_3">38,338</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_JC7bpRUO3k6bjAa-0Gyd6g_38_6">73,702</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_1be022ac_e7f4_4f4f_89e6_cb4466a91647"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">BIOXCEL THERAPEUTICS, INC.</p><a id="STATEMENTSOFOPERATIONS_773604"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(amounts in thousands, except per share amounts)</b></p><a id="_7d904eb2_cd1b_452c_b415_1dc164155aa1"></a><a id="Tc_b6aofboxnEmzBDf9URF1Og_1_2"></a><a id="Tc_pPrhRxtwhkeedpvxNff68g_2_2"></a><a id="Tc_3xq7FmAa5062iQ3BDwBxPw_2_5"></a><a id="Tc_Q-yrxShLB06xlEtyg0ryYg_4_0"></a><a id="Tc_gNv0SjNMQ0GOVc14WCUf4w_5_0"></a><a id="Tc_h6FnlYNtsE2YgTOwhoyHAw_5_2"></a><a id="Tc_Utusi_-UDECy3PoRv7L_UQ_5_5"></a><a id="Tc_o7BRW-vviE-Uw-sb7O0qxA_7_0"></a><a id="Tc_18Q3w_MVz0mIzF_sw6P8JA_8_0"></a><a id="Tc_OprcHJjOs02fjgd2BoO0UA_9_0"></a><a id="Tc_NnP4XfuX8EOPLsSbad-OCg_10_0"></a><a id="Tc_tvQSQNr76EC41d-H3_swDg_11_0"></a><a id="Tc_BfEYXPq1aUm4Oh95qU9Bhw_12_0"></a><a id="Tc_Ms4E_-EFrE-3WO-EVmcZeQ_13_0"></a><a id="Tc__VmGisR2tkiBTg4CiMtz6w_14_0"></a><a id="Tc_lf_lqhXCFUaojRq_Es_h6A_15_0"></a><a id="Tc_cBclh5tEZEWUZg6_JoOuYA_16_0"></a><a id="Tc_Ex2WeXM2OEagWIeVpx4WEQ_17_0"></a><a id="Tc_0Q-brPvc5E-_rGpXg9oq7w_18_0"></a><a id="Tc_417C9f66pUOcKErUnk39Ig_18_2"></a><a id="Tc_r4wJeyTYPkG0zuWAL68OiQ_18_5"></a><a id="Tc_cYSV4QMF3UmhA3RKG3Yl5A_19_0"></a><a id="Tc_B4Mk91blZkGLf3R1-laiCw_19_2"></a><a id="Tc_jcITn8hKMkm-V3GI5Xd72Q_19_5"></a><a id="Tc_aBS9fdpZa06lbNojkZXtkw_20_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Product revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc__DRUaMxmF0qCxoNrjEuEow_5_3">2,266</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_g-qtegWCjkujIkV7t31Uug_5_6">1,380</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_M5ui7YXppk2I2HJVnLa2eg_8_3">2,143</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_rDrDHP39nUeSKt0G8CYWbA_8_6">1,260</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_JtKz9xxJyU2JVfkHNUD8eQ_9_3">30,435</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_Nj4jZWCSNk6pJBt9JDK4tA_9_6">84,326</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_lqu6EJneiUe10lYz_cQMLQ_10_3">34,492</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_CSIrpq8PF0mWmE3cXcNRZg_10_6">83,413</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Restructuring costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="3" id="Tc_gU1RFB8SykOfa7aId3p-3A_11_3">2,441</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="3" id="Tc_jEQdYyKJjUKS1CU4LeonIA_11_6">4,163</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_MJPLFbs-zUCY9EVpKvNImA_12_3">69,511</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_b1uyunSyp02RIr5o5gnNfg_12_6">173,162</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_DXlUIO7vkEWDqfR_DHxjTg_13_3">67,245</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_iKxQ6cNwdEi7fa4chuQMRw_13_6">171,782</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other (income) expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" id="Tc_rWK2ejghzUW8mmc22w9VBw_15_3">15,129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" id="Tc_f5mdIHkUZkazeToOnsmceg_15_6">13,314</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_nwkP-HbgWEWTyZDtKA7f5Q_16_3">2,602</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_3qsPkgMKBkekTZhKf9_VJw_16_6">5,649</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other (income) expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_BhQetiGC6E2BG2NIHjUCLA_17_3">20,173</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_PAkUN6XmUUKjVSRuRaHypw_17_6">394</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_x0K6UNZDp0mXuac0fJjcSg_18_3">59,599</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_rygaUMPjlEy9C-gXEzH9UQ_18_6">179,053</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted net loss per share attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_fQCBuA7EaUGiL5YVNxerxQ_19_3">23.51</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_iLx_AVer9k-G-x-tZrQa6Q_19_6">98.33</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares outstanding - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_r_k5fA-XCEamT02Wqxl31Q_20_3">2,535</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_H4GqXKkTd0qn3NqfhaMkcg_20_6">1,821</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_32e42da5_528c_41b8_a8b3_5ff094321931"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">BIOXCEL THERAPEUTICS, INC.</p><a id="STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY_"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; (DEFICIT) EQUITY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(amounts in thousands)</b></p><a id="_40fa7b67_9cfc_4dcd_9a63_d1374915c3a8"></a><a id="Tc_y8_byUo9bkuOX4kDI21Ymw_1_7"></a><a id="Tc_kiX0tQYe4E-OLflYBKTJVg_2_2"></a><a id="Tc__ijUmjNETEaeKb2Du0YelQ_2_7"></a><a id="Tc_FIkxDkU8UE6v4lmDJYZNEg_2_10"></a><a id="Tc_6XnCGMx-uEC1hjjtnSyU0g_3_2"></a><a id="Tc_No4cNtu6WkS3a-I6z7mHCg_3_4"></a><a id="Tc_G3O6y7HSK0q4AmkKPYijvA_3_7"></a><a id="Tc_WXBE_YJOHkGwdQXGw7Vkkw_3_10"></a><a id="Tc_binQCnsbdESIODTN6VcZow_3_13"></a><a id="Tc_oOPuCB-720GzJJ_o0GaTOw_4_0"></a><a id="Tc_B59ntUb7bECvAHKaQMKX6A_4_4"></a><a id="Tc_5hq6qqyoIU6IlRgbe0Zi0g_4_7"></a><a id="Tc_WYqaEoLmtEC1xG4bABHbkA_4_10"></a><a id="Tc_KbaPAQpIVUKf1PInTz9UxQ_4_13"></a><a id="Tc_16pzdMcoAkmTM09-Df09dA_5_0"></a><a id="Tc_-MunEYVbuUuvkqNT_blJIg_5_11"></a><a id="Tc__UdQYuMk3k6wrx6r0g-yWw_6_0"></a><a id="Tc_W4PqyjsfaUmZQwJXSfCyRQ_6_2"></a><a id="Tc_ExEFPJUtFUCKqmkmJIh5xQ_6_5"></a><a id="Tc_t40Y3Yoqm0GKyyfEuJ6XVQ_6_11"></a><a id="Tc_IPhUXbHIdUqLIg25LMDYOg_7_0"></a><a id="Tc_1_F1GYcAWU-xY1onSuh9Ig_7_5"></a><a id="Tc_GHh62bPDvUyhkCve6aGH0w_7_11"></a><a id="Tc_bTlPeVH2SU6HKMpqlTPx2w_8_0"></a><a id="Tc_Gt4c9ZAcbUqFn4XBE6eUMw_8_2"></a><a id="Tc_FHMg1j4nG0-XK90Y8xSySw_8_5"></a><a id="Tc_RDMm_JceXU-F-O3OUgVlig_8_11"></a><a id="Tc_Jujda8fv30-SadgxSbyKTQ_9_0"></a><a id="Tc_zcARQ2b600m3i44yzBiKqw_9_2"></a><a id="Tc_qBoSeoXAx0yIBt3v5-Jkgw_9_5"></a><a id="Tc_sVVG2lsLokyxhC9GCiFguA_9_11"></a><a id="Tc_QJFQkrPxcUmQ_8ppVmEg_A_10_0"></a><a id="Tc_Rb58FzTT90Gxex4_qzIsAg_10_5"></a><a id="Tc_-35pYx4Z8E6kg-ykTEE2nA_10_11"></a><a id="Tc_u3t2F9xuBk2OFO_MqPdAQg_11_0"></a><a id="Tc_7aLs3oMjgkS4YPh_Eo35NQ_11_2"></a><a id="Tc_77NjXHwhsk20YHJw_iB7Pg_11_5"></a><a id="Tc_IBfUsEAxbEqz17-piXvOwA_11_8"></a><a id="Tc_cffXw03M802vr0eWf-S1Cw_12_0"></a><a id="Tc__4sRPqR1YEmTuU0XH5MjhA_12_4"></a><a id="Tc_2s5TkXPeME2n3r4edfh1jw_12_7"></a><a id="Tc_cLLN3keB0kif0lN_aV40rw_12_10"></a><a id="Tc_hZn8XkI-0U-x3RThH9Gh3A_12_13"></a><a id="Tc_TPtd9zJLzU-1DkuFfjL2Eg_13_0"></a><a id="Tc_Ud8deDjKvkKeg1TNtKOeVw_13_11"></a><a id="Tc_W8xNTlvYF02yqyi-0rtW8A_14_0"></a><a id="Tc_OrsjvQKXf0CPofVhy0Z12g_14_2"></a><a id="Tc_5C9bKkCEFEeVBdmFtVMsfw_14_5"></a><a id="Tc_poK-NYlW0k6cxRvASI72tQ_14_11"></a><a id="Tc_HjL05DuiVU2A3Rfj7OlBIA_15_0"></a><a id="Tc_sxxosXkpsU6LpkmW54pmRw_15_2"></a><a id="Tc_FGBskYcI00iNYGHfST-wzQ_15_5"></a><a id="Tc_nlBo56H3jkuem4UVRfOmJQ_15_11"></a><a id="Tc_5yubC2_1PUiKxT-suEi93Q_16_0"></a><a id="Tc_grlcV9l9bUGuQXYaKVCGVg_16_2"></a><a id="Tc_Ka7rwlIbn0Oy4uu0l1hPSg_16_5"></a><a id="Tc_J3CoUFcbxEqJ_7rD6LtvaA_16_11"></a><a id="Tc_UuFmAmqTFUKV3XUoDcAM2Q_17_0"></a><a id="Tc_OS_zaLOTpUen5zUVJy4kJQ_17_2"></a><a id="Tc_VGn94i9j50iRBXr1TA8SSQ_17_5"></a><a id="Tc_3y-Rd7tshk-8n0--oszjZA_18_0"></a><a id="Tc_37bh4efKPEa9te5Z2UITYA_18_5"></a><a id="Tc_747UafmcdEOXnzFbqeX5xw_18_11"></a><a id="Tc_Wwr3IGjxIE68n7qZtvkLig_19_0"></a><a id="Tc_u-JYrTdi-EWLCOiYIwWGuw_19_2"></a><a id="Tc_Za76EcPNFUKnOhI0zua5pw_19_5"></a><a id="Tc_9KmCLO35F06r-Hm7Th0CJA_19_8"></a><a id="Tc_FtFsvowH4k2ICwBKXtTeNg_20_0"></a><a id="Tc_ZY4nP1gUUUqhZGlXSfxsXg_20_4"></a><a id="Tc_BjjLcByMAkmbiWhgW-4sDQ_20_7"></a><a id="Tc_qN8vcSOu7kaJSKmKGGOMqQ_20_10"></a><a id="Tc_IvxkBFIuuUC95CTXlQEY9Q_20_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance as of January 1, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WhUd_ZOlBUmqQn-nMAVDoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="Tc_SD-K-vdmPkmqVpTYF5PDAg_4_2">1,759</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WhUd_ZOlBUmqQn-nMAVDoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_YyjfrstR7E-lvf3zGH6FYQ_4_5">28</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QQDsQgcnEkyWGJT2fjUW4Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_KjeYjhShJUyp2CUTw1hkWQ_4_8">488,292</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2OE8-Puy-k62aulMwMTDvg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_4wnvvl432Ei94OWpXPV-_g_4_11">411,545</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2022_jhStatqo5EaSoSvdA9RW0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_9ke2M_kdck-bTdK7HYND4Q_4_14">76,775</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:44.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Issuance of common stock, net of offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gdYMQB6xIEGwPzlcPnEPVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Tc_9gkd_-q-h0eRVk0jhNzKGw_5_2">88</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gdYMQB6xIEGwPzlcPnEPVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_8NIhAKk9OU2ESBPVdXI6sA_5_5">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0DAGDztWUkKwXUglANCasg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_Cbe200upiUqUgWeKKKG7iQ_5_8">26,219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_8LpAsR4m2ku5YPowz1CA1w_5_14">26,221</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0DAGDztWUkKwXUglANCasg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_hMz3p6A0jUCucu-Loxbm4w_6_8">18,614</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_P3bEk81xUkWrwrfKzJKGoQ_6_14">18,614</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gdYMQB6xIEGwPzlcPnEPVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_AnOf7Y5RmU-VqwZIwnMV6A_7_2">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0DAGDztWUkKwXUglANCasg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_9CrOyNzF_E-02MabGfWOiw_7_8">508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_PYMyNEc6CUWWzyLq4ZKqEQ_7_14">508</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Repricing of stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0DAGDztWUkKwXUglANCasg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" scale="3" id="Tc_4BkgoPJ3CEurBwxkJMifYg_8_8">254</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" scale="3" id="Tc_uWEfvFxM5068Ay1tH2x6GQ_8_14">254</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Issuance of stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0DAGDztWUkKwXUglANCasg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_5cZ4gy4osEKPYU-3_b8EvQ_9_8">200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_2qRyfMNrm0OIOFvw-N0sLA_9_14">200</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Vesting of restricted stock units, net of employee tax obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gdYMQB6xIEGwPzlcPnEPVA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" scale="3" id="Tc_ctB_kWHU60KlbZNr43u0Sw_10_2">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0DAGDztWUkKwXUglANCasg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" sign="-" scale="3" id="Tc_f9QM71w3O0yuWTn7SahtZQ_10_8">27</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" sign="-" scale="3" id="Tc_LWV88Pq7HEGF1D-oc_0NwQ_10_14">27</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oXWwEn3ERUe7z06ZWkBHXA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_LmaZVA23r0uKp6_oOyKIvA_11_11">179,053</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_pGmrOQXZv0CaY7hPHoBXIw_11_14">179,053</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance as of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tk2nuQrdU0uVZYuijUkSUA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="Tc__TqgxHUzfEGfBdkseFfYOw_12_2">1,871</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tk2nuQrdU0uVZYuijUkSUA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_WjO2lUfeD06LFyVbzmRefw_12_5">30</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gi1gHYnNBk66zzB63nP9Xg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_cKtj3vhvOUGfRADRppRjTg_12_8">534,060</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6eSNIlZJN0KWpLFkIG2zfw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_6kbeMNBQDEGGKgzEOBInhg_12_11">590,598</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_ub53iDpYjE2gchvfBzIlJQ_12_14">56,508</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Issuance of common stock, net of offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aq06NwagjEu8lcUy9jbLbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Tc_fqp6NtAhE0SC6sTPqAW6Jw_13_2">1,209</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aq06NwagjEu8lcUy9jbLbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_h2V6iaOW0k2N3yzteQgfAQ_13_5">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IE4SFBMuyECxTHM_3bnLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_9BvmRlzVAEyZ__TQmkm5_Q_13_8">9,907</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_INhPPGOvGU-vSbsxrzOHbg_13_14">9,926</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IE4SFBMuyECxTHM_3bnLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_g5ohsxcbkU-TyO1rjC6nDw_14_8">6,156</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_ELJ7UccM1EG4fjF_Wl1RsQ_14_14">6,156</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Issuance of stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IE4SFBMuyECxTHM_3bnLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_A6RsqA672kyw1xWVb_cqyg_15_8">2,540</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_scjv-xJ9mkC_mrksSABAWg_15_14">2,540</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Repricing of stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IE4SFBMuyECxTHM_3bnLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" scale="3" id="Tc_6vZQ6jiXPk2Bcqla4PEMKg_16_8">59</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" scale="3" id="Tc_4AM_HelPxE6oUA5T9zOLnw_16_14">59</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Issuance of pre-funded stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IE4SFBMuyECxTHM_3bnLDw" decimals="-3" format="ixt:num-dot-decimal" name="btai:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" scale="3" id="Tc_tTglCQ5UAEiIQGHSyozCgg_17_8">4,379</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="btai:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" scale="3" id="Tc_6aCezCO2l06jOcLcfn4dDA_17_14">4,379</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Vesting of restricted stock units, net of employee tax obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aq06NwagjEu8lcUy9jbLbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" scale="3" id="Tc_mP-yIj7fs066P6Xg8jqIcQ_18_2">22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IE4SFBMuyECxTHM_3bnLDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" sign="-" scale="3" id="Tc_BdwnH8Wvrk6vNw0s01ahyA_18_8">54</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" sign="-" scale="3" id="Tc_jjKI6dwYA0u-hp4OK3zJ_Q_18_14">54</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E9MLp3OJ8EufrFv1jvE6sw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_FbbTJTUs-EuKN0TzLu4Vcg_19_11">59,599</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Yya2HamnQ06e1Sov7Azzfw_19_14">59,599</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance as of December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uVBBMguAlEqRZE6UprsHRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="Tc_kASOo1R_AEGmekm9MawLQw_20_2">3,102</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uVBBMguAlEqRZE6UprsHRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ZryX6dz2kkOAqCQyhNMtpQ_20_5">49</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JBhziCHFEUu1-FicgIwmyA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_RHNZUmAky0KNc9Fi52wWbA_20_8">557,047</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mVjyx3cGLEy1gJnnx6T0VA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_GmizxBLxv0CBeG0NreA4IA_20_11">650,197</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_FB0AIPkyL0CG2D4o7jBYXw_20_14">93,101</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_6ba715bc_3085_4f17_af4b_d8841b33acdf"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">BIOXCEL THERAPEUTICS, INC.</p><a id="STATEMENTSOFCASHFLOWS_770795"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(amounts in thousands)</b></p><a id="_df2869d6_2136_4086_83bf_410edcbe9eb5"></a><a id="Tc_r5goUOUn_kGhKDC8C4jZVg_1_2"></a><a id="Tc_T4m68Wl4okybh7DQv1LQww_2_2"></a><a id="Tc_YHCd6ua8Y0u7swT3ufViJQ_2_5"></a><a id="Tc_xZ2P2D-h9EqWm7_bhus_SA_3_0"></a><a id="Tc_viIqUePsykaIiuQelU4mIg_4_0"></a><a id="Tc_6rUXKsmdfEmiiN-0kJJxxQ_4_2"></a><a id="Tc_CNp0ymLUzkeKfLuiWMvQ5w_4_5"></a><a id="Tc_HXaCqo956ke6a0IJNNuVIA_5_0"></a><a id="Tc_rSi0nRfk4kCVF_WhU26leQ_6_0"></a><a id="Tc_10vDAY65f0ihUm_zgjfQ4w_7_0"></a><a id="Tc_Yfyfm0UmAUq_ch7_CzcbxQ_8_0"></a><a id="Tc_JmpKfEsY9U2rt0ysHNaNsg_9_0"></a><a id="Tc_5kBaawXZMUSBxPI7rEEdQA_10_0"></a><a id="Tc_wi-jiQujZ0aXOTkpFInLCA_11_0"></a><a id="Tc_JTW1jPEAoUGWCJ6X4z0oWw_11_3"></a><a id="Tc_CejC6VEKDECP_akPPwcqLA_12_0"></a><a id="Tc_hikhl43oD0yeigAiZ4VP8w_13_0"></a><a id="Tc_wZZ3_PaxJUW2k7zCEfX8TA_14_0"></a><a id="Tc_Kcfg5tihdEihCZklSGb2bg_15_0"></a><a id="Tc_8G71x7nDu0eW2SYPmsA8kg_16_0"></a><a id="Tc_R20Z0PsZdEiGW33XJv_Rhw_17_0"></a><a id="Tc_2by2oWPfbEKUe3Khn4Leaw_18_0"></a><a id="Tc_WBMfGNzkG0S6loKxAb_9qQ_19_0"></a><a id="Tc_2uGrKCwdv02p1coCU2tveA_20_0"></a><a id="Tc_TfmvX8Mgo0W7dDpWDtyNoA_22_0"></a><a id="Tc_4ZJZvzGkZkKsUbdbaCOoxg_23_0"></a><a id="Tc_Fuj-mw5O6E2_jZC4mmzaVQ_23_3"></a><a id="Tc_a0R6Plfzhkaxc9NykmD1_g_24_0"></a><a id="Tc_OVP_lToSZ06ZVWk3rkfihw_24_3"></a><a id="Tc_mzZBi2ssEkCQn6nxfp2baQ_26_0"></a><a id="Tc_lgnVHFT5y0GuUPJ3V733Ag_27_0"></a><a id="Tc_-uge1lSpoEOPeFk8YL-Urg_28_0"></a><a id="Tc_FHaxAcvIyUCZFu3zPOxpMA_28_3"></a><a id="Tc_tgowfc_sJESbo5yzPAFo1g_29_0"></a><a id="Tc_JeXvVYkDmkySLWDIwQqHfg_29_6"></a><a id="Tc_gHxlZsvgqUCWwXjnszu_kA_30_0"></a><a id="Tc_TkVpLMWHl0yh8MQvBU4FnQ_31_0"></a><a id="Tc_2NQteF6HnkaHigIIl_yDWg_32_0"></a><a id="Tc_ZV0gsQRE2k63nzHED0R4-g_32_3"></a><a id="Tc_3hDQ5-bP3USHK47i4xyWvw_33_0"></a><a id="Tc_lHi1o1sZKkGI_Njl2JZD1Q_35_0"></a><a id="Tc_FcOmgI-ItkmxHzqBgv7FmQ_35_2"></a><a id="Tc_aNo3hOlSSkyrW0zD26YtLw_35_5"></a><a id="Tc_4IdxlzXqRUWOHuE4vJWwTA_36_0"></a><a id="Tc_lUVkuWDrwUmvJ5RymaIpZQ_37_0"></a><a id="Tc_U8NSPrIXHkeeOEaJZ1I35g_37_2"></a><a id="Tc_jy7dETzV3UK6hXEaNw1wsg_37_5"></a><a id="Tc_141958ng-0ijFA9T5iJZjQ_39_0"></a><a id="Tc_dOQcHkzqiESBw1IRdIlKig_40_0"></a><a id="Tc_tE56MXjL-k-qFFNwGk8-Ng_40_2"></a><a id="Tc_2KVJkrE_1E2kDcQwFIm41Q_40_5"></a><a id="Tc_hzlCVCyDfEC4X0nNh39wzw_41_0"></a><a id="Tc_k9_Zwozs0UGYJjUNlzoOfw_41_2"></a><a id="Tc_vXGbPb9BVkSYzxx8QhKoWw_41_5"></a><a id="Tc_BxOmaDuzskyPOATMTaqd_A_42_0"></a><a id="Tc_khkxwNm0hUCu8pRd6jp43Q_42_2"></a><a id="Tc_eKcKOIdHrEeCUM3CRKE-vQ_42_5"></a><a id="Tc_jJZCCjDoH0-N7iyG4V03_A_43_0"></a><a id="Tc_EDT42wGH_0aaIamHKNQ5-g_43_2"></a><a id="Tc_ElvfuwmvRkCv6VI71q9PeA_43_3"></a><a id="Tc_QFTrN0vlMEiAzy73iMxxGQ_43_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OPERATING CASH FLOW ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_NPXlII4cf0mzKjsDVPl1bQ_4_3">59,599</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_PVP9Uf5FgEOEAt7lfkjS4Q_4_6">179,053</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Reconciliation of net loss to net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_YDIPajfnfkaSg65yC3hrHg_6_3">309</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_Ju8E22o_vECZq2KmmLw18g_6_6">318</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accretion of debt discount and amortization of financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_0LB6Z04JTEGnRIfL3AI1og_7_3">467</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_vT3zvaBUx0280BW5SjbGNQ_7_6">1,373</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of derivative liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_z3V5OGt2jEi5vICNWXaLZA_8_3">20,180</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_HmPu-ezXbkiK1njSwTkh0w_8_6">438</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_dVJkP8AGTkqVE0EvSiXo5w_9_3">6,156</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_UCTEbD3Jjk6vWlGqB0Azgg_9_6">18,614</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Payable-in-kind interest on Credit Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaidInKindInterest" scale="3" id="Tc_j2m1o7VKi0Wt0YnE2G39cw_10_3">6,543</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaidInKindInterest" scale="3" id="Tc_dQ0vejjH80akm5HBfxXMFA_10_6">1,872</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Loss on disposal of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="3" id="Tc_wwS9kThs5kKediq3dyObtA_11_6">2</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_LelWDZsPIE6apsCUfCsj6w_12_3">306</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_rOtalHdbck-cNiKYL7T0Ow_12_6">288</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Changes in operating assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="white-space:pre-wrap;">   Accounts receivable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="3" id="Tc_piKo2GVdxU2V0iFv8wgX7g_14_3">60</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" sign="-" scale="3" id="Tc_cXtTQWimGEO5MxsuJbHRZQ_14_6">177</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc_ygpe8_wScECCCfUE_eABVQ_15_3">1,312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_M9YSJ-Y9bEWa0PwvV3gU_A_15_6">6</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Prepaid expenses, other current assets and other assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_jgXjyF7NM0GhE1As7eTrmw_16_3">1,872</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_LDZnTgWOxkG-z7SLC3HdWg_16_6">2,888</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accounts payable, accrued expenses, due to related parties, and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_LlhJY5316EWzlFx4FqlR1w_17_3">4,327</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_K3RmUyF1_ECAs06KjNp9pQ_17_6">3,219</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInterestPayableNet" sign="-" scale="3" id="Tc_TIVXgdEmmkyrQ-S3rlSbKQ_18_3">736</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="3" id="Tc_VePVpZte4U-pw1CmWkz6_g_18_6">2,497</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_fcF-k6o4PkyeSpnFsKv1ww_19_3">346</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_YkZxIviQl0SHy-pyuI882w_19_6">319</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_ORDREqeU_kS-uru2ObC4jA_20_3">72,027</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_7auEB7nnBEuTjUqMfWXdlQ_20_6">155,006</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">INVESTING CASH FLOW ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Purchases of equipment and leasehold improvements </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_VBwODVTZmU-QsSelfLnLnw_23_6">20</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash from investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_a1THV5mJGkiG3-oZGUYCVA_24_6">20</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">FINANCING CASH FLOW ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of common stock and warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Tc_MQ1buLidQkKeMB63lBKOdA_27_3">39,688</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Tc_E6F2UrHC5EeS1WDAwuehkA_27_6">27,032</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Debt Issuance Costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="Tc_OxX-Q_9Z3EOtoWpbcIJwyA_28_6">180</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Payment of principal of Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="Tc_n011BKLqAU6UYApAt_tk4A_29_3">2,500</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Offering costs for common stock and warrants issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_2hKVRxhjEE-zZv1xfOrZvg_30_3">474</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_5SDu9yUVLEu7b5jUz4tsWw_30_6">811</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Payment of employee tax obligations related to vesting restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_gz8ujaGf4UepyHOQSNXO6Q_31_3">54</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_HjdrIcY9Z0yXmHUjMEj7lQ_31_6">27</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_22VykyxxMEu0P9RcabN-Vg_32_6">508</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_lGsdgsdBK0ib5V2X_4a4Tw_33_3">36,660</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_k_N3Szc3MUqGMORULACs8Q_33_6">26,522</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net decrease in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_-ul54TSijEGwLDFG2pCOcg_35_3">35,367</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_vMv4Nq9pokmoOf7IUhnaNQ_35_6">128,504</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents, beginning of the&#160;period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_banP-UBuiUGYVVnVUhOBew_36_3">65,221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2022_jhStatqo5EaSoSvdA9RW0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_sjcYvGd2f0yg71IhlR-VLA_36_6">193,725</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents, end of the&#160;period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_p8Sc7emTKEOqdci9B2CECQ_37_3">29,854</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_eXVD-qyXGE2tp9Z15IOeMA_37_6">65,221</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental cash flow information:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Issuance of stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="btai:FairValueStockPurchaseWarrants" scale="3" id="Tc_sdGz0KqF50qjMPkNrjPmSg_40_3">2,540</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:FairValueStockPurchaseWarrants" scale="3" id="Tc_BzkXsToZAU2cUpAIERREcw_40_6">200</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Repricing of stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="Tc_CiPqX7uSp0WWM-7ggb6-0w_41_3">59</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="Tc_moC3X-HKvUyGul9H1DGFVQ_41_6">254</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_8F7UCu-FIkWt-DnVe_4McA_42_3">7,968</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_S7kh_Dm340miFn5MW18jsA_42_6">7,551</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Conversion of accrued interest to long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:ConversionOfAccruedInterestToLongTermDebt" sign="-" scale="3" id="Tc_hU0Z7rNDzU-u4VVNG32NRw_43_6">767</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e3f8bb70_30b1_4969_8519_869f20de3d80"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">BIOXCEL THERAPEUTICS, INC.</p><a id="NOTESTOFINANCIALSTATEMENTS_564668"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(amounts in thousands, except per share amounts and where otherwise noted)</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:NatureOfOperations" id="Tb_b2EBZSxDbUatlKdXxP0iHA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;1. Nature of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BioXcel Therapeutics, Inc. (&#8220;BTI&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company utilizing artificial intelligence (&#8220;AI&#8221;) approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company is focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients&#8217; lives. BTI employs a unique AI platform to reduce therapeutic development costs and potentially accelerate timelines. The Company&#8217;s approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI management believes this differentiated approach has the potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As used in these consolidated financial statements, unless otherwise specified or the context otherwise requires, the terms &#8220;BioXcel LLC&#8221; refers to the Company&#8217;s former parent and current significant stockholder, BioXcel LLC and, its predecessor, BioXcel Corporation. &#8220;OnkosXcel&#8221; refers to BTI&#8217;s wholly owned subsidiary for its advanced immuno-oncology assets, OnkosXcel Therapeutics, LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April 6, 2022, BTI announced that the United States (&#8220;U.S.&#8221;) Food and Drug Administration (&#8220;FDA&#8221;) approved IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (dexmedetomidine or &#8220;Dex&#8221;) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is approved to be self-administrated by patients under the supervision of a health care provider. On July 6, 2022, BTI announced that IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, was commercially available in doses of 120 and 180 micrograms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s most advanced clinical development program is BXCL501. In indications other than those approved by the FDA as IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, BXCL501 is an investigational proprietary, orally dissolving, film formulation of Dex for the treatment of agitation associated with psychiatric and neurological disorders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s advanced immuno-oncology asset, BXCL701, is an investigational, orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment na&#239;ve to checkpoint inhibitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI was incorporated under the laws of the State of Delaware on March 29, 2017. The Company&#8217;s principal office is in New Haven, Connecticut.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_y1Zc7t9nykGULModqYlIYQ" continuedAt="Tb_y1Zc7t9nykGULModqYlIYQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;2. Basis of Presentation</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_8DWbtQZfJEKLZbqij2-2ww" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements include those of the Company and its subsidiaries after elimination of all intercompany accounts and transactions and have been prepared in conformity with United States (&#8220;U.S.&#8221;) Generally Accepted Accounting Principles (&#8220;GAAP&#8221;).</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2024, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Narr_Fs4zfcqSDUalFhudCTd5CA">29,854</ix:nonFraction> and an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Narr_cKHh4VSP8kqaVtsSJNHUwA">650,197</ix:nonFraction>. BTI has incurred substantial net losses and negative cash flows from operating activities in nearly every fiscal period since inception and expects this trend to continue for the foreseeable future. The Company recognized net losses of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Narr_L-q2_ays6kOnCGQGZw_9Fg">59,599</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Narr_ImI6IKc-cUKyf0QZoALZSQ">179,053</ix:nonFraction> for the years ended December 31, 2024 and 2023, respectively, and had net cash used in operating activities of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Narr_uo6BSIkqG0eneOy0Qv5vyw">72,027</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Narr_5jMGOEVSOUyO8PIVVNuJUQ">155,006</ix:nonFraction> for the years ended December 31, 2024 and 2023, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under ASC Topic 205-40, Presentation of Financial Statements - Going Concern, management is required at each reporting period to evaluate whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_y1Zc7t9nykGULModqYlIYQ_cont1" continuedAt="Tb_y1Zc7t9nykGULModqYlIYQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s history of significant losses, its negative cash flows from operations, potential near-term increased covenant-driven amortization payments under its Credit Agreement, its limited liquidity resources currently on hand, and its dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, have resulted in management&#8217;s assessment that there is substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of at least 12 months from the issuance date of the financial statements included in this Annual Report on Form 10-K. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">This going concern evaluation takes into consideration the potential mitigating effect of management&#8217;s Reprioritization (as defined in Note 4, Restructuring). When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered probable of being effectively implemented, the plans need to be approved by the Company&#8217;s Board of Directors. The Company&#8217;s Reprioritization was approved by the Board of Directors on August 8, 2023; however, such plans, including the additional restructuring actions taken in the second and third quarters of 2024,  will not mitigate the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business and does not include any adjustments that may result from the outcome of this uncertainty. The going concern analysis does not consider possible future amendments to or restructuring of the Credit Agreement (as defined in Note 9, Debt and Credit Facilities) or other potential sources of debt or equity capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to support the Company&#8217;s cost structure and operating plan. Management&#8217;s plans to improve the Company&#8217;s liquidity and reduce its operating expenses and capital requirements include, among other things, pursuing one or more of the following steps to raise additional capital, none of which can be guaranteed or are entirely within the Company&#8217;s control:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>raise funding through the sale of the Company&#8217;s equity securities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>raise funding through third-party investments in or other strategic options for OnkosXcel;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>raise funding through debt financing and/or restructuring of its existing OFA Facilities; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>establish collaborations with potential partners to advance the Company&#8217;s product pipeline;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>establish collaborations with potential marketing partners;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>reduce overhead and headcount to focus on core priorities; and/or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>any combination of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If the Company is unable to raise capital when needed or on acceptable terms, or if it is unable to procure collaboration arrangements to advance its programs, the Company would be forced to discontinue some of its operations or develop and implement a plan, beyond its Reprioritization initiatives, to further extend payables, reduce overhead, scale back or cease some or all of its revised operating plan until sufficient additional capital is raised to support further operations. </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_y1Zc7t9nykGULModqYlIYQ_cont2"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_Vxw582losEGMk5tlVjsqZg" continuedAt="Tb_Vxw582losEGMk5tlVjsqZg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;3. Summary of Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:UseOfEstimates" id="Tb_5g1rXGgsz020SIKHUQ3klw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the consolidated financial statements and notes thereto. Estimates are used in the following areas, among others: revenue recognition, inventory valuation, derivative liabilities, stock-based compensation expense, accrued expenses and income taxes. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="btai:ReverseStockSplit" id="Tb_hESLlgQl5k-ThHhHerbhsQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On February 10, 2025, the Company completed a <span style="-sec-ix-hidden:Hidden_MAC978-QcU6PY1cLIWQ4hg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1-for-16</span></span> reverse stock split of its issued and outstanding common stock (the &#8220;Reverse Stock Split&#8221;). As a result of the Reverse Stock Split, each 16 shares of common stock issued and outstanding immediately prior to February 10, 2025 were automatically converted into one of a share of common stock. The Reverse Stock Split affected all common stockholders uniformly and did not alter any stockholder's percentage interest in the Company's equity, except to the extent that the Reverse Stock Split would result in a stockholder owning a fractional share. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise would be entitled to receive a fractional share instead were entitled to receive cash in lieu of such fractional share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Reverse Stock Split did not change the par value of the common stock or the authorized number of shares of common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">All common share and per-share amounts in this Form 10-K have been retroactively restated to reflect the effect of the Reverse Stock Split.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_G9o9t0Qh0k67SLrqA4M1Aw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of December 31, 2024 and 2023, cash equivalents were comprised primarily of money market funds. Cash and cash equivalents held at financial institutions may at times exceed federally insured amounts. BTI management believes it mitigates such risk by investing in or through major financial institutions.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="Tb_KHPbwTe2w0igfsywezL1yg" escape="true"><p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Accounts Receivable, Net</b></p><p style="font-family:'Liberation Serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Accounts receivable arise from sales of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">IGALMI</span><sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"> and represent amounts due from distributors. Payment terms generally range from </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_eSrtMnrTnkmoVkWywMsDcQ" format="ixt-sec:durday" name="btai:AccountsReceivablePaymentTerm" id="Narr_gwH8SeDJWkCJPRD9dcAHuQ"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">30</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"> to </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_WO_5QqewW0WCAmc5bwIHMA" format="ixt-sec:durwordsen" name="btai:AccountsReceivablePaymentTerm" id="Narr_xjUbxg9zGU6IZAogykeSKQ"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">75 days</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"> from the date of the sale transaction, and accordingly, do not involve a significant financing component. Receivables from product sales are recorded net of allowances which generally include distribution fees, prompt payment discounts, chargebacks, and credit losses. Allowances for distribution fees, prompt payment discounts and chargebacks are based on contractual terms. The Company estimated the current expected credit losses of its accounts receivable by assessing the risk of loss and available relevant information about collectability, existing contractual payment terms, actual payment patterns of its customers, individual customer circumstances, and reasonable and supportable forecast of economic conditions expected to exist throughout the contractual life of the receivable. Based on its assessment, as of December 31, 2024, the Company determined that an allowance for credit losses was not required.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_WCRAb3QpE0yKTPnIi60dsQ" escape="true"><p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Concentrations of Credit Risk</b></p><p style="font-family:'Liberation Serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Company sells IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';"> through a drop-ship program under which orders from hospitals and similar health care institutions are processed through wholesalers, but shipments of the product are sent directly to the individual hospitals and similar health care institutions. BTI also contracts directly with intermediaries such as group purchasing organizations (&#8220;GPOs&#8221;). All trade accounts receivables are due from the distributor that fulfills orders on behalf of the Company.</span><span style="font-family:'Times New Roman','Times','serif';"> For the years ended December 31, 2024 and 2023, one customer accounted for approximately </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_btai_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_W_hOEF0UGE6XdSlHUL5Rsw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_ANW2_yuB9EaYNNx-h1SZ0w">32</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_btai_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_5C4QWry9fk6gmoPexiMApw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_mJ5Bi097NEaVxDHrmmBH8w">39</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';"> of the Company&#8217;s net product revenue, respectively. </span></p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_0c3ae8bf_0e34_45f9_84ae_7a0727287831"></a><a id="Tc_xD5ZpxPL8ECg-POPgoEooQ_1_0"></a><a id="Tc_vOPPdDSoA0mknvR_Tmxikw_1_1"></a><a id="Tc_oH5iyVs9h02ROVtzyMJEsg_2_0"></a><a id="Tc_J_SY1N-ZSk6k27mj8PSl7A_3_0"></a><a id="Tc_PvF2e4dBp0O_bFnNA25XPA_3_1"></a><ix:continuation id="Tb_Vxw582losEGMk5tlVjsqZg_cont1" continuedAt="Tb_Vxw582losEGMk5tlVjsqZg_cont2"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:InventoryPolicyTextBlock" id="Tb_2ntKSYA_ok6gwcA7muIQ0Q" escape="true"><p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Inventory</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or net realizable value. Cost of inventory is determined on a first-in, first-out basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">BTI capitalizes inventory costs associated with the Company&#8217;s products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development expense in the Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, will be recorded within Cost of goods sold in the Consolidated Statements of Operations. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected, write-downs of inventory may be required.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="btai:DeferredOfferingCostsPolicyTextBlock" id="Tb_Xb2ynxG2Z06UZjcc_ERtnQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Deferred Initial Public Offering Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Deferred initial public offering costs of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="3" id="Narr_RqyGVl2LSES2zgoTt9Jkgg">2,570</ix:nonFraction>, consisted of legal, accounting, and other costs that were directly related to the Company&#8217;s proposed initial public offering of OnkosXcel. These costs were charged to the Consolidated Statements of Operations during the year ended December 31, 2023 as the initial public offering was delayed for an extended period of time. The costs were recorded as Selling, general and administrative expenses. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_4YG4IP4P706I8QygkVDYKA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Property and equipment are recorded at cost and depreciated over the shorter of their remaining lease term or their estimated useful life on a straight-line basis as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="btai:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" id="Tb_za4Bqbh_CEytdwSYVhzBPg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:2.15pt;"><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Equipment</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember__lhd_4aX8kyoPoUbqHBE0A" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_rshY3B3M6k-VFmAv9TtYYQ">3</ix:nonNumeric>-<ix:nonNumeric contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_MsiOU9Br5ESWVEwY_A5X2w" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_Eho9Tl-y3E-S3iMeZZ1WxQ">5 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Furniture</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_bGkvra2V9Ue26IMBxqrCww" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_WsiIVQj4bEmetxBd_UAGHw_2_1">7 years</ix:nonNumeric></p></td></tr><tr style="height:13.1pt;"><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">Lesser of life of improvement or lease term</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Expenditures for maintenance and repairs which do not improve or extend the useful lives of the respective assets are expensed as incurred. When assets are sold or retired, the related cost and accumulated depreciation are removed from their respective accounts and any resulting gain or loss is included within Other (income) expense, net in the Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to undiscounted future net cash flows expected to be generated from its use and disposition. Impairment charges are recognized at the amount by which the carrying amount of an asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_e4g6Ns5NN0em99G-4SpDhQ" continuedAt="Tb_e4g6Ns5NN0em99G-4SpDhQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, other current liabilities, and the long-term portion of operating lease liabilities in the Consolidated Balance Sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">ROU assets represent BTI&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses the implicit rate when readily determinable. As BTI&#8217;s leases do not provide an implicit rate, it used an incremental </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_Vxw582losEGMk5tlVjsqZg_cont2" continuedAt="Tb_Vxw582losEGMk5tlVjsqZg_cont3"><ix:continuation id="Tb_e4g6Ns5NN0em99G-4SpDhQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any prepaid lease payments made and is reduced by lease incentives. The Company&#8217;s leases may include options to extend the lease; such options are included in determining the lease term when it is reasonably certain that BTI will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:DebtPolicyTextBlock" id="Tb_Ly9jnhFfOEKGH079vCR8GQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Debt and Detachable Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Detachable warrants are evaluated for classification as either equity instruments, derivative liabilities, or liabilities depending on the specific terms of the warrant agreement. In circumstances in which debt is issued with equity-classified warrants, the proceeds from the issuance of debt are first allocated to the debt and then the warrants at their estimated fair values. The portion of the proceeds allocated to the warrants are accounted for as paid-in capital and a debt discount. The remaining proceeds, as further reduced by discounts created by the bifurcation of any embedded derivatives, are allocated to the debt. Detachable warrants classified as derivative liabilities are accounted for as indicated under &#8220;<i style="font-style:italic;">Derivative Assets and Liabilities</i>&#8221; section of this Note and as a debt discount. The Company accounts for debt as liabilities measured at amortized cost and amortizes the resulting debt discount from the allocation of proceeds to interest expense using the effective interest method over the expected term of the debt instrument. The Company considers whether there are any embedded features in debt instruments that require bifurcation and separately accounts for them as derivative financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company entered into financing arrangements, the terms of which involve significant assumptions and estimates, including future net product sales, in determining interest expense, amortization period of the debt discount, as well as the classification between current and long-term portions. In estimating future net product sales, the Company assesses prevailing market conditions using various external market data against the Company&#8217;s anticipated sales and planned commercial activities. Consequently, the Company imputes interest on the carrying value of the debt and records interest expense using an imputed effective interest rate. The Company reassesses the expected payments during each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of the Company&#8217;s current and long-term portions of the debt.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:DerivativesPolicyTextBlock" id="Tb_QZhStKG2Pku-UYssk1qU0g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Derivative Assets and Liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Derivative assets and liabilities are recorded on the Company`s Consolidated Balance Sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded as other income or expense within Other (income) expense, net in the Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company does not use derivative instruments for speculative purposes or to hedge exposures to cash-flow or market risks. Certain financing facilities entered into by the Company include freestanding financial instruments and/or embedded features that require separate accounting as derivative assets and/or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure" id="Tb_rr8SpmddcEKuvcOr0L3X6g" continuedAt="Tb_rr8SpmddcEKuvcOr0L3X6g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Revenue Recognition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s revenues consist of product sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition, BTI management performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The exercise of a material right may be accounted for as a contract modification or as a continuation of the contract for accounting purposes.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_Vxw582losEGMk5tlVjsqZg_cont3" continuedAt="Tb_Vxw582losEGMk5tlVjsqZg_cont4"><ix:continuation id="Tb_rr8SpmddcEKuvcOr0L3X6g_cont1" continuedAt="Tb_rr8SpmddcEKuvcOr0L3X6g_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such goods and services are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the Company&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company allocates the transaction price (the amount of consideration it expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#8217;s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI distributes IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the U.S. through arrangements with a distributor, wholesalers, and GPOs. The distributor and wholesalers help process and fulfill orders from hospitals on the Company&#8217;s behalf. The Company believes the hospitals are its customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company recognizes product revenues, net of consideration payable to customers, as well as variable consideration related to certain allowances and accruals that are determined using either the expected value or most likely amount method, depending on the type of the variable consideration, in its consolidated financial statements at the point in time when control transfers to the customer, which is typically when the product has been delivered to the customer&#8217;s location. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company&#8217;s only performance obligation identified for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is to deliver the quantity of product ordered to the location specified by the customer&#8217;s order. The Company records shipping and handling costs associated with delivery of product to its customers within Selling, general and administrative expenses on its Consolidated Statements of Operations. Under the Company&#8217;s current product sales arrangements, BTI does not have contract assets (unbilled receivables), as it generally invoices its customer at the time of revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI sells IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> at wholesale acquisition cost, less any agreed upon discounts and calculates product revenue net of variable consideration and consideration payable to third parties associated with distribution of product. The Company records reserves, based on contractual terms, for the following components of consideration related to product sold during the reporting period. Calculating these amounts involves estimates and judgments, and the Company reviews these estimates quarterly and records any material adjustments in the period they are identified, which affects net product revenue and earnings in the period such variances occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Trade Discounts and Allowances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company provides the distributor and wholesalers with discounts for prompt payment and pays fees to the distributor, wholesalers and GPOs related to distribution of the product. BTI expects the relevant third parties to earn these discounts and fees, and therefore it deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Government Rebates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is eligible for purchase by, or qualifies for reimbursement from, Medicaid and other U.S. government programs that are eligible for rebates on the price they pay for the product. To determine the appropriate amount to reserve for these rebates, BTI applies the applicable government discount to these sales, and estimates the portion of total rebates that it anticipates will be claimed. The Company deducts certain government rebates from gross product </p></ix:continuation></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_Vxw582losEGMk5tlVjsqZg_cont4" continuedAt="Tb_Vxw582losEGMk5tlVjsqZg_cont5"><ix:continuation id="Tb_rr8SpmddcEKuvcOr0L3X6g_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">revenue and accounts receivable at the time it recognizes the related revenue; other government rebates are recognized as an accrued liability at the time BTI recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Chargebacks</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI provides product discounts to hospitals associated with certain GPOs. The Company estimates the chargebacks that it expects to be obligated to provide based upon the terms of the applicable arrangements. BTI deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product Returns</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company provides contractual return rights to its customers including the right to return product within six months of product expiration and up to 12 months after product expiration, as well as for incorrect shipments, and damaged or defective product, which the Company expects to be rare. Management expects product returns to be minimal, thus BTI recognizes a nominal allowance for product returns at the time of each sale. In the future, if any of these factors and/or the history of product returns changes, the Company will adjust the allowance for product returns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI classifies all fees paid to the distributor, other than those discussed above and those related to warehouse operations, as Selling, general and administrative expenses on its Consolidated Statements of Operations. Fees paid to the distributor for warehouse operations are classified as Cost of goods sold on BTI&#8217;s Consolidated Statements of Operations.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:CostOfSalesPolicyTextBlock" id="Tb_WWXNblWIREKIonLG92-jdA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Cost of Goods Sold</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold includes the cost of producing and distributing inventories that are related to product revenues during the respective period. Cost of goods sold also includes costs related to excess or obsolete inventory adjustment charges, as well as costs related to warehouse operations paid to distributors.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="Tb_A38KZjV58UeOnOzV6MU8XA" continuedAt="Tb_A38KZjV58UeOnOzV6MU8XA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company measures and recognizes stock-based compensation expense based on estimated fair value for all share-based awards made to employees, non-employee service providers, and directors, including stock options, BTI restricted stock units (&#8220;BTI RSUs&#8221;), OnkosXcel profit sharing units (&#8220;PSUs&#8221;), OnkosXcel restricted stock units (&#8220;OnkosXcel RSUs&#8221;) and BTI performance stock units (&#8220;Performance Units&#8221;). The Company&#8217;s 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;) became effective in August 2017. The Company&#8217;s 2020 Incentive Award Plan (the &#8220;2020 Plan&#8221;) became effective in May 2020. Following the effective date of the 2020 Plan, the Company ceased granting awards under the 2017 Plan; however, the terms and conditions of the 2017 Plan continue to govern any outstanding awards granted thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s stock-based awards are valued at fair value on the date of grant and that fair value is recognized as an expense in the Consolidated Statements of Operations over the requisite service period using the accelerated attribution method. The estimated value of the BTI RSUs and Performance Units is based on the Company&#8217;s closing stock price on the grant date. The estimated fair value of OnkosXcel RSUs are based on the OnkosXcel valuation on the grant date. The estimated fair value of stock-options and PSUs was determined using the Black-Scholes pricing model on the date of grant. For awards subject to performance-based vesting conditions, the Company recognizes stock-based compensation expense when the achievement of the performance condition becomes probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Black-Scholes pricing model is affected by the Company&#8217;s stock price, as well as assumptions regarding variables including, but not limited to, the strike price of the instrument, the risk-free rate, the expected stock price volatility over the term of the awards and expected term of the awards. The Company has elected to account for forfeitures as they occur, by reversing compensation cost when the award is forfeited.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_Vxw582losEGMk5tlVjsqZg_cont5" continuedAt="Tb_Vxw582losEGMk5tlVjsqZg_cont6"><ix:continuation id="Tb_A38KZjV58UeOnOzV6MU8XA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_FPRDWzP4nEOa3EQqqd71CQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Research and development expenses include wages, benefits, non-cash stock-based compensation, facilities, supplies, external services, clinical study, manufacturing costs related to clinical trials and other expenses that are directly related to the Company&#8217;s research and development activities. At the end of the reporting period, the Company estimates the progress toward completion of the research or development objectives and, depending on the amount and timing of payments to the service providers may record net prepaid or accrued expense for associated research and development costs. Such estimates are subject to change as additional information becomes available. The Company expenses research and development costs as incurred.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Most of the Company&#8217;s service providers invoice BTI monthly in arrears for services performed. The Company estimates its accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to management at that time. BTI management periodically confirms the accuracy of the Company&#8217;s estimates with the service providers and makes adjustments if necessary.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Although management does not expect its estimates to be materially different from amounts actually incurred, management&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in BTI reporting amounts that are too high or too low in any particular period.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="btai:PatentCostsPolicyTextBlock" id="Tb_2sgDRV6JWEGVs5W2j2iOew" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Costs related to filing and pursuing patent applications are recorded in Selling, general and administrative expenses in the Consolidated Statements of Operations and are expensed as incurred since recoverability of such expenditures is uncertain.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb__BpBBHgDQUayy24T23mSNA" continuedAt="Tb__BpBBHgDQUayy24T23mSNA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company measures certain financial assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources, or observable inputs, and (2) an entity&#8217;s own assumptions about market participant assumptions developed based on the best information available in the circumstances, or unobservable inputs. The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). Fair value measurements must be classified and disclosed in one of the following three categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Level 1</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Level 2</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Level 3</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management&#8217;s estimates of market participant assumptions.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considering counterparty credit risk in its assessment of fair value.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_Vxw582losEGMk5tlVjsqZg_cont6"><ix:continuation id="Tb__BpBBHgDQUayy24T23mSNA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_Qf57rZ7aWU6i-F4yF6gUWQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI uses an asset and liability approach for financial accounting and reporting of income taxes. Deferred tax assets and liabilities are determined based on temporary differences between financial reporting and tax basis assets and liabilities and are measured by applying enacted rates and laws to taxable years in which differences are expected to be recovered or settled. Further, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that the rate changes. A valuation allowance is required when it is &#8220;more likely than not&#8221; that all or a portion of deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">U.S. GAAP prescribes a comprehensive model for how a company should recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on a tax return, including a decision whether to file or not file a return in a particular jurisdiction. The Company&#8217;s financial statements reflect expected future tax consequences of such positions presuming the taxing authorities&#8217; full knowledge of the position and all relevant facts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company does not have any unrecognized tax benefits as of December 31, 2024 and 2023. BTI reviews all tax positions to ensure the tax treatment selected is sustainable based on its technical merits and that the position would be sustained if challenged.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_B1dhGlLyz0uaVfPL-8HaGw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Earnings (Loss) per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Earnings (loss) per share (&#8220;EPS&#8221;) is calculated by dividing net income or loss attributable to common stockholders by the weighted average number of shares of common stock that were outstanding, including pre-funded warrants. Shares of common stock into which the pre-funded warrant may be exercised are considered outstanding for the purposes of computing EPS because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date. Diluted EPS is calculated by adjusting the weighted average number of shares of common stock that were outstanding for the dilutive effect of common stock equivalents. In periods in which a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be antidilutive.&#160;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_J68cTCSbrUaHGlgbiNrObA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Segment Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company operates in a single segment. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. To date, the Company&#8217;s chief operating decision maker has made such decisions and assessed performance at the Company level as <ix:nonFraction unitRef="Unit_Standard_segment_u3k5mJIKoECDA2MsRZB6Gg" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_5SefTZ4e-USl2lG4ksXgPA">one</ix:nonFraction> segment. See Note 19, <i style="font-style:italic;">Segment Information</i> for further information</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_nTdf79PS8UGpGhBW44h2Hg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently adopted accounting pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In November 2023, the FASB issued ASU 2023-07, Segment reporting, which requires disclosure of incremental segment information on an annual and interim basis. The standard is effective for years beginning after December 15, 2023, and interim periods beginning after December 15, 2024 and early adoption is permitted. The Company adopted the new standard in fiscal year 2024 for annual and retrospective reporting periods with all interim disclosures to begin in the first quarter of fiscal year 2025. For additional information, see Note 19, <i style="font-style:italic;">Segment Information</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting Pronouncements effective in future periods</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, Improvements to income tax disclosures, which requires disclosure of disaggregated income taxes paid by jurisdiction, enhances disclosures in the effective tax rate reconciliation and modifies other income tax-related disclosures. The amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the effect of adopting this guidance on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="Tb_C-8iiDJ4_kqu_k6VLMq9_A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;4. Restructuring</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="background:#ffffff;">On August 8, 2023, the Company&#8217;s Board of Directors approved a broad-based strategic reprioritization (the &#8220;Reprioritization&#8221;). The Company took actions to reduce certain operational and workforce expenses that were no longer deemed core to ongoing operations in order to extend its cash runway and drive innovation and growth in high potential clinical development and value creating opportunities. These actions included a shift in commercial strategy for </span>IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="background:#ffffff;"> in the institutional setting, a reduction of in-hospital commercialization expenses, a suspension of programs no longer determined to be core to ongoing operations, and a prioritization of at-home treatment setting opportunities for BXCL501.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;background:#ffffff;">As part of this strategy, the Company&#8217;s Board of Directors approved a reduction of approximately </span><span style="font-weight:normal;background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_8_8_2023_To_8_8_2023_1AQEFh0qkU22JOe-2n46Ww" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="Narr_EMzvvq-4ZEupTQWo_ERqVg">60</ix:nonFraction>%</span><span style="font-weight:normal;background:#ffffff;"> of the Company&#8217;s workforce. The Company notified impacted employees on August 14, 2023 and recorded total restructuring costs of </span><span style="font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="3" id="Narr_1gd8MEuARUyaZln0ugdqSw">4,163</ix:nonFraction></span><span style="font-weight:normal;background:#ffffff;"> for the year ended December 31, 2023. These costs consisted of severance and benefit costs of </span><span style="font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_dCk4KHjYVECYOD1bNWMxhA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="3" id="Narr_aghL1WJnWEO1oZd3eCmsFQ">4,063</ix:nonFraction></span><span style="font-weight:normal;background:#ffffff;"> and contract termination costs of </span><span style="font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_0Fa5GpoDykyuoxmj8TA-dQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="3" id="Narr_2DJ2KY8Do02Ur9pcYcGK1w">100</ix:nonFraction></span><span style="font-weight:normal;background:#ffffff;">. The Company paid $</span><span style="font-weight:normal;background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_dCk4KHjYVECYOD1bNWMxhA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRestructuring" scale="3" id="Narr_Fnd6m4WoDkC4UP_oeqGHeg">3,998</ix:nonFraction></span><span style="font-weight:normal;background:#ffffff;"> of severance and benefit costs and </span><span style="font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_0Fa5GpoDykyuoxmj8TA-dQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRestructuring" scale="3" id="Narr_YNeEMBUwX0aqwD3n7sdAVQ">100</ix:nonFraction></span><span style="font-weight:normal;background:#ffffff;"> of contract termination costs in the year ended December 31, 2023. The Reprioritization is substantially complete as of December 31, 2023, and any remaining costs are expected to be paid during the first quarter of 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;background:#ffffff;"> On May 8, 2024 the Company took additional actions as part of its continued efforts to preserve cash and prioritize investment in its core clinical programs.</span> <span style="background:#ffffff;">As part of these actions, the Company initiated a further reduction of approximately </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_5_8_2024_To_5_8_2024_IhAulVfqfE-gUqz51YDtXg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="Narr_rrbhC145UUGnsWGrnK8SkQ">15</ix:nonFraction>%</span><span style="background:#ffffff;"> of the Company&#8217;s then current workforce. The Company notified impacted employees on May 8, 2024 and recorded total restructuring costs of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_4_1_2024_To_6_30_2024_Sa7bc9y2BEeY9w4XybT9qQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="3" id="Narr_QtGZu3MJP02Th6GPxFhGuQ">856</ix:nonFraction></span><span style="background:#ffffff;"> for the three months ended June 30, 2024. These costs consisted of severance and benefit costs, all of which were paid during the three months ended June 30, 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On September 17, 2024, the Company approved a plan for an additional reduction in its workforce of </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_employee_g1iuox2T4U2nGaIKFGYE2w" contextRef="Duration_9_17_2024_To_9_17_2024_OiBFsSYoqEGoJgxld_C82A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="Narr_EXNdDpaD7kuXQTSMOVp8aA">15</ix:nonFraction></span><span style="background:#ffffff;"> employees, or approximately </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_9_17_2024_To_9_17_2024_OiBFsSYoqEGoJgxld_C82A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="Narr_QzXFCoHu70Ox6fUpwhy2yA">28</ix:nonFraction>%</span><span style="background:#ffffff;"> of the Company&#8217;s headcount (the &#8220;Clinical Prioritization&#8221;), in order to extend its cash runway and prioritize investment on the clinical development of its lead neuroscience asset, BXCL501. The Company incurred aggregate charges in connection with the Clinical Prioritization of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_9_17_2024_XxyLTPFqzUyn2yLJ69oiWg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="3" id="Narr_qDPb1X8YgEClFJeaQBkw8A">1,586</ix:nonFraction></span><span style="background:#ffffff;"> which relate primarily to severance and benefits costs. Accordingly, the Company recorded a restructuring charge of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_7_1_2024_To_9_30_2024_UmSoTOy6ZEqdvjDqQLaKEw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="3" id="Narr_0rsOnjxVy0qM_zsihiwpHA">1,553</ix:nonFraction></span><span style="background:#ffffff;"> in the third quarter 2024, and </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_10_1_2024_To_12_31_2024_3PEv7wfJfUKxY2X6WXJQ_g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="3" id="Narr_43pzq9w4C0qeKvp2Zu_9Zw">33</ix:nonFraction></span><span style="background:#ffffff;"> in the fourth quarter. The Company completed the Clinical Prioritization in October 2024, and paid </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_10_1_2024_To_12_31_2024_3PEv7wfJfUKxY2X6WXJQ_g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRestructuring" scale="3" id="Narr_xsyDwB8gRUKtpA_TxSSSXA">983</ix:nonFraction></span><span style="background:#ffffff;"> of the related costs during the fourth quarter of 2024 and expects to pay the remaining </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringReserveCurrent" scale="3" id="Narr_dJ8V48jLXkOre0BC_lqsIg">603</ix:nonFraction></span><span style="background:#ffffff;"> in the first quarter of 2025,</span> <span style="background:#ffffff;">which is included in Accrued Expenses on the Consolidated Balance at December 31, 2024.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_43adc588_173f_4edc_96cf_54fa1edbae91"></a><a id="Tc_U-Mkck4fzU27ZPC2_Po1Nw_1_2"></a><a id="Tc_5DqsVE2Knkud2ZL0yoZo1w_1_5"></a><a id="Tc_jZjK1Cl160uvyrTETr8PUw_2_2"></a><a id="Tc_iJUTSJrvP0OIyRrBRKdXEw_2_5"></a><a id="Tc_JcPBTF8iq0ex-M9SOj1V3g_4_0"></a><a id="Tc_EbhM-OaF6kSV06yoRWxQaw_4_2"></a><a id="Tc_tOIWwKBiHEeLJ3czKHyT1A_4_5"></a><a id="Tc_mNxKqC2Lwkui8kn81N7Y_g_5_0"></a><a id="Tc_sF84VcnW1USF_bV0fQvK6w_5_3"></a><a id="Tc_814kV0Jk_EG4X5mDzESDKw_6_0"></a><a id="Tc_wKaypteUhUG9bH5c-Padig_7_0"></a><a id="Tc_7K4x764k_0WQuHI26WK3fQ_7_2"></a><a id="Tc_iHP0hAM_NUm0lO4g7nT1UA_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_m97jkR_Wxkqy4NToLw7Aww" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;5. Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Inventory consists of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_rUk3n8q2ek-FXVBhAMrrMg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="3" id="Tc_N9_aUdvfz02lo9SGxKiOyQ_4_3">506</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="3" id="Tc_xAKez48BPEqQeADEoXNl6A_4_6">935</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="Tc_LWuw0Z4my0uEDpVinv0M1w_5_6">651</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_Qo8EP9n3q0Cq1bgnFKpD0w_6_3">173</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_s1WGbsxzJ0OCJJDLRMGleA_6_6">405</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total inventory</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_DFp61K_yO0G2zRtZ23-wlQ_7_3">679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_YoUQv1wqFEq19fGB_Q9j-A_7_6">1,991</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"><span style="font-weight:normal;">The Company recorded inventory write-downs due to excess inventory of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="3" id="Narr_i8Qe1GoG2UKZCerApkW_og">1,980</ix:nonFraction></span><span style="font-weight:normal;"> and </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="3" id="Narr_rzpGtQdwbkeJufyBmYO7zQ">1,191</ix:nonFraction></span><span style="font-weight:normal;"> for the years ended December 31, 2024 and 2023, respectively. </span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_4Dv2-rhPAk-hho3NqZtQ-g_1_2"></a><a id="Tc_Y035oNwmUkCoDy2nOLPMdA_1_5"></a><a id="Tc_EMFtafvzF0ycG5JKtGPmmA_2_2"></a><a id="Tc_FFmzQMApdEKCVJ0zC_O13w_2_5"></a><a id="Tc_mCI4mD2qJUex1Yu0Shh5Lg_4_0"></a><a id="Tc_7U5ydwKFH0ufd7YDu-GzJA_4_2"></a><a id="Tc_xNxeRNYHCk6jQXbsoB33kQ_4_5"></a><a id="Tc_hhlzVIrQn0GRsazMhGnhxg_5_0"></a><a id="Tc_VjBlW7sZRkKjcwAyTq0UGA_6_0"></a><a id="Tc_rhj6pO7uSkCkB_TRFC_keQ_7_0"></a><a id="Tc_YxWMnmiDhEaw5DidGDpD_Q_7_2"></a><a id="Tc_0Q76zkEdAUqEo44lYne4_g_7_5"></a><a id="Tc_CvHuhYorq0SpRwSIKnjl4g_8_0"></a><a id="Tc_13r5BPC4QkCnDvqEiuXjzQ_9_0"></a><a id="Tc_L592ajgg1U6s6rbeFjvxRg_9_2"></a><a id="Tc_s2MuzjfluUmR_Nx_Ytk6bw_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_RkDe0T9R8k-VG95x6i46Cg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;6. Property and Equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Property and equipment, net consists of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_dqyqXLST-0WPG5_RJwlYDQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_MJeawgIMDEyPxu7dj7F8aQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_qVG17WtNXk2uiCK10g8svw_4_3">202</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_zmvJP9XWKUylAuis6tmJsw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_EwWv_oMfSEaH8NrkmWyBSw_4_6">202</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_bGkvra2V9Ue26IMBxqrCww" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_beOGo0y9S0uQ0bozpotd_w_5_3">575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_kXPimCUV7keG3q0uOSWbGQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_128qP_96PUOo6DeEAl9xdw_5_6">575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_awYc1AER0EGr0NZ0NV2hSg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_kJ1aE3zR00-GInc3qqyulA_6_3">1,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_3NEbuF2yQ0q1F_2-3706qw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_-yU0HZEuzkahsIDUMRB8lA_6_6">1,200</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total property and equipment</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_HCemepjXdUGQOLe0UU6UZw_7_3">1,977</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_xRILo3N2UkSECx5SU4XXYA_7_6">1,977</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_tWyIDfJR3UG3r-yi8vZz9Q_8_3">1,502</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_nBJhpiO-aEucXhTI7ycCSw_8_6">1,193</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_3WfFViRN6USXILpBdVpm2Q_9_3">475</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_szjT7xc5n06gSuRHn3kUCw_9_6">784</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"><span style="font-weight:normal;">Depreciation expense was </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Narr_dKpsQHHPUkaxWfMzrLvmJQ">309</ix:nonFraction></span><span style="font-weight:normal;"> and </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Narr_XJPwnO91m0entE9XWX4qtA">318</ix:nonFraction></span><span style="font-weight:normal;"> for the years ended December 31, 2024 and 2023, respectively</span>.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_EaVb5jye30ak7XwLNnX4eQ_1_2"></a><a id="Tc_XgUbk2GbR0K6sYsBDQxFlg_1_5"></a><a id="Tc_9K5JZq4FiUCAzYR2GYe1_w_3_0"></a><a id="Tc_Q-9vx_0OgUGH5VnKGugeBw_3_2"></a><a id="Tc_KdB_BA-ZD0mnGc5kYa2E6Q_3_5"></a><a id="Tc_yzwq8qaKxkuHFNuJOjATCw_4_0"></a><a id="Tc__tbKhxmoDESPBp7qEwqxUA_5_0"></a><a id="Tc_z94rqFH55kqiT7t5FUR3Gg_6_0"></a><a id="Tc_u4kJcxgnVkal6LTpNuc5Dg_7_0"></a><a id="Tc_TIdkjhojFEikP53BvtvbSA_8_0"></a><a id="Tc_-DtupntgE0ivqnYhICLyaA_8_6"></a><a id="Tc_43t_PkqWbUG8BzqHAEEVQA_9_0"></a><a id="Tc_SSUlDDD2N0eYXTaczqq4Mg_9_2"></a><a id="Tc_fngJSOzD-UmWgBebSS_Oag_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_iJQnt4jIik6OkffjhTQ8AA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;7. Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Accrued expenses consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_MOcbDLYkY0K3LZRkhUnCjA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:AccruedResearchAndDevelopmentExpenses" scale="3" id="Tc_lhznq-vKX0SilfstPM4OBA_3_3">3,107</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:AccruedResearchAndDevelopmentExpenses" scale="3" id="Tc_rPUlTrJK0Uq65RtnIujVTQ_3_6">6,406</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_qLa2A5JLaUaNZ6MVaxXAgg_4_3">35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_WZwqkPk-oku1NwtFMZQdmQ_4_6">163</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_jvP6LykweUuVOdDFhKv3-w_5_3">1,604</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc__TC84mtqX0mZ3oy2k6Ad6w_5_6">5,562</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_tqTwPo0RdE-cqmBzyHQdIA_6_3">91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_ups9l_ZtqkO9COAHJYVgfA_6_6">116</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_M_bDtcbPkES3zxYHnDqVuQ_7_3">322</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_rATNd_fAhEKyxGcbJiUNwQ_7_6">177</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued restructuring costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringReserveCurrent" scale="3" id="Tc_LlsWX6JVEEqdaCFZ8PT2hg_8_3">603</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total accrued expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_fCRsPh05fkOCn7st9QjHDQ_9_3">5,762</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_KPv-qz3ouUOb4Xg1V05ouQ_9_6">12,424</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_ak-1n17HIkKMcgqnTBGG1g" continuedAt="Tb_ak-1n17HIkKMcgqnTBGG1g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;8. Transactions with BioXcel LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company entered into a Separation and Shared Services Agreement with BioXcel LLC that took effect on June 30, 2017, as amended and restated thereafter (the &#8220;Services Agreement&#8221;), pursuant to which BioXcel LLC had agreed to provide the Company with certain intellectual property prosecution and management and research and development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the Services Agreement, the Company had an option, exercisable until December 31, 2024, to enter into a separate collaborative services agreement with BioXcel LLC pursuant to which BioXcel LLC shall perform product identification and related services for us utilizing its EvolverAI. We agreed to pay BioXcel LLC $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_6_30_2017_To_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__Rfp0WkOeUSwkyApqU9Aow" decimals="-3" format="ixt:num-dot-decimal" name="btai:AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" scale="3" id="Narr_vuOMByfm7UOIhMKncJFRng">18</ix:nonFraction> per month from March 13, 2023, to December 31, 2024 in exchange for this option. This option was not exercised. However, BioXcel LLC continues to perform certain administrative services under the terms of the expired contract. We agreed to negotiate any such collaborative services agreement in good faith and to incorporate reasonable market-based terms, including consideration for BioXcel LLC reflecting a low, single-digit royalty on net sales and reasonable development and commercialization milestone payments, provided that (i) development milestone payments shall not exceed $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_DevelopmentMilestonesMember_jNVSm8QxO0KzJACAONNxDQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:CollaborativeArrangementMilestonePaymentsPotential" scale="3" id="Narr_kNp3h3hYG0Cp9bD_9yY3eg">10,000</ix:nonFraction> in the aggregate and not be payable prior to proof of concept in humans and (ii) commercialization milestone payments shall be based on reaching annual net sales levels, be limited to <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_SalesMilestonesMember_ivfM8IqGnEukjOEO4xau4Q" decimals="2" format="ixt:num-dot-decimal" name="btai:CollaborativeArrangementMilestonePotentialPercent" scale="-2" id="Narr_ipZ0ZW4cykSlX_ytfxcrQw">3</ix:nonFraction>% of the applicable net sales level, and not exceed $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_SalesMilestonesMember_ivfM8IqGnEukjOEO4xau4Q" decimals="-3" format="ixt:num-dot-decimal" name="btai:CollaborativeArrangementMilestonePaymentsPotential" scale="3" id="Narr_e2yrzqpYxUahda9ob-pJVw">30,000</ix:nonFraction> in the aggregate. We did not exercise our option to renew the agreement for product identification and related services utilizing BioXcel LLC&#8217;s EvolverAI. Subsequent to December 31, 2024 no development activity has been carried out by BioXcel LLC and none is contemplated.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_8wC4aQpjR0WNS8jVufTb_g_1_2"></a><a id="Tc_PHLeC4nDu0eJbC35iKqWdw_2_2"></a><a id="Tc_Zg_593RTDU2pckE52vzDrA_2_5"></a><a id="Tc_iVifN7EKWki5BMbVY-Mxlg_4_0"></a><a id="Tc_MInHZlkzF0ark8qYZW_mbw_4_2"></a><a id="Tc_spGCRIZaxkqHF7Y47oZWlA_4_5"></a><a id="Tc_sLKFIsl9WE6sIHmT2L2JKg_5_0"></a><a id="Tc_OU7vmjRFuESA8HvUAA_Cjw_6_0"></a><a id="Tc_6JW_rSCi7EyG2agjqhtiBg_6_2"></a><a id="Tc_Xrie5RaSwU2JkBpoNn3_Qw_6_5"></a><ix:continuation id="Tb_ak-1n17HIkKMcgqnTBGG1g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Service charges recorded under the Services Agreement for the years December 31, 2024 and 2023 were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="Tb_jF5Lnz3RckqDrCgq8Q3Fuw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_I-pOhJgS20CdZAck10nsIQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_qs9wWCHpAEq8vteFrJ5LuA_4_3">938</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_2OCsk1QU00-KJSY3sMd-yQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_Zg8Mo6m2z02z4jeQom0RkQ_4_6">1,075</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_I-pOhJgS20CdZAck10nsIQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_UetzDKmFTk6-PxyoCuvxOw_5_3">392</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_2OCsk1QU00-KJSY3sMd-yQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_1mFaI-aVEU-BEESjiDYq1g_5_6">211</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_I-pOhJgS20CdZAck10nsIQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_9LfEuHBScEeGBi296-kOKw_6_3">1,330</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_2OCsk1QU00-KJSY3sMd-yQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_6nlYvwnR2EqCDe6EelIEew_6_6">1,286</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">There were <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_CDdL6odIhEyB7dtSsjWgHg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Narr_iipxHS0P70eY42aaxk6DRQ"><ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_AF3B6HHa0kyLVVlQaBJT2A" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Narr_EfMgLa3-6EK4ICVIRj93Jw">no</ix:nonFraction></ix:nonFraction> service charges due as of December 31, 2024 and December 31, 2023.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_5539d5f6_fa3b_4ed0_a750_b08d5e0ea52e"></a><a id="Tc_N67mrlfIP0e54Nx90m8Piw_1_2"></a><a id="Tc_sdMMG3b_x0ekhsZfwUhcTg_1_5"></a><a id="Tc_dyZmofuKhU6jrrBSFyHFMg_3_0"></a><a id="Tc_XoTR-gSFX0qEq7YMzVGClA_3_2"></a><a id="Tc_huQeeY5ysECiM97Mzf_ftg_3_5"></a><a id="Tc_33NEKc4LPUSHGKetX5c_OA_4_0"></a><a id="Tc_sODYw9tUM06aH60vj-fmyg_5_0"></a><a id="Tc_TY_bPSd6N0ukOwKxYssjgw_5_2"></a><a id="Tc_mqbzHSa6V0GYYzPKOR_UhQ_5_5"></a><a id="Tc_SIBgunXiLk-eTg6DRLIdlA_6_0"></a><a id="Tc_rOcnr0zlyEmkC4AoDaLQwA_7_0"></a><a id="Tc_D_ZhcPV-_02_Yn_xmjZ2eA_7_2"></a><a id="Tc_OIfOuEjjqUCwB65gE767wA_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:DebtDisclosureTextBlock" id="Tb_pnlowyoIIka0thGS0TAsIg" continuedAt="Tb_pnlowyoIIka0thGS0TAsIg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;9. Debt and Credit Facilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Debt, net of unamortized discounts and financing costs, consists of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="Tb_Kij1Ur66H0CBcFdcp3k-eg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Credit Agreement and Guaranty</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_4QXVMUpriU-O3ONSCTxFLw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_bb5pZaglkEmYPd964WCr0w_3_3">102,319</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_d7MaxUhhVECHSCm80cC1Ow" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_ciBEmfGnck6LyAUYMujJsA_3_6">102,319</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payable-in-kind ("PIK") interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_vDidZuvwFUuTvGIhGHCssg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="3" id="Tc_AmTlVCa_lUumkCiBM4vfZg_4_3">4,403</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_qKlv5oEboUGlNN_gzIoC-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="3" id="Tc__EA0tJMPk0OVquvltP6JdA_4_6">361</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total long-term debt liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_nvkpEcHBU0ip7OGCG64NnA_5_3">106,722</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_F_bX0hXkQECrgV30k33e2w_5_6">102,680</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unamortized debt premiums, discounts and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Tc_aC3QB6UhzUKvjDxV2DGJmg_6_3">4,214</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Tc_g4T8dasIkUmp4EWdhvAH4w_6_6">2,082</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total long-term debt</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_R8mp4VT2SUyAzyzNeHdIMw_7_3">102,508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_o6Y5qxO1J02FuJqgsmh7sw_7_6">100,598</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April 19, 2022, the Company entered into two strategic financing agreements: (i) a Credit Agreement and Guaranty (the &#8220;Credit Agreement&#8221;) by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the &#8220;Lenders&#8221;), and Oaktree Fund Administration LLC (&#8220;OFA&#8221;) as administrative agent, and (ii) a Revenue Interest Financing Agreement (the &#8220;RIFA&#8221;; and together with the Credit Agreement, the &#8220;OFA Facilities&#8221;) by and among the Company, the purchasers party thereto (the &#8220;RIFA Purchasers&#8221;) and OFA as administrative agent. Under the OFA Facilities, the Lenders and the RIFA Purchasers agreed to, in the aggregate between the two OFA Facilities, provide up to $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_r6Nt5rznFkuA80tgQ2K1yA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="Narr_z6ud9DbfMUuRDDjCtmLQaA">260,000</ix:nonFraction> in gross funding to support the Company&#8217;s commercial activities of IGALMI<sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> sublingual film. In addition, the OFA Facilities are intended to support the expansion of clinical development efforts of BXCL501, which includes a Phase 3 program for the acute treatment of agitation in patients with Alzheimer&#8217;s disease, and for general corporate purposes. The Lenders and RIFA Purchasers are comprised of affiliates of Oaktree Capital Management, L.P. and Qatar Investment Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"><b style="font-weight:bold;">Waiver and First Amendment to Credit Agreement and Guaranty</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On November 13, 2023, the Company, the lenders party to the Credit Agreement and OFA entered into a Waiver and First Amendment to Credit Agreement and Guaranty (the &#8220;First Amendment&#8221;) that provided for (i) a waiver and a modification to the covenant in the Credit Agreement regarding investments in OnkosXcel and (ii) an agreement among the parties to further revise key financial terms in the Credit Agreement and terminate the RIFA. Pursuant to the First Amendment, the Lenders agreed to permit the Company to invest up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_a4FuB-EA3US0t7LRQkJ_0Q" decimals="-3" format="ixt:num-dot-decimal" name="btai:LineOfCreditFacilityInvestmentAllowed" scale="3" id="Narr_3QTP4VdmM0O8FhJf01N7gA">30,000</ix:nonFraction> at any time outstanding in OnkosXcel, increased from $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_11_12_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_1pH0cdjOhkqjWy9MM_KenA" decimals="-3" format="ixt:num-dot-decimal" name="btai:LineOfCreditFacilityInvestmentAllowed" scale="3" id="Narr_IIuGE9KDN02Nb0em-EEwTg">25,000</ix:nonFraction> at any time outstanding. The First Amendment also waived any defaults or events of default arising under the Credit Agreement due to a breach prior to the date of the First Amendment of the OnkosXcel investment covenant, or a breach of the Company&#8217;s obligation to notify OFA of such default. In connection with the First Amendment, the Company paid the Lenders a fee of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_a4FuB-EA3US0t7LRQkJ_0Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFeeAmount" scale="3" id="Narr_5N--k_YxFEOKVS44X9gtKw">180</ix:nonFraction> (representing <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_11_13_2023_To_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_9T8VX87-MkurojwuBrp51A" decimals="4" format="ixt:num-dot-decimal" name="btai:LineOfCreditFacilityAmendmentFeePercentage" scale="-2" id="Narr_qWxQHnFLuUCLTAUo9yN8HQ">0.25</ix:nonFraction>% of the loans outstanding under the Credit Agreement on the date of the First Amendment) and agreed to pay to the Lenders an exit fee equal to <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_11_13_2023_To_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_9T8VX87-MkurojwuBrp51A" decimals="4" format="ixt:num-dot-decimal" name="btai:LineOfCreditFacilityExitFeePercentage" scale="-2" id="Narr_UMLkMNYZBkqZQFGmH7FGMQ">0.25</ix:nonFraction>% of the loans under the Credit Agreement repaid upon maturity or prepayment of the loans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_pnlowyoIIka0thGS0TAsIg_cont1" continuedAt="Tb_pnlowyoIIka0thGS0TAsIg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"><b style="font-weight:bold;">Second Amendment to Credit Agreement and Guaranty and Termination of the RIFA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.25;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On December 5, 2023, (the &#8220;Second Amendment Effective Date&#8221;), the Company entered into the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement (the &#8220;Second Amendment&#8221;), which further amended the Credit Agreement. On the Second Amendment Effective Date, the Credit Agreement was amended to provide up to $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_ots7YDarCkyspj_MFv5RgQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="Narr_4lQliM05dEiW8htnSDS98g">202,319</ix:nonFraction> in senior secured term loans, including the initial Tranche A of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_4_28_2022_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_na3LkfDiw0K2aagoP_bMuA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Narr_mzErjDzyT0SaOwyyHNWwmw">70,000</ix:nonFraction>, which was funded on April 28, 2022, and related capitalized interest on Tranche A through the Second Amendment Effective Date in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_xroiFJrnD0eA_jiPBHLdvA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Narr_40e1QPjxK0eUttA4DF_ayw">72,319</ix:nonFraction>. In addition, the $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_T8y78WMP4ECZ9sQKm-yKhw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Narr_1ZBZ42r0YESa8qMdtET-CQ">30,000</ix:nonFraction> in financing previously provided to the Company under the RIFA on July 8, 2022 was converted to a term loan under the Credit Agreement (the &#8220;Tranche A-2 Term Loan&#8221;). The RIFA and all commitments for potential future funding thereunder were terminated. In addition, pursuant to the Second Amendment, the Lenders agreed to permit the Company to invest up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_ots7YDarCkyspj_MFv5RgQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:LineOfCreditFacilityInvestmentAllowed" scale="3" id="Narr_9vAbj-kYCk6J4bmov5yffQ">30,865</ix:nonFraction> at any time outstanding in OnkosXcel, increased from $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_a4FuB-EA3US0t7LRQkJ_0Q" decimals="-3" format="ixt:num-dot-decimal" name="btai:LineOfCreditFacilityInvestmentAllowed" scale="3" id="Narr_06rhDkjdxUGMZRaQ25h21A">30,000</ix:nonFraction>. In connection with the Second Amendment, the Company agreed to pay to the Lenders an exit fee equal to <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_12_5_2023_To_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_54xfhc08YEGFKmDToW_EHg" decimals="4" format="ixt:num-dot-decimal" name="btai:LineOfCreditFacilityExitFeePercentage" scale="-2" id="Narr_bzDLw6CtE0KJYp_x_iQF1w">0.25</ix:nonFraction>% of the loans under the Credit Agreement repaid upon maturity or prepayment of the loans (which exit fee is in addition to, and not in lieu of, the exit fee provided for by the First Amendment). As of September 30, 2024, $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember__PljhQkwa0ehF3g8M7cQfA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="3" id="Narr_PzKEej3WL02HwzJh7vI1AQ">100,000</ix:nonFraction> in commitments under the Credit Agreement remains unfunded, and Oaktree has an Equity Investment Right (as defined below) to purchase up to $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember__PljhQkwa0ehF3g8M7cQfA" decimals="-3" format="ixt:num-dot-decimal" name="btai:EquityInvestmentRightAmountUnfunded" scale="3" id="Narr_og4AmSifw06MQrk3vpLseA">5,000</ix:nonFraction> of Common Stock from the Company. The blended effective interest rate on the Tranches A-1 and A-2 as of December 31, 2023 was approximately <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_d7MaxUhhVECHSCm80cC1Ow" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="Narr_B-2_ykkTRU2_IcjP2axH5A">13.5</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The remaining tranches may be borrowed at the Company&#8217;s option prior to December 31, 2024, subject to satisfaction of certain conditions, including regulatory and financial milestones. Tranche B of the Credit Agreement is $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheBMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_6ZZ0nOytkkyfb35YWqDR_A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="Narr_A2BL2VRohUipEUJt7jNgrw">20,000</ix:nonFraction> and is available upon satisfaction of certain conditions and financial milestones. Tranche C of the Credit Agreement is $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheCMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_KEur4f2KVkKKQYGXeBkN_w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="Narr_jt--ezaRrUyr4GEiZcq4eA">30,000</ix:nonFraction> and is available upon satisfaction of certain conditions, including receipt of certain regulatory and financial milestones. Tranche D of the Credit Agreement is $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheDMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_KgqW-5X7r06gLp9NBzxFsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="Narr_6_6Le6AvKkGP89Vkh5YjjA">50,000</ix:nonFraction> and is available upon satisfaction of the Tranche C Term Loans conditions precedent to, and the funding of Tranche C Loans, including specified minimum net sales of the Company attributable to sales of BXCL501 for a trailing twelve consecutive month period, on or before December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;">The loans under the Credit Agreement do not amortize and mature on April 19, 2027. The Company may, at its option, no earlier than September 21, 2026 and no later than October 21, 2026, request an extension of the maturity date to April, 19, 2028, provided that the Company satisfies certain conditions including receipt of certain regulatory and financial milestones. Borrowings under the Credit Agreement are issued at a </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_WSKgB0WSZUCURjOJ6-sK0w" decimals="4" format="ixt:num-dot-decimal" name="btai:DebtInstrumentInterestRateDiscountRatePercentage" scale="-4" id="Narr_Tgjz261VhkukSTWZcEKdnw">200</ix:nonFraction></span><span style="font-size:10pt;">-basis point original issue discount and bear interest at a variable annual rate of TERM </span><span style="-sec-ix-hidden:Hidden_q_7viYeZgU21L0rksnVcQQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">SOFR</span></span><span style="font-size:10pt;"> (but not less than </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_07DuWNjS7E2tMACIgVlBjw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_CGDPzmKqIE-DmHZO4Gz_cQ">2.5</ix:nonFraction>%</span><span style="font-size:10pt;"> or more than </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_LmEJHhC5GEuhV4cvR-CyZw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_ptoeuyLDP0--QU4xerthbQ">5.5</ix:nonFraction>%</span><span style="font-size:10pt;">) plus </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_WSKgB0WSZUCURjOJ6-sK0w" decimals="3" format="ixt:num-dot-decimal" name="btai:DebtInstrumentIncrementalOnVariableRatePercent" scale="-2" id="Narr_T632fGPrPUy8w9bdHbDukA">7.5</ix:nonFraction>%</span><span style="font-size:10pt;">, payable quarterly. The rate resets every three months based on the current Term SOFR rate. Of such interest, above </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_hoC3FYJ7zkS3zSkEUQbGEw" decimals="2" format="ixt:num-dot-decimal" name="btai:PaidInKindInterestPercentage" scale="-2" id="Narr_4FaxuBCRYUGTEx6o2soihA">8</ix:nonFraction>%</span><span style="font-size:10pt;"> per annum is, at the Company&#8217;s option, payable in kind by capitalizing and adding such interest to the outstanding principal amount of loans from the first payment date on which such interest is owed through</span> <span style="font-size:10pt;">March 31, 2025, unless, with respect to any payment date, the Company elects to pay all or a portion of such interest in cash. The Company is required to pay a ticking fee equal to </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_WSKgB0WSZUCURjOJ6-sK0w" decimals="4" format="ixt:num-dot-decimal" name="btai:TickingFeesPercentage" scale="-2" id="Narr_03lQWHfk6k-Zr2a6gRQjtw">0.75</ix:nonFraction>%</span><span style="font-size:10pt;"> per annum on the undrawn amount of the commitments, payable quarterly commencing 120 days after April 22, 2022 through the termination of the commitments, which is expensed as incurred and recognized as interest expense in the Consolidated Statements of Operations. The Company may voluntarily prepay the Credit Agreement at any time subject to a prepayment fee.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s obligations under the Credit Agreement are guaranteed by BTI&#8217;s existing and subsequently acquired or organized subsidiaries, subject to certain exceptions. BTI&#8217;s obligations under the Credit Agreement and the related guarantees thereunder are secured, subject to customary permitted liens and other agreed upon exceptions, by (i) a pledge of all of the equity interests of all of the Company&#8217;s existing and any future direct subsidiaries, and (ii) a perfected security interest in all of its and the guarantors&#8217; tangible and intangible assets (except that the guarantees provided by the BXCL701 Subsidiaries (as defined below) are unsecured).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness, and dividends and other distributions, subject to certain exceptions, including specific exceptions with respect to product commercialization and development activities. The Company must also comply with certain financial covenants, including (i) maintenance of cash or permitted cash equivalent investments in accounts controlled by OFA for the Lenders, of at least (a) initially, $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_r6Nt5rznFkuA80tgQ2K1yA" decimals="-3" format="ixt:num-dot-decimal" name="btai:NetCashRequiredMinimum" scale="3" id="Narr_F3QH9sDgu0mwF77K0Z0E7Q">15,000</ix:nonFraction>, (b) from and after the funding of the Tranche B </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_pnlowyoIIka0thGS0TAsIg_cont2" continuedAt="Tb_pnlowyoIIka0thGS0TAsIg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">loans, $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterFundingOfTrancheBLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_M-8oLHEl10ODoYzrqVk1qg" decimals="-3" format="ixt:num-dot-decimal" name="btai:NetCashRequiredMinimum" scale="3" id="Narr_Sf_A1bfVpUKkRehezZ5baQ">20,000</ix:nonFraction>, and (c) from and after the Company&#8217;s satisfaction of the funding conditions for the Tranche C loans, $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_HHsV3q--b0-Hi4NmC1wOxA" decimals="-3" format="ixt:num-dot-decimal" name="btai:NetCashRequiredMinimum" scale="3" id="Narr_j0M99_lXVka0D1Td0I3-xA">15,000</ix:nonFraction>, provided, that the liquidity covenant applicable at any time will be increased upon certain events related to a sale of OnkosXcel (up to a maximum amount equal to $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_r6Nt5rznFkuA80tgQ2K1yA" decimals="-3" format="ixt:num-dot-decimal" name="btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" scale="3" id="Narr_Hvn3vYKTzkuTy9QdQPfTrg">37,500</ix:nonFraction>), provided that the minimum liquidity amount will in no event exceed <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_cP_MaCBZ7UyPaY583or7dQ" decimals="2" format="ixt:num-dot-decimal" name="btai:PercentageOfOutstandingLoan" scale="-2" id="Narr_5EYwhps1hk-2vUNDmk6mbg">50</ix:nonFraction>% of the aggregate amount of loans outstanding under the Credit Agreement at any time; and (ii) a minimum revenue test, measured quarterly beginning with the Company&#8217;s fiscal quarter ending on December 31, 2024 (such six-month period the &#8220;Revenue Covenant Measurement Period&#8221;), that requires it and its subsidiaries&#8217; consolidated net revenue for the six consecutive month period ending on the last day of each such fiscal quarter to not be less than a minimum revenue amount specified in the Credit Agreement (such testing date, the &#8220;Revenue Covenant Measurement Testing Date&#8221; and the covenant described in this clause (ii) the &#8220;Revenue Covenant&#8221;). The Company&#8217;s failure to comply with the financial covenants will result in an event of default, subject to certain cure rights with respect to the Revenue Covenant. If, as of a Revenue Covenant Measurement Testing Date, the Company&#8217;s revenue for the applicable Revenue Covenant Measurement Period is less than the minimum revenue amount specified for the applicable period then required under the Revenue Covenant, the Company would have a right to cure such shortfall for a total of three fiscal periods by making a revenue cure payment (which would be treated as prepayments of the loans subject to a prepayment fee) to the Lenders in an amount equal to the difference between such minimum required revenue amount and the Company&#8217;s actual revenues for such Revenue Covenant Measurement Period, such payment to not be less than $1,000. If paid, the Company will be deemed to have complied with the Revenue Covenant as of such Revenue Covenant Measurement Testing Date. Any such payment will be applied to the prepayment of the loans under the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Notwithstanding the foregoing, the Credit Agreement permits OnkosXcel (together with OnkosXcel Employee Holdings, LLC (&#8220;Employee Holdings&#8221;), a subsidiary of BTI, and their respective subsidiaries, the &#8220;BXCL701 Subsidiaries&#8221;) to receive third-party investment or transfer all or substantially all of their assets to an unaffiliated third party, in each case subject to terms and conditions set forth in the Credit Agreement, including the escrow of certain proceeds received by BTI and its subsidiaries (other than the BXCL701 Subsidiaries) in respect of these disposition events and, under circumstances set forth in the Credit Agreement, the mandatory prepayment of such escrowed amounts. The Company&#8217;s equity interests in the BXCL701 Subsidiaries have been pledged in support of its obligations under the Credit Agreement, and the BXCL701 Subsidiaries have provided direct guarantees of BTI&#8217;s obligations under the Credit Agreement on an unsecured basis. However, the pledge, guarantee and other obligations of the BXCL701 Subsidiaries under the Credit Agreement will be released upon certain agreed upon events, including an initial public offering by the BXCL701 Subsidiaries or the ownership by unaffiliated third parties of at least <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_r6Nt5rznFkuA80tgQ2K1yA" decimals="2" format="ixt:num-dot-decimal" name="btai:SubsidiaryOwnershipPercentage" scale="-2" id="Narr_ul7K1ZQy6U-Rv8sSfeLyrw">20</ix:nonFraction>% of the equity interests in the BXCL701 Subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Credit Agreement contains events of default that are customary for financings of this type relating to, among other things, payment defaults, breach of covenants, breach of representations and warranties, cross default to material indebtedness, bankruptcy-related defaults, judgment defaults, breach of the financial covenants described above, and the occurrence of certain change of control events. In certain circumstances, events of default are subject to customary cure periods. The Credit Agreement also contains certain regulatory-related events of default, which do not have cure periods. Following an event of default and any applicable cure period, the Lenders will have the right upon notice to terminate any undrawn commitments and may accelerate all amounts outstanding under the Credit Agreement, in addition to other remedies available to them as the Company&#8217;s secured creditors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"><b style="font-weight:bold;">Waiver and Third and Fourth Amendments to Credit Agreement and Guaranty</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">On February 12, 2024, the Company entered into the Third Amendment to Credit Agreement and Guaranty (the &#8220;Third Amendment&#8221;), which amended the Credit Agreement. Pursuant to the Third Amendment, the Lenders agreed to waive the covenant that the Company shall not receive a report and opinion from the Company&#8217;s independent auditors that contains a &#8220;going concern&#8221; or like qualification or exception or emphasis of matter of going concern footnote with respect to the Company&#8217;s financial statements for the fiscal year ended December 31, 2023 and, as a result, such event shall not be an event of default. As a condition to the effectiveness of the Third Amendment, among other things, the Company shall have received at least </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_2_12_2024_To_2_12_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_QkgOxhTM3EWQV2UEUZ202A" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_4iuZqeLCkEGHiG1ZRy3Bew">40,000</ix:nonFraction></span><span style="background:#ffffff;"> in gross proceeds from a registered public sale of the Company&#8217;s common stock, warrants and/or pre-funded warrants</span> on or before February 20, 2024. The Company did not meet this condition and therefore the Third Amendment did not become effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_pnlowyoIIka0thGS0TAsIg_cont3" continuedAt="Tb_pnlowyoIIka0thGS0TAsIg_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 20, 2024 (the &#8220;Effective Date&#8221;), the Company entered into the Fourth Amendment to the Credit Agreement and Guaranty (the &#8220;Fourth Amendment&#8221;), which amended the Credit Agreement. Pursuant to the Fourth Amendment, the Lenders agreed to waive the covenant that the Company shall not receive a report and opinion from the Company&#8217;s independent registered public accounting firm that contains a &#8220;going concern&#8221; or similar qualification with respect to the Company&#8217;s financial statements for the year ended December 31, 2023. Accordingly, while the Company&#8217;s independent registered public accounting firm&#8217;s report contained in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 contains a &#8220;going concern&#8221; explanatory paragraph, it does not constitute an event of default under the Credit Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Fourth Amendment includes a covenant that the Company will receive, (i) after the Effective Date and on or before April 15, 2024, at least $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_5ZybN_dt3E6T6rIGI2RnCw" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_dvZx9-7y0EiuNxBzNOn0Qg">25,000</ix:nonFraction> in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or in non-refundable cash consideration from partnering transactions entered into after the Effective Date (so long as such partnering transactions would not require the Company or any of its subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made) and (ii) after the Effective Date and on or before November 30, 2024, at least $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_8e8qqxErlUCxNND1J5ekRw" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_eD_xyibvvk6NH58SqdT-ew">50,000</ix:nonFraction> (for the avoidance of doubt, inclusive of amounts previously counted toward the preceding clause (i)) in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent (as defined in the Credit Agreement) in its sole discretion ) from partnering transactions entered into after the Effective Date. Failure to perform this covenant would constitute (A) a default under the Credit Agreement and (B) an event of default under the Credit Agreement, subject to a cure period, solely in the case of clause (i) of the preceding sentence, until May 15, 2024. For the avoidance of doubt, failure to perform clause (ii) of the preceding sentence would constitute an immediate event of default under the Credit Agreement without any cure or grace period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, the Fourth Amendment provides that if the Company has not, after the Effective Date and on or before September 30, 2024, received at least $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_jyI3cFSKl0a4pfcKd3ZJiA" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_momK8UdtTES6w60bp05hiQ">40,000</ix:nonFraction> in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the Effective Date, the &#8220;Minimum Liquidity Amount&#8221; (as defined in the Credit Agreement) that the Company is required to maintain at all times will increase to $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_3_20_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_t-V_k3tNdUCIUzhMpzNVHA" decimals="-3" format="ixt:num-dot-decimal" name="btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" scale="3" id="Narr_EUnNgCc1ukaLE7nwxCIr5Q">25,000</ix:nonFraction> from $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_2_12_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_jnGiVGydjU-NmDn4wyec3A" decimals="-3" format="ixt:num-dot-decimal" name="btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" scale="3" id="Narr_sldbe_iBAUCg_tVGwZN2qg">15,000</ix:nonFraction>, unless and until the Company has received, after the Effective Date and on or before November 30, 2024, at least $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_8e8qqxErlUCxNND1J5ekRw" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_oW_wGVx-o06k8g8Dp7NYGQ">50,000</ix:nonFraction><span style="white-space:pre-wrap;"> in gross proceeds from the issuance of the Company&#8217;s common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the Effective Date.  On March 27, 2024, the Company received </span>$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_3_27_2024_To_3_27_2024_1d4XGKCHW0m2lIKs8HPE9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="3" id="Narr_D-4UU8PkU0uThszFM_VxlA">25,000</ix:nonFraction> in gross proceeds from the issuance of its common stock, warrants, and pre-funded warrants discussed in Note 11, <i style="font-style:italic;">Common Stock Financing Activities</i>, satisfying the April 15, 2024 covenant requirement of the Fourth Amendment. During the third quarter of 2024, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_7_1_2024_To_9_30_2024_UmSoTOy6ZEqdvjDqQLaKEw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="3" id="Narr_72AmK-XXgEK8QlEFOtl6Ow">467</ix:nonFraction><span style="white-space:pre-wrap;"> of gross proceeds from the issuance of the Company&#8217;s common stock.  As of September 30, 2024, the Company had satisfied </span>$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_g-3YkuAMa0WFmUst9waAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="3" id="Narr_x86QvB4eTEq7xJFg7BxLMQ">30,943</ix:nonFraction> of the $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_7_1_2024_To_9_30_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_xR9vxlNSTk2dU3JYtP5BmA" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_EW78NtWuNUOSyXL8UgI70w">40,000</ix:nonFraction> required to maintain the Minimum Liquidity Amount and the $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_7_1_2024_To_9_30_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_FD1LiU8FskaLMx-wupgQpw" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_GCRR9U-NMUiWEswLG2D1Pg">50,000</ix:nonFraction><span style="white-space:pre-wrap;"> gross proceeds requirement.  As a result, at September 30, 2024, the Minimum Liquidity Amount increased to </span>$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember__PljhQkwa0ehF3g8M7cQfA" decimals="-3" format="ixt:num-dot-decimal" name="btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" scale="3" id="Narr_YSVWVKMU60WmcHsHef1scQ">25,000</ix:nonFraction>. As of September 30, 2024, we were in compliance with all restrictive and financial covenants under the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0pt -0.25pt;"><b style="font-weight:bold;">Waiver and Fifth Amendment to Credit Agreement and Guaranty</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On November 21, 2024, the Company entered into the Fifth Amendment to Credit Agreement and Guaranty and First Amendment to Fourth Amendment to Credit Agreement and Guaranty (the &#8220;Fifth Amendment&#8221;), which amended the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the &#8220;Lenders&#8221;), and Oaktree Fund Administration LLC (&#8220;OFA&#8221;) as administrative agent (as amended by the Waiver and First Amendment to Credit Agreement and Guaranty, dated as of November 13, 2023, the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement, dated as of December 5, 2023, the Third Amendment to Credit Agreement, dated as of February 12, 2024, and the Fourth Amendment to Credit Agreement and Guaranty, dated as of March 20, 2024 (the &#8220;Fourth Amendment&#8221;), the &#8220;Existing Credit Agreement&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_pnlowyoIIka0thGS0TAsIg_cont4" continuedAt="Tb_pnlowyoIIka0thGS0TAsIg_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the Fifth Amendment, the Lenders agreed to, among other things, (i) waive the Credit Agreement&#8217;s covenant that the report and opinion the Company will receive from its independent registered public accounting firm with respect to the financial statements for the year ending December 31, 2024 will not contain a &#8220;going concern&#8221; or similar qualification, (ii) permanently waive the Credit Agreement&#8217;s minimum revenue covenant, and (iii) waive the Fourth Amendment&#8217;s requirement that the Company raise, after the effective date of the Fourth Amendment and on or before November 30, 2024, at least $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_8e8qqxErlUCxNND1J5ekRw" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_yeamzHZmE0uzJQfynRx0dg">50,000</ix:nonFraction> in gross cash proceeds from the issuance of its common stock, warrants, and/or pre-funded warrants, and/or in cash and/or non-cash consideration from newly entered-into partnering transactions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Fifth Amendment includes a new capital raising covenant requiring that the Company receive (A) after the effective date of the Fifth Amendment and on or prior to November 27, 2024, at least $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_X9rWZSSabEakPXkM8Eutyw" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_IbpJEfyPqEewv52wR5ZtVQ">7,000</ix:nonFraction> in gross cash proceeds from the issuance of the Company&#8217;s common stock, warrants and/or pre-funded warrants(&#8220;Raise 1&#8221;), (B) after the effective date of the Fifth Amendment and on or before March 15, 2025 (provided that the Company was required to use its commercially reasonable efforts to satisfy the requirement by February 15, 2025), at least $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_tXi0TB25sk2fARG5mILYWg" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_iwZP0WlSlky_zjhXSrbY-w">18,000</ix:nonFraction> in net cash proceeds (including the proceeds of Raise 1) from (i) the issuance of the Company&#8217;s common stock, warrants and/or pre-funded warrants, (ii) non-refundable cash consideration from partnering transactions entered into after the effective date of the Fifth Amendment (so long as such partnering transactions would not require the Company or any of its subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made), (iii) the issuance of the Company&#8217;s subordinated debt (subject to terms set forth in the Fifth Amendment), and/or (iv) asset sales permitted pursuant to the Credit Agreement or consented to by the Lenders (such capital raise, &#8220;Raise 2&#8221;), and (C) after the effective date of the Fifth Amendment and on or prior to the earlier of (x) August 15, 2025 and (y) the date that is 30 days after the final data readout of the SERENITY At-Home Phase 3 trial, at least $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_G6VSgb21CUeRJAKu7-undQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_JvWchaReuESUpt5iCdT8TA">29,000</ix:nonFraction> in net cash proceeds (including the proceeds from Raise 1 and Raise 2) from the same permitted capital raising activities listed in the preceding clause (B). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the Fifth Amendment and the required capital raises described in the preceding paragraph, the Lenders agreed to modify the Credit Agreement&#8217;s minimum liquidity covenant to require minimum cash liquidity of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_R53JeYIpIkKLogFP9f7n0w" decimals="-3" format="ixt:num-dot-decimal" name="btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" scale="3" id="Narr_GqR9bBlgSUqjeWg3uvhqsA">7,500</ix:nonFraction> (instead of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_3_20_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_t-V_k3tNdUCIUzhMpzNVHA" decimals="-3" format="ixt:num-dot-decimal" name="btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" scale="3" id="Narr_7S768G2XOk62usHK8NePaA">25,000</ix:nonFraction>) from and after the closing of Raise 1until March 30, 2025. On March 31, 2025, the minimum liquidity amount will increase to $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_DBnAiitHfkaS-GOZJ2VMnw" decimals="-3" format="ixt:num-dot-decimal" name="btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" scale="3" id="Narr_8vm0Fv417EuJDZrlOnqWRw">10,000</ix:nonFraction> and on September 30, 2025, the minimum liquidity amount will further increase to $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_V7ch7PHY70Gc6KcqC2X73Q" decimals="-3" format="ixt:num-dot-decimal" name="btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" scale="3" id="Narr_2TNBeIW5QU6oVry9kkwgdQ">15,000</ix:nonFraction>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the Fifth Amendment, the Company paid a one-time amortization payment of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_hsgX06rVV0aG4JHyHT8zVg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="Narr_W9NZ9qAb-0WHeISeqS9c1w">2,500</ix:nonFraction> principal amount, together with accrued and unpaid interest and a portion of the prepayment fee and other fees payable in December 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;">The Fifth Amendment also modifies the interest rate of the loans provided under the Credit Agreement from a floating rate of Term </span><span style="-sec-ix-hidden:Hidden_kFih0nmoC0-H7vISN9YfvQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">SOFR</span></span><span style="font-size:10pt;"> plus </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_hsgX06rVV0aG4JHyHT8zVg" decimals="4" format="ixt:num-dot-decimal" name="btai:DebtInstrumentIncrementalOnVariableRatePercent" scale="-2" id="Narr_H-cE9QD2OEqjJTXe4lG4ZQ">7.50</ix:nonFraction>%</span><span style="font-size:10pt;"> per annum, to a fixed rate of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_m9UZs2c2l0S2PukXjZUImg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_Yvr1qV1v60SYkUQJh4eBUg">13</ix:nonFraction>%</span><span style="font-size:10pt;"> per annum, retroactive to and effective as of September 30, 2024. For the quarterly payment dates ending December 31, 2024, March 31, 2025, and June 30, 2025, the Company will have the ability to make interest payments of up to </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_m9UZs2c2l0S2PukXjZUImg" decimals="2" format="ixt:num-dot-decimal" name="btai:PaidInKindInterestPercentage" scale="-2" id="Narr_1lHo102UjUOiPnfmolG8Lw">10</ix:nonFraction>%</span><span style="font-size:10pt;"> per annum &#8220;in-kind&#8221; by capitalizing and adding such interest to the outstanding principal amount of the loans under the Credit Agreement. In addition, pursuant to the Fifth Amendment, the Company will be required to make quarterly amortization payments equal to </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_hsgX06rVV0aG4JHyHT8zVg" decimals="3" format="ixt:num-dot-decimal" name="btai:DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded" scale="-2" id="Narr_5Ple9qk5MEm6Q437iM9XTA">5.0</ix:nonFraction>%</span><span style="font-size:10pt;"> of the principal amount of funded loans, together with applicable prepayment fees, beginning on March 31, 2026. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On the effective date of the Fifth Amendment and as a condition to effectiveness thereof, the Company&#8217;s wholly owned subsidiaries OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC (collectively, &#8220;OnkosXcel&#8221;), which previously provided unsecured guarantees of the Company&#8217;s obligations under the Credit Agreement, granted security interests in substantially all of their assets to support such obligations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Fifth Amendment amends the negative covenants under the Credit Agreement to remove flexibility the Company and its subsidiaries previously had thereunder to undertake various transactions, including, without limitation, with respect to potential dispositions of OnkosXcel or out-licenses by OnkosXcel of its intellectual property. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Pursuant to the Fifth Amendment, the Company committed to appoint a new independent board director (subject to customary background checks, applicable law, confirmation of independence and Nasdaq rules), and to provide the independent director with various privileges and committee memberships on the board of directors of the Company </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_pnlowyoIIka0thGS0TAsIg_cont5" continuedAt="Tb_pnlowyoIIka0thGS0TAsIg_cont6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">(including the appointment of such director on committee to be formed to focus on capital raising and evaluate strategic options). The Company also agreed to engage an investment banker reasonably acceptable to OFA and the Lenders to assist the Company and its board of directors with evaluating and exploring strategic options. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company also agreed to covenants requiring that the Company&#8217;s cash expenditures be monitored by the Lenders according to a board-approved budget provided to the Lenders prior to the signing of the Fifth Amendment, which cash budget will be updated on a bi-weekly basis going forward. The Company will not be permitted to make disbursements for any two-week period in excess of <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_hsgX06rVV0aG4JHyHT8zVg" decimals="2" format="ixt:num-dot-decimal" name="btai:MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod" scale="-2" id="Narr_QLv4ydk7z0ykM8OQ4wuZpg">115</ix:nonFraction>% of the aggregate budgeted amount of disbursements for the applicable period. Finally, pursuant to the Fifth Amendment, the Company is restricted from paying cash bonuses for its employees or executives during the fiscal years 2024 and 2025 without OFA&#8217;s consent or increasing the cash compensation for fiscal year 2025 for certain senior officers of the Company from their compensation for fiscal year 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Revenue Interest Financing Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As noted, the RIFA was terminated when the Company entered into the Second Amendment, which amended the Credit Agreement (as amended by the First Amendment). The $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_12_5_2023_To_12_5_2023_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_NN4G50mhQUiE2MWFIStQGA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ExtinguishmentOfDebtAmount" scale="3" id="Narr_TgKCJ0oseU6iFU4q3-EPSw">30,000</ix:nonFraction> Tranche A previously provided to the Company under the RIFA was converted to the Tranche A-2 Term Loan. Prior to termination, the RIFA provided up to $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_OgOR5W9P3kGRnS_l9vYR4A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="Narr_eT8rTzud_kysYJTKpkPpcw">120,000</ix:nonFraction> in potential financing in exchange for a capped revenue interest on net sales of IGALMI<sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and other future BXCL501 products, if any, that received regulatory approval for sale. The initial Tranche A of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_7_8_2022_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_rBZ8Wee2aUaWKVAwuLAbJQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Narr_xwEoZzBoBESKh6LNhpXUSg">30,000</ix:nonFraction> was funded on July 8, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the terms of the RIFA, the Purchasers were to receive tiered revenue interest payments on U.S. net sales of IGALMI<sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and other future BXCL501 products, if any, that receive regulatory approval for sale, equal to a royalty ranging from <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_TfYSaq0lxkWKFNAMb3ByvA" decimals="5" format="ixt:num-dot-decimal" name="btai:BorrowingsBasedOnNetSalesPercent" scale="-2" id="Narr_nfapiErS1ka0_FNzlCC0Rg">0.375</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_c3NRP_HuykWiud2XxAIfdw" decimals="5" format="ixt:num-dot-decimal" name="btai:BorrowingsBasedOnNetSalesPercent" scale="-2" id="Narr_mEagg9q8SE2ZNc8XyTTN0g">7.750</ix:nonFraction>% of net sales of IGALMI<sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and other future BXCL501 products, if any, approved for sale in the U.S., subject to a hard cap equal to <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_vxYm8GIUnUOKESLLX6fb8Q" decimals="4" format="ixt:num-dot-decimal" name="btai:ThresholdRatioOfDebtToRevenueRatio" scale="-2" id="Narr_moNtva-RlkyfpJf7Vsg8bQ">1.75</ix:nonFraction>x the total amount funded. The Company would also have been required to make certain additional payments to the Purchasers from time to time to ensure that the aggregate amount of payments received by the Purchasers under the RIFA were at least equal to certain agreed upon minimum levels as of certain specified dates, subject to terms and conditions set forth in the RIFA. Revenue interest payments due under the RIFA were payable quarterly based on net sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Warrants and Equity Investment Right</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the closing of the Second Amendment, on the Second Amendment Effective Date, the Company amended and restated the warrants granted to the Lenders on April 19, 2022 to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_V2jj_eDlt0q_u0vXSYoyKQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_wLRZp7cVa06Af5mnAofUgg">17</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_V2jj_eDlt0q_u0vXSYoyKQ" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_lvPt7qybgUeakS6Xg7mrYA">320.6</ix:nonFraction> per share (the &#8220;Closing Date Warrants&#8221;). Pursuant to the amendment and restatement of the Closing Date Warrants, dated December 5, 2023 (the &#8220;Amended and Restated Closing Date Warrants&#8221;), the exercise price of the Closing Date Warrants has been reduced to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_uPbZgXmXZUiSsb-dyLE4HA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_QARI2Y83iUSSM7IT-OB_ew">58.3232</ix:nonFraction> per share. In addition, the Company granted new warrants to the Lenders to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_W5J6mPqvkkqYc6G6pFfyUQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_NPai5LrwL0ek0dCRMGgExA">4</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;2023 Warrant Shares&#8221;) at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_W5J6mPqvkkqYc6G6pFfyUQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_Zs8mLkC7-ka-3SWLlpM5ig">58.3232</ix:nonFraction> per share (the &#8220;2023 Warrants&#8221;<span style="font-size:12pt;"> </span>and together with the Amended and Restated Closing Date Warrants, the &#8220;Warrants&#8221;). The Amended and Restated Closing Date Warrants and the 2023 Warrants will expire on April 19, 2029 and may be net exercised at the holders election. In addition, pursuant to the Credit Agreement, the Lenders have the right to purchase shares of the Company&#8217;s common stock after the Second Amendment Effective Date, so long as borrowings under the Credit Agreement are outstanding, for a purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_V2jj_eDlt0q_u0vXSYoyKQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:RightToPurchaseStockLenders" scale="3" id="Narr_Kl7T-hn3BEmsuz21Gbe-DQ">5,000</ix:nonFraction> at a price per share equal to a <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_Hql-Wv3mXkKp2hBGSh3usg" decimals="2" format="ixt:num-dot-decimal" name="btai:PremiumSharePricePercent" scale="-2" id="Narr_2gll38NJAUWYMkzJN2uz1Q">10</ix:nonFraction>% premium to the volume-weighted average price of the common stock over the 30 trading days prior to the Lenders&#8217; election to proceed with such equity investment (the &#8220;Equity Investment Right&#8221;). BTI entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the Lenders and filed a registration statement on Form S-3 to register the shares issuable upon exercise of the Warrants and, if issued, the shares related to the Equity Investment Right, for resale. The maximum shares of the Company&#8217;s common stock issuable under the Warrants (including the Closing Date Warrants and the 2023 Warrants) and Lenders&#8217; Equity Investment Right was <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_3_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_0htohoQg0EW5M9buTb1qzQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="3" id="Narr_YvdeUC90KUOAUfEFyXZzeA">366</ix:nonFraction> as of March 31, 2024.<span style="font-size:12pt;"> </span>On the Second Amendment Effective Date, Company amended and restated its Registration Rights Agreement (the &#8220;Amended and Restated Registration Rights Agreement&#8221;) with the Lenders, dated April 19, 2022, pursuant to which the Company agreed to register the 2023 Warrant Shares for resale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As part of the Credit Agreement, OnkosXcel, a wholly owned subsidiary of BTI, granted warrants to the Lenders to purchase <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_M-TubXQul02zZZfaAcmBuA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_AGj20-0Ot0ygGGaBir5sOA">175</ix:nonFraction> individual limited liability company units (which number of units is not in thousands; referred to herein as </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_pnlowyoIIka0thGS0TAsIg_cont6" continuedAt="Tb_pnlowyoIIka0thGS0TAsIg_cont7"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">the &#8220;OnkosXcel Warrants&#8221;). The strike price of the OnkosXcel Warrants is formulaic based on the value of OnkosXcel at the time of exercise and can only be exercised upon occurrence of an equity related liquidity event for OnkosXcel of at least $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_M-TubXQul02zZZfaAcmBuA" decimals="-3" format="ixt:num-dot-decimal" name="btai:ThresholdLiquidityEventAmountForExerciseOfWarrants" scale="3" id="Narr_e0giVGQs1kyBZb13Sr-tEQ">20,000</ix:nonFraction>. The exercise price per unit of the OnkosXcel Warrants will be set upon the earlier of the closing of the next sale (or series of related sales) by OnkosXcel of equity securities of OnkosXcel with aggregate proceeds of not less than $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_M-TubXQul02zZZfaAcmBuA" decimals="-3" format="ixt:num-dot-decimal" name="btai:ThresholdLiquidityEventAmountForExerciseOfWarrants" scale="3" id="Narr_2ISEd3JlZEiLLP96IWMFPA">20,000</ix:nonFraction> to unrelated third parties (the &#8220;Next Equity Financing&#8221;) at an exercise price per unit equal to a <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_w_gcoxE8C0GzioKd7L0Zdw" decimals="2" format="ixt:num-dot-decimal" name="btai:PremiumSharePricePercent" scale="-2" id="Narr_b6ICsD0Ruk2jh0_swMajiQ">10</ix:nonFraction>% premium over the price per unit of the equity securities sold by OnkosXcel in such Next Equity Financing or, in the event of a sale of OnkosXcel prior to the Next Equity Financing or an initial public offering constituting the Next Equity Financing, the lesser of (x) <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_w_gcoxE8C0GzioKd7L0Zdw" decimals="2" format="ixt:num-dot-decimal" name="btai:PercentageOfFairValueConsiderationToBePaid" scale="-2" id="Narr_bR1_VrKJqkuEgxhswQlukQ">75</ix:nonFraction>% of the fair value of the consideration to be paid for a unit upon the consummation of such transaction and (y) <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_w_gcoxE8C0GzioKd7L0Zdw" decimals="2" format="ixt:num-dot-decimal" name="btai:PercentageOfValuationApplicableToInitialProfits" scale="-2" id="Narr_Mpjd835JBkiL_yW7R6nAzA">150</ix:nonFraction>% of the valuation applicable to the initial profits units issued by OnkosXcel after the closing of the Credit Agreement. The OnkosXcel Warrants are transferable with approval from BTI, which cannot be unreasonably withheld, expire on April 19, 2029, and may be net exercised at the holder&#8217;s election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the closing of the Fourth Amendment discussed below, the Company granted new warrants to the Lenders to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_zFzFVctYTUm5PGuvO5mZ0w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_hTr5mMA63UakHECdGstXHQ">6</ix:nonFraction> shares of its common stock (the &#8220;2024 Warrant Shares&#8221;) at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_zFzFVctYTUm5PGuvO5mZ0w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_8eUuV0oBCUaVgLR0zAzUuw">49.1568</ix:nonFraction> per share (the &#8220;2024 Warrants&#8221;), which represents a <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_3_20_2024_To_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_4EZhC-NYEUGDlhcjArlf5w" decimals="2" format="ixt:num-dot-decimal" name="btai:PremiumSharePricePercent" scale="-2" id="Narr_r2tTbYWFFkWJUgKHnYEU_w">10</ix:nonFraction>% premium over the arithmetic average of the volume-weighted average price of the Company&#8217;s common stock on the Nasdaq Capital Market during the 30 trading days preceding the Effective Date. The 2024 Warrants will expire on April 19, 2029 and may be net exercised at the holder&#8217;s election. On the Effective Date, the Company amended and restated its Amended and Restated Registration Rights Agreement (the &#8220;Second Amended and Restated Registration Rights Agreement&#8221;) with the Lenders, originally dated April 19, 2022. Pursuant to the Second Amended and Restated Registration Rights Agreement, the Company agreed to register the 2024 Warrant Shares for resale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Fifth Amendment Warrants, Registration Rights Agreement and Equity Investment Right Termination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Prior to the Fifth Amendment, pursuant to the Credit Agreement, the Lenders had the right to purchase shares of our common stock, so long as borrowings under the Credit Agreement are outstanding, for a purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_V2jj_eDlt0q_u0vXSYoyKQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:RightToPurchaseStockLenders" scale="3" id="Narr_G3xj6b5AR06NM0pz3Ym00Q">5,000</ix:nonFraction> at a price per share equal to a <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_Hql-Wv3mXkKp2hBGSh3usg" decimals="2" format="ixt:num-dot-decimal" name="btai:PremiumSharePricePercent" scale="-2" id="Narr_gV7eBlBvqEiM5Pju7l8rGg">10</ix:nonFraction>% premium to the volume-weighted average price of the common stock over the 30 trading days prior to the Lenders&#8217; election to proceed with such equity investment (the &#8220;Equity Investment Right&#8221;). The Equity investment Right was terminated as part of the Fifth Amendment. We entered into a registration rights agreement with the Lenders (as amended and restated in connection with the Second Amendment, the &#8220;Amended and Restated Registration Rights Agreement&#8221;) and filed registration statements on Form S-3 to register the shares issuable upon exercise of the Closing Date Warrants, 2023 Warrants and the New Warrants for resale. The maximum shares of our common stock issuable under the Closing Date Warrants, the 2023 Warrants and the Lenders&#8217; Equity Investment Right was <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_V2jj_eDlt0q_u0vXSYoyKQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="3" id="Narr_FScMXLbuN0GhqPszg9m2CA">366</ix:nonFraction>. On the Effective Date, we further amended and restated the Amended and Restated Registration Rights Agreement (the &#8220;Second Amended and Restated Registration Rights Agreement&#8221;) with the Lenders. Pursuant to the Second Amended and Restated Registration Rights Agreement, we agreed to register the 2024 Warrant Shares for resale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the closing of the Fifth Amendment, the Company agreed to, substantially concurrently with the closing of Raise 1, grant new warrants to the Lenders to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_JyNR98gl_k-4MeLePLJWaw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_m5SC0sqHZUObDNgqkhRHXA">313</ix:nonFraction> shares of common stock on the closing date of the Fifth Amendment, at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_JyNR98gl_k-4MeLePLJWaw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_J9-3py89o0mTx8WguRp16Q">0.16</ix:nonFraction> per share (the &#8220;New Warrants&#8221;). The New Warrants will expire on the seventh anniversary of their issuance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, the Company agreed to, substantially concurrently with the closing of Raise 1, amend and restate all warrants to purchase stock of the Company issued to the Lenders prior to the effective date of the Fifth Amendment, to revise the exercise price thereunder to an exercise price equal to the lower of (i) the price per share of the common stock of the Company issued in Raise 1 and (ii) arithmetic average of the volume-weighted average price of the Company&#8217;s common stock on the Nasdaq Capital Market during the 30 trading days preceding Raise 1 (such existing warrants, as amended and restated, the &#8220;Original Warrants&#8221;). The Original Warrants provide the Lenders with the right to purchase a total of <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OriginalWarrantsMember_NyepRdGwwE65aulGXbIqFQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_potX2l4ni0aP0Q0ca4O7Ig">28</ix:nonFraction> shares of common stock of the Company, and the exercise prices of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_uPbZgXmXZUiSsb-dyLE4HA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_KCJIdAI6RkS2tqPO9PwESQ">58.3232</ix:nonFraction> per share and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_zFzFVctYTUm5PGuvO5mZ0w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr__Li9Q2frYkePaIgyR9oaug">49.1568</ix:nonFraction> per share were reduced to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OriginalWarrantsMember_NyepRdGwwE65aulGXbIqFQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_7tptBFElsEiHhgFz0Jotpw">7.68</ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On the date of issuance of the New Warrants, the Company agreed to amend and restate its Second Amended and Restated Registration Rights Agreement with the Lenders, dated March 20, 2024. Pursuant to such amendment and restatement (the &#8220;Third Amended and Restated Registration Rights Agreement&#8221;), the Company will agree to register the shares of common stock issuable under the New Warrants, in addition to all Original Warrants, for resale. </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_6c5fc411_4b95_43c2_b8a5_527345c8e46a"></a><a id="Tc_948i1I_IFkO0r6KlvoV8pA_1_2"></a><a id="Tc_CvMCWnnqlUWBepjRaq3nqw_3_0"></a><a id="Tc_geh0W1arqE-0bSjz_-biBg_3_2"></a><a id="Tc_Yji3F0sVqkGcfmTozImQDg_3_3"></a><a id="Tc_DfCTeXxUCkOEhCCnNifp8A_4_0"></a><a id="Tc_vdo-rPr3-EKcYNlspYc1YA_4_2"></a><a id="Tc_AbeMd9y3QE2jyo5XdhLr0Q_5_0"></a><a id="Tc_nvcrI4IxqUmymrOlPipWBw_5_2"></a><a id="Tc_UoUvk6ApnEqlTtn_iHv5Sg_6_0"></a><a id="Tc_jIWxvDxqPEWi6vLUyABp1g_6_2"></a><a id="Tc_DT4ra66DcEuYdE5GenBTow_6_3"></a><a id="_e384deda_270c_4c3d_b742_581205ab41a6"></a><a id="Tc_J1EW2g1Trk-giMmGnRVnmg_1_2"></a><a id="Tc_BZEmjFst4kaKnNqL07LQZQ_2_2"></a><a id="Tc_uLOVMSfbmEKnh7se05vCfg_3_2"></a><a id="Tc_mUpImVOy8E2H6Cxe6LRSGg_3_5"></a><a id="Tc_ImvbnKfix02e0t0TzmP45w_5_0"></a><a id="Tc_cb0j0fnfO0q7dGjw7zrtJA_5_2"></a><a id="Tc_Yv-OFIOhYU-1uJpLjyOdnA_5_5"></a><a id="Tc_9UxrDtBLaE6H0QJvFeMOWQ_6_0"></a><a id="Tc_mbJbO1R6_Ue2mCzYO96rbw_7_0"></a><a id="Tc_isBBCLPfnk-4KzCF4RmA3g_7_2"></a><a id="Tc_0OxJmu9IzEKmzAtfsacV7A_7_5"></a><ix:continuation id="Tb_pnlowyoIIka0thGS0TAsIg_cont7"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As part of entering into the Credit Agreement, OnkosXcel, a wholly owned subsidiary of BTI, granted the OnkosXcel Warrants to the Lenders to purchase <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_M-TubXQul02zZZfaAcmBuA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_dZeUqWJAmkOKDtghKIG19w">175</ix:nonFraction> individual limited liability company units. The strike price of the OnkosXcel Warrants is formulaic based on the value of OnkosXcel at the time of exercise and can only be exercised upon occurrence of an equity related liquidity event for OnkosXcel of at least $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_M-TubXQul02zZZfaAcmBuA" decimals="-3" format="ixt:num-dot-decimal" name="btai:ThresholdLiquidityEventAmountForExerciseOfWarrants" scale="3" id="Narr_cJYXcv04WEyFg9akO4triQ">20,000</ix:nonFraction>. The exercise price per unit of the OnkosXcel Warrants will be set upon the earlier of the closing of the next sale (or series of related sales) by OnkosXcel of equity securities of OnkosXcel with aggregate proceeds of not less than $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_M-TubXQul02zZZfaAcmBuA" decimals="-3" format="ixt:num-dot-decimal" name="btai:ThresholdLiquidityEventAmountForExerciseOfWarrants" scale="3" id="Narr_40EigtwIb0i5Xg9wixUzOQ">20,000</ix:nonFraction> to unrelated third parties (the &#8220;Next Equity Financing&#8221;) at an exercise price per unit equal to a <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_w_gcoxE8C0GzioKd7L0Zdw" decimals="2" format="ixt:num-dot-decimal" name="btai:PremiumSharePricePercent" scale="-2" id="Narr_2nXF3eVmx0qIoXJpLT08eA">10</ix:nonFraction>% premium over the price per unit of the equity securities sold by OnkosXcel in such Next Equity Financing or, in the event of a sale of OnkosXcel prior to the Next Equity Financing or an initial public offering constituting the Next Equity Financing, the lesser of (x) <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_w_gcoxE8C0GzioKd7L0Zdw" decimals="2" format="ixt:num-dot-decimal" name="btai:PercentageOfFairValueConsiderationToBePaid" scale="-2" id="Narr_qKywLVGcIkaKGSTb-mBaQw">75</ix:nonFraction>% of the fair value of the consideration to be paid for a unit upon the consummation of such transaction and (y) <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_w_gcoxE8C0GzioKd7L0Zdw" decimals="2" format="ixt:num-dot-decimal" name="btai:PercentageOfValuationApplicableToInitialProfits" scale="-2" id="Narr_U9Gg0Kxz50CiHeq-qL0yUQ">150</ix:nonFraction>% of the valuation applicable to the initial profits units issued by OnkosXcel after the closing of the Credit Agreement. The OnkosXcel Warrants are transferable with approval from BTI, which cannot be unreasonably withheld, expire on April 19, 2029, and may be net exercised at the holder&#8217;s election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Maturities of long-term debt are expected to be as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="Tb_aN85nPDAdkWcym4d6veUJw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="Tc_M7kJ0Tx4AUqeCmOFFibaSw_4_3">22,431</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="Tc_yfAGY13orkW_f1f08UKrwg_5_3">84,291</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Interest expense was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="btai:ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock" id="Tb_rC9m098uT0-fJNoymaqjmQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_bg2qDPwALUODXyL1aPFECQ_5_3">14,662</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_fShetc6VFkmJnnD-qPSfbQ_5_6">11,941</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion of debt discount and amortization of financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_qpxQG-3zUUKR-mHRLTKz2g_6_3">467</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_YJBi5D-CRUKoQLiFPAzgcw_6_6">1,373</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total interest expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" id="Tc_C4frGGlVMk6AE9NxcdtR_g_7_3">15,129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" id="Tc_hD2ueJJZqUGGgrsc-rNhNQ_7_6">13,314</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-size:12pt;font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="Tb_ZKGXBNc1h0e6WwdVzjebEg" continuedAt="Tb_ZKGXBNc1h0e6WwdVzjebEg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;10. Derivative Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">BTI identified certain freestanding financial instruments and/or embedded features that require separate accounting from the borrowings under the OFA Facilities. This includes the OnkosXcel Warrants and Equity Investment Right held by the Lenders, along with certain put/call options.  The OnkosXcel Warrants and Equity Investment Right do not meet certain scope exceptions under U.S. GAAP, primarily because the exercise prices and number of shares of the Company&#8217;s common stock issuable under the instruments are variable, and the instruments meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Consolidated Balance Sheets. The respective derivative liabilities are recorded at fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#8217;s Consolidated Statements of Operations.</span><span style="font-size:12pt;"> </span>As discussed in Note 9, <i style="font-style:italic;">Debt and Credit Facilities</i><span style="white-space:pre-wrap;">, the Equity Investment Right was terminated on November 25, 2024 in connection with the Fifth Amendment to the Credit Agreement.  The Company recorded the termination gain of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_11_25_2024_To_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_DqkDewrv3kmwfGEQUIsTbQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" sign="-" scale="3" id="Narr_qXvgRJcmTESr0XESPDr5bQ">1,263</ix:nonFraction> within Other (income) expense, net in the Company&#8217;s Consolidated Statements of Operations for the carrying value of the Equity Investment Right. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;">With respect to the Securities Purchase Agreement discussed in Note 11, <i style="font-style:italic;">Common Stock Financing Activities</i>, BTI determined that the Accompanying Warrants fail the equity classification criteria and are therefore classified as liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity ("ASC 480") and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The Accompanying Warrants failed to meet the requirements to be indexed to equity and equity </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_ZKGXBNc1h0e6WwdVzjebEg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">classified, and meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Consolidated Balance Sheet as of December 31, 2024. The respective derivative liabilities were recorded at fair value on the date of issuance in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_oiu1ThMdnUOs-KiwIduWmQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Narr_d52i4YluhEaWqS_ROy451Q">19,347</ix:nonFraction> and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#8217;s Consolidated Statements of Operations. We value the Accompanying Warrants using the Black-Scholes option pricing model as discussed in Note 14, <i style="font-style:italic;">Fair measurements</i>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;">On November 21, 2024, the exercise price of <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_G-NzlEzfREKwJKc_rBs35Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Narr_XURSzU6e60mtXippLHiedQ">534</ix:nonFraction> of the Accompanying Warrants was reduced from $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_oiu1ThMdnUOs-KiwIduWmQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_XUUNZMsoO0ijtbbCgfWZEg">51.20</ix:nonFraction> to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_-Q7xp87Es0iyjocCWGGiMg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_0AOhGgJS3Eeem6t8y_2Qfw">9.136</ix:nonFraction> per share. As a result of the repricing, the Company recorded the increase in fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_KgwhcGdOLE6rb5LSOLdQQw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="Narr_3id09s4HGU2oshUzJX9qTg">1,000</ix:nonFraction><span style="white-space:pre-wrap;"> as an increase to the carrying value of Derivative liabilities, recorded as an increase to their carrying value, and as a loss in Other (income) expense, net, in the Company&#8217;s Consolidated Statements of Operations.  For the year ended December 31, 2024, the Company recorded total net gains of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_5eL_-_utPUCNyy4fj-GOyA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="Narr_Kgn_JvCe9UifFyyHcImJFw">17,027</ix:nonFraction>, including the $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_KgwhcGdOLE6rb5LSOLdQQw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="Narr_u-6wRRiz_Ee3bZugf2WbaQ">1,000</ix:nonFraction> repricing loss, in Other (income) expense, net, in the Company&#8217;s Consolidated Statements of Operations. As of December 31, 2024, the fair value of the Accompanying Warrants was $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_JBeXWTEcBki5v7foWKB49w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Narr_j952oct2DEiHun8DobxGTQ">2,320</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;">On November 25, 2024, as discussed below, the Company issued additional warrants (the &#8220;November 2024 Accompanying Warrants&#8221;). The November 2024 Accompanying Warrants failed to meet the requirements to be indexed to equity and equity classified, and meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Consolidated Balance Sheet as of December 31, 2024. The respective derivative liabilities were recorded at fair value on the date of issuance in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_DdDbFFCDBE64P_O4BJl7kA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Narr_-uPk3XgLnEK61NOKavGbNg">5,562</ix:nonFraction> and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#8217;s Consolidated Statements of Operations. For the year ended December 31, 2024, the Company recorded total net gains of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_p63njE8R7Eu_9LSZHS_XWw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="Narr_gSUBK2h8PUazwFONTY_P9g">1,289</ix:nonFraction> in Other (income) expense, net, in the Company&#8217;s Consolidated Statements of Operations. As of December 31, 2024, the fair value of the November 2024 Accompanying Warrants was $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_XYejg84PY0-8-DI1vMLBvw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Narr_AwY-FMeQvE6JjnJkz-r21A">4,273</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="btai:FinancingActivitiesDisclosureTextBlock" id="Tb_Ech13adQ10-3jkW5KFGFww" continuedAt="Tb_Ech13adQ10-3jkW5KFGFww_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;11. Common Stock Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"><span style="font-weight:normal;">In May 2021, the Company entered into</span><span style="font-weight:normal;"> an </span><span style="font-weight:normal;">Open Market Sale Agreement (as amended, supplemented and/or restated from time to time, the &#8220;Sale Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) pursuant to which the Company could offer and sell shares of its common stock, having an aggregate offering price of up to </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_5_31_2021_To_5_31_2021_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_7HqDJsFg10yEnahziR0XDQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:SaleOfStockMaximumValueSharesToBeIssued" scale="3" id="Narr_PApXZWbGFE2q4kmQ6AE2lg">100,000</ix:nonFraction></span><span style="font-weight:normal;">, from time to time, through an &#8220;at the market offering&#8221; program under which Jefferies will act as sale agent. In November 2023, the Company amended the Sale Agreement to increase the size of the &#8220;at the market offering" program to </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_11_1_2023_To_11_30_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_EVFuPSms4EKLkPgGiKPLIw" decimals="-3" format="ixt:num-dot-decimal" name="btai:SaleOfStockMaximumValueSharesToBeIssued" scale="3" id="Narr_b1wboK9GRUCmVMmoxgduqg">150,000</ix:nonFraction></span><span style="font-weight:normal;">. For the year ended December 31, 2023, the Company sold </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_DmobgouGJEKpKx5umwnDTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Narr_bHjMndFqpkmNFW4U_c8ypQ">88</ix:nonFraction></span><span style="font-weight:normal;"> shares of its common stock for a gross amount of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_DmobgouGJEKpKx5umwnDTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Narr_P-l9s5EMTk-ft7ozvnf6rg">27,032</ix:nonFraction></span><span style="font-weight:normal;">, incurred issuance costs of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_DmobgouGJEKpKx5umwnDTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Narr_70xMgkDVXkmSspsmWkI5tw">811</ix:nonFraction></span><span style="font-weight:normal;">, and received net proceeds of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_DmobgouGJEKpKx5umwnDTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Narr_CX1_W8zOi0im1x3AS9-49Q">26,221</ix:nonFraction></span><span style="font-weight:normal;">. For the year ended December 31, 2024, the Company sold </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_AhSo6vKkHk2Ijnc-39vr0A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Narr_32U-3Q6hmE-EghzoTJKTJQ">240</ix:nonFraction></span><span style="font-weight:normal;"> shares of its common stock for a gross amount of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_AhSo6vKkHk2Ijnc-39vr0A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Narr_-R9hXF7Q0UKnkRevX12IMw">7,682</ix:nonFraction></span><span style="font-weight:normal;">, incurred issuance costs of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_AhSo6vKkHk2Ijnc-39vr0A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Narr_tQmE4RISRkGFrW0ALVoZ7g">231</ix:nonFraction></span><span style="font-weight:normal;">, and received net proceeds of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_AhSo6vKkHk2Ijnc-39vr0A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Narr_M11C5RDGuk-hx0uG1wrpDA">7,451</ix:nonFraction></span><span style="font-weight:normal;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 25, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with the purchasers named therein (collectively, the &#8220;Purchasers&#8221;). Pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Purchasers in a registered direct offering (the &#8220;Offering&#8221;) under an effective shelf registration statement on Form S-3 (File No. 333-275261) and a related prospectus supplement filed with the Securities and Exchange Commission on March 25, 2024 (the &#8220;Prospectus Supplement&#8221;) an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_3_25_2024_To_3_25_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_p4L6ETPqFEWoA9lBndZOtQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Narr_CCxOm-c5ZUCdHv6rvPXaTA">191</ix:nonFraction> shares (the &#8220;Shares&#8221;) of common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_3_25_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_qU4qYdPWcke_ZGR8vt26Xg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_1OBjeUMWn0ucow-THWco9Q">0.001</ix:nonFraction> per share, and accompanying warrants (the &#8220;Accompanying Warrants&#8221;) to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_IrTiliqP_U6VjgDahhs3oQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_3xyzvmfCR0q2gf2QqzpBOw">191</ix:nonFraction> shares of common stock at a combined offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_3_25_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_qU4qYdPWcke_ZGR8vt26Xg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_5GhdMbO1EkWsR7X-GwNvvA">4.416</ix:nonFraction> per Share and Accompanying Warrant and pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_ao0h5xCb-0is227s68HQKA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_NVU3ef06sUO-i99MsfNSMw">348</ix:nonFraction> shares of common stock and Accompanying Warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_ao0h5xCb-0is227s68HQKA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_ub3bt0n000uWmPPpR8EW8A">348</ix:nonFraction> shares of common stock, at a combined offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_IrTiliqP_U6VjgDahhs3oQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_sRipCJu6MkmvwBcoz2MMsw">46.40</ix:nonFraction> per share underlying each Pre-Funded Warrant and Accompanying Warrant, which equals the offering price per Share and Accompanying Warrant less the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_ao0h5xCb-0is227s68HQKA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_0OEUi39XXkWr3NUGAXZHHw">0.016</ix:nonFraction> exercise price per share of the Pre-Funded Warrants. The Pre-Funded Warrants and Accompanying Warrants are not listed on the Nasdaq Capital Market or any other securities exchange or trading system and the Company does not intend to list them. On March 27, 2024, The Company received $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_3_27_2024_To_3_27_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_RvjnXZnJAEar_nFyvWCG8g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Narr_dL6qF8WIUEO02E-neGjLaA">25,000</ix:nonFraction> of gross proceeds from the Offering, incurred issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_3_27_2024_To_3_27_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_RvjnXZnJAEar_nFyvWCG8g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Narr_STMK8SmTrkqtsMpSBFUwoQ">248</ix:nonFraction>, and received net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_3_27_2024_To_3_27_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_RvjnXZnJAEar_nFyvWCG8g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Narr_lu8P-JzdeUmXJL_TGlz51Q">24,752</ix:nonFraction>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_Ech13adQ10-3jkW5KFGFww_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Pre-Funded Warrants have an exercise price per share of common stock equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_ao0h5xCb-0is227s68HQKA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_oCT9RSAFJEC6TSVO4IDzbA">0.016</ix:nonFraction> per share. The exercise price and the number of shares of common stock issuable upon exercise of the Pre-Funded Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The Pre-Funded Warrants are exercisable at any time after the date of issuance. For the year ended December 31, 2024, <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_Wv-fkHFxikOa4i1-EXoS9A" decimals="-3" format="ixt:num-dot-decimal" name="btai:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" id="Narr_3rg3dzx140W_fE_ukqOFJQ">348</ix:nonFraction> Pre-Funded Warrants were exercised and the same number of shares of common stock were issued in exchange for $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_Wv-fkHFxikOa4i1-EXoS9A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" id="Narr_SNDKpqyv1EuaP-6ZRdNEeg">6</ix:nonFraction> of proceeds received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Accompanying Warrants have an exercise price per share of common stock equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_IrTiliqP_U6VjgDahhs3oQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_GL940G2DW06TkkFK-md8tw">51.20</ix:nonFraction> per share. The exercise price and the number of shares of common stock issuable upon exercise of the Accompanying Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The Accompanying Warrants will be exercisable at any time after the date of issuance and will expire on the fifth anniversary of the date of issuance. The Accompanying Warrants do not meet certain scope exceptions under U.S. GAAP, primarily because they did not meet the requirements to be indexed to equity and equity classified, and the instruments meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Consolidated Balance Sheet as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On November 22, 2024, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Canaccord Genuity LLC, as underwriter (the &#8220;Underwriter&#8221;), in connection with the issuance and sale by the Company in a public offering of (i) <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_11_22_2024_To_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_qCNNy1whp0ivehAR5sAVYg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Narr_xZD2Vw6OQk68t55MyDj7fA">350</ix:nonFraction> shares of the Company&#8217;s common stock, and accompanying warrants (the &#8220;November 2024 Accompanying Warrants&#8221;) to purchase <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_LGUU816Yp0m2LKivHXs1uw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_PZbqZ0fFRkysqcMsxJWuZQ">350</ix:nonFraction> shares of Common Stock, at a combined public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_GIUFHpY0_EqDv2ibJW6xSg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_HSdSjDq7u0KnQ_y3Zw-T9Q">7.68</ix:nonFraction> per share, and, in lieu thereof to certain investors, (ii) pre-funded warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_aWycUKhL-06MF4rymZ6neQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_cc31xntSlEykzkaCATiyLw">563</ix:nonFraction> shares of Common Stock, and accompanying warrants (the &#8220;November 2024 Accompanying Warrants&#8221;) to purchase <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_aWycUKhL-06MF4rymZ6neQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr__UtSg8HGI0qDIQ9FUoiYfw">563</ix:nonFraction> shares of Common Stock, at a combined public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_tv06eTkorUuLZsqZJC7L6Q" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_bMIUcLzcXEidjl7UTLWUUw">7.664</ix:nonFraction> per pre-funded warrant, which equals the public offering price per share of Common Stock and accompanying warrant less the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_Olx3FwfBuUyeg4UcTjGZjg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_9Z9f5jBVqkCzlJtPWy9s6g">0.016</ix:nonFraction> exercise price per share of the pre-funded warrants, less underwriting discounts and commissions, pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-275261) and a related prospectus supplement filed with the Securities and Exchange Commission. For the year ended December 31, 2024, <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_g6yAJhZGY0yVCcOg2tqiqA" decimals="-3" format="ixt:num-dot-decimal" name="btai:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" id="Narr_umca_E17mEyB2Dao3PLY9w">80</ix:nonFraction> pre-funded warrants were exercised and the same number of shares of common stock were issued in exchange for $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_g6yAJhZGY0yVCcOg2tqiqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" id="Narr_Z63IXbKN_0eHj68euqPx4A">1</ix:nonFraction> of proceeds received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Each of the November 2024 Accompanying Warrants in the offering is subject to customary beneficial ownership limitations on exercisability, is exercisable at any time after the date of issuance of such warrant and, in the case of the accompanying warrants, will expire on the fifth anniversary of the date of issuance. Each of the November 2024 Accompanying Warrants will have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_GIUFHpY0_EqDv2ibJW6xSg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_kKPJkEjKd0CdiuCjNmdA2A">7.68</ix:nonFraction> per underlying share of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company received net proceeds from the offering of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_11_22_2024_To_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_qCNNy1whp0ivehAR5sAVYg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Narr_JVhplASQyEehCfB-wz6xbA">6,128</ix:nonFraction>, after deducting underwriting discounts and commissions and offering expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_11_22_2024_To_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_qCNNy1whp0ivehAR5sAVYg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Narr_w8fZ-LlxKkGRilm96WMZaQ">871</ix:nonFraction>. The Company intends to use the net proceeds of the offering to fund the SERENITY At-Home trial, prepare for the initiation of the TRANQUILITY In-Care trial, working capital and general corporate purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_w4XCdc3kwEOCwQ113U_K1w" continuedAt="Tb_w4XCdc3kwEOCwQ113U_K1w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;12. Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">2017 Equity Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s 2017 Plan became effective in August 2017. Following the effective date of the Company's 2020 Plan, the Company ceased granting awards under the 2017 Plan, however, the terms and conditions of the 2017 Plan continue to govern any outstanding awards granted thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">2020 Incentive Award Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s 2020 Plan was approved and became effective at the Company&#8217;s 2020 annual meeting of stockholders on May 20, 2020, and unless earlier terminated by the Board of Directors, will remain in effect until March 26, 2030. The 2020 Plan originally authorized for issuance the sum of (i) <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_vDwwtKHeaUKjbZq0pfe-PA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="3" id="Narr_DytSpWfXaUiWskDHTMyJjQ">57</ix:nonFraction> shares of the Company&#8217;s common stock and (ii) <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_StockPlan2017Member_L_iPsP7adEiG4elxGlZNHw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" id="Narr_buItFEJDjUSwe9V0eEMIsw">15</ix:nonFraction> shares of the Company&#8217;s common stock, which represents the number of shares that remained available for </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_68DZY39d5EGnikTRmE-ZMA_2_2"></a><a id="Tc_twAVhsUR7Eu1FxjkUvJ0Bg_3_2"></a><a id="Tc_9voUwpEhsEKlj4HUiZm08Q_5_0"></a><a id="Tc_k_9wFVePvE2yoHhqGl3KUA_6_0"></a><a id="Tc_PhwRgOZLCk6qJ9fsYNrS-g_7_0"></a><a id="Tc_2V5rhAftKUyjuUlvK8K3Aw_8_0"></a><a id="Tc_IybnoSZD0UuxT69-2rk2tg_9_0"></a><a id="Tc_GE0B-BAQr0mpmCGY2Az5VQ_1_2"></a><a id="Tc_2Vn_q3oMwkShHOfS2kDRpQ_2_2"></a><a id="Tc_VUDMm3vsz0mHTN1qnrgvIA_4_0"></a><a id="Tc_LTRxJick00yU9SY0Xriayg_5_0"></a><a id="Tc_L2W_odXnbEuzxgYcGuJ4Kg_6_0"></a><a id="Tc_j-wEQnRAc0KcKM0kGt2gRg_7_0"></a><a id="Tc_7le4Fm3gPk-zEigCd_EdGA_8_0"></a><ix:continuation id="Tb_w4XCdc3kwEOCwQ113U_K1w_cont1" continuedAt="Tb_w4XCdc3kwEOCwQ113U_K1w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">issuance under the 2017 Plan immediately prior to the approval of the 2020 Plan by the Company&#8217;s stockholders. Any shares of common stock which, immediately prior to the approval of the 2020 Plan by the Company&#8217;s stockholders, were subject to awards granted under the 2017 Plan that are forfeited or lapse unexercised and are not issued under the 2017 Plan will increase the number of shares of common stock available for grant under the 2020 Plan. In addition, the number of shares available for issuance under the 2020 Plan will increase on the first day of each calendar year, beginning January 1, 2021 and ending on and including January 1, 2030, by a number of shares equal to the lesser of (A) <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_IRUWqt-XME6DBPhp1Szf3w" decimals="2" format="ixt:num-dot-decimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" scale="-2" id="Narr_FKEqmhJHFkaI4DCv6CKiOQ">4</ix:nonFraction>% of the aggregate number of shares of the Company&#8217;s common stock outstanding on the final day of the immediately preceding calendar year and (B) such smaller number of shares of common stock as determined by the Board of Directors. The shares available for issuance under the 2020 Plan increased by <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_tHUExHKUMUmrePF-CWMIfw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" id="Narr_9RzAfBMTvkW_dm6nOICUGQ">75</ix:nonFraction> shares and <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_RvCrri81RU2aLpOi6LE4XQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" id="Narr_QjXkTj2JtUOUWRDNHsX0lQ">70</ix:nonFraction> shares on January 1, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Stock-based awards granted under the 2020 Plan have a term of <ix:nonNumeric contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_IRUWqt-XME6DBPhp1Szf3w" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_RSWSoak-NUqH2Dhpqkjx2Q">ten years</ix:nonNumeric>. The vesting schedule of all awards granted under the 2020 Plan is determined by the Board of Directors, which is generally <ix:nonNumeric contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_IRUWqt-XME6DBPhp1Szf3w" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_AoyhVKjXAk-N-ByJLJx17A">four years</ix:nonNumeric>. Stock-based awards granted under the 2020 Plan include stock options, BTI RSUs, and Performance Units.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2024, there were <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_vq2yym5s9EyjbM2-H8oIkw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" id="Narr_JmCyXVdwT0-gWAzrz5VseQ">42</ix:nonFraction> shares available to be granted under the 2020 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BTI Restricted stock units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The table below summarizes activity relating to BTI RSUs.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mnMmxsdqv0CnwoCMs9Wk3Q" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="Tb_3LVvkB_iPkeNgCVM3t5uAw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares </b></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OZo6Dpf0wkeLIC74MDokcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="Tc_JK5tCM_jiUag0cVgsZ2V1g_5_2">12</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mnMmxsdqv0CnwoCMs9Wk3Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="Tc_ulPtLyxjekmgWfQD8UmKtA_6_2">22</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mnMmxsdqv0CnwoCMs9Wk3Q" decimals="-3" format="ixt:num-dot-decimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" scale="3" id="Tc_Rfq4QqSe8U-hBsKv4SsszQ_7_2">1</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mnMmxsdqv0CnwoCMs9Wk3Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="Tc_XPUQXN2oEEe4oc1jxT14PQ_8_2">6</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_4epNlYQKv0iKvwBrZlbiTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="Tc_8G_0-wOhy0O6-M9H2mYEZQ_9_2">27</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In 2024, the Company granted <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mnMmxsdqv0CnwoCMs9Wk3Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="Narr_je2esAzPd0OEyXOIEk6zzQ">22</ix:nonFraction> time-based BTI RSUs to certain employees, executives, and board members. The RSUs granted to employees and executives vest <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mnMmxsdqv0CnwoCMs9Wk3Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_Z4It-7WfJUq8PaPBXp6g9g">100</ix:nonFraction>% at the <span style="-sec-ix-hidden:Hidden_O-R2_NsEcUirYc0hrciCHQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-year anniversary of the grant date. The weighted average grant date fair value per share for the BTI RSUs granted to employees and executives in 2024 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_p0pq-UOWxEu_wI0sw4gUPQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_0Izr3jfUKUOz8iDb4Xt8aA">23.43</ix:nonFraction>. Unrecognized stock-based compensation expense related to these awards was $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_j0QU6pzy1kWBLf65tC1seA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_NNPbjO7Az0-dk1Mshe0uxA">13</ix:nonFraction> as of December 31, 2024. The RSUs granted to board members vest monthly over a <span style="-sec-ix-hidden:Hidden_ZV8mysUnJEKMO7_R1BXZ3w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12-month</span></span> period, beginning in November 2024. The weighted average grant date fair value per share for the BTI RSUs granted to board members was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_A8ZHOdOBykqthS4c1Q8gUA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_OsIjeO4ke0qm-u9pMS4Lpg">9.12</ix:nonFraction>. Unrecognized stock-based compensation expense related to these awards was $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_Mb79eA35SUKhSf2JoRymdA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_5nprP3xroEOOtkoDZaCRlw">185</ix:nonFraction> as of December 31, 2024. Unrecognized stock-based compensation expense related to awards issued prior to 2024 was $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_4epNlYQKv0iKvwBrZlbiTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_rXsESn35p0eQ6OrG-6I3Nw">575</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OZo6Dpf0wkeLIC74MDokcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_2tjc0VoQNEy77Z8n4SxrBg">1,715</ix:nonFraction> as of December 31, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BTI Performance stock units </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The table below summarizes activity relating to Performance Units related to BTI common stock.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_CrXc_wq4WE6253aRHA7iZQ" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" id="Tb_v1_RaLknT0azb28FEA9rXg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares </b></p></td></tr><tr><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_S6eKsZBc2UGXa8jiNAbKrA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="Tc_osd9tHcXlUaILwZ1zcDO8Q_4_2">33</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_CrXc_wq4WE6253aRHA7iZQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="Tc_l21IQ64PAU6xXLPQsG8P1w_5_2">87</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_CrXc_wq4WE6253aRHA7iZQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" scale="3" id="Tc_KzHMgA06XE2HZ3mZEjYhZA_6_2">27</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_CrXc_wq4WE6253aRHA7iZQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="Tc_6g3fI_dZDkmnHD-N_Unfpw_7_2">23</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:86.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_sog3pKgdW0eiohkZeERd4Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="Tc_BRfMkzegwE2fDT-KoBZzfw_8_2">70</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In July 2024, the Company granted <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_hTkGBWRuAUSz0YVpoWxPsA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="Narr_5nvvrvf_-k-uX9h9Kmekgw">87</ix:nonFraction> Performance Units to employees. The Performance Units vest on the <ix:nonNumeric contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_hTkGBWRuAUSz0YVpoWxPsA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_VyVQ9G0kq0uLB1BBi642YA">one-year</ix:nonNumeric> anniversary of the grant date, provided certain performance criteria are met. The weighted average value per share </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_2Ye-KSzVFU25bcASpFKHtA_2_4"></a><a id="Tc_INTdwB6Ff02h5ktJfLwG_w_3_2"></a><a id="Tc_128NzDB7S0-8xQpOyszrlw_3_4"></a><a id="Tc_abLnWjtl606kl7lW4A0FjA_4_2"></a><a id="Tc_XdsZPi-aYU22kIzZmzQemA_4_4"></a><a id="Tc_KUtMafiwPEWhorAErtWWMw_6_0"></a><a id="Tc_3xvwTfctfUmxFzrWyfiIrA_6_4"></a><a id="Tc_6DSyFf1s5EeHDmUAExZl9A_7_0"></a><a id="Tc_WJX5sYt8VEi4_MyLlT-DxQ_7_4"></a><a id="Tc_L_p3J30Cu0Oa9JkRmmbVlg_8_0"></a><a id="Tc_7DtDWyS9tE2SCXzrq5-KFQ_8_4"></a><a id="Tc_-qptq0TIb0CiELPUX6esvQ_9_0"></a><a id="Tc_tDza21cH0kO6iag_ZBF-Lg_9_2"></a><a id="Tc_t9n2Dd-exUSonPKxy3ogEg_9_4"></a><a id="Tc_VvdVhuAyWEKHaLIYL-yULQ_9_5"></a><a id="Tc_d8Dcr2CZcEioL43J5G2e7w_10_0"></a><a id="Tc_kM_Ip4UcN0aw3caAeoFT5A_12_0"></a><a id="Tc_zcyWKR1sw0OJG1iC52l7nQ_12_4"></a><a id="Tc_PcKupboa50u_EAo-OP6UMg_2_2"></a><a id="Tc_Bd80VkyI5Ue5jH65_ObpqQ_4_0"></a><a id="Tc_6O6s777prkWLgnX4i0_GOw_4_3"></a><a id="Tc_QNmHCVPxz0SLGBzxL0MlHw_5_0"></a><a id="Tc_BOFGfI2Ml0OjmgETP4tFtg_5_3"></a><a id="Tc_63N1FsWxh06b5KnY_r-Uew_6_0"></a><a id="Tc_IvkWn-IO6UWUfA5wii6MfA_6_3"></a><a id="Tc_z0bRj39wDEqY9zL2k0rneg_7_0"></a><a id="Tc_dmpYLFQQl0OcA0naBwLEuA_7_3"></a><a id="_a75825b6_04d7_40c0_8692_03d6ff9fc96d"></a><a id="Tc_ErA_Si6e8UWwLkP3ix0kSA_2_2"></a><a id="Tc_Ano_7rQov0CXvvjqYoCySA_3_2"></a><a id="Tc_t423URyej0qgJtVkY-Q3ew_5_0"></a><a id="Tc_51oTvtbOQUuXo1d5apvOmA_6_0"></a><a id="Tc_nc-9i1dhRk2aLKzVq-t_-A_6_2"></a><a id="Tc_LvfPrBVh906_vntcDoys2g_7_0"></a><a id="Tc_vNYAM4FoEEWA3x-U0Wf_0w_8_0"></a><a id="Tc_NBYuBKiF-kW5rnCqqT80zQ_9_0"></a><ix:continuation id="Tb_w4XCdc3kwEOCwQ113U_K1w_cont2" continuedAt="Tb_w4XCdc3kwEOCwQ113U_K1w_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">of Performance Units granted in 2024 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_hTkGBWRuAUSz0YVpoWxPsA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_2EQopZo7d0KE77PQdcqi6Q">19.20</ix:nonFraction>. <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_CrXc_wq4WE6253aRHA7iZQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="Narr_zaHiYx7mZUK0FJlSuXn1PQ">None</ix:nonFraction> of the Performance Units had vested as of December 31, 2024. Unrecognized stock-based compensation expense related to these Performance Units expected to vest was <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_sog3pKgdW0eiohkZeERd4Q" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_RVdjYtFmqUONntd-WwYwnA">zero</ix:nonFraction> as of December 31, 2024 since it is uncertain whether any performance criteria will be met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">OnkosXcel Profit sharing units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The table below summarizes activity relating to the PSUs associated with OnkosXcel as described below.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" id="Tb_g7EWuwCyvUqhEukX91rBhA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price per unit</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in whole dollars)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_urjzmG69Fk6Da0LeQweFZA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_SG8Nve11vkS4idfjMjScaQ_6_2">1,240</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_urjzmG69Fk6Da0LeQweFZA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_lX04YYC9fEO2JrMNn3blqg_6_5">5,626</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_s0Effp49l0e3vEYGym69pw_7_2">15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_5E3jDf2MzESNdQfjRn-OoQ_7_5">10,176</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ" decimals="0" format="ixt:num-dot-decimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" scale="0" id="Tc_seTg2e45ZkWOGf87DdGEMQ_8_2">89</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ" decimals="0" format="ixt:num-dot-decimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" scale="0" id="Tc_snrdCXe5rUq7o4oO5hM47A_8_5">5,506</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_3fPI5jL5i0amKn6Rp0WTxA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_EymraiM9ZUa-dWmDgH9BsA_10_2">1,166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested units as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_3fPI5jL5i0amKn6Rp0WTxA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_VTfd6dXSR0eeXz6vYtT7pg_12_2">941</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_3fPI5jL5i0amKn6Rp0WTxA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_sigdsAeU7Eewp8dGvD-shQ_12_5">5,570</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">During 2024, OnkosXcel Employee Holdings, LLC, a management holding company used to facilitate the grant of equity interests to service providers of OnkosXcel granted <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_2AJ8iXFoCkGYFIe4Fy4QrQ">15</ix:nonFraction> individual (not in thousands) time-based PSUs related to OnkosXcel to certain employees of the Company in consideration for services provided to OnkosXcel. The PSUs represent indirect equity interests in OnkosXcel. These PSUs vest ratably over <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_OWMKyjoSQU62xaUA5jREvQ">48 months</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The fair values of the PSUs granted in 2024 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_urjzmG69Fk6Da0LeQweFZA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" scale="0" id="Narr_Xq6NSpalFUuhdJW7VSI2xg">8</ix:nonFraction> per unit, and was estimated at the date of grant using a Black-Scholes option pricing model. The total fair value of the PSUs vested during the year ended December 31, 2024 was $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="3" id="Narr_6zfZDEfPnk2cCogUmrasxg">1,165</ix:nonFraction>.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_D2x87gjqo0W4usCOGOupGA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:22.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024 grant profit share unit valuation inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_PXsWhw_HnUmCJ3BRP8Hhpg_4_2">97.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_9OROBP9JQEifVo4E8qqnQQ_5_2">3.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ" decimals="3" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_tsAjFBQedUqbtPh2K3ppEg_6_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_vxRV85kK3EigZ1nm-fRL3g_7_2"> 5.8</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Unrecognized stock-based compensation expense related to the PSUs was $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_3fPI5jL5i0amKn6Rp0WTxA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_TGboIdn2m06gV6t4IO2-EA">377</ix:nonFraction> as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">OnkosXcel restricted stock units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The table below summarizes activity relating to the OnkosXcel RSUs.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_pyA1UGmh10OZkxGv9jCGdQ" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="Tb_uwmcdaIEU0yASUtrONdT8Q" continuedAt="Tb_uwmcdaIEU0yASUtrONdT8Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">units</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_B1zotSn0RUq8Gi-caKB5-Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="Tc_A7gYG0lKJUiu50OF4eAWtw_5_2">225</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Granted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Vested</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_pyA1UGmh10OZkxGv9jCGdQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="Tc_bNZIJ2_1rEitSHVoY4iA8g_7_2">41</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Cancelled</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_pyA1UGmh10OZkxGv9jCGdQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" scale="3" id="Tc_nln9tHp7Kkq5T1sy-crcFA_8_2">8</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_ZZb5ojV8nECXF6PGT2Sv6w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="Tc_tKALX5RNRkiI86m5CxWRfQ_9_2">176</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_VDk8-raUSkOZiAPSB-hS9A_2_2"></a><a id="Tc_5vbnvLQPAkGe1ewunZASrw_2_4"></a><a id="Tc_FdjABGCXCEGs057ngkgn1Q_3_2"></a><a id="Tc_Ccl5sxfjJEafGhSksPW-yw_3_4"></a><a id="Tc_taLf_E5Ih0m0LmBDsGOIcA_5_0"></a><a id="Tc_foo9YlhbbkKKvim-m3TZAA_5_4"></a><a id="Tc_mLZ3jKVui0eEQX3H-2_-ow_6_0"></a><a id="Tc_QUPHGvLUGk6fNW6AzKvixw_6_4"></a><a id="Tc_D-BhgrcFCEuBo-sOEZdXrw_7_0"></a><a id="Tc_bMz5GjFmiUiBjpbOXJ0EDA_7_4"></a><a id="Tc_XEDS9xQMY0WZAJ-XXPuQfg_8_0"></a><a id="Tc_TxQhbCJ7I02p1qgWuvuXkg_8_4"></a><a id="Tc_hVujfmotL02kf5xhmVIsLQ_9_0"></a><a id="Tc_IapTT8tO8kSXLPhpHU4dIg_9_2"></a><a id="Tc_Z8PZ1s_aIEeWkPBvRkPiFw_9_4"></a><a id="Tc_gI21HWjDU0SK8u3fiOX2QQ_9_5"></a><a id="Tc_KUt4JUGjvE-FzTtmZ4ESCQ_10_0"></a><a id="Tc_HmVxI5htOUSL92au_ZKnWA_10_4"></a><a id="Tc_vbnCjnLGa0WlTOcMV-Qbeg_12_0"></a><a id="Tc_ly5S4bkCfUuUw3fAOUirjA_12_4"></a><a id="Tc_IvUEakvYgUSlydJKncNrmQ_2_2"></a><a id="Tc_X6EChcvN1U2EqQFbmLJ2hw_2_9"></a><a id="Tc_f__eClt990-y3tmpX23oDg_3_3"></a><a id="Tc_iFYxkONW5kq-2wnVqAkdBQ_3_9"></a><a id="Tc_iYd0ro_52kyL2uAZAWs9kw_5_0"></a><a id="Tc_E0K_q9uKmUiDVJkLjYUEpA_5_4"></a><a id="Tc_2Wdu0aqA5UWPgsEAMdxfUw_5_5"></a><a id="Tc_lTCmsNDAykunkCne8Mawuw_5_7"></a><a id="Tc_WLxC1WYMfE2qMCy071GB0Q_5_10"></a><a id="Tc_wT-fvIL0-ECMLhDhNC34GQ_5_11"></a><a id="Tc_xv3AW-0aS0-oegVZ8oCa2g_5_13"></a><a id="Tc_XIkZYmIXvkyn190__fOuwQ_6_0"></a><a id="Tc_LzCGNi1viUyUGWL1GGI7zA_6_4"></a><a id="Tc_fJTKd2j7OE2cNnzO98NvKA_6_5"></a><a id="Tc_Ukh7QmK1sUOPB3Z0MLiLYg_6_7"></a><a id="Tc_dFDADT-l9Uamy-f8ujoNAQ_6_10"></a><a id="Tc_B9f9KO-t-Eanm_e3jR8HZA_6_11"></a><a id="Tc_Ou-Y7d0ZCUG3v0A_0frhGA_6_13"></a><a id="Tc_iP5oxgcCAkmPi3Oo7FvoXw_7_0"></a><a id="Tc_ATLngbbv-EOXQhQ8w5IEug_7_4"></a><a id="Tc_8m1gqvoFe0m_atsHoPOi_A_7_5"></a><a id="Tc_SJQnVmkcckCSy9UsovlVmg_7_7"></a><a id="Tc_dNolCpcdJ0igW6HVpCJAag_7_10"></a><a id="Tc_bBa87G5EFky8LhBg0xDLSQ_7_11"></a><a id="Tc_Bn8mT0nkaEej74KhScvdjg_7_13"></a><a id="Tc__sFB2l0bxUOuksaVTs4BqA_8_0"></a><a id="Tc_edNYEqC19EyiZmdcaKYOnA_8_4"></a><a id="Tc_G-rEadSCDUKHwwfWzm1Mbw_8_5"></a><a id="Tc_nENc8iWA80mJHXnufFyKQQ_8_7"></a><a id="Tc_Tbv2HEHHp0KeWOQ3CYu_0Q_8_10"></a><a id="Tc_Cd5Wc-jesUCD8P7OqnVB6w_8_11"></a><a id="Tc_AvnmzOr4tUKTqYtV4ivTpg_8_13"></a><ix:continuation id="Tb_w4XCdc3kwEOCwQ113U_K1w_cont3" continuedAt="Tb_w4XCdc3kwEOCwQ113U_K1w_cont4"><ix:continuation id="Tb_uwmcdaIEU0yASUtrONdT8Q_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2024, the Company had <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_ZZb5ojV8nECXF6PGT2Sv6w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="Narr_5CvY1EMHLU2mnIEkjNLMJg">176</ix:nonFraction> OnkosXcel Restricted Stock Units outstanding. Unrecognized stock-based compensation expense related to the awards expected to vest was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_ZZb5ojV8nECXF6PGT2Sv6w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_LjzgBVMw6UGvu_O0nulHVQ">210</ix:nonFraction> as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BTI Stock options</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A summary of the Company&#8217;s stock option activity for the year ended December 31, 2024, is presented below.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_3X_RCJ835UiX1GbPfXOhVA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price per share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xOcQ1mX8HUS3oomqLm_lMg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="Tc_4LvNdyFbWUuK5bEQdJGl_Q_5_2">311</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xOcQ1mX8HUS3oomqLm_lMg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_R3bBf9z81EuOneuuocEM2A_5_5">296.36</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="Tc_rnmmoEJdvE2k81kiX3WPBQ_6_2">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc__X6ztAOWnUa5I3n4w4o2lQ_6_5">20.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="Tc_824DSkS7AkK58_C9NxjFtA_7_2">24</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_JGmnGmoj9UydPEsNdCzCWw_7_5">214.56</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA" decimals="-3" format="ixt:num-dot-decimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" scale="3" id="Tc_AUEHHyQWK0CHj7n1gs5rHQ_8_2">16</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA" decimals="2" format="ixt:num-dot-decimal" name="btai:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_c0gviB4hS0qv2O44ZgK4Dg_8_5">339.74</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Lm8AZQPL40KMLw_EFZsryQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="Tc_7S2_YR_Sbky2WNVjp3vuaA_10_2">311</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Lm8AZQPL40KMLw_EFZsryQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_mbHqjhq-B02VaAdV7Uacvg_10_5">265.36</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options vested and exercisable as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Lm8AZQPL40KMLw_EFZsryQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="Tc_HXNXuUdfW0a7-CsEpMNhxA_12_2">249</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Lm8AZQPL40KMLw_EFZsryQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_oUrocvpDREm5_yEYOZyqRA_12_5">291.94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2024, the intrinsic value of options outstanding was $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Lm8AZQPL40KMLw_EFZsryQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Narr_1lKK3VgCZ0S67L-BK4rxpQ">0</ix:nonFraction>. The intrinsic value for stock options is calculated based on the difference between the exercise prices of the underlying awards and the quoted stock price of the Company&#8217;s common stock as of the reporting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The total intrinsic value of stock options exercised for the year ended December 31, 2024 was $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Narr_a3eVEhAez0qsMCgeG3wBvg">0</ix:nonFraction>. The total intrinsic value of stock options exercisable as of December 31, 2024 was $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Lm8AZQPL40KMLw_EFZsryQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Narr_lH7lPlJiHkmO-tj_0kUf2A">0</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The weighted average grant date fair value of options granted during the year ended December 31, 2024 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_eqmj8xg1okihiWZYDzzMzA">16.63</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The weighted average grant date fair value of options vested as of December 31, 2024 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="Narr_Nyl365e6wkasUjfz12L7wQ">215.98</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The weighted average remaining contractual life is <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Narr_A1WZc3bedkmN_lwW1wuiWQ">4.9</ix:nonNumeric> years for options exercisable as of December 31, 2024. The weighted average remaining contractual life was <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_Ov1qMAjAhEW4GsD55OVENw">5.6</ix:nonNumeric> years for options outstanding as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Unrecognized compensation expense related to unvested stock option awards as of December 31, 2024, was $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Lm8AZQPL40KMLw_EFZsryQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="Narr_HJp3_lDbMkeJYAK5AOU9ww">7,691</ix:nonFraction> and will be recognized over the remaining vesting periods of the underlying awards. The weighted-average period over which such compensation is expected to be recognized is <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_Vl6HSpNAGkG8t52MUQRvMA">0.9</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The fair value of options granted during the years ended December 31, 2024 and 2023 was estimated using the Black-Scholes pricing model with the following assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_396TYDIOAEGdWkJH8-Bg-A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.15969849%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;width:28.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;width:28.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dHuj7RaJ8EKL0Sny_5o-CQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_lcOv27roJkWQN-8LMidvGQ_5_3">5.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xVBddGnbW0ybwujG6xab2Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_B2IEgDXi1EKn1aktvvbS1A_5_6">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SRyiKYrKEE6xThkeoaB7WA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_3RRA-ukr7Em26VxgR5P3Eg_5_9">5.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ida0xzaxyUGKvrdsH2Fr0g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_sR6yqJv5-Eyh5xYcPMggZQ_5_12">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected stock price volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Tc_gxtGFMKEsECd92oQbpjfjA_6_3">108.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Tc_r3AWElxGbke67u2Ir2rv3w_6_6">112.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BcKPgE027Eq07dZFNZcBVA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Tc_oiRIN87T7Uau_LFVukq3_A_6_9">96.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BcKPgE027Eq07dZFNZcBVA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Tc_lgCL_OFJ6UqR91LgvHmtaw_6_12">109.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Tc_2OSGOcrtk0yKLrGMXzJ-mA_7_3">4.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Tc_vyLM5LagA0WeBsJaVF4mAQ_7_6">4.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BcKPgE027Eq07dZFNZcBVA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Tc_0rGLekzUp0C2zNUZgTHUDQ_7_9">3.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BcKPgE027Eq07dZFNZcBVA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Tc_4lIUTR7q30KBaiA1tPcAjg_7_12">4.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dHuj7RaJ8EKL0Sny_5o-CQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_YeEHIdN5OE6r4KKlsy4n7Q_8_3">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xVBddGnbW0ybwujG6xab2Q" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_cr5UmTG6R0ShStXEAQbB4g_8_6">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SRyiKYrKEE6xThkeoaB7WA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_f-1MBhjsl0Cvcc6GD_Uuaw_8_9">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ida0xzaxyUGKvrdsH2Fr0g" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_Yme81ypqi0WKWRS29BUspw_8_12">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_VDKdFHh9EkOr1f09t8VPLw_1_2"></a><a id="Tc_eqLXlixhZEqgyQJqbD1UQg_2_2"></a><a id="Tc_PRy-1Dl8UEi1FZu0d-cO9w_2_5"></a><a id="Tc_Z3nDVbR4KEOoxiqr456Pvg_4_0"></a><a id="Tc_yjZy8CA19U6JG0lpxak0jg_4_2"></a><a id="Tc_LZd7C2tOAUieGLrvggDHZw_4_5"></a><a id="Tc_-OiwzymBHkm-_J_81-jZmA_5_0"></a><a id="Tc_lpfNRai1kkuIgFX1-M7U-A_6_0"></a><a id="Tc__h2nW0P7rUKVQu6xsJquUg_6_2"></a><a id="Tc_Tq7BhAUKVkCBTWDO_HtHIw_6_5"></a><ix:continuation id="Tb_w4XCdc3kwEOCwQ113U_K1w_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In 2024, the Company continued using the historical volatility of its common stock to estimate volatility. Prior to 2023, volatility was estimated using a combination of the historical volatility of publicly traded peer companies and that of the Company&#8217;s common stock. The expected term of the awards is estimated based on the simplified method, which calculates the expected term based upon the midpoint of the term of the award and the vesting period. The Company uses the simplified method because it does not have sufficient option exercise data to provide a reasonable basis upon which to estimate the expected term. The expected dividend yield is <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_Rfhv7J7za0aS8BToHCF-1w">zero</ix:nonFraction> percent as the Company has no history of paying dividends nor does management expect to pay dividends over the contractual terms of these options. The risk-free interest rates are determined by reference to the U.S. Treasury yield curve in effect at the time of grant, with maturities approximating the expected term of the stock options. The fair value of the underlying common stock is generally determined as the closing price of the Company&#8217;s common stock on The Nasdaq Capital Market on the grant date, with consideration of whether there is material nonpublic information that could impact that estimated fair value when it is released.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company recognized stock-based compensation expense related to awards issued under the 2017 Plan and the 2020 Plan, as well as the OnkosXcel PSUs and OnkosXcel RSU&#8217;s, of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_CRdbko3nTEmJ46mw5Du7qQ">6,156</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_JmdFsj47BU2T-DSwcGOSqw">18,614</ix:nonFraction> for the years ended December 31, 2024 and 2023, respectively, which were comprised as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_a3Khwuo_xESyJKkMFwhR3A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_vlhYBLGO70Kx9W7BpuYnNQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_uKRR59a5VUSrUpnLr66NOQ_4_3">2,251</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_oEnUYj2nH0S7nHVXLQ4q4A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_pAZTyWjVl0ORvW6PJ0AmAg_4_6">6,324</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_OQGpm4OmO0GvGOO9BwRRtQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_TGrzPJvJGEaH0QooPSwVOQ_5_3">3,905</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_QvezY-cudU6QqyNRbmjCmg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_55KFj9_CcEinBbgsoB1jew_5_6">12,290</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_S27lB7MvckmUmcbj3JSVQA_6_3">6,156</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_8PU91MvRi0CA92DUKE1GzQ_6_6">18,614</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">2020 Employee Stock Purchase Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s 2020 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was also approved and became effective at the Company&#8217;s 2020 annual meeting of stockholders on May 20, 2020. The ESPP is designed to assist eligible employees of the Company with the opportunity to purchase the Company&#8217;s common stock at a discount through accumulated payroll deductions during successive offering periods. The aggregate number of shares that may be issued pursuant to rights granted under the ESPP is <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_N0vp5VFCUkqtRrwPRBSFFQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="3" id="Narr_vUEJ-1qj2EiGLDzLM97ArA">6</ix:nonFraction> shares of common stock. In addition, the number of shares available for issuance under the ESPP will increase on the first day of each calendar year, beginning on January 1, 2021 and ending on and including January 1, 2030, by a number of shares of common stock equal to the lesser of (a) <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_jWcBt1FrAUy7Aw7aYKtEBA" decimals="2" format="ixt:num-dot-decimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" scale="-2" id="Narr_liODfQ7RDUGj9flfoP1pBw">1</ix:nonFraction>% of the shares outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the Board of Directors. The number of shares that may be issued or transferred pursuant to rights granted under the component of the ESPP that is intended to qualify for favorable U.S. federal tax treatment under Section 423 of the Internal Revenue Code (the &#8220;Section 423 Component&#8221;) shall not exceed <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_jWcBt1FrAUy7Aw7aYKtEBA" decimals="-3" format="ixt:num-dot-decimal" name="btai:EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" scale="3" id="Narr_XoPS5sN1qkaN0vICFtVgcw">31</ix:nonFraction> shares. The purchase price will be determined by the administrator of the ESPP and, for purposes of the Section 423 Component, shall not be less than <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_jWcBt1FrAUy7Aw7aYKtEBA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_eeuCXgkS3Uyc0qYLvSdnKw">85</ix:nonFraction>% of the fair value of a share on the first trading day or on the last trading day of the applicable offering period, whichever is lower. The shares available for issuance under the ESPP increased by <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_qoDjPOgKl02zcP5r7FAQuQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" id="Narr_dT9SgqSnjkqZ9Lh6adeBQg">19</ix:nonFraction> shares and <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_OpSGdiyFOEqI7cFehOL59A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" id="Narr_YMHHaIxI40iEfWP4TZcz-A">18</ix:nonFraction> shares on January 1, 2024 and 2023, respectively. To date, <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_mzi71qMtwUW4NC2oL1_1RQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="Narr_JjiYAnzFmUuj26dozWVN9Q">no</ix:nonFraction> shares have been sold under the ESPP. There were <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_v9I1drvLSkCReDIKAPrJEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" id="Narr_Xo-Dg0rJ-k-wa8D6OPzmqQ">75</ix:nonFraction> shares available for issuance as of December 31, 2024.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_DnqbMHzgOkCGrUWsBlRTvA" continuedAt="Tb_DnqbMHzgOkCGrUWsBlRTvA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;13. Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI leases office space for its corporate headquarters at 555 Long Wharf Drive, New Haven, Connecticut (the &#8220;HQ Lease&#8221;) under an operating lease that expires in February 2026. The Company has an <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" format="ixt:fixed-true" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Narr_JEYYfJ-iNkKM4ptopKBgvw">option to renew</ix:nonNumeric> the HQ Lease for one additional <ix:nonNumeric contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr__wqTJCnF_EerPbbI2hgpoQ">five-year</ix:nonNumeric> term. Payments under the HQ Lease are fixed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company also leases equipment such as copiers and information technology equipment.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_EwwIzKv7XUic1iBVYxKRUQ_1_0"></a><a id="Tc_lvklSTb4t0e335NSsuTlEQ_1_2"></a><a id="Tc_zOXs73oKUUKUzifoxTEy6Q_3_0"></a><a id="Tc_ypMeVYQSOkWYBVU7oHHK0A_3_2"></a><a id="Tc_IbltD6LKRE-SRxjfsu7pyg_4_0"></a><a id="Tc_2DEl2342F0ake5pwk7ngww_5_0"></a><a id="Tc_HuNLV9Gtvkm0BB0Cqm763g_5_3"></a><a id="Tc_dkzP7eqXrkiljlc0fo-tfQ_6_0"></a><a id="Tc_Pz9DNrijQE6PibaMicidzw_6_2"></a><a id="Tc_e-ucjghEo0GkF1qtraE-Fg_7_0"></a><a id="Tc_G_IuKY-AaEujeWPWXOkeRw_8_0"></a><a id="Tc_c0TlX-01ZECuseAVfZ65JQ_8_2"></a><a id="Tc_RgI9jhv8TUOLLHgT0KgxSw_9_0"></a><a id="Tc_JfZOBFRHS0eySWSoGv7Oxg_10_0"></a><a id="Tc_PfepcBGNv0mov45l0K-Fsw_10_2"></a><ix:continuation id="Tb_DnqbMHzgOkCGrUWsBlRTvA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The future minimum annual lease payments under operating leases, as of December 31, 2024, were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_iGxtDmnr7ka2iT4aWc-1nA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year ending December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_hk1j1jNepkWOp0qlrEq32w_3_3">391</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_2Au4khYNp0qWWeHJ3U9xcg_4_3">65</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total lease payments</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_3boxCoW3PUOm5l3Tezt5bg_6_3">456</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_dlZ1MzUWSUC61lyfnD6JPQ_7_3">17</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_v1VlaICbTES2BzOmextnDg_8_3">439</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less current portion of lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_9RGRMJmjGEiMQmi-JoJT1Q_9_3">374</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Long-term portion of operating lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_tJCKJBckRU6Siu-qwmQBEw_10_3">65</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The current portion of the Company&#8217;s operating lease liability of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Narr_EaMb015Ot0K3E85WxBmvFQ">374</ix:nonFraction>, as of December 31, 2024, is included in <span style="-sec-ix-hidden:Hidden_a6pX1JmlWkyKm9cKj1tV7w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other current liabilities</span></span> on the Consolidated Balance Sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Lease expense was $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" id="Narr_d0YYYFWSeE2bjzlxM07ryQ">394</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" id="Narr_MVwLD-57AUemN4__MOiJbg">392</ix:nonFraction> for the years ended December 31, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Lease renewal options are not included in the ROU asset or lease liability.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:DefinedBenefitPlanTextBlock" id="Tb_Up-G7bDkO0OFuhijvK1a0A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 14. Employee Benefit Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company maintains a defined contribution retirement plan for its employees that complies with Section 401(k) of the Internal Revenue Code (the &#8220;401(K) Plan&#8221;). Employees are eligible to participate in the 401(K) Plan and can contribute a portion of their pay into the 401(K) Plan, subject to annual limits established by the U.S. Internal Revenue Service. Participating employees receive an employer matching contribution equal to <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_UAl0p0HwF0mkaAl_1pfbnA">50</ix:nonFraction>% of eligible employee contributions on the first <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_6NPBv2bSBEq3jePcSL1lUQ">5</ix:nonFraction>% of eligible compensation contributed. Employer contributions to the 401(K) Plan were $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="3" id="Narr_7ZTcEtNW9kmDQF1sUk8N9w">289</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="3" id="Narr_BCXBAA7oeEqKkyi731cB7Q">788</ix:nonFraction><span style="background:#ffffff;"> for the years ended December 31, 2024 and 2023, respectively.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9a46bd27_9319_4583_83b1_f1cae431eee2"></a><a id="Tc_w9XM6GMUOUesJouHT3eeog_1_2"></a><a id="Tc_3D-hoWX2-kyGpi0fyA3Wmg_2_2"></a><a id="Tc_bduuGLxOvU6MHP8PpXFzBQ_3_2"></a><a id="Tc_SDm76_tp9UCovtFbN0J9gA_3_5"></a><a id="Tc_psKAVP8rWUuHvltjOF9Jhg_3_8"></a><a id="Tc__uNfsHdpPEaVBqoA9a0o4w_3_11"></a><a id="Tc_fxxLZydLSEmqQVurZVtdbA_3_14"></a><a id="Tc_MV84by-6GUWAxmoYV6uwqw_5_0"></a><a id="Tc_Sd3ct7nQrEC-Ro1SXkCJiQ_5_2"></a><a id="Tc_A3AWSYUs_UC1OOZACa4s2g_5_5"></a><a id="Tc_N_5ElDtcOE6pcJXg8lX_SQ_5_6"></a><a id="Tc_j9zsIBJeRkyP-I5buubcTw_5_8"></a><a id="Tc_Xj7p6R8DXEWn-CWRCWbmfQ_5_11"></a><a id="Tc_ZEeWrA4IikCJq8KrCgmClQ_5_12"></a><a id="Tc_-f69A8YswUCTgk1wMP_1zg_5_14"></a><a id="Tc_hI3Tp3urSE26yhYxDR4y9Q_6_0"></a><a id="Tc_WBJpvsWElUahdvlCe1LFQA_6_6"></a><a id="Tc_K5IglvAYsU2LAO8jtfl0Rg_6_9"></a><a id="Tc_xhAZ4vp1q0eo_4UFzIeKgw_7_0"></a><a id="Tc_4jyfaVlldk6DZEAngtO5mg_7_2"></a><a id="Tc_v3e4pXlptEW0P_IqLM20Wg_7_5"></a><a id="Tc_EnjETxtZtUurFh0Qsx1FFg_7_6"></a><a id="Tc_VZwoHOm5xUWWUyik-QOPAQ_7_8"></a><a id="Tc_-MRpd18BwEmwPyB-RzHc1w_7_11"></a><a id="Tc_EzNmiVbtUkOR96vDXlDmWQ_7_14"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_P4AF5ciWSEmrb3tg5IdOXw" continuedAt="Tb_P4AF5ciWSEmrb3tg5IdOXw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;15. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company groups its assets and liabilities measured at fair value in three levels based on the nature of the inputs and assumptions used to determine fair value. Refer to Note 3, Summary of Significant Accounting Policies, for additional information on the accounting policies related to fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The carrying amounts of Cash and cash equivalents, Accounts receivable, net and Accounts payable approximate fair value due to the short-term nature of these instruments. As of December 31, 2024 and 2023, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_waelNlOubE2wBVFPlyHhnA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Narr_Yx-1T2erikKnn9WerkX1KQ">29,036</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_Lzrt-ozGkUiBpO-gtGyjpg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Narr_eEp335E7tEWmIpL9a05QQw">64,860</ix:nonFraction>, respectively, primarily in money market funds that hold U.S. government cash equivalent instruments (included in Cash and cash equivalents) which were valued based on Level 1 inputs. There were no transfers between levels within the hierarchy during the years ended December 31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Derivative liabilities measured at fair value on a recurring basis are summarized below.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_KfqBRRIJq0eWZoL8AjttPg" continuedAt="Tb_KfqBRRIJq0eWZoL8AjttPg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - BTI Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vpbgA0Y3d02GV60wknoGug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_72WUJbdxIE2vmLD87TYDQw_5_3">6,593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_2DCibhs95kq8Jc8YpX7xJw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_-vguBhTDoEmy7uoNVXkNEA_5_9">6,593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MeVvKC1qK0CFc5qbgrTI9A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_ZRXOB6F6nkyL52ZAN7m5oQ_5_15">6,593</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - OnkosXcel Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_aidNv9HgNk2DhIo_TgvNhA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_Qbo5dHmdI0C1QS8MAVZ1ew_6_3">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_TN6VQOKYb02WtCDp3elR3w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_vth1vAP5G02VGzBOAMFbLQ_6_12">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AtesnzW9Vk62r5o4Z5MLOg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_arbe1Xi-YUW3VxKy5X76mw_6_15">40</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total derivative liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_iXjg5DQGe0ydE6a0tFygQg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_M_xOmUiy-EqfFVIeEBgLXA_7_3">6,633</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_WvQM_Cfj6UW7acmcXHo-pQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_Y7LE8H59bUumE0SYcmlxNQ_7_9">6,593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ExafltryU0uKvGWyPhUsBQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_mEem8GzLdkCU9jNPUfm90w_7_12">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_HN9QZyHZZEqqvDSOhHwi6g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_s6wzWmLgyUOkOy5_3A9kfQ_7_15">6,633</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_29c2dead_25a4_4e44_b4a2_1ca08ed3a344"></a><a id="Tc_kId5xh1NbkeqDeHIUDV68Q_1_2"></a><a id="Tc_SAjqNqNjmEqR4r9qzeI8Pw_2_2"></a><a id="Tc_Br0fsOKhUUCRm0G6UCca-w_4_2"></a><a id="Tc_AHBPhGMY00S1JzIFM0S3Ew_4_5"></a><a id="Tc_304cv6pC7U-utyEXhlrDkA_4_8"></a><a id="Tc_JAQrMyEgB0uwDfwYyvVoCA_4_11"></a><a id="Tc_JhKs-DAkb06Uv11D_p8VlQ_4_14"></a><a id="Tc_2pJZjHJLh0-l-60jfQ0xVg_6_0"></a><a id="Tc_LFOjmJZh30eeT3ZzOY5kWA_6_2"></a><a id="Tc_TLPly8PmPUK8pgGM1gJFhg_6_5"></a><a id="Tc_MbM_-O4_dUquWyjBQnynfA_6_6"></a><a id="Tc_rCILkTkdt0OcNfe1w3fnog_6_8"></a><a id="Tc_XbZiXWcgaUSP3usOCoPHEQ_6_9"></a><a id="Tc_XXDylrIqfUWAsdYN8P1r4w_6_11"></a><a id="Tc_83D5_ah52EuWKqm1eMfZhg_6_14"></a><a id="Tc_3plzkN_7c0mnaVuoOfiyVQ_7_0"></a><a id="Tc_3PALZpn4Ek-UcLWOCXmrEA_7_6"></a><a id="Tc_Y2epgw7QHEm4lL-PFBZWGQ_7_9"></a><a id="Tc_vU2KG02AGkOynfUqJAjJ1A_8_0"></a><a id="Tc_IVmmYWb-iEi2rg7d0YvGEQ_8_2"></a><a id="Tc_1O2Saja1ZkyfS_gOKyMfzw_8_5"></a><a id="Tc_UMQWsR-yQkmRn1VeXHBRzw_8_6"></a><a id="Tc_9jIzvRXse02-gGSKJId-UQ_8_8"></a><a id="Tc_ZB3sRuI8fEKoMlAG7NJznw_8_9"></a><a id="Tc_XXXOp51vcEqPNKTO4j-Eaw_8_11"></a><a id="Tc_HxX18_HXt02bZ_08Sv7WvQ_8_14"></a><a id="_250f3ea2_69e6_4a4b_bb5f_e6214034625f"></a><a id="Tc_If_eP2GVgUSCsUI_a9acdg_1_2"></a><a id="Tc_4uwKpFkxdkaju2bci_3FwA_2_2"></a><a id="Tc_OvmLiu-amEO3dUUDoDm_lg_3_2"></a><a id="Tc_R_4jQj6kqUOnYW_Mcd1nTw_3_5"></a><a id="Tc_pt482t39MEij2tocv4nWPg_5_0"></a><a id="Tc_gKf6zWHp90-Izr9QeYNrYA_5_2"></a><a id="Tc_iVlP5rv6B02LdC8XygekkA_5_5"></a><a id="Tc_yLcbj2cVMUS12BJvFMx0NA_6_0"></a><a id="Tc_0JkcwizelU2_MnvbiGboKQ_6_6"></a><a id="Tc_OURkFz2Ka02Dpfpv_iqz7A_8_0"></a><a id="Tc_E8YcaaBVgkSMt5muGskDIw_8_2"></a><a id="Tc_wwUzAio6BE-qaeWUAfy9IA_8_5"></a><a id="_6b9bb593_b1f3_45ca_b18f_40c7d8d983cb"></a><a id="Tc_nyhhAU_XV0qGXcjXReNMRw_1_2"></a><a id="Tc_lL3ypcE_7UiZsT2YkQ9VRQ_3_0"></a><a id="Tc_nDmKgy8vBUq10hPRlsqrrw_3_3"></a><a id="Tc_6zSxGyre6UWXGdH5eueQJw_4_0"></a><a id="Tc_acK2W2lb0UC1VjPFxCiUig_4_3"></a><a id="Tc_xfkCtwQ2kkuAKFAVL6eJVg_5_0"></a><a id="Tc_iEod_IRsw02R2fWzTaE1iA_5_3"></a><a id="Tc_DQjppGeQl0CdmamOhIik1w_6_0"></a><a id="Tc_BAqvG3S_3kOV0KNbdwsAKw_6_3"></a><a id="Tc_prZ2CRgxYEGLoN8vJlN92Q_7_0"></a><a id="Tc_BB6qaSr1Uk-sn4CQKUxEoA_7_3"></a><a id="Tc_-ErCIHcRtkWh9h5wnaPxSg_8_0"></a><a id="Tc_-h-7nkXzb0CqdhcvAu4DPA_8_3"></a><ix:continuation id="Tb_P4AF5ciWSEmrb3tg5IdOXw_cont1" continuedAt="Tb_P4AF5ciWSEmrb3tg5IdOXw_cont2"><ix:continuation id="Tb_KfqBRRIJq0eWZoL8AjttPg_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - BTI Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ecW8VPGztk2Gf79xQBkyNA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_hWBZXzEGy0OkfhKlD1KrSg_6_3">1,193</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AmN6FsQg1EitMV_BHxN7_Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_mnprdyph8E-Jyzn6gxTAHw_6_12">1,193</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1mPU0Lx-nE-RmcrvYY9V3A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_h2WLEXWhxkSP4cuRHk8thA_6_15">1,193</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - OnkosXcel Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_HcAF3jq9Q06V5LIYvzVw4w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_LS7N3c9KuEiCoCspeWGdjg_7_3">712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_nJRaa39oO02skohtFNO_CQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_hoqMhTRCvUOBY5W3Cf8w4g_7_12">712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rgfcXxi9006PlNFx3qH35g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_ppN3WqIgxk-2McIFQABnVA_7_15">712</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total derivative liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KTr0ds-yYES_mpozAK0KPg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_a8FLKDQh0UewzumQApLAlg_8_3">1,905</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_cPgf57S61Uyah5MXLI1evA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_U1n3_lvFp0iftTj6eWnTUQ_8_12">1,905</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5D28fXSYSUCIMdnKx2CzdQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_a2gl0i0VnkS9NkTcBX31ag_8_15">1,905</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Derivative liabilities are comprised of the OnkosXcel Warrants and Equity Investment Right held by the Lenders. The fair value of the derivative liabilities was determined using Monte Carlo simulation models for the Equity Investment Right, and Binomial Option Pricing and Distribution models for the OnkosXcel Warrants.<span style="font-size:12pt;"> </span>As discussed in Note 9, <i style="font-style:italic;">Debt and Credit Facilities</i>, the Equity Investment Right was terminated on November 25, 2024 in connection with the Fifth Amendment to the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table presents changes in Level 3 liabilities measured at fair value for the year ended December 31, 2024. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="Tb_ymuULb7c8kii2Pc5Q1p2ug" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liabilities, Balance - January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_NgiXRCw8Pkum2He_H4qHmA_5_3">1,905</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2022_jhStatqo5EaSoSvdA9RW0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_Lu6yb6haJEiYn2IQPW1eFw_5_6">2,343</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Termination of Derivative liabilities - Equity Investment Right</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_N-lEdCI780-JkLi3BNV9Ig" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" sign="-" scale="3" id="Tc_YRJ0-RgZ1EGQsQnsyNIcrw_6_3">1,263</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_pNs2n3-e20CuK4JoOz4cQA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">   Change in fair value</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" sign="-" scale="3" id="Tc_eg_j3K3JFU-Lx3M2haqIhg_7_3">602</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" sign="-" scale="3" id="Tc_lgJevMl-kUOTmRIpNW7pFA_7_6">438</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liabilities, Balance - December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_lBJmMafRb0G-Ki46KGMbrw_8_3">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_rH23dbxBJECIAlyUX9A2XA_8_6">1,905</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The derivative liabilities were reported at their fair values in the Consolidated Balance Sheets. The changes in the fair value of the derivative liabilities were reported as gains in the Consolidated Statements of Operations as Other (income) expense, net, for the years ended December 31, 2024 and 2023, in the amounts of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="Narr_CgPhfjGHZUWhhJwi2DYdJg">20,181</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="Narr_nhC3PVzD3k2-SZ7EkwfGGw">438</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Inputs used to calculate the estimated fair value of the Equity Investment Right were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_0ABcwZINVUe9wkzF0spJeg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:22.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity Investment Right</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Strike price relative to volume weighted 30-day average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_fnIGASQkZ0KT8yEsdC0CCQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_SG_Hzl5Ym0WN4qT_lxPcHA_3_2">110.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility (annual)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_RYPqtdbPfUOCOJbUwsxRdQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_TYyyQ2_0bEu8S9Gyo-8bIA_4_2">112.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Probability of exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_btai_MeasurementInputProbabilityOfExerciseMember_R6UHsXs59kO6T0pv-5n4Pg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_vtNuzWlxj0-lgBgkUS7-5g_5_2">91.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Time period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_HWoZmdDBn0OhfgBS6ig-MA" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_vnbH2b6cvk6tsJ16seh7xw" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Tc_3FYmf9XQlEq_-4WfcgLNvw_6_2">1.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Estimated premium to 30-day average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_btai_MeasurementInputEstimatedPremiumMember_Nx0QCxfhw0uGTxWALoXeBQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_wZN6npRSn0OAzslaMXig6Q_7_2">24.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_0MsOXlyLLki32Y4tNC1zZQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_gUvG4McpVkix-okSVxeNoQ_8_2">4.26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The changes in fair value of the Equity Investment Right up to its termination date were recorded<span style="font-size:12pt;"> </span><span style="white-space:pre-wrap;">in the Consolidated Statements of Operations as Other (income) expense, net.  The final carrying value of the Equity Investment Right of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_N-lEdCI780-JkLi3BNV9Ig" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" sign="-" scale="3" id="Narr_-6osztAr3keOITjdCHrfew">1,263</ix:nonFraction> upon derecognition was recorded was recorded as a reduction of derivative liability with the offset recorded as a gain in Other (income) expense, net, in the Consolidated Statements of Operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In estimating the fair value of the derivative liability related to the OnkosXcel Warrants, inputs included third-party fair value estimates of OnkosXcel limited liability company units along with the volatility of those units (which was set at <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_LcJiex4QpE2YqESAdf6fpQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_UO3ujvaWwkei-P-nFhsMpA">100</ix:nonFraction>% based on the historical volatility of the Company&#8217;s stock, along with a peer group of comparable publicly traded companies), and the timing and probability of the relevant capital transactions occurring.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_f6875a81_f354_456a_9a1b_723f418e105f"></a><a id="Tc_doZUysJpo0mtucXhRSOKwA_1_0"></a><a id="Tc_yve__qxdEk2BZg5MGui6iw_1_2"></a><a id="Tc_SdRLUhJqx0Syk8F9r3C4vw_1_4"></a><a id="Tc_zwctW05h3UKSYFljl1Ac1w_1_6"></a><a id="Tc_g_dbsRv64UiLjrNocCMSvg_1_9"></a><a id="Tc_QlvW41v2u0-wMj5h9WWULw_1_11"></a><a id="Tc_RHsIa6Kjfki6ltg8b9LTMA_3_0"></a><a id="Tc_BxGIBuuHPkmPSJcpd1WZcA_3_2"></a><a id="Tc_7riArUXSt0u0VDj2hW8tlQ_3_4"></a><a id="Tc_KBseudw4IkCahxbBTZf0rw_3_6"></a><a id="Tc_oV2G0LBzQkmis_2uZLidfA_3_11"></a><a id="Tc_I2jFlAZykkqRlqQtOa4eJA_4_0"></a><a id="Tc_dwqpSfALm0GMMR_3adSTjw_4_2"></a><a id="Tc_1c8u7_rt90WSGAEzVUQbHQ_4_4"></a><a id="Tc_XuSGGv-QxkimOokfuCnpzw_4_6"></a><a id="Tc_khK5mHDaIUS6VSIZxZ2C5Q_4_11"></a><a id="Tc_5qNZACxRoE-UYZwkhpBQ9A_5_0"></a><a id="Tc_ZiRbNdlfH0KxdGhXKsSm3g_5_2"></a><a id="Tc_n5oOS4hH0E2F9Km78kls5A_5_4"></a><a id="Tc_GTPKadJdKUycg3xerFavlg_5_6"></a><a id="Tc_r-deE7fb9EiyYQVVLHnrMA_5_11"></a><a id="Tc_YE5Gqc3FaUyudXDsVU1zCg_6_0"></a><a id="Tc_rfaSVA2y40O9SzfoHVWvrQ_6_2"></a><a id="Tc_xSLMWEctXUS0mn0zJeww5A_6_4"></a><a id="Tc_i-rv0E1qw0K5MqruuMdKSw_6_6"></a><a id="Tc_8J16s3qnxkutB2o7woNrig_6_11"></a><a id="Tc_FaIwfl_lWEqYuGAovUBk_Q_7_0"></a><a id="Tc_TVJQazK-4kyu78xOrR9_9A_7_2"></a><a id="Tc_8aIHVkv8MUGatmCHyhHXRw_7_4"></a><a id="Tc_Iq-z51-Nb0WPR6Ecnlpdfw_7_6"></a><a id="Tc_zyDX8Eu-O0aVft4YFwzRZg_7_11"></a><a id="Tc_G3uwulv4w0yaFyot1ojMYQ_8_0"></a><a id="Tc_XZyQXejMTEGMVupjJ3TZIQ_8_2"></a><a id="Tc__U4axvc27kCIlqB2PVciPA_8_4"></a><a id="Tc_4O1n_-VvSU21ddYuVF7hPw_8_6"></a><a id="Tc_LXYwxaxB9UubMcFthnn3QA_8_11"></a><a id="Tc_K4g_ZnTGHU2vOfry2zO-ZA_9_0"></a><a id="Tc_vww8TZZk70y9s1MscKRfYQ_9_2"></a><a id="Tc_xYhrcbdz8UKFvs_rlzNM0A_9_4"></a><a id="Tc_jSeJwIJUw0abNLDP6vNqIw_9_6"></a><a id="Tc_B_iCjXp3BE2nxxxAChRDvg_9_11"></a><a id="Tc_BsgrwNMxp0qwHbupeTyoIA_10_0"></a><a id="Tc_8EP8byGpKUC6LF_NXpCAEw_10_2"></a><a id="Tc_B2IUq22jkkmqM-q8vTNCKA_10_4"></a><a id="Tc_4mfr_eTdV0yRzpSiSX_zkg_10_6"></a><a id="Tc_ejWHKCVTFUe7qLOcUuXpGg_10_11"></a><a id="Tc_DNg5gRT4Ck29OxZqeUgWMQ_11_0"></a><a id="Tc_1iUdBPwMwEGaEPZ0lIyhZw_11_2"></a><a id="Tc_MoL0euRVd0KnObRmaA71SA_11_4"></a><a id="Tc_JEsRTC9CpUSz_8nycZS2XQ_11_6"></a><a id="Tc_BvWvOAUiskmrwZWnV9wXCg_11_11"></a><a id="Tc_vGHi_RQEUEK5eHO_gBUx6g_12_0"></a><a id="Tc_XVt88upP0U-9k_86wVaPcQ_12_2"></a><a id="Tc_K8J002_SeUS3qPttm9yeoQ_12_4"></a><a id="Tc_dWNEkPmuJ0KZiEIsvmmUFg_12_6"></a><a id="Tc_JHTmgimMqkut_KL-tKz6SQ_12_11"></a><a id="Tc_k03IHcrJmUaUrFVxUAWqpA_13_0"></a><ix:continuation id="Tb_P4AF5ciWSEmrb3tg5IdOXw_cont2" continuedAt="Tb_P4AF5ciWSEmrb3tg5IdOXw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The estimated fair value of the Credit Agreement as of December 31, 2024, was $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="3" id="Narr_IALmiBbQBkyfeqCfJQDmig">94,204</ix:nonFraction>. Both observable and unobservable inputs were used to determine the fair value of long-term debt, which was classified within the Level 3 category.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following table presents the BTI warrants issued by the Company and the corresponding balance sheet classification:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_vgoOoCX4P0yqgJsmS7iaPw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Warrant Recipient</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issue Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Classification</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Closing Date Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4/19/2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_UVB3pFbO506ugN_GMsELIg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_gYGF2gKd20G4Jp2K6Zhw3w_3_7">7.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_UVB3pFbO506ugN_GMsELIg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_UqOxqJlfcUC8FRc-l_I8_g_3_9">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">2023 Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/5/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_sWnPUgoZNUaV48uFc0AzEg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_-0pEx3jb5UCr9Qa_sS9g2A_4_7">7.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_sWnPUgoZNUaV48uFc0AzEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_71qBnk45uUioGYtmj4KCTQ_4_9">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">2024 Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3/20/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_FRRTD6E8_UWc7CqpvzLbPA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_khacn_CpKkCj7LMpNv08RA_5_7">7.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_FRRTD6E8_UWc7CqpvzLbPA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_NktHRmJZWki2PnoYz3q1HA_5_9">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">New Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_WWey9zxoakaXp0S1ZYs4vg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_rLqlh3NOAU6cF_WUTjUMVg_6_7">0.16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_WWey9zxoakaXp0S1ZYs4vg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_l5wyGU8N2kOGIlYV-iaMPA_6_9">313</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Armistice Capital Master Fund Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_lI6dv2jX_EWXRmyQX2VxXw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_oc7jeAJXOEihf6eR-VhtBA_7_7">9.136</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_lI6dv2jX_EWXRmyQX2VxXw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_3pOOow48sUa1dVM9Wx0OzA_7_9">534</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Armistice Capital Master Fund Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_kfeh-8yR4k-MMGH2ApsgLQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_IaN1VnW04Eerr2shWvZWXw_8_7">51.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_kfeh-8yR4k-MMGH2ApsgLQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_9M4tuiwPdEy96ct--tw8_Q_8_9">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Armistice Capital Master Fund Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_ArmisticeCapitalMasterFundMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_mhbEOSMN9E-6fQNPjBHEBg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_j6uEPsnAZ0qLVTD1cN3flQ_9_7">7.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_ArmisticeCapitalMasterFundMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_mhbEOSMN9E-6fQNPjBHEBg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_o__pnvJOmk25lX47AIgFFQ_9_9">846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Heights Capital Management</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_HeightsCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_gmwEIZ8DKkiPWDp5YfOhFg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_PVQY4A9QmkqBjmYz2_2Qvw_10_7">7.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_HeightsCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_gmwEIZ8DKkiPWDp5YfOhFg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_8HiCHTa-4UKeP1qGVxnoHw_10_9">27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Hudson Bay Capital Management</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_HudsonBayCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_McrVOhYGbEC_tS_1BvXkKg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_aQ5_UQJqcUyGWjrajM5WZQ_11_7">7.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_HudsonBayCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_McrVOhYGbEC_tS_1BvXkKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_CMLxpyV3gUSYd5OjuS2JIg_11_9">27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">IntraCoastal Capital, LLC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_IntraCoastalCapitalMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_b02B55BM6EG9d7CRINubvQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_cbFh_RUsOUO2i6N0Oj2qbQ_12_7">7.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_IntraCoastalCapitalMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_b02B55BM6EG9d7CRINubvQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_xcAirjtQ6kibcgbGhUgQUQ_12_9">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total warrants issued</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_1LqgdJglcUGaBJlfQgrsyg_13_9">1,792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The fair value of the Closing Date Warrants, which was a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_V2jj_eDlt0q_u0vXSYoyKQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="Narr_IfCNEcr2FU2hlNh1v4Z5rA">3,245</ix:nonFraction> was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the OFA Facilities. This non-recurring measurement is classified as Level 2. The inputs used were a strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_0FNSOQxNAE-0IkMjsa2iKA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_zP7CztmVwkqsSwGcGdp30g">320.64</ix:nonFraction>, the Company&#8217;s stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_hovoRwmQvEeyatpC8QBdeQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_mlPb1kSkSE2a8sx_ViDzRQ">238.88</ix:nonFraction>, volatility of <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember__BmWodN8tEOta3SjGS5jbg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr__mNGtxWtlkGV9jwprWfhxA">95</ix:nonFraction>%, term of <ix:nonFraction unitRef="Unit_Standard_Y_HWoZmdDBn0OhfgBS6ig-MA" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_goRVwXyuWUydp4Kjx4bF3w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_H_dSYWfo3UO5tUI1t18kXg">7</ix:nonFraction> years and risk-free rate of <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Cs-w0dC4c0WGpoXT9tdaBw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_CB4BlM8pik2Ehkv01A6JWQ">2.95</ix:nonFraction>%. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As discussed in Note 9, Debt and Credit Facilities, in connection with the closing of the Second Amendment<span style="font-size:12pt;"> </span>of the<span style="font-size:12pt;"> </span>Credit Agreement, on the Second Amendment Effective Date, the Company amended and restated the Closing Date Warrants granted to the Lenders to have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_uPbZgXmXZUiSsb-dyLE4HA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_EtwfBFxgZUa46iuthVrw5g">58.3232</ix:nonFraction> per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Using a Black-Scholes pricing model, the Company determined that the Closing Date Warrants&#8217; fair values at the original strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_V2jj_eDlt0q_u0vXSYoyKQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr__cK1r9nU_0CeQxSGmsl_3A">320.64</ix:nonFraction> and the amended strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_uPbZgXmXZUiSsb-dyLE4HA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_bPV52s73f0yqgKJ174viNg">58.3232</ix:nonFraction> were $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_V2jj_eDlt0q_u0vXSYoyKQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr_fotGYMvTQESYtKKjO86hbA">548</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_uPbZgXmXZUiSsb-dyLE4HA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr_sRQkVBEN4UWb3-IdeYEqrw">802</ix:nonFraction>, respectively, as of the Second Amendment Effective Date. The Closing Date Warrants&#8217; incremental increase in fair value for the repricing of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_12_5_2023_To_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_3RWlGpXOtESBeWP1E_X8Xw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" scale="3" id="Narr_CZh6qz6mSUy_uM5i5VDXwg">254</ix:nonFraction>, was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts refinanced under the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the Second Amendment, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_W5J6mPqvkkqYc6G6pFfyUQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_BnCCiLg7WU23yDMf3k7Plw">4</ix:nonFraction> &#8220;2023 Warrants&#8221; at a strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_W5J6mPqvkkqYc6G6pFfyUQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_m4HXoHg4wUiRO0p8LnBRDg">58.3232</ix:nonFraction> per share. The fair value of the 2023 Warrants, which is a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_W5J6mPqvkkqYc6G6pFfyUQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr__knjBFoulEaroamvQyRXJQ">200</ix:nonFraction> was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the Credit Agreement. This non-recurring measurement is classified as Level 2. The inputs used were a strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_c4v5KMKYk0ChF42pkKq26w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_G2sS02W_Wkuv_yEX0EelPg">58.3232</ix:nonFraction>, the Company&#8217;s stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_CGrKS2JtHkaQ1g9h6LmHqw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_SNj66793hUKMLXO3HZ2BSA">59.36</ix:nonFraction>, volatility of <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_oWedOZ60s0mXTRW5Lcn6Tg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_3bIZgG3ucE2EOP4vTElLsg">99</ix:nonFraction>%, term of <ix:nonFraction unitRef="Unit_Standard_Y_HWoZmdDBn0OhfgBS6ig-MA" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_1xcAi6iP-EO-REO2QzswUQ" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_Xm0_YFWzJUKLRLv6045P2w">5.4</ix:nonFraction> years and risk-free rate of <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_9G_zTSXx60uhtuDGxqBgBg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_yPrpa08X7Ue2IF2ZF7t7Eg">4.14</ix:nonFraction>%. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the Fourth Amendment, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_5ri5JcF8t06zRgfNuESzxQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_y8OT7YHwV02pE0AulyKW2A">6</ix:nonFraction> &#8220;2024 Warrants&#8221; at a strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_5ri5JcF8t06zRgfNuESzxQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_Y0G5jgXw2UeW2ytvEM2o1Q">49.1568</ix:nonFraction><span style="white-space:pre-wrap;"> per share.  The fair value of the &#8220;2024 Warrants&#8221;, which was a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_5ri5JcF8t06zRgfNuESzxQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr_Q53NZogRvECoQNorDdMBkg">224</ix:nonFraction> was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the OFA Facilities. This non-recurring measurement is classified as Level 2. The inputs used were a strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_qc0Go_Cfk020vCx7lAeh0w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_z5n40YCbDkmubmm_oEcc7Q">49.1568</ix:nonFraction>, the Company&#8217;s stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_yGOW9iQj6UGPG-rEriM09Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_jqFvNXxG70Gn8c4DkirsEQ">44.48</ix:nonFraction>, volatility of <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_oLqCI4mI10aP6GWCCHFvVQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_KSf0yEzTlkCbdS9KvssB9Q">112.2</ix:nonFraction>%, term of <ix:nonFraction unitRef="Unit_Standard_Y_HWoZmdDBn0OhfgBS6ig-MA" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_icjol4YP1kutdR0RMqnOew" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_RosgqvyR90WzF3BUZ8YBYQ">5</ix:nonFraction> years and risk-free rate of <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_6kMEiu_1N06tYfLStTj0oQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_Z0yO87uCmEiRhUgXSDyvHA">4.25</ix:nonFraction>%. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_P4AF5ciWSEmrb3tg5IdOXw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, in connection with the Fifth Amendment of the Credit Agreement, on the Fifth Amendment Effective Date of November 25, 2024, the Company amended and restated the Closing Date Warrants, 2023 Warrants, and 2024 Warrants granted to the Lenders to have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_ULyHbDGAWkiYKXfDf_TeDQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_gb-Ev_EijU-GSpege_ZXiA">7.68</ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Using a Black-Scholes pricing model, the Company determined that the Closing Date Warrants, 2023 Warrants, and 2024 Warrants&#8217; fair values at the previously amended strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_uPbZgXmXZUiSsb-dyLE4HA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_RBQP2KWXWUKE4iqYng4-IA">58.3232</ix:nonFraction> and original strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_7Rf_XFQB_kmb6iMCoS8NYQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_Q9c3QrYBPkmRO-Cl77c_Eg">49.1568</ix:nonFraction> the amended strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_ULyHbDGAWkiYKXfDf_TeDQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_7uw-9rLv0EGdMv9iMVCkgw">7.68</ix:nonFraction> were $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_7Rf_XFQB_kmb6iMCoS8NYQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr_fcTNiuT6qkakYX6Ajxyo-A">105</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_ULyHbDGAWkiYKXfDf_TeDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr_StLHP9la0kGKQXvnerGnrw">164</ix:nonFraction>, respectively, as of the Fifth Amendment Effective Date. The Closing Date Warrants, 2023 Warrants, and 2024 Warrants&#8217; incremental increase in fair value for the repricing of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_QAwpylSU5UyaB8Q_rrtbYQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" scale="3" id="Narr_cBXuh5ugYk-wE6cZMdWPxA">59</ix:nonFraction>, was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts refinanced under the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;">The fair value of the Accompanying Warrants at issuance on March 25, 2024 was determined using a Black-Scholes pricing model and the fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_oiu1ThMdnUOs-KiwIduWmQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr_NnWQ-LhmyUW-an7iLxWVQg">19,347</ix:nonFraction> was recorded as a derivative liability with the offset recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Consolidated Balance Sheets. This fair value measurement is classified as Level 2. The valuation inputs used were a strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_cLng8ai8UkazAQbJGlFaNQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_ZpSP8ej5Fk6cwKk16ZBHNg">51.20</ix:nonFraction>, the Company&#8217;s stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_u9-8OCpVJkG9nsYV-XtccA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_0UccDEgA9kCqb9S7ZzQg_w">44.96</ix:nonFraction>, volatility of <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_mLs5yiiHEkCXZbPPpDd3Ow" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_DaFlzXFFUkK5PuN6j-8lig">112.2</ix:nonFraction>%, a term of <ix:nonFraction unitRef="Unit_Standard_Y_HWoZmdDBn0OhfgBS6ig-MA" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_jgX2LEyonkeD7lRM74FyMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_BrSsBC3Dx0-asrBzmfF6_Q">5</ix:nonFraction> years and a risk-free rate of <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_p6z9MJatyUSUOiTjIZSLJA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_ofZvfnDtcUKNIj9sQKOgiQ">4.2</ix:nonFraction>%<span style="white-space:pre-wrap;">.  On November 25, 2024, </span><ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_T6cTQVW5iEu7v6aQO3r8Lg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Narr__TXsu-IPaEimVO85SB3W4Q">534</ix:nonFraction> of the <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_tnK7lRA_PkmprsVLffcXvQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Narr_DqoV2NEFe02IFVz8hmPYYA">539</ix:nonFraction> Accompanying Warrants&#8217; strike price were amended to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_P_lWwiR8M0e2d17J1qElcg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_qdIqWh38i0G1gHvtfPAfug">9.136</ix:nonFraction><span style="white-space:pre-wrap;">, as part of the consideration provided to one of the investors in the November 2024 Equity raise discussed in Note 11, Common Stock Financing Activities.  The increase in fair value due to the amended strike price of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_11_25_2024_To_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_355-JNdbG0a2GsWONO9ZWw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="Narr_k_5unHlIckqoTJ8hQdUKrw">1,000</ix:nonFraction><span style="white-space:pre-wrap;"> was recorded as an increase in the carrying value of the Derivative liability, with the offset recorded as a loss in Other (income) expense, net, in the Company&#8217;s Consolidated Statements of Operations.  We remeasured the Accompanying Warrants&#8217; fair value at December 31, 2024 of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_JBeXWTEcBki5v7foWKB49w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr_zKMZsAAXi0Wy94W8AWjTAQ">2,320</ix:nonFraction> and recorded a net gain of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_5eL_-_utPUCNyy4fj-GOyA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="Narr_N5bS-PTwqkKntQs2kPSCJQ">17,027</ix:nonFraction>, including the repricing loss of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_11_25_2024_To_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_355-JNdbG0a2GsWONO9ZWw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="Narr_XrFAt-RjR0CjUYEj3PtQIw">1,000</ix:nonFraction> for the year ended December 31, 2024, respectively within Other (income) expense, net in the Company&#8217;s Consolidated Statements of Operations. The valuation inputs used as of December 31, 2024 were a strike prices of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_B-Y0cXQAQ0Sb_-x7Pz9oew" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_XRXRxeKOpE2xKmXwmrjruQ">9.136</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_V0NHkt3bfk2Ba2s21MfECQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_WAlyBo_Yq0uVB1mmWsXGWw">51.20</ix:nonFraction> for <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_lI6dv2jX_EWXRmyQX2VxXw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Narr_sSslnN4dKkWcqeMPd3gZyA">534</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_kfeh-8yR4k-MMGH2ApsgLQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Narr_qowBgTDF4kWjnQGVAmWH6Q">5</ix:nonFraction> Accompanying Warrants, respectively, the Company&#8217;s stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_387uYLHD2EqiYkh3ZygEsA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_rMwtYr_WeUCDVJVcoS5X1g">5.984</ix:nonFraction>, volatility of <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_mCar_ZgvpEWSra0NQcz42g" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_j5Il53NgZkWo78JNjsTElw">112.3</ix:nonFraction>%, term of <ix:nonFraction unitRef="Unit_Standard_Y_HWoZmdDBn0OhfgBS6ig-MA" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_7e_v0kd2N0eBHM_SA31z7g" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_X-cR1tZ2hkGRC-l7uTXOig">4.2</ix:nonFraction> years and risk-free rate of <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_S1WaCx3EFEyAR8UWU9J9zA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_4Ubumsl_4kuybKlJ_qLmwg">4.4</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;">The fair value of the November 2024 Accompanying Warrants at issuance on November 25, 2024 was determined using a Black-Scholes pricing model and the fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_DdDbFFCDBE64P_O4BJl7kA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr_5uyBc8Eadked2Nd13wRTUg">5,562</ix:nonFraction> was recorded as a derivative liability with the offset recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets. This fair value measurement is classified as Level 2. The valuation inputs used were a strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_T8m7TXv_3kCCweETb2zyjw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_efH-sfKzf02lYz5EQBKyDw">7.68</ix:nonFraction>, the Company&#8217;s stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_OQu-LcOiKkqIepIPSq1fgg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr__8YQ7lahJ0Gf0FSvTifIig">7.52</ix:nonFraction>, volatility of <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_nUBe9GYzxE-ZmBiqq4O37Q" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_yC_qJaIBRkyPHw1RIeWXow">112.5</ix:nonFraction>%, a term of <ix:nonFraction unitRef="Unit_Standard_Y_HWoZmdDBn0OhfgBS6ig-MA" contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_k8T7cHsMIUGhoBLO_zrk7Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_0RYn7FdBy0q7Io2TeWAmLA">5</ix:nonFraction> years and a risk-free rate of <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_qJT7c0kn9Eu2AFMTvKrocQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_DIrjVNwM5kC_VacEBjAuZg">4.2</ix:nonFraction>%<span style="white-space:pre-wrap;">.  We remeasured the fair value at December 31, 2024 of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_XYejg84PY0-8-DI1vMLBvw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr_WdwZDbTpP0qxET1IkNyr1w">4,273</ix:nonFraction> and recorded an unrealized gain of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_p63njE8R7Eu_9LSZHS_XWw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="Narr_N67ZcGyW306eJXZwcyOzGQ">1,289</ix:nonFraction> for the year ended December 31, 2024, respectively within Other (income) expense, net in the Company&#8217;s Consolidated Statements of Operations. The valuation inputs used as of December 31, 2024 were a strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_P_XszpuZj0GQUjB1hTtEgw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr__diLg1yyhECOyd9ObjVFZg">7.68</ix:nonFraction>, the Company&#8217;s stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_2mozctssp0KbH0y09FoRew" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_khp_xIDqMUi1OxFRzUto7A">5.984</ix:nonFraction>, volatility of <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_OG-f8LWXVEuAP6w4PvNKlQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_CIUwvQ8yM0a81OD8Zv0Kjg">112.3</ix:nonFraction>%, term of <ix:nonFraction unitRef="Unit_Standard_Y_HWoZmdDBn0OhfgBS6ig-MA" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_6A5TfvgGDkyeNTAS_CDIyA" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_iTSQ1B0YaU2wj3w8wv_bJw">4.9</ix:nonFraction> years and risk-free rate of <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_SeVI2KEJJkaPytkbFhDmdg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_etNGQiazv0G7UEfncxuYKw">4.4</ix:nonFraction>%.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_48gd2FjgdU6bDWyknSslHQ" continuedAt="Tb_48gd2FjgdU6bDWyknSslHQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;16. Income Taxes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The significant components of the Company's net deferred tax assets at December 31, 2024 are shown below. In determining the realizability of the Company's net deferred tax assets, the Company considered numerous factors, including historical profitability, estimated future taxable income, and the industry in which it operates. Based on this </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_YeUMHKv1ekmN3rdGoQLSYQ_1_2"></a><a id="Tc_KPVk2a8-6EScKVGlQXU7Zg_1_5"></a><a id="Tc__xA9ZBOIREiNIbyb-KzkEw_2_2"></a><a id="Tc_m-kmPq3mkkWjyolwrHX9Og_2_5"></a><a id="Tc_R1GgrMqlcEa6vj51WspxGg_3_0"></a><a id="Tc_Dw4o4Z9R3EODEJj8NLSCwA_4_0"></a><a id="Tc_65AG22UIGUSAlcezigCiPg_4_2"></a><a id="Tc_M8WeyTrOt0m-6lAOsuNvAw_4_5"></a><a id="Tc_5nRwVzI3Gk2Z4TlKU7LVLw_5_0"></a><a id="Tc_J9_QUe8BJkS2QVWl9jsapg_6_0"></a><a id="Tc_2fK8B_f5AUqqimSLkX9rYg_7_0"></a><a id="Tc_ona_vWnp2k-qMMzIFseb9A_8_0"></a><a id="Tc_HFds1_tHqEeKZSNqS3SC5A_9_0"></a><a id="Tc_2Peh3AyvjE23hH7JlUQQKw_9_6"></a><a id="Tc_W7gvrFGTwUyDZIBb8wjO_g_10_0"></a><a id="Tc_pDrE8_hgWkaMnrmn85uNRA_11_0"></a><a id="Tc_XdNy0Ms2-UK_hNjf1ZhGCw_12_0"></a><a id="Tc_h1vFxmPzPUeQkNQcnSGUCw_13_0"></a><a id="Tc_FNk8Bgv_gkeKnHnvd36Ihw_14_0"></a><a id="Tc_SkwR0X7AFUqxf0siOZsptw_15_0"></a><a id="Tc_pFkYPMKxVUCB1kPF14cOAw_16_0"></a><a id="Tc_wDJpylLkcE2a0botHT_Wjw_16_2"></a><a id="Tc_Ph-OXhKzUUOCmU0qkixiHQ_16_5"></a><a id="Tc_HZy6rycP-EOGXAfy7If_Yw_17_0"></a><a id="Tc_2FfjdzhJGkeEyxr7hJr0cQ_18_0"></a><a id="Tc_Lhl06RbdP0KZscHT7K0xmw_18_2"></a><a id="Tc_0k6GMjr9mESwNtKNZnnLtQ_18_6"></a><a id="Tc_B8Au3fh62E2BM9zQfoLVUQ_19_0"></a><a id="Tc_cbocwsETkUeCiTYPpD-m8g_19_3"></a><a id="Tc_6-rufvb_rUSRH7h7r-IGeQ_19_5"></a><a id="Tc_ZgXDJSjOCU6-cmGDO_ocVg_20_0"></a><a id="Tc_jlLeB6frO02Xj6wKN4NqOg_21_0"></a><a id="Tc_1-jYcUBbek-HTU4LZm1keQ_21_2"></a><a id="Tc_w5ttWI69FkGnb3LyvpDm3g_21_5"></a><a id="Tc_9IwMCL3-rkuBvw5Oke_GYg_22_0"></a><a id="Tc_SMpnc4b93kq1CUjrv9PvFA_22_2"></a><a id="Tc_lSUBKyGVJU-WyRMCyQeeHw_22_3"></a><a id="Tc_M3G8ISbwoUSOdZfLGbUaQQ_22_5"></a><a id="Tc_dDMiw2HZg0SHxoteczKqxA_22_6"></a><a id="Tc_p3Yn8Ww_pkK-yZiedkzsXA_1_2"></a><a id="Tc_gyusbrlpyUqi8eDBrZbPzw_1_4"></a><a id="Tc_XCHELzptGUO_Dtj7D9l3ZQ_1_7"></a><a id="Tc_LjAdNM_RCUWG-3aH3aVQmw_1_9"></a><a id="Tc_KFXXsCVCVUmsQGNCyAfgog_2_0"></a><a id="Tc_9kyLKSoRkE2u_IeqMzklfg_2_5"></a><a id="Tc_qR4gNSqDJUmu_b5txnvU6g_2_10"></a><a id="Tc_yEJaHBvj6U6_tLcFKIYpyg_3_0"></a><a id="Tc_Q1OmXcGSuU6AzS6b3LCgEQ_3_5"></a><a id="Tc_ojY4Ldmzf0mc9KcMf7FxjQ_3_10"></a><a id="Tc_Dr8OEkbVDU61sAcPvUQVVA_4_0"></a><a id="Tc_AJ1pbItGXUG8grHzet6g8w_4_5"></a><a id="Tc_xFHnxcxRJkiowGfBO7yGPg_4_7"></a><a id="Tc_C1U3ZkuU1USChHbJdFGtSw_4_9"></a><a id="Tc_9Ee5Ao9_YU6284ASgmoiag_4_10"></a><a id="Tc_MAF3c7TVz0mc8lXqOIyrlg_5_0"></a><a id="Tc_2Ht5cKD3g0u46lJmKDF5gA_5_5"></a><a id="Tc_F9jXQ7YTNkO633gnQWofgw_5_10"></a><a id="Tc_YphFf-nB2kqH07TCHGmoMA_6_0"></a><a id="Tc_d0yUuYIMgUSp1KBP8ny69w_6_5"></a><a id="Tc_RzeR24wQVk2fu9fv3EFAKQ_6_10"></a><a id="Tc_9E3lB1dITkiXPg4tXow-qw_7_0"></a><a id="Tc_pfj6rzD3Uk6lUBWhyF7Ibw_7_5"></a><a id="Tc_LjaI6Lqh506aSx5irsoHKA_7_10"></a><a id="Tc_lCecCNpKDkGlqcMVVIrMEg_8_0"></a><a id="Tc_zAoTRddWKkyNdpQP7UPVUw_8_5"></a><a id="Tc_qOX1mYe-HUK-fhJzGAfUVg_8_10"></a><a id="Tc_g85K17YwlUif8ymYEXDbgg_9_5"></a><a id="Tc_t4kqkiknz0e3Kotdv_SYdA_9_10"></a><ix:continuation id="Tb_48gd2FjgdU6bDWyknSslHQ_cont1" continuedAt="Tb_48gd2FjgdU6bDWyknSslHQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">information the Company has provided a valuation allowance for the full amount of its net deferred tax asset because the Company has determined that it is more likely than not that they will not be realized.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_IAzJQcoBHkWBEJx-exTqyA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal net operating losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="3" id="Tc_-aYLNdByDESEKKntkq4VSQ_4_3">90,853</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="3" id="Tc_o5FxJw8PtEuCAylzvTQgQA_4_6">73,770</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State net operating losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="3" id="Tc_00-IfM6KBUW4RvWETNYXzQ_5_3">23,152</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="3" id="Tc_pCNFJQrtQkOtklShtHNGew_5_6">21,255</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_--3eNQs0xkencSY8k5e5rQ_6_3">14,601</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_0_PIlG-S-EOrjVHcliBIfA_6_6">13,915</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_i6eGEyNDnUeQN1eyCNgjlQ_7_3">17,188</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_u7RlniXCrkayKcdA94J0PA_7_6">15,048</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research &amp; development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_PBXkb5TehkaDHbQMpAsW8w_8_3">44,377</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_ih9PBMTHlkSXa4HQfARhXQ_8_6">49,603</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="Tc_NzRlTFkvt0CxU-GFTibREg_9_3">202</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="Tc_QesD3uUYWEWQlL_7D4dlaA_10_3">103</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="Tc_5WDGZY75ck-D0l5QC10Osw_10_6">73</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease accounting - liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:DeferredTaxAssetsLeaseAccountingLiability" scale="3" id="Tc_-10ExVHU0EaMizVeZ3x8Fg_11_3">115</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:DeferredTaxAssetsLeaseAccountingLiability" scale="3" id="Tc_pXN4arWqF0iTXtfevTav8g_11_6">212</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Disallowed charitable contributions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" scale="3" id="Tc_2VwnwSArGk2CFADqugUW9g_12_3">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred Costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:DeferredTaxAssetsCapitalizedIpoCosts" scale="3" id="Tc_BEgPqcegfkiV3_cqWf1Ahg_13_3">674</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cancellation of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:DeferredTaxAssetsCancellationOfDebt" scale="3" id="Tc_B8Uj-QWUBE-Xkh62U4If0w_14_3">1,483</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_kyDdec1tSUub8ADb_aKOUQ_15_3">192,149</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_CXeEg040HE6KkkmDiZwzuw_15_6">173,679</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_cQSrmDx-eke8TpZPDlxiYg_16_3">600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_tqc0A1U1t0iBdRMbd4mdWw_16_6">197</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Debt amendment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" scale="3" id="Tc_b4mc_RnCI0G37KYegAmgFg_18_3">500</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesDerivatives" scale="3" id="Tc__H1lXtpbfkeMeHMt1L5Czw_19_6">12</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="Tc_OToRdRsRqEeqIZ7nadBEvg_20_3">100</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="Tc_2YbJse8YxEuMJkJD7jkYkg_20_6">185</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_4gNZgQOg00iPq4IzxfVqug_21_3">600</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_eZt5ZTLx0UCROKg2kldg8w_21_6">197</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net deferred tax asset (liability)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The income tax expense/(benefit) for the year ended December 31, 2024 differed from the amounts computed by applying the U.S. federal income tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_Hzh8sOLj0kG-5XtLulvqWg">21</ix:nonFraction>% to loss before tax benefit as a result of tax credits generated and changes in the Company&#8217;s valuation allowance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A reconciliation between the Company&#8217;s effective tax rate and the federal statutory rate are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_VlyBtO7DsEmYhEA5gYk39A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="3" id="Tc_b99KLTJSyE6QrIIzYi_u7g_2_2">12,516</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_Qcm3z3HGjUCxTIq_jJqOWg_2_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="3" id="Tc_Z-eh5BYXPE62WdhgFsjRKg_2_7">37,601</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_4y2Ngrkxg0iJJuI90OZzTA_2_9">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="Tc_IHmg61sfBkiEbDlu-jRk7A_3_2">381</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" sign="-" scale="-2" id="Tc_EKfUfFBYi0SwqLjLajG34Q_3_4">0.6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" sign="-" scale="3" id="Tc_797SceW4b0iWsGEIY1dHxw_3_7">573</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="Tc_x0ywU-OZwkWCM8j-wtE24A_3_9">0.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant mark-to-market</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="btai:EffectiveIncomeTaxRateReconciliationWarrantValuationAmount" sign="-" scale="3" id="Tc_zpP6vFXCJkCxYJCbz-QfJQ_4_2">4,238</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="3" format="ixt:num-dot-decimal" name="btai:EffectiveIncomeTaxRateReconciliationWarrantValuationPercent" scale="-2" id="Tc_4C0CdyAoLE6iElYBi540hA_4_4">7.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal and state credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="3" id="Tc_DCzqP88Yf0SdauwaXdS79A_5_2">1,870</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" sign="-" scale="-2" id="Tc_ZCtMq8JnUUy3QbTA3lOofg_5_4">3.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="3" id="Tc_xuOGaCCNhEOgrtbtAHlTgg_5_7">4,082</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" sign="-" scale="-2" id="Tc_aW8LiEm9q0ySdCRHG_vD6w_5_9">2.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" sign="-" scale="3" id="Tc_9cHFXIn5sUiP33Hia2UVXg_6_2">343</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_4K436LkfnU6Pnz8HK4LTMg_6_4">0.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" sign="-" scale="3" id="Tc_CqESKsHk60eRt9OJLJdeFw_6_7">14,261</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_buSR0qjOQEy_2nSA0F9QfQ_6_9">8.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="Tc_QdFnc5s-Fk61TzcD17G6-Q_7_2">116</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_ltJ_sxKTfkuChxpuZsT8ag_7_4">0.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="Tc_mOeyn9HLTU-TWrsCIQP7WA_7_7">1,210</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_HGyBbVa9Lk67u0DXhO7EFg_7_9">0.7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="Tc_BMnS8KarjUOQ5eooSgnSdA_8_2">18,470</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_I54ulXiMdUy6HL_u8tAlUQ_8_4">31.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="Tc_bWtA4ZBfsEiJczC7V964Bw_8_7">55,307</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_AsAzc_N_KEaCRxg5ektE3A_8_9">30.9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_XgcGESru60uMR_gvJHuMng_9_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="3" format="ixt:fixed-zero" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc__RKihOyc1Uy9Jyb4d-4ePQ_9_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_k2yXXbtZcUu4-eX1lnOc4Q_9_7">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="3" format="ixt:fixed-zero" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_BvBayO8PxkimGxQqCV2g6Q_9_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">At December 31, 2024 the Company had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_WgBqcPiqCk2sU5U9HArJCg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Narr_xRKEydazU0-iG01pRCksCg">432,634</ix:nonFraction> of gross federal and $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_QcDNt3XBCU29K3TtzRineQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Narr_HIhJSAARY0aIRqHzuc47oA">443,454</ix:nonFraction> of gross state net operating loss carry-forwards. If not utilized, the federal and state net operating loss carry-forwards will begin to expire in 2037. The federal net operating loss of $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_WgBqcPiqCk2sU5U9HArJCg" decimals="-3" format="ixt:num-dot-decimal" name="btai:OperatingLossCarryforwardsNoExpiration" scale="3" id="Narr_f4tWTzQBYUifGIvAvgi9fQ">429,988</ix:nonFraction><span style="white-space:pre-wrap;"> incurred after December 31, 2017 will carryforward indefinitely.  The utilization of such net operating loss carry-forwards and realization of tax benefits in future years depends predominantly upon having taxable income. The Company has approximately </span>$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_WgBqcPiqCk2sU5U9HArJCg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="Narr_4OW40Uiv2k23DEHqPwtzJw">15,965</ix:nonFraction> of federal orphan drug credits and research and development credits which will begin to expire in 2037 if not utilized. The Company also has approximately $<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_QcDNt3XBCU29K3TtzRineQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="Narr_uQG4vDnRQkGI97Xh5aVJ0Q">1,548</ix:nonFraction> of state research and development credits which will begin to expire in 2040 if not utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Utilization of the NOL and research tax credit carryforwards may be subject to a substantial annual limitation due to ownership limitations that has occurred or that could occur in the future, as required by section 382 of the Code, as well as similar state and foreign provisions.  These ownership changes may limit the amount of the NOL and research credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively.  In general, an </span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_48gd2FjgdU6bDWyknSslHQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">"ownership change" as defined by Section 382 of the Code results from a transaction or series of transactions over a three year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a by certain stockholders or public groups.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax positions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of December&#160;31, 2024, there were no uncertain positions. The Company's U.S. federal and state NOLs have occurred since its inception in 2017 and as such, tax years subject to potential tax examination could apply from that date because the utilization of net operating losses from prior years opens the relevant year to audit by the U.S. Internal Revenue Service and/or state taxing authorities. The Company did <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr_54RjO3puV0Oo_-DzGrfn4g"><ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr_tuJToK8tV0-KR9wiMC8XLw">no</ix:nonFraction></ix:nonFraction>t have any unrecognized tax benefits and has <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" scale="3" id="Narr_i3kICxQCL0iUZHR4t0aNAQ"><ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" scale="3" id="Narr_x0M-NhxW0kqMhivWmM8a4Q">no</ix:nonFraction></ix:nonFraction>t accrued any interest or penalties for the years ended December 31, 2024 and 2023. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_KC9fUci5tkujWhQmfmvmGA_1_2"></a><a id="Tc_T7LNbLvLP0KhFPCBA6gaFQ_2_2"></a><a id="Tc_3bFrMXCWxUyZWieIVJMJAQ_3_2"></a><a id="Tc_wLyKKGXc_0OnsHeEuPmyMw_3_5"></a><a id="Tc_HDwNmUkHp062Xy4sPh-d_Q_5_0"></a><a id="Tc_56CFwi47sEi902FS9G7BcQ_5_2"></a><a id="Tc_pNL9MFSGDEumXFBNdQDOJQ_5_5"></a><a id="Tc_jvn5mnTB_0WRhq_GkNtS_A_6_0"></a><a id="Tc_YlRCtp_bbkaMr96BzszanA_7_0"></a><a id="Tc_h4JhF_b4akijThK7ouH_cw_7_2"></a><a id="Tc_MH8T_ywamUC8fc6Ff10NbA_7_5"></a><a id="_5b9ef2dd_75fd_4038_9867_f754b5449166"></a><a id="Tc_2QBtMMYvyka4IM-TBQtQXw_1_2"></a><a id="Tc_zfz8iX5Pf0eX948id2G7Fg_2_2"></a><a id="Tc_pPDt72HgzEekJ3Ic6-5qIA_3_2"></a><a id="Tc_o4uHOupvnki90gBcOxwF4Q_3_5"></a><a id="Tc_i35dz0bm6UOERLfhfsxDYw_5_0"></a><a id="Tc_CZ18aASssEyXksBjBxe-AA_6_0"></a><a id="Tc_KOlL9Cx1rkqe-5LQlITdjg_7_0"></a><a id="Tc_G1gEKKEnwkKkFu6FIn2iTw_8_0"></a><a id="Tc_lLJOlih3ZUKQ4pLHHeYCvg_9_0"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:EarningsPerShareTextBlock" id="Tb_aszjcJ4lUUK1qgQmIFp9mA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 17. Net Loss Per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Basic and diluted net loss per share are as follows</span>:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_AUYZG1VJ00e_EU0jy_pwOQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss (numerator)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_GcNlUIjM6UqLUOFmdQMAlQ_5_3">59,599</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc__62zOC11IkaZX3V4INfqxQ_5_6">179,053</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares (denominator)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_QsM5_28TeUGNpi1Wd23Z4A_6_3">2,535</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_xBJe3XurZEuM6tdWrjqbiQ_6_6">1,821</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_mu-6FZvUdEar2ChaXrevbw_7_3">23.51</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_wIjEUQeVHEObyGQnEh3OHQ_7_6">98.33</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Potentially dilutive securities outstanding consists of stock options, RSUs and performance units, and BTI warrants. The Company had common stock equivalents outstanding are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_V2TmzLxX90GaVJhLgyqABA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_uVcJZBaEUU2RieeIBXowxA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_PW61Q56hLkmicjq9lZ7zZg_5_3">311</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_1Vg-MGOfMUG52-OKD_lr3Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_qSzpjeeEfkKFhy6WfcubSA_5_6">311</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_8wNKxgPGRUu5CFwHgwGsEw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_qe3u61zynEiEm9akqIwhJA_6_3">27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_lFtYhgCxvUaKZc-Y-rTpsQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_7MMisImvLEiaWmZK6V-w3A_6_6">12</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Performance stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_a-yRAQ6nhkmrbi3aQ6cBLw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_sA-rgOrPdkqipnWtq_WO5A_7_3">70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_ufIYMMNpvEWk__kIwMRFvA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_5ShsUn-BTUu8LlTJCXVnxw_7_6">31</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">BTI Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_btai_BioxcelWarrantsAggregateMember_D-VgH0D5EkWR5T5lmAPfSQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_0Mhy_Lu7AE2UCTJHN3Qs8Q_8_3">1,792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_btai_BioxcelWarrantsAggregateMember_yQW7FSPMyU-tXyPdIkz20Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_VMlHxkqiukuNs_jHXlnFDQ_8_6">22</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total common stock equivalents</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_Cmz-QKhW60em3tPfV7z50Q_9_3">2,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_Oi0BuD5DwEatsFn0jtvlJw_9_6">376</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_CHLjQEC-OkOmSORwZuLAwg" continuedAt="Tb_CHLjQEC-OkOmSORwZuLAwg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 18. Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">From time to time, in the ordinary course of business, the Company may be subject to litigation and regulatory examinations as well as information gathering requests, inquiries and/or investigations. Other than the below, the Company is not currently subject to any matters where it believes there is a reasonable possibility that a material loss may be incurred.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">On July 7, 2023, plaintiff Katelyn Martin filed a class action complaint against the Company and certain executives in the United States District Court for the District of Connecticut, captioned </span><i style="font-style:italic;background:#ffffff;">Martin v. BioXcel Therapeutics, et al.</i><span style="background:#ffffff;">, 3:23-cv-00915 (D. Conn). </span>The case has since been renamed to <i style="font-style:italic;">Hills et al v. BioXcel Therapeutics, Inc. et al</i>. <span style="background:#ffffff;">On October 4, 2023, pursuant to the Private Securities Litigation Reform Act, the court appointed two co-Lead Plaintiffs. The co-Lead Plaintiffs filed an amended complaint on December 5, 2023, alleging violations of Sections 10(b) and 20A of the Securities and Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) and SEC Rule 10b-5 promulgated thereunder. On July 11, 2024, the Court dismissed the amended complaint without prejudice and, on August 1, 2024, co-Lead Plaintiffs filed a second amended complaint. The second amended complaint alleges that defendants made false or misleading statements regarding the TRANQUILITY II trial and the development of BXCL501 for an expanded indication related to the </span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_CHLjQEC-OkOmSORwZuLAwg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;background:#ffffff;">treatment of certain Alzheimer&#8217;s-related agitation. The Company moved to dismiss the second amended complaint on September 6, 2024. On February 24, 2025, while the Company&#8217;s motion to dismiss remained pending, Plaintiffs moved for leave to further amend their complaint. The Company filed an opposition to the motion on March 17, 2025. Plaintiffs&#8217; reply is due April 7, 2025.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">On November 28, 2023, Plaintiffs Pratheesan Panancherry and Jeffrey Bastress filed a stockholder derivative complaint in the United States District Court for the District of Connecticut purportedly on behalf of the Company and against Vimal Mehta, Richard I. Steinhart, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption </span><i style="font-style:italic;background:#ffffff;">Panancherry et al v. Mehta et al</i><span style="background:#ffffff;">, 3:23-cv-1554. Following the initial action, Plaintiffs Maria Vomvolakis (3:24-cv-3) and Kelly Fowler (3:24-cv-203) each filed separate stockholder derivative complaints in the District of Connecticut raising similar claims as Panancherry and Bastress, including business torts and violations of the Securities Exchange Act of 1934. The cases have been consolidated under the caption </span><i style="font-style:italic;background:#ffffff;">In re BioXcel Therapeutics, Inc. Stockholder Derivative Litigation</i><span style="background:#ffffff;">, 3:23-cv-1554 (D. Conn.). The consolidated action is currently stayed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">On January 11, 2024, Plaintiff Jeremy Smith filed a stockholder derivative complaint in the United States District Court for the District of Delaware purportedly on behalf of the Company and against Vimal Mehta, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, Richard I. Steinhart, Robert Risinger, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption </span><i style="font-style:italic;background:#ffffff;">Smith v. Mehta et al,</i><span style="background:#ffffff;"> 1:24-cv-00041. Following the initial action, Plaintiff Janice Korff filed a stockholder derivative complaint in the District of Delaware raising similar claims as Smith (1:24-cv-130), including business torts and violations of the Securities Exchange Act of 1934. The cases have been consolidated under the caption </span><i style="font-style:italic;background:#ffffff;">In re BioXcel Therapeutics, Inc. Derivative Litigation</i><span style="background:#ffffff;">, 1:24-cv-00041 (D. Del.). The consolidated action is currently stayed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">At this time, the Company does not believe the claims in the above-captioned matters have merit, and intends to vigorously defend against them; however, the potential costs and liabilities associated with this litigation are uncertain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">In April 2022, the Company signed a commercial supply agreement that requires minimum annual payments for the first three years of the agreement that in aggregate total </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_4_1_2022_To_4_30_2022_AGdwF45rAUaEqJM-M8UB2g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermPurchaseCommitmentAmount" scale="3" id="Narr_Nowc3FRmWEiVzRzRUcEJxg">10,000</ix:nonFraction></span><span style="background:#ffffff;"> for the </span><ix:nonNumeric contextRef="Duration_4_1_2022_To_4_30_2022_AGdwF45rAUaEqJM-M8UB2g" format="ixt-sec:durwordsen" name="us-gaap:LongtermPurchaseCommitmentPeriod" id="Narr_6f-4VtPZMUu4v0HpIrfK4A"><span style="background:#ffffff;">three-year</span></ix:nonNumeric><span style="background:#ffffff;"> period, of which </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_4_30_2022_Zfgyqm8oPECQksmotjQKJw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" scale="3" id="Narr_OOhLULeKRkCCJ8Ifx29enQ">5,000</ix:nonFraction></span><span style="white-space:pre-wrap;background:#ffffff;"> was originally due in year ended 2024.  On July 11, 2024, the Company entered into an amendment to the commercial supply agreement (the &#8220;Product Supply Agreement Amendment&#8221;) that reduces the specified minimum annual payment over the next three years starting in the year ended 2024 and, thereafter, for a specified interval, provides for minimum annual payments to the extent that the Company receives approval of a supplemental new drug application (sNDA) or a new drug application (NDA) from the FDA for enumerated indications. The Company&#8217;s renegotiated agreement reduced the minimum commitment for 2024 to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_7_11_2024_M-RCVSP_HEGMyNg657_jKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" scale="3" id="Narr_zxZ_xY9ZKUiP0v2FFGUvDQ">1,000</ix:nonFraction></span><span style="background:#ffffff;"> and thereafter for the term of the agreement in annual amounts ranging from </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_7_11_2024_To_7_11_2024_srt_RangeAxis_srt_MinimumMember_l8F9i5yxlk2GrsHmZ41AHQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermPurchaseCommitmentAmount" scale="3" id="Narr_jUkqeiYjk0mKaoOe20jN6Q">2,000</ix:nonFraction></span><span style="background:#ffffff;"> to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_7_11_2024_To_7_11_2024_srt_RangeAxis_srt_MaximumMember_MahkWQ1D0kWY8CGoanrcrQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermPurchaseCommitmentAmount" scale="3" id="Narr_zlTDSjxSTkGU-6Nyq95_ew">5,000</ix:nonFraction></span><span style="background:#ffffff;"> subject, in certain instances, to the extent that the Company receives approval of an sNDA or NDA from the FDA for enumerated indications. In accordance with the Product Supply Agreement Amendment, the minimum commitments were reduced to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_7_11_2024_M-RCVSP_HEGMyNg657_jKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" scale="3" id="Narr_ErlXrWBmH0yzQ1DwA4Q0YA">1,000</ix:nonFraction></span><span style="background:#ffffff;">, </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_7_11_2024_M-RCVSP_HEGMyNg657_jKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="3" id="Narr_QtBhqDigdEO8ibV3NVteqw">2,000</ix:nonFraction></span><span style="background:#ffffff;"> and </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="As_Of_7_11_2024_M-RCVSP_HEGMyNg657_jKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractualObligationDueInSecondYear" scale="3" id="Narr_jFARImbbYkKa7zNVq-SgCQ">2,000</ix:nonFraction></span><span style="background:#ffffff;"> in the years 2024, 2025, and 2026.</span> <span style="background:#ffffff;">In addition, the Company agreed to make a reconciliation payment of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_7_1_2024_To_9_30_2024_UmSoTOy6ZEqdvjDqQLaKEw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" scale="3" id="Narr_3zhFol5FQ0KFVi355dgNpQ">1,200</ix:nonFraction></span><span style="background:#ffffff;">, paid in the third quarter of 2024 for full settlement for amounts due prior to the July 11, 2024 amendment.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:SegmentReportingDisclosureTextBlock" id="Tb_88ypPxPhg0OEUE-YNOneJg" continuedAt="Tb_88ypPxPhg0OEUE-YNOneJg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 19. Segment Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company views its operations and manages its business as <ix:nonFraction unitRef="Unit_Standard_segment_u3k5mJIKoECDA2MsRZB6Gg" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_mgr_hkifLES4Bpb8bNas7w">one</ix:nonFraction> operating and reportable segment, utilizing artificial intelligence (&#8220;AI&#8221;) to develop transformative medicines in neuroscience and immuno-oncology. We are focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients&#8217; lives. We employ various AI platforms to reduce therapeutic development costs and potentially accelerate development timelines. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Consistent with the operational structure, the Chief Executive Officer, as the chief operating decision maker (&#8220;CODM&#8221;), reviews weekly cash usage and allocates resources based on consolidated net loss that also is reported on the consolidated statements of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets. The CODM utilizes consolidated net loss by comparing actual results against budgeted amounts on a quarterly basis. As part of this process, consolidated net loss is a critical performance measure used to evaluate the </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_BUl9dL68bk-r5XKULhQvKg_1_3"></a><a id="Tc_3Lj_dUeNjkWN7YVVkv5PQg_2_3"></a><a id="Tc_t6_pZLsnVU2GsB2L9nwjzw_2_6"></a><a id="Tc_HqHHUzc6IEuzxpM6-m-Pmw_4_0"></a><a id="Tc_SV9H4uXoo0WDc_T58maQWw_4_3"></a><a id="Tc_rcGo51G2ykOyRCF41U248w_4_6"></a><a id="Tc_ZPVzr7pvOEejqiXbE_5H0g_5_0"></a><a id="Tc_OWNxz-sgAEisCvUlYJgoiw_6_0"></a><a id="Tc_NjK7NNoqhEqtyiiNzKYkwQ_6_3"></a><a id="Tc_xMC_IxPaAUWB2IiuMYYNbQ_6_6"></a><a id="Tc_5z9KFUDfm0eMYPJhuCDKcA_7_0"></a><a id="Tc_W97I7tqTdUi9zt6EWmD1pQ_8_0"></a><a id="Tc_5p30XvVCWEy9gzXs47UEjA_8_3"></a><a id="Tc_Vte5J3HJXUyArQ6VWSuO_w_8_6"></a><a id="Tc_z1_GcuNE20CUoXOBrPn9kw_9_0"></a><a id="Tc__lgVyrgtUku7OmeoHDyr2g_10_0"></a><a id="Tc_qQ8jfABsQ0G--C6n_G8-aA_11_0"></a><a id="Tc_aqFeWDvL4UW5xWfsMU81Ow_12_0"></a><a id="Tc_SmgLeP55lEmil4CPN9YbUw_13_0"></a><a id="Tc_b9qadBfX4EuDlHZkSbmUMg_14_0"></a><a id="Tc_69dgKCZKNU27MWaEC2AXBg_14_3"></a><a id="Tc_ga2E2dwDikK3z88jE0IIfQ_14_6"></a><a id="Tc_6-U0Zj-kQUabpcy3KIFn3g_15_0"></a><a id="Tc_t-9DYyVhuEGDXI6AU3VgoQ_16_0"></a><a id="Tc_L3uf7V2ZHkCM70XzfJ5s_Q_17_0"></a><a id="Tc_WK0fkW4hHU-AYDG7lIqBaw_18_0"></a><a id="Tc_QX4AtmCSqEyVyDtfCTGxmg_19_0"></a><a id="Tc_6s2CFiDBtkCpu7jYBj8WMw_20_0"></a><a id="Tc_uZg7DZ7MdEGixzJ_CR5sDg_21_0"></a><a id="Tc_A1ZgTqaY-EqT5od48uMDTg_22_0"></a><a id="Tc_j_EdALiCxU2qNGd_V2H7LQ_22_3"></a><a id="Tc_lIiOjwlJRk6kn2SpWzHMwg_22_6"></a><a id="Tc_2uR99rmtgk2ExrODa0v7Yg_23_0"></a><a id="Tc_4kPBzR2yMUm4xcaOIATpWw_24_0"></a><a id="Tc_TkZ-ohdEBEW8i12sy4eYxA_24_3"></a><a id="Tc_B7Rt32iea0eMP_bR1X2iqA_24_6"></a><a id="Tc_DyOT_ts9iECVpWnM9TO4Dw_25_0"></a><a id="Tc_0B7w0OhP3EaQQ2R7qNNLCQ_26_0"></a><a id="Tc_IlAt8jQqi0uqmBEkU75D-Q_27_0"></a><a id="Tc_StPA58F-3UKZbr4OYdgsTA_27_4"></a><a id="Tc_Xtwyj7kIkkGQ8BWzEfIdWA_27_7"></a><a id="Tc_GkxR_ih74U62Vz6HImOJlw_28_0"></a><a id="Tc_TCNEibqvxkOWSz_XnaafsQ_29_0"></a><a id="Tc_Txx8x4CpfkqqLFzZ4pZxXg_30_0"></a><a id="Tc_uT-Dw1AxKESCWJmP8cMedw_30_3"></a><a id="Tc_xSkgu0PNNkijWWZhYzytPA_30_6"></a><a id="Tc_qNqhcti6-0a773bhVBxkbg_31_0"></a><a id="Tc_zG0A-vuPAUqE0R81iZ8Dvg_32_0"></a><a id="Tc_qstjm266yEe06bdOGwOttA_32_3"></a><a id="Tc_jrLTIWJUfkONe22rRo2Vcg_32_6"></a><a id="Tc_XcOqC80N10GAMcg_DBS69Q_33_0"></a><a id="Tc_zOyRBKpJXky5jkSHAt7IYQ_34_0"></a><a id="Tc_VD49USKXN0-S06w8x356WQ_35_0"></a><a id="Tc_YU_mw1QVYkWMN-scRlOsuw_36_0"></a><a id="Tc_Ha8vSQ8lO0m9fBO6VgYkKA_37_0"></a><a id="Tc_R0blrtitxUiKtQFxGFpxwA_37_3"></a><a id="Tc_4l4mCinMakiL3PhuTNyM5Q_37_6"></a><a id="Tc_655GMaXEwESy7vpCojzd_w_38_0"></a><a id="Tc_xiXDYmVLiki3VoFBP0nGDQ_38_4"></a><a id="Tc_4oJDFuH_dEetXr7jcThUGw_38_7"></a><a id="Tc_cb2yR-9bvUC4Y-3f2-kpCA_39_0"></a><a id="Tc_wTmYdnYWLEW3ZDYMLrLMyg_39_3"></a><a id="Tc_qXAEGdZpCkih-sbhvHUE1A_39_6"></a><ix:continuation id="Tb_88ypPxPhg0OEUE-YNOneJg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company&#8217;s operating performance and guide strategic decisions and resource allocations, including additional investments in research and development and commercialization activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table provides information about the Company&#8217;s <ix:nonFraction unitRef="Unit_Standard_segment_u3k5mJIKoECDA2MsRZB6Gg" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="Narr_V89GXYh-RkS6Fb2pTYZuLw">one</ix:nonFraction> reportable segment and includes the reconciliation to consolidated net loss.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="Tb_0O0Klvog0UqvgKunFBQGfQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Product revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_GuQvf4ivIEaez-H_oGkY9w_4_4">2,266</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_R-pypFpH5E6zn9aRGgGq5g_4_7">1,380</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Less:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_9Tf5q6M1BEeHyWeoisbnYQ_6_4">2,143</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_U4MDeMhkTk2huujaL1jW1w_6_7">1,260</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentExpenseLaborAndRelatedExpense" scale="3" id="Tc_so_hNCyaqUSV8hd696KMVA_8_4">9,796</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentExpenseLaborAndRelatedExpense" scale="3" id="Tc_37M693IcZ0qUqX6wBFgm3A_8_7">16,351</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" scale="3" id="Tc_SJLbon_MG0SUAlePV7xZeA_9_4">2,251</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" scale="3" id="Tc_X-2dSv9IBEiU5I7d9Mwoug_9_7">6,324</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentExpenseProfessionalFees" scale="3" id="Tc_HVqMY44vxE-pyldN2JPykg_10_4">5,067</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentExpenseProfessionalFees" scale="3" id="Tc_lhh7YHBABUixMCJDCyYqrw_10_7">14,590</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Clinical trials expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentExpenseClinicalTrialsExpense" scale="3" id="Tc_VUkdVeKlPkyOLc7-kHlxxA_11_4">9,384</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentExpenseClinicalTrialsExpense" scale="3" id="Tc_VTa4TFIrQ0a9k2K4ElWb3Q_11_7">35,094</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Chemical, manufacturing and controls cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" scale="3" id="Tc_GdahhxyJfUukBKeqoyapiQ_12_4">1,927</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" scale="3" id="Tc_QXV9cx5V2kS1RJ4d9MEgrA_12_7">8,687</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentExpenseTravelAndOtherExpenses" scale="3" id="Tc_36rQcptcAEyhaUsHuwQCxg_13_4">2,010</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentExpenseTravelAndOtherExpenses" scale="3" id="Tc_rrh9RB63CU2MLyDB0cmJ4g_13_7">3,280</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="white-space:pre-wrap;">     Total research and development costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_VP6VyV4aS0WxO1-9sAmjyw_14_4">30,435</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_8FDKGXxkOEa-zmwVYli9Uw_14_7">84,326</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsLaborAndRelatedExpense" scale="3" id="Tc_wlIqq0fes0aW1CcQ1E5adg_16_4">2,516</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsLaborAndRelatedExpense" scale="3" id="Tc_2MtiVBnkZUCSEk4ahyWu9A_16_7">19,331</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsShareBasedPaymentArrangementExpense" sign="-" scale="3" id="Tc_4zon9lBmUUevEGAJasA_TQ_17_4">401</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsShareBasedPaymentArrangementExpense" scale="3" id="Tc_Nz4gtSgUhE2E6RhyY2vnzA_17_7">1,081</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsProfessionalFees" scale="3" id="Tc_zcw22piTV0-RlzMg0j0PSQ_18_4">554</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsProfessionalFees" scale="3" id="Tc_INQPU3GUikWfRc2jUBLjvA_18_7">965</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Commercial and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsCommercialAndMarketing" scale="3" id="Tc_mTQTLtQP_EKQxE_eYqc0Ng_19_4">1,389</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsCommercialAndMarketing" scale="3" id="Tc_7yoIhSJI9E-tefvwX7E1Tw_19_7">12,485</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Travel related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsTravelAndOtherExpenses" scale="3" id="Tc_NpDqQKTN60qyd3u63PSXuQ_20_4">309</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsTravelAndOtherExpenses" scale="3" id="Tc_1MeQx3LtHUKWROLW8MMZHQ_20_7">2,004</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsOtherExpenses" scale="3" id="Tc_AXgZzPdjz0S64dQlK3aeRg_21_4">906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsOtherExpenses" scale="3" id="Tc_vlF4QWT0m0W09iaCwcm3sw_21_7">2,038</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="white-space:pre-wrap;">    Total commercial costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherCostAndExpenseOperating" scale="3" id="Tc_ilMPDnV-Bk2ardNDySoywA_22_4">5,273</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherCostAndExpenseOperating" scale="3" id="Tc_omHITt1XZkyWlWHQTzauiA_22_7">37,904</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="btai:SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" scale="3" id="Tc_c6uZ0r7vME267WXWWH8WUw_24_4">5,340</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="btai:SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" scale="3" id="Tc_LZLvgRVXL0GscvDVozgBCA_24_7">7,840</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="btai:SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" scale="3" id="Tc_RBER1YKJHU2eV8yEWelztA_25_4">4,306</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="btai:SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" scale="3" id="Tc_xEnq1yu6wUOGaLpukPefkw_25_7">11,209</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="btai:SellingGeneralAndAdministrativeExpenseProfessionalFees" scale="3" id="Tc_rA82zl4Og0yGfwWRLRNzuQ_26_4">15,583</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="btai:SellingGeneralAndAdministrativeExpenseProfessionalFees" scale="3" id="Tc_hRj-OBzwIUaic-yttb6JmQ_26_7">21,345</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Commercial and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Travel related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="btai:SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" scale="3" id="Tc_GX2zMDjw4UaJoxkBmSfAYA_28_4">446</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="btai:SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" scale="3" id="Tc_Git4ZdgMBUCsJ4A2YkDYhg_28_7">982</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="btai:SellingGeneralAndAdministrativeCostsOtherExpenses" scale="3" id="Tc_RiWClZEE9kOZDhX2pW9iRQ_29_4">3,544</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="btai:SellingGeneralAndAdministrativeCostsOtherExpenses" scale="3" id="Tc_uHAQ9-vvdEWGWpHINrFxhw_29_7">4,133</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="white-space:pre-wrap;">    Total selling, general and administrative costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_3BVQSHsoSUudSjq4Bc8YyQ_30_4">29,219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_x9Soc_2VqkG32Gc6C4ujCw_30_7">45,509</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restructuring costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="3" id="Tc_FPYlMipogkiOtacyFfgPkA_31_4">2,441</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="3" id="Tc_B_rx7Lcnb06tbXglApxGlg_31_7">4,163</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_cSD8ViH2vUe-Fet8eb5ifA_32_4">69,511</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_XaXON9XdHk6BbLdmQ8UMVg_32_7">173,162</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other (income) expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" id="Tc_c7wydqsIuEaH8o08aIlT_w_34_4">15,129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" id="Tc_DZUmBEPzX0-0aXwNkcBMkQ_34_7">13,314</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_-c8gDhvZOUCRkYY-GDj0WA_35_4">2,602</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_N9HMYFCWZkuzIuidm-clnQ_35_7">5,649</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other (income) expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_rbLtvLz9MkeqgiRqQXI7dA_36_4">20,173</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_hQGl6wcJWEG7KgAy2LGCJg_36_7">394</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Segment net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_9UjKEocG0Eq6I7rfdodBSQ_37_4">59,599</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_mqut_NAbuU2_gogYOJJRTA_37_7">179,053</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments and reconciling items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consolidated Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_DybdfURVkE2pIPyGgkv-LQ_39_4">59,599</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g" contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Dd9IuWWb0ESXCphqe4s_Hg_39_7">179,053</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw" name="us-gaap:SubsequentEventsTextBlock" id="Tb_MhdA_xXsX0CA_ZhGYiqjJQ" continuedAt="Tb_MhdA_xXsX0CA_ZhGYiqjJQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 20. Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As discussed in Note 11, <i style="font-style:italic;">Common Stock Financing Activities</i>, in connection with the November 2024 issuance and sale in a public offering of (i) <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_11_22_2024_To_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_qCNNy1whp0ivehAR5sAVYg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Narr_bhIrfx3tfkuTGXG8wGNU0A">350</ix:nonFraction> shares of the Company&#8217;s common stock, and the November 2024 Accompanying Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_LGUU816Yp0m2LKivHXs1uw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_UYVnWD0MsEir9JwdJVT-IQ">350</ix:nonFraction> shares of Common Stock, and (ii) pre-funded warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_aWycUKhL-06MF4rymZ6neQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_uL_YXyE87EqkptaVeQGEPg">563</ix:nonFraction> shares of Common Stock, in February 2025, certain investors exercised the remaining <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_2_28_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_3zrIDKZAEUqRigs4dt4KAw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_D-ZKB4YChEeE_oguBkHZUw">483</ix:nonFraction> pre-funded warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_2_1_2025_To_2_28_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_KmnbJXUr7EyUFHylcIdSIw" decimals="-3" format="ixt:num-dot-decimal" name="btai:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" id="Narr_brbmGn__mkiFD2YAbf2T_g">483</ix:nonFraction> shares of Common Stock.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_MhdA_xXsX0CA_ZhGYiqjJQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 3, 2025, the Company entered into the Purchase Agreement with the Purchaser named therein. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Purchaser and the Purchaser agreed to buy in a registered direct offering (i) an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_3_3_2025_To_3_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_N0FLHzjjW0ebf_9f1FrfOg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Narr_PGWmJRgExE2dNNOG5LC09g">188</ix:nonFraction> shares (the &#8220;Shares&#8221;) of common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_3_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_nr25qN2kxkCVXTVDwzfXDg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_xGdSCibeR0G4Jo5O--SDvQ">0.001</ix:nonFraction> per share and accompanying warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_tkaY4qbmDUqjsdxXtER_7A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_qmaRdVkadkOh8Bt9Va2VVQ">188</ix:nonFraction> shares of Common Stock at a combined offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_3_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_nr25qN2kxkCVXTVDwzfXDg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_gSV0BvJ8XEexVzOxrGIZSA">3.50</ix:nonFraction> per Share and accompanying warrant, and (ii) the Pre-Funded Warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_PrefundedWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_yKIZRxNDvEu7Hv10JhQ-7Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_YPKn1pYWUEmwqO3NlbOdbA">3,812</ix:nonFraction> shares of Common Stock and accompanying warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_PrefundedWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_yKIZRxNDvEu7Hv10JhQ-7Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_MBRHm-puxU-70-atvFP6Lw">3,812</ix:nonFraction> shares of Common Stock, at a combined offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_tkaY4qbmDUqjsdxXtER_7A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_4JtrnfixIEC9dOiBc31ajA">3.499</ix:nonFraction> per share underlying the Pre-Funded Warrants and accompanying warrant, which equals the offering price per Share and accompanying warrant less the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_PrefundedWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_yKIZRxNDvEu7Hv10JhQ-7Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_IIw4fOCurUWx3c4dFRaYmQ">0.001</ix:nonFraction>exercise price per share of the Pre-Funded Warrants, pursuant to an effective registration statement on Form S-3 (File No. 333-275261), including the base prospectus included therein, and prospectus supplement filed with the SEC on March 4, 2025. As of March 28, 2025, <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="Duration_3_28_2025_To_3_28_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_PrefundedWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_zbIxHgjTxE2SCgROmOBKRw" decimals="-3" format="ixt:num-dot-decimal" name="btai:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" id="Narr_hUrTXzBiyUy1taK5pJjQgA">1,688</ix:nonFraction> Pre-Funded Warrants were exercised. In the 2025 Offering, the Company also issued to the Purchaser warrants (the &#8220;Option Warrants&#8221;), to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_c4ZQpDZ5ekCFoY0FzRG6JA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_Y5BTWT2_Z0i1xsb9SBscaQ">4,000</ix:nonFraction> shares of Common Stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_c4ZQpDZ5ekCFoY0FzRG6JA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_Ev3BgZEWu0m6I4MNG3GT3A">4,000</ix:nonFraction> shares of Common Stock to the Purchaser. The pre-funded warrants and accompanying warrants issuable upon exercise of the Option Warrants will have substantially identical terms as the Pre-Funded Warrants and the accompanying warrants. The exercise price of the Option Warrants is $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_c4ZQpDZ5ekCFoY0FzRG6JA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_jWn8o43H6kalsMEKsE-tZg">3.50</ix:nonFraction> per underlying share of Common Stock and accompanying warrant to purchase one share of Common Stock, or $<ix:nonFraction unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_tkaY4qbmDUqjsdxXtER_7A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_DOmjG037SEWIIcvSxMEDzg">3.499</ix:nonFraction> per underlying pre-funded warrant to purchase one share of Common Stock and accompanying warrant to purchase one share of Common Stock. The Option Warrants expired on March 18, 2025 without being exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 26, 2025, we and Jefferies terminated that certain Open Market Sales Agreement, dated May 10, 2021, as amended on November 1, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>btai-20241231xex4d1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/28/2025 07:21:29 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 4.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">BioXcel Therapeutics, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). References herein to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and the &#8220;Company&#8221; refer to BioXcel Therapeutics, Inc. and not to any of its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following description of our common stock and certain provisions of our amended and restated certificate of incorporation (as amended and/or restated from time to time, our &#8220;charter&#8221;) and amended and restated bylaws (as amended and/or restated from time to time, our &#8220;bylaws&#8221;) are summaries and are qualified in their entirety by reference to the full text of our amended and restated certificate of incorporation and our amended and restated bylaws, each of which have been publicly filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;). We encourage you to read our amended and restated certificate of incorporation and our amended and restated bylaws and the applicable provisions of the Delaware General Corporation Law (the &#8220;DGCL&#8221;) for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are authorized to issue up to a total of 200,000,000 shares of common stock, par value $0.001 per share. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of our stockholders. Holders of our common stock have no cumulative voting rights. Further, holders of our common stock have no preemptive or conversion rights or other subscription rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon our liquidation, dissolution or winding- up, holders of our common stock are entitled to share in all assets remaining after payment of all liabilities and the liquidation preferences of any of our outstanding shares of preferred stock. Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of our assets which are legally available. Such dividends, if any, are payable in cash, in property or in shares of capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The holders of one-third of the voting power of our issued and outstanding capital stock, represented in person or by proxy, are necessary to constitute a quorum for the transaction of business at any meeting. If a quorum is present, an action by stockholders entitled to vote on a matter is approved if the number of votes cast in favor of the action exceeds the number of votes cast in opposition to the action unless a different vote is required by law, the charter, the by-laws or, with respect to a class or series of preferred stock, the terms of any resolution or resolutions adopted by the board of directors. Pursuant to our charter, the election of directors requires a plurality of the votes cast by the stockholders present in person or represented by proxy at the meeting and entitled to vote thereon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Preferred Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the designations, powers, preferences, privileges, and relative participating, optional, or special rights as well as the qualifications, limitations, or restrictions of the preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, and liquidation preferences, any or all of which may be greater than the rights of the common stock. Our board of directors, without stockholder approval, can issue convertible preferred stock with voting, conversion, or other rights that could adversely affect the voting power and other rights of the holders of common stock. Preferred stock could be issued quickly with terms calculated to delay or prevent a change of control or make removal of management more difficult. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of our common stock, and may adversely affect the voting and other rights of the holders of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Anti-Takeover Effects of Certain Provisions of our Charter and Bylaws and the DGCL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Delaware Law</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are governed by the provisions of Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a publicly traded Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A business combination includes mergers, asset sales or other transactions resulting in a financial benefit to the stockholder. An interested stockholder is a person who, together with affiliates and associates, owns (or within three years, did own) 15% or more of the corporation&#39;s voting stock, subject to certain exceptions. The statute could have the effect of delaying, deferring or preventing a change in control of our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Classified Board of Directors</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our charter provides that our Board is divided into three classes, with the classes as nearly equal in number as possible and each class serving three-year staggered terms. Directors may only be removed from our board of directors for cause and only by the affirmative vote of holders of a majority of the voting power of all then-outstanding shares of capital stock of the Company entitled to vote generally in the election of directors, voting together as a single class. These provisions may have the effect of deferring, delaying or discouraging hostile takeovers, or changes in control of us or our management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Board of Directors Vacancies</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our charter and bylaws authorize only our board of directors to fill vacant directorships. In addition, the number of directors constituting our board of directors may be set only by resolution of the majority of the incumbent directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Stockholder Action; Special Meeting of Stockholders</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our charter and bylaws provide that our stockholders may not take action by written consent. Our charter and bylaws further provide that special meetings of our stockholders may be called by a majority of the board of directors, the Chief Executive Officer, or the Chairman of the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Advance Notice Requirements for Stockholder Proposals and Director Nominations</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our bylaws provide that stockholders seeking to bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at our annual meeting of stockholders, must provide timely notice of their intent in writing. To be timely, a stockholder&#39;s notice must be delivered to the secretary at our principal executive offices not later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the first anniversary of the preceding year&#39;s annual meeting; provided, however, that in the event the date of the annual meeting is more than 30 days before or more than 60 days after such anniversary date, or if no annual meeting was held in the preceding year, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting or the 10th day following the day on which a public announcement of the date of such meeting is first made by us. These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Authorized but Unissued Shares</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval and may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital, corporate acquisitions and employee benefit plans. The existence of authorized</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Limitations on Liability, Indemnification of Officers and Directors and Insurance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The DGCL authorizes corporations to limit or eliminate the personal liability of directors to corporations and their stockholders for monetary damages for breaches of directors&#8217; fiduciary duties as directors and our charter includes such an exculpation provision. Our charter and bylaws include provisions that indemnify, to the fullest extent allowable under the DGCL, the personal liability of directors or officers for monetary damages for actions taken as a director or officer of us, or for serving at our request as a director or officer or another position at another corporation or enterprise, as the case may be. Our charter and bylaws also provide that we must indemnify and advance reasonable expenses to our directors and officers, subject to our receipt of an undertaking from the indemnified party as may be required under the DGCL. Our bylaws expressly authorize us to carry directors&#39; and officers&#39; insurance to protect us, our directors, officers and certain employees for some liabilities. The limitation of liability and indemnification provisions in our charter and bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions may also have the effect of reducing the likelihood of derivative litigation against our directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. However, these provisions do not limit or eliminate our rights, or those of any stockholder, to seek non-monetary relief such as injunction or rescission in the event of a breach of a director&#39;s duty of care. These provisions will not alter the liability of directors under federal securities laws.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>3
<FILENAME>btai-20241231xex4d5.htm
<DESCRIPTION>EX-4.5
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/28/2025 07:21:30 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 4.5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BIOXCEL THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AMENDED AND RESTATED WARRANT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TO PURCHASE SHARES OF COMMON STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant No.&#160;[&#9679;]</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Number of Shares: [&#9679;]</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(subject to adjustment)</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date of Issuance: November 25, 2024</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">BioXcel Therapeutics, Inc., a Delaware corporation (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [&#9679;] or its registered assigns (the &#8220;<b style="font-weight:bold;">Holder</b>&#8221;), is entitled, subject to the terms set forth below, to purchase from the Company up to a total of [&#9679;]shares of common stock, $0.001 par value per share (the &#8220;<b style="font-weight:bold;">Common Stock</b>&#8221;) of the Company (each such share, a &#8220;<b style="font-weight:bold;">Warrant Share</b>&#8221; and all such shares, the &#8220;<b style="font-weight:bold;">Warrant Shares</b>&#8221;) at an exercise price per share equal to $0.571 per share (as adjusted from time to time as provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9</u> herein, the &#8220;<b style="font-weight:bold;">Exercise Price</b>&#8221;) upon surrender of this Warrant to Purchase Shares of Common Stock (including any Warrants to Purchase Shares of Common Stock issued in exchange, transfer or replacement hereof, the &#8220;<b style="font-weight:bold;">Warrant</b>&#8221;) at any time and from time to time on or after the date hereof (the &#8220;<b style="font-weight:bold;">Original Issue Date</b>&#8221;) and on or prior to 5:00 pm Eastern Time on March 27, 2029 (the &#8220;<b style="font-weight:bold;">Termination Date</b>&#8221;), subject to the following terms and conditions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font><i style="font-style:italic;">Definitions</i>. For purposes of this Warrant, the following terms shall have the following meanings:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>&#8220;<b style="font-weight:bold;">Affiliate</b>&#8221; means any Person directly or indirectly controlled by, controlling or under common control with, a Holder, as such terms are used in and construed under Rule 405 under the Securities Act, but only for so long as such control shall continue. For purposes of this definition, &#8220;control&#8221; (including, with correlative meanings, &#8220;controlled by,&#8221; &#8220;controlling&#8221; and &#8220;under common control with&#8221;) means, with respect to a Person, possession, direct or indirect, of (a) the power to direct or cause direction of the management and policies of such Person (whether through ownership of securities or partnership or other ownership interests, by contract or otherwise), or (b) at least 50% of the voting securities (whether directly or pursuant to any option, warrant, or other similar arrangement) or other comparable equity interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>&#8220;<b style="font-weight:bold;">Commission</b>&#8221; means the United States Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>&#8220;<b style="font-weight:bold;">Marketable Securities</b>&#8221; means securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;<b style="font-weight:bold;">Exchange Act</b>&#8221;), and is then current in its filing of all required reports and other information under the Securities Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the Fundamental Transaction (as defined below) were Holder to exercise this Warrant on or prior to the closing thereof is then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market, and (iii) following the closing of such Fundamental Transaction, the Holder would not be restricted from publicly re-selling all of the issuer&#8217;s shares and/or other securities that would be received by the Holder in such Fundamental Transaction were the Holder to exercise or convert this Warrant in full on or prior to the closing of such Fundamental Transaction, except to the extent that any such restriction (x) arises solely under federal or state securities laws, rules or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">regulations, and (y) does not extend beyond six (6) months from the closing of such Fundamental Transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>&#8220;<b style="font-weight:bold;">Principal Trading Market</b>&#8221; means the national securities exchange or other trading market on which the shares of Common Stock are primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Capital Market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>&#8220;<b style="font-weight:bold;">Registration Statement</b>&#8221; means the Company&#8217;s Registration Statement on Form S-3 (File No. 333-275261), filed with the Commission on November 2, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font>&#8220;<b style="font-weight:bold;">Securities Act</b>&#8221; means the Securities Act of 1933, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font>&#8220;<b style="font-weight:bold;">Trading Day</b>&#8221; means any weekday on which the Principal Trading Market is open for trading. If the shares of Common Stock are not listed or admitted for trading, &#8220;Trading Day&#8221; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in New York City are authorized or required by law or other governmental action to close.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font>&#8220;<b style="font-weight:bold;">Transfer Agent</b>&#8221; means Equiniti Trust Company, LLC, the Company&#8217;s transfer agent and registrar for the Common Stock, and any successor appointed in such capacity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>&#8220;<b style="font-weight:bold;">VWAP</b>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (i) if the Common Stock is then listed or quoted on a national securities exchange or other trading market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Principal Trading Market as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (ii) if the Common Stock is then listed or quoted for trading and neither OTCQB nor OTCQX is the Principal Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX, as applicable, (iii) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the &#8220;Pink Sheets&#8221; published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (iv) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font><i style="font-style:italic;">Issuance of Securities; Registration of Warrants</i>. This Warrant, as initially issued by the Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant to the Registration Statement or an exchange meeting the requirements of Section 3(a)(9) of the Securities Act as in effect on the Original Issue Date, the Warrant Shares, are not &#8220;restricted securities&#8221; under Rule 144 promulgated under the Securities Act. The Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<b style="font-weight:bold;">Warrant Register</b>&#8221;), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font><i style="font-style:italic;">Registration of Transfers</i>. Subject to compliance with all applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable taxes (if any). Upon any such registration or transfer, a new warrant to purchase shares of Common Stock in substantially the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant No. CS-1</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">form of this Warrant (any such new warrant, a &#8220;<b style="font-weight:bold;">New Warrant</b>&#8221;) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company&#8217;s own expense any New Warrant under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3</u>. Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any notice to the contrary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font><i style="font-style:italic;">Exercise and Duration of Warrants</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>All or any part of this Warrant shall be exercisable by the registered Holder in the manner set forth herein at any time and from time to time on or after the Original Issue Date and on or prior to the Termination Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>The Holder may exercise this Warrant by delivering to the Company (i) an exercise notice, in the form attached as Schedule 1 hereto (the &#8220;<b style="font-weight:bold;">Exercise Notice</b>&#8221;), completed and duly signed, and (ii) payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised (which may take the form of a &#8220;cashless exercise&#8221; if so indicated in the Exercise Notice pursuant to Section 10 below), and the date on which the last of such items is delivered to the Company (as determined in accordance with the notice provisions hereof) is an &#8220;<b style="font-weight:bold;">Exercise Date</b>.&#8221; No later than one Trading Day following the delivery of such Exercise Notice, the Holder shall deliver to the Company payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedures specified in Section 10 below is specified in the applicable Exercise Notice. The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. No ink original Exercise Notice shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Exercise Notice be required. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. <b style="font-weight:bold;">The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font><i style="font-style:italic;">Delivery of Warrant Shares</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Upon exercise of this Warrant, the Company shall promptly (but in no event later than two (2) Trading Days after the Exercise Date), upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company (&#8220;<b style="font-weight:bold;">DTC</b>&#8221;) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in the Fast Automated Securities Transfer Program (the &#8220;<b style="font-weight:bold;">FAST Program</b>&#8221;), issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. The Holder, or any natural person or legal entity (each, a &#8220;<b style="font-weight:bold;">Person</b>&#8221;) so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder&#8217;s DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant No. CS-1</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>If by the close of the second (2<sup style="font-size:7.5pt;vertical-align:top;">nd</sup>) Trading Day after the Exercise Date, the Company fails to deliver to the Holder a certificate representing the required number of Warrant Shares in the manner required pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5(a)</u> or fails to credit the Holder&#8217;s DTC account for such number of Warrant Shares to which the Holder is entitled, and if after such second (2<sup style="font-size:7.5pt;vertical-align:top;">nd</sup>) Trading Day and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction, provided such purchases shall be made in a commercially reasonable manner at prevailing market prices) shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<b style="font-weight:bold;">Buy-In</b>&#8221;), then the Company shall, within two (2) Trading Days after the Holder&#8217;s request, in the Holder&#8217;s sole discretion, either (i) &#160;pay cash to the Holder in an amount equal to the Holder&#8217;s total purchase price (including commercially reasonable brokerage commissions, if any) for the shares of Common Stock so purchased, at which point the Company&#8217;s obligation to deliver such Warrant Shares shall terminate, or (ii) (A) pay in cash to the Holder the amount, if any, by which (1) the Holder&#8217;s total purchase price (including commercially reasonable brokerage commissions, if any) for the shares of Common Stock purchased in the Buy-In exceeds (2) the product of (x) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue, times (y) the price at which the sell order giving rise to such purchase obligation was executed (assuming such sale was executed on commercially reasonable terms at prevailing market prices and, if the sale was executed in multiple transactions, the volume weighted average price), and (B) at the option of the Holder, either (1) reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or (2) deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. The provisions of this Section 5(b) shall be the only remedy available to the Holder in the event the Company fails to deliver to the Holder the required number of Warrant Shares in the manner required pursuant to Section 5(a) and a Buy-In occurs. Irrespective of whether there is a Buy-In, no remedy shall be available, notwithstanding the requirements of Section 5(a), unless and until the Company fails to deliver to the Holder the required number of Warrant Shares by the close of the third Trading Day after the Exercise Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>To the extent permitted by law and subject to Section 5(b), the Company&#8217;s obligations to issue and deliver Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in Section 10 below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Subject to Section 5(b), nothing herein shall limit the Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font><i style="font-style:italic;">Charges, Taxes and Expenses</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other similar incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or the Warrants in a name other than that of the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant No. CS-1</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Holder thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Each Holder agrees that applicable withholding taxes (including backup withholding) may be withheld from payments and deemed payments on or with respect to this Warrant, and if any such withholding taxes (including backup withholding) are paid on behalf of the Holder, then those withholding taxes may be set off against payments of cash or the delivery of shares of Common Stock or other consideration, if any, in respect of this Warrant (or any payments on Common Stock) or sales proceeds received by, or other funds or assets of, the Holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>On the Original Issue Date (or in the case of any transferee, the date such transferee becomes Holder), and thereinafter upon reasonable request or as required under applicable law, to the extent permitted by applicable law, tax forms or other documentation (including any applicable IRS Form W-8/W-9) reasonably satisfactory to the Company or other applicable withholding agent to establish an exemption from United States withholding tax on payments and deliveries hereunder as well as an exemption from, or a reduction in the rate of, U.S. withholding that may apply to any dividend or constructive dividend (e.g., under Section 305(c) of the Internal Revenue &#160;Code of 1986, as amended). The Company may determine in its reasonable discretion the amount and the timing of any such constructive dividend.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</font></font><i style="font-style:italic;">Replacement of Warrant</i>. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company&#8217;s obligation to issue the New Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</font></font><i style="font-style:italic;">Reservation of Warrant Shares</i>. The Company covenants that it will, at all times while this Warrant is issued and outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved shares of Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and non-assessable. The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the shares of Common Stock may be listed. The Company further covenants that it will not, without the prior written consent of the Holder, take any actions to increase the par value of the shares of Common Stock at any time while this Warrant is issued and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.</font></font><i style="font-style:italic;">Certain Adjustments</i>. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this Section 9.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Dividends and Splits</u>. If the Company, at any time while this Warrant is issued and outstanding, (i) pays a stock dividend on its shares of Common Stock or otherwise makes a distribution on any class of capital shares issued and outstanding on the Original Issue Date and in</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant No. CS-1</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">accordance with the terms of such stock on the Original Issue Date or as amended, as described in the Registration Statement, that is payable in shares of Common Stock, (ii) subdivides its issued and outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii) combines its issued and outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv)&#160;issues by reclassification of capital shares any additional shares of Common Stock of the Company, then in each such case the number of Warrant Shares shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock issued and outstanding immediately before such event and the denominator of which shall be the number of shares of Common Stock issued and outstanding immediately after such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, provided, however, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the number of Warrant Shares shall be recomputed accordingly as of the close of business on such record date and thereafter the number of Warrant Shares shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii), (iii) or (iv) of this paragraph shall become effective immediately after the effective date of such subdivision or combination or reclassification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pro Rata Distributions</u>. If the Company, at any time while this Warrant is issued and outstanding, distributes to all holders of shares of Common Stock for no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of shares of Common Stock covered by the preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security, or (iv) cash or any other asset (in each case, &#8220;<b style="font-weight:bold;">Distributed Property</b>&#8221;), then, upon any exercise of this Warrant that occurs after the record date fixed for determination of stockholders entitled to receive such distribution, the Holder shall be entitled to receive, in addition to the Warrant Shares otherwise issuable upon such exercise (if applicable), the Distributed Property that such Holder would have been entitled to receive in respect of such number of Warrant Shares had the Holder been the record holder of such Warrant Shares immediately prior to such record date without regard to any limitation on exercise contained therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fundamental Transactions</u>. If, at any time while this Warrant is issued and outstanding (i) the Company effects any merger or consolidation of the Company with or into another Person, in which the Company is not the surviving entity and in which the stockholders of the Company immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the outstanding capital stock or at least 50% of the voting power of the surviving entity immediately after such merger or consolidation, (ii) the Company effects any sale to another Person of all or substantially all of its assets in one transaction or a series of related transactions, (iii) pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the outstanding capital stock of the Company or more than 50% of the voting power of the capital stock of the Company, and the Company or such other Person, as applicable, accepts such tender for payment, (iv) the Company consummates a share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the outstanding capital stock of the Company or more than 50% of the voting power of the capital stock of the Company (except for any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or (v) the Company effects any reclassification of the shares of Common Stock or any compulsory share exchange pursuant to which the shares of Common Stock are effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by Section 9(a) above) (in any such case, a &#8220;<b style="font-weight:bold;">Fundamental Transaction</b>&#8221;), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant No. CS-1</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fundamental Transaction, the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations on exercise contained herein (the &#8220;<b style="font-weight:bold;">Alternate Consideration</b>&#8221;). The Company shall not effect any Fundamental Transaction in which the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i) the Alternate Consideration consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities or (ii) prior to, simultaneously with or promptly following the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this Section 9(c) shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any successor entity to the Company shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is not within the Company&#39;s control, including not approved by the Company&#39;s Board of Directors, the Holder shall only be entitled to receive from the Company or any successor entity to the Company the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the successor entity (which entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &#8220;<b style="font-weight:bold;">Black Scholes Value</b>&#8221; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg, L.P. (&#8220;<b style="font-weight:bold;">Bloomberg</b>&#8221;) determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of (1) the 30 day volatility, (2) the 100 day volatility or (3) the 365 day volatility, each of clauses (1)-(3) as obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the highest VWAP during the period beginning on the Trading Day immediately preceding the public announcement of the applicable contemplated Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder&#8217;s request pursuant to this Section 9(c), (D) a remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within five (5) Trading Days of the Holder&#8217;s election (or, if later, on the date of consummation of the Fundamental Transaction).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise Price</u>. Simultaneously with any adjustment to the number of Warrant Shares pursuant to Section 9, the Exercise Price shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant No. CS-1</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the par value of the shares of Common Stock then in effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Calculations</u>. All calculations under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9</u> shall be made to the nearest one-millionth of one cent or the nearest share, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Adjustments</u>. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company&#8217;s transfer agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Corporate Events</u>. If, while this Warrant is issued and outstanding, the Company (i) declares a dividend or any other distribution of cash, securities or other property in respect of its shares of Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii)&#160;authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such transaction at least ten (10) days prior to the applicable record or effective date on which a Person would need to hold shares of Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is issued and outstanding, the Company authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9(c)</u>, other than a Fundamental Transaction under clause (iii) of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9(c)</u>, then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10) days prior to the date such Fundamental Transaction is consummated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font>Voluntary Adjustment by Company. &#160;Subject to the rules and regulations of the trading market, the Company may at any time during the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors of the Company. &#160;The Company may extend the duration of this Warrant by delaying the Termination Date; provided, however, that the Company will provide notice of not less than ten (10) days to the Holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.</font></font><i style="font-style:italic;">Payment of Cashless Exercise Price</i>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares in an exchange of securities effected pursuant to Section 3(a)(9) of the Securities Act as determined as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="btai-20241231xex4d5001.jpg" alt="Graphic" style="display:inline-block;height:35.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:74.99pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">where:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">&#8220;X&#8221; equals the number of Warrant Shares to be issued to the Holder;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant No. CS-1</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">&#8220;Y&#8221; equals the total number of Warrant Shares with respect to which this Warrant is then being exercised (determined solely for purposes of this definition as if the Warrant were exercised by means of a cash exercise rather than a cashless basis);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">&#8220;A&#8221; equals the last VWAP immediately preceding the delivery of the applicable Exercise Notice (to clarify, the &#8220;last VWAP&#8221; will be the last VWAP as calculated over an entire Trading Day such that, in the event that this Warrant is exercised at a time that the Trading Market is open, the prior Trading Day&#8217;s VWAP shall be used in this calculation); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">&#8220;B&#8221; equals the Exercise Price per Warrant Share then in effect on the Exercise Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in such a &#8220;cashless exercise&#8221; transaction shall take on the registered characteristics of the Warrants being exercised and shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued (provided that the Commission continues to take the position that such treatment is proper at the time of such exercise).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Except as set forth in Section 5(b) or Section 13, in no event will the exercise of this Warrant be settled in cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.</font></font><i style="font-style:italic;">Limitations on Exercise</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not be entitled to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving effect or immediately prior to such exercise, would result in (i) the aggregate number of shares of Common Stock beneficially owned by the Holder, its Affiliates and any other Persons whose beneficial ownership of shares of Common Stock would be aggregated with the Holder&#8217;s for purposes of Section 13(d) of the Exchange Act (such as any other members of a Section 13(d) &#8220;group&#8221;) exceeding 4.99% (the &#8220;<b style="font-weight:bold;">Maximum Percentage</b>&#8221;) of the total number of issued and outstanding shares of Common Stock of the Company following such exercise, or (ii) the combined voting power of the securities of the Company beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of shares of Common Stock would be aggregated with the Holder&#8217;s for purposes of Section 13(d) of the Exchange Act (such as any other members of a Section 13(d) &#8220;group&#8221;) exceeding 4.99% of the combined voting power of all of the securities of the Company then outstanding following such exercise. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company&#8217;s most recent Form 10-Q or Form 10-K, as the case may be, filed with the Commission prior to the date hereof, (y) a more recent public announcement by the Company or (z) any other notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three (3) Trading Days confirm in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage specified not in excess of 19.99% specified in such notice; provided that any such increase will not be effective until the sixty-first (61<sup style="font-size:7.5pt;vertical-align:top;">st</sup>) day after such notice is delivered to the Company. For purposes of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11(a)</u>, the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of shares of Common Stock would be aggregated with the Holder&#8217;s for purposes of Section 13(d) of the Exchange Act (such as any other members of a Section 13(d) &#8220;group&#8221;) shall include the shares of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">9</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant No. CS-1</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Common Stock issuable upon the exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (x) exercise of the remaining unexercised and non-cancelled portion of this Warrant by the Holder and (y) exercise or conversion of the unexercised, non-converted or non-cancelled portion of any other securities of the Company that do not have voting power (including without limitation any securities of the Company which would entitle the holder thereof to acquire at any time shares of Common Stock, including without limitation any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, shares of Common Stock), is subject to a limitation on conversion or exercise analogous to the limitation contained herein and is beneficially owned by the Holder or any of its Affiliates and other Persons whose beneficial ownership of shares of Common Stock would be aggregated with the Holder&#8217;s for purposes of Section 13(d) of the Exchange Act (such as any other members of a Section 13(d) &#8220;group&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>This <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11</u> shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9(c)</u> of this Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12.</font></font><i style="font-style:italic;">No Fractional Shares</i>. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the last VWAP immediately preceding the time of delivery of the applicable Exercise Notice) for any such fractional shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.</font></font><i style="font-style:italic;">Notices</i>. Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via confirmed e-mail prior to 5:30 P.M., New York City time, on a Trading Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via confirmed e-mail on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or (iv) upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery. The addresses and e-mail addresses for such communications shall be:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;">If to the Company:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">BioXcel Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">555 Long Wharf Drive</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">New Haven, CT 06511</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">Attention: Javier Rodriguez, Senior Vice President,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">Chief Legal Officer and Corporate Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;">Email: jrodriguez@bioxceltherapeutics.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;">With a copy (which will not constitute notice) to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">Latham &amp; Watkins LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">200 Clarendon Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">Boston, MA 02116</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">Attn: Peter N. Handrinos; Keith L. Halverstam</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 108pt;">Email: peter.handrinos@lw.com; keith.halverstam@lw.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant No. CS-1</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If to the Holder, to its address or e-mail address set forth herein or on the books and records of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Or, in each of the above instances, to such other address or e-mail address as the recipient party has specified by written notice given to each other party at least five (5) days prior to the effectiveness of such change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.</font></font><i style="font-style:italic;">Warrant Agent</i>. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10) days&#8217; notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or stockholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#8217;s last address as shown on the Warrant Register.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15.</font></font><i style="font-style:italic;">Miscellaneous</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Rights as a Stockholder</u>. The Holder, solely in such Person&#8217;s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of capital stock of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&#8217;s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authorized Shares</u>. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, amalgamation, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Warrant, and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</u>. Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction in which this Warrant is not automatically &#8220;cashless exercised&#8221;. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant No. CS-1</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment and Waiver</u>. Except as otherwise provided herein, this Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acceptance</u>. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law; Jurisdiction</u>. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Headings</u>. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant No. CS-1</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.087963104%;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BIOXCEL THERAPEUTICS, INC.</p></td></tr><tr><td style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44.73%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Richard Steinhart</p></td></tr><tr><td style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant No. CS-1</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Schedule 1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FORM OF EXERCISE NOTICE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[To be executed by the Holder to purchase shares of Common Stock under the Warrant]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Ladies and Gentlemen:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</font></font>The undersigned is the Holder of Warrant No. CS-1 (the &#8220;<b style="font-weight:bold;">Warrant</b>&#8221;) issued by BioXcel Therapeutics, Inc., a Delaware corporation (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(2)</font></font>The undersigned hereby exercises its right to purchase <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u> Warrant Shares pursuant to the Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(3)</font></font>The Holder intends that payment of the Exercise Price shall be made as (check one):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</font></font>Cash Exercise</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</font></font>&#8220;Cashless Exercise&#8221; under Section 10 of the Warrant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(4)</font></font>Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the Warrant. The Warrant Shares shall be delivered to the following DWAC Account Number:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(5)</font></font>By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 11(a) of the Warrant to which this notice relates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated:</p></td><td style="vertical-align:top;width:35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:35%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name of Holder:</p></td><td style="vertical-align:top;width:35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:35%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:35%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:35%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant No. CS-1</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22_6
<SEQUENCE>4
<FILENAME>btai-20241231xex10d226.htm
<DESCRIPTION>EX-10.22_6
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/28/2025 07:21:31 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 10.22.6</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Execution Version</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">SIXTH AMENDMENT TO Credit agreement AND guaranty</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This Sixth Amendment to Credit Agreement and Guaranty (this &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Amendment</font><font style="font-size:12pt;">&#8221;) is made as of March 4, 2025, by and among BIOXCEL THERAPEUTICS, INC., a Delaware corporation (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Borrower</font><font style="font-size:12pt;">&#8221;), the lenders party hereto (collectively, the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Lenders</font><font style="font-size:12pt;">&#8221; and individually, a &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Lender</font><font style="font-size:12pt;">&#8221;), and OAKTREE FUND ADMINISTRATION, LLC, as administrative agent on behalf of the Lenders (in such capacity, together with its successors and assigns, the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Administrative Agent</font><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, the Borrower, the Administrative Agent and the Lenders previously entered into that certain Credit Agreement and Guaranty, dated as of April 19, 2022 (including the exhibits and other attachments thereto, as amended by that certain Waiver and First Amendment to Credit Agreement and Guaranty, dated as of November 13, 2023, that certain Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing, dated as of December 5, 2023, that certain Third Amendment to Credit Agreement, dated as of February 12, 2024, that certain Fourth Amendment to Credit Agreement and Guaranty, dated as of March 20, 2024, and the Fifth Amendment to Credit Agreement and Guaranty and First Amendment to Fourth Amendment to Credit Agreement and Guaranty, dated as of November 21, 2024 (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Existing Credit Agreement</font><font style="font-size:12pt;">&#8221;, and as further amended by this Amendment, the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Credit Agreement</font><font style="font-size:12pt;">&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, pursuant to Section 8.22 of the Existing Credit Agreement, Borrower was required to, on or prior to December 6, 2024, select, and on or prior to December 12, 2024, engage, an investment banker reasonably acceptable to the Administrative Agent and the Lenders to assist the Borrower and its Board with evaluating and exploring strategic options (collectively, the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Banker Engagement</font><font style="font-size:12pt;">&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, by email on December 6, 2024, Borrower, Administrative Agent and the Lenders agreed to modify the foregoing requirement to require Borrower to complete the Banker Engagement on prior to January 24, 2025;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, an Event of Default has occurred and is continuing under Section 11.01(d) of the Existing Credit Agreement as a result of Borrower&#8217;s failure to satisfy the requirements of Section 8.22 of the Existing Credit Agreement (together with the Event of Default arising from the failure to deliver a notice of Default pursuant to Section 8.02(a) of the Existing Credit Agreement, the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Specified Events of Default</font><font style="font-size:12pt;">&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, the Administrative Agent and the Lenders have agreed to waive the Specified Events of Default on the terms and subject to the conditions set forth herein; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, the Borrower, the Administrative Agent and the Lenders have agreed to amend the Existing Credit Agreement on the terms and subject to the conditions set forth herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">NOW, THEREFORE, for and in consideration of the above premises and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the parties hereto, each of the Borrower, the Administrative Agent and the Lenders party hereto hereby covenant and agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><font style="color:#010000;font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u><font style="font-size:12pt;">. Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to such terms in the Existing Credit Agreement.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver</u><font style="font-size:12pt;">. Subject to the satisfaction of the condition precedent specified in Section 5 hereof and the condition subsequent specified in Section 6 hereof, the Administrative Agent and the Lenders hereby waive the Specified Events of Default.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendments to the Existing Credit Agreement</u><font style="font-size:12pt;">. Subject to the satisfaction of the condition precedent specified in Section 5 hereof and the condition subsequent specified in Section 6 hereof:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Section 8.22 of the Credit Agreement is amended and restated in its entirety as follows:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"><b style="font-size:12pt;font-weight:bold;">8.22&#160;&#160;&#160;&#160;&#160;Investment Bank</b><font style="font-size:12pt;">. On or prior to March 15, 2025, the Borrower shall select and engage an investment banker reasonably acceptable to the Administrative Agent and the Lenders to assist the Borrower and its Board with evaluating and exploring strategic options.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Section 14.04 of the Existing Credit Agreement is amended by deleting the language, &#8220;an instrument in writing signed by the Borrower, the Administrative Agent and the Majority Lenders&#8221;, and replacing it as follows:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;">&#8220; agreement of the Borrower, the Administrative Agent and the Majority Lenders, which may be evidenced by an instrument in writing signed by such Persons or by email confirmation from such Persons&#8221;.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reaffirmation of Loan Documents</u><font style="font-size:12pt;">. Except as otherwise expressly provided herein, the parties hereto agree that all terms and conditions of the Existing Credit Agreement and the other Loan Documents remain in full force and effect. &#160;The Borrower hereby confirms that the Security Documents and all of the Collateral described therein do, and shall continue to, secure the payment in full and performance of all of the Obligations.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conditions Precedent to Effectiveness</u><font style="font-size:12pt;">. This Amendment shall be subject to the following conditions precedent:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">This Amendment shall have been duly executed and delivered to the Administrative Agent by the Borrower and the Lenders, which constitute all of the Lenders under the Existing Credit Agreement;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">After giving effect to the waiver in Section 2 hereof, each of the representations and warranties in Section 7 of this Amendment, Section 7 of the Credit Agreement and in the other Loan Documents shall be true, accurate and complete in all material respects (unless such representations are already qualified by reference to materiality, Material Adverse Effect or similar language, in which case such representations and warranties shall be true and correct in all respects) on and as of the date hereof</font><font style="font-size:12pt;"> with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date</font><font style="font-size:12pt;">,</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-size:12pt;">in which case such representations and warranties shall have been true and correct in all respects on and as of such earlier date;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">At the time of and after giving effect to this Amendment, other than the Specified Events of Default, no fact or condition exists that </font><font style="font-size:12pt;">constitutes, </font><font style="font-size:12pt;">or with the passage of time, the giving of notice, or both</font><font style="font-size:12pt;">, would</font><font style="font-size:12pt;"> constitute</font><font style="font-size:12pt;">, a Default or</font><font style="font-size:12pt;"> Event of Default</font><font style="font-size:12pt;">; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">(d)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">The Borrower shall have paid all costs, fees and expenses of the Administrative Agent and the Lenders, including, the fees and expenses of Sullivan &amp; Cromwell LLP, as outside counsel to Administrative Agent and the Oaktree Lenders and the fees and expenses of </font><font style="font-size:12pt;">Allen Overy Shearman Sterling US LLP, </font><font style="font-size:12pt;">as outside counsel to Q Boost Holding LLC, incurred prior to the date hereof, to the extent invoiced on or prior to the date hereof.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Condition Subsequent to Effectiveness</u><font style="font-size:12pt;">. This Amendment shall be subject to the following condition subsequent: &#160;Prior to 5:00 pm ET on March 15, 2025, the Borrower shall receive at least $6,000,000 in gross cash proceeds from the issuance of the Borrower&#8217;s common stock and warrants and/or pre-funded warrants, in each case, for common stock.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties</u><font style="font-size:12pt;">. The Borrower hereby represents and warrants:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">None of the execution, delivery and performance by the Borrower of this Amendment and the documents, instruments and agreements executed in connection herewith (collectively, the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Amendment Documents</font><font style="font-size:12pt;">&#8221;) or performance under the Amendment Documents (i)&#160;requires any Governmental Approval of, registration or filing with, or any other action by, any Governmental Authority or any other Person, except for (x) such as have been obtained or made and are in full force and effect and (y)&#160;filings and recordings in respect of perfecting or recording the Liens created pursuant to the Security Documents, (ii) will violate (1) any Law, (2) any Organic Document of the Borrower or any of its Subsidiaries or (3) any order of any Governmental Authority, that in the case of clause&#160;(ii)(1) or clause (ii)(3), individually or in the aggregate, would reasonably be expected to result in a Material Adverse Effect, (iii) will violate or result in a default under any Material Agreement binding upon the Borrower or any of its Subsidiaries that, individually or in the aggregate, would reasonably be expected to result in a Material Adverse Effect or (iv) will result in the creation or imposition of any Lien (other than Permitted Liens) on any asset of the Borrower or any of its Subsidiaries.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">This Amendment and the other Amendment Documents have been duly authorized by all necessary corporate or other organizational action including, if required, approval by all necessary holders of Equity Interests, and duly executed and delivered by the Borrower and constitutes, and each of the Amendment Documents when executed and delivered by the Borrower will constitute, a legal, valid and binding obligation of the Borrower, enforceable against the Borrower in accordance with its terms, except as such enforceability may be limited by (i) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-size:12pt;">affecting the enforcement of creditors&#8217; rights and (ii) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law).</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Release</u><font style="font-size:12pt;">.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">In consideration of this Amendment and agreements of the Administrative Agent and the Lenders contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Borrower (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Releasing Party</font><font style="font-size:12pt;">&#8221;), on behalf of itself and its successors, assigns and other legal representatives hereby absolutely, unconditionally and irrevocably releases, remises and forever discharges the Administrative Agent and the Lenders and their respective present and former shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives, in each case solely in their capacities relative to the Lenders and not in any other capacity such party may have relative to the Releasing Party (the Administrative Agent, each Lender and all such other Persons being hereinafter referred to collectively as the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Releasees</font><font style="font-size:12pt;">&#8221; and individually as a &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Releasee</font><font style="font-size:12pt;">&#8221;), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which the Borrower or any of its successors, assigns or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the date hereof, for or on account of, or in relation to, or in any way in connection with the Credit Agreement or any of the other Loan Documents or transactions thereunder (any of the foregoing, a &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Claim</font><font style="font-size:12pt;">&#8221; and collectively, the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Claims</font><font style="font-size:12pt;">&#8221;). &#160;The Releasing Party expressly acknowledges and agrees, with respect to the Claims, that it waives, to the fullest extent permitted by applicable law, any and all provisions, rights and benefits conferred by any applicable U.S. federal or state law, or any principle of U.S. common law, that would otherwise limit a release or discharge of any unknown Claims pursuant to this Section 7. &#160;Furthermore, the Releasing Party hereby absolutely, unconditionally and irrevocably covenants and agrees with and in favor of each Releasee that it will not sue (at law, in equity, in any regulatory proceeding or otherwise) any Releasee on the basis of any Claim released and/or discharged by the Releasing Parties pursuant to this Section 7. &#160;The foregoing release, covenant and waivers of this Section 7 shall survive and remain in full force and effect regardless of the consummation of the transactions contemplated hereby, the repayment or prepayment of any of the Loans, or the termination of the Credit Agreement, this Amendment, any other Loan Document or any provision hereof or thereof.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Each Releasing Party understands, acknowledges and agrees that its release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-size:12pt;">instituted, prosecuted or attempted in breach of the provisions of such release.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Each Releasing Party agrees that no fact, event, circumstance, evidence or transaction which could now be asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the release set forth above.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fees and Expenses</u><font style="font-size:12pt;">. The Borrower agrees to pay on demand (a) all out-of-pocket fees, costs and expenses of the Administrative Agent and the Lenders accrued prior to the date hereof and (b) all out-of-pocket fees, costs and expenses of the Administrative Agent and the Lenders incurred in connection with the preparation, execution and delivery of (i)&#160;this Amendment, (ii)&#160;any Amendment Documents, other Loan Documents or other post-closing amendments, agreements, arrangements or documentation, (iii) any other instruments and documents to be delivered hereunder or thereunder, in each case of clauses (a) and (b), including the fees and expenses of Sullivan &amp; Cromwell LLP, as outside counsel to Administrative Agent and the Oaktree Lenders, and Allen Overy Shearman Sterling US LLP, as outside counsel to Q Boost Holding LLC, with respect thereto.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">10.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</u><font style="font-size:12pt;">.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Except as otherwise expressly provided herein, </font><font style="font-size:12pt;">(i) </font><font style="font-size:12pt;">all provisions of the </font><font style="font-size:12pt;">Credit</font><font style="font-size:12pt;"> Agreement and the other </font><font style="font-size:12pt;">Loan Document</font><font style="font-size:12pt;">s remain in full force and effect </font><font style="font-size:12pt;">and (ii) the execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of the Administrative Agent or the Lenders, nor constitute a waiver of any provision of the Existing Credit Agreement or any of the Loan Documents. &#160;None of the Administrative Agent or any Lender is under any obligation to enter into this Amendment. &#160;The entering into of this Amendment by such parties shall not be deemed to limit or hinder any rights of any such party under the Loan Documents, nor shall it be deemed to create or infer a course of dealing between any such party, on the one hand, and the Borrower, on the other hand, with regard to any provision of the Loan Documents</font><font style="font-size:12pt;">.</font><font style="font-size:12pt;"> &#160;This Amendment shall constitute a Loan Document.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">This Amendment may be executed in several counterparts and by each party on a separate counterpart, each of which when so executed and delivered shall be an original, and all of which together shall constitute one instrument. &#160;An executed facsimile or electronic copy of this Amendment shall be effective for all purposes as an original hereof.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">This Amendment expresses the entire understanding of the parties with respect to the amendments contemplated hereby. &#160;No prior negotiations or discussions shall limit, modify, or otherwise affect the provisions hereof.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;font-size:12pt;">(d)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">This Amendment and its contents shall be subject to the governing law, indemnification, venue, service of process, waivers of jury trial and severability provisions of the Existing Credit Agreement, mutatis mutandis.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[SIGNATURE PAGES FOLLOW]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered as of the day and year first above written.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.92%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#2a302c;font-size:12pt;font-weight:bold;">BORROWER:</b></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#2a302c;font-size:12pt;font-weight:bold;">BIOXCEL THERAPEUTICS, INC.</b></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Vimal Mehta</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Vimal Mehta</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Chief Executive Officer</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Address for Notices:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">555 Long Wharf Drive, 12th Floor</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">New Haven, CT</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">06511</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to (which shall not constitute notice):</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Cooley LLP</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">3 Embarcadero Center </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">20th Floor</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">San Francisco, CA 94111-4004</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Mischi a Marca</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: gmamarca@cooley.com</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Sixth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.9%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:43.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:12pt;font-weight:bold;">ADMINISTRATIVE AGENT:</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:12pt;font-weight:bold;">OAKTREE FUND ADMINISTRATION, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:43.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Its:</font></p></td><td style="vertical-align:top;width:43.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Managing Member</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:43.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:43.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:43.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Managing Director</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:43.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:43.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:43.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Senior Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Address for Notices:</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Fund Administration, LLC 333 </font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: &#160;&#160;Oaktree Agency</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: Oaktreeagency@alterdomus.com</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P. 333 </font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: &#160;&#160;Aman Kumar</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: AmKumar@oaktreecapital.com</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Sullivan &amp; Cromwell LLP 125 </font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Broad Street</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">New York, NY 10004</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: &#160;&#160;Ari B. Blaut</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email:&#160;blauta@sullcrom.com</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Sixth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.92%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:12pt;font-weight:bold;">LENDERS:</b></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:12pt;font-weight:bold;">OAKTREE-TCDRS STRATEGIC CREDIT, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Its:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Manager</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Managing Director</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Senior Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Address for Notices:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Fund Administration, LLC </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Oaktree Agency</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">Email:  Oaktreeagency@alterdomus.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Aman Kumar</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: AmKumar@oaktreecapital.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Sullivan &amp; Cromwell LLP </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">125 Broad Street</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">New York, NY 10004</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Ari B. Blaut</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: blauta@sullcrom.com</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Sixth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.92%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:12pt;font-weight:bold;">OAKTREE-FORREST MULTI-STRATEGY, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Its:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Manager</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Managing Director</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Senior Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Address for Notices:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Fund Administration, LLC </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Oaktree Agency</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: Oaktreeagency@alterdomus.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P. </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Aman Kumar</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: AmKumar@oaktreecapital.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Sullivan &amp; Cromwell LLP </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">125 Broad Street</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">New York, NY 10004</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Ari B. Blaut</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: blauta@sullcrom.com</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Sixth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.92%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:12pt;font-weight:bold;">OAKTREE-TBMR STRATEGIC CREDIT FUND&#160;C, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Its:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Manager</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Managing Director</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Senior Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Address for Notices:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Fund Administration, LLC </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Oaktree Agency</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: Oaktreeagency@alterdomus.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P. </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Aman Kumar</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: AmKumar@oaktreecapital.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Sullivan &amp; Cromwell LLP </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">125 Broad Street</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">New York, NY 10004</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Ari B. Blaut</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: blauta@sullcrom.com</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Sixth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.92%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:12pt;font-weight:bold;">OAKTREE-TBMR STRATEGIC CREDIT FUND&#160;F, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Its:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Manager</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Managing Director</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Senior Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Address for Notices:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Fund Administration, LLC </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Oaktree Agency</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: Oaktreeagency@alterdomus.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P. </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Aman Kumar</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: AmKumar@oaktreecapital.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Sullivan &amp; Cromwell LLP </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">125 Broad Street</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">New York, NY 10004</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Ari B. Blaut</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: blauta@sullcrom.com</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Sixth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.92%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:12pt;font-weight:bold;">OAKTREE-TBMR STRATEGIC CREDIT FUND&#160;G, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Its:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Manager</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Managing Director</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Senior Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Address for Notices:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Fund Administration, LLC </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Oaktree Agency</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: Oaktreeagency@alterdomus.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P. </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Aman Kumar</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: AmKumar@oaktreecapital.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Sullivan &amp; Cromwell LLP </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">125 Broad Street</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">New York, NY 10004</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Ari B. Blaut</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: blauta@sullcrom.com</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Sixth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.92%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:12pt;font-weight:bold;">OAKTREE-TSE 16 STRATEGIC CREDIT, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Its:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Manager</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Managing Director</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Senior Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Address for Notices:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Fund Administration, LLC </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Oaktree Agency</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: Oaktreeagency@alterdomus.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P. </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Aman Kumar</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: AmKumar@oaktreecapital.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Sullivan &amp; Cromwell LLP </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">125 Broad Street</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">New York, NY 10004</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Ari B. Blaut</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: blauta@sullcrom.com</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Sixth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.92%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:12pt;font-weight:bold;">INPRS STRATEGIC CREDIT HOLDINGS, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Its:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Manager</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Managing Director</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Senior Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Address for Notices:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Fund Administration, LLC </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Oaktree Agency</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: Oaktreeagency@alterdomus.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P. </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Aman Kumar</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: AmKumar@oaktreecapital.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Sullivan &amp; Cromwell LLP </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">125 Broad Street</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">New York, NY 10004</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Ari B. Blaut</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: blauta@sullcrom.com</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Sixth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.92%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:12pt;font-weight:bold;">OAKTREE SPECIALTY LENDING CORPORATION</b></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Fund Advisors, LLC</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Its:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Investment Adviser</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Managing Director</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Senior Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Address for Notices:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Fund Administration, LLC </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Oaktree Agency</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: Oaktreeagency@alterdomus.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P. </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Aman Kumar</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: AmKumar@oaktreecapital.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Sullivan &amp; Cromwell LLP </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">125 Broad Street</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">New York, NY 10004</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Ari B. Blaut</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: blauta@sullcrom.com</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Sixth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.9%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:43.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:12pt;font-weight:bold;">OAKTREE STRATEGIC CREDIT FUND</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:43.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Fund Advisors, LLC</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Its:</font></p></td><td style="vertical-align:top;width:43.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Investment Adviser</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:43.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:43.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:43.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Managing Director</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:43.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:43.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:43.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Senior Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Address for Notices:</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Fund Administration, LLC </font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Oaktree Agency</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: Oaktreeagency@alterdomus.com</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P. </font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Aman Kumar</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: AmKumar@oaktreecapital.com</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Sullivan &amp; Cromwell LLP </font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">125 Broad Street</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">New York, NY 10004</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Ari B. Blaut</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: blauta@sullcrom.com</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Sixth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.92%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:12pt;font-weight:bold;">OAKTREE GCP FUND DELAWARE HOLDINGS, L.P.</b></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Global Credit Plus Fund GP, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Its:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">General Partner</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Global Credit Plus Fund GP Ltd.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Its:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">General Partner</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Its:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Director</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Managing Director</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Senior Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Address for Notices:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Fund Administration, LLC </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Oaktree Agency</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: Oaktreeagency@alterdomus.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P. </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071 </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Aman Kumar</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: AmKumar@oaktreecapital.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Sullivan &amp; Cromwell LLP </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">125 Broad Street</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">New York, NY 10004</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Ari B. Blaut</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: blauta@sullcrom.com</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Sixth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.92%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:12pt;font-weight:bold;">OAKTREE DIVERSIFIED INCOME FUND INC.</b></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Fund Advisors, LLC</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Its:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Investment Adviser</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Managing Director</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Senior Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Address for Notices:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Fund Administration, LLC </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Oaktree Agency</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: Oaktreeagency@alterdomus.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P. </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Aman Kumar</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: AmKumar@oaktreecapital.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Sullivan &amp; Cromwell LLP </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">125 Broad Street</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">New York, NY 10004</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Ari B. Blaut</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: blauta@sullcrom.com</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Sixth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.92%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:12pt;font-weight:bold;">OAKTREE AZ STRATEGIC LENDING FUND, L.P.</b></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree AZ Strategic Lending Fund GP, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Its:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">General Partner</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Fund GP IIA, LLC</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Its:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">General Partner</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Oaktree Fund GP II, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Its:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Managing Member</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Authorized Signatory</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Authorized Signatory</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Address for Notices:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Fund Administration, LLC </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Oaktree Agency</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: Oaktreeagency@alterdomus.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P. </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Aman Kumar</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: AmKumar@oaktreecapital.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Sullivan &amp; Cromwell LLP </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">125 Broad Street</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">New York, NY 10004</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Ari B. Blaut</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: blauta@sullcrom.com</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Sixth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.95%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-transform:uppercase;">Oaktree LSL Fund Holdings EURRC S.&#224; r.l.</b></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">26A, boulevard Royal L-2449</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Luxembourg, Grand Duchy of Luxembourg</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">R.C.S Luxembourg Number: B269245</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Martin Eckel</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Martin Eckel</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Manager</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Flora Verrecchia</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Flora Verrecchia</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Manager</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Address for Notices:</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Fund Administration, LLC </font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Oaktree Agency</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: Oaktreeagency@alterdomus.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P. </font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Aman Kumar</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: AmKumar@oaktreecapital.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Sullivan &amp; Cromwell LLP </font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">125 Broad Street</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">New York, NY 10004</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Ari B. Blaut</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: blauta@sullcrom.com</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Sixth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.92%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:12pt;font-weight:bold;">OAKTREE LSL FUND DELAWARE HOLDINGS EURRC, L.P.</b></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Life Sciences Lending Fund GP, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Its:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">General Partner</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Life Sciences Lending Fund GP Ltd.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Its:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">General Partner</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Its:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Director</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Mary Gallegly</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Managing Director</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:44.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Jessica Dombroff</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Senior Vice President</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Address for Notices:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Fund Administration, LLC </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Oaktree Agency</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: Oaktreeagency@alterdomus.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Oaktree Capital Management, L.P. </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">333 S. Grand Avenue, 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> Fl.</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Los Angeles, CA 90071</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Aman Kumar</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: AmKumar@oaktreecapital.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">With a copy to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Sullivan &amp; Cromwell LLP </font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">125 Broad Street</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">New York, NY 10004</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn: Ari B. Blaut</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: blauta@sullcrom.com</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Sixth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.95%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:43.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Q BOOST HOLDING LLC</b></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:43.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">/s/ Ahmed Nasser Al-Abdulghani</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:43.3%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Ahmed Nasser Al-Abdulghani</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:43.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Director</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Address for Notices:</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">c/o Qatar Investment Authority</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Ooredoo Tower (Building 14)</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Al Dafna Street (Street 801)</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Al Dafna (Zone 61) Doha, Qatar</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">A copy (which shall not constitute notice) shall also be sent to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">General Counsel</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Qatar Investment Authority</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Ooredoo Tower (Building 14)</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Al Dafna Street (Street 801)</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Al Dafna (Zone 61)</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Doha, Qatar</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email: </font></p></td><td style="vertical-align:top;width:43.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">notices.legal@qia.qa</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">A copy (which shall not constitute notice) shall also be sent to:</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Shearman &amp; Sterling LLP</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">535 Mission Street, 25</font><sup style="font-size:9pt;vertical-align:top;">th </sup><font style="font-size:12pt;">Floor</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">San Francisco, CA 94105</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Attn:</font></p></td><td colspan="2" style="vertical-align:top;width:44.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Michael S. Dorf</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:44.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Tomasz Kulawik</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">Email:</font></p></td><td colspan="2" style="vertical-align:top;width:44.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">mdorf@shearman.com</font></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:44.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">tomasz.kulawik@shearman.com</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Sixth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>5
<FILENAME>btai-20241231xex19d1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/28/2025 07:21:30 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 19.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BIOXCEL THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">INSIDER TRADING COMPLIANCE POLICY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">This Insider Trading Compliance Policy (this &#8220;<font style="font-style:italic;font-weight:bold;">Policy</font>&#8221;) consists of seven sections:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section I provides an overview;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section II sets forth the policies of the Company prohibiting insider trading;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section III explains insider trading;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section IV consists of procedures that have been put in place by the Company to prevent insider trading;</font></td></tr></table><div style="margin-top:10pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section V sets forth additional transactions that are prohibited by this Policy;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section VI explains Rule 10b5-1 trading plans; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section VII refers to the execution and return of a certificate of compliance.</font></td></tr></table><div style="margin-top:10pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">I.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">SUMMARY</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Preventing insider trading is necessary to comply with securities laws and to preserve the reputation and integrity of BioXcel Therapeutics, Inc. (the &#8220;<font style="font-style:italic;font-weight:bold;">Company</font>&#8221;) as well as that of all persons affiliated with the Company. &#8220;Insider trading&#8221; occurs when any person purchases or sells a security while in possession of inside information relating to the security. As explained in Section III below, &#8220;inside information&#8221; is information that is both &#8220;material&#8221; and &#8220;non-public.&#8221; Insider trading is a crime. The penalties for violating insider trading laws include imprisonment, disgorgement of profits, civil fines, and significant criminal fines. Insider trading is also prohibited by this Policy, and violation of this Policy may result in Company- imposed sanctions, including termination of employment for cause.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">This Policy applies to all officers, directors and employees of the Company and its subsidiaries (if any) (collectively, &#8220;<font style="font-style:italic;font-weight:bold;">Company Personnel</font>&#8221;), as well as such Company Personnel&#8217;s spouse, minor children and any other family member sharing the same household as such Company Personnel and any other company, account, trust or other entity over which such Company Personnel has control (collectively, &#8220;<font style="font-style:italic;font-weight:bold;">Related Parties</font>&#8221; and, together with Company Personnel, &#8220;<font style="font-style:italic;font-weight:bold;">Covered Persons</font>&#8221;). Transactions by Related Parties should be treated for the purposes of this Policy and applicable securities laws as if they were for Company Personnel&#8217;s own account.Company Personnel will be responsible for compliance with this Policy by their Related Parties. This Policy extends to all activities within and outside the Company Personnel&#8217;s duties at the Company. All Company Personnel must review this Policy. Questions regarding the Policy should be directed to the Company&#8217;s Chief Financial Officer.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">II. </b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">STATEMENT OF POLICIES PROHIBITING INSIDER TRADING</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">No Covered Person shall purchase or sell any type of security while in possession of material, non- public information relating to the security, whether the issuer of such security is the Company or any other company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">These prohibitions do not apply to:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">purchases of the Company&#8217;s securities by a Covered Person from the Company or sales of the Company&#8217;s securities by a Covered Person to the Company;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exercises of stock options or other equity awards or the surrender of shares to the Company in payment of the exercise price or in satisfaction of any tax withholding obligations in a</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 72pt;">manner permitted by the applicable equity award agreement, or vesting of equity-based awards, that in each case do not involve a market sale of the Company&#8217;s securities (the &#8220;cashless exercise&#8221; of a Company stock option through a broker <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">does</u> involve a market sale of the Company&#8217;s securities, and therefore would not qualify under this exception);</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">bona fide</i><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> gifts of the Company&#8217;s securities, unless the person making the gift has reason to believe that the recipient intends to sell the securities while the donor is in possession of material, non-public information about the Company; or</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">purchases or sales of the Company&#8217;s securities made pursuant to any binding contract, specific instruction or written plan entered into outside of a blackout period and while the purchaser or seller, as applicable, was unaware of any material, non-public information and which contract, instruction or plan (i) meets all of the requirements of the affirmative defense provided by Rule 10b5-1 (&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Rule 10b5-1</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) promulgated under the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">1934 Act</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), (ii) was pre-cleared in advance pursuant to this Policy and (iii) has not been amended or modified in any respect after such initial pre-clearance without such amendment or modification being pre-cleared in advance pursuant to this Policy. For more information about Rule 10b5-1 trading plans, see Section VI below.</font></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In addition, no Covered Person shall directly or indirectly communicate (or &#8220;<font style="font-style:italic;font-weight:bold;">tip</font>&#8221;) material, non- public information to anyone outside of the Company (except in accordance with the Company&#8217;s policies regarding the protection or authorized external disclosure of Company information) or to anyone within the Company other than on a need-to-know basis.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">III. </b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">EXPLANATION OF INSIDER TRADING</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">&#8220;</i><font style="font-style:italic;font-weight:bold;">Insider trading</font><i style="font-style:italic;">&#8221;</i> refers to the purchase or sale of a security while in possession of &#8220;material,&#8221; &#8220;non-public&#8221; information relating to the security or its issuer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">&#8220;</i><font style="font-style:italic;font-weight:bold;">Securities</font><i style="font-style:italic;">&#8221; </i>include stocks, bonds, notes, debentures, options, warrants and other convertible securities, as well as derivative instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">&#8220;</i><font style="font-style:italic;font-weight:bold;">Purchase</font><i style="font-style:italic;">&#8221;</i> and <i style="font-style:italic;">&#8220;</i><font style="font-style:italic;font-weight:bold;">sale</font><i style="font-style:italic;">&#8221;</i> are defined broadly under the federal securities law. <i style="font-style:italic;">&#8220;Purchase&#8221;</i> includes not only the actual purchase of a security, but any contract to purchase or otherwise acquire a security. <i style="font-style:italic;">&#8220;Sale&#8221;</i> includes not only the actual sale of a security, but any contract to sell or otherwise dispose of a security. These definitions extend to a broad range of transactions, including conventional cash-for-stock transactions, conversions, the exercise of stock options, and acquisitions and exercises of warrants or puts, calls or other derivative securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">It is generally understood that insider trading includes the following:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading by insiders while in possession of material, non-public information;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading by persons other than insiders while in possession of material, non-public information, if the information either was given in breach of an insider&#8217;s fiduciary duty to keep it confidential or was misappropriated; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">communicating or tipping material, non-public &#160;information to others, including recommending the purchase or sale of a security while in possession of such information.</font></td></tr></table><div style="margin-top:10pt;"></div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">A. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">What Facts are Material?</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The materiality of a fact depends upon the circumstances. A fact is considered &#8220;material&#8221; if there is a substantial likelihood that a reasonable investor would consider it important in making a decision to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">buy, sell or hold a security, or if the fact is likely to have a significant effect on the market price of the security. Material information can be positive or negative and can relate to virtually any aspect of a company&#8217;s business or to any type of security, debt or equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Examples of material information include (but are not limited to) information about:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">corporate earnings or earnings forecasts;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">possible mergers, acquisitions, tender offers or dispositions;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">major new products or product developments;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">important business developments such as trial results, developments regarding strategic collaborators or the status of regulatory submissions;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant incidents and risks with respect to cybersecurity, data protection and personally identifiable information;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">management or control changes;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant financing developments including pending public sales or offerings of debt or equity securities;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">defaults on borrowings;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">bankruptcies; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant litigation or regulatory actions.</font></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Moreover, material information does not have to be related to a company&#8217;s business. For example, the contents of a forthcoming newspaper column that is expected to affect the market price of a security can be material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">A good general rule of thumb: <b style="font-weight:bold;">When in doubt, do not trade. </b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">B. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">What is Non-Public?</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Information is &#8220;non-public&#8221; if it is not available to the general public. In order for information to be considered public, it must be widely disseminated in a manner making it generally available to investors through such media as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dow Jones</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Business Wire</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reuters</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Wall Street Journal</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Associated Press</u>, or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">United Press International</u>, a broadcast on widely available radio or television programs, publication in a widely available newspaper, magazine or news web site, a Regulation FD-compliant conference call, or public disclosure documents filed with the Securities and Exchange Commission (&#8220;<font style="font-style:italic;font-weight:bold;">SEC</font>&#8221;) that are available on the SEC&#8217;s web site.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The circulation of rumors, even if accurate and reported in the media, does not constitute effective public dissemination. In addition, even after a public announcement, a reasonable period of time must lapse in order for the market to react to the information. Generally, one should allow two full trading days following publication as a reasonable waiting period before such information is deemed to be public. For the purposes of this Policy, a &#8220;trading day&#8221; is a day on which national stock exchanges are open for trading. If, for example, the Company were to make an announcement on a Monday prior to 9:30 a.m. Eastern time, the information would be deemed public after the close of trading on Tuesday. If an announcement were made on a Monday after 9:30 a.m. Eastern time, the information would be deemed public after the close of trading on Wednesday. If you have any question as to whether information is publicly available, please direct an inquiry to the Chief Financial Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">C. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Who is an Insider?</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">&#8220;Insiders&#8221; include officers, directors and employees of a company and anyone else who has material non-public information about a company. Insiders have independent fiduciary duties to their company and its stockholders not to trade on material, non-public information relating to the company&#8217;s securities. All officers, directors and employees of the Company should consider themselves insiders with respect to material, non-public information about the Company&#8217;s business, activities and securities. Insiders subject to this Policy are responsible for ensuring that their Related Parties also comply with this Policy, and such Related Parties should be treated for the purposes of this Policy and applicable securities laws as if they were for the such insider&#8217;s own account.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">D. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trading by Persons Other than Insiders</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Insiders may be liable for communicating or tipping material, non-public information to a third party (&#8220;<font style="font-style:italic;font-weight:bold;">tippee</font>&#8221;), and insider trading violations are not limited to trading or tipping by insiders. Persons other than insiders also can be liable for insider trading, including tippees who trade on material, non-public information tipped to them or individuals who trade on material, non-public information that has been misappropriated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Tippees inherit an insider&#8217;s duties and are liable for trading on material, non-public information illegally tipped to them by an insider. Similarly, just as insiders are liable for the insider trading of their tippees, so are tippees who pass the information along to others who trade. In other words, a tippee&#8217;s liability for insider trading is no different from that of an insider. Tippees can obtain material, non-public information by receiving overt tips from others or through, among other things, conversations at social, business, or other gatherings.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">E. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Penalties for Engaging in Insider Trading</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Penalties for trading on or tipping material, non-public information can extend significantly beyond any profits made or losses avoided, both for individuals engaging in such unlawful conduct and their employers. The SEC and Department of Justice have made the civil and criminal prosecution of insider trading violations a top priority. Enforcement remedies available to the government or private plaintiffs under the federal securities laws include:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">SEC administrative sanctions;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">securities industry self-regulatory organization sanctions;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">civil injunctions;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">damage awards to private plaintiffs;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disgorgement of all profits;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">civil fines for the violator of up to three times the amount of profit gained or loss avoided;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">civil fines for the employer or other controlling person of a violator (i.e., where the violator is an employee or other controlled person) of up to the greater of $2,140,973 (subject to adjustment for inflation) or three times the amount of profit gained or loss avoided by the violator;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">criminal fines for individual violators of up to $5,000,000 ($25,000,000 for an entity); and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">jail sentences of up to 20 years.</font></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In addition, insider trading could result in serious sanctions by the Company, including dismissal. Insider trading violations are not limited to violations of the federal securities laws. Other federal and state civil or criminal laws, such as the laws prohibiting mail and wire fraud and the Racketeer Influenced and Corrupt Organizations Act (RICO), also may be violated in connection with insider trading.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">F. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Size of Transaction and Reason for Transaction Do Not Matter</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The size of the transaction or the amount of profit received does not have to be significant to result in prosecution. The SEC has the ability to monitor even the smallest trades, and the SEC performs routine market surveillance. Brokers and dealers are required by law to inform the SEC of any possible violations by people who may have material, non-public information. The SEC aggressively investigates even small insider trading violations.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">G.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Examples of Insider Trading</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Examples of insider trading cases include:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actions brought against corporate officers, directors, and employees who traded in a company&#8217;s securities after learning of significant confidential corporate developments;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">friends, business associates, family members and other tippees of such officers, directors, and employees who traded in the securities after receiving such information;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">government employees who learned of such information in the course of their employment; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other persons who misappropriated, and took advantage of, confidential information from their employers.</font></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The following are illustrations of insider trading violations. These illustrations are hypothetical and, consequently, not intended to reflect on the actual activities or business of the Company or any other entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trading by Insider</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">An officer of X Corporation learns that earnings to be reported by X Corporation will increase dramatically. Prior to the public announcement of such earnings, the officer purchases X Corporation&#8217;s stock. The officer, an insider, is liable for all profits as well as penalties of up to three times the amount of all profits. The officer also is subject to, among other things, criminal prosecution, including up to $5,000,000 in additional fines and 20 years in jail. Depending upon the circumstances, X Corporation and the individual to whom the officer reports also could be liable as controlling persons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trading by Tippee</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">An officer of X Corporation tells a friend that X Corporation is about to publicly announce that it has signed an agreement for a major acquisition. This tip causes the friend to purchase X Corporation&#8217;s stock in advance of the announcement. The officer is jointly liable with his friend for all of the friend&#8217;s profits, and each is liable for all civil penalties of up to three times the amount of the friend&#8217;s profits. The officer and his friend are also subject to criminal prosecution and other remedies and sanctions, as described above.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">H. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prohibition of Records Falsification and False Statements</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Section 13(b)(2) of the 1934 Act requires companies subject to the Act to maintain proper internal books and records and to devise and maintain an adequate system of internal accounting controls. The SEC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">has supplemented the statutory requirements by adopting rules that prohibit (1) any person from falsifying records or accounts subject to the above requirements and (2) officers or directors from making any materially false, misleading, or incomplete statement to any accountant in connection with any audit or filing with the SEC. These provisions reflect the SEC&#8217;s intent to discourage officers, directors and other persons with access to the Company&#8217;s books and records from taking action that might result in the communication of materially misleading financial information to the investing public.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">IV. </b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">STATEMENT OF PROCEDURES PREVENTING INSIDER TRADING</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The following procedures have been established, and will be maintained and enforced, by the Company to prevent insider trading.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">A. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pre-Clearance Requirements</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">To provide assistance in preventing inadvertent violations of applicable securities laws and to avoid the appearance of impropriety in connection with the purchase and sale of the Company&#8217;s securities, <b style="font-weight:bold;">all transactions in the Company&#8217;s securities (including without limitation, acquisitions and dispositions of Company stock, the exercise of stock options and the sale of Company stock issued upon exercise of stock options) by officers, directors and such other Company Personnel as are designated from time to time by the Board of Directors, the Chief Executive Officer or the Chief Financial Officer as being subject to this pre-clearance process, as well as such officer&#8217;s, director&#8217;s and other Company Personnel&#8217;s Related Parties (each, a &#8220;</b><font style="font-style:italic;font-weight:bold;">Pre-Clearance Person</font><b style="font-weight:bold;">&#8221;) must be pre-cleared</b> by the Company&#8217;s Chief Financial Officer. Those designated as Pre-Clearance Persons are listed on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule I</u> hereto, which list of Pre-Clearance Persons may be updated at any time and from time to time by the Chief Executive Officer or the Chief Financial Officer, and such current list shall be maintained in the Company&#8217;s records. Pre-clearance does not relieve anyone of his or her responsibility under SEC rules. For the avoidance of doubt, any designation by the Board of Directors of the Company Personnel who are subject to pre-clearance may be updated from time to time by the Chief Executive Officer or the Chief Financial Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">A request for pre-clearance may be oral or in writing (including without limitation by e-mail), should be made at least two (2) business days in advance of the proposed transaction and should include the identity of the Pre-Clearance Person, the type of proposed transaction (for example, an open market purchase, a privately negotiated sale, an option exercise, etc.), the proposed date of the transaction and the number of shares, options or other securities to be involved. In addition, unless otherwise determined by the Chief Financial Officer, the Pre-Clearance Person must execute a certification (in the form approved by the Chief Financial Officer) that he, she or it is not aware of material, non-public information about the Company. The Chief Financial Officer shall have sole discretion to decide whether to clear any contemplated transaction, provided that the Chief Executive Officer shall have sole discretion to decide whether to clear transactions by the Chief Financial Officer or persons or entities subject to this policy as a result of their relationship with the Chief Financial Officer. All trades that are pre-cleared must be effected within five business days of receipt of the pre-clearance unless a specific exception has been granted by the Chief Financial Officer (or the Chief Executive Officer, in the case of the Chief Financial Officer or persons or entities subject to this policy as a result of their relationship with the Chief Financial Officer). A pre- cleared trade (or any portion of a pre-cleared trade) that has not been effected during the five (5) business day period must be pre-cleared again prior to execution. Notwithstanding receipt of pre-clearance, if the Pre-Clearance Person becomes aware of material, non-public information or becomes subject to a blackout period before the transaction is effected, the transaction may not be completed.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">B. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Blackout Periods</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">No officer, director or other Company Personnel designated from time to time by the Board of Directors, the Chief Executive Officer or the Chief Financial Officer as being subject to quarterly</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">blackout periods, as well as such officer&#8217;s, director&#8217;s and other Company Personnel&#8217;s Related Parties, shall purchase or sell any security of the Company during the period beginning at 11:59 p.m., Eastern time, on the seventh calendar day before the end of any fiscal quarter of the Company and ending upon the completion of the second full trading day after the public release of earnings data for such fiscal quarter or during any other trading suspension period declared by the Company,</b> except for purchases and sales made pursuant to the permitted transactions described in Section II. For example, if the Company&#8217;s fourth fiscal quarter ends at 11:59 p.m., Eastern time, on December 31, the corresponding blackout period would begin at 11:59 p.m., Eastern time, on December 24. Those subject to the quarterly blackout periods are listed on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule II</u> hereto, which list may be updated at any time and from time to time by the Chief Executive Officer or the Chief Financial Officer, and such current list shall be maintained in the Company&#8217;s records.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Exceptions to the blackout period policy may be approved only by the Company&#8217;s Chief Executive Officer (or, in the case of an exception for the Chief Executive Officer or persons or entities subject to this policy as a result of their relationship with the Chief Executive Officer, the Chief Financial Officer or, in the case of exceptions for directors or persons or entities subject to this policy as a result of their relationship with a director, the Board of Directors).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">From time to time, the Company, through the Board of Directors, the Company&#8217;s disclosure committee, the Chief Executive Officer or the Chief Financial Officer, may recommend that some or all Company Personnel (including their Related Parties) suspend trading in the Company&#8217;s securities because of developments that have not yet been disclosed to the public. Subject to the exceptions noted above, all of those affected should not trade in the Company&#8217;s securities while the suspension is in effect, and should not disclose to others that the Company has suspended trading.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">If the Company is required to impose a &#8220;pension fund blackout period&#8221; under Regulation BTR, each director and executive officer shall not, directly or indirectly sell, purchase or otherwise transfer during such blackout period any equity securities of the Company acquired in connection with his or her service as a director or officer of the Company, except as permitted by Regulation BTR.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">C. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Post-Termination Transactions</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">If any Company Personnel is in possession of material, non-public information when his or her service with the Company terminates, that individual and their Related Parties may not trade in the Company&#8217;s securities until that information has become public or is no longer material.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">D. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Information Relating to the Company</u></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">1. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Access to Information</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Access to material, non-public information about the Company, including the Company&#8217;s business, earnings or prospects, should be limited to Company Personnel of the Company on a need-to-know basis. In addition, such information should not be communicated to anyone outside the Company under any circumstances (except in accordance with the Company&#8217;s policies regarding the protection or authorized external disclosure of Company information) or to anyone within the Company on an other than need-to- know basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In communicating material, non-public information to Company Personnel of the Company, all Company Personnel must take care to emphasize the need for confidential treatment of such information and adherence to the Company&#8217;s policies with regard to confidential information.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">2. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Inquiries From Third Parties</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Inquiries from third parties, such as industry analysts or members of the media, about the Company should be directed to the Chief Financial Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">E. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitations on Access to Company Information</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The following procedures are designed to maintain confidentiality with respect to the Company&#8217;s business operations and activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">All Company Personnel should take all steps and precautions necessary to restrict access to, and secure, material, non-public information by, among other things:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining the confidentiality of Company-related transactions;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conducting their business and social activities so as not to risk inadvertent disclosure of confidential information. Review of confidential documents in public places should be conducted so as to prevent access by unauthorized persons;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restricting access to documents and files (including computer files) containing material, non-public information to individuals on a need-to-know basis (including maintaining control over the distribution of documents and drafts of documents);</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">promptly removing and cleaning up all confidential documents and other materials from conference rooms following the conclusion of any meetings;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disposing of all confidential documents and other papers, after there is no longer any business or other legally required need, through shredders when appropriate;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restricting access to areas likely to contain confidential documents or material, non-public information;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safeguarding laptop computers, mobile devices, tablets, memory sticks, CDs and other items that contain confidential information; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">avoiding the discussion of material, non-public information in places where the information could be overheard by others such as in elevators, restrooms, hallways, restaurants, airplanes or taxicabs.</font></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Personnel involved with material, non-public information, to the extent feasible, should conduct their business and activities in areas separate from other Company activities.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">V. </b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">ADDITIONAL PROHIBITED TRANSACTIONS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company has determined that there is a heightened legal risk and/or the appearance of improper or inappropriate conduct if the persons subject to this Policy engage in certain types of transactions, whether or not unlawful, are not consistent with a long-term investment in the Company or are designed to profit from fluctuations in the price of the Company&#8217;s securities. Therefore, Covered Persons shall comply with the following policies with respect to certain transactions in the Company securities:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">A. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Short Sales</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Short sales of the Company&#8217;s securities evidence an expectation on the part of the seller that the securities will decline in value, and therefore signal to the market that the seller has no confidence in the Company or its short-term prospects. In addition, short sales may reduce the seller&#8217;s incentive to improve the Company&#8217;s performance. For these reasons, short sales of the Company&#8217;s securities are prohibited by this Policy. In addition, Section 16(c) of the 1934 Act absolutely prohibits Section 16 reporting persons (i.e., directors, certain officers and the Company&#8217;s 10% stockholders) from making short sales of the Company&#8217;s equity securities, <i style="font-style:italic;">i.e.</i>, sales of shares that the insider does not own at the time of sale, or sales of shares against which the insider does not deliver the shares within 20 days after the sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">B. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Options</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">A transaction in options is, in effect, a bet on the short-term movement of the Company&#8217;s stock and therefore creates the appearance that Covered Persons are trading based on inside information. Transactions in options, whether traded on an exchange, on any other organized market or on an over-the-counter market, also may focus the Covered Person&#8217;s attention on short-term performance at the expense of the Company&#8217;s long-term objectives. Accordingly, transactions in puts, calls or other derivative securities involving the Company&#8217;s equity securities, on an exchange, on or in any other organized market or on an over-the-counter market, are prohibited by this Policy.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">C. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hedging Transactions</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Purchasing financial instruments, such as prepaid variable forward contracts, equity swaps, collars, and exchange funds, or otherwise engaging in transactions that hedge or offset, or are designed to hedge or offset, any decrease in the market value of the Company&#8217;s equity securities, may cause Covered Persons to no longer have the same objectives as the Company&#8217;s other stockholders. Therefore, all such transactions involving the Company&#8217;s equity securities, whether such securities were granted as compensation or are otherwise held, directly or indirectly, are prohibited by this Policy.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">D. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchases of the Company&#8217;s Securities on Margin; Pledging the Company&#8217;s Securities to Secure Margin or Other Loans</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Purchasing on margin means borrowing from a brokerage firm, bank or other entity in order to purchase the Company&#8217;s securities (other than in connection with a cashless exercise of stock options through a broker under the Company&#8217;s equity plans). Margin purchases of the Company&#8217;s securities are prohibited by this Policy. Pledging the Company&#8217;s securities as collateral to secure loans is prohibited. This prohibition means, among other things, that you cannot hold the Company&#8217;s securities in a &#8220;margin account&#8221; (which would allow you to borrow against your holdings to buy securities).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">E. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Director and Executive Officer Cashless Exercises</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company will not arrange with brokers to administer cashless exercises on behalf of directors and executive officers of the Company. Directors and executive officers of the Company may use the cashless exercise feature of their equity awards only if (i) the director or officer retains a broker independently of the Company, (ii) the Company&#8217;s involvement is limited to confirming that it will deliver the stock promptly upon payment of the exercise price, (iii) the director or officer uses a &#8220;T+2&#8221; cashless exercise arrangement, in which the Company agrees to deliver stock against the payment of the purchase price on the same day the sale of the stock underlying the equity award settles and (iv) the director or officer otherwise complies with this Policy. Under a T+2 cashless exercise, a broker, the issuer, and the issuer&#8217;s transfer agent work together to make all transactions settle simultaneously. This approach is to avoid any inference that the Company has &#8220;extended credit&#8221; in the form of a personal loan to the director or executive officer. Questions about cashless exercises should be directed to the Chief Financial Officer.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">F. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Partnership Distributions</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Nothing in this Policy is intended to limit the ability of a venture capital partnership or other similar entity with which a director is affiliated to distribute Company securities to its partners, members or other similar persons. It is the responsibility of each affected director and the affiliated entity, in consultation with their own counsel (as appropriate), to determine the timing of any distributions, based on all relevant facts and circumstances and applicable securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">VI. </b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">RULE 10B5-1 TRADING PLANS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">A. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Overview</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Rule 10b5-1 presents an opportunity for insiders to establish arrangements to sell (or purchase) Company stock without the restrictions of trading windows and blackout periods, even when there is undisclosed material information. Rule 10b5-1 will protect Covered Persons from insider trading liability under Rule 10b5-1 for transactions under a previously established contract, plan or instruction to trade in the Company&#8217;s stock (a &#8220;<font style="font-style:italic;font-weight:bold;">Trading Plan</font>&#8221;) entered into in good faith and in accordance with the terms of Rule 10b5-1 and all applicable state laws and will be exempt from the trading restrictions set forth in this Policy. The initiation of, and any modification to, any such Trading Plan will be deemed to be a transaction in the Company&#8217;s securities, and such initiation or modification is subject to all limitations and prohibitions relating to transactions in the Company&#8217;s securities. Each such Trading Plan, and any modification thereof, must be submitted to and pre-approved by the Company&#8217;s Chief Financial Officer, or such other person as the Board of Directors may designate from time to time (the &#8220;<font style="font-style:italic;font-weight:bold;">Authorizing Officer</font>&#8221;), who may impose such conditions on the implementation and operation of the Trading Plan as the Authorizing Officer deems necessary or advisable. However, compliance of the Trading Plan to the terms of Rule 10b5-1 and the execution of transactions pursuant to the Trading Plan are the sole responsibility of the person initiating the Trading Plan, not the Company or the Authorizing Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Trading Plans do not exempt individuals from complying with Section 16 short-swing profit rules or liability. Furthermore, Trading Plans only provide an &#8220;affirmative defense&#8221; in the event there is an insider trading lawsuit. It does not prevent someone from bringing a lawsuit.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Covered Persons may enter into a Trading Plan only when he or she is not in possession of material, non-public information, and only during a trading window period outside of the trading blackout period. Although transactions effected under a Trading Plan will not require further pre-clearance at the time of the trade, any transaction (including the quantity and price) made pursuant to a Trading Plan of a Section 16 reporting person must be reported to the Company promptly on the day of each trade to permit the Company&#8217;s filing coordinator to assist in the preparation and filing of a required Form 4. However, the ultimate responsibility, and liability, for timely filing remains with the Section 16 reporting person. The Company reserves the right from time to time to suspend, discontinue or otherwise prohibit any transaction in the Company&#8217;s securities, even pursuant to a previously approved Trading Plan, if the Authorizing Officer or the Board of Directors, in its discretion, determines that such suspension, discontinuation or other prohibition is in the best interests of the Company. Any Trading Plan submitted for approval hereunder should explicitly acknowledge the Company&#8217;s right to prohibit transactions in the Company&#8217;s securities. Failure to discontinue purchases and sales as directed shall constitute a violation of the terms of this Section VI and result in a loss of the exemption set forth herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Covered Persons may adopt Trading Plans with brokers that outline a pre-set plan for trading of the Company&#8217;s stock, including the exercise of options. Trades pursuant to a Trading Plan generally may occur at any time. However, the Company requires a cooling-off period of 30 calendar days between the establishment of a Trading Plan and commencement of any transactions under such plan. An individual may adopt more than one Trading Plan. Please review the following description of how a Trading Plan works.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Pursuant to Rule 10b5-1, an individual&#8217;s purchase or sale of securities will not be &#8220;on the basis of&#8221; material, non-public information if:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">First, before becoming aware of the information, the individual enters into a binding contract to purchase or sell the securities, provides instructions to another person to sell the securities or adopts a written plan for trading the securities (i.e., the Trading Plan).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Second, the Trading Plan must either:</font></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:90pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">specify the amount of securities to be purchased or sold, the price at which the securities are to be purchased or sold and the date on which the securities are to be purchased or sold;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:90pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">include a written formula or computer program for determining the amount, price and date of the transactions; or</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:90pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibit the individual from exercising any subsequent influence over the purchase or sale of the Company&#8217;s stock under the Trading Plan in question.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Third, the purchase or sale must occur pursuant to the Trading Plan and the individual must not enter into a corresponding hedging transaction or alter or deviate from the Trading Plan. For clarity, the requirements of this Section VI.A do not apply to any Trading Plan entered into by a venture capital partnership or other similar entity with which a director is affiliated. It is the responsibility of each such venture capital partnership or other entity, in consultation with their own counsel (as appropriate), to comply with applicable securities laws in connection with any Trading Plan.</font></td></tr></table><div style="margin-top:10pt;"></div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">B. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revocation of and Amendments to Trading Plans</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Revocation of Trading Plans should occur only in unusual circumstances. Effectiveness of any revocation or amendment of a Trading Plan will be subject to the prior review and approval of the Authorizing Officer. Revocation is effected upon written notice to the broker. Once a Trading Plan has been revoked, the participant should wait at least 30 calendar days before trading outside of a Trading Plan and 180 calendar days before establishing a new Trading Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">A person acting in good faith may amend a prior Trading Plan so long as such amendments are made outside of a quarterly trading blackout period and at a time when the Trading Plan participant does not possess material, non-public information. Plan amendments must not take effect for at least 30 calendar days after the plan amendments are made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Under certain circumstances, a Trading Plan <i style="font-style:italic;">must</i> be revoked. This may include circumstances such as the announcement of a merger or the occurrence of an event that would cause the transaction either to violate the law or to have an adverse effect on the Company. The Authorizing Officer or administrator of the Company&#8217;s stock plans is authorized to notify the broker in such circumstances, thereby insulating the insider in the event of revocation.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">C. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Discretionary Plans</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Although non-discretionary Trading Plans are preferred, discretionary Trading Plans, where the discretion or control over trading is transferred to a broker, are permitted if pre-approved by the Authorizing Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Authorizing Officer of the Company must pre-approve any Trading Plan, arrangement or trading instructions, etc., involving potential sales or purchases of the Company&#8217;s stock or option exercises, including but not limited to, blind trusts, discretionary accounts with banks or brokers, or limit orders. The actual transactions effected pursuant to a pre-approved Trading Plan will not be subject to further pre- clearance for transactions in the Company&#8217;s stock once the Trading Plan or other arrangement has been pre-approved.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">D. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reporting (if Required)</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">If required, an SEC Form 144 will be filled out and filed by the individual/brokerage firm in accordance with the existing rules regarding Form 144 filings. A footnote at the bottom of the Form 144</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">should indicate that the trades &#8220;are in accordance with a Trading Plan that complies with Rule 10b5-1 and expires <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u>.&#8221; For Section 16 reporting persons, Form 4s should be filed before the end of the second business day following the date that the broker, dealer or plan administrator informs the individual that a transaction was executed, provided that the date of such notification is not later than the third business day following the trade date. A similar footnote should be placed at the bottom of the Form 4 as outlined above.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">E. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Options</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Exercises of options for cash may be executed at any time. &#8220;Cashless exercise&#8221; option exercises through a broker are subject to trading windows. However, the Company will permit same day sales under Trading Plans. If a broker is required to execute a cashless exercise in accordance with a Trading Plan, then the Company must have exercise forms attached to the Trading Plan that are signed, undated and with the number of shares to be exercised left blank. Once a broker determines that the time is right to exercise the option and dispose of the shares in accordance with the Trading Plan, the broker will notify the Company in writing and the administrator of the Company&#8217;s stock plans will fill in the number of shares and the date of exercise on the previously signed exercise form. The insider should not be involved with this part of the exercise.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">F. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trades Outside of a Trading Plan</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">During an open trading window, trades differing from Trading Plan instructions that are already in place are allowed as long as the Trading Plan continues to be followed.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">G. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Public Announcements</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company may make a public announcement that Trading Plans are being implemented in accordance with Rule 10b5-1. It will consider in each case whether a public announcement of a particular Trading Plan should be made. It may also make public announcements or respond to inquiries from the media as transactions are made under a Trading Plan.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">H. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prohibited Transactions</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The transactions prohibited under Section V of this Policy, including among others short sales and hedging transactions, may not be carried out through a Trading Plan or other arrangement or trading instruction involving potential sales or purchases of the Company&#8217;s securities.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">I. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitation on Liability</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">None of the Company, the Chief Executive Officer, the Chief Financial Officer, the Authorizing Officer, the other Company Personnel or any other person will have any liability for any delay in reviewing, or refusal of, a Trading Plan submitted pursuant to this Section VI or a request for pre- clearance submitted pursuant to Section IV of this Policy. Notwithstanding any review of a Trading Plan pursuant to this Section VI or pre-clearance of a transaction pursuant to Section IV of this Policy, none of the Company, the Chief Financial Officer, the Authorizing Officer, the other Company Personnel or any other person assumes any liability for the legality or consequences of such Trading Plan or transaction to the person engaging in or adopting such Trading Plan or transaction.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">VII. </b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">EXECUTION AND RETURN OF CERTIFICATION OF COMPLIANCE</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">After reading this Policy and on an annual basis, all Company Personnel should execute and return to the Company&#8217;s Chief Financial Officer the Certification of Compliance form attached hereto as &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Attachment A</u>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 7pt 0pt;">* * * * *</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 7pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 7pt 0pt;">Effective Date: August 12, 2020</p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ATTACHMENT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION OF COMPLIANCE</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">INSIDER TRADING COMPLIANCE POLICY OF BIOXCEL THERAPEUTICS, INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;">I have received, reviewed and understand the above-referenced Insider Trading Compliance Policy and undertake, as a condition to my present and continued employment with (or, if I am not an employee, affiliation with) BioXcel Therapeutics, Inc., to comply fully with the policies and procedures contained therein.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NAME</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SIGNATURE</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">DATE</p></td></tr><tr><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TITLE</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Pre-Clearance Persons</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Executive officers </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All other employees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Persons Subject to Quarterly Blackout Periods</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Executive officers </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All other employees</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>6
<FILENAME>btai-20241231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/28/2025 07:21:40 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">OnkosXcel Therapeutics, LLC (Delaware)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">OnkosXcel Employee Holdings, LLC (Delaware)</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>btai-20241231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/28/2025 07:21:43 PM (UTC)--><html><head><meta charset="UTF-8"><title>Consent - Form 10-K or Form 8-K</title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:14.71%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#333333;font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#333333;font-size:12pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We consent to the incorporation by reference in the following Registration Statements:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statements (Form S-3 Nos. 333-265277, 333-275261, 333-276488 and 333-284224) of BioXcel Therapeutics, Inc., and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statements (Form S-8 Nos. 333-235282, 333-238580, 333-266922, 333-270652 and 333-278492) pertaining to the 2017 Equity Incentive Plan and the 2020 Incentive Award Plan and 2020 Employee Stock Purchase Plan of BioXcel Therapeutics, Inc. </font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">of our report dated March&#160;28, 2025, with respect to the consolidated financial statements of BioXcel Therapeutics, Inc. included in this Annual Report (Form 10-K) of BioXcel Therapeutics, Inc. for the year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:13.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Ernst &amp; Young, LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Stamford, Connecticut</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">March&#160;28, 2025</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:14.71%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:73.53%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>btai-20241231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/28/2025 07:21:43 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">I, Vimal Mehta, Ph.D., certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">1.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2024, of BioXcel Therapeutics,&#160;Inc.;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">2.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">3.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">4.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">a.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 27pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">b.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 27pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">c.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 27pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">d.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 27pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">5.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">a.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 45pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:5.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">b.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Date: March 28, 2025</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.82%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">/s/ Vimal Mehta</p></td></tr><tr><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Vimal Mehta, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>btai-20241231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/28/2025 07:21:44 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">I, Richard Steinhart, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">1.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2024, of BioXcel Therapeutics,&#160;Inc.;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">2.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">3.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">4.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:88.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">a.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:88.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:88.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">b.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:88.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">c.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:88.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:88.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">d.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:88.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">5.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:88.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">a.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:88.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">b.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:88.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:2.25pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Date: March 28, 2025</p></td><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.82%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">/s/ Richard Steinhart</p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Richard Steinhart</p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>btai-20241231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/28/2025 07:21:49 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In connection with the Annual Report on Form 10-K of BioXcel Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) for the fiscal year ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">(1)</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">the Report fully complies with the requirements of Section&#160;13(a)&#160;or Section 15(d)&#160;of the Securities Exchange Act of 1934, as amended; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 42.5pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">(2)</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:47.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:47.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:47.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:47.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Date: March 28, 2025</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">By:</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.11%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">/s/ Vimal Mehta</p></td></tr><tr><td style="vertical-align:top;width:47.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Vimal Mehta, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:47.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:47.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>btai-20241231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/28/2025 07:21:52 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In connection with the Annual Report on Form&#160;10-K of BioXcel Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) for the fiscal year ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">(1)</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">the Report fully complies with the requirements of Section&#160;13(a)&#160;or Section 15(d)&#160;of the Securities Exchange Act of 1934, as amended; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 42.5pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">(2)</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Date: March 28, 2025</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.82%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">/s/ Richard Steinhart</p></td></tr><tr><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Richard Steinhart</p></td></tr><tr><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>btai-20241231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 btai-20241231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (9 [L# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&#DJ/O#+"O5OV2OVH?$/Q6T[Q;X7\90);>./#43O)*D0C\]5)1RR#A71P 0
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M)IKN24445YYN%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?'G_  4[_P"2*:#_ -AM/_1,E>+>
M(AG]I;]FKC_F7M%_]&RU^C>N>'-*\36R6VKZ;::I;HV]8KR%95#=,@,#SR:K
M/X)\/27ME>-H>G-=V2+':SFU0O J\JJ'&5 R< =,U]#A<TCAZ$:+A>W-U_F5
MCAJ89SFYW[?@?$O_  5+^_\ "O\ Z[:C_P"VM=S_ ,%+;>2;]G71G1&=8M?M
M7<@9VK]GN%R?Q8#\:^I==\)Z)XH\C^V-(L=5^S[C#]LMTE\O.,[=P.,X'3T%
M6-9T/3O$6ESZ;JEC;ZCI\Z[9;6YC$D;CK@J>#T%9T<RC26&7+_";?K=W*EAW
M)U'?XK?@?#_CK5M/^._[ ]AIW@^XEU74O!^G:4NIVL43AHW@@42K@CYL ,<C
M(^7VKQ'PWK'[/EM\&;.[UJ?Q5>>,8H5@N?#]O?2Q)-)G#%6VE%3'///;%?I[
MX0\ >&OA_936GAK0K#0K69M\D5A;K$KMZD <UC/\#OA[)KG]LMX*T)M4W;_M
M9T^+?GUSCK791S:E24J:4E'FYE9V>NZ?EZ:F,L+*34KJ]K;'R)\4O@W#K/["
M%FW@WPWK&C6UOJ"^(_[)U.3S[KRMKH[<#IL;S!QG Z55M?VV/"^H_LN_\(9:
MZ=J5WXU.@MI!L(;8F-2(C&9B_(V!1O/?C''6OKSX[>'O&/B/X8:I9^ -6_L7
MQ2FR6SF#!0Y1@3%D@@;@"O/'/.!S7Q?#?_M"1^"=5\&3?!:SF\0:G;3V%QXG
M2RBAD>*4%6R\96+< ?O;L< D'OU8.K#&4KUK.T^9)SLU?O?=?.YG5BZ4O<OJ
MK;7_ .&*7P.1A_P3S^*K%2%:XEP<<'_4U](?\$^@!^RYX;XZW-[G_P "9*W?
MV6/@)-\(?@?!X3\3):ZC>7LTEY?VI42PHS[?W7(PVT*,GIG.,C!KV32-&L-
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M.]L-\O QR*\3_8R_: \.?LUZ3XO\ ?$?S_#FHP:H]XKR6SR;G\M(WC.T$_\
M+)2IZ'<>:_0+1-!TWPWIT5AI-A;:;8Q<);VL2QHOT &*P_%OPI\&>/+A)_$7
MA;2=:G3&V6]LTD<8Z<D9K&./PUJE%TVJ4K:)ZIKK=]^I;HU/=FI>\ON/B_\
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M]XPU;Q]\8M<4'4/$-_);VP[*N\R3$?[.YD0>GEGUJ']JZ3XY?&/5-4^%^A>
MO*\+2WT9_MX'$=U"I5TW.QVH%;!;&6)3CT/U'\&/AI;_  @^&/A_PE;R+/\
MV=;!)IU&!-*?FD?'H6)Q[8KOK8CV&60HR:<Y::.[Y-]>VO0QA#GQ#FEHOSV.
M6_:WT;6M?_9S\<6/A])9-3DLU*QP9WO&LB-*HQUS&'&.^:^(/AW\9?@A_P ,
MK2_#SQCI=_;ZTKS7$CV-H&F>ZR?+G20G 8*0N&XP"#Q7Z>UPVJ? SX>:UJW]
MJ7W@G0;O4-V\W,MA&7)ZY)QUKAP./I4*/L:L7;FYDXNSNE;[C:M0E.7/%K:V
MI^6W[-7B>/PG\;/A[J_CBPUS4=&MU:#0@(68 F1Q&8U;[\:RR2'"'A_7!!_8
M$'(!]?6LNX\*:+=OIC3:392-ICB2Q+6ZG[,V,9CX^7@XXK5K/,\?',*D:BAR
MM*V]^O\ 5QX>@Z$7%NY^;/Q;^(6D?"G_ (*077BK7FF32=/\AIVMX_,<!]*6
M,87O\SBNH_:;_;;\-_%_X;7G@/P!IFKZKJFN/%;L[VFW";P2J("6=V(4  =^
MO8_;NK?#OPMKU_)?:EX<TK4+V7&^XN;..21L  98C)P !^%/T?P%X:\/78NM
M+\/Z7IUR 0)K6SCC<#Z@9KM6985NC4G2;G3BDM=-/EW,OJ]3WHQE92;>W<^.
M?B5^S;X@T#]@/3O#$-L9?$&CSKKM]9QJ"[$M(94&.I1)??(CP.<5X3X=UC]G
MR'X+65[K,WBBZ\8PP);77AZ'498TGD'RLZ-L*+&<;@#R,XQWK]62,C!Y%<3)
M\#_A[+K?]L/X*T%M3SN^U'3XM^?7.VGA\XY8RC73UDY>Z[;[I^7XA/"W:<+;
M6UU//?@?\-/#FO\ [+R>'+'0M1T30/$%G<,NG:U,)IXEFSA\CH#PZ]",@]:_
M/?P'X7\4?$#Q]X8^ FJ-(NE:-XCNWNH8V(*X(%P3R1\JQ2;2.AD8]Z_8
M 8 ["LJ#PEH=MK<FLPZ/8Q:M)G??);H)VR,'+XR<CWK'"YM+#NJW&_-JM=GK
MKY[E5,,JG*K[?BCY0_X*2^!+S4/@KX?O=(LB=-T"_7SX;=2$@A9/+4[1P%!V
MKGMGWKYWUK6/V;XO FC36J^,?$VN7?E1W&@IJ$D1A;'S$EE*'##@+G/'2OU*
MFACN89(98UEBD4HZ.,JP/!!!ZBN-TCX)^ - UO\ MC3O!FAV6J;MPNX+&-9
M?4$#@U>#S6-"A&C44O=;:Y7:]^C_ . *KAG.;G&VO=?D?'/[;7AJS\(?LE_#
M;2;#3;S1K2"]C,>GZBX>XM]T,CF.0C@L"Q!K6_;+^&.J>-?V5?ASKVE02W;^
M';2"6ZMXADBWDMT#28[[61/P9CT%?:>N>&])\36R6^KZ9::I C;UBO(%E56Q
MC(# \U=BM(8+5+:.%([=$$:Q*H"A<8P!TQCM65/-94E2:C[T)2EZ\VZ_X)4L
M,I<UWHTE]Q\5>-?V\? /B?\ 9KU.R$L@\9:KHDFF2:+%:LJQ7$D)C9@V-GE
ML2.<D # KSVR^&6K_#K_ ()N^-9M;MWL[O6]0M-1BMI#AD@-U:K&67^%FVEL
M>A7//%?<L7P0^'L&MC5X_!6@IJ8.1=+I\0<'Z[:Y+]KWP)KGQ)_9Z\4>'/#5
M@=3UF[-IY%JLB1E]EU$[<N0HPJL>3VKJH8_#QJ4Z-"+C%SC*3;[/;T7F9SHU
M'&4YN[2:5CYO_9R_;/\  _PT_9NL] \0-=6NOZ/;3I;6*V[G[<K.[(4?&T9+
M8))&,=ZY']G/P7JN@_L1?&C7+ZU>VLM:M7^Q&0$&5(D96<?[.YBH/JIKZF^
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M= CU*5&MR1SRR%7PV  .N>U?IEI?@_0M$LKFST_1K"QM+G_7P6]LB)+QCYE
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M;V R[GW9BS'W)K?HK.5=NBJ"5DG?U>WX(UCA8K$RQ4G>32BO);V^;U^XYY/
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MJ**F4Y3?-)W9=.G"E'D@K(****@T"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0!AT44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%-DD2&-I)&"(HRS,< #U)H =17B_B3]KKX=>'=2DLEO[G57C)5Y-/@\R
M,$>CD@-]5R/>LG_AMCX??\\M7_\  5?_ (NO5CE..FE)496]#P)\0953DXRQ
M,;KS/?J*\!_X;8^'W_/+5_\ P%7_ .+H_P"&V/A]_P \M7_\!5_^+J_[(Q__
M #YE]Q'^L64?]!,?O/?J*\!_X;8^'W_/+5__  %7_P"+H_X;8^'W_/+5_P#P
M%7_XNC^R,?\ \^9?<'^L64?]!,?O/?J*\!_X;8^'W_/+5_\ P%7_ .+H_P"&
MV/A]_P \M7_\!5_^+H_LC'_\^9?<'^L64?\ 03'[SWZBO ?^&V/A]_SRU?\
M\!5_^+H_X;8^'W_/+5__  %7_P"+H_LC'_\ /F7W!_K%E'_03'[SWZBO ?\
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M8^'W_/+5_P#P%7_XNC^R,?\ \^9?<'^L64?]!,?O/?J*\!_X;8^'W_/+5_\
MP%7_ .+H_P"&V/A]_P \M7_\!5_^+H_LC'_\^9?<'^L64?\ 03'[SWZBO ?^
M&V/A]_SRU?\ \!5_^+H_X;8^'W_/+5__  %7_P"+H_LC'_\ /F7W!_K%E'_0
M3'[SWZBO ?\ AMCX??\ /+5__ 5?_BZ/^&V/A]_SRU?_ ,!5_P#BZ/[(Q_\
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MA]_SRU?_ ,!5_P#BZ/[(Q_\ SYE]P?ZQ91_T$Q^\]^HKP'_AMCX??\\M7_\
M 5?_ (NC_AMCX??\\M7_ / 5?_BZ/[(Q_P#SYE]P?ZQ91_T$Q^\]^HKP'_AM
MCX??\\M7_P# 5?\ XNM'0OVPOASK5_':R7EYIAD(59KVV*QY)QRRDX^IP/>I
MEE./BKNC+[BH\093.2BL3"[\SVVBH[>XBNX(YX)$FAD4,DD;!E8'H01U%25Y
M.Q[Z=]4%%%% PKP']M#QC>>&OA?;V%C*T#:O=BWF=3@^4JEF4'W(4?3([U[]
M7S!^WA_R)_AC_K_D_P#1=>UDL(U,PHQDKJ_Y*Y\QQ-4G2R?$2@[.UOO:3_!G
MQ=1117[<?R\%%:'A[0[GQ-K^F:/9[/M>H745I#YAPN^1PJY/89(KU'Q/^RQX
MW\,:1J&H'^S-333U+W4&G7JRS1*/O,4X/'?'-<M7%4:,E"I-)O:YW4,#BL33
ME5HTW*,=VE>W4\>HKU6V_9I\:7?B:318XK(20V,6H3W;W(2W@BD^YO<@8)P>
M.O!]#65XD^!?C'PSXMTKPY+IHO+_ %8;K!K&598KE>Y5QQ@8R<XP.3QS41QN
M&E+E517M??IO^6IK/+,;"//*C*U[;/>]K??IZZ'G]%>G^-_V<_&/@30SJ]W#
M9W]E'(L4[:;=+.UN['"JZCD9/'&>:TW_ &4?B FD&\^QV1NQ#]H.DB\3[:$Q
MGF+UQVSGMC/%3]?PO*I>U5GIN7_9./YW#V$KI7>CV_I/[F>.T5U/BOX<:QX/
MTOP[J%ZL4MMKMO\ :+-K=B_0@-&W'#J2 5[&NVL/V7O%U]K6N:6;O1K:XT46
M_P!L:XO0D:-,I9%W$8SA3D=C5RQF'A'GE-)?Y.S_ !=O4RIY=BZLW3A2;:MI
M;NG)?>DWZ(\@HKVFW_9/\77=W>00ZGX>D%I#'/-.NI Q(KLZJ"V, Y0\?2H+
MO]E3QQ:WL=NHTRY\^UFNK66WO%=+GR@"\<9 ^_@@X.,\\\'&7]HX1NWM5]YT
M/)LQ2YO82MZ>=OST]3QVBNI7X<:N/ ,_C";[/:Z3'=BQC$\FV6>7J5C3'.T9
M)],&N6KNA.,[\KO;3YGEU*4Z5N=6NKKT[A5C3M0N=)OK>]LYY+:ZMW$D4T3%
M61@<@@CI5>BJ:35F9IN+NMS]4_ FO/XI\%Z%K$@Q)?645P^!CYF0$_K6[7%_
M!3_DD7@__L%V_P#Z *[2OP#$14*TXQV3?YG]>8.<JF&ISENXI_@%%%%<YUA1
M110 4444 %%%% !7A_[87C"\\*?")HK%VBEU6\2Q>53@K&4=VQ]=FWZ,:]PK
MYP_;I_Y)?HG_ &&$_P#1$U>QE$(SQ]&,E=7/G.(ZDZ64XB<'9\K_ !T/AZGQ
M1--*D:#<[D*H'<GI3*N:/_R%['_KNG_H0K]O;LKG\N15VD=)JWPB\8:'XHTW
MP[?:%<P:SJ*AK6T(!:4$D9&#C^$_E5^Q^ OCW4M:U32;;PY<RZAIAC%Y "N8
M?,0.F>>ZD&OL_P")&LZ<VH^(?%TLL:ZOX":YM[96/)-U;1B$GV\QB!_P*L77
M;"TUKQ3\<[:]T&]\3VLQT0MI6G.5GGQ# 1M(Y^4@,?937Q<,\Q$XIN"6BOZ\
MT5W6G+)/=:]3],J\+82G4E%5&_>=MOA4)O6T6[\\''1/1:)L^2;KX#^/;/7K
M31I/#-Y_:=U$TT5NH#$HI 9B0<  D<GUJ*_^"'CG2]<MM(NO#EY#J%S%)/#$
MP&)$0$N0<X. "3S7T9HWA06_A#QWH/@[PCJO@3Q+JUA;M96FJ7!6XO4CD?SQ
M#(Q'\+H"N1U%0?!+P;XO\#>)/!<'C'56^R26^I/;>')Y=T]K&+=\OWVANF,\
M9Z5U/-JJA.5XWC?3J_=O=6;5NF[V>JV."/#]"52G#EG:35Y)^['WE&SO&+O;
M79/5>ZUJ?+%AX3U;4]$U35[6RDFTW3&C6\N!C;"7)"9^I!_*KNI?#KQ'H_A.
MQ\37FDSP:%?,$M[U@-DA.<8[\[3^5?2O@ZR\*_$SX3^.M"\ >'KS0;J\OM.M
MIS>W1G#LTK!6Z\!1O)]OI75:R/#/C]O&7PVT[Q5:WX32HK/1]%2VF22VGLU+
M%O,90C,6W9VGD<=JN>;SC4<7"W*];K51M'5VNENWVLNYG2X=I5*49JJFY1]U
MII*4[SLES)-KW4FDKWDNA\BW_P ,/%&EWVA6=UH]Q#<:ZJ/IR-C_ $D/C;M.
M<<[E_,58G^#_ (QMIM/B;0+II;^ZELK9$4,TLT9(D4 '^':V?H:^T+75]'\1
M>)/A[X&UM$MM1L=,TO6M(O"!N$T:CS82?]I5X^GJ!535I=6BO_!+Z'=:?;ZD
M/$.N^6FI.5BG!DF#19'(9E)P?6N7^VZ^D7!)V;UO;:33]--?F=_^J^%M*2J2
M:32TM=.\%)-=_>NNZL?(6O?!'QSX8N-.AU/PY>6CZC.MK;%P"LDK=$R#@$^A
M]ZU+G]FKXE6=M+<3>%+N.&-2[N63  &2>M>N?%KPI)9_ [7+R;2M5^'[IJD;
M/H5]J*W=MJ$I;YI(MPW@C[VX<$ ]>HY#Q61_PHOX+_\ 80O/_1ZUW4L?7K1@
MXN.LG%Z7VBY=)6Z6T;]>AY5;*<)AYU(SC+2"FO>2WDHV=X)];ZJ+Z6ZGG5G\
M&?&NH>*+_P .VWAZ\GUBP56NK=%!\D,H9=QS@9!!'-8WB_P1KO@+4UT_Q!ID
M^EW;()%CG7&Y3W!Z$<=J^Q_B_I^H^+K7XM^'O";[_$IU6PN+JS@D"3W-I]BB
M!51G+#/8=<$=\5\W_&;PQXL\(:+X1T[Q;KRWUTMK))!H[R>9-IL9*C:Y[;L#
M R?ND=JO YC/%2ASN*O;W=>;X5*_IK_P;Z&>:9-2P$*CIJ<N5OWM.7XW'E?G
M9='O]FVIY94UI=S6%U#<VTKP7$+AXY(SAE8'((-0T5]"U?1GQZ;3NC]2_AIX
MAF\6?#[P[K%R,7%[8PSR8_O%1G]:Z6N$^!'_ "1KP9_V"X/_ $$5W=?@&)BH
M5ZD8[)O\S^NL#.53"TIR=VXQ;^Y!1117,=H4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >>_M ^)[KP=\'/$^
MJV4ABNXX%BCD4X*&21(]P]QOS7YI,Q=BS$LQ.22<DFOT3_:Q_P"3?_%/_;K_
M .E<-?G77ZGPI&*PDYVU<OR2_P S\&\0*DGF-*FWHH)_-RE?\D;G@_P5K7CW
M5_[+T"PDU*_\MI?)BQG8,9/)]Q72ZO\  'X@:";+[=X8O(!>7*6D+$*0TKG"
M+D'@D\<UV'[(4EO#\2M7>[C::U70+TRQ*VTNFU=P![$C->T> M1T2X\&^$9?
MAMI#6GA^Z\56/]MPW=V\UQ:2+*NS"G("M\OS _AW'HXW,:^&KN$(IQ5MUWON
M[Z;::.^QXN5Y-A<;A8U:LVI/FT3UTY=H\KOOJ^966MF?-FL?L\_$/0-+N]1O
M_#-U;65I$TTTK,N$11DG@^E1_P##/WQ$_L7^U?\ A$]1^Q>5YV[R_FV8SG;]
M[I[5]&^,/"?AJR^(EYK-S\*?$<1@U5;NXU^69VM-BS!I)BN<;-H8UIZ1\+]:
MUCXY>)O$&NZKXEM;6XF,VC:]H5[ MG'9,6.QVD#  +Y8V@=03@]:X_[9JJ'/
M)Q6E]5OMHK2??U_NGI?ZMT'5]G!2>O+H]M_>;=./:R6U_M'RC8?!OQGJFKVN
MEVGA^[GOKFR348XD .;=\[9"<X .#UJ2;X)^-[?Q3;^')?#MW'K-Q$T\-LX
M,B+U93G!Q]:^N?%MMJB?$&]L_#\%GXIL&\%6,$^DS7GD7.HP>;, T,J# 8#D
M\8.< <BO#OVE_#O]C>$_ LI&IZ,'CN$C\,ZM=K<RV" J0RN/F"M_=8Y&,#'0
M=&&S2MB*L*?NKF7J[VOM>_X6_O7T./&Y%A\'0J5?>ER/7HFN91T?*UU[WO\
M9:U.+N?V;?B39F$3>%;M#-((D!9/F8]!U]JI>(_@+X^\):/<:KJOAF\M=/MP
M#-.0K!!G&3@G KW: C_AJKX4<_\ ,!L/_262M"TDT37_ (=_$.'X5Z!)#XAN
M[C[#JUE?7KR/Y32$>=$G(;)+>F.>O2LWF>)@X<R3346W:R5Y-:MRTVWLS99%
M@:BJ<CDG%S27,FWRQ4M$H:[ZJZLM;L^7T^&_B63P>OBE=(N#H#2"$7V!LW%M
MN/7KQFNL'[,GQ-*;_P#A$[O;USN3_P"*KZ7M[/PLNL'X1OXPM)(/[ _L(Z-]
MEF#?;\&4W D*^7NW8(&[L!UKP+6M-GT;]EJ;3[I?+N;7QTT,B'LRV;@_J*UI
M9E7KNT;1NU:\7K&6SW79WZ'/7R7"X2+E-N=HN]I1TG&W,M%+356O9K6Z.#B^
M$GB^?Q';Z#%H-U+JUQ;K=QVR*"QA89#G!P![FI/$/P<\9^%-0TZRU;P_=V4^
MHRB&U#J-LKDX"A@<9]J^M=<%QJQ\7Z!X?N5M?&>H^$M(_L\B8122QIN,T<;D
MC!(([C.1Z5R7PZT/6OA_\,+#2/'(>UOM0\4:<^A:=>2AYH2DJF60+DE%*[QV
MZ_[0SE'-ZLH\UHWT7+K=W5[K79>G1ZF\^'</&?(G*WO/FTY5RNW*]/B=M-5\
M4=&?-K_##Q1%XCU'07T:X35M/@:ZN;5@ T<2J&9SSTP0>*Y:OO\ >_T7Q_XD
M^(NL*T=KXI\,V>JZ-=Q+Q]JM2'\B3ZKM*Y^N>U? %>GEV.GC.95(V<5&_J_T
MV:]3Q,YRNEEO(Z4^:,W*S\DTOO3NGYH*_1G]E[Q7>>+_ (-:-<W\K3W5LTEH
MTKG)<(V%)/KMQ^5?G-7W[^QE_P D3MO^OZX_F*\?BF,7@HR:U4E^3/H^ ZDH
MYG*">C@[_)JQ[G1117Y0?T %%%% !1110 4444 >=_M"^*[KP7\'?$FJ6+F.
M\6%((G4X*&218]P]P')_"OS49F=BS$LQ.22>2:_0[]K?_D@GB+_?M?\ THCK
M\\*_4^%(16#G.VKE^27^9^"\?U)/,:5-O103MYN4K_D@HHHK[4_,0JQI]A/J
MM_;65K&9KJYE6&*->KNQ 4?B2*KUTOPR_P"2D>%/^PM:?^CDK.I)P@Y+HC:C
M!5*D8/JTBP?A1XL'BNY\-'1+A=<MX3<2V9P'6,*&+=<8P0:V[3]G3XC7VF0Z
MA;^%;R:TFB$\;IM.]",@@9STK[,L=7T/QW\4_%=PZQVGBOPI#=V#[1C[792)
ME&]RC9'MG_:KRWQ+X$\9:W\2_A/K7AVRO%L;71=.%SJ41\N&-%8M(K/D#[O;
MOFODH9U6J-1DHP?+=WO:]F]-5H]+>I^AU>&<-2BYP<JB<FERVO:Z6NCU3NGM
MMT1\P>$_AWXC\<:M=:9HFD7%_?VJ%YX$7#1@':=P.,<G%8%Q!):SR0RH8Y8V
M*.C=5(."#7V]K^H^'? ,OB/Q5#XIM/#=WXH\1K<6MVUO+.L]M:.I=5$2L=KR
M[B3T8$=:^>?VG_"-KX=^)]QJ>ENLVA^(84U:QE3[I609<?\ ?6XX]"*]/!YE
M+%5N24;)K31[JW,K[/5O;L[GA9EDD<#AO:0GS2B_>U6SORNRU5TD]?YE8\CH
MHHKWCY,**** /M_]A_Q5>:SX$U?2;J5I8M*N4%N6.=J2*3M'L"I_.OI&OE/]
M@K_D#^,?^N]M_P"@R5]65^*Y[&,,QJJ*ZK\4F?T[PK4E4R;#RF[NS7W2:7X!
M1117@GU85\P?MX?\B?X8_P"O^3_T77T_7S!^WA_R)_AC_K_D_P#1=>[D7_(Q
MH^K_ "9\IQ5_R)<1Z+_TI'Q=1117[6?S$==\'W6+XM>"7=@B+KEB2S'  \].
M:^F=.\'7OPT^+_C_ ,?>(KRPL/#-S!?B ?;HW>],OW$$:L6YZX([5\<45Y6+
MP4L3.ZG9-<KTOI>^COI]S/?R_,XX&FHNGS24N:+O9)VMJK.Z^:/N'Q#=7-_\
M0-8@T34M$O;FY\.Z:C^&M:5#;ZH@#' D+ *Z$]#_ 'ORH6NI>%_AYX]\&+J=
MU;>'M5O-*OK"XTVVU)KRST>23'E2*Q8^5N P0IQ\WH":^+:*\]9*K<CJ:6MH
MK/:W>WGJF^E[:'KRXF?-[145S7NKNZ7O<VFET^FC2Z\M]3Z.\+_#:?X)RCQ-
MXQ\4V]C:PZM9SPZ7I]VMS_:B)-N=V1&Z*,,,Y[Y XSUH^'MZG[09^)Y\4Z5#
MX+%[_:?]KKJ"$O%C/D;,[LG[A&,8)^E?(E%=,\NJU&YRJ^]).+]U6L[;*^^F
M[;]-CBIYQ0I1C3C0]V+4E[[OS*^K=M5KLE';>]V_L3X4^(?"OQ-T36;S6IHK
M*T\'>)9_$MG&X&[[)(TDODJ..-X!P.ZKZUSWP:U6\^)WA[XL7TVA6'B74=5U
M*QNO[*U"]^S1L-\Q^_N7[@QCGL*^7**EY3&T^2=N9JWE9IO9IZM7>J-(\03O
M2=2FGRJ2E9KWKQ<4]4U[L79*S1]?Z;8Q?#GPC\2KK7_ NCZ99S66G,NA6NJ&
M>*Y FF#,761F!Y'&>PKG/C1XSN=-\-?#;Q1X >TTKP?9.9[6QM 1-9WN?WB3
M9)W _, >_P ^<Y&?F.BG3RM1J*K.5W?5:V:Y>79MZ^>_0FKGTI470I4^56LG
M=<R?.YWNHQTUMRV2T3W/=?VN/%+:MXXTW2[9;>WTBST^*XAM;0!8EEG'FRM@
M<9+-S]*\*HHKT\+06%HQHQZ?CY_,\/'8N6.Q,\3)6YGMV[+Y+0****ZC@/T\
M^"G_ "2+P?\ ]@NW_P#0!7:5Q?P4_P"21>#_ /L%V_\ Z *[2OP'%?[Q4]7^
M9_76 _W2C_AC^2"BBBN4[@HHHH **** "BBB@ KYP_;I_P"27Z)_V&$_]$35
M]'U\X?MT_P#)+]$_[#"?^B)J]K)?^1A1]3YCB;_D3XG_  _JCX>I02I!!P1T
M(I**_;C^7BW+J]],)Q)>W$@G(,NZ5CYA'3=SSCWK1T*[US5]<M[.PU&Z%_J$
MT< ;[2RF1B0J[FS]!STK#KIOABZQ_$;PPS$*HU*W)). /WBUC5M&G*26R.J@
MW.K"+;U:_/\ X)UGB'X1_$/1])UG7KYYIK?P_>&RNITO3(\$F%R5YSM^9<D5
M+I_P1^(NM7NGW41+/=Z8-26^FU!46*U8D O(S#;GGC/K7TMX@^)FG^ =.\7W
M5\D.HZ-?>,Y;+4;7(?S;22W57('?'7WQCO4WC'3EBU73=%\(:_HEW"/"T<$&
MC:VHDM]6A$S$*7WKM95.01S].2/CEFN)LE*"5]G9VM97]+-^FO2S/T>608+F
MDXU)2M:\;J][M)J^Z:5N]UI>Z1\PVOP-^(.F>+=,\.V>(;S6(FN;.:UOU^SW
M*(,EA(K;3C/Z^]5?!WP2\;^)K >(+!8=-M6F:&+4+Z_2T\Z3)4B-F8%CG(R/
M>OICPII6E^&_BO\ #%9C;:%K"P7YNO#]IJ;75G9JR AT#$B(N<Y4=<=\5Q\G
MAVQ^-WAKX<S:<UKJEAX=CELM8T$WZVDZL6^^"Q'!QG</\:W6:5GO9)I7E;_'
MYVUY4EK;7<Y7D6'BO=YG)-VCS:[4W_+=<O/)M<M]-M&>)^+_ (3>//!>G7>N
M:[%-:+IMW'8F5[K=(KLNY-A!.5(Z$'%7=+^"WC7Q#9Z)<'4;*&/4H?MU@+_5
MDB+[GQE0S?>+=AS7TK\4-=\$^ _A+J4<%I#XWLX=4MHIM.O]7DN1#-Y1R!+D
MGY,8P.!GM7E_Q6US3]<U'X$WMA96^D6CPHPL()2Z6P^T)\N3S^=5A\QQ.(C&
MT+7;5[::1OM>_P"EC/%Y-@L).=ZCE91?*I:ZSY;\W+9JWSNMCA]5_9^^(5YK
ML.BSW=GJNH*)'D@75XYC:*F-[2Y;]V!N49..3BN6\?\ PT\5?#RQTN76-DNE
MW.XV5U9WBW%L2#\P5D) /Y5[+8&ZO/VG?B0NDZUI-E>W(NH8K35XA):ZFK,N
MZW8[EQG .<_PUF_M"Z!::#\,O#<=W!:^'?$#7LAD\.Z5JC7%F(]O,ZQ%F$9)
M]">O4]NBCC:WMJ5*;3YDG9+75-]]O-)KO8Y,3EF&^K5Z])23@Y*[E=>[)*WP
M[O>S:>UKH^?UU>^6]:\%[<"[88,XE;S#QC[V<]A4-U=SWLS37$TD\K=9)6+,
M?Q-145]+9+5(^)<I-6;"BBBF2?IK\"/^2->#/^P7!_Z"*[NN$^!'_)&O!G_8
M+@_]!%=W7X%B_P#>:G^)_F?UQEW^Y4?\,?R04445R'H!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y'^UC_R
M;_XI_P"W7_TKAK\ZZ_13]K'_ )-_\4_]NO\ Z5PU^==?JO"G^Y3_ ,;_ "B?
M@7'_ /R-*?\ U[7_ *5,FMKN>R=GMYI('92A:)RI(/4<=JDL]4O=/5EM;N>V
M5R"PAE9 2.A.#VJK17V32>Y^;*36S-*7Q-K$\3QRZK?21N-K(]RY##T(S40U
MK41:?91?W(M<;?(\YMF/3;G%4J*GDBNA3J3>\F>S#]GSQU'9+K*ZYHPM83]E
M6^77X=J$#/E!]^ <'.W/0TV;]FSQ]J\U@;F\TN>^OH$FM8+K68O/E1AE=JLV
M3FDMYX_^&1YXO,7S?^$Q9MF?FQ]DBYQZ5[]+XU\'V_C7X>Z1JFC:<=;E\/61
MTWQ'<NTBVMSL_=H\8905W#KN!R1^'RM;&8RBWRVDTY+2/2*6OQ>?3Y7/OL-E
MN78E)3;BFH/6?63:M\.^FE].[1\L>*/ASXQ\&:;IFN:LLUJ9[F73[=OM&9TD
MB)5DP#E0,$#M5WQ/\(_'/PSU71(+Y7T^[UYA';26]W]]BRC:[*>#EER#7U!+
MX6F\1:;X%_X36\MB^CZSJ>KZO(CKL=8V9UVC^ZQV8']VL2RUCPM\8M U&/2]
M?O-5U?2O$,/B.'^TK9;9HT>91+&GS'<H7)QQ@A:B.;579N*:3:DTG;=J.ORN
M[[HTGD%"+DE-J32<$Y).ZBI3NMV];*VS6I\I^+/#^M>"O&=[I6INZ:Y9SA97
MBFWMYA .0X/)Y'-=UK7[/7Q%L-#O;J\ACF%M%_:%WIZZC')<Q*1_K7A#;LX/
M7&:[KX_?!'Q/JGQ/\4^+HA:1^'S/]K-Z+R)F2)47<_E[MQ(VDXQDXKTB]\/3
M7DGB#6/%-QH#:9)I3^7XZT*_:QO+H>6 JR1K(0^XA05. <#KTK>IFC]G2J4Y
M1;:U6[OIHM5W>E[]D]3FHY$O;XBE6C-)-\KO96][WGH^RULH[W:T/BTZI>M<
MQW!NYS<1@*DIE;<H'0 YR*6XU>^NYXYY[VXFFC^Y))*S,OT)/%53UI*^GY5V
M/A.>6URTFJ7D4TTR7<Z2S@B619&#2 ]0QSSGWJK113LEL)MO<*^_?V,O^2)V
MW_7]<?S%? 5??O[&7_)$[;_K^N/YBOD>*/\ <%_B7Y,_1.!/^1L_\#_-'N=%
M%%?DQ_084444 %%%% !1110!X]^UO_R03Q%_OVO_ *41U^>%?H?^UO\ \D$\
M1?[]K_Z41U^>%?JW"O\ N,O\3_*)^ \??\C2'_7M?^E2/1_"'P!\8>-="M-8
ML;:SM[&]D:*T:^O8K=KIP<$1J[ MR,5CWGPJ\2:=H&O:O=V0M;;0[Q;"^25P
M)(YF( &WN.>HXKW_ .$^BZIXD^&OA&.'_A&O&^CVT\@FLM0E^QWNBL7R=DPD
MSC^+.WTQ[6K_ $C2O&^C_%WP/X6\11ZOJ4VJ6E]:/J=_O>Y5%02*LKG]YL92
MH.>FWGO74\SJQK2C*UD]='HN9)WUT=G?5)=5=' LCP\\/"I!2YI1=M5[TN1R
M5E:S5U;1M]'9GB'AG]G[Q?XLL-*O;&"S%KJ=M/=P23W:1CRH659&;)^7!8=:
MMO\ LY^-K:;29;1+"^BOKQ;."\T[48IHTG()56=&.T\=37TU\/(;?PO_ ,(I
MX)NIM/U/6]-\,:F;VQ2Z7RPTTD12%G!P"V".O Y[BKWA73++0=+T&WU#1M,^
M'LZ^(K>>#3=-U-+E=0;:02_<;02>O\.:X*F<XB,I62MK;3=7E9[WV2>B:[V/
M6H\-8.<(\SDGI?79VBVOALM6U9R3Z*[/E>Q^"/Q!N/B=?^$8%9/$L4'GW#?;
M-H:,A3DR9YSN%-_X59\1FCLK6&2YN!=ZG-HL-O%?$YGBSO7&[ 4 'D\8%?5-
MMXHTE=9T[Q9'=Q_VUJFO1>&9?G&5AAU"5RQ/N@1?H*Y&ZU#:N@&S\1VGAV['
MCS5FBU"X02QH2'VAUW#Y7^[G(^]51S3$3>L$K*VSW2=_.UT9SR+!TU[M23N[
MZ27PN4;+6RO9ZW:5^Q\]>./@IXT\(Z'!J&I+#?Z7#/\ 8Q)97R726\I/^K(5
MCL)/:M#7OV>/B'I^BSWE]!#<#3;83S6"ZA'+<VL)&<F(,64>P%>L?$+PM'HG
MPPU:;Q%;Z/X&U9]1M?LW_"-:B[6VH?O/GD>U#D8C7Y@?T7OU>H^')K@>)M6\
M53>'UTZ72Y/*\<:!J#65W> H-JR1*Y$FXA05X!P.M;?VI54(RNMVMM_AV]ZS
MW>SOY;G/_8.'=2<&I+W4_BV^+XO=NOA5KI1_O:IGS#:?!#Q?J.I>';"STT7=
MUKUBNHV:12J1Y!_C<DX0>N:L^)_@%XO\*Z=#J%Q:VMYITEPMHUWI]Y'<1Q2L
MP4*Y0G;R0.>]?1.C:[IATKPMX?DU6VTK4->^'(TRROII B13L3A&;^'=_05R
M_@CPK-\!? /BJV\6ZA8"[\0RVMGI^F6UTLS2.LN3,0N<  YR?3U(K19G7OK:
M]TE&SO)7:;6O3T>VIB\CPB6G,U9MRNK0:BFDU;7F>VJW5KM'C]W^S_XSL?B%
M9^"Y["*/7+N+SX%:=?+D3!.0_3L?RKSJ6-HI'1N&4E3]17Z(Z-XX\/\ C#X]
M:IHNK30PZSX9F%SH]X& $MO);1B6$MWPS;L?X&OSSO\ F^N/^NC?SKMRS'5L
M6W&M&S48O_P*[T\K6]'='F9YE>&R]1GAI\RE.:]%'E5GYW;]59GU[^P5_P @
M?QC_ -=[;_T&2OJROE/]@K_D#^,?^N]M_P"@R5]65^:Y_P#\C*K\O_24?MO"
M7_(DP_I+_P!*D%%%%?/GUX5XM^UC\-[WXA?#+=I<37&HZ5<"\2!!EI4VE74>
M^"#_ ,!Q7M-%=6%Q$\)6C7AO%W.''8.GF&&J86K\,U;_ (/R/R1=&C=E=2K*
M<%2,$&FU^G_B#X.>"/%.H27^J>&-.N[R0YDG,(5W/JQ&,GW-9G_#._PW_P"A
M0T[_ +Y;_&OT6/%F&LN:G*_R/QF?A]C%)\E:+7G=?H_S/S3HK]+/^&=_AO\
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MTL_X9W^&_P#T*&G?]\M_C1_PSO\ #?\ Z%#3O^^6_P :/];,+_S[E^'^8?\
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MV7G^JL?G;17Z+>%/V<_AI#X;TU(]%L=<00*1J3G>;D8SYF5.#GKQ6M_PSO\
M#?\ Z%#3O^^6_P :)<586,FO9R_#_,(< X^<5+VL-?7_ "/S3HK]+/\ AG?X
M;_\ 0H:=_P!\M_C1_P ,[_#?_H4-._[Y;_&I_P!;,+_S[E^'^9?_ !#_ !__
M #^A_P"3?Y'YITH!8@ 9)Z 5^E?_  SO\-_^A0T[_OEO\:O:+\$_ GAZ_CO;
M#PKIL%U&=T<IA#E#V(W9P?<5+XLPUO=IRO\ +_,J/A]C6US5HV^?^2/.OV._
MAUJ'@CP!>7^J0/:76L3K,D$@PRQ*I"$CMG+'Z8KWNBBOSS%XF>,KSKSWDS]D
MR[!4\MPE/"4G=05O7JW\V%%%%<9Z(4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%+@D9QQZT )14AC5"ZNWS#ICD&E$JJRLJ#@8
M(;G- $>#Z4OEMDC:<CD\=*7S&V!,_*#FD,C$DECENO/6@ \MOE^4_-T]Z3:1
MG@\4HD8%?F/R].>E+YC;2N>"<D4 ,HJ7SMSEG4-QC'2D"HP0 X8_>+=!0!'1
M3C&0"<94'&X=*;0 4444 %%%% !6-XSDTJ+PEK+ZY'YVC+:2F\CP3NAVG>,#
MGIGI6S6=XDO9M-\/ZE=6VGMJMQ#;R21V*?>N&"DB,<'KT_&M*?QQ]?3\>AC6
MM[*5^SZ7_#KZ=3$^%$_ANY^'VC2^$8#:^'FC8VL+*P*C>VX'<2<[MW))SZUU
ME<_X U:[UWP=I=]>Z')X;NI8LOI4OWK?!("XP,< $# X/2N@JZ]_;3OW>[OU
M[]?7J982WU>G:UN5;+E6W2+V7ETV"BBBL#K"BBB@ HK*\3>*]'\&Z7)J.MZC
M;Z;91]99W"Y/H!U)]AS7S3\1OVWK:V=[/P7I?VV3./M]^"L?_ 8QR?Q(^AKT
ML'EV*QSM0A==^GWGBYCG.!RJ-\542?;=OY+7]#ZK) Z\5S&O?%#PEX7=DU3Q
M%IUE(O6.2X7</PSFOCB+3?CE\>D\V2348=)EZ>8YL[5@?1>-X_ UU7AK]A+4
M+A1)K_B:&U/4PV,!E/XLQ4#\C7M?V1@\-_ON)2?:.K_KY'S"XAS+'?\ (MP,
MG%[2F^5?U\SV?4_VK_AEICE#XA-TX[6UK*X_,+C]:PYOVTOAW%(%1M4F7^^E
MI@?JP-5M,_8D\!V:C[3=:M?MW,DZH/R516Q'^Q]\-$7!TR[;W:\?-3;(H:7J
M2^[_ (!IS<55-4J4?O?^86?[8/PSN642:K=6N?\ GK92G'_?(-=;I'QY^'VN
M,JVGBO3B[=%EE\H_DV*X:\_8P^'5RI$46I6I/>.[SC_OH&N-\0?L'Z9*CMHG
MB>ZMGQ\L=_ LH)]"RE<?D:%1R.KI&I.'JK_DA/$<4T%>5&G4_P +:?XM'U%:
M7EO?P+-;3QW$+#*R1.&4_0BIJ^%Y_P!G/XO_  KFDO?#5Y+<!#N)T:[96<#U
MC.-WTP:T?"O[8?C3P9J T_QGI U&.-MDHDB-M=)Z]L$^Q ^HHED,JJ<\#5C4
M7;9_<$.+(X>2IYIAYT&^K5X_?;\DS[7HK@?AO\<O"/Q20)H^I*M\%W-87/[N
M<?13]X>XS7?5\W5HU*$W"K%Q?9GVN'Q-'%TU5H34HOJG<****Q.D**** "BB
MB@ HHHH **** "BBB@ HI0"02!P*D$:JV)&P"N1MYH BI<4\.%"84;EZD\YI
M#*Q#CH&.2!0 GEL3C:<XSC%&QMH;!P3@&E,KE@=QR!C.>U)O; &3@<@4 !1@
M2"#D=?:FT_SG^;YC\W7WI1+\R;E#!1C'3- $=%/^0KW#EOPQ0T14MCYPO5EZ
M4 ,HHHH **** "BBB@!EP4$$AE&8]IW#';'->?\ P/N_!5YX6O'\"VC6>EB^
ME6:-U<$S<;C\Y)P1C'.,>G2O09&*1LRJ7(!(4=_:N1^%WB+4/$OA^XN-1\*R
M^$9DNY8ULIN#(H.?, VK]XD]N>N377"_L)[VNNMEUW77]/F>=5Y?K=*]KVE]
MEM]-I;1\T]_D=A1117(>B%%%% !11574]5L]%L9KW4+J&RM(5+R3SN$1!ZDF
MFDV[(3:BKMV1:HKYL^(_[:N@:$);7PI:-KUX.!<RYCME/K_>;\,?6O)(_%?Q
MP^/3LFFF_M]-8X9K(&SMA[&3(W?3)^E?1T,AQ,X>UKM4X]Y.WX?YV/B\5Q7@
M:53V&%3K5.T%?\?\KGVAK_CWPYX6R-6URPT]ASLGN%5ORSFN&U7]J7X9:3P_
MB6.Y;^[:P2R_JJD?K7@WAS]AGQ!J+B7Q!XAM-/#'++;(UQ(3[DE1^.37HVD_
ML/>"K-5-[J6K:A)W_>)&I^@"Y'YUN\)DU#2IB)3?]U?YW_,Y5F'$F*UHX2%-
M?WY7?W)I_@:=U^VA\.;<XCEU.Y]XK,C_ -"(JQ:_MC_#6XQYE_>VN?\ GK9.
M<?\ ?(-/A_8]^&L0YTZ\D/J]X]0W/[&OPXG!"6M_ ?5+MC_,&E_PA/3]Y^ [
M<5K7]R_+WCK-)_:)^'.L[?L_BNQ4MT6X+0G\G KN]-UBQUFW$]A>07L!Z26\
M@=?S!KYMUO\ 83\.W*L=)\1ZC8OC@7423KG\-AKSK4/V2OB9X$NFOO#.JQW4
MJ?=DTV[:VF(].<?EFFL!E6(TH8EQ?]Y?KHA/-L_PFN*P2G'O!_IJS[BHKX;T
MC]ISXH_"W4$T_P 6:<^H)&</#JD#0S%?]F0#GZD-7T7\-/VFO!GQ)DAM([PZ
M1JTN +&_(0LWHC?=;Z=3Z5Q8O)<7A8^TMS1[QU7^9ZF7\39=CY^QYG3J?RST
M?^7RO<]9HH!R,BBO!/JPHHHH **** "N9^)DV@V_@/6I/$\#7.@K;DW<2AB6
M3(X&T@YSCH1735A^-]3N=&\)ZI>V>COK]S#"633(^3<'^[T.?R/TK:A?VL;=
MUUM^/3UZ'-B;>PG?L]U=;=5U].NQ'\/IM$N/!&B2>'(O(T)K5#9QD,"L>. =
MW.?K705D>$=1N-7\,:7>7>EOHES/;H\FG2?>MR1]P\#I]!]!6O2J_P 25^[Z
MW_'KZCP]O8PMV6RMT[=/3H%%%%9'0%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %* 2< 9-"J68 =34A/D\#*S*W7/
M% "*JJ%<D-S@IWI&D)#*/E0G.VLW7_$&G>&-(N]6U>]AT_3[5#+/<W#A411U
M))KX-^/O_!0R]U&2?1OAK&;&T&4?7+E,ROV_=(>%'^TV3["O2P67XC'RY:*T
MZOHCGJUX45>;/M/Q]\7/!_POLS<>*/$%EI"XW+'*^97_ -V,99OP%?*_CO\
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M[ <.UL0E/$/DCVZ_\#Y_<>76QT(:0U?X'Z _$+_@I)X1T2XFM?">B7OB)T)
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M;*[2XU#P/<FRN1EQI=U(3&Q_NHYY4^FXD>XK\W/#WB75?"6K0:IHNHW.EZA
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M.(H4E5JQY4]KZ/[M_F>7A\TP>+KO#X>HIR2N[:I?/:_E>YU-%%%<)ZH4444
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MGAGP4OA:/PCXB.A7)&G?9O[1M2(U2X8[1YHWC <YSN;GFIAFM.;IQ<;<U_\
M)>J;T0/#22D[[?U^!\-45^E7B7]G7P7J?[3.A^(_#7A_3)_#MK->:3XCT);*
M,VMI<K82O!(8<;%5QY9!QC<%/WC7 ?#'3_ FJ>"?!.C:#X3\#>()[O3%36])
MU\_9->NKMP0QM9I%QM)(V;6'M62SFG."E"#>B;\KWW^[T=T6\(T[-_UI_F?"
ME%>\>,_".G:+^S/<7/\ 8<>FZM!\0KS3S)<1*;R*!;.,B!Y<9(4DG&<9R<<U
MT'['G@*V-CXO^(NL>#SXWTS0HHK*UT3[#]K^UW,SKN(C*L#Y<>6Y'5UY%>A/
M&PA1E6ML[>KO9&"HMS4#YGHK[W\%>%]+^'/[74OPLO\ P%X8U;POXAN[G6K*
M\U;1XYKA+=[-Y4CB9U^5%>$KMQ@$/67X/T[0/VB_A!K7VSP=X6\+WS>+],T.
M.^T/2H;:2*"2:,.58+G<0Y'7!X%<;S5*TN3W6HN]^DFTM/D[FJPS>E]=?P/A
MRBOMH^)O 4_[01^"<GPFT$>%VOO[!34(+;_B;*Y^47!N/O<-ACSPN:V=;_9M
M\*:_^SGI?A/3;6R7XE6UYKDFEWL%NJ3ZJMC?212PLX&7)1D*AB2-HQP#3>:P
MI\OM8-<UNST:;OIVMKV!89RORN]OS['P917WU<?"#0=/_:A\?^(1X)M-5\.^
M#_#MK=1^&[/35>&[O)K1%CB\E4*DLQ=ON\$;NQJCJ7P/\/\ AOXY_%&<>'+1
M?#^K_#B_\1Z58WEDNVPG80[A&C+^[9'+[< % P QBI6;TG;W?LI_?;3ULTP>
M%DNO6Q\**Q5@RD@@Y!':OU3_ &)_CRWQA^&2:=J<H?Q)H"I:W3$\SQ8Q%+]2
M!@^ZD]\5^5=>O?LJ?%5_A%\:M"U22X,&E7;_ &#4,G"F"0@9;V5MK9_V:K.<
M"L;A9)+WHZK_ "^886M[&HK[/<^F?VE/"%[\&?C'I_C'0E-K:7TWVV!XS@)<
M*094(]&R#@\$.1S@U]F^#?%-IXV\*Z7KMBP:UOX%F4 YVDCE3[@Y!]P:X3]I
MGP$WC[X2:O#;QB34+!?M]L,9),?+J."<E-P '4XKS3]AKQM]O\,:QX7GE+2Z
M?,+JW1CTBDX8#GH'&>.[^]?&8A_VCE4<0_CHOE?G%[?I^)XF#7]C9_4PBTI8
MA<T?*2W2_'\#Z?HHHKY$_1 I0"Q ')-)3X]N27#8QQM]: %EP"%V;&7@\]37
MR-^W]\>I/ ?@V'P3H]SY6M:[&6NI$/SP6F<''H7(*Y] U?5VH7]OI=C<WMW,
MD%K;QM---(<*B*"68GL  37XP?&KXCW'Q9^*'B#Q1.[,E[<'[.K?P0+\L:X[
M84#\<U]1P_@5BL3[2:]V&OSZ?YGG8ZM[.GRK=G$4445^JGS8445].>";;P[\
M$_V;-$^(UQX2TGQEXC\2ZK/8Q+KL N+6Q@B+ @1'@NQ0G<>Q'X\V(K^P2LKM
MNR7G_2-(0YV];6/F.BOL&PM_"/CWX9?&?Q+;?#2W\(W:>'--NX8I[</&DSO)
MNGL]RYB1QC&PX( K@/V6_#6D:_X+^-,^IZ59:C-8>%9;BTDN[=)6MY03AXRP
M.QO<8-<JQR]G.;BURM)K3K;MZFGL=4D][GS[17Z7>)?V;O!WB+XN_#W6O#F@
MZ2T>CR6=MXFT*.RC$+PS0EXKAHL;6&258XYX]#7/S? [P+K3> =0OO#5A]BT
MO2O$>L7=E90);G46M[I!%'*R %E4' ![<=,BO/CGE%I/E>J^[1NWSMIZHW>#
MGKK_ %I_F?GC17O/BWXB:7\;?"$EA9_"/3=%\0+J$,%AJ_ABW^RP1B1MHAG5
M5PY;H"2#GGU!]U^/7P%T>P^!>O\ A_1_!XL=<^'L5C<R^(DTWRCK$;18NF\[
M:#($8LQ&3@ >E=L\P5*4(58V<G;=:;*_WM&*H.2;B[I'PC17N_[8GAW2O#7Q
M \,6^D:99Z5;R^%M-N)(K*!(5>5D;<Y"@ L>YZFO"*[Z%95Z4:J5KF,X\DG$
M****W(/4/V<_C1>? WXFZ?KL3,^F2$6^I6PZ2P,>>/[R_>'N/<U^PFEZG;:Q
MIUIJ%E,EQ:7423PRH<JZ, 5(]B"*_"NOTK_X)W?%5O%WPOO/"=[<&2_\.R@0
MAVRQMI"2OX*P9?8;1Z5\1Q+@5.FL7!:K1^G3[G^9Z^7UK2]D^NQ];R@MB0E<
MMV7M4521@NK(J;F/.?2HZ_.3WALFX1ML +X.W=TSVKE?AM+XPFT2X/C2"Q@U
M,74@B6P.5,/\)/)YZ_AC/-=5*I>-U5BC$$!AV]ZX_P"%GAS4/#/A^XMM0\4R
M^+99+N65;R4Y,:DX\O.X]"#WXZ8%=,.7V,[VO=='?KL]EYWW.*HI?6:;5[6E
M>S5NFZW?E;;6^YV5?('[;'Q#DU+5=*\"Z=(TIC*W5W%$<EI&XBC('?!W8_VE
MKZWU*_ATK3KJ]N7$=O;1/-([=%5023^0KX;^ ND3_&G]HF]\2WR^9:6L\FJ3
M;QD9W8A3\"5X]$->_D5.$)U,=5^&DK_-[?UWL?(\5UZE6G1RN@_?KRL_**W?
M]=+GU1\$_AW;?"'X:6=A<>7#>>6;O49\C'FD9;)]% QGVK\ROVJ?CG<?'+XH
M7E]%*?[ T\FUTR'MY8/,A]W.3],#M7W%^WS\56\ ?!EM&L[CR=3\22&R7:<,
M(  9B/;!53_OU^7-?09!AY5I3S&MK*3=OU?Z'K5XT\+2A@Z"M&*2_P O\PHK
M9\&01W7C#0H9HUEADOX$>-U#*RF1000>H(K](O&O@#PSIFM>.YO$7A'X96OP
MTTRWEBDN-(L475[61HQY0;RDS&Y8]R.HKZ#&8^.#E&+C>_\ FEIW>IA2H.JF
M[VL?F)17Z%W?ANST/X=?#*30- ^#MNE]X7L;JYD\9P6T5Y/,T0S)EERP/=CU
M.:Y?4M%L/AM<^ ]#\,?#'PGXU\9>.89]7NI]1MTELP S-Y%J&^2-%56P1CC;
MUS7-'-E/:'?JNE[M]M$:/#-=3X<HK[2_:9^%>E>#OV?-1U4?#NV\#:K=>*;9
ME@,D=S+'&UM*75)E&5B9UR(\X&/H!NVWP[\*GX/27;>&='-X/A-/J/GFPB\S
M[4)& GW;<^9C^/K[U:S6FZ<:BCHW;=>7;0GZM+F<;]+GPA17JW[+_P -5^*O
MQL\.Z/<VYN=,AE-]?ILWC[/%\[@CN&P%QWW =Z^A/C8EAX N_!WQ4T?X7Z'I
MVG>(HI-'O?#>NZ$BPV4T<Q*2B$JH5WC[X_@/K737QT:594$KR:[^ME\[/^F1
M"BY0<[Z'Q+17Z!>*?#WA+QY^TUKGP[NO OAG3/"_A.Q3Q(PT;38[2\O]EC$_
MV9I(P"4+W.2O?8/2O,_"&N^%OVH?#GC_ $:Z^'?AWP??Z+HESK>EZGX?M1;M
M$T(SY4VT#>K=,G^=<T,SYHJ;INUDWJM%+;U\RWA[.W-KK^!\DT5^GL?PVTJ+
M4/#H7P9\+V\$V^@6=]KK7>GQ_P!K1QM%F24!$+#.,ACU.>:\-\">$/A%\?-,
MO5*6WAFU\ 7]S>W,\%N(I=5\/J[%&D* %IE 1"Y^;YN22:RIYQ":<G!V5KM:
MVO>WSOT\RI85JROJSXTHKK/BIXQLO'OC[6-;TW1[+0-,N)<6FFZ?;)!%!$HV
MH-J #=@ D]R37)U[T&Y13DK/L<;23LC] O\ @GC\>GU?3I_AMK-QON;-&N=)
MDD/+0_QP^^TG</8GL*Z3]MGX7F-K'QUIT6UMRVNH%.#G_EE)^FTG_=K\^/ /
MC*^^'WC31O$>G2-'>:;=)<)M.-P!Y4^Q&01Z$U^QE_;Z7\:?A21#(LFF^(--
M62&7KLWH&1OJI(_*OA<?'^R,QAC:?P3W_7_/U-,;@XYSEM3!R^)*\?5;?Y>C
M,G]GSXCK\3?AEINH2S"74K8?9+W/WO-0#YC_ +P(;\:](KXH_8W\1W'@[XHZ
MSX.U',#WJO&8F/2X@+9'UV[_ ,J^UZ^9SC"+!XR4(?"]5Z/^K'3PWF$LQRVG
M4J?''W9>J_5JS^85C>,7UM/"^I-X<2WDUP0G[(MT<1E^V:V:P_'&EW.M>$M5
MLK35WT&XF@94U*/@V_\ M9R,?7(KR:5O:1OW6^WS/H,1?V,^6][/9V>W1O1/
MLV6/"KZN_AS3FU]+>/6C OVM+4YB$F.=OM6I61X0TZXTCPOI5E=ZH^M7$%NB
M/J,GWK@@??/)Z_4_4UKTJEN>5N_38=&_LHWO>RWU?S:T;"BBBLS8**** "BB
MB@ KQWXP-X7\+>/O#'C;Q#XFBTI])AFCATWR?,ENMX(RN&W#&?[I'N*]BKQ_
MXZ_ FX^*NH:3J^GZO'IFIZ4C"%;FV$T+DG/S Y[^Q^E>EE\J<<0O;3Y8M--^
MJM;9[[7MH>)G$*T\(WAZ:G-.+2?=-.^ZO;>UU?8\P\5?M7W>O7=MIW@KPW-<
M7%],MM;7FI?)&[L< !01G\6%>D^!I/$VG>'K27Q)-$VO!Y'E:WQL +$JHQQP
MN!7B?C__ (6AH6H^%I?$OAJWU*Q\.WZWB7>B1C;,!C(*K]WI_=7Z5[5X5\9V
MGC_PS;:W903VT$Y=?*N5 =65BI!P2.H-?2XRA2IX>'L(1Y7NT^;76ROYK6UD
M?$Y=BJ];%U5BJLN=+2+CR*VEWRZ[/2]WIZGJ.@>(H=:C*$B.Z0?/'Z^X]JUZ
M\5FO)K"Z6>WD,4J'*L*](\(>,(/$EOL?$5[&/GCS][W'M7R]?#."YX[?D?=8
M3'*J_95/B_,Z)ONGZ5\[_&V"&'X'>.3%:);$QVV2N?F_TF/UB3^9KZ(;H:^?
M?C?9R1_ [QS_ *YR8[<X>T$/ N8R<8ACS^9KJRO_ 'B'^*'_ *4CASY7P=7_
M  5/_26?"-%%%?MY_+@445M>$/!VL>/->AT;0K)K_49E9DB4A>%4LQ))  P.
MYJ92C"+E)V2+A"562A!7;T26[,6BMYO VN)9^(+IK!TAT&9+?4BS &WD=V15
M()R3N1AQGI6#2C.,_A=_ZO\ D.=.=.W.FK_YV_-->J"BBBK,SZN_8)_Y"OC+
M_KC:_P#H4M?3DL<W_"QX'\O5?(_LQAYBRK]@W>9T*?>\WISTQ7S)^P4C?VGX
MR;!V^3:C..,[I*^D9K9?^%L07!LX2PT@I]L-^1(/WI^3[/G!'.?,Q[9X%?D>
M>?\ (SK>B_\ 25YK^NA_0_"VF28;_$__ $M^3_3U.T<E8U4.&4_-@=C7R)_P
M4@\=G0/A1H_AN&4I/KU\6=1GYH8 &;_Q]XN#_2OKN8Y?&T(0,8%?F;_P4@\3
M/JOQMTW25D<P:5I,:^43\HDD=G9@/=?+!_W17'D5!5L?"^T;O[MOQL?9XR?)
M1=NNA\H4445^NGS 48.,XXKL_@SX1L_'WQ8\(^'-09DL=4U."UG*'!V,X#8/
MTKZ%^(7Q<LKSQIX]^%]G\'M$U'P_ICWNG646CV9CU&W,#LBW7F@,205WD;><
M\DC.>&MB73J*G&-W:[U2LKVZFT*?-'F;L>>?#;]KCQ1\,+;P/!IFG64D/A:&
M^MT64OB[2Z<NPEP?X6VD8QRHK,A_:A\6V4_@2\M4M8]1\)7NH7T%W(&<W3WD
MJR3"89Y&01Q@\GG-?5'P3^ %M_PH;2/!VH>$C?:AXYTF_P!4EUY[0/\ V=/M
M0V<?F$90%4W?[Q/K7(>$OA/X?\??LL^&_ ]QI\-E\1KZ;5[S1[AHUC>>XLI5
M5[5W.#EUF( ;CY23C:*\+ZU@>>3]G]JS?D^>\O3XK^6IV>SK62YNG^6GY'C/
MB3]JO4-5T*\TG1?!7AOPI::C?6^H:F=)MY%>\>&598U8LQVKO4' _P :=\2?
MVGK'XH2:U>:K\,/"XUW5(BDFKQFX^T(VP(L@R^,J ,9':OI3Q?=V_P &? ?Q
M \067A;0YM8TO2_"\:V^JZ<LD<;RQ%)LKP0QR<\]1S4'AG0O#OQ-^%MQ\4)?
M#.C:+K6I^!O$=O=V5G;!(99;=XA'<Q(<[2HR"W7+#FLXXG#Q2JJC97LGS.]V
ME+7RM;OL4Z=1OEYM?3SL?*$O[0&L2ZK\,-0.F68?P"D262_/BX$<HE'F<]R,
M<8XJ/Q_\?-6^(?@R[\.7>FVEO;7/B2Z\3-+ 6WB:<,&C&3C8-QQWKZ8\:_%F
MW^&WB/X0>#(_ OA;6M"USPOHTU^MUIBM=2M/F.3;(#U(4'D'G-=/\*/@+I?P
M?^(7Q-UV#PL?%^G0Z];:#IED;;[0(+>5HYKB3!!SY2,JYZ_(1_%6SQE"E%5)
M4K/>.N_O6^6KN0J4Y/E4O7[O^ ?'7PA^-$GPLTKQ-I<OAK3/%&E>((X([NSU
M3S/+(AD,B8V,#][!_ 5VF@_M4VWAB;6X]+^%_ABSTS6;%;&_TV/[1Y,ZJY8%
MOGSGG'6OHKX6J_PV^-OCGX3W7A7P[=:#H>GZAK&FW-WIPENG0XEA#2%CN4!]
MO3/R]:R_A#\1+OX@?!_Q/XSDL/AKX<UP:W;V*SZ_IYBTY8A"254+N82$X/H<
M&HJXFE4<JCI73Y7?F>M_A=EZ?*PXTY127-WZ=MSY*^)7Q*TCQW96=OIO@'0_
M"$D$AD>;2/-WS C&UM[MP.O%>?U]\>'/&6AK<^*;S6_^%;VWC!7M;73_ !-%
MI,TWAR2'87:!6P-DP9SN)Z@KP=M?/'[7/A[^R/B)I]ZOAC3/#D6J:9#="30[
MH3Z?J#'(-S;_ "KL5N/E(!R,]\GTL)BU*HJ"@X^KOY]=7O\ YI&%6DU'GO<\
M.HHHKVCD/KK_ ()O>/)-$^*FK^&9)<6FM67F*A/'GPG*D?\  &D'Y>E?I-&5
MW88G:>NVOQM_9E\2'PI\?O E]O\ +1M5AMI&[!)6\IL_@Y/X5^R"L58$'!!Z
MU^7\2T53Q:J+[2_%:?E8^BR^=Z3CV85B^-(M+F\(ZS'KDODZ.UG*+R0,1MAV
MG><CGIGI6Y*<R-\ZN<\LO2L?Q9>0:?X7U:ZNK%]3MH;6222RCC#M.H4DH%/7
M/3'O7R]*_M(V[H[*]O92O:UGOMMU\C'^$]OX;M/A[HT7A&X:Z\/+&WV65F8L
MPWL6SN .=V[@@8]*\<_;B\3?V=\/-+T9&P^I7@=P.Z1C/_H17\J]H^&.JV6M
M^!-'O=/T:3P]9RQ'R]-DA$1@PQ!&T<8)!(/<$&OE;]N74WU'Q_X9T6,Y,%B9
M0/\ :EE*_P#M,?G7TF44O:YNN>^CDW?5Z7W?>Y\5Q#B%0X>?L[>]&,5966MM
MD]4K7LNQ[I^RIX3;PK\%M%,R;+G4=U^_T<_N_P#QP(?QK\T_VH?'!^(/QW\7
M:H)?-MX[QK.W(.1Y<7[M<>QVD_C7ZK>(M3'P[^#VH7T>$.BZ&\D8_P!J*#Y1
M^:@5^*\DC2NSNQ9V))8]2?6O=R&^)Q6(QDMV_P W?_(]25%8/!T,)':,4ON1
MT/PZ\;7/PW\<Z+XGLH(KJZTJY6YCAGSL=E[''.*ZBP^.NJZ?JWQ+OTT^T:3Q
MW!<P7BDMBW$TWFL8^>QX&<\5YI17V,Z%.H^:2N_\G?\ ,Y5.459,]W\#?M>>
M)/!OA;0M+ET?3=:O_#R7$>BZQ?;S=6"2QF,JI# ,%!.T,#CCT%97A[]JCQS8
M:/XBTG7=1F\8:9K-E]D>VUJYDE6!@P9)8^>'4@$=N*\=HK#ZEAKM\BU_SO\
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MMVWJ4(P PVE>/X6-0\5A*3]ZG[UN;>[NKM*[UV7I]Y2IU9;2TV_K[SY U/\
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M_:#U;PYH5['H=GHT4EE/?HI$AB1\.&*X9@9"<+G'?WKVC]D[_D@'A;_MZ_\
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M,Y!8'!)HT'XHW^G?"+2;ZS\6B!K'P+=Z=#%_:B^;!??:V"A8M^Y9!"5VL "
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MOD"OTM_X)R>"FT'X.:AKTL9237+]F1B/O11#8OX;O,_6O!SZM[' 3[RLOO\
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M_8_T2V>]1_&=WFTM_M,F-*'W,S#C]]U_T=_T]:/[;P/\[_\  9?Y"7"^:O\
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M^C/!SRV9YAALEI_"GSU/1;+Y_JCZF1!&BHHPJC 'H*6BBOBS]&"E!P<BDHH
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MSU!_A8=U/(^A!/F]?>TJL*T%4INZ9K*+@^62U"BBBM"0HHHH **** "BBB@
MHHK<\%^"M:^(7B2RT+0+&74-2NWV1Q1CIZLQ[*!DDG@ 4I24$Y2=D@2;=D)X
M+\%ZQ\0?$UCH&A64E]J=Y($CB0?FQ/8 <DGI7ZW_  3^$N@_LX_"Y; 21(\4
M9N]5U)^/.EV_,Q/]T 8 ]!ZDUS?[,/[,&D_L^^'VN[MHK_Q7=Q_Z;J&/EB7K
MY4>>BCN>I/M@5Y'^TG\=;OXEZTO@/P>9;G3S.(9Y+?DWTN[A%Q_ #^9]A7P6
M*KU,]Q"PN'=J4=9/]?\ )?/TUQV-I9%A7B*NM26D8]6^W^;.9\1:EJ7[5WQR
MM[.Q\V#1HV\J$L,_9[53\\I'3<W7'J5&>*^Z]!T2S\-:+9:5I\0@LK.)88HQ
MV4#%><?L\_!:#X0>$0ERD<GB"^ DOIUYV^D:GT7]3D^E>JUX&;XZ&(G'#X?2
ME3T7GW?]?J'#N5U<)3GC,9K7K.\O)=(_+K]W0****^?/L HHHH 4<&GR@L/,
M"A58XP*CI\;!&R5##'0T ?,?[:?[,X^,7A;_ (2+0;?/B[28CLC0<WL(Y,9_
MVAR5_$=^/R^G@DMII(9HVBEC8JZ.,,I'!!'8U^[LD9C(!(.1G@U\;_M@?L8C
MQY)=^-? ]N$\0D&2_P!,7 6]QSOC]).N1_%QT/7[;(LX5"V%Q#]WH^WD_+\C
MR,9A7/\ >0WZGYST5+=6LUC<R6]Q$\$\3%'BD4JRL.H(/0U%7Z.>"%%%% !1
M110 4444 %%%% !117T3^RQ^R5JWQQU6+5]6233?!EM*/.N#E9+LCDQQ?U;H
M,\9-<V(Q%+"TW5JNR1I3IRJ2Y8K4V_V*/V8I/BKXFB\5^(K)_P#A$=,D#QK(
M,+?3J>$'JBGENQZ>M?IU##G;'&H4 8"C@ 5G>'?#VG>%=$L='TBTCL=-LXEA
M@MXAA44=!_\ 7[UJ2*(P8RHW@YW U^0YEF$\QK>TEI%;+LO\^Y]1AZ"H0Y5O
MU&NP;&%VX&/K3:**\DZ0HHHH **** /C?]L#X4W/AGQ#;?$+00\$<TJ_;'@)
M5H+@8V2@CINQU[$>]>[_  2^*6F_&_X?_P"EK#-J"1?9=4L9%!!)&"=O0JXY
M].2.U>AZYH=CXETB[TO4K9+NPNHS%-#(,AE/^>O8U\)ZUIOB;]D?XKI=V3/<
M:/<DF)F_U=Y;[N8V]'7]#@]#7V6%E'.<(L)-VK4_@?==OZ\O,_-<=&?#68O,
M::OAZSM42^S+^;Y_YKJCQ?\ :U_9MN_@7XTDNM.@EE\(:BY>QN2,B%CR8&/J
M.<9ZCZ&O!*_9U&\'_M'_  P>*>)-3T+4X]DT#<202#MZJZGH?H1P:_,S]I#]
MF'7_ ( ZZ6=7U+PQ<R'[%JB+QCLDN/NN!^!ZCT'T649K[?\ V7$Z58Z:];?K
MW/HZU&,HK$4'>$M4UY_H>*U[UHGQ>\#1>(O"7C748M=_X2GP_IT-M_9=M!$;
M.ZGMX_+MW\XR!HT("%U\LG(..M>"T5]%5HQK*TOZ3W1R1FX;'<>.O'5IXJ\&
M^"=,BBFCO='@O$NF=0(V::[EG79@DD!7 .0.<UTNH^,/ 'Q#MO#E[XLF\0:7
MK6FV=OIMXNEV<-S#>P0($B96>5#&^P*AX8?*#U)%>145+P\;)1;5K_CJQ\[Z
MGM5]\4/ _C+0]?\ #^IZ7?\ A+1IM8BU;2QH=O'<^2%A\AHY$>2,$LN&W _>
M)XP:B\=_&?1O$WA[Q?I-A9WUO;WJZ+9Z8;C:7-M812Q;IB#P[!D.%R,Y&> 3
MXU14+"4TT]=//T?Z(?M9/^OZ[GO^K_'#PIXLTK6?#^J1:O9:3J6C:/;"^M8(
MY9H+NRB"$F(R*'C;+_Q@]#CM6KX-_:*\-^"O">I^#]$N]<TC2/M\.H6NK7.E
M66IW$KB!(I4D@G.R-3L!78Q*]"2#7S7163P%%QY'MV\U;7\/0I5I)W/IC5O&
MOAWXI^#_ (GZ_P"(KW6X-/N]:TA;>ZAM[=[H&*UGBC,D*&*,@HF"JD8RIRQ&
M3S6M_&?PQK=MXPTA8=4L]'N] T_1M)G:*.6=C9E?+:==X"[]ISM+;<C ;%>&
M44XX*G'KII9=K6_R0.M)_P!>O^85;TK2KS7-2MM/T^VEO+ZYD6*&WA4L\CDX
M  '4TNCZ/?>(-3MM.TVUEOKZYD$4-O A9W8G   K],/V1_V0+;X.6\?B;Q.D
M=YXQF3]W&"&CT]2.57U<]V[=!W)QS',:674N:>LGLN__  "J%"5>5EL=5^R=
M^SO:? 3P%YVH(C>*-219M2N&((A &1"I[*O<]SGL!7A7Q[^(%[^T#\4-.\*>
M%R]UIMM,;>V )"32GAYC_LC! )[ GO7?_M3_ +1!C%QX'\*SF2ZE_<ZA=P<E
M0>#"A'<]R/IUS78?LL_ 8_#C13K^MVRKXDOT^1&Y-K"<';[,>_IT]:^1H2E@
MH2S;&:U9_ OU]+?AZH^?S*J\]Q*R7 O]U!WJR7E]E/O?\?1GK/PY\"V/PX\'
M:;H%@ 8K6/#RXP99#RSGW)KI***^)G.56;G-W;U9^CTJ4*%.-*FK1BK)>2"B
MBBH-0HHHH D8>8FX*JA0 <=Z\:_:>^ %C\>_ $MD%6'Q!8AI],NSQMDQS&Q_
MN-T/H<'M7L:,%8$C<!V]:5TP _ #9P >E;4:T\/4C5INS1$X*<7&6S/PP\0^
M'M1\*:W>:1JUI+8:C9R&*>WF7#(PK.K]4/VK_P!DNQ^.>G'6M%\JP\9VL>V.
M5OECO$'2.3T/HW;H>.GYA>)/#6I^$-;N](UFRFT_4K20Q36\Z[65A_/Z]Z_7
M\MS*EF-.\=)+=?UT/E\1AY4)6>W<S****]@Y0HHHH **** "BBB@ HHHH *]
M@_9H_9]U+X]^.H;(1S0>';1A)J=^@P(T_N*3QO;&!Z<GM5/X!?L\^(_CYXE%
MEI<9M-*MR#?:I*I\J!3V']YSV4?H*_5SX6_"[0?A!X/M/#GAZV\BS@&YY'YD
MGD/WI'/=CCZ=AQ7R^<YO'!0=&D[U'^'GZ]CT<)A76?-+X?S-_P /Z!8>&=&L
M=(TNV2ST^SB6""",8"*!@#_Z]:4@V (5 =2<G/6E*^4I#*&+#((/2HJ_*VVW
M=GTFV@4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** .$^,'P@T?XP>&FT[4%$%[%E[._0?/
M _\ 53T*G@_4 CY$\$^/_%W[*7CFZ\/Z[;R76CN^Z:T5LI(N<">!CZCZ9Z,
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M 2J,YPL@PR_@17T']LX;%6^OX=2?>.C_ *^9\?\ ZMXW 7>4XR4%_++WH_\
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J1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>btai-20241231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 btai-20241231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'K \L# 2(  A$! Q$!_\0
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MZQ<1:6L^K>1]ET;[<!J#"5]D9\IE ;G&0K,5!^8"J_X3;VM#[D'^T>?XD?\
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M&_Y]1_\  5_D3[6I_,_O/I,_M0?%G_A2QU7_ (6!K/\ :/\ PD"VWVG='O\
M*^SNVS[F,9 -<1_PUQ\9_P#HI.N_]]Q?_&ZQC_R;\W_8SK_Z2O7GE<]'"8=\
MUZ<=WT7^1I*K4T]Y_>>N?\-<?&?_ **3KO\ WW%_\;H_X:X^,_\ T4G7?^^X
MO_C=>1UZA^SG\+-/^,7Q''A_4SJ?V;[#<W8CT<QBYE:.,LJ)YBE<DC'(JZM#
M"48.I.G&RU^%?Y"C.K-J*D]?,N?\-<?&?_HI.N_]]Q?_ !NC_AKCXS_]%)UW
M_ON+_P"-UZ%XO_8Y,\&E2^&KJ[\,WDME<7^H:+\0+J""ZLH(B!Y[/ I78<]U
M'3K7&WW[('Q#MO"9\0VL.F:Q9%!/&FF732R2VY8*MP@,84QDG/W@V.=N*Y(5
M,MFD^6"]4C1QQ"ZO[S/_ .&N/C/_ -%)UW_ON+_XW1_PUQ\9_P#HI.N_]]Q?
M_&ZZSPA^R->/XT31_$VO:0\0@N_M,7AW5H;F[LKF*W,HBFC9?EZ $@,.V[-5
M]8_9*U>>>2?2M1TK1M)MK+3IKFY\2ZND>V6Z4E-K)$!M)& N-PR,YZT<^6\W
M+RQ[[+T[!RXBU[O[SF_^&N/C/_T4G7?^^XO_ (W1_P -<?&?_HI.N_\ ?<7_
M ,;KH;W]D?Q1!I^GV"VJP^)'U6ZL;J6YU&);"**&(2M+G8&50IW%B3D=%S6-
MH/[+/B?Q+XDDT?3M?\(79\F*:"]@UM9;>Z$A(58MB,[-P<@H,=215*67--\L
M/N0K5]KO\2O_ ,-<?&?_ **3KO\ WW%_\;H_X:X^,_\ T4G7?^^XO_C=1?%W
MX*+\*O!?A"^NIK@ZYJ<U];ZA;.Z/#"\$FP>65 )!ZY)/X5Y1732H8.M'GA3B
MUK]E=';L1*=6#LY/[SUS_AKCXS_]%)UW_ON+_P"-UVVE?M0?%F;X0>(M3?Q_
MK+:A!J=G#%<%H]R(P?<H^3&#@?E7S;7H6C?\D+\4_P#88L/_ $&2HK83#)1M
M3CNNB[KR'"K4N_>?WFU_PUQ\9_\ HI.N_P#?<7_QNC_AKCXS_P#12==_[[B_
M^-UY'171]3PW_/J/_@*_R,_:U/YG]YZY_P -<?&?_HI.N_\ ?<7_ ,;H_P"&
MN/C/_P!%)UW_ +[B_P#C=>1UZO\ LX_"73OC%XSU'2=275YHK33)KY+;0S$+
MJX=,8C3S%*Y.>]95:&$HP=2=.-E_=7^1<9U9M14G]Y+_ ,-<?&?_ **3KO\
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M=E\'_P!J+XM:Y\2=#L=0^(&LW=G-*RR0R-%M8;&/.$]J^<:[WX%?\E9\._\
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M?_HI.N_]]Q?_ !NO(Z*W^IX;_GU'_P !7^1'M:G\S^\]FTO]K3XR3:G9QO\
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M"O\ _HHMG_X*9/\ XY65'-\%&G&+J:I+H_\ (J=";DW^J/AVBON+_AV%?_\
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M*U(OVT-:LM;;6M/\'Z%IFL7][;7VN7EM+/NU9X!\@968K"I(#,(QR1S7K/\
MP["O_P#HHMG_ ."F3_XY1_P["O\ _HHMG_X*9/\ XY3>*RAWN]_*77^OO"U?
MO^*/ -._:6U73/AWK/A2+0[';J-SJ-P-0^T2B6W-X-LH11P<+D GUKD/B1\4
M+SXE>+[7Q!=V,%E-;VEK:"W@D9D*P(%4G/.3CFOJ[_AV%?\ _11;/_P4R?\
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M\4?#M=?\./B/=_#>ZUF>TLX+QM3TR;3'$[LOEI(,%QMZD>AXKZS_ .'85_\
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M<:[T_5'P[0>A^E?<7_#L*_\ ^BBV?_@ID_\ CE!_X)A7^#_Q<6S_ /!3)_\
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M/_'Q)_O&HJEN?^/B3_>-15S+9%RW8N3C&3CTJ&]O3I]E/<E99%AC:0QP\NP
M)(49')Q4M& >HR*9)YO%^T'X6NW,-O-?33FTT^\2)(,EUO&VPJ!NY8$@NO\
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MLR0K+),R+.\D:#<!\R_>8*,DC-4?!/2==T9##KUW=6\VJ7FL"[6.,^8]S;O
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M-S^,/^@!H/\ WS/_ /'*/^&Y_&'_ $ -!_[YG_\ CE?-]%']D8'_ )]+\?\
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M #0?^^9__CE?-]%']D8'_GTOQ_S#_6'-/^?[_#_(^D/^&Y_&'_0 T'_OF?\
M^.4?\-S^,/\ H :#_P!\S_\ QROF^BC^R,#_ ,^E^/\ F'^L.:?\_P!_A_D?
M2'_#<_C#_H :#_WS/_\ '*/^&Y_&'_0 T'_OF?\ ^.5\WT4?V1@?^?2_'_,/
M]8<T_P"?[_#_ "/I#_AN?QA_T -!_P"^9_\ XY3D_;J\8QN&&@:#D?[,_P#\
M<KYMHI?V1@?^?2_'_,/]8LU7_+]_A_D?2/\ PW/XP_Z &@_]\S__ !RD_P"&
MY_&'_0 T'_OF?_XY7S?13_LC _\ /I?C_F'^L.:?\_W^'^1](?\ #<_C#_H
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MR,#_ ,^E^/\ F'^L6:_\_P!_A_D?2'_#<_C#_H :#_WS/_\ '*/^&Y_&'_0
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MHCDESDEE4D9VACT&<53;]I+2HVN2=#U1(K&RDO-1=GB!M62=[<P[=V9)/-3
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MM;2%)1M1BR]"5)Z@=JYW2G&]UL!Z)11160!1110!\X?MS_\ )-_#_P#V%O\
MVB]?$U?IA\7_ (/Z;\9/#EEINI7]WI\5K=_:%>S5"S'85P=P/'->1_\ #"OA
M3_H9=;_[]P?_ !-?<91FV%PF%5*JVG=]&?EW$/#^/S#'O$4(IQ:75+9'Q717
MVI_PPKX4_P"AEUO_ +]P?_$T?\,*^%/^AEUO_OW!_P#$U[/]OX#^9_<SYO\
MU1S7^1?^!(^*Z*^U/^&%?"G_ $,NM_\ ?N#_ .)H_P"&%?"G_0RZW_W[@_\
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M%/\ H9=;_P"_<'_Q-']OX#^9_<P_U1S7^1?^!(^*Z*^U/^&%?"G_ $,NM_\
M?N#_ .)H_P"&%?"G_0RZW_W[@_\ B:/[?P'\S^YA_JCFO\B_\"1\5T5]J?\
M#"OA3_H9=;_[]P?_ !-'_#"OA3_H9=;_ ._<'_Q-']OX#^9_<P_U1S7^1?\
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MB_\  D?%=%?:G_#"OA3_ *&76_\ OW!_\31_PPKX4_Z&76_^_<'_ ,31_;^
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M7_GFWY4?9I?^>;?E5^WE_,')+L>>ZI\&M(U#Q)-XAAO]2T[7&D@DBOK62,M
M8HGBPJO&RD,DC!@P8'@C! K,N_V?])O+Z:YD\0>(&:YNK2^NU:>%C=7%LRM%
M)(YAW$91<H"$^4?**]5^S2_\\V_*C[-+_P \V_*DJS74.678\UE^!>ABQTF&
MTO\ 4M/N=,6ZCAOH6A>9HKB4RRQMYD3*1N(((4,NT8/7,GC;X976NVG@FRT?
M5;C2(- U&*Y:Z6;?<^4D,D?RM(KAV)<9W@@C=FO1OLTO_/-ORH^S2_\ /-OR
MH]J[WN'++L>:6_P%\,0V>HV\IOKI-0T\V%TTUP"\NZ=YVFW!01*9'+;AP.,
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M*C[-+_SS;\J.9=PY9=B*BI?LTO\ SS;\J/LLW_/-ORHYEW#EEV(J*E^S2_\
M/-ORH^S2_P#/-ORHYEW#EEV(J*E^S2_\\V_*C[-+_P \V_*CF7<.678BHJ7[
M-+_SS;\J/LTO_/-ORHYEW#EEV(J*E^S2_P#/-ORH^S2_\\V_*CF7<.678BHJ
M7[-+_P \V_*C[-+_ ,\V_*CF7<.678BHJ7[-+_SS;\J/LTO_ #S;\J.9=PY9
M=A8.DG^Z:AJS#;R@29C;E3VJ/[-+_P \V_*I35WJ4XRLM"*BI?LTO_/-ORH^
MS2_\\V_*JYEW)Y9=B*BI?LTO_/-ORH^S2_\ /-ORHYEW#EEV(J*E^S2_\\V_
M*C[-+_SS;\J.9=PY9=B*BI?LTO\ SS;\J/LTO_/-ORHYEW#EEV(J*E^S2_\
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M\I?]]:3&B#-&:**8@S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@">V/RS?\
M7,U!FIK;[LW_ %S-0TEN,,T9HHIB#-&:** #-&:** #-&:** #-&:** #-3V
M)_TJ/Z_TJ"I['_CZC^O]*3V&MR GD_6C-!ZGZT4Q!FC-%% !FC-%% !FC-%%
M !FC-%% !FC-%% "J?F7ZBI;P_Z3)]:B7[R_45+>?\?4GUHZCZ$.:,T44"#-
M&:** #-&:** #-&:** #-&:** #-&:**8$]T?]5_N"H,U/=?\LO]P5!4K8;#
M-&:**8@S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@!\W^ND_WC3*?-_KI/\
M>-,H6PPHHI54N0%!8GH ,F@0E%.:&12 T4BD\ %",_2DV/ACL;"_>^4\?7TH
M 2BE,;JH8HP4]&*D _C0RE#A@5/H1@T )13FAD0 M&Z@]"5(!I&1D;:RLK>C
M#!H 2B@@J2""".H(P:* "A?O#ZT4+]X?6@":]_X_)O\ ?-0U->_\?DW^^:AI
M+9#>YG>(=>L_"^A:AK&HR&*QL8'N)G5=Q"*,G [GL!W)%9^A^/-$UWPC9>)4
MOH[#2;M RRZDZVIC;<5*2;R CAE*E2<Y!%9'Q6\):GX[T[2-"M)3::9<:C%-
MJEW&\?F1V\690J(ZL'+R+&I!4C&[(Q7 VOPN\3^&/&(N&LQXR\.66HW6HV]M
M<S6L4TCWD&V8^6P2(&.5689"@K<-@D@@],80<=7J0VTSVE]:TZ.%Y7U"T6)"
MJM(;A-JEAE03GJ000.X(Q65X<^(7AWQ7HVE:IIVL6;VFJEELO,G1'N&#;2J*
M6RS9_A&3R..:\AG^%_B8ZE<6MMX7L;+3;[Q%I.MDP7T'D6<,$<:20A,*S,IC
MXVJ%(/!& #SME\!_%T&CQ6,M@Q$ND1Z0JVUY8HEL\=S(YE9Y(Y'5'$B.#!B0
M-'@KG:1HJ5.VLB>9]CZ&U;QMHNA>(-*T2_U"&UU+4TFEM8I75=ZQ*&D))(P
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M:#2YHDG2[GG2.+:X!4ER=HZ@=>O%9A^(6C-XUM/"L,YNM6N;(ZAMMVC9$@R
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M_%5\LT4?V#@?Y7][#ZY6[_@?4W_#7'AW_H ZO_WW#_\ %4?\-<>'?^@#J_\
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M_P -<>'?^@#J_P#WW#_\57RS13_L' _RO[V+ZY6[_@?4W_#7'AW_ * .K_\
M?</_ ,51_P -<>'?^@#J_P#WW#_\57RS11_8.!_E?WL/KE;O^!]3?\-<>'?^
M@#J__?</_P 51_PUQX=_Z .K_P#?</\ \57RS11_8.!_E?WL/KE;O^!]3?\
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M._\ 0!U?_ON'_P"*KY9HH_L' _RO[V+ZY6[_ ('U-_PUQX=_Z .K_P#?</\
M\51_PUQX=_Z .K_]]P__ !5?+-%']@X'^5_>P^N5N_X'V-X(_:+\-^-=;CTL
M6]WI5Q+Q$UZ4V2-_=!4G!^M>JU^<JL48,I*L#D$'!!KZ@^!'QV76D@\.^(9P
MNH* EK>2' F'9&/][T/>O S3)%0C[;"K1;K]3MP^+YWRU-SWJBBBOCCTPHHH
MH 5?O+]14MY_Q]2?6HE^\OU%2WG_ !]2?6CJ/H0T444""BBB@ HHHH ****
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M_IG_ -_%_P :+H+,@HJ?[%+_ -,_^_B_XT?8I?\ IG_W\7_&BZ"S$MONS?\
M7,U#5VWLY LV=G*$?ZQ?\:A^Q2_],_\ OXO^-)-7'9D%%3_8I?\ IG_W\7_&
MC[%+_P!,_P#OXO\ C3NA69!14_V*7_IG_P!_%_QH^Q2_],_^_B_XT7069!14
M_P!BE_Z9_P#?Q?\ &C[%+_TS_P"_B_XT7069!14_V*7_ *9_]_%_QH^Q2_\
M3/\ [^+_ (T7069!14_V*7_IG_W\7_&C[%+_ -,_^_B_XT7069!4]C_Q]1_7
M^E'V*7_IG_W\7_&IK.TD6Y0G9C/:1?\ &DVK#292/4_6BIS92Y/^KZ_\]%_Q
MH^Q2_P#3/_OXO^-.Z%9D%%3_ &*7_IG_ -_%_P :/L4O_3/_ +^+_C1=!9D%
M%3_8I?\ IG_W\7_&C[%+_P!,_P#OXO\ C1=!9D%%3_8I?^F?_?Q?\:/L4O\
MTS_[^+_C1=!9D%%3_8I?^F?_ '\7_&C[%+_TS_[^+_C1=!9D%%3_ &*7_IG_
M -_%_P :/L4O_3/_ +^+_C1=!9D*_>7ZBI;S_CZD^M.6REW#E.O_ #T7_&I+
MJSD:XD(*8S_ST7_&E=7';0IT5/\ 8I?^F?\ W\7_ !H^Q2_],_\ OXO^-.Z%
M9D%%3_8I?^F?_?Q?\:/L4O\ TS_[^+_C1=!9D%%3_8I?^F?_ '\7_&C[%+_T
MS_[^+_C1=!9D%%3_ &*7_IG_ -_%_P :/L4O_3/_ +^+_C1=!9D%%3_8I?\
MIG_W\7_&C[%+_P!,_P#OXO\ C1=!9D%%3_8I?^F?_?Q?\:/L4O\ TS_[^+_C
M1=!9A=?\LO\ <%05=N;.0^7]SA!_RT7_ !J'[%+_ -,_^_B_XTDU8;1!14_V
M*7_IG_W\7_&C[%+_ -,_^_B_XT[H5F045/\ 8I?^F?\ W\7_ !H^Q2_],_\
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M#/\ 9UUJU\1_#?3=?^',<6E>'?$.NW6HWES%9RVMW#.&-I(%#%G4 J@#KE<
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MI/%>RI<397(FD7&UR<\D8&"*K6OA3PQ;>(7U.WTS3$UN0,[7"*GGMT#-USZ
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MQ7&S0\F_:6\4ZQX4\$:7<:-J=SID\FH^6\EL^TLOEL<'VR!7S?\ \+E\=?\
M0VZM_P!__P#ZU>^?M;?\D_T;_L)_^TGKY1K]&R.A1J8)2G!-W>Z7<\/&3E&J
MTF=E_P +E\=?]#;JW_?_ /\ K4?\+E\=?]#;JW_?_P#^M7&T5]!]5P__ #[C
M]R.+VD_YG]YV7_"Y?'7_ $-NK?\ ?_\ ^M1_PN7QU_T-NK?]_P#_ .M7&T4?
M5</_ ,^X_<@]I/\ F?WG9?\ "Y?'7_0VZM_W_P#_ *U'_"Y?'7_0VZM_W_\
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M_P#ZU<;11]5P_P#S[C]R#VD_YG]YV8^,_CL9QXNU89X/[_\ ^M2?\+E\=?\
M0VZM_P!__P#ZU<;12^JX?_GW'[D'M)_S/[SLO^%R^.O^AMU;_O\ _P#UJ/\
MA<OCK_H;=6_[_P#_ -:N-HI_5</_ ,^X_<@]I/\ F?WG9?\ "Y?'7_0VZM_W
M_P#_ *U'_"Y?'7_0VZM_W_\ _K5QM%'U7#_\^X_<@]I/^9_>=E_PN7QU_P!#
M;JW_ '__ /K4?\+E\=?]#;JW_?\ _P#K5QM%'U7#_P#/N/W(/:3_ )G]YV7_
M  N7QU_T-NK?]_\ _P"M1_PN7QU_T-NK?]__ /ZU<;11]5P__/N/W(/:3_F?
MWG9?\+E\=?\ 0VZM_P!__P#ZU'_"Y?'7_0VZM_W_ /\ ZU<;11]5P_\ S[C]
MR#VD_P"9_>=E_P +E\=?]#;JW_?_ /\ K4H^,_CM3D>+M6!]?/\ _K5QE%+Z
MKA_^?<?N0>TG_,_O.R_X7+XZ_P"AMU;_ +__ /UJ/^%R^.O^AMU;_O\ _P#U
MJXVBG]5P_P#S[C]R#VD_YG]YV7_"Y?'7_0VZK_W_ /\ ZU?0/P.^.:>,8H]%
MUR98];08CG;@7(_^*_G7R94D$\EK,DT+M%+&P9'0X*D="#7%B\LP^*I."BHO
MHTC6EB)TY7O<_1>BO,_@/X[U?QQX3\W5K.19+<B-;XC"W/OCU'<]*],K\MKT
M98>K*E/='T,)J<5)=0HHHKG+"BBB@ HHHH 5?O+]14MY_P ?4GUJ)?O+]14M
MY_Q]2?6CJ/H0T444""BBB@ HHHH **** "BBB@ HHHI@3W7_ "R_W!4%3W7_
M "R_W!4%2MAL****8@HHHH **** "BBB@ HHHH **** 'S?ZZ3_>-,I\W^ND
M_P!XTRA;#"BBB@04444 %%%% !1110 4444 %"_>'UHH7[P^M $U[_Q^3?[Y
MJ&IKW_C\F_WS4-);(;W#.*,G&,\>E%%,0I9B>6)/UI-Q]3110!R7C/XHZ%X
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MQ:?$85N9D5'D&XME@O //;CZ=*Z&N65N9\NQHMM0R?4TNXCN?SI**D HHHH
M\2_:U&? &C?]A/\ ]I/7RE@^AK]"_$?A+1O%^CQ6^M:;;ZG!%/YB1W )"MM(
MR,$=B:Y?_A27@+_H4M-_[X;_ .*KZ[+,YHX+#JC.+;3>UO\ ,\W$8656?,F?
M#F#Z&C!]#7W'_P *2\!?]"EIO_?#?_%4?\*2\!?]"EIO_?#?_%5ZO^LF&_DE
M^'^9S_4)]T?#F#Z&C!]#7W'_ ,*2\!?]"EIO_?#?_%4?\*2\!?\ 0I:;_P!\
M-_\ %4?ZR8;^27X?YA]0GW1\.8/H:,'T-?<?_"DO 7_0I:;_ -\-_P#%4?\
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M_P"$\T+_ *#,'_?9J5E^(N_=?W,IY]A$D^:/_@2.T^QS_P#/&3_ODT?8Y_\
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M_GC)_P!\FC['/_SQD_[Y-8WF/_?;\S1YC_WV_,T>P?</[27\GX_\ V?L<_\
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M^>,G_?)K&\Q_[[?F:/,?^^WYFJ]@^Y/]I+^3\?\ @&S]CG_YXR?]\FC['/\
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M$3HBDOO5#YC[F.P#.,UTW@OX.6'@_2_$L,NLZKK^J>(@1J6LZH\9NI@(?)0
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MPK/PA_SXWG_?^C^W<-_++[E_F'^JN-_GA][_ /D3P2BO>_\ A6?A#_GQO/\
MO_1_PK/PA_SXWG_?^C^W<-_++[E_F'^JN-_GA][_ /D3P2BO>_\ A6?A#_GQ
MO/\ O_1_PK/PA_SXWG_?^C^W<-_++[E_F'^JN-_GA][_ /D3P2BO>_\ A6?A
M#_GQO/\ O_1_PK/PA_SXWG_?^C^W<-_++[E_F'^JN-_GA][_ /D3P2BO>_\
MA6?A#_GQO/\ O_1_PK/PA_SXWG_?^C^W<-_++[E_F'^JN-_GA][_ /D3P2BO
MH&W^%W@^593]@NSM0MS/4/\ PK/PA_SXWG_?^E_;V&_EE]R_S&^%,:DGSP^]
M_P#R)X)17O?_  K/PA_SXWG_ '_H_P"%9^$/^?&\_P"_]/\ MW#?RR^Y?YB_
MU5QO\\/O?_R)X)17O?\ PK/PA_SXWG_?^C_A6?A#_GQO/^_]']NX;^67W+_,
M/]5<;_/#[W_\B>"5O>$?"-SXIOMB9BM4/[V<CA1Z#U->N_\ "L_"'_/C>?\
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MJ\)\:_$/6-+\?^*;2S\4-'>::^E#3/#02#%[Y[$2@@KYCY /W6&S&3Q7O_\
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M-=W]LX+^?\'_ )'E_P"K>:?\^OQ7^9Y#17KW_"AA_P _E]_X#+_C1_PH8?\
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M?\_E]_X#+_C1_P *&'_/Y??^ R_XT?VS@OY_P?\ D+_5O-/^?7XK_,\AKLO
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MTAC$,2B&*26&-II&+-\D2,GF-U8]*AT+Q=XB\2+HNNS^)KO2O$<OPLF$FO\
MV26XF@D6_",[I$I<L%7#,!N'+'D$U][#CIQW_&@  Y  /J!6WUA?R_U]Q?M%
MV/DWX.^&]+_:'\':[X>U_5=7UNTTG4(+B/4O[476+1I&A/RVE[-"LI .UGC8
M'!PN2A(/U3I>G0Z1IEI8VZHD%K"D"+'&L:A54 850 HXZ  #H.*L]L=!Z45S
MSGSO38SE+F"BBBLR IR??7ZTVG)]]?K2 LZD[#4+GYC_ *P]ZK;V_O-^=3ZG
M_P A&Y_ZZ&JU3'X4:5/C?J.WM_>;\Z-[?WF_.FT59F.WM_>;\Z-[?WF_.FT4
M .WM_>;\Z-[?WF_.FU5U;5+;1-+O-1O)!%:6D+SS2'^%%!9C^0H N;V_O-^=
M&]O[S?G7&>%OBMH7B/P2GB>YE/A^Q$K03Q:LZ126\H('EO@D;CN4@ G(85JP
M^.O#=Q8RWL6OZ;+9Q)%))<)=(41921$2<X 8@@>I!IN+70=F;V]O[S?G1O;^
M\WYUQ6C?&/P?K&BP:I_;MG8VMQ=SV4/VV98FDDB<HP )]L_0C.,UT&O^*-'\
M*6R7&M:I::5 [;%DNYA&K'&<#/7@$_2AQ:=F@LS5WM_>;\Z-[?WF_.N'M_C/
MX.EU;5M/DUVSM)--D@ADEN)E6.5I8_,01G/S_+Z?AFMF+Q[X9FN+^"/Q!ICS
MV"&2[C%TF8%'5GYX R,^F>:?*UT"S-_>W]YOSHWM_>;\ZY=_B?X/CTZ&_?Q1
MI*64TC11W#7:!&=>67.>HR,YZ9&:T]=\3Z1X8L%O=6U*UTZT8A4FN9E178C(
M )ZD@9XI6?8-35WM_>;\Z-[?WF_.N%T+XR>&M8T&'6+C4+72+"6"*=6OKR(.
M!(SJ@958D9\LD'H1TZ&MT^.?#BWEA:'7M-^U7\:RVD/VI"TZ-]UDYY#=CW[9
MH<6MT%F;N]O[S?G1O;^\WYUR=[\5/!]A975U)XETLQ6TC0R$7:<2@',?7[WR
MGCM@YQ2>'OBCX;\0V>AR+JEM97NL6T=U:Z==3H+DHXROR@GDX/3KCC-'*[7L
M%F=;O;^\WYT;V_O-^=<'K'Q7L;9[.?2!::[I37D=E>7UK>?+:R/($ .$9>"2
M3N9 -N,EB!7=D8)'IQ0TUN&J%WM_>;\Z-[?WF_.FT4A#M[?WF_.C>W]YOSIM
M% #M[?WF_.C>W]YOSIM% %'6O&FE>'K>.VO[QH)Y'\Q5$;ME<8SD ]ZQ_P#A
M9_AW_H)/_P!^9/\ "N,^,G_(8L/^N#?^A5Y]7U6#RBA7H1JR;N_3_(^ S'B'
M%X;%3H0C&T=-4^WJ>Z?\+/\ #O\ T$G_ ._,G^%'_"S_  [_ -!)_P#OS)_A
M7A=%=O\ 8>&_FE]Z_P CS?\ 6C&_RQ^Y_P#R1[I_PL_P[_T$G_[\R?X4?\+/
M\._]!)_^_,G^%>%T4?V'AOYI?>O\@_UHQO\ +'[G_P#)'NG_  L_P[_T$G_[
M\R?X4?\ "S_#O_02?_OS)_A7A=%']AX;^:7WK_(/]:,;_+'[G_\ )'NG_"S_
M  [_ -!)_P#OS)_A1_PL_P ._P#02?\ [\R?X5X711_8>&_FE]Z_R#_6C&_R
MQ^Y__)'NG_"S_#O_ $$G_P"_,G^%'_"S_#O_ $$G_P"_,G^%>%T4?V'AOYI?
M>O\ (/\ 6C&_RQ^Y_P#R1[I_PL_P[_T$G_[\R?X5.GQ4\-BRDC.I/O+J0/(D
MZ?E7@E%)Y'AG]J7WK_(I<4XV/V8_<_\ Y(]T_P"%G^'?^@D__?F3_"C_ (6?
MX=_Z"3_]^9/\*\+HI_V'AOYI?>O\B?\ 6C&_RQ^Y_P#R1[I_PL_P[_T$G_[\
MR?X4?\+/\._]!)_^_,G^%>%T4?V'AOYI?>O\@_UHQO\ +'[G_P#)'NG_  L_
MP[_T$G_[\R?X4?\ "S_#O_02?_OS)_A7A=%']AX;^:7WK_(/]:,;_+'[G_\
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MHH =O;^\WYT;V_O-^=-HH =O;^\WYT;V_O-^=-HH =O;^\WYT;V_O-^=-HH
MN7[-_H_S'_5+WJKO;^\WYU9O_P#EW_ZY+52HA\)I-^\QV]O[S?G1O;^\WYTV
MBK,QV]O[S?G1O;^\WYTVB@!V]O[S?G1O;^\WYTVB@!V]O[S?G1O;^\WYTVB@
M!V]O[S?G1O;^\WYTVB@!V]O[S?G1O;^\?SIM%("6Y_X^9?\ ?/\ .HJEN?\
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M!?$6AZ=:&:#3[J^MK2RCADT_5YK"6VFB-QO>&41-@8F"[64AE+ CUTK?X/\
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M=>_Z ][_ -^31[>C_.OO0?5<1_S[E]S,>BMC_A#=>_Z ][_WY-'_  ANO?\
M0'O?^_)H]O1_G7WH/JN(_P"?<ON9CT5L?\(;KW_0'O?^_)H_X0W7O^@/>_\
M?DT>WH_SK[T'U7$?\^Y?<S'HK8_X0W7O^@/>_P#?DT?\(;KW_0'O?^_)H]O1
M_G7WH/JN(_Y]R^YF/77_  \\+WVKZI'>Q2O:6UNV6G7@D_W5]:F\)?#'4M:O
MG^WV\VGV<*[Y&E7:SC^ZO^->OV=G!I]K';V\:Q0QC"HO:O#S',X4XNC1=Y/?
MJD?4Y-DE2M-8C$)QBMELVU^2)J***^*/TT**** "BBB@ HHHH **** "K6F_
M\?T/U_I56K6F_P#']#]?Z5$OA9I3^->I6;[Q^M)2M]X_6DJC,****8!1110
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M0<?0BKA.K4FH1D[O3<3H4(IMP7W(Z;^S+/\ Y]D_-O\ &C^S+/\ Y]D_-O\
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MM_C1_9EG_P ^R?FW^-6:*/;5/YG]X?5Z/\B^Y%;^S+/_ )]D_-O\:/[,L_\
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M_P#/LGYM_C1_9EG_ ,^R?FW^-6:*/;5/YG]X?5Z/\B^Y%;^S+/\ Y]D_-O\
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M+[GFUC^T/XN\,?#JQOKVWL_$>I6UA-JE^8;>X>5XA<RHH;:=ENH6-L22,0<
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M%%% !1110 4444 %%%% !1110 4^'_6+3*?#_K%H 9ZT4>M% !1110 4444
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M)/-/\YO]G_OD4><W^S_WR*F=2=3XW<:BH[(9F@'D4_SF_P!G_OD4HF;(Z?\
M?(K,H2<_OG^M,S4TTK"5QQU_NBF><W^S_P!\B@!F:,T_SF_V?^^11YS?[/\
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M?^IA_P#)/_[.O;?.;_9_[Y%'G-_L_P#?(H \X\#_  :L/".H&^N+K^U+I?\
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M/_?(H\YO]G_OD4 ,S1FG^<W^S_WR*/.;_9_[Y% #,T9I_G-_L_\ ?(H\YO\
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MT4>M% !1110 4444 %%%% !1110 4444  ZCZTZ7_6-]::.H^M.E_P!8WUH
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M?Z^L_''@2V\=Z3!:7=Q<6J0S^:&@4$D[2,'(]ZXG_AG/1_\ H*ZE_P!\1_\
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M-K?W3^5 "44NUO[I_*C:W]T_E0 @ZCZTZ7_6-]:0*V1\IZ^E.E5O,;Y3U]*
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MP&?6F>:_]]OSI9_]<_UIE #O-?\ OM^='FO_ 'V_.FT4 .\U_P"^WYT>:_\
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M<^F;V(QO8CTW'%)6,\1*6D/=7]?\,7&"6^H4445R&@4444 %%%% 'EG[0_\
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M:.AE.7EE;?(WH-WI[5V=% &3]EE_N&C[++_<-:U% &3]EE_N&C[++_<-:U%
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M00@C)3+ $H< DY !C3 [;1C&*LZ#X#T[P]Y+6TERTJ74][)(\@!GEFSO:0*
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M55+2=&L=!LQ::?:Q6=L"6$4*[5!/4XJ[0 4444 %%%% !1110 4444 %%%%
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MMQE1R&7 ]0#5/4_@WXQU/59[F?3+*6Q:6*1]/74V190DJ,H#X)R$4KDXP>F
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>btai-20241231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 btai-20241231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &D \(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#T[XM?\%$O
M'/P\^)_BGPQ:^&]"NK;2=0EM(II7F#NBMP6 .,XKD_\ AZ'\0/\ H4_#W_?R
M;_&O OVG/^3A_B+_ -AJX_\ 0J\RK]=P^48&=&$I4E=I=^WJ?+SQ593:4C[*
M_P"'H?Q _P"A3\/?]_)O\:/^'H?Q _Z%/P]_W\F_QKXUHK?^QLO_ .?2_'_,
MCZW7_F/LK_AZ'\0/^A3\/?\ ?R;_ !H_X>A_$#_H4_#W_?R;_&OC6BC^QLO_
M .?2_'_,/K=?^8^RO^'H?Q _Z%/P]_W\F_QH_P"'H?Q _P"A3\/?]_)O\:^-
M:*/[&R__ )]+\?\ ,/K=?^8^RO\ AZ'\0/\ H4_#W_?R;_&C_AZ'\0/^A3\/
M?]_)O\:^-:*/[&R__GTOQ_S#ZW7_ )C[*_X>A_$#_H4_#W_?R;_&C_AZ'\0/
M^A3\/?\ ?R;_ !KXUHH_L;+_ /GTOQ_S#ZW7_F/LK_AZ'\0/^A3\/?\ ?R;_
M !H_X>A_$#_H4_#W_?R;_&OC6BC^QLO_ .?2_'_,/K=?^8^RO^'H?Q _Z%/P
M]_W\F_QKI?%'_!1;Q[X>\,^#]47PWH$TFNV<]V\9:8"+9.T0 YYX7-?"%>B_
M$O\ Y)W\)_\ L#W?_I;)6-3*,#&<$J2U?GV?F7'%5FG[W]71]"_\/0_B!_T*
M?A[_ +^3?XT?\/0_B!_T*?A[_OY-_C7QK16W]C9?_P ^E^/^9'UNO_,?97_#
MT/X@?]"GX>_[^3?XT?\ #T/X@?\ 0I^'O^_DW^-?&M%']C9?_P ^E^/^8?6Z
M_P#,?97_  ]#^('_ $*?A[_OY-_C1_P]#^('_0I^'O\ OY-_C7QK11_8V7_\
M^E^/^8?6Z_\ ,?97_#T/X@?]"GX>_P"_DW^-'_#T/X@?]"GX>_[^3?XU\:T4
M?V-E_P#SZ7X_YA];K_S'V5_P]#^('_0I^'O^_DW^-'_#T/X@?]"GX>_[^3?X
MU\:T4?V-E_\ SZ7X_P"8?6Z_\Q]E?\/0_B!_T*?A[_OY-_C1_P /0_B!_P!"
MGX>_[^3?XU\:T4?V-E__ #Z7X_YA];K_ ,Q]E?\ #T/X@?\ 0I^'O^_DW^-'
M_#T/X@?]"GX>_P"_DW^-?&M%']C9?_SZ7X_YA];K_P Q]E?\/0_B!_T*?A[_
M +^3?XT?\/0_B!_T*?A[_OY-_C7QK11_8V7_ //I?C_F'UNO_,?97_#T/X@?
M]"GX>_[^3?XT?\/0_B!_T*?A[_OY-_C7QK11_8V7_P#/I?C_ )A];K_S'V5_
MP]#^('_0I^'O^_DW^-'_  ]#^('_ $*?A[_OY-_C7QK11_8V7_\ /I?C_F'U
MNO\ S'V5_P /0_B!_P!"GX>_[^3?XT?\/0_B!_T*?A[_ +^3?XU\:T4?V-E_
M_/I?C_F'UNO_ #'V5_P]#^('_0I^'O\ OY-_C1_P]#^('_0I^'O^_DW^-?&M
M%']C9?\ \^E^/^8?6Z_\Q]E?\/0_B!_T*?A[_OY-_C1_P]#^('_0I^'O^_DW
M^-?&M%']C9?_ ,^E^/\ F'UNO_,?97_#T/X@?]"GX>_[^3?XT?\ #T/X@?\
M0I^'O^_DW^-?&M%']C9?_P ^E^/^8?6Z_P#,?=_AO_@HMX]UWPEXMU=O#>@1
M2:)#;2I&&F(E\V4H03GC'6N:_P"'H?Q _P"A3\/?]_)O\:^>OAY_R2_XI_\
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M3]!T+PA!I%O)?^&;Z /<7*>5\V/KZ5\GZYHGPPL/@G-\0SX.&MZAKGB>\L+
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M!S5++2K;1+.XM[AH;"T7$<*97"C\.]?*FHWTVJWUS>7#!I[B1I9&50H+$Y.
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M\WJ!CD9]:\CO?VTO&6JZWX@OM2TC0-3M=;BMH[K3+NT,EL6@&(Y I;.X?7'
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M9IJYUNT2ZF:'[/<LQ9ON@[D)/W3Q7%26.J1YDW:^NJN]7\/;IN:R=&+MI?\
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M>J_])B7+:/\ 75A111700%%%% !1110 4444 %%%% 'HOPE_Y 'Q+_[%I_\
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MB@ HHHH **** "BBB@ KZ _8,_Y.F\)?]<[K_P!$-7S_ %] ?L&?\G3>$O\
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M,CG">I]:@^T3_P#/23_OHUE'/JJE)^S6OF^Q;A"RW/Q@_P"%2^.?^A+\0_\
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MR0\S\8/^%2^.?^A+\0_^"N?_ .)H_P"%2^.?^A+\0_\ @KG_ /B:_9_[1/\
M\])/^^C1]HF'_+63_OHT?ZP5?^?:^]AR0\S\8/\ A4OCG_H2_$/_ (*Y_P#X
MFN_U?X8^,G^!WAVU7PEKK7*:S<N\(TV;>JF,8)7;D#WK]8/M,W_/5_\ OHU.
M\\OV.,^8^=QYW&LIY]5DXOV:T?=EQA#7<_%G_A4OCG_H2_$/_@KG_P#B:/\
MA4OCG_H2_$/_ (*Y_P#XFOV?^TS?\]7_ .^C1]IF_P">K_\ ?1K7_6"K_P ^
MU][(Y(>9^,'_  J7QS_T)?B'_P %<_\ \31_PJ7QS_T)?B'_ ,%<_P#\37[/
M_:9O^>K_ /?1H^TS?\]7_P"^C1_K!5_Y]K[V')#S/Q@_X5+XY_Z$OQ#_ ."N
M?_XFC_A4OCG_ *$OQ#_X*Y__ (FOV?\ M,W_ #U?_OHT?:9O^>K_ /?1H_U@
MJ_\ /M?>PY(>9^,'_"I?'/\ T)?B'_P5S_\ Q-'_  J7QS_T)?B'_P %<_\
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M_@JG_P#B:/\ A4GCG_H2O$/_ (*I_P#XFOV?^TS?\]7_ .^C1]IF_P">K_\
M?1H_U@J_\^U][#DAYGXP?\*E\<_]"7XA_P#!5/\ _$T?\*D\<C_F2O$/_@JG
M_P#B:_9_[3-_SU?_ +Z-'VF;_GJ__?1H_P!8*O\ S[7WL.2'F?C!_P *E\<_
M]"7XA_\ !5/_ /$UW_Q ^&/C*X\!?#V*+PEKLLL%E<+*B:;,6C)FR PV\?C7
MZP?:9O\ GJ__ 'T:FGN)1! 1(X)!_B/K64\^JRE%^S6C[OLRXPA9[GXM?\*E
M\<_]"7XA_P#!7/\ _$T?\*E\<_\ 0E^(?_!7/_\ $U^S_P!IF_YZO_WT:/M,
MW_/5_P#OHUK_ *P5?^?:^]D<D/,_&#_A4OCG_H2_$/\ X*Y__B:/^%2^.?\
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M1_PJ7QS_ -"7XA_\%<__ ,37[/\ VF;_ )ZO_P!]&C[3-_SU?_OHT?ZP5?\
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MWX5E*E&S<)7MY>=@/H0LHZLH/N0*7<,9W#'KGBOEW]L_P=H/]E6=W9V=S/\
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MJ\O;EHTVN9/[J_,2.Y-7_A'XZEG^!EIXAUF\;4;NQM9WO7QB16B+9C;_ &U
M /N*OZ[\+[RZN-!OM$\2WF@ZII5A_9OGQQK+'/#A1\\;<;LJ"#VK3\+?#72_
M"_@:?PNK2WEI=+,;N:8_O+AY<F5V]R2:T<H\EGW_ ,QG 7'QK\5^&_!<WC3Q
M!X9LT\,OI[7T/V.Y+3Q,<>5'(I')?<.5Z5A1_M/:I:V&MM=:1:7MS;:-+JML
M]CYPA#QXS!*SJ,,0PP1P<&NE?]G*'5M(71=?\3ZCK.A6UE+8V%D56+[.KX <
MLO+NH4;2>F*O7'P3U/6=%U73M<\;:AJD5WIC:9"H@CB2)&QF1E48>3@#)K5.
MCU_4#C?B%\7/'>G>&]=TZ?3M.TK5IM#_ +7L+NUG9Q&FY0RMD??&X<CBH-3_
M &D]9T!Y]*%CI]UJ6C6$$M^)&F)NI7B#^7#M4\[2.6QR:]+\8_!NS\97!EGU
M&>W!T1]%Q&@^ZQ4^9]05''2L0? ?4;.XN[G2_&M[I=YJ5K%:ZG-#:QDW!C78
MLJ C]V^T 9'I1&=*WO+\PT*3?'#Q'J^K:TVA>&XKC2=(T>TU>9;AG6[D\^)G
M$*IC[X*$<UK?!CXOWWQ+NKF*YCTIHTMTG#Z=<,7A8]8I8W 8,/7&*W+/X5Q6
M-_XHNH=8OHYM=T^SL#,K 30?9XW19%?J6._))[BJ/@;X/-X6\6MXDU/7)-<U
M46?V&.7[-';@1YR2X0#>QQ]XU#=)Q:2 ]'HHHKE$%7M%_P"0E%]#_*J-7M%_
MY"47T/\ *HJ? S:C_$CZHZBBBBO%/I3D=0_X_I_]\U7JQJ'_ !_3_P"^:KU[
M<?A1\O/XF+7S1KG[('B*?QOXK\0>&_C/XB\'1>(KY[^YT_2[11'O/&"?,!;
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M?7_#*'PV_P"@3<_^!;4?\,H?#;_H$W/_ (%M7N?ZPX3^67W+_,^5_P!3\?\
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MJ]%%GW"\>Q8^QM_STB_[[H^QM_STB_[[JO119]PO'L6/L;?\](O^^Z/L;?\
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MQO8#A<]LGBODCX?_ +6?C.#PRESKW@^77-1U;Q//HNF1VUY'&&<9Q'T^4*0
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M#:;<13PZ-F:*":VCDDG=RD,J%)(UR>%*DC%5[:GJVN_1>=@3.&_9Z4#QC=X
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M_P#?-5ZL/_QY1_[YJ7T+CU]"O1115$!1110 4444 %%%% !1110 58N^D/\
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M%%% 'F_QWU6Z@\,:/H=G.UI-XFUBUT1KE#AHHI"6E(]S&C ?6O-/B5X!NO\
MA/M=U+5/!^H>//"@MK>WTT:%JNRYT,1Q[73[/O7<Q.'# [NU>N?&'PE>^*O"
MD$FD@-K>CWUOJ^GH3@22PON\O/\ M+N7\:S=9^"MAKFNWNOZ=K6O>$+W5T1]
M1M]*N51)W"@ NI4@.!\I88Z5U4YJ"6O?].VHSS'PG>VGQ/\ $G@WPK/KVIZ]
MX3@T66];[:#;3WLRR; EP%.28^A&>3R:D^*?A+2OAW'8Z?H.OW"17'BK0ICX
M=-QN%BK7(4NF3N"28Y4\<<5ZC/\  WPZND:+9Z;+?:+=:/O^QZG8S8N5W\R;
MF8$/N/)!'6LS4?V<] U71KVVN=5UB75;R_MM1GUUIE-XTL#9AP2NT*IZ*!BM
M%5AS)WT[?/<";]HO7-0TGPEIEEI]Y+IO]L:S::9<7D!VR10R28?:?X21P#VS
M2K\)?"?@?Q1HM[I>I2^&I97>TDLOM+.FK J?W;J['+#KN'-6XO@S;7>D:GI>
MO^(];\56-\BJ8M4F3]PRG<LD915*L" 0?:GZ+\'['2-=M-<U+5]8\4WVFHPL
M%U6976WR,$H%4 L1QN.36*DHQY4^_P P*_P6OKF"/Q3X9N9'G7PYJTEE;S2-
MN9H& DC!/^R&Q^%>D5POPF\*7WA_3=8U+5X_)UG7=1EU&ZAW9\K/")GV0**[
MJLZEG)V$%%%%9@%%%% !1110 4444 %%%% 'E7[5W_)MOCS_ *]X/_2B.ORT
MK]A_'7@:P^)/@76_#6J2316%_'&DKV[!9 %D##!(/=17@?\ PP'\.O\ H(:Y
M_P!_T_\ B*]W+L;2PU.4:E[MW_!'R^<Y;7QM6$Z5K*-M_-GYZ45^A?\ PP'\
M.O\ H(:Y_P!_T_\ B*/^& _AU_T$-<_[_I_\17K?VKAO/[CY_P#L'&=E]Y^>
ME%?H7_PP'\.O^@AKG_?]/_B*/^& _AU_T$-<_P"_Z?\ Q%']JX;S^X/[!QG9
M?>?GI17Z%_\ # ?PZ_Z"&N?]_P!/_B*/^& _AU_T$-<_[_I_\11_:N&\_N#^
MP<9V7WGYZ45^A?\ PP'\.O\ H(:Y_P!_T_\ B*/^& _AU_T$-<_[_I_\11_:
MN&\_N#^P<9V7WGYZ4H!8@ $D\ #J:_0K_A@/X=?]!#7/^_Z?_$5L^#_V*?A[
MX.\16>L1G4=2FM'\R."^E5HBPZ$@*,XI/-L.EI?[BHY!BVTG9+U.2_8T_9D7
MPM9#QQXIM =:FBWZ=:2K_P >J'_EH1_?(Z>@KZIJQ:\1SXX'E_U%5Z^3K5YX
MBHYS/OL-A:>$HQI4U_P7W"BBBL3H"BBB@ HHHH **** "K$'_'O<?0?SJO5B
M#_CWN/H/YU,MBX;_ '_D5Z***H@**** "BBB@ HHHH **** "K#_ /'E'_OF
MJ]6'_P"/*/\ WS4OH7'KZ%>BBBJ("BBB@ HHHH **** "BBB@ JQ=](?]P57
MJQ=](?\ <%2]T6OA9S/Q =H_ /B9D8HZZ9<E6!P0?*;FOE;PCX-37O"/@-_!
M'@#Q3H/BW9IUS-XGO)/(M0@5&GD),S>8KC=A=O.X=*^O-9TN+7-'O]-N"RP7
MD$EO(4.&"NI4X]\&H_#NBP>&/#VE:-:,[VNG6D5G"93EBD:!%)]\**ZJ=7V<
M6D2?.G@OQ?XV\':/>:T+[2[OPX_C"YT]]-EMW-R4DN"N\3;L*0>B[<8J_?\
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M .?4ON8>VI?S(].HKS'_ (:0\"_]!"Y_\!FH_P"&D/ O_00N?_ 9J/[/Q?\
MSZE]S#VU+^9'IU%>8_\ #2'@7_H(7/\ X#-1_P -(>!?^@A<_P#@,U']GXO_
M )]2^YA[:E_,CTZBO,?^&D/ O_00N?\ P&:C_AI#P+_T$+G_ ,!FH_L_%_\
M/J7W,/;4OYD>KV?^KN?^N?\ 456KS>W_ &E/ <:3AM1N<LFT?Z*W7-0_\-(>
M!?\ H(7/_@,U2LOQ=W^ZE]S'[>E_,CTZBO,?^&D/ O\ T$+G_P !FH_X:0\"
M_P#00N?_  &:J_L_%_\ /J7W,7MJ7\R/3J*\Q_X:0\"_]!"Y_P# 9J/^&D/
MO_00N?\ P&:C^S\7_P ^I?<P]M2_F1Z=17F/_#2'@7_H(7/_ (#-1_PTAX%_
MZ"%S_P" S4?V?B_^?4ON8>VI?S(].HKS'_AI#P+_ -!"Y_\  9J/^&D/ O\
MT$+G_P !FH_L_%_\^I?<P]M2_F1Z=5FW_P"/6Y^B_P Z\H_X:0\"_P#00N?_
M  &:IH?VE/ :03*=0N<N!C_1FJ7E^+_Y]2^YA[:E_,CTBBN3\&_%'PYX]N)[
M?1[XS7$*[FBE0HQ'J >M=97+4ISI2Y*BL_,UC)25XNX4445F,**** "BBB@
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MJ3RQ[GFGA/PO\0?!NB#P38Z)8MI\6J7-S_PDDUQ$\4MI+*\N/))WB?Y]N2,
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M445]6>:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQC/%+ZS+MUN/V:/FWP[;:IX=\)P^&!\.GUKQ/9WMW<27=[#MMG#%V$RS]2S
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M'&@P%4= *F))HKQ,=F%7'S4JFB6R.RC1C15HA1117F&X4444 %%%% !1110
M59?_ )!\?^^?Y56JR_\ R#X_]\_RI/H,K4444Q!1110 4444 %%%% !1110
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M50.I)[4 /HID4J31I)&ZR1N RNIR&!Z$&GT %%%% !1110!9MO\ CUNOHO\
M.JU6;;_CUNOHO\ZK8/H:2W8^@448/H:,'T-,0448/H:,'T- !11@^AHP?0T
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M#Q6JK!E#*05(R".]-IK<!:***0!1144UU!;R0QRS1Q23MLB1V ,C8SA1W.*
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ME8U?^$LUK_H*77_?PT?\)9K7_04NO^_AK*HKV/9P_E7W')S/N:O_  EFM?\
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M #]Q?K_A1MM_^?N+]?\ "BS[![6G_,OO(Z*DVV__ #]Q?K_A1MM_^?N+]?\
M"BS[![6G_,OO(Z*DVV__ #]Q?K_A1MM_^?N+]?\ "BS[![6G_,OO(Z*DVV__
M #]Q?K_A1MM_^?N+]?\ "BS[![6G_,OO(Z*DVV__ #]Q?K_A1MM_^?N+]?\
M"BS[![6G_,OO(Z*DVV__ #]Q?K_A1MM_^?N+]?\ "BS[![6G_,OO(Z*DVV__
M #]Q?K_A1MM_^?N+]?\ "BS[![6G_,OO(Z*DVV__ #]Q?K_A1MM_^?N+]?\
M"BS[![6G_,OO(Z*DVV__ #]Q?K_A1MM_^?N+]?\ "BS[![6G_,OO(Z*DVV__
M #]Q?K_A1MM_^?N+]?\ "BS[![6G_,OO(Z*DVV__ #]Q?K_A1MM_^?N+]?\
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M2=WH/VM/^9?>1T5)MM_^?N+]?\*-MO\ \_<7Z_X4[/L+VM/^9?>1T5)MM_\
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M %Q'\ZJ'I5O4.EK_ -<1_.LY?$C6/PR*E%%%:&04444 %%%% !1110 4444
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MJ'2U_P"N(_G6<OB1K'X9%2BBN+\6?$?^Q/$=KX<TG2YM>\03VYNVM(7$:PP
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M:<)TB<AQG&]N.,UQ_@OXW:GXKU+48[KP3<Z)IFE74MIJ6IW6I0M':-&NYRP
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M0 4444 %6Y/^09#_ -=&_E52K<G_ "#(?^NC?RJ)=/4TAL_0J44459F%%%%
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M1^J6Q\2MH^I6VOQ6FFZ/(+J226P 7!2-!Y;1LN<NW(.:]R_9D!'A#Q_D8/\
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M[7_CRO/]U?YU4JW:_P#'E>?[J_SJ)[?=^9I3W^3_ "*E%%%69A1110 4444
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MNGJRGRA>+]K"@<[_ +^<<]:^O([*WA_U=O#'U/R1@?7H*6.U@B&(X8T&,85
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M[-I=W_7R//\ _A&=2_Y]O_'A1_PC.I?\^W_CPKT"BCZ_4[(/[-I=W_7R//\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>btai-20241231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 btai-20241231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '8 T4# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRG!Z<=!7OW[)/A[2K#X*>'-3MM,L[?4KR&47-Y% BS3A9Y H=P,M@#C)K?\
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MD:7:#[_,*^H]'^%&GVWPCMO .JS?VKIZ6(L99Q'Y1D Z.%RVT@X(Y."!7&_
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M!?!C]FK2/A-JMSKESJ=SXD\27 93J5VNS8K?>VKN8Y/=BQ....<I\$OV>?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BD8[035$W<A[@52BY;$2FH;E^BL_P"U2>M'
MVJ3UJO9R,_;0-"BL_P"U2>M'VJ3UH]G(/;0-"BL_[5)ZT?:I/6CV<@]M T**
MS_M4GK1]JD]:/9R#VT#0HK/^U2>M'VJ3UH]G(/;0-"BL_P"U2>M'VJ3UH]G(
M/;0-"BL_[5)ZT?:I/6CV<@]M T**S_M4GK1]JD]:/9R#VT#0HK/^U2>M'VJ3
MUH]G(/;0-"BL_P"U2>M'VJ3UH]G(/;0-"BL_[5)ZT?:I/6CV<@]M T**S_M4
MGK1]JD]:/9R#VT#0HK/^U2>M'VJ3UH]G(/;0-"BL_P"U2>M'VJ3UH]G(/;0-
M"BL_[5)ZT?:I/6CV<@]M T**S_M4GK1]JD]:/9R#VT#0HK/^U2>M'VJ3UH]G
M(/;0-"BL_P"U2>M'VJ3UH]G(/;0-"BL_[5)ZT?:I/6CV<@]M T**S_M4GK1]
MJD]:/9R#VT#0HK/^U2>M'VJ3UH]G(/;0-"BL_P"U2>M'VJ3UH]G(/;0-"BL_
M[5)ZT?:I/6CV<@]M T**S_M4GK1]JD]:/9R#VT#0HK/^U2>M'VJ3UH]G(/;0
M-"BL_P"U2>M'VJ3UH]G(/;0-"BL_[5)ZT?:I/6CV<@]M T**S_M4GK1]JD]:
M/9R#VT#0HK/^U2>M'VJ3UH]G(/;0-"BL_P"U2>M'VJ3UH]G(/;0-"BL_[5)Z
MT?:I/6CV<@]M T**S_M4GK1]JD]:/9R#VT#0HK/^U2>M'VJ3UH]G(/;0-"BL
M_P"U2>M'VJ3UH]G(/;0-"BL_[5)ZT?:I/6CV<@]M T**S_M4GK1]JD]:/9R#
MVT#0HK/^U2>M'VJ3UH]G(/;0-"BL_P"U2>M'VJ3UH]G(/;0-"BL_[5)ZT?:I
M/6CV<@]M T**S_M4GK1]JD]:/9R#VT#0HK/^U2>M'VJ3UH]G(/;0-"BL_P"U
M2>M'VJ3UH]G(/;0-"BL_[5)ZT?:I/6CV<@]M T**S_M4GK1]JD]:/9R#VT#0
MHK/^U2>M'VJ3UH]G(/;0-"BL_P"U2>M'VJ3UH]G(/;0-"BL_[5)ZT?:I/6CV
M<@]M T**S_M4GK1]JD]:/9R#VT#0HK/^U2>M'VJ3UH]G(/;0-"BL_P"U2>M'
MVJ3UH]G(/;0-"BN>U#Q.FF:GI]I+RUX7"_\  =N?_0A70*=R@^HS4-6=F:Q:
MDKH6BBBD4,E_U;?2LRM.7_5M]*S*WI=3DK] HHHK8Y0HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZ[KEEX
M:T:]U74I_LUA9Q-//-L9]B*,DX4$G\!5ZN%^.O\ R1OQG_V"Y_\ T UO1@JE
M6,'LVE^)S8FJZ-"I5CO%-_<BCX:_:-^'7B_6[72-+\2QSZA=-LABEMIX0[=E
M#2(JY/0#.2>!DUVOB?Q-IO@W0KO6=8N?L>FVBAII_+9]@)"CY5!)Y(Z"OGWP
M=\-/'GQ'\+_#,:_=^&[3PGI$=CJ5J=.29K]T2%?*1RXV@D8#;2!GG!P!7'V+
M^(KOX/\ Q \;2^-_$_V_3M0N+*TM4U.18(T$D?S8SDL-Y Y  [5[\LMPTZB5
M.>B:35[ZMV6JBDMNSMYGR,<ZQM.BY5J6KBY)VY5:,4W>+DV[7[J_D?7UA?0:
MG8V]Y;/YEM<1K-$^"-RL,@X/(X(ZU/7R)KEWXC\2:]XP"^,_$.EPZ-X.MM8A
MAL+]XQ)<+:H_S<]&);=C!)()/%6_"?C/7O#'BOPCK&K^+M<U*SU_PQ=ZMJ4,
MLBR1P&.%I ;>$KL4J(QC@Y.<\,16,LIER\T9J]KVL^W-;[CHCQ#'G49TFE>U
M[JWQ<M[7OO;Y'UA17QQX4\=WL'Q#TU-#\9ZWJVCZOHVH3O;:KKHOKB';;R2)
MYD:(%MY R @*S,!W&2*OZ#9^*-,^!.C_ !/3QIXEU35+6YBO;G3[K4I7M9+:
M.X9'C\O/S94 L6/0'I3GE$J;2E42O9+1[N]EY;"I\11K*3ITF^52;U6BCRMM
M=])(^N**\H^ NMZCXV'BWQ?<W]W<:5JVJ/%I-M.S>5%:0Y17C0G"ECNW8')7
MDD]/ O'GQ(\<7'Q.\6_8];N-.NM)U+[/I\$_B6TTVS2)'R/,M)MOV@,O.[</
MO#.0 *PH99.M6G14DG%*]^^FGR>C.K%9[2PV&IXETVU4;LEJ[*]G\TKKUU[G
MVI3)IDMX9)9#MC12S'&< <FODGQ WBGQ)J'QBU&7QCXBT-_#<4%S;Z=I^H,D
M*2-$S,AP3\HVD84@$G.3BI=3\<W_ (P\16*>*O'5_P""[&'P?::M:-9W*VB:
MA<R1H[LZD;9AN+KY8'.T@ ?-G993)V:FMKO1Z72:]=^AS2XA@KITFKMI7:2=
MI2BV[[:Q>Y].^$_%FE>.?#]KK>B77VW2[K?Y,_EO'NVN4;Y7 8892.1VK7KX
M=\#:PZZ+\)-&O/&NI>#- O;'43=7-E?FU4L+N<KEC\JDD ;B/;O6W:_$GQ+/
MX:T[1+CQA?P^$)O%LVDMXS$^RZ:U3:Z#[0?N[LD^8>RD9VJPK:KDLE4:ISTN
M]T]DY+>UF]-D<M#B:,J495:>K2V:^)QB]F[J/O;O1'U9XN\::-X$TM-1UR\^
MPV;S);K)Y3R9D;[HP@)YQUQBMNOC+7_'VOZ3HOBS2=#\9ZKX@T#3-:TZ.Q\0
M&]+3MYH<RPF9<&5<C&0<?+TPPK5\6-XCUG4OC1J<?C;Q'IB>&9TDL;*QU!XX
M<D-D,,YVX7[JX&3GFI_LBR5YV\]>O+;2UT_>UO\ \/HN([RERTV_+3HIN7O7
MLU[CM;_AOK%K^V6^2R:YB%X\;3);EQYC1J0&<+U*@LH)Z L/6L_PQXNT?QG9
M3WFB7\>HVD-P]JT\.=AD0X8*2,,/]H9![$U\R>%+*U\2?M":)?>(/$-Y%)K'
MA*SOW@ENTCBO)9/+#6>PC#PN-[&$#D@GIQ7K%G\/;7PCX6U.QUKQ/_PB=G=^
M);C4K2XTG4!9?))(6BMV9E Y'!0<<<$XKEK8&E02C*;YFD]N][^MCOPV:5\4
MY3A32A%R6^NEK>2O=[W/5;R\M].M)[JZGCMK6!&EEGF<(D:*,LS,>   22>E
M<)X3^/O@#QOK@T?1O$D%SJ+ E(9(I8?,P0"$:15#GGHI)(!(& :QOVIK34+S
MX)ZZEA%).J&&:ZCB^\;=)%:3WP ,G'8'MFJTWC_X3Z[K7P[M8'L=8O1*%T2&
MR F.G'RAM\V-3F/ " !A\K ' V%ESH86$Z'M7&4F^9>[;2R3N].M^ZT3WV-<
M5CZE+%^PC*$4E%^]?WN:35HNZM:W9ZM+3<]BHKXMF^(VM2>%M0\9/\0]3M_B
M%%K7V:'P<MR/L[*'6/ROLF/[I)WXP2/[_-6?&&M>*_LOQ7\3Q>,=?TZ?PSK<
M"V6FPWS&V DG5&1U_B4 C"\+P>#NKM62SO9S2UML][I?-7DM=MSS'Q-2Y7*-
M)O3FW7PVE*[UT=HN\7KMW/LFBOD/Q#KOB?P3<_$?1T\7ZYJ2KX;MM5CN;R\)
ME@G:6(,8BN/+7]XPVKCC .<"GZ%XUU3PUXB\+R^%?'>I>/KS5= N[O5-+O;T
M726TZ6OFQ[5_Y9$R#&P_,-NTGYJC^R)N/-&:?5:/^7FU?3YFO^L5.,U"=)IW
ML]5=>\XZ+>6NKMT/KFBOD#PAXYU&WD^'>NZ;\1=3\3^*/$&J+!J_AN>[66".
M%W8R%8 ,6^S  .!P<KA015CP3XPU'PY\6=)B\0>-=0\3OJ.H^1%<Z!XGM[NP
M=Y6PJ/8%-T:#=@L" I V]J)9/4CS6FM$^C3=KI[V[?/HM[$.(Z4^2]-I2:5[
MII72:NU?775=.KU5_I7P]\0_#OBG2WU'3M5BDLEO/[/,TP: &XW!1&/,"DL6
M90,=20!FNBKX<U6:Z\4>$?!^I:]XJU>%(_',EB]Y)J)46L)*'SE=\[&C )5L
MX7)XJ3Q-\1?&<GCGQ NF>)KM)-'O$MM,>Z\4VEC:O!&?E>6WFV_:?,7YBX8
M[AG(P*Z7DG/*U.=M]^EG;?2_]:'#'BCV<4ZU)N_+;EW=TV]-6NRU?JC[%\8>
M,M'\!:%-K.NWGV'38657G\IY,%B%7Y4!/4CM7*^%/VA?A]XWUR#1]&\1QW.H
MSY\J&2VFAWD#. 9$4$^V<FN4_:QDGF_9\U&2YB$%RSVC2Q @[',J9&03G!R.
MM<MJ,_B[6_C?X.TOXDC1M+.F^;J.BRZ+%((=4N %_<":5B4(.TD%1G&/XD-<
MN&P-&KAW4FWS>]LU]E)Z*SOOKJK+4]#'9KB:&,5"DER_N]XO[<FG>7,E'1:7
MB[O3>Q],45\3_"[XD^.]>\<:!J<FM7$MS=:J(M0LKWQ-:+"\#2;7CBTYRKHX
M'0C))' YKH/"OC#4?#'Q7TP^(/&NH>)A?:IY$4WA[Q/;W=DS2L0D;Z<4WJ@R
M0S+@*<;><5=3):E-RCSIM*]E_7_!\C*CQ-1K1A-4I*,I6N]%TU_'T\]K_7%%
M?#H\<:C:^#O$/B(?%#6D\7:9KC16'AY]0+QSQ^:O#0L29%P6_P!D!=N*ZKQ?
MXTU/5=:^(U[XB\?:EX'USPZ(UT?0;*]$$,^$+KF+K/YAV\C. XSE=H#>2U$[
M<_X/NEMU7O+78F/$U*4;^S=]_BC:UI/5WLG[KT>NWG;ZXHKY)L[_ ,6?$GQ;
MJZ:GXI\0>''M_"%MJS6FE7K0+]I\I#N*CA58DL54 \@$\51U7Q7XJ\1?#SP#
MJ\_C?R%.G2+<:7!XGAT74+J0321K/YLBE77;&H.[G(..234K*)72=17TOY73
M:UVZ&CXBA:4E1E97MMK:2B]-U:ZTLV?8E,FF2WADED.V-%+,<9P!R:^-?&WQ
M<U?7K7P%:Z1JWB&#0+C2I)VFN==M](O+B>.62)O,O'38^T(.WS;@3\U>_P#P
M<U?7M:^#$%QXCG@O-16&>+[7;W<-TLZ*656,D3,K-QM)SG*G/.:Y\1EE3#4E
M5G):NUNN[7Z'9@\[I8ZO*A2@](WOTV3W^>GZ:7J0_M6?"N>5(U\5*&=@H+V-
MTHR?4F+ 'N>*]7BE2>))(W62-P&5U.0P/0@]Q7P_I&H^-8/V;] TZ]31K;X;
MZI.]I<ZO%;2W%YIZ&\;,LJ;PN/,W8*@\8'#$9ZKXV>*K#31J=AX:\;:_IE[X
M:TVT@BMQKL=C:S(8U,1@B2,O=.5.YCE0 1\V-HKTJV44Y552H-[R6_-LTM;)
M6=WJM?ROXF'XBK1H.MBHI^[%I)<KO).32O*7,K+26B>O9V^L3J%JM^MB;F$7
MK1&9;8R#S#&" 7"]=H+ 9Z9(]:GKXV2]N+7XMWGB.;Q+J$.NR>"H]9MHS=I&
M+R\,*,+4)C#QD@MY0'49[5;_ &?/''C'5O'WAV676;C4[/44F_M.WU#Q3:79
M?*%E>&SRLD&UADJ QV\< 5S5,GE&FZD9JR5W?36S=E]WWG;2XCA.M&C*D[RD
MTK:Z72N[;;W?9=^OU]1117SI]D%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q'C?_D<?"?UN/\ VE7I
M47^J3Z"O-?&__(X^$_K<?^TJ]*B_U2?05RS^)GH4O@0^BBBH-1DO^K;Z5F5I
MR_ZMOI696]+J<E?H%%%%;'*%%%% !1110 4444 %%%% !1110 4444 %%%%
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M .L. ;C3J-J4M+-==/SNK?C8^G;.SM].M(+6U@CMK6!%BB@A0(D:*,*JJ.
M   .E9J>#M CTFZTM=#TU=,NW,MQ9"TC$,SD@EG3&&)(')'85Q'P+\8^-?B#
MX=A\0^)(-"M=*OH ]E#IJS>?N#%6,F]BH!VY !)YY/%>?>%/ASHGQW\<?$/4
MO&K3ZN^E:S-I%A8_:I(DLX(SA754(Y;\02I)'.:RCA73G456I90M>VNM[=UL
M_,Z)X^-6G1>'I<SJ7Y5+W5:UW?23LULK:GO(\'Z"KW3C1-.#W5L+.X86D>9H
M NT1/Q\R;>-IXQQBB+PCH4$UE+'HNG1RV,)M[5UM(PUO$1@I&<?*I!(P,#FO
MCVZUG7VL_#.B6EP?$,_AOQZVG:1>7TORW")M,:.XZ@'&2"<*P P *ZCXI?%C
M6[CP_P"(_"OCCP_H=]K>CZA8S#[')<BREBEP5(Q(L@921U;!SRO'/>\JK\T8
MQJ7O]]KVO9M7W7:VQY"S_"\DYRH\MMK[-V<FKI.ST=M[VOV/H^S^'/A/3UB6
MU\+Z-;")G>,0Z?$FQG7:Y&%X+* I/<#!JGXM\"OJ?@.Z\+^')[#PQ:7,3VS>
M7IPECCA<,'6.-7158[LYY'7C)R/#OB%^UQ?^%_'6LZ?90:,NFZ-<BUEL[T7)
MO;YE?$K0NB^5&!T D_NYYSM'4M\8_'?CCQ#KR?#W0]&OM)T/[.LT6K2O'=7C
MR*6(B(8(F "/G..,Y.=HP^H8Z'+5F[+>\GITM>^G5?U<ZO[5RNJYX>DKO6+4
M4[O>]N77:+\]%W5_6O!/A.S\"^$]*T"P+-:Z? L*N_WG(^\Y]V))/;FG7W@K
MP]JFLPZO>:#IEWJL!1HKZ>SC>>,J<H5D*[@0>1@\5\[:WXS\=7_Q!^*%EJPT
MZ;0=/\-7$TVBSR2[4A:V=XT'EL 92S*LC;NFX(P 7&KX7^-UUX T'08-4TW3
M[#PW<^$O[3TD6JS9-Q$@+VVYW;/'([@,N2>M$LOQ'\2,[REKIUNK[]_E;K<(
M9O@_X4Z?+3A=:K;E?*M+:*^B=[WTL>\MX4T1CJ9.CV!_M0 7^;5/]+ ! \WC
MY^"1\V>IJ"]\#>&]233TN_#^E72:<@CLEGLHW%LHQA8\K\@&U>%QT'I7SWXO
M_:A\2^&+;P_87*>'=+URZTE=5O9M1@NVMP9&/E6\:1;F#[-I+,=N<C(Z5ZOH
MWCI?B7\!KGQ(+;[(U]I-T7@#;@CJLB, ?3<IQ[5C4P6+P\8U)NT6[)W^7Y+[
MCJH9GE^+G.A22<HQYFFO1O[F]?/N,UCX$Z'JGC;P[JZV^GV^B:1:3VO]@#3D
M-M,)=Q)QD*N&;=C:<GFNV;PGHCZ#_8;:-I[:+@+_ &:;5/LV VX#R\;?O<].
MO-?"&AZ?X7O? OAG3=%\):[8?$W494.FZ_),UM:RRK/G?$[2[3A0!E4'S8Y!
MKV3X@?M7:KX,\8:CI%LNBR0Z(T,%U%J"7(NM2D&/.\AHU,<7<#S/KSG:/4Q&
M68J<XTZ<W)QONDMGOHW>[;LWKO?1'@X3.\!2ISK5J2@I<MVFY)N4?A=XQLU&
M*O%76UM7K]"KX&\-IH\>DKX?TH:5'+YR6(LH_(63.=X3;M#9[XS4S>$M#==3
M5M&T]EU/!OP;6/%WCIYO'S]3][/6O"_&/[0WB?3O%]M;V46@>'?#E[':OI]]
MXI@O%%_YL:NQ2:%6B0)O56WG"]2>H74U_P"*_P 0=1^(>O>'O!]GX9N+;3--
M@U+[1J#S,)%>,,51D8!R2WRG"C Y/(KS?J&+LG*5DU?5^:Z][M?/S1[?]JY?
M=QC"[3Y;*.NSV6]K)_+;1GKK^#/#\EWI]TVA::UUIT:Q64QLXR]JB_=6-L90
M#L%QBK>KZ'INOVZ6^J:?:ZE DBRK%=PK*JN.C ," 1G@UX1H/[0/BWXFOX:T
MSP3I&CPZS>Z7)JE_+K4DIMH%29H"JA,,<NN0>>&'N14_X:/\6:W8>$;;1M&T
MF#7]2U.[T6]AOWD:WCN85C^=&0@A,R;B,,<# )/S%_V;B^:S=FO/;?[MF3_;
M67<C<4W&5MHZ2ORJR[M<R_I'T?6)HO@;PWX;OI;W2?#^EZ7>RH4DN+*RCAD=
M202"RJ"02 <>H%>'/\?O'D'A;Q$C:!I=QXBT/6UTV]NK2*YFL+>WVLSW+HF9
M=B[#DCL<XR-I;>_M.W^D?"^VUJ:_\*:IJ]]J2V4$VFO=_9;9"&+2W$+H)EV[
M#\HY8$%01U(Y9BU[L.KMH_FOPU'+/,N;YJFG*G+5;6=G:_6^FFGF>[/X,\/R
M:_\ VXVA::VMY!_M(V<9N<A=H/F8W?=^7KTXI)_!?AZYM]1@FT+3)8-2D$M[
M&]G&5NG!R&E!&'((!RV>:\]_9]^--S\6[778+X:?)>Z3-&K7>E+,EM<)(&*L
MBS 2+C8P.[TS7ENF>(O&_A+QA\9]:\*V6BW5AIVHF[U :J\GF.B([$0A"!D*
M&)+'N,9.:(8'$.I.E.?+*"6[[M6UZ;W0JF:8-4:6(IT^:%1RV6NB=W:VNS3_
M %/>?B%\+=+\<>&M:T^&&TTK4=3M%LWU6.S5YEC5E8*2"I91M'R[L=/2M#P9
M\/\ 1?!-C;+8Z;81:BMM';W.H6]HD,MT54 LY R<D9P2>:\@O?VF+_3+'Q#>
M76GVB1/H-IK>@(5<--YQ6-HY?F^<K*ZCY N0I/&01V/Q>FU&X_9VU^75TBBU
M231M]U' I5$E*@LJ@DD '(Y)Z4I8?%04*%25HRDE\VE^6FG<J.+P%253%4(7
MG"+;Z:)RMZ7=VG:[6IW5AX,\/Z5K%QJUEH6FV>JW!<S7UO9QI/(6.6+.!N.3
MR<GDTRT\#>&[#6WUFV\/Z7;ZN[O(VH164:W#,V=Q,@7<2<G)SSDU\:^'M&\.
M:I=?#_2?!GA/7/#7Q#D:TOI-5U&5K>&>!8R9YHP\K;T;#,-J#(!QW4Z5KX%_
MX2WXF?$F7_A6'_"?>3KLZ_:/^$@_LW[/EF.W;N&[/7/:O0EEG*WS5FM.MD[7
MMUFE9]+OY'CPSQ34>3#1;<M+.35^7F>U)RYEUM'2Z=SZVE\!>&9M*?3)/#ND
MR::\QN6LVL8C"TIZR%-N-W^UC-$_@/PS<ZC:ZA-X=TF6_M!&+>Z>QB:6$)_J
M]C%<KMP,8/':O"#X/T[QM\4- ^'>M6$VD>%=%\-IJ*^&4OW9'N78!@\JL&D\
MO=@')Y4D<,P.3\7OA[I_PY^%6HZ=I.NSZEI?_"46OD:8\WF1Z4#ES N2S GS
M-QW$9#*<9RS<L,)S3C2]LU*5NFEF[;I[VU:V\V=U3,.6E4K_ %:+A"ZWL[Q5
M[6<4[7ND]^O*D?3NL:)IWB&P>QU6PM=3LG(+6UY"LL;$'()5@0<'FH]7\.:3
MX@-L=4TNRU(VLGFP&\MTE\I_[R;@=IXZBOG?]I'P-?77CR#Q'K?AR_\ &?@H
M:=]D:'3)VCN=)?=E[A$4X<[<MEAM. &*A5)M_$KPAX,\?_L\1^+8?MNN3Z9H
MK+INIZC.ZW*A3@B4(51W# @DJ<D$Y/4YT\''EHS]J[2=M%>S?3XEKWO;RN;U
M<RESXBFZ"O35[2=G**Z_"].UN;71\K/=;?P5X>M=<;6H-!TR'679F;48[.-;
M@EAAB9 N[)!(//--MO WANSUQM:M_#^EP:PSM(VH1V4:W!9@0Q,@7=D@G)SS
MDUQ7P ^&OAOP9X'T;5]'T[['J&L:59S7TWGR/YSF(,3AF(7EF/R@=:\_L-+\
M1V'[5OA^;Q-JT&HW=UI=W+#!:1E(+2',@2-,\L<#)8@')QR #6<:'M)U8QJN
MT4]]W9;6N]/G_D;2Q7LJ5"I4PZO4DMFFH\S23NTG?5;+YV5ST;X:_ S1? <%
MP][#8:]J1U*;4+?49]/19K;>5(1&)8C!&<@CKT%=CJW@OP]K^HP:AJ>A:9J-
M_  L-U=V<<LL8!+ *S D8))&.YKGOC+IWB+5?!-[;^']5@T5##,U]=O$9)A
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MII^HZ%IE_86@"VUK<V<<D4( V@(K A<#CCM6E;6%M9V,5E;VT4%G%&(8[>-
ML:1@8"!1P% XQTQ7R]IWQ!\7Z3XX^'<%K-IUCX4B\)6^JMI<+3;!:B!3/G+$
MO*H1A'N8@ +DY+$W?AI^UI?>+?'>C:;J,.C?8-9F>"*TT\7/VRP8G]UYSR*(
MI >A\OUSQC:;GE>*<'*+YHI7WVW_ !T_2YE2S[ *HHS7)*3Y5IO\/7M[RMY:
MV2O;Z'B\*Z)!H)T2/1["/12I4Z<MJ@M\%BQ'EXVX)))XZG-4A\.O"BS12CPQ
MHPEB@-K&XT^+<D)4H8P=O"%692O3#$=Z^8_$OQ4\8_$#X&S^)_$VA^%[OPY+
M<QPPV:?:TF>=9PN]MDPP@&[C=DD ].*]#^,OQH\8?#R_U2[TD^%M2T73FB6>
MS47=S?1;BH_?-&OE6Y;=\OF$9 .-QXI_V=BE)4XS]YMIZZ75NO?773YB6<X&
M4'6G3]R,8M::V?,UI;1+ENK-^BZ^PGP7X>-WI]V="TPW6G1K#93_ &./?:QK
M]U(VQE%&> N *-'\%>'O#VH37VE:#IFFWTZE9;FSLXXI) 2"0S*H)!(!Y[BJ
M7B?Q+<6/@.?6K&XTK3[EK>.6&;7;@PV<3.5 \UP,X^;H,9.!D9R/#!^TEXRT
MO2?'46J:=HLFKZ%9V]Y;2V]K=PP2"25$(:.?9(>'R&&T<<9!S7+0PN)Q47[-
M]4M_-+\V=^+Q^!P,X^UCJTY)I=DW]]HGTS17S[:?'WQ=X7UXP>,]*T4V5UX?
MFU^S71WE\Q516812,^06(7!(& 2#DCBN2U3Q)XV\6^,O@OK'BJRT6UL=2U#[
M9IRZ4\OF)&ZQL!,')&2I4@J?7(!Q6L,JJM^^TE9N][WLF]/NU.>IG^'4?W<6
MY72:LU:[BKOM\2:[^1]7T5\R^$OB+K^FZ;I47AG3].NO%'Q!UK4=3A?4W<6]
MO;QM@%]N&/[N/( /0="3BK6N?M'>+M#\.ZK:3Z/I'_"7Z/KEMI-VL;2/97"3
M+*R/'E@R']V!\Q/J1S@#RJNY<L+/YVZVO;MS:7&L_P *H<]1-:7V;6W-:_?E
M:E;]3Z0HK&\(#Q"-!@_X2EM,.M$MYPT=9!; ;CM"^8=Q.W&2<<D^F3LUX\H\
MLG&]['T4)<\5*UK]'O\ ,****DT"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH XCQO\ \CCX3^MQ_P"TJ]*B_P!4GT%>:^-_
M^1Q\)_6X_P#:5>E1?ZI/H*Y9_$ST*7P(?1114&HR7_5M]*S*TY?]6WTK,K>E
MU.2OT"BBBMCE"BBB@ HHHH **** "BBB@ HHHH **9--';0R332+%%&I=Y'(
M"JH&223T KQ[_AJGPD)HIFTWQ!'H$MS]E3Q(^G%=.9N1D2;MV,@C[N>#QQ73
M1PU;$7]E%NQQ8C&X?"6]O-1OW_K;N]D>R45Y7X^_:$TSX=:P]EJ'A?Q3=0&2
M*&'4K+3U>TN7D0.J12-(H=N2,#G*MZ5'=?M':-9PV44GAGQ9_;EV6:+P\-)/
M]H>2N<SF/=@1Y4C.[).>, D;+ XF45)0T>QS2S7!0G*G*HDX[[^G_#=^AZQ1
M7)_#CXG:)\4='FO]':>)[:8V]U97D?EW%M(/X9$R<?4$CJ,Y! ZRN2I3G2DX
M35FCT*5:G7IJK2E>+V:"BBBLS8**** "BBB@ KSWX@_!73?B'XDT_79=<U[0
M]3L8&MH9]$NUMV",23\VPGG)'!'%=/H/BC^W=4UFR_LG5-/_ +-F$/VB_MO*
MANLY^>!LG>O'7CJ*VZZ(3JX:?-!V?^9QU*5#'4N6HN:-_P 4_P!&CRN7]GK3
M;[1O[-U/Q7XKUN%;^WU"-]4U%;AXY(@X55+1\*=YW#&3@<C%)K_[.7A[7]7\
M3WS:MKME'XB15O[*UNU6W9@5(<(R'YLKD$DXW-@#->JUQ'Q%^+>F_#B_T?3Y
M],U;6]3U8R_9;#1;87$[", NQ4LO !_0]@:ZZ6)QE6?+2D[_ /#/]+_(\[$8
M'+J%)SKP2BK:N_6Z7GKS-?,@U+X)^'=9U?1[^^-W=#3=*?1TM9'7RIH'0HWF
M +G=@GE2/I5'PW\!M.\-VMW:+XH\5ZCI\UE)I\=C?ZJ9+>VB9-G[N,*%RJG"
M[@P''&17IE%8?7*ZCR\[M_7^9U_V=A.?G]FK_P# 2_1&'X(\(6?@+PIIWA_3
MY9YK.PC,<3W+*TA&2?F*@#OV KC?%?[/NA>)?$UYKUIJ^O>%]2ODV7K^'[_[
M,+KWD&ULGCM@'J<GFO3JCNI_LMM--Y<DOEH7\N)=SM@9PH[D]JF&)K0J.I"7
MO/?SOW-*N"PU6E&C4@G&.R[65M/EH>8:O^S=X0U/PEH7AV#[?I-AI%R;R%]/
MG"323$<N[LK$L>N1C& !@  <#\1_V>K^TT./1O"MI?\ B.]US4H;G5O$>N:G
M&TUND)41AL@%UPSGY06&T_>^4#UWP5\8O"GCRZ:QT_4OL^LQ_+/H^H(;:\AD
M RZ&)\$E,$-MW $'FL?3OCQI^L>,+KP_8>%_%%]]EU)M*N-4M].#V,,RL%??
M*'^51D$Y&0#G%>K1KYA2F[IOEU:?WW>S>NN^K[G@8C"Y/7IJS2Y_=3C;HK66
MC2TTVNDWL+JWP%TC4/%EYKUEKWB3P]+?2I->V>B:FUK;W3KU9PHW9(X)##U&
M"2:@\7?LZ>&_%VNWVI/J.N:4-26)=2LM,OS%;ZAY?"F=2I+'''!'<]22;.N?
M'*RTG4=1M++PMXI\1_8+PV,\VB:<+F-95C1V&=X(P) .0.0<9'-:7PK^+6F?
M%S3;^^TK3M4L(;*X^S2?VE L9:3&2%VNPXR,C@C(K'GQ]*"K7:225_+2WY*U
M^QTJGE->J\,HQ<I-NVNZO>W3J[V[ON9&I_L^>';_ ,0ZAJL%]J^F?;]+;1[B
MQL;E4MG@-N8%RA0Y*J05R2 RJ<=<R>(_V?O"_BKP=X9\-Z@U[)9>'RGV642(
M)755VE)#LP58 9P!T&"*BN/C]IH\97_ARQ\+^*-9GL+I+.YO--TX36T+MCEG
M#Y4#)R2!T/6O3ZRJ5L90Y'.375?=I^#-Z.&RW%*I&E!23;4M-+WN_+==.J."
M\=?!O2_'&NV^MKJVM^'-9BMS:-?Z!>_999H=P81N=IRH89[?C@8Z6'PO;Q>$
MVT![J]N;=[5K5[FZN&FN7#*0S-(^26.2>>!V&.*V*Y?2_B)INK>/]:\(0P72
MZEI,$5Q/*Z*(660 J%(;)/S#.0*YE4KU8<J;:AKZ?U<[71PM"HYM)2J.WJ[7
M_)?@8%Y\!O#=_P##/3?!,TE\UAISB2TOA*@NX'#EMZN$P#\Q'W>A]>:K:E\
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MZEB?2].O/[1T^UN_(FM?/B67R+E-DL>X [77LPS@CL:L5BL9B8+E4WH[_/\
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M;='RU\/O">G^ OC1\,?[%6>V.N^&WFU(M<22?:I/)+[FW$_Q ' P!@8 K?\
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M_P"> _[Z_P#K4?VHO_/ ?]]?_6HYY=P]E#L<+_PG'B'_ *%5?_ __P"U4?\
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MHYY=P]E#L<+_ ,)QXA_Z%5?_  /_ /M5'_"<>(?^A57_ ,#_ /[57=?VHO\
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M  /_ /M5=U_:B_\ / ?]]?\ UJ/[47_G@/\ OK_ZU'/+N'LH=CA?^$X\0_\
M0JK_ .!__P!JH_X3CQ#_ -"JO_@?_P#:J[K^U%_YX#_OK_ZU']J+_P \!_WU
M_P#6HYY=P]E#L<+_ ,)QXA_Z%5?_  /_ /M5'_"<>(?^A57_ ,#_ /[57=?V
MHO\ SP'_ 'U_]:C^U%_YX#_OK_ZU'/+N'LH=CA?^$X\0_P#0JK_X'_\ VJC_
M (3CQ#_T*J_^!_\ ]JKNO[47_G@/^^O_ *U']J+_ ,\!_P!]?_6HYY=P]E#L
M<+_PG'B'_H55_P# _P#^U4?\)QXA_P"A57_P/_\ M5=U_:B_\\!_WU_]:C^U
M%_YX#_OK_P"M1SR[A[*'8X7_ (3CQ#_T*J_^!_\ ]JH_X3CQ#_T*J_\ @?\
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MCV+[A_KGA_\ GR_O1]W45\(_\+'\6?\ 0T:U_P"#";_XJC_A8_BS_H:-:_\
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MXB\.V=EJ.OZ=:ZC=?8K":X2.>X_YYH6 9N>!QW/2OMWXC_\ )//%'_8+NO\
MT2U?"-=5'9GY5Q@U'$T&U>R_4]$N]"T3PY\8]$L?#^J_VOIRWUHPGWJ^&+KE
M=Z@*WKD#OCJ#7K>F?\(=_P -"/Y/]N?\)-Y\V=_D_8MWD-NZ?/C;G'OCM7S/
M87T^F7UM>6S^5<V\BS1/@':ZD$'!X/('6M>'QUKEOXL/B:.^VZV69S=>4AY9
M2A.W;M^Z2.E:.+9\_A,UHX>5W35O:*5K722[7>_8]4U72_"UM:_#V?Q/+>#2
MKB&^><&XGDCW!EV@*"2BD\'RP.<9]1M>'_"&BZ7\2O"MW:^&=..DW8FCAO+#
M66O[8W"J75AO4'<H1ACI\P(Y6O&K?XF^)K272I(-5>)]+61;0I&@V*Y!<'Y?
MF!('#9Z58U'XN>+M6U;3]3NM:EDO+ EK9Q%&JQDC!.P*%)(..0>.*7)(ZX9K
M@HR4W3U3@U[D;^ZHIWDVWT=DDM[MZZ=_JVD>$=.T;6_&-]X9EU2.XUA[*+3H
M[^1([;:#N=I -V68,<'(&Y0/6MO7_ 5GX4\(^/\ 2=/F:*SO'TN:-;D_-;B2
M<#:Q_P!D@]><8SGJ?*K+XR^,M/U._P!0M];=+F^96N#Y,11V50H.PKM!VJ!D
M 9P,UDW7CO7KVUUFWN-1>>+6)$DOA(BL9F0Y3DC*@$# 4@8 '2CED2\SP*C+
MEIN[4E\,5O&2O=.[YKJZVC;W;GL-U\-O!]WXEU?P3;:+=V6H6&FFZ77Y+MV+
MN ART1^38=V"1CH0,=1+HWPW\&VGB7PQX6O?#]WJ=W>Z>+^;5ENI$1B0Y*E%
M( 08P""#G:#G)SY5??%SQ?J>@-HMSKD\NG-&(F0H@=T'9I N\@]#D\]\UZ5X
M8^/^B:%X7T6V-OK:7FF6[(+&*5&M)Y=K!2\CDR;><A1PO  .T5+4TCNPV,RN
MM6O*,8I:^]".W,O=LKIV7VOB?831_ACX9UJ/1]<6Q%OH=A'>KK<7VB0Y>#[I
MSNR-V0V 1P*\Z^%WA>Q\=_$2STZ[7[-I\S23-!%(0Q559A&I.2>@'7. 3G-7
M[7XC6ND_#76-!LY+Z;4]9N1-<R21K'#"O&]4(=F<MMP20O!]N>'TK5;S0]1M
M[^PN'M;R!M\<T9PRG_/&.XXJTGJ>-B<3@U4P\HTTTK2FDEKLK?<KVVO)GKFA
M^$?"?Q%UW1(-/\-ZMX9@:]E@N7>1Y;>94C9P@E<DB7Y>4 X!8Y.*GMO!OA+Q
MGI1U33O#UUX=&GZU;V$]K-=22"ZCDE1&#;CE' ;D*>,]3D$>?:Y\5O%GB*[L
M;F^UJ=YK%_,MVB5(MC?WL( ">V3V)'>EUWXL>+/$L^GRZEK#W#6$XN;=1%&B
M+*#D.550&([;@<9/J<G++N;K,, HR4J=V_[D%?1);/W;--VC\5]3U'5_!G@=
MCXVM;3PU+;S>&?*N//.H2G[2N2S1X.0@P"N>3@YR#78^++B#6O'5SI)6]MHK
M3PS/=_N-2GC1R2@0;%8 ;0&SUW;AD?**^<G^(7B"276Y6U#+ZTH2_/DQ_O@
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M.,_*" 2">N#7C_Q'U5=.^*.L1/XCT7PZEUX7AB+ZS%Y@E!GN1M0>:G(SZ/\
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MBB@ HHHH *P+G_CYE_WS_.M^L"Y_X^9?]\_SH CHHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110!]5?LJ?\D\U'_L*2?\ HF&O9J\9_94_Y)YJ/_84D_\
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MC^SKC_GG_P"/"E=]QGG=]\(M+BTC5;;1#_9UYJ5D=.GO+UY[YC;D$;<22\D
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MG_CIH_M&W_YZ?^.FL6B@#:_M&W_YZ?\ CIH_M&W_ .>G_CIK%HH VO[1M_\
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M_P &$/\ \519A]:P_P#S\7WHZ*BN=_X6/X3_ .AHT7_P80__ !5'_"Q_"?\
MT-&B_P#@PA_^*HLP^M8?_GXOO1T5%<[_ ,+'\)_]#1HO_@PA_P#BJ/\ A8_A
M/_H:-%_\&$/_ ,519A]:P_\ S\7WHZ*BN=_X6/X3_P"AHT7_ ,&$/_Q5:NE:
MWIVO6[7&F7]KJ,"N8VEM)EE4-@':2I(S@@X]Q19EPKTJCY833?DT7:***1N%
M%%% !1110 45SO\ PL?PG_T-&B_^#"'_ .*H_P"%C^$_^AHT7_P80_\ Q5.S
M.7ZUA_\ GXOO1T5%<[_PL?PG_P!#1HO_ (,(?_BJ/^%C^$_^AHT7_P &$/\
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M;=JD*ZA@HR#SG./P8TQM'NM(.L:U_9$L300Z>+E!#:H91)A $^8@C ,F\@<
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M#W8X+):O-*-=JUW:]K::6YHIR?2WX[7\ZUGPKJ>@1+)>VZQQF1H2T<J2!9
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M*N-K^\)E;4?B5>Z5]C2X\.7*3ZI:Q2:7!YOSS7+ ;[:8%?W+)N!)^8;%D;^
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MA:63<0FX +M'SGKQA-6^'^L7&O>([[3->M;"#7;>*WGCFTYII8@D;)NC<3*
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MHHHH **** "BBB@ HHHH **** "OJK]E3_DGFH_]A23_ -$PU\JU]5?LJ?\
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M@**** "OEGQCXQU^U\7:Y##KFI0PQWTZ)''=R*JJ)&   /  [5]35\A>./\
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MM].;6].74+A5>&T-W&)90PRI5,Y((Z8'-*S&;?VF;_GJ_P#WT:/M,W_/5_\
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M(WM_WAGR,J(P/O$CD8[<] 35BV\16,WAVWUN:=+'3I;9+HRW;K&(T90P+DG
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M_P#Z '_DY;__ !RNBBTKW/SOB["XC$^P]A3<K<U[)NWP]CSNBO1/^&?/'_\
MT /_ "<M_P#XY1_PSYX__P"@!_Y.6_\ \<KHYH]S\\_LO'_] \__  &7^1YW
M17HG_#/GC_\ Z '_ ).6_P#\<H_X9\\?_P#0 _\ )RW_ /CE'-'N']EX_P#Z
M!Y_^ R_R/.Z*]$_X9\\?_P#0 _\ )RW_ /CE'_#/GC__ * '_DY;_P#QRCFC
MW#^R\?\ ] \__ 9?Y'G=%>B?\,^>/_\ H ?^3EO_ /'*/^&?/'__ $ /_)RW
M_P#CE'-'N']EX_\ Z!Y_^ R_R/.Z*]$_X9\\?_\ 0 _\G+?_ ..4?\,^>/\
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M5Z'-'N?SQ_9>/_Z!Y_\ @,O\CSNBO1/^&?/'_P#T /\ R<M__CE'_#/GC_\
MZ '_ ).6_P#\<HYH]P_LO'_] \__  &7^1YW17HG_#/GC_\ Z '_ ).6_P#\
M<H_X9\\?_P#0 _\ )RW_ /CE'-'N']EX_P#Z!Y_^ R_R/.Z*]$_X9\\?_P#0
M _\ )RW_ /CE'_#/GC__ * '_DY;_P#QRCFCW#^R\?\ ] \__ 9?Y'G=%>B?
M\,^>/_\ H ?^3EO_ /'*/^&?/'__ $ /_)RW_P#CE'-'N']EX_\ Z!Y_^ R_
MR/.Z*]$_X9\\?_\ 0 _\G+?_ ..4?\,^>/\ _H ?^3EO_P#'*.:/</[+Q_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %><:K\"- UC5+R_FO-26:ZF>=UCEC"AF8L<90\9->CT5
MM3K5*+O3=C@Q> PN/BHXF"DEM<\N_P"&=_#G_/[JG_?V/_XW1_PSOX<_Y_=4
M_P"_L?\ \;KU&BM_KN(_G9Y?^KN4_P#0/$\N_P"&=_#G_/[JG_?V/_XW1_PS
MOX<_Y_=4_P"_L?\ \;KU&BCZ[B/YV'^KN4_] \3R[_AG?PY_S^ZI_P!_8_\
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MPN2 .!C5M_"FIC7='D\B#3HH/#DVG226#YBMIV:#:L0.UBHV-M.!PHS@FH/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>btai-20241231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 btai-20241231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (2 \L# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>K5]HM79*Z=GIOITNO,\._;Y_P"1$\.?]?[_ /H%<5^T+X7U#5/V<_A?K5K
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ML=P"!GV-:O[2OQ"TOX\?$GP;H?A%SJD=L6B^T1QD;WE=,@9&<*$!_$U]5M\
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M-'\/V(T[3D=I%@$CR89CDG+DG]:W:\[$XJ-7&RQ,8W3E>S]=F>W@L!.AEE/
MSE:2@HMQ;T=K73T?H?*7P8_:H\.^)?"LVF?%&_MWU:.1@;B\LE\J>/J 51,
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M"_=&[O@#/>NXHKC4Y)63.EPBW=HX+P]\!_A]X3U"^O=(\)Z=I]S>Q/!.T,9
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M^ =:\):9KGAAK.YUJ,/<@7ZN+#]X$.2J$.!D'((J_9RO85T>Q45SOC_QG;^
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MS52LYT8\J;T78^_HPE3H*%:7,TM7W*/B'X>Z1XJ\!R>$M3B>XTJ2U2U.&VN
M@ 5@PZ,"H(([BN2\._ '3[#5FU+Q!KVK>,KM+&73+5M8D0K:V\@Q(J*BJ-S
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MTN%(D?(&U>>3DCCW%;=92J5'\3_J]_S-(P@OA04445B:A1110 4444 %%%%
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M_!WQOJ6M:WXI\/>(=,L+/Q)HTL7VNZTP?N;L.N5?/4-CJ">_;D!GQRNM ?\
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MU>Y$L/%VL> Z#^SQJ6D:1;?N/#\>K6NI6%WOC:X>*ZCM@R_/OR8V(=L!00.
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M /HI@E1C@.I/H#3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** *>J:>VI6PB2[N+)@P82VS*&^A# @@YZ$&L.
MR^'NFV%S:RQ3702!HY#"779+(F[:[?+G(W'H0.!QQ7444[M %,\F/^XOY4^B
MD SR8_\ GFOY4>3'_P \U_*GT4 ,\F/_ )YK^5'DQ_\ /-?RI]% #/)C_P">
M:_E1Y,?_ #S7\J?10 SR8_\ GFOY4>3'_P \U_*GT4 ,\F/_ )YK^5'DQ_\
M/-?RI]% #/)C_P">:_E1Y,?_ #S7\J?10 SR8_\ GFOY4>3'_P \U_*GT4 ,
M\F/_ )YK^5'DQ_\ /-?RI]% #/)C_P">:_E1Y,?_ #S7\J?10 SR8_\ GFOY
M4>3'_P \U_*GT4 ,\F/_ )YK^5'DQ_\ /-?RI]% #/)C_P">:_E1Y,?_ #S7
M\J?10 SR8_\ GFOY4>3'_P \U_*GT4 ,\F/_ )YK^5'DQ_\ /-?RI]% #/)C
M_P">:_E1Y,?_ #S7\J?10 SR8_\ GFOY4>3'_P \U_*GT4 ,\F/_ )YK^5'D
MQ_\ /-?RI]% #/)C_P">:_E1Y,?_ #S7\J?10 SR8_\ GFOY4>3'_P \U_*G
MT4 ,\F/_ )YK^5'DQ_\ /-?RI]% #/)C_P">:_E1Y,?_ #S7\J?10 SR8_\
MGFOY4>3'_P \U_*GT4 ,\F/_ )YK^5'DQ_\ /-?RI]% #/)C_P">:_E1Y,?_
M #S7\J?10 SR8_\ GFOY4>3'_P \U_*GT4 ,\F/_ )YK^5'DQ_\ /-?RI]%
M#/)C_P">:_E1Y,?_ #S7\J?10 SR8_\ GFOY4>3'_P \U_*GT4 ,\F/_ )YK
M^5'DQ_\ /-?RI]% #/)C_P">:_E1Y,?_ #S7\J?10 SR8_\ GFOY4>3'_P \
MU_*GT4 ,\F/_ )YK^5'DQ_\ /-?RI]% #/)C_P">:_E1Y,?_ #S7\J?10 SR
M8_\ GFOY4>3'_P \U_*GT4 ,$2*<A%!]0*?110 4444 %%%% !1110 4444
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MC?XT 345#]DC]9/^_C?XT?9(_63_ +^-_C0!-14/V2/UD_[^-_C1]DC]9/\
MOXW^- $U%0_9(_63_OXW^-'V2/UD_P"_C?XT 345#]DC]9/^_C?XT?9(_63_
M +^-_C0!-14/V2/UD_[^-_C1]DC]9/\ OXW^- $U%0_9(_63_OXW^-'V2/UD
M_P"_C?XT 345#]DC]9/^_C?XT?9(_63_ +^-_C0!-14/V2/UD_[^-_C1]DC]
M9/\ OXW^- $U%0_9(_63_OXW^-'V2/UD_P"_C?XT 345#]DC]9/^_C?XT?9(
M_63_ +^-_C0!-14/V2/UD_[^-_C1]DC]9/\ OXW^- $U%0_9(_63_OXW^-'V
M2/UD_P"_C?XT 345#]DC]9/^_C?XT?9(_63_ +^-_C0!-14/V2/UD_[^-_C1
M]DC]9/\ OXW^- $U%0_9(_63_OXW^-'V2/UD_P"_C?XT 345#]DC]9/^_C?X
MT?9(_63_ +^-_C0!-14/V2/UD_[^-_C1]DC]9/\ OXW^- $U%0_9(_63_OXW
M^-'V2/UD_P"_C?XT 345#]DC]9/^_C?XT?9(_63_ +^-_C0!-14/V2/UD_[^
M-_C1]DC]9/\ OXW^- $U%0_9(_63_OXW^-'V2/UD_P"_C?XT 345$MLB,""^
M1ZNQ_K4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 <K\1;YK70PD5RD$QE1F1KH6Y>,'Y@'/2JGPWNH+E+WR=W!7.
M[5!>_P ONU8^(MK =)2ZD61I$=8D/VAX8TW$#<Y7G:*S?A/=QWEE.Z1%6:.)
MV=9WE3)'*_-T(/;T(K3[)/4[^BJ>J:K!H]L)KCS"K,$58HVD9B?15!/0$_A5
M"'QEI-Q=6MO'<EWN A1A&VW+@E5+8P"=IP#SQ4691MUQ?QK_ .2->//^P!?_
M /I/)7:5Q?QK_P"2->//^P!?_P#I/)6U#^-#U7YF-;^'+T97^+7_ ")&F_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 F<4GF+_>'YU1U60@(
M 2.>U9NX^I_.@#H/,7^\/SH\Q?[P_.N?W'U-&X^IH Z#S%_O#\Z/,7^\/SKG
M]Q]31N/J: .@\Q?[P_.CS%_O#\ZY_<?4T;CZF@#H/,7^\/SH\Q?[P_.N?W'U
M-&X^IH Z#S%_O#\Z/,7^\/SKG]Q]31N/J: .@\Q?[P_.CS%_O#\ZY_<?4T;C
MZF@#H/,7^\/SH\Q?[P_.N?W'U-&X^IH Z#S%_O#\Z/,7^\/SKG]Q]31N/J:
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M,<*N]X@H)/J:[FKG3G3=IQ:]="(5(55>$D_1W(?LJ?WI?^_C?XT?94_O2_\
M?QO\:IZ_XETCPI8?;M;U6RT>RWB/[3J%PD$>X]%W.0,G!X]JSO#_ ,2/"7BV
M^:RT/Q3HNLWBH93;Z?J$,\@0$ L51B< D#/N*%";CS).PW.*?*WJ;OV5/[TO
M_?QO\:/LJ?WI?^_C?XU-1699#]E3^]+_ -_&_P :/LJ?WI?^_C?XU-10!#]E
M3^]+_P!_&_QH^RI_>E_[^-_C4U% $/V5/[TO_?QO\:/LJ?WI?^_C?XU-10!#
M]E3^]+_W\;_&C[*G]Z7_ +^-_C4U% $/V5/[TO\ W\;_ !H^RI_>E_[^-_C4
MU% $/V5/[TO_ '\;_&C[*G]Z7_OXW^-344 0_94_O2_]_&_QH^RI_>E_[^-_
MC4U% $/V5/[TO_?QO\:/LJ?WI?\ OXW^-344 0_94_O2_P#?QO\ &C[*G]Z7
M_OXW^-344 0_94_O2_\ ?QO\:/LJ?WI?^_C?XU-10!#]E3^]+_W\;_&C[*G]
MZ7_OXW^-344 0_94_O2_]_&_QH^RI_>E_P"_C?XU-10!#]E3^]+_ -_&_P :
M/LJ?WI?^_C?XU-10!#]E3^]+_P!_&_QH^RI_>E_[^-_C4U% $/V5/[TO_?QO
M\:/LJ?WI?^_C?XU-10!#]E3^]+_W\;_&C[*G]Z7_ +^-_C4U% $/V5/[TO\
MW\;_ !H^RI_>E_[^-_C4U% $/V5/[TO_ '\;_&C[*G]Z7_OXW^-344 0_94_
MO2_]_&_QH^RI_>E_[^-_C4U% $/V5/[TO_?QO\:/LJ?WI?\ OXW^-344 0_9
M4_O2_P#?QO\ &C[*G]Z7_OXW^-344 0_94_O2_\ ?QO\:/LJ?WI?^_C?XU-1
M0!#]E3^]+_W\;_&C[*G]Z7_OXW^-344 0_94_O2_]_&_QH^RI_>E_P"_C?XU
M-10!$MNJ,"&D)'K(2/YU+110 4444 %%%% &9JWWDK/K0U;[R5GT %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% '&?%+_ ) VG?\ 80C_ /07KT/P[_R"H/\ =%>>?%+_
M ) VG?\ 80C_ /07KT/P[_R"H/\ =% &G1110 4444 %%%% '.^+M!TS4HA=
MZEJ$VFPQ1O$\R7(A4HV,AB>,'%1>#;71(GN9=)UK^V7*I'(_VQ;@HHSM'R]!
MUIOQ&AEE\.J8899F2XBD801AW50V20#QD>]1?#^X%S!<R*;YHR1AKRVCB!_W
M=G6K^R+J=+J&I6>DVQN+ZZ@LK<$ RW$@C0$]!DG%1IK>G2W-O;I?VKW%PGFP
MQ+,I:5/[RC.2.#R/2J?BEKQ+",V&F_VE=>8-G^KS!D$&0;V4$@$C /?TS7(V
M7A"^M-3LT@T^6*S,]I<>=/)'F$1!]ZL%8_,2>-N1\QY%))- >CUQ?QK_ .2-
M>//^P!?_ /I/)79GI7#_ !JCE'P<\>9FR/[!O^-H_P"?>2M:'\:'JOS,JW\.
M7HQGQ:_Y$C3?^P[H7_ITM*[RO/OBS'*/!.G9FS_Q/-#_ (1_T%+2N[\J;_GO
M_P"."G+^%'U?Y1%'^(_1?J>9_'#_ )"_PR_[&63_ --.HUFZ#_R73P[_ -BW
MJ_\ Z5:95[XV(ZZQ\,BTF\?\)+)QMQ_S"=1K/T56;XY^'0K;#_PCFK\XS_R]
M:97LTO\ =%_AE^I\U7_Y&<?5'LU>2^.O^2Q:7_V 9_\ THBKU3RIO^>__C@K
MRCQLKK\8M,W/O_XD,_;'_+Q%7GX#^-\G^1ZF;?[I+U7YHM_"G_D?/'/^[8?^
MBY*]2KRKX6H[>//'&V38-MA_#G_EG)7I_E3?\]__ !P5.._COT7Y(URS_=(?
M/\V>.V__ "4CXA?]A*V_]-]K72? C_D1KK_L.:O_ .G"XKF;0,OQ&^((9MQ_
MM*VYQC_F'VM=%\"XY&\$7967:/[<U?C:#_S$+BO1Q?\ ND?^W/\ TEGCX'_D
M8U?^WO\ TI'I%?(:_P#)E@_[)]_[CJ^MO*F_Y[_^."ODE?\ DRP?]D^_]QU5
ME/VO\4?_ &X6??\ +OTE^A]>5P?QV_Y([XN_[!\G\J[;RIO^>_\ XX*X3XZ1
MRCX/^+29LC^SY.-H]*\;#?QX>J_,^DQ'\&?H_P CC_%O_'WX6_[#]A_Z.%>X
MUX;XO!-UX7 .T_V_8<_]MA7MGE3?\]__ !P5WYA]CYGB9+_"GZ_H<;\20#K'
M@$$9'_"0K_Z1W5)KJA?C#X.P /\ B5:KT_W[*H_B/'+_ &QX!S-G_BH5_A'_
M #YW5&O1R_\ "X/!W[[G^RM5YVC^_95S0VC_ (9?J>O+>7K']#O:\/\ '>G/
MXB^,^K6-SJNN6UE:>']-FAMM-UJ\L8Q))<Z@)'*P2H&8B*,9.3A17M7E3?\
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MA^P_]'"O<:\.\6_\??A;_L/V'_HX5[C7?F'V/F>)DO\ "GZ_H<1\2/\ D,^
M/^QA7_TCNJ37_P#DL/@W_L%:K_Z'94OQ(_Y#/@#_ +&%?_2.ZI-?_P"2P^#?
M^P5JO_H=E7-#:/\ AE_[<>O+>7K']#N*\;U[_DNWB+_L6](_]*M3KV2O&]>_
MY+MXB_[%O2/_ $JU.M,O_B2]/U1PYO\ [M\T:/P/_P"0O\3O^QFC_P#33IU>
MIUY9\#_^0O\ $[_L9H__ $TZ=7J=98W^._E^2.G+O]UA_74\2T7_ )'#Q_\
M]AW_ -L[6NN^!/\ R3.P_P"ON_\ _2R:N1T7_D</'_\ V'?_ &SM:Z[X$_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN9)L6<LML69A^\)\LD<\XZ>U6='LO[ ^(GPKU?4M)N9;>7PO#:-(MFTA%UM
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MO/\ O(]O_",W/'EG/^I?WKV6O']'_P"35I_^Q9N?_1#UYE#;_MZ/ZGT-;?\
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M]^S_ /%4;+C_ )ZQ?]^S_P#%5-10!#LN/^>L7_?L_P#Q5&RX_P">L7_?L_\
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MJ2BZ;CMT:1Y^7^VA2:Q%[WZZG;T5Q']L_$3_ *%+PW_X4L__ ,@T?VS\1/\
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M<9*+H1LT]NODSY_ TIPQ564HM)W_ #%^+,LI^%?C+,) _L6]YW#_ )X/6/\
M%J60_L^>,P82!_PB][SN'_/H];OQ:_Y)5XS_ .P+>_\ HAZQ_BW_ ,F]>,_^
MQ6O?_21ZX:'_ "[_ ,7^1ZE;[?\ A_S.^\V7_G@?^^A7G7Q]DD;X>0AHBH_M
M[0^=P/\ S%K2O2Z\X_: _P"2=1?]A[0O_3M:5GA/]YI_XE^88W_=JO\ A?Y,
MYG5"5^('PU*KN/\ ;D_&<?\ ,*OZ]G\V7_G@?^^A7C.H_P#)0OAI_P!AR?\
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M5#]K3^[+_P!^F_PH^UI_=E_[]-_A0!-14/VM/[LO_?IO\*/M:?W9?^_3?X4
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MVW^%'VN/_;_[]M_A4U% $/VN/_;_ ._;?X4?:X_]O_OVW^%344 0_:X_]O\
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M^"O^2@?$/_K^M/\ TBAKQZ?PS]/U1]+4^*'K^C(O 5U&/&/Q)^_SKD'\#?\
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MM[6:;O>WEM;]#SO]9Z7-=TI*-G>]KW4HQM:_5R6M^J\[?8%%>+^ =9\?>./
MFOZ;-/J'A_7+:Z1+#6=6TK[/)-#O5BS1,-NXJ&4X&!D5Z+XN\4Q^ / ][K6H
ML;G[!;;Y"@P97  X';+?SKRJN$G3J>RNG*]K+Y6?SOZ]T?0T,PIUZ/UAQ<8<
MO-=V\[K>]U:[Z6:LV:_]M:?_ &I_9GVZV_M+9YOV/SE\[9_>V9SCWQ4%MXHT
M:]U673+?5["?4HB1)9Q7*-,F.N4!R,=^*^0?A-X]L+[X[MK>J:^;FYU?3)/-
MFCCD'DS,#B%,K_ BJ >G'6J_@#17TV\^'^LS:?;V>CW/B"<6NO6__'_=DNRJ
MDH[(2".I[\>OO3R-4G)3FTU%/;=M2=E??X?7J?(T^*I5U&5*FFG)IZWM%."3
M=KVOS7N]%:U]3[*M/$&EW^HW%A;:E:7%];?ZZUBG5I8O]Y0<C\:GLM0M=2B:
M6SN8;J)7:,O!(' 8'!4D=P>HKY^UWP!J7PKNGU&PU6.ZU2_GN['1H44K,\]Y
M(IWRL3@B/!;/L,XKTOX2ZUX4@T.V\,^'M5CU"33( )&",IF.XAY5+ !P7W?,
MI(]Z\FO@X0I>UHR<EZ???MTM\UT/HL)F56K7^KXF"A+M=:[62[O>_E9_:.^H
MHHKR3Z **** .,^*7_(&T[_L(1_^@O7H?AW_ )!4'^Z*\\^*7_(&T[_L(1_^
M@O7H?AW_ )!4'^Z* -.BBB@ HHHH **** .7^(L*S^'E3+><;B/R56-7+R9^
M5<,0N#ZDXJM\/YKD/?VU_!':7L14M!'!&@VG.&W1DAL\_2KOCF$SZ6L;W$<4
M,KK%Y;VOGEW+#;@;ACO69\-/LRPWJ6TZ3*2K@BT,!=3D!P2S%E.#@UI]D74[
M>BJ>K:I#HVG3WDY/EQ+G:/O,>R@=R3P![URUG\1VO1:R+IA6V98#=.9_F@,S
ME4 7;\_(Y.1C/>H2;&=K113/-3^^OYT@'T4SSH_[Z_G1YT?]]?SH ?13/.C_
M +Z_G1YT?]]?SH ?13/.C_OK^='G1_WU_.@!]%,\Z/\ OK^='G1_WU_.@!]%
M,\Z/^^OYT>='_?7\Z 'T4SSH_P"^OYT>='_?7\Z 'T4SSH_[Z_G1YT?]]?SH
M ?13/.C_ +Z_G1YT?]]?SH ?13/.C_OK^='G1_WU_.@!]%,\Z/\ OK^='G1_
MWU_.@!]%,\Z/^^OYT>='_?7\Z 'T4SSH_P"^OYT>='_?7\Z 'T4SSH_[Z_G1
MYT?]]?SH ?13/.C_ +Z_G1YT?]]?SH ?13/.C_OK^='G1_WU_.@!]%,\Z/\
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M^,DNX@?\2 ]3_P!/"UU0_P!R^3_]*9QU/^1JOE^1Z[7#^"O^2@?$/_K^M/\
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M10!QGQ2_Y VG?]A"/_T%Z]#\._\ (*@_W17GGQ2_Y VG?]A"/_T%Z]#\._\
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M]W'U;!Q^58^KZGK?Q!^)FB>&/$ME9>%_[-F3585CG:X>^V9P(WVJ  >HZ\4
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M>Y)$(N'V[R.N/S%)KWC_ ,.^%[^SLM6UBTL+N\ -O#-)AI 3@8_'BO"OVKM
M;Q3XM\%Z4B[IKF*\2(?]-/*)3_QX+7CNMZ[=?$B?P_XKN%*)I]]I>B*#GE_+
ME>0_FBG_ (%7UF$R:EB:-.M*;5T[[=VHV];.Y^>YCQ+7P6)K8:---Q:4=]59
M2G?T35O4^]J9-,EO"\LC!(T4LS'H .2:^2-=^(/C?5M?\5:Q8W>O1SZ/J@M;
M6"VN((M+B16'R7".P+%LD9_4]!U&O:SKOQ#^)/BO3+KQ/J'A.ST+1H[F"RL9
M5C69WA5W:7.0ZY;&/3'3G/&\GG&SG-6M=];?#T7^)?B>BN)*52ZITI-WLKV2
M?Q:W>GV'^'R]NM/B1X8OX],>WURSF34Y&ALBKY\]U.&5?4@BNDKX[^&.L7VG
M^'_@U;VUY-#!=:M>K.D;E5E'FM]X#K0GQ)\2OXJ\.^)-,\1:[>Z5J7B$61:]
MFCBLYXS(%,<5H-Q"A#]XMD9!P#S754R1^TE&G+17WZV<DNG]TXJ/%*5*-2O3
MNWR_#TO&#;U=VDYKMY]+_8E%?+.J2>)?$6K_ !>NT\::]ID/AS=<65K976V/
M<(V;:V03M^7&T$=<U[+H7C#4G^!]MXDD/VG5!I'VHLR_?D"$Y('N*\NOETJ,
M8M23;:771M)K\SW<)G,,3.<73<5%2=]'=1DXO;S1V&M>(],\.K:MJ=[#9+=3
M+;PF9L>9(W11[G%:-?'NK66H7O@_X9^)M0\9:CKESK.M02SV%U,KP1ON;_5+
MC*;.5."0<]N!752^.]9@\&_'">37;M+C3=8E@L':Y8-;+YI"K'S\HP. /2NV
M>3VBN2=W>ST>_,H_FSRZ?$:<I>UI67+S+57MR.>NMM4M#Z8HKYJT\:_X^^(W
MAG1)/%^NZ3I\OA*TO[@Z;>&.268J,MD@C))R3C)Q7'?$#XA^([75=2U_0?$>
MOO9Z?K:V"M+=)%9#:<")8/F:8_*<LQ&>I!S2IY-*K-4U45[7Z]=$K^9=;B6G
M0I.M*D^5-K=7=E=NW9:'UG-XFTJ#4+FQDU"W6\MK?[5-!O&Z.+.-[#L*ET/7
M=/\ $NF0ZCI=W%?6,P)CGA.5;!P<'ZBOFT>&I[7]H'XB7*:SJT,EIHYO4"7(
M EW*,(_'*#.0.,$#FJ/@_P 7^(/%6E?##PB_B*_T2VU>VN;F\U6VE"W5P4D;
M9$DC [3\O;KN QCJY93%P4H3Z)OR3BY/3KMH1'B&<:KA5I6UE%)=6IQ@M6[+
M5ZW_ . _JZBODO7OB%XJT[X<>/-*A\27EY)X?UNWL['7%DQ<21NS95W7[V-H
MR?\ :],5Z'X._MOPA\=8O#<_BC5O$&GWVBF_E75)1)MF#X)C  "+Z*.GJ:PJ
M95.G"4G-75VEKJDD_EI);G51X@IUZD(1I.SY4W=:.3E&V^NL7JNFI[C5#7->
MT[PSI<VHZK>0V%C#CS)YVVJN3@<_4BO)_BGK.K:[\5_#'@>#7+SPQI5Y;RW<
M][I\@BN+AE!VQ(Y!QT[=>X/%>-_$/4]7\1?##Q)IVHZ[?ZI;>'/$$=E:WWFC
M_2XW8<3$#]XR=FXY-7A,J==TW.=E*S?>S=EY7OT(S#/UA56C3IMN',D]+.48
MJ35KWLD]^NW8^O-"U_3O$VF0ZCI5Y%?V,V?+GA.5;!P<'ZU?KSGQ!9S>"O@9
MJ$5AJ%ZT]GI3-%>S2YGW;<[MR@<^X%>-ZQJ'BCP=\'O#&MIXJ\0ZGJGBA[6"
MX9[I7^S(X+8MPP 1R %W,3SZ9K&CEZQ+;ISLG+E5_O\ R.G$YP\$DJU-MJ'/
M*UK+I9:]_P#ASZJHKY?T?Q#X\B\,>.M'M]8N]/:W6)M/O/$U];_;8"V!)&\@
M8A2>2I.,=L&I_#7B?6M \/\ CK3=0USQ-;:Y'X;GOXM.U]EFF@=86S-#<H1\
MN[H-H/ /6M7E,DG:HG9K;71VU_'^M#GCQ%3DXIT9)-/5V237,K:]7RZ=7=66
M]OIFBOE#1O$/B3PMIGPN\31^--7U^Y\07JVE[I=W<++ Z$@$(F,AAW8DG)'3
MO8N_$_B37_"_CCQZ?&NH:-J&A:@\-GHT,JK9HL; *DL1!WE^@SW]:MY--/\
MB*U[7L]^;EM:U]^IDN):;C_!ES6YK7C\/*IWO>VSVWOY:GU/17S#)JWB7XA?
M%FXTY_$NM>'+-O#<.HO:Z;<^7MEV*>,@A?F.3@ D<9YK.T_Q5XY\:?#+P6\&
MM:A/(MW<V]]'I=]';:G>QQOM1D+CYRHZ^O!/)S2_L>=HMU$KVOY73:UVZ/\
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MC&W]:K?$#X=P^.#I-S'>R:5JNEW(N;6^A0.R?WE()&58<$9KJ/L-M_S[Q?\
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M'3ZC?W&HW.MZUJ3*UWJ-W@.X48554<*H'0"NF^PVW_/O%_WP*/L-M_S[Q?\
M? H P-!\$QZ%XM\1:ZMTTSZPT3-"4 $6Q O!SSG&:Z:H/L-M_P ^\7_? H^P
MVW_/O%_WP* ,$^"XS\1U\6_:F\U=).E?9=@V[3,)=^[/7C&,5HV>FZC!KVH7
MD^KO<Z=.J"WTXP(JVQ PQ#@;FW'GGIVJ[]AMO^?>+_O@4?8;;_GWB_[X% &
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MO^?>+_O@5VK%35'V-E;\=[]S@E@J4J_UAWYOPVL3UP_@K_DH'Q#_ .OZT_\
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M?H<V)KQPM"=>:NH)MVWLE<Z#6?!6B^(-:TK5]0LOM&H:6S/9S>:Z^46&#P"
M?Q!K#7X*>"TTM=.71%6R741JHB6XF&+H @29WYZ,1M^[[5\VZ#\;?%=OJ7AN
M:Q^(B>,KZ[NH(KCP\ND-$VUQ\X,GE@$J>,J>N#R!6S\0OBOK]E\5?%&DR_$I
M?!NG64D8M8I-,^U"3*Y8 I&Q&..O7=[5].LJQU.:I1JVTO\ ;Z.VW+?=WVMN
M^Y\++B#*JU-XB>'NW))W]GNXWUES<NT;.\KZ)6V/>]6^"W@G7?$Z^(;[P_;W
M&JAUD,I=PCLO0O&&V,?]Y34WB_X0>#_'>HVU_KFAP7MY;IY:3!WC8K_=;8PW
M@8X#9 R<=37E=]\2O$EG\/O!NF:'XB@\2>(O$]Y+;P:_):F"-(U;EO+91R R
M@9'8FNE\&Z7\5/"OB:>V\0ZS:^)_#\EH\O\ :'EI!)!*,X4(!DYZ],>XZ'BE
M0Q5*//*O9QNHIN2;2=G:ZT7D[-]CTX8K 8B7LH83FC/E<VHP<4Y+F7-9N[LT
M^9<R5]SK-.^#G@_2H=$BM='$4>BS//8+]IF/DNY)8\O\V23PV16</V>OAXM[
M)=IX9@BN'N%NM\4TJ;) VX% ' 09/W5P.!QP*\5?XR^-A\#M&UC^UGBN+O6)
M;2]ULVBRFTA#?*=BKC],_C7=?!KQ'XH\8:9XBM4\>Z3XGB>V9;'4X(O*NK6<
MJ0&DMRBD*#@C(YQ715PF.P\)U95[6;3UEWUUM;=WLW=[V.2AF&4XNK3P\,*F
MW%25XPTO'32]]DE=*RT5STZ/X:^&XCXAV:;C_A( 5U/]_)_I *E3_%\O!(^7
M%:^D:%8:%HMMI-E;B+3K>(0QP,2X"=,$L23^-?..FV?Q;O/B?J/@\_$E1+8V
M4=\]R=.BVNK,!M VY!YZYKV_Q]X]@^&?A>VOKZ*;4KN:6.RM[>W #W-PP.%&
M>!G:QSV K@Q.%K1E"DJOM'*S23?;1ZI=/N1ZV"QV&G"I7=!THPNFVH]WS)<K
M;WW[MZ7,BW_9Y^'MIJ2W\/AN**Z2=;E'6YF 20'(*KOPHR>@&/;BIM?^ G@'
MQ/K%[JNI>'8;B^O/]?(LTL8<_P![:KA0W^T!GOFLRQ^/-G#HGB6]\0Z'J'AZ
MYT"18[FUE E#LP^14D7Y68Y'&>A!YS1H?QP>?5[?3-?\+W_AF\O;-[W3UNI4
MD6Z15+,N5^XP&/E/(SSBM'',TW/GE==>;I9/3756LW:_<Q4\C:C3]G"TG>W)
MI>[BK^[H[W2YK-NZ1V&E_#[0-&UFVU:SL/)U"VL4TV*;SI&VVZ?=3!8@X]2,
M^]8&J? #X?ZSJ6H7]WX:@EN[]M\\@EE3+;@VY0K (Q*C+* 3D@Y#'/&:/^U&
MFHZ7I6LS^#]1L_#]]>C3VU-KB-DBE)QC:/F(]\ =<9Q7.7WQ*\=:A\0O'GF/
M?Z1H?AVPN)6MK5K5A%BWD:-V+ LQ9@K#&0. PQFMJ6"S&,Y-SY&EOS=FE;1O
M6[V_X!RU\SR:=."C2512>RAM>+?-[R2LXIZ]4GV9[-JWP@\(ZYX@BUR]T@3:
MK%"+=;D7$JDH%*@$!P&X)&2":9=_!KP9?^%+/PW<:%#+H]F2UM"TLF^$DY.V
M7=O&3UPW/3I7 :'\?KSS/#>@V?A^_P#$VM:CI:WRR&XAA9^N[>2 HP 3GZ #
MFGZM^TT=*O?$,3>#]0FMM N$@U&ZBN8]D(8X!Y^\<@\#/3-1]4S+F4(R>FWO
M>=DUKIJ[+UT-?K^1N,JDHQ]ZZ?N-WNN9IM1:>B3EJ]$F^AWY^$'@_P#X1 >%
MUT2*/0Q*)S:QR2(6D!R'9PP=CP.23T [5KGP=HY\4Q>(S9_\3F*V-FESYC\1
M$YV[<[>O?&?>N'\-_'>VU?Q(=+U+0KW089=-;5[2ZNI$<36HS\[*A)0X4G:<
MD8Z57\+?M V_B+5]&BN/#U]I6D:Y))%I6J7$B,MRRD@!D4[HR<'&>O;(YKGE
MA\?[W-?JWKWWZZW2UMKIKL=E/&Y3[BARJ[27NVMRM)=-$G)6;LO>TW.X\:?#
MWP[\0[*&T\0Z9'J,4+^9$2S1O&>^UT(89[@'GO5*3X1^$9/",?AC^Q8DT-)%
MF%K%(Z9=3D,SA@S'/<DY[UY/\3/VAM4N/!/B>]\*Z+J,%A8W"V<7B9?+,0E$
MJ!OW;<[2-R[L$9*]"17JVK>-SX3^%8\47D3W[VVG174L:L$:4E5SSC Y/I52
MP^-H4Z:YFKRLHWV>G2]D]?7N3#&97BJU:7(G:%Y2<=XW:M=J\E[K[I]+G1:I
MH=CK.BSZ3>0>=I\\1@DAWLNY",8R""./>LV]^'_A_4?",7A>ZTR.XT**)(8[
M21F.Q5^[AL[@1CKG/O7!CX^S6_A6UUJ]\)7MI_:<T,&CVGVJ)Y=09PQX /[L
M *,EO[PITW[1.G6'A/7]3U+1[NPU70[F.TO-)>1&99)"1&1(#M*L 3N[8/U.
M<<'C8V4$]'T:WVOH^^E^CTO<TGF>5SNZC6L7>\7\-F[.ZZI-\O5:I-:G6:-\
M(O!^@>&[_0;+0K=-*O\ )NH)2TIF_P!YW)8X[<\=1BL*Y^!GAOP_X-\5V/A3
M1X;+4]6TNXLEFFGDD)+Q,JC?(S%5R1G%11_&NZMO"WB#6-5\(:EI1TFW2Y57
MD22"Z1L8\N=,HQ^89 )Q5;PS\?/[7U?PY;:KX6U#0+'Q$@;3+^YE1TG8J&"D
M+RN<\$]<@XP:WC3S%<T[MJ]W[U[M*_?WM->NAS2K9-+DI\J3:M'W&G%-N._+
M[NNFMM?4E^%/P%\.^"M/T34;S1+4>*K6W"2W22/(BR=V52=H;_:"@]>>:WM6
M^"?@?7?$O]O7WAVVN-4WK(TA9PDC#H7C#;'/^\ISWKE-0_:.MK5K_4+?PUJ-
M]X3T^[^Q76OPNGEH^[:2L>=S*"0-PXYJ?7_CX]CXOU#P_HWA:]\13VEA'J/G
M6LZ1HT+*K%CNQC 8>I/I5RIYG4JNHVTVG]JUEI=;Z6NM'WV,J=;(Z-!45&+C
M%JRY+W=G:27+[S?*_>2=[/4[M? &@)XGN?$*Z>%UBXM192W E<;H>/DV[MHZ
M#D#-8=Q\#/ UUX<M]"ET"-],MYGGAC,\N^-V.6*R;]XR>HW8KF[G]HZQFTKP
MG+I.B76J:GXC$C6^GFXC@*;#M8&1R%SNR .^#TXSJZE\;8M+\):3J4_AW58-
M8U2X^QVVAW4?D3M-W&Y\#9W#]"/3MBJ&84W&SDG>R][M==]$M==MSJ>*R:LI
MW46K7?NW7O<KWM9MWBVM6]-#;3X0^#X_!S>%5T*W&A,YD-MN<L7SG?YF=^[_
M &MV<<9QQ6CX-\!Z!\/].>Q\/Z;'IUM(YD<*S.SMZL[$L?Q/%<!=?M&:=I?A
M#6]5U+1KNQU32+M;*ZTEY49UE;.S]X#M*D#.X<?6NM^'_CV^\9->Q7_AJ_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI)M<JCOT5K?DM]/+5GAN@_ O5M&\#:]9P6WABQUC490PM8K62:R\I<XB8O\
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M5G2='11?9>=[>E]3SZ>58>G7CB=7)=W>[LU=]W9VOV.,^*7_ "!M._["$?\
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M\O\ W\;_ !H^RK_?E_[^-_C4U% $/V5?[\O_ '\;_&C[*O\ ?E_[^-_C4U%
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M;^26R273U\SW,MRIY?6K5>9-3=[)6ZMZMMM[[;=DKA1117DGT 4444 %%%%
M!1110 4444 %%%% '&?%+_D#:=_V$(__ $%Z]#\._P#(*@_W17GGQ2_Y VG?
M]A"/_P!!>O0_#O\ R"H/]T4 :=%%% !1110 4444 %%%% %74=4LM(M_/O[N
M"R@R%\VXE6-<GH,D@9J"#Q'I-U);)#JEE*]R"8%2X1C+CKM /S8]JAU@:O\
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M=;7G7Q<=/(MXP@CG,4C+.TC)N P?+7:#EF., ^E*.K!F[\.'=_"UJ9;^2_N
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M9I.HIJVF6M[&C1QSQB15;J 1T-<IK6FS7/B&]NY;N$-;+']DMIVC,4BD?.K
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M%Z[.S-/;PK$K$GT4D9]ZTJ'N!YWXP\;PKJ-SI<5MLN+=U)GDF2+=M"R,.3D
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M@_#KO@_PKH#:G)"F@W=O=+.(03,8E90I&>,[O?I7(WO[*^DSP>,8X-6EMO\
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M<5?'3_=I/JM6O=5_\2]]^>ATE%%%?.GV84444 %%%% '&?%+_D#:=_V$(_\
MT%Z]#\._\@J#_=%>>?%+_D#:=_V$(_\ T%Z]#\._\@J#_=% &G1110 4444
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M!45U:Q7MM+;SQK+#*I1T<9# ]014M%(##TCP3H.A&![+2+*&>$82X6W02_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAQ$-2UJ'2;B"PAU;1TFA^RZS]C1([=KG,1?(6.,'RFC#;0&!'%>W?\*7N?\
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M!I#3P&RCO;N)H[AL>3YA#;BV#(<'I@9%>U?\*7N?^B@^*?\ OWIO_P AT?\
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M9>RM+<1$R0,FW<P*D('7:I# Y)]Y_P"%+W/_ $4'Q3_W[TW_ .0Z/^%+W/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHK%U"_O[?Q1I-K'Y7]GW$<WF_*2^]0"O/0#DTP-JBO-O''Q*
MU+PUXAN+&&/3[6.&W2>%=49HAJ3%OFBAF)$<;8P!NSRPR .:M:E\8-.M+RXM
M$LKQ67S((KV5$^RM=I"93;[@Y;?M5N<;3M(#$U7*Q7._HKSKPQX[UR?4?"T6
ML1:?);>(K5YH'LD>-H)$C$A1@S-N!4GD8Y7IS753^+K&WU7^SW@U0S[PF]-)
MNGAR?^FHC*8]]V!2<6@N;=%>?_$+Q]J/A758K6#^S["V:TDN%OM55Q!-*O2
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MZK(\6X2,&>9551MXWE2V1M!YQ@V'QUCU#6=OV&:TT>2>SC@O)8E8NLT$DIW
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M[E$O%0&6%\[)%V.V <?=;##NHKK:EIK1C"BBBD 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>btai-20241231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 btai-20241231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" () \L# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5MY*9;@QCH.]2Z+XN\5^"=*U;6/BSJ'A#0]%MT0PW>FW4RJK$D,)#,JCGY0
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M&-]UNO/[SRLU5>6"JK#4U.=M(RV?=/;I^)X)JO[#VJ6;IJO@?QBDL3J)K4W
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MZ!P,>F0I[5]=>&_@_:?#SX.ZCX0T(&YN)K.<--)A6N)W0C<>PSP!SP *XO\
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MSC;OKLSOX>AC(8R7/2?L^6W-*FJ<[WTCI\2MU_I]U1117R)^BA1110 4444
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M /%5\[44?V9A_/[P_P!=,U[Q_P# 3Z)_X:"\.?\ /O??]^U_^*H_X:"\.?\
M/O??]^U_^*KYVHH_LS#^?WA_KIFO>/\ X"?1/_#07AS_ )][[_OVO_Q5>AZ/
MJD6M:7:W\ 98;B,2('&#@^M?&=?6_P /?^1(T3_KU3^5>7C\)2P\(RI]6?:\
M+9]C,VKU*>):M%75E;J=#1117B'Z05)+N7SWCBMS*$QEMX')&:3[3=?\^?\
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M_:;K_GS_ /(HH^TW7_/G_P"115RB@"G]INO^?/\ \BBC[3=?\^?_ )%%7**
M*?VFZ_Y\_P#R**/M-U_SY_\ D45<HH I_:;K_GS_ /(HH^TW7_/G_P"115RB
M@"G]INO^?/\ \BBC[3=?\^?_ )%%7** *?VFZ_Y\_P#R**/M-U_SY_\ D45<
MHH I_:;K_GS_ /(HH^TW7_/G_P"115RB@"G]INO^?/\ \BBC[3=?\^?_ )%%
M7** *?VFZ_Y\_P#R**/M-U_SY_\ D45<HH I_:;K_GS_ /(HH^TW7_/G_P"1
M15RB@"G]INO^?/\ \BBC[3=?\^?_ )%%7** *?VFZ_Y\_P#R**/M-U_SY_\
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MJ0@5(#$EM,LBX3(>,JJD#Y\]:] _:1N=,LO%_P ,Y]8UZ?PSIRWMX)-3MYQ
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M%+.ACE95 X92P( [C- 'T%KGC/2- \/ZKK,]Y%-9:;$TUP;>1790HSC&>IZ
M'O4&D>-+;7]3M(=/CCNK*>S^U&\CNHCY397$;1AM^2#G(&!C&<U\O>$_L?BK
M3?&T&F1Z+=V]WX++OI^B:>T4,,Z.Q6)RQ/FRINY; .<9'2M"1=/U/5(;OX>0
MV:75W\.[X0R:9 (C)<AD7^$#,@;@$]#0!]4P:K972S-#>6\RPY\TQRJPCQUW
M8/'XT^VU"UO'D2WN89WC.'6.0,4/OCI7S!I4_AG45U*?P+%;1Z;;>!+VWUHV
ML!C7[1M3RDEX&9AB4G=D@;L]177_  E\.Z=X8^(WAJ+2[..Q2[\#137/E+@S
MRB:+]Y(?XW^=OF.3SUH ]N?5;*.Z%L]Y MP6VB%I5#DX!QC.<X(/XU:KYL\7
M>'=-N/%/Q4UJ2QADU:U\1:$MO>L@,L(\JQSL;JN=Q!QC(.#72W/P\U"3XGKJ
MH\!,]N-42X_M;_A-KQ?E$@/G?8P/+XZ^5]TXQT- '7V'Q6DD\;:;X>U/PUJ6
MBKJWVD:;>731E;DPC<X**Q:/*Y8;@,BI;7XLV%[\6;CP+#9W#W,%F;E[\$>2
M'786B]=P62,G_>%>63:]8ZE\=="U+PCJ][XLU4F]@U#1]0+&/28MA.Y,J/LY
M,BHG.=P;%9_PVM_%6C_&[PG;^(O#+6&IW.E:E<7]V+V&1))9)8W>10A.%#;(
MPO7!7L#0!].T444 %%%% !1110 4444 %%%% %;4/^/;_@:?^A"K-5M0_P"/
M;_@:?^A"K- !1110 5\H_%/_ )*#K?\ UW_]E%?5U?*/Q3_Y*#K?_7?_ -E%
M>YE/\67I^I^:\=_[C2_Q_HSE:***^I/Q$**** "BBB@ HHHH **** +&GV%Q
MJM]!9VL9FN9W$<<8(&YCT&3Q5OQ!X:U+PM>K::I:FUN&0.%+JV5/?*DCM7<?
M K07OO$5UJBQ>:=/@9HE)P#*P(7GZ;JVOBCX9U6Y\ :3J>K1!=7T]S!<%6#;
MXF/RDD=<87\S7GSQ7+B%2TM^-W_7XGU=#)'6RJ6.M+FU:_EY8M)WTWU;6NT6
M>2:5I=UK>H06-E%YUU.VV./<%W'ZD@5'?64VFWMQ:7*>7<6\C12)D':RG!&1
MP>1VKV;3]%T+P?\ $7P[HT.F-->-$LS:B9WW>80W1,[=O'IW]N<O5/"%GXP7
MQ-_9]L!X@M=<D1W\QOGB>9@"5R0 "3R!_#26,3EJK1:6OJ[=]BY</S5%J,TZ
MJE)-*_V8J32]W66KZVTT9Y/17L,/@/PY>>)M<AM[539:):*KQO=-&MQ/@DLS
MEOE4=."!Q4$7@GPY>ZUX8*"S5KN9H;W2[2_^T*,*Q#!@Q8#CU[BJ^N4^SVO^
M%_R,?]7L5TG'>V[_ )E%N]K:/YV3:31Y+17J=CI7@^[\;:EI5U96^F6]GYD<
M!FNY0MQ(#@;V+?*.O3'XU<UCX664FK>'+=;%M.6\F,5S+:3^=;, I;Y&9BX)
M"GJ,?ERWC(1=I)K2_P"O<F/#^)J0<Z4XRM+ET;WNH]4K:OK;NCR"M#0M O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ!_S[P?^!,?^--_5VV]-28K.(QC!1G:.VC[-=NS:79/0IGQM?_\ "/Z7I"I
MD&G7/VJ&0*?,+Y)Y.<$98]JUI?BSJLNJ37PLM-1KF(Q742P-Y=R",?O 6.2.
MV".IJK_PJ[Q!_P ^\'_@3'_C1_PJ[Q!_S[P?^!,?^-#6&>]O^''#^V8)*,9K
M;H_LJRZ=%IZ:%+Q%XSO/$5E9V+P6MC86F3%:V<92,$]3R22>3W[U@5UG_"KO
M$'_/O!_X$Q_XT?\ "KO$'_/O!_X$Q_XUI&=&"M%HY*V#S'$3]I5I2;]'TT7W
M')T5UG_"KO$'_/O!_P"!,?\ C1_PJ[Q!_P ^\'_@3'_C5^VI_P R,/[-QO\
MSYE]S.3HKK/^%7>(/^?>#_P)C_QH_P"%7>(/^?>#_P "8_\ &CVU/^9!_9N-
M_P"?,ON9R=%=9_PJ[Q!_S[P?^!,?^-'_  J[Q!_S[P?^!,?^-'MJ?\R#^S<;
M_P ^9?<SDZ*ZS_A5WB#_ )]X/_ F/_&C_A5WB#_GW@_\"8_\:/;4_P"9!_9N
M-_Y\R^YG)UM^"?\ D:M-_P"NG]#6C_PJ[Q!_S[P?^!,?^-:WA3X<:Y8^(K&>
M:"$1H^6(N$)Z'L#6=2M3<)>\MCKPF78R.)IMT96YET?='GIZT5UI^%WB#/\
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MJK26G,CQGEV.DVW1E=^3.3KZW^'O_(D:)_UZI_*OG3_A5WB#_GW@_P# F/\
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M"R!BL8!]]\"ZK_;?A#2;W["FFK+ NRUC.411PNPX&4( *\#@CBMZB@ HHHH
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MJS0 4444 %%%% !1110!!]H/VWR,#;Y>_/?KBIZI_P#,7_[8?^S5<H ****
M"BBB@ J"UG-PLA( VR,G'L:GJGIOW+C_ *[O_.@"Y1110 4444 %0W<QM[6:
M4 $HC, >^!FIJK:G_P @V[_ZY/\ R- $Z'<H/J,TZFQ_ZM?H*=0 4444 %%%
M% $,\YBEMU !$CE3[?*Q_I4U5;S_ (^;'_KL?_1;U:H **** "BBB@ J%)BU
MU+%@8158'ZY_PJ:JL7_(1N?^N<?\VH M4444 %%%% !1110!#:S&XA#D '+#
M ]B1_2IJJZ;_ ,>@_P!]_P#T(U:H **** "BBB@"*ZF,%N\@ )49P:EJMJ/_
M !XS?[M6: "BBB@ HHHH *AEF,<\*  B0D$^F!FIJJW'_'Y:?5O_ $&@"U11
M10 4444 %%%% $,4QDN)HR !'C!]<BIJJV__ !^W?U7^56J *VH?\>W_  -/
M_0A5FJVH?\>W_ T_]"%6: "BBB@ KDM5T":ZU">598PK-D DY_E76UFS_P"N
M;ZUTT)RIR;B>?C*,*\%&?<YG_A&+C_GM%^9_PH_X1BX_Y[1?F?\ "NBHKN^L
M5.YY']GT.WXG._\ ",7'_/:+\S_A3)O"<T\,D331A74J=K,IP?0@9%=+12^L
M5.X_J%#M^)PGAOX56?A..Y7352-KF3S9I)97EDD;U9FR3^=;/_",7'_/:+\S
M_A7144E7FE9#E@:,W>5V_4YW_A&+C_GM%^9_PH_X1BX_Y[1?F?\ "G>.O%0\
M'^'Y+Q(_M%[+(EM96W>>X<[8T_/D^P)KCW^,XTSX0OXMU*W@BU%));7[&KE4
M:X61D" \GHN?SH^M374%EU%[+\3KO^$8N/\ GM%^9_PH_P"$8N/^>T7YG_"N
M;T;XX:!JWB+4]/%];?8]/LHKJ6]5FVNS, P (X"Y7Z[AZ5-JOQ<TSR;J[T;4
M=.U&SL;&[O+I=TGF'R@ OEX7:1N)!)/<8SS1]:GW#^S:/9F]_P (Q<?\]HOS
M/^%'_",7'_/:+\S_ (51\#?$S1_&.BF=-2LY+^UMTFU""W<D6Y*Y;KU P1GG
MI6IJ'CC0M*L+2\N]2B@MKNW:Z@D8'YXE0.SCCH%(/XT_K-3N']G4=K,A_P"$
M8N/^>T7YG_"C_A&+C_GM%^9_PKG_  _\;?#=]X+LO$.JZG::7%<RO$(VD)VL
M"?EZ9)"E22!@$UT.I_$/PUHVA6NLWFM6<&F76/(N3)E9<_W<<GWQT[TOK4^X
M?V=1[,3_ (1BX_Y[1?F?\*/^$8N/^>T7YG_"J/@+QY_PG6I>(VM5ADTC3[M+
M6TNX23YY\I7<D]."PQCL>:SO#GQK\.ZY:>(K^74+6TTW2+L6YN&<X="/E?D#
M[S!P ,_=H^M3[A_9U'M^)O\ _",7'_/:+\S_ (4?\(Q<?\]HOS/^%7O#?BC2
M?%^FC4-&OX-1LRYC\V!L@,.JD=0>0<'L0>]<?K'BWQ=J'C+5]'\+VFB26^EP
MP/<3ZK+,A+R!B%78#G 7G..HI_6:G<%EU#M^)T7_  C%Q_SVB_,_X4?\(Q<?
M\]HOS/\ A7,P_%'4!X8\*>([C38HM)U&40:BRL2;7<2B2JW0QE@.2.C YI9O
MBT//UC58H8O^$.TI#&^HC+R7MQG'EVX! 89P-W()Z>H7UJ?<?]FT>WXG2_\
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M)A020N H[>]%V"43H=+\?WEA'OOO[3UNZLM.M!>V&F:<LC&>4;_,!!!Z=5P
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M?%&O7?\ ;VF:!IDRVUS<*;N[NB%8VUJA&X@-D;G/R@D$#YCSBN?^'WA+7?\
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M %*?2LZFQO0^)DE%%%<YVE:W_P"/N[_WE_\ 015FJUO_ ,?=W_O+_P"@BK-
M!1110 4444 %%%% %/\ YB__ &P_]FJY5/\ YB__ &P_]FJY0 4444 %%%%
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M\9Z+XOTVUM7N%>U:&*^61/OQ^0A[;6SD^G/4#9T'XTV?B3PZVMV'AKQ'-8$
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M;IXD7XE6.B6WC&]U"ULXA>ZJL]K; !"<1Q I$"&<@D\C"C/<47'9H]4 C4
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MCWKJ\K_=/YT97^Z?SHM8&[]3A/ ,8U'Q5XQUZ+FSO+J*T@?M(+="C,/4;V<
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ME_\ 08Z@K\>SE)9A52[_ *'W^7ZX6GZ&M_PEVN_]!K4?_ N3_&C_ (2[7?\
MH-:C_P"!<G^-9-%>*>@:W_"7:[_T&M1_\"Y/\:0^+=<8$'6M0(/4&ZD_QK*H
MH UO^$NUW_H-:C_X%2?XT?\ "7:[_P!!K4?_  +D_P :R:* -;_A+M=_Z#6H
M_P#@7)_C1_PEVN_]!K4?_ N3_&LFB@#6_P"$NUW_ *#6H_\ @7)_C1_PEVN_
M]!K4?_ N3_&LFB@#5/BW7"03K6H$CI_I4G'ZTO\ PEVN_P#0:U'_ ,"Y/\:R
M:* -;_A+M=_Z#6H_^!<G^-'_  EVN_\ 0:U'_P "Y/\ &LFB@#6_X2[7?^@U
MJ/\ X%R?XT?\)=KO_0:U'_P+D_QK)HH UO\ A+M=_P"@UJ/_ (%R?XTG_"6Z
MX"3_ &UJ&3W^U2?XUE5Z9I5E)>_"*^,FAK86ULDDZ:\UG!(MV_FQJ+?S6B\Q
M' +$!9.@/RD'- 'V[^S-=SWWP.\+3W,TEQ,\,FZ25BS']Z_4FO3Z\J_9<_Y(
M/X4_ZXR_^CGKSGQ;X]T![?XQSZ3\29+2*QTN9#"WB',Z7Z-*2859]UNBLT4(
M$84.>G(!:S-GTW17RMXTU7^QY)_&.FZU;>(M-U*RL;C40+CRHD@?[/ D3W@,
M@$;R0N_^K. UQWD!'U!IMV-0TZUNA$\ GB23RI!ADR =I'J,XH$6:*** *NF
M_P#'H/\ ??\ ]"-6JJZ;_P >@_WW_P#0C5J@ HHHH **** *VH_\>,W^[5FJ
MVH_\>,W^[5F@ HHHH **** "JMQ_Q^6GU;_T&K55;C_C\M/JW_H- %JBBB@
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M'%==5+8B5FW8****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6E;_ .I3Z5FUI6_^I3Z5E4V.BA\3)****YSM*UO_ ,?=W_O+_P"@BK-5K?\
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M\O\ SR?_ +Y-?KK_ &79?\^D'_?I?\*/[+LO^?2#_OTO^%'^MB_Y\_\ DW_
M#^Q'_P _/P_X)^17V>7_ )Y/_P!\FC[/+_SR?_ODU^NO]EV7_/I!_P!^E_PJ
MIIVEV92?_1(/]>__ "S7U^E'^MB_Y\_^3?\  #^Q'_S\_#_@GY3K;R_V-;_N
MW_X^)?X3_=CJ#[/+_P \G_[Y-?K5_9=GC_CT@_[]K_A1_9=E_P ^D'_?I?\
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M)!_K3_RS7_GF_M5K^R[+_GT@_P"_2_X46#F/R5^SR_\ /)_^^31]GE_YY/\
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M>8/[B_K3**+!=C_,']Q?UH\P?W%_6F446"['^8/[B_K1Y@_N+^M,HHL%V/\
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M #JY5/3?N7'_ %W?^= %RBBB@ HHHH *K:G_ ,@V[_ZY/_(U9JMJ?_(-N_\
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M^[_@G445R_\ PD-]_P ]$_[]K_A1_P )#??\]$_[]K_A1]5J>0?VE0[/[O\
M@G445R__  D-]_ST3_OVO^%'_"0WW_/1/^_:_P"%'U6IY!_:5#L_N_X)U%%<
MO_PD-]_ST3_OVO\ A1_PD-]_ST3_ +]K_A1]5J>0?VE0[/[O^"=117+_ /"0
MWW_/1/\ OVO^%'_"0WW_ #T3_OVO^%'U6IY!_:5#L_N_X)U%%<O_ ,)#??\
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MOA_2WN+E]9N0-2U&[E#3%&/[R1CQD[5V@*.XXQDUWUO!':P1PQ*$BC4(BCL
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M+_\ %4?\-Y>*_P#H7=&_.7_XJBX69]NU5B_Y"-S_ -<X_P";5\6?\-Y>*_\
MH7=&_.7_ .*J-?V[/%2SR2_\(]H^755(S+VS_M>]%PLS[AHKC?@_XVNOB-\.
M=&\17EO#:W-\CN\4&=BX=EXR2?X:[*F2%%%% !1110!5TW_CT'^^_P#Z$:M5
M5TW_ (]!_OO_ .A&K5 !1110 4444 5M1_X\9O\ =JS5;4?^/&;_ ':LT %%
M%% !1110 55N/^/RT^K?^@U:JK<?\?EI]6_]!H M4444 %%8WC#Q&/"?AV\U
M5H#="V4,8@^W=D@=<'UKC=+^-EOJ/A&\UK^R9EECO(-/M[-)@S7$\SHD2[B
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M"PX) (Y/8GUS6BQ#;2M_5[&$L$E%R4ME?;R3U^_\#UC5O&NFZ/XETK0YI/\
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MU_W!7GE>AZ-_R"[7_<%>9C_@CZGT62_Q9^GZEVBBBO%/KBM;_P#'W=_[R_\
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MJT'L92PE6+M+3KN>DT5YGK7Q*UV35/$$>@Z59SV6@*#>O>S,LDK8W%8PH(&
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K6E_P#'_#_O55JUI?\
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MZ3\:9M.L]5OKRRCL5:5&LR@+%C@@[E/I7F__  P?X._Z#VN?]]0__&Z^B_\
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MP?X._P"@]KG_ 'U#_P#&ZBN_V%?!]O:32KKVMED1F +0]AG_ )YU].56U/\
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MD6)"R^<SN)1N?)B0*-O+A@QZ+X4:S_:4?B6V?6VUR2SU>:))I9D>01[4*@[
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M:?XDZ3!KFIZ=B9HM*A\[4-0 46UIQD([%@=V.< &G];EV0O[+I]V1_V->_\
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M;_=JS5;4?^/&;_=JS0 4444 %%%% !56X_X_+3ZM_P"@U:JK<?\ 'Y:?5O\
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M"L9;<W)'(! [USMC&MS\/'L[<3:A<Z[XHBCLM1N0?M%]%'-')Y[YZ@+&ZY
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M>A?^#"+_ .*H_P"%U^ /^AST+_P81?\ Q5?EY11<.4_4/_A=?@#_ *'/0O\
MP81?_%4?\+K\ ?\ 0YZ%_P"#"+_XJOR\HHN'*?J'_P +K\ ?]#GH7_@PB_\
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MJ[5( !^8CO7S7_PRI\3O^A;?_P "(O\ XJI9:V/):*]:_P"&5/B=_P!"V_\
MX$1?_%4?\,J?$[_H6W_\"(O_ (J@JZ/):*]:_P"&5/B=_P!"V_\ X$1?_%4?
M\,J?$[_H6W_\"(O_ (J@+H\EHKUK_AE3XG?]"V__ ($1?_%4V/\ 99^)DH8K
MX<8[6*G_ $B/J.O\5 71Y/17K7_#*GQ._P"A;?\ \"(O_BJ/^&5/B=_T+;_^
M!$7_ ,50%T>2T5ZU_P ,J?$[_H6W_P# B+_XJC_AE3XG?]"V_P#X$1?_ !5
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MMW]5_E5JJMO_ ,?MW]5_E5J@"MJ'_'M_P-/_ $(59JMJ'_'M_P #3_T(59H
M**** "LV?_7-]:TJSYW82L,]ZUI[G/6V1#13O,;U-<+X)^+5KXJ;61>I!HHL
M-6?2(C/=J?M,@)"[<A?F;!PHR?K6]SDLF=Q16(GQ"\-/9)>+XDTEK1YOLZW
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M6OT%.IL?^K7Z"G4 %%%% !1110!5O/\ CYL?^NQ_]%O5JJMY_P ?-C_UV/\
MZ+>K5 !1110 4444 %58O^0C<_\ 7./^;5:JK%_R$;G_ *YQ_P VH M4444
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M,B0$R/'LZMG<,],5@?9]9;X1:=H>KZ9=7:^%?$,46IVD,;-Y]FK$_+Q\Z\D
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M_P @V[_ZY/\ R-6:K:G_ ,@V[_ZY/_(T 3Q_ZM?H*=38_P#5K]!3J "BBB@
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MY2JY(4,^U3@;B<468[QL=M1115F04444 %%%% !1110 4444 %%%% !1110
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M_A7HO[3'W-%^K_TKPJOM,MHTIX:,I13>O3S/ Q=2<:S2;.P_X6_XP_Z#D_\
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M"Y8JH& ,DDG\35FJ,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH_B3K^@>+_B!-J&G+<Z=I]WIUM!"+_B+SC%&-H\O^(2F0^XV\]1T/CSXO?\
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M *K:G_R#;O\ ZY/_ "-6:CGA%Q!)$V0KJ5./0C% #H_]6OT%.I%&T >G%+0
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M6U1XO,^RQF.&*.-2(T0,2?XF))/):MKQ!JKZ'HMW?QV5SJ,D";DM+1"\LK=
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#%4 7J*H_V-;?]-O\ P(D_^*H_L:V_Z;?^!$G_ ,50!>HJC_8UM_TV_P#
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M2?\ Q5 %ZBJ/]C6W_3;_ ,")/_BJ/[&MO^FW_@1)_P#%4 7J*H_V-;?]-O\
MP(D_^*H_L:V_Z;?^!$G_ ,50!>HJC_8UM_TV_P# B3_XJC^QK;_IM_X$2?\
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M+2VUZPFN6/14$P&X^P8J?PKO*I:UH]IXATF\TR_A%Q9W<30RQMW4C!^A]^U
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MM2:YIT30J^H6J&8 Q!IE&\'IMYYS@]/2@:YIQM)+H:A:FUC;8\_G+L4^A;.
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M@@BN+_2[2#]YN,&F6K1.=I.2&)5^.IP#0!Z/9>-M!U"74H[?5K1SITHANR9
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M>*7Q*);:TBBE@UJ&>&!6QSY2R*HZ@],X!]Z].H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>btai-20241231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 btai-20241231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (; \L# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"!;#4- MI#]FO9K65FDC SN)$Z@]^PKSOPC^U?\9?'LMS%X?\ !^AZK);
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MP*2'.,Y)WJ<8^;KGI7J'QB_:4U#3_@)X9UO16%CK?B2'894'-L5!$Q3T.X$
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MN_-96DKW>GGYW/L^BOD_]C7Q_+HNB^,?"VNRO'<Z$[WI6=CE$&5E'/3# ?\
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MQ7,**P2XW-G<[[B<8/O[I^T?X?UOQ!^S;>VT2G7-0AAM+F\CLP3]MCC='F"
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M0C!T\+2Y5*2E*[O>SNDNRN71R#%3JQK8[$>T<(RC"T;6YE9MZZNQ\P?L!_\
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MY,O?'H"H_"O3]5\.:3KK1-J6EV6HM%GRS=VZ2E,]<;@<5?1%C4*H"J!@ #
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M,D!N.",CGZ5@^+OB0?BQ^T3X;\11:?/I^GR75M!:+<##/&CXW'MU)Z?3M7Z
M:KX?TO70@U+3;/40GW!=P)+M^FX'%0R>$M#EEMI7T73WDM0%@=K6,F( Y 0X
M^7GGBNB&>4.?V\Z/[QQY6[Z;6O8XZG"N*]G]4IXE*@I\ZBXZK6]F[[;FM7Q5
M^V7_ ,EL\%_]<XO_ $=7VK69J7AG1]8N8[F_TFQOKB+_ %<MS;)(Z<YX)!(Y
MKPLMQBP&(]M*-]&OO1]7G>62S;"/#1ERNZ=]]G<^1/VWO^2H>!O^N"_^CZ]'
M_;F_Y(U!_P!A.'_T%Z]UU/PUI&MSQ3:CI5E?S1#$<EU;I(R<YX+ XYJ;5-'L
M-<MA;ZC8VVH6X8,(KJ%9%SV.&!&:[:>:1A]5]S^#?KO=W/,K9#.K]?\ WB_V
MBUM/ALK:]S@OV</^2&>#/^O!?YFO%?V[/&DCV?A_P99L7FNY?M<T:<DX^6,?
MB2:^K+.RM].M8[:T@BM;:(;4AA0(B#T ' JG?>&-&U2^CO;S2;&[O(\;+B>V
M1Y%P<C#$9&#S7-AL=3HXYXR<+J[:7F]ON.S'955Q.5++:=3E?+&+=NBM?[['
MS#I_[ FC26%LUYXFU"*[:)3-''#&55\#< >XSFO.O!.G/^S7^U);:+)<R3:;
M.5M?/D 4RPS ;6...&Q^(K[VK+U'PKHNL7B7=_H]A>W2 !9[BU21U .0 Q!(
MP:[Z6?8B2G3Q;YX235M%:_78\G$<)X.#I5<N2I5(24KZNZ71Z]3XR\?W6I?L
MZ?M0W?C&\TZ6]T/59))XY8QQ(DH'F*#T#*V>#VP>]<9^TS\:K?XT:OI%WI6F
MW=IHMB&ACGNT"M+(Q!/0D# QQDU^A&I:/8:S;"WU"RMKZW!SY5S$LB9^A!%4
MI?!?A^>SBM)-"TR2UA):.!K.,HA/4A<8!^E=.'SNA3G2K5:-ZD%RWO;3T[G'
MC.%L55IU\+0Q*C1J2Y^5QNTV[M7OM_P/,^0OVNO 5W;WOA#QHFFOJ>CK9P6]
M\B@D*5P0&QRJLI(SZCW%8T7Q!^!%]+86^G_"K4;Z\GPLD*3R JQ[(!(2_/TK
M[J>VAEMS \2/ 5V&)E!4KTQCICVK-T_P?H.DW/VBQT33K.X_YZV]I'&_Y@9K
M&CG48T(T:L97C>W+-QT\[=CHQ'#$Y8N>(H3@E4LVI4XSLUORM[7/F?\ ;/L+
M;2_@KX.L[.R;3;2"YCBALW;<T""$@(3DY(''4].M=CXR_P"3*;?_ +%:P_\
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MP&Y17G^C?%5;WX/-XYN[-;8+:RW!M5D+#*LRJN['<@=N]=#'XOL],\/:;?\
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MTN:V^'<.K7:XO]=N)=5G)ZYE8E1^"XKTNH+&RATVRM[2W01V\$:Q1H/X548
M_(5/6$G=W*6@4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]S$]J-$@DM_*.\;S,H 0+M#$\?CUKT77([EOVF?""2RA+P^&;@/*B@@/N;)
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M@?;=)Z?5:.6/PV_JP7>Y[Q1117*:!1110 4444 %%%% !1110 4444 %%%%
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MM_\ %4 7Z*H>5J7_ #\VW_?EO_BJ/*U+_GYMO^_+?_%4 7Z*H>5J7_/S;?\
M?EO_ (JCRM2_Y^;;_ORW_P 50!?HJAY6I?\ /S;?]^6_^*H\K4O^?FV_[\M_
M\50!?HJAY6I?\_-M_P!^6_\ BJ/*U+_GYMO^_+?_ !5 %^BJ'E:E_P _-M_W
MY;_XJCRM2_Y^;;_ORW_Q5 %^BJ'E:E_S\VW_ 'Y;_P"*H\K4O^?FV_[\M_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=8\2ZKKEYJ\!9X;Z56BA*RNN4  (R ,YS0![917C&EZEXAL?VGY](OM?FO\
M2+G0)KZ*P$8CA@(N(U7 ')(!.6)YS73_ !V;6;?X7Z[=Z)K$FB75G;27+7$,
M8>1E5&.U2>%)..<'@'UH ] HK@/#.M7US\"[#59;F2347T 7+7+'YS)Y&[=]
M<\U\X?L^_%S6T\2^&9=9\0>(I-/OM%N+N^7Q#"%@N9HUW_Z$P'S *&)R>@H
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M0BO9J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0!YCX*_9X@\#-+#8>+]?.EK;2VME8,\06S5P1E6";F*Y^4L3CWJG;?LNZ/\
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M6_"JP^%UEJBV]_>ZOJ.K79OM0U'4'4RW$Q &2%  & . *[>J'F:C_P \+?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*DXJW-&[]4VOQM<^IRW$SKRKQF[J,VD_)QC)+Y7M\@HHHKS3VPHHHH ****
M"BBB@ HHHH OZ1_K9/I6I67I'^MD^E:E !1110 52L_^/^__ -Y/_0!5VJ5G
M_P ?]_\ [R?^@"@"[1110 4444 %%%% 'B.N?"+7=;\6:W=!(K<WZW<3:A]H
MS&]O);F..,08^5P^PE^I"GDYQ7<_#_1M:@U/5]7URS@TZYO([:W2T@G\X*L*
ML-Q; 'S%S@8X %=K10 V2,2QLC9PPP<'!JE_8MMZS?\ ?YO\:OT4 <"WQ#\
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MVO[KP@89$FVK/G'..5K[/KXX_P""@'_'UX._W+C^:U\SD'_(QI_/\F>QF?\
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M ,_<7YT?V]I__/W%^=:%% &?_;VG_P#/W%^=']O:?_S]Q?G6A10!G_V]I_\
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M,F1ER0<;@<@$>]?>SG@9U/<Y-.=?87V5RVOHU?9OJ?DE.GFM.C^]]IK[-_\
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M/YUQ:R) ZQKNDV2%=K%5() -6?"?C;3/&<-P^G_:4>W*B2&[MG@D4,-R-M<
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MU?\ F:]OA/>M_P!N_J>=G?\ R[^?Z'ZF_!__ ))1X._[!%I_Z*6NOKD/@_\
M\DH\'?\ 8(M/_12UU]?#8C^-/U?YGT=+^''T1YY\6?CGX<^#)TP:^MZW]H>9
MY/V2$2?<V[LY88^\*J_"K]H3PM\8=4O+#04OUGM8A-)]K@$8VDXX(8UX1_P4
M$_UG@?Z7G_M&L+]@?_D>_$G_ &#T_P#1E?40RO#RRCZZ[\]GUT^*QX\L;56.
M^KZ<O_ N?<-%%%?'GNA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSA+.5+L7VA< A4P ./6H(/$OCGQEXS\7:%8^+1HD/A6VC0S"TB:2]EPV9&#
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MFR"$)!ZUOUE^*?\ D6-7_P"O.;_T U^=P^)'U,MF?E_-\7_' +X\6:N,$_\
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M\IF'J V,BG:5X^\/:Z91IFJV^I&+'F"S;SMF<XSMSC.#U]*^/?V^@#X]\-Y
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MC3;"VDN+JX-M;Q+NDFFC9$0>I8C 'UK(B^+'@V>5(HO$NF2R.0JHERI9B>@
M!Y-8_P"T/S\#_&W_ &#)?Y5^;_P\5?\ A/O#? _Y"-OV_P"FBUZV5Y/',*$Z
MTIVY?+RN<.,QSPM6--1O<_53^W+3UF_[\2?_ !-']N6GK-_WXD_^)K0HKYD]
M@YG4/B7X6TBZ:VO]=LK&Y4 F&YE$;@'IE6P:MZ9XUT36X&GTW4(]0@5MAEM
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M^-,\:Z)K<+3:;J$6H0JVUI+0&50?0E01FM.UOX;PL(BY*\G=&R_S KYR_8.
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M_P :_P"[:_\ M2OL:OC+]@:2X2?QG]GB27Y;7.Y]N/\ 6>U?7WGZC_SZP_\
M?X_X5S<0?\C&I\OR1KEG^Z0^?YLP/B[_ ,DL\7?]@JY_]%M7Y7VG_'Y;_P#7
M1?YBOU#^+4U^?A?XL#VT2K_9=SDB7)'[MO:OR\M/^/N#_KHO\Q7T_"O\"KZK
M\CQ\Z_B0]#]?1T%+6>)]1P/]%A_[_'_"E\_4?^?6'_O\?\*_-SZP^%OV[/\
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M?LT9-C=JR@W<MTP&"Q?=U/3@< 5Z5^U;HU]KOPGDM=.L[F^N#?6[>5:Q-(^
M3DX4$\5FL)0AB\.KITY6^[3?UO\ *UNAJ\PQ=3+\8VI1JPYO2^J2CZ6^=T^M
ME3\/?&CQ3I?CZW\+>,M+THS7NG/J-K=:*\FS:L;.599,GD(P[8([YJ3X4_%7
MQO\ $R:SU:'3_#P\-SW#Q2V\5R_V^V0$@.X)VGZ 9K9\&_![1_ AE\3L=7\2
M>(/L6P2ZI<^=,J[.8HQA0,].>>V>3GR"?1(;KXCZ!K?@#PMXB\,WB7!GUA)[
M62&U,0Y8 'AF.",+P<]*Z(0P>)]HJ4$G9>\U[MTG?2]U?2S[K;4Y:E7,L%[*
M5>HVG)^XG[W*W%+7EM*VK:TT>^AW?Q7_ &@]3\ _$&/2K'3[6[T.P%LVLW,B
M.98!*W 3# 9V8/(/45[FCK(BNC!D89# Y!'K7RAHGPT^(7C_ ,)>-M1>VTJR
M7Q/=2326VKVTRWJK&Q\M8^0%'  W ]/2O:?@5J6JZO\ "'28M5L[NPU.U@-D
MZ7D31N=@VJV& .-NWGV-<F886A3H1]DUS0?+*SWNKW^]->ECOR?'XNOBIK$1
MER5$Y0NK62;5EZQ<7KUN8OQI^.6F^&_!NLKX;\16!\3V<D*K;JRR.N9D5QM.
M0?E+?2NVO_B7X=\,6&F'Q!KEEIMU=VZ2A+B0*6R!D@>F:^5KS0;^W^#&H>$)
M_ VJ7'BN'4C</J(L&9=OFJ3(LF/F)4;<#/!K;\<>$/$NF_$W4-1N7U2WTS4M
M*@@ANK'0DU,A1$JM"48?N^0>1@_G7H_V7A7%4N:UG)WTO*W+:UD]-VE9O?U/
M&6>X^,Y8CV=[J"M9V@VYMWNTKJR3=TMO0^G-7\>^'=!TBWU74-:L[33K@ PW
M,DHV2 ]-I[U2F^*_@^WM+.ZE\1Z>EM>([V\K3#;(J?>(/MBOGFR\$:EX'C^&
M&JWNE:QK_A[33=>;9R6.ZXMFDD8HQA4MZ@@9X]C6]XHT&'QG\2?AG>6G@^[L
M="%U<//;SV!C1>20\B@87<0#\W6N'^S<,FO?;C[SNK6]WFLK/6[LOO/4_MO&
MRBVJ:C+W%ROF;][DO*ZTY5S-?+Y'L^H_%GP=I%M97%YXCT^WAO4$MNTDP'F(
M>C#VJWK/Q"\->'M,M=1U+7+*SL;L9@GDE 64>J^O45\X_$OP=K^C?&'7+X?V
MC::-J-DL-O<Z;H4>IJ$Q@P[&'[OG/(Q1J6F^*/!OA'X?Z9IUA?+I\45TTNK2
MZ#'>WUL7D+"/R3O" C;W[#IC%6LJP\HTY1J?%Y^3>]MU:VEV^R,Y9_C:<ZT:
ME&W)I>W7F4;VYEHTVTWRI6W>Y]'#XA^&3X<_MX:Y9?V-NV?;?-'E[O3/K[4V
M+XC>&)_#KZ\FNV+:.C;&O?.'EAO3/K[5\M>$O UR_P (M7L/$.D^(;9_^$@^
MT0S66GEIH6"C][Y/1E)[+QZ&EUW0/'OB?P%HU_=:3<(NG:ZTTDL&DHMQ<184
M)</:D .PP?E(YSS6G]CX;G<?:Z<UKZ;6TMW?3R[&/^L>-]FI^PNW#FLD[WO9
MWUT2W\]?>3/J_P ,^,-$\96DEUH>J6VJ01MM=[:0,%/H?2MBO"/V>O#%S;^+
M/%&OSW>KSF\BAC=M2T==-29\L=RQJ>J@8)VC[_?FO=Z\#&T(8>NZ=.5TK?EZ
M+\D?7Y9BJN,PL:U:/*W?\&TGN]_5^K+^D?ZV3Z5J5EZ1_K9/I6I7">J%%%%
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MQ_W^;_&K]% %#^QX?^>EQ_W^;_&C^QX?^>EQ_P!_F_QJ_10!0_L>'_GI<?\
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MV<5E>I<26L\<!)C+ICE<Y('(X)/UJ/0?A%%H7Q#B\5+J;S/'I46F?93" "$
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M_<W13S;J\DWR,J+M1<X'"C^9H Z"218HV=B0JC)P,U1_MVS_ .>C_P#?E_\
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M,Q7D[D9?YBOG/]@__DENK?\ 83?_ - 6OI6O*SG_ )&%;U.W ?[K#T"J4_\
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M_-WMW/:-!\9:-XFU#5K'3+T75UI,_P!FO8PC+Y,G/RY( /0],CBH]6\?^%]
MOC9:IXDTC3;P $V]W?1128/0[68'FO(?V91?KXM^*BZHT#ZD-847#VV?+:3,
MFXKGG!/K7(>,[FR@_:&\7)>>$+SQD9M)CCBL[.T6<QN0,.Q/W!VW#D9KICEM
M-XJI0N[1BGTUNH][+J<4L[K1P%'%<J4IS<=;V5G+HKN_N_>?35[XDTG3=+74
M[O5+*UTU@"MY-<(D)STPY..?K4FDZUIVOV8N],O[;4K1B0)[2998R>XW*2*^
M6T^!7C:+X5>#'^PP:AJ&B7T]])X=OG!22.0J50\X)&T\$_QGZ5N6_P 8=#T[
MX(>,Y])T%?"6L07!M;K3$&U5NI5"!U[ $*>.,;/Q+GE4)1_V>?.^;ETM9:V5
M];Z[WVZ"IY_4A*^,I>R7)S).]W[O,TG:VFS3UZGT%HGB?1O$JS-I&K6.JK V
MR4V5RDPC;T;:3@\=ZTZ^4_@C?:)\/?B_INAZ/K%GJMEKNC0BX:SG654O8T^<
M$@\9PQ_&OJ2'4+6XD:.*YAE=1DJD@)'X5Y^/P?U2KRPNXM)IM6?]7N>OE&9/
M,<.YU$E--Q:3NKK71^C3+%%16]U#=H6@FCF4'!:-@P!_"I:\S8]Q-/5%_2/]
M;)]*U*R](_ULGTK4H&%%%% !5*S_ ./^_P#]Y/\ T 5=JE9_\?\ ?_[R?^@"
M@"[1110!P?QP:.'X:ZG<2BX\J%X7D:VG>%D3S55W+)\VU59F('4*:X_X1CPM
MI7Q"ETCP?J\^N:6FC>;)*=2DNH[9O.4*F"2H++DC'("'L:] ^*&MMX=\(7%^
ME]%8O')$JB>V-PEP6<*(2@^8[R=N5Y&<]L5YA^SU)<W?BG6[];FVT_3[V SI
MHD483&9 $E0!%&Q0&0D$Y)&<$8H ][HHJEJ]S>VMDTEA9K?7(( A:41@CN=Q
MH M^8F\IN7>!G;GG%"2+(,HP8=,J<U\T^(;G4)/'OB&6R0B^*Z@D,<)/V])/
ML1P7[&WR/DQSO*UZ/\&3I;:CKY\.C_BGO+LQ$8P1&;CRV\[&>_\ J]WOG/.:
M /4:*;)OV-Y>W?CC=TS5+.I_W;3_ +Z;_"@"_15#.I_W;3_OIO\ "C.I_P!V
MT_[Z;_"@"_15#.I_W;3_ +Z;_"C.I_W;3_OIO\* +]%4,ZG_ ';3_OIO\*,Z
MG_=M/^^F_P * +]%4,ZG_=M/^^F_PHSJ?]VT_P"^F_PH OT50SJ?]VT_[Z;_
M  HSJ?\ =M/^^F_PH OT50SJ?]VT_P"^F_PHSJ?]VT_[Z;_"@"_15#.I_P!V
MT_[Z;_"C.I_W;3_OIO\ "@"_15#.I_W;3_OIO\*,ZG_=M/\ OIO\* +]%4,Z
MG_=M/^^F_P *,ZG_ ';3_OIO\* +]%4,ZG_=M/\ OIO\*,ZG_=M/^^F_PH O
MT50SJ?\ =M/^^F_PHSJ?]VT_[Z;_  H OT50SJ?]VT_[Z;_"C.I_W;3_ +Z;
M_"@"_15#.I_W;3_OIO\ "C.I_P!VT_[Z;_"@"_15#.I_W;3_ +Z;_"C.I_W;
M3_OIO\* +]%4,ZG_ ';3_OIO\*,ZG_=M/^^F_P * +]%4,ZG_=M/^^F_PHSJ
M?]VT_P"^F_PH OT50SJ?]VT_[Z;_  HSJ?\ =M/^^F_PH OT50SJ?]VT_P"^
MF_PHSJ?]VT_[Z;_"@"_15#.I_P!VT_[Z;_"C.I_W;3_OIO\ "@"_15#.I_W;
M3_OIO\*,ZG_=M/\ OIO\* +]%4,ZG_=M/^^F_P *,ZG_ ';3_OIO\* +]%4,
MZG_=M/\ OIO\*,ZG_=M/^^F_PH OUX]\6/V8/#/Q@\4)KNKZAJEK=+;I;!+.
M2-4VJ6(.&0G/S'O7J6=3_NVG_?3?X49U/^[:?]]-_A710Q%7#3]I1E9F52E"
MM'EJ*Z.*^#OP0T7X*66IVVBW=]=IJ$B2R&^=&*E00,;57UKT2J&=3_NVG_?3
M?X49U/\ NVG_ 'TW^%36K5*\W4JN\GU'"$:<5""LD<5^T/\ \D/\;?\ 8,E_
ME7YP?#S_ )'[PW_V$;?_ -&+7Z3_ !;\.Z[XN^&?B71;&*TEO+ZRD@B3>5RQ
M'')&!7QWX1_9)^)6D>*M'OI]+M5@MKR*9V^UJ<*K@GC\*^WR#%4*&$JPJS46
MV]WY'SV9T:E2O"4(MI?YGZ 450SJ?]VT_P"^F_PHSJ?]VT_[Z;_"O@CZ4_/K
M]LK_ )+MJG_7M;_^@5]!?L'?\DCU7_L,R_\ HF&OGG]L+S?^%Y:GYP02?9H,
M^7G'W/>O??V%S>?\*FU7[.("G]L2_P"L)!SY47I7Z/F/_(BI>D3Y3"_\C*?S
M/INO'OVN/^3?_$__ &[_ /I1'7J6=3_NVG_?3?X5Y%^UB;[_ (4'XF\X6XC_
M -'SL+9_X^(_45\1EW^^T?\ %'\T?0XK_=ZGH_R/A_X'_P#)8O!?_86MO_1@
MK]3*_+'X)[_^%O\ @WR]N_\ M6WQNZ9\P=:_3_.I_P!VT_[Z;_"OJ.*_X]/T
M_4\?)?X4_4OU^=G[9G_)=]2_Z]+?_P!!-?H)G4_[MI_WTW^%?GO^V+YO_"\M
M1\X()/LEOGR\X^Z?6N7AC_?G_A?YHVSC_=UZK]3Z"_8/_P"26ZM_V$W_ /0%
MKZ5KYA_87-W_ ,*PU7[.("O]IOGS"<_<7TKZ6M3=9;[0(0.WE$G\\UY6<_\
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M /&];^%7B#Q%)>Z5,;"UT22ZN]22Z6=GG,T]N\8B*;  JM(S;MQR !@9KL/
M&@:W9ZAJVK:_%9VM[>QV]NMM8S-,BI"K ,795Y8NQQC@8&37:44 -D02(RDD
M C&5.#5/^R(_^>US_P!_FJ]10!1_LB/_ )[7/_?YJ/[(C_Y[7/\ W^:KU% %
M'^R(_P#GM<_]_FH_LB/_ )[7/_?YJO44 4?[(C_Y[7/_ '^:C^R(_P#GM<_]
M_FJ]10!1_LB/_GM<_P#?YJ/[(C_Y[7/_ '^:KU% %'^R(_\ GM<_]_FH_LB/
M_GM<_P#?YJO44 4?[(C_ .>US_W^:C^R(_\ GM<_]_FJ]10!1_LB/_GM<_\
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MKNK_ -6/=:*\9\4?%#QGX3N=$\,/9Z)JWC?6)G:$6@FCLX;< ?.X9MV<ANA
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MIEGNYFED8*-JJ6/.%' % &W+(L,;.YPJC).,U2_MZQ_Y[-_W[;_"M"B@#/\
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MW_?MO\*/[>L?^>S?]^V_PK0I"0H))P!U)H H?V]8_P#/9O\ OVW^%']O6/\
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M"?M!Z!X[\1W>A)I/B#0M3M[07K0:YICVK-$7V!E!))&X$9QC@^E.\??'_0/
M&NV&CRZ7K^N:C>V[W,=OH>FO=.(T8*S%000,L.<8YK*M/^3O=3_[$>V_]+YJ
M->_Y.P\)?]BKJ'_I1!5>RI>TVTY;VOY7W(]O7]B_>7-S\M[=.:VQ7_X:DTS_
M *)_\1?_  F9O\:CE_:Q\/V4EO\ VAX1\<:3;SSQVXNM0T"2"%7=@B[G8X&2
M0*]L#J6*[AD=1GI7CW[5+J_PJMV4AE.NZ5@@Y'_'[%4T?85:D:?):[MO_P
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M$F@L;A1#8R!)9E9XLMD@C:,#\6%6OA]X<T_P^^MBRUN]UJ::[S=F\F5S',%
M(P%&"1M)]>M<O\6$\+MXV\.GQ/IL]Y:BSN?])#8@M5+P@O(!AL9VC/0<Y]:W
M_AS;>%=-U/7K#PQ9V\"Q-!)<3VLOFK.73*G=D\@ C'ICUH [FHKN/SK6:/<%
MWHR[CVR*EJ.X*"WE,@S'M.X>V.: /GO3[;PVVGZ?I-]XZ\3RPVTD:">.)TLA
M(C#;ME,6 N1@'=^-?0Z_='.>.M?,3:CK@6UT^YN]73X>W%N;N.V4V;3BS655
M(9@F\(-Z]RVWOFOIR/;Y:[?NX&/I0 ZO+/BK;V5IXMT75+OQ'J6C$65Q:QVV
MCQM)<SEI(F+;0C?(NSGCJPYKU.O+_BI<1VWB?3)[?6+CP[JEKI=[=?VC&L4B
M&W5H=\31R AR6*$8((V]<'! -#X16VC16NLSZ1K>IZN]S="6[35<K+#+L ^X
M54KN !Z<]:] KS3X075G=W_B*9=9G\1:I+]EENM2E$2HZ-%F)$2(!4"C=E3D
MY.2>17I= %+6K;[9H]] 9!")8'3S&Z)E2,GZ5X7H,7ANZ70;&Z\;^*+D6LL'
MD32Q/':/*F NV0Q ;2>!\W(.,\U[IK4D,6CWSW"&2W6!S(B]67:<@?A7S]8^
M)-'O;30+%_'FKZKH$T]NB:.NF1K*BY!19)A&"R*=H..<=^IH ^CJ*** /)_B
M1'8Z?XUBOKKQ+K&E2SV*PI9Z)"TDKA78EW"HWR_-@'CG-=%\)K72;;P]<G1]
M6O\ 5H);N265]1)$L4IQN0J54KZX([^]<C\9=0U?2]<DOO"TUW:ZS9Z8;B]E
M0P&$VH<D!EE4Y8$.1MQWSVKI?@YEM%U-KN6]GUI[TMJ4E\(PS3&-,;1& H39
MLQCMUYS0!W]4M;M?MVBW]MYBP^=;R1^8W1<J1D_3-7:J:JUNNEWANUWVHA<S
M+ZIM.X?EF@#P;0(/#-W'X=L;KQQXHN19RV_V>>6)XK1YDP%VR&(#:QX'S<AL
M<YKZ$KYCTK4-<E?3].UN\U@^!(TLKJ.WS9M*+9Y +<3.B!]@95!V_-C&3U-?
M3E 'COQS_P"1_P#@W_V,S?\ I)/5KXDQV-AXT@O[KQ+K&E2367DI9Z)"TDK@
M.278!&^7G':JOQS_ .1_^#?_ &,S?^DD]1?&S5M5T/5I=2\-37=KJ]AI;W-[
M+&8#";56SAEE4Y8$$C;COFNNK_"I>C_-GGX?^/7]5_Z2CH/!%MI%OX"UUM'U
M>_U:*;[1+*VI$B6*4H=RE2JE?7&.]5/V7/\ DWKP#_V"XOZT_P  *R^#?%'V
MV6\FUTM*=2DO1&&,GE?+M$8"[-N,8_'FF?LN?\F]> ?^P7%_6A?[M+_$OR82
M_P!]A_AE^<3L?B#8QZGX'UVTEO4TZ.:SEC:[D^[""I&X_3K7+K\/K.RUWP_<
M7_C/6[NY@N/,LX+FZCV2N%.Y>$!(*YR,\BNA^*'V?_A77B3[7'+-;?8)O,C@
M8*[+L.0I/ )]Z\[T:V^&EI<:'>V^AQ6NM)J4%J+*XE(NK.X8X4E"W.#W&00<
MCBN0] ]LKQGX9_\ )ROQJ_Z]M!_])YZ]FKQGX9_\G*_&K_KVT'_TGGKKH?PZ
MO^'_ -NB>=BOXV'_ ,;_ /2)D_C]+#2_']W>77BC6]-FN[&W1;'0H6E<*C2_
MO) L;X!+X'3[IKBOB%9Z38^ _AC'HNIW>JV)^(>E.);UOWL;FY8NA&T;<,3\
MN!C-=E\0=?T_3/B#=I;^+;OPAJXL+?SW6Q2[ANHB\NSY2I*LI#\@CAN_;@?&
M-S8W_@'X;WEG=7U]+<?$C3)+NZU&,1RRS_:"&;:JA0N NW:,8Q[T83^/$,P_
MW6?]=3Z@K!\=V2:CX-UBUDO%L(YK9T-T_2($?>/TK>KF_B0(#X"U\744LUN;
M.3S(X6"NXQT!/ )]ZY#T3E[?X?6=CJGAZ>^\::U>3PRA[.&>Z39*X0Y7 0$@
MKGC->F5XAH%M\,K9=#OK71H8=7CO8;;['<3$75I.1@%HRWXY P0<CBO;Z /'
M;G_D[_3_ /L1;C_TX0T>.H]/TGQ_J%W=>*=;TZ:]M+<"PT*%I654,@WR 1OC
M); Z?=-%S_R=_I__ &(MQ_Z<(:;X\\0:=IGQ!U%;7Q=>>$-76SMA<E;%+N"[
MC)D,9VLI*LOSC((R&Z'''7B-H?X5^IY^#WJ_XG^2.2^)=GI5C\(/!T6BZI=Z
MM8?\)GIC+-?-F5&-X"R$8!7#9^4@8KZ-G_U$G^Z?Y5\S>.)]/O/@[X5N["ZO
M;Y[GQSITMW=:A&(YI;C[8H=BH 4#@8VC&W%?3,_^HD_W3_*G/^!3]7^@J7^]
M5?2/ZGS_ /!#34UC]C?PY92:@-*2;32AO6./)_?M\WUKT"V\!V6G>+=$NKWQ
M?K-]J$)E>TM[NY0K(-H$BX"#(P02,]@>U>:?"46K?L3:(+VVGO+4Z4PDM[9@
MLD@\]OE4G@$UUN@VWPVL]5\/7VEZ5;IJLM[]E2)I3]ILYMC9#1LV01@@\=#G
MI4XO_>*G^)_F/+_]SH_X8_D@M/\ D[W4_P#L1[;_ -+YJ->_Y.P\)?\ 8JZA
M_P"E$%%I_P G>ZG_ -B/;?\ I?-1KW_)V'A+_L5=0_\ 2B"NS[?_ &Y_[:><
M_P"&_P#KZO\ TI"^.TT_2O'=]=77BC7-/FO+:'%CH4#RLJKN&^0"-\9SQTZ&
MN0^+-II=E^S[8QZ-J=WJUB?$6G,)KYLRJQOXBR$8&W!S\N!BNL\>^(-/TOQY
M?K:^+KSPCJHMH1<$6*7<-RAW%"%*DJR\C.1P>AKB?B1<6%[^SS;75C=7M\T_
MB>PDN;J_C$<LLQU"+>Q4   ]L#&,5R83_>*?JCT<Q_W.K_A?Y'TU7S5\!-,C
MU?\ 8GT2UFU%=(A:UN'>^;_EBJWLC%OKA>/>OI6OFSX OI\?[$^C-JB3R6/V
M.ZWK:L%ES]KEV["> V[;@G@'KQ3C_NT_\4?RD34_WZE_@G^=,ZOPH?#VJ^-=
M%N3XL\3W.HV[2&SAU:-H(I]R$,@+1+OX&[;G^$'M3%_Y/2?_ +)^O_IQ:LKP
ME?>([SQWI=MXYO=2N8+#4/*LD M?*%V8&9#,8E#$["^,87/7M6JO_)Z3_P#9
M/U_].+48;[?^%AC?^77^-?J>UUXMXO73=)\<:W)=>*]?LY;P12-8Z';O*L2A
M-N9,1O@G!].*]IKPCXEZKXATKQI?S>$+F\LC)/9V>HM_HS1/-*0D1195+;OF
M )!QTKC/2/4?AO9Z;8>#=.@TC4;C5-.12(KBZ?=)C<<J>!C!R,8XQBNFKD/A
M4EJG@RV%LUVSB67[2;_;YYN-Y\W?M 7.[/W>/2NOH *I3_\ (6M?^N<G_LM7
M:I3_ /(6M?\ KG)_[+0!=HHHH *0]*6D/2@#G:*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** +^D?ZV3Z5J5EZ1_K9/I6I0 4444 %4K/\ X_[_ /WD
M_P#0!5VJ5G_Q_P!__O)_Z * +M%%% !1110 4444 %%%% !1110!Y5=7'@/P
M?XQO-4U!] TRVUN(VT=U+* ]U*7(G3!.,9"[L 9/6O48(HX8(XX55(44*BH,
M*% X ]J\"N='5Y;NZL?$;6>G7-IJ216$VGI+,;99LW C;<!]XG;NYPWM7N>A
MBW&B:?\ 9':2U^SQ^2[]63:-I/OC% %ZN=\8OY%E+-8I9/XB2VF_LX79 !;;
MR/\ =Z9KHJ\N^--UIZ3Z+:76HS:/<WHGMH]0%N);>.-T"NLW(VJV0 W&#CD4
M ='\/-3\%:I;7TW@R31Y8C-_I;:0L8!E]7VCD^YKKJ\Z^&VBG0=<O[.\U4:I
MJ<-A:Q!X;=88A;J&$> "<G(;)/X5Z+0 A( )/2O(!IWPUT3Q(D.I6GABWM-6
MF@O=(,^QGN+C+9=-V< $KMQ@98XZUZ[,5$+EQE0IR/:OFW2[&QUWP;?:O!XF
MGA\-16$=I=:9<Z<BW]M9AMZIDL. IRK@'*X(R: /I6BD'2EH YKQE-;V<+7,
M8T_^U4@;:U\0 +;>AG)S_"%P3VSBHOAU?>#M0T:67P4VE-IIF;S?[(5%C\WO
MN"@<].O;%<Q\8K32]4O;+3[CQ##X<U&YLKF-)[I4:&6 F,2(=Q'.=A&/0U=^
M$US9ZC=>(KI-=AUS4Q<1V]U);1+'$H1/W>T*6!!5L[L\].,8H ]$I&(526("
M@<DTM1W.S[/+YO\ J]IW?3'- 'E5FO@+PEXMOTNQX?TZW\1)"+#?*-][DDR
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MIYJ^<['(RNT,0&RI*C@XKI/"6LZ!XCTY]5\.W5G?6=U(6>YLB"LC@!221W
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M("%5+X.=PZD<<UL^!OC%I'CG5-2TQ+#5=$U'3T62>UUFV%NZJW0XW']<5O/
MXF$7.4'9;_A_FOO.6GFN"JSC3A53E+9??_D]/)G=T4V.5)D#QNKH>C*<@TZN
M$]4OZ1_K9/I6I67I'^MD^E:E !1110 52L_^/^__ -Y/_0!5VJ5G_P ?]_\
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M! MY21D!3D>O%?/7_"3^"[[P+I5_X@\+V]AK=C96[V>ESS,1=P?*8EBD _?
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M+PO('(9XV(!96(R#CO755RWPROM5U'P7I\VLZ5%HM^5(>QA&$BP3@ =A74T
M%4I_^0M:_P#7.3_V6KM4I_\ D+6O_7.3_P!EH NT444 %(>E+2'I0!SM%%%
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M%_2/];)]*U*R](_ULGTK4K(W"BBB@ JE9_\ '_?_ .\G_H J[5*S_P"/^_\
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MY?+_ -7CCC9_#Z=L4 >#:C^T=JUKX&BUQ9M$-[J%S*MGIL>Z2:%(Q*S),-P
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MQ3418D5$4(BC 51@ >@IU !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !5*?\ Y"UK_P!<Y/\ V6KM4I_^0M:_]<Y/
M_9: +M%%% !2'I2TAZ4 <[1110 4444 %%%% !1110 4444 %%%% '(?%;QV
MWPY\%W6LQ6R7MTLD4$%L[E1+([A0,@'U)_"N7T#XQ:I9>,)_#WC;1[7P],-/
M.I1W4%WYL)B!(;<2 01@_E6A\;?!&O\ CK2M#MM"_LXFRU.._GCU&5XTD$8;
M:GR*QY+<].E<1XF^ _BKQU;Z[K&NZKIS^)[RWCL[2WM]XL[>!9 Y3<1N.[G)
MQW-?082G@Y4$J[2;OKK=:I+3:V[=SX_,*V9QQ<GA(R:BE967++23E=O6[]U*
MSW.RN/VCO  T?4+^TU^*^^QPM,T,44@9L<!>5X+' &?7TINE?M%^![OPMI6M
M7^KQ:2NH95+>=79U<8W X7H,CYNGO7'7?P0\8:WIOC>6_O-%M]4UJPMK"SCL
M_,$$,4>"4.5R!\N 0#GK@=*->^#OCR\O6O=/N/#\%Q<>'QHT@E:4BUP"#Y)V
M'@J0"3@^U="PN6/W>?KOS+LM/A[MZVZ>9R/'9XGS^R35MN1[\S5_COLEI?[5
M^A[+;>--$N_"_P#PD<>H1#0_*,WVV0%$V#JWS ''%<YIOQX\!:O;7MQ:^);:
M2"SA^T7$A211&F[;DY4<D\ =3Z5E>+?A1J&I_!*R\&Z7<VT-[;16P)G)\B8Q
MLK,K$ G:2#VKBKOX&>,M3B\57E\?#MQJ.LO:1K;J\R016\2M\JL%W*P;80<'
M[OO7)0PV!G&3J5+>]9:K:Z\NJ;?2UCOQ6-S6E.$:-%/W4WHVN:TFTK2TLTE:
MS;OY:^V^&/&FB>,M$_MC1M1BO=-RRFX7*JI7[V=P!&/>N;LOCQX"U)M12T\3
M6<[V$$ES.%W "-!EBI(P_P#P'-4]-^&>K0?!.Z\(W.JQOKEU:SQSZD@.'DD9
MCECP6X(4L>2!DUY/XA\*:S\.=$MM3\1/IR:A9:++H.@V&@PS2&>:2/9YDC;!
M@\D\\$YYS58?!X2M.<5-O6T5?5KH]M;_ "LM7V(QF99CAJ5*HZ:2Y4YMK1/J
MOBT:]9<SLEW/3O@M\4-2^).@:YK]Q)8M8Q3O':VD$;QR1!03B1W.UB04.1@#
MG-8&@_M'W%Q<^(I-5TBS&EZ18_:VOM*OA=1;R0%A+@;=YST4GI7=:'X7U;P_
M\)-,T31C:0ZM;V,4:KJ"%H2W!=7 YP<L/QKRQOV<-?U#3_%MS-/HFCZEJZP+
M!INDHZV,?E.&^;Y0<G'4+QD^M;TE@*E2JZMHQNE'>Z5TNGEK?[_/DKO-Z-'#
MQH-RFHMST5FVFTM;[2LK)K?3R[[P!\4M<\0>+VT#Q!X?AT6YETY-3MQ%<&5O
M*9BH#@@;6XZ5<^+_ ,49OAUIT TW3AK&L3)+.MF7V!8(D+RR,1G  ''J3BL/
M0_@YJVMZEK&L^,-5:VU:^2&VB7P[=2PBV@CZ(LA ;DDDC%4YOV?9_$.I:Q=:
MWK>H)BW_ +.TLV>HR[Q;!<?OV(!=F;EAR#[UERX#V_/)KE25TKV;\G>]K[^A
MT<^;?5'3A%N<F[2=DTKO=6LG9:>;5UHSHK?XM2:AXK\#Z/96,<H\0:>^HW$K
M2$?9T" @ 8YRV1SBL:]_: %C)XE']DF[^Q:LNC:9';29>_N-N7'(P N5R>>#
M6#H7P?\ 'WA#4/#VKZ5=:%=ZG9:(='FBOY)3%'^\W;XB$SV'! ZGUJXWP&US
M2O#V@7&E:I9R^*]-U2;5Y9+M&%M/+* '' )  50#CM[UO[++XR2<DUMN][MW
M?96M'T=SF^L9S.#<8236KT6W+%67=W<I6[JS['3_  X^)>M^,/$$]A?66A""
M*$R22:1K"7;P-G 21!RIZ^W%2?&#XCZ_\.-+GU6PT&VU#2K2-9+FYN;ORCEG
M"A$4 EFY'7%<_P"$/@;>M?\ B74=?FM]$N=7> K!X2G>U6%8UP0'"J?F/)XY
M-9_B?X4>.]6\5V!WZ-K7A72BGV#3]8OKAG9E _>S8C/F/G/4D5FJ>"EBKWCR
MI:K6ST5TG?>^G;J:RK9G' \KC+GDW:6C:U=FURZ*ROM?6VFZT?'WQXU+PJ-+
M:RT:QNGN[>WF^PSZ@JWLAEQ\L<"@LVW/)( XKV*UE:>VAD>,Q.Z!FC;JI(Y'
MX5XM\0_A#XI^(7B")+H>'+73(KV.XCU:"%UU)8D.1%G;CUYW?A7MD:>7&JY+
M;0!DG)-<&+6'5*E[*W-K>UWVM^IZV7/&RQ%=XAODTY;I+O>UOEY=AU%%%>4?
M0!1110 4444 %%%% %_2/];)]*U*R](_ULGTK4H **** "LS[0;._NRT$[K(
M5*M'&6'W0*TZRM7\6:'H$Z0ZIK.GZ;,Z[UCN[I(F9<XR Q&1D'FJC%R=HJY$
MYQIKFF[+S)O[67_GUN_^_!H_M9?^?6[_ ._!JW!/'=0I-#(DL3@,DB,&5@>A
M!'45)4E[ZHH?VLO_ #ZW?_?@T?VLO_/K=_\ ?@U%X=\3Z7XMT]K[1[V._M%E
M:$RQ9P'4X8<^AK4JI1<7RR5F1"<:D5*#NGU10_M9?^?6[_[\&C^UE_Y];O\
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MG_YYM1]BG_YYM0!!14_V*?\ YYM1]BG_ .>;4 045/\ 8I_^>;4?8I_^>;4
M045/]BG_ .>;4?8I_P#GFU $%%3_ &*?_GFU'V*?_GFU $%%3_8I_P#GFU'V
M*?\ YYM0!!14_P!BG_YYM1]BG_YYM0!!14_V*?\ YYM1]BG_ .>;4 045/\
M8I_^>;4?8I_^>;4 045/]BG_ .>;4?8I_P#GFU %C2/];)]*U*S]-@DAD<NA
M4$=ZT* "BBB@ KY;^/L%M<_M%>'DN[KPQ:0_\(\Q,GBV%);/_7OQM9@-_H<^
MM?4E8NM^"O#WB:XCGUC0=,U6>-=B2WUG',RKG. 64D#)/'O7HX'%+"574DNC
M6GF>-FN!EF&'5&+2:DGK?H[VT/GWQ%\5?%GAKQGJ'@;3M1A:?5GT^7PW=6=K
M%Y,-JYQ,$ 7:RKM;!.>E9,WQ^\46_P =8-$@UTW>D_\ "1'1YK"6"U10N_8=
MH'[[@_QGY3C\*^GSX7T8WEG=G2;$W=DGE6L_V9/,@3^ZC8RH]ABH'\$^'9-4
M.I/H.F-J)D$QNS9QF8N.0V_;G(['.:]"&885*TJ"?NVZ;Z*^WE?UOW/&J9/F
M$G>&*:2E=*\OANWR[ZZMK7[*2Z'RY\'OB3/X"M_",%YJT6D^&K_5-8%[)<JB
MQ,ZJ3&#(PROS;>A&<C--\0?M"^)X_ 7A>ZM_$\EMJ6HSZDYN([>S598HI (A
MNF"HN!G@#<V1U/7ZDF\$>'+BQ2RET#2Y+-)3.EN]E&8UD/5PNW 8^O6BX\#^
M'+NT@M9_#^ES6T$C2Q0R64;)&['+,JE< D]2.M:O,L).K[6=&[OKM_>\O-7]
M$81R3,*=#ZO3Q-E9)6YE;X+[/1>Z[?XGYW^1=0^(NJ^(O$OP[\37?BFV\*:K
M<>&;DR:K+!$R%UED& KC8"Y7T[\5HZ#\3]?U'6M*\;75NEQKT?@>^N-JQX65
MHYY%60J.S! Y XY.,"OJ:?P%X9NK>*";PYI,T$2&*..2QB940MN*@%< ;N<>
MO-7X] TR&ZAN8]-M$N88?LT<RP*'2+_GFIQD+_LCBJEFN'<>54>ZZ;.^FU[:
M_AH13X?QD9\TL3V?7XDH^]9NU_=?36^NR/G_ /9G^*WC'QYXCN(-=U6UU73G
MT\70(FLO.AEW*-HC@;>%(8_?7(QS7._$+XV^*]$\6>.8K7QI::<VAZA FGZ'
M+:0M)?HY4-&"1N(')R.>>3CI],Z/X-T#P]=RW6E:'INF7,HVR36=I'$[C.<%
ME )YKG=&^#N@:9XMU_Q#<VT.JWNJW27:_;;>.3[*ZKC]T2,C/K[5E''8-XB=
M9TDHV5HV6]U?HTKJ^OZF\\JS)82EAHXAN2D^:7-*]G%VV:;L[-*[\]#P#Q-^
MT-XKL/BW%I]GK3"P75K:PGTN6WM510^T.!G]^V"3\PX_E7+ZGK6I^%?"GQ?$
MGBFUU34+;76#:9?V%K+YK><H-R8G5ASTQC:.W-?8]SX)\.WFI-J-QH.F3Z@S
M*QNY+.-I25.5.\KG((&.>U%UX)\.WTUY+<Z!IEQ+>8^TO+9QLT^#D;R5^;&!
MU]*VAFN&IJ*C1M;EOMK9I]O4YZN08ZLYRGB6VW*VLM%*+6FO333;<^:/&?QU
M\>VOQBU72=,O[2TLM.U&&VCTR[ELH$N(CMW$F9EE)(/&SCI5F?XK>/K6>]UX
M^)4?2K+Q<NA?V4;"'$D+'.6DV[@0" ,8[Y)KZ.U/P5X>UK4$OM0T'3+^^3&R
MYN;..21<=,,P)&*E;PGH;PO"VC:>T3W'VMXS:IM:;_GJ1CE_]KK6']HX51BE
M06B2>BU[_?WW.EY-CW.<GBY6;;6KT[*R>R[:IVV/E32/$>O>"M1^+K6?CRSM
M]:BU5ECM=1C@C$C$H/M'(^7 .WGY.YKV'X.^,-=^(WP@U>XBUMKKQ!%+=V4&
MHM! -DRK^[.$!B< LIRN5(KT:Y\&>'[RYN[FXT+39[B\79<S26<;/.OHY(RP
MX'!]*O:7I%CH=DEGIUE;Z?:)]V"UB6.-?HJ@ 5CB<?2KT]*?O73O9=$E;1;'
M5@<HQ&$JW=9NG:2M>7VI-IZO1J^Y\AV?[5'BN**TU*[F/]F)I4NG7 -L@_XG
M"Q,R,3MX)95&/N_.>.*L^++_ ,3W^G_$_3M0U6*+4+7PM87=W=1:=;I-<,8B
M9(W=4#8.<=?EQ\N*^HV\#^''MWMVT#2V@DN/M;Q&RC*M-S^](VX+\GYNO)JW
M)X?TN:YO+B33;1Y[R,0W,K0*6G0# 5SC+ >AXKJ_M3#0ES4J"C]W1IKIY-?<
M<"R+'5(.&(Q3EOWZQE%]>[37S[GR9?RZY=>._#-YH'CB.ZO[;P7/<?VW%:02
MB41S3$Q! "@VX\LG&?E.>:]4U/XI:]/^RH?&UO=+:^(#IL<OVE(D($OF!&8(
MP*\\G&,<UZO:^#M L/+^S:'IMOY<+6R>5:1KMB8DM&,#A2225Z')]:G/AS23
MHO\ 8YTNR.D[=GV#[.GD;<YQY>-N,\XQ6%;,*-9T[T_A:>RU2;;6BZW6FR.O
M#9/B<.JO+6:<XR6\M)-12DKO=6>N[OJSYBU#QI\4X)?$:CQS"JZ;X;3Q*I32
MH,G*%_LXRI^7@C<<GIS6;XY_:'\=-XDL[?1]1M=*C72;.\6&=[.&.ZED0,^Y
MKAE.W.1B,Y%?5K^&='D,Y?2K%C/;_9)2;9#YD&,>4W'*8XVGCVJMJ/@7PUJZ
M6R7_ (>TJ]2U01P+<644@B4=%3*G:/85K3S+"J2=2@G;R79=DK[?B<]7(\<X
M.-+%R5W_ #2?5Z7;=M'TWMJ?+WCK]HOQ5HWQ,-M8ZT4LK>^L[>XTHPV@CPZI
MYBJ23,_);YU^4<=*UKOXW^*K3QWX_P!.?Q)!<);V6K-I-G8PP2"WD@1S'OX\
MP.I4Y#@JQ'&17T7=>!?#=]??;;GP]I5Q>85?M$ME$TF%QM&XKGC QZ8J>W\*
M:)::A<W\&CV$-]<@K/=1VJ++*#U#,!EL^]']H8/E25!72MTWTUV_'<:R;,O:
M2D\6[.5]Y:+73?S6FUU?R/ +#X\ZAKT:#2?$<%]+;?#^?5;T01Q,8M23R_F;
MY>&!+?)]WGITK"\7?%GQOX5^'7@N^NO&3_VMXC$]XLD5E9Q+'&D47[O=+A
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M.BLFHZZG@#?&O7E^.6C:=-K]O'X>O?LD:Z3;QPO*'EMED(E!_>CYG!#+E<$
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M?^B::;_X4B?_ !FCZE4_FC_X'#_,/[3H_P L_P#P74_^1/4J*\M_X37XJ_\
M1---_P#"D3_XS1_PFOQ5_P"B::;_ .%(G_QFCZE4_FC_ .!P_P P_M.C_+/_
M ,%U/_D3U*BO+?\ A-?BK_T333?_  I$_P#C-'_":_%7_HFFF_\ A2)_\9H^
MI5/YH_\ @</\P_M.C_+/_P %U/\ Y$]2HKRW_A-?BK_T333?_"D3_P",T?\
M":_%7_HFFF_^%(G_ ,9H^I5/YH_^!P_S#^TZ/\L__!=3_P"1/4J*\M_X37XJ
M_P#1---_\*1/_C-'_":_%7_HFFF_^%(G_P 9H^I5/YH_^!P_S#^TZ/\ +/\
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MM*?4[K[3?>7L*321/&N(VW',9(/ .>U 'K%%4=$U6/7-&L=1B4I%=P).JMU
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MS6KE#AMC*5.#CK@^E8-[\-K&=+$V>H:CI-S:V(TX7=C(BRR08 "MN1AD8R&
M# DX(S7744 >->*/A#?S6VH:'X?@;2=%O88+=V@O@(W"8!>6-D+E@!U1UWX
M;/-=LOPOTA=&N]/\RY N+T:B+A) )8;@;</&<<8VC@Y[@Y!KKZ* .3;P [YE
M/B?Q!]M:7S&N3=(01M"[/),?DA<#.!&.><Y.:H2?"#3#HB:/#JNL6VE&W-O<
M6D=TK)=*S,SE]ZL59R[[C'L)W8Z 8[NB@#AHOA!H]C+'<:;=ZAI5]'/-+'>6
MLJ>8JRJ \7S(RLAVJ<,"05!!!JQIGPJT32))GMC<J9M,.E2;I0VZ,N[LY)&2
MY:1B3^E=C10!3T;2X=#TFRTZW+F"TA2",R'+%5  R?7 JY110 4444 %%%%
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M/_P>W7_Q=>IT4?7\5_S\?WA_9. _Y\Q^Y'EG_#./A;_G^\1_^#VZ_P#BZ/\
MAG'PM_S_ 'B/_P 'MU_\77J=%'U_%?\ /Q_>']DX#_GS'[D><:'\ _"V@Z]I
M^L1/JUW>V$AEMS?:I/<)&Y4KN"NQ&<$BO1Z**YJM:I7:=63;7<[:&&H86+C0
M@HIZZ*P4445B=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
K!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>btai-20241231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 btai-20241231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (W \L# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K,\1^)=*\(Z/<ZMK6H6VEZ;;+OFNKN01QH/<G^7>
MF>+=<;PSX5UG6%MGO6T^RFNQ;1??E,:%]@]SC'XU^,OCC]H/Q;^TSXYLH?%W
MB&UTFSN+@):Q7,Q@TRP5CP6 !Q@=7()/J*]?+\O>.DW*7+%;O_(\C,<P^HP7
M+'FD]E_F?:_CK_@ISX=T;Q UGX8\*77B+38GVOJ-Q=?9!(.YC38Q(]"VW/I7
MO?P*_:A\$?'RQ T6]-EK:+NGT6^(2YC]2HSB1?\ :7/OBO+_ (._L!?#/0O!
M[G7RGCG4-2M@&U'S"D$:L,YM@AX]GR2?8'%?//QT_80\8_"&_;Q1\.KN]U[2
MK5S/&ML2NIV..<C;CS /[R8;U7O7K>QRG$MT*,G"2VD]G_7R/&]OG&%2Q%:*
MG%[Q6Z_KYGZ:45^>'P!_X*/7'A^6T\/_ !8#7%ON$*>((8\31=O](C'W@.[K
M@CN#UK]"K6ZAOK:*XMY4F@E0/'(ARK*1D$'N"*\'&8*M@I\E5>CZ,^AP>.HX
MZG[2B_5=42T5Y)\;/B;XI\'>*O /AOPEI^CWFI^*;NZMA+K4TL<,(AMS-G,8
M)Y"D=/2JOP]^/$TFK>*_#WQ&BT?PIKOAR[M;:6XM]0WV-TMS$TD#1O(%920C
M@JPR-O7FL%0FX<Z_X.]MO4Z/;0YN1_UI?\CV6BO/]6^/_P .-"TK1]2U'QKH
MMA8ZO%Y]A-<7:H+B+./,7/)3_:Z>]:7B_P"+?@OP%:Z?<^(?$^EZ3!J"E[1[
MFY51.H )9.?F4 @EAP,CFL_93T7*]?(TYX=T==17F4W[1'@JW^+D/P]DU>W7
M69K**ZB<SIY<CR.%C@7G)D92' QC:0<UL:+\:O ?B/6-3TG2_%VCZAJ.FQO-
M=VUO>([Q(AP[$ ]%/!(Z=Z;I5$KN+[B52#T3.UHKROX:_M+> OB;X6U?7K'7
M;.QLM)DF%[]MN8T^SQ)*\:S.<X5'V%E)/((^E=AX(^)'A?XE:?-?>%M?T_7K
M6"3RI9+&=9/+?&=K <J<<\]11*E4A?FBU8(U(3MRO<Z2BO%_$OQ9\8^)?B/J
M_@KX::1H]U<:!'"^M:UXAGE6TMI95+1V\<<0WR2%/F)R H(SDFNB'Q13X=>$
M;2\^+.K^&_"^IS320@VMZQMI\'(,?F /]WDC!V^O>J=&:2[OIU^XE58MOLNO
M0]&HKD->^+W@GPOI5AJ>K>*](T_3]0@-S9W,]XBI<Q@*2T9S\XPR_=SU%36O
MQ2\'WG@M_%\/B;2G\+HI9]7%VGV9,'!R^< @\8/.>*CV<[7LR^>-[7.IHKA;
M3XY_#Z]\(W7BB'QCH[>'[67[//J!NU6*.4XPA)Z,<C"]3D8JW:?%[P1?>&[7
MQ!!XLT=]#NIC;Q:A]MC$+2@$F/<3@, IR#R,4>SFOLL.>#ZG7T5GZ!K^G^*=
M&L]6TF[COM-O(EFM[F$Y25#T93W!K0J&FG9E[ZH*\Y^//Q:7X-> 9M<6VCO;
MUYX[:UMI7*+([')R1S@*&/X5Z-7QM^U1?S_%;XY>$OAO8N3#;N@N-HSMDEPS
ML?\ <B&?Q->OE6%ABL4HU/@C>4O1?U8^<X@Q]3 8"4Z'\2348_XI:+[M7\CT
M/]GG]J.X^,/BR^T'5=)M='NDMOM%MY,SMYNT@.I# <@$'Z U]#5\-?&BS'P#
M_:;T'Q/81&WTBZ$-P40$+L $,Z>_RX;ZM7T[\=?BPOPI^&-UXBM$CO+N4I!8
MACF-I)/NL<=5 !;WQCO7=F&!A4JT)X*-HU4K+L]FCRLGS6K1H8JEF<[SP[?,
M[;QW3MYZV^1Z#>7'V:UFE4!FC1F"D]<#->'?LY_M%:E\:]:URROM'M-,73X4
MD5K>9W+DL5P=P'I7FG@>#X]>*_!K^/8O%EO-;S1R3PZ)>1KMNHAD'"JN$S@[
M1G/3D5A?L-:K!H^K^/-3NSY5M;:<EQ*?[JJS,?T%=2RJG1PF)E*49SCRI6;T
M=[-=#@EG];$9A@HPC*E3GS-\R7O*UT^OZ=#[?) ZG%+7QOX2\9?%[]I?6=;U
M/PSXCC\':%8.$A@4=202J$A26; !9CP,\"NZ_9J^-WB7Q!XLUOP#XW,<^OZ7
MO,=VJA6D\M@KJV, D9!# <@G->;7R>M0ISESQ<H).44]5?Y6];,]O"\1X?%5
M:<%3E&%1M0DTN637;6ZOTNE<^C<CU% (/0YKXEMOB9\5?$7Q_P#%'A'PUXB;
M]Y>W=O +_#0642.27 V]5 P.O6KVF?$KXG?!OX[:/X3\5^(O^$GL=1E@1MZC
M:T<K; Z< HRMGCV]ZW>155HJD>;EYDM;M?<<D>*L._>=&:AS\CE964OOO^!]
MFT@8'H17SE^TG\>M?\+^)]+\">"%C_X2/40GF7+*',6]MJ(H/ 8\DD]!CUKB
M?&TGQT^ ^E6OBO4?&$'B73TD1;RS=-Z1%C@ Y4$KGC<I!!(XK"AE%2M"$I3C
M%S^%-N[_  Z]+G7BN(J&'JU80I3G&E\<HI6C][3=NMMC[$I-PSU%>$>-_P!I
MNVTGX#Z?XXTJV1M0U0BVMK68[EBN.=X;'4+M8^_'3->8V.C?M!ZYX%A\<6?C
M%YY[E!=0Z'#&N]XCR,+LVY(Y"^G?-31RFK.+G6G&FK\OO=6O1/[R\1Q!0IU%
M3P].55\JF^1+2+V>K6_1;GV-2;AZBO';7QO\3&^!TVIR^$9!X[3,"67R /R
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MA4M4NHNRU:Z+7\=C[@!!Z'-!('6OD7X2_%3X@^#?CTWP]\8ZS_PD,,SF+SI
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M2,W3YAC&, D5\>_M!?\ !/7QK\&[]_%7PTN[[Q%HUHYN$2V8IJMACG<-F/,
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MO)Z6L=N,R'Z[BZ]:I.T*E/DTW3O>Y\S?#+]K?P3H7PAL;/5+B:VUO3+1;7[
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MP?8@FOQ$^-?@[0?A+\5;D?#'QC=:[86$OF6^I6ZM!-:2 GY%E4CS-O\ ST7
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M=9 FX[5&X9&>#TS71>-/AQHOCN2PGU!+F"_T]F:TU#3[J2UN8-P <+)&0=K
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M&2,-M!QVZ5S^M? _0;N^U75=.26QUFZ%Q/;L\\LEI;WLL31-="VW;/,(;E@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#?1_PKY2S1FC^R:7\S_ /]>\=_SZA^/^9]6_\ "U/"7_0>L_\ OH_X4?\
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MC^R:7\S_  #_ %[QW_/J'X_YGU;_ ,+4\)?]!ZS_ .^C_A1_PM3PE_T'K/\
M[Z/^%?*6:,T?V32_F?X!_KWCO^?4/Q_S/JW_ (6IX2_Z#UG_ -]'_"C_ (6I
MX2_Z#UG_ -]'_"OE+-&:/[)I?S/\ _U[QW_/J'X_YGU;_P +4\)?]!ZS_P"^
MC_A1_P +4\)?]!ZS_P"^C_A7REFC-']DTOYG^ ?Z]X[_ )]0_'_,^K?^%J>$
MO^@]9_\ ?1_PH_X6IX2_Z#UG_P!]'_"OE+-&:/[)I?S/\ _U[QW_ #ZA^/\
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M('F3V[HN3T&2*SZ](U6*35+C2]/N/'1\26UW>10RVL)8%5)^_P DCC^M:/\
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M:S;^+'T/V+@3_<JO^+]$0Q?Z^;\*FJ&+_7S?A4U>$?I@4444 %%%% !1110
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M@&.O?BJ?+9V%J=[1116)04444 %%%% !1110!#!_K9_]\?\ H(J:H8/];/\
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MVT+[(NR&\%YY_F')/]W;C]<ULS?%>>XUW4KV;3(9;+4;=;>YL'E;:P4$ AP
M0>3VKAA&[*S*C,J]6"D@?4]J#%($#F-PAZ.5.#^/2M'0I/=?T_\ ACBAF6,@
MDHSVMT6T4TNFJLVO.^MSL;;XCK8Z_IM_9Z):6EM81M'':Q.<MD8+/)C+'ZBJ
M5GXWDM-$\0Z<+-'76)"[2>808LDG &.>OM7."WF*[O)EVXSNV'&/7.*&AD5
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MG4I4G>6C-</A<9C8J-)-J]MTE>U^K6R7]71!X:^+NO:#.#/=3:E;K$8DMY9
MBIQ@$$+VJ?2_BJEKI%W97^APZLUY*9;F:>Y*M,>VX!>@'%8%UX1DT_2]1O+R
MX$/V6Y^RQ(J9\]P><'/  YJ.#PP;OPG<:U!<;S;3"*>W*X**>C YY_*L'2PT
MM;;M;76O38]*&,S>E:GSMVC)V=I:;/25^WK:]M&5=?U*TU743<66F0Z1 5"B
MV@<LH(ZG) ZUG445VI**LCYVI.56;G+=^27X+1?(Z;X9_P#(^Z)_U\"OK*OD
MWX9_\C[HG_7P*^LJ^8S;^+'T/VC@3_<JO^+]$0Q?Z^;\*FJ&+_7S?A4U>$?I
M@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11535KI[+2[RXC&Z
M2*%W4'N0"10!;HKS*+5=?FLIS!?R2QVXCN))G9%8!D#%<[<$ YXZ\CFNE\$^
M(CK44RSR2M=Y,I5X]JJI. %]0,8YJG&PKG44445(PI*P/&+ZB+2U73A,2TP\
M[[/*D;[ I)P7XZXKDK[Q'JT!M[V"[G_LV]B58 ^QI!]T$[<?>!R,YP=R\52C
M<5STVBJ6D:C%JNG0W,)<HZ_\M%VMGOD>M7:D844C9VG;C..,UYS+KNLN]W9S
MWY1VU%X/M%M&J>4@B+A5SGN.IR>M-*XCT>BO+Y_$>O6]O:7TUR4@OH$5%CVD
MJ2%RP3&=P.>2<?,M>AZ/J,6JZ=#<0L[(PQ^\7:P(X((]<TVK!<NT45D^*I;Z
MWT"^ET^:.WN8XG<2R)OV@*3P,CGCOQ4[C-:BO.SK6K+<V-S<RW2V<L$$4<L3
MQ^69W4\R)]XC) XQ3=*\2ZCIFL1V>L7,Q2-R&V!9,LVT .P  4%AT_O@=C5\
MK%<]&HHZT5 PI*Y;Q-<7D&KV@T^]N'N=P=[-54Q+",[V?C//0<]>G0US=KJN
MOW^G2_9]1=F^S07TDDC(GEAU?<%.W 4$*<'G (S5*-Q7/3J*Y+P5XG;6)9XK
MJ24W;DR+&T>V-4&!A3W(XSGN:ZVDU884F:&&0<'!]:\^N;C6YGO$TF[O=1M3
M+#$)V:)&+AF,OE,0!MV@#H><XZ&A*X'H)P>M+7F-YXEU6"UM]1M[N9-/EB,"
MBX*.Z. 0Y90/F92I;<#M(&.]=]H6I1:IIL<L1E.W,;B==KAE.&##UR*;BT*Y
MH4452U>*2>PD2*XDMI#]UH657)_N@L" 3TS4C+A /7FEKRZP\4:O+Y+27LK2
MV9@CDB"IB5GN7B<.<?,0%'*X&1GO5BS\2ZIH>K)::U=2ND;F65H0LAY4#!P!
MM0$E\=0"@R:OD8KGI-%("",CI2U PI,UR_C6[N]+C@O[>\FBC@EB$T:E/+5&
MD 9F4C<V1P #QUK CO\ 7;C[7:-+>6^J2AKM$>XA\LVXE(Q&P!"$ KRV<C/?
MI2C<5STBBN,\$^*I-6N98;V:22YD4&,"/;$515R5/7+;PY]G4=C79TFK#"BB
MO,+[QW=7_B*\MK345BM9%MX(DCV^9'NNA%)(<C@X)P#T&#CFFDV(]/HKS*77
MM?M+"VU+[5YEM"\UJ/,91YK)+*@+*%RQ("'(Q@(Y(YKMO"VJ1ZII$3)---)%
MB*5[A DA< ') X&00W'8BAQL%S7HHK/UW5X]#TN:\EQA,!03@%B<*">PR1D]
MAS4C+]+7E=AXIU.?2;'4KJ\N+RPMEN#>W&GR1(-XN-JY4\E0G0#J#W-6Y/$>
MK:!K1M]6NI6A$IN7\@+(?+ D.  !M4@;L') C;GD5?(Q7/2:*:C!T5E.5(R#
M3J@845R/C6_OK"ZMIT^UII=M#)/=O9RQJV 5QPW) &XX'7UK&@UC6M4N)5L[
MV1WO%NBL1V*(UBG10$)7Y24)Y;/)![52C=7%<]'HKB/!OBB>]U VNH7$DLQ4
M0Q%$'E,5#$MN'5FPWMA,CK7;TFK#(8/];/\ [X_]!%35#!_K9_\ ?'_H(J:D
M!\3T445^BG\CA1110 4444 %%%% !1110!8TZPEU34+:S@4M-/(L2 #/).*]
M\N=:\,Z!XQTBQ?5[B&;3+<6 M%M]T+;P,[GQU/RG\*^?8II+>59(I'BD4Y5T
M8JRGU!'2EDGDFE:621Y)6.XR.Q+$^I)YKDKX?V[5W9)/\3W\MS7^S(2]G34I
M.47=WM:.MM&NMGVTV/9M-T"?PM'X[M-'1_[=C*O9^4,R_9V.<IW[D<=P/:K6
MLZ_J?AGP_P"!]0U4.EXEPPNE889D8$'=_M;3D]\UXK_:E[]I%S]MN?M &T3>
M>^\#TW9SBF3WUS=($GN9ID#%@LLK, 3U.">OO7/]3<I)S:??37:WW=3U%G\*
M5-PP\''2T5?W5[_.G:V_2_8]@\:V=AX&TI=+BD0QZ[J0N9F4\"U# [3[<_J:
MZ;Q"4AFUR.:WU.YT;[" L3I"E@BXX:-RP);Z<_I7SQ/=SW6SSYY9MB[4\URV
MT>@R>![4]]1NY;9;9[NX>W7I"TK%!]%SBD\$VE>6O7\/\BUQ%",JG)2M%I<J
M3V24KIZ:IN3;/4_%FMZAIO@OP+:VMRT4-S;XGC+[$F VC:Y_N\G/;FNSUM)-
M:T_6H)8[[2G-GN>*^B$VGJ O'E./E!^ASQG%?.TUW/<1QQRSRRQQC")(Y8(/
M0 GC\*D?4[V6V%N]Y<O;@8$+3,4_[YSBG+!72L[--].[N*GQ%RRJ<\&XRC%6
MOMRQY>UU??1^J>Y[YH@2WTOPH-*35);$VQ:6*PCB-K*V!O$[.1@]:\1U+[/_
M ,)9<_9(_*MOMA\M 00HW= 02"/H:H0ZC=V\#PQ7=Q%"_P!Z..5E5OJ <&JX
M)4@@X(Z$=JVHX=TI2=[W_K4\W,<VCCJ=."AR\MNMULE9::+2_P#5W]!>/(-4
MDUYC:^ ['7HO)3_39T!8GG*\GM_6N<\$Z:/%^F:CX7U.,6%QI]Z+V.$_\LD+
M9>,<] #C\:\O_P"$@U7_ *"E_P#^!4G_ ,55>._NH9WGCNITG?(:596#M]3G
M)K&.$E&GR75]+/7I\STJV?4:N*]NZ;<7?FBW&S3Z744][/5O8]MT#7+;Q)KW
MC"\A>X^V00B"Q^PJKSK"N03$&.,D_P ZMVDBGQMX4,T%XNHBUFWS7PC6>5-O
M!D5"2#]?>O!(+B6UE$L$LD,@Z/&Y5A^(YJ3^T;O[4;G[7<?:3_RV\UM__?6<
MTI8'5\KTM;\+#I\26C'VE.\E+F>NC]_FVMOTOV^X]837[_6O GC.:[G>1[.[
M#6W;R"&.-G]W&*WM4O=7?Q7X2N%AFU"Q-DKF.24)&\Q3J&;Y3)R2!UKP9;RX
M2*6);B98I3F1!(P5S_M#.#^-/;4;MX8XFN[AHHSE(S*Q5#Z@9P/PIO!J^ENO
M3NDB(<0M12FI-I1UONXS<NJ?1VUOL>P?$VV-]X&DNVGOXE@NN+?6H,3[B>5C
M?NOTR,=Z\7JQ=ZC=W^W[5=W%SM^[Y\K/CZ9)Q5>NK#TG1ARMW/$S3'1S"NJT
M8\NB6][VZ^7H%%%%=)XX4444 %%%% !1110 5N>$/^0A=?\ 7G-_Z :PZW/"
M'_(0NO\ KSF_] -9U?@9VX+_ 'B'J80Z"EI!T%+6AQ'1?#O/_";Z+C_GY7I7
MJL6K7>LZ]X\TZ\E,]A!;GRK9E&Q",<@>OO7A44KP2+)$[1R*<JZ,5(/L14JZ
MA=I)+(MU.KRC$C"5@7'^T<\_C7%6PWM9<U^GZW/H\NS?ZC15'E;7,V];73BX
MV?WW.K^$ C/CO3_,QN <IG^]MXIND>+=;T37[^SL!%-+=WA_=W,/F8DW$*PR
M>"/6N;T759M#U6UO[<XEMY X]\=JN:OX@-SXEN-7TT2Z<\DAE4;P61CUP:J=
M+FJ-M737XIF-#&JCA:<83<91FWINU)).WI:WS/39- TSQ*TMK>/=7,&F3):G
M[(X7?<2G,DI.#G!XQ65X6T]=)T+X@61D$L,$117/0D'C\:\_TWQ%JFC2326.
MH7%H\W^M:)\%_K5^#Q3]F\*7FDQQ/]HO9Q+<W+L#N4=%'?KU-8/#U$N5.ZNO
MSNV>I'-<+.:JN'+-*=WWO%J*_%+7:WF<^.@I:**](^..F^&?_(^Z)_U\"OK*
MODWX9_\ (^Z)_P!? KZRKY?-OXL?0_;.!/\ <JO^+]$0Q?Z^;\*FJ&+_ %\W
MX5-7A'Z8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A 8$$9![
M&EHH H0:!IMK:O;0V-O';N_F-$L8"LV<Y(^M2VFEV=C//-;VT4,LYW2.B %S
M[U3\4:R/#VC3Z@T;3+!AC&C8+=L9K@/^%]6O_0'N/^_R?X5239YF*S+"8*2A
MB)\K>NS_ $1ZK17E7_"^;7_H#W'_ '^3_"C_ (7S:_\ 0'N/^_R?X4<K.+^W
M\M_Y^_@_\CTK4=*L]7@$-[;1740.X+*H8 ^HIDNB:?-&$DLH'01^2%,8P$_N
M_3VKSC_A?-K_ - >X_[_ "?X4T?'BV#L?[(N,'MYZ_X4^60?V_EO_/W\'_D>
MHVEI#8V\<%O$D$,8VK'&N%4>PJ:O*O\ A?-K_P! >X_[_)_A1_POFU_Z ]Q_
MW^3_  I<K#^W\M_Y^_@_\CU6J%SH.G7D,\4]C;RQSOYDJO&"';^\?4^]><_\
M+YM?^@/<?]_D_P *0_'FU_Z ]Q_W^3_"GRR#^W\M_P"?OX/_ "/2IM'L;D 2
MVD,@$9A 9 <(?X?I4UI:0V-O'!;Q)##&-JQH,!1["O+H_CQ;(@!TBX) Z^>O
M^%._X7S:_P#0'N/^_P G^%'+(/[?RW_G[^#_ ,CU6F30I<1/%*BR1NI5D89#
M \$&O+?^%\VO_0'N/^_R?X4?\+YM?^@/<?\ ?Y/\*7*P_M_+?^?OX/\ R/1/
M^$=TP7<-T+"W%Q"H6.3RQN0#H!]*=+H.G321O)8V[O'*9U9HP2'/5A[^]>;R
M?'>V9<#2+@<@Y$Z_X4[_ (7S:_\ 0'N/^_R?X4^60?V_EO\ S]_!_P"1ZK17
ME7_"^;7_ * ]Q_W^3_"C_A?-K_T![C_O\G^%+E8?V_EO_/W\'_D>AS^'-,NM
M0%]+8P/>#;^_*?/\O3GVIT'A_3;:"XABL+>.*X.946, .?<=Z\Z_X7S:_P#0
M'N/^_P G^%-_X7O;>86_LBXQC&//7_"G:0?V_EO_ #]_!_Y'IEOI5G:W<UU#
M:Q17$P DE5 &8#IDU;KRK_A?-K_T![C_ +_)_A1_POFU_P"@/<?]_D_PI<K#
M^W\M_P"?OX/_ "/5&4.I5AD$8(-8T?@S0XH7A32K58FQE!&,<=,#M^%<)_PO
MFU_Z ]Q_W^3_  H_X7S:_P#0'N/^_P G^%/ED']OY;_S]_!_Y'I T6P$44?V
M.#RXHVB1/+&%0XRH'8' J:RL;?3;9+>UA2W@086.-< 5Y?'\=[9$ .D7!/J9
MU_PIW_"^;7_H#W'_ '^3_"CED']OY;_S]_!_Y'JM5[[3[;4[9K>[@CN(&QF.
M1=P..17F7_"^;7_H#W'_ '^3_"C_ (7S:_\ 0'N/^_R?X4N5A_;^6_\ /W\'
M_D>AIX<TN-[1TT^V5[08@(B ,8_V?2GW&@Z;=G,UC;RGSA/EXP?WF -WUP ,
M^U>;R?'BV="!I%P#ZB=?\*=_POFU_P"@/<?]_D_PIVD']OY;_P _?P?^1ZK1
M7E7_  OFU_Z ]Q_W^3_"C_A?-K_T![C_ +_)_A2Y6']OY;_S]_!_Y'H]WHEA
M?W<-S<V<$]Q#_JY9$!9><C!^O/UIEOX=TRT^U>386\7VH$3;(P/,!SD'VY/Y
MFO._^%\VO_0'N/\ O\G^%-/QWMO,#?V1<8 (QYZ_X4^60?V_EO\ S]_!_P"1
MZ7!H]C;7C7<-I#%<L@C,J( Q4=!GTX'Y"KE>5?\ "^;7_H#W'_?Y/\*/^%\V
MO_0'N/\ O\G^%+E8?V_EO_/W\'_D>JU3N](LK]I6N;2&<RQ>2YD0,63.=I]L
M\UYM_P +YM?^@/<?]_D_PH_X7S:_] >X_P"_R?X4<K#^W\M_Y^_@_P#(])CT
M>QBBMHDM(5CM@1"@08CR,' [<$C\33]/TVUTJV%O9V\=M "2(XE"C)ZUYBGQ
MWME!!TBX/)/^O3U^E._X7S:_] >X_P"_R?X4^60?V_EO_/W\'_D>JTG6O-]&
M^-%OK&KV5BNESQ-<S+$',JD+DXSC%>DU+36YZ6%QN'QL7+#RYDO7]3+D\,:3
M,\#/IMJS0,6C)B'RDMN./JW/UYJ6[T'3K_S/M-C;S^8ZR/YD8.YE&%)]P.*L
MW1*P,0<'(Z?45-1=G<(!@4M%%("C?Z)I^JR0R7EG!<O$<HTJ!BO^<#\J6'1;
M"WNKFYBLX([BY&)I%0!I/J>]7:AD)%S$,\$-Q3N!7@T33[:YBN(K*".>*(0I
M(L8!5!T4'L*O444@(8/];/\ [X_]!%35#!_K9_\ ?'_H(J:@#XGHKW;_ (1;
M0/\ H!6'_?#?_%4?\(MH'_0"L/\ OAO_ (JON?K/]T_G;_5RM_S]C^/^1X31
M7NW_  BV@?\ 0"L/^^&_^*H_X1;0/^@%8?\ ?#?_ !5'UG^Z'^KE;_G['\?\
MCPFBO=O^$6T#_H!6'_?#?_%4?\(MH'_0"L/^^&_^*H^L_P!T/]7*W_/V/X_Y
M'A-%>[?\(MH'_0"L/^^&_P#BJ/\ A%M _P"@%8?]\-_\51]9_NA_JY6_Y^Q_
M'_(\)HKW;_A%M _Z 5A_WPW_ ,51_P (MH'_ $ K#_OAO_BJ/K/]T/\ 5RM_
MS]C^/^1X317NW_"+:!_T K#_ +X;_P"*H_X1;0/^@%8?]\-_\51]9_NA_JY6
M_P"?L?Q_R/":*]V_X1;0/^@%8?\ ?#?_ !5'_"+:!_T K#_OAO\ XJCZS_=#
M_5RM_P _8_C_ )'A-%>[?\(MH'_0"L/^^&_^*H_X1;0/^@%8?]\-_P#%4?6?
M[H?ZN5O^?L?Q_P CPFBO=O\ A%M _P"@%8?]\-_\51_PBV@?] *P_P"^&_\
MBJ/K/]T/]7*W_/V/X_Y'A-%>[?\ "+:!_P! *P_[X;_XJC_A%M _Z 5A_P!\
M-_\ %4?6?[H?ZN5O^?L?Q_R/":*]V_X1;0/^@%8?]\-_\51_PBV@?] *P_[X
M;_XJCZS_ '0_U<K?\_8_C_D>$T5[M_PBV@?] *P_[X;_ .*H_P"$6T#_ * 5
MA_WPW_Q5'UG^Z'^KE;_G['\?\CPFBO=O^$6T#_H!6'_?#?\ Q5'_  BV@?\
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MQ:Y3IPW#U6%:,O:1T?G_ )'SV.@I:]V_X1;0/^@%8?\ ?#?_ !5'_"+:!_T
MK#_OAO\ XJM/K/\ =.;_ %<J_P#/V/X_Y'A-%>[?\(MH'_0"L/\ OAO_ (JC
M_A%M _Z 5A_WPW_Q5'UG^Z'^KE;_ )^Q_'_(\)HKW;_A%M _Z 5A_P!\-_\
M%4?\(MH'_0"L/^^&_P#BJ/K/]T/]7*W_ #]C^/\ D>$T5[M_PBV@?] *P_[X
M;_XJC_A%M _Z 5A_WPW_ ,51]9_NA_JY6_Y^Q_'_ "/":*]V_P"$6T#_ * 5
MA_WPW_Q5'_"+:!_T K#_ +X;_P"*H^L_W0_U<K?\_8_C_D>7_#/_ )'W1/\
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MIX=S+:Q3E8YP\FXAQW&>.,''&<5?UOP/I^O3W$UP]PLTNP>9%+M**JLNU>.
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MX8-=U/\ Z"5Y_P"!+_XUI&+:W/F\SQ&%I58JO14W;=I=_-'L_P#PJ;PM_P!
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M_C2_V[J?_02O/_ E_P#&CD?</KN7?] D?NC_ )'LW_"IO"W_ $##_P"!$O\
M\51_PJ;PM_T##_X$2_\ Q5>,_P!NZG_T$KS_ ,"7_P :/[=U/_H)7G_@2_\
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M;%=1112.JCAZ.'35&"BGV27Y$-W_ ,>[?4?S%35#=_\ 'NWU'\Q4U!N%%%%
M!4$G_'U#]&J>H)/^/J'Z-0!/1110!#!_K9_]\?\ H(J:H8/];/\ [X_]!%34
M <1_PC$W_/>']?\ "C_A&)O^>\/Z_P"%=#17K_6:G<^8_L^AV_$Y[_A&)O\
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MY;B;4KU+&&.#:2'8$Y;)&  "3WJ;5?$MGI&JZ5ITQ9KK4I6B@1 /X4+,S9/
M 'YD"E]:J=P_L^AV_$I_\(Q-_P ]X?U_PH_X1B;_ )[P_K_A70!U9BH8%AU
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M)_S3_P"*H_X0#Q%_T")_S3_XJBZ#ZK7_ .?<ON9S]%;[> O$*C)TF<#ZI_\
M%4O_  @'B+_H$3_FG_Q5%T'U6O\ \^Y?<SGZ*Z#_ (0#Q%_T")_S3_XJC_A
M/$7_ $")_P T_P#BJ+H/JM?_ )]R^YG/T5T'_" >(O\ H$3_ )I_\52?\(%X
MAW8_LF?/7JG_ ,51=!]5K_\ /N7W,P**Z#_A /$7_0(G_-/_ (JC_A /$7_0
M(G_-/_BJ+H/JM?\ Y]R^YG/T5T'_  @'B+_H$3_FG_Q5'_" >(O^@1/^:?\
MQ5%T'U6O_P ^Y?<SGZ*WU\!>(6&1I,Y'U3_XJE_X0#Q%_P! B?\ -/\ XJBZ
M#ZKB/^?<ON9S]%=!_P (!XB_Z!$_YI_\51_P@'B+_H$3_FG_ ,51=!]5K_\
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M2;$)R54GU(%'*Q<RWL>>^.=:A\8VWA_0=)O%FM?$,A:2Z@8X-F@W2E3_ +0
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M-$$SOY%]@@#_ %2__%5XY11R(/[:Q?=?<>S_ /"Y-#_Y][[_ +]+_P#%4?\
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M_MJ>%)+S&D1W\S2OM PY#.2VTGGDUOV5I%\1]=UV?4C(=%T]VT^WACG>(,X
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MM57P[X3OM,\2)*0T6FVRRK$C3*X)<CD84'M_%^%=Q11S,+',_$?_ )$[4/\
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M%OIM,U2SMEDM[NW(#QMYBC()![$_G7Y7?\-=?&7_ **/KO\ W^3_ .)K]/\
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MF7[5'YAAE8_(% !<8.Y"0=HRPY\1A\+0INI[&+MY+_(Z*%?$UJBA[5J_F_\
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M^"2Y_P#B*_9Z;XI>'73"WDN<@_ZB3U^E/_X6IX;_ .?R7_P'D_PH_P!;*_\
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M +IJGI>K66MV,5[IUY#?V<N?+N+:021O@X.&'!Y!JU^)H =L?&-K8]*/+?\
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MB=J'^Z/YBO ATKWWXC_\B=J'^Z/YBO ATK2&Q\1GW\>'I^K"BBBM#YH****
M"BBB@ HHHH **** "BBB@ K0T[2XK^VN96N_(,"&1E:$D8Z ;@>I/;%9]6XK
M\PZ9<6BIS-(KL^>R@X&/J<TC2FXI^\M#U#X5?\BW)_U\/_2NT1#(P4$#ZUQ?
MPJ_Y%N3_ *^'_I7:(VQPW7%-;'W&"_W>G?L3V7^M;Z5E^(_%4'AR_LHY+>XN
M'NY(X%,,9*IN;&YVZ <_4]JU++_6M]*H^(="_M]K>'S_ "/)GAN<[=V=CDXZ
MCKZUC+XM3VJ/P&#+\4K:%9G:RD6(F1;5VF0><8Y!&^[^X 6!R>V3VQ6SX7\7
M1^*0SV]M(D21HSR,P(#L,[!CJ0,'/3D52L_ :0^)9M9FDM))3'+'&L5DL9.\
M@DRD']X1@#MQGUJ'1_AU_9.OV^I_VBTKHI,H,6&D<YW<[L!23G;CJ!SQ2]VQ
MMJ=G11168R&T_P"/=:FJ&T_X]UJ:@ HHHH AO/\ CW?\/YU*.E17G_'N_P"'
M\ZE'2@!:*** "H6_X^T_W&_F*FJ%O^/M/]QOYB@":BBB@ HHHH AM?\ 5M_O
MO_Z$:FJ&U_U;?[[_ /H1J:@ HHHH AN_^/=OJ/YBIJAN_P#CW;ZC^8J:@ HH
MHH *@D_X^H?HU3U!)_Q]0_1J )Z*** (8/\ 6S_[X_\ 014U0P?ZV?\ WQ_Z
M"*FH R:4=1GIFDHKM/*/FCPII6DZ[;?$+6-6\+Q>-O&,6M2P2Z5/(BS1P;@L
M?EE^$ 7<<C^[CM4/A[QU>KX)\ Z9X)-QX4MKS7Y=)DCN)DOVVA0Q.YUQU8D
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M-U+"4)[_ ",.?>D]5H5%I/4YWX"^&=3\.^#KBXU:V73[G4[N2^%@@PMLK=%
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M_AX-\<_^AKM?_!1:_P#QNC_AX-\<_P#H:[7_ ,%%K_\ &Z]7_5?,/YH_>_\
MY$\;Z_E'_/I_U_V\?II_PI2Q_P"@G=_]\)_A3%^#%B963^T[O@ _<3_"OS._
MX>#?'/\ Z&NU_P#!1:__ !ND'_!03XY!BW_"5VN3W_LBU_\ C='^J^8?S1^]
M_P#R(_K^3_\ /I_U_P!O'Z:_\*4L?^@G=_\ ?"?X4?\ "E+'_H)W?_?"?X5^
M9?\ P\&^.?\ T-=K_P""BU_^-T?\/!OCG_T-=K_X*+7_ .-T?ZKYA_-'[W_\
MB+Z_E'_/I_U_V\?II_PI2Q_Z"=W_ -\)_A0?@I8C_F)W?_?"?X5^9?\ P\&^
M.?\ T-=K_P""BU_^-T?\/!OCG_T-=K_X*+7_ .-T?ZKYA_-'[W_\B'U_*/\
MGT_Z_P"WC],HO@O8R1JW]IW8R,_<3_"G?\*4L?\ H)W?_?"?X5^92_\ !03X
MY(H4>*[4 ?\ 4(M?_C==5\*OVZ_C+XH^)GA32-0\46T]A?:I;VUQ&NEVREHV
MD 89"9'!ZBHGPSCX1<G*.GF_\BXXW*)R452>O]?S'Z%_\*4L?^@G=_\ ?"?X
M4?\ "E+'_H)W?_?"?X5W'VN7^\/RH^UR_P!X?E7RG+/N>_\ 4L#_ ,^_S_S.
M$E^"]C&F?[3NSR!]Q/7Z4_\ X4I8_P#03N_^^$_PKMGN)'&&;(SGI3OM<O\
M>'Y4<L^X?4L#_P ^_P _\S/\->$(?#6GM:Q7$LRF0OND !Y^E:WV%?[YJ2UD
M:6,ECDYQ4U0Y23M<].G1I1@E!:$,-L(6)#$Y]:!_Q]G_ '!_,U+40_X^S_N#
M^9J&[[FZBHJR)J***104444 0VG_ ![K4U0VG_'NM34 %%%% $-Y_P >[_A_
M.I1TJ*\_X]W_  _G4HZ4 +1110 5"W_'VG^XW\Q4U0M_Q]I_N-_,4 34444
M%%%% $-K_JV_WW_]"-35#:_ZMO\ ??\ ]"-34 %%%% $-W_Q[M]1_,5-4-W_
M ,>[?4?S%34 %%%% !4$G_'U#]&J>H)/^/J'Z-0!/1110!#!_K9_]\?^@BIJ
MA@_UL_\ OC_T$5-0!EY']P?F:,C^X/S--HKLL>7<=D?W!^9HR/[@_,UXD_CC
MX@_$#4]=G\&R:'I&@Z3=/8I<:NC.]Y*GWL=E .!SZBNDB^+7_"+>%-!N_&]D
MVEZOJ,QM?LNG*;M3*!D8V$XR,?+DG)Q4W1?*STG(_N#\S1D?W!^9KSO5_CGX
M<T-5-Y;ZS$RVZ75RO]E3$V<;'"F?C]W]#4_BOXP^'_#K16J7$]Y?7-D;Z);*
MTDN!'#C*S2;1\J=\GL#3NA<LNQWN1_<'YFC(_N#\S7D7@?XW0O\ #OPUJ7B$
MS7FN:JLSK::18O-(ZQNP9Q$F2%4 9->D^'O$>G>*=%M=6TRY6ZL+E=\<H!'L
M00>00<@@],4)I@TT:F1_<'YFC(_N#\S7A7PT^+6H>/?%LL4GB[2+.(ZA.EMH
M9TTF>>W1B!B?>%W$>@)XZ5[G0FF$DXZ,=D?W!^9HR/[@_,TVBJL1<=D?W!^9
MHR/[@_,TVBBP7'9']P?F:,C^X/S--HHL%QV1_<'YFC(_N#\S3:*+!<=D?W!^
M9HR/[@_,TVBBP7'9']P?F:,C^X/S--HHL%QV1_<'YFC(_N#\S3:*+!<=D?W!
M^9HR/[@_,TVBBP7'9']P?F:,C^X/S--HHL%QV1_<'YFC(_N#\S3:*+!<=D?W
M!^9HR/[@_,TVBBP7'9']P?F:,C^X/S--HHL%QV1_<'YFC(_N#\S3:*+!<=D?
MW!^9IR$9/RCH>YJ.G1_>_ TFM"D]0W#^X/S-&1_<'YFFCI13L3<=D?W!^9HR
M/[@_,TVO(/%/QAU2V^*.A>&],TV2#39+X6MW?W<'RS-C)2(Y[#JU2[(I)O8]
MAR/[@_,T9']P?F:\NT/XIZAJ?Q5OO#<EE;I91@HD@N%/S+RQ5L?.V,93@KZF
MNI\3>(KJTUS1-&T[RQ>7TC22/(NX)"@RYQZGH/K1=;A9IV.HR/[@_,T9']P?
MF:\OU?Q%XQ\,W&GZAJ5UI;0WNH+:+HL-N3)Y;-@%9MWS,!R1MQ74^'O$5S<>
M)=;T._*-<V;+-!)&FWS('Z9'J",$T)H;31T^1_<'YFC(_N#\S3:*JQ%R6$CS
M5^7'/K6C6;!_K4^M:5<]3<[*&S(8O]?-^%35#%_KYOPJ:LCI"BBB@ HHHH *
M*** "BBB@ HHHH 0UY;'JFN?V=9O%-$T9U1T1WGD+OC=A&&,;>.F:]3J*2V1
MXB@ 3.<%0,@^H]ZI.PC@9/B)?3V]K/";&SMYYV@$UXK;5*+EOXA_%D"J5[\1
MM6NK&<11P6DQ0HL.QC,#LW>:.?N_AW'-=NOA/3Q%8QF-G6S9G3<<[F/4MZUJ
M?9HB^_RDW[=N[:,X],^E5==@U/.)?B/J=BWE".UNA# A+,50RDQ[MX)DSC/8
M*?J*FD\?:O;HRR_V=O3RW:15(^5D#X"-(-QYZAL^BFO0!9P!E(ACRJ[0=@X'
MI]*)+2"5=KPQNN0<,H(R.E+F78+'F^F^/[N*VS"+?9N:4+<-(SW&9=NR/<V0
M0.<8./05N>$_%]_K6HQ0W:VHCGMVG00HRLF'*X)+'/3T%=:;:$E"8D)0Y4[1
MP?44Y840@JBJ0,9 H;78#Q;]M#_DV/QY_P!>:_\ HQ*_&.OV>_;,B>;]F;QT
MD:-([6:@*BEB?WB= *_&S^Q]0_Y\+O\ \!W_ ,*_3^$VEA:E_P";]$?GO$B;
MQ,+?R_JRI15O^Q]0_P"?"[_\!W_PH_L?4/\ GPN__ =_\*^WYH]SY+EEV*E%
M6_['U#_GPN__  '?_"C^Q[__ )\+O_P'?_"CFCW#EEV*E%6_['U#_GPN_P#P
M'?\ PH_L?4/^?"[_ / =_P#"CFCW#EEV*E%6_P"Q]0_Y\+O_ ,!W_P */['U
M#_GPN_\ P'?_  HYH]PY9=C2\!V]O=^-M ANX)[JU>_@$L%M#YTLJ[P2BQY&
MXD#&WOFO>=2TAX_CU\+=;#2VMMJNKQ/!I-[I$&F7-DB76T*T,7!0XRKGDCZ5
M\ZC2-0!!%C=@CD$6[_X5WOP8MM6N_C9X'N+R&_G<:S9[I;A)'.!*O5F'05YV
M*AS7J*6T7^1WX:?*E3<=VC]J111^!H_ U^*'Z8%2("$)(RO/;O4=+D^])C3L
M7+'_ %1^M<I>QW#?$6&WN-0GDL;G3IC]D#>6B89!D;<$GD_,3],5UEC_ *H_
M6IC&I;<5!;&,XYQ7/)VDSOI_ CR8:7>#PNFMVVI3VL4ERUPEO+<S-\I91"J?
M,<M@8P?E)<DUTGPXU]M6^V6TWG->0?//)+(&RS,V0 #\F"" AZ#'K7:&%"BI
ML7:N,#' J&*&.*]D*(J%U#,5 &XY/)]:3E=&EBS1114#"BBB@"&T_P"/=:FJ
M&T_X]UJ:@ HHHH AO/\ CW?\/YU*.E17G_'N_P"'\ZE'2@!:*** "H6_X^T_
MW&_F*FJ%O^/M/]QOYB@":BBB@ HHHH AM?\ 5M_OO_Z$:FJ&U_U;?[[_ /H1
MJ:@ HHHH AN_^/=OJ/YBIJAN_P#CW;ZC^8J:@ HHHH *@D_X^H?HU3U!)_Q]
M0_1J )Z*** (8/\ 6S_[X_\ 014U0P?ZV?\ WQ_Z"*FH R:*@_M"T_Y^X/\
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M#T&/6O+<;*YZ%SMZ***@84444 0VG_'NM35#:?\ 'NM34 %%%% $-Y_Q[O\
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M:%&TB01[4=\CENQ;W/->N4;CC&3CTHKIIP]FK'!6JNLU)]%8****T, HHHH
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M?^&R?@K_ -%%T;_OZ_\ \31_PV3\%?\ HHNC?]_7_P#B:/\ 6'&?] <OQ_\
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MTJ*\_P"/=_P_G4HZ4 +1110 5"W_ !]I_N-_,5-4+?\ 'VG^XW\Q0!-1110
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MMJVK()?L;2^6+2,<2/.P!VA3E<8R3P*7UB?\Q7U&C_(=3_PC-M_SUF_(4?\
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MC:*=Y;_W31Y;_P!TT7068VG1_>_ T>6_]TTY(VR?E/0TFU8:3N1CI13O+?\
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MA;_P7S?_ !^OL,EAFLJ,G@)I1OK>V]EW3/F,UGET:L?KD6Y6TM?:_DT>B_\
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M2JU7>3W/9I4H48*G35D@J$?\?9_W!_,U-4(_X^S_ +@_F:P-2:BBB@ HHHH
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MQ)QQF>9#Y&>J45X;;^--?TK7FGTK2K[6;'2M MYKJTNM4.V)Y297)D<$RRA
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MZ1_]]BOU#A/_ '6I_B_1'YYQ(F\3"W\OZL=13?,3_GI'_P!]BCS$_P">D?\
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MCE?E;YAQP:Z.AJP!1112 *A'_'V?]P?S-35"/^/L_P"X/YF@":BBB@ HHHH
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MHHH AN_^/=OJ/YBIJAN_^/=OJ/YBIJ "BBB@ J"3_CZA^C5/4$G_ !]0_1J
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M0X(!P00.A]LFERL+EWQ;JKZ)H<]]'&LKP88(Y(![=OK7G/\ PNK4/^@;;?\
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MTI:* $P!VHP,TM% $-W96]_;26]S!%<6\BE7BE0,C ]00>"*D5%10JJ%4<
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M (]V^H_F*FJ&[_X]V^H_F*FH **** "H)/\ CZA^C5/4$G_'U#]&H GHHHH
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M. _X=R?&C_H':+_X-E_^)H_X=R?&C_H':+_X-E_^)KO_ /AZCXO_ .A'T/\
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M_F: )J*** "BBB@"&T_X]UJ:H;3_ (]UJ:@ HHHH AO/^/=_P_G4HZ5%>?\
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M5#=_\>[?4?S%34 %%%% !4$G_'U#]&J>H)/^/J'Z-0!/1110!#!_K9_]\?\
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M:Z]:?9KM7*!@ZM&Y1E8="#VKZ8_X5-X6_P"@8?\ P(E_^*H_X5-X6_Z!A_\
M B7_ .*HYT7#A?,*<E.%2*:\W_\ (GRS;^"]+@CO4*33K>(%G^T3%R^.^3SG
MWI(/!.EPQ74;"XN3<QB&1[B=G?8.@![8KZG_ .%3>%O^@8?_  (E_P#BJ/\
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MX9H^$O\ T37PI_X)X/\ XFO2Z*VA6JTU:$FO1F4Z5.H[SBGZH\T_X9H^$O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:#&PP.XH-A<][_M#2S<M;K<QO.LPMV19"2LA7>%..AV\\]JO?8XO[I_[Z/\
MC7S7'=ZQ8V^JZAX:GOH-0E_MG4[E \SJK_:5MH@R'<"4CS(!@GY1P<"MBSN=
M9U%X]*TW5[Y=.U74;.T6YL[VYN67RM\MU-%<RJO#(BH=ORALXY)%/V?F%SW6
MX>QM);>*:5(I+A_+A1Y"#(V"V%&>3@$_0&I_L<7]T_\ ?1_QKYR^TM/KYO+N
MZU:&VL4U>\TN13/<2PH)([>-XU+9DV[9I"#GY7QTXKT;X(SW-Q::J)[JYO!
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6 !B@#%%% "T444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>btai-20241231xex4d5001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 btai-20241231xex4d5001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  P &0# 2(  A$! Q$!_\0
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M]1M+VZT*/Q-XFNK>WL_-AG,%RUN('N)BZ[6*>9"BDX)/&#SEE^R-<> ?B_\
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M8\+)I,LEUJ%G+?1:Q?2V<4UI%<)++")(H)B#($V9V\!B>>E9WA3X7^,-1^-
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?UC17M4,WQ.&I1HT[<L59:'B8G)\+BZLJ]6[D_,__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>21
<FILENAME>btai-20241231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/28/2025 7:22:09 PM-->
<!--Modified on: 3/28/2025 7:22:09 PM-->
<xsd:schema targetNamespace="http://www.bioxceltherapeutics.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:btai="http://www.bioxceltherapeutics.com/20241231" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>995200100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails" id="DisclosureInventoryDetails">
        <link:definition>99940501 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetDetails">
        <link:definition>99940601 - Disclosure - Property and equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>99940701 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" id="DisclosureDebtAndCreditFacilitiesDebtSummaryDetails">
        <link:definition>99940901 - Disclosure - Debt and Credit Facilities - Debt summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails" id="DisclosureDebtAndCreditFacilitiesInterestDetails">
        <link:definition>99940906 - Disclosure - Debt and Credit Facilities - Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2" id="DisclosureLeasesMaturitiesDetailsCalc2">
        <link:definition>41002 - Disclosure - Leases - Maturities (Details) - Calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" id="DisclosureLeasesMaturitiesDetails">
        <link:definition>99941301 - Disclosure - Leases - Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails" id="DisclosureIncomeTaxesDeferredTaxDetails">
        <link:definition>99941601 - Disclosure - Income Taxes - Deferred Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails" id="DisclosureIncomeTaxesReconciliationDetails">
        <link:definition>99941602 - Disclosure - Income Taxes - Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails" id="DisclosureSegmentInformationDetails">
        <link:definition>99941901 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity" id="StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity">
        <link:definition>995200300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>99931203 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails" id="DisclosureBasisOfPresentationDetails">
        <link:definition>99940201 - Disclosure - Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>99940301 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsDetails">
        <link:definition>99940302 - Disclosure - Summary of Significant Accounting Policies - Concentrations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails" id="DisclosureRestructuringDetails">
        <link:definition>99940401 - Disclosure - Restructuring (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" id="DisclosureTransactionsWithBioxcelLlcDetails">
        <link:definition>99940801 - Disclosure - Transactions with BioXcel LLC (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" id="DisclosureDebtAndCreditFacilitiesCreditAgreementDetails">
        <link:definition>99940902 - Disclosure - Debt and Credit Facilities - Credit Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" id="DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails">
        <link:definition>99940903 - Disclosure - Debt and Credit Facilities - Revenue Interest Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" id="DisclosureDebtAndCreditFacilitiesWarrantsDetails">
        <link:definition>99940904 - Disclosure - Debt and Credit Facilities - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" id="DisclosureDerivativeFinancialInstrumentsDetails">
        <link:definition>99941001 - Disclosure - Derivative Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails" id="DisclosureCommonStockFinancingActivitiesDetails">
        <link:definition>99941101 - Disclosure - Common Stock Financing Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails" id="DisclosureStockBasedCompensationDescriptionDetails">
        <link:definition>99941201 - Disclosure - Stock-Based Compensation - Description (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" id="DisclosureStockBasedCompensationNonOptionsDetails">
        <link:definition>99941202 - Disclosure - Stock-Based Compensation - Non-options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" id="DisclosureStockBasedCompensationOptionsDetails">
        <link:definition>99941203 - Disclosure - Stock-Based Compensation - Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" id="DisclosureStockBasedCompensationAssumptionsDetails">
        <link:definition>99941204 - Disclosure - Stock-Based Compensation - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationExpenseDetails">
        <link:definition>99941205 - Disclosure - Stock-Based Compensation - Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" id="DisclosureStockBasedCompensationEsppDetails">
        <link:definition>99941206 - Disclosure - Stock-Based Compensation - ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" id="DisclosureFairValueMeasurementsHierarchyDetails">
        <link:definition>99941501 - Disclosure - Fair Value Measurements - Hierarchy (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details" id="DisclosureFairValueMeasurementsLevel3Details">
        <link:definition>99941502 - Disclosure - Fair Value Measurements - Level 3 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" id="DisclosureFairValueMeasurementsInputsDetails">
        <link:definition>99941503 - Disclosure - Fair Value Measurements - Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails" id="DisclosureFairValueMeasurementsWarrantsOutstandingDetails">
        <link:definition>99941504 - Disclosure - Fair Value Measurements - Warrants outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails" id="DisclosureNetLossPerShareDetails">
        <link:definition>99941701 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails" id="DisclosureNetLossPerShareAntidilutiveDetails">
        <link:definition>99941702 - Disclosure - Net Loss Per Share - Antidilutive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>99941801 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>99942001 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNatureOfBusiness" id="DisclosureNatureOfBusiness">
        <link:definition>995210101 - Disclosure - Nature of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
        <link:definition>995210201 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995210301 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureRestructuring" id="DisclosureRestructuring">
        <link:definition>995210401 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureInventory" id="DisclosureInventory">
        <link:definition>995210501 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>995210601 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>995210701 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc" id="DisclosureTransactionsWithBioxcelLlc">
        <link:definition>995210801 - Disclosure - Transactions with BioXcel LLC</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities" id="DisclosureDebtAndCreditFacilities">
        <link:definition>995210901 - Disclosure - Debt and Credit Facilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstruments" id="DisclosureDerivativeFinancialInstruments">
        <link:definition>995211001 - Disclosure - Derivative Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities" id="DisclosureCommonStockFinancingActivities">
        <link:definition>995211101 - Disclosure - Common Stock Financing Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>995211201 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>995211301 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlan" id="DisclosureEmployeeBenefitPlan">
        <link:definition>995211401 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>995211501 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995211601 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>995211701 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995211801 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformation" id="DisclosureSegmentInformation">
        <link:definition>995211901 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995212001 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>99920302 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>99930303 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables" id="DisclosureInventoryTables">
        <link:definition>99930503 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>99930603 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>99930703 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables" id="DisclosureTransactionsWithBioxcelLlcTables">
        <link:definition>99930803 - Disclosure - Transactions with BioXcel LLC (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables" id="DisclosureDebtAndCreditFacilitiesTables">
        <link:definition>99930903 - Disclosure - Debt and Credit Facilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>99931303 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>99931503 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>99931603 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>99931703 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>99931903 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails" id="DisclosureDebtAndCreditFacilitiesMaturitiesDetails">
        <link:definition>99940905 - Disclosure - Debt and Credit Facilities - Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>99941302 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlanDetails" id="DisclosureEmployeeBenefitPlanDetails">
        <link:definition>99941401 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="btai-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="btai-20241231_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="btai-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="btai-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd" />
  <xsd:element name="OrganizationAndPrincipalActivitiesAbstract" id="btai_OrganizationAndPrincipalActivitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredOfferingCostsPolicyTextBlock" id="btai_DeferredOfferingCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DevelopmentMilestonesMember" id="btai_DevelopmentMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SalesMilestonesMember" id="btai_SalesMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementMilestonePaymentsPotential" id="btai_CollaborativeArrangementMilestonePaymentsPotential" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="BioxcelCorporationMember" id="btai_BioxcelCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementMilestonePotentialPercent" id="btai_CollaborativeArrangementMilestonePotentialPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="PatentCostsPolicyTextBlock" id="btai_PatentCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="JefferiesMember" id="btai_JefferiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncentiveAwardPlan2020Member" id="btai_IncentiveAwardPlan2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" id="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeStockPurchasePlan2020Member" id="btai_EmployeeStockPurchasePlan2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" id="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockPlan2017Member" id="btai_StockPlan2017Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedResearchAndDevelopmentExpenses" id="btai_AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="FinancingActivitiesAbstract" id="btai_FinancingActivitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FinancingActivitiesDisclosureTextBlock" id="btai_FinancingActivitiesDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" id="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" id="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" id="btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredTaxAssetsLeaseAccountingLiability" id="btai_DeferredTaxAssetsLeaseAccountingLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="OperatingLossCarryforwardsNoExpiration" id="btai_OperatingLossCarryforwardsNoExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="RegisteredOfferingMember" id="btai_RegisteredOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CreditFacilityMember" id="btai_CreditFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RevenueInterestFinancingAgreementMember" id="btai_RevenueInterestFinancingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PaidInKindInterestPercentage" id="btai_PaidInKindInterestPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="TickingFeesPercentage" id="btai_TickingFeesPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ThresholdRatioOfDebtToRevenueRatio" id="btai_ThresholdRatioOfDebtToRevenueRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" id="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EquityInvestmentMember" id="btai_EquityInvestmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantOaktreeAndQiaMember" id="btai_WarrantOaktreeAndQiaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BorrowingsBasedOnNetSalesPercent" id="btai_BorrowingsBasedOnNetSalesPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PremiumSharePricePercent" id="btai_PremiumSharePricePercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RightToPurchaseStockLenders" id="btai_RightToPurchaseStockLenders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock" id="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TrancheMember" id="btai_TrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheBMember" id="btai_TrancheBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheCMember" id="btai_TrancheCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OnkosxcelWarrantMember" id="btai_OnkosxcelWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ThresholdLiquidityEventAmountForExerciseOfWarrants" id="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PercentageOfFairValueConsiderationToBePaid" id="btai_PercentageOfFairValueConsiderationToBePaid" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PercentageOfValuationApplicableToInitialProfits" id="btai_PercentageOfValuationApplicableToInitialProfits" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DebtInstrumentInterestRateDiscountRatePercentage" id="btai_DebtInstrumentInterestRateDiscountRatePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PercentageOfOutstandingLoan" id="btai_PercentageOfOutstandingLoan" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OfaAdministrativeAgentMember" id="btai_OfaAdministrativeAgentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NetCashRequiredMinimum" id="btai_NetCashRequiredMinimum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SubsidiaryOwnershipPercentage" id="btai_SubsidiaryOwnershipPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="MeasurementInputProbabilityOfExerciseMember" id="btai_MeasurementInputProbabilityOfExerciseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TimeBasedProfitSharingUnitsMember" id="btai_TimeBasedProfitSharingUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MeasurementInputEstimatedPremiumMember" id="btai_MeasurementInputEstimatedPremiumMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RestrictedStockUnitsOnkosxcelMember" id="btai_RestrictedStockUnitsOnkosxcelMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" id="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" id="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TrancheDMember" id="btai_TrancheDMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LineOfCreditFacilityExitFeePercentage" id="btai_LineOfCreditFacilityExitFeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LineOfCreditFacilityAmendmentFeePercentage" id="btai_LineOfCreditFacilityAmendmentFeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LineOfCreditFacilityInvestmentAllowed" id="btai_LineOfCreditFacilityInvestmentAllowed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccountsReceivablePaymentTerm" id="btai_AccountsReceivablePaymentTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EquityInvestmentRightAmountUnfunded" id="btai_EquityInvestmentRightAmountUnfunded" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ConversionOfAccruedInterestToLongTermDebt" id="btai_ConversionOfAccruedInterestToLongTermDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" id="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NewWarrantsMember" id="btai_NewWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheTwoMember" id="btai_TrancheTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SaleOfStockMaximumValueSharesToBeIssued" id="btai_SaleOfStockMaximumValueSharesToBeIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="VimalMehtaMember" id="btai_VimalMehtaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RichardSteinhartMember" id="btai_RichardSteinhartMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="JavierRodriguezMember" id="btai_JavierRodriguezMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MatthewWileyMember" id="btai_MatthewWileyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FrankYoccaMember" id="btai_FrankYoccaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" id="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FromAndAfterFundingOfTrancheBLoansMember" id="btai_FromAndAfterFundingOfTrancheBLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" id="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="Warrants2024Member" id="btai_Warrants2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtInstrumentIncrementalOnVariableRatePercent" id="btai_DebtInstrumentIncrementalOnVariableRatePercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PeriodOneMember" id="btai_PeriodOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PeriodTwoMember" id="btai_PeriodTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PeriodThreeMember" id="btai_PeriodThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Warrants2024AccompanyingWarrantsMember" id="btai_Warrants2024AccompanyingWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Warrants2024PreFundedWarrantsMember" id="btai_Warrants2024PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RegisteredDirectOfferingMember" id="btai_RegisteredDirectOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CustomerOneMember" id="btai_CustomerOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ReverseStockSplit" id="btai_ReverseStockSplit" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SingleReportableSegmentMember" id="btai_SingleReportableSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ResearchAndDevelopmentExpenseLaborAndRelatedExpense" id="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" id="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentExpenseProfessionalFees" id="btai_ResearchAndDevelopmentExpenseProfessionalFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentExpenseClinicalTrialsExpense" id="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" id="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentExpenseTravelAndOtherExpenses" id="btai_ResearchAndDevelopmentExpenseTravelAndOtherExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" id="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" id="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SellingGeneralAndAdministrativeExpenseProfessionalFees" id="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" id="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="November2024AccompanyingWarrantsMember" id="btai_November2024AccompanyingWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockIssuedDuringPeriodSharesWarrantsExercised" id="btai_StockIssuedDuringPeriodSharesWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="November2024PrefundedAccompanyingWarrantsMember" id="btai_November2024PrefundedAccompanyingWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredTaxAssetsCapitalizedIpoCosts" id="btai_DeferredTaxAssetsCapitalizedIpoCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DeferredTaxAssetsCancellationOfDebt" id="btai_DeferredTaxAssetsCancellationOfDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded" id="btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod" id="btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" id="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AccompanyingWarrants2024StrikePriceNotAmendedMember" id="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PurchaseAgreementRegisteredSecuritiesMember" id="btai_PurchaseAgreementRegisteredSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AccompanyingWarrantsMarch2025Member" id="btai_AccompanyingWarrantsMarch2025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PrefundedWarrantsMarch2025Member" id="btai_PrefundedWarrantsMarch2025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OptionWarrantsMarch2025Member" id="btai_OptionWarrantsMarch2025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BioxcelWarrantsAggregateMember" id="btai_BioxcelWarrantsAggregateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Warrants2023Member" id="btai_Warrants2023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantShares2024Member" id="btai_WarrantShares2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" id="btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ArmisticeCapitalMasterFundMember" id="btai_ArmisticeCapitalMasterFundMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="HeightsCapitalManagementMember" id="btai_HeightsCapitalManagementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="HudsonBayCapitalManagementMember" id="btai_HudsonBayCapitalManagementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IntraCoastalCapitalMember" id="btai_IntraCoastalCapitalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationWarrantValuationPercent" id="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationWarrantValuationAmount" id="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OriginalWarrantsMember" id="btai_OriginalWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommercialCostsLaborAndRelatedExpense" id="btai_CommercialCostsLaborAndRelatedExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CommercialCostsShareBasedPaymentArrangementExpense" id="btai_CommercialCostsShareBasedPaymentArrangementExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CommercialCostsProfessionalFees" id="btai_CommercialCostsProfessionalFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CommercialCostsCommercialAndMarketing" id="btai_CommercialCostsCommercialAndMarketing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CommercialCostsTravelAndOtherExpenses" id="btai_CommercialCostsTravelAndOtherExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CommercialCostsOtherExpenses" id="btai_CommercialCostsOtherExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SellingGeneralAndAdministrativeCostsOtherExpenses" id="btai_SellingGeneralAndAdministrativeCostsOtherExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="FairValueStockPurchaseWarrants" id="btai_FairValueStockPurchaseWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>22
<FILENAME>btai-20241231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/28/2025 7:22:09 PM-->
<!--Modified on: 3/28/2025 7:22:09 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureInventoryDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureDebtAndCreditFacilitiesInterestDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureLeasesMaturitiesDetailsCalc2" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureLeasesMaturitiesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureIncomeTaxesDeferredTaxDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureIncomeTaxesReconciliationDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureSegmentInformationDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638787865247908486" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_638787865247908486" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638787865247908486" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638787865247908486" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638787865247908486" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_638787865247908486" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638787865247908486" xlink:to="us-gaap_ReceivablesNetCurrent_638787865247908486" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638787865247908486" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638787865247908486" xlink:to="us-gaap_InventoryNet_638787865247908486" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638787865247908486" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638787865247908486" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638787865247908486" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638787865247918485" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638787865247908486" xlink:to="us-gaap_OtherAssetsCurrent_638787865247918485" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638787865247918485" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638787865247918485" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638787865247918485" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638787865247918485" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638787865247918485" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638787865247918485" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638787865247918485" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638787865247918485" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638787865247928506" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638787865247918485" xlink:to="us-gaap_LiabilitiesCurrent_638787865247928506" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638787865247928506" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638787865247928506" xlink:to="us-gaap_AccountsPayableCurrent_638787865247928506" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638787865247928506" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638787865247928506" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638787865247928506" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_638787865247928506" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638787865247928506" xlink:to="us-gaap_InterestPayableCurrent_638787865247928506" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638787865247928506" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638787865247928506" xlink:to="us-gaap_OtherLiabilitiesCurrent_638787865247928506" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638787865247938483" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638787865247918485" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638787865247938483" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638787865247938483" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638787865247918485" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638787865247938483" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638787865247938483" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638787865247918485" xlink:to="us-gaap_LongTermDebtNoncurrent_638787865247938483" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638787865247938483" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638787865247938483" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638787865247938483" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638787865247938483" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638787865247938483" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638787865247938483" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638787865247938483" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638787865247948482" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638787865247938483" xlink:to="us-gaap_PreferredStockValue_638787865247948482" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638787865247948482" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638787865247938483" xlink:to="us-gaap_CommonStockValue_638787865247948482" order="3" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638787865247948482" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638787865247938483" xlink:to="us-gaap_AdditionalPaidInCapital_638787865247948482" order="4" use="optional" weight="1" priority="4" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638787865247958484" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638787865247958484" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638787865247958484" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest_638787865247958484" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating_638787865247958484" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpenseNonoperating_638787865247958484" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638787865247958484" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_638787865247958484" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638787865247958484" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638787865247958484" xlink:to="us-gaap_CostsAndExpenses_638787865247958484" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638787865247968524" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638787865247958484" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638787865247968524" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638787865247968524" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638787865247958484" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638787865247968524" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges_638787865247968524" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638787865247958484" xlink:to="us-gaap_RestructuringCharges_638787865247968524" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638787865247968524" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638787865247958484" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638787865247968524" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638787865247968524" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638787865247958484" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638787865247968524" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638787865247978489" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638787865247978489" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638787865247978489" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638787865247978489" xlink:to="us-gaap_ProfitLoss_638787865247978489" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638787865247978489" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638787865247978489" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638787865247978489" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638787865247978489" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638787865247978489" xlink:to="us-gaap_Depreciation_638787865247978489" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638787865247978489" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638787865247978489" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638787865247978489" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638787865247978489" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638787865247978489" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638787865247978489" order="5" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest_638787865247988484" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638787865247978489" xlink:to="us-gaap_PaidInKindInterest_638787865247988484" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638787865247988484" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638787865247978489" xlink:to="us-gaap_ShareBasedCompensation_638787865247988484" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638787865247988484" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638787865247978489" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638787865247988484" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638787865247988484" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638787865247978489" xlink:to="us-gaap_IncreaseDecreaseInInventories_638787865247988484" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638787865247988484" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638787865247978489" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638787865247988484" order="10" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638787865247988484" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638787865247978489" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638787865247988484" order="11" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638787865247998484" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638787865247978489" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638787865247998484" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_638787865247998484" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638787865247978489" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_638787865247998484" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_638787865247998484" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638787865247978489" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_638787865247998484" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638787865247998484" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638787865247998484" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638787865247998484" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638787865247998484" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638787865247998484" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638787865248008516" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638787865248008516" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638787865248008516" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638787865248008516" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638787865248008516" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_638787865248008516" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638787865248008516" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_638787865248008516" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_638787865248008516" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638787865248008516" xlink:to="us-gaap_RepaymentsOfLongTermDebt_638787865248008516" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638787865248008516" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638787865248008516" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638787865248008516" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638787865248018527" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638787865248008516" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638787865248018527" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638787865248018527" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638787865248008516" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638787865248018527" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Inventory (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638787865248018527" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_1" xlink:to="us-gaap_InventoryRawMaterials_638787865248018527" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638787865248018527" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_1" xlink:to="us-gaap_InventoryWorkInProcess_638787865248018527" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638787865248028490" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_1" xlink:to="us-gaap_InventoryFinishedGoods_638787865248028490" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Property and equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638787865248028490" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638787865248028490" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638787865248028490" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638787865248028490" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638787865248028490" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638787865248028490" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_AccruedResearchAndDevelopmentExpenses" xlink:label="btai_AccruedResearchAndDevelopmentExpenses_638787865248038487" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="btai_AccruedResearchAndDevelopmentExpenses_638787865248038487" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638787865248038487" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638787865248038487" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638787865248038487" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent_638787865248038487" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent_638787865248038487" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_638787865248038487" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638787865248038487" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638787865248038487" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Debt and Credit Facilities - Debt summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638787865248048864" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent_2" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638787865248048864" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638787865248048864" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent_2" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638787865248048864" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails" xlink:type="extended" xlink:title="99940906 - Disclosure - Debt and Credit Facilities - Interest (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638787865248048864" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseDebt_638787865248048864" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638787865248048864" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638787865248048864" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2" xlink:type="extended" xlink:title="41002 - Disclosure - Leases - Maturities (Details) - Calc 2" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638787865248048864" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_638787865248048864" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638787865248061098" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_638787865248048864" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638787865248061098" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638787865248061098" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_638787865248048864" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638787865248061098" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638787865248061098" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638787865248061098" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" xlink:type="extended" xlink:title="99941301 - Disclosure - Leases - Maturities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638787865248068520" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638787865248068520" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638787865248068520" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638787865248068520" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails" xlink:type="extended" xlink:title="99941601 - Disclosure - Income Taxes - Deferred Tax (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638787865248068520" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_638787865248068520" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638787865248068520" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638787865248068520" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638787865248068520" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638787865248068520" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638787865248068520" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638787865248068520" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_638787865248078497" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638787865248068520" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_638787865248078497" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_638787865248078497" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638787865248068520" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_638787865248078497" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638787865248078497" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638787865248068520" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638787865248078497" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DeferredTaxAssetsLeaseAccountingLiability" xlink:label="btai_DeferredTaxAssetsLeaseAccountingLiability_638787865248078497" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638787865248068520" xlink:to="btai_DeferredTaxAssetsLeaseAccountingLiability_638787865248078497" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_638787865248078497" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638787865248068520" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_638787865248078497" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DeferredTaxAssetsCapitalizedIpoCosts" xlink:label="btai_DeferredTaxAssetsCapitalizedIpoCosts_638787865248088494" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638787865248068520" xlink:to="btai_DeferredTaxAssetsCapitalizedIpoCosts_638787865248088494" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DeferredTaxAssetsCancellationOfDebt" xlink:label="btai_DeferredTaxAssetsCancellationOfDebt_638787865248088494" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638787865248068520" xlink:to="btai_DeferredTaxAssetsCancellationOfDebt_638787865248088494" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638787865248088494" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638787865248068520" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638787865248088494" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638787865248088494" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638787865248068520" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638787865248088494" order="11" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638787865248088494" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638787865248068520" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638787865248088494" order="12" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638787865248098532" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638787865248098532" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives_638787865248098532" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638787865248098532" xlink:to="us-gaap_DeferredTaxLiabilitiesDerivatives_638787865248098532" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_638787865248098532" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638787865248098532" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_638787865248098532" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638787865248098532" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638787865248098532" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638787865248098532" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails" xlink:type="extended" xlink:title="99941602 - Disclosure - Income Taxes - Reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638787865248108543" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638787865248108543" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638787865248108543" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638787865248108543" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EffectiveIncomeTaxRateReconciliationWarrantValuationPercent" xlink:label="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationPercent_638787865248108543" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationPercent_638787865248108543" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638787865248118485" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638787865248118485" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638787865248118485" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638787865248118485" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638787865248118485" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638787865248118485" order="6" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638787865248118485" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638787865248118485" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638787865248118485" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638787865248118485" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_638787865248128468" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_638787865248128468" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EffectiveIncomeTaxRateReconciliationWarrantValuationAmount" xlink:label="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationAmount_638787865248128468" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationAmount_638787865248128468" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_638787865248128468" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_638787865248128468" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638787865248128468" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638787865248128468" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_638787865248128468" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_638787865248128468" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638787865248128468" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638787865248128468" order="7" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails" xlink:type="extended" xlink:title="99941901 - Disclosure - Segment Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638787865248138468" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_1" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638787865248138468" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense" xlink:label="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense_638787865248138468" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense_638787865248138468" xlink:to="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense_638787865248138468" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" xlink:label="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense_638787865248138468" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense_638787865248138468" xlink:to="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense_638787865248138468" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseProfessionalFees" xlink:label="btai_ResearchAndDevelopmentExpenseProfessionalFees_638787865248138468" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense_638787865248138468" xlink:to="btai_ResearchAndDevelopmentExpenseProfessionalFees_638787865248138468" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense" xlink:label="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense_638787865248148466" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense_638787865248138468" xlink:to="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense_638787865248148466" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" xlink:label="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense_638787865248148466" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense_638787865248138468" xlink:to="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense_638787865248148466" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseTravelAndOtherExpenses" xlink:label="btai_ResearchAndDevelopmentExpenseTravelAndOtherExpenses_638787865248148466" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense_638787865248138468" xlink:to="btai_ResearchAndDevelopmentExpenseTravelAndOtherExpenses_638787865248148466" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating_638787865248148466" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_1" xlink:to="us-gaap_OtherCostAndExpenseOperating_638787865248148466" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsLaborAndRelatedExpense" xlink:label="btai_CommercialCostsLaborAndRelatedExpense_638787865248148466" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherCostAndExpenseOperating_638787865248148466" xlink:to="btai_CommercialCostsLaborAndRelatedExpense_638787865248148466" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsShareBasedPaymentArrangementExpense" xlink:label="btai_CommercialCostsShareBasedPaymentArrangementExpense_638787865248158489" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherCostAndExpenseOperating_638787865248148466" xlink:to="btai_CommercialCostsShareBasedPaymentArrangementExpense_638787865248158489" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsProfessionalFees" xlink:label="btai_CommercialCostsProfessionalFees_638787865248158489" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherCostAndExpenseOperating_638787865248148466" xlink:to="btai_CommercialCostsProfessionalFees_638787865248158489" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsCommercialAndMarketing" xlink:label="btai_CommercialCostsCommercialAndMarketing_638787865248158489" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherCostAndExpenseOperating_638787865248148466" xlink:to="btai_CommercialCostsCommercialAndMarketing_638787865248158489" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsTravelAndOtherExpenses" xlink:label="btai_CommercialCostsTravelAndOtherExpenses_638787865248158489" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherCostAndExpenseOperating_638787865248148466" xlink:to="btai_CommercialCostsTravelAndOtherExpenses_638787865248158489" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsOtherExpenses" xlink:label="btai_CommercialCostsOtherExpenses_638787865248158489" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherCostAndExpenseOperating_638787865248148466" xlink:to="btai_CommercialCostsOtherExpenses_638787865248158489" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638787865248158489" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_1" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638787865248158489" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" xlink:label="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense_638787865248168489" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense_638787865248158489" xlink:to="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense_638787865248168489" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" xlink:label="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense_638787865248168489" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense_638787865248158489" xlink:to="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense_638787865248168489" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SellingGeneralAndAdministrativeExpenseProfessionalFees" xlink:label="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees_638787865248168489" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense_638787865248158489" xlink:to="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees_638787865248168489" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" xlink:label="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses_638787865248168489" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense_638787865248158489" xlink:to="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses_638787865248168489" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SellingGeneralAndAdministrativeCostsOtherExpenses" xlink:label="btai_SellingGeneralAndAdministrativeCostsOtherExpenses_638787865248178494" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense_638787865248158489" xlink:to="btai_SellingGeneralAndAdministrativeCostsOtherExpenses_638787865248178494" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638787865248178494" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_1" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638787865248178494" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges_638787865248178494" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_1" xlink:to="us-gaap_RestructuringCharges_638787865248178494" order="5" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>23
<FILENAME>btai-20241231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/28/2025 7:22:09 PM-->
<!--Modified on: 3/28/2025 7:22:09 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity" roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureRestructuringDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureTransactionsWithBioxcelLlcDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureDebtAndCreditFacilitiesWarrantsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureDerivativeFinancialInstrumentsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureCommonStockFinancingActivitiesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureStockBasedCompensationDescriptionDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureStockBasedCompensationNonOptionsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureStockBasedCompensationOptionsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureStockBasedCompensationAssumptionsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureStockBasedCompensationExpenseDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureStockBasedCompensationEsppDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureFairValueMeasurementsHierarchyDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureFairValueMeasurementsLevel3Details" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureFairValueMeasurementsInputsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureFairValueMeasurementsWarrantsOutstandingDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureIncomeTaxesReconciliationDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureNetLossPerShareAntidilutiveDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureSegmentInformationDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
  <link:roleRef roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xlink:title="us-gaap_LiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:title="us-gaap_OtherLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_OtherLiabilitiesCurrent" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:title="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesNoncurrentAbstract To us-gaap_DerivativeLiabilitiesNoncurrent" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_1" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_DerivativeLiabilitiesNoncurrent_1" order="3" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcceleratedShareRepurchasesDateAxis" xlink:label="AcceleratedShareRepurchasesDateAxis" xlink:title="AcceleratedShareRepurchasesDateAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcceleratedShareRepurchasesDateDomain" xlink:label="AcceleratedShareRepurchasesDateDomain" xlink:title="AcceleratedShareRepurchasesDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AcceleratedShareRepurchasesDateAxis" xlink:to="AcceleratedShareRepurchasesDateDomain" xlink:title="definition: AcceleratedShareRepurchasesDateAxis to AcceleratedShareRepurchasesDateDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="GranteeStatusAxis" xlink:title="GranteeStatusAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="GranteeStatusDomain" xlink:title="GranteeStatusDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="GranteeStatusAxis" xlink:to="GranteeStatusDomain" xlink:title="definition: GranteeStatusAxis to GranteeStatusDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember" xlink:title="definition: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="CumulativeEffectPeriodOfAdoptionAxis" xlink:title="CumulativeEffectPeriodOfAdoptionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="CumulativeEffectPeriodOfAdoptionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CumulativeEffectPeriodOfAdoptionAxis" xlink:to="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="definition: CumulativeEffectPeriodOfAdoptionAxis to CumulativeEffectPeriodOfAdoptionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" xlink:title="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_1" xlink:title="srt_EquityMethodInvesteeNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" xlink:to="srt_EquityMethodInvesteeNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1 To srt_EquityMethodInvesteeNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:title="us-gaap_FairValueByMeasurementBasisAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" xlink:title="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementBasisAxis_1 To us-gaap_PortionAtFairValueFairValueDisclosureMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis_1" xlink:title="us-gaap_AwardDateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_1" xlink:title="us-gaap_AwardDateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardDateAxis_1" xlink:to="us-gaap_AwardDateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardDateAxis_1 To us-gaap_AwardDateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis_1" xlink:title="us-gaap_RestructuringCostAndReserveAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_1" xlink:title="us-gaap_TypeOfRestructuringDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RestructuringCostAndReserveAxis_1" xlink:to="us-gaap_TypeOfRestructuringDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RestructuringCostAndReserveAxis_1 To us-gaap_TypeOfRestructuringDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByBenchmarkAxis_1 To us-gaap_ConcentrationRiskBenchmarkDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="us-gaap_ConcentrationRiskTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="us-gaap_ConcentrationRiskTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByTypeAxis_1 To us-gaap_ConcentrationRiskTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_1" xlink:title="us-gaap_StatementBusinessSegmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_1" xlink:title="us-gaap_SegmentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementBusinessSegmentsAxis_1" xlink:to="us-gaap_SegmentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementBusinessSegmentsAxis_1 To us-gaap_SegmentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis_1" xlink:title="srt_ConsolidationItemsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_1" xlink:title="srt_ConsolidationItemsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidationItemsAxis_1" xlink:to="srt_ConsolidationItemsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidationItemsAxis_1 To srt_ConsolidationItemsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended" xlink:title="Individuals">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember" xlink:title="ecd_AllIndividualsMember" />
    <link:loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_VimalMehtaMember" xlink:label="btai_VimalMehtaMember" xlink:title="btai_VimalMehtaMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="btai_VimalMehtaMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To btai_VimalMehtaMember" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_RichardSteinhartMember" xlink:label="btai_RichardSteinhartMember" xlink:title="btai_RichardSteinhartMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="btai_RichardSteinhartMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To btai_RichardSteinhartMember" order="2" priority="0" />
    <link:loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_JavierRodriguezMember" xlink:label="btai_JavierRodriguezMember" xlink:title="btai_JavierRodriguezMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="btai_JavierRodriguezMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To btai_JavierRodriguezMember" order="3" priority="0" />
    <link:loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_MatthewWileyMember" xlink:label="btai_MatthewWileyMember" xlink:title="btai_MatthewWileyMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="btai_MatthewWileyMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To btai_MatthewWileyMember" order="4" priority="0" />
    <link:loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_FrankYoccaMember" xlink:label="btai_FrankYoccaMember" xlink:title="btai_FrankYoccaMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="btai_FrankYoccaMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To btai_FrankYoccaMember" order="5" priority="0" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_NonrelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_InterestPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity" xlink:type="extended" xlink:title="995200300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xlink:label="btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="99931203 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_RestrictedStockUnitsOnkosxcelMember" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="btai_RestrictedStockUnitsOnkosxcelMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TimeBasedProfitSharingUnitsMember" xlink:label="btai_TimeBasedProfitSharingUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="btai_TimeBasedProfitSharingUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_AccountsReceivablePaymentTerm" xlink:label="btai_AccountsReceivablePaymentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="btai_AccountsReceivablePaymentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsDetails" xlink:type="extended" xlink:title="99940302 - Disclosure - Summary of Significant Accounting Policies - Concentrations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CustomerOneMember" xlink:label="btai_CustomerOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="btai_CustomerOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Restructuring (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCost1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserveCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Property and equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Transactions with BioXcel LLC (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_BioxcelCorporationMember" xlink:label="btai_BioxcelCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="btai_BioxcelCorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DevelopmentMilestonesMember" xlink:label="btai_DevelopmentMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="btai_DevelopmentMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SalesMilestonesMember" xlink:label="btai_SalesMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="btai_SalesMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" xlink:label="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CollaborativeArrangementMilestonePaymentsPotential" xlink:label="btai_CollaborativeArrangementMilestonePaymentsPotential" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="btai_CollaborativeArrangementMilestonePaymentsPotential" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CollaborativeArrangementMilestonePotentialPercent" xlink:label="btai_CollaborativeArrangementMilestonePotentialPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="btai_CollaborativeArrangementMilestonePotentialPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CostsAndExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Debt and Credit Facilities - Debt summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OfaAdministrativeAgentMember" xlink:label="btai_OfaAdministrativeAgentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="btai_OfaAdministrativeAgentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CreditFacilityMember" xlink:label="btai_CreditFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="btai_OfaAdministrativeAgentMember" xlink:to="btai_CreditFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Debt and Credit Facilities - Credit Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OfaAdministrativeAgentMember" xlink:label="btai_OfaAdministrativeAgentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="btai_OfaAdministrativeAgentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CreditFacilityMember" xlink:label="btai_CreditFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="btai_OfaAdministrativeAgentMember" xlink:to="btai_CreditFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TrancheMember" xlink:label="btai_TrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_TrancheMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TrancheTwoMember" xlink:label="btai_TrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_TrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TrancheBMember" xlink:label="btai_TrancheBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_TrancheBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TrancheCMember" xlink:label="btai_TrancheCMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_TrancheCMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TrancheDMember" xlink:label="btai_TrancheDMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_TrancheDMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_FromAndAfterFundingOfTrancheBLoansMember" xlink:label="btai_FromAndAfterFundingOfTrancheBLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_FromAndAfterFundingOfTrancheBLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" xlink:label="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PeriodOneMember" xlink:label="btai_PeriodOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_PeriodOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PeriodTwoMember" xlink:label="btai_PeriodTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_PeriodTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PeriodThreeMember" xlink:label="btai_PeriodThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_PeriodThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_LineOfCreditFacilityInvestmentAllowed" xlink:label="btai_LineOfCreditFacilityInvestmentAllowed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_LineOfCreditFacilityInvestmentAllowed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_LineOfCreditFacilityAmendmentFeePercentage" xlink:label="btai_LineOfCreditFacilityAmendmentFeePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_LineOfCreditFacilityAmendmentFeePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_LineOfCreditFacilityExitFeePercentage" xlink:label="btai_LineOfCreditFacilityExitFeePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_LineOfCreditFacilityExitFeePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EquityInvestmentRightAmountUnfunded" xlink:label="btai_EquityInvestmentRightAmountUnfunded" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_EquityInvestmentRightAmountUnfunded" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DebtInstrumentInterestRateDiscountRatePercentage" xlink:label="btai_DebtInstrumentInterestRateDiscountRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_DebtInstrumentInterestRateDiscountRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DebtInstrumentIncrementalOnVariableRatePercent" xlink:label="btai_DebtInstrumentIncrementalOnVariableRatePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_DebtInstrumentIncrementalOnVariableRatePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PaidInKindInterestPercentage" xlink:label="btai_PaidInKindInterestPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_PaidInKindInterestPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TickingFeesPercentage" xlink:label="btai_TickingFeesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_TickingFeesPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_NetCashRequiredMinimum" xlink:label="btai_NetCashRequiredMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_NetCashRequiredMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" xlink:label="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SubsidiaryOwnershipPercentage" xlink:label="btai_SubsidiaryOwnershipPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_SubsidiaryOwnershipPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PercentageOfOutstandingLoan" xlink:label="btai_PercentageOfOutstandingLoan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_PercentageOfOutstandingLoan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" xlink:label="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded" xlink:label="btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod" xlink:label="btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" xlink:type="extended" xlink:title="99940903 - Disclosure - Debt and Credit Facilities - Revenue Interest Financing (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_RevenueInterestFinancingAgreementMember" xlink:label="btai_RevenueInterestFinancingAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="btai_RevenueInterestFinancingAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TrancheMember" xlink:label="btai_TrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_TrancheMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_BorrowingsBasedOnNetSalesPercent" xlink:label="btai_BorrowingsBasedOnNetSalesPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_BorrowingsBasedOnNetSalesPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ThresholdRatioOfDebtToRevenueRatio" xlink:label="btai_ThresholdRatioOfDebtToRevenueRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_ThresholdRatioOfDebtToRevenueRatio" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" xlink:type="extended" xlink:title="99940904 - Disclosure - Debt and Credit Facilities - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_WarrantOaktreeAndQiaMember" xlink:label="btai_WarrantOaktreeAndQiaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_WarrantOaktreeAndQiaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_NewWarrantsMember" xlink:label="btai_NewWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_NewWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OriginalWarrantsMember" xlink:label="btai_OriginalWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_OriginalWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_WarrantShares2024Member" xlink:label="btai_WarrantShares2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_WarrantShares2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OnkosxcelWarrantMember" xlink:label="btai_OnkosxcelWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_OnkosxcelWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_RightToPurchaseStockLenders" xlink:label="btai_RightToPurchaseStockLenders" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_RightToPurchaseStockLenders" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PremiumSharePricePercent" xlink:label="btai_PremiumSharePricePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_PremiumSharePricePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" xlink:label="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PercentageOfFairValueConsiderationToBePaid" xlink:label="btai_PercentageOfFairValueConsiderationToBePaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_PercentageOfFairValueConsiderationToBePaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PercentageOfValuationApplicableToInitialProfits" xlink:label="btai_PercentageOfValuationApplicableToInitialProfits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_PercentageOfValuationApplicableToInitialProfits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Derivative Financial Instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EquityInvestmentMember" xlink:label="btai_EquityInvestmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_EquityInvestmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2024AccompanyingWarrantsMember" xlink:label="btai_Warrants2024AccompanyingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_Warrants2024AccompanyingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" xlink:label="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="btai_Warrants2024AccompanyingWarrantsMember" xlink:to="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_November2024AccompanyingWarrantsMember" xlink:label="btai_November2024AccompanyingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_November2024AccompanyingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Common Stock Financing Activities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_JefferiesMember" xlink:label="btai_JefferiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="btai_JefferiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_RegisteredDirectOfferingMember" xlink:label="btai_RegisteredDirectOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="btai_RegisteredDirectOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_RegisteredOfferingMember" xlink:label="btai_RegisteredOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="btai_RegisteredOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2024AccompanyingWarrantsMember" xlink:label="btai_Warrants2024AccompanyingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_Warrants2024AccompanyingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2024PreFundedWarrantsMember" xlink:label="btai_Warrants2024PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_Warrants2024PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_November2024AccompanyingWarrantsMember" xlink:label="btai_November2024AccompanyingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_November2024AccompanyingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_November2024PrefundedAccompanyingWarrantsMember" xlink:label="btai_November2024PrefundedAccompanyingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_November2024PrefundedAccompanyingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SaleOfStockMaximumValueSharesToBeIssued" xlink:label="btai_SaleOfStockMaximumValueSharesToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="btai_SaleOfStockMaximumValueSharesToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="btai_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Stock-Based Compensation - Description (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_IncentiveAwardPlan2020Member" xlink:label="btai_IncentiveAwardPlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="btai_IncentiveAwardPlan2020Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_StockPlan2017Member" xlink:label="btai_StockPlan2017Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="btai_StockPlan2017Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" xlink:type="extended" xlink:title="99941202 - Disclosure - Stock-Based Compensation - Non-options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TimeBasedProfitSharingUnitsMember" xlink:label="btai_TimeBasedProfitSharingUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="btai_TimeBasedProfitSharingUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_RestrictedStockUnitsOnkosxcelMember" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="btai_RestrictedStockUnitsOnkosxcelMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" xlink:type="extended" xlink:title="99941203 - Disclosure - Stock-Based Compensation - Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:label="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xlink:type="extended" xlink:title="99941204 - Disclosure - Stock-Based Compensation - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TimeBasedProfitSharingUnitsMember" xlink:label="btai_TimeBasedProfitSharingUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="btai_TimeBasedProfitSharingUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="99941205 - Disclosure - Stock-Based Compensation - Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" xlink:type="extended" xlink:title="99941206 - Disclosure - Stock-Based Compensation - ESPP (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EmployeeStockPurchasePlan2020Member" xlink:label="btai_EmployeeStockPurchasePlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="btai_EmployeeStockPurchasePlan2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" xlink:label="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" xlink:type="extended" xlink:title="99941501 - Disclosure - Fair Value Measurements - Hierarchy (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OnkosxcelWarrantMember" xlink:label="btai_OnkosxcelWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_OnkosxcelWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_BioxcelWarrantsAggregateMember" xlink:label="btai_BioxcelWarrantsAggregateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_BioxcelWarrantsAggregateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details" xlink:type="extended" xlink:title="99941502 - Disclosure - Fair Value Measurements - Level 3 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EquityInvestmentMember" xlink:label="btai_EquityInvestmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_EquityInvestmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" xlink:type="extended" xlink:title="99941503 - Disclosure - Fair Value Measurements - Inputs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EquityInvestmentMember" xlink:label="btai_EquityInvestmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_EquityInvestmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OnkosxcelWarrantMember" xlink:label="btai_OnkosxcelWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_OnkosxcelWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_WarrantOaktreeAndQiaMember" xlink:label="btai_WarrantOaktreeAndQiaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_WarrantOaktreeAndQiaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2023Member" xlink:label="btai_Warrants2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_Warrants2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2024Member" xlink:label="btai_Warrants2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_Warrants2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2024AccompanyingWarrantsMember" xlink:label="btai_Warrants2024AccompanyingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_Warrants2024AccompanyingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" xlink:label="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="btai_Warrants2024AccompanyingWarrantsMember" xlink:to="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" xlink:label="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="btai_Warrants2024AccompanyingWarrantsMember" xlink:to="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_November2024AccompanyingWarrantsMember" xlink:label="btai_November2024AccompanyingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_November2024AccompanyingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_MeasurementInputProbabilityOfExerciseMember" xlink:label="btai_MeasurementInputProbabilityOfExerciseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="btai_MeasurementInputProbabilityOfExerciseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_MeasurementInputEstimatedPremiumMember" xlink:label="btai_MeasurementInputEstimatedPremiumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="btai_MeasurementInputEstimatedPremiumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails" xlink:type="extended" xlink:title="99941504 - Disclosure - Fair Value Measurements - Warrants outstanding (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_WarrantOaktreeAndQiaMember" xlink:label="btai_WarrantOaktreeAndQiaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_WarrantOaktreeAndQiaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2023Member" xlink:label="btai_Warrants2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_Warrants2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_WarrantShares2024Member" xlink:label="btai_WarrantShares2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_WarrantShares2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_NewWarrantsMember" xlink:label="btai_NewWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_NewWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" xlink:label="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" xlink:label="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_November2024AccompanyingWarrantsMember" xlink:label="btai_November2024AccompanyingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_November2024AccompanyingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ArmisticeCapitalMasterFundMember" xlink:label="btai_ArmisticeCapitalMasterFundMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="btai_ArmisticeCapitalMasterFundMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_HeightsCapitalManagementMember" xlink:label="btai_HeightsCapitalManagementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="btai_HeightsCapitalManagementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_HudsonBayCapitalManagementMember" xlink:label="btai_HudsonBayCapitalManagementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="btai_HudsonBayCapitalManagementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_IntraCoastalCapitalMember" xlink:label="btai_IntraCoastalCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="btai_IntraCoastalCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails" xlink:type="extended" xlink:title="99941602 - Disclosure - Income Taxes - Reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EffectiveIncomeTaxRateReconciliationWarrantValuationAmount" xlink:label="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EffectiveIncomeTaxRateReconciliationWarrantValuationPercent" xlink:label="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OperatingLossCarryforwardsNoExpiration" xlink:label="btai_OperatingLossCarryforwardsNoExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="btai_OperatingLossCarryforwardsNoExpiration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails" xlink:type="extended" xlink:title="99941702 - Disclosure - Net Loss Per Share - Antidilutive (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_BioxcelWarrantsAggregateMember" xlink:label="btai_BioxcelWarrantsAggregateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="btai_BioxcelWarrantsAggregateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99941801 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ContractualObligationDueInSecondYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails" xlink:type="extended" xlink:title="99941901 - Disclosure - Segment Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SingleReportableSegmentMember" xlink:label="btai_SingleReportableSegmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="btai_SingleReportableSegmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="srt_ConsolidationItemsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense" xlink:label="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" xlink:label="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseProfessionalFees" xlink:label="btai_ResearchAndDevelopmentExpenseProfessionalFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="btai_ResearchAndDevelopmentExpenseProfessionalFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense" xlink:label="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" xlink:label="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseTravelAndOtherExpenses" xlink:label="btai_ResearchAndDevelopmentExpenseTravelAndOtherExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="btai_ResearchAndDevelopmentExpenseTravelAndOtherExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectOperatingCostsAbstract" xlink:label="us-gaap_DirectOperatingCostsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_DirectOperatingCostsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsLaborAndRelatedExpense" xlink:label="btai_CommercialCostsLaborAndRelatedExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DirectOperatingCostsAbstract" xlink:to="btai_CommercialCostsLaborAndRelatedExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsShareBasedPaymentArrangementExpense" xlink:label="btai_CommercialCostsShareBasedPaymentArrangementExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DirectOperatingCostsAbstract" xlink:to="btai_CommercialCostsShareBasedPaymentArrangementExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsProfessionalFees" xlink:label="btai_CommercialCostsProfessionalFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DirectOperatingCostsAbstract" xlink:to="btai_CommercialCostsProfessionalFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsCommercialAndMarketing" xlink:label="btai_CommercialCostsCommercialAndMarketing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DirectOperatingCostsAbstract" xlink:to="btai_CommercialCostsCommercialAndMarketing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsTravelAndOtherExpenses" xlink:label="btai_CommercialCostsTravelAndOtherExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DirectOperatingCostsAbstract" xlink:to="btai_CommercialCostsTravelAndOtherExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsOtherExpenses" xlink:label="btai_CommercialCostsOtherExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DirectOperatingCostsAbstract" xlink:to="btai_CommercialCostsOtherExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DirectOperatingCostsAbstract" xlink:to="us-gaap_OtherCostAndExpenseOperating" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" xlink:label="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" xlink:label="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SellingGeneralAndAdministrativeExpenseProfessionalFees" xlink:label="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" xlink:label="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SellingGeneralAndAdministrativeCostsOtherExpenses" xlink:label="btai_SellingGeneralAndAdministrativeCostsOtherExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="btai_SellingGeneralAndAdministrativeCostsOtherExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_RestructuringCharges" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_CostsAndExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99942001 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_RegisteredOfferingMember" xlink:label="btai_RegisteredOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="btai_RegisteredOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PurchaseAgreementRegisteredSecuritiesMember" xlink:label="btai_PurchaseAgreementRegisteredSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="btai_PurchaseAgreementRegisteredSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_November2024AccompanyingWarrantsMember" xlink:label="btai_November2024AccompanyingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_November2024AccompanyingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_November2024PrefundedAccompanyingWarrantsMember" xlink:label="btai_November2024PrefundedAccompanyingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_November2024PrefundedAccompanyingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_AccompanyingWarrantsMarch2025Member" xlink:label="btai_AccompanyingWarrantsMarch2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_AccompanyingWarrantsMarch2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PrefundedWarrantsMarch2025Member" xlink:label="btai_PrefundedWarrantsMarch2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_PrefundedWarrantsMarch2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OptionWarrantsMarch2025Member" xlink:label="btai_OptionWarrantsMarch2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_OptionWarrantsMarch2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="btai_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>24
<FILENAME>btai-20241231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/28/2025 7:22:09 PM-->
<!--Modified on: 3/28/2025 7:22:09 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Act File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related and Nonrelated Parties [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related and Nonrelated Parties [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonrelated Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonrelated Party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term portion of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant derivative liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Excluding Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 18)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' (deficit) equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.001 par value, 10,000 shares authorized; no shares issued and outstanding as of December 31, 2024 and December 31, 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.001 par value, 200,000 and 100,000 shares authorized as of December 31, 2024 and December 31, 2023, respectively; 3,102 and 1,871 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in-capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' (deficit) equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' (deficit) equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product revenue, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods and Services Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total research and development costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total selling, general and administrative costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (income) expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Nonoperating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (income) expense, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss (numerator)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net loss per share attributable to common stockholders (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net loss per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net loss per share attributable to common stockholders (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net loss per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares (denominator) - basic (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares outstanding - basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares outstanding - diluted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares (denominator) - diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of offering costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repricing of stock purchase warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock purchase warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xlink:label="btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xlink:to="btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase in additional paid in capital (APIC) resulting from the issuance of pre-funded warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments To Additional Paid In Capital, Pre Funded Warrant Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of pre-funded stock purchase warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock, Value, Shares Issued Net of Tax Withholdings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted stock units, net of employee tax obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted stock units, net of employee tax obligations (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OPERATING CASH FLOW ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of net loss to net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Issuance Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of debt discount and amortization of financing costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative, Gain (Loss) on Derivative, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of derivative liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paid-in-Kind Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payable-in-kind interest on Credit Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on disposal of equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts and Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses, other current assets and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable, accrued expenses, due to related parties, and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Interest Payable, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INVESTING CASH FLOW ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of equipment and leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash from investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FINANCING CASH FLOW ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock and warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issuance Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Long-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of principal of Long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of principal of Long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs for common stock and warrants issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment, Tax Withholding, Share-Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of employee tax obligations related to vesting restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net decrease in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, beginning of the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental cash flow information:</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_FairValueStockPurchaseWarrants" xlink:label="btai_FairValueStockPurchaseWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_FairValueStockPurchaseWarrants" xlink:to="btai_FairValueStockPurchaseWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_FairValueStockPurchaseWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of issues of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_FairValueStockPurchaseWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Stock Purchase Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_FairValueStockPurchaseWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock purchase warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repricing of stock purchase warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value adjustment warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ConversionOfAccruedInterestToLongTermDebt" xlink:label="btai_ConversionOfAccruedInterestToLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ConversionOfAccruedInterestToLongTermDebt" xlink:to="btai_ConversionOfAccruedInterestToLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ConversionOfAccruedInterestToLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The total amount of accrued interest that is converted into long erm debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ConversionOfAccruedInterestToLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion Of Accrued Interest To Long-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="btai_ConversionOfAccruedInterestToLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of accrued interest to long-term debt</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OrganizationAndPrincipalActivitiesAbstract" xlink:label="btai_OrganizationAndPrincipalActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_OrganizationAndPrincipalActivitiesAbstract" xlink:to="btai_OrganizationAndPrincipalActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_OrganizationAndPrincipalActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_OrganizationAndPrincipalActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of the Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of the Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transactions with BioXcel LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transactions with BioXcel LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt and Credit Facilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt and Credit Facilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_FinancingActivitiesAbstract" xlink:label="btai_FinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_FinancingActivitiesAbstract" xlink:to="btai_FinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_FinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_FinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Financing Activities</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_FinancingActivitiesDisclosureTextBlock" xlink:label="btai_FinancingActivitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_FinancingActivitiesDisclosureTextBlock" xlink:to="btai_FinancingActivitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_FinancingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for Financing Activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_FinancingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_FinancingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Financing Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAbstract" xlink:label="us-gaap_DefinedBenefitPlanAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_DefinedBenefitPlanAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:label="us-gaap_DefinedBenefitPlanTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanTextBlock" xlink:to="us-gaap_DefinedBenefitPlanTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ReverseStockSplit" xlink:label="btai_ReverseStockSplit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ReverseStockSplit" xlink:to="btai_ReverseStockSplit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ReverseStockSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy - Reverse stock split.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ReverseStockSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ReverseStockSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Stock Split</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DeferredOfferingCostsPolicyTextBlock" xlink:label="btai_DeferredOfferingCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_DeferredOfferingCostsPolicyTextBlock" xlink:to="btai_DeferredOfferingCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_DeferredOfferingCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for deferred offering costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_DeferredOfferingCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_DeferredOfferingCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Initial Public Offering Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt and Detachable Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivatives, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Assets and Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure" xlink:label="us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure" xlink:to="us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition Accounting Policy, Gross and Net Revenue Disclosure [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods and Service [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods Sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PatentCostsPolicyTextBlock" xlink:label="btai_PatentCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PatentCostsPolicyTextBlock" xlink:to="btai_PatentCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for patent costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent Costs [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings (Loss) Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:to="btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of Property Plant And Equipment Useful Lives.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property Plant And Equipment Useful Lives [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of property and equipment useful lives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of service charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-Term Debt Instruments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Maturities of Long-Term Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of maturities on long-term debt</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock" xlink:label="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock" xlink:to="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of interest expense associated with long-term debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Interest Expense Associated with Long Term Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of long-term debt interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BTI RSU</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BTI PSU</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TimeBasedProfitSharingUnitsMember" xlink:label="btai_TimeBasedProfitSharingUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_TimeBasedProfitSharingUnitsMember" xlink:to="btai_TimeBasedProfitSharingUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_TimeBasedProfitSharingUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to OnkosXcel time based profit-sharing units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_TimeBasedProfitSharingUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Time Based Profit Sharing Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_TimeBasedProfitSharingUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OnkosXcel PSU</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_RestrictedStockUnitsOnkosxcelMember" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_RestrictedStockUnitsOnkosxcelMember" xlink:to="btai_RestrictedStockUnitsOnkosxcelMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share instrument associated with OnkosXcel, which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units Onkosxcel [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OnkosXcel RSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of activity relating to RSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Performance-Based Units, Vested and Expected to Vest [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of activity relating to PSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Valuation Assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of maturities of the operating lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of changes in Level 3 liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value unobservable inputs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of effective tax rate and statutory rate reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of potentially dilutive securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reportable segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock split</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_AccountsReceivablePaymentTerm" xlink:label="btai_AccountsReceivablePaymentTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_AccountsReceivablePaymentTerm" xlink:to="btai_AccountsReceivablePaymentTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_AccountsReceivablePaymentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The credit period offered to customers or receivables by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_AccountsReceivablePaymentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Payment Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_AccountsReceivablePaymentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable payment term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Useful life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Product and Service Benchmark [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue benchmark</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer Concentration Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer concentration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CustomerOneMember" xlink:label="btai_CustomerOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CustomerOneMember" xlink:to="btai_CustomerOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CustomerOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer classified as one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CustomerOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CustomerOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer one</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration risk (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Cost [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Restructuring [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeSeveranceMember" xlink:to="us-gaap_EmployeeSeveranceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Severance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance and benefit costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractTerminationMember" xlink:to="us-gaap_ContractTerminationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractTerminationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Termination [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractTerminationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract termination costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Cost and Reserve [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees eliminated (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Restructuring</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for restructuring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Cost, Number of Positions Eliminated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees eliminated</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCost1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Cost, Expected Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected total restructuring charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Reserve, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued restructuring costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Raw Materials, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw materials</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Work in Process, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Work-in-process</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Finished Goods, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Write-down</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory write-downs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computers and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_AccruedResearchAndDevelopmentExpenses" xlink:label="btai_AccruedResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_AccruedResearchAndDevelopmentExpenses" xlink:to="btai_AccruedResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of accrued research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation and benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued professional fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_BioxcelCorporationMember" xlink:label="btai_BioxcelCorporationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_BioxcelCorporationMember" xlink:to="btai_BioxcelCorporationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_BioxcelCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents BioXcel LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_BioxcelCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BioXcel Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_BioxcelCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BioXcel LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement [Member]</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DevelopmentMilestonesMember" xlink:label="btai_DevelopmentMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_DevelopmentMilestonesMember" xlink:to="btai_DevelopmentMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_DevelopmentMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development milestones defined by the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_DevelopmentMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_DevelopmentMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development milestones</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SalesMilestonesMember" xlink:label="btai_SalesMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_SalesMilestonesMember" xlink:to="btai_SalesMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_SalesMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales milestones are payable when annual sales reach certain levels.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_SalesMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_SalesMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales milestones</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transactions with BioXcel</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" xlink:label="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" xlink:to="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of fees per month to be paid to enter into collaborative service agreement option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Fees Per Month to Enter into Collaborative Service Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Monthly agreement option fees</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CollaborativeArrangementMilestonePaymentsPotential" xlink:label="btai_CollaborativeArrangementMilestonePaymentsPotential" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CollaborativeArrangementMilestonePaymentsPotential" xlink:to="btai_CollaborativeArrangementMilestonePaymentsPotential_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CollaborativeArrangementMilestonePaymentsPotential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of potential maximum payments that could be paid under the collaborative agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CollaborativeArrangementMilestonePaymentsPotential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Milestone Payments Potential</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CollaborativeArrangementMilestonePaymentsPotential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential milestone payments</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CollaborativeArrangementMilestonePotentialPercent" xlink:label="btai_CollaborativeArrangementMilestonePotentialPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CollaborativeArrangementMilestonePotentialPercent" xlink:to="btai_CollaborativeArrangementMilestonePotentialPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CollaborativeArrangementMilestonePotentialPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the maximum percentage of net sales payable under a collaborative agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CollaborativeArrangementMilestonePotentialPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Milestone Potential Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CollaborativeArrangementMilestonePotentialPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum milestone (as as percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-Term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OfaAdministrativeAgentMember" xlink:label="btai_OfaAdministrativeAgentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_OfaAdministrativeAgentMember" xlink:to="btai_OfaAdministrativeAgentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_OfaAdministrativeAgentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents OFA as debt administrative agent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_OfaAdministrativeAgentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OFA Administrative Agent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_OfaAdministrativeAgentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OFA</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CreditFacilityMember" xlink:label="btai_CreditFacilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CreditFacilityMember" xlink:to="btai_CreditFacilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CreditFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information related to a Credit Agreement and Guaranty (the "Credit Agreement").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CreditFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CreditFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Increase, Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total long-term debt liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unamortized debt premiums, discounts and issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TrancheMember" xlink:label="btai_TrancheMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_TrancheMember" xlink:to="btai_TrancheMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_TrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Tranche A.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_TrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche A</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TrancheTwoMember" xlink:label="btai_TrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_TrancheTwoMember" xlink:to="btai_TrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_TrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Tranche A2.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_TrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche A Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_TrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche A-2</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TrancheBMember" xlink:label="btai_TrancheBMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_TrancheBMember" xlink:to="btai_TrancheBMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_TrancheBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Tranche B.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_TrancheBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche B</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TrancheCMember" xlink:label="btai_TrancheCMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_TrancheCMember" xlink:to="btai_TrancheCMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_TrancheCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Tranche C.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_TrancheCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche C</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TrancheDMember" xlink:label="btai_TrancheDMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_TrancheDMember" xlink:to="btai_TrancheDMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_TrancheDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Tranche D.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_TrancheDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche D [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_TrancheDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche D</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_FromAndAfterFundingOfTrancheBLoansMember" xlink:label="btai_FromAndAfterFundingOfTrancheBLoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_FromAndAfterFundingOfTrancheBLoansMember" xlink:to="btai_FromAndAfterFundingOfTrancheBLoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_FromAndAfterFundingOfTrancheBLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the statement scenario, from and after the funding of Tranche B loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_FromAndAfterFundingOfTrancheBLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">From and After Funding of Tranche B Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_FromAndAfterFundingOfTrancheBLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">From and after the funding of Tranche B loans</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" xlink:label="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" xlink:to="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the statement scenario, from and after satisfaction of the funding conditions for the Tranche C loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">From and After Satisfaction of Funding Conditions for Tranche C Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">From and after satisfaction of funding conditions for tranche C loans</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PeriodOneMember" xlink:label="btai_PeriodOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PeriodOneMember" xlink:to="btai_PeriodOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PeriodOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information reported for the first period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PeriodOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PeriodOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period one</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PeriodTwoMember" xlink:label="btai_PeriodTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PeriodTwoMember" xlink:to="btai_PeriodTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PeriodTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information reported for the second period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PeriodTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PeriodTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period two</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PeriodThreeMember" xlink:label="btai_PeriodThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PeriodThreeMember" xlink:to="btai_PeriodThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PeriodThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information reported for the third period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PeriodThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PeriodThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period three</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_LineOfCreditFacilityInvestmentAllowed" xlink:label="btai_LineOfCreditFacilityInvestmentAllowed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_LineOfCreditFacilityInvestmentAllowed" xlink:to="btai_LineOfCreditFacilityInvestmentAllowed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_LineOfCreditFacilityInvestmentAllowed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount the Lenders agree to permit the entity to invest in subsidiary.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_LineOfCreditFacilityInvestmentAllowed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Investment Allowed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_LineOfCreditFacilityInvestmentAllowed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum investment allowed</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Fee Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument fee</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_LineOfCreditFacilityAmendmentFeePercentage" xlink:label="btai_LineOfCreditFacilityAmendmentFeePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_LineOfCreditFacilityAmendmentFeePercentage" xlink:to="btai_LineOfCreditFacilityAmendmentFeePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_LineOfCreditFacilityAmendmentFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The line of credit facility fee for credit agreement amendment based on a loans outstanding, expressed as a percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_LineOfCreditFacilityAmendmentFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Amendment Fee Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_LineOfCreditFacilityAmendmentFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment fee (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_LineOfCreditFacilityExitFeePercentage" xlink:label="btai_LineOfCreditFacilityExitFeePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_LineOfCreditFacilityExitFeePercentage" xlink:to="btai_LineOfCreditFacilityExitFeePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_LineOfCreditFacilityExitFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The line of credit facility exit fee, expressed as a percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_LineOfCreditFacilityExitFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Exit Fee Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_LineOfCreditFacilityExitFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exit fee (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Face amount borrowed</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Remaining Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EquityInvestmentRightAmountUnfunded" xlink:label="btai_EquityInvestmentRightAmountUnfunded" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_EquityInvestmentRightAmountUnfunded" xlink:to="btai_EquityInvestmentRightAmountUnfunded_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_EquityInvestmentRightAmountUnfunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The total amount of equity investment right in the OFA that is currently unfunded.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_EquityInvestmentRightAmountUnfunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Investment Right, Amount Unfunded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_EquityInvestmentRightAmountUnfunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Investment Right</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Effective Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DebtInstrumentInterestRateDiscountRatePercentage" xlink:label="btai_DebtInstrumentInterestRateDiscountRatePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_DebtInstrumentInterestRateDiscountRatePercentage" xlink:to="btai_DebtInstrumentInterestRateDiscountRatePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_DebtInstrumentInterestRateDiscountRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of  basis point original issue discount at which the borrowings under the credit agreement are issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_DebtInstrumentInterestRateDiscountRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Interest Rate, Discount Rate Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_DebtInstrumentInterestRateDiscountRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DebtInstrumentIncrementalOnVariableRatePercent" xlink:label="btai_DebtInstrumentIncrementalOnVariableRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_DebtInstrumentIncrementalOnVariableRatePercent" xlink:to="btai_DebtInstrumentIncrementalOnVariableRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_DebtInstrumentIncrementalOnVariableRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental percentage points added to the reference rate and variable rate on the debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_DebtInstrumentIncrementalOnVariableRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Incremental on Variable Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_DebtInstrumentIncrementalOnVariableRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PaidInKindInterestPercentage" xlink:label="btai_PaidInKindInterestPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PaidInKindInterestPercentage" xlink:to="btai_PaidInKindInterestPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PaidInKindInterestPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paid-in-kind interest rate for funds borrowed, under the debt agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PaidInKindInterestPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paid-in-Kind Interest, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PaidInKindInterestPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt paid-in-kind interest (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TickingFeesPercentage" xlink:label="btai_TickingFeesPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_TickingFeesPercentage" xlink:to="btai_TickingFeesPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_TickingFeesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents ticking fees percentage relating to debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_TickingFeesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ticking Fees Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_TickingFeesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ticking fee (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_NetCashRequiredMinimum" xlink:label="btai_NetCashRequiredMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_NetCashRequiredMinimum" xlink:to="btai_NetCashRequiredMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_NetCashRequiredMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum maintenance of cash or permitted cash equivalent investments in accounts controlled by lenders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_NetCashRequiredMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Required, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_NetCashRequiredMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash maintenance in controlled accounts</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" xlink:label="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" xlink:to="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum liquidity required per the financial covenant of debt agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Financial Covenant, Minimum Liquidity Requirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Liquidity Amount</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SubsidiaryOwnershipPercentage" xlink:label="btai_SubsidiaryOwnershipPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_SubsidiaryOwnershipPercentage" xlink:to="btai_SubsidiaryOwnershipPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_SubsidiaryOwnershipPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of ownership of common stock of subsidiary.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_SubsidiaryOwnershipPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary Ownership, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_SubsidiaryOwnershipPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary ownership (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PercentageOfOutstandingLoan" xlink:label="btai_PercentageOfOutstandingLoan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PercentageOfOutstandingLoan" xlink:to="btai_PercentageOfOutstandingLoan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PercentageOfOutstandingLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of outstanding Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PercentageOfOutstandingLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Outstanding Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PercentageOfOutstandingLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding loan (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" xlink:label="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" xlink:to="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum amount of gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants for debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Gross Proceeds From The Issuance of Common Stock, Warrants And (Or) Pre-funded Warrants For Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum revenue required from equity sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock and warrant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed rate</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded" xlink:label="btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded" xlink:to="btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the quarterly amortization payments as percentage of principal amount of funded loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Quarterly Amortization Payments as Percentage of Principal Amount Funded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal payment of loans (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod" xlink:label="btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod" xlink:to="btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum percentage of budgeted amount allowed for disbursement in applicable period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Percentage Of Budgeted Amount For Disbursements in Applicable Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum percentage of budgeted amount allowed for disbursement</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_RevenueInterestFinancingAgreementMember" xlink:label="btai_RevenueInterestFinancingAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_RevenueInterestFinancingAgreementMember" xlink:to="btai_RevenueInterestFinancingAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_RevenueInterestFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information related to the Revenue Interest Financing agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_RevenueInterestFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_RevenueInterestFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue interest financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extinguishment of Debt, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt extinguishment</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_BorrowingsBasedOnNetSalesPercent" xlink:label="btai_BorrowingsBasedOnNetSalesPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_BorrowingsBasedOnNetSalesPercent" xlink:to="btai_BorrowingsBasedOnNetSalesPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_BorrowingsBasedOnNetSalesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the maximum borrowings allowed based on a percentage of net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_BorrowingsBasedOnNetSalesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings Based on Net Sales, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_BorrowingsBasedOnNetSalesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowing allowed per net sales (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ThresholdRatioOfDebtToRevenueRatio" xlink:label="btai_ThresholdRatioOfDebtToRevenueRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ThresholdRatioOfDebtToRevenueRatio" xlink:to="btai_ThresholdRatioOfDebtToRevenueRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ThresholdRatioOfDebtToRevenueRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents threshold ratio for debt to revenue ratio.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ThresholdRatioOfDebtToRevenueRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Ratio of Debt to Revenue Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ThresholdRatioOfDebtToRevenueRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt to revenue multiplier</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_WarrantOaktreeAndQiaMember" xlink:label="btai_WarrantOaktreeAndQiaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_WarrantOaktreeAndQiaMember" xlink:to="btai_WarrantOaktreeAndQiaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_WarrantOaktreeAndQiaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information related to the Oaktree (OFA) issued April 2022.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_WarrantOaktreeAndQiaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Oaktree and Qia [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_WarrantOaktreeAndQiaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing Date Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_NewWarrantsMember" xlink:label="btai_NewWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_NewWarrantsMember" xlink:to="btai_NewWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_NewWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the warrants issued per the credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_NewWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_NewWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OriginalWarrantsMember" xlink:label="btai_OriginalWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_OriginalWarrantsMember" xlink:to="btai_OriginalWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_OriginalWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the Original Warrants issued per the credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_OriginalWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Original Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_OriginalWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Original Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_WarrantShares2024Member" xlink:label="btai_WarrantShares2024Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_WarrantShares2024Member" xlink:to="btai_WarrantShares2024Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_WarrantShares2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the warrant shares issued in 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_WarrantShares2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Shares 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_WarrantShares2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 Warrant Shares</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OnkosxcelWarrantMember" xlink:label="btai_OnkosxcelWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_OnkosxcelWarrantMember" xlink:to="btai_OnkosxcelWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_OnkosxcelWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to OnkosXcel warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_OnkosxcelWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OnkosXcel Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_OnkosxcelWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OnkosXcel Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_RightToPurchaseStockLenders" xlink:label="btai_RightToPurchaseStockLenders" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_RightToPurchaseStockLenders" xlink:to="btai_RightToPurchaseStockLenders_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_RightToPurchaseStockLenders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum equity investment allowed for lenders in entity's common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_RightToPurchaseStockLenders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right to Purchase Stock, Lenders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_RightToPurchaseStockLenders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum equity investment allowed for lenders</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PremiumSharePricePercent" xlink:label="btai_PremiumSharePricePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PremiumSharePricePercent" xlink:to="btai_PremiumSharePricePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PremiumSharePricePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents premium percentage for share price determined over a specified period of time.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PremiumSharePricePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Premium Share Price, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PremiumSharePricePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Premium share price (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" xlink:label="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" xlink:to="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold amount of  liquidity event for exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Liquidity Event Amount for Exercise of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold amount of liquidity event for exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PercentageOfFairValueConsiderationToBePaid" xlink:label="btai_PercentageOfFairValueConsiderationToBePaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PercentageOfFairValueConsiderationToBePaid" xlink:to="btai_PercentageOfFairValueConsiderationToBePaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PercentageOfFairValueConsiderationToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of fair value of consideration to be paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PercentageOfFairValueConsiderationToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Fair Value Consideration to Be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PercentageOfFairValueConsiderationToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of fair value of consideration to be paid</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PercentageOfValuationApplicableToInitialProfits" xlink:label="btai_PercentageOfValuationApplicableToInitialProfits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PercentageOfValuationApplicableToInitialProfits" xlink:to="btai_PercentageOfValuationApplicableToInitialProfits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PercentageOfValuationApplicableToInitialProfits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of valuation applicable to initial profits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PercentageOfValuationApplicableToInitialProfits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Valuation Applicable to Initial Profits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PercentageOfValuationApplicableToInitialProfits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of valuation applicable to initial profits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issuable (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EquityInvestmentMember" xlink:label="btai_EquityInvestmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_EquityInvestmentMember" xlink:to="btai_EquityInvestmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_EquityInvestmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information related to the Equity Investment agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_EquityInvestmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Investment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_EquityInvestmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Investment Rights</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2024AccompanyingWarrantsMember" xlink:label="btai_Warrants2024AccompanyingWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_Warrants2024AccompanyingWarrantsMember" xlink:to="btai_Warrants2024AccompanyingWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_Warrants2024AccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2024 Accompanying Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_Warrants2024AccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants 2024, Accompanying Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="btai_Warrants2024AccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024 Accompanying Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" xlink:label="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" xlink:to="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertains to 2024 accompanying warrants Strike price amended.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants 2024 Accompanying Warrants Strike Price Amended [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024 Accompanying Warrants, Strike Price Amended</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_November2024AccompanyingWarrantsMember" xlink:label="btai_November2024AccompanyingWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_November2024AccompanyingWarrantsMember" xlink:to="btai_November2024AccompanyingWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_November2024AccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertains to November 2024 Accompanying warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_November2024AccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2024 Accompanying Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_November2024AccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2024 Accompanying Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) carrying value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Derivative Instruments, Net, Pretax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (loss) on derivatives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_JefferiesMember" xlink:label="btai_JefferiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_JefferiesMember" xlink:to="btai_JefferiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_JefferiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Jefferies LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_JefferiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Jefferies [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_JefferiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Jefferies Sale Agreement</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_RegisteredDirectOfferingMember" xlink:label="btai_RegisteredDirectOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_RegisteredDirectOfferingMember" xlink:to="btai_RegisteredDirectOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_RegisteredDirectOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to registered direct offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_RegisteredDirectOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Registered Direct Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_RegisteredDirectOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Registered direct offering</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_RegisteredOfferingMember" xlink:label="btai_RegisteredOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_RegisteredOfferingMember" xlink:to="btai_RegisteredOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_RegisteredOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information related to the registered offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_RegisteredOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Registered Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_RegisteredOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting Agreement</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2024PreFundedWarrantsMember" xlink:label="btai_Warrants2024PreFundedWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_Warrants2024PreFundedWarrantsMember" xlink:to="btai_Warrants2024PreFundedWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_Warrants2024PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2024 Pre-Funded Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_Warrants2024PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants 2024, Pre Funded Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_Warrants2024PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024 Pre-Funded Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_November2024PrefundedAccompanyingWarrantsMember" xlink:label="btai_November2024PrefundedAccompanyingWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_November2024PrefundedAccompanyingWarrantsMember" xlink:to="btai_November2024PrefundedAccompanyingWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_November2024PrefundedAccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertains to November 2024 Pre-Funded Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_November2024PrefundedAccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2024 Prefunded Accompanying Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_November2024PrefundedAccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2024 Pre-Funded Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SaleOfStockMaximumValueSharesToBeIssued" xlink:label="btai_SaleOfStockMaximumValueSharesToBeIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_SaleOfStockMaximumValueSharesToBeIssued" xlink:to="btai_SaleOfStockMaximumValueSharesToBeIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_SaleOfStockMaximumValueSharesToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum aggregate net offering price of shares permitted to be issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_SaleOfStockMaximumValueSharesToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Maximum Value Shares to be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_SaleOfStockMaximumValueSharesToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum value shares to be issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="btai_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of warrants, stock issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_IncentiveAwardPlan2020Member" xlink:label="btai_IncentiveAwardPlan2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_IncentiveAwardPlan2020Member" xlink:to="btai_IncentiveAwardPlan2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_IncentiveAwardPlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2020 Incentive Award Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_IncentiveAwardPlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 Incentive Award Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_IncentiveAwardPlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 Incentive Award Plan</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_StockPlan2017Member" xlink:label="btai_StockPlan2017Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_StockPlan2017Member" xlink:to="btai_StockPlan2017Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_StockPlan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information related to the 2017 Stock Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_StockPlan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2017 Equity Incentive Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_StockPlan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2017 Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Authorized shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available for grant (in shares)</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of aggregate number of shares of common stock outstanding of the immediately preceding calendar year as a increase to common stock available for grant under the plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Percentage Of Increase In Common Stock Available For Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual increase in shares available for grant (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in shares available for issuance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Terms of award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-options outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonemployee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonemployee consultant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in shares)</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Cancelled in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested aggregate (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Weighted average price ending balance (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Weighted average price beginning balance (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted, Weighted average price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a cancelled event.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Cancelled, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled, Weighted average price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested, Weighted average price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value, non-option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares under options that were cancelled during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Cancelled in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options vested and exercisable (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, end balance (in dollars per shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, beginning balance (in dollars per shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options forfeited (in dollars per shares)</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:label="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:to="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were cancelled.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Cancelled in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options cancelled (in dollars per shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options vested and exercisable (in dollars per shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intrinsic value, outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intrinsic value, exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intrinsic value, exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant-date fair value of options granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant-date fair value of options vested (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual life, exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual life, outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining unamortized expense period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected stock price volatility (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected stock price volatility, minimum (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected stock price volatility, maximum (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free rate of interest (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free rate of interest, minimum (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free rate of interest, maximum (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Income Location, Balance [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Income Location, Balance [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Ownership Plan (ESOP) [Table]</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EmployeeStockPurchasePlan2020Member" xlink:label="btai_EmployeeStockPurchasePlan2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_EmployeeStockPurchasePlan2020Member" xlink:to="btai_EmployeeStockPurchasePlan2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_EmployeeStockPurchasePlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the 2020 Employee Stock Purchase Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_EmployeeStockPurchasePlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan 2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_EmployeeStockPurchasePlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" xlink:label="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" xlink:to="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the maximum number of shares issued or transferred under ESPP.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan, Maximum Number Of Shares Issued Or Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum number of shares issued or transferred under ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price as a percent of fair market value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued under ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturities of the operating lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Imputed interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less current portion of lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option to renew the lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Renewal term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer matching contribution, percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer contribution percent on eligible contribution</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer contribution amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Basis [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Portion at Fair Value Measurement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimate of Fair Value Measurement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_BioxcelWarrantsAggregateMember" xlink:label="btai_BioxcelWarrantsAggregateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_BioxcelWarrantsAggregateMember" xlink:to="btai_BioxcelWarrantsAggregateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_BioxcelWarrantsAggregateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertains to the aggregate of BioXcel equity Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_BioxcelWarrantsAggregateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BioXcel Warrants, Aggregate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_BioxcelWarrantsAggregateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BTI Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value money market accounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3 reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3 liabilities reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination of Derivative liabilities - Equity Investment Right</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2023Member" xlink:label="btai_Warrants2023Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_Warrants2023Member" xlink:to="btai_Warrants2023Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_Warrants2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the warrants issued in 2023.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_Warrants2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_Warrants2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023 Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2024Member" xlink:label="btai_Warrants2024Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_Warrants2024Member" xlink:to="btai_Warrants2024Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_Warrants2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the warrants issued in 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_Warrants2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_Warrants2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" xlink:label="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" xlink:to="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertains to 2024 accompanying warrants strike price not amended.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accompanying Warrants 2024 Strike Price Not Amended [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024 Accompanying Warrants, Strike Price Not Amended</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Exercise Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Strike price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Price Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility (annual)</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_MeasurementInputProbabilityOfExerciseMember" xlink:label="btai_MeasurementInputProbabilityOfExerciseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_MeasurementInputProbabilityOfExerciseMember" xlink:to="btai_MeasurementInputProbabilityOfExerciseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_MeasurementInputProbabilityOfExerciseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement input using rate at which there is a probability of exercise.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_MeasurementInputProbabilityOfExerciseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Probability of exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_MeasurementInputProbabilityOfExerciseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Probability of exercise</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Expected Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_MeasurementInputEstimatedPremiumMember" xlink:label="btai_MeasurementInputEstimatedPremiumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_MeasurementInputEstimatedPremiumMember" xlink:to="btai_MeasurementInputEstimatedPremiumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_MeasurementInputEstimatedPremiumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement input using estimated premium.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_MeasurementInputEstimatedPremiumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated premium to 30-day average</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_MeasurementInputEstimatedPremiumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated premium to 30-day average</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Discount Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Risk Free Interest Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Share Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value inputs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative liability input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Settleable in Cash, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value warrant classified as equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding value</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ArmisticeCapitalMasterFundMember" xlink:label="btai_ArmisticeCapitalMasterFundMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ArmisticeCapitalMasterFundMember" xlink:to="btai_ArmisticeCapitalMasterFundMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ArmisticeCapitalMasterFundMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Armistice Capital Master Fund Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ArmisticeCapitalMasterFundMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Armistice Capital Master Fund [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ArmisticeCapitalMasterFundMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Armistice Capital Master Fund</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_HeightsCapitalManagementMember" xlink:label="btai_HeightsCapitalManagementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_HeightsCapitalManagementMember" xlink:to="btai_HeightsCapitalManagementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_HeightsCapitalManagementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Heights Capital Management.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_HeightsCapitalManagementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Heights Capital Management [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_HeightsCapitalManagementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Heights Capital Management</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_HudsonBayCapitalManagementMember" xlink:label="btai_HudsonBayCapitalManagementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_HudsonBayCapitalManagementMember" xlink:to="btai_HudsonBayCapitalManagementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_HudsonBayCapitalManagementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Hudson Bay Capital Management.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_HudsonBayCapitalManagementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hudson Bay Capital Management [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_HudsonBayCapitalManagementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hudson Bay Capital Management</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_IntraCoastalCapitalMember" xlink:label="btai_IntraCoastalCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_IntraCoastalCapitalMember" xlink:to="btai_IntraCoastalCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_IntraCoastalCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to IntraCoastal Capital, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_IntraCoastalCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intra Coastal Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_IntraCoastalCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IntraCoastal Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal net operating losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State net operating losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Asset, In-Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research &amp; development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DeferredTaxAssetsLeaseAccountingLiability" xlink:label="btai_DeferredTaxAssetsLeaseAccountingLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_DeferredTaxAssetsLeaseAccountingLiability" xlink:to="btai_DeferredTaxAssetsLeaseAccountingLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_DeferredTaxAssetsLeaseAccountingLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease accounting, liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_DeferredTaxAssetsLeaseAccountingLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Lease Accounting, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_DeferredTaxAssetsLeaseAccountingLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease accounting - liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Charitable Contribution Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disallowed charitable contributions</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DeferredTaxAssetsCapitalizedIpoCosts" xlink:label="btai_DeferredTaxAssetsCapitalizedIpoCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_DeferredTaxAssetsCapitalizedIpoCosts" xlink:to="btai_DeferredTaxAssetsCapitalizedIpoCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_DeferredTaxAssetsCapitalizedIpoCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized IPO costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_DeferredTaxAssetsCapitalizedIpoCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Capitalized IPO Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_DeferredTaxAssetsCapitalizedIpoCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Costs</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DeferredTaxAssetsCancellationOfDebt" xlink:label="btai_DeferredTaxAssetsCancellationOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_DeferredTaxAssetsCancellationOfDebt" xlink:to="btai_DeferredTaxAssetsCancellationOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_DeferredTaxAssetsCancellationOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from cancellation of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_DeferredTaxAssetsCancellationOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Cancellation of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_DeferredTaxAssetsCancellationOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancellation of Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Amendment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:to="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Derivatives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Leasing Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax asset (liability)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Jurisdiction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Jurisdiction [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Tax Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation between effective and statutory rate, Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal statutory rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EffectiveIncomeTaxRateReconciliationWarrantValuationAmount" xlink:label="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationAmount" xlink:to="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to warrant valuation adjustments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Warrant Valuation, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant mark-to-market</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal and state credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total effective tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation between effective and statutory rate, Percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal statutory rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EffectiveIncomeTaxRateReconciliationWarrantValuationPercent" xlink:label="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationPercent" xlink:to="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to warrant valuation adjustments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Warrant Valuation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant mark-to-market (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal and state tax credits (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State Taxes (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective tax (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carry-forwards</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OperatingLossCarryforwardsNoExpiration" xlink:label="btai_OperatingLossCarryforwardsNoExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_OperatingLossCarryforwardsNoExpiration" xlink:to="btai_OperatingLossCarryforwardsNoExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_OperatingLossCarryforwardsNoExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of operating loss carryforward with no expiration, before tax effects, available to reduce future taxable income under enacted tax laws.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_OperatingLossCarryforwardsNoExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards, No Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_OperatingLossCarryforwardsNoExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforward with no expiration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carry-forwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Examination, Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax related interest and penalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="us-gaap_EarningsPerShareDilutedLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_EarningsPerShareDilutedLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDilutedLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDilutedLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potentially dilutive securities (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Purchase Commitment, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase agreement expected cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Purchase Commitment, Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase agreement expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Obligation, to be Paid, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 purchase obligation, remainder of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025 purchase obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondYear" xlink:to="us-gaap_ContractualObligationDueInSecondYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026 purchase obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SingleReportableSegmentMember" xlink:label="btai_SingleReportableSegmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_SingleReportableSegmentMember" xlink:to="btai_SingleReportableSegmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_SingleReportableSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertains to single reportable segment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_SingleReportableSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Single Reportable Segment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_SingleReportableSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Single reportable segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidationItemsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation Items [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidationItemsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation Items [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Segments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development costs:</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense" xlink:label="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense" xlink:to="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense during the period related to salary, wage, profit sharing incentive and other employee benefit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Labor And Related Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel and related costs</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" xlink:label="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" xlink:to="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense during the period related to expense for award under share-based payment arrangement. Excludes amount capitalized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Share-Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseProfessionalFees" xlink:label="btai_ResearchAndDevelopmentExpenseProfessionalFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ResearchAndDevelopmentExpenseProfessionalFees" xlink:to="btai_ResearchAndDevelopmentExpenseProfessionalFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ResearchAndDevelopmentExpenseProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense during the period related to a fee charged for services from professionals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ResearchAndDevelopmentExpenseProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ResearchAndDevelopmentExpenseProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense" xlink:label="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense" xlink:to="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense during the period related to clinical trial expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Clinical Trials Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical trials expense</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" xlink:label="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" xlink:to="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense during the period related to chemical, manufacturing and control costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Chemical, manufacturing and controls Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chemical, manufacturing and controls cost</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseTravelAndOtherExpenses" xlink:label="btai_ResearchAndDevelopmentExpenseTravelAndOtherExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ResearchAndDevelopmentExpenseTravelAndOtherExpenses" xlink:to="btai_ResearchAndDevelopmentExpenseTravelAndOtherExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ResearchAndDevelopmentExpenseTravelAndOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense during the period related to travel expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ResearchAndDevelopmentExpenseTravelAndOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Travel Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ResearchAndDevelopmentExpenseTravelAndOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Travel related expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectOperatingCostsAbstract" xlink:label="us-gaap_DirectOperatingCostsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectOperatingCostsAbstract" xlink:to="us-gaap_DirectOperatingCostsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DirectOperatingCostsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Direct Operating Costs [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DirectOperatingCostsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial costs:</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsLaborAndRelatedExpense" xlink:label="btai_CommercialCostsLaborAndRelatedExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CommercialCostsLaborAndRelatedExpense" xlink:to="btai_CommercialCostsLaborAndRelatedExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CommercialCostsLaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of commercial costs for salary, wage, profit sharing; incentive and other employee benefit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CommercialCostsLaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Costs, Labor and Related Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CommercialCostsLaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel and related costs</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsShareBasedPaymentArrangementExpense" xlink:label="btai_CommercialCostsShareBasedPaymentArrangementExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CommercialCostsShareBasedPaymentArrangementExpense" xlink:to="btai_CommercialCostsShareBasedPaymentArrangementExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CommercialCostsShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of commercial costs for award under share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CommercialCostsShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Costs, Share-Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CommercialCostsShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsProfessionalFees" xlink:label="btai_CommercialCostsProfessionalFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CommercialCostsProfessionalFees" xlink:to="btai_CommercialCostsProfessionalFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CommercialCostsProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of commercial costs related to a fee charged for services from professionals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CommercialCostsProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Costs, Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CommercialCostsProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsCommercialAndMarketing" xlink:label="btai_CommercialCostsCommercialAndMarketing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CommercialCostsCommercialAndMarketing" xlink:to="btai_CommercialCostsCommercialAndMarketing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CommercialCostsCommercialAndMarketing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The commercial costs recognized in the period for promotion, public relations, and brand or product advertising.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CommercialCostsCommercialAndMarketing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Costs, Commercial and Marketing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CommercialCostsCommercialAndMarketing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial and marketing</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsTravelAndOtherExpenses" xlink:label="btai_CommercialCostsTravelAndOtherExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CommercialCostsTravelAndOtherExpenses" xlink:to="btai_CommercialCostsTravelAndOtherExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CommercialCostsTravelAndOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of commercial costs related to travel expenses during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CommercialCostsTravelAndOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Costs, Travel Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CommercialCostsTravelAndOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Travel related expenses</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsOtherExpenses" xlink:label="btai_CommercialCostsOtherExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CommercialCostsOtherExpenses" xlink:to="btai_CommercialCostsOtherExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CommercialCostsOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of other expenses related to commercial costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CommercialCostsOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Costs, Other Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CommercialCostsOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Cost and Expense, Operating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total commercial costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative costs:</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" xlink:label="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" xlink:to="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of selling, general and administrative expense for salary, wage, profit sharing; incentive and other employee benefit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense, Labor and Related Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel and related costs</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" xlink:label="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" xlink:to="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of selling, general and administrative expense for award under share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense, Share-Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SellingGeneralAndAdministrativeExpenseProfessionalFees" xlink:label="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees" xlink:to="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of selling, general and administrative expense related to a fee charged for services from professionals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense, Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" xlink:label="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" xlink:to="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of selling, general and administrative expense related to travel expenses during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense, Travel Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Travel related expenses</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SellingGeneralAndAdministrativeCostsOtherExpenses" xlink:label="btai_SellingGeneralAndAdministrativeCostsOtherExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_SellingGeneralAndAdministrativeCostsOtherExpenses" xlink:to="btai_SellingGeneralAndAdministrativeCostsOtherExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_SellingGeneralAndAdministrativeCostsOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of other expenses related to selling, general and administrative costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_SellingGeneralAndAdministrativeCostsOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Costs, Other Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_SellingGeneralAndAdministrativeCostsOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Reportable Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of reportable segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PurchaseAgreementRegisteredSecuritiesMember" xlink:label="btai_PurchaseAgreementRegisteredSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PurchaseAgreementRegisteredSecuritiesMember" xlink:to="btai_PurchaseAgreementRegisteredSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PurchaseAgreementRegisteredSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information related to the Purchase Agreement. A registered security offering March 2025.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PurchaseAgreementRegisteredSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Agreement, Registered Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PurchaseAgreementRegisteredSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_AccompanyingWarrantsMarch2025Member" xlink:label="btai_AccompanyingWarrantsMarch2025Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_AccompanyingWarrantsMarch2025Member" xlink:to="btai_AccompanyingWarrantsMarch2025Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_AccompanyingWarrantsMarch2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertains to March 2025 Accompanying Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_AccompanyingWarrantsMarch2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accompanying Warrants, March 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_AccompanyingWarrantsMarch2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2025 Accompanying Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PrefundedWarrantsMarch2025Member" xlink:label="btai_PrefundedWarrantsMarch2025Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PrefundedWarrantsMarch2025Member" xlink:to="btai_PrefundedWarrantsMarch2025Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PrefundedWarrantsMarch2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertains to March 2025 Pre-Funded Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PrefundedWarrantsMarch2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prefunded Warrants, March 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PrefundedWarrantsMarch2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2025 Pre-Funded Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OptionWarrantsMarch2025Member" xlink:label="btai_OptionWarrantsMarch2025Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_OptionWarrantsMarch2025Member" xlink:to="btai_OptionWarrantsMarch2025Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_OptionWarrantsMarch2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertains to March 2025 Option Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_OptionWarrantsMarch2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Warrants, March 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_OptionWarrantsMarch2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2025 Option Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_VimalMehtaMember" xlink:label="btai_VimalMehtaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_VimalMehtaMember" xlink:to="btai_VimalMehtaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_VimalMehtaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Vimal Mehta.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_VimalMehtaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vimal Mehta</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_RichardSteinhartMember" xlink:label="btai_RichardSteinhartMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_RichardSteinhartMember" xlink:to="btai_RichardSteinhartMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_RichardSteinhartMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Richard Steinhart.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_RichardSteinhartMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Richard Steinhart</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_JavierRodriguezMember" xlink:label="btai_JavierRodriguezMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_JavierRodriguezMember" xlink:to="btai_JavierRodriguezMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_JavierRodriguezMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Javier Rodriguez.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_JavierRodriguezMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Javier Rodriguez</label>
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_FrankYoccaMember" xlink:label="btai_FrankYoccaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_FrankYoccaMember" xlink:to="btai_FrankYoccaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_FrankYoccaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Frank Yocca.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_FrankYoccaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Frank Yocca</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>25
<FILENAME>btai-20241231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/28/2025 7:22:09 PM-->
<!--Modified on: 3/28/2025 7:22:09 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity" roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureNatureOfBusiness" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNatureOfBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureBasisOfPresentation" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureRestructuring" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureRestructuring" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureInventory" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureInventory" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureAccruedExpenses" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureTransactionsWithBioxcelLlc" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureDebtAndCreditFacilities" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureDerivativeFinancialInstruments" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureCommonStockFinancingActivities" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureStockBasedCompensation" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureLeases" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureEmployeeBenefitPlan" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureFairValueMeasurements" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureIncomeTaxes" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureNetLossPerShare" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureSegmentInformation" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureSubsequentEvents" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureInventoryTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureAccruedExpensesTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureTransactionsWithBioxcelLlcTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureDebtAndCreditFacilitiesTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureLeasesTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureSegmentInformationTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureBasisOfPresentationDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureRestructuringDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureInventoryDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureTransactionsWithBioxcelLlcDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureDebtAndCreditFacilitiesWarrantsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureDebtAndCreditFacilitiesMaturitiesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureDebtAndCreditFacilitiesInterestDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureDerivativeFinancialInstrumentsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureCommonStockFinancingActivitiesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureStockBasedCompensationDescriptionDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureStockBasedCompensationNonOptionsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureStockBasedCompensationOptionsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureStockBasedCompensationAssumptionsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureStockBasedCompensationExpenseDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureStockBasedCompensationEsppDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureLeasesMaturitiesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureLeasesAdditionalInformationDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureEmployeeBenefitPlanDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureFairValueMeasurementsHierarchyDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureFairValueMeasurementsLevel3Details" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureFairValueMeasurementsInputsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureFairValueMeasurementsWarrantsOutstandingDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureIncomeTaxesDeferredTaxDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureIncomeTaxesReconciliationDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureNetLossPerShareAntidilutiveDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureSegmentInformationDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20241231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638787865249888556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638787865249888556" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638787865249888556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentAnnualReport_638787865249888556" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638787865249888556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638787865249888556" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638787865249888556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_638787865249888556" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638787865249888556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638787865249888556" order="5" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638787865249888556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638787865249888556" order="6" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638787865249888556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638787865249888556" order="7" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638787865249898555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638787865249898555" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638787865249898555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638787865249898555" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638787865249898555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638787865249898555" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638787865249898555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638787865249898555" order="11" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638787865249898555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638787865249898555" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638787865249898555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638787865249898555" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638787865249898555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638787865249898555" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638787865249898555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638787865249898555" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638787865249898555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638787865249898555" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638787865249908554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638787865249908554" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638787865249908554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638787865249908554" order="18" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638787865249908554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638787865249908554" order="19" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638787865249908554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638787865249908554" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638787865249908554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638787865249908554" order="21" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638787865249908554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_638787865249908554" order="22" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638787865249908554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_638787865249908554" order="23" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638787865249918558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638787865249918558" order="24" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638787865249918558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638787865249918558" order="25" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638787865249918558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_638787865249918558" order="26" use="optional" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638787865249918558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityPublicFloat_638787865249918558" order="27" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638787865249918558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638787865249918558" order="28" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638787865249918558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorName_638787865249918558" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638787865249928554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorFirmId_638787865249928554" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638787865249928554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorLocation_638787865249928554" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_638787865249928554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_638787865249928554" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638787865249928554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638787865249928554" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638787865249938595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638787865249938595" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638787865249938595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638787865249938595" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638787865249938595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638787865249938595" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638787865249938595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638787865249938595" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638787865249948573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_638787865249948573" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638787865249948573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638787865249948573" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638787865249948573" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638787865249948573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638787865249948573" xlink:to="us-gaap_RelatedPartyDomain_638787865249948573" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_638787865249948573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638787865249948573" xlink:to="us-gaap_RelatedPartyMember_638787865249948573" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember_638787865249948573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638787865249948573" xlink:to="us-gaap_NonrelatedPartyMember_638787865249948573" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638787865249948573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638787865249948573" xlink:to="us-gaap_StatementLineItems_638787865249948573" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638787865249948573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638787865249948573" xlink:to="us-gaap_AssetsAbstract_638787865249948573" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638787865249948573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638787865249948573" xlink:to="us-gaap_AssetsCurrentAbstract_638787865249948573" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638787865249948573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638787865249948573" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638787865249948573" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_638787865249958598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638787865249948573" xlink:to="us-gaap_ReceivablesNetCurrent_638787865249958598" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638787865249958598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638787865249948573" xlink:to="us-gaap_InventoryNet_638787865249958598" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638787865249958598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638787865249948573" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638787865249958598" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638787865249958598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638787865249948573" xlink:to="us-gaap_OtherAssetsCurrent_638787865249958598" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638787865249958598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638787865249948573" xlink:to="us-gaap_AssetsCurrent_638787865249958598" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638787865249958598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638787865249948573" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638787865249958598" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638787865249958598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638787865249948573" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638787865249958598" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638787865249968601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638787865249948573" xlink:to="us-gaap_OtherAssetsNoncurrent_638787865249968601" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638787865249968601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638787865249948573" xlink:to="us-gaap_Assets_638787865249968601" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638787865249968601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638787865249948573" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638787865249968601" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638787865249968601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638787865249968601" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638787865249968601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638787865249968601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638787865249968601" xlink:to="us-gaap_AccountsPayableCurrent_638787865249968601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638787865249968601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638787865249968601" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638787865249968601" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_638787865249968601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638787865249968601" xlink:to="us-gaap_InterestPayableCurrent_638787865249968601" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638787865249978577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638787865249968601" xlink:to="us-gaap_OtherLiabilitiesCurrent_638787865249978577" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638787865249978577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638787865249968601" xlink:to="us-gaap_LiabilitiesCurrent_638787865249978577" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638787865249978577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638787865249968601" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638787865249978577" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638787865249978577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638787865249968601" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638787865249978577" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638787865249978577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638787865249968601" xlink:to="us-gaap_LongTermDebtNoncurrent_638787865249978577" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638787865249978577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638787865249968601" xlink:to="us-gaap_Liabilities_638787865249978577" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638787865249978577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638787865249968601" xlink:to="us-gaap_CommitmentsAndContingencies_638787865249978577" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638787865249988578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638787865249968601" xlink:to="us-gaap_StockholdersEquityAbstract_638787865249988578" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638787865249988578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638787865249988578" xlink:to="us-gaap_PreferredStockValue_638787865249988578" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638787865249988578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638787865249988578" xlink:to="us-gaap_CommonStockValue_638787865249988578" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638787865249988578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638787865249988578" xlink:to="us-gaap_AdditionalPaidInCapital_638787865249988578" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638787865249988578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638787865249988578" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638787865249988578" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638787865249998618" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638787865249988578" xlink:to="us-gaap_StockholdersEquity_638787865249998618" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638787865249998618" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638787865249988578" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638787865249998618" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638787865249998618" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638787865249998618" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638787865249998618" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638787865249998618" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638787865250008580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638787865250008580" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638787865250008580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638787865250008580" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638787865250008580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638787865250008580" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638787865250008580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638787865250008580" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638787865250008580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638787865250008580" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638787865250008580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638787865250008580" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_638787865250008580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract_638787865250008580" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638787865250008580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638787865250008580" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638787865250008580" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract_638787865250018610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638787865250008580" xlink:to="us-gaap_CostsAndExpensesAbstract_638787865250018610" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638787865250018610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638787865250018610" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638787865250018610" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638787865250018610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638787865250018610" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638787865250018610" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638787865250018610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638787865250018610" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638787865250018610" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges_638787865250018610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638787865250018610" xlink:to="us-gaap_RestructuringCharges_638787865250018610" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638787865250018610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638787865250018610" xlink:to="us-gaap_CostsAndExpenses_638787865250018610" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638787865250018610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638787865250008580" xlink:to="us-gaap_OperatingIncomeLoss_638787865250018610" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638787865250018610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638787865250008580" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638787865250018610" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating_638787865250018610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638787865250018610" xlink:to="us-gaap_InterestExpenseNonoperating_638787865250018610" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638787865250028585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638787865250018610" xlink:to="us-gaap_InvestmentIncomeInterest_638787865250028585" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638787865250028585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638787865250018610" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638787865250028585" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638787865250028585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638787865250008580" xlink:to="us-gaap_NetIncomeLoss_638787865250028585" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638787865250028585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638787865250008580" xlink:to="us-gaap_EarningsPerShareBasic_638787865250028585" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638787865250028585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638787865250008580" xlink:to="us-gaap_EarningsPerShareDiluted_638787865250028585" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638787865250028585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638787865250008580" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638787865250028585" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638787865250028585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638787865250008580" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638787865250028585" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity" xlink:type="extended" xlink:title="995200300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638787865250038615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638787865250038615" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638787865250038615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638787865250038615" xlink:to="us-gaap_StatementEquityComponentsAxis_638787865250038615" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638787865250038615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638787865250038615" xlink:to="us-gaap_CommonStockMember_638787865250038615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638787865250038615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638787865250038615" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638787865250038615" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638787865250038615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638787865250038615" xlink:to="us-gaap_RetainedEarningsMember_638787865250038615" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638787865250038615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638787865250038615" xlink:to="us-gaap_EquityComponentDomain_638787865250038615" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638787865250038615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638787865250038615" xlink:to="us-gaap_StatementLineItems_638787865250038615" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638787865250038615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638787865250038615" xlink:to="us-gaap_StockholdersEquity_638787865250038615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638787865250048598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638787865250038615" xlink:to="us-gaap_CommonStockSharesOutstanding_638787865250048598" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638787865250048598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638787865250038615" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638787865250048598" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638787865250048598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638787865250048598" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638787865250048598" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638787865250048598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638787865250038615" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638787865250048598" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638787865250048598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638787865250038615" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638787865250048598" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638787865250048598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638787865250048598" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638787865250048598" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_638787865250048598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638787865250038615" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_638787865250048598" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_638787865250048598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638787865250038615" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_638787865250048598" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xlink:label="btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued_638787865250058593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638787865250038615" xlink:to="btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued_638787865250058593" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_638787865250058593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638787865250038615" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_638787865250058593" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_638787865250058593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_638787865250058593" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_638787865250058593" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638787865250058593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638787865250038615" xlink:to="us-gaap_NetIncomeLoss_638787865250058593" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638787865250058593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638787865250038615" xlink:to="us-gaap_StockholdersEquity_638787865250058593" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638787865250058593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638787865250038615" xlink:to="us-gaap_CommonStockSharesOutstanding_638787865250058593" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638787865250068632" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638787865250068632" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638787865250068632" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638787865250068632" xlink:to="us-gaap_ProfitLoss_638787865250068632" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638787865250068632" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638787865250068632" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638787865250068632" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638787865250068632" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638787865250068632" xlink:to="us-gaap_Depreciation_638787865250068632" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638787865250068632" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638787865250068632" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638787865250068632" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638787865250068632" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638787865250068632" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638787865250068632" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638787865250068632" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638787865250068632" xlink:to="us-gaap_ShareBasedCompensation_638787865250068632" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest_638787865250078637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638787865250068632" xlink:to="us-gaap_PaidInKindInterest_638787865250078637" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638787865250078637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638787865250068632" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638787865250078637" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638787865250078637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638787865250068632" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638787865250078637" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638787865250078637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638787865250068632" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638787865250078637" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638787865250078637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638787865250078637" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638787865250078637" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638787865250078637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638787865250078637" xlink:to="us-gaap_IncreaseDecreaseInInventories_638787865250078637" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638787865250078637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638787865250078637" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638787865250078637" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_638787865250078637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638787865250078637" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_638787865250078637" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_638787865250088603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638787865250078637" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_638787865250088603" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638787865250088603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638787865250078637" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638787865250088603" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638787865250088603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638787865250068632" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638787865250088603" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638787865250088603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638787865250088603" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638787865250088603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638787865250088603" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638787865250088603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638787865250088603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638787865250088603" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638787865250088603" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638787865250088603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638787865250088603" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638787865250098599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638787865250088603" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638787865250098599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_638787865250098599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638787865250088603" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_638787865250098599" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_638787865250098599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638787865250088603" xlink:to="us-gaap_RepaymentsOfLongTermDebt_638787865250098599" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638787865250098599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638787865250088603" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638787865250098599" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638787865250098599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638787865250088603" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638787865250098599" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638787865250098599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638787865250088603" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638787865250098599" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638787865250108628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638787865250088603" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638787865250108628" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638787865250108628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638787865250108628" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638787865250108628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638787865250108628" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6387878652501086281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6387878652501086281" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638787865250108628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638787865250108628" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_FairValueStockPurchaseWarrants" xlink:label="btai_FairValueStockPurchaseWarrants_638787865250108628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638787865250108628" xlink:to="btai_FairValueStockPurchaseWarrants_638787865250108628" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_638787865250118604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638787865250108628" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_638787865250118604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638787865250118604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638787865250108628" xlink:to="us-gaap_InterestPaidNet_638787865250118604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ConversionOfAccruedInterestToLongTermDebt" xlink:label="btai_ConversionOfAccruedInterestToLongTermDebt_638787865250118604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638787865250108628" xlink:to="btai_ConversionOfAccruedInterestToLongTermDebt_638787865250118604" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureNatureOfBusiness" xlink:type="extended" xlink:title="995210101 - Disclosure - Nature of the Business" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OrganizationAndPrincipalActivitiesAbstract" xlink:label="OrganizationAndPrincipalActivitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638787865250128594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationAndPrincipalActivitiesAbstract" xlink:to="us-gaap_NatureOfOperations_638787865250128594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation" xlink:type="extended" xlink:title="995210201 - Disclosure - Basis of Presentation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638787865250128594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638787865250128594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="995210301 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638787865250128594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638787865250128594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureRestructuring" xlink:type="extended" xlink:title="995210401 - Disclosure - Restructuring" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_638787865250138633" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_638787865250138633" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureInventory" xlink:type="extended" xlink:title="995210501 - Disclosure - Inventory" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_638787865250138633" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock_638787865250138633" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="995210601 - Disclosure - Property and Equipment, net" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638787865250138633" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638787865250138633" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="995210701 - Disclosure - Accrued Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638787865250148622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638787865250148622" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc" xlink:type="extended" xlink:title="995210801 - Disclosure - Transactions with BioXcel LLC" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638787865250148622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638787865250148622" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities" xlink:type="extended" xlink:title="995210901 - Disclosure - Debt and Credit Facilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638787865250148622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_638787865250148622" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstruments" xlink:type="extended" xlink:title="995211001 - Disclosure - Derivative Financial Instruments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_638787865250158601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_638787865250158601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities" xlink:type="extended" xlink:title="995211101 - Disclosure - Common Stock Financing Activities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_FinancingActivitiesAbstract" xlink:label="FinancingActivitiesAbstract" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_FinancingActivitiesDisclosureTextBlock" xlink:label="btai_FinancingActivitiesDisclosureTextBlock_638787865250158601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancingActivitiesAbstract" xlink:to="btai_FinancingActivitiesDisclosureTextBlock_638787865250158601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="995211201 - Disclosure - Stock-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638787865250158601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638787865250158601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureLeases" xlink:type="extended" xlink:title="995211301 - Disclosure - Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_638787865250168629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_638787865250168629" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlan" xlink:type="extended" xlink:title="995211401 - Disclosure - Employee Benefit Plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAbstract" xlink:label="us-gaap_DefinedBenefitPlanAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_638787865250168629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_DefinedBenefitPlanTextBlock_638787865250168629" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="995211501 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638787865250168629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638787865250168629" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="995211601 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638787865250178600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638787865250178600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="995211701 - Disclosure - Net Loss Per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638787865250178600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638787865250178600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="995211801 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638787865250188599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638787865250188599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformation" xlink:type="extended" xlink:title="995211901 - Disclosure - Segment Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_638787865250188599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_638787865250188599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="995212001 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638787865250188599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638787865250188599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="99920302 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638787865250198599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638787865250198599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638787865250198599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638787865250198599" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ReverseStockSplit" xlink:label="btai_ReverseStockSplit_638787865250198599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="btai_ReverseStockSplit_638787865250198599" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638787865250198599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638787865250198599" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_638787865250198599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_638787865250198599" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638787865250198599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638787865250198599" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_638787865250198599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock_638787865250198599" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DeferredOfferingCostsPolicyTextBlock" xlink:label="btai_DeferredOfferingCostsPolicyTextBlock_638787865250208601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="btai_DeferredOfferingCostsPolicyTextBlock_638787865250208601" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638787865250208601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638787865250208601" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638787865250208601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638787865250208601" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock_638787865250208601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock_638787865250208601" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock_638787865250208601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock_638787865250208601" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure" xlink:label="us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure_638787865250208601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure_638787865250208601" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_638787865250208601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_638787865250208601" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_638787865250208601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_638787865250208601" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638787865250218602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638787865250218602" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PatentCostsPolicyTextBlock" xlink:label="btai_PatentCostsPolicyTextBlock_638787865250218602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="btai_PatentCostsPolicyTextBlock_638787865250218602" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638787865250218602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638787865250218602" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638787865250218602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638787865250218602" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638787865250218602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638787865250218602" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638787865250218602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638787865250218602" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638787865250218602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638787865250218602" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="99930303 - Disclosure - Summary of Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_638787865250228600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_638787865250228600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables" xlink:type="extended" xlink:title="99930503 - Disclosure - Inventory (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638787865250228600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_2" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638787865250228600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="99930603 - Disclosure - Property and Equipment, net (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638787865250238600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638787865250238600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="99930703 - Disclosure - Accrued Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638787865250238600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638787865250238600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables" xlink:type="extended" xlink:title="99930803 - Disclosure - Transactions with BioXcel LLC (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_638787865250248633" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_638787865250248633" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables" xlink:type="extended" xlink:title="99930903 - Disclosure - Debt and Credit Facilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_638787865250248633" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_638787865250248633" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638787865250248633" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638787865250248633" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock" xlink:label="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock_638787865250248633" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock_638787865250248633" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="99931203 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250258603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250258603" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638787865250258603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250258603" xlink:to="us-gaap_AwardTypeAxis_638787865250258603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638787865250258603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638787865250258603" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638787865250258603" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638787865250258603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638787865250258603" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638787865250258603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_638787865250258603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638787865250258603" xlink:to="us-gaap_PerformanceSharesMember_638787865250258603" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TimeBasedProfitSharingUnitsMember" xlink:label="btai_TimeBasedProfitSharingUnitsMember_638787865250258603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638787865250258603" xlink:to="btai_TimeBasedProfitSharingUnitsMember_638787865250258603" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_RestrictedStockUnitsOnkosxcelMember" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember_638787865250258603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638787865250258603" xlink:to="btai_RestrictedStockUnitsOnkosxcelMember_638787865250258603" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638787865250258603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638787865250258603" xlink:to="us-gaap_EmployeeStockOptionMember_638787865250258603" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250258603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250258603" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250258603" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_638787865250268654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250258603" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_638787865250268654" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_638787865250268654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250258603" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_638787865250268654" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638787865250268654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250258603" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638787865250268654" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638787865250268654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250258603" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638787865250268654" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638787865250268654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250258603" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638787865250268654" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="99931303 - Disclosure - Leases (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638787865250278633" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638787865250278633" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="99931503 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638787865250278633" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638787865250278633" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_638787865250278633" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_638787865250278633" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638787865250278633" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638787865250278633" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638787865250278633" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638787865250278633" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="99931603 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638787865250288603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638787865250288603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638787865250288603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638787865250288603" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="99931703 - Disclosure - Net Loss Per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638787865250288603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638787865250288603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638787865250288603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638787865250288603" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationTables" xlink:type="extended" xlink:title="99931903 - Disclosure - Segment Information (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_638787865250298604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_638787865250298604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Basis of Presentation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638787865250298604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638787865250298604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638787865250298604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638787865250298604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638787865250298604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLoss_638787865250298604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638787865250298604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638787865250298604" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638787865250308603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638787865250308603" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638787865250308603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638787865250308603" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638787865250308603" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638787865250308603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638787865250308603" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638787865250308603" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638787865250308603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638787865250308603" xlink:to="us-gaap_EquipmentMember_638787865250308603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638787865250308603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638787865250308603" xlink:to="us-gaap_FurnitureAndFixturesMember_638787865250308603" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638787865250308603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638787865250308603" xlink:to="srt_RangeAxis_638787865250308603" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638787865250308603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638787865250308603" xlink:to="srt_RangeMember_638787865250308603" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638787865250308603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638787865250308603" xlink:to="srt_MinimumMember_638787865250308603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638787865250318603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638787865250308603" xlink:to="srt_MaximumMember_638787865250318603" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638787865250318603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638787865250308603" xlink:to="us-gaap_SubsequentEventTypeAxis_638787865250318603" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638787865250318603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638787865250318603" xlink:to="us-gaap_SubsequentEventTypeDomain_638787865250318603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638787865250318603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638787865250318603" xlink:to="us-gaap_SubsequentEventMember_638787865250318603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638787865250318603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638787865250308603" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638787865250318603" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638787865250318603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638787865250318603" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638787865250318603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_AccountsReceivablePaymentTerm" xlink:label="btai_AccountsReceivablePaymentTerm_638787865250318603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638787865250318603" xlink:to="btai_AccountsReceivablePaymentTerm_638787865250318603" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts_638787865250318603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638787865250318603" xlink:to="us-gaap_DeferredOfferingCosts_638787865250318603" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638787865250328604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638787865250318603" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638787865250328604" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638787865250328604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638787865250318603" xlink:to="us-gaap_NumberOfOperatingSegments_638787865250328604" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsDetails" xlink:type="extended" xlink:title="99940302 - Disclosure - Summary of Significant Accounting Policies - Concentrations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable_638787865250328604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract_1" xlink:to="us-gaap_ConcentrationRiskTable_638787865250328604" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_638787865250328604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638787865250328604" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_638787865250328604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_638787865250328604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_638787865250328604" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_638787865250328604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_638787865250328604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638787865250328604" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_638787865250328604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_638787865250328604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638787865250328604" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_638787865250328604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_638787865250338605" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_638787865250328604" xlink:to="us-gaap_ConcentrationRiskTypeDomain_638787865250338605" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_638787865250338605" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638787865250338605" xlink:to="us-gaap_CustomerConcentrationRiskMember_638787865250338605" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638787865250338605" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638787865250328604" xlink:to="srt_MajorCustomersAxis_638787865250338605" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638787865250338605" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638787865250338605" xlink:to="srt_NameOfMajorCustomerDomain_638787865250338605" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CustomerOneMember" xlink:label="btai_CustomerOneMember_638787865250338605" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638787865250338605" xlink:to="btai_CustomerOneMember_638787865250338605" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems_638787865250338605" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638787865250328604" xlink:to="us-gaap_ConcentrationRiskLineItems_638787865250338605" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_638787865250338605" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638787865250338605" xlink:to="us-gaap_ConcentrationRiskPercentage1_638787865250338605" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Restructuring (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638787865250348600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract_1" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638787865250348600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis_638787865250348600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638787865250348600" xlink:to="us-gaap_RestructuringCostAndReserveAxis_638787865250348600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_638787865250348600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis_638787865250348600" xlink:to="us-gaap_TypeOfRestructuringDomain_638787865250348600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember_638787865250348600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain_638787865250348600" xlink:to="us-gaap_EmployeeSeveranceMember_638787865250348600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember_638787865250348600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain_638787865250348600" xlink:to="us-gaap_ContractTerminationMember_638787865250348600" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_638787865250348600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638787865250348600" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_638787865250348600" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638787865250348600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638787865250348600" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638787865250348600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges_638787865250348600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638787865250348600" xlink:to="us-gaap_RestructuringCharges_638787865250348600" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring_638787865250358605" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638787865250348600" xlink:to="us-gaap_PaymentsForRestructuring_638787865250358605" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_638787865250358605" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638787865250348600" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_638787865250358605" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1_638787865250358605" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638787865250348600" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCost1_638787865250358605" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent_638787865250358605" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638787865250348600" xlink:to="us-gaap_RestructuringReserveCurrent_638787865250358605" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Inventory (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638787865250358605" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_1" xlink:to="us-gaap_InventoryRawMaterials_638787865250358605" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638787865250358605" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_1" xlink:to="us-gaap_InventoryWorkInProcess_638787865250358605" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638787865250358605" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_1" xlink:to="us-gaap_InventoryFinishedGoods_638787865250358605" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638787865250368601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_1" xlink:to="us-gaap_InventoryNet_638787865250368601" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_638787865250368601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_1" xlink:to="us-gaap_InventoryWriteDown_638787865250368601" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Property and equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638787865250368601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638787865250368601" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638787865250368601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638787865250368601" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638787865250368601" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638787865250368601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638787865250368601" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638787865250368601" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_638787865250368601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638787865250368601" xlink:to="us-gaap_ComputerEquipmentMember_638787865250368601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638787865250368601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638787865250368601" xlink:to="us-gaap_FurnitureAndFixturesMember_638787865250368601" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638787865250368601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638787865250368601" xlink:to="us-gaap_LeaseholdImprovementsMember_638787865250368601" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638787865250378631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638787865250368601" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638787865250378631" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638787865250378631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638787865250378631" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638787865250378631" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638787865250378631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638787865250378631" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638787865250378631" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638787865250378631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638787865250378631" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638787865250378631" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638787865250378631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638787865250378631" xlink:to="us-gaap_Depreciation_638787865250378631" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_AccruedResearchAndDevelopmentExpenses" xlink:label="btai_AccruedResearchAndDevelopmentExpenses_638787865250438636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="btai_AccruedResearchAndDevelopmentExpenses_638787865250438636" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638787865250438636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638787865250438636" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638787865250438636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638787865250438636" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638787865250438636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_TaxesPayableCurrent_638787865250438636" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638787865250438636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638787865250438636" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent_638787865250448614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_RestructuringReserveCurrent_638787865250448614" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638787865250448614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638787865250448614" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Transactions with BioXcel LLC (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638787865250448614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638787865250448614" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638787865250448614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638787865250448614" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638787865250448614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638787865250448614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638787865250448614" xlink:to="us-gaap_RelatedPartyDomain_638787865250448614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_638787865250448614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638787865250448614" xlink:to="us-gaap_RelatedPartyMember_638787865250448614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638787865250448614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638787865250448614" xlink:to="srt_CounterpartyNameAxis_638787865250448614" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638787865250458614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638787865250448614" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638787865250458614" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_BioxcelCorporationMember" xlink:label="btai_BioxcelCorporationMember_638787865250458614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638787865250458614" xlink:to="btai_BioxcelCorporationMember_638787865250458614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638787865250458614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638787865250448614" xlink:to="us-gaap_TypeOfArrangementAxis_638787865250458614" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638787865250458614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638787865250458614" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638787865250458614" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember_638787865250458614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638787865250458614" xlink:to="us-gaap_CollaborativeArrangementMember_638787865250458614" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DevelopmentMilestonesMember" xlink:label="btai_DevelopmentMilestonesMember_638787865250458614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementMember_638787865250458614" xlink:to="btai_DevelopmentMilestonesMember_638787865250458614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SalesMilestonesMember" xlink:label="btai_SalesMilestonesMember_638787865250458614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementMember_638787865250458614" xlink:to="btai_SalesMilestonesMember_638787865250458614" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638787865250458614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638787865250448614" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638787865250458614" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" xlink:label="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement_638787865250458614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638787865250458614" xlink:to="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement_638787865250458614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CollaborativeArrangementMilestonePaymentsPotential" xlink:label="btai_CollaborativeArrangementMilestonePaymentsPotential_638787865250468612" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638787865250458614" xlink:to="btai_CollaborativeArrangementMilestonePaymentsPotential_638787865250468612" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CollaborativeArrangementMilestonePotentialPercent" xlink:label="btai_CollaborativeArrangementMilestonePotentialPercent_638787865250468612" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638787865250458614" xlink:to="btai_CollaborativeArrangementMilestonePotentialPercent_638787865250468612" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638787865250468612" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638787865250458614" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638787865250468612" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638787865250468612" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638787865250458614" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638787865250468612" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638787865250468612" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638787865250458614" xlink:to="us-gaap_CostsAndExpenses_638787865250468612" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638787865250468612" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638787865250458614" xlink:to="us-gaap_OtherLiabilitiesCurrent_638787865250468612" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Debt and Credit Facilities - Debt summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638787865250478653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_2" xlink:to="us-gaap_DebtInstrumentTable_638787865250478653" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638787865250478653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638787865250478653" xlink:to="us-gaap_DebtInstrumentAxis_638787865250478653" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638787865250478653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638787865250478653" xlink:to="us-gaap_DebtInstrumentNameDomain_638787865250478653" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OfaAdministrativeAgentMember" xlink:label="btai_OfaAdministrativeAgentMember_638787865250478653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638787865250478653" xlink:to="btai_OfaAdministrativeAgentMember_638787865250478653" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CreditFacilityMember" xlink:label="btai_CreditFacilityMember_638787865250478653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="btai_OfaAdministrativeAgentMember_638787865250478653" xlink:to="btai_CreditFacilityMember_638787865250478653" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638787865250478653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638787865250478653" xlink:to="us-gaap_DebtInstrumentLineItems_638787865250478653" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_638787865250478653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638787865250478653" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_638787865250478653" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638787865250478653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638787865250478653" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638787865250478653" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638787865250478653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638787865250478653" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638787865250478653" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638787865250488656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638787865250478653" xlink:to="us-gaap_LongTermDebtNoncurrent_638787865250488656" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Debt and Credit Facilities - Credit Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable_638787865250488656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_7" xlink:to="us-gaap_LineOfCreditFacilityTable_638787865250488656" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638787865250488656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638787865250488656" xlink:to="us-gaap_DebtInstrumentAxis_638787865250488656" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638787865250488656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638787865250488656" xlink:to="us-gaap_DebtInstrumentNameDomain_638787865250488656" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OfaAdministrativeAgentMember" xlink:label="btai_OfaAdministrativeAgentMember_638787865250488656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638787865250488656" xlink:to="btai_OfaAdministrativeAgentMember_638787865250488656" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CreditFacilityMember" xlink:label="btai_CreditFacilityMember_638787865250488656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="btai_OfaAdministrativeAgentMember_638787865250488656" xlink:to="btai_CreditFacilityMember_638787865250488656" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638787865250488656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638787865250488656" xlink:to="srt_StatementScenarioAxis_638787865250488656" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638787865250498621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638787865250488656" xlink:to="srt_ScenarioUnspecifiedDomain_638787865250498621" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TrancheMember" xlink:label="btai_TrancheMember_638787865250498621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638787865250498621" xlink:to="btai_TrancheMember_638787865250498621" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TrancheTwoMember" xlink:label="btai_TrancheTwoMember_638787865250498621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638787865250498621" xlink:to="btai_TrancheTwoMember_638787865250498621" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TrancheBMember" xlink:label="btai_TrancheBMember_638787865250498621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638787865250498621" xlink:to="btai_TrancheBMember_638787865250498621" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TrancheCMember" xlink:label="btai_TrancheCMember_638787865250498621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638787865250498621" xlink:to="btai_TrancheCMember_638787865250498621" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TrancheDMember" xlink:label="btai_TrancheDMember_638787865250498621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638787865250498621" xlink:to="btai_TrancheDMember_638787865250498621" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_FromAndAfterFundingOfTrancheBLoansMember" xlink:label="btai_FromAndAfterFundingOfTrancheBLoansMember_638787865250498621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638787865250498621" xlink:to="btai_FromAndAfterFundingOfTrancheBLoansMember_638787865250498621" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" xlink:label="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_638787865250498621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638787865250498621" xlink:to="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_638787865250498621" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PeriodOneMember" xlink:label="btai_PeriodOneMember_638787865250498621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638787865250498621" xlink:to="btai_PeriodOneMember_638787865250498621" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PeriodTwoMember" xlink:label="btai_PeriodTwoMember_638787865250508615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638787865250498621" xlink:to="btai_PeriodTwoMember_638787865250508615" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PeriodThreeMember" xlink:label="btai_PeriodThreeMember_638787865250508615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638787865250498621" xlink:to="btai_PeriodThreeMember_638787865250508615" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638787865250508615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638787865250488656" xlink:to="srt_RangeAxis_638787865250508615" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638787865250508615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638787865250508615" xlink:to="srt_RangeMember_638787865250508615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638787865250508615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638787865250508615" xlink:to="srt_MinimumMember_638787865250508615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638787865250508615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638787865250508615" xlink:to="srt_MaximumMember_638787865250508615" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638787865250488656" xlink:to="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638787865250518620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638787865250518620" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_LineOfCreditFacilityInvestmentAllowed" xlink:label="btai_LineOfCreditFacilityInvestmentAllowed_638787865250518620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="btai_LineOfCreditFacilityInvestmentAllowed_638787865250518620" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount_638787865250518620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="us-gaap_DebtInstrumentFeeAmount_638787865250518620" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_LineOfCreditFacilityAmendmentFeePercentage" xlink:label="btai_LineOfCreditFacilityAmendmentFeePercentage_638787865250518620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="btai_LineOfCreditFacilityAmendmentFeePercentage_638787865250518620" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_LineOfCreditFacilityExitFeePercentage" xlink:label="btai_LineOfCreditFacilityExitFeePercentage_638787865250518620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="btai_LineOfCreditFacilityExitFeePercentage_638787865250518620" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638787865250518620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="us-gaap_DebtInstrumentFaceAmount_638787865250518620" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638787865250518620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638787865250518620" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_638787865250528615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_638787865250528615" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EquityInvestmentRightAmountUnfunded" xlink:label="btai_EquityInvestmentRightAmountUnfunded_638787865250528615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="btai_EquityInvestmentRightAmountUnfunded_638787865250528615" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638787865250528615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638787865250528615" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DebtInstrumentInterestRateDiscountRatePercentage" xlink:label="btai_DebtInstrumentInterestRateDiscountRatePercentage_638787865250528615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="btai_DebtInstrumentInterestRateDiscountRatePercentage_638787865250528615" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638787865250528615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638787865250528615" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_638787865250528615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638787865250528615" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_638787865250528615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DebtInstrumentIncrementalOnVariableRatePercent" xlink:label="btai_DebtInstrumentIncrementalOnVariableRatePercent_638787865250538620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="btai_DebtInstrumentIncrementalOnVariableRatePercent_638787865250538620" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PaidInKindInterestPercentage" xlink:label="btai_PaidInKindInterestPercentage_638787865250538620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="btai_PaidInKindInterestPercentage_638787865250538620" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TickingFeesPercentage" xlink:label="btai_TickingFeesPercentage_638787865250538620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="btai_TickingFeesPercentage_638787865250538620" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_NetCashRequiredMinimum" xlink:label="btai_NetCashRequiredMinimum_638787865250538620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="btai_NetCashRequiredMinimum_638787865250538620" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" xlink:label="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement_638787865250538620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement_638787865250538620" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SubsidiaryOwnershipPercentage" xlink:label="btai_SubsidiaryOwnershipPercentage_638787865250548622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="btai_SubsidiaryOwnershipPercentage_638787865250548622" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PercentageOfOutstandingLoan" xlink:label="btai_PercentageOfOutstandingLoan_638787865250548622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="btai_PercentageOfOutstandingLoan_638787865250548622" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" xlink:label="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt_638787865250548622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt_638787865250548622" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638787865250548622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638787865250548622" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_638787865250548622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="us-gaap_RepaymentsOfLongTermDebt_638787865250548622" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638787865250558622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638787865250558622" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded" xlink:label="btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded_638787865250558622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded_638787865250558622" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod" xlink:label="btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod_638787865250558622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250508615" xlink:to="btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod_638787865250558622" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" xlink:type="extended" xlink:title="99940903 - Disclosure - Debt and Credit Facilities - Revenue Interest Financing (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable_638787865250568622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_5" xlink:to="us-gaap_LineOfCreditFacilityTable_638787865250568622" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638787865250568622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638787865250568622" xlink:to="us-gaap_DebtInstrumentAxis_638787865250568622" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638787865250568622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638787865250568622" xlink:to="us-gaap_DebtInstrumentNameDomain_638787865250568622" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_RevenueInterestFinancingAgreementMember" xlink:label="btai_RevenueInterestFinancingAgreementMember_638787865250568622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638787865250568622" xlink:to="btai_RevenueInterestFinancingAgreementMember_638787865250568622" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638787865250568622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638787865250568622" xlink:to="srt_StatementScenarioAxis_638787865250568622" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638787865250568622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638787865250568622" xlink:to="srt_ScenarioUnspecifiedDomain_638787865250568622" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TrancheMember" xlink:label="btai_TrancheMember_638787865250568622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638787865250568622" xlink:to="btai_TrancheMember_638787865250568622" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638787865250568622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638787865250568622" xlink:to="srt_RangeAxis_638787865250568622" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638787865250568622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638787865250568622" xlink:to="srt_RangeMember_638787865250568622" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638787865250578678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638787865250568622" xlink:to="srt_MinimumMember_638787865250578678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638787865250578678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638787865250568622" xlink:to="srt_MaximumMember_638787865250578678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems_638787865250578678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638787865250568622" xlink:to="us-gaap_LineOfCreditFacilityLineItems_638787865250578678" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_638787865250578678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250578678" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_638787865250578678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638787865250578678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250578678" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638787865250578678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638787865250578678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250578678" xlink:to="us-gaap_DebtInstrumentFaceAmount_638787865250578678" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638787865250578678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250578678" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638787865250578678" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_BorrowingsBasedOnNetSalesPercent" xlink:label="btai_BorrowingsBasedOnNetSalesPercent_638787865250578678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250578678" xlink:to="btai_BorrowingsBasedOnNetSalesPercent_638787865250578678" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ThresholdRatioOfDebtToRevenueRatio" xlink:label="btai_ThresholdRatioOfDebtToRevenueRatio_638787865250588656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250578678" xlink:to="btai_ThresholdRatioOfDebtToRevenueRatio_638787865250588656" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" xlink:type="extended" xlink:title="99940904 - Disclosure - Debt and Credit Facilities - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable_638787865250588656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_6" xlink:to="us-gaap_LineOfCreditFacilityTable_638787865250588656" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638787865250588656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638787865250588656" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638787865250588656" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638787865250588656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638787865250588656" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638787865250588656" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_WarrantOaktreeAndQiaMember" xlink:label="btai_WarrantOaktreeAndQiaMember_638787865250588656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250588656" xlink:to="btai_WarrantOaktreeAndQiaMember_638787865250588656" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_NewWarrantsMember" xlink:label="btai_NewWarrantsMember_638787865250588656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250588656" xlink:to="btai_NewWarrantsMember_638787865250588656" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OriginalWarrantsMember" xlink:label="btai_OriginalWarrantsMember_638787865250598668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250588656" xlink:to="btai_OriginalWarrantsMember_638787865250598668" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_WarrantShares2024Member" xlink:label="btai_WarrantShares2024Member_638787865250598668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250588656" xlink:to="btai_WarrantShares2024Member_638787865250598668" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OnkosxcelWarrantMember" xlink:label="btai_OnkosxcelWarrantMember_638787865250598668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250588656" xlink:to="btai_OnkosxcelWarrantMember_638787865250598668" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems_638787865250598668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638787865250588656" xlink:to="us-gaap_LineOfCreditFacilityLineItems_638787865250598668" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638787865250598668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250598668" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638787865250598668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638787865250598668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250598668" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638787865250598668" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_RightToPurchaseStockLenders" xlink:label="btai_RightToPurchaseStockLenders_638787865250598668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250598668" xlink:to="btai_RightToPurchaseStockLenders_638787865250598668" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PremiumSharePricePercent" xlink:label="btai_PremiumSharePricePercent_638787865250598668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250598668" xlink:to="btai_PremiumSharePricePercent_638787865250598668" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" xlink:label="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants_638787865250598668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250598668" xlink:to="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants_638787865250598668" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PercentageOfFairValueConsiderationToBePaid" xlink:label="btai_PercentageOfFairValueConsiderationToBePaid_638787865250608709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250598668" xlink:to="btai_PercentageOfFairValueConsiderationToBePaid_638787865250608709" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PercentageOfValuationApplicableToInitialProfits" xlink:label="btai_PercentageOfValuationApplicableToInitialProfits_638787865250608709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250598668" xlink:to="btai_PercentageOfValuationApplicableToInitialProfits_638787865250608709" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638787865250608709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638787865250598668" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638787865250608709" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails" xlink:type="extended" xlink:title="99940905 - Disclosure - Debt and Credit Facilities - Maturities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638787865250608709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_3" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638787865250608709" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638787865250608709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_3" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638787865250608709" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails" xlink:type="extended" xlink:title="99940906 - Disclosure - Debt and Credit Facilities - Interest (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638787865250618726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_4" xlink:to="us-gaap_InterestExpenseDebt_638787865250618726" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638787865250618726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_4" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638787865250618726" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating_638787865250618726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_4" xlink:to="us-gaap_InterestExpenseNonoperating_638787865250618726" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Derivative Financial Instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638787865250618726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638787865250618726" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638787865250618726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638787865250618726" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638787865250618726" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638787865250628688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638787865250618726" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638787865250628688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EquityInvestmentMember" xlink:label="btai_EquityInvestmentMember_638787865250628688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250628688" xlink:to="btai_EquityInvestmentMember_638787865250628688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2024AccompanyingWarrantsMember" xlink:label="btai_Warrants2024AccompanyingWarrantsMember_638787865250628688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250628688" xlink:to="btai_Warrants2024AccompanyingWarrantsMember_638787865250628688" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" xlink:label="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_638787865250628688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="btai_Warrants2024AccompanyingWarrantsMember_638787865250628688" xlink:to="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_638787865250628688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_November2024AccompanyingWarrantsMember" xlink:label="btai_November2024AccompanyingWarrantsMember_638787865250628688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250628688" xlink:to="btai_November2024AccompanyingWarrantsMember_638787865250628688" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638787865250628688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638787865250618726" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638787865250628688" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_638787865250628688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638787865250628688" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_638787865250628688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638787865250628688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638787865250628688" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638787865250628688" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638787865250628688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638787865250628688" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638787865250628688" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638787865250628688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638787865250628688" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638787865250628688" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_638787865250638636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638787865250628688" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_638787865250638636" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_638787865250638636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638787865250628688" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_638787865250638636" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Common Stock Financing Activities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_FinancingActivitiesAbstract" xlink:label="FinancingActivitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638787865250638636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancingActivitiesAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638787865250638636" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638787865250638636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638787865250638636" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638787865250638636" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638787865250638636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638787865250638636" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638787865250638636" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_JefferiesMember" xlink:label="btai_JefferiesMember_638787865250638636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638787865250638636" xlink:to="btai_JefferiesMember_638787865250638636" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_RegisteredDirectOfferingMember" xlink:label="btai_RegisteredDirectOfferingMember_638787865250648593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638787865250638636" xlink:to="btai_RegisteredDirectOfferingMember_638787865250648593" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_RegisteredOfferingMember" xlink:label="btai_RegisteredOfferingMember_638787865250648593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638787865250638636" xlink:to="btai_RegisteredOfferingMember_638787865250648593" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638787865250648593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638787865250638636" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638787865250648593" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638787865250648593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638787865250648593" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638787865250648593" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2024AccompanyingWarrantsMember" xlink:label="btai_Warrants2024AccompanyingWarrantsMember_638787865250648593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250648593" xlink:to="btai_Warrants2024AccompanyingWarrantsMember_638787865250648593" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2024PreFundedWarrantsMember" xlink:label="btai_Warrants2024PreFundedWarrantsMember_638787865250648593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250648593" xlink:to="btai_Warrants2024PreFundedWarrantsMember_638787865250648593" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_November2024AccompanyingWarrantsMember" xlink:label="btai_November2024AccompanyingWarrantsMember_638787865250648593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250648593" xlink:to="btai_November2024AccompanyingWarrantsMember_638787865250648593" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_November2024PrefundedAccompanyingWarrantsMember" xlink:label="btai_November2024PrefundedAccompanyingWarrantsMember_638787865250648593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250648593" xlink:to="btai_November2024PrefundedAccompanyingWarrantsMember_638787865250648593" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638787865250648593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638787865250638636" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638787865250648593" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SaleOfStockMaximumValueSharesToBeIssued" xlink:label="btai_SaleOfStockMaximumValueSharesToBeIssued_638787865250658594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638787865250648593" xlink:to="btai_SaleOfStockMaximumValueSharesToBeIssued_638787865250658594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638787865250658594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638787865250648593" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638787865250658594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638787865250658594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638787865250648593" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638787865250658594" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638787865250658594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638787865250648593" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638787865250658594" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638787865250658594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638787865250648593" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638787865250658594" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638787865250658594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638787865250648593" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638787865250658594" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638787865250658594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638787865250648593" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638787865250658594" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638787865250658594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638787865250648593" xlink:to="us-gaap_SharesIssuedPricePerShare_638787865250658594" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638787865250668595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638787865250648593" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638787865250668595" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercised_638787865250668595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638787865250648593" xlink:to="btai_StockIssuedDuringPeriodSharesWarrantsExercised_638787865250668595" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_638787865250668595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638787865250648593" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_638787865250668595" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638787865250668595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638787865250648593" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638787865250668595" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Stock-Based Compensation - Description (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250678677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250678677" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638787865250678677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250678677" xlink:to="us-gaap_PlanNameAxis_638787865250678677" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638787865250678677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638787865250678677" xlink:to="us-gaap_PlanNameDomain_638787865250678677" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_IncentiveAwardPlan2020Member" xlink:label="btai_IncentiveAwardPlan2020Member_638787865250678677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638787865250678677" xlink:to="btai_IncentiveAwardPlan2020Member_638787865250678677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_StockPlan2017Member" xlink:label="btai_StockPlan2017Member_638787865250678677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638787865250678677" xlink:to="btai_StockPlan2017Member_638787865250678677" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250678677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250678677" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250678677" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638787865250678677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250678677" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638787865250678677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638787865250678677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250678677" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638787865250678677" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_638787865250678677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250678677" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_638787865250678677" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638787865250688618" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250678677" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638787865250688618" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638787865250688618" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250678677" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638787865250688618" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638787865250688618" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250678677" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638787865250688618" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638787865250688618" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250678677" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638787865250688618" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" xlink:type="extended" xlink:title="99941202 - Disclosure - Stock-Based Compensation - Non-options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250688618" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250688618" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638787865250688618" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250688618" xlink:to="us-gaap_AwardTypeAxis_638787865250688618" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638787865250698601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638787865250688618" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638787865250698601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638787865250698601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638787865250698601" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638787865250698601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_638787865250698601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638787865250698601" xlink:to="us-gaap_PerformanceSharesMember_638787865250698601" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TimeBasedProfitSharingUnitsMember" xlink:label="btai_TimeBasedProfitSharingUnitsMember_638787865250698601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638787865250698601" xlink:to="btai_TimeBasedProfitSharingUnitsMember_638787865250698601" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_RestrictedStockUnitsOnkosxcelMember" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember_638787865250698601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638787865250698601" xlink:to="btai_RestrictedStockUnitsOnkosxcelMember_638787865250698601" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_638787865250698601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250688618" xlink:to="us-gaap_GranteeStatusAxis_638787865250698601" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_638787865250698601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_638787865250698601" xlink:to="us-gaap_GranteeStatusDomain_638787865250698601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638787865250698601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638787865250698601" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638787865250698601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_638787865250698601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638787865250698601" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_638787865250698601" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250708642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250688618" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250708642" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638787865250708642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250708642" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638787865250708642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638787865250708642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638787865250708642" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638787865250708642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638787865250708642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638787865250708642" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638787865250708642" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638787865250708642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638787865250708642" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638787865250708642" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_638787865250708642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638787865250708642" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_638787865250708642" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638787865250708642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638787865250708642" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638787865250708642" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6387878652507086421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638787865250708642" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6387878652507086421" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638787865250718601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638787865250708642" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638787865250718601" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638787865250718601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250708642" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638787865250718601" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638787865250718601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638787865250718601" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638787865250718601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638787865250718601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638787865250718601" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638787865250718601" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_638787865250718601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638787865250718601" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_638787865250718601" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638787865250718601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638787865250718601" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638787865250718601" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6387878652507186011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638787865250718601" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6387878652507186011" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638787865250728599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250708642" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638787865250728599" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638787865250728599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250708642" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638787865250728599" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638787865250728599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250708642" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638787865250728599" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638787865250728599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250708642" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638787865250728599" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_638787865250728599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250708642" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_638787865250728599" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" xlink:type="extended" xlink:title="99941203 - Disclosure - Stock-Based Compensation - Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250738628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250738628" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638787865250738628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250738628" xlink:to="us-gaap_AwardTypeAxis_638787865250738628" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638787865250738628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638787865250738628" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638787865250738628" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638787865250738628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638787865250738628" xlink:to="us-gaap_EmployeeStockOptionMember_638787865250738628" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250738628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250738628" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250738628" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638787865250738628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250738628" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638787865250738628" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638787865250748625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638787865250738628" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638787865250748625" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638787865250748625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638787865250738628" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638787865250748625" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638787865250748625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638787865250738628" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638787865250748625" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_638787865250748625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638787865250738628" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_638787865250748625" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638787865250748625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638787865250738628" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638787865250748625" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6387878652507486251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638787865250738628" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6387878652507486251" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638787865250748625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638787865250738628" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638787865250748625" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638787865250748625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250738628" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638787865250748625" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638787865250758600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638787865250748625" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638787865250758600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638787865250758600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638787865250748625" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638787865250758600" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638787865250758600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638787865250748625" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638787865250758600" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:label="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_638787865250758600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638787865250748625" xlink:to="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_638787865250758600" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6387878652507586001" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638787865250748625" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6387878652507586001" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638787865250758600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638787865250748625" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638787865250758600" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638787865250758600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250738628" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638787865250758600" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638787865250768599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638787865250758600" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638787865250768599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638787865250768599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638787865250758600" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638787865250768599" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638787865250768599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638787865250758600" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638787865250768599" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638787865250768599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638787865250758600" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638787865250768599" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_638787865250768599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638787865250758600" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_638787865250768599" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638787865250768599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638787865250758600" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638787865250768599" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638787865250768599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638787865250758600" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638787865250768599" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638787865250778599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638787865250758600" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638787865250778599" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638787865250778599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638787865250758600" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638787865250778599" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xlink:type="extended" xlink:title="99941204 - Disclosure - Stock-Based Compensation - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250778599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250778599" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638787865250778599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250778599" xlink:to="us-gaap_AwardTypeAxis_638787865250778599" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638787865250788621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638787865250778599" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638787865250788621" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_TimeBasedProfitSharingUnitsMember" xlink:label="btai_TimeBasedProfitSharingUnitsMember_638787865250788621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638787865250788621" xlink:to="btai_TimeBasedProfitSharingUnitsMember_638787865250788621" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638787865250788621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638787865250788621" xlink:to="us-gaap_EmployeeStockOptionMember_638787865250788621" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638787865250788621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250778599" xlink:to="srt_RangeAxis_638787865250788621" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638787865250788621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638787865250788621" xlink:to="srt_RangeMember_638787865250788621" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638787865250788621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638787865250788621" xlink:to="srt_MinimumMember_638787865250788621" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638787865250788621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638787865250788621" xlink:to="srt_MaximumMember_638787865250788621" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250788621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250778599" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250788621" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638787865250788621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250788621" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638787865250788621" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638787865250798636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250788621" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638787865250798636" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638787865250798636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250788621" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638787865250798636" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638787865250798636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250788621" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638787865250798636" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638787865250798636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250788621" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638787865250798636" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638787865250798636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250788621" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638787865250798636" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638787865250798636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250788621" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638787865250798636" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638787865250798636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250788621" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638787865250798636" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="99941205 - Disclosure - Stock-Based Compensation - Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250808605" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250808605" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638787865250808605" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250808605" xlink:to="us-gaap_IncomeStatementLocationAxis_638787865250808605" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638787865250808605" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638787865250808605" xlink:to="us-gaap_IncomeStatementLocationDomain_638787865250808605" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638787865250808605" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638787865250808605" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638787865250808605" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638787865250808605" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638787865250808605" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638787865250808605" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250808605" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638787865250808605" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250808605" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638787865250808605" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638787865250808605" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638787865250808605" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" xlink:type="extended" xlink:title="99941206 - Disclosure - Stock-Based Compensation - ESPP (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_638787865250818603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_638787865250818603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638787865250818603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_638787865250818603" xlink:to="us-gaap_PlanNameAxis_638787865250818603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638787865250818603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638787865250818603" xlink:to="us-gaap_PlanNameDomain_638787865250818603" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EmployeeStockPurchasePlan2020Member" xlink:label="btai_EmployeeStockPurchasePlan2020Member_638787865250818603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638787865250818603" xlink:to="btai_EmployeeStockPurchasePlan2020Member_638787865250818603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638787865250818603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_638787865250818603" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638787865250818603" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638787865250818603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638787865250818603" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638787865250818603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_638787865250818603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638787865250818603" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_638787865250818603" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" xlink:label="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred_638787865250828604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638787865250818603" xlink:to="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred_638787865250828604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638787865250828604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638787865250818603" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638787865250828604" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638787865250828604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638787865250818603" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638787865250828604" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638787865250828604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638787865250818603" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638787865250828604" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638787865250828604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638787865250818603" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638787865250828604" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" xlink:type="extended" xlink:title="99941301 - Disclosure - Leases - Maturities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638787865250828604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638787865250828604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638787865250838608" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638787865250828604" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638787865250838608" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638787865250838608" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638787865250828604" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638787865250838608" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638787865250838608" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638787865250828604" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638787865250838608" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638787865250838608" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638787865250828604" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638787865250838608" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638787865250838608" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638787865250828604" xlink:to="us-gaap_OperatingLeaseLiability_638787865250838608" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638787865250838608" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638787865250828604" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638787865250838608" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638787865250838608" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent_638787865250838608" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638787865250838608" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638787865250838608" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638787865250828604" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638787865250838608" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails" xlink:type="extended" xlink:title="99941302 - Disclosure - Leases - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_638787865250848620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_OperatingLeaseExpense_638787865250848620" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638787865250848620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638787865250848620" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638787865250848620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638787865250848620" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlanDetails" xlink:type="extended" xlink:title="99941401 - Disclosure - Employee Benefit Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAbstract" xlink:label="us-gaap_DefinedBenefitPlanAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638787865250858674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract_1" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638787865250858674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638787865250858674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract_1" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638787865250858674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638787865250858674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract_1" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638787865250858674" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" xlink:type="extended" xlink:title="99941501 - Disclosure - Fair Value Measurements - Hierarchy (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638787865250858674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_2" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638787865250858674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638787865250858674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638787865250858674" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638787865250858674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638787865250858674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638787865250858674" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638787865250858674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638787865250858674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638787865250858674" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638787865250858674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_638787865250858674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638787865250858674" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_638787865250858674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_638787865250868628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_638787865250858674" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_638787865250868628" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_638787865250868628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_638787865250868628" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_638787865250868628" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638787865250868628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638787865250858674" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638787865250868628" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638787865250868628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638787865250868628" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638787865250868628" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638787865250868628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638787865250868628" xlink:to="us-gaap_FairValueInputsLevel1Member_638787865250868628" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_638787865250868628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638787865250868628" xlink:to="us-gaap_FairValueInputsLevel2Member_638787865250868628" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638787865250868628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638787865250868628" xlink:to="us-gaap_FairValueInputsLevel3Member_638787865250868628" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638787865250868628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638787865250858674" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638787865250868628" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638787865250878627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638787865250868628" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638787865250878627" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_BioxcelWarrantsAggregateMember" xlink:label="btai_BioxcelWarrantsAggregateMember_638787865250878627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250878627" xlink:to="btai_BioxcelWarrantsAggregateMember_638787865250878627" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OnkosxcelWarrantMember" xlink:label="btai_OnkosxcelWarrantMember_638787865250878627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250878627" xlink:to="btai_OnkosxcelWarrantMember_638787865250878627" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638787865250878627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638787865250858674" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638787865250878627" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638787865250878627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638787865250878627" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638787865250878627" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638787865250878627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638787865250878627" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638787865250878627" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details" xlink:type="extended" xlink:title="99941502 - Disclosure - Fair Value Measurements - Level 3 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638787865250888654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_3" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638787865250888654" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638787865250888654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638787865250888654" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638787865250888654" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638787865250888654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638787865250888654" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638787865250888654" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EquityInvestmentMember" xlink:label="btai_EquityInvestmentMember_638787865250888654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250888654" xlink:to="btai_EquityInvestmentMember_638787865250888654" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638787865250888654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638787865250888654" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638787865250888654" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638787865250888654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638787865250888654" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638787865250888654" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638787865250888654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638787865250888654" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638787865250888654" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_638787865250888654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638787865250888654" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_638787865250888654" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638787865250888654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638787865250888654" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638787865250888654" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_638787865250898656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638787865250888654" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_638787865250898656" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638787865250898656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638787865250888654" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638787865250898656" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" xlink:type="extended" xlink:title="99941503 - Disclosure - Fair Value Measurements - Inputs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638787865250898656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_4" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638787865250898656" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638787865250898656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638787865250898656" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638787865250898656" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638787865250898656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638787865250898656" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638787865250898656" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EquityInvestmentMember" xlink:label="btai_EquityInvestmentMember_638787865250908628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250898656" xlink:to="btai_EquityInvestmentMember_638787865250908628" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OnkosxcelWarrantMember" xlink:label="btai_OnkosxcelWarrantMember_638787865250908628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250898656" xlink:to="btai_OnkosxcelWarrantMember_638787865250908628" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_WarrantOaktreeAndQiaMember" xlink:label="btai_WarrantOaktreeAndQiaMember_638787865250908628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250898656" xlink:to="btai_WarrantOaktreeAndQiaMember_638787865250908628" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2023Member" xlink:label="btai_Warrants2023Member_638787865250908628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250898656" xlink:to="btai_Warrants2023Member_638787865250908628" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2024Member" xlink:label="btai_Warrants2024Member_638787865250908628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250898656" xlink:to="btai_Warrants2024Member_638787865250908628" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2024AccompanyingWarrantsMember" xlink:label="btai_Warrants2024AccompanyingWarrantsMember_638787865250908628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250898656" xlink:to="btai_Warrants2024AccompanyingWarrantsMember_638787865250908628" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" xlink:label="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_638787865250908628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="btai_Warrants2024AccompanyingWarrantsMember_638787865250908628" xlink:to="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_638787865250908628" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" xlink:label="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_638787865250908628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="btai_Warrants2024AccompanyingWarrantsMember_638787865250908628" xlink:to="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_638787865250908628" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_November2024AccompanyingWarrantsMember" xlink:label="btai_November2024AccompanyingWarrantsMember_638787865250908628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250898656" xlink:to="btai_November2024AccompanyingWarrantsMember_638787865250908628" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638787865250908628" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638787865250898656" xlink:to="us-gaap_MeasurementInputTypeAxis_638787865250908628" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638787865250918626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638787865250908628" xlink:to="us-gaap_MeasurementInputTypeDomain_638787865250918626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember_638787865250918626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638787865250918626" xlink:to="us-gaap_MeasurementInputExercisePriceMember_638787865250918626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638787865250918626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638787865250918626" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638787865250918626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_MeasurementInputProbabilityOfExerciseMember" xlink:label="btai_MeasurementInputProbabilityOfExerciseMember_638787865250918626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638787865250918626" xlink:to="btai_MeasurementInputProbabilityOfExerciseMember_638787865250918626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638787865250918626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638787865250918626" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638787865250918626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_MeasurementInputEstimatedPremiumMember" xlink:label="btai_MeasurementInputEstimatedPremiumMember_638787865250918626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638787865250918626" xlink:to="btai_MeasurementInputEstimatedPremiumMember_638787865250918626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember_638787865250918626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638787865250918626" xlink:to="us-gaap_MeasurementInputDiscountRateMember_638787865250918626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638787865250918626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638787865250918626" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638787865250918626" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_638787865250928649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638787865250918626" xlink:to="us-gaap_MeasurementInputSharePriceMember_638787865250928649" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638787865250928649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638787865250898656" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638787865250928649" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_638787865250928649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638787865250928649" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_638787865250928649" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_638787865250928649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638787865250928649" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_638787865250928649" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue_638787865250928649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638787865250928649" xlink:to="us-gaap_DebtInstrumentFairValue_638787865250928649" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_638787865250928649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638787865250928649" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_638787865250928649" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638787865250938652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638787865250928649" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638787865250938652" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638787865250938652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638787865250928649" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638787865250938652" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_638787865250938652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638787865250928649" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_638787865250938652" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_638787865250938652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638787865250928649" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_638787865250938652" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638787865250938652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638787865250928649" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638787865250938652" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_638787865250938652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638787865250928649" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_638787865250938652" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_638787865250948653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638787865250928649" xlink:to="us-gaap_WarrantsAndRightsOutstanding_638787865250948653" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638787865250948653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638787865250928649" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638787865250948653" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails" xlink:type="extended" xlink:title="99941504 - Disclosure - Fair Value Measurements - Warrants outstanding (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638787865250948653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_5" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638787865250948653" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638787865250948653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638787865250948653" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638787865250948653" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638787865250958662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638787865250948653" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638787865250958662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_WarrantOaktreeAndQiaMember" xlink:label="btai_WarrantOaktreeAndQiaMember_638787865250958662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250958662" xlink:to="btai_WarrantOaktreeAndQiaMember_638787865250958662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2023Member" xlink:label="btai_Warrants2023Member_638787865250958662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250958662" xlink:to="btai_Warrants2023Member_638787865250958662" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_WarrantShares2024Member" xlink:label="btai_WarrantShares2024Member_638787865250958662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250958662" xlink:to="btai_WarrantShares2024Member_638787865250958662" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_NewWarrantsMember" xlink:label="btai_NewWarrantsMember_638787865250958662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250958662" xlink:to="btai_NewWarrantsMember_638787865250958662" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" xlink:label="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_638787865250958662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250958662" xlink:to="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_638787865250958662" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" xlink:label="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_638787865250958662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250958662" xlink:to="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_638787865250958662" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_November2024AccompanyingWarrantsMember" xlink:label="btai_November2024AccompanyingWarrantsMember_638787865250958662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865250958662" xlink:to="btai_November2024AccompanyingWarrantsMember_638787865250958662" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638787865250958662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638787865250948653" xlink:to="srt_CounterpartyNameAxis_638787865250958662" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638787865250958662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638787865250958662" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638787865250958662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ArmisticeCapitalMasterFundMember" xlink:label="btai_ArmisticeCapitalMasterFundMember_638787865250968654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638787865250958662" xlink:to="btai_ArmisticeCapitalMasterFundMember_638787865250968654" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_HeightsCapitalManagementMember" xlink:label="btai_HeightsCapitalManagementMember_638787865250968654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638787865250958662" xlink:to="btai_HeightsCapitalManagementMember_638787865250968654" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_HudsonBayCapitalManagementMember" xlink:label="btai_HudsonBayCapitalManagementMember_638787865250968654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638787865250958662" xlink:to="btai_HudsonBayCapitalManagementMember_638787865250968654" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_IntraCoastalCapitalMember" xlink:label="btai_IntraCoastalCapitalMember_638787865250968654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638787865250958662" xlink:to="btai_IntraCoastalCapitalMember_638787865250968654" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638787865250968654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638787865250948653" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638787865250968654" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638787865250968654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638787865250968654" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638787865250968654" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638787865250968654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638787865250968654" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638787865250968654" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails" xlink:type="extended" xlink:title="99941601 - Disclosure - Income Taxes - Deferred Tax (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_638787865250978662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_638787865250978662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_638787865250978662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_638787865250978662" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638787865250978662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638787865250978662" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638787865250978662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638787865250978662" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638787865250978662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638787865250978662" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638787865250978662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638787865250978662" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638787865250978662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638787865250978662" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DeferredTaxAssetsLeaseAccountingLiability" xlink:label="btai_DeferredTaxAssetsLeaseAccountingLiability_638787865250988672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="btai_DeferredTaxAssetsLeaseAccountingLiability_638787865250988672" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_638787865250988672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_638787865250988672" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DeferredTaxAssetsCapitalizedIpoCosts" xlink:label="btai_DeferredTaxAssetsCapitalizedIpoCosts_638787865250988672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="btai_DeferredTaxAssetsCapitalizedIpoCosts_638787865250988672" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_DeferredTaxAssetsCancellationOfDebt" xlink:label="btai_DeferredTaxAssetsCancellationOfDebt_638787865250988672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="btai_DeferredTaxAssetsCancellationOfDebt_638787865250988672" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638787865250988672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638787865250988672" order="12" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638787865250988672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet_638787865250988672" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_638787865250988672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_638787865250988672" order="14" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives_638787865250988672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDerivatives_638787865250988672" order="15" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638787865250998654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638787865250998654" order="16" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638787865250998654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638787865250998654" order="17" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638787865250998654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638787865250998654" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails" xlink:type="extended" xlink:title="99941602 - Disclosure - Income Taxes - Reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638787865250998654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638787865250998654" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638787865250998654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638787865250998654" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638787865250998654" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638787865251009009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638787865250998654" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638787865251009009" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638787865251009009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638787865251009009" xlink:to="us-gaap_DomesticCountryMember_638787865251009009" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638787865251009009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638787865251009009" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638787865251009009" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638787865251009009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638787865250998654" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638787865251009009" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638787865251009009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638787865251009009" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638787865251009009" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638787865251009009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638787865251009009" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638787865251009009" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_638787865251009009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638787865251009009" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_638787865251009009" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EffectiveIncomeTaxRateReconciliationWarrantValuationAmount" xlink:label="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationAmount_638787865251009009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638787865251009009" xlink:to="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationAmount_638787865251009009" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_638787865251018635" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638787865251009009" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_638787865251018635" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638787865251018635" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638787865251009009" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638787865251018635" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_638787865251018635" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638787865251009009" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_638787865251018635" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638787865251018635" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638787865251009009" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638787865251018635" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638787865251018635" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638787865251009009" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638787865251018635" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638787865251018635" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638787865251009009" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638787865251018635" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638787865251018635" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638787865251018635" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638787865251018635" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638787865251028659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638787865251018635" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638787865251028659" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_EffectiveIncomeTaxRateReconciliationWarrantValuationPercent" xlink:label="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationPercent_638787865251028659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638787865251018635" xlink:to="btai_EffectiveIncomeTaxRateReconciliationWarrantValuationPercent_638787865251028659" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638787865251028659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638787865251018635" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638787865251028659" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638787865251028659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638787865251018635" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638787865251028659" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638787865251028659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638787865251018635" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638787865251028659" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638787865251028659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638787865251018635" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638787865251028659" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638787865251028659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638787865251018635" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638787865251028659" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638787865251038664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638787865251009009" xlink:to="us-gaap_OperatingLossCarryforwards_638787865251038664" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OperatingLossCarryforwardsNoExpiration" xlink:label="btai_OperatingLossCarryforwardsNoExpiration_638787865251038664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638787865251009009" xlink:to="btai_OperatingLossCarryforwardsNoExpiration_638787865251038664" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_638787865251038664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638787865251009009" xlink:to="us-gaap_TaxCreditCarryforwardAmount_638787865251038664" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638787865251038664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638787865251009009" xlink:to="us-gaap_UnrecognizedTaxBenefits_638787865251038664" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_638787865251038664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638787865251009009" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_638787865251038664" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="99941701 - Disclosure - Net Loss Per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638787865251048661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss_638787865251048661" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638787865251048661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638787865251048661" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638787865251048661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638787865251048661" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638787865251048661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638787865251048661" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638787865251048661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638787865251048661" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails" xlink:type="extended" xlink:title="99941702 - Disclosure - Net Loss Per Share - Antidilutive (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638787865251048661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638787865251048661" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638787865251048661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638787865251048661" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638787865251048661" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638787865251048661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638787865251048661" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638787865251048661" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638787865251048661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638787865251048661" xlink:to="us-gaap_EmployeeStockOptionMember_638787865251048661" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638787865251048661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638787865251048661" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638787865251048661" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_638787865251048661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638787865251048661" xlink:to="us-gaap_PerformanceSharesMember_638787865251048661" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_BioxcelWarrantsAggregateMember" xlink:label="btai_BioxcelWarrantsAggregateMember_638787865251048661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638787865251048661" xlink:to="btai_BioxcelWarrantsAggregateMember_638787865251048661" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638787865251048661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638787865251048661" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638787865251048661" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638787865251048661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638787865251048661" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638787865251048661" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99941801 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable_638787865251154866" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638787865251154866" xlink:to="srt_RangeAxis_638787865251154866" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638787865251154866" xlink:to="srt_RangeMember_638787865251154866" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638787865251154866" xlink:to="srt_MinimumMember_638787865251154866" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638787865251154866" xlink:to="srt_MaximumMember_638787865251154866" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638787865251154866" xlink:to="us-gaap_OtherCommitmentsLineItems_638787865251154866" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638787865251154866" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_638787865251154866" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638787865251154866" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod_638787865251154866" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638787865251154866" xlink:to="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_638787865251154866" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638787865251154866" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_638787865251154866" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638787865251154866" xlink:to="us-gaap_ContractualObligationDueInSecondYear_638787865251154866" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638787865251154866" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_638787865251154866" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails" xlink:type="extended" xlink:title="99941901 - Disclosure - Segment Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_638787865251154866" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_638787865251154866" xlink:to="us-gaap_StatementBusinessSegmentsAxis_638787865251154866" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_638787865251154866" xlink:to="us-gaap_SegmentDomain_638787865251154866" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SingleReportableSegmentMember" xlink:label="btai_SingleReportableSegmentMember_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638787865251154866" xlink:to="btai_SingleReportableSegmentMember_638787865251154866" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_638787865251154866" xlink:to="srt_ConsolidationItemsAxis_638787865251154866" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis_638787865251154866" xlink:to="srt_ConsolidationItemsDomain_638787865251154866" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain_638787865251154866" xlink:to="us-gaap_OperatingSegmentsMember_638787865251154866" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_638787865251154866" xlink:to="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638787865251154866" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638787865251154866" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638787865251154866" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638787865251154866" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638787865251154866" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638787865251154866" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_638787865251154866" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense" xlink:label="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638787865251154866" xlink:to="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense_638787865251154866" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" xlink:label="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638787865251154866" xlink:to="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense_638787865251154866" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseProfessionalFees" xlink:label="btai_ResearchAndDevelopmentExpenseProfessionalFees_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638787865251154866" xlink:to="btai_ResearchAndDevelopmentExpenseProfessionalFees_638787865251154866" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense" xlink:label="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638787865251154866" xlink:to="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense_638787865251154866" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" xlink:label="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638787865251154866" xlink:to="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense_638787865251154866" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_ResearchAndDevelopmentExpenseTravelAndOtherExpenses" xlink:label="btai_ResearchAndDevelopmentExpenseTravelAndOtherExpenses_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638787865251154866" xlink:to="btai_ResearchAndDevelopmentExpenseTravelAndOtherExpenses_638787865251154866" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638787865251154866" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638787865251154866" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectOperatingCostsAbstract" xlink:label="us-gaap_DirectOperatingCostsAbstract_638787865251154866" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638787865251154866" xlink:to="us-gaap_DirectOperatingCostsAbstract_638787865251154866" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsLaborAndRelatedExpense" xlink:label="btai_CommercialCostsLaborAndRelatedExpense_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DirectOperatingCostsAbstract_638787865251154866" xlink:to="btai_CommercialCostsLaborAndRelatedExpense_638787865251208178" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsShareBasedPaymentArrangementExpense" xlink:label="btai_CommercialCostsShareBasedPaymentArrangementExpense_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DirectOperatingCostsAbstract_638787865251154866" xlink:to="btai_CommercialCostsShareBasedPaymentArrangementExpense_638787865251208178" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsProfessionalFees" xlink:label="btai_CommercialCostsProfessionalFees_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DirectOperatingCostsAbstract_638787865251154866" xlink:to="btai_CommercialCostsProfessionalFees_638787865251208178" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsCommercialAndMarketing" xlink:label="btai_CommercialCostsCommercialAndMarketing_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DirectOperatingCostsAbstract_638787865251154866" xlink:to="btai_CommercialCostsCommercialAndMarketing_638787865251208178" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsTravelAndOtherExpenses" xlink:label="btai_CommercialCostsTravelAndOtherExpenses_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DirectOperatingCostsAbstract_638787865251154866" xlink:to="btai_CommercialCostsTravelAndOtherExpenses_638787865251208178" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_CommercialCostsOtherExpenses" xlink:label="btai_CommercialCostsOtherExpenses_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DirectOperatingCostsAbstract_638787865251154866" xlink:to="btai_CommercialCostsOtherExpenses_638787865251208178" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DirectOperatingCostsAbstract_638787865251154866" xlink:to="us-gaap_OtherCostAndExpenseOperating_638787865251208178" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638787865251154866" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_638787865251208178" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" xlink:label="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_638787865251208178" xlink:to="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense_638787865251208178" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" xlink:label="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_638787865251208178" xlink:to="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense_638787865251208178" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SellingGeneralAndAdministrativeExpenseProfessionalFees" xlink:label="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_638787865251208178" xlink:to="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees_638787865251208178" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" xlink:label="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_638787865251208178" xlink:to="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses_638787865251208178" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_SellingGeneralAndAdministrativeCostsOtherExpenses" xlink:label="btai_SellingGeneralAndAdministrativeCostsOtherExpenses_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_638787865251208178" xlink:to="btai_SellingGeneralAndAdministrativeCostsOtherExpenses_638787865251208178" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_638787865251208178" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638787865251208178" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638787865251154866" xlink:to="us-gaap_RestructuringCharges_638787865251208178" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638787865251154866" xlink:to="us-gaap_CostsAndExpenses_638787865251208178" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638787865251154866" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638787865251208178" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638787865251208178" xlink:to="us-gaap_InterestExpenseNonoperating_638787865251208178" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638787865251208178" xlink:to="us-gaap_InvestmentIncomeInterest_638787865251208178" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638787865251208178" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638787865251208178" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638787865251154866" xlink:to="us-gaap_NetIncomeLoss_638787865251208178" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638787865251154866" xlink:to="us-gaap_NumberOfOperatingSegments_638787865251208178" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638787865251154866" xlink:to="us-gaap_NumberOfReportableSegments_638787865251208178" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99942001 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_638787865251208178" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638787865251208178" xlink:to="us-gaap_SubsequentEventTypeAxis_638787865251208178" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638787865251208178" xlink:to="us-gaap_SubsequentEventTypeDomain_638787865251208178" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638787865251208178" xlink:to="us-gaap_SubsequentEventMember_638787865251208178" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638787865251208178" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638787865251208178" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638787865251208178" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638787865251208178" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_RegisteredOfferingMember" xlink:label="btai_RegisteredOfferingMember_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638787865251208178" xlink:to="btai_RegisteredOfferingMember_638787865251208178" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PurchaseAgreementRegisteredSecuritiesMember" xlink:label="btai_PurchaseAgreementRegisteredSecuritiesMember_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638787865251208178" xlink:to="btai_PurchaseAgreementRegisteredSecuritiesMember_638787865251208178" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638787865251208178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638787865251208178" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638787865251208178" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638787865251261173" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638787865251208178" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638787865251261173" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_November2024AccompanyingWarrantsMember" xlink:label="btai_November2024AccompanyingWarrantsMember_638787865251261173" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865251261173" xlink:to="btai_November2024AccompanyingWarrantsMember_638787865251261173" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_November2024PrefundedAccompanyingWarrantsMember" xlink:label="btai_November2024PrefundedAccompanyingWarrantsMember_638787865251261173" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865251261173" xlink:to="btai_November2024PrefundedAccompanyingWarrantsMember_638787865251261173" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_AccompanyingWarrantsMarch2025Member" xlink:label="btai_AccompanyingWarrantsMarch2025Member_638787865251261173" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865251261173" xlink:to="btai_AccompanyingWarrantsMarch2025Member_638787865251261173" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_PrefundedWarrantsMarch2025Member" xlink:label="btai_PrefundedWarrantsMarch2025Member_638787865251261173" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865251261173" xlink:to="btai_PrefundedWarrantsMarch2025Member_638787865251261173" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_OptionWarrantsMarch2025Member" xlink:label="btai_OptionWarrantsMarch2025Member_638787865251261173" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638787865251261173" xlink:to="btai_OptionWarrantsMarch2025Member_638787865251261173" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638787865251261173" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638787865251208178" xlink:to="us-gaap_SubsequentEventLineItems_638787865251261173" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638787865251261173" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638787865251261173" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638787865251261173" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638787865251261173" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638787865251261173" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638787865251261173" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercised_638787865251261173" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638787865251261173" xlink:to="btai_StockIssuedDuringPeriodSharesWarrantsExercised_638787865251261173" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638787865251261173" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638787865251261173" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638787865251261173" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638787865251261173" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638787865251261173" xlink:to="us-gaap_SharesIssuedPricePerShare_638787865251261173" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638787865251261173" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638787865251261173" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638787865251261173" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase">
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember_638787865251278642" xlink:to="btai_VimalMehtaMember_638787865251278642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember_638787865251278642" xlink:to="btai_RichardSteinhartMember_638787865251278642" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember_638787865251278642" xlink:to="btai_JavierRodriguezMember_638787865251278642" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember_638787865251278642" xlink:to="btai_FrankYoccaMember_638787865251278642" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember_638787865251278642" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_VimalMehtaMember" xlink:label="btai_VimalMehtaMember_638787865251278642" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_RichardSteinhartMember" xlink:label="btai_RichardSteinhartMember_638787865251278642" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_JavierRodriguezMember" xlink:label="btai_JavierRodriguezMember_638787865251278642" />
    <loc xlink:type="locator" xlink:href="btai-20241231.xsd#btai_FrankYoccaMember" xlink:label="btai_FrankYoccaMember_638787865251278642" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended" xlink:title="995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>106
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( +& ?%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( +& ?%I<QPUB\0   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL%*Q# 0AE]%<F\G3:E(Z/:B>%(07%"\A61V
M-]@T(1EI]^U-ZVY7T0?PF)D_WWP#T^H@M8_X%'W 2!;3U>3Z(4D=-NQ %"1
MT@=T*I4Y,>3FSD>G*#_C'H+2[VJ/(#B_!H>DC"(%,[ (*Y%UK=%21U3DXPEO
M](H/'[%?8$8#]NAPH 1560'KYHGA./4M7  SC#"Z]%5 LQ*7ZI_8I0/LE)R2
M75/C.)9CO>3R#A6\/CX\+^L6=DBD!HWY5[*2C@$W[#SYI;Z]V]ZS3G#1%+PN
MQ,U6<,D;68NWV?6'WT78>6-W]I\9-]^,SX)="[_NHOL$4$L#!!0    ( +&
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MAN3;;!7^(Y>2A]G;#:,>$^D7X/,5YW*WD1Y@_\N/JW\!4$L#!!0    ( +&
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M ?W[@NM.9O-B+O&VE[;3_P%02P,$%     @ L8!\6DD:6ECE @  0 H  !@
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MT0T:ND%O/B9<*L3G:,%Y(I'D>6*B6\<(#K.!/?<D&VTC3(*.; P:>(->>"]
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MJ&?\^D3Q934FOW(%0W=UF#(*I:H-X/Z<<[4[T0]HOK2,_P-02P,$%     @
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M<7W)&/]YD+\U4[Z'-?X74$L#!!0    ( +& ?%HPRB7?K0<  &\A   8
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M&QGD[-+9C7"\&VC\$$.-UB"G#1?E+CBL:MB%V0<9&D?"9B(4)!:-Q[KWE^,
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M%OB?@QQOP'IF,:>[%W;0_Q<S^P=02P,$%     @ L8!\6@F0>PH6"0  #!@
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MX/O2@B;3#U+0_0/ ]7\!4$L#!!0    ( +& ?%HV3SUMM"$  /UI   8
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M; *]SR0=]FU@-VC_7_-_4$L#!!0    ( +& ?%H%/$D&T0(  '\'   9
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MK)+($#.D*UWKT)5%^E-?/ZII*K2< +VC-%P'TP>=/AQT++E<YUNU3[9U?5_
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M;0-J D6*!!FY+I7X)RF7!84]])4@1IZWZ2Q0 &6>I10J?6G@/VN3P?D(QR<
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M#.<MOPZ+#VIC,Z6"8##)0O#JT&]#!YMTJ G!"@F:D'5M#(POK70.3C,$C]G
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MTB'WG:?<&<O[*B.5VP.(^T8L^2F+ZA%+O_=KCDK.;QN5/&HT\B[Z@2X>],&
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MTM#-ZX;V_$1E%]#[7-(YO)K8 .W'T_1_4$L#!!0    ( +& ?%K5429W*@,
M $('   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;*55;6_3,!#^*Z<
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MI5@1B:.!&EYH4?5L8(ZGN"DWN82W'.;EIY>42_*5Q@4C'QA5A62@\5R]'N5
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MUV#LP6+_49Q\%$L3<?5ZN_D:W*&.-9P$D]V<F=-;U>(K!6"4M,/*S^7(.WZ
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M3G>8JY-%ER5/PC$H])!.YTF',1PG./N+:TT-).:WNS.KSN@KNEQPD@9QLNB
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M0_<+JS;NW7JIK%5K]W,E.!R-+N"\4'")9D$$]O_(N/H?4$L#!!0    ( +&
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MY9) >J]M(,64"A_#\5GT0?#T%<ULR<@^BAF%4%TOX8<VGM0B@6?0I\74$G>
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M9WA\C#"_,AH=0)W<"G8/^1PP=\?=B"8EH4:V CI_0LP<@- 1$QI'!'T#VVQ
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MUB?I-I^[PRD"4N(SZ7!HG\N!Z_ZA]AW@_?X=\+JV?9<JP]Y5%[)WX2_T^""
M#Z+VUFO3NKDSO&JORK;#VPO'M](L\%TE*IIC:G@Z&0V$:2_QVA>G5_[B;*:=
MT[7_NR19D.$!Z)]K?(AW+[S YB;U\K]02P,$%     @ L8!\6G=WTO?;!
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M60':7T@:J)H7:Z#]HIK^!U!+ P04    " "Q@'Q:Q3VN'$\"  "E!0  &0
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M;F<#.GB[\""25%<7O/ETQ1-X!/WGZEZ9,Z]5B40.12ED013$L\$5O;P.QE5
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M9N6\D+]E&':^/>+1)W(AL+@/_ _9DD"+R*FN;9D(\#+11S-'6.]4O+=A2T&
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M6(D=\&:9'( 5/LR !%K@!9<3O$324^(9!\QC*98I>@&O"@EORKKA9SN*8V]
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MVS8?VN"NH"\'$XA;HG%^>KS/V[K\ZC0"=J)_5? ]B5UM W7Q\LIE9TL,[Q%
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M2]OW=L?_W!HR&AT>H._7EMA:_\ &X==L7_XO4$L#!!0    ( +& ?%K64S5
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M3(V.^[V Z$8\&\.JR@O65%F4/[\M\7\#V@7@^4PINS)<@?8/EOT&4$L#!!0
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ML1&45<#SA91FN[$7M(/H]#]02P,$%     @ L8!\6EDQZ#;8!0  @QT  !D
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M?3C%B?S&+^\HGIE;MGNN%$_,XY31D D] =Z/.5?+COY >>\Z^@]02P,$%
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MF#S(-B[5!&CJX P3@^0S85F1L8/U"70^,P;7@2_0_E44_P!02P,$%     @
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M=P84-S0] <<GG*M50RLH'N0'_P!02P,$%     @ L8!\6@Z1YKJL!   N0T
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MX4H2#;-A<!F?CU-G[PV^<UB9K3UQF4R5>G*'FWP81(X0",BL0V"X+.$*A'!
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M366R]<]VHD7C+&@CM+GH;EB:3PY*&V#V<R'T<6(3]!^Q]"]02P,$%     @
ML8!\6ODP]L) !0  ,BX  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL
MK9IK;^(X%(;_BI4=K3K2BL0)@= %I$*N*U6JVIW=SVXP$$TNK&U**\V/W]P:
M" 0/T9PO;1+.^]B.W\2.CZ>'C'WG6TH%>D_BE,^4K1"[>U7EX98FA ^R'4WS
M7]892XC(3]E&Y3M&R:H4);&J:]I(34B4*O-I>>V)S:?97L112I\8XOLD(>QC
M0>/L,%.P\GGA.=IL17%!G4]W9$-?J/BV>V+YF=I05E%"4QYE*6)T/5,>\'V
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MO*:LVJ!<G8AL5^Y>?<V$R)+R<$O)BK(B(/]]G67B\Z0HH-DF/O\?4$L#!!0
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M)K]0@*D ^3ZE5+Q,U"6HOWFBOU!+ P04    " "Q@'Q:BI-.+] $  !O'
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M:&\!5EBV=+2)%ME":^N(&AV1,2,+'YV^ ;SFA&B#HS; XMO4BO3O?!7>H?6
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M9K8#[7[];">D0--LG?@"?MQS?,Z-'W>X8?Q)9  2/1<Y%2,KDW)U9=LBR:#
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MXS*OJGRS^^=-$J^2HGE"_?VK/*\>OF@FN,N+K[O%._\_4$L#!!0    ( +&
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MP/@&=[[5&H^%G]_AZY/] E!+ P04    " "Q@'Q:(<A!@ZX"   ?!P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6RM55UOVC 4_2M65DVMM#7D@[!V
M(5*!5>M#I:H?V[-);HA5QV;V!=K]^ME.R"A-V2;MA=C./<?G7..3="/5HZX
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MTY'1I)HX;B8HER[1YA)-/KIA9;Y@H&R!>5]*B=N)W:#[)F:_ %!+ P04
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MU02JR4;3GI[=W2"UXT[[I[M0VZ47<9NDVN8H]<UGO)C=WE5-:@&JA:@6H9I
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MC&HAJD6H)E!-HEJ,:@FEZ?7?YL">.0?N?B7HC9?JF.?J>W",:@&JA:@6H9I
M-8EJ,:HEE*;WSM9G\7K'O5CDH2$QJ@6H%J):A&H"U22JQ:B64)K>#VV6[/V@
M:Y\;UQ[KBZFQM[N:0L-A5 M1+4(U@6H2U6)42RA-[X V1?;,*?(AJZD#S\\V
MS]1[WX'&S*@6HEJ$:@+5)*K%J)90FMXY;2+M'7G9LX<&T:@6H%J(:A&J"523
MJ!:C6D)I>C^T0;1GONSYS2>F-NXK)W]>FJ?OW0!H\HQJ$:H)5).H%J-:0FEZ
M [3)LV=.GH\_,=4\0>\]!II;HUJ(:A&J"523WOXI!M/=CVY"9TPH36L#OTVC
M?7,:??AYJ6:H;[FC6H!J(:I%J"903?K[YQCL?F0(.F%":7JUMVFT;TZC7SQ^
M_CU[4,NOU<*G7R!AGJYW3Z!A-JJ%J!:AFD UB6HQJB64IK=/&V;[1U[D[*,7
M.:-:@&HAJD6H)E!-HEJ,:@FEZ?W0AMO^#[[(V>^XD'COC%;S1O1N S2G1K4(
MU02J252+42VA-+T-VIS:-^9^AZZJ#@PFS)/UWH>@H3:JA:@6H9I -8EJ,:HE
ME*8W3QMJ^_Z1:RKT^F=4"U M1+4(U02J252+42VA-+T?VHC;-T?<QZ^I]C^Z
MUQ^[NVLJ-*]&M1#5(E03J"91+4:UA-*>VF!8W"I5!FF97IPM57ZC+M5B451U
M?;^J^/H ?'.KE:OK^B,?W\7V8+AW^WO[W7NGOGW8,A=G=^F-^ICF-_-582W4
M=46.3B95'^?SF]O--V5V=SZP!];7K"RSY?K+6Y562[?Z#M7/K[.L?/ZFGN Q
MR[^M-_OB_U!+ P04    " "Q@'Q:?L-O;*X#  "H%   &0   'AL+W=O<FMS
M:&5E=',O<VAE970V,"YX;6RM6.]OVR@8_E>0)YTV:8M_)NEZ2:0V]FD]:5*U
M[G:?J?TF1K7! Y*L^^L/;->S.X?6)[[$AO \O#P/AA=6)\8?1 X@T8^RH&+M
MY%)6EZXKTAQ*+&:L JK^V3%>8JF*?.^*B@/.:E!9N('G+=P2$^IL5G7=+=^L
MV$$6A,(M1^)0EI@_7D/!3FO'=YXJOI!]+G6%NUE5> ]W(/^I;KDJN1U+1DJ@
M@C"*..S6SI5_F?B!!M0MOA$XB=X[TD.Y9^Q!%VZRM>/IB*" 5&H*K!Y'V$)1
M:"85Q_>6U.GZU,#^^Q/[7_7@U6#NL8 M*_XEF<S7SH6#,MCA0R&_L-,G: <T
MUWPI*T3]BTY-VZ5JG!Z$9&4+5A&4A#9/_*,5H@?PHS. H 4$KP6$+2!\#@C/
M *(6$+VVAWD+J(?N-F.OA8NQQ)L59R?$=6O%IE]J]6NTTHM0/5'N)%?_$H63
MFSO)TH</UTKJ#&U9J>:?P+6#'U ,(N6DJDMO8Y"8%.*=JA<YYB">'H2BKSD[
M"$PSL7*E"DD3NVG;_773?7"F^[\QG2'/?X\"+XA&X-O7P\,1>&R&?\:/"EFC
MO1%T8D;'D,Y0.!J[JUSHK @Z*X*:+SK#IZ- -S0%JK\=='7"/$.W!:9CLAJI
M].IR*2J<PMI1RX< ?@1G\\<;?^'].2:R3;+8)EEBB6S@1]CY$=;LX<1/8\R.
MT*8=-LEBFV2));*!'5%G1V3\/*X.,F><_%1N-$O/F ]&BJD^V"2+&[)%3:9W
M[^-FOERYQ[ZZEOH;J#OOU)V;U3VJY1W?%X!4\H'V'%.)WJJUO9'ZW9C61L*I
M6MLDBVV2)?/?C(N"SKB!UHM.ZX59:TH/N% [9ZI2.P&HDQGA,1>PJD<5<+TQ
MC!IA[&VJ$3;)XH;,]WKB>3,O>C;O+74Y\&+9>;$T>G'SD@E$B -6F_)+7\/R
MMVFRG _'N1UIX@V;Q,9@I\Y<2V0#72\Z72^,NGX%7@K$=@CK-&9,,"-^ZJRU
M21:;1^9[Z!$P']M^$DMA#!3_V"G^T1C7-Q"2T+U>*0@;5=R(GZJX3;+8/++H
MO."6HA@([GN_SD[>"QF[OT3)]P.1C[W$_5S*;B:;JK]5MM@J6V*+;6A+[TCK
M6TO<6RI;IMADBZVR);;8AJ;\.MSZYM/M_T@PS8R3O;%ZRFW9^INY_VR_3VSU
MV"CN]BYY]!W>9\SWA I4P$[1>[.E2E1Y<RW6%"2KZGN?>R8E*^O7'' &7#=0
M_^\8DT\%?97474YN_@-02P,$%     @ L8!\6H1752D0"   .D<  !D   !X
M;"]W;W)K<VAE971S+W-H965T-C$N>&ULM9SA<YLV&,;_%9W7VZ5W20P";*=+
M<M>$=>ONVN62IMU78BLV%T >X*3=[8^?P,1"2'YMS2_]T& ;/1(_@WB>U\#Y
M"\^?B@5C)?F>)EEQ,5B4Y?+=<%A,%RR-BE.^9)GXY)'G:52*E_E\6"QS%LWJ
M1FDRI(XS&J91G TNS^OW;O++<[XJDSAC-SDI5FD:Y3^N6,)?+@;NX/6-VWB^
M**LWAI?GRVC.[EAYO[S)Q:OA1F46IRPK8IZ1G#U>#-Z[[\)@4C6HU_@:LY>B
MM4RJ37G@_*EZ\7%V,7"J$;&$3<M*(A)_GMDU2Y)*28SC[T9TL.FS:MA>?E7_
M4&^\V)B'J&#7//D6S\K%Q6 R(#/V&*V2\I:__,Z:#0HJO2E/BOI_\M*LZPS(
M=%64/&T:BQ&D<;;^&WUO0+0:"!US ]HTH-T&HRT-O*:!UVW@;VG@-PW\FLQZ
M4VH.851&E^<Y?R%YM;90JQ9JF'5KL?EQ5GWO=V4N/HU%N_+RKN33IY,K06Y&
MKGDJ=J<BJK^0$_*99R=\6;THR%'(RBA.BK?B_?N[D!R]>4O>D"$I%E'."A)G
MY#Z+R^)8O"F6ORSXJHBR67$^+,48JYZ&TV8\5^OQT"WC<<DGGI6+@OR:S=C,
MT/YZ1WL*" P%G TA^DKHBH**?ZR24^*YQX0ZU#<-"&X>LBG8/-R_N0=LC;?Y
MOKU:S]^B=_7E([F]NS=],6##:OYY5RRC*;L8B FF8/DS&US^_),[<GXQ0<$4
M"Y'$%&#^!IA?JWM;@'U>I0\L)_RQV==-Y'Q,<IAB(9*80B[8D O 7>W/55F4
M8A:(L_DQ>6#S.,O$HIBEDRB;,G(D)HHUTK<FIJ"V+=.UV*@6J\Z$SV*><!SG
M?/C<AH74I0)KM($U F']ED=9*>;@'51 $5LJ(XT*-5!!ZE*A,MY0&8-4OK)B
M#RB@ABV4L0;E9*1#0>I2@3+90)F 4*ZKPR=)=G,!96RY3'0NKLX%J4N%R]F&
MR]G^\PVK_^X[V8#"MJ3.],-JK)-"ZE(AY3K2]3G@6>U;[8?%+A0]LUSX>[+,
MXRDSVC4'DPVJ6HBEID)L66=WY^Q4[61+EL?<Y%6O8 %K>/!P7/*#1;F1$](P
M5$Y4<J)[<3J*"A)5M*8L*XW'(2QDS6NM5NTE\KS?.0RQ>E312#?NPG;\/LO9
ME,^S^!]Q+!9U%GNHL]BTG<78]VK9?'BBNO9&+6@!"\9!%YF^DCMVY5HJ"NFS
M7=",OB83\B_Y-5TF_ <S;R^JUT95"['45(#2;KL!UIR.:JY1U4(L-16BM.'N
M7C[\F)AIUD9BQI,DRHMJ)EN;"O-<ANK5&[5)VU5XI[[7/3;[<.NNM.LN[-</
MG\Y0O7RCILQ4&K$^K+PKO;P+FWDYZWWF&6LF/H$K*U:),+.E$1*JL4=5"['4
M5)PR KAG6',@JN='50NQU-1ZIPP'%/3-B',@W)$MY$:M/0>>G;KN6?M?Y^C&
M&H!*4B8$>FA"@ 6L">U(")2D=7'<6(?N(R10&1(H'!(./G7 ^M8DJ7[JF'2=
M,%:7*C(9'NCN6OZ-N98/M[2&@5K-QU)3J<F<00\OZ%/4E(&J%F*IJ?ADRJ!]
M5O5A<6NP>EW?\_12&U:G*C$9*2A*:9_JY?B)7C>\WF^U$![3_]UF&00H1N$>
M%K'>&_32O4:E#[-/I=FG2)5[6,<:C*%V;RI)8_6JTI'>G<+U^P\\?V3Q/KL-
MJG6G>KW^A)IFD3Y,N2=-N0>;\@-^W8"5K7_9=S1>U;[4Q875J8I+.F_/10J"
M'JH#1U4+L=14B-*3>[ GQPN"34>NXJ?/3FGGY :/QYI>'_;<:UUI ]OSW>%O
MA\#6'W2NX8;6G/HPY)XTY!Y<^#\X^<'ZUD>PKR4_;6[KPX)[TH)[.RQX]L2+
MOX23V);^X/;60%#K^UAJ*CMIQKW1P>G/0ZW<HZJ%6&HJ/NGK/=C7'Y;^8'%K
ML+K?=ZFO':M]6'Y/6GX/MOQ[AC]8Q9J,;OC=;NT*JT>5BS3['FSV]XY"L(XU
M&8/9GW2+QEA=JM>;2J?O]^;T867K*U%UI^^ZHU&'%E:?*BUI]/W=)?;*F,[G
M.9M'Y6Y$J':_46LC.O.[UYA@=:D2DB[>ITA1R$<MH:.JA5AJ*D1IYGW8BRL'
MY98X9#X?[A>0X.ZMT1NNXQE1[<CMY;KZUH7UL._'2Y=P1];P?'W:<]RQ1J^/
M$.#+$.##(6!S L7@AYH7?+TJ'P2.AJ^/'.#+'.##1?GU:0.#'6I8:-24 S<8
M=STM5I\J.QD"_-W%?;BP 0M80X&'XT^ 7[6Q1J*BDO;?A^W_P;4-6-^:Y$3;
MO;SQN+MW]9$,?)D,_!T_ T1Q3IZC9,6.2;:Y!='(!C4:-&I*A=(==6,35I_J
M'54R&P1P-I!P+*8H6-/Z7BK42_@;M3;UB?E*XD!&@@".!+(^=GMW;ZSPP +6
M1%!K_EAJ*CR9%@(X+>Q3( M0<P*J6HBEIN*3.2&PR GV-SVBIH!&3;W!+S#<
M]]A'#@AD#@C@'+#?M0*PB#4:W>.?^(;[V;!Z5=&T[J#=T^3OI(-[NZSNX$\F
M!CA]6/A 6O@ MO 'U,E@96M<^B4Y(BX:>/5AVP-IVX,Q4ATH0+7OJ&HAEIH*
M41KZH&=##^M;L]4-/76U_0[5T ];#QM)63ZO']I2B.U?9>7ZN2.;=S</AGE?
M/PYE*%=?/U7F4Y2+$V1!$O8HFCJG8[$=^?I!+>L7)5_6CRYYX&7)TWIQP:(9
MRZL5Q.>/G)>O+ZH.-H_+N?P/4$L#!!0    ( +& ?%K;2[-BIP0  ,,2   9
M    >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;+68;6^K-A3'OXK%JJF5VH =
M0I(NC=2GJ]T7=[=JU]W7#IPDJ( SVTG::1]^MB% ![BDT]X$</#Q[QP?_P_V
M;,_XBU@#2/2:)IFX<M92;BY=5X1K2*D8L UDZI\EXRF5ZI&O7+'A0"/3*4U<
MXGF!F](X<^8ST_; YS.VE4F<P0-'8INFE+_=0,+V5PYV#@V/\6HM=8,[GVWH
M"IY /F\>N'IR2RM1G$(F8I8A#LLKYQI?WI! =S!O_!'#7M3ND79EP=B+?O@:
M73F>)H($0JE-4'79P2TDB;:D./XLC#KEF+IC_?Y@_8MQ7CFSH )N6?(CCN3Z
MRIDX*((EW2;RD>U_A<*AD;87LD287[0OWO4<%&Z%9&G161&D<99?Z6L1B%H'
MOZL#*3H0PYT/9"COJ*3S&6=[Q/7;RIJ^,:Z:W@HNSO2L/$FN_HU5/SE_DBQ\
MN;A1?D7HEJ5JL@4UX;I WS?Z1J#3.Y T3L29:KM/-PE[ T"F7_$*.D$N$FO*
M0: X0\]9+,5YK>'W-=L*FD6J\>3=\\R5R@4-XH8%[DV.2SIP,4'?6";7 MUG
M$43O#;C*]S( Y!" &V*U> ?A  WQ.2(>\='STQTZ/3FK>Y1?+",-RU /S4C#
MCI%^VZ8+X(@MT5.+R9PUM^"W6] K]%)L: A7CEJ" O@.G/G//^' ^\7"YY=\
MOLWZ_/M6"JFF)<Y6YV@!JSC+U*W*^81F(:!3-7-Y+,[0WZU1R5W(!PG,(%H3
M=O,AQC-WUT(V*LE&=K(B$U><9E(E:E^440/%]]I)@I(DZ$6BY' )\3$L08/E
M@OCM,.,29MP+)M3SDR1'P(R;,#AHAYF4,)/^V0/F>G3J3/JGSK3$FO:*T0Z$
MGBT%B. 5>!@+NDCZDTT;9,2?MI-AKY)>SRH(/TS)4%37.^"J!*+[G S0 X]5
MV#9*+8Q4M.JD]S](!:Z5#?Q?Q2)B24*Y,&X4,6YU)!]H4H_M-!@,._(1DPJ1
M'*T:#:9V)-*<[@[AP)7Z8ZMX=TA'WR#EMK%?1\+^8-05I4KT\0>JWRHB?;'\
M)M9P.!V,.Y0-5XJ//Y#\?\G)IS)KU!*T8-2=6E45P/W*@$55^C(&+=F/!].N
M %:U 8^MXE(@MHYI+2N?E8ZJ4&![I?B:21ZKS_H0[6BRA7/$JKE6(GS2BIR;
M'-7"U+4@J\J [:6AP5%,H9K0+HIF&>B@(%41(%:A[J0PB=3!49CL$0U2"3JQ
M"_JA&%W0HA@9V;R(J 2TI#'/\?37*_NTKI*FU.-@$ P[V"NE)W:E/YZ]6+A'
MH)/F.L6CP732P5Z5!6(O"^5'P(&=@]Y,Z[40JIT.5]O6+4U0$B_?YT8KI'TH
M'[V!]A1[*,TW46K'$]$WV^:&5(6$V O)48[4EGRK(_:A1H4CXX,?P8=N5(6'
MV O/<\8A9*LL_DNY$M9WQ/"J[[L7Y:BQ*,?!M./SE52EAMA+S6,9Q6U&4\:E
M 3NPJ*2-6=2*8S?;*P?<VKE""GQE3D_4IP+;9C(_8BA;RQ.:Z_Q<HGH]/][Y
M1KGZ1A0H@:7JZ@W&*DX\/S')'R3;F%.*!9.2I>9V#30"KE]0_R\9DX<'/4!Y
M;C7_!U!+ P04    " "Q@'Q:/83,DC@$  !G%@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970V,RYX;6RUF&N/HS84AO^*1:5J*^T$;')O$FF2V6K[8;2C&6W;
MKQXX25  4]M))E)_?,TE$%CPD S[)0'B\_H\OAS>>'9D?">V !*]!7XHYL96
MRFAJFL+90D!%CT40JE_6C =4JEN^,47$@;I)4.";Q+*&9D"]T%C,DF=/?#%C
M>^E[(3QQ)/9!0/EI"3X[S@ULG!\\>YNMC!^8BUE$-_ "\GOTQ-6=F:NX7@"A
M\%B(.*SGQCV>KH@=!R0M_O+@*"ZN48SRRM@NOOG3G1M6G!'XX,A8@JJO ZS
M]V,EE<>_F:B1]QD'7EZ?U?](X!7,*Q6P8O[?GBNW<V-L(!?6=._+9W;\"AG0
M(-9SF"^23W1,VPZ&!G+V0K(@"U89!%Z8?M.W;" N LB@(8!D :0:8#<$V%E
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M"D('X/,5YVH_T1O4?6[X#U!+ P04    " "Q@'Q:_[1H;[L#  "T$   &0
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M9",KUTBC3#E_UHW;V=!R="*2D%AI"PQ_:S(B2:*=(,>?PM0JQ]3"ZO76_<;
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M](K/Z4#07?F6S ,5@F;EQRW!LNXB0'Z_IE0\'Q0OWM0O6BW_!U!+ P04
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M+5#S%DIC4!J'T@2*9JO"F+<4W3Q+SYMGS^L6J"$+I3$HC4-I D6S[PQF#-G
M;<BVJUL^)'DF%ZG49<525RY-0G%/UC7K0&DAE,:@- ZE"13-EI1Q<P-\_VP
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MHYS\0O)-=AKRP*7D4?9U#4PU+:F!^GW)N=Q?I .4!VJS_P!02P,$%     @
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MJFC5D*PPA>B)2576S&NJ/CR ZP UOF),[AIZ@N93)OH#4$L#!!0    ( +&
M?%JHK>U8: ,  "X0   9    >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;+58
M:V^;,!3]*Q:3IDW:2@PIM%V"U*2;-FF/J-GCLPLWP:K!S#;)^N]G R4A(6S5
MO"_!CWN/[[$/YMY,MES<RQ1 H5\9R^74294JKEQ7QBED1)[Q G(]L^(B(TIW
MQ=J5A0"25$X9<[W1*' S0G,GFE1C"Q%->*D8S6$AD"RSC(B'&3"^G3K8>1RX
MI>M4F0$WFA1D#4M0WXJ%T#VW14EH!KFD/$<"5E/G&E_-<6 <*HOO%+9RKXT,
ME3O.[TWG0S)U1B8B8! K T'T8P-S8,P@Z3A^-J!.NZ9QW&\_HK^KR&LR=T3"
MG+,?-%'IU+EP4 (K4C)UR[?OH2%T;O!BSF3UB[:U;>@[*"ZEXEGCK"/(:%X_
MR:]F(_8<--%^!Z]Q\ X=QB<<_,;!KXC6D56T;H@BT43P+1+&6J.91K4WE;=F
M0W-SC$LE]"S5?BKZK)7RD4N)%B#0,B4"T&MTG2N:4%::'48O;D 1RN1+/2&-
M@7Q\T!Q]37DI29[(B:MT- ;3C9N59_7*WHF5L8<^\5RE$KW-$TBZ *ZFT7+Q
M'KG,O$'$&XC/D(]?(6_DC7L"FO^]NS\0CM]NK5_A^2?PYCS+M%#U$<;W"'Z6
M=$,8Y*IWJVJD<3^2>96O9$%BF#KZ794@-N!$SY_A8/2FCZ8EL [I<4MZ/(0>
M+;C2'"EA[ &U$I(0EX(JJC7S0HNFEL_+OGVHP8,*W-Q F\C3%]+$W>SS.S;R
MPZ"UZ81]WH9]/ACVVZQ@_ $ +:O3^E*8.Z8OP$&8IQZ4); .XZ!E'%A39V"3
MM"6P#NFP)1W^3W6&Q\+#^$"<PS:=J"_:J"\&HYY]_8!NE]_Z(AIT?.K)6 +K
M<+QL.5Y:D^.E3=*6P#JD\6CW]1W]3T$VZ)W[,CP09(\-]OH%B?>R!OQ'22[Z
M)3GL^=3CL876Y>GM>'K69-E V2)N":U+?)>[X,$LX9^%Z1^)+CS\C/?8^"=N
M2KQ+/_!P_F&$^8,(04X=TJ#[DP_)$EJ7["YIP>?VU&DU<[&%UB6^RUWP8);P
MS^H,CJ_$\-([U.>QE7=X<;I[E5<&8ET5I!+%O,Q57;BTHW71.S-%KZG<#L9U
M,7Q=E8#N#J:NI#\1L::Y1 Q6&G)T%NJM%W5Q6G<4+ZKZ[HXK72U6S507]"",
M@9Y?<;U;3<<LT/Y%$/T&4$L#!!0    ( +& ?%HEQ"63I ,  .T3   9
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M_H4$_M]<(F+"(DR8Q(3-D6!GHO*CJ!RBS[X6^7*_J/0H\ZRRO?K@9<IUR3V
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M".9"%B>H[Q=IFN]WB@2'%1*G_P-02P,$%     @ L8!\6@#_Y@QQ P  >1@
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M(+9$6BVL^%HYNO'VN!M@7@B(O3#C.[:M?W#U[2H3;"1MEFO787U(S H!L15
MIW()70)2EF5M+0.YR_/;\00S0T!LAF/&F<ZEZQQU=YD9'Q-31D"LC.%N(8P5
M&905D#4_2?O"'KCB^V"RQC0&)H\^L3S0$NW?P,?$)-(GE@B.V?<Q,:_TB;WR
MLVQC%W,.'VW_\,G0^2IBKR#UFV/U,3&S](G-<ES#M<81\TN?V"]H,<<N?$S,
M-GUBVYPNY^J(^IB8;_IGJD)^-+N/B2FG_UN*D=;?(J:8/K%B3B3^!TY_$AI3
M3$@^E_6K &B+88B))206R]M*H!41DTI(+)66;+N5$=-+2*R7UDEH=C$2)9=Y
M$Q-=$*$N7- T(O0Q,<F$Y$4,AAGYF)AD0F+)-&;.VQL;DTM(7LS\3,;:T#"A
MA,1":61CXB@;&_G>"S'!A,2">9N-M00RPMP2$;L%3<<:Y4N$628BM@R2CEVR
M1GM'F&DB8M.@F$._M(XPV43$LD$QGQK1Q&03G6U)!3"_^"57A*Z_DZ^K()@/
M#4Q,-M'Y*II+2(U\3$PZ$;%TT%6JYH"$"2@B%A"Z2M7$Q 04$0OH9'WH1DV;
M^9M#, O%U)-HIS&G6EWZF)B%8NI)M-.8CYO&TF2,62BFKG=.8PZLK7Q,S$(Q
ML8403)<O^9B8A6+JD@?!3&<S'Q.S4$QLH1]3+,XXKI[8SU2U9)LQN@N,V$$_
M(0=+4!"<K<?VMC6P&'-03.R@UM7J]FAB#HJ)'71J^NJ2W4EA_,0CQAP4GVF6
M[9)-Q%;D_B9 S$')>78!U,G1IO*WQR28@Q)B!YW&_,)-H]$3S$$)^4*.-V?I
MDHV5,)!WN@-'!7J".2@A=M 1YI/(M')I\8_I-Q\3<U!"[*"V2=:6T2C!!)00
M"ZB%$<9Y5<JES*M&<I1@"DI^P_:RD_M#FBV.[DFF7MAIF[-N:W),0 GY]N2C
MO2+MB)A\DEH^W?IB^^GC$G2KQ'(*C[=P/.-Y-C/,O=1;V((P<MO85E6>#^'8
MHYIHOCS\J\KAWVP^_0=02P,$%     @ L8!\6KM)TM]B @  M"X  !H   !X
M;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W:2VZC0!2%X:U8+""X[JN<5IQ1
M3S)M90/(*3\4VR"@U<GNVW(&]D$]Z$G$&:$"<?E'GU#!TZ]R;,9#>Q[VAVY8
M?)R.YV%=[<>Q^U'7PV9?3LWPT';E?+FR;?M3,UZ6_:[NFLU[LRNU+)=1]_<S
MJN>G^YF+U\^N_,_$=KL];,K/=O/[5,[C/P;7?]K^?=B7,E:+UZ;?E7%=U1_'
MV^FAOA[2PV5RM7AY6U?]RUNJZKF#!()D_B"%()T_R"#(Y@]R"/+Y@P*"8OZ@
M#$%Y_J 5!*WF#WJ$H,?Y@](295P2)$VP)M Z(=>)P.N$8"<"L1.2G0C,3HAV
M(E [(=N)P.V$<"<"N1/2G0CL3HAW(M!;4&\AT%M0;R'06R8OVP1Z"^HM!'H+
MZBT$>@OJ+01Z"^HM!'H+ZBT$>@OJ+01Z"^HM!'HKZJT$>BOJK01Z*^JM!'KK
M9+.$0&]%O95 ;T6]E4!O1;V50&]%O95 ;T6]E4!O1;V50&]#O8U ;T.]C4!O
M0[V-0&]#O8U ;YML=A/H;:BW$>AMJ+<1Z&VHMQ'H;:BW$>AMJ+<1Z.VHMQ/H
M[:BW$^CMJ+<3Z.VHMQ/H[:BW$^CMDX^5!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$
M>@?J'01Z!^H=!'H'ZAT$>@?J'01Z!^H=!'H'ZAT$>L?D9Q,"O0/U#@*] _4.
M KT#]0X"O3/JG0GTSJAW)M [H]Z90.^,>F<"O3/JG0GTSJAW)M [H]Z90.\\
M^5F00.^,>F<"O3/JG;]3[V'\/);AUO.UAN>OOI/J\7)ON3W^NOPZB3BOKCC7
M]Q7#\U]02P,$%     @ L8!\6MTG:PL8 @  A2T  !,   !;0V]N=&5N=%]4
M>7!E<UTN>&ULS=K?3MLP% ;P5ZERBQK7_S=$N0%N-R[V EYRVD9-8LLVK+S]
MG!20-K$*5*1]-XU:V^<[\9%^5[WZ\10H+0Y#/Z9UM<LY7#*6FAT-+M4^T%A6
M-CX.+I>O<<N":_9N2TRL5H8U?LPTYF6>:E375[>T<0]]7MP=RL^I\^.ZBM2G
M:G%SW#AEK2L70M\U+I=U]CBV?Z4LGQ/J<G+>DW9=2!=E0\7>3)A6_AWP?.[[
M(\78M;2X=S%_<T/9Q0X]2_FIIU2?+O%&CWZSZ1IJ??,PE"-U"I%<FW9$>>CK
M8]&+T\FYW# =/_G9^7.94X%EYWWT(96)1?IXW,M(IM/+4 I1S-WI5WQ-+*7/
M?C^:IMU2^\[L<KV_?-S/\TAL?IQ_QW_.^+7^!_L0('U(D#X42!\:I \#TH<%
MZ>,+2!]?0?K@*Y1&4$3E**1R%%,Y"JH<156.PBI'<96CP,I19!4HL@H4606*
MK )%5H$BJT"15:#(*E!D%2BR"A19)8JL$D56B2*K1)%5HL@J4625*+)*%%DE
MBJP215:%(JM"D56AR*I09%4HLBH4616*K I%5H4BJT*15:/(JE%DU2BR:A19
M-8JL&D56C2*K1I%5H\BJ460U*+(:%%D-BJP&15:#(JM!D=6@R&I09#4HLAH4
M62V*K!9%5HLBJT61U:+(:E%DM2BR6A19+8JL]G_*^M/[_2?'S\]Z<-WXDL_F
M?U]?_P902P$"% ,4    " "Q@'Q:1L=-2)4   #-    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( +& ?%I<QPUB\0
M "L"   1              "  <,   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( +& ?%J97)PC$ 8  )PG   3              "  >,!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ L8!\6EO_06F9!P  !3(  !@
M             ("!) @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( +& ?%JJ/<G8.P8  , =   8              " @?,/  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "Q@'Q:21I:6.4"  !
M"@  &               @(%D%@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ L8!\6F2V3 VJ!   =1$  !@              ("!?QD
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( +& ?%IU/!4\
M"@8  ),E   8              " @5\>  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " "Q@'Q:,,HEWZT'  !O(0  &
M@(&?)   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ L8!\
M6F((<GC/!0  T0P  !@              ("!@BP  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( +& ?%H)D'L*%@D   P8   8
M      " @8<R  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" "Q@'Q:-D\];;0A  #]:0  &               @('3.P  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ L8!\6L4DZ0@"!@  Q \  !D
M             ("!O5T  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " "Q@'Q:S+)Z[;<"  #+!@  &0              @('V8P  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( +& ?%H%/$D&T0(
M '\'   9              " @>1F  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ L8!\6KGNSN2T @  &P<  !D              ("!
M[&D  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "Q@'Q:
M ([1Y'L%  #^#0  &0              @('7;   >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( +& ?%KRTA>/U"$  'N)   9
M      " @8ER  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ L8!\6J6J?^[G!0  '!,  !D              ("!E)0  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "Q@'Q:ZR3JUR8)   ''@
M&0              @(&RF@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( +& ?%I)Z?\R-@\  /@W   9              " @0^D  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ L8!\6E_J<*KI
M P  2 D  !D              ("!?+,  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " "Q@'Q:U5$F=RH#  !"!P  &0
M@(&<MP  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( +&
M?%J#2[>/EPP  .\U   9              " @?VZ  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ L8!\6KLYATH@"0  U!@  !D
M         ("!R\<  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " "Q@'Q:P=5 H48#   \"0  &0              @($BT0  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( +& ?%H#Y3A3I@D  )@9
M   9              " @9_4  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ L8!\6M]L(F,C!P  514  !D              ("!?-X
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " "Q@'Q:=W?2
M]]L$  !=#0  &0              @('6Y0  >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( +& ?%K%/:X<3P(  *4%   9
M  " @>CJ  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
ML8!\6HW#K8*C!   %Q@  !D              ("!;NT  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " "Q@'Q:/*4S.!$"  #=!   &0
M            @(%(\@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( +& ?%K0S2 ^A0D  !,F   9              " @9#T  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ L8!\6BQT0#*B(P
MV78  !D              ("!3/X  'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " "Q@'Q:UE,U0%X"  !;!0  &0              @($E
M(@$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( +& ?%H=
MH?D=7P(  /4%   9              " @;HD 0!X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ L8!\6D&GH "3 @  S08  !D
M     ("!4"<! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +& ?%KJ_DP#E@(  #8&   9              "
M@60Y 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ L8!\
M6OOKVC=:!0  G!<  !D              ("!,3P! 'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    " "Q@'Q:#I'FNJP$  "Y#0  &0
M        @('"00$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( +& ?%J9P$S8$P,  -X(   9              " @:5& 0!X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ L8!\6O<-^6R[!   I@\
M !D              ("![TD! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    " "Q@'Q:+3?U\<4"  "7!P  &0              @('A3@$
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( +& ?%K^66,T
M"P0  *H7   9              " @=U1 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ L8!\6E[R<ZB" @  T 8  !D
M ("!'U8! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " "Q
M@'Q:^3#VPD %   R+@  &0              @('86 $ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( +& ?%HN@!FJO@(  !4(   9
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M970U,BYX;6Q02P$"% ,4    " "Q@'Q:NE(ZR9X3  !P0 $ &0
M    @($_< $ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (
M +& ?%JDG<50FP,  $L3   9              " @12$ 0!X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L! A0#%     @ L8!\6H;XRP>K!@  0CT  !D
M             ("!YH<! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"
M% ,4    " "Q@'Q:U?%D008"  ")!   &0              @('(C@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( +& ?%HAR$&#K@(
M !\'   9              " @061 0!X;"]W;W)K<VAE971S+W-H965T-3<N
M>&UL4$L! A0#%     @ L8!\6IS*A-S3!0  SRT  !D              ("!
MZI,! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " "Q@'Q:
MH##*E!8,  !>J@  &0              @('TF0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Y+GAM;%!+ 0(4 Q0    ( +& ?%I^PV]LK@,  *@4   9
M      " @4&F 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%
M  @ L8!\6H1752D0"   .D<  !D              ("!)JH! 'AL+W=O<FMS
M:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " "Q@'Q:VTNS8J<$  ##$@
M&0              @(%ML@$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+
M 0(4 Q0    ( +& ?%H]A,R2. 0  &<6   9              " @4NW 0!X
M;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ L8!\6GZ?\^3U
M @  \PH  !D              ("!NKL! 'AL+W=O<FMS:&5E=',O<VAE970V
M-"YX;6Q02P$"% ,4    " "Q@'Q:_[1H;[L#  "T$   &0
M@('FO@$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( +&
M?%I<D%]L*@,   ,+   9              " @=C" 0!X;"]W;W)K<VAE971S
M+W-H965T-C8N>&UL4$L! A0#%     @ L8!\6CM7\&J* @  0P<  !D
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M=#<Q+GAM;%!+ 0(4 Q0    ( +& ?%HQ8P,0V <  $A>   9
M  " @2?N 0!X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @
ML8!\6NPF^U<W!   -Q   !D              ("!-O8! 'AL+W=O<FMS:&5E
M=',O<VAE970W,RYX;6Q02P$"% ,4    " "Q@'Q:*-H?=8(%  !<&P  &0
M            @(&D^@$ >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4
M Q0    ( +& ?%KCN?/(\0(  -8(   9              " @5T  @!X;"]W
M;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ L8!\6JBM[5AH P
M+A   !D              ("!A0," 'AL+W=O<FMS:&5E=',O<VAE970W-BYX
M;6Q02P$"% ,4    " "Q@'Q:)<0EDZ0#  #M$P  &0              @($D
M!P( >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( +& ?%I
M4',2P D  *]7   9              " @?\* @!X;"]W;W)K<VAE971S+W-H
M965T-S@N>&UL4$L! A0#%     @ L8!\6LB#2R,4!P  +5$  !D
M     ("!]A0" 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4
M" "Q@'Q: /_F#'$#  !Y&   #0              @ %!' ( >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( +& ?%J7BKL<P    !,"   +              "
M =T? @!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( +& ?%K&NJ4%+@8  .HS   /
M              "  <8@ @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "Q
M@'Q:NTG2WV("  "T+@  &@              @ $A)P( >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "Q@'Q:W2=K"Q@"  "%+0  $P
M            @ &[*0( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     5P!7
+ -@7   $+ (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>114
<FILENAME>0001558370-25-003985-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-25-003985-xbrl.zip
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MT5FG_=OM:"K+FA+/.2(5RQDS>GC#L"OJ,<?^-&=^FMUYFU$?MW>4*:\;,0;
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M52ZI5;&(8H##H^1*'.*#^RP9QO<+H?$]^"+YQ_9"7[XH^=F.A!#(F))R]5\
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M#G!OBXG^_=3P5&AXX;%?_@]02P,$%     @ KX!\6DZEENDD20  \.D$ !4
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MJYCP6 >;LHPVAF+RR1T"DF3>!4XH4"AXGW*\JY\L@LV50O['&NCV98]+7ZP
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M2FOP23-S!6UA).=JR5N910)LH-R@I'FAG'8 +K-261)<GT"DA JN#E(6*/H
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M>!'9*5L<+S5<[-"8*^B-KW8/ *Y 5"AH34X_4W)LDHV0BK7O%K=L <<+,M8
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MO$&$GBM>XK(3)8^PV4.OR#/M."H  XVN+%>S2COB#6SUJF),I#W ./\Z;:]
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M7=8:@ M/0WSVIY$,E4%R?IZ+C5U,7DXC &8%$ZIR,!CB 2KBKWPZFIJBHI8
MKO@F9!6A,=R&<+]VJ+;&/BMW@V93 '?Q%EM!$X\A1#?\BB.FAN:32D17T!+
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MPR\70(QZ!8>1]A6P1HY*<69K9@ Y4-^&I=?:L=,3EU[!(OH6$O='*8\S#)F
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M1UI(I#;?Q @/P$D> *Q5"8A;'"N9V&H8BSI/%_ZUPG4 UMWBIW1P\PU1MR>
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M[ :@7GPWEC51@A'2UN_=_V:$F@WR::'D% U&T;XK.X@M.,>7==3,5M_5UZ%
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M^W#%\+G"1+[PJ^M>Y;,8;#9K'H^!Z5>-Q>R^(Q^?<R6_I&;Q*\V;;A;?0HG
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M=(3J!85;C0! )]'A8"O< "U?O-G@,(7_SB%SDC[;XOWJ! FB.*0(B):H3D\
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MDC'ATTW.AC36TE;@R*0%J&!B97*M',H+C%RU0%U27&IP0CPAITTYU_JVE4J
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MPWC#IB'?M/6OQ67O3'-*>V%PY3L/?N##'3DV7>9UA9^BP&.8 %/G]+4GU7!
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MI\O"XK1GJ=S5?D$1.^=BL3UL-2^1E3*#M*I=SQ'JB%N3^4):-3[*'-*M]'"
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MK]87=WP.LD!].T"A(][H'2;^Z()+?,HKV!#!APA&*_%JXXHP9J*!G=HN9NP
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M%GV>C4DQ%&=,2,'%UBMSFG7/*0$2B)".]M9><5<_T)M\(H@^S(?;8MQA.-[
M'Z&#P<-O3&DTNDS"TVCV%9.43[O8S:8!(\#_AS3#9R<04ZA\:@(_K$.O_H=*
M2U% ]/B.6?;\Z/F+R\OHW;+)SSE;D$DS<8P+@1NP['R3*NB9E0 O<%JRP^BJ
ME4R E8#?BAPK4HI(1!/8#6K\L=Y#R$Y:[KA6GQ?.52"@ Q%*6$'SA7TG&!&\
MC ]<!..C WP3_@]:BK:X$4'']WG;>#T[_+Y1-$4#CCH ;L\AZ#SLW.*R;[Y6
MC%H1"C5_MB1]HD0HHL]$=ZD3IXLTT@-]],,01LTN4YG)<SWL]P'?K'4"D/@B
MB+Y<AMLHWO']RIZT>?7>N%%[H!5J6:UJ7?$B\5 %1A_&5?@(( 5.I,+*=N:[
M%4N(2S5@";]D-2;E_2%U?![?'W[X\0./<?C+WRX</_X5GI;D.YWYO;_?LN/?
MAB74>N",Y0':0OPJ-+<;LU[D'KB/M)P$#Q%^]*6,VJ.DD"8@;HOFF0/?ZHC1
M-J RIBRGO\J.*G(6Y+?VK&F]D&1"Y\M*KK@XI-CG.MO,%"^T7GO_=4A2"('-
M5H)7JGUP(M8@C:MSCLX.>&<::F)/#V%2T@??MA+ 9G2^I7NV>,D6$FHQ;"JQ
MR\#'%H.34WYLF[!55M/TO:XRLLU6N*%)HE6]4&2M"5[XD0DZONAC4=O5]U:P
M 9YMA6</4/G_H.5KO"O]U=[4ZT!JL@/4M9]OX7(:A0QF$C;YW6RSNK(YI_NH
MXV[*X,XX(W"<#8J5C7)/Y(N<X7J,=>/[)ZAB#DMR9P<ESV%(=1KUC$GZY*1L
M+41<+E8J?HI(P 0A^?4(LPLC<P8J.9'-MBB.7T3_?63W0I ]:[0ZBG"*29=F
M),"XB1^=,'L&=1UZ-_E%G=YB)\-[(X;&X58HL%&]*W)P'*'(Z&/JB'GQU@_%
MF^/.L^,'4#3>+-:9U-=)#S'-SV<^'A(_I(F=]$TNR6:;S1^C4)JFV=809P3W
MZU9+NSQJA7>1T2'K=%<LB9+/]_0E)1^9R_UNJ4R03D5MQUP5:*"&1Q3X7HDZ
M-,E!>;/-DD2=X([]191*[#DSG8LV[LB>U8)5,)B%,%[\F%>]L9'XT4E\?MA3
M9;FX0#SS$S>($H8I )8<*W58O9W-&P[/#KO.%JDM/-YHT'9I.OH&>$4@432L
M$(FG)%6%@C OQ"*E7*04S/YL YV%T2!D]D"?'S[>,*.X_:5..SO@1JU^7:OX
M(V^-%TD49!Z?=;3;.?$KKX;A/X;^UG<=N*Y=<"0Y2RMYB*5(QS;H&[Z5.^-V
M[V$VJ"4A*O7$Z_8#Y1\= MU^;W^8,V4'U%# 4[(/;GJ HBT\19M73%"NY3VD
M/VY &&R)>MDZQ<YX86&X"N,3:2J<4#J]^F)V)*F%AX+BHG0,G04'B(ZE3XUI
M=D-*U+2I%+''M'BT;R4["6G/;%T:Q:^E=CT#9W</W/B@H&T]:4W:'&^TJP@]
M/HDKHXW$5?L&N9XNBW/6SD&KJ_VBW'4^>"V(HQIIS*ALJ3)<^U-T/6.*2C_<
MP:JL>:,R7'<GO&&K+OJ$RG"<0_W1Q14)J9W2TC*%U4>C@206ZO"*H]60_@L,
M QW0WGB.M!X8J$8X*V;! A3.*^0\)DQMGEOL!'U;D=T]D,- O[:->LNRYHB#
M7$'HL<Z;)\B?OT"!83M;Z=F.?I+IF:M)O2O?>?"#@1N+XZGA]O2)5FHY<QY*
M"F^$3%5H0O1POB1CS(> /*0JO%$-CA:-91UJLDW5&X>-UY7W[?H/ZWJ[X08/
M5;WKAQ#=??#"@;+DHV_A58B2+W[Z1#[ZT5]<IM;5U2DFOQYR'C>$PC*]7?GT
M3;G[\F) SRF2.%GCS$@M.# -?"9-@@XAX#JI\AF;M#'NN._6L1KB[2WQ1G./
MO&.]E+_G"7/6TYAZ?DHN'#>; -IWT;X!2]YZ24[:.1!)FB[%3>=#4^ZGF(82
MK8HB"LC8?W92_YE>AI G(JYOA=Z?J/=8>W%BP, RA2+VP)YLK7KPCR:'&2"F
M*S4^MG+>E9M$%3$6$F']X^(DDF\NQGI&V/'TWE24S3F$%6%6X<X'M8P_U@Q,
M+&:;"YUDM9:/7XSJ*L73W1PG7*CJ6998EK=%7EU'1?*Q/AE^YY@MGZQ1EU/Q
MMK0HFZSPJ-N\ =8_? _KN:RPZQF,!W1;7C!JV5Q\HH2)X;-!TRO'3WA!O<VQ
M#9= -V."-D513"9,&D$'IDU?TA2*;K;5=ZNSW?=3>-Z>OVP-.GCY*]A]^P93
MB>($S'EM5EO83**(>&DSCUZC[R1#J&5/R5?9HPZTCU53]&X?3*;Z1D*MVVJC
M8JV=Y!L(MA[%1D<;T,ZB+:-.UE \_Y&7S$&P8V#;0(C@Z K>!NT;QX\:X0:+
M=IVJL5]O@3>4)7*.=3Q!SHZ;)0FEQ3,%0I"^0:VW$W8W5-&Y[I9=/3"[J9+<
MX]T6R%=?N1 <[(\DVA6W%:]G4(^;>A]IR/Z1PH6<WB/BC@ZXX[1?U_K9DZPU
MWOA4D'FLBY[O]D'T2BG)B/-+9C@\MO_(M:O'TGRVY\!4VGQ)7COGN1VG7?-:
M^\.)3HW1!&KQ>%NY#.M;?_1TP1VJ*OJV/L#8TAYOL"I)/?K8H'Q^\1.;$C':
MUE)_VO3L&VCZ^BS/?SL'F\X.R_+@&4^^2A>NT+<_Y!C3VG;@7H9NM*/WSLN
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MWG@Q880.<\1$QJQZ7Q(+.EBRB)-9A(KL4<NK@BR1_<9AN'4?.V'BN+Q0Y$"
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MQ:$Q'"T,!_@4@\4 T-E4*3W TX_B3W%-',OXY<10<RJYH7&>1.2[#-+/_.
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MC6 ]P.N;,/DEVILH\?D!P'G@<T2BW@VO^9/M7JK8;S3E!<'#-.M)T6,<V86
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M%"NE4LZWLONDT?*7?8!<7/ZPG!W)-7_H-^)#TXCG+WL_YHU%@FG71YJ)_@+
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M?\,T/;_;W%1>?[V'^I0R.!U/#C<\3+53;4HQDA9>")FLT>AMT8P=X?Q(P9
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MKR^+].;XDY.Z3TSOVN_B7L1FRW^4V&T.NK@18#;+53%B,E&\*#*?:F-C+9.
M5%ED-U9S*4@N1JU1<6T*)A^\A95)AGT+%F;:Y69R:V;:M]XN0PYDLUO[#4/7
MO)CU%L$*"4KE]Y.2/Y"?XRA)X)[HPD!K/K2J@E1YK3,D-/ ?^99GM0%"\()"
M,C&%OSKQ:[519U;29**+!C%%FPT LAZ*BP4S5;UT EI-AGI+#0E,,V&7;L.U
MXY?39@\C*%5].8FFR3KT*C?9/K&5\2&FWB:\I7!NS#"=-;B.PCC_SX].XG=6
MHIV3/F[LFMV251B;C3A>1)M?Q;$Q6KZ4!MM5&7U>([[*<$(]V_FB]N-K9ADX
M![Z(Z=\/-'1?.Q[]4NNYD$CKU[XUAN3=%A ="L*/OF1<$B8%98N/@!4ZMVG<
M^1286L^%>/G_7][U/<>-(^?W_!5X2GFK1I?<[EZJDDM=E2S;>[J2+96DW<V5
M'U(4!R,QYI"S)$>V]J\/&OR%F2% @ 2(AO;%ED9 =W\]Z(\ V&B,HQ\<Y?)N
M 8QR#>,MCW*/5X(-H2Z[!X_REB#-KN&-=!G^L:%^W"^LL2ZUWNY4QNM5/XO@
M[N3AF9WQ":KQS$SL%4@4JU&/S\BZ+@'$[HCA-IY17*K'6=A-G2A^7G6@NQ_Z
M8MC*AY29!-RC?((WQ!%OT!WOZ)\"8G(1Q^:80E2)%YB+\2%YF"US_4)9)=NH
MHM>;R<%A* )W=$SQQ\%E"P;]\<;')!23-Y0;9?P0@%&$+#/=6]09O0,\S_NZ
M'_^>T *NI7VY@BMI]:9_ZLZX&<#,!Y+)H*(GWJ@WM'_^$">=]'IO^OP79'MU
MY:D?C'?M5#("B003CXQN;\@$!! 71C#<A >&3;[+;+>O2DX(?];;VQOL$<C@
MEZ,='.JGS0,8V JC;>S;U>)7A"L@?T:R>^< = ,02W1^;QR=WP<<G=^;1>?W
M(4;GL='VH_-[?-%I"W0#$$MT_F <G3\$')T_F$7G#R%&Y['1]J/S!WS1:0MT
M ]#>;9%OD_Q;3--?([C*IRK/'Q\+7L!&?J_V: ^<86> MKO$4=T<^0V-FL9/
M?_6JND.[;&_0CEJUL'')3/H?9A*AO^WA9H?6M&5O8'3LEQ9C*W]%.@T>;\YV
M#?K^L@,<:GKSU<C5V;9UX*1)IQZUG>I\A?\N;C<P;<R9:H/XIIE@4OM&:0V'
MK!19T4VZPI7G6[P1NI=?,DBBWKMI;Y$/;KR(RB<&&_Y[SYZ[S+R#G=G^Y9S$
MQ2;]<7.:L2=$OM+NC)>+S"%,#010P<<^_T%0MA)?7O<*O7#'<NX0>&&;9_2E
MO8\TBGD-;0Q3I@&NY.3X<Y8_E+1XAC,P?#W+_LPBC?$9G^\;G F;J0$WM3CP
MIF*R-$<\7GIR =+B1&EX8L1-@O+]O5'U;A0Y- O%,;)9CC5<'UG0\D<(>9,U
MTEP5KSWTG:Z3YH8_LI62=Q>W6_7%@7RO]*A>.NJXYR)*XWW*?[S-T_1#7GR-
M"EG1U27T!D*AKCT_2*JNE 9 L\ZAVR#>\5TI7?9=$<%<\AD,)HW%GLD8[1?1
MTK.P>86)JH4DPU^3ZNG$1^6AD\K;HQV_ILP^ES7V'5G6%0@EN_#P6-KK;$4!
M4*\3N#;H5CQ*\I59-D"KY0FOGG!Q9^#@^0PK;M[1(LG7[S/E'3LX_<V,!E\]
M1*Q_[- Y=U545.&YYRU]3+),[B'4SQB)9^YH5:5U-KSE[T)+X>M\VNC[VL8C
M9US;ZWON&&!&^/!9$<%0-.4OD/@=BM\G6=1>"_>./3&>V6_/]&"R?\9?V['G
M^&7V3,N*?S.WR>.3W_*%=KSY4Y1D5WE97F9QNE_3]67V/BK@N;,012OU_Z$8
M>_R;<$C@<N5_&#[7< %*>@>[R1NP_#O2VD[81ZWUKX'S'7XW%T^L'P6';;K4
M!*^\;O@2XLA#PI6-S%GYEFK=%KJ8\D 8?9'O8)#.G6H.@,N7P6]S3_YE@)XU
MMN$%VCZZV+2VG.0%N<BWNX(^ 8)GVGZ.Z9)3&SFGT+].5Z'Q4Y;\MJ?.RVLK
M5 9"4 [];3LS7:8O #)RB=I"N0=Q*ME,'"'1M%-->MTS<JXDI^7:,R[L+\,'
M4^6M<,;8"*KN)-QI$^2GWQ0&6S[Q5M"TOOFP.?'VM=%,DK+<UZL2,&+90VX.
MX+<B.1J/1]D<0..(9IQ?&V>+'[78XL? V.+'<;;X,32V.#;8"UO\Z(TM;,$7
MV>)''&QA"QI'9)\MSF.VTME%V0L;':+5=U61?*$W11+33WEUSL;QFJ[E=#)-
M#&*^F>&7CI FR$#.6',0.3SRSV,C$FSK":[DEI$=F$:RO")1;=RR5.?#;Z).
M<DB,M5K"]1*FF#2:/3*F#P]]A )^M4<&G;62.LK'!I"P!.4KT'NF2U'R5=$<
M)^WJXA0W361M\6YXC%ILHZI_O0T*HCT6;1U"JJS0JNP0WIB5UUZ5MPYKW#JX
M,TD<N1[KJ1ZC??^-%G%2UL\A96TXO9YAC68%>M6P'N@6SOA6&6]MH*](JZ:9
M8GBM(+>$"^Z$Z3B&P.;8?LEA=P3>+QJ%MJQO6,&M]( JO <[AA/@:O,MAG@=
MV;TF7$'NQ@T"VC=1ENVC]#M[6U:G$/*')C_@>M.2EGRKRJP[SF">ZH=N:\J@
M+_(MJ2E(;$1WPF>J^Q(V# HHLQA5Y.M3$C_!!GM!25*2B#WG.F,@W80VYBR[
M^;2DAVZ& 2^_GX0/M*>%RX[&%5U#]KWANF6@(TXR-,>N7K4<]PIG3J.PW>J:
MI=9"0 VNV8P#!X H=W.7]@*S]0W[,-D/QZA93YQ!.@&]=+(RW"VP><H("-M3
M%-JJ8W,2KL_O',01^O?'*.'MX __?K:.7DCT3(OH$<%4! UV+S,2*' )Y2=O
M9>7^C3KB)#MS[*H9R6FO<&8D"MLMSDA:+>366[W[!1W0H85E)X:0ODW*+Q\*
M2B\SYA[VH#$.;:6 L$)\W!>J4)?W#B?D-3!8#'W01D =:?4A) &'+@'19QO
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MW#BF98OX*"GY<XMY*>X]$POZ+-XK?HJPWRB[W.7P=N^8*TSZX20&8^3RB=I
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M^)P*8$%M':'M)U W-^4U-01C(+_G=+7N?]V-QJ/-5D7)ZQ'1W_;)<Y3"F:@
MR4Z9LV)+]JNF.7D>C!7!KY;@;-UW:8?=7.;B:)S Q.'+F[QB-)9$:?I".I^6
MO4_?)(ST0%_IYW@!G!@%[DWJ(ZBJ?4596]Q4I$1X<)Y@J"%>JE";.^\$L2#6
MYZ[:,<2Q582J?5B#5#G/ES8.9[#:FS<.#%C?<VIW8$68D"U2GX![I%GL*6/D
M*L\>[VFQO6%.?&(F]@8J)\$:W7#'JRYN,6S'^N"-7FW+IXYK4' &&DBK0HAH
MKRG=SJ%W@*/'@O(JQ7TUT#@OO=S3 *"K0=!L<ISDLA12C6[XHUH']W%4J_K@
MCFHMRQU%=:W%6U0[A:Z*:E#L(ZI;FZX?TN21+WH_\(.!'Y,LV>ZW3;WT\I;"
M2X8U+:XW'Y(RCM)_TJB0^'&F2-QL8,-?(E/,D8>71:R@FAUFO?85''Q]H.0F
M2M8KTJF%':I:,0'-7EC'JZN #LBN]5<N^*L0??1RZIQ%R E6,G GUCY*>_>\
MV]/+[!/]5MU_I>DS_<C:/,G6_D8"<!./N2]$FM'OC9=4)F"8OJ3N5$E9! *0
M7&?'&:/+L,:"OF!1^9<ACL!%"'=0F&BMF)5H=@V5!$[QZX5_WR_$P!^PWGG(
MWW_-D86\12^PB/L/;,'^:U(]7>S+*M_2XBJ)'I(TJ5XN]EN>X?M,+Z(J?OIY
MUU=,O<]OZ3/-]HP U\DFB9M7>:VX$??:UQ8&I3CR\A +65:%G[A< 9[+=76-
ME]:R%>EL6Y'>.L+-.]OOA$+*P(J-B2LB&@FKA5:Z5Y;$YO*C6WEW];+.!ZT>
M59O>=#6 ;HI\DU1P' K2(.[H8_T&.6<^*/,T6<.Y9%4F@!7!N,G2GN]$7IPO
M%2\%6L1F*?080_5EKVHKR)NK_LZSUA3@.-$8GSD/_*X(L.KMODPR6I:MD8JS
M0&-]<$>:%N*#XWBJ#GCC0\_LR7>,M&/9WR&8Q@3EB9?C-LB'YA"B@Z$H-D \
M] ;-G#_4IA](D51;O6-,G=);?G$F4'"CZB/=/M#C[1ZM#CC'ES[6KJ2JLC7R
M2JIZMD]_Z.^8U7Q )MDF+[;-O)LR94G&'^XE-Z"YD)4702UK$Y8M=^K6#[5T
MTHMOYS?D<ZUAV6RXY1"??JW6GGYE40E//O9;_]1CO_QO/VED(XZG^ W,TI0-
M<?+3.#;@)7DK?$]"#5MG;+'T8NN\4]N3,.-A.#@'&VD:TE \G9&IVH4R'"W-
MSP8'I,>SP]T:O)TX#D[GQEOC'*":* =OKCALBF^8ZAH\ORAYOZ;P,5=9#F<S
M0?%3WK'67<_&F#'=;EGV""3Q(2_46W:'.W97(X=QW&G#S0..O3RP^V!;%5X>
M<@UXYHX(Z0Q;$<$T_@@F;&6JM1M]NAE]Y?D\4S!>]_..K:2,'9[.L_4[^DS3
M? <VO?^VHUE)SQ]*52*";E_<A&?D@<.781H=\9*1F?G3=[=J+?R\GZ"'-(K8
M4K-1Y8<</'AA+7@!CDB5_V5O UH)A_DA+]A?;NO*W<VG0_M>T\3@C/.Y?NFV
ML"?(0+ZQ/0>1]5"@#2&L]P7,,*HG"GO@2;[N*LW#3GB41L7+BGR-'NF*[.I9
M"-2?@"Y)!M=<0B(0R,[YR6JZW:7Y"Z7M%1?+[IA[=_  XZX(5TR89M*H;O^T
M_ :[#P?=,(OR+&/8P$/MX.),O! 1UR4FF3'KYM#,>5' %=)"$V-GZ<D,E:(-
M/*;'UQH"0R9O$WA^F+QM!.O*B%_C5]_HR(L)G8&&=9M[2*+>^#^U59Q*$M4W
M3\;1+JFB%.XR0D3NBW\!@TS/K3CC9I#&#B(8LD)*_$LX[U.>G<51^527[&L&
M7)QO0?K4@P13G@6PY4#+DBF,T@^4'F]'3A(0*LO+?*%'Z<>]0^9O*18_9!V1
M#9M"QRPL'Z%\'J/LDA;/2<Q8F._][01S%[Z#UZ,;!RE75$E )S)NM>Z2 \";
M4\"NB/."]4_B*+TO$C;HIDZ;95)"I5"E5_1X=%!$R&2J!N2'4>/&)E*!46T?
M3-RY@-<&";352VK%2*>H;KQS<3 JRG98+,6H3W0+VC]&V7X#YW=A_+*6_&A9
M/H-CM>4&R[IFGM/D83VA03.S(41/7-U8N2);T4XN+*XMK;</,;&W#\\.\_FX
M]]"2_$).U'+1Q&J*4QX$]T7$/F)_XJ5@FP_-=R:D8D*E>;5?]%A]6$;()#Z"
MR ]G5]PHC//J)=PU2,2UXO9W;/L2CMS2@&Y'QO0)]>Q,JW=)0>.J2S6[@ G#
M2(+52!><-&J"5TRG4K7'FT6E9?74P5L+%](NN7C?*5-.(4,I6UK$L"=B.S>J
M%\U-UL^&TNV(,Q[-L7<3&:U>R*<N9A@F7SE4OXO.-_ *\6  UV]+%&E+?T68
MM[2,TX18YVK:S*0(0V;2,BY8)!?I",K$[*-)4L*AQ"D91N8BPB++)?(P1IC3
M(#7()T,NX:E3NL2;WN/!/0LF]!RATTGA&>\2#E6.INF,M ^+!*TG3"@8+XR4
M&]<..B4Z!$DUKD$[3*,Y,KW_E<UG/T;%%PK+> W,TH[A4)<:NXS AGN%16,C
M&";OKS[1(1J+\\<,,K+9VE;<H <:8\2US>N*Y;O]0YK$->NQ#UB@PRKHH>#+
M8-YRO8_9'&_]3(LJ@2I87HG.D0M/Z4[X!%S1J?+.>NX] 'BW$KSV*%#_!:=N
MQW H4/,EIE:OL"C0T2LFO?G<T0O)T[>77JG-D6M.J<W[2\AE@ ^_=G0WIS/E
ML7#IRXBU B8KR^.1T4S4\53SBJ&E(C'5[8C!O)*2:RZJ[]Y&0T5VX5X??,=>
MZN;5]XB7%6/7!E;WTECR:GFD"TZ6,L%[4$9/T1YOPH.6U?,&+4CG"X$N=:G3
MX"1(\RI*50D/3B'?@_83WO537R]EXAY_HAG#!E.B\_4VR1)([("7TPWRD90E
M8R&X8WJ:3PZ+W)E(P!OW$W%,+X[&U:U(HY#SP:%*+"6D?'GF4?!,=.@9VZE3
M>A#U,ZIFRL/)&=8\U5^:,$,8\M6.%6CS=VQ*C6!J\\U#3.3RZF8##D>5^N75
M:8MDA.DAG)@H9E-X\$P_):W,FN17\0Q8-@G-](& -3\-CV^-G@)X,]KP.'3!
M1#<]T#KY;Y,E!?\$&,V6FR;F57"[P]PZ$R(/(^W.DTN-^!M!HIXG-SG,W]-#
MI)_3,E->\(RLF0$S1]BK8&?G^3(3.1I9*HU79QJQL_?D&Z^N<IZ3,X).+U%G
MBI!P&5DCI<=80MC<ZS'Y1X>./60%+>\P'5)%DD.TO'/\)Q9]VL.MAM>;DWN9
M97?Y*3O@)$]]K&*R@;PUWL0"#9LG[Y1QT4!ZI[>*+QNKBX(]O5#<3S[1_J&D
MO^UAY_.9_7,/!LE2*(:;X@Y-%;Z##*"!=GC#46GMY =J)Y1PJ>0SESOE.F?)
MW/N&^>")Z3I_+"C?;;^EC^PI2 NZOJ,Q6R!6"1V^N'E"=YSC<JH?NIFV05_D
M<^PI2*:.[<MLDQ?;^K)R<9."3;I;,TAGQY_(.6O4VL+HF1OSPEA[0_DFQD=>
MPX^-[[\L.\E>TF.G;H'[9CNG]/K\W*:-P!_V>/$\AC>#4?;"!M>O_&5T5?(Q
M!D-,SH=ZW1#SH 'NCO\T^B#G/1,$TPN-[ICM,*DDB4!].\JFG$E6 O?U)$9$
MBTAKTK+4MH13!F&N1$?XH[(E\(]]XQ8G>NR/D&ZS-F SC3Z(J4P7<3^/&^F
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M$,P6MV'DHB4R\:F<<J%A:IP#@U:/P1/"2.< IU%-8P:?UIY;FW"V4FA8*A/
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M>#8GY2MES5R@/\_T'G";<4W<'2I#CJ8>+C=64F'#E?PND>KO2-+ P6&Y[VN
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MG8Y)'(DPKC\8J1TY:NJB8RG:JY*AJ00&Q0.,A)J,D:.F;CQHJC@!"C# :Y)
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M9&#?*:YM5C5=M-E 2QPJY@$[9,]F%7 .E^KA9E73GA0\>N6A!P?L(=-C#MX
MC$%Z3QLF8^,W-WJ=Q&'DKT" %E9.;.,E599U>R,/QGNXK5K5GUP<K*B22X54
M!N]]KS%<QE$LI8;VQ&DY55%Q2O)\Z3%+,8]@*37*TCE%TCG7BP4,1?(L3.E@
MASPCY<-A!3-UQF'4TIX2#(764*(!8#TG"V;$U7_[08XV)(265@OIKW&.J4
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M<5'W *VC<8[=Z6H=^&_I.Z545E!JF$L+4= *W#N:+!?N):="1W^>[L>BD2X
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MX=Z[UHOK):D;Z'&HS'H#(T4[7(JWK7WL0[!UH+EO <(PP7('6)2@5QHH'QJ
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MAAH%$M$JDQWIB5+2&)T/NGE.Z4<_0G^XN/M5.HFW4A;8!1+8R> I)$D*6N7
M:TR;'&+]0Q'-&ME/TO (06F4:0^'SY0X?'+ &;F.8<1ICMFL[.M/P$/-+7\%
M$ 26AR.YG!7.,AFEUD0G#%]E0YG3 KQ9.=>3YZ+P1;[Z:T^D8H;2@@NFK,!6
M/?)X)M'=8@'NK"!08^@@@E92R*O7[U75&_""K_5.4'?=Z,ZR,^#XQT_Q:F4U
M2+Q_58UZQ<TEZ3[3[XRV'\I_&:8?TS\"%O>6.R=_?>$_.C\>P_V80AS.S\KO
M65.RS'[\YVFOMDX6:M6@>>$,.="LC)%RQETMJ*-J>=3%4C01FSEZ)L8BL8KK
MK7.BYE@J9P#L4?$$C])L897W(.,EZ9":65YOG3)4L^,?$L:IZ=%F:4E5'P%,
M+*>+/ILI9-?AQPNP;T5*'J%9)YF$TKKH7O:<3 <X^./L,M@IM .<+32[13G%
M9VH@I&T3F'7UY@5=NRQNB$#6ZI!1,FTF5A!\X&<A5SC$EXLMY2HFDX0#J58G
MB9*Y\15::>Y%X.#=+Y;!8P!6;KQ*3D-0T3",+6B#Q*=)3D+8LE63&29'&&V/
M)AF)+CNGX;T/E\\@6&$!//C0IOJ+ZPN7Y72)_NPG$8H<T@A@[.0)L%X]Q>F_
M-W%!#;S%)T+>XNQGFP_NA\?X<^=&CVQBMBAOW6A^8V)Y'4V_7L UABX$RAS?
M8@L?<O\*%E.:N"?9.&U+\B3WKWE.S37U)/>O^,X]R;KIE*&:QIYDN:K5UY/<
MGSZ;*438DZR)(ALE'WA"BDB6M$\V@!9:Y1,R2M26TT7/;6=A,8"2_#WR)F&6
MBC- 7V&X!K:[<(%#S"=!+%N6Q-7EQ4D_3P2(J6I'Q4+@])MR<8R9_0K(8W&I
M@%8:$Y+\S@#,1J6MJIY_^$QM;<J8IC ZL+[/WNB*NV:J[=I,I=%@2;K^(M_,
M)DQM3<S4%@V6)"^P?&W=,+5U8Z:V:+ 4W/>0H;([) !\;V6!&KZ+H>/"Y6R1
M#Q7WOD7(;2-4UQ@UMP*L()&Y; (\(2V$B_22PVR1(9SX,+W2'=[Y03XL"3"C
M4:-&4D:>)&0E1I?,I4> Q.3,(&4'LU/$&#WSX,JT=JFEUJ@[F9TB)73G1Y<7
MQ^=#UAH=5Z:U*SVUALHPK:U0R#3-,9#E?H.C0;ELYSAY <%-N_F=+IJ4X9JE
M@^IQ5]I<?;4VN?-;753(5D&-NCBL;B@*^^)"=Q6OB"HK_5X[I5&Z558;&\8@
M#[B^6.]T[15_/V#M,6'T[7!5$AUVS[CN0JVCB[9E!1&)@U60J*9_3F2F<.T'
M@?\#;Z&M-?I-]"% $5(392$>HZ7GD7:,H6N<CS5"^+6Z&T/8#M6!G,(W$$9)
MU);G^3^VD<+%+1)719-HT1*UR9=A[@ 0N".U*6T2.YI 59HU3^'X,$;0G Q>
MEA706NZ&H@O6-HD+,J!KE2E/@!NW[VXS6E0J[@4C^%";E?-N9XBT;*')8U/<
M)'XTPFK6"\\JKUX;R0X.O J.._N\^5HCPCG !Q]("FTVM>1&RE(]T=(1(F-;
M*R@!!0>RTA<GMW_&I;W9W%V^1JFM?(6+N'@!MK@TX:AF$BE:859PPJO-!)0G
M/9E;$;A=+("-+\@05[6-VC")1_($H.+H6?K@0H:99ZK ?Z=O@D3;,(DN\@20
MTT4/)ZOD0>C:"MWP"0&QG!G\W0I<?.:!A7+,-?Z0JYO$)2G8<QH9Z9[-X1=-
M#+].>8L3@80N^LTM1 73)VBYF"74HFYD:T44%N_:2T9N%(CRJ<\.DAN'EE>6
M'N7=';$6RC(Z'?1&7A;\G"):GQP\6JXSA7]WX2:!('T]1"MO' F$P>8JU_I
MX-FUO[MPF;U@1]%U;4'CE,R/,M>N'AY^@G8?0#2QPM<Y^#-V48>RL+@Z]=:7
M-$Z_ C!S!>OAK.>:VN]<:$';M;R)_P;07Z,,W[V+X#J)TS#!37KCLWEKQA%%
MLBAR,NGAUR>])1V_A B-%7S,?D#TH5=W39\3J!7*<CA#<NCWA:/6E!!'FVM=
M:Z_[%L-L,8NC,+*2RWKX7A[AG@VIN'$:%\6:ZUL/]SI!W]G0]6O@A^%CX-L
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M<L!+*FN<HH6 #N$X?W-.N<GF>?N&KX?FJ1[RT6P[D%$/>+E;,8X9DD0PA""
M8FZ0.\L-?K>\&$Q\&+I.]E# LW\-<,KPVK&"NW9)0!='EY^/KH;-D9;0M7I
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MPWA[!%@<:CBKED5SCD1SI@EWN!6Y,\JT 6Y6+&8B@Q3M38S=-8\ =<9))?$
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M9L0VM.69N-XY%]Y"DACRQ+<!.H7K. H3X1WS;=.J-;3E26/54NC""=^<>:P
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MV"(VH7\B=!&;<'74^XU%48V(QR;D(/N.3>CB0M+P%2H LN\#>8)"<^36]R@
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MEN=_F166Q-M%3/@ HL< 1-8[@7B\U0\,K&5@*_$I<&7KD(-G[/QWG%Y0W<X
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ML7[OFLS!T@VQD]N9+5 /T'Z2_*0)J:QVRFVFG)W(+"&T?8_\!.WF[^>.EP$
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M-RI]3T06?_TE)5'VLW___U!+ P04    " "O@'Q:^7CXB$I5!@#5S#P %0
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M[%LC51XLZZ4$"IA2H<3$638FRC_^><N__A?K^>D50S<FP)NV+F]>,X&O^:Q
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ME$*[F/3; 2'MF((-2<!C_#I/H&F<RAI(@[Z=AV\Q'6^X._U&FT!2[(P@[M=
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M/[J !NF$?<%&[LJ9'!DF[5BV,0:FM><VKK]B]>.PF39T&%C:JZZ]6X-2;@K
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M8%-\23=Q<EK!U85*MSK-5GJ^''32H4VI/4.V'3Y.TNUZW^(LP=>>UP<H?B/
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M-[,92,X%4_)^]Q[89+K4N?;41CIEADJGJL,)UE@.B- Z.?N3V]Z.?7YV-P,
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MKR_GS9R:16MRME&JD35U_@YXNL *D6Q]0JE5C!LIV/N6\X@'<XCPL6+;4"Z
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M.A9D&7;A87[LYZZN<]3/*P5QE11O>4GQ$0@57X_X^UX#SV+!GDX9-V_/5YA
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M>*%;?O[5"W'*1F"Y.U?_]N<JE^ 61JG)"[(@>"3H8]+JDWQ)RKEDJV9N!WM
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M%"]G4'%*=K]/NC46"XW05O.\TO#2"S3G06Z%W!8YF]M,L8>!*=#M?JZ]P,R
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M)_O=IK\Z6>W]C1/P4'4Z2-5T1YNX&#[02)6*AC>M%'F6)1 4=>21M#&:>P#
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M+^ -Y'(VG8@(.PI=I3, :-D!Q1&&,V5&PZ4\FB+D.*X_Q=F=#>J@NZ,D@O3
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M&27^-9(*O& 1Y6+JQ:*!S=/%1E!>2ZCJHX1N.=^JMO"L&B2S%0_"KO>SYQ0
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M3.1Z7^W<%XJ]VB&3**5@EP#Y#%XPVK)Q.#J2XQ1.[?W E:.#X^"A0LZTPIO
MJ32+NODM1:A(T#Y2N+U. HPL'XD8N<RKIF-5;96W6*6"EM!RL/S]LF,=9',*
M-E[(?)A/&Q=_)1PW0Z"QCT2()9H=?1<\@;,3>C&48]=?&A"FF4J*_XK)6NE
M0#7,- ?<!C)7L7<)CJ&/A[A A9*+[%R)#'#$*$!/O 3Z"BDU1;OSS%&X$L@X
MCM=P^\0U9O.>(,?Z=/YB!Q)E&P>[-F%QX[G7Z5/'3ZR(@ T=P(X])S*]C]T
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MM&?:Z [1N -W$\/#M3E VX",B95A(MF/=?W62U847QOWUNVPH$LE;EFHL$N
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MY$':=;MR"])^BFD0P4+68H^66K/4?MVX%@5VSG>LA+TV#7IR02]&2D3R21,
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MDV?]X7X :;0'P@U[].C13=)HX9LGC[(LVL<987QQB# .$<:'$&$\HO+2_\H
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M;*!LY.(2TJ5VBA-,*YN["0)>LL0)$]VN5/$UR^Z&6Y0;-$0&1_:]0B+9Z#P
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ML5[6L(?%'\S!BN!563:-+IOWVLV^ "K0O^596K,24N"\K]8X^L-^G.7O@N9
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M:.]G1=LB:P1QC)ZWR\0JIJ;J>-"BU0X'W2U%&NH(@6Z@/1>R%T%<)!]A+,C
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M_1W15<MBPR?8FMCI!"YR(L79V!WIGBOGP_J;SQ3TLOS6[^T 2S2D#DJI-V>
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M_+1IFJ6+'IF/PAI))?NT\.OQ]-'LHJC/M1HW2*]K):E?X;-P)9%&U</@PV<
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MX96P/EIUX62?][GO#;C*=7U5=9E:0U[DC*\[/.M1OI%5M/MCA;9]>N\ ;3M
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M.TR/JTI,TR1!D*0$@G.Z+A4'X[WQ:8^SLVT03-\BJ.E:^_-#4Q\]MK?]RB'
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MV2NB]1V'"3L7=.296"A2@XJ5'YUYM]Q&7D3JL&=\(A0_EHO!<X'%&KFB8 !
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M0'0R?Q[Y.7 ^,9\3^J1)&&%'2B_K-9BN_.F(0.5M)F>S>9!H^*=#5;NE%B1
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MK7IS!Z,!B1P'AMX/JI"#-EM2"VBX,AR[0R.QJ)*RRX'XL^VN^]]A=X7[(HR
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M&"@*8+$C-$<U2%!<]S$+X<G1O2(OTC$; ^<8%1NX7*H(2Y3'H!QH39PQH8N
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M%Y4#&-*W#9"H&B.Z(U%=$F>%<;6+T9[5U17DI$"0%L/98595XRAA%6<>AR-
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M18C1&.W55H)$2@02G)SR:53^#]L,J%6\'@2U>&[+';L1BCP/!SNSS(9SG[U
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M83O/+5D^%_J>N39P=KJPWH$M+SH9CG8*!P,3FRU$ ZMBC1W\6WOY^#ZDO/(
M>Q/]<H"R:>)LGNR:[;J3Q?2E9O&U.*#!OXRMBO&[0SA7V+#Z3:Z(Z4N;D_5-
MUA=/53D\Q;@XLPX^(F#GA>EL",8VF=%D1ATS8HZ0+F+01=J.Z&?2B+B!1L3U
M^")X*>/]=7-+"%'E8^M9&K6S@!V89D/I2^736XTURB7.4ESW]'I*%*AUS#?
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M>8"S#&*;-/WO0W6\[V!P2[5?VFU9- G^Y/W%W0IW,*"@5E^RVW](1V'B9(<
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M0+9CW_DA\KW"^-152 A60WP=< <\SZ#Y:S\]-7_-9>W ,N&?ZW#)[C$-?8:
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MKEV$VIHREQ.+!FP49PNU^\L9P-]E$*>P[6OJ)2GD*+>(YFSL$K5MY,X'9EK
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M@RROT\:<-J9LS'+G2:YI.PY:3$)?UF?Q"PLTF=1D4I)>=,A"]1N*\I)XQ,X
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M?1.,[=$AG5C!BG(]Q;!!M,>EVU-2;= D<O3H:^I4:S=_L1[3X:A3FZ)A4,U
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M< I7X=#(RP2I6]379=O4?)BE33DQJ"+,:W"1LHA>= R,R@B5P!]DU&VB8DR
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M=J77W(9'PQF(<HSU[?_YQ4]9PN\_Y'[WE/>F )L.)%Z!:/W7S6HOPBH,L'B
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M$<X'O3)Z[&(S XHL"W(,^2+!X6W1K6HS(@$!A=S2B=/N!3OM0'Z^4<9@KZX
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M)PK4D8H 5N$J/<.2UPF3P$!0QLC"E>@DT="&>:+C+,$3L@D9GT=.IJWD6V(
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M;X)+.]FM>E9'R=M1[HE/XR(B'3(2)(-+KDBQ.K_$:8OAL.4S;N@TJ@0QA1(
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MD@;Y?P0W-Y@R<H/A;84'??KB%??JZ<A)Y(>+2CVZNZWS2C??Q8NX]VSL\ +
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MU!QTT7&B3OJ#/A?BR\S/-L9!.OU^+<GA"\?]XR_/OS0Z=\751[(.&HOKAO,
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MLP*EA!=[RI:<!9>=4"7[NOS'G@$6?7')(?O%\[.^.:.\S9E?EZM\IX*@\>J
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M@< W-3!T1FWE<RQ;<-N0 K2:TJU-1Z^*"6UEE\JG-)2GT-9: (FQP)@]4;)
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M-!P"V]4S_=+W]*5B]2*<"2@?P-T 2MCEE_[<EMTFDF6&.Q.EAEN3_")*P2R
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M/KEIK_N^<DH0U_R*D0,*3RW^,?#)!-<!QID34MV2#S#GDPY/)JKDLD40+4*
MJOCHS7GQAF3$%"8=[(J&30\H%U 0M!=F?SX$P7?&J44O@@C$!UA,Q:9K;4.
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MUP]4*WQ%A3H@#VM<@$+&G(EQJ3^(,>QLY'H3$<%@IGC3Q.'28J:+F8J9%A(
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MC+R!981"DC,O)83KL^QAMYJ@<$^;8AP*0^A^IUM_(/]SVO/,[B=\C,AE:$A
M-6$\@,0N$+/@NZO;9!W-9#L!9]Y<M6QMQO;%/GX> @'B>R'S'2^O  M1TW9C
M;LE!U3KP7V=N@(X/>[%P&\)OZ.YDN*JBMNELS(==XFH]#E%OF(Q><?.S7QV3
M>,;B&)*'@0OK52!A<PT\\ QE^&<F:KMJL6L(0U3XQ.M*F8[H.?I;-MV<*U-:
M\QE"N5Q'%N]7MH3T&L<#(\!I7KM<"RC)P#H"]S:R. 2V>G8X:,VMKX"1SRA0
MW0B/X7V)K@PX4*O-KT5=3B>49,[E3=DIN6I,.BF01?9"G='D4VRU+X?@-9AY
M*IYP=\2P;#=-!4:#\R(M<W@[RNZ**9R9E70:'4PB R),B9P"GU_3J($PCPGA
MW]N=ILRQ.$P?"UXTO>)-U=>$$9.(U.H6;3S:(D?NK6=-7PW#CF14T&YQB;Y:
MA9P0,* "(63JWZ9-E2Y]V"I!*]]<3T2^3(S4S*(W,J'Q"5@9.DHA:H_O&L\!
M;>8AE*Y$;;Q]"))QHFA3[A70RD^._D3Q,@*0(ES-;F3)IE-'C^AU&5S&FPF^
M=OPH@UB*4\%4W4_!0-ES "+Y3K"/X1-7]06Q#^+)Q&SW;F /X*W(K]K?[40U
M<!*4SEAM*+J?& N(/U&SP%XT*0@'O?PT7$^9:T'BJ3M 1$$05SARNOK:<^Q.
M)JY:X8_7&3$_;XN^)A\+11$"?Z9-PQ[0:WR"J%U+V/U=OIL%M1<,=W=J=3,3
M;^][R*&0#-,FCI5S5)!/4N00:[.XQ4\R\T3"[Q*8CD0W'S/BYM&"N%D0-POB
MYJ[S6W,'QE14^\V.7J;=#7Z^J4+0\.P:F&FVTKR)DPD7,G!H&(4-+JI,QPE@
M/!B\-7G/GI,HB'8@*<1,BH.-L$KE98K>T$0,CI:C_R'6FJ/(F,(L4#^ ?#TA
M D^+R%<0!*9U$;P3RC\<@2RR04"$#3TP&)Q!!E@(( 2;^:HZVBH:5>!-V[VR
M XA/G7 J='0P<9D[B\R<\%FD9T U.>F$ESVN4YKV$@U,Y9;EY"$GVKC3<X[>
MAF@.MR'M:ZF2\['.$+[/0FN(B?[SZR<\@6+ I9<\J_?YP\\_N?CTDT>?2H&I
M9QILK.O5_:N(M"RN0^E0CJ!1]A7K2HPUDPY3>K$)ONOH;8^*AD)M3NT,J+_-
ME,#OMW#[?5[;Q@@^G3Z#+3,OX3=A[;?^&>>6G\WYFZ^?/CG+_)DHRGO16^'!
M-XJ:\043WTT)4BHE>$BF94AI;;21'=T4Z+5R0-@/(="NM*BBI-%(PX.X[(*#
M[\+/K8G?%/!W_"=1\:3D$CI8G%:AVA:3Y)-.J#VR'_ B.ZHHYR0#U>^M#M!6
M[Z_"98,S@]WJ7!>_ \VHP0)I+K%NB$$?U(W+;360G]+Z,;96<)%6%R%E!B51
M^T64;=;1O;[<LT80K/4ER)P$LZ)R97@U_1TVGWO[A1_3@W(5]G:<1]RQI+W*
M[_*7_UH.ZZL'?R]?!_M?/5E3,?9(!W5FX##]."?#>,,9U ./V$&!HKSLRL/5
MZOE_Q;<GFB/TC\=4LZ$/;Z<?K$;IW\KWV#E=_;EM7Q63,0Z\!.\_?05ZF:R]
M%%*?!<*&8D9.134;6(%%1@[< 5A0UYQYF62"DN]%DOY$ BF^J;"<]]2&_4DA
M+],W#?]*:MXVR^GZ.?D]J&M/]A&SK62/ ,R)4 "JOH83.JQXO7:3J'.6%+9.
MC4+B?O(S_PM6*\0;ZJ9OP+P03W=^]OEJ$Y*T=" 6ZCYJD'C/!WR??--#<%B7
M4/TOH6O[ .9""U Y;L&QKHN0RCQ V6$8NS[:?C8;=[$6]^^GI@*FN@/'(QI-
M3DD+1>6C*O^VO&Z[VU>3%J:0F)4O7;T^U%VE B+T[L-#3>6;2 [I&OI 9:07
M[T38:U9%A[E"&D[,]2%\NSMSHJ*6QY!VN_PO4B#AAE#= O&#4/U^>G%V:5$H
MNTE[^I;0E','D?,<"L,(JU#OT$_1A# OL,Y-3>N,R!T +\\((%P05*Z:X!'6
M5]4>!WBE"A;[3^<S5?MZYJ22Y4 %,GSO)*>&T8DV&:4%1<=K"#A0(=&_,T<N
MM@[[$V].XH6V$VUY'I $:,L!JF5X9VL4*[/J8/Y.XQ0"]*[ L+ )MA>6#/J;
MR^P0-X,!)F0TZZLZ&)U87,@-QAVT/8^ZP$RTES>3[++\+/D*MS&BF)DCL9X/
M9[^$Z"'QA_SGLB' >1(">(7;Y+TPM2;"Q;%B'6X<48=A@Y88",W',_P;D5&(
M[4""CLP?(IS):KRHO&,;[X+>1[B%KD2-73 ,VO;([-ELDI<F<[!;:EL6X#;
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MDRCAE+:=V^G#Q"$21KT$TQ'U+_X>#T0D59^+=N/>3]0YQ!K11=>6&RZT[2N
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M27 -:PV)#4&88$U=6$0-U^#/SB3YCT%SR8R )P)X;V@Y?W:3U?!&3*F6"Z]
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M84Z6T=M%,$NI&6 UYNK88\S)6B$F*1E<4RTY: 71<A<RBO7D<]&N<F.--)/
MQ*3Z)7D@<?X)0:S4,4J*BG,X_C+:";C+&O7>WGF[V-DSNV*>;(<()2>%'4+B
MF3,XX=G: A189Q]Q94K";W"?1-$QH8B?J^:$>]?J,%(D><<CX Y0941#0I%M
MKB'CZ;>'&=T&&3_N<"IGTJD.!3+Q(  0IUO@*:1C"(9Q&&S[0G^./0T4C2O
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M2+N6ARO%3QO#;I#.A8*1W F+%<7U#*UAE#W-FY905@262&(-Z88FO.NK&O5
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MM\6@/#ZNZ#U[>Z-!.!R<#8/A :+(P=E!]^  O<,'@_&@W5/[HP5DZ?]",PP
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M!;3G*4^UQ/Y).FA&]<D1X ^\\J\2D&$L5AO"#( &.@"@$ANT-P"@UGW$R6(
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MJJ)RU<^WB.HFHL)QH4M)0Y)\3OZ.I0+90E4F+ST7J.EN/A!EW@8TRU[A:.H
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M.1YCX#@=T88!H^,(/L(?AW\B:[I@3H4+)+A#-%1VO8W*OX<;O.?.3D^/$[@
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MN1SEU#O0E4Y(:O&O8 T$K!SM>$N@1>]H?^\%PQ2L3]Q3X(51/BI)M<,WD-V
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MZKN>X'\D^"\P];T$#E9U,N5Y"M(%3;K+J !I,@F2<U93QD&4>0#!DKQ><&D
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M$B-4840:<8G6;U98O<$I_MAE"!O>^@#>VJOEK4??E[?R==5?F2(K\X6)8NF
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M073)DY%QN7&U5"TQ4;I"JO;OUX;5%P7SXS*:Y:Z(?GT^M1U]SSBRA)B'E%"
MGD0D@-6]LVWJT%3A(*[AGF91=A2I=FDM<F7ZE1A/@;SZUFY=J-VZ X" 7Z^N
M8_$6SZA@#T)<997-O<VM[E;7K-A4I=15"7G="1S\1&0(6I4%-N6+;N(PGPBI
M&>'TY<?%V2P[#GD7W[FI[W[6U7$DU,ZJE[A%4!Z?\T;FJ:6HU(9LCCFQ!1@
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M=0:0#ZUAN0?5[KM5*<);#N'6U33,(Y4FK=O(+DPXJS;8KD=GJ<BW+*P_U^R
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MO!-7)!$6?PM'@?-54% HTB#HH"PV;CE OZ3QR!.&3&.9Y'OO;%0Z,'M#,#"
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M8S=U8*XWG//M.A,NXR-[;7)>.6PD;%Y_F@2ATVUW=NF+F"%^1P=@@V'E$;"
M$'Y_TSE*-GFBCANFL34!&K(*_'*&23S1W\>L]]=BD.3X"58CVG1^%=2<'0?C
MCM]RP;02F5*J!\9,T[4HGND/3D\/*2V^9:?<9]2M7DRYD48$+VKW9 6QMYP7
MW^YNM:RYXS=J01H6A+>R4?9>C.$<\0SH[/"5AV,Q"=),K1\'_!C!EY,4KAYW
MTPW'H#Q@13)7M:.?AH(R^)US;'M^%"-Y UV\%K@RZGI>&%FVWRZ.^Q:H:PI?
M"!#"]9IZ<<-$3<_+4$2CC,I]86M7STT$/FBM!+9CY"81=69U'8HITG&D6!%/
M%FG#@09!/!V[L&-,C,(-LS$.YP@O3N<I5JQ05#H0(G)<*A\6SF$--W%XPRT\
M?9JZ<$9A/("58K-T^$5$V(:5JR<$6>!R-WG@ TC]:<JM7!6EP5; /R.^$UB\
M##M/M]2( \5+?.Q''D\G.BG/C#"$]25N@.-N.GVF9$.&+5@;K6(LPBE6I1N[
M4T'/R#=CZUH83[\)_OH7<::Y,QL'WMBBIH& <\&U?,Z!%0RQJM<XF%!50Z1%
MOL>^9&RZ4S??^54H]WHO9J8RZ$XV[20Z9F=%GH6K>W"6D>9(?)$[>YM YG#%
MSF#/D/\I-F,> !4]L>92FL#]WUQ]40]?1" A?"M1"C:YKAOR]1G>UPLQ$?X<
MV 1>'$_DI-.DR 8\.?H;-Y+,L;.-HU\"&V/&3N\KK@0;ABOV;]K'XOL,;7IQ
ME.8A7%XJ.2)O;B:\<12'L;PV,"F<"%X2G#I01HY5&$4J)Z4$2'L'>^;&^6AL
M&N5BN_+R#E.G;V!G\9Q[E[\]/NUS#H0GY&JI#!W,)JC"BGGCQ?)6]-C='&NX
ML;PJB1M[OK$1?UTE_BYAME_PUN+@,!P,7M@'N5U4;F]_ORMESE]Q@#RIO O5
M+7/AFY$[PF>/+": M>G2#)X%7ITYA^X4[][+R_ZQ\SO,'/8 *_\X@QBHZ3/5
MV,1RFE3;<.!&U\0-;_A!X/?T9>: Q8[O2"2Z]_8P]G+9*-[B[/@EBW*XG391
MR7F"EQB%^SWFNN26+-AWV(1C$'I3:B/]0<T@4+14W$I=C#2FOL+"*)&R23FR
M(-@09RY<U!YAFI^<7X"JIYHRR_M5V11U84KW2,M$=;7-'K5 &.#LY>)=YQ>2
M<J%S#E..%'!^$>,ITDI05/>,?"FHQ?!+'V1N%.23>H:#"U45Q'!>(%KS"<ME
M7122;S?.K9_%:<K3AD'T$'I5 S$"08%*!?)79B.&"6^7UT!,.)5,H*)\]7,_
MR%#R38(L$P(/:?%:]!18(T5E#A;$ZG*U%I89-;W_G$J+K\X/-JAT*CB-NL=0
MG(LH95U6?T1Z,&N1!YL'F_U->O8M_^@++.B9,OLYAZ7;.I]^]2&:R*!3@/:>
M#T VPXYYH,(0YU\#DB+]:WW3><[U&;M-?<:F/N-B8GUN]1F?@3;/">-@U!9S
MQA>I\\9*?D NK%3I+56J:U0II<67E"TTX+&F^X.,B;=2;!<5>JW E\T&M(II
MV?<U&:I+*RG0;#$8?XQ6AA9EV+V[="ZHYN&1Y0Z1@Y); X;#8>W)@J$*RAVJ
M<],0#7X7K7?T'B0Q5H=&68KFP7]!F,'3T]!K2<T(U;_R#"YM\_KX-D,I&@9_
MD_AJ 9'F29RR2@M?33*P:T$QB.(;+LI/&PYF,0HLE$+P^[JS!A/N;."LUUMU
M>_DKS-AZ,7Z5=X(\4UCR^CYO:,NMZ7#9Q(7OP8%I4*P+C5K"'+^N=[:];FFW
M&:@W^L@,J6ME77ID#I(@S>+0>3O'ZHR7G_-@,"BI+6 )IH)([21*LR#+T0^!
MA]K9W]OF5[>WC68CZ0_4="]/$ER ?:PBG8+^SGY=]"E@G<F -:#" 1V&H$'A
MRTG;I;X(QVX2\MF>HIJDGS@R[A(X"2"-@I;/^U!W/:J;4B(2L\MRN?N[<KE;
M%169:E(.4(&#U\H%67X<5GW0:X:_L4(%EZ3B&H+;R$7M\7G>-]T3HC WN%ZD
MRA^)*:B#] KU5CUK>,$TG7OCP"47'"K&X=\@>R<B,5T0U"YZZ#+#$NPIZ7=J
M5;#&HO;>QZ,;SF&#8S_WLL+N2YT1QD>30-X\,(+<B=[!?;F#TKZM>T/IG,TI
M4'TJZW4X<%HAQ<ZFS5^DL_-@\Y)\G6#U>$5W)YBQ8S<#S1-F'H9BQ)HO_/I6
M?D5:2<9RLERG$1Y)X0$:\S+;=-[$XTCOLM&!I4[[#*1IM:+ E_K%[I5U+06K
M\2FAPQUM'CT!>C,UZ>BVI4$,% -; "8*WN*BCS.DEUH6M<5IJK:O=".9:,4@
MB5W?YES62!/E^:!WM-@='J#!UK)N]$B;<2UJ"@/$Y9',F0+)@/TSIXX'(-22
MX,;UYFRY\I?X,@V'8-1AN=QX*-(4;A+8C!9C4ZX:%5[X  S)G=*"#..O/8#,
MX>8B,,[YZ:&S=GIY_,HY>7?T^SJ:V=(;7=R@5'H'YEP8&!?@<M\!V%(ZD^VV
M0R9<0@X$N@:VOVF[K!.U+1:* Z3N#(SB4)Z;7'QQBPH;7?2+F\V&TP$C-8&=
M.A!#9"Z9>TVA #;X4:^P=Z!5HC'<-.7N.(3UI+"SY SUKL'XA3$C^ '(OVS:
MLW-'KP@[C5%0XEK,RVH-,XY13-$"["*$/M#<\^"0AWD(K(\;F.3\*0L28*DC
M>7?2*5@*\7"HV&6<C-Q(\5J*(&&W+7;G2R\2[%084RS"=7[:[;4=8#<A/IYB
MZQV,UXEDXH0Q< A\PT_6$XG " B%,>!!4%N&KD<Q63S/(<4WHXU13#MLB$).
M3<[;=U#31-Z'K!V92A 50CJE:XXZ(>M_Z)N(/'2?X@L*RL.\_EA.3P];S@%L
M?H(ZD_(&UCNQ*5 KDE#<RC_\:KN&F!!YBC(RUV;W-:HN(]YO-TUCD'49T13<
MP%!$,*G E\6_S_$V@$9X>GI.KBK@['_&R;5S2+NAW2A&/AT"48;.<03L!5Y+
M/DZ\21=Y-D+]S,@1O*DHH8[I:Z" @BS.D6@KWZV)NP%I!"-YV*[S!H79@D?/
M112E\_ &*,Q]-E&=^N(0==)K802K/AI='W>5C^8CD" R\OR)F"2RQ2U+5!4X
MJW+"HEO6$BXROLES1V>95*)#[B)FQ*N<@GJ2B=UYC1XE:?!(OHG:NOXK<$/O
M.D3:X,F$R)VR,4E ZIH4YREJD'#CT/><P]S0Q9@#T_9RY"$IQDA<WT\$!S=#
M&#_R6&[B?$ ]2S9&"4>W/1@8@[A\DUU@ I/ 2^(!^HMQ(1BGQ9BO-!$[4H7K
M[&CY55BOLBZ7VN?H ;T%>1BZ<D\HX% ((TE19DS3+?G>[>+NUYD*)27G%SY2
M;2&5551F PLGBZK][Z +B-M:%J7$F[]D#5)7MR/59=L#M@0&@]E?LST+8OXW
M-YS[PHOI#]UU%J=GR;4[&03TMVW;ED1V",>,409@<SSADDMC@5-@T<:T:.D'
ML1@CHX*=.('_#=$V6<"K2440PE N$A /#0K2*$%+8"V83'+>'U2YAJ$[F<B[
MX&'O)+##4Z!B-S$43CH7B'O<,]">YNN:D$L;B*J)G^0CRTY25] K-9:;Q4GH
MSV #'#B];!B#'.4X19+Q/ES&.?S4IT9J+ECUH$[ZS _>N#!2"X500-@ _!Z:
MG?<]YLMI@%>^A6QL$-S01O>S)+Y1"OGO >Q4'HG- J$#"Q0!CHH.2K1]"$T
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M"B(9@XWFW0%C$N6GD\_FKG\OKK0(I<Y=$))JED\<L9R:(;LFD$\>,>,(G-!
MA<S=?AG>BV?$Y8,+=N:\8#;#^PSAQ!Y%/O0<KSBX7"KC!/5#7B"P(^9R&T;Y
MO-EA(#Y7_0 7%_PQJ/@$5!I_FMS=389PEC,&*),7K^"]\.(PAL4J#"5X05,C
MO/D UB-P;%?<<V (]6NP>9ZXYP S\17F\^]86.GD^H6Z&(+_@,9 6/+D"<RY
M#=ICC_U87IJ0-S#40\E+SIJ=%5W#OL'*)I*&P#0OM0V*XO!;'.KS;"X &>__
M<?GKA_=X 8I[F(+CS%IJ75S'=F[Q0O4W(;'%MK,)%V@!-0^GSAPD"!-\9BU,
MI#07R462D:,NB$G4"?CGKG]@#\5F)?YD$@?B-K98PD6#>,,,K8T ]0-4)44L
M&"J0WXTS8B,7I E>C/BU#Z"T%4)\86U 25+-2>_!'<=,?.$3.1_8%W5EZ!,
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MEX.M5Y+H/ *$*H:88VE2Q::A8[;TMK/DZ)'I)03I9'(:YJ!/\X ;;*<58NO
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MM3J2Y=8=!?VR]^U."0*2IM8> KV^V2[[F/@IP4!RS;K (',_6AJY'QI1QKH
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M3> 8_I6LI0(><U>ZJ>PF=MQ(-.;YKB^L'$=?%@%C"-!-N.NKUTDS&H!>+LI
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M-P93!TFI?K3#L?TW"V)72#85).Y2.^FPP>^8,+2W>$X3'"P?GD8S(P'(\-"
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MMQ_>?OQZ_>G=I\]OOUQ^??_IX_6?O5ZKVR@!H^P)T+HN[&=\FJOJ;$]":T)
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MKLBO]<)WH\0D2^52A=.0 927Z.L$"^12?7(II\@Y559?JT6AP-YKE#;!J'C
M?7_:[[?1E#2XZ+ME+:GISSL$W )W%N#W+/P6N+< Y:9PN,!]!5W.P'*!>YLR
M5/-Z>"Y&UX1&X%I6!52]052]CG2__T?Y?E67BW)>UG)!5]7+!35O%AKX4<NL
M+>$_E=MG^7^V7#DZ9N(M!0&@)US3DU+F&U .OBD')/5%(!.0M^>=(,B%G*+2
MU+P.V!^POWB.!CQ!]/X O!6ILP"%N8/"D+%-#V &7:8)7$/V'1 XSPA<RVJ
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MO$\Z1D\UAH4#(E$@J /PSVN@#B "8R&VHH*"N*8A4 < AL$QPX Z@#C4 >H
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M)LNE?+DXVJ1'DS5->60[^Z\MN3]W@YYG=NU?L&/_Z$P >QB>":"JD-\7A=I
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MP,]@K0?WI$M1<JH"50_@4WSR*:AZB,.XH.J1(@P,58]4X67(E*<'58,NTP3
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MWN*>_<BEG%R D[> V/!);*#\( [U 1"<(A ,Y8=4X65(6:<'58,NTP3 H?P
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M/R6 P@PKS*BP7.9]%694 9;+*"7I.EO/5K.C$HJBY>5GZRQEN0!U%B!50*J
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MD <@_Y[A'P!YGKL'0!Z /&] 'M+Q<3K^_+(&\)W;=/RYAWVB.-BX!L \@'D
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M%%B;N-CPTC(ZR#.E>H MA[P*0'?\(T10&A>]>P(@[EL.(E"#( T B#QIY\4
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M]I(2,>/F>Y:'C<#UI*55*E\FAI5'T26I:SWP;Z*A3U76^ I";PS'2QF4UAL
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MI@5>_-CH=DK4HJ<FW!%SC'NG9_6%,V 3W4[<G,))6A6*XU;\/D//\=T._71
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MBOTH%W\4 #AZO@6?.3:L]3[BMO\]CL+IW_P(TQINPG<C.T&P[57H0!XY%LK
M?G%$YVT<\6@@_.,O1!4_FTSA(D)< R%23VDF(L05$()Z2GU8LA<1XK<1@J(C
M0EP!(9)/Z4@BKH$0$31=#2$B:+H*0D30="6$B*#I:@@10=-5$"+UE(P<NFL@
M1 1-5T.(")JN@A"II\2'Q[<B0OP<(7[R@-)WH]^_;]6I4]5<OZF*_^/ \R/L
MP?=BOE]<^7NEN_(]??T(G/$]5?D(>_ ]WSZ2CMOG#,4RT(?X /*O[4?ZB?S:
MH^BI'V"2CPJ >3@=9.+(QJ'H-^* "!_/83U\'&"(\/%1.2.2CN_[N#<M'9'#
M^>@.Y\%P8G_5<*+23Y?M?_Q9PRJ+VZGYY_#;J*=:9%\]IH7=D#759P/-C'C@
MBW@@];5=S3[M92F*-_<,&7=0BE@@,B0C0_+^#<G[L!M3H15_!'3'MRR_OG'Y
M+*CGIR1NV"KT&_K<B@[X(MJ?R^B[83[@<=N%B \>G0^R\D)S;R?V?L6,@#R
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M*&*PL#53T1:R@7ZI6.8D[@)[#LDP.E^GU<>SEA_52[C*F,'O@+<O#Q.TP.(
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MAOHA.A[> ;^V#SHQ+Q:O94#'"/T16OX+/%E?R1[A=O#&&!0-$W\QP /?)9A
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M,W'/QF%WL+ A7X[FO[GXOAYT!AIKV/!",=-.Q5:-Z08MG#BUTR_+32? ^^=
M 4+ I,^9>HC4ZXN&XAUVQS&0:3@!"MR99V,@6MZ^Y=03G;/CIKKL,><\GSJQ
M,:>;"OT&?H>KN#"=+/C"_3Y1]L@ERGZ)LO_-4?;HNZ+LL=UC[-=:WZ'C"J?
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M=B:NF83UM/WP!%!W4+H'EX@EA7GZO]!PG&'#1CERW0.+2&*$])+PQ?MH9,)
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MZ(<ZSEMW',ZA]S9U>*<[N[AG'20V$C IDBSA*Q .Z B$)N)%Y'E'E<G7PQO
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M2@*Q'W+%Z)KC*>][HI:P-X :,L!))K^QY,!];!W?*N8.\*M.Q)FI_&8__',
MCR+S,GO_Q.J&\"3"$W&-Z.QW7UTILM>'QMRS1*7U-Q*GCV&$S?_Q?O"I&6_6
M,8%<Q*V.AZJEA)$Z)X&;<VF(K/LQGH"GP3$N>THGDNE_-ALH^Q_:5M _=<N\
MYH#%"Y%!%\&\N.% W_P4RKQ^DPY_Z*>MC\E@6"W!;2,QQ3-E]VO7]>/?WUS#
MQ[<_78[^%<#$CB8/D5J"D+M+TC-WQS:;[Y%)^Z4-W2LFVAP#8:N[](4Y+\QY
M..843L><>>9YQ;GECA\V .G:W/:FR@29E8 *X;QT@GM&7#4>7<B;@>6_QK'3
M2T6+%(U=.NFVD( GMK2!+0D"CA+RQ2O*V,)F@[C@ 9TWT 07DNZ (^XD"=,B
M(&0T$H]31Q!)#)SOTOZ?#HRZ!\R%H1%0JX^$S-$&^S0VVW2!9<BP(5IEXFGU
M83@(!Y[0.4V-#U%@.</0>[K!&C<Q3#?/X6)%E7B'\$ZA3^G&>K4JT^Z!%F@1
MMQ))S9],?.'W()CY<Y*?%_'Y?<5G]'3BLQ.$\\_$!T332 -V:"VI0B,.$!^:
MSD0CC5HQF!&,,HZYB781\ H.CQN8R1"LYIA43)D;<-!;Z5J^S"'3@T"%';1>
MZ4.:(P0YA5UG,YK=?K-S#_,')U-$*'&21(-+YXA7.T=LI/D39!T2B@40;0,.
M9@V-^V25]!9A\&L>"%8TH+O2[YZ^%+ND+UW2E_[F]*4]"4E[W>^G2$BZP:VC
MVN)J9^.S?CQI/"?%ATY"#1=CZV)BT'DX5A;21[O'D%5P:!G'Z6E&A!^X4]3^
M^KW%I39.&6!>>J\5M"90.I!'@)-EW;"!IQ$4UEF8*0BMR\A:+5@K='?M*SB\
MA7[?UTG-HZ>X[FEEBMX+ 6 6PI8\GGEW-IY L$8&(AVL=PU'HW!.N]4>"1#@
M!HN*)N(\8=>LFHA+<O6**RQ=UCA+PVTS[)D:B^VQ3..>$\]3*-PU[L)VQ15)
MC]V0IU(%%BR_8;-PWPR:E .V(7J2S-5?2 %W/#F(35@ZZD;##;UH4?05E_$H
M,FX1-'XE-EYE;Q=R6I\S!;PPB@J+JXV1L<N:Y!+E%T/^0L,4%PXI:(D.7BG>
M+Q$4J\-C,G^813!X52F3J>.N])*A]A32<V2*?D>;8F*7!,[#!R89ZDOZ*6X;
M,\1Q,>=@0HSJ0DZ/>V]P@*EF@>DX3LP7[QV[%DQNJ_D0Y+M;XEC16$<^6N /
M?R/--#'5X*IVKTL&NA=+JHD]-ZQ!  ZC4WO%(C^+#/% Q7TYW7R*D8W42UF5
M7)3<S2R>P'4QB\?A'-K?%28IL5:I$B%][/YPEPY[:$]9%0KZ EZ&;0W!E8NX
MA0Y,_!20K33!+?A8S0=]#Y$(DXF+H8<3GLZ'!'V 8#X 5VR+:!Z^Q]*/YGU2
M9UU>D:#!G\%%(R$H@(OA]:(?HE<TCX; 7\(.;%"6CN2AB<^";"]G0?]OXKAB
M%14 \8Z6A.@2BT='>L,$B$T$<3C0#Z@T<^C5V7\G>$Q?I.#^0D@X328*DD\[
M"BJ.K7H4* QG73%:4(VZ2P/)1N1A:5)9O_"V>-^O5\*I:[%TCCDZ;$'<SPJR
M'7_!E<#AE9T!F(QK=OW^KS[^CV_"$V?"N##8*7,MU%M.=2@@;3/\7-JV?J%B
MP4;:C;(>I? NI^K/05S7IU, E(;\Z"':5T@GI*549+<AC N).4A\:#9F)Q!'
M,!D*:>M^GV9$0(MS3XFG5](BN17N@W=+=GK>7Y&CV'X9;O'INFBVO\K:9K'6
M6O)F.Q%OG:F#GNBT)L7#S0C$ =I.7&1KFX3EZ?KH -"4EF*"^]Q8&^CN,#H(
MW#4NWJ/A[ZVN9ACI!L9 HGJ 86*<GK<D?R.O3G#+:IC3UM&2V"$3_ <Z(6=S
M9!@:IWE1U6SCVZ 3(7V)8$#=:$YG7$<I%#')84)3W8:YD(?/7HG^##%(G#T[
MT\%69<F:=&A3D6R#Y>,[00+Z;4=@@C>>?>7J__VO2(+_YQ3IC$QDMA3LD6PR
MA7Q_3MAM(B6U<ZV>T1&O2Y-!3[TS:KUS!S6A2T3'[J3,G$4C4 KC00-E0#(#
M"*THU$5,LQ"A\EAAK9)\X-3$>^A%Z29Y1XHQ,Z"%#\DQ(N3M- 2F70C]<1\W
ME4CU5 60-BZNE<$ ^X>JTF<0)!!+9!HHY'$;)* W]G[@+5-E#8M8NQU'E\.>
M35KHP<IZ"5"L4WVZ59B]?R*@4V, "JR!NI-QAU/\G0\W='*<[ 1[3'FP:-#<
M-H!MP!P(]>/=%H@BM+HN/:6N'1W'I[<W9;V0RV>$JME\SB9*M+7N9WD75C$5
M)^;__7%S5_S!D7/[OS]41'Y(^OQ&0G0)B.>*MLGF=UB\UOH.45&F,']PB'6!
M 7C"Y'?HANK&6TJ__1Q3PIW61)B48F/S<5#/_/@741H34&PW_G4)MJ4HW!T2
MC%PD'4*;MAMT;@=+JO\2GP6QM+UD>1+)B-C?TUK9T#4=S#F\:?N%I-:6^\ET
MO97JE&:E8?8A%AL*UX,SU"Z;"CC?.7>5G'^99Z!DO@FQD*P#0/]E?8:5"D_S
MT(T5G1#,$*D==_J"&'9@RQ&I5LRTLDQ/R[0Z^),PGPQQC$<<7QG+NW3:ZLE.
M7V_JQ2,Y5KCV;T ;];FB72?MD37-I@GR."%!G1+7&['^32K,,*BX \<"7$E\
M:#T%K0V'V8@VZ!BJD7B(KLG[9J9EO?:U&&NBP,Z07D4S<#!:UF8M%3MFV#X-
MG90[:_ Q@CS#TR5OQKEF[J+1W6?H#K+79GTA:ZHUF3AK<#>9%NH,L*..YDX8
MIL6:3N"0G'_T.$7-""S#0TKBIP7F'P,JNE/&^*&!J!^)'L:7P_1K+F6^QJ#H
MQ&ZF4,?&FD?K'C>ZEVA>X5KTFS@8@(*$/3,>3SQ)O4=*E]=)%T(*WI"4\GD)
MD]*CNY?,R8PM&0WJA%U=BS1D!A.+WK-LS# KQ?&\FO7.4C39U4']HH%RUYN9
MW<_,JM,)"3$_TS9]B%!8L\52 ?\9[#!;E4D+K#>V)3L?/L&OV4X2A<#T BFH
M)(CS>ZC*Z/TX+2@E\-&]%N)VA._0D;/-E;QUHG]HMD'\DFUPR3;X5MD&QP8@
M018-19/(:#+%_LPXP YYYS;9MI5RX92JYF]CW?'<[HX3]Y7J/-T]ED-I2R_9
M+;E!+2/..71=^59XP)O$U_3G2HB_>K6DWN&)KSFHCJF01YO9=*)D=5"<(>;$
M0#=)!@'4 XJD[(N"C^!*6G2W2Z UD](+]85H%5X,R.;&AX$HEE#B/>:(!\$D
MB.RR#3AN-%SJ -Q2K7VI&V.D:DC*!@0)]@=K4"VN#10 ]5"F&"8%%Y0C[6"@
MXQ0'MYY7I>6*!)S7 J@1K$  THIA:T@TD^BN011235^X>A/:XB4R#M K<*&Z
MXP-V 5-\P"8:@R&4( )'Y@'6!KB/6*F+J3B;X/0E%0$@OH]KYL&%#0YXK,O@
MW2?-E*C4.F9;J=<)C"F=D#:N6C8]+4B8P+:J2,Z491' Y4$;17B6Q0B(G2I\
MS;1-^,7M;4@:3WE/V4D\(1D;N\^;F*,BMT&OH%!::#Z@]GK"H];V*>'MSC[F
M*G$^\H<A400>6L;$X7\23X<X,"6KCP@'W_GBOZ]PCC'2XW?F=;]ABF]TM\[0
M?=(UNPLC,[4RY4YK^5"(%-KY3#V]R]>:0O\%00BWG/-S)-,H%(?\?-P1A-N:
M$A:T6.+!YVD5?'Y6\+&&91VGML,#;[P- >J ^6#K+%I? %Q&#3ZN8]L)_1/T
M4\<E&Q8\/ME"]66QF(=CSP5[UFX\Z-U"<WX_^/%O@M]RR?[G,]N_"\[%$<%^
M0:[I-!BAHM]Q=H$#]@S6&;V"(C%R!WG:<F+N)8W6/#M&H870'#ZSAO]^(PUU
M6OGN<##,E]2<51NW;I;K44ZXO6GSK[CKHSY%*=I-+I[6ST\WUZ/"PRS;B2%I
M=BW-&UXB"D<_3D6D%9#KJ8]ZJ"(RD%/5@IUI=M;B\T3C[8$\;RU__!L+11+1
M+<+X%%VP4"MV;BDXG+V9IQ)EEQHY15I&KL@$+08BO3C.HLDLX>7//&YZ2EW_
M*:&58'['/0LS*]5TGBM0CFBQ+:CB7>O*N7&L?#UZNB_DGFKY2._NH;H:9KZ"
M;,3!L!)YN-4>"K6(_BQ'E=S4+#: ;/A#DPU%VB9-J\G%[6*R?ONCS]&5M]V%
MT\/GBV*\--/SZ_':UE?34:J="<M?(C.$_*U0?DKE=5[H&.F9]"25RA$D,Y""
M>-"C]U\4V)OYWU^@&'Q[+J]3X,&B;OCF%GC814U.3&,/>GZ<BW7J75V9EZX5
MI#9$0^ETZK"<_HJ0A[]<6/T@K/XN"GBZ4PK5;&?YR(OS93ZJ)4TY<]\X/+O3
M-O&[!#VU%E_5'KA-!P))5_76,5-D3V5'MBP-0A*L^:E(R@(I#6ZG^V.YY.G[
MLQ73PR&+$P2.A6!+SUM4#)F%N*PX^$!JI-=&BL98K2W_BQN79%X(T;4/:6"%
M8'U!* 99Q2;IFD3[,F.O"09K8P=&VAO1ID8J"\[@[E_41<+L>;:CW.N.!I_-
MZG&9^.L[53#827L()X7DG1;JUYJC<6*"8J>K\_/-,&-/[OOS?B$\Z,Q?XI&G
MO/4X.$-SU#!ZPUPD%N]T2IKY4#*T<JHU!JD2?YLY^B[;TX)*%AHE_* AZF6$
MSQFA7WLYQ3RN^40WRI-?6F*R)Z770K:@/*67L<=UKYW^&H.S896>[6CUMLX+
M[6&B5%\5AR4;G7LJGGC3;;+?MB2 6K2U)KDE;FU-X:*\)W3\;OLR1.J:^C02
MCYW&FV+_U9'/YP;8Y>YO*3.+1MJ39-)^">EQW<V@QQ&)W7MO 5=>4MGM^MW?
MPPQOY 7&G]U!1$5ZD=".=02M)-Z4BZ6G@K#<P1#I;B3I<(3[2TW-%LW6DSXO
ME/3;P6HB=W,I(;,O8_(XHC,PG[+P>"?G9V(^.;8?&^U6M78_2XF90&'Y=I[Q
M-%6#@SRSV^W#QW0F]UOCY;&8TZ_M)%];)?J=V7*X%M;HR(1MH^GS]]M0$672
MX<8;2<LQG:D>&% +O368%:R=43#)P-@5U?XF:%J<IMB&;DJJ@D4KE'^&G("(
M/Y&'P>(Z^4RLK24)96F:(KD84W@;@A=XTHLW8W9K?0_!/J[6E7:].'_IK#5A
M7;E-I'7U87"HF]9/L05JF<#/D<#;=YZO]R*/J:=!(3<IWBIB(SM>ID"0A.*I
MS]R_+$4-I@+T@FXBP)O"@+ !UZK)&A% 6A].[)^LMYM\&3(-$_E4*TP2YZ%;
M)3VZ5=K1K3K3EMZNK1//A;F\&.7GC8I8+BR_0K?B#;.FC5;W:WY>[;Z8ZE!=
MSJ[)Z<;?YI7=&ZBUAJHA.Y8MT0]V.66^V /#!R>@1.N%17+9O^UWRJLGX3'Q
M\'C;Z!Z,^?8=12PZ>YDCS3K'SY7R8B8\V]WT\_+'O]$#G$-?!_.4'81?B#+7
MAKQ70*(7U21+[_F.$6NT?]%9OLL)MC+7^64V-6AVRM8LTVVO6JW6(V*M=.HS
M!^K@*I*T66*5>'U)OI-FSB1/*SSB3Q'7]#7,677BV\]S:LNVNKH;QYI28?Y@
MWXNUCOXTDPYF:%(W:HY8]H$')]^F[F.I4>5Q7#,4/IOK3N;F#0Y['X(3 WQ]
M\=#;/5,.RKJ3O .]=&EOEP++5-(#&@YD:9,7T=HN]M_;WN*TIJ<_A_F->< B
M/DTD4I&2&T^ED&H5[7=CBBQUTPFIWXW'^F)$D7NBDL: 12+[1EOJ=L+5L32.
M]5\Z0O*YGA.Z=3URMP0!L_ED/#\W[PM"61O;LO!<X=?ZLQZ!)^.;3XZ>1^5(
M;A))\/9B;;0+;2-5[RR[PO8[U=M.NW5K+.I\[6;=-++-LOQ8@">WWGDKU;/M
M8DJ=\\HJ7$VW:J/(?730C77YS2<+O6$U7!.+B7'KGD^L]>;#JB$NT9-;HUNU
MFX=E.:M>%Y3*;51Z*5^OVY$,>G)K].G=JCS/"97EV%938RT5N4L^=0?=^/;H
M9C$5NY>TATBG5>SV[OE^8U%.+-&3T<TG4Y'8^)Z_'7<+I=AC?)I_*;3RY64W
ML?W.95E<SRRE,^R4TKWKN!2NB[(Z0,K5UI/)<FR53,3&7?ZA85_?"(F'<K3?
M0$]N[_QUG1]FJMV[SI2?U&*#I-:.=#+H2;;VXX-8+1!OZ,9Z7_+J-)T<C9O=
MA]5XOH[=M?7*,IE9?AF,Q%N25^-0[$Y7<JJB-SK\1E,!#XP^0<T_>J&[-%1D
M>Z+4^LZ4Z+V#D\*W3]?HC*-::BXHXW#Q\3Z+R-$PJL<JX_0DUWL3RW?BON)O
M\F^7P>^ [263@HQ_.B%(9Y=(OKR_OF [(7V[@L,RV*@L#97B\CH0MQNIJ*08
M9#=V;B)Z%4W\Q[L_&QBYGOQYSY  Z=5'],9VB?V.XV>_28$&U$Z_6ACA@25V
M'A5[Z&:WK<W,^V/7X7SH-O96Y6R #;_S)*)7$>%R$&=P$,*5$+T<Q!D<1$2X
M2E]DTSF<Q$4VG<E!7&33F1S$138=^"0P,KZ_O<2A5=ES*>0^JB@^PB*)\;O]
M3]]JD-4#2\01YP^R5/PJDC[JTE+[JM?I(/N@SYAOD2P_&@FQ?>A=3O8O.-F+
MB+H0,B9DZO%A:".S%8=#$1S#KCAC0@<7WT5>_0W''+T(KS^$JK]^D:^9D=]B
MD:^::-]BE1=Z_2Z+_*/H]6#7B3<31)(4I=__VAUHBDL.TKP-59R8!^/'4Z_J
M5"QZZG7_]^'X\ 1+\6A\. #L302( @*1!UGOK3C:YY.KYB0*():K,H[;S%)K
M2]V[=%?LR(O^"R],]'2KM"JKM76C&X.LFC@?E)=]8=H+TUZ8%JKL<RU3N>4C
MN<2X5:E4XY5$2U_EOH)I5YFR\A)+9>N%>4/)Y OZX]TD >EUB1__IJ-!A5E_
MMF'ZH!OCL*J%9X8N*>;A%(>_0N!\\T5^D2+_+L&#B^.$?RYT>J'3LZ;3/_>"
MA!OA1JN3^R#@AJP\V$O^.39=\W8A/[M7M05?C4"R.+HA$_'(5]R0IU;TBJJF
MFD-%Y@8Z[D=PT=L/K;>?,&1Q#ONRVPHX]<:<D1 \IFG/.+P$#!X@!!MZJE!/
M:]$YGYM'>@.M6)[E>:B#0;9])!E4@W:1$1<9<9$1WTE1>DU&F)&'4L]<O=SR
MM=SM;;[2K)8F2@;)"*0HQ?COYTIX'8\.'3?\IXVQM52W NT20WR_//3Q>!3Q
MN*S;4,QU$NEW2,_GJ1=V1M+KF!K.G;)568]D5KXX2T3*W76-+PDO3>M9B(:7
M$ZC%17I-(ID^GEYS8=H+TWX/ICVFRA',M$]ZI[&(+.?%PCR2[I>RW49Z%(:R
M^ 2 !*73K_ID_@?7 ?][!%0)8?9:=\5=)1CPZ1M9\^N;K@3.>ZNK6!#PE:/U
M<$L#>$K6EQJ PR@$K0U\;IYGW@Z#?WP@[/<WH_ZP!Q)V)H\V)A#Z14TUE$A)
M+PF=\G-.,3*S\4-7'V!*3WT8NIIV)#B;S3YZ*Y$W;K;Q,BM9#7G9&RNW=G^=
MG3[5DB^ YQN*!(J5MVZVMVN(N0/XFR B$>1N0V'->2?K*\YW+W\U$LXF[W^B
M9><?V@DS<>F$>>F$N9M:_[1.F Z\4"R_$,+&L)X9AX=#/7HW?[8:X4$0K-03
M'XWK=\MI9YS3\VM!JU7J53D3!"M5J!8ML;]X*?)KJ12_+5NE^G2:"8*5*A:G
M+XUJ9B87RKG[6_XEUZU%HH&P4M/<36R:%^:W'645>;+YUG 8KP3"2B4[\;6\
M+!>O>;LO)Y_R=KCT<IL)@I5:W:V4YMW3=6Z<&#4>>Z:>C4;'C2!8J>%P\G)_
M8S0TOM0TQ9?JL*0-5X&P4O>C[.0A:3XWQ^61M,RLVW.^4\H$@449PU%B5DO:
MK7%NG.VVF\5<=ZPT@L"BGE8/56VJYH<%<1G/JW(I/\MW \&B^$8R\3(NR)G.
MO*#'8I,G38EU!QZP*.?)W.+:'C[IQIQOS9K+UDU9&TUB@VYJ>_1(U(AGZ[E8
M8YS3\HMY0;4?1R^-;GK[R4H\+8BCP2#229@)HZ<41XM5<X">W)JG*53MEU%_
M8G>FS>[=JOMDC1.])7KRJT"MZ@9T1K36]8FH01>3PMQ6,>#O/I"KYCBO\.UT
M,S4.WY?2\55"C25RQX)!VE+-WP)RE;CBV,JP(N$L*\1IBG4:V"O?A!3?A$X-
MA+63"K;/7IZOYX^55CO,/]1+\6[S=CEYRC?^<@@L[^4GVI;NO_GP7[X.)8O$
M .)7L=C?">U ]-4K/GY O,I#@I^DXY=S.<=SB5R.Y?R.)?+W@@6=]\%<Y-BY
MGLM%CIWAL2 YMA\]YG(P7X2\]3;U^&2;D HR>;\H3+U?HA\$#V3OCNP# ]F-
MFK*! W, Y)385?2XQ/$:,LH[]^:XD%X7NO#0Q;<CBXO@O##(@07G&4-.O7/O
M#@@T=B$2GQ3]5C3R892RBT@]%;?\B5NRU[ _<C+(G[%'KWH++[MT8:X+<QW)
MA?6==NEC=_A)"S2W-P<2D&VT@Z8_Y>!@(N3,EGN*RH[(V>W"@2H[3H2I]89:
M#N]BCUZ#13-DNCLS9++K]GJF9%:JZ3S+V,YYIHK=,-WJK2(N!S?5?&%=7]E)
M>90LIL3/Y''OG%3)T /A.^;WI4CRP;I[' NVFBM'^$'*7"P)*AU:[C$JO"Z2
MXKM+"HPR_K=+BNA!)<7+='%;3S\^E#OK2<96S80UO34_4U[S;DE16#XLNGJU
MWRJ(UZD[8SQ]6&=;2P*%MU]2_'G>CZ)M(!*P#>7[V5;?QW@ZKR5_O:/A#&3<
MQ[0AA[O0<T4DJM!/)A5SO=)X88C"?;JC"(F;:G8U-W+++Q5S/:56TOEUNL7;
M#;ZGO\QT2^[2YM?QY#Z8CHN$N$B(\_*6G(&$^)@6M$="C!_KZC37N4^.E5)T
MSMNUUD.O]*4F4T1(S>O==*+>J>F)O%+(3-(KF2(>[I<0W\*%5%%$4QGJ$YE3
MIS-#7RA34AAXL0N/:Q>>&L;KO'9IMS_JU/MT7O+W8QJ:P^,W'A:G EA</DF1
M3*')%TH&?_?,W]T+P];@*P7P^#8B%J(O39X/EVXT*3J?K^U)AJ(MA@0^"/;A
M(ITNTNG+5;TSW*?SDDX?TP[W2:?H7:%G%X5U@Y]'BETA'$WRB?F7&I#A=8>_
M?B[8+V-Q:-[D.]5F-C6A.(^O2:<_SU/V3I3'66#%\[=-9/@[3.D#QA?_+O%W
M!$#'=XNKZQR2G[/1H]PI-6H5A>]T$IWG)8%XC(32R>3%XW5AT[_=AW5P",=W
ML^FJ>5/1HW="9]PJY%;Q5B?V^/CD@CKN9=-OX7;*2)(]M2>BI<AHVY%V(:D8
MYN1BVEU,NXOCZ36AN;5QW,\_3K7Q2("\1P"@GR<*_(#$:&:JH\-\P7_?*6(#
MI*OUL+[)]V^;T4XI:H37:FKQ_))N=%-$"8H'9#?\NLB=B]RYN)3.3NX<05<[
MHMS1LK?#F5H+BP5;>ARV;Y)K*==:(KF3()BZVYV#?OWUSB**UW?Q&'U6XIX:
MI/^K4M9/O<[S,F:_TN<4W)\@^M OWJO-NT2G]7A3F67E^]E4 -14I&S%+AE6
M%R;_B%ITZG6>%Y-_I<<JF,G-EU$[N9+B&I\8M.SFM18==W( 8XPTFV0J=KH6
M),YA48A>/Y%N<BKYY"-H_F?:A<2KP7+*:J9HIL(M1?-\>ET<O;&(=PL"NUS(
MY9G9N+ZN=\;BZJ%??3$JB^EMX\>_43ZHX]4;M^TO:RCRZB8_WM:76BT=F?*(
ME OIQX?'V-S*H$V.I$[42(2.<O6G]Q%QFPV(][WX:*U$>7&<?%Q6[K3'F-((
M:F#P..CTQD*IU^3+"?/)S.8;J^)D$-3 (%V.WS[/8T6UD\N\/#6%TI,2Z2Z[
MT6W(^T8XO5AU^=J@4[J.WVOEDCU0LO#DUNAE.=O-9L+/>7ZJE:3X^$D4"HD&
M>G)K]/7+<IZ:B^75V+XNWMFWM5&FG5L&M3KH6KWR<#75\X56/3M+S@O+^:J3
M"6I+\)*.&?/B=3P^GJOMI!4O=IK1TB"H+8$=&]]*JX%V/Q8GB4I[=F=+\?P@
MJ"U!^T8>CX;ZJ%A0Q_5X-+NP%KU6)JB%0#AOV3/-&A1X=3'7GH8WN<I:S! /
M@/_)6-3JUL?SAUZGE,J^S*\SA<)](Q/4;*#5ZDSR^;QPQRM/CVU1>IG/8]7
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MZS],]HNSV00I.T"#&_00<NCT(K .0@\G$%6*L#9>YK.G54<<RF):[X5GM_=
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M$AP$*RI*<*(/)MWX73@\[CZMBH5:^;X5BSVF!U9Y^>/?2$"*#_?34&;(FE4
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MG[[EU9C6T>(QNLX]MF1]_<B1C_#*P--S,Z')9P_Q+DT]'=3DF%\V-*(+K.G
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MD&RG1!>Z&&]))J*I5'! S9V)[TQLZ],_G(GC/B:.3]/;Q\/DL5IYHD?K/),
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MK#NS:EZ:I.X[2@T._]%$> D>BG-Z!7H=^"$OS-$H(!Q&9\'?#K&[UZ/)/IH
M-)> 9G;IP<=I @=- Q[6SGL8QIZ?"8?+6)/'X$0K&'5!$^ORK,S"H97])5B0
M-583; *<-P-_SH??R?] PS?%"C\$WAV^$-HH^ "4-$ _0]>A$9P"RRTC,VL%
M.EP!_ATD:QG/LCI]35TP#!G^6K.F$$4MFENRRL)]1\^"9H*Q$P0%/'@-XR&
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M%Q@P#O8,Q>[ ?_%;6+Z'_[:VFX%MHIHPGX,]!MO?:!0<;)/SJ7/QVM2@88Q
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MUP3@EV6NE]1SP\=W1:O?CAG=3XK4<)=J=Z54QD@FFX?B4WH.@0G)$ 5W^2S
M2S&+K^CHYT.[7+.7//4J4^G"7DOOI9E&F6$R9.IQ3:RH1EW<5L8Z:;ZG5],U
M4"Z=R6PS(>:EGG30-UQ3W]=&YJ3[(C%YN]Z<HEQ.V?XSP"X?R.KE*E.JK!^)
M*;TI;BEQ5ANE]OW%9R%3*GV^_U3<I$VBKG2GA_AD%QM Q''Z(142&O #CI&X
MED7!Q,45D.=5Q\H1T90Y%8XX_24"*1P&9KQ]=@6^/U[T%?F6'1TXIKYLQ(A4
MLY30#JM)2A%N#6[,<7%RKQA]F3Y(1XDMY ;BH0']G+ QAV?Y]@\4^'<*LBAH
MRAC]1:92KA*;8K6;+3&J^#A_-07=HN3_HDC)"1$86R(E#"158\S&1-],:H5T
M(]7]+ 3\K%EEN,:1&],B_R2GF4%CQ# [I$=2(2-GH"():H00R&+X$?MB9;Z.
M>.=$S*<@&=]'&Q\69SXAC+:\CY=V\[S)'(1%@N$&3^7)TSM*(SXN>):=9.?)
MI_QP(Q6.<LWHC Y9/;5X,X@QQ,2(XG/W.;FPS3ALA8!C6)Q3K @N]G;?>V-Q
M9<][S:<46=X3<Q<PP2)UR-66D_(C<1@6N/:",C;BYBM3<N:*8Z<TF5[1ASQ5
M9-5XI_&8A1U]PJ+&(;;S/2-WPT3RCES<)!6OCF?UUI00*D^IC&!N.OL$K-"]
MY^+>O%0:EDZ\HE&W%9-VC Y1]V9..!,PT0HF!&:"(LQ%3F3EB+I3!$U?BFO@
M$*]$P\YN*&Y" FU%%-[K#3D*R,JP!;]MS=C>-QY$Y:9^0KVKZ#O3&Z_=/O2T
M,UG.>UCF(G-:JG=J$OU4YXD"+YJ%I]:*SU&YY\(RGDJA4,OX+AC.).D#]2 ^
MO+M3G>#-*J#<Z1Z<LB'(A^L.V/HFV85W8^%KP^5:SO6[!UI8%N;YV.Z8VD-<
M8"I*4J$5"DA6\G P*3+J+[/PT=_.25KC(JX\Q^/;'.*K:TIVF?DDUI#W=:G<
M$^55-C5J3N!8M$PZ:*P\^&JO<+T6"@!;V>U E8F/Y\!UT/[%#A'=HUO5P6,D
M9\0J*FQ\K0$%#)/FPAK*O;GE#*$$-FOGL.$G@UZNU66J#?CCJA(KP*NM'^]4
M38(/XJP:-4@G"Z#=-?!O3M76J@:U(G /URH@F&\G2Z\U9.)3%G^MB1+.2!)G
M@@0J=X,RP1)>R$U'](\T=1X86KS-)<%I$[O$N,!S<6E'MPN[+DG&F6F=#)DV
M$7[=#4Z;H!ZPZ1!#+Q[Q[LT7#9DX72Q%D.D(C<$M5066\L!@34=F/W*!KUC/
M("3GC=8(EX3 /$!>N5$E8,#GS 5P)]!%,(XCR^K.ACZYU]DFN2>E_G_AC2D"
MW=@/\. $=%H+:(LC3 =P W@;9 0O=!84C2S5G0#,?WP#H&16ML94\)0]1Q*[
M+V%3,Y3)"^ ,: HNXW4'DMM/1"NP.Z^AQW^2W#P]E?^=G1W2 TD([*)+.SFX
M=HN"9E]BB'H(QSI?-#@*V9Q;*](3H"1K8D+H+8"/!_&C$-QEV:\H"+0$[P_[
MT*GV3!84)R1PELY44-Q48#59A&0#2 .B^.!H1@R\R:MPGR N"^$U49X7^7V:
ML,+I7VMUU@ YJQ([!1\2)[ UX+Z@JHE@+U@96-.L:2S!GT<X;05H<L<#1L$M
M<W4]4 _V("$(%BH/PK'/X );8+==D\RA%D0L\'OX \LLVQ9W.Z->$5BF_C2;
M;(CU7(AUWM7[TE$]7@&<@[[V D6,\X> =D(+<_)U: ]RSKZ&VG+%@]%?C^9C
MEA%'NE2L#)J'VA.PY9+! <.OP/@@6D+I_Z\\+]R'#1T3F;;!,E.QHW?2+$^+
MY80@[\ORI%5Y#UCFHXYIRXHRC R55*T,!6CXR :S:I3H6O&)Z>^$[) 0Z&85
M]A,AD^]#9.'T&YQ?+.@85!J&1C:60-Q@/H?RR%XQXM<?5?>;OM?]WNM^?T[=
M+XL]%6Z:RA0GC_$LGZ3+BB@->BLZ-FGFIM24^@MO@'.EL<L-ESH#!X22I?V3
MQ&QK1'X!JT5.K\QN56:WII<Z79>?$A5&G*R(3!?(9^+T2FF:W96&0F=+4P>U
MLMR4Y7B=R4U3P2L[RUUOT9XT"E)J4\O.]<>6UH\MING@E=0PJ2US<Z/.')Y,
M1M[6,_5X;C?-!*^L'F:*VI\4"<;<#U+9&*5)E+&89H-7EFDB'\OGNAJQ6J\*
MY4<J=TP.N]#3##Y=F6[B:G,G]9<5(,DIJ=A;=\/V<\@4FZOX5C\2J\J@16X4
M;;&MYJ:)X-,;@]Z^)G(201R8;/^1&&LB>UB$[6>#&DU5?JS,:/.X7SQR9;.6
MJ"_"]O,IMJ.[2B_'$76NWB2DLD$M>J'[F9:%1&D57W2DV)$6%P5^2O/EG&<_
MS]20/^_;OL(3IJXE1CQ^@6-;AOA&$7&U$G@11WC7F@B#2KB%,S;$8<K'=HUL
M*]:/27=4K-?:?HCDX*B-,UE9J'VC5WIR%"=]O15 ?C<M;!.0IK>":G-!-/"P
M9YE=PVZ"BC_[;/=^LM+*8;=##H)O^-N+F6J_=8'6ZKNUM0-H'IT]&SX:?FO_
MK4(/WW&X? MU,F::#H=BHTP9ZL8&#3-HMR+@111X98#0%.ACU5C %]HA@K$7
M)*[!P<ZQJJ"_P,UEDP]<&P?^%SA,-KAZIP@0+@4Z9_C;7[F+;>NUJ0E3?;K5
M<BLC5P>6XX@FZ4$Q!V<LGYO':!O7:![C.SVC:H\9;8S8N$FGBOG.<DWVC_/X
M[O49-8S >*NYW0$T"_X-C+'VO&J=<%7QM+DZ;X''*(\)7JK3F]6R5BE);#51
M+&Q3A;K8!@Y3$.SV;R<YZW0S#R/[%WTI;XC%(4G@--LDB8+>/MDA< */H]H>
M.L4^6?XW3BCK*XCAU"Y@1!T<%(X#/!<%P)[]ZSG.9C9TZ\]"*DU/("BO)&BC
MPM#[2IUI,BM-Z)1BA5&S.O]2'S)G24!6OLCIS_:.N7F^.=A*HRF_2BGM:H$I
M0_#_>3<2$L]G35FT__W&X^EM"YHF9L@>0[&-=5M,->C$^%U]]S_Y>+I/8VGP
M1-4,ILV,>L5611\3,CR>9TIEE!/=DT GAN=J@@O6]N2++PK%XGS"##'Z,_:'
M+14PB 2%'ST3()Y-!7V.SO)034P7N+]Y4]L!WUT7E%"BF;U,-+-3HJ$A7 ==
MC,&%'L+H]4=]E95B+693H8K+]49ZVE. ,( CBT2\?AJ!P5(9%N0@? BW%'@3
MN[\LG.[[\D&(ETE_.X($+K>RI_+A^Y[:6U@=_=\0;S0^-])S<#GUL!S6G\8Y
M<':Q_*'6J.W)=.ZO?^:JJ9T[N5>R##8L!=MF6%N5]_E!-=+K,SH.[X.5H;V
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MN;TE]M^QG08(!N=&H$)^,2=AY8E\06]VIJNR:9P&O:\21 2TD'1E3C@5D*^
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MZB&9OI_+[9T+23RD[@QS,ZT#7I1??V"QUDNBXP_<DA>Y]M9J.S^F[OG.'5_
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M;>55Y>"/;16.7>W6;0F8;4E>\!O0I0T-QJ_? F2Y-27[M=CH_GTWY5_]QYK
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MP W5?_=WQS9?_?CE'6"%8U36/W=I[P"9W3^%]*ZU>J)%L/WCI!O1OGYYJ).
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M"*##30P5= <NX\%?-(,75.#*SL1K)!JJ:BS\D<9V-?]E?GK"N1\G.AK:N8G
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M9("(?PKJAP)5+/'U>(-*6+%*1;57,3W98E)P<0H-#R^%^Y3?!!$NFI3V4(C
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M[><:3-$IEN"!W>U['F&G?]V86<0&69XCE 75R"Y:&$;03 5;,+!I[+SH*.L
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M :+#:0XA56[DQ%:RG:,+T[2HBD83,S.0.")@QW_M2' V"G8=&ZIF8R2^T>E
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M&,*C0TF_QT;WF-$.W!9_@ACEB8*06W?RZC'%-P8D.*'N+HP3.(23;DR9#.L
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M3QQL>%4#M+8B?\LZ9VC"/Q$P2Q!T6WB)Z(+S<L P9+]%,>0Q"D'7>MD^G-7
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M*3_TIBE/'>D)GTU+XX8\:*_#(L'XT,\]Q.3.[R"0Y"/UON9X)V],0N;[4V4
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MM)3";H\]<4V'P1G:E/?!4PTXH7<9#=]5Z$VU(UGYLC[(L]5U JQ[2Q2,OTA
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MHE^N"LTTMY#<1#9D"D??0Z(%,CNVL#1(6/O%69Z+=!5"&MPZNB@6?B"BG4C
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MTK>][RHZFYE431H\7R.6:F=>*2YR<_H;!J#@7<"97"@LSQL].BG,L&ULYCE
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M5><A?)SO53!?M&W1=",]F%"%U'QN[3IL8:@WU J20]B<Z^#MQX>7KWUJF89
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MF]1I3F@TJ&9\4:V6TT!8)S2KH+-.8MI8J*2[,%*<QL>CF3!H>D*S6DZ=C2:
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MT;5M$+^H,P)U*Q()$?]5GR]*^.]?J@,P5D1ACV$ &&TY8-*(K#H39B(D2EF
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MJ9#/<OB>?P;3'VGR9!KGTE2ETUF<NS3-_XQ,:0/^9^(8^C__'U!+ P04
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M645986 ,UF66Z+0$T[NW6^1P&OC@]R3\P]2C1+/8*&[B>T_EYSLO.YH&=6\
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MK%LIX7U5[ 9^%RWX2S<B6]#@0^QD*3=%&,F7>V57Y)T*6F&B:R%:$R+'=1_
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M4!'6J+N_OK90O2_D'^-Q8.V- I(X9I-<%:M6'3M^B-9/ZIC0;W#]D:=K(FM
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M:TCG[(Y>;0'Z'&KC8\*9MHQ6?8'5KU\A=WTP*?.U5C=G).41@U"&EC/S1JU
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M]..%[S]DEM,EUV$ZOL'S=AESW H=!]!NQNQLF&^_N:CZ^$W*I);HJ,7K6>Y
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MKH6#A39=PS^((S.HE@]AE4-C9RYS=V4Z?PVP*R_JB/<#EN<>UEF-W1?R#?Q
M#)\<BQ8W/^:SPE^UYF"7HAE(L@\'3QUF3!#=S)-H!&- 1C]:* LCDYJZN"PZ
M0;:\[Y9S;CBD^PGB/WW)1PX3,7,I99ZAC>GRBLPOLO$(H)5)E??^]V#"\Y,8
M22^E>]OJF/2>HQD=G1K.KQ]_Y#PYMZ&,&G/\K6B(;VL-DJXQC_1H(UY+:(W,
M\LODL5.29=0D]@6:Z*8A[=2-"M4)SD?.G_$6.FU,BO'"@\D1\R6E?7_.SC(C
M<>1_$RL#P?^^ R38WP80X;V*O]VLOQWHW[;\$[(=_&<)VPIR<78QR&$0EO-W
MT>6O0;?D$^SP0+R-TD:[20/3D*ITP"TZ@&]7+XQZ)X[H37(>_ :Z,CQ\@])\
MEV^VQ#WC$MB>*>3Q"Q\>[0G?#MV1C-7^=<%$Y:Z$>+E#I&+RH)L>6\M K)DY
M^O!7IP5#=*3F,/';&!6FXUDUV_L;<>(?"*)CR'_+&9(N_U^O@MW04 #Y4TE)
M9D#X!U->M6N)=H)? %[21UIDD.^5==QX:QI0JPDF1@FMJ5&E,&[6N\S=!9^?
MQ ^T9C"09'8W_<5#I<@7&IY::)R[)T2TB06?7UO_79%*L'L<><VMTK"IOCH0
M?<FUHON.#K.9HZ%CSZ3 [O3*<3A&?#XZ]Q^93SO% 6^$N4SC6#^ZU 0:]3CW
M0G+FH5>,QOQCIDZ,9)6HS+K&O]BL^9\VVY/SA-/[QOBZD@?/;9(U#GS=0K2S
M%D>^I(U3'U3\&2W)DQ+*'V#75'3K>$TJ^.X8\_FB V4?D<0$<-&;W:V-5_/[
M[V W1K>'X?]]C+:#D+&QC!^"77#4N15GC5O<T;J?E98[26THZUHVYKG3VJ.M
M&#L^3/E>T"Q'4N[%MDSXT0J[EIW8CD1QD(D!W%?0]6$#)?8N"^63,07R,\[J
MDK]M]1C]"6:S?Q4DT&%JVHVR/[:$5JY3T:E&C<72^__+'43^+MW_;3@M^'>\
MDO1WZ$'[Q#/ 5<$O;$?0O^U4A!5O 9_T]:<I3#*=7_UFJ>ZC<?NMO.JOR(F6
M S;Q\+MC!PX]=(#X[AT0T,;<8C3;)>.0KQ]C@PDU"WVC>,(/6?B F&36OGY/
M^4:;B/;7FWS5[EVK80=U0J@!"=_/"\+]#0=QX.>]WXQVI@04!02]SKA8E5!^
M'2/23O^;__A!5PV_/9?_SY/Z!IRC%XK0/^[;?'1X6%A<G"_'>;.V#Z 1O*JS
M5*V)=9=7],S9O?[T$>7+[X_?VV--E^IVQUXQB3;!XBG32JLR,>E,K%GJ9X)L
M=O:6<\0_36HOOW%7 ]P+2^J?6DI3=8OP_'H^XO*I$+ O6OD!\Z">Q,<_.HVX
MG+EO5_Y;O9^);,3B4!8^L?QH,<@[HCHVY3M>;\4[;>%4^N=5<^FT>9V)REFF
M-:@)]I@_7)[LYO>^?5#*>9M7HF5]F%!RF^*VOT?QYQQ#ER>004F4^T=>$B!6
M"*X^(Q0KU<3\"DORR[:!7Q ^F1W@S. FJ(!VUQHH\4H8()TRJ1]'<.?,6JVX
M^SJOF98?&6'\9T^_JFGN ER^*Z<D_*4(A712. BHW]\>'R](O#(+S8.;)[RL
M-9GF)5I9RASGG&_W_Z4\OX<@&[:'/+OJ[GA_)MLE=T)C[,F4&.0+MQ:1:[P/
MS(QQ6H?;!X#/K"*=XN3(@21A(.6L1#=%\^C:WC<_;V&N314.RZ/ Y?!/RW)<
MA;(=1EK$:4SL^!ZHB)^Q 2J!0CS&)[V;CC,BL*?9\NY'Z;R; E_\W207KDM:
M(JPJ3O"/6 _9KOZ6KZAZ&L@1N8"7'O6%$Z^,B+%JH4C)UPU'VFQ.Q--$.AY0
M(@-@$YR*LN0M 4'L?<SZ(J)UGJN7FP[@G;J8:C64L@0;_T$,A!!1)-M<>=5Y
M%L^%JJKB4O#=&BJ<T652!S=E<$9]]!9L.R>78:UYU$F2R(_G3HZNG'8<WYSJ
MOO^%DJ#V4H,,1$BIM0R+34ZC@-(RWS-SUG2VZ(!7#GT=QM+:\4$'-&M[\E.*
M9*WME6,B>$RKTJL-4I&S-\;-OR+\2(&E]TKRPO;F-P=MDWK <<]JX ._VG"C
M/3&L9@D%2@OU_>#M+_!( L,&,%<["BOX8:LD RCB@Q?YDJ'2 P7&9.I_7UN]
M%A=:B%E\2^ R5+8R<ABA RXXT$2!^F96YK/-%>80[G:1>^4/<?'4<P5%.#\Z
MP!X<3@><_QU[T :-G3JM\&&P=.))\W[$@L_PV4J$,-F:--R2_&J88O_UDKK<
MY/,LS<BJ(7]B"ZB=*3_KR<7"/,5+IB.6U4A7U7"^T-B\9.MEY:82*W @AG^@
M:J64 8?I$C]',7B0#/I:A.#P,+6@;;GM&1Z$UO3YC.YZO1C)E#U?YA;XF5B#
MT.6RE#9Y.Y)UE.>:%2;,\E4H*PSP=RT'\%&3Z_Q']<)?,=_.+SK]?L6;TZ$H
M]_B3?JU_7+_#Q6+5J-=1FJR ='.6R#RY?@GU3NQUAM-SUPR%$QG<OG/V!QBX
MO#P1]_H[*X#UJ>:-12]B[C!E^;#)9M?K(.<*I;M6]0QGUZ.?IST-:2J-;8D4
M"=6'1M4@U\8G_H]/_4<U;%N43X?H?R*FM7&7]1VO8#,9<\;*UXQ N?!BS-^T
M*<$N<K1%TJV&LIC*'.$1X>^)4HX)4_]1:/%*4W\66PM\-\,[HJB#(X=':K26
MD]2?UR=*EZ<$\P9GW+U4=/!!J78]SM(5\RV=6+=N.^XUOG>8[F4%*QEJ1#D$
M)L[JYE0BAF<7O8_SJ#O/^W^)'<8C^^9*[)WP:96UZ\*:1@UQ_3AFAH);R;KU
M-V6R2J=C',,.*^;!FT5?7JB8P\Z;R33ZRG'<^ZU@"\+,N+0!S78T*5!"V\)P
MN4,N;5;7)@1^X^5F:%D<G\^PX"I,0_5F>S_/6+W1PHS>;.CA+U(#E&W.P8C(
M:;1NM'D&V44I#<Q$D0[:TMF_CU;U7E(*51"L,7;IE2^];DPM"+KJH C^8%/K
MLH5M$<$4%@!+?&5#P=89EQW%! @,[YVD\%TBU=_'K[!L:>F3%L>S'<#?#MX4
MC^INY10Y7O&ASJOGK9Q<#/*J;WT^(E7P/G[V 'HXNRMO8MW^J>0%[J8N,@B*
M='>@G4T;W\S$_YZ:E_=2R/ M_GX,?-X7L6.JP6WF$7Y)!]7_T\7TW(ZS6C D
ME*A$@E]>UFOX>-2X,"(++D.U?6CY XX\L:]3#?YQ#89_NT==GE-P,QL_$.^=
MN=\G2/Q \BC>)(/#-HS0:C6B?U!2SV_M33_K>H)F^66E''!B5:#A]?CNV2:G
M,3K &LPX5<0MV.X?&;[PVNN*7BU%YMINB2I1F_1Y3B>W"=]?Q#U2</!\V!F+
M?:8DW[64##^1\$PJ\X,;<@96^AXB,X!/GO^F[;;-<.0X4)./"MF+QGK,1[=.
M*TO1 >P. _G\]DR,!:=4)6#$YZ<R"B[!U"A2U-R&JX1;FDY\#??52\0 99B;
M%V2S9*==\@Q7+4P;DCC>15>BI0*ZC&GV!4D$&<OHC++?GFM(D3WDTD[CP).L
M5^[WA%"GC_[MGEVI_?QS["7,J_T"1<@IBQ5A9]TI;<[$1U%GAQ@]HMY"=4V#
M9$>V/%W^6$NJ]E=8/[C;^D3J^Z$L [F1$<FW5Y(/PW9.CYL'*2GY<_U*"?AC
MMF+:TFG4:V^]#-BV6JD3??I%K*^[.)\*W$C&[6-SL>\<]]3RNN69Y[X:^C6C
MQ\1^QG+5)<MBP#GZ5IK@#)H_L*UY=0^H;+972 =<@6X=S1+6UQ25&B-$)UZ6
M#*,A>L<TWT3CP7\LF?]'FL$KK>:K4G<2GS(8&K LXN]5"'L-L +""C,M/D[-
MY?FK?_S8 S(25(#+P@AGTW"1O-LFH]O6PWMDHWL#'JXX?58O_F22[,(VA?7>
M@7YLX'5<L5WG3UN@1>VC'BK&,_0=<%,&\@VE<R9I7F)G*:MR[8@OO<17'YH"
M&B8<= PP4,0K9'F$"&<2/]9,E?4<)M !TQ&V*7BV'4P4'3"7@^6.*&_!B5^T
M=$QQ9]\V^/@@<HO91P94 QK%BU64K/'PCN2->.FL1ZK3O&=%^T9"M+B.$A63
M<V ![W -T@+^FWW47@H=P-)1$%T@'JRZ"F%'MCR@B9#>_7(XJ/,)?:;$WMIG
M6;8UM$T%H,!-U *:J*.8&8QG_3R$0OCT$,Q_LJ$T[&!UB:2M_3,'6,ME@#(Q
M[TY/<R+K4:"5KMT+5-<8.D!)+#RZN\(R(P3C/! !XDEX-',S^,E;9"^W=L\M
M!MKIU^9T  \J([\PG>&"OIE1%DU3NTIS4_ @P\M7G'8>+N2[0+!_RQ:7/>7
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M CYZ,;5_/.7C2YF<:9"GFHQCY8D[9@K'GZO2%[-[\4B%1^< >]U/G'.TT;6
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M'U#%=D2I&.),;%J;_ >T[:]XW];QH$VXK543D,(;1?:(>(",5-6C7PFZSP.
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M6&HP#_\2:[&J<H<TW(7'?I;&W-PPK!G0JPY(X>#PH.L)5I[\]<,_SOJ=[:K
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M$!&\=W:?;?>EH.BV-N9:+E(JRA5MGE \049M)+:(=K(.TH>3<@I/7;4K"5"
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M@:S7'7 8"8PS(L87R(U^8 W2>$AM'NFN'KE+6 [N"YOY:SA"4QW808913"
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MA3W-#>'Z38-65^8'[B/#!"!A.N%-9L"@FY&![D!%Y[#!G[.+YX#/4(I_(,@
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M'AW),II9I[*$[9N[9)^.!Q&,5+Z>1%PMW_:J8[TOJ]E>]9KNQZ,*[E,SRW,
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ML&4V17WY S>3WM$Y _%%6(XBYC'S.4MOT:@."0]<M#3$'-Z<H*IR#IC_H:(
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M(NK(=3_H2E?&;<YC6#=29.-OWZIJ>(H:N]I>!1^:Y&/6JBN5$J3:0.7J>TL
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MQH3X*P>R>1(M4$'SOY@!G#B!?K./%L*D@4>4OLE;18R[P.OIX_99O@L1^5X
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MID^I7&D[9<I!8$_02!4.@?QS/@^:LC$O?)9UR+[6FAD#K1]?V78YA.4:W.#
M<C[K.O)+D #>'#?9,*>[LL4?UZJWECA!U!9>U[RH)3X0+NC(AYIB%A"_[N\7
MC#Z*YN%@T->@H?[SX/Q-:U9)VHYAHT_-!6^0F\/YV8XWC%R9QPE$INA7!*E5
M#T%MOAW/SA& ,V3P\6IF=YCIOO*GM8Y"4Z-&NLUSHKR+'(BL&&1HY6%)//@:
M@%>K.W8]:^:":%@V\GI.W)9,4LC /A"N+V:-,RM/CELZIV5-CE[75=D29PB:
M,<F1:FU#3@4Q$Y21$X?TSJBP"^T$!9K/)&X2R5\!)%O"\9-(!SC#+O#.\Z7P
MVDPWO%JE/;W( !P7!;"SC9OS&0NN?S$WXV^2IF?6=3<R1//I;'%+!JK+V^[0
MM_& 2'E5=)JW B+'/V[C@*CUPF:=IC(<)I\WNAY\[W_\H?Q.*$^MS0,Y=*O0
M(9J_9QVSWI9=%C3,:C0<4]QRQCAJC5<]Z;)C/TA^)QIF#=0\IQL^"E3>8<LT
M*VQH# _M$]$V2HQ\%")/"S+%7_8%\=S(GRW^L>=5:UE@_J4^,GH'A%#>'M7^
M(9Q%Z+H3RWI< X$89,D]:MTX:\.Y7@!!+5M%>OT*K6EI29(M2FBWN#:Z,>],
M\MR0/D/,M\F]IE];YLAP,=[Q/9X/IM\?!MN\)0.X/J*XR-@HQF.Q%L:LTPG%
MF#.4HI)GP=!*>(Z2M.'8R:7CO?&'O/?_>__[5E+ 1T[A+2#J<UUCVV/\KT5Q
MO(5;M8;+ Q7.<%8.CB+IQ##R8]?9<1C+\,4>5 ES,:B#F<K$&+S%JD7DCQ=C
M6IH"#V+=8.@/WNE?,H=,<?L*+"9N0SDMGM:O>L8,5\V]OJU7+(&MVIKVJ]-V
MO)KT-]SU_8,"J4.A5,3G>,%*"!BM;<W2'#' ]EDL-[!L5K/>1,SH)PDA[XB$
MZULSE^9)E2[N,[X6L_H28YO3N.*V%T#.8:=+L^U2[GA&$],@,FS(^(Z35Y+D
MZ$A&7'%Z$L45[-+V!,J"H>ZX\E*[2_!_+O^KLL4Y0&LB_I/2@/K@"5^+#.X2
M6P>BA3)ATKJENZ6*UE"'LS->3ZO^"M)> ]H8P,4Y$LSSVHX3A=ES)D>:EE7^
ME]V:R04Z Q);2"UB9*HC"-%6X_AC?NLB-Z2%"VTAB-#*MN2K?<]#-#QF;QM9
M#"9]O\0Q]!$RC4N;:K%882;(V=^X,VJ\@4Z,88)).!3HPEL3O4+O8'NU0C)=
M[+G8$A)]-D5.S>(I &[LW!FJL#P]_));=QA-Y(<<=EJ+3;G4C5= 7&4+&IYV
M[R1_7SLFT93)2NK++H(].%[B@+0=]Q$EIPA:I6H4,BC$6D-MG^O].&M5D5<A
M&B3\L<FF7L836_H%;O9L9A;KC1)91=BG^='"'M1CP"]+3-#7+IC+%9-0J+@G
M;S$"[C E+OI7IUY;7L2A?*FK,?3C*?I7BPO& *VV=_JC)*Y2\</9"'W>Q)-X
MC:?DTLKONJ-,>$B^4LOUN$!?X:6J=H%D02SXYBX5^;/($RU)'LUVN==Q'XTM
M,9K2J_'GZ$91W57^;B0J02>TPYC5I?!M:KS6^;[1-U.2+O6_;R9&9-F32,?:
MQ$FK!!2!_+4ZE]9@4%##MDM"PO#SWNEX44-O<^NN5-Q<4=,2^J9YE"S4KNJA
MC\4BG2Z^M>[)EX6QH",H_T6Y_S'(2:_4?1 T=Q$ \;C0I9EY.#6Y)OUSIG?1
MH%KY17=R: [9E7##Z#7 YC RU5PIBS4^4RP/QJY9NQ!8;DC7)O<N[^>] $-4
MY%XH!K71B19V>0+6BHQ+E>N9K[3Y(.O,V-&Q>:\%!OY:O-JO9'T1Q+J/SSF<
MQ->4CJ#&=4014U<GB.EY2&18$ 7^$%<U7@VUJH(D*6B]3C6M?)]M-BK#]HV&
M_<E'@"[/_I:[E6[[890R#V:/*(7W1 >$NOOF;4]+F&OVN>OR?GHKX]UQQ_ZG
M5,P*%PWT_54&>D)1U'&E!NZ8(*E4B"9-?=2'3_P:&MHAY$<ZGK'=1@EEQS[_
M!)GK4Y:(^C'M7:6\PUQ5U/[5+R;5A^1@$W!K@F*Z*C;+BK6\[L>VX]X8XC H
M.U"77+!(*K9KD/I!=.M2O4=K1GU#6P(HHF]#@;U&^22E\FG?K@;(.3#X_[ZD
M9QU32."(/^RX 'Y!@%@A 5VI3;7:]3^=7F&+8((AC4_8_  LW*TVD,V58O@R
M\*%*OB6SE%SUN^B=X54=F^<FG_Y()*E^(B/-^<$>\LQ4M55.ZYN2-T'F,N93
MD@D+I@O-68 IZ//7C3XI=:F6HI16$=&SJGBNK?GM/.2K/V>WB1EF"1<^J<Q^
M#>BT8L4'O,!2ID7SQ%M<<KA.;@9_7W-D<HJTCIW=!'J99$@G^S=%SE!FH2]]
M1FJ91]*;QUTE,U"C+:2ENZSA/5D;2ISJS@=N,DZ:V(HO>NF)GPI3%30_CRO2
M"0F-Y3U?>-T$\O %>4ZXITPE*NF?X9#8AYPLDW4)Y'A0%R<@V8"VJK=H14O#
MN1I7X I0YY4]4(YU<KL=A+H&T"HRY7>]]Q9MB.%I:$XZ6+SLUG7W]B2#Q&I'
M$QT4I),^!21;,WO%K(]'_'"NOAOE$K+6O6BFG%D3.T6LPB"[+Z03\YQ,6%_W
MUTU5M4W;_5,%00,&;KN/\WRBEGUTQC BPD<UGQ0]290^;.LI1[AYC6C\@SF+
MLVW50(%QHB>#*1B+>:60D8>10\=&R70KO:^$OUDU?Y+?:%$]6(>+%?_^1#*P
MSWUWBTRN(FIER%C]H-!*8C]IXEMV&,5__WE3]@WBITT*"$Q8QHJ5!6'K;^_&
MZUSTW#*F</O?N3--)^<YRKL9%Q >]]#4[S-03[M6,E.<X=> N\2JI/D=AU-B
MY2<OH]]>,;LQ+&X??OU.&N:.$J/C>Y9WYOS. #V*$-PWWU!2WM'R3AAR-&84
MH.=QY6?N?<F"DYK^VYQNEN*0'_V.X<1^CP3B G-4>BP9GC-P('WA]QJ9$7T^
MW!9]]5E49V1?,/\GBZGSP9I;2=(@8<8D,WUNQPA.@!_)=%T#&)5+SP9UV'I
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M4&"R,=Z^$M(TA9-[DUCZTM&O9._Q:K2M#?M<$X-8['?VT!#(D[:!@NBXPOU
MY2OJ-X)+*@N$MSCYZ4BHHR>6BIKDJIZ-C$MKND4RX+:5$U-12LG!#Z@Z_)C1
M_H5::?4T^K ;3KVTQ2EA)>=\T,+MG<=;G\8&02@/5*W_"'M9+,*;GRH#2#RZ
MFAH$Z$#G/#%VF[IXH,MJYI#*GX!><<=BT<JDYZEH-_YAOX</8UGN!)-VN$2R
M#'GZCW0E,$!\54.-)Q65RK8O/G;?/SAPL9;]GI@8P<T^'</.RYJDFVLWB="\
ML$:=^[OE3>P,"VXWGAKGKB*IYR#)?:#9L[?S^)!=5<R)3ZT9/D2)S^Q1?">M
M^T,96U-2NCOSH8Z/3>U#J'R_$#QMR_"9O14_=N2MP[&W853;]?7^B+:VY'16
MZ7L[DO[ZO#*BS%%:)".I[7)#$-+NW! B'QY<YN3H5[RH4S@[G_F^(L9$RU&W
M],.S_K,R11N, 0BSV5VEUN%O6T?DF:A$1]@1AQM\>3]&R'G6?0R^$VR/*F:V
M5'#2*PN =W@<5E4AIK\OF%6QPTH\%[QRV?!Q=58&FI.*WB763MN!>8L@1'QE
MZ:^Y_+]IY,*IY.X"(!Z-NK;E<C(%2!$,'6A^K-G6@/=<)>>B=HI9%=7?-?:>
M1/\$?\GY[U*D:#9M*/Q%VB.Z>WZD3]K>(<<.GU>]LF ;-*MR^P 3T_+[6E'@
MSZ 8:ET&; =3LG6;NX4C#ED=+V1BW#[$971J^7&2:]B^_?=:<;?S&45C^[O&
MM:GDSG^%YUD-4_,-YL)*3+J#+X624E,)NMKX3&P$!W67LF#:C8F-8M+4N@9P
MZ7BPJ6?N'6D!$#&;;PN?QA52!%*Z<PI,M0B2[GMY!VI4B2L*H=9;%^:ZZM5Y
MC&?&GI$\CD!W)Y3"I<:5F2"U5K\GWH^U &$5,/L!C&5_2:<KMYI!B$RQX<D.
M]1NGME#,63=1@,>1]5Y1&<TARZ5H;7_$"W+!]AT9B@1W"X,NO<(,@ZUQ?Y"%
M*]&<5B@Y>>:"Q!KK^^4$284O!K% #L:MD)GFM;\QQ[-@08_1@>2#)/0\=_(=
M:SUN+H%U5=E51EW6XJI+EY[*'=:MEK%]@F$GVV4F4H*YRG@E^JZ/+&VPQ]-/
MM^",H]"[:"#]PL*<HSEG'DPJEP M:JUM#,WB6*9.R]O=MN+JU@TSX:+FGQ;=
M1,KXREL7@-\-<A1^YI&TJ)MK6'5*;'#M]&5/NG>KNU*)6:.CW_/Y5$QKZH)\
MX.IFIL;<ZVO '=QO@FT^7UP)?D/)=0BJ)E$2QHLX3AM6'UNSVV2Y!AA/97Y8
M:-\=\A?OIN::LR:XC)U:,?7*6X+(1'^D*MEK)AA&/?G6H(4K2IKSL?,S^U7)
MT."J3\UP9-37D4N['40ZI:A1,6.U]<]4PR[18G%.T<6CX=Y;%C*2S^N>1$QE
MQ<UT(HJ/[3D?NBE*EJ-0UO*OW9[7QY<)(^>->#S>J)+Z=RR7OC$Q4JC.UO_G
M+]K,M&_/@,G5($AA=:KS,!6:_T[=:.>VY.6WTE(/8<6[__R>D6SD\AUJI03A
MC$7NK?4_*J92!0] ?=$5<0$X%[S[NZ9!J]=%()#%@JG2EEW<H.OGEJ19%,UO
MXUY2;F[%%4@?+A#;$*88&+A"O:?5:F%4%RV7>RF_J*&7F,(Q>+16[='89R3U
MUR&7ND4'K:-ZT*4Y*L7Q"C<"=&AH0/A"/KD? R3D3JNVW_XHVB^0 A\'GA$.
MKP& J#<^:^#!HVL =\E5%E06:H)=:L_P&7G&9M*0870:+T,'),I'('5@8!WP
M)=>RW>_/]?W^&'/^MH_&[Z\!T J3WO]M>E-'IIFG]0[IFC8C( 68T\R*J+=E
M&FL*#.I*5'<B,7#_JV:"UOKV(LLH[7F2AOA'75NVA]> U2%K1IDKN'S>:Q<V
MX%7SD?K*D'"@+D_W9$#_\[:@PQUO6 W?-YQXV)GOQW>+3A+*@:_*X2=2)[R?
M@+>@ E 63$*7O%?,KV5457=[+"U/KASIO&O?BM4I](VMF4FO46F]AWUKTOM%
M>M&N?ZD[0L0J*^)C_:[?D48//%HV\DM4#67GR<4_"0\IU:;BBU;ZL+Y=;@^W
M:JK/X2>#F9#I290T^04:2?=%2)W[CO<]I*_I^R\=G+U(5J3#$DEN9"X;U"J_
MTEJG":2(VXV]]3#RKW8 H#V(X2Q+U$S0*)^0NW4-4.GY^[[0S@_Q4 _T(^?1
MC4%/[I%N([U9BXL&I+8QZYA1A9C?87(_&C.R>P2# -3/;C?*&][*5I&>Y$_M
M_21DSR#[N_7[>&V34H$A7LT6&"_5:F.,C8BA#M-.7A(KLRU[*=4S(+T1QQT,
M_/[Q@Y'F-S8/C676,[?9RVZ4;N0'O*^C-_J_)@PAP_.J]8"@<[<HKK9_XZ ^
M4)%BX/*[[1J_'.D/AF/.*@S(\"<>40)A1*$5=N,TM4 UUKV%:L\E\^4U)>?
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MW9"D)CCHC_P3T4$NE@7T(@L_#/^-NBE.J!X8N$M.3(&Y+,.RKP'+$M> Q]>
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M./2I'NSF8B.0ET *+C\<FM1-G>#PH<7@#_?)OH7G.^[3:]4EG-OS42TVDG"
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M%J@HW:6NKY#EY]\Y$4>[S>H]WU,_>&C(\8SI61>Q*SHT\-S8^QL2,,CP]-2
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M=((=:XV.^K3T!Z=Y"S7]X$W'/"S#G19W4E.*NVY457^PC9::5?OEC]P[PE@
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MXH6DH5Q?.@'UE8[WOBH]>.]!'U#5<+L=9DU#D5SO6KJJ=WS&W'BO\@M/VT
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M+N-/G&K=>EYY8HPR!&?(+RH@_:H_YC4%B:)"8KU['\)\P[U+SX /ZRI3[X<
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MFMX"ZD.+/>]OA;X"[D;B.FYV<7FMB$[0#]]??UC/Q-I8<O0C'FLG/TF\@Z4
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MT.J$7L:-">J[JU5.T%NUN592B<1N,MSHE%C1"*+##G&SN\-1$SE^6Q0 //V
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MCSH?#7.=A:1>[O\S?O#HS!T%W].P+1IDW(P]H?K6=#U+M:?J_M( 40JDC[#
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M--1G%*H>/G1@]I(@//<:?0>2B,2T47.#W?45C<$93,L1R\E'JN*89?2/U2P
MTGXUZP+#V<T.'3';\F+YZZE&*0LP#%N :?%+4-WT.V^Y"!7->:/1V8@7268T
M/VX>][$@R6=PIP-0:"!X==?N8FV^V8['RAI:4K1JW2;E^=WBA;]<!KRALT!4
M1:$@[K@YDTFJ;FX;2PIVG7:<JG(UJ"W1!1+@D-UU?\3CU4>L=2!VKA_0H3+R
MB2\N Q^"5L+T&]W06"WU.T+B'][MI !R2TI/0VI G9FW3Q$QQTC>1/T-4*^7
MM0T%4(D,F^VU<C%3@P!D'$&XWU(AME#Z*_O3WE[#UZ28P'\R(K7XW76KZXN)
MU!K1J^_+,,?SY]9, 4B735( +G\B8&[-+5RMW84B7_ROUCV)<,_U-B:Y# =J
M$7R=#I*:@!$5KV#/]<Y,).!]S8@L;T73/<B*THUEYX9)V0N0BSJ34A1 8$D%
M!= )KC[M_$/?4S7K9]VGTWXM]4"_\P*3.G<O@/!6A%2D]0#U?@>LPH%R[QD<
M6_UBDOS-(.E0'W'N5.F'<:==%$ <B$<\,(MKZ7#I%]GP8B)S*//\'='K),\9
M+/M"H"HI:K,Q6XD"N.[<5<W,GWI/HG$F6]M?FXC=; /"\'/R26ST7"*WM[Y+
M"D]F6>++;/<J7S_-_XU8I@ N;$S(&[S_'A#8758Z3!A>)"#TYGN0F/JP8RC-
M]H?B+0M7+OL\"J!?GH.V=2;;C)"D[VJH$3A0*-S;9X#.<;]T_]/3&TEZ+VK4
M-=B>IOY7)5^[ZF.?F?ME2;8Q0&QIZ(/D(1C5H[RW_)+UP[&2!@5<3IHT+W@U
M-004[+UM?L:KM<L %@S#ANFB?3/F[VW&;AX42C<ZN"U4_D06 F3M'$0 8#D(
M#'H[_+DVK<&E/]I648 DM2T5X1HJ\:W13.H!&CNA6"X[)<G'!FHK1B__KY_-
M_<,__/>DD90I=)J:L#<+;JFA,O@G_"?\)_S_&Q;^5Q;Y#__P#_\MH*/,_@]0
M2P,$%     @ KX!\6K&+AHXP$0$ >V<! !@   !B=&%I+3(P,C0Q,C,Q>#$P
M:S P,BYJ<&?LO&=44VO7+API(@(B"-)!BJ(BO4F1J$@7$) :(-*DA"(BO41
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M;C/N9_J:EOC21*7N?LPXGWZZ)^\0G(U/<<BAI&H%YNBC5ISC;56OK0/AN>_
M\TQ DC)RN93UR$E2\([W>I,,F0 7LN&D_]?&XY]ZG*;36*S6^8S\[_Q%;7-*
MHXXECKEU(^:@"UG!G'QJ:?X)#],ZPJ38&,2C/N)ZY7BW!<-X!O?0T%8&Z^YP
M&\%G8V,@[TQ.3CW^T/Z^EB\WA4=BG^8FB4T3&,:GC]K<YCM;]12VW6>RL+>W
MP&\$87FUTDOYXOO-F?8;,92")"EDB4^)'JS%:<Z::IF(%3Q;4TJGFQM#6+UR
M6W^4KW?IGX"-=,CU&^&X^ASS8(Y?'0LMJ<X\GV]-J4^:_2.TY?#FD7"@_Y%^
M'_RGD23V+8(.#_ANWH8'/(C+JKY"^<Y!0P864;_#>GNDX3!CRN$W$$H_N"\K
MB3V.P1$AO@R@1G#6A^EU?XOPSW_HQQ9<5_& RIA6$YEYALA]-EYM$U.;4K'N
MLK@)>6&*XI#'YF*[=# -[S%=&[.;+2-I=\>AKM!8YS1#.#WO8=S9(?4:RSQA
MP]@IPXS80$9;HUM;>\<U!X+AUE7A2YW*"[HZK[8#BJ\0I[YFB=Y?JH>N1\V;
MR'?P9][(GLWY4)I9#Z]WT!<"*PGX5#KJ4C2_\/P.V%!P?@@#$;*JV] !C2V.
MYG2%>F;\EJ,2F2>W,,LJ6VD;37['_.\DAM6)4,9VG+RU-BF0H_NPSN6/ HP'
M]*!.1"59-)9XAA$++C8R$D@)-?(P2TN>&U'#E?3D$D5N'QJ6ISN#RM97Q.*"
M81/\7TZ/QS:W.7['@E?UT);22VL'ODA9+]G'-?6+47V-2LH5QKE%RAU*Z5\;
MZUHXGVP)I\,7GL/SY<GU4Q)37[GYK4YOW- I9C'5!(N.G4GDQNCPB54/IZ-]
M#BPI-)9]+'\7V'BL-EN#?K!MK5N^'3CE<W_,T6A8/GV.",VQL<#81AU? +N)
M(RQ2B0=<YS7^5ZC"ME)P#Z9D"-VOV_*Q?@8[?(#R!@M*W?ONWL\&+V9IN)1^
M(V[WM\SY^1\Z;HW^<W(P_JT:TWS1X^K G'4'\)('^$GZ'&I I_ZR&G_>M/@#
MW,:,HE]6<PRP'!JTL7]/ J4B"YYE$A"_9:_7U3[PG+=909$+XL(\<^W:E28O
MYIFR.^>9?1)N=1X@6A&PX"W=5;Y.S4U9_3/5:!6"&/=N'X1XF>1(=P7?&-Y_
M( JR6ROA,Z+F_S38$#3P7MI!U]%++\ZO<_JRW'C9 V>!0+.KT8,\2/?DL&AR
M(X4[_BR]\]=<7[QVYRILA#MF'@H<H'_HM;L_!YY1$(8)I<T*'"J)H-Z0-4V4
M@.1WT-40C<,JG>\(5R,3B H??@S$/DM]067C<QXC/P,-=VOMTD:*M\S)!(I2
M.-P8)6U.(^)TJC+NYII]FR[TAN91<R:CJAV-G0SJUL06*7I"%0W^VO<[*=A)
MJ=5#K7IHZW[@CGVKFL9*=-]LW3DYN,$O/Q@/R-#" S[K'S%Y&V5\Q>TB?V6]
M&Y@,#[ 3C#!:;D^[U/4$XU\R.=['=^?MET$'L_*8NYIV1YT-T_[@'3T? LA,
M)O" ^W:MS5<H"]6+G,?WP O&MT>63'=/^N.6#ZHQ/4FBM['*2*(PQG/- N?G
M\8#'JX*_=,^F.NYX $<2Q_XHX8_<3\9ZR?YM(LW_ '4[TC4YX[#,HG&C!I&<
MW9S'O2/GGY%SI%&3!ZOB>H"8BWC M;_FS(*SA<\;&@HU'[AH&V?W210S?#^X
M:WV)S1T$X<ZWNZ'XQ"+0/$P2V\5$EB]O:K8M>J ZAN6;XW]XC_KID/B]JVR&
MKQ BOGJ<]U+N]K TTW-]Z9[)R/5\5[P(-WG'U63>B/CZ\YTPS22B<?E,"E:G
M'(AA7LLJ07)YCBD'C0WD<I)3W3<<2"Y.J/ O.O7[7CY>9AT%4N"^9%SV,9.
M)9O;BN:EO7#0LT),TR\TN-O[QQI(LDW8K"N+UTB ("B.EUS?(R; [=F_I;B:
M,XBV:0I,35?,+)1Q<DW:,??.M&5U];!Z%;B9*GC7*A7]I/DU[22I\]2]K1Z,
M:&?]U)MXE1?)KC\2>^]\>Y_6FDKT9(?*B?FNU--7"3<G^;!\3K4AMXMD?PQL
MRDR?>7\@J^8_I$?ISQ;R7HK:::F<B'KA>"<>0+/?J90N;B7(<.T3";08%C,W
M@%;;=E' Q,ZQL%"'2O>5IC(H< 5+1-A19?N_*R,B",2"H 4> *:!_C2O1T1E
M[.C)$@ &#B'4;*-EC\>2U6KC7=:#[J:*Z6/YW(2B_0IQQL1KJF0:=0+$2I1C
MX-M*C[?Z<_GW])*TOJZ_FDOWIE-OT?'@B_-8T$L0PJ@^<;VN(6&$Y<.&1:YV
M%Q0"&\=^!\R;6-L3'G*'5Q=D;^5[I"ANL^=Z\S?8^(DDCC[?H7GIZ/^:J)Q:
M.Q]51V#@=SR@JUXQT_UJKD10[DKU0:&;:^_I_99GJV@XO:5'&P-_YU! [:P.
M?S+BCGZW%\O=N2N3I^M??\>(%<(/A*A= 8$,;96K=S%9RSHGE^/8%)B[K!.6
MK$^?^/C_H+UWKK!1YN2:R23(8]0UXRK&K_-0OC+<6\>I(*3FPV1KC'B/8]2#
M>5)BQ\\K?>S#_*K8\I,D;[=+Q@IH]\/4C#/4=*R-,)_? =-#6Z5]5&;:BM_H
MQ8V[9@U<W:PMR>*:2)$%Y(_,U<=0^W4>?>,7$)]\B;IGO\9@9-498UN@P!)S
M0^1[%$J"\HCIVA;#U+LBJW+]Q3\[+#IGZN*3 >#O1."M7V^Z2,8CYD@1FS5G
MGO,'_+0F*M JU#>Y:6#WQ*%,?.I\ZE,_Z=/WC89;!%%!P4I]"S!N1V)E/-/C
M*_7Y&2[V%9&= ^PMK_WJ#DKU#USL;@LALO  +JA?P@8></D?+.! S<_+46.-
MT]SS#__J\%ZQAZR89/S[9EFD;ZGF$M1S+Z,=#T %SO6_]>$_$.18DYBV_8:&
MW=A! :>4/V]8O%N%A/X#J:.V0\H"H>LF53C%QIVZGV9"_<F.J7Z+.,7X8IV4
M.:CG6L:9N#>A;ANX]&">F@T#E:]/5': L_PLM8QC==)]WL+WEE#;JQ,9*"[4
M26M5X BM*1>]:M0$07+=?TMR-F)QK7[L'+0^6GG=<_PZ.!H0E93CJY,%F\>'
MH@GF%A:5CG29_0#Q>>A6-[MXBNJP.)]:T_F=,=P!'^G5XZ3D@R&5M #S@J<O
MI%!]@2/Z:1K5ACHV'0Z-VM,+KU090_=_M]<<'SAA6>6>W>\OA)39,B>66Q2J
M.Q1J6A6$B?7)71AV$1LZ>I#0,D_L+GO.@)ECW7^^%-Q6[Q3*5M5KPKZ=%9L3
MM_@F%B2#9J#,)5K?8ZEY*9)5JLEOARV?FA#<N5[R<&AS4^1,Y6\HH_%K2[^3
MU"F]E#++<BII.+1^_;*\J[/;HZ0K]C^^O8Y]R\/69J9X_X?Z<P_B ]41.!]?
M[S3#JD3R96;^I4)(3H=7H([S91F3CY; >IYG;UWV<M$ON]BM&$][CH\,?/ZZ
MO_EK:O^NPJSA?(/_H<,N)__<+_Q#YRCW'VT&V9_R+2GKB@=PUX1"U[F=\8!L
MHT]KFQR7H2UBF_ H;VT$Q^62.09]D7YNZ:=O8$O\D4>I\^+R.+8@*"$Q5PG9
M(16!;O?L9J8^>ZKM"B2'QF9G:I_XW<2X-1'/#G34;,D%PCQ<M+<.TN8V*2""
M=$@CC5R>3T'I=XY<%.X\9I<$O'WAR<I\'/'K@L#9[_J$ &C9XP%;.KQX &MA
M8?+BOD6OU,J*X ZKK6Y$/79P9A W%/O5=1*HA7&=A6Q>6 TF%)-9EE!U" DM
MB.I33T5GJZ)O/J32=SORL+\1#ZBV#H=3TV)<3$;$HB1V3AXA!<1K7WMR1Z%
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M=]1IXR?FYL60P;I:9;%L6NG\ 8^P-R@$M7R- 3CU)>Q.7STHV+MAA U\WQ"
M#ZX#8N,<5UV6'#DG4_QY*W>^!0H.$=/<7N2K&]K0)[-!W:H^3WE?X[">TIK$
MY2$G*RVK>M@7OUTNM1%IN6#NBRSI*5S& @ 8D*J^%2(O\,WH]4@U(W;,6'SC
M9LFSZ2?%$KD?U-8C:KGD4T7^^5"YCO5*>,K9&P&0':4LJ:FJJ:Z0B8U?<=-R
M">+C]9=$]V$H'/S<F51-^E!!:499?K[R]-J]S?44;_4291_S3<Y6\0YZIIE3
MO&7^*Z[LKQ%HZ*+L]Q/257M?8_:7^A+R)S/:-2\2,<-T"F>V-T4:1RGKN8,-
MG>R8Y$K+RWQI2!2"6464D[\X%CI)V]9/-+G2X"IH?+\N?.O8?_]FGTN]V(H
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MHX"B6N71^JBJ8T#&R_5* J*!IV%/M12S=GJC.2H7KCFWXMAB&:H75D+4_*'
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MW,E2 ;X;XD]@KR!IT(2]AZA+55>6]5]*B%TY2_DHRP*L0KSR//8PLP5N%1A
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MFT2^VD!K23;F6XP!>(R8^> V 7B*:T6L8 4VOU)#_GEJ49CU %Y_5Q _7DL
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M)6JV:=M+8%F@G+49%T=,I^4R]A!$<_.WX'UO;(*GS20( "6+ (Y\G0!,W"(
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MB%% J=#,47YFEC*G7^.-)GNFM('Q3VT6[#BT4Q\YQ.T;#)_'*)9TZ %HG_+
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M\1H\0C@R9BN=)N.BJ2SF]?CY/TX\M +63\'/\L*V."\&XX,,\C07--7-+J;
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M6W!X,&;(@D+8B[#X+%Y%)3[^9! CT@!/Q34-7DN<][;ZY[<W@;[+J,LU[/.
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MWA\W]7*PJD J1+?"NXSDYQ#[.4;(HM!DE:QD1XT#^I0QTF!J;+0D-4C(U5O
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M^@(BP,$B$Y':BD#IJR_9T/H\J@9BW'8OJUKS_@/+Z?_T!NB,,#ZFCR#+F,:
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M<44B5LAC^N-'[4;5B:VW+"Z],!"]D!3(]#YH.X384?T3@C2 D@"* &\L.]&
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M7D2]2M["J?<QFU'?>-] 6P;N-8;LO:O7<B$@@B',RH9R,B.7*]]7OW=\*"?
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MHO?U):F:^_$,4DNMM[U$G@JM(Z.A>@7?%G:6EV=2\DY'Y7?M9O;WW3@:]/C
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M>0TBP_,@CKC0966_6R\65.X&M0:2YA'^FC4Q)A4QHYA$&N #27,S7N6TUV^
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MDY]WC9V]:Q_48U5U<D<'$Z/--]<LMIM'JZ^^1%W[DLVA,AN+[AN'=6F*UI/
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MVL%'HB?;4M_U,.])%H+QC\F3U-!N*QJPW_+]SHF=!M 4Y GHW_#B6*#'81H
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M!/>:/_J C\Y,#H'H![@RPV^=&R !;&</N69$28#2*R3 ZE[90/V)ZBFE/1*
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MT:@9=A##0[*\I$N;NG.W>>)!/DG!<VF,[8S.;KD&@L5;-LXO3%3N!P$>JY
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MA7Z,<O<'.+;5>LF^D2;RL);F!0%#4 61/@^CO$QXH0),EQ<I)-H^7;)4OD(
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M,P"=9Z(Q>CO\?+C)!D7-4!+\HA#*-:;.W*==X2)=$*H7%AZ='[PC1KY/^]Y
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M6IN1,KUVTW\"83W+WYYSSN",,T# %<4#?]XC6<%=$N'U<=X%P7^"&8<TIDV
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M)&^I@C(6O#]IY$RHYG?G:SQW2=T1':]_^D:S;;#F#N1+\VVX":XK5(EYW?O
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M6J=C^\Q%VZIQ.RUM;9L\B1L'84Q'VM)TW:M[)25F'81;G[%;M1]A_IURH^>
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M\864[D5<5GG[/>ZG^FAZ2[?Q^PP\DJN\F'^A_7=D_WO @OZ/D/T/8/\3%QQ
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M<;U,K9"Q%OZ?"\L(G'L7XL'U[Q;J[7%<PV%WK5]T<Z-P,L-@D;;W.D5;X)'
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MWY],EC28$-.^JCXU9ILZUJ*8PDY$T5DC2Y"EB1>*G&=F*;NQS__491) [-#
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M^^-Y$*/9VT6H38F9CU67BV#^ HHV$-WJD4B>[[+-] 09XR).U0&=+\5S^#2
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MN2%N '?/\$VCOXLW%(5ZDUCRNT<9Q#IBPUP= [ELXZ04_0VGTIZWU5.^D']
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M"L8TEKWW<51KGO84P ];V-+J*2PP8[FB$D*(,ML,=U<#Y6X _:R8S.N@K1O
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M]B"ZC6<&6M1N)GNYI>LP[^91PZ:FVLE2OH:&#'G'=]2Y2;YI7&H1$D-#/@"
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M%DPVG:"ME5]:#I,;>!?IS\2\G$J?/I JJ-5)V1@Z$T%U!#+A%F%%LUF4SV6
M7A#J3R3 J_B@,LB)D72/H;HOY5O^T3_YO$OK3 =V M*D%<[K%=@WUM3$/>*Y
M%O),O)CG[I75AA(;OCWA[OBWJU-E+I+ERLOEBRDL".Q[ZLSGRT\.K*@65]8>
M)[U+R(RGXJI-C:EMX>LU=$[WB7Y8^=42.P?2<87 J.[>Y/WK?EZ.77AXGVVM
M>X_JD,?/C@5WP^"A(QVX9*LT;&&/P$ZUN/VJ5$^K8%KF!,,W+FD^4I?#%6B-
M"_)M7U025),VM^'* -=8<RP?,!A:?C"26&*\[Z;)?.U]HFR%CLD>7VPS:%$T
MY*PWJJP6!.+0,3A_G=ED/+C"XU+UG8Z"Q^Z;T:T<J[?NP$Z!DGG4F)G+2<M6
MQOC.Q.JW'-P$',:X[)5>8X:,0F[O/42><IF/@L4).@LBK87K328V+..'FY7T
M@:I3" X]IHG9[I:69NA;L LS<4?Q+:WJSZ0H1$7PZ)S(SPN%$HQ^WCH7/G7M
M;+DNR:>J-M[>+4FH+)[30IQK]MT!W8:&+-E ::-'Q\BJ2UT+TM/)O8P$N/5U
MQ%"JX!@*'8*<+#N;7>KG\Y>YWJ"]'4M.2] &/9<?%5ZEYK!C;'-1>'H:[J[@
MGNC>KYRF(+4XH%CMWK(51,\[PB (O.0D <1RHP1TKT;Q?_D_'33</23 OBQ!
M?].=!*@M'<LE 4QR5&T@__$J487EQ?/#1X$W@N@-#9S%_W[[>SSU$A0D*%Y?
M,+%4^9,_-^K7\K]_5B5)EZ-67%<RFM[P&RRA[U8)N1;/X=7F ")K4<=3QT*H
M3->=M;LSE\F*FF?NUG(9"0D/MW_U<>^LON]E&->@!MV!VS-NN;]\W!#(V](\
MX3I_AD5.<_:K^8'C6QUU)7!3WX^!X:$7QMY7$OEM)\IJCP)T4A/(2M2X-;]B
M$\7D!NH+-+S/-1RGW*;5^,("+2\;?2QS\?@Q_>/PQ,8?*TJ_[BQK#F\E98O=
M9!.B>6AH9#"ZY:DCU?[4HT@@4G:WM>A")CB\S- JIS,^$L/7S<$)N>0HBMPN
ME#XQ,T\XA3&.T>(2Q-V/KL7ER5VCJ6X4,,YZ)*MKF?>S )CE[US^R$;T=4@4
M?]E0R/_->?/) FV[M<P"5Z3DI8^UI\W/(P5F5@S+H0ZB_D6,EHITAU\_^YUN
MKS/:*)5Z;]W7@^=\)N,D0,WKVY>Y1.Q V*;<Z>\W69N]-O)1V(H(O0K6P)\^
M\!7WB8)G'#HIN2NQ)  ]": >+YAZ[#_N6NNZ-:O?'2PXA0.=!SV5F91B:/!=
MBI U-1K%%_G-_$G7ONZ'K>=RO@'@R0O]0$P=TIXK(L&,.#"U;3;[F>%^ASA7
MAN!'+=F97V12&XBN0#5"?>&%;.OHX>GA$ @T<?1*=/J-),C67>%&FTBWCBB
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MU]=<>)(2Y;.3T:-6(PS6/8\]?>+FS+ [:SYEY(P266JZ-C#]X?/+RX C?M\
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MQJ6,I8HHF-V/_9(X9\''%AO$J^9P^546G>78NS#?2KQ6MG.&@!Q94V?KZUD
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M9*_AB$J6>]UJ.;Z;B]H96+!=4%'NI-22E0C6+^[UI ,^D&AZT<=VY=U3346
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M:>&4LN+M"SQ7/BM55.SUN>0]@ Y)[2GY4MVDYN^<,I&G[3V AOL>T !/M)Q
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M,Q<T/4ES,G@/H'X)-]&!#X)NG)30S5D&S^T[;TX>[O*E^>?U1]J!I;>)UO<
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M0T)XN,H4OA!FY52FX-B=1Z]Y.]H*MTM&7S1I[]J/CNQI  /X&TA<K@?=2*X
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M<7G0=0P[@\S\Q]MS>OI]A-2%>]9^W7!*'"@E0E?_2*6K9Z"DWE*+L!K8*M'
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MJ__[IJ^,7TKB[B;7Y/_*I]C#AY=2DX%R?^,%$I R3[WO%\*;YTCZX+UL#6'
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MXYF/_SL+4W_=VZGG\IW4OE*&7N>GTXS@94K4DF<QSPZ0$T2Q%X*UTW/,0>0
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M=X+]<^GOX5WZ7A=(6-^#2<C^##.BW[[X*\\U6=34)JY,UV2W)&_C?H=JGY!
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M4E/YB[]2E? "O"X]\B:KFJ[X352JH6GMA 2==F",;8N@/$/FU;?- KP.ISL
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M9#_HGB*93O*\ 005>+-8!*EX?5% ?>#,:%^OB*>(7>_FT]T]754S:"?4:+W
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M6+KP)NQS\#?[*40U9-[J=T@4V'V-U&A5X-,S"_5-]$/W6A.R.8V2E1:^\6K
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M4"LW-'K]TO<["\N'N% G4J(^<7GYFRJ?16_-)1=^N.BQ2=\C[HJ%M67:TUM
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M1?#4>M].WC?HGUM65K+AO^6)K7RS6T 1]&;\NG0=.']^XQZ&JPG9AY\1%QD
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M3!6H/EU!W+-?H#D1Q#<[R;6?Y8ODBE7HI43'@IW?CYP?J?:\ZV*HZV4E5./
M/6\6DMHK5P[3./_M[YY?EP/5&^[TR.BV$?+\EO:[E)X&WN)VA$3*P>5-;S)"
M'*&/L+8==$OT&(MY!\2E"6A"+=\FZ;D:WJ>OW9*=)["[UOP6!%LUZB<54<2"
M=L&2Q,\Z&^%&5"]<!H0X"'5J0PE5M //R>G  &SP6K#:*:E]UUF:1#5+"T:D
M8R38N&^HX2IC$6W?#26YEH4G+7=G\%5\2V+Y,U;XGTST3E6(+G.RK49PK3Y1
M:DIJ2ZJ)<?=KRA(5+ML5+/A2'!63KUEN^Q?&4:>=]P]Q)"UM^J(R31[](B\&
M\#_KZ'8D^5DSVKU#+%F[\=LN[H70$50%;MWZ:GM"X@VP$@XN1FE3[ #KVTK]
M?X)&46LFS@^,D:#N;L\4<>X _0:^;JB-5M"]F=_M[L"Y1_U"UTH(W#.L']*=
MTB%MG]_-!CZT,$>1"TPN?=SGU=CO:0JLIK^FH7Z#9HN'87GZD'R%\87=4:LS
M/J4>,>2:DWWYR;MK.3I6ULKAW" %YW"HG-9YC97 9/$Q;:EA<?P9*-U+;[O<
M5R!G;^P8&M5><]ZG, OK54 G8P,O-S6?TPTZ9[SCHWQ[,Q^5\)*HX;W14FOW
MF>U-*804V]Z?N&<I@W:+1)%'I1$_E7\2PV)J+G&.]GKBO=A\"PBB/:^%<*$W
MFU%X%:3:6JWHX=[&;\NB13.5#UF2^C?F$5*5(P+1=[3H%M"I@'S4BRP#$H(U
M[%&W -K\I RYP>\N8G2[FE4*_C_0+8$DACZ>CU@?JE 39BRIWP*@I^Z*IK5L
MA)Z@@,+L<?=;@)J"9OGATZ;/4KF)SR.4R)*4.U.^'3]@+RJ!/)X070QZTS8)
MCP6YG307F?)\YU>8'F!D>+_48Q2.ZVXGO?9&5ZY\,R5/&%(*)ETOG!C>I,IT
M$ EM_L2.__DE4:AS_4WA+6!]J>VI9PXV<=%S[ZK&2HI;7>SFFUVPJ^]%CA)3
M@G[PKWQ7 ?L+UN'\[7_&A2FN?+]2\X!/7&T2C0.L/>L!)_VTF4'HT:ZFM# ;
M=-;,)UM/U!];X[S)#U$,^097S2HN?NR)5N(@?H025F9%"NP-[&25Z<H83LAQ
MI<LI4O+$:]V?3(FZK_<-_S='=E_SL-GJ%A3"M(NGA4FIBPX2+\A?WF5R[?O&
MH103Y ">B3"P\7JPW9$0&3,WEI%VN($M1^0',7*/.Y_'7D**W0)9*SM& 2:@
MUVM=:)">)O15XU=-L>^QT1RLK)E'=*S??T!-?8#XLD2N*Z70!_TH5RE9&<_'
M&6:4P,'C^P^^UOG3X]]GOE,W"#$[3)A^XRT@_%73Q&Q(EZW]6>Q?^W/-LU?B
MU/.>_7*E(]=/KEY?OVY!2WR"/'86EWZ KH\2DW'E=V;6ECAX=X$@7/Q(HC7Y
M;R6E7W$F7*L%OKFW7-&>$,>R72X5Z+<#0Y7(V?8 \=L8E!XY(9<C?*!/!_OW
MCRVL*G3XQE79K&W#X&K=XJJGY68A7]H>9MS5BZ8>)MI,B^VZ/<*T $K7L<[I
M=X(*PO[WJF408=<?,'<[INWI-3>V."AWSF$ 12HF<!+-=YB.F_-XJIL\6"9O
M@/1ZG3BRE"\6LBIQ<*_T6G"B=GD_=ACXKGY2M)GQ2#2\MK&A^7C1R#-)]5/"
M@FV*L*UD.2W3A!J7,[QR!_?ARE2M?@@&.YT]DU-8\0_U":'+H3$!&6G6("32
M(7,T9JK>TUUAM4);?'%7"(T*;(@RIC!:/*MTUM19VF 0=7!H:V+S-9A,9<WR
M(7D,V#/X2A.4KXV;KDGKJ@*I3^HRZ0\]T:%)6B C]'@F(S@\5J2#+ 5+86&K
M?$%WJH+LFG-%D_/-V%$E6%*L-,RO6JP@I2%YR'CMI;\07S8LE/N9<G[MCTIG
MWWF-;R631C'QE2'9=7**2C<_Y!FQ(6^G?:Z A#M5<[N)#P2>)C)920MZT:1Q
MA)(]P&-X3&G(BP. I2</#G/KT0F9+/Y^[3:-;";/0?Z1\T\X!?X!O.9D?2L%
MK9#4?::E#A!@U<1)K!6]QJK,**G3<]1ZD.IZ!-Z+#%EPKXE?%BS;,_MT.^2A
M;- J:Y 5QCY"UH T\@P1N16NN?2=\7U#C/Y2'&TTM\KCN.QO,":,EFY:]BV
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M?"O/3<=*97P%%X39OX_5?JV'%Q!V^2S<D]/VP]R>PUB0G\KQL%?># [)^^/
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MDH@Y-ISC:9Z4'5'=ZU"CQBP5MT749LTD 8_92<#!9Z'#LCT[;FC_$W* W*8
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MC8+DP.MVDM=55AOD7E&%'O5.3E"$E,&Z03'ZM-HSM 2M":3Z* FHC;LG<+%
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MDZT )5ND,>#LT.XLA"R<PBF6 "+J6$+/6#V@!ZJ37\R2U\E.YD;&&;^_^I"
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MY'IU(!N9,<3/32LOI0V9VGI5O'I_&][\_;#@2 [%?6R6;V!8^/A+S%^>161
M<4:YBC]24@B1T#=\X'VTX)G)["0;%D9\.)D,WCX')0$%>Z:UX$0&DY/WID2N
M5G9MY'<R$+R@F_.>C^_,1W6#C $_%A:?F<QM-Y" W&KHPE<2T&/&]#</D9<T
M_NTALEYOSUL(Z%)]TVT2\"I#E^4""7BGF[\+ :O1A\OA AR$\G :4N$69% @
M;NG<4*GW?Q6TACCVX0_CB80\HE!+?F^G"C;^T?SW!>RU/$XST!Z6K1%F Q/
M3N(S1,6)[7=)P,8#D[5%<.(>-&73:6$W]= N2P!GR:^LB.WM4^-\=K=1DP1D
M>(?$'1 R0?L3XF='4%S9?_\8D ITI8T7?2W[3&LF_2IHCP%^7!6_:/DC]$I
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M\SSWG/.>]SGG/>]=Z][[6[^[UODC:[%FUG>8V;._>W_V[)GY*OZA)(XU1\-
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M>_>C(1VO=H$9<.<0^T#5PO9JSH4=WR^:GT2O=FMN*'K;N[1=30\+^C]"?S0
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M07CKAJ^I",$S[E<.8!L#>*MNX$8L#T*;#"I5*R:DXUI'U*>V*A<KU[8CC&F
MO9XFW<,+M?)TAT^')4J0F8+3@%YU'<YH?N$Q)'NR6C(U6_1?G_SXM"E@!V*E
M6'OCO;&-4[SEO)*Y8^\-9GAP7:>Z%W!/:8#[W O3<M[D;YL?S1H;,*QKM;[9
MI&CR\4:=^$3KA52Z&\1?3.:4[H!==,(]GW49?==R!S?.?^@^SXT_X(];.RRJ
MVE92&/$I;<W_)96@K0O[,ROVT0".E(<T0)I6(X*D3[>>;;)ML"E^4C0*WCT
M$002!L5.(442/OC=NR-<_HY<MB>UYQKA5:3$[Q]G:5\>AS0:']SL?':=Y,7H
ML*G;.4@RH &$%J,0D[_STBMP'C@:KG6/%(V/1%@.)M'']XWW<]5O-V=XL!U;
M0Z'0$OY%KV4(^,]2- @/+2^</Y4XD+]6V_&CQ? E\>U0(F:A6^%?GGE[U4?2
MFGD8<(4H6' 4A(^IKN@$_R9%>B3::2XQ$\I#YKJS539>I&B,?.V.>4=E[+49
M2&I,Y:V10GC[+K"<[_[,/M%^P\+_[1%.FF<S@@CY%LJ#_R0D@O#*7RH\3/5D
M"S:#C\79<J8?8#B_K!K]IRV_:8C*@,N(WBP\AG*-CGYSO,0^ FSF">FBTK&C
M)'RT/)45MR9514<""Z>>T=IH>=N10P3G!-FF0/*3'71,0^+Y/D0J(+V+L.NJ
ME/I+8HP&B(S.A@61UFD 8:]FW!Y+[($A9AS$"EK2)^"H%^CV<(OI*?RP<48^
MTH^GT$X+CV$RDSVJN2NJ<CFEP;9>I4'Z )MP/RG81%/;5';(:U>YNB?U4P9'
M@6[:^S_G>H:5^(A"ADD:KFEP&U#Q"N=^DT" 6ZT:OI*.=0D\+=(0[)^G!O*Y
M*7]K2T,12L<DZ8Y?RX:-#9J%3IY -M"<]#0+F9L^%8\V\F3I9"FNPD0#%!L7
MT%5KU%CT?2%5"/YFOW$ '5(K"^BO8 TP)(5Y;@-"3.@!0VLT<-4MU<>WWX$3
MP8JNM4U?S6BTY%4=0$FN1P )'W6T#KJ.=0<TMBBE?E[TJGC&;:JV;I=9!7%9
M\+E54Y\"QEL-B;7L;AY(3M%9K,2%SMG]*)UJW#KR'7+G&MR%!F"DH];!J6]T
M &6DJ-<1][)F0&LL3)<M[>-]X/1Y>?OFE>%/B<'@??_P%)S]<>Y96S]B-K/*
MKU=N]O:37I:V5ZQT/)9>&8"]Y%08Z.\'=,;K*(+^VBSGZ* -T *$*T%$X,^J
MU&LIM<KX@A*40WAN?O3Y[M0GG)[#9)9#UAZY^;+6J5;'5#39=D;TB-&2C\ZF
M\0CJO4+BD[TXB_2A\I4:*6D_-O=B EW+;Z?\ZVS4[!H]NKG<8TID(O;6WFHT
MPI#M=-</6N.5/F>,(TO<J 5W9M$5,!*##BER&G-V?)F%KAV0<@,+K85H5IW7
M![%*WUI'=+5)%+&J"[/Z;Y_QB)'KP \'5KP_7^>P?[YBF&RFLW=0DUIB"<J@
M*WB!+@WPO*N'^LYGY<\J/NM8>Y-X>0 OD\JDP!!BIM8_/U _2N?<$]._+75@
M7$9JG+NE+62>_:J P>NP6@>IS;K>2]4JJ:$H.]#6\0',ZACHZ 18@AA.516C
M:XV[U)&BF:&"/PW09"YV%N:&UV7Z'B(2[441CHV8/H8D$0N1O*84-:)-M,N+
M>E["4$FX?C%FRD]5\84YI/$E&/@,"%>M4JZR37Z>GB+/6Q+K@(6 $?K9FQK-
M$DXCH_^8'_,&OQ</$((=]@2[A-+U\72?K.@@#\N[')?;LBE=E;T!C:WRQ\IZ
M)EO](C?_K$6?EJNXA8?#JS<HK0SV&A4UZW-OB3A*%(ZN[&LWZ=2=O5HMA9FK
M7$+N2?WNJK13GJWN(5@K4&Z-"J\)V) T7N6Y!!OIF6L]2?5C=IZ+:TI679.I
M 1N*?:ZV1%X7_A%2$)45S72R<J!(G E#$3:8CRAM(%?YAU;%1EB1Z@I,&GXI
MH(-1PX<'!U]J)I>'0&V[FG]"_**D/RE:$<B4@&WR![?@QF<;J;SO$67#K6TJ
M%Y.3W_/LVZY!UZVXUXV"HDOSNN1BRE8PG0M_,><;2UC2/;KDP/165P_I\:K&
M9?03-)#@'$H$-E17O7/AH]OS[[R%Q,?GX2$>6WOW2V9!S^]T3^RM0G3_P:*'
M_6[1.5$Y1J/>B4\SKIO &QRZ$%]^DOXEZW^#,/Q$L,G8N60H<(58DW4R? -.
M8Q?Y'N[?>LQ%5?H^OF"E3$P5\_TA!V6MY9B&,I.\*;+X@LI^]U7?XR^55!7.
M/-;+=Q[?8X]8[[[E@W66:$&IF&C(!ZSV=&Z_.N2P R>OJ&;2 )V[?-&D_82C
M 4K!/.:@XC-H38\^8HV3OGZ)54VF0M9T Z';:/52"$2(T?W=/<Z#"'E4$41#
M;O1/S*@E]S:7.D1L'3E>Q=WV5IVN^4=E$509ZPT9EW7A^(+\9<2-+CNCIF^^
M5ZM@U-"^W1;*LR%T.2B4MVLAR4LD>$L<)M!Y3ZNUVE#_[E.UE[I/'*3^K'#%
M2K[/B'PMJ>SU?0ET'"F'I7S^3 KS.ENIZHQ\!IQLG;6TYC7.XY)#>?B##U+7
M-2R9U/:KOKP1)3('SK@PEA"CRG)_>N6WPI11TY4WV_G4+UU<"S9YE9&&=D>?
M'_S=F)#U>C="@O&?>)T.+>.HN.2#0".L"\7;=;^:#'8]*B.R4X.EZ-J-UP+1
MX1%K>>MFWM5J9T5W>\$ Z'J:1J'J9D!U2AU'$^)/&"'SYP+913*/%]2'[C<&
M%J']MBZJKL _>37K<=)VJY?EU4&9"X2 UU+BCNOH3+>9.[6EL;5+KX$EMA?'
M-5(5..;F\/GL7@YCWNAM]CP.&/7Q3K58EPQ"@+1ICAE>OTA_LG29*]SJ3FR3
M&Z#[:<A+,*>ZD./2G=:+Q-X4W3]+-_2^JZ<G&7OP)H\KG_)EO,_RGC71JP6,
M-?O$2I)797GFN?<JGGCAF^17-O#1V1RA(I6X++PN$+[:(@@L&Q:O!7YMA;EG
M?;0E\O]LX49?-&4=%-S-+/;X^CTSQK* TOGL?9:^SGDOF'^/=GKM;).*#'$S
MI)Q)%UQ-" V=&M>MB-\P"F]RX[K&R_GTZ\AKG6,MC_*G+I-"9Y'G2(H&1 EL
MT Y7\<":R*#UHUKUFQ]:^6W4&)D^G"QF/G;1MDZST3 .Y>0^B?A24,#AN[-E
MFZMGH?[G]\ZD7HH4/HL\:=>1AX.#[L5,%JV+OQDG1=DX[7.QCJ?]+#U^;%[?
M>XGYF!('O[)&NYI<S39T@:V 6_67F<A<CUYZ;0@B//56D$GOSC#!.<QV:".U
M^Y3@Y02'ZO&N.^(!S3_&CT<=FXL:%<JACI+>TUDU(80&(&0A:8 /#CG!!=I9
MBF('Z&WIK'=9IFX&7I81ZTMH,2)7$X:/9*O7[UA4*Y"F5)T<HWXFO,F 0_^=
MQ4;7A];CE=ZY.[@P2]DA/\TQ?A7FWN%U)Y7Q.HKJ5>VD!BO0\^Y7_B#>K*#"
MV1YK%R/JBUHC#H/1.[Z3%<K/PV9 ?W)2'?T4[]DZ<Y-A]Q$_X%?Q0\.21D70
MNP7&YAG34[@=236LP-U%V9@T>4]43B)=+;WTKV,I7Y;=P8GV@HK$J8H\F.<-
M..BN:7EX9EER^\R=-V7EK#J,,VUS3E_4;\\!\P;_8=!V[J(" O6[U*?YJNL'
MTE7IM2X/2%VS3 %C*[Z(4W9M\?M8']_W2@^N7M&"O9>8$^*TG9=B/^_S0>VN
M$A/B-)P.0I:RA/CW,WQ AJ6;HP[#-Z _$@2%OKPPF8^$/#CVXJ[CC>XS/!LP
MT^E5 W"BU@*FLR%5,M)F5@<,&]P9$WM33Q1M$E#Y-;.B>YKDWGK"2>@D4?C@
MXKEDQ%<RF$^^-9KC)YZ[]N$48[]V1'S?Y G!2[&=8]/G;^XIV2X(+.4$H<#3
M&A3L0;"%$:_$]9B*(UV7]._*4H;$IK&W9W))+O?+2VR:RL9A ]J7I?+3RNZV
MCA0?8DTM2L.#RB@#E*C,#7HP?+?AGT7DQWOJY2@:=20(7LP?K%L<JE^=N*6H
M^H8>P@;X1K\4BR$LMJ!Y[LU"&!X2HX-0.[<]<NQ0MI5U&N\]>.;$^%F*%(8V
MQT(;N:@2!&9DSHC]OEFX7(%S?[,]NV(AXH;-#P: +<JUGI^D"/P)"J_6IG[Y
M:@$[/)6=:O+]?.W \JU9OO?'^9@W,GUV6D%Z;[."XL_NOU>(3AS'/439=L9L
MYGN-NTV7,1Y\D@9-M.=?&Z@?!COO6Z!JUC,3) 9\N&1ZHD&LM09YJWIPEQ^5
MO%G92;XB28_'WC2]*KS;YBEPMX=C$(Z>E:O#CTLQ+Y^'0\D/6A-K55SVE SR
MPG ,"^+3L]P]=UKK_/"BC1WO_+1F-&1[@NNO8<?\-;TE-APCBD7C(>^F'XZ7
M8>^@H4,R&':2Y^Q/X'D_$/[L^+LUF;1L",D3?&6+._#TYX,'-W_P-,1.1+S
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MW5D7NY]$MKSVL,I3UP;]*LSV56>)0G+]Z5:>9BN2P4^SC310,_]2JE"@;!<
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MP.HGY*'LZG +#5#3.G\@_;.#!IA:]:-'8P]FL)08- \-,,*Y3P,\5+:BF-,
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M0QQ#0%(>'+6#EH>13:#%7[R;L% "F/*)Y1UB]XC>N<PGV&A=/#)G)3HKC_@
MN_/"\K=X*.EQ@#!U#DE*O4=Y$$V*-\&Z_%4GQ"()+)0H*!MF[0X#-4D<]BV]
MJJE.Z.!B%@$#/BC[4<\3XPZQ^QA$ YR1P[3F4+0W5JM)Q\2#IM4;7UX21C3(
M9F]_<Z.&"[S$,8'F6%!TW]F%ICO/J8V:S5$:@/I(OM&%S%F..Q*)JBML)+E0
MH M^W7I4(DAW<+E6BSZ4* ?,-Q!Q68K(LL%[L*]/E\-)6QQ5A!-Y>,YC1_V_
M=$R#\\BSN]#<;704LF=')<Y46/S8V]S=B>MF5]%(E<*_FO_./YR/G0/.6TSE
M;Z#YQZ^5Z!7FZ,>%[UB'Z<5VE)='U/B4+%WPC;D+-!M!2Y+Z"+--EBK?^JS[
M=Q6YQ65:83G%]8'S6E]>'YP]*:2H]E)9UV>EH2%%LR_2_E5K ;5F[:75RG!&
M2#*!L(!47<5FCQ^,8$FR1 FJ.%R>[+%#S&9W$_[MF-27AMGD:8\>S;H9ES J
M*\&Y@#,)!=M+]-]YS7HB0@O@P_[:DWJ[Z/B>8:^?.IX&..%P U:Y\.L*YN/Z
M>G8EW$9?8ZJK)K^JH^IXR:I%U?N=<?JDD+ SCX:4./+@W2QLA2S/1%"U,4TK
M7UFNJ.M8,;KVD(_S@TL))MZS,/WP?:M2;5B^F?RH(D;WR[9>)_%3::VRMU0
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M./5>]\W59&*$3;U17^V9F2.I'S@6CWLY,#EUC=IJ]E:7[+/A-704?654]3'
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MKAYUEF VAGX_J''%;2R:\DDJ!+G'CZ0!M,&[ZW$S9AGOJ!?]9*UB3GT'39Y
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M)<?Q)<V%T]E'6C_=^+)=K^4>AL@,MC Q%2LKA/_^7+)NJ$5V)?VU]2=FWU+
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M&8\GPJ3C+"\9%NXY)1K.%L3%OA2I.%XV'O8H;&AOJ7!;=ODHP S,AB@04I[
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M(B3U^5.AN8!'ZS"0MM'"E;MY$AU7^.;_%J9-%0^RO< -87LVC/MGRT+BQ^\
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M"PK6QZW2#@G #9J' 8I[1_JOQ VFSBLE#C.NEI:3KV,0,=UC9=^HBOA]179
MMS!SSTE-S8(1SBX]'6OQX'MV%CG"2H^9FNC<$YP,#+,]9+>+)R'YSI%,O 2E
ME"0O)68>OQ/;/E8'++RHQ?UN]#))@U;HA$5G7&WD/B&?4V+;C,N44Y_M#U/"
M[U]JY;=-+?6D9P)QGFP>MC_;T6L7G6IE>7-LKW]>Y4F66/I%YB5CT-R8GS:\
MDFQ+M+ALWCR)I\0HFR5K U275C;!E3XUH:JTEAA5'C$B$M"9J&9<;+"B1B7^
MB5+',&.19$(U#K(YGL8D(7+PSDF%I>3)IH(.?;F37-">T[2.]2JKK@73?8>0
M'UWY@F]#"*QC7JX(((+EOIAZL'X/<.81T51\_V^KC_^/P-[_Y4!67W?Y-LUS
M8X$C[Y*K ='\QCV+^YS._TF]3GVAW$35R ^:XM#6T*]F-?A%[!)MDM2VA*+(
MO@)?E]5K YL6@Q^)"1T?[9XJW@2&/M%Q5F?@".O:,<LSDUM)!D)R'K, ?>V/
MXSF^-R7.OA1+'J.27R4#LYP.5)F6YJS*L\4\3UJ6R5"LEYMDT7JR((1C(^F!
M0]_>S:_1=?%C:5!4;O5QO7,IMBR??9BD#UA[O(*!:$GH1J)@BN,\XJ8I)B;:
MX7)59N@QP-MKEJW;.+*RGJ;$T<+SB'[1T%%UG/'X(H$4[X'P_3#>!.^W:<UT
M&C*5*OTU@WA$K=0[D\]CC62IA P_6P@+L7C3TK?AN]5OF5/0B45#?C[:XE8<
M%E4<;,1CX' /3K6(P=Y1%OEA?=0=[H&L+TG%J%P'" Q9??RRX&86@'&;UN=>
M(6;:@:HXX;*N+I#G6"?FCOD09K["6@N,Z]'7> /%\<R-K_<\/3""C.4YGKM#
M\B&2=1+C++;$89.OU7%?^\0DQWQH&2>D(@BWV%PH6&]7/LP16*BA=7O8,?LG
M UTE&R[>6_X0-S1\P%UGRY*>;9UBX,!"KB5 $"Z\[<\@\^M(LH[/6S27>;_]
MHS)&XX)'Q)5<:^[>0IN9YOV&CDIST^'WI?U>'7;O:2.]!M>)GUUF,+7=NVD1
M7K<1@Y7!X@=+^QU=SU$[3Z%/SVN&/W,Q+;TXB>AZQ]V8.F#V94U\.R!]GSQ]
MU6YIOAL>4SW&8<KH_/PC@D $B6\W:QYUCX%@5\+2D<>3L%EHC"I,Y$EHDX)X
MOJ$]ZZG=*Z[V^8(TD@7'QF46F_<X#S"L+,'! \S'!Z!1,=92FD6_QS1JU=R#
MSR(YZ\X3K$+>1S(&4.*%LL4P&)TVESBPN"P)-0K WZB[$>[_]IN@S-!\WO="
M">=EU]:W?A]BPZ6'J8+3CDG+^F MLBCQ(Y:0M#0VEV)F+(V/).SC/>; ZP?<
M3 %J/W'2\VUG'VQM6;]5I!RX 5$@3!QITY@4!9+O49JR>L2^Q^O2E 5(K23"
M&.,^PW[2:<A64JRJIJ$T/H#Y%??SB(>.2%4_6,3F0Y]XX%DY]7,"FZM$T#7#
MS:/$.(+/J9XLU,4$?B:[G3QXZ$(:A(4Y>'%(:.&"&.V!^3%X6N6.ZC7Z<_)R
MIWPSDY#_@,5"FY/=Z\8_?"/&LET;R6A;^72CYY@OEBT';3* "_!<\292L-]]
MJ?+)F-ZWTCY/&?6@2"QC4M:#OAOTT<HZ-LUQ))XZ2/Z3.F**$6:(,)?$$+?Q
M+0RP9G46K!.V<C-7'MX!C! WLJ5J5JLMV^4<%4]79<.\TQ(4)5U5E+]HD<O$
MD(XS.IDNA]U4H15.CY[/'3 =DWXDH:W!(\#7:9"*93]I8U9OFZV8O9HW2SH^
ML '(0W$4Z%E$YREQ@C(_Y3NA8=_UDPSMNZH.+-38AVPYW$O@Q[C%X5^(@#_>
MXKIDN7:*714'BSO4M.J*&J$=M5,<'^3L.5P[I*L\BA/Z2  YKS#J0R6]P9#/
MO/DU[$($=9Z0^70(&,/JZE^WUUL3KGH(!^EGC'B%U)3^CIT#^FZ5%VL_*?WJ
M%,3;N)*K?%0V>L-63G,'(.L9+S)@X,_7;9DRDFIZG&1 A$W@E&MT&O5'6]Y!
MQJSBE=]@8."GAE:/R0>H[E_^S!%A^%D*(528<=WF8IUQ>\S%DF']HOU3DGCK
M^\\K;EOQD[EK.VOU4^5;D#47NDERNT&B;XRQD^](H<E7>H[=94?U:A*W KAL
M$+UWYS$8L\D>@&[[GE..2)"(YKELR0*,9DV8S'ZV>F%O+V^NCB7%L,?A#B"T
M\-HKJ D0W+79PGYR!X@2W&%(!I^+VMD04WW(\$4,VV QP27N -5"!71=V0\#
MMRA$2(;2@JX6-USP@K2?$6]MW(_W\3,%?BUGP&FB9PA;K$B:JWA<S\2DW#">
M]HGEGDN\\E+^!=6&&?^,XZL;.2?0[=<:V5>!R#0PX5Q_6JC^S^RO N;B)P.K
M;4 E$GS.$161A>'UPLNI_'#;84*+V=;N7JA+_RI8G@8/'I[ T=O4E"K0V".5
M_KI42NMUTU:!EW78V^UFSZ@'#1'S_0T/]BCAKXMV)BN-GW$,5UQH3+9>O)FU
MGN2H^\V"NM]::P)0I;"=)$Q'<C,E0L4?[)^8A7A1HV(E$,SM&2\^:I[N/ \9
MM862U U'*AJ,R6,-+D,+L38_ZW;E3!C2<S8E375[A4R8<)1'T[^I5,0=.,1B
MGA(Z,CJ+7]U2O!'V^;/OB@//7_9]DJ9=0?6+N988QVSY$.?O5B_V^[/"KFC[
MY$$N7@[W"F<>\<:09H\F_@XTG?%<#N87:$,]3JS;(S,TTE%I$\]_TJNK]*'\
MM?1BS%60^-X$>T%CX@CDT"IHLJNH_9H\L5FW<5[P\WZ! 7X%+#B,N5%;MY6T
M6,V_='=NFD*S+O1#%!4V73_-X*M\@D\*S,%1&I'?2?/AKZJ+K7/M38:9%6B%
MY1<;B]GPFDP\%F=+?(!+%NV\/X>%%14_#XVUFQ'T8 4PVQZ,XVA?/YL^*HM$
MN4)K(4E+/^>U@I: T:XG[SSA+V4B";8T/@<IKA7SS^OG^DBW&^-;\Z3JP;35
M;$DI6J(4Q<:([\69LXDKD',O4$VCC?K^2&%$<)**830Q#Y_MRR"51;6*!Z-'
M150G4G5U[<WJM!%9AN(<\=Q$5 /NLX]T1;0V!8Z3WC&(L_EN4*G)J&34^H]:
M&V(%'&Y@C>(#$^*Z+*S@7#]0=?6S\A4F_[J@@,@X"3\15#__1@YS$\B1<I$_
MME7EDVJUB(K8MPAN!T\I0&D,Y^+"L9R7=>C&'<#"X/(M?YV?,CCTZFN_K"[K
M=Q*V=A9#$R+W1)IW5TXF1<%&5[YLZJE3QL&: 7TY/AZX;3,_!$,_29_UK8 J
MFJ196TN[T@T?/?/*$=7_O.WU<[C$+J)9]W-"#V.$&"%C8S2;?5GV5UY.GNXB
M(Z;*P!RHH1E[DFVKJ!_2M/\]>X_R@O*\KD11EI<-K74]B+0OE@1BK&5W -]]
M]E15N5=I_=VZ\VO/@9VHE,8QA<[FK+0<9L755N).1O>DQ:.E[3%(E\GW0&@[
M@>>.6;*9+O+2 )+*Q7]_VMOFFN^7!G,_U:5/?S=!?&Y;SM<8_=(9#2?F3%2E
M$8<P/1)NS-])^O%+SWZ+AHRX2.Y[G5;2$HU2>Z_@VS8WW!=Y<4)6.&6OUP^M
M&-\E_-&9F D4=QZU7+/(=[&DSRKIEI:*SD6L44&>5)07I;FX8A-V[(O2C,W'
M[R6\!\:_#&T0'6+;:?[V"M;8#]=NK21<?;*D4F+<2WZJAU0BTFR^WM]\NCP2
MXD_93WE^47G<2!AA%.*>,9IH*M*W>?A"I>=B:'33 5S(]_^P]]9!<7;?FF@3
M+'C0X"2X$X)[",%#<->$$)Q&@DL3"!H\ 8*[!1KOQMU=&FV"$]P:;:P9OG/O
MF:KYOE/W=\[,K9KY8_[855W=7?M=[[.>]:RU=N]^-ZZ8U)54#_LA_DXS*XLI
M!3\/W&QU^6,)7]J)DX2LTP8^NK%0[*IQC7>>PN8H%X6^%YQ=9OJ/0=!0^\JZ
ME,1,C^IOZT2OR#W-K.[4D!_4D</%'Y-=EP0?$<4Y8F"*S0\\=TL_C3P;$5:7
M> >)&^85Z09O?@F\0M_L<SBOX$&PY@_Y@W>.Y]MGQB03AO"K^VM"'^,I?>5X
MS)"]]WVVG MVYC5#QSHHJ/C&@%C7ZF8%DQ)[J=R84?.3PY5ZZ..'HG-;:F^P
M%JRR=^/125I<W.BM,^#ACIW H?.]_=L0@*(#0")#?:[<_T0Y<4DXO?BH3P71
M1ICD[\]JX'<G5A HE*Y/PL#S[46T$E?00%2BI&4;F>(G85]Y,DW#J']YG#/7
M[M/QG:2G(LF$51T8CEPUM(#LCPD@7&3015??$B/LG(_!$/E!C)MY&JN!OM))
MTXDIDF>PN*29KIX-Z>JK__N['%VW.EEQ=?=**5-4*'8Q4PL_-WB]EJ($0]GA
MJ46(!L;"3ETAU]S0*6:@EAVNVD+ HEX&ZHAI\]0O8W,45]>$B>S WCQE_US]
M304DLREO\X@,&;/<<P^@E$0O@T.W^?R$W%Y<# [$(VDC]]L^9ETQZ66=W[C?
M _((?)I]*-+PWDSL7!2_UXI/#%'HD7JU'NCJ12Z5$0W- (3.+''9R#(KXF*8
M9!8]*B6.#3$1F5[%8W%J26^[XFN/HM?4)HKV&DPD!:9>&QNR\]X#?M^J)P30
M(<4%D53K0');O5BVR+6&YLB90YY> \O!L!/$^ %?_V;RBF->T;?:J\\CEF\@
M=?X4VB7&VSR^+JXKO1X#+VPB<1(O$/7TV>CQ66"'?9Y:9)0>%&&L8%"EI/&,
M^5R4;E>"CKY+U99Z=! ^D7^S^3@1S]]9K'Q@ZUV^7:]FP W,-!'LV.C4/":<
MC/]+H&N45'6^P%_$=FEWQ+ EZW."M!)2 \[W-8#1RXQ+-4.F^W3I]\@CNU2U
MD6[J0/Q!57/C^MYERYUTA,D4O]>K6VE$V>GHTSY->ZU[P"?._C67FYZ%C>*]
M[TVB8ZVB%5#',RGA243Y"NS@?:/#8::HKLE6N0'^J4EL%^CKC-FCRI:@-57_
M#][G5!7K#4D3FCFG_"?X29*6Q4P[IIJCMG6<8&75Q;V6-&!!PLR(H<E*,OZL
M"AGCVNK1WE ^D+( Z'.P#7>$-K861>P5*4U)L]D1^QG]Z"KLR5YH34I^-X#C
MAIL2Y;4RT#;<YZH@Q94**Q-B((7[T=<B%.%.'QJGRC4Q895)JH[+[&ZSV!AN
MT^HY%940 L8NO<=\9>"C1ZZY:RS?@3"F2+]K?_#P^)!0[<LAG.%WB*")K OE
M':0^MT#(XQYVN\2Z"5^P&2?<[-)_WW-JM4C+]<<OUK16^.!I%)C-WW%HB$[P
M+7*O^^(R@&(<Q643P/"4HI&NO,*.%0KA]BO]Q-#<YTPT2%1GU,2(=!I:.Z^^
M%4Q7IPV@:K:1SZOY-?9'C,9M(A8CUF0K]7KQ\Y"@?:BQ$KH)0HRXW&J=081!
MA!Y"4/BET$ E ;XSDS3YC#,6'[= =A<-/6KZ'N#(JY=.!S_*<^(P,[*O6_N$
M_&2"<"DN2[5?G.%XIU5K>J:7F)E!C+CL&+(/0P"_ECL(F6(M:'IMBD=1:"VI
M^G_^>;?22&\H;^%-DZ*8(S1^RW;,^L7[6+O[^N LMG 7Z.;M(/0S.\';D;$?
M@Y--(@ ARM!MORMA2J->79_DZTMC[_T'0YE;XU?-QL;&E^]:QK874 U!BHOQ
M#CR2MRX*Y,I27K1NVN;B[GP#%.7KLS5."][GK8NU?#A=G$&1)2Q<'#P9%2QD
MF=<R'H<S/D?^ZBD@ZV_1?++(+_;Y<+F"79&GU$[O2E:;&HRP=*6</C@_&O0Z
MZU/9;K-5;:)9)D.JRTWI=<)G=MCB=JF'J_$D7)]2G4P%GA"JA(JRH4?--LS9
M- ;\&)W1HYAQN.4/(G^];$)H>PDW32HNKDN*,_U%-\@68<)Q3D6K+UC#/D19
M95)A#P3O/V"ZXN !&^"4X_$B="]57YV<?3>SN+2P=)U%;-!UUW \UNYC.M(U
MYB1I=)$G]CH^ 0L@6;R!6!":OK4XGBX*:V63S?GFC_?VN)9:5;EH80^F3A#9
M;WP9315%8C4@.G;:7E$:$U:8@ ,[4":Y:K_BZLY:WKELN88=G:71Z6H"'0Z.
MR EU3-Z4D]U\=#&MD+S;30U679J\^WCD7V?L-[_)2P[!5IMZ9[;9W/(,;%T^
MYFO^N:ZJSP\O!L478O1H5V3GUSM&QSJ;ZB_,O@M##UU-^#W S69 $WE>?A*O
MPQBB0?ZJ'6"!IFHN9%0$+>5,@BR O"^0=C+Z.;@B;9PJJ,@ET$]->?*(R7]?
MV?A?>CSE?Q^ZYW@]L#)>IT7#R<>I>CI4'\A(7EVNE>DZJHZB1AMO!/(]Z;6O
M@&R+>AT=TO/9A#1=2V)A!@BABF2[9S$Z]D >-H6N]>'?C\XI*1?W>GS(O2M"
M:O?Z_>2L7B2H(:T:[+]]\R9/Q@[O9.<ZM4!\B9HMT!V<'5<:0/#6W'U[3QNT
M<."J]M*XC]CBEV$,UJ8DFJ$T^4R"FM.-&@>CR0L1USY> 31FON0O4RYQ/D_L
MCJ)S&]/D.&P9%7IU^)+D/P1N?.7%#3UCUM,/<CSL+?44G&RN].8,![)%^@;.
M,]]NH\W#@C-]-%J?['HDCB";>J H*N*KB]: [25=[L$\KD L]0#0,[7/B7U^
MLC69MT:O3:"9GM[C/=R:_2.]D_B!QV*C_"KB+;+)?N@^3GXR=$T9)_-U\TN:
MS^(_/D.O?[%R7I[0,/:HRQV8)^A)2"T4%T[6*)%K8<'_BBRSI30OUSA(-/8I
M,INGYR(%@YA[O+?5JGM6LW.0TND*G;:.0=;TT_?B0G"AT5)O-*U;+[.N4S;Q
M^"P'V+;&!!EZ<6A<+V?,#?H(S<CC5\KWVVV/"NV_F5]G;)3!O\M'@M1%PD3,
M5*ZR7@#3Z/."U> =4[ *@6EIQ@7E,J8^FPG6+-=>BT_RWLD\%,);+#7]9LU$
M1F>#)T-[!%JF9H;1O>X8C=:AVB[ "UW3WY]>-M74!8_N7^8*[^*?BY?^,N=-
M*?R]6.O(V46CI"D.Q9;5^Y59=1&[W]16K11O<J7VI_DG'!R#,T:.+KJ(W1._
M:_:"@$PEZ53^0C"&(Q':N/GZ1E%4HJII3M_?#+AR)[S99QYJ0+5.<BB295,?
M),O'T$XLBRUY;0GQD3>I&U<:1E#4$ 87M/R^.%E\74:>0/;;6TKI[%<F95/"
MFO'=A3[TRY]3_0.7KX G6-,=4L);B )$? NUS#5^+]9+OI^Z$W1Y6\^I.M :
MW<ON 1@9KTS,N"^U1SZ1^]4V-<1XR[E];P"L%QGQ'(9I@\NU>Y?XZXYAQL8C
M=K-$SE&#"XFO+4+Z>:;^A*%#U=S=^[PNE@XW[<F5#1T\VE+HFB=Z^ .$XT:)
MAJ+;O\34YK5F#Z'0IV5JFZ7#%8^X?\/[UV2?>6B\[ C#H(WM$YK0EUA1]4TS
MQ>]QWNZOK@S1C4]A6D<;!!0TGF 7?-;)7)>\[,WDCZ@H_VP [O94&?B6PJ84
M-A3Q>$ ,\"76+TOEX PL*^3X<N9"Z*-J^(RN/N4SXDS[8$1HEJ<OV/1J4IE9
MU+RFH*6GV:Z>X63"5-DRT[N_Q]-'M)Y:]V>CUT8#,7O\ZDU(U0#E@<[!1V:3
M"F%@^,SE]71)Y' G])(J6>"9+?HGH2NWA/8$E7-*>LB.T)^2HEWU,CF!T9%B
MEM$CP=_&:18%#0OTB^V)Z[-2V]&-P5(J)7OB"3;7:G].>T]9FM4X8OB3'/!7
M= ?SROU+;Z@O][5Z"+82EG2^6WZ BK))!KBS6[.L'I'W@-8N8D1_R+DP) 1Q
M)'96<W@XYB'?N32U8GJZ;TGCP9P<W)&96 GL5GHB]FXN&*%RP746T;*4_\8'
M(1VP/T94+,D>MF+-5W!Q<]*:59!H2B>'Y6Y?H&A9&X[=#BNXV!;YPX3?OL$R
M#2V;>\&OS > AIV#5=NL3SX%UZ30UYOY'D$>O-A+1TCTED3L[%K'C*$V@W<S
M<TL/,LWZ$:>1YF/TE+4H,S^SK]8VUKG;-:J))3./_ >UF_G 1EH8YR[5$UHK
MV9N^.7U9DZV(#U,TVM6^/%IC:K&696 7W*;U8JX$T7Y I*I+DB1#<5>Q37P9
M"=4Z5.83J8BA!P"/X;4_EU/-9[Q/$-A%R^^GY:/#L(7.*BX2?[+X+)_)G$/L
M#&17[W%YGEM!CV/UVN)4RD8*XV(M=Y28&" ((#4J[^GCOKMKY ^&<S&JDPS^
M6GQE04BT96)64V2J7FIW^7*Q_>2Y;EUM1MZ)U3<+T6=1803UAV,N\,9EHHC>
MX,)O>8T;QHJ;Z<')<('^O5&[C+(RIM?U.6MHO^SUOG<4V,6#TT\4V8V=R>>B
MV_C'G!IZ/,(*O&MY*@B4:6X40%"JWDN1.)K7:0WT9HO+GK$FE[GL5#NZ<B;3
MI/*3O!7YT05*VB[RO>I;^GL"W4/.<,SC6A>ZCJB0#Z_Z*MBBUJ7^6NH"X7@-
M\@"[U?\LA#,V?)6GM7\IW!M>95G[F: M>-E&:J^IG.T-;!/6+&M%WC*L/^-+
MV3)@@YJ(KB=NT! !>&,?'YA"Q(RN<:BDF6>?CSMH>1^P-45L&%QT4?J1. L<
MI.."5SDVO'@35(T70$NU@4L*I,\C1"G9OKQ%U"VTU613:/]\,BAY#^!]$Z/W
MEIXX_0FARU&@BX;7L^4UA%.Y5>84^0G%IM=FBL_A[WYL["CKS-J#!U$H*??L
M$5\S:/9@[3S9M2_^+<]2*WM!ZS; %#_3R+G>;'^7#3QXHZ_=8_DG86+^=Q]&
MZR<OYGHQ$P_*S1^>6$ O)_WO\A#]T#6L"(PWIJRSCMD$W1_/]XS<OZUBM3F2
M$^:(UJ?Y.OKO[I/*L'MHD%72*9%#E \%QFXMURF_GN[$MU>9<N]*[K JQ<Q=
M#"[ZTCK2-U_KN[SW:@R);ADL91S^]DR?DHE)<C;3J^9M4\ML.6O*DF)X;-5/
M7IYU@U"9*/&$=Z[>8^3;1L",NRS'BV1E7DG(*;U,HS%M_($NER$.:1.&P@<<
M@/67$>\-:;&@>T WM<[X0OCZ,^[XLH&FS_DA@^<L'K=+*15RWY_3V*)5.AL7
M^N\-G46+:'PS@S:=JE]\5\$</G)Q&E=*N0K*-NV2:KI.94S*'M/Z1;U92A^1
M;VJN1J-*B],0C\T&,2^K( /#O'RN'/(-RM]Z*7[ $MO"."84B+KL4?EM+;$*
M(OZ61::.7Z40[?O8RQ+:H#S)3[DEH3Z4T045+5^J=R12KX=)RA8NP$WD78HP
MXO-_2 ;8#MZ6/-,0L3B3/O\-2UI3T ^'%->J"B;9BQV1*%-(Q2G0;ISU7T^;
MXXPQ]7A5&RTM)-4G6 "9<+JJ)!39ODRFK&O[WV4]KJFW>3)P<\2I\T"+SPK.
MK\3Z6F17@D'?JMS<N"^R*Q+J!/H$AV8]# $KB*@-6%TCW;O"^GL C=<H =:N
M!#;DY9"@1)(V8_;K[E_Q60'*=-BL3;AKDMZV;I[%"Z7*SRM/E$X.BB*I1!)<
ME9V5M5Z\D#I-U5S6^'3Y5>CY+R^?&8T7EE@4$L&/^CT2'J\$*;@9"T6LS#E9
M')_7>O+&[!KP=H;AU!]@9./%\:<30NH>N!$]Z[[J7B+UP^A3/FQ^C+9:%0AX
M/D7[)3VJI,<=H;S9':,;5QT,"6.:F\VTWS)&S;;:'!V2:"!KA6?C%#'L8W\H
M1>4G$+JE;T&YQAWQ0V=(!9B&JCRK_2?G-F+M"FM?,S!=N=2L9&2G$Q8V'S+0
M=)5X?7^;2@/B9+\'N#.KO@1^^AE89+&1.#]6J%[@0]O47 1_Y4!+"A/:%%=(
M U&T #U89.#J+YX*M/0TO=K)^LG)&;KQN9<(3*RJ85T\(4^._N\+#@)"P.;$
M+"/JNB65L7_;G?-OHV$L@G?"3QRAFD?F/ED>69W^Q"]I0U_1<(EY8K;;C&Y:
ML/!'>]U,-3SEU<"K;7W1HZB9VOP\K9>^K#%^;ZS$!;YZVJ(4>Y;($#.E.7X,
ML\V<3N7,TY &[GM 37K_VQ!>'$*TO2B%+A06EZ_<Q*W^&M'\UMLPY63-*9[W
M,T74^12DCDVI *4KJIKQF <MI-6O,$ -7^L6UJW<*4/$K)*[9I84EIF):N/K
M\[+2_L -:/&WR+*.1X3M5TKI*!B>+,\_://9[(Q/2^:')(JX/\DV3HKHZ<&)
ME$QQ 6N%MD%.9XMI"=^;C;=GDS^B_*=CA]@WQ-(MA_1X"M0Z6)@S*JB Y76N
M1J5"-,+?&WK]\.N#<)K5\[S<NL7OH#DN%B?&-O3LP0[C:H$8G:]>B9WABC*)
M]3@'D-3< [X*=,,E42S3DN]794@5/0H/+^XP1].<#4\KR>&OW)F8OT>E7@(?
M!XP*&TDME?JO$3W9S>2>JCB@[EY<5NI8^WJ.J\H_EC.*76!I%# X7U\#G99T
M+]^CIX6D?(Q]4Q_?G,XQR+?,A%Z$*U5E6-:%]4O7J3!!=7_W#!H#K^#@DTA3
M91O.H,;1O,Q>3!:./!"$;S8&.">E,?L4=0/)55?:,'=]>AKA#Y6)=[C9,&.8
MR[-'(]L"Z83J*B=\Z 'C <]G>27UK8N-=YX*[*0*IH+!2UD8"+GGFN-ET<E:
M+J<<@-/(<V#$/8"(1YK=2_BHZ]+SY7P?O[[R&N"'NQ@V=O%%N80B$L?-^M>>
M45+!VD++ITO=B8U)EB1?';7(.=Q!LL 7V.\VMH165]F^Q%"KM/4%C TN5P"S
MU$N&;3=K>CL-C&\$(=/&!V:7MO< GMJ T@K^;#\/1-VMAGAF7:&-;8Y7YHK1
M?LUI2+>#%XG5SV(M[X4@Y\=C8F5\$5FD?I;K%6%F0E.U>U(OQSKU/'DLHC[&
M ^?RV&W1T6NHQ'JQL:FD[&'Y2%(@6U@S3@'(0>EI9QV7<\(5N@BEU./%$Q0D
MNAPUHJA1-WLV(M%S>:T>)O0MV%,X#KK#R=V'$;=QB/[,F3\.P#Q;H$J:U/NK
M.$%->G1&Z_:WH_7E',)^I:9D]8]\@[+H/4 0.+Q3T%376.1;D=KXTDG2_BZQ
MPC:U[(!E)#9$DC49UED&\I9$ZFKY.V=OG V U9ZN748++MP#'IL@2U4FUB?\
M=!GE/PG.?#^@ #\CH$QV(W<($J@EVC%5"#G6?U=9BY""%GE=U_KLOS!6_=FM
M()H;KA"93[J3?CUC'=KZJ#6QU$9[%\4U)2E79(.1P:9>'T'L.";/W96"&X66
M^9.R?:UAT0]_;0I2O7\^T2(A[3E;]-M##B<5EFZ%5]K4)#IOI.P[NRAN:\@U
MOSRMAQ1",/0NDYS3+#0-^>/"NB[TO\.5GD>^=^,P.>!*YA3K=9M-1]-MLP6%
M0GTN0]QER%M+?LTO[U"[73TQ_,WM+(UC8>J1X'/!V)05<@\@9$1:YYO/]?A=
MKNU>&'<>4:H5C'JLLQ6![;VV.@?6@8_MX'B_A7+M* [0,O1=WE[V*MA_W_N\
M8SEM(M.$,3-4I#UAZ.^@H,TM_?+T%\RG#3(Y8EL8-I IC#1G" T@1%KKP-S!
M=HZ*W4^AMIR_3;'>L'+$/,'$</7]#J]JY;I],^5GM<+W>-YHT41>.KJP&9[7
MQX$]0G*7X6G9JI'I*UI1XGX4?+S72G1<'@A/CRL,]@1^K@F7%:!,_,%!M2[1
M<JW/Y'O#M2/0L4ZY,ET ?0CTT(]QQ !@=7%<@_R07WN"F.B.N6S8R'%=%(*D
M.8]U)H.F#OAG=L//0R#,9>==)J'PUY7O^L8%(\M7TUD5E@/2+]*,CV*H,Z E
M#)% 'M)WD,]A7;R2/4 .;XOVJ  Z^^E[@!7>//.XGZ+-[&RU\8(=-Q1*7;IY
M,L/]$4<!"V>OCPJKP@MVX=6,X(MV\E,N0"YK'T]/72",Q7>V-1+E\8:X2IZM
MBY;GK2IVBDI3RI>,L%9X5]C!?^2J@E^?99Q8.(NQG3+/TO,QA)8F_R).W/BA
M6W9I? @^?7MVLE]*)R>:Q.E<2UMXY/[+$SIZ5!AM2&_OOAZ_8AYM3BJ45L/3
M4YB1)_=R 5O4FCM'QX/J Y;+$I2[E1>YKCC=S,\0\3F#RJ%9JZS1!1;5:E5;
M(*=0X^0@*I',XG$I/3VU?$L,$XHE1Q;I33EM-$(0F)%S8Q^?\"5E!U&92[FB
MT3K;A84&H$.3UPA(-6;\M$%K$HZ8AI_3N,(3!*%C@"JSCQ;\ UM?%B*WO*+P
M5[UWI[3FSZ(33%.3+A<])9B"1TIT[-+L>!U+1>?-"A82SVV[WB25G!FGX[=!
MI$N!P%7VI3YUU'A#4RJ!*S_9%T=-5H,NMK%>3^N,1:YIZ2>WLE,!3'UK4J^]
M>#Y,\D#$N,]FOU!*5A7INQH$I\<$?A8:,0T8]N%9@JQ+R5:D@SKE216J'F/Q
MX(FZ]GNZ#<:JG/&%23^N0[JMM AT06N$AO64AK9>AKP4X/_T0>)C59D+Q'7K
M]9S-S0&*2/]2QG-\>^C%U;"+?I_ZI:UTJ5[+- C!YW^U_?F'IKS?SL7[_U_W
MU9 -Y,2L/8W4,62,5VE\T6_A]2S2GPPM.!?Y]-6X9&CU)/=:)NU^PXVX=YX8
M2M(ZIV^RKC@WS?,W+O5FB.6:E+@JW>M%7I[?P9!V4:8<JJ.WD[<B^=M.1T6V
M21XOQ0\\H75*0T2O=?!G$LE,]]$,C69#:BN(5>U9"RPQ5Z$?)B+R]&FCGLAB
M,]URZ44:HVFK37(+VKP5]T]LB6(^Y%]X4U4B7:_!N4BF@45W#PCZ+*6OYZAP
MJ5K;W&#3_=;IF3(:X-BY_43<>A)R 'Y?71>#YY7PF$FCA$R%7(<P$*V=G(?L
M< [3;>)6YGC-U,0$&O%>L&9@LT;-D29N\5BI__QZ5DX>!U*)*>]N3WY0"SWM
MK>[B_/'9):[]'$.G5@N=2.GX77 .)?V04G6HEP+)JN.XZCW 'RU]Y@^9MM/-
MEXSR;6%I9EAFG\87Z[H/-/8 9]E^)L%&\[!:,'&^H\3;FDI; *&CX^3+]L^C
MXP)&9)J>E9@?]P+()OT4I<H:$Z.>QCIT]VTIE+]0>/PL.![U"%*<>_&H,"U_
M;GMFDT!Z=*GW4<^PW@2W?>86 "T3TS@W\M7[)2\FV2F(LCO>".OHR:;.XP.7
M1\KIGR6#QQQF>EIJ]9P5,8B9G_0*Y[L4ZVIN W:T--_M/VJX40=X>8RN*<_*
M5WEG6LJDL%0+<-$':"DH2M[HR\H_M7F4TU0;A)HQMO^9X.NMD]>[SOG7_4]I
MH9/*'^N%K)ZBS^T(.YN\;M+Z\P! E,6?]K%W4GM.D1QU_NUCLX(T#,1S-%(/
M'+#@9K O%GUV[%WN:O^-Z+%=71)<,<PAQZ8LY$_WN$/=H-/[F*=9]>K2D/D9
M@N6O#A ^DM827Z"C5YN5ZN=(+_(+<@_']BS3N5N.HM^O,D4FZ0T^"*C4J%(W
M]O)L.%"HK;XDB[[Q7DC/4ME<,'J0TIS*:7??QREY$=3L3CS#HWZ_ ].$26ZC
MHAMV,A.+?%=*AY;)>GX)%Z1YE6NM27@0>@#25-":@"6C M\-A=MPM^KJ:D9S
MHUVL:?F[!V,B7V-K-]D'#S9L*TK_UN4U6RUIL%IKP[.IE+/_> PW;N0>HBLH
MY;8K7Y 3GN[\4\^\G@D!JB-"(!???$LH>2U#9PP_N)_0_=P7[4=S51QW6<XI
M8T;:3"R8*]3%YS1"8TBA H%#'*Z_J]C$SL&?C].SCF-W4XU-"9*U59E=GUFQ
MT]59K)P.2/'WL U2_URBKSV>C1624M3^WH60W&6,T6^MP9 @7^P]N^D2%3V(
MF2O??<P$#15]'_TA4NAQ?&[@K[Q  !V@#(CK942$9Z1.^^Y$61+,U"3Q8M<C
MD#+]O;/ ,GF#RKNC5[(FYQ5=#[G6<(QY(-= L((CS2^I?[C,>R4^?N2SH%:3
M'&Y%L8'Q;I(VW/1-C?%P"+TP%09UE?PS_C,0]G8JGCQ+:**5HZ1MI8F\T[?G
ME!U# "*IO0\/)' 6$'J8U1;%6J/JJ "7^)D@GRA7+&KA]CL PQ-C*M4LN-#F
M@VR1[4RJUW<:U-"COB8Z@5K\<Z& 2-X+0%FT9:>18C@?3SF$3GKIPMA9%Q_!
M%47?_<158J:%S*Q=%W8V),4X9SP'E[5RPGE/WFQ/O7$N"L"%R),%=C8>"W\!
ME?PV7]RAT/<4""&<I=AA>WO:+WEZC3L?]/@@1RDGFC$":_J-QJ^\<;3)_-R,
M!30J.0X]0- +V2,35-KQ/:"K42?S([50;#J+ '.%0\A$Q-C@7'_'SACY^(0\
M'/ +'I,%+#48L_;$'7-\^2-!A J?<X0LL&_BEB'7AH<L25PWL191V.%"U\C]
MU1*;&R!Y"8YD+UQL'YF5E"I")LQ(^"O,2!0_P*$GCX^&O7PB>,?W"B:H+G C
M\:ZV\I2_;;^2V[>UZ=6(>>ZWED N!H/CT-@UO!O[%D7UNN;414/2L0@3<JGP
M9UN9B@4.FO+[F/8$XC 5B+$]EX'#P2S+^[HH1OST=+0^HYH',-JSV@/HFZ;*
M@>6?[6E*OT514?M^_L[LN4%+NCQ+WD"FC&]+:U/5&\B9&X6)GOTH2UX"^NAE
M*,:3QY)/?&>PLE88"'=BF(/E*TFY0W53P'&-"6Y=EDQT+5S9N=]J'Q*-UG__
MVX7 7[MOSW/^[=EA@'__N?I_=JQ+<X#Z:=[= RJ_@J[Q9G.0GBA9#5 CU]A_
M_#X[^KM_;T#_OT:IG6?6/-Q]>FE,H#_BSWRZ$QRG%X1;8]C*>@^(=].]!U0H
M@\[0=<D]XE]."#LW/HT*8/$*>P,[5P5A(35YCL#K#=%6"-U^Y_*<0 O!28'@
M49S2Y049,IEM]>-8%+FG^2VX(L1)QC&+WD\8BHQ=W5L(/_C\0-*EY0[X "2\
M '(KK#'$DI]"Z8H8I!,)4E:DO;AN/;JH&?],5>%8?@8VUZH=UW\7UBU^GJ^)
MIR;N6S\=;R 8>138/_(G#Y-0(&91E^WQ2(&:S3V@!64M^5Q,7D0$"8I?O <X
MW&K< W)D.F60NHN@$VCL058DPQD;4O$>@-M4@=*;30^86B87 J)Y!:_RQ&2M
ME6;AV*"89@IKILYI:)1X69^ \Q/*.P1?%DM,>\]YE1&%+M?VA=?RT,C#)/7S
M[,U>3$O*KV68*QZWG(,+6GY<9R16>G^HSZ#+B<9Y8_7[5PX4O=9:* L2=GMC
M?B5RE;S_Y_;H(8"8YMN@ >R@\:Q5AEO.P[8K8\6+L1ZB:]+;A[HCQ'3V'L!E
M/^"'>:.-/26DAJL$&:/SR@0^L;NX:#0%AQ3\2((F14D.5Z4K3/0:/I%XX<DK
M;5:_Z\=Q8^#EV]<J?%P7ZB>48V_4L]22(Q*>]-F ,69TFE</KBF2PEGY.3Y4
M5\[W4ZP]T=5%VPGPE,B:;PL4=D47^_?KVZ#FD3GW@->@KZ#CTL9[P!]'+Z(#
M=$1-]Q+-7;X[$,L(>:KY$'C 8X2?['NLE )C,V6WDK2%\$3CD;K$R,1HK&FN
M_I6H]+'L )C9R^/EV ^Q?5!'H"/PN$\509^38]A%!J0O$MH?'Y3K[[+I9(>/
M09Q]-R8.WM\#I&=1:JCW_P[4@P/_%5*]X'N XYR?ON^*03/+RH$"TCZ J^&X
M-X]\?UQ>Z$?<:RO_;%7( (V!\+XCP70E9U$PR*'4GT\V@4!AK#M ;/JK^&:9
M-016MI_"O<\;Y<HZ5NO(0G9;).;<@OZDUM< - :Y!WP'_?05 TG<RO1?$OV-
M/Q-W-0@YU->'9O,>L*KO?@\8A*^>JR\0=5P[I8&7R[-*%XUVS*AJ$-K-F@J2
M"\9)"]3/K+&'Z3K:+X52RE%P(XI8\+(MPDNB&YY@N"><BE_G46K_YUO33ST#
M,JQT?@QAG%XTVI4GRO]$9O)?(R/2>0^@/VM[ZO<,\5 SG37MV9RQ3&F=JK;,
MU?0)I;APO\D3/[%<*7D?Q(6W8E71#:3P,NZ@EYA!/2OX[7,09-<8&Z80[<2=
MJQI^.Y<#B1<>H0H7Y_#^F!8PZ1'=9?M/BRK^P1F&OPE %NB3^8+!7A;.9]6Q
MB/%=BL8F&_&*\*)9^-*B(Q\/]V&^LI%@2!T7XSXE>U.ETIC1[OX] ,B :>9E
MKC&=+#]CM#OJS_ET<M57><MJBL&J)C3&(\IO'K^@BT,+]S_@SO2_1FCTEN?F
MX[;TL]FSD9>7G0&,Q[>>C=.S8=&'V3QO7RQWD XB1)(EJC"?Q.WBGD8%IW-G
M07DC6.,I\AQ7'1W@=A[4T9=AY>5OB>7*O@GQ[GY5&J'X@YD\(C\8'*A.]@_J
MG,G\:^I<979=S")T$R^#FM7+D>8:]%13 ?2@3OU?MM0&M1XA=3DB[$?LEO2]
M+-H!M\2)BZGG8\0!\TOHQUNQ#K<"+YK21K+>0;,T%;]\@"8@T1VHA>-4V@_?
M5C-A+HD0C]#/,)P>@#:6-^E'S4?O 40G$F/_VJ"50QE[,#T==H_/)%+=_+O:
M,0IZC3YJ-H(Y,JE:==L"B^*,:K!>:&\?LM!SCSV K()=^SI>V@20(5CK?-?J
MA93!#CQ:\Q\#Y\AO7@^.O<R6$<'@QZ8<5<*XJ+P'9-G? QZ2RXL+5Y3G@U;O
MM/V/;/GKD4F25B7(7^8D\WOB:H7Q)=M&J3LP1<N V;B!QLFE/Z8?;3[(>/S1
M"4HGETP]^717+XG/;?;G\YU5\PA)ETE5>!=URZVG/H]#U1O\X,N(%X]WYP#5
M*W'V$P$4#<D]]P#R]#P%X^Y*DNAIT)IJH;/]FU4MTDN2ZM;DPV2]F[BI'/:;
MD<4KCP %,S#"O =TG.3U365"DB//W'#[TO:3$X3 Q]B0Q:,NU/6-K34[ "?P
M9DM">2WW@5DI""+4UPI\T*JVRP."NV,PF0U_9.P]X'U_V]F"I7'B@2)1V$;T
M#CC9T%UU^(KZ*I23O(AR[ U\WO.,XQ[0.8P,>X@A_5"9XY+ZAQAR9SBN^>L@
MH/'$U=A;3B>9*U-]KC\R40R4M^IYMU:(V3"'9BM0=D\^T@FF.5&[1\"[M'>0
MG"#8GI^V$C^8$?ZB+$-=2* @-*BIL/4*="*K2A/]"QZMW@&*/\>^Y1X+!YVQ
M>%D^N#\M%J6O>0_ $UACN,,QHWRPHW#]'I XO4I==$!3+)?K%?:Z8<+=E*^G
MD2WD_<RYJ<H,GC?X[#+IJ86>&*LV$Y?",BL_+/WC-V$9B%Y(@8W&D+]CJ=U,
MJF[2S^M[0/A#X4W)G=\4*A(^Q)!23T'"1/S$.:U/4FOC0:#&()=#MT/7,^\G
M'W2C_^((:9CUY!ZPK7+<AR(78;@MST-16'?+7),T\_]U8&3?0]26QAXK]I2"
MZ+V&>HP(8B)*Y!C"^ A"EHJ<WS^1[-"%9I,\E131RG:VW[)"KJX/+9/NQ6\O
ML;5,0_88: IC@:M"DP?P25.984TFR5) /&ZOZ64**/ 1H:T*I<$]8.C!FGM
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M_3OEC9D/;2F"6[XVUE^X\VW*/5-8=%A,54+T/LS3R.;GA.RI\:6W#==%#%/
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M^/.Y/9B#W2-S>:3V8([X!5-DWA#9GVI5ZPF6N2N[>3-6=VO!Q#1@P'YD YW
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M$\S7"S74:A+A:9[#=,*5HL\V] U7E@';F6BU#<&*0:MJ4ZWN/2,'^Y?) JT
M N;3IGXD *TA!M!>'OJ_MIWEOSZJW/%N;D!DML)55^;SE\0CF[?YK>> "BG
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M !@   !B=&%I+3(P,C0Q,C,Q>#$P:S P-BYJ<&?LNG=44W^T+QA !*G2.ZB
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M<TMK+[RO?V!P:/C'Y-3TS"SB]QQR%87^L_9W?6-S"WMP>'1\<HH[._\'%Q&
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MUD<'R@%QF O:Q)"[2>BD^""I,H@5:KX7*9;=,>)2#')OG&C*L4(9++E*-,>
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M&,AGC?[J+!V"Y[N>7?"7]83UVMG']YCDL+]XD=*27%S NEQG_MEFWE<S$V<
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M'A"]"WA3!?EJ/'O-P.;[V:\R5F",SIG>N30^RL(,E<Z>UMHR\[*K%'EG39X
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MMF93,QK:WCU_8J3;$G2:*.(E^-R^*728K?!"#X$_(P#^&!HT$0!);5VGZ03
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M9J56:U$X_707*]8R>05ND>D2SY7\_==X-:5)A?>16$X%R,^'W+?-WLRDT71
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MGV-  \EN(!@+"%Z4>3**R>CTH1"S9<CZC\8U!R=-;32 5]=.?[B/@[K6A1*
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M; 6P*K?"=0T\GR2MU>_Y]/\A:=]_3,1L,CP\?21F,=JWV?=,+8,IH\_&L+S
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M09YAVR TDRJ^;$A"0"FOR3.I(1V1+#?Q/DMQC'.__3&?=YQSY*O3EJ6:Z?E
M*CNX7,!1(I^NHK:@"$N@]FZA>F._L?KKS_P)>\>T'#_*BXC <94-2Y9W*QI"
MBHZP W'71E!=E)'O5G,7K#OQ0F8PW=)/97)S@BJZ '; )=8&]8^TSX(J6+NZ
M<@4]*>E=\<$57K'IM9%P]5C''8]_UGM>/4[\1;>N,=FU=JZ)'UH@KIANN,5G
M>0+-2.PX<I^W)MD:YA9=E1H@S3+ @F$RC:;RG)O#@$J089#R\%Z2=$Y6>_00
M;7N$.0.Y!DX9[PK<X%*?)'.M<"R41I%B*(93OS60K2#TT?^3Z88\'4,DI UU
MK/ZOB^<H,K <(OQ81G4\D$B'/3C8EG3;U8,PPH;3J>;8LS+<*!0*N'-ZE+1
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MUWX$)T-K",F?[<4S(0YR!P4(ZKO,"DRE!5)+Q]B:NW/6K<RT*#]BQ*\'A"7
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M'I$@KLCJMW\7]N7I^>ADH B=3%B/ZFD"V3*#TZGDV#J(L)Y\&70-0:U</B*
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MM"C9#),L$A8F$P #WCC;D'Y;_\>TZX0_A/A2-(0XR#]+]HRU.U#C;G3>W7R
MR:[:P6QEL_[,F48< C4K'95Y5.>D6'PW*JX;"4,AUK9/ =W,IX!J&=<2[*3L
MRKK8RQ3WM,8&'\A7)7,2H7<*$ F"3B:? JX>$U9\HL"]1@?*7RC:JRJQ6[-_
MG)6[RJ.E[:33CKER2+[O %W$;ETG[P868+D4BL4<\ARM_M("*'\-OMA'?+P+
MG]:../H!7^S&R)P" '.8!NC.#G:FN;N*N<3H'&*7N(/6Q'.,E9\"]$:@W4G
M@V5H7>!:!=?AK@?FA NE@"GF.MPY!81":XC7L(LC"$2,8IY3&<'"$B-W"G".
M%.GF0F]#C^>&5W/WM2+01T]/ :X1:-:4Z.21S[$GI,1[FZ< ]N'A98F?S(#R
M@&@T&C05^WG5C&N?![XQB1&Y@[EQ\F.%^&>W!D\B# )19TSDHA1^Z2+JFRGC
MZA>?X:*RF.;>Z?03[<]&VON@.ZY_,-+[%TAP=?A/-"3.<<<&:Y9[<,CV[] <
M_(54=KJ1K:XL%IOG'B>O3P'M/+LB ZK\@:V;?U;@_@O,W*%/NQ5<'-#>FTN@
M^1#LYD;PF+,=XW+S% "7QI"=5=+Y=Y5RST']"VEVNN:YW'\'L\JYCK!@VO-/
M ;&2H$VLCN-)0:2[K?)S3($&$1@'T,DV>,]]4[K@6"SBB FX*H<NT#E<P R"
M_]_#7>8Y5LC5.3B[C\5GSR:.Q1G@>V;&6%JQKNUM*E,2GC@720@K@4=K>RN?
M6V8DY9D,TSP2TFK(CM[_?\$P_>@#FW.&PZ8Z>13H:.%HJ/" /W/MXP[^ >5>
MBIP=>98,>Q-+@D*XG:"BBQ2W"LQ9-3^P"4I9R3A-KVVDBUP;ZM=J-0WY,K2B
MU$46[&X1F,M,#S:([Z176]N/#,N)\US7<Y\GFRKDI,-=KDU'UYXTGH 7S:Z,
MH51JM$'#696"B?:!3P:@!3DT@C*B0FK2<W.'K67MW^_8"POL9NL0H\6V(,-U
M45#*E9B;/=:UKG4L8N,%2>8XC/><TW49KZ=>!M"WSH3URG+%;\2\P<Q@BJ[
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M5?XTW&=S84#3IP#'C,$_2RE0 IY$M.110OJJ&'XVN?A3,?)9]8/&<4E4W2E
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M?%UB[:]TU<S9MC2M!5VSCKF!](_]R&'VKBC<R8?+-')[QLF](BDL3/$;:T8
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MUQ4=O/E!9XF<E=#*8QX(Z%A$DN(^+R=@C%8H1N!='E:#'CE^Y2O?E\-SS?1
M(5"NR(DE@;>=X8?:5<!E_HNX W-(-L2NC!+/.$.[ NS>&]@&633C-\!*UD,<
M0/ WH'J%S*"<MDY'F)>%9H99B>S0^@_D-8)]>WBOF?6]@&PK"[Q 06F(J<FL
MV.BD_8/7X;K-'2X"KS1=NX;[ELL#OD06M1F5J-0=W@2+Z=[8:#W,)WAOH3T^
MW>F*:*3A*4[79Z(H 13J*XVJ/;M.R^!-S="@',9EF&VJTXUNM[[C5%9QQ'FP
M/K;%837EB8G/,"ZAL4UW25)?!5P3'V)Y]93W\1VU,E%Q*[\]-.O&5Z3)T@1[
MR1#[D.J;DOZF6/HO@;<4K04+0J!7=[4(&H=<;PW9C L,\7^,%%HV$\J)$]]H
M 5Y^VMID;HDO4J0KOG4MI4HDF3S>]OA2N_J+CE*\)SAOA"V^N3S-V&\[F-?Q
M(;Z\WK:P#K8^!3!Z(?GJV^$74>KM8G*\ZQ"_CR][USC*Q5V_"O/I(K,WU\"3
MA_NAVSGEI>L&,R^,8A@K>B%"H"RPG6U0,T^]46_=JP=WU]TB@F5E^Q%%Z@UM
M]YB"/^8O*8:&AE8,IQX28YJJ3@&Q1B!64%XN='%4KBT*OY'^+EB.2.N0,G@$
M'!)E;\KD+_KL_OAQF:M))FD6'@XUO;$1AFGY/C@R)MHGDH,5*"@_ %" &#6)
M"E+@V_+7X,4.S8\0''/&VDK\*0X4H;K8[5-W86R80A&JRN!!80P$7S._SS19
M,GXP!Z($:;4JHIINS\B[>:$-GW% 12H1E3"L,623S7LY18T[G='+2!/@UQ&%
M3"*5Q:%NH9=0%RGA;&%0D;&!?@C]5Q+*6V8-.U,[3G>&/?<0OK2O<'4TDO"8
MNP"(<OGF$+P'(8X*6<ZJ>7UW-2P25PZ&T_5+#FS#@QBE=&\08HXY :;$;<F!
M^-2)JY9K'M@^V*$HH'\ $_@'TJGVH3,1WLX<<6K&)7;Q,]6*8$'[[_IEXWXF
MHN*. ;* #7!6ZEZ9K2BF(Z6\(/A?\"U?83D:.+X%U7^%T;<$_1B&[ZPSSTO\
M(4!5M,2 6*D)/!.:WP+_C525&$H=P=_7XUHP8/S7GML,*.RE[S\]^2I]^+7E
M%/#G8^ ?1+1LR%R,78)^I:S,?<*Z+?CC:_:X(H,4>?_KQ..9SWFOC#(I"<N_
MO8^>\&:P=AK#:OV_-H,I$FD)7&O3Z>B2.*8YP+@DH=/^ZN=JIM]6;J,66RW?
MY-OPH6/%:@V#JLA)61^MN!+M?)$%>7S\:KFW4C-SY;>R<J)&\G7^0#7QCX8R
M$WIMG"!0R?R!M:0="-<MJ1FHTIO+:(<L,Y2J([LZQWZ>C26[M9,1S9WJ,CW5
M1;8@YVK+,7=\0,CC3J!&Q!ERQ_DE?P=.D:]AG ]S??U1@Y21"[M 5)*RLM%U
MOAL5H=\OC7\(2LZ7I)J;B2M"%23+&;^/Z<+4V1==+D1$::2%Z16'Z.R9H-[Q
MT@4HQL!_FW?0$>MC>$WLO_8[+14+_O-3P"_P:G5]]J>(-@VXFA]WD6'P56'V
M*6 @M:_L 7GRJWN/^FNF;WE'69@IGJ5BP5G_[UW\>78R"SK$*OT(XI/('*6?
MQ;]>X_STG!QL^ZF7NW'^97P^EWPEDT?C]2D@"#)Y8@F=,[Q@?PH8S.UYG8[5
M13-UXE+/I?+N1AUB'^8TGP+$JM0S2F*W=G2Q) (QOHY%/U/ */EB1/E >UV@
MA4'C\]KDKVG!M?@PPOC'FZ> >)HBI7,.\']Y32@/0&>;S Z,._\JG$OX\I<9
M:S#CG-YH^&N^EY]^[DI_)2%7Q#F?;GSPO/O[[Q7UNS%EU47):CMW]4PE=-2'
M8A9Y7(*OD:W'K![V%HQ#!9;*6O5Y8;;=-NBED0UX-"7!@\+7Q4ZYB^)G3TK5
M8B1F*Z)5FC"">7W<M-(RXL/U(<G[\?3S]<]N=#W=UAU+.V0[:&E.MG"?Z$'=
MEB-&11* #?N;1-D^AIC4DPI2MQ")SI&QQTT9V%6YT!2O^#6*WM,-9\1EGHC<
M#Y:*;J5]O\$/F#L:4)]/&0H7,2Y'8MP7&X?*%7F'1F,R9P@@5UG6D?D:&KC4
MN@%Q?&&WYFP[55$?XI<=+U;S!<JXJ2/J4T>7@66B&^_+(IR[',,A&4E[S#R[
M9C]FB'3:?1T$2]X8B!2FC%QARGH?0A4C$. 5P0I\)&)?X4(L*D<^84]?V4DS
M6;\PNK$_^HSID9;@-%6)A-XKZ?M+M/@IN,YJ,]=HU7:F^NEY9(CK)LC*<'K,
M8%+OE7P IGZ 9R&/@??W<A-(^UAF'V0\SXM) P P9+YZ5^\IP>Z\X@T"U#)\
M7J.;D.@0V A,7DJM'WUOYW@-[JW;JUL-$U;FUR^N+G_7SI;F,R#T1;&&"3EV
M%9Z4[!^% DNC/MANH2RLTW,A$+.P69B:NEDX[ZL.U23[43^I.;O<Q-$V"D7E
M@-LW-MSQVW=W4Z7!= CGA@"95$9S?+(R^<.O"Z "3#0XU1D4^]JC0\-%]FAA
M3V@L0M7CT,+C6^BV>*73\%>4=GN].<JLGH\R%Z([/6Z*V9A5#Z9]?_?YNZ&A
M_ON/E7 0\X_IWARI]/M<;8I__2YM"0^0AJDG#IL_5'!PZ.H@-%B6;1=UB$8(
M(:8*KS/%,$=)>&F876EW3I3RR6=DS?O UD!\B^9E<(# 3*G9.NC:"L.]K9S,
M-.<GE<C&W@&& ;7E@RU&:;JKUX'LB8](:Y'XFDBV);V/MSVU,A+=\ &*S"^+
M.$H1M17\78U=AM]U-&* ]./-/M5 >VB-LH S.$=378)C+/E%2OB'$O8-G);/
M09<U%RT6_1:H(0VQ%TVMY_J9CEV#TQIX5A_[A*B-\BNE!L7D5HFC=VKW<YTT
MWDL8*/EK5>\07G M9+^:U7$!SZQ2_*%KH:IS=UZCAK-JCPWDV<M^M/!#E/O,
M<HW-=WX-U;Q0IE2J)X]I9:\P4^6H3(,:8@FB(.\65AMH;*KVL[/&QNX4#DO>
M&=5D>F;$WS6HOO<C:Z:$N2V 96?X#2X/5=^ZT@<*Y 7^B[?[#T-3AAZ[B)-O
M131>-F%Z=V3@?4NZ[.VB282E0?NUU;R'D\HZ+V8WA=0@T[-;I VQ?(U'R<>U
MNF]\ORXJ^Y#B*8SC2=_H<1Y?132PGO%MFJ3+O"K#F_?U>3+C0R+<*8.=N!O;
M0AZ-U3?R^B'5]$M>0]0\:J;K$(;5=KRGE\JY<W!6\.;IA66<+K$]R6IKN*5W
MG#3+N"Q])@&,6V37(#\%@AWYE]%[".'AG42#\K-D$TV]LF>"@1;[)&'ZGT2%
M_UE6G[//4L6_6+2@E_GB^NP8$Z+/VN3%?B4[4T"K<P\MZ[T&)$4[N=BY.+W-
MX<G.7U(8?;E554_J=HG@H*;I\M)#R\>YF6>MOG12G;.QDQP9WL@#!.^F&\^+
ME19\W-K/S%B"X_&P#0<U9C4GIX6(325EQ:MYIURYF^$L@<2$39\"/A8\&;JO
M&?VP14/U,-AKA"W-DPIWTHJXJR*0!.6*:#@BBD^:H$-HUR"E"K=Q"=\[!13I
M=\M1C+I4986XI+;Y7V_EO&(9Y]P\Z==#\*P%P\1$PU/B5BGHD@;W+F09MHYL
MNQYX\?OS3%)VOZM-&E:6$C>O"PX+ZM*,H86<!"UXXZUR4 DL:T6T0:Z]+F16
M$LPQARL7FE:# *,X-9TN5SCR92O>J\YIEYJ0J$G4[6_;PSBTC81&(-/W1QM$
M/Y9<.QBQ0,NX/73$^>#W+9,LQBO[Y[A4?!WQ_R/GV0GVV=!'W.NI?7GI>;U/
MC5M9$F U:_]\O@ACP^MNGJ :T)'7D"-9YI-)C2[QO;8K"PFPG7G)U]I--QL)
MF$@(O4FX&*@.Z]J>E"^"+0S9;T"2Y;<Z";PE\.,OFHL!9+ +'3[_#!?EDNOU
M@;<1FH-KA9]2/F69.0DTT'F$X+Q[I 9'EJ-Q3@'/8CQ/ 1Z7X:@,)! QB7D:
M0X9=9?O.%OUJ@63+D+(S>QE!;@UPEW])!W7?]S?/-DH=-]"250\<^9;R[$*3
MB,^O2@_E!D H+5< =CGK%CT%U'[4.?,6_!L%=&6"K_>]?VTQ8PA((W315V23
MVA#\]9O?9'-+]Q#\@6'"=)MK_"F@;A6)?T+D2(DAO/V[@Y_G\!3Q$=TN%YI*
M[.P"E/EY,DW^_RODTWB(_1EP0NKF59K4:1\]K\&!4DC5'N1V"+"46L:F*:"-
MD0 Q(/+KDA8^&MZ(X?X7X/Y3N_\&* 7S>1!6"9BV0>%BO(4)3@%X)- M1>BO
M7<S<WH9QTJ4NCP\W!>)P[[^W;W]V2X\I& K$U276L5 &_5I;Z=!!C)+H]1[Q
MWZA)H#GA &C/8CQTJHX+PPKG8CG#LVCIJ-/[$_>2V6Y["]=:2FO S.B3K6HB
M(BISAXM*H]MF(RIGF1-. 6-19Z>:CIT*.$KOL/J9?_>)5>!AD7+9%F^@7KI,
MZIAQ\7V=>O#^,D2O3"Q<T#ELY^N5ED#6>@NJ%J$M98X1;8SM*^J7"D%/6Q@7
MX@BLSX<#_D]Z_OUAP?YYV\OYX,,GY$7_9&U2_MVVI*YT+MSPTU(";.EQW1_Q
M,X2G@.O@XACJ7C,>Z04VL+'GI&$[0ZVB'5,08$,R"PSRH>&9=$,T=O0CEN_1
MMLRHG@(<*S3C7V7("7H]B)P5N6/LF JKU$LU="0**3^I]N1V]$HW.9 VHY5\
M>E]<TZN+2#-'D+@>)FFR6<W YXV6(G0TAM;ISLD11KRY4_[H*^PPT= L*'_1
M+X1(0)'?V# Q);5Z!!72=J 1*^4'1TR52']->-_\.4>V1^[E-P8\1Y=[Y8N?
MII&'RF7%Y4X69L(=)0IBY2RO[A#:%=LS 3_;U>[FQMY!;GA?V7)<ROJ^$AE0
M 9D^MH;-QTC;/Z+6OYD'XHM@9@=Y>_C!\F;7@;+(#-2"(#7#1!_B94G_^W U
M!I6'X]+E1JIY3-$95XYZ.YI;<ERN)!CW@D>%PY,O6HI=&V-[R%2#?[6>\>:-
M+N)LK=SH^=)>Y]M"*EP>-LQ5?6]ZA"H0A15\UWEFJW]$.=RQN\0170IX%]&(
M8>HMDM]W=-EUS/&?#KPZ]I6I),I2BOM3L'C%P%00OKQ]:^(73>^*)9J]5)_"
M+SQL%':%L7;A&\G2@$8KCQ^SC CR>!TVE+=D0>];),83DF88A++DH.81#U09
M9/8B6(U@SUGJ)=5,4ZKS:-K Y\E,ZK[8@P(_0WGD$$")[X9RQE]MM>$HUWH0
M09(H"+$=8;C\NILQE\SJ6GV&\*K8EEYX5=:J(R2C3;_OCB0GDQX.]0CNM*Q#
MS6-^W,B"9/"^X\"1GW) 'X]G;=&7L)M7+K@_Z=8T!?H['*R= E(1RQ.XE8.O
M#,(G7\/+*J52W_4YL$YH.ODL;C01SVH;36L B9Y.3Q)3;\[V[1*3ZHQW9\ER
MJ<E_:>?!KG81AP^SI*@);;<-%WYH9F"'0^7&##$LO)SR$Z>U?2&'G7IY<0#_
M7<C=#ME@[U;Y9O-:03G3P5"DPMMG,WJ]2:41=03.E))&24;7W=QDYA^1OG1]
M8V+EM[$9V8[,"9N1NXX*;5*?\)TAD+D].JL(?A)J!#?FO*G ,#5AC-T.4*&-
MQC33^:QZG6_-' -IEN]B&@T^,F5?'#I0^++@KG3<LOK#+[!#>=QY>(N@WM+>
M2:.PA],FFV.W'W(WVX;YTV9*0:!\A</5B@4Z"CV<^VY(*IMLXFN&)=JL.KB&
M-%7K#>$6:MK&H1R%!7=7Q?4"+OL6C_"NZVN;OY@RB-0<QYLJ*=N]HV_$<*MX
M*-=& VP=:AMESJ%O!V 3:;2D_/8-7SO.2ALWSEYYM*][>AW-1]FL,,"3SM#3
M:G-+0_KB3A)+AL:E%Y>8@EP/-*_&)W8GHCZJ@B/%4[91BXI;!)I/(9<0IL5N
M'=+>G^@NH^-#.BH#VP+>;@/E%54B+%35Y:P>F7B1&=%7D1&&'EX]7%3N>QY#
M/U0)L1+NK#PHWVF\--HQ;7W\FJ7$X0F=@7%PJ8>?^X.A@J)6ZT!BN(])Y27[
M W7VHQ>J6H4J,E:F!U9MC('@D'K7)DL+B?MEQ'&%0++Z&?*"D(FV_<><62%[
MG'<_L3MI)%!<1)^T[&YJ*.T,%66@;-LF&YL;2'S;%9S,$HV&S&R'5MF+>]+X
M@QZNR6](,;F)%%$$Q]L[U58#D<LRT)<A]*^UO%Q>;--N/FP#WE)_>Z&EP_[B
MI<, #3N1YON60#$%'6%C]3;4T:)*9-VV:K;-YO6198J"IH;[7N,70P0<]<("
M+-!*L3-<N,O%-,# C?CPO2P3,]V"?O:N^ =B57H^ZM"J<)<^+LW SUL2?&_F
M-KJ3P:Q0TI':&;#6Q<- J(7)P1M6=#K-=\V\;DO[)D>&: P$594KECX)SK80
MB>3D9@EI>KPGHVR_,2H/>UG<(^9FV1G=^6WJQH>:P6%B;Q[B&^#9IO+ZDUR)
M7I.UM\64,F0E-SX:V&I>?V^^<9]_/M])H8.':+%/49G+G;':N[:<QMC58!\V
M(LHIU!^QPWMMY* +;)S5\J?[R=DM/C)GFB[QV^RF7C&RRVP!6W:-!, KX*'R
M!WU[$-U7I25\HI,OBF[D-]&:+M!ZX8'S<K]A."=0MB 25*9JP99R=@IJM&V"
M5EKC\MW[IKKNGV!X>LI"P2T+*;(MI6Q5<G'6_L]71O6*IHO*\G9Z0".;-][G
M+19PRA(7@Q\":8TL55<$/A:XA$KG!R> C[V4O%[!G>.[)"^2?",,LOBF3.F_
M-Z[S',4#36]Y23-C9/Q>[_"E53Z@03>>4 K-!IH!>G)#"*9I-<94ZQU.@O7F
MU=@SJYZO5;_B[:\5_&(I<7'.2JPAN(JOH?.!$+G!C/UZ;HY)+CWIZ,3E9YHO
MU?;C%+OY5_"L8+#V&9>L??.Q"</R(7^RDCS5W/WHN(^;H;<T:*LWS*_LW?[N
MK)&*$FD60P9Z":DY[O/*UUV#1STH=A>'W?PH%.='QW]H1[A8S>93^![J7:)N
M&MDWMDP3"..80J*^CDRVJKT+'I&V^DXU7WL@G*Z5\/FUB%<"C+6C[@]3TY_1
MNJQ1]&3_O9R_]M+V;(T16%"KJOVMDK26%5982V1L 'S5SHV)DAV6I)14ECJF
M5P.(S6P3W(18Y:[9>ZVJAD@Y,^;6$XX>C$9/#W(4)Q="5_:)BXB8] AG =,C
MYO9I;U%.L]]-<GHW;P[>HGC U)WF)3GP5&",0GZ.KZ-WT5T6A[J9X4 ,X'P<
M;_^H6=TU-JF5(R#=PHE\]ZXT]<+_8N^MH^)ZMG71)I! @@9W"1T@0$-PMQ#<
M$H)[D""-NVN X X)&K3QQKH;=R>X>W!W#?K(V?OLG=\^9]QW[AGOO?'NN/>/
M'F/U6K6J:E6M5?.;->?\9B#H^9L7<DPBLSG1Z<7%'">O?NASN:NW4@AHC7BR
M"94B3$"IY?,/KQ)[T9P"UEA[G%6B*BY>-04TP->V9D8@E %Y=?!?D36TK@G<
M%.1->YGT('1ML+8VWB6/K\:J8A7!I %47R//3O1OV"'M!U>$B_> 1[\Q8:$F
MV*C'#*IU#PA2N4R[![R9O0?\?/MO*+<W Z]I4]OG!NTWYOQ>E/U?*L82]3*K
M 7Q'\F'9Y1;=Y@$4_<:A4_< DXR0V""FI4X!C8)[@'14_LZ-RN/AU5/U$I\V
M1D_%!WAM=0\X?,'Z.XFGB5+(XBFHZ0[E-PI_1R05.ZP'NP=@%!P)W 4^S'#S
MEZ;?,2@)PO0^0_![P.7SWZ!45)=23L)]\E\>KJ#BKH\*CR9BU0?KM>KCD.NW
MG@_X^M%#'^FS&LR\>YOPOJ"X6AWZ;"W_/]QN_G\8)B1'-Q#!#O8ULZ=\1(QV
M6SAZ6M%=#!4]RCW 8XC4Y5]O1\_N 8\[@HSD'W02$>$,4$<Q+Y$5K]P630U'
M'%$T"DWKCX@!&<EG^,>0XJ:_CG_VOXS\L\UKHG/5>T L]I+/!=T]8'A0)RJ2
M.;MN4IA:<WHS>6!V)X)=D\6GK!3B]T,Y@U\A[P6"L2Z)[97 )(TK2I3X;48]
MJ."2=8DN('N'L'/T/5P3I2P1$\%>3A[)_UPO1$5<6)D*\RR-JFU"JS$A;SO,
M!3.KQPLR:+AG99MAH:(,[R[BUN*=4$.H$TLG"GVOH=\2P=#56]30TME66QY\
MG]RY()?BM(6?*^-(X4X>U0HO_)/-];O$_V+\K6E3LFU".UH>J6?PMYP?ZCO/
MN%HOZ9?'H:$IFD0%3T*9N4Q'7G#,%US+^T;7V1.M6Y(S]%Q-7/ Q?YM[KQ'R
M '&4C)/"EA5>EE#:5)8T-W[I'#&@\$,8P-%X=[H+8"*D9N[,@UB9I>83N)W^
M4I'K^[S3[U*?T'QIIO<UJ]88SZK<\U3-6=P6,8"/[Y:RUF>*3!O62";U4>-<
MBPV,D"BZVPM9T*[HHID?>#O-\VKD-(KK>I6*O#*^6[+\R8/08B&4V/$@ \N8
M)J*[9L8Z+S)U^LE';+<[B6B%;KP=A;[U7VZ=L /ZJ^.VEM0T-QO%]   V'J,
M"0=1G@)Y<PJ/%[]4U6DNV9'']'N0LO.M,CV:1KDBK2RZA,H<7OIN)S=$)K,\
MQ4GIBP_[T<F!L"/9YG</?=06%)A7TJ<3P3^DP^EO]-K/)0G@V[XB4*8DY%:@
M+5?IIJ56Y9=C3JCF@!NK*TD0TO5^ZARRS;/W$3(W][-GM7W$<H#' "_\CF"9
M4+^JL8';-_U%QM+>C*L9SX$3,1=^G"'JS ^<SAKJ<Z"7E);"5"ZE5909?)AS
MAXF$N6079% 1)["W'*C&/:B33\R7)[ZTQSBS($TSRKSL+WT#"0$-,=')S(@2
MTS*[7@C#,!8XAZVH1]=JQW=W@[Z'GA>Y\+\=?0*(R/P"/.:EA$6(M#L'+R<@
M AK;,OA;H-ZS&XXMM-;]C?,NWO@Z:OQ/ZX5R=22L\&M-4LL?UL]\*;]G'7<_
M:=>V9G*:1IB=])GVX&H7Z1]LHO:>,^W:O(]IN5)%$_1:VJF&&L,G3V=S*R)R
M:P@O[+H_BHV5H?J=%=L\OC$8\C19*DJSL]D[W6&@,UN]-OEA9DA6%D'/JS#5
MC3)L6SXYJ]5F\DC,!L/V388S;SPC=.A9GJ= +H50L>*W3Y::B!2;2DBB=JGS
M"LE% 5X[OV>RV/@'99@7,TW27A'_5V>LDB8!6[9)KMY+F^4&1*@WM84>>5DD
M68J<-K ^2@51B]OU^A.R&<#(7TD@2M:%(')@88%) Y>85OIC^&/IE7>%WQT!
M6/[?P*8V1B21,VA[*\PZ.=+XA/3 GRYTU2)ABR2HK56CC\RCBG462(A;R!>T
MI?#!-:O7)=&HHYGK=6^/7OH-94T8-P8MRL?B5Q-]D,9E(P.($_("[/F'O?WZ
M<KNV286"2M:\:GMG+GJMAF^S7L9]/",A)TW:55O?G/OUW.M[UQH)''.-(ZUF
M)_PD=*FJ*<)=,7-%P532(XS,B[L5C2Y, WSZ>HY$E$;=ES_5MHNW=!RV@S\V
MJ6#U9MJ),&J ,,CD1-;'XY,#8I$XZ^))234F73NH-DS %MZKC/-"YVV.0>"*
MKQ2Y<W[QC4CNULFO\UJKW*I9%#WCUXS<+</V3^R:E[/+CH+""K7F=:;![EYK
M,,B-I\+C,>OHHXS4@,!-]RM5UT;J2VL/CY#E([H$(.%FA<(+_;=J0,-'E113
M@%@ ?:D9.JDY1$O*V')B@J"*N@#QW(\$-7]V-#4YB )5'E$I)UVU([UG9,<H
M&LT@86M/S/(:RZW_)33DM&[OU9F<E=K BKQH!]2P6C+PS>UN-2_Q0;]"+ABN
MM9<\OX4XOXK(QLWRD$E4 3J1Q<=T -1J#SLCO*B2''*FYNB_CNPE3A/;V-1/
MT19TT3?0W[R8>5U.J#]-2&6$O8[N4TF?5'<]:Q=^/9GAFK&BV)1W>:%\V!GX
ML\93BBN<30%8OHW^=&8;>YXM?8,"7'J8%%'JY"&@,KE+>]@)<SQ&<_QVH*QI
MK+K=YXN.86_+F^L1OV+B8"%$I!28;;8+BNZ@E2/14+%T7OIJUR+4S[1%R"XY
M#$NHDQSYM1OTDKHG]8"6RD-PHT3TCF5X.>C*=,)2F0GU>'\5'(]N/<_=[7!,
M911*UC'#;OYNVZIXBB6% R7R<)X^=E<1H#[PM%L063X%J^YP/<['<5*=7S>A
MHX\^\5/B/$GO"G$/2>=38DA?IGGEG)1@LE=Q7->K;R]=\2MZFA>PV,G6]-QO
MLD<JG/1#O"E'JBC4U>^FJNI@HZA72M,LM#$QM2C4/!A* '+C<2ODY=* HDLI
MA:/'$R60+>?)PB<L-D;O8HWHV-O]JK&R2Y@BNS0E@$3F3B@.XNS]&*$4P(@
M)N1NZLBLC'6> D@!/V96VL-!]@^;#TKOAJSP#]@:%"B-W).Y,)^,9E\O1SW\
MY><C<UV/JQXOE9(0>"@F]74A+SUKR.I#AL3H/G2Y,;EU!CPEJK%O'*CUECP:
M^7G,V.D9E\??"R9F9B8L1V&W+$.Q++2$>I@>[V(CLY_IMB$%5PO>$7#R&PHG
MV)AX5;Z;)@?3*A"_D-2AZ%!TZT:=&K\'_+TCR&_RLG.GM\_O),YRB,J,>1+L
M2+MK*+#0:+E2[@%H5<JND;,JW\9'>K'I6L=IIQ*O@RAJC]L_2@$ :%W B8.'
M+OQ^!.0_GLP]3.SO#("_1Z $#>NC\M\8>*R<'S"]&NK'_T8\^I_'_[2O*BE<
M)U&=S=\#TG0*W6WFJA]0QL'-YJ.U?[>N_L7#LO+/I!Z^]'\CID_Y&Q///W<<
M_T))_U="'I5_1D3]0;NC]E> \U<ZL_^E]B]W5OL.L'7U+CTTX1F*Z1J02]_B
MX2K02;N\+T*I+F RU\M4PG)\0*,O_A>X70\5S@_IY*#\G&((^S+U&;:D[>]9
MC(4E>@US$V2]A:T\!8Y5P>LT&JE>14!\R[0COO!V7U]^NH#F;N;VZE>9]GEC
M'XXE*WL2UR%&%B8.YP;/>V(?51C$BKC:I1K$#!II\*?,37FR3'@RL:0\ &\K
M[.>WF9G:KV2+M9LF;&81),T[Z5+$ZXVM69&BY^E2_5J(ST;C7(L12>KN4C.?
M"#]/RX%JC.KZC+[V4-BCRFYX*BQ=#^>;3?+O7DRXZPY^WOON;W;JEX^[_/*$
MYEG;A;6BXCX:T-BOW\M&@MRWD-.ND7@D=\0;?U9#0+<?R ^6%)[%B?2T%!#_
M#O)_\H3=7;T_6;\-_59D22]LV1Q/98+9J-IG3P1CD+. K&,]FI1+'D<*%95O
MP*MH5^M5]9RL%163Z[64E507/^QLK^,LTJ_0_#5+HL'PXR-7?X"!J-2^#K<'
M5&?56*WD+J70U:?SRC,D3V]G$/QS,JRW[G/1@'/,6C=^*C<6&H82ZI/&^*PD
MAEN(^!H5\HQ"R8WLX=G(UG 7^$'WU58P-\\62BNI3Y>[6V'AH+DNU@PAL42.
M?"*<DCF7$7Q'&,K+PKDV<O8-JVIQ6H%#HCX& XI'1Z>*=$E67@?A.N?"KT'=
M$XQ*@ I2.!&UO;*V%('!O+#O<(FA4-#&Z&-HVC-_BN5 C3A*Y]2/[HXKD9-+
M^N=.&UU*N-NDE$G<&=D*N6_+!30;JNQ?&\^I:DKR&WW?!,\S0/H,=?:CTFX4
M\ER;EJDZHI[KFKE[)X""OAD[FLWJ:*JQ U&ZCW:WI^<X1@G\SKU,&I^;SU!"
M\W1UH8&>XOA::3ELE6[G%NTW]9X[/0]?C_Z'8:F'QX\Y48M:\A+I\F:[3+'*
MWOJ@84X:F8!6Q6IVWGU<.H%5V&RT\<X=6T=5 ;GMCN'H'N K:+,,+@)_/J+H
MS,"* S]5KN"T0^&(1MNAPT:><X'F,V3'"V4+:QY&!;^%:S6L)9Q#G 3UR!(7
MEI$R0>'/9(_P7L\81_/P/9NFZM!2=B62IZI\4.(4^M/VDYPV) 0O$OEMJQUM
M!X.JHX*,R1J(3W^>0G,9LJ,?JI1)43RBK#P<U?"?50R?TMI1NR B3<_(3?DT
M1D/65PXWR(1S2#6_0].3^J '.21[&SJH><22:9J_372>)/G2G'Z$2!$1*X&Z
M'OI:K)N<*L;#"6J4%4@F$#*PW=5'A6]0B;A<6B9+T[BLF!B0TS8)]<&(*-ZE
MU0D&&D1!W#>YWM%=JF9=)K6Q@2==THG&;BZ;$.H\L9G4LA ;51K?E;)S:.9F
M=KSG-17SS@+2^*XWN:N4RE?%H LU*VU-USWAD8_L]X"B3Y\#ZJE_^F,#K\:T
M-@*_WM"-/XZO32\Q\5@F?OG(BUFSB/)M%+ZL/<[1N#I$]JHTE ]YAF.#"M]5
MI/L(VMZ'R2$U_9$U^,7KEL>-+]S4/SX6)6;F$X;]6-CBM^H*K"?QLKB88<DT
MR2.3H4L1XW%6X#G*SGS3J@AQ;D6;/;'3UWHO1<T8C'XH"_[52&:N/T/Z5@M8
M5/^R^/G7H;QCU59<V?T!6R^'YA=UA0Q%6B0(%]L'I1#G]_KVVS4L13'J()2R
M33OBWT_^^5-+:+J*OU+[]\0 )A^,LH+;?]M;-P1D_^+,-/YG(,0_-<_?JFG&
M3<<]8"_XKE^=\9^'#/]43O\AD;;7_L%H(DKTCW@W..0>0#W;=+5Z#^@>3_Z#
M+(X32?#?Z$3&IO[FX/1/9;ADX\;SX>2DT3T@:^%!Y?V+G],?U&U_>#/!_C3)
M_94+_/]-1_A_,,S!'P;SVN5,?TVML.2_',Y6:?H@6Q>U1OY.2P:#U/3K&TM)
MX*N+=?Z[:.765$9+UR0&FN5^BQ)%_:#/[\K3F1AUA*UT9#?^G=TU],J+?T7I
M1/+R>S=AN(KC/4"]YQZ0%S#1<-'.SWN$%>B3Q]6>6.""+CHJ'K%-;!"3SA':
M,WE'9>Y^$1 53*(U,6X8R9 7\$@:;F3TBC9_AE'+LKH*P;MS#_BB!]*X,<W7
M$LN.8&U+BGVC;+9V8OV<5LJ 6)C U[J:>M66+;FNV%-NG+/Z1L$,/E&Q0SBB
MS9* -3'+6]W:46_=T[:/BF(K\ F1?>ED5HL:4H6HKTYP^F62O&Y4Q5_9'@.?
MPW 4=7>B*W?"1E. >FH.P^A&(8BRH3T*TF-3W21KYZ_^#,";;_8RR'$=("G7
M)&$6BXLK$3^ OY&-DXN#E<G+.1)]H,R+HNJ=R*?(Z>C/5CT]<BY-E[:JJBL/
M[TH@2I\.YWQLS)V+&/,7D&1T<\@0CC25%T43L'FLP?9DB8EO^1(;TW-Y/7B\
MPM\#IOR14,L)NA<\F;RT6H5X5(Z$RPO,&=6=4B-P?_DIJ@@4HGZ,YD^WZ^<.
M)(Q14CR"ACA1B'>,;KR%#9_*]12O@#.!EKOE3/['-C2B+#4";A1L.ALWK!X-
M+\[/6(U'G>HTJGJ@([KL,QZVE.S9GXR9R2G:UO42%@8/)Q5KAST5\N2$VL2@
M>ER[/] PR1+",5,=*973'18J,W[>IF?FWU9JC$-A$&X.\WZ*YHAW;=0D2.]%
M48SXR%>OGZD9*0HI*JE.G,US=.GACM](<YZ'"O%?[:DK2BG[BA)GSO57G_X*
M$DYP:14AA@F!5882URRM03"U9Q,3SDFO0.EKS(&K/C%=$D"DGN[NTJ"^)2#;
M]HS7?F;)-G^MAK:<*29L,:E,XH6E@7,^<*6&K^!4*>CYYH76^SB=,>BN8^IM
M4.=27%_P&F,-C;CP."]92 >A4;VE\]A["<WH_TK4\5\6KT+^[6W6;#V6Z"&Z
M/,./UA>B7\>O"9%35;<9GI_< UK2I"]Q+Y;3#K[ >)J\^(\H]T^A_4R/+7]Z
MI .NU'Q:,3_MJ%R>%%IHE8R)@,=.<])H-,715+_)OL%R8_QN[+[>$"QY^3''
M7"LXI)1.?X\7=NUGYP3V()7!H>5%DEYU6!1B3(\[-&KCIXK,:#]7(SP?=7O$
M4$(##Z$.#+ZI$L6W<ABE'9OPA(I;&^^SAK#DCM_17]J(BARMV5AQE_/? [RR
MC2-I3C%I+-W]MG0X+DM%"#PU#H.J9W*KW 5=$,Z)W'WL-[V@3Y@")RW.K= R
MJ@6HY!%]<"EVA*# L@##C+E5?1]Z?A+Y;%] 4]P-2Z'=IE(NZ*+U'H"E9W$E
M^3U9-:UR:Z2^B)R[O+!7BUM>I*^;#(%MRYALG!?3YUHGWQ2PPAH +77BHZ]*
M=QN9Z5!AMF6<O6E_6,O#\'HV7S,QM6MQ0Y=LB'4O(W:1-&!$M0K2BKFEAJZ$
M#,7^IM[RU2MD4CJ3^6!A0L3#YX&GDFB.:_5J+18H;V6_5;6_,CJ2.UXO\*2R
MT%S=A5V +HU6B:*)4EM:W:+./0%E96X#1DC$UN[)-7D*+G(3%&#4T5E8"/NV
M;[W_L9TT//-\[I<IO7T1]QP.+S() ?0P3MFC"7-^2GJ/UIPTL#,9Z!#;0^;Y
M[8J6X>:5HTTPH1[AN B,IKJA7HZSEML96* AN($KB^<K\PF9+$+WTF'IUXW(
M4ADKCE3^PB#H; 8YNJ)[-G3C-B;P ?D,E6*6!BO]"S,[ 3=7YA&[+$-6S<#(
M_Y .M:8IA#1M(>(G%8Z^QH 5%+2;&TN2((YO"T%YA,9[@8\T\EX/R>C(IWW&
M>(&VK*D:'J<Q0E,)=TR<JK?A[H/$&K]EM'LA0?:S^MG3G7 *.:5(_G6(@Y6Y
M::Y&7[[NHA"L(45:O-;'*/>8VV%!:CK]ZZG@$"IL6 ^4=V,Z"74JRJ>I0#26
MC]@F%]\#C&*GVA<;3\C7I8XG.(A1#-],V:,UHY9<*JQ<#U+,@/WO&)17Y!NU
M]=D7Z$*,U1!!!LX<;"AN'>XG5>08/P$.BY2"JH67FJ<%CD5=E;'OMG=]*9H=
MMYEZ1)9L+MON GXSE3/=$6PV577-#7M#;YE:B_;89S@A0>&Y^ L-@H/(1,IV
MQ2.6NW\ICN_3NG@4?(OZFW);_88IJD17=F!""$^VUI\G4K-^+,EC?TX%2NL7
M"8D:F\S9?*? (@&-Y2.0C;P[N?Z!'=)$Y>F3)9QVSHH[-_O+7^%:E:]SSDG?
M04?JAG.P??&*S/H></#E'G"97/+0QJ>$TZ1[@#&4#QK4U2&%Q]NA2247Z#EF
M.+UU#S@<%<'SV;1ZP"B-M/> 9?.8NY$FW&5,1$>2D1VSM_15>E.;GJF$+86:
MU.^D]?(W#VIH)OS@[C+J'A"2?4=JNFQSBXGPN6CWN5%P"\1_'/,?J_P=^OCM
M\@$MB%LMWAY1W0/P]#Y*(!F[^_QK5RTSJA#M-4;&/H2Z%674$3''(@?))XP,
MZ+2CP7L<1YP8V(3S*[?=OTOJ7YIGA#2=<C^\>8O/'R "USK!U"75FU&N/0'U
MT.V7X&HKT^J0Q-7BG!R)>*!K"PE*.3U$48I:D\KZKL>;9U+0Z[!W1WGR["D7
MT]C8FM^G>, ;M&5J6U1GD30/5<^3:\Q[0 ]%PSV@[*%[C*2G=?,NZDJ4KL&R
M<>I592-+P]_'J*L]/J;(]S#V#ORXM*8%XOGR=O/R9?/4S _K"X!%< 6=<EJR
M=R(<Z89M0*8:.A*D3WUY'ENGL_,<$4WG(MFBJ>M8.Q+L>^-/6)T]K$;F%^<(
MW'D)9E&WRKP>=-;>V3%'@V9_U#>8CUCT_K=*=]>?<>O@!=;R2!T_?^OX7L*1
M_./?-S( BD^4'M6?4U%=!K<?>-@M*3QZ -DR\)A,N?DWI[.W)6/1"[*?+?-I
MR;[F"]6MU#4BP$5,7PC@G#$53TZ!1ES+SR8G&I%&ZUF%HU;002ZR$=_#-^68
M7^OPHC"E?*9Y1DF\_S$\_0R41. P#JIW@+1E:2[NR OR 8^J(L %M1U #^]S
MATG*[')*&-!;^'"NMIC?$%SK8<%A=;PGT>L6%1,3..!&T.KJTDJ:>D=S.+(#
M'[7X8)9,]-7:1DZV0J_W4J3>,LCDZ;9=-97L<E4=-HZ%.S38L'H45B0S4(,Y
MD6M*&4+1\)GLY7R]7*7GYWA45WLL&:#Q,W6C-?ES)2)/Z:$;>JM\X$Q"G$4B
MO$*G-'WRV<MHQKB(!I_/YP6@1FJS0_&<MJ)M-5(UJ)<-?I-!\IIXD!.J&2K*
ML=U(/5A]I-3&\Z7#4H@@1<%@Z3;IE,>M0M7%ZT >@<]]W*^E$A^%.Z)L4"R/
M"^(5+VY[TX^8!+?CSF]?I01I%"_)O0*Y&-+S*.$E/*44?O>P8%)LKANM236Y
M!NL%M+F#]77:G+AJV4.$>Y#ENW..U]2!^=NV3\]SASTE\EPCGZ3(-P:=X2S=
MY/71G)IL0P): (=@IHZ= G-O/(VJ *^78]XZVL69H6#_ *30$,T/O/L.4>(C
M97>4LR_ ZAR#2X,XVA8<DO+)\#H@.^&ORG)NV=;7<G@P BGR4P+UL3 FG9DC
MFR].\]S',X-OAD:5$Z47S$NM-[C/A[+.66$5JZ< QQY>@MY%3_O0V59OJ@FC
M$9-$!=%Z!'>6/ Q6KP!WLT?]@;]"65-$A>^$,K8'$\&V6, ;/Y-[9:C);,U9
M%:N:+$])_IWRO5K7PDOIC1G8#=Y/Z6)!GMQ[@)56!W=%K:QYDGRQK)O&^NLF
M1VQEP, KL->S8:;*\E"5=& L-S:9;V^O/9H0&D35BD<1,<)Y[<&DPC:KW?DB
M!#V1\;L!1JS,C8)F(<=_,S>-%>J*=<KR@S:QLQ3Q!"]?6P(E3F=;<Y9XMI,6
MQ7/%KM.5PBZFWUW!C:?M'H"A(W84U\F?;<Z:9YYX?G[EG7$7^3$D&@,1_QI)
M!VK-EW.0^1Z6-BAZ9/JE*\@QT[:,K*YG30XL]ZY%?I2OM51);"QNZI&'^LL5
M5C+7IM9W9 %9FXAW]2&/Z^7R>^FK$\H>O7"C3XU;!&#$ KA$PI#G/'4/.7%/
MS!(O+M @F=_4N%"W"0:$\XK%C9R@-Q^J&^JJDD$\XC -RW05QC@E!CH9G)B!
ML9EO)"V@'9DYB^X^G]"9>&^Z "5^KII*[6LOQG6G.F&#VEBA75J%)G9Z9Z 7
M4^'A1LC&D>!5ZL1$:+(\+C'(>G[ .LW5&9F<VB:>\E+0L#J#V)7G[1%K5$3I
M-P,\O?37,W H'MP*U+L'<("9Q$B.\W:_ZRQKQ+\\/NBO2=1](\.IRR.7:/6F
M;1>,P:]2> ]X60L?:O^L/K#LCKR0,..>8#P^O'V'>B1[V==&Z)[_1;N^;D1#
MW/IX59)A)Z,PHXV@3L>TY19WX\VE#T3*@R1H?RFW/I%V@H,Y@EH_'P/IHM_9
M2<Z(I]'O7U!4FD+$IJ=\;"A#J4/5_S#A:N3R E,U)<FR3&8T@>OJN]ZVH8 Q
ME?AW3ZP>Y&I5A(HLJV,14\LKR;@]PLWK7M./?.1[/5UYKOF0PZ! )[N-_BSS
MD<&U7\)&,Y+]:WM,E4!3ZQ%)?H.8!=CF=XPO-U3?VT"IY9O)CO;3K^34M:7;
M1.L/@ZD85@_9QL;3Z,5''=&-;/+,SVN=:JPZF:35@/23SP#]>EF^@ASG7Z^3
M6<?O ;FNJEY14%=]V2/)7'SWDGB7 GR)&./!7IG50XNH&T8E-)^A9[,G-D?0
M[)9UE;(Q53X)>!1C(ZZ3!5]>5$SA?&>)BY,)9DXE$?SS.N_AZR;9J[H[ OK/
M(IN/K7XA?F=_>Q;72G7Z"'XS>P,NW^"D//0)_O75ZTW6M?3-S0.8JI2]DKL'
M5*BG3FXM0 ZIFOE[PA<N#0=^=J6E]!VE-W7L,D;=<)BVL5[A[?KP_'9X7K=3
M574?*:#XMCL<59'W_8HJ645]R^8O90IA4;M+AQ.J*2Z?+;5Q:R/UOPOZ$-AK
MS'Z]F<UJDO-92A$F\1G*,/K5]&^NSW_>F5_F\)_4]]OWP_+2Y$'Z>46MWP-N
M5 FQC$YD0V]!_WI>S.>:YX8SM'-IM)6;L8\,Q_Z&G.K\=YTI7!"C9:L/\J-Y
MY;"&1'09A$T$MFX;9L"8,0"+/Q)V]3JCTJ:-/53I,[-#E/IO+Y?%P_X,C*9-
MI?*;Q=]LKRT_;#/*%F]B9A>O,1X 7%8F5&_BCL35J#UI<C(Y/0ISK^/TT<1:
M[J<7&N41X1P1C5/[7A8'GST)LERQY;T$1$>S1IG3/W"(/^5E$7U<0U\1U0O?
M#OF$[XTZE%W.;:H8*>>  N^@ ]'OYW9]_6:H2(8L(CLZRMFG2Z:$*"_W Y6
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M/[1[/QH_LW+HG.E )&#ENN1*Y)E=8-VT/^H>$*.R38H+F"4I5-/'@F(VQA=
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M#I>,!8R*&Z._D#^#,,"8_?]- %!+ P04    " "O@'Q:NJ:$\ ^  0 ZLP$
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M$OR7]>UJR.TZ@)#R'M43L1=$U/JVQ!R>-$_#4PKN<RI7=] :C&*YQ-]Z?7Q
M0D?/P,C$S</+QR\@(2DE+?-,5N6EJIJZAJ:6H9&QB:F9N87=._OW#HY.SMX^
MOG[^D(# B$^14=$QL7&I7]+2,S*_9F7_*"PJ+H&6EOVLJ877U2,:&ILZN[I[
M>OM^_^E'C8U/3$[]FT9CEI975M?6-S:W< >'1\<GI_BS\_]PW0$0W/D_X_\1
M%^4MKKN$A 2$Q/_ANG/7_[\-E(3WGH@14;W0)[;UI.9X&GZ?1CFEH+KC :>X
M 9;VK=<H"1V7!(8;]Q^T_XGL?P_8Q_]/R/XO8/\W+C2 C.#.[<<CH 0H :X,
M?\3Q ?[_/8=PQ#%P)(F3X59@SU5;#K2]N:BA\3,'WWFVD]3.)[36SNB/EHA.
M4!VR$\2\O:R*"K9W$OX^6$T%60E_Y_[2_W4EGNEX\04@XG-0'*J8*<WZIRIT
MK<)>JTZV_ZBHJ"6WYT<<D//-_VXZL+1K[NLQY",X>P)3],<6D0+'\_*^QTGH
M9ZYK 45GTBPI3Y-M.MLJ8.&*W)!,?6STKG](^:;%RZ:] E<O)B'%1SUK/()O
M[A$><6'E3%$K9H&0N#J:Q6+'^B_H<S-\*+#7I .S(6O,0O.3:]:_5O=D-"^\
M*A0%8KZD=904H;Q4''.5@+_A^FRIFX\__=816F0Z"GIPS>-T Z!KH798$E+D
M16AJJTNV1 N1E9]F*EP\"OH(7*5(9(>');=H+UKN,AOB@WPQ\:2K!R7-+1_=
M3!]CM']\"-E&M5%!:I7Q>A<""^# A\5L=0K?4P-4$G/<9G]^X@L V"M^IYYO
M9?&[H_W@P04M29(6,'U.XF(+-?47=U QUR5:IK?]M$Q-8C9?%O[%.OU+H'MQ
M<G$I;%B/!*+L'G_.4[RT0!5L6HV2/$D9K"L^/E?G%%W_;,4P?L2L&CC<SIYX
MS8,C[EA@F=;V06?&7#Y[_ZZZP6Y-4R ]I%&I!PX%*0,CJ%/Z$U@*]#5[BKG?
M5X9(!Y7G59'&%<26,1C_6"PIYE.TYQDW1CL%"\_PA-BKAOH&R]X /E'WH7V/
MKA5P\\W%D!ISJR[Y5&HWI29-=/?A###!= Q)UD;KS)3?,>?0Y0]Z9-B-=H.R
M9X)++=CE=@H_*E>[Y"WP]P+EWQN2T:4+-)=D5#L%P$_\SIA76U0,Q2<3"<=T
MRHWB_2WYA5C<#ZNKL<LG$0A\+D[/$MN;!87+AJ839#9_NSYPHGL>33H=>+QR
M8?K+=)V]??AC&8Y]R:VQ0 JAF"V1>T :\V-VS"5-^/ZL6%ZK3FB2P1 6$DSK
M.-8U\*-I2D<::7E]SZ/-/N$OMK8\/K%UW<&W"J8MU.ACL1>\CF->0O3N4T 0
M9O78&T"XBR3Y7;3*"7BZTOY]JJAX0XILQ,(OF!PV>1>$R^RKF>W!W "(-P(K
M,MH9,^917H8*XCEQ%Z36-X#//(4W )N#L V>MI=7'Y56Y)9%SM?IKS]-;+S9
MPFR] 9MDL F-K>Y7'DT9]OTMM7-<^QHL(99. WZ&J,\PU70ZFSTWQ; AEY!4
M$"G@ N/FHXWLY5=;)Y_5?A?<.=-E_'=X7(5JX\$EC@]<>#IY/BBB#'.T2 Q/
M4II(F@@Z.6K*7NB^)J74X7K3H:@LQGB&:IS7W\49E97Q79@=.L*3$F="='NZ
M04;M;X%:#]TI%'7L*^JTL]JLI5LK0C)5@STO7!9F_SFRD_,@LI92WF8=5,YR
M$3I,-B0GY#\(!F&;NYAXD^HH&$$VX%/O)]\>6-O,*S='3<T-B26)RBQ!R5,[
M6V4-T^WI]>'I.1-R_D#F[F/1]&U4%..@OKY7\!]S3=X)]ZHYE_GHA7'3CCQ1
MO/\RB"7X\9>EM<:E/\5M9BA''WR'JIE*S$'#8_YK86+)[?R'H<^V O5V"GV7
M!I5-QR5=Q4.^>0T?TH=@. 2#EKW6-\U-_A23./LX\[>YJ:4ZHXZ#SG,9W+@3
MM5#0F!^;?2GC\:YR';XUTV?6^=JCH(>7,OA[2S< -&E7#7[&!I<[472:= .P
M>VBA/&/IIO=72O@%@$)K-\P^.?::"W494'$IBK->7AB&PLM=Y?>L)PI=GA+)
MUZ3\'GZQJQJ<)X'11U5 !<*H:DWV'28[.SU9MHU_5#,XZ.:Z?]2!ADYI@RL1
MBI4_D%+!K(LPFDL3?/&2'ME&8/F_'J&_AW-_N"HXS5 &1,]7#KK"MW=!D&!F
M+/E4EU+TN5]X4"FK[M9"D*9G8PSWUV_DLQ\4@/(#@M#,'A&78EY7(5>F!>_@
M3/G*;[HZMM_XRZO<P"5CTT#>];"4KNNQ&P!SW<+';,58_P*TTZD!2!>G(7E_
MQ0-@E>#BN[Z=?=CLGI0/%UK]9/HK6!:U6I?Q1,*K\MO*4\K/ZN?JGKI7R!O
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M'? 1Q7YYQQ_L-G7<B9?FQJFI96#A-B297I#NSF2\TZ%J4"5O^=[893*<#Y:
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MD5/ ^8&842%D^XC3:-1GU^O.PT);UU)E*(=<J8DQ\109N5%^1].]B0JZ,<=
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M>=G"#B$NR0E(NXX; /UR7_YQ__(-0$LUI,"\R3\*GLBQ95E.+M#?OV85RX-
M:,P=>'D])SP<=#+-R;*CDT76Z]?'AOP^.;"J-S>AWD)EBC?[S_A[K]P 9FX
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M(SH4 8C6KZY'?F*)V2LPIV&W$I7<5)>%DKW<5LO1^@%/]9MJ MMUYY.9E$5
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MR1/WQH/\W59;UV(\<;M?AI\K%-T^R&*2Y#52F@#XM') S*H3HH[%VK6S,1)
M3^P1UW$6(Q,M2L7;FTS.@:YY/ZJ__9AK3XU4+/20*?_5Q=JB2:-1_3*.EI*(
M]ODB0([D ,>P"GJ@3>'Z=F5_?AWYJ7^>7A26N&92^B.U?O9G7SNR3C$V#%N[
M3%1>ZL1=61FL8\?1-D0@&/&NO*\,<"UYM-\!BHS%W  ^T,VS9HNQ3I;9<R'D
M&JY6!A;8/I1> L>.00^=9+=?HC,R[4OAY@>#<TU:A@J>#2S&1ZJ)RJ4DW]\
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M.\]7IQ\28U#G!)0.D;,67L_5C@+V2F!]Q5C^.6IGJ6=:[WU)/T%F7E(DN-T
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MN!6G"!^FCX:'E^H$__&8MU-A9JWN95BI90$\'P+KE0^A!T#Y^6>4NY@03NC
MP.5PF:\[ =[="DQ=ML%D\GW2C"YJKY__%<,&YRS436R&-K3+9.SXP=YN!4RH
MBJ?Z\PMO,BJ@! 5<5!UP"74B)JZF/6 K6V9G"M;'[K<GVK9H*T:46N-_6$MM
M/H8_9W/$-+-Y%W Y4"[VI7ZO#PRW5MWO2:9R1$\E25@+'5U86VSW9H2RU4VP
M#0(^:=J3)<O_;#ADW[_3<*H_8@ QOQ2VV#Z8[#*+V7=54A .(0!C+SHG98^R
MYQ"WXB7$65E[2\SL)8),S^ =:<.USX;\/4R.TZM?M^TRSM!+1+LX0:MWT2?G
M2>@-@'=M>]CB;&%)J0?)'LPR%AQ2,+L].<\Y?C1W5\C_U<1*M48>Q]1=WCC'
M\5W;.8V.#LYZ<!-VK7D91!QL/Q(LMB1"U;64*-=M83^Q)#J&FJA8^]"K85VT
M>O]S@I1&^\IX$RU-0&.K] 1WV%295H7(P,"94PB%#1-=MJ!=#5-(:6UB1#'R
M<YN%J%PX:<)=BF?'/Q'S#T<D==[/F+:,',VT6OQ[2WJVRQFPQ+[S6VWUDMQ%
MW\IJT&6HG,=N%B+]O&7J[>3ZR-'T<>D'RJVG%FI3]XF?<W%Z7&XKC^G5C77_
MF$0SVPI&F1.*?9I?+V?QY6TLIWD]$_2KYH4JC0&#OBH-X'_- ..^;B3]UK4P
MCN@+QIW,Z3R])/&IY:!O4"D#J8:I)X#0+>MX3R#-\I^I@DG<(/:X%^I;.*-=
M,=UA6R:JZ-O:,N_\Y$\O.X&\79U*&;[O^:A#*KFZU9@+3P(_9*]J.3%->HY+
MC&'8W<)D0_QMW)\)>>L"1[ ;.J,.ZK3M(:WL5E48HZ%@ZLEX*;!RGIM;%]Z6
MO7>_XF- U.J*/@/(NGN9[<@\W#GN+TI>KW#[Y&"X>&M2-HTRK"(#M<IM=)[.
M]3 :5FR<W!?*E TV*\0]3#N8(YOY,=]MX:9Q1K2?\UF=M8?NC=NHL:2.39<*
M'-RJ=K*@5V<8E;=E'$L\\35<?_/\)*O\'_,VJQKJY,\+GK5YWU2Q)*0HEZ<&
MZ9$)!V2Y*]7:TE(D1J*^H<D8\H2^.C/=,IU/VCY\1]VBL0)\[A!=&=E;7HIV
MREC9I9K7K7ZBF/7VGIRHR*@5Z%,H!V^\O/V2 MM]6["UT!M'V).<O]2Q]'X0
MAO83'H0M+BK"^V=]YD,$5+NLK*-6N^%O^[D+L5*Q5#;M8""0T_!V_8<>%U,2
M FJFPU3>XF_JV=M?X5$4]?B#GLI\5M@RB,+)^P7Y7FN)A;9L=-RS?4ZU%#WE
M[XC'YW$F=E*E182BA(]>K% :O9F"#^2 RV-\F35==\U3EXQRS9_87W3\EC&0
MBT!]IM^H&%NR?NRDOQ5M7,/TKHBP]4(Y0.1+>/300SU6IVQDO(02Q1^RP)):
MZ&:-SG6EB' JQPU@+XI3*5).5-+QIVG3?&Y)A[O"W%5EA?13P=>:$OWQP%_]
M/U-#WWIX$%O W)<&'QYJYQA$F(^MCQ5POVM.VF2BX2QU("8HW7*L)3")&QZ]
M?%&,CYN#HNJ "KKWY%[5>U?\I"@0T*@"+U-T\RO2XQ]>=(N9\WP_V8E['$!"
M--ON"S@_?_W%K=T/;LJ/'>[3Q)'^#_;>.BBNZ%L3[00+#L$=@@8-[I8$"P$"
M!+<$0I .$+QQ"V[! P1W#\'=:=PE--)TXQ"@.U@#33.Y=>_4W-_,W%^]>?5F
MWJMZ]X]5IVJ?O?;>:^_U[?-]=:S/T/0@V$23U;.U>;UC-,DXPGS38\@52APH
MSYV(UH>OXLX;3FO/;)T5=3S.<-@:)U[]+-R_5U&Y[7M-L'\QQ@<6FX[-E41J
M)]UUP>X!#P=\\KMW6_SB7ZJYRCQ4W4ET8-P*UG+20"Z_M/IR#T#D\$L2.P9Y
M7\H]$,KKL$OUL_,.TK;?_FK!G*("NJQ" H<Q%'/+YDB:D/=-,_I <PU@>;2S
MP,Q723D_I2UV*:XNQ[$_ L^G",L9_$6'?Q;Y5A&%7=-K"^",[E?'VPS3DT9^
M5/>T<-&>YW)-2_AS(I49^<-:U)#K[Q+:"W!EZS;&,#2_;4G:>],@&C#S)>];
M;J]GR4>1.ZJ,8E29RO)N%I.HT8^%CY%W'[PRGO)QW_9I@+<,+J;I]B&4R6;F
MA\UDAPKZ&DRIR^K)HR%?'Z:DY+U7R>UUUK4,*O(W,(.&36YE=X@W$P(%^II,
M"(FJ1"I/P&YXSA<S8/BMO.@ Q.D>$'7RVP/_)%\MF:^C)%[O>?Y/7'\[;'@>
MW_.V'I4W*5;S;'-!31P+3A2O>UV:&P_9^J3P EU'63T/'<3JR!U,C]:XLBM6
M#DD_]=F9F7U)'=3^S. @JX-75\)'-%/8V0,72NQTW_PF'J\-[8=8G(2]B]!U
MYRH=Y<O'XK9+_^R>*VJ(?K!%R@@J=O"&Y$5X3,J^[&XV2W+%+;9-,TAQ\X\0
M7F:70QJ,'+N:GYORC2D\]/_L$M=,G[+F "S>,/G)PLDI@A??![EF]39D">?J
M0HX<!-&+]3Q<=8CVI!H>;.T1M1E-2FV>:=W; 5R<ZB0;N1+63!L7=OJ.PWOB
M_37A>90.@4R(TDP?EP(H W?NJ;Z]R;1-R[A\UU$I"HCDVAKVSII*J7(@+CBZ
M>1F381BAS$LVX/;SV>&C(6[<T/V3_5IN>-Z@M *3\;XDN0DG<N$")#9L]+4L
MG<-(%HS'\>G@U(*Z 9Y#,Q!/MMCD1\P_CJFV-"^6Q61'36KE;HGS5.H=^7JP
MV)P)'=O< IV:UD42Y;:DM -M$D"30I=#D9=EEW:K-3V-_CVROP,=KU=%XU=%
MO]MU"ZL3IAJ8R>N-ZR;#935;!8N;@W@](PS<*;9DC;'^?&>.J'GS0(7R?YOA
M"2-IX$:1"I2@CP%!0_3?92RSR1]QI)ZQYT:%50GW;1KUY\K>-7:R(_>&"6$"
MWK!L4&P?#?=(R+Q 9?47I-C[P-/;HMSK8\OE>P .UEV>9UZ"%='Y> T!AE;(
M7UIL.=[!DR>&(6H%\*E^4^1X,_>9V5+W@[OT((=1Q8^)-&NCY2A'L,7/UO>,
M9V+ R]7/4@JO>]8O+".7NNOX^V=SF0U2?0X%,YH24R>0XEM1X<RV!"[>P+6+
MZ>@@A)80X[[IH&_>@/R+6S/5#EV.9] ) :$:JLB;-M('/TA$G@6HJ!7[LZ)\
M;I^9"18AO3"D]*@YQ:S5OIN7V071'0R9,LQ^'I>.!PH2?T7VBXM[0'1(IR*B
M'W*DVM#VA )$XU4@+.<4K^IE5ZIJ-A/3A&#!X)_6H>!P@2"X[>14H@T?OIDV
M:?9JW-GML/1*[IW9/G"Q3.;<WGV7RN?)C5 T>OG@J@A<12]^="O7GB&7880
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M@%7:R]C6IK88+B,FTET??:EL/AECH)UZA,<]UX"A0PD-=(L@%.,N7,B-3:'
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M.>S]68FQYT*T^Y)5F?Y41>.E$%E!S;$69M]GYYS6RGFJM4>PVIX:3431\#V
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M_=.0A*8<6#'*%0F\-$%"!Q+##"$YDY@<(-/%@)69CSM4VTPV>G1M<B<IX1?
M:.U-X1))]N"<>3SX;;,Y9$P/<[G4#1Y9K,SE=0Q7FTAM\>MPH&(1.%T;:$*V
M#"N&TGL/D$9O\*+"%*,]6&C,5W->*.>0C!O;/1B>TQ8A;^@U)T]0$_\-I>V4
M13; ,X8UX[$&<MD[4"Z;\@J#K\5_/=EP+NWE^""2BQI6>J"QV^V]%,@Q?JL)
MDMR\ZF=B>;[(BJ2.=G4@:9U?34M89%6)+^;^T2LPPIP#[+IK['$TS@ [(;*(
M/QX-F#XBD%.I^M5KV\XSQC(2]? 90=KH:0>3".G+'Q=E4:5%VKPE94&>#I3+
M_-6-SLN::NZ/EDH(1-V^?Q=B<+Q(:S+RXSO]==ACIQ,31*W BJ9!)9;\@IJB
M$H=N<&X=LE3;/C\'N^<2ILL)ZZ9C7XR%F1L-6-&C]1%"QVPP13QSM'HV7&41
M$832\/"*^W8>P>+S(EF-;L06_-HF*4\9]1YI-W#)TA 9I7\)FK5=./47WA&%
M *EKF0^^[ZJQ&=.X%21B>P",XC2V)B6W[@'#0A$RD0-!>.L@/_!2>R($;52^
M:LK@^<;D=14?:4]>7L;>][?Z9=/ZY+ZOGGFO\PW]V=]9Y&YO:K)=R./G@12E
M+C8[3[H[9JC>R)XKJI47QJ#8?X?&\.0__"?V2*AF<B=^\$%SILT'(K\/UFTN
M7[IQ,F M W=" RD6)>?I'ZWMX@EPH:*C,RGS@8H$OWG*O('_(EF#_^O7D?Z9
M\<4@Z[[XJU0"?0/K8-./NY-<G1A><*:-B2VY5T@3S4:P/,-<H8R *F*_\? W
M22,E QF6+^K(CWP+CYA9%U^ZCHN]N=95>4S$^V1[,T#+VT/WA=-A[]]VE?X"
M&?#OC:H/E=?/S)\R>%H-<ADBM$Y1^C%>YOBL:>@'*V*_(&+I FQZRE.:$[S5
MS0AZ@"9WJ9CV*6<R,EYTUEH_AFF%0 & JA4EP .+>,HWZ^N__J)6_9_-V?][
MQB=?TIG[!R[%$2$657Z]Q:^MI% 8+,93R6Q8<@]0E(!>[?2@*N5J-#&!3CVG
MXT'(MP\"8PIV'*W.SISN 8%F]X"8HK&%GKW=50RZY1Y I42S_Y^N_^GZGZ[_
M/W15M^V(N>&Q2Z9[_/+CW9JM.CMS\<T,;OC_3C*DUW /2+R]!UREW .4J+PJ
M3.X!X+M[P.WHO_Q$!M#QO_S@I__ZK1X(HD/TES"E9UAR+W6*%ZR90+4\!:/I
MD@T]R%/'PIUQ=5KDDLRIZY%XPPTH*QCWY6457'U[\?B4JXV9-IJCJRV*L7<'
M5]7+B9M)Q![K]R'?'JV+^#V "72EBB#.B!$_QGI5C[AQ7#9R?\)5YO9'@9R#
M@ZS#?02K^:EXCA$XBWMP'=A_H]JFT%1ABF*K_3347QE=BYEM^L W'[@ASX.U
M?\.W<P^(D-0#W?9#,!G<B?ZVI:C2,>RVGGEQ3G7!&HXW*SQ>[P;!":(S'K7S
MEWJ-BTV*$:9&,9Z)CP_;=W;K'MA%W!C8%_#QU;X!/!K!DIX$^-E2;=%;EL 9
M6""! 4]NK;+N >IM,US=,;VJ[!$/!=D->AF3'TA;^TQZ_(TBVZ0%956[OI\U
MF,6YF-.8(>!*]'[;]JU-DP9,0VH/+SC 'FN&IQ9K0&;Q8KJW@]C0+)-CP4J)
M1L -O"?BP] 2X#[I#[M50)LOS0]VTV68(/&BBN=/&\UB.W:01&SOVK+$H9@O
MO?Z]/-9NO@2 6YF8ZSS8]'&89+SG4G.*<G,RY+#_\*9?0.)@MTV'DS"J3"_$
M($=Y>$X55 TE#YS9D%W&$%FA4E2;9OB%V!:<GJP[E(M-4^HI$+FQLSYE=:I4
MIAUX3$KYX,* "J[(@C: ZY!@IA.KM#S$M((D"G<M>)_#G\SQN#*0I_3)5TW+
M42'A>[T;#*@0^(-*QVXA1&F&0%-M-E<C-HV0#Q?6\,J;L>"O;N/?[0 S>$MB
M1A,0[V.7\C40RZ!OK+U,P$E5\9KIP.[!LM[H.STWI;1MX4B#UTS0I\='9BU0
M9K2Y56^[5PKLF,)XJ5/+!;3U&U( ?&GO13;.8_DF@B/.^5B)^5K%_[8$,Y=U
M&G,N1&(*"NJ_G$/-OVWO;,P:_H,  QV7BO&-1RC3]=.&<7TNRPOO2CK5*DU!
MOM.O$?$-H-Q[@$'GK.#Y;?9ZO=E:;QL_!V!7X4XT 5<+$$"JX@^M"%SP/<X(
M\^@H1>SFV-9J59D?T/RTVFAW6$I67F@<^P*[$50579A7X Q<RK#$7ZII['#B
M>Y5^ M6*U%W 6<KO,Q\186O^H$KR"WOGAS3E@_,<JK,]\#0=*._M#(9I'<2+
MV=+L6A(D'E.>GWZX7F)L3CZ3E#A<M<_"<.$$'.Q^LBQFCUMO>Q=2NF%F?V4T
MNP*F_*E^Q",B!:DN)G-?=U5B49FUE"\&[0W= \C1W' >J$X30F6G\=6LI8EC
M\TW5S\T, -=#1J*'*T??72W=*_R?(^44?X+#Q)N6ZA36O3V)3,,7.]AZ<A__
MIE5BB/BZ^8[D,S$@0$<%-/V["1Z@,Z3P:+%6G,DZP)2GR0360!]BU;+:VPK)
M8 .9B*8D/N=;*?]?^JUAI?X]8,1T&=/V=]?YN0@I442'UP0=?<^[%0!8_&N=
M%W/!/$' .O298@X+Y.@>(#>]9Y(&1@W H5_0^$%4"4U5 EV_8[N<"B,T=E8/
M#<6M\=IJ'.8J3,U3X:N_TR;XC$HB(AMKQ&FOG#A1N9%WM3UG$QB/?VO0W9(1
MR9P#7Z=>-9QS5MG(^\PP_NVI^;%U]3,EUM#B=PF+);H\K9)T?&(.^,/%;S=/
M<BMJLL3N 4W+&)^\J<1CSWM KMU9]1BOYO^DD =+Y]8B:"\3O8]9MKK>#9*9
MJ-6>AM>%"QF9V2Z]BY&G?H^#;GE0H,Z8#.#?Q/K.K*KB0.!>X?VHQ7GCHSC?
M7.%<!4>=GP7DTBC(;?&:Z1YPV7X/F!:]GOW7"#R3L)'KRHPS[>.4,4Q,VB\>
MBCP2Y_SHF'.AFO??5<Q4P?J_-+J_S/7_=K6I93F5$M3'4><+X&V Q.+WEUQM
M7Y]DR--PMPV]M=Z^MJX=3=UZU*:UPE[\;\TH_FL+#3P5///_6/1#/-YZ?.#&
M=JJH?(VS)*W=)=V!E( O Y$QK/,(M&64HCE[X:I00$]'W/A#DS"-2?TQ[W8
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M&F!#F/I&Y.3:WWA)5_F+_&[@W7%78)[W;Z#E5CPO._#9_W)R$JR*E&_D.+
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MEN5T W/;V[MU=R#C 4'@1HI<8\*5NU9+5\7 YX>&"6WB@6:9X5L S='N3^P
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M&W=0^R9D&N#.*&YY8A&VI?-X4.:$ORL5Z4XMQLUA?) ^%$@\_$$'8L=>D>_
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M-Y2*X"SH^IE1D@->50Y10J$T)CHAG7.\4B)GG+9'&BI4)D_>"8MI):\,1-,
M#P8#%/SD,)MQ94:$NTMF;]#F,$AI,U.;B^HS&Z3#(3"TOLAE>=N*>WNW;\*(
M,":WU+_2L-G;L"4R8";JN>\>T&71WIVDLSJ($>YMJ3,S"L=?NL!G7%O>IVQ6
MC4[NH(0H5V>TS?M/R<N+^,OS==5>::A3M/L8P$^VCS'M2^M?%W]E6CB;JC(B
ML#6R\-A']NFS752!2*'#0FFN)X?9"I:0DQ7MT3N(F7!EX!'63A!-41-(V0W#
MC\4:;@BA-JR6)"J HN8J=_KJ<*=E:("+4"(XLW[;?)G]+N&@H?TRL/$37##V
M_)3W'IOOM.7@^QRR>H)^3\$SO"2*VL)%\GW<^V)B;E4U"G8C:NR-;/A)9OW0
MHZNA.DK[!Z-\A+XD'057CZ4Y)[$+F[CUVE@'U(^-ML(9)AVR$=Y7NA=3VWQO
M3?P2)BUB^/X+4+US+U*-;6MA+)WZF5H!SG(PLOIG^OC6?X=Q.H.5\BK9J.-C
MVO6W;A81Q 1J</GG<DZ#[SP-Q^21FYXJ6-,+W$1Q4Q)K#"FU,Q3=S."'T=,K
M_X.]]XYK\MGV1J.(2!?I(D0% 4% I=?8Z$($!80 49$:0^@=HJ(@74! 08A(
MDQ(B)2"A1+J @/3>>T^H 5)>_.WS[NW>YYSWGO>6/^Z]YX]\DH%G9CVS9IZ9
M]?T^L]8RL/>52U70MW&X^,'F842%:E\]@^"ID?&:F"K/\&Y[!_+<G2LV3=Z/
M[+GG:0#&&C$P\?BFU;!I?/9W.'D68F J&1&[=:Q,Y]WQ5-_.VXT /T\N$RGK
MZ8/A%A2X5'_DK=;%..@5CHGYVD_,MQQ^AEQ=?DIW2?8'4$\X0=2J"_>CHNG!
MK%T5L(DWV1H]$^4IQQ/>W&"JHKEL>/Z)M(STTV!)OO6ZJY4E*Y'>A?F3 [L0
M)Y5#DA](IGY>]1I/@R3_1ZUQKV,;>XI RX6/OQB^=/WA I*UL S:6F&G4/\M
MQGK0[\/>7VF B1DJE^]!#/F@_DB5,7_+Q('Z?6:\ +1'^GVT_,\+?\=?_T<[
MVG]>]U=VCW^T8_3_&W%"]XGUNTX]5$687U"6-WK,$6'O#&_P(N2'T$<\75@Q
MI=('=7J!Z"[UIW4^K.@SS+[ (GWQP=#<1M.U =7..>ND_T2B'_O5ABI0GR6E
M8]@;7[@@46]D$E@N4SV*M]QK4!==@!(8PCS:1,Z,6R\E*1#2SSM[AR5H@>GB
M)/4[>Y$+_<!#,K(N!F1$ Z >(C>.GA*FZ5<?13)Q@F<L6[*# H^,C6)@XRD9
M>&8@T_G<BR7 LOI?'-2^H#>0=!WA^[5,Q\AY.?^9FKB7Y_FSGK4EC8A4(,I1
M[;M*7[^I^.@?*NRL0S%'N-@9LR^Y"]IEBCA:!/T.<_YQ-S4<E&_6IJ2*)_::
M44?B9Z8@+DU[&/T0_,1 AK([8@^1K(HDB6T<T !G:8!*V)$Q++GJ1&K;/1DW
M)49$#4WK!D$LUP._T0#F:U#H'V-AIG@:^:,IIVU3J\+^,%,#F7)50YH&:+E"
M]*:\+$1N0\SF G/(OW,)#FA2G^#O4:4,@H)X25_52_7P0][*%RUC#\MV,6UM
M8-)A,!4GL\6]398D,]7D;ZH%K)#>;H.@VC?US:<#M>DH/']U(^D?/<(K:GPE
M07:/C.>XYAP:8) '2!&4]P.OTM$ %P<BD"OKOVF+]]31*%GRHYZ?Q ($)8J=
M:21$;:@ZOPO_J$+Z?GV:Y.8%7>WAJ8Z]D9BWAV:+),R^V,P2\.>^"FA3-BF?
M'(->Z: !'!#[%X.N_<5<#.__T7%4T"]9J&(MDH]1:OH.M3->1#\.I$=2 QZV
M@X@R/P\L:( Z5 8YIF,B%+AY+T"&!GBL#Z6<Q1[4J9C-;M17Q0!)-@[T^-(U
M%\8FI!_V('=A&?AO,Q%JTXALR%H\&L*ZEB#&@\^4@"/<=:14AV!J[5\,Q1CU
MSQE!L%_#=>.;=%BZCOJ8P, T$CH15[5^-(Q(&J <NNAI1P.L3\CYQ9 Y#ZF:
M$_S(@;&_J(FH@*C#$[IN:4!B:"R3GL8 (G6C'"CL;]9G_6?CC6DTP(\F3-NF
MMA:$NL2.FN^0W T]4CEP!G%X4I^<OQ4\M4".&1<XTD\4GAII0>&D?+*K1KQ,
MDSL#:0BC?)!^J!^GM-T8Y$G6$/'9JJ^\(45)/WF$E0M?UN2$T "C^7[X'\02
MQ%XX<N#^3MQ_N@($N02:[^\<VB);O/I *\,3-, -S"?\HXU]$3\,)<26!NBZ
M.M )*N/4FSCG*7M= C3TZ8?IC\,T[ ;^:U62+B'%Y/3M<V&4(FG]EM*%UHAA
MO/9/Y*RF?K=8ZV/DK"WHP_:8S]Z:*PT@>@3WD8?>-$#WFY7>*HHV-?#QT:[6
M3);\@8?Q(P0F@6&ORH@BR,5]VW@QJH;P6C@ILI*R&T/*V,]8=(6N[Z@#9P-
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MY+<T@ !R\#IT#OH1R Z:#2),4%[!:8#M)P.]A(G#!(39OI "G$H$'RP'Y=(
M?]X-<*0,N=4-/CR2-V7!9;; T(?Z2 .4<3=X0\]Y*@N+Y)8%QV4B&=)_DU([
MDOZ@5P=Y>C_Y5LY\O/)LU-?(CXF &)&DZI<=M6K]-Q]=^D,&9(MP'W)55H8:
M%O+O#L'R[JZAR-OQ5#*>9!8;U*^"Q79^!W-J"U2X[P;0";#O^\14<*]A9R:P
MS>0CG8:#UB9H #UAS)LV_(3#[W*R1B@W=>-^%U6[#DHO\K!&QD=^<,K,I%SD
M!6K?07+[\(]QEMQBGT22$V7H:8!!BQ$:0(N)<A?S91H_T[-- 0,O4;DH=VF
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M-I] 5Z>2C7]\9XGC?IA&[RM3#]>NLU8G8"*NS!$T$X,+EM 7\#UVY=IW4FP
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M:E?=E/B3:WXJL6!]3[T#1>^:UM6#N/#]#5-2/)'!B,C>\*8T\+9><4^51.W
M&D^VK@@]\XES,R3(E<!O.6)->"Y2!Q+@, [DL;!&8Q[*4\;Z?EH_<Y5(M)28
MM;_$M[.=<2A1'8\KM_+:\\7VE,,B*(_JQIH3S:H3(\8#R,DP\MC:Z&X40Y.%
M8AB6U:+Y;C6OF<61U6!7'2DL$R\&DM8!;*M?5_JR@P"2H#=J%"QRPN2B% @
M@^JQ;2/=X%]K=@S)F\"A=U!,1)"$])=?&IGRKWG9X2BIS)\IX0L?.5<L0R/7
MGWVBI%=9)J6=KB+&INA&*Q6LKO&X"[R]N@H>%2QGTX)E*\,5PW-OK7>%!\KC
M8ORE<[A*<%W?C1K=LBZW-T.&S-L^5^(K]U &UJ1XW1X/;._ZCKZDE?QS25_Y
M.A$Q]:NS,RBT;N:*A1?>3GJ[[1"NUQ5VW%\W\6'+NN+EBS40\ MKA8@ILV#@
MZE6GLR%A@>K;:8(U+L8ZLQ(F[$HB<#5.LOT2))$&X/-05YT,C5SH]N F)!;1
MUV)Q/:?A)KB$6PS6WT_G1%\K(4K[/K@$W/7=JG&VDK)%)^S45$XXO\Q!];["
M1&:M)HE=-]P+VI#5'1Y^UC.0N\T3-ATHT) OZW@6&YWW5:'%(*'UKC!":]B0
M77#%L.8^23CP<X Z"9^]Z*=19)\W!,/)79PJ6# WD;$!?SS#SE\/;*K)#+V'
M_1:;$3[/;Z6EE_D\EF2&BJFE&&.N2$]W.V+M*=8+F'=VX&OU%;VZ!HH\\3C<
M@/9BSQ4C(\C8;:_7GY*5WYWCB0H&()D2J]IC7.5V-/^5#'C\._?0/Z-_JS\=
MDO_*1'*LENSB,$6"Y8[J2:M]L>:-1>?XF'.VFWA?02GTF=J=]V2"Q9"TU*2R
M FXEZ1"",!H56=E1\RV7>S-QT4-5<TSO1;Y<J1 ^]SRT"'.#E(XN#PVXX!J4
MU/6PRNU.GEB9(J.+>=T;/?;W&V+.9K$?=QM]0U=W+K5/A'M6[E24]6P?#K(L
M?=;DNVMWX\R#8US/[O$SGIB-_<@1#MC#B>=95+>OH>-U']N5#YQ_?L'QSJ/H
M!==/S$%/$)<KO%^D5BQPB42<;[WZN$?"'2I'"EFX%]]<<R&QY52-Y!>1:W7@
MD6YPT3G>5?BFQEWW*K0?J#8^JRP#@V*+(>5455[CB.3@_[8YTM'D3P/DCVU\
MW$H&[)R]7(P8'+<>(\UXW^V[LHP<*Z4!:E+(XL<IW+=54'MPT$;V$=Z2/8(*
M7CW4 P3A$_.V"<L_+NO(H8R #Y?P=<]ENA[\XZJ,?U0%X#7O_?VJR/\6\/]N
M 0,Q 0\I[]5DB<&-C(7+!R&Y,(^RI6=G.G3Z%'*?L/$S=O[T'\BUOT]=RZ%L
M3TQI>8+6AY$3!E3NKML<9JP@1RU3.Y/+MTI]G20SPDFJA-N:I,NVN2,.Y=X#
MCE]TXGX@4OER[]UHZH-:;.NEIX(/RU![/<C7_+U'.-V1!@A4)#WH1QM7C>D5
M;@9JG]+Z^.!\06QCT"\:8//VW\-?N02H':&SPWKD+D<Y#= 5 <VD 7C(JH6D
MRBE4F >$#WVIJJ8X[E2\KV71.3<M^@#O*>"0V+1I[#1:Z"!0NN]1656X/0*;
M6Y?_TH<LN;;)8L+$I_<U7YYG9&P?J/ZA*]>XZM*ILJ1]U">N_U!#-:<.[F^M
M_*_/?*0AG\DH4GD3<Q9.G E,9MGW;1[=^XW4VQ?($G"SU>GCJ)$S1YNXR+E]
M(S^SQ?T8\IM<OSO[=V7(D3E;&BD8(4HA:':"#*8!G(^PNY&@7^+?M3P+Q8;5
MT "O&:812I W1]W?^EJ&G)D&&?U'YT-"J0PT0,L3 I3R&HW??H3I;247D<3P
M5!X:(#B@NI(&P,*)E=D!M?UX\-;?9\8_0W']G7\]KGG ^/=A"_*G#M8@R#)2
MVAVG1 XOU014S:RC+/YKKJB68T=8_6M?4,=Y24KV_A9CYRA4[\"B=\RVYM<%
MNO)WNN0M:],C0T>8:3S'F8[2+_0Z_ _<;?5/D'P@TCOIWV7"T[ZW_&!;F*OT
M'D-$\Z$DR5F548Z(7ID8BA\-S%YN7M.Y4!$X$K(S-)+#5QC10 /0><"1UL$6
M);V>8+9EU^$(A6_=8@]_OGWQ'%WQT$6)3.\GS[U8U<Q]V5TE^H"J>I FY_:L
MAL,EBBL1]7K-N;]RI'+=-Z%Y=6?*O 88PR@V/%G*>YPPKBVN*!JTR7,^$I4M
M>5N?!,I9HDIV!6@JH/.<5+*3X%)Y[;X2RN^5GUC</=\B$'WMQ??IRF%)Q:B&
MTIZ4?AH@.F9#/MKL962&>+=N/H0ZYATSNJN,I M0[R$?'QYY"':_UH>9N)>R
MQI+S+!)PP86AK3D Y9>331;OVI[@(\4WW(*D1*3Z'4-X(F0OOSK/MW_CGN^>
M:*6>)*B@W]EXOE^OL]V1JC/VZ.ORU="+I8(#\=XT@.)>FBX-P#*6GO.J=(.]
M'@V[!W'$Q3MYN3?+!3T[<^YTWET?IE.C2AVZ\^6\DSL)>Z%8=5YH_TX,U^ $
M?>MR3T:IB(=#Z^<UY0TK"G=I$>D#0J-\JWK#?Z.BG26''CR5C89!(/(P\_RA
MI>R<9)+_I&?V"_5<#3$B3P8,)M",L/7U0;,\?H?1O/F1KDGW2+?'2RDR=3B%
MT&Q2L%5WCUZ<[X7*DHH["54#X[54@P+9GKGI:NEPL. ;YW5D$FH?7R6<\.AS
MA0E(:B)^?.]0<ET)?X(LUE7%G+7<7^8V-C;J5-#IC_0][SO_Y%3+LV.CV]RP
MJ9QZM.H4XO7,K]**=6<I8[.DGY6V]I>*4#C VM(]$@TPW1Q"Y6\4@"7%<,5)
M[X3P)6M+?G3^OB@[VCM^GI0R=:0L'\/.!HNHH6!PM<[XX#-1<^_GK7G!<2Y^
MIG$'<P[CNEBCW3$T>M&6?754;HV7#Z>[0WJ ]5[SPJW;DB8FQQ-FP!Q#*RM?
MEOV$L'".5]9+]Z\X$U%3\-;O>VL/Y&.>^VGD^&8O\QS48+.<=DU?MAT:MBXR
M+KSQ>EO\MCF^XUAAZ'<\EQSP#<*?)T%NR?OI=TL+ZUN_VH7\SD1UL'J^T^>,
MJ)<W-'9LUM?HS,F9Y*BU'1S$$<+C4JH'/ <,TE+0X"M)N^Z$2A^-@?JNMD#6
M*L6V+]6MK=F^\X)C'W24=X_C5(_6F@/KC!D8GK/-U4/&N;2\V_J2[695]OE$
M.F=OUY48IU7Q@JRH!GUS@QVR]^%J])NY]THB&;I2^$W(R'KE8:<L\KD*,QG4
MK78>X0E<I5S?D?F<XN=;L/SP>;/=M2VAYZ:[P83.NX2-Z)T-[I%.C[V#UHM@
MKLAL$>9(^+&;@JKQ5IZFO5@!^,6ZZ=U-VW)L^6V1XG)-HQ;1T(B&!U66*?/5
MY/4>I+^.<-+DXK?>!]VS6)3S@^[#>-B\[QSFN]3)GMJ@2X16Z^63;= *1;/K
M2>#K"E?0KU2OGGS@>1(+KC,XOT+EZHO<@RN&7DENZK_>5JPS+,QQG;5"S%']
MU'PZT;L)SEPWSM5=I<F;DN^8G%H'&6EQC$EQ%?9NCSYVLG)X."O@J4V[46GF
MW-Z0%O1UO/*7*;?AN%V/)RGA$3V?*]\A!4I]G1,.08Y^YZ:.,.%IGY>=NKQ
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M#JD"&!V6_<AR\(M+_#N W6EZO49JT51EKA_EDO3V-F(^PTF&X>!RG-+/XCM
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M:%38EWS#I&A1+Q;5A#8@;-2[-_X/]MX[K*FG71L-HJ @H"C2B_2.TGNPT$1
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M7;I5)9G:LUK,@XI)8M[@8VM#;!O@UP.YX0G]!V$C.Z92VH;$MY#JE85(!,<
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MIGC-;L1+-_A;_1Z70FOA9X!899(O:9'$G,TV3<_>%^G]GB8$;LV>\PT ;:9
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MP0!V-':'F58EH!79]#9<]WD[,\777BOAN8C'0G')Z*@03]@W9QB=Z2"2-&6
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MXKS#00)Q:X?OH;_]DY,D17;N^52 NJLS0.>?9(UL=_\F>?3OJ%F+Z7MU<"[
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MMUD.R'2D%<,X*NDE:2$5*P$TK/S.LSW,@0"#W*Q0P&%&B.=B\!'%O<TI@]W
M^/:>?!-5!O@/CM ?PW$T=J3U/:T#!LSDWN^R\)$^6G(D_:,+0P2$)Y,?GM<[
M]RD![DI'/V/ 4DTL;NH:Y,?C!E0$F_(IE=>5F,W)OUIE%D)*EJIT#=W9ONB'
ME4?<\-?4<ECPXRQ8AT3WSKHA56>W>U[%A@).\K#G0I /^:8V+0_&7.8U]'+&
M[4LSM&-\?\647R B8%%)ETB2.T0MWR/@2CEW;Q#TY+ZK_5,]RQ>6M+LCD)F\
MGI03R4'&==9)#J5K5KCET1K5] R9QMSC*6NP%WH:?K )%[C5;] \E9"E]X(K
MH6BZC]<-6A6)W:2Z7_MM3J MXNY6X,T?)_ZQ=VB/>IFC?Y*_0,*_'2W>XRP3
MG2=1IY0QC+DG8/W>\#LO2>_/HO25>\HWF53:Y'(?OKGEA5]*Z$8*.N!<([XF
M2=([#&^:2F^TWO,F+'%/Z*N)D%'[KNS*?[0]+^X:4T'_Z:N18IL< =DAA7'S
M90S+$Y;P@'&Z3!ODA7"GV:)&C9^=T%F=MG?G2GJ:DP+=7T[N 8L4BZ+86!!H
MKIMTOA!7#E,6413_^4MTU;B"TNZFPR(M\ FJ1OX1V&F;SOC4V-UWN"/QT11)
M!-A<*(G>+E2*T&I X_/2_<AY<.&XLS$0]"1EF\^K@]0^?)BRI1M+RZ!3H_B\
M2YO'/.[+I!_C&].AA$F)!ZKTKV*ZAT8*^MX3J1"VV'IR$ZX+D:M<,HVQ3>:.
M>C\5#"AN;E#--]QR&O1BT&0]L4[I'GW[XP%=( ,#:*3F"V2)F4Q_*T KX-D8
MLI6LR2BWDIAL.]6E]!2 68R$'@#/Z:^195+K4:RG:82;YZWF0]42&UUXHN[D
M<\/';JY_%!W7=$P%7W_NS0E^_VR)B0=H+</XV3:#'-M,W3&UP$['66<O"!&]
M2+=/@*R^CM@AUF7<BBS&@'6G/MS; A)ZZ_C<D[KCP)CB!Z4%CSCGZL;+JUEG
M:#>T[&"R36B\%2VT3FL@]&=\E9;[':[PX%\F;)5!'>I5"2/YD3:B(0M@FY2!
MH54W^D@"0,#8P]:_L=4R1\TP:6Q+L%/>-62_):MO\3"ZR3J&(XLUX:;5#5//
MG;]$92BVY*GP/$N[;+HU7HROAC4C>797NC?FK%A0>=KS_#):-;/&[S;.J$A&
M8&'AF5[< \Z3>W*C.R[R(G6/TBDG+<&/"_E=8RNJ[.( ^;R^-4B$^EX\1:<<
MM\U!1XFU[G%"+9JC&RYZ>"?G=4G%<\=<MMXA#:4[RU1'JK14\59(@0>:K1*3
M",7X9B3["<:PJ%7.@U#LE^=:C?MP!_!$RC3"%+O[\QH\RF)W)@Y7$!FA\O3>
M[OB(TF=+9&Z=IR;-1 FU4]*@N&J:QS%&C'OY)7Z^1(V?!Y+%6.$.1V=O?31%
MZ 551PK&*A-JU2]"RM(A=*8,6'O2S061/^_>58UB2=>_(% +I]C2F26C[X3,
M;(Q=M?O+4BLN958]#?E!8E$ ;Z$Z=*H 4?PU;R)6U8T8#]9_N>Z[L\XE=_!L
M1]V%VI1:S&N[H,S.E]B]"(5BT>%(D!&W("ZX.6 T'-GT#)41 F^Y.;HK_P@?
MI@ ?.P?EV292N_G/O6!XJI[(SOX53>[I*E;+]'5S0BN^I&GJ)+7NMS'O.(<&
M->0*X&I\09$+IN@^QIV:?A4+:VQ\ZP4F*VZJ[5S^;>18WW:I4_\Z^?:>F7NN
M8JP$S4>':.4ZV)-CS4?HA2HDG^&\^(#&"+9980OTN6F*^H]1'($B)UO]U*V'
MJ>9LM,-BN_&=[CV=)IPCYX;(1C)Z9<-YULW^12/F$[/L/*EE#!97MN GZ[I^
MJ7$%N"8<%8^6KP :]R:$0GT9:S!NG=^0P<KHH^3(-+-*N?5O@FO?5"I% !4]
MS NDY:LARY]I"EI8U5%"MWW_2-N'5>\3;5WRCEX!D#2)KZ [,#YG)S'$*Y'F
MJ8B*C-_:!ON=8<,/3DP15P"")O5"FA9D?=!@_X6(@*<8=W_)>R2D$084Z<H.
MR7_N8JZU>2B![CLRCAET7[TFVGAM$]H S=%/U0Z0Y5+I.\BQC\*&JL(+W!YL
MC@06=N0J0XX4KTYMH5A*: ,TWGMLN13<V0(</1= S@LA);XUR=C8H,BDL7EU
MAA;^-&9U(*>OT>E)LB2G)N\-N ACM4-#1YPWGPLO[!?Y--(A\XJFBK5X$"/S
M8HL-RL&^0V^ZG,XXW0UXJF?$OIF^CC'IILQ<?\>V"G(@!'XK/**59]Z4GO1'
MB">N@@>]:X>)\CZJ]<*#?H>7.>Y($=0OH1V,$MN$&/ #R.!V&#G>X-HV7&&"
M>T<#3G?C#"]2!AR-4]B$ Q;KRFJW49=57B[V+@[H%UU.1K.U&Y8Q_ /=/MHG
M]51E7!1:+OG<B,&6XM;"8?]NK?S W#OS8@\S&@4'>N'__=I5R7ZPB'M8UR(S
M5I/:UH1\HHDO#]HN0I[(C(/%-ZCJ;JY(3N]VSQ"OV"P^3.F4I\&O(C,>V:3?
MF_#6R3?<<'-](!B_NA^IRAF1*#.O]"2H!K[O(0CK@TSB]BNB)/88U62\U';V
M[2Q*2Z&_8)C1PW9Q$^ ?YG=C1S[*6H_@9 Y,F>YHU94H(=M,9D&4:O>>O):P
M2'('/AN*A*CA/"OJT#Y9TYL4* &))_P6X@.X#?B*F]3>'>+)!C L++D9.P<"
M,1,VZ<C]?M4;V\>8(AP0[O>ZF9QXU0C>Q?S0'8:R#^+WEOF SNAL$-\UZ%XM
MLPLL#Q(-79-BB(Y],*+Y3/]#^6&@]2O=2G#1%4#DDYU@O)'8J\^-$-'F&6C,
M49?W#)KHDE$$QSDJ*,AO/IYI2%\.L? )X;1;)72B:*AGB94&:-J>:K08X!E1
M&=3>PGBY+'<)$/X%*N(5F'LMU.VK(8T%A6A4N.C/F&# BN>D\_NM-ZGFX 4Y
MK4W!-7QR:*1@O&J^G7[I T\X>1_.$NY7D^(NSW(-/@)+W(X?P8.Z+.F.X&#&
MML#907C@U(]V_]R0_@3Y^%&AOZV!:9?CTZ"Y8HWZY[<Q<L6&CR,?A=)S/"W<
M>ACB3I2%)L3'=0.K(X;#Q2B(;"^I1M^U0V=X$;#XQ!\F=]RG=]MTKP ]ZL:\
MPKFT_:YX4YU+2QV,Z';_=YOYEH^7M$*#3,<F'!C!:R_1I*EBE-%@8@L]&.43
MGQ!*)[4AN(OR>.N+?IY#3C$8J>@%<9*7&RF%-0%]W"[";$JVQ/_(S"H[D?0=
M$G2+G"RWOCK4_!2%S"MFJD&JP"BO49<J9^*0H;(0:2]#D/NTG[Y>>$ D=@(D
M@.X_TQGWILX?+-E\:PU?5?&B4:+D?^!'_,%8_1HH_^V[)(W_],V2_W@EZ3^I
M#3.49K1?!^II]P2(+R/KK8F/#ESI2J_J[DH(9<K,RK<&>F1TME+@PW3Q<2@!
MD^%7#<ED$AT4-OFR#K%<=?&1Z/0<OOL]N5XU5(O*]%K?+W*:U\'@V4MZS:05
ML\I^R5"3;B94JT1#;..4::NIMC<,V+9X#Z]N#VH_A<Q1_W'7DO$0#&"< CE*
M'E(9RL:_7B)/)0")#@?%FG8M%4-$V@P2 L$7Q?8.16G/ZA-W-IOZ6%>^U(<!
M/.'P5Z>.H4=,3B9J.C ?+Y<I0SM8Q7(9;7NWR4ZR<4GCHKIHP\BL2_U!;132
MGF;K&,$9Y814VY:,ZW23GLST^?SP!;N?U#<AH!LQK63?KR(F>KP]2D#9%#UW
MZ"Y].F90T]#8/%[3>/#4Z<E=L[>'S-'>=5P,:&):H-%;T$7-6V.E.Z93I>?G
MN%G%Z<'/742H=5V-0;OLL81Y4;R;P=99!JNW#-X&14\__\)HPAE&.0R;G362
M4:IU,+C(4A7.U5W_[1KMUY7(+46UV5H%\A<ZY\K>KC3>!$F#U7E[;(]';MMQ
MA=]P>_7E!]&<RGRZHI<+50*71''H5R1W[J!]/=@\F["CSON6@<L'SCFA5A"'
MY:(A8M&M]%*C!LT<(GC.@^(+0#*:,3,)I;$GCPU6[?(>\E:_0;9\6$EZ^N<&
MD4ARA#P-^-"FA:_QCS</%#DH\JZB9I1U3)#B].60Q0N!#A8N:P"3ZCZV9[):
M=W'616?W5O/IB8Q];;)K8\7@93%R'O9VH[3ZW4SQPE2C)@A7 JLX4(YL(B7V
MKU[\YCIB4PJV\GF4D6?C8/1TW@/8UV+1-W!O]HM]+A@/0VH4_NQ!G0')-JB?
MWQR!B((?U89_<?P8K_X[X[A7"I9=(T1F(SV(C=_%I8$]W#YVE>:GLPS?P6IY
M.C/RO8K:30Y1ZM\OQ;FNJJ$C6TJ $\G"W_=VTL8_Q8]Z[Q[MRPF<%_\^:>UL
M)2Q%8312/MC\U'3Z:8V@ZAK8F:_%G;3_-+H"/+CW,.9RT-PZX[;W"V2]]U/Y
MF)SY%R6&>-<MP^(IR[Z&&-<> O:E3SW]+5BL.M5WI]3G46P3'HO&QV>+R.D%
M;[& >&4M:9G%E]5P@=*\A%6U_;WA2%D9=$J7N,D]#%.FN16L P7=V:_Z5#^V
M7/U@WT5XUR4>847(\I2T9]4D"2WR2SW76W$"^\.;QP.ISB,Z#>%'MEP!#)\*
M)#&B5>ZZEBEZS3_<7A>KN)?*GMA\8I-O=VUSKCL=>I\8#70><YY(R]AB)_=U
M6FH]9USEW^+#EH#W\"F=EUR1^VVG0;D%"UO1'.F54O":\EN.;.LR4;\I:-IP
MQ?(L>& 1&)[.-I$S J-_TS"U^ZGZ^'U;Z0YRFNP7XQ/M]\SVGJ<)H07K.C^S
MLA^6YIL* ?=*@;^3/G?3Y>3SQMDGP2LOCQ-*G60DRN9C#N3KT<.=\KP8C4S[
M8KS:FX9QNW.50.SZV@*CI"1)A5,O@MS]:-^D'M,PI0=]@']T.J#0/%6]*XPS
MK$>6MT%%E<]25_RH?>_()\&,LBK2;:3COJ;J9"77-NMD&,N6.(_VVKS-U4VU
ME1GL@EM 78T&\AKVO6J]JW*]!:>\524"6::J2>L@%BWC-<WZ4J1K3SJ?Q,HY
M1'VVC8=W[-^S:6#VW\':W]Y*7@^.VYVBIA/()#&OBU4Z2%!007QQ-9<3GL"F
M4<%Q$_:KNKNPX]HIS3 HN^,5H)C&RS1M4?U3#9QS:Q(\-PO1/["*\*4!-^15
MH!B9+^]=O'A3'VTP@_=Z)P+-LJFM* I/Y'I<+K7,OH[)Z+X"W!%+LV6FLI60
MUIE?*)C"T;D$CO^/]MXZ*JXNV!?LA"0$2" $=Q+<@SN$$#QH<$V0($U#<(<
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M.7(8K \=^GO 0,_^.>RK8GE\@"V8R%@ZG#%,%J)BY):^#^8/K%RK4W2OQ3>
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M29P*"\K&.*HDR)97.#7IU9?LZFQK*,;D%N<<<@=(=01=G9\=,V&FS"[/&NX
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M3$VU8@SN'A;32<5P>%Y-^2QXHI/HE*M0SMMFL_+MU$IXU!MY<[4OGF*1'R4
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MOG1RNRI]0[L0@'+;==4\N]&[N0GP#+!<EMX:]%_WLK[A!X>T;%UW!J EZ^\
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M]?@1S./) @*%+0;VR)I"_S5;SON=_0;9EG2Y&[U?#WBQ)X;07876]QS=PO!
M] [;\0?<7D@@6B*XYU/!Z;J+L >B*,BX5YLX^;5KF^RP[S:!/& D+:NK-9S
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M*F ;H!3K@;=$JT5#3>%GN=0\:1P*NRRYTLP]/0=L*PHRPV--;W<[EW;V0H[
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M.-O4J$2E,4D+%22X,17M%8[3GJ<2-6ML2E STG86H&W/B+6<$<D5+ZX0&D\
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M=;Q],,";U[Q=(:GE(5S[[N"6BS% &^2F9<^BN[*<MG<)#MQZN\*:NAJU[99
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MIFC6;3@9SG !PUA=:.J(4LF!VK^AIQ'>V7STK*F\][$*-Q_,*H%J!D LKHF
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M(U4R<'4<$,QE/^;QDQLL]TQ;OL^<LN39STV?V6EBU;S4;HWF#$5O>UL_H9,
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M)<9QYP!OQE980UR')4O^!VJSA_?%/$=T?ZK/J@T^[AR=R%33!E6=59:.]H/
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MEL+-,YE2D0"OB-(^A6N7E86Z!B5C(ZI61RLH?EU/U;'"J8C;=;_[>M%A77O
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MAFN"6]G3P4,X;4B$+9(ENO@6X 0<_PD[/@-&7] 2R7A"KY_,8-T BH$'0;>
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MXRN^+Z)C8/9GF7#Q+HUTS ?80EC5.;G2. ;M,;(9IC(XA2)HS<27?>GY#+>
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M!@;GGGF'16F%S*G(8] #CHU(%ZEL9'?-*=8#0_,O_X.<T"W@GVFL2 .1V4E
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MYQ7_JH8AD"G5(VYNN4$XK$.Q^^9N5]R6AW;>DBUAZYF^TWE5D"F(.I%_]8'
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MXP&>GF!T'N2W>-G?*KMW_/N[JK3AB>18%S2_(\$M1?4>6%WF,SGG104D<Q:
M2?&=3%^CW;R,A!8 EQPM0 >[/FB [^4]F"PS\AGMK';SUHYH&HJ4,1ACC9PL
MG&S\C(?]ZYN1]N%"#.\!_N>"6!>J&'>A2?4_&?$'#O]3EOW+FQJT2 YJ0BCG
MBI&I!0;Y,32@RE!0\S %>*ZE6E-Y( +F+6L@[[H.%TX5.,F*)J9:)F?,+'%;
M\>+XO*<F,UZ%[25@W*CSVB?4D/<.+F3 (/Z&NUAP#C5KIRY>?Q*C^>=G/65C
M>&UW1=W!-N.OFH)&7=XIRXO)(+U[3:6H>^@($2\K8N2^^W#HA92\?]=4O3$+
MYW@9KD5JND=@O8"0@<!4F W4W"T;6U8S-!ROIA8K#@I<NTYU$!K5A@;@KTS8
MIU<F=@K+&4HV97\L+#0V]N[E.H_\EE5??;N#0].+5,;< C@\D=LAA3$":;;4
MU,-?J(3J,E_%;D%%H@'!!P5O89F-:$"4&Q*8\EQ(^>JP%!% G1T-H+5$+8.>
MJ/UY^93PM\T$5W#^$DM4YX-LSEZ<H %#$0H_,R[^.4KX<Q."^J^\@(+-V\#E
M3=HLY>N'*E* OUA,A63 "2@*@8$EI?"4W-<4Y#Z\QG\2P1>Z72[24#;_YSV;
M_P^W3POS/!X1%\L*F6%T#=27SRD7QI8G$A59UPN03O8PSA *K?=+DQEZ[KS=
MA]:B?*P=<\<K0O+"[91,SN^,HX>EY,L?L?05'(J=H/:RO$#NDV\1H^VI7%$J
MB "WE\=RUEC3AWK2Y^JMLBNQEM\(_*(>GQ;*_5 W%9F4!+9S$GP?MM:4?#XR
MO]"F^89:>E^^X)DY,F: RHACS<:F16#3:4S]@*/#L:]NJV'.S02A<HF>^\/2
M*A@UMT'BP=,1X\399_ CR R[?=5M3;*9%] ']X4_KSPBO5%OO++/.L2S&Q)6
ML&#(X[I!DV2=T58DSQ8NF?4<F^UUS3?R 9ZA9+/(W7[[70J13M0>^$XL3+->
M1-(41OV<TMH 2P%^MNDV\6& Q=QR'^]&YP@2P$]E7%: Y#Z7EO)P<KK(3]2/
M;^W5&T=UU,5XT$WQDZW="^7'>W,GA@N'PR(J1J;&WFDND1^"0;<TH]2]IMV0
M"ZX85[*A.2/5]&UZ;-P&;# G14"RG]MME,16-QLG$CJ#" 9OD0#QO 5Q*N-#
MLJ;UH(4+IQ6RQ:;BE:OJQHMBZC38]QQ"W0P">X_K-FDN9=@$E5 :TOKT'4(@
M(L.1D:YO=78C)2@0W+<RS:/UXN1-O.KPYP^E"Y]8SK.7Z7FUEG,++,H16L^;
M%23T*!L.V,=T7[XX:'R2P7 %%QH>-\A<7]7"Y*5_Y+\C%$^K$OJ3):GL2+E<
M;Z$Q3A'Y3$O/[>"@C J^49GB/@>*>8,&\,?\A.OUV^1LB$Y<S]D1D 6YG3,(
M7YZ-0C/++4\GK)9AN/1A_+RJ]H/VSF>:.+61GZ_3L#AQ9*TD2,Y> L_R.DO<
MQTX+F>?W/U$KL\>QQ)N;F6+,A7)D,"78XP^JJA(R2@:\;73I@>4O8-B7>G_/
M-;;@NY!Y(]@R'7MC>Q=,P_S \CT==7J\;7Z+^VYLJ."'.O.YXX4GD$:+ \KS
MSL9LI-$X;PA;4$BV[J?L$2V-^B3E6C,]#7;_>U_E?28ZL42<R?,V%HA$)(\C
M")7'G2F%.>]9.]VRI1&NMJZMX3#U4"X=HB3_RO!6VG+^?A_]V FDR%?]<IP8
MWE\LT=W5:!S5Q';?K<+>X,6Q(B^URY5=:CM5N4KT07FO!8N\F[PHWHC$6PT'
M\GYG]W" P(=?]AUXUGDV9)ZEM!P0*%^XTW+>_D;H-<_'!)/]YO6R4PQ<&<Q
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M!^;Q+@(D]-$Y_<;E.>U_A+_^#(2]9?S] '=*HR-;U#D:\%TZ-]\6-%YSCF%
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M/^>C?]L;K(#9FN<BHG!6 WAG AP%M4U9&A5Y>E:"!DPOV+R1[KU)ZL89?B^
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M'TI#L\1R82L-55>S7Y#6.F )PB=VPKR2W_V/M9LR,-I-=_)BSS#0T.LOUQS
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MO;K7-!49-X-&5G3*@F3)C+/SC1B.5F7!TK&J%:&WUKSZS(*4ZNA?9.A]=PI
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MIB$"I9&J!I7)8DM*D.[UX?Z[.1_40&M5G0K&C\G,<["T:-9>SI@"*+!3+E-
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M+X<"3<R[*I\'V/,HA(?FOF[F6,C?J$[ 9)U79/>9K(U#I(%?RZJJ8TQGF-_
MAN8^.JT!,!&+%;CB&>*UR&.#WQP-/YHVY^,<RLS9S=0KGQR*I>UD&UQY85.\
M#O#8(UC'KK7NX-FS&&\FWZFP\'HT8E.""EJO5MJ3E\5NH[E9Y:"SM2O_/B*!
M)QXM J\2JLK^!^^*&AXW/[UEK\$=0(][65GE#_A3^#3K/\L38"#IJL_<YJ/Y
M*JZM0(75M9[N--=#!/@@323L9SFN-"O&WSW:&<UA^H'@W1N(XA8HC8=$CW1Q
M!E2F]2CNX +[5:KL_%$=]D=GO-E(=0H1\1;<$N%1FI W+$CO\PR^O6I%'+":
M#7?'\2RL]7S>K9%J6E'CJHT'(J9E; W%DA?DR4OJF%'^9F+%-9+]8CW^%?-*
M<T*//)^JKJ!??L>BAV@+UQ3VH"E9+;F1KE55VP+9:\O07$3DZD:Z5>!4%>97
MCI?47"LN&Z*;MD.\C(6I*<#@+3WQL:RA7723/D9[M.28\;.LKR,<^WPF<:/M
M,S/ Y51"5=3K2'HKK??C)Q2S8G"YB![(^4;+-2O#<?BOG:IG!!<&Q\LT]#?$
M)_(HUYVEW2QLPE?;%+<7#.=/GMX!'//A+",4J7;/;)ZB@UEV>A3E3I_"W>X!
MCV>P0.<=(#7J?CEOT+QTQ0S\X8B[R"J\F06^_)'Y+>(?;1!C+P3MEY@3<EP"
M5&/$)BK1^;>J" ]P%G96AJ2B92:1C8+H,*HQLE"8*E-[?'JF6X[>FH528'@8
MDP#0+-RE402IY&]W3RO>',=5I&U?QA%;-[GF_EC J.&:K"DFM7]L^*2@E9O4
M7B]]\4AV4@VJM;+'5@.3EYJGO ,,X)9&#>?W\_!5V$BN7D&D8N7XSE:M5(<K
MZ3,Y3%I8A)84Q^T@YC&?& T!I*?AL5@\@K:@K:[LM\FG<Z/&S]4GU+8K=S^9
MLFG-X_+31@LN8Y;,A<(=-ZL3_3/S7=P[2I\4NG,UV9%:/@O[+*DB?$C[V?!@
ME3IFBG"CZ=5'$20C\NZO&T<Y01^.*NLE0L/0?,,2YU$E4"B?\  N2E3VW$Q3
MS(4H)V"LQ;<0M994"_M7M3%[1316/G: !\A=E#A FF6>(8N)M 1F*IEWZV1B
MB'OF_MD9H"G;VM3V&7V:P,,-T>*ZSQ^SUNYG \W7#P$('_D0Q)Q_XHPHOS^!
M2GX!]CUL^T59_9>,PO]Q14Y&(TJWB7H'Q$*#+)<83O;,FPD#S)TJ*BTF\3?^
M$16RMQU2; >D7_<D)&0O0.!:LQN.ECD.>^;E >9N[F".V7W3CLL+/L>C,1;F
M9ZRTTZ$ML:GH@$>;1#V"%D$M4)1EXY&BM%&.!@P&E8KH!>DJXTJUVN?<:K1?
MWD>W8LF#@YN$]T;O +8C/T6;ZS$0*VN1Z[L?E:HE8FA03NT;<O.MN4TTR.;&
MGTRK<\?3':)\$5)%)+$E:-)I@1IRW@'\8<HYU7D9JWI-W.PZA*BS%+U([LY.
M*MWVB]EN!-/9\.7,/\2;12SNN9ID'B5I-(V?KV(&2^1$E;S-N1CEQS)65\7#
MY\F>/R%+R^<1( =T2:Q@^KBEP&;6B!6"E*5&.2W4K;*KM"C85*1C##(&&O59
MDT--8P;=>GY+'ZV4<DVURO.@L7H#QNIX7E"^K5D"L3&I/I[YQ-30SDJ"PN2=
M&5-92G/>)8+9SC H*SN1-G7^H^2 Q0HCV?3MV.@0H0@OF^O[ZFU41)KD]^\1
M8G33?WMZ'UO7- 5JOWS08+-*HH?M$M(991&/7VT#0GJE?IO(<XDW\*FIV0!%
M..?E9J 0A5PI-&?S78R2]-GL(--90Y)PQ892D<Q<M/65*S6O<C+0[K=@]Z:.
MQ:8]U^$ +^*=R9G4"+M2:*2%VLS+_;'B]U_Q^TFLVVAR[6UL&Q];D:8R>%VV
M2U[V\.D%$N]B_]"4LR$KDY?M!;(T"'[&#G7>U1'^BZL/0A;W/L"%CL"PYS.$
M%5HMY3IB',Y<EYA8"4KBO#J]+L9[4NDE1AZT38VCUI3C5;TES"4':7'V%@;5
M%[N/K4GZPRE[K/<^=,9 ](//#G\-OU_"YXDW-4F?5QR=K*K$=)V4Y%%!=+WY
M56QHHFQP\I$\#[]$?W-W+')O\9T9-7?[7 \,!LI]':?T[S?#^!@M[LTQ@V33
M:&4?MXED/]JD\'O$F5V*V)<$H&;"F,I'6ZK33V4U]#3$<L5PO,D?*1(:.GD9
MR%H/H7!&&!XE:1J7A:@=OS%7FWG+1![_0/V1*H6^>+0'[RF1RG%8IL!4_N]'
MB/S0]G*8@>*1(P,&GW0E!+LDQ8DCT.$+LT2^(19&/1#191UZ[=B7L;@L7^V!
M:;?<$.8LJ^5X,O-M&L2$T[VUW/>92+V7,-P5:>U4-_]WN(K)EP]35;G;;J64
MK70]M3IEP)[Y)*K1BJ;K68KB-XD<KS?1>LAD>G@'K7<6,7/&K1M5/R3ZOALL
MFNXQQCY!O>$P)Q'N.C5UMG3 F_/\TU1^<<'37D>(-W?%PEQ?MD5U');.CRY#
M[AF'K+I$SC"G"-H!C(_GU"B)B<*^;A<IMM$@<H80.>7<MAP^,@'9FRP4>RIF
MKCHZRN1/<\3G$7_&*MLL_)3-@S=M!JHG]G6TJ,,S=?)5L/9Z4IV!IPP-I-AL
M_/?4 G2<"]=P>I:1_:N/OPSCC;==CS=X^5+O=^P3G)_<-\J5NFQ!5/C5<*TF
MDAQ8]7RBACBDN1,Q&X_EOMDZQ4^I$+8#!<8&;.##8Y_E[LQC?E$?F<JIIU*5
MIQX#?A;V+*DH$CR.J\(I?YT<1JU99#]_CJF78EU2P#0GQ_].-693LF?=22@-
MKM@+*S+[Z#"C\]7S5'LJP(,];SC=)5[&_^12M(6X*!Y+KSL@\H>QM2V92QN%
MGYOIGS(=X Y-"\L@)X$(X)%7DUF-_?P.G=ZQ9"G66'IM30771?4[<AWO]?(>
MFK@^G@=-#.*C^M\KW9GXY@S0U=5P+P&&PF&@G[Z #/URDNBZCDB^D.]?IV35
M;PTA<3J^?W#)YG79/.O-*@%PNI7EC;F1J2C+S/W7M.POBV9BFYK.FS+KG@X1
M=J?+].HV7J2AJZC*<2O73!0WW@#9)&ISWL2ND9)767]$>\F0]&6?:3U5N9IG
MO('4%/ X,3]KMUISI7_R0X*X$7(_7ALU==Y9&@8:?<&I;M?#;UBOP&R6^[,D
M>*LETH0480#U7Q^"TQH;P]OG<^-=);H]*IE=>;80.-G*?C+P;'QD\U!VS-8P
M&U,H'C1%_NQ+$L2)+/$)>/OU#D!/U*.Y!%YFA=+=OZH6$<!+.A'02:G]#(3;
M+XVN49"S?Q2T: %O,D]*R_H^&"<HQDHI=@_-N%%OL&N/++WL1D,# J?&;ROO
M$7_'$N06Q>/A'>"3D_"J%.PY!=+]^I]_B06&7GX'((;)SK3,4\22_!*5?@=0
MS;P#"*]?@ML$%,Z#]4[7*:HA1U\\[N%:VN''EB/F'A@H9)7">\%^4^<(?^XQ
M./O''2#,B\Y*[R"B/ZSP=N1*$5XH!0</W+_XO2EV<5LV^X6MA)=?_4M'XA*.
ME9?E0YYVY4([VB99Z^;ZK/)G)%'/J=2!RT,3\"U8WB^39)>E!<F<[RTA7N%E
MRJ>^E(43V'1$7%-X,-T!?))LX,R5#BR!<,QCU56-K53Z$<Z05G\Q&_T\,8%/
M4FHSH?*\I#=3RT(1F3H6U\6I2;FSG!/G:P-(6)(M'.$]:"@K%KMZ4+JI )9&
MNAN%74VA7.OJF;#P6'ND8V2U'[LT[\,&(L%HI\?)W%+HDHYX)G.J^T9.^A4[
ML3N23Z)E&K1O16K,.E%K2^R&S%^/;'K7P1BX<<]$H].H49XU4TQ?090*A;I3
M\![N[S>G@)@&Q_ML;'#B7(W>%V2.)W8+\8\*#9@Z/$_8MX[58<:?$2,N)'UA
M,NO7MYK8/9CB/S%U_8]=)R"/@$WF0DT,7D>EOX,?09]=8[0M,!RX;O/%KJTD
MW+_H'O4H ?YF(^DO6S__T_:1'@1;!FU0,TOW=JLL35$OL2#.0<DQWBH4*A16
MS74O$;V%--#1Y,WM=RN@Y,.?S1&[J3]IX:A:(B#X63<:=US2E#MO05 S,F!G
MEZ<YGV6_[<N+BM=\04+,]L!/MR0K.4;KLIGSF"SRF&QEAY4I/(JS.@&$U_4E
M6FN@)_A5NUP 9.%-,B41[QI:LR1#:IN$BW_L,7]GO%O39H"2XD4=)X.5$,FM
MZ*"!"]%2-*A&,E0U.,O0;)CVR$WM>>RJ'I;$*I/FPJB&(WJ*[+O$'SM<3@,O
M9"WH1^1[$[RM0294X;9"UGSZ-UP,$ DE4\Y.%YMN9V48BQ#EI.[,I%E:JE0M
MC2MCX#<<Y?7X5F-5 ]QDH_")/MBK[UE'IJ'['!KK8U6%^96&GO;Y(N;4J;R/
MTTA[>1TB*_"8A@^&K9%.#OA3N^7I2Y_K,$@?@\,:;0JAWH^L'5*>\SCT&M4+
M-P1FF6C,D0>#77R<%:OK=#"[O6@C)*N]IYFLJ]P%R:E!MVE/]S\T=1ZNOV0O
MF[L#F(0XM4MN=+N/K=5J7^,$'PW8!'M1CV^4C5K21!]HD.]H'%*-O6[PYGEK
M;A"-8JP:*?"%$56GEM)><8>"X/Q*@)UL\AAD9YC#>0N+4P,Y")T&:@3%&% 7
ML.MK))5U\WH-^@T[9S3JW@%6@$$$BJ/KKL4<-S(&%4'SE 3X[2>OB;5 TS+1
MR!V4\JQQ1 +!SC[PY]"8SL2-  >K1$%A8'TBJS$CMF2Y5@E,.OHJ:<VN7!:C
MEB2P=3:ZCJR$0/!S\KLG%OU>-*Z)=X!.&XRMW2RP]<RTUG"^SH\$1;RO2(K6
M"Z)1<08H!3=J0O$4@8U,*ZB5 [Q,9_P,E743FV5^#X=_O)<(PZ8>PF5OWJ T
MEN+93,1EKD%/791P<9SJ*@9WN)D$E>C)6A6(%8%.=RBFJX_V;A@M"!WTG\M0
M&JL&$0[8A1JDE+IL=FLBI]L;):9"\K7)V%ZT:KW.(*G;E,X0.[6G^-9I&E.Y
M-G9AR>SNB;=</]6I@ ^JCVL V;!KWP'TOT0.3;XJ MK7SI=/9^F]>*4JR28O
MT]?-H'FXPER!$FX8;#'+0(8O&^N]($.M866*YCM,(A_Z5CD?P^\][OYAC%]O
M^V:)HBZJ\[%89^2T^?&BC)D-3;5)S=AF!29N(4T;9=R".*UI8(!.6Z!EV2IR
MU;Z 9_',[-9UP=ST?>#G=WID J2"?R"?1,UP>2ZMO?HQ_)'+C_ R,\IOV"BK
ME/8($BX@4[@K1!"W<C C*VANT?<PV:GAK1.H92"R><5Y\[U@LW7"1D4SW?RB
MPC&2N9K""P74'SEIQ]V=#/&?D27/O\G0DH9?H*=.2[@(^WC(%>Q>7^3,F&22
M0_"+.2=S;#8"9>$AJ-*&ZM^3'R='*^CO6$BU"E%->E%"9Z7&F5G><E7S*<O1
M-K(:O)A?-QL5B99^'*CNAMBC24J,-VQ"A^M8BG5LM>:\B",@E:<#-5# W:XG
M3\&5LR[%/ID/D?Z63P5(*>"SU^!C"7$<?# I2"<;W__578:S33"9P9FL4:GF
M($V9.DT%D3:IG(=P5V%Z_N%P>EXI$CGOA/7YQ;@/NI6!++J@$+]+!C<:W><$
MDY/O7)-46%BRAN,KA37AG"WX&"]1QG/\F#@M<C\7%]#48,V*4^!0&F1N7KDL
M'4M5Z-MO\3&T6<%9H3GMW1@FUYU-5>N?:[S[U0W]WFLC/J4.0N]MS#, 0AL,
MZBF>@"UVA/&M]"<XS:H0<[:?;XC88'XN'V!_^.,U'35">:I+UM+D:MTN!S"@
M)LAQ$:I0!:P:/TD,SR8/,AEK?ZS6'[0AO=/2.;=:@MKM!G1<8L'3-7?B.]EY
MVN56K[H7-^"):\"9HBJ&\YKF 2KE:O@+'LX\[7W[H1<6K<BQ()8.V6'<@:<L
M0>=:F[5CUIET^U0S<F49J;7MX2B$G%5W -3AX)RJN'.;XOM5ZM=M+GSO<2Y;
M5:.H)%Y+LC6$3ST<5_QHFU]'=,5;L,Y3W+N!FIQ^YU6QG^.5NC!.7].P9F'[
ML" M!QF@" (X)SQ8)ATI<*'B"Q8XLPL<4T]I/FAU?>5]ID:?2R1HJZ![EJP)
M-*R;MKZ&JU2=KG>GZ.?HN@P 1SG"..:[\F9!]9HREN0<GPT9"<;C-PEOJK(+
M8&+'3BD%%EQE_5.RF3*DDLK&:%V.#$NQSB""@7=/D'F%<@JG+PSJ#CB 0>9@
MO/.*XFDYLSU&:T>\LG#,L@BJ<G@-.[L_<Z[SO$X+BUOZ\C .-(ZPJ+'8^&W]
MMZG$SY?<3@4;)-(G!=@?>'FT$5LSI\OJ#C\#/[9T+>*;75OYI_-KF2O89?>Y
M3$;-7+D+>4:66TT/X*"28KY5"X%)''LE@0HTWP1>0JO#)RUFS59>V#'LSXS0
M^'[>$>$1<.1PY^)/G95P42LL=DGJY(-YD5@9AXII!#]U!)F7QXM'?$O@@\3*
M\UT(3-6E4;VFL^O1TPP@?R>_FO=S:^8GQWH7O-FF/2?O'UN5_TJBI'W1M%Q1
MO.NF?8(Q6;U+EU -#/O::D@B+5SLP*$LW^IJDK1LT<2B*DN:&QG5YV@;52%$
M:CK *]C+^<1O:5#T]$UEO1:#0\VC9BO?Z$@66X5O=P 6E*@I08;)%^9U/XI<
M5>\ '?MNX(J7M[&)N&A?@P#O7[6F&V0'KCE0N@6K0NT*RE*%GX^B4D2Y5>!
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M,%=[!ULH8P3_9/*12K]J4M[CK6#^Y D;J]>3$<M3?L@)G-%FFK85J<:IXNI
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M^0W5JN+<]94\:,%['-DT_2X<3B>F^1IL;]9P>.S3?P51_59; 2?IA5RCV"$
MNXLW_F:U _Z6'WRZS[CR\KH.*:9_Y!1T("H?=#!W9L@'.L*N0?J7CS)7[/'
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MM>8,FQ%&*FA>UG>=BKE^J_^( /@K+MA?8 "OL&(1@*#4O]0K2 2"X#DF#4E
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MP/(,V;VG8\W)9PSO;BB)%+Z57HS2P-^ ZB*./4&=]<L>F5?<,LV&%_3UA A
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MKQ.&T&?=8#CR9"PU=681X9?,B/T/QU>CT':2F%05 >J%C6ME' _5?6?LQ6+
M8TVW.P[9 ZB.$U'3^-13QMR0*I_.W,O6UL;FUJO>ZR==C I]J-DC?@1=G#8\
M<WCK_3Z-$T2$<:AZ>T0X1PF".=S4$/@LOT;#XU3,KBZ>M=<)*?>G+_?#8*A)
M,WF3GO1T5";\(':[,O^]^[WMYO8KY^G66(D3:8UDU^V[A)JR,<J]K!7N9.Y!
M8N"H_"_U%S<<>:L+'FE![OY\"86[0QWF1^/.GP1[.CQQ4.WJ\2*2,7L>(AS'
M_:ZODN<*-^H"Z==,$ZO@[XF^ND0#5RRW/3O_5E.35HVC\\M&C4U)IE?8R,BE
M%LP2+;;<Z5#<SQGMT(UD/L>\"@+MHE4LP['2U/=KB0?M2G<4)TW:[[M=5_K=
M6[[YS<"E=(?\.S<C3ZUUO_O!C2=[5VF@+M74E"LCD::PDK+:],46R<OS,UW)
M8[MDGN\D%RO2J,2!@J[@)MHK'MNY)Y3GG!76"X#ZWX,PO5>'6O,J#&B\G)FD
MSRWD3?]AH-TY/YDGK->3WS>3%UZGK\3!4*\[)A_EUA233_)+BK.+E2.*9=8[
M%&5_7W?ZU-'V'._&N8WV]5KB!QI3W_YUOQ.$A%2ROK@YLPAIT-+FU+NK_OQ$
MGU^?Z?2SY$G!W%)@+D8EG?%H"/Z^MKDFNM+SDC?-?H]X1E+_3M\(Z9]>^@X4
MK%"<XGB)&7I1)QCM4T^/Y3I_4>Y1%P^=40*ZLBEY0&I4D;TL):UJA!P?'_"Q
MSVG2M<];4X[_3=S+-T6IC!K/N615V'+>VF<*7,@=JP'STYOQ$T/2ACAP1BJT
M_"^/V&H,'D?THQY@E6>F$%B/.S<T#%%H3+>?7! -',_3PSZ[^Z%T?&K\*)D3
MUU& FD_7]W;]QZ.!N\"^8:*_4?T#W>1YW60;W>3A;J+GW>?I(:WI>%1GJ4XW
M'ZEE,2I':UW)PX:(LJ1"3[ZK/^^J?D/?2N.CR3<I[(THZ7WPJ^^2KSXG&M=Q
MUER)#GI>@3UO!SWOX9Z7K0!$:9=Z9.6A<MUS;[7]Z.'.,<,RNSK<*^=U57K<
MHW2^;YKSSHR).UE-9I[R.JQ:+"0V\F('7>)2FGW[4#)]EY1%I]>3:9'WV\\N
M&&73?_G+UKO-_8?^W9PL(/%TO2H[>\))G$\O4.GUWJW=M+QH:M%(A[1Z>4NO
M$:G%@"HM76T4F5O"Y=SO<CIFN9RMMQN;;Y]>6G&G2EEZU$OBM!K&<_RKL5KE
M358X5(\A<NI:?W)/-Z&KKDYRPV2J\1G3B:?.GT1Y\FU)[YFJ.@CER%,L%F[\
MDYW?9L[W/;WXLKF?JZA]_ASK;*/4D@G>H7,K.I+<ADL13U>W]QR0J'3]@N[#
M4^[D+[/E6@J&^FXXU'/4:MDL?VD"Q0KFY!=KV_Q,Z29FXE;C!-\BT7DXT;F4
M3G_28:A?GP34_0Z3O4]SS<XU?G!,H<K LADX&O<IY.,*QU$8<-].)^-J]RS<
M).LJJEB.PYK),EMN7>WI1?S$T^CEIVDSR.T.N02/_M\?TQ/Z0=B5.D#I]VEL
MV1 Z:FOGHYML!4AYE$B_GYJAD-VQ\F63^ZO5(;IQ&@Z35Z=H)W0\&GVB;NAV
M9$]76M(;] (]%.@8+BE?D*J@*>([RZ2);E/WIUZ9OS&2(6^ X$UJ_*3< \\[
MQ"7G;ER%29+E?,<N?,?#ON-@TCLOLCD+ZLX-U:<H!O#)!<SC0=I319=)QZ"H
M8&:57<=*W/ES?B&;+<&D!B8U%L\P[J6@6C+J2$D^>\S%^FIC8C*CD91?Z=6C
M!\/?F>QA-K%.HV NC8C=F&Z>=^II]JW+VAX=_?9!?J37"Y._S@47XLJ]9FKI
MB"AE]8W>^I&;1-[.UGCRY3:4UU+ 1TS408@B^HT3\D8!#O1RWW^OOS)=9C_S
MQWLF%),BI <CO&S0H+R1:[BY2M2)91)&)M6SO%I,5PTY-G,I.*-7'M&3(_%J
M['LT6.ED\8XM(7?+4#J]6_&?,36MFE>GKAW*/C4%1V-<VIO<5.W'.DV?4.]1
M\U% K,=$3E4CEY!WPMQ,!&>XV@TXD7S@%::;<\K8Q,0PY <D%J:&O>;2M62W
M0]*RO&DC@7"NTLM)>6KD#&5*#X?CX6!\-= ;(J>>HBS@QQ!%=&Z0D(F8J9SK
M'!9.$@A57:-:F/"6#@4F!#[??:ZWK[WLQ J*MNPMVBJ:!2LK%GUL$>31SK2H
MHYK$44_YJWL<2;[+%SH+AJ#F_J"F:TA0HR=K8GJR2%;+G8?BG.E@1,<7\<#Q
MGRI(J0D_$+R0SP/[9!U><IB>3!C--4I-XG]*">;Z1I#;-C)RHH@7_WB )VOU
M%%MB)7VFMX?4U#0YF3;?L"EN@K'7FR] F+S]G/=V)CL7YMM2?V=GS%S?NK.W
M 8G12_F0GAD^9&H^.#>6C1Q7S_=V ^KH-=&7R=X'"ENESQLADF![GM5U3@"2
M#?NZZ]Y[M];8\]QK<DF_.,/1/N5'P?"&N"E.3B[4WOU@'//N"GJC,7W%8[_V
MZ,//G>\QS[IG>Q23S^]]^%S=K>YY-,*?$]-O16M PS;!)EJQFDJ\$E];^E7G
MNM7]]OR3L*#V%K\%GE(W4.H9U'9Z.V!6.#&3Y-1FL@_7OP[<KKRS(7CF:YA&
M+] ?O,,T^AS3Z%PFF-;OO>PT>JYR<"]9"KM(^\7NWN:F& U%H\T]9HZJ)+6I
MB[?8Q8+2,.JO__==C1J)_^%PGU+8*.(,8L!K@UTI>]%D?ZL;\;Y5O;R5OW6V
M%;<;#(?\OG'0_9Y/-I3/>J/ZLUSOCU7M1_HG-<.B)JLX;]%[VO+W05<OL*N_
M1U=_;+7];K;\+<N6Y^OC=U>HLQQ\*OU^JJ8(H2\6Q![;"!SXF1>6J2)G+5WV
MNKU3CS"[TG5GDC^+,%-A7>67TS*O:++!5O^:+;;IG<=^LD# E%>)[^J%3R9O
MGBN'F2-XS=0">33*M=!D&>^>.XM7[FL]\":J$MP@M^(XH,;V^0I>2QAQ,8W#
MZX,UZO1726BOX]B^J\)L;AN5ZO.W$[4OW7(=EL6[<\MQ/-!U>5-?T>5RV?0]
M#YBO?KS6\W%.E)O/"SHL;<7!=)@H(S**H7RPTD;]^.HVL56_=)141I+3[*E?
MZ<O)A"#3B-N0@>;9C'!RF4ZA7,I1,H7FO.S%_84Z-6IG]S6U$KW:M1NHE857
M6Z^5Z2?.#?UY6_]R'EXYOMO-OCD;D&3MU5<5T!RYN3W7"7G2DUMK1]]&>5<]
M_?10RR<J8<G:EII9I>N[GC..I&XE?F5^20Y;U,?*"'I$;4KUD/^>W,6YHHYT
MI59@U#Q.O@2\HZJSJ$'UTG4B>\+SL ^M6JE&FVTU!<7DJ[UD0D>3G*V=W"Q;
MP^OPZ[).RR@15)BG-;EU7LA0A9Q[G5@Z^8("ACF6]#5WF"XCI- R#\6KW,3A
M!6O2Q?QH1=%D'8[W.[! Q/QD6G%LBD'<Z(7]]OTCL.;I?:/03,6+HYW4?Y.Z
M;.H4- Y3-LKZ4JETK7(%^HZ!<IK_5?V$.E<R\.1FM]Q^)N!&@U$ZG-VY]8 &
M8)Z3HO[0H*O)@:=:CI$NG7RL'.>^DINI^74U&.5*%^YKAYN!].=]@'(6DR?P
M]+9'/LFKL?2)J[^=>KX@J].\6T,O?358JA[M7#D<&TT_B%U7ET<_%4YD2J^J
M7#8;JYVDB"&[FUIH3.OL/9>\DK:! @ZU02@<C^+NK8K% N^:Y5<XN,A#61-#
M!IJ(,!Y.5S#<*(RNI*]*70E0"J62)V+='>ON6'<O9MW=Z:<!L,K&=,].H]*N
MJI0*]#ZCK??[0@&F8VH5[*HX27?-U/&D/784DG-V1YZ>Y9?:U[[BB"KLJ7HH
M)<2D5>KN\RI:?D^I.NE,S4GG]-0.)S^])<<W,?N+UX7N^K,K*/F F;7'9M9X
MKEG.,86&@!JS8@L'U,U[9?#N!-FY>:QG+ 2KO4!.7KF(+^AGX?4J)?5F5G)6
MH=VMNR@/#!<LM/?,LQ2F3D.@L%=Z_6S_^>2L@UIZT$%.B5 %XU.%:M=RT@8=
M\B 4M?,<XMC/%L34-(.Z?1C*ZZ"K)A1"[6,BCH\G<H>LX\LETCTWXH.[KM24
MQ9R )[^[83K?Y6HQQ2B]F"</]<):*).LB$SL\[R9HY*9*#=74!,\1\(G)M&/
M=)>>S%JEYW*UG?HQ8$[H^U#/"'UYR\G#<.0%MU*E1U?9=*QNOYF6FUY-$]1\
MU'C)+ D9DIQ)P3,W::B73L?EK6;!+M?/33FF9UGH.$-+,7+2HC+2V3O-4$G3
M];X63XK4]9.S77KJ$?F9SHBXQ7?3W4Z7B:GB[F1_1WZN69<^KZAW2+G<R2=:
MRGA%K_;<'JL[J%K;Y5;O27+;/6:8FA>@'[H\F:E<I/Z(Z>QRCI^J;JH??4*T
MF_W(<ZB1JXF:.EEF>Z!Z)-]AJ.XX#(C9:A\ 96Y\"86LGNJZW>^!TG_C\PN&
MSE72C=7D7+J+4S/2<]RA>NR89Q_27WO$"U][ 1UH<Z&JC->I7]52&]6=J(NJ
M,)F[PLW B:- ^0D.M-4*BL_E]*HO./$XE#7!WEC-+XY]]2,;$R43F.K3[->:
MJN1+8NIT:X2.M=,M18_,+][G+K-!YGYOR3V17HDOXSZB>XAZ1?9*-=U+@Z3-
MN,<D(KN368R,W[F7H<^'[.)J:D:XEFSDUU.XZ<QJUPV[!&G,<QZUC">*.7P]
M#;Z\ZC%I7FT]"V<SL+&ZAZX!?;3<1U<%\/_]E#-JF45/-6O_PY/60?H1WY=R
M[IGEJ:PF\ZZ$<-[J^[>P\(OQ(6=)_] ;AO6$^JO<=S/A^!4<<W3 ^#W; ZU\
M*4Z]UO-6W_);NF>'B\GFDEP(E%N!Y'UY#&2Z")70Y2#Q 'J])M9[HZ*LOHS7
MN_BXF:3.;)2M '"8D4R->:Q <E.;\C9JAWPR:N=R]P[EZ'WNKKP!78]$2AMC
MZF9?-UH;HB][*IOGJ3E66=*/2 B7I?A,'W5Y4OJB+E*FZ)63R>9]-4FH%/%5
ME^4[9<%-VBT3%Y6TR<S*&Q_SEF[H2G$XTF>M#(,P*5">!66!@"P;)G+0:>02
ME]AWK@/M<3D*2%W0!$">N>5()!I+ZF*Q;I.<*TWZ.?6WL<<3H+?YZ8W497*;
MZ=6^[ ')\E:'[(O2%E,ME;9I+RU7RAHVFU>>;A<>/)YNW/9@^CP)]8S),)J4
MA?#\=91E+),M=XF8U#B\5F5;:BWV4;D$,3U#E(C0T<@[G)K:GG)F/'ASE*D6
M:C76:<*22AWHZJWLMW[>8;*KC&K:XVLA]MR)3_<YW-J=LOY)K#GE=R<=)>F&
MJ;Z>?M8+U()BSL#H1;C&Q/=,O)T:UCFJT0'QO:-0ZJ>BS!-/#A?0NOO)J@YY
M=Z>G3^)R)FHAV:[7)&)5'R;?4/K)ZG+MH[3,/W7X/\GGJFZ5QFYJP,E%YY-(
M,><*\UI.6/C!P@\6?HK:<)DL*O=4BALEZ]%J.85'TZ0^C@DQ6<^>Q)/9'LK$
M?T!R$=LGEQJU\N-2LO.QQK,9'%Y-)^JIH-],4IOIG7#&P1,*':E*HL*$UI.!
M9#+-0)=PE!SHZ@L=K.H5T30^IT;RD]+*/H6%7BW+(M28-Y5&)+,M$]V*>T=6
M; DHL$M\Q,+EPPN71^E^NT:RW^[9NP#23AFP9ARGGGH24O!A;VHV<\R3D^NC
MH/N=2:ZF-]2^Q85W+/(,63A^9,^=+C[HK.SYV::_!V;?5!J9KHIEU>OY.BZ5
M6&8UU[.I(M=-Z+^P>[FG0*SVX Q>$AN3?>M=+U"^T\G$Y*<GK=4^C2N9?34M
MC$_>6Q?=3K+6V6+YK(Z> 6 GF56H3>8-TQQ6_3:S<I-5&4>:*AJRW&[4G[89
M5=?HS;>?]!E;1:?G]+3V)!Q]D6<>;<+3/^SI3RF((;8XO@S&\WAY3#JA4&7Q
M\/UYHKQS+:UPQ?!\V_>G5C72D7VNK^IIW/E$01[2_IWKVU,C]US?>%)%>,[&
MR==E/K2S3N;W?M]39*2S('7JV4AJG3N>S$O4^I*I<S6!4Z-8)%D"YJ.*>[>/
M!EK)_'HV#OM:UR83IYQYPF3._$EYYNGUS^FX*5W&R.\Y?.CUU&X;7<[A1KGM
M1KG*>AK_):_8$U!WU'WR*R;J(EVH2M?=;>1.KAAE(F;%C:ZB+6Y-?I9>+N.5
M<3=[FTEI /^6*VF9; *<;@+=U/H)[LP#]/8VO>[<5R<^4Z03Z@BN)QT5#G5D
M?,/;-J8?5TM7HKAA!T2L6M95)OL.@KRJHKXHB91XD4<+[]T#]:Q0^!S4WYBO
M7Z<(W</X*2Y.O0&&2ZS1%+91*CV5(K<'.>+J$L=+JX&X>R7K]+<ZI]+]F[-,
MNE9EGS)_\40N5<]QJ1U&4?#0)J-,O,/ALA7W*IG6FLC,)U4^Z1GR=[H']_A)
MQIBZO7IN5U/?Z:J=/,JSJ).$PH"WO':#T>V#0TY'3L8FO6K$8_TXI(27\\0H
M_[XOHZ2#GFGT//1,STQBV*3(5A\CEEM,323OXMP9$_=5\DQF9.ZK2YB$(\D$
MER^O@MA--#N2HHUQI(-;W2U4#,#[Y'ID4VVJ-"2=JYY9FD'?@#S="K;WNBFE
MIS2Q9Q2@KI00 ?>5I."I)X>^VT\VB-4$I1VLH4V67+M:BTFM]4=<%S>I(OIS
M3,E*K+;1J\T&:H!,-H;=S?X>S RHUXQYRC-2_Z4N_-2>]\*7:;LJ$9A_.7GM
M\_]K-8_/ZNVOEPUQ43]NM,31^<G)^;?_7>6Y4K,O]=Q%;6I8\G*WU(U].5V=
M\/12^@)OOXGJ"U1?E*+Z0GW$/LZ/];#UC([>/!/?FNVS1JLEOOW6N&R<']U[
M@)6J=E<UZ;W9L#E9FWE$L" OS:]G?VX)3M%W0RZ_4G5>?  >N?07.+=N8W-7
M_U@,J$Q2A<;?UYCC:VE(D_9QW5>X?MP917(O_2'_EHQ8TI.9W,G@-MUU-B?!
M2-)Q^!/=#SY^W/BX_==]%1NESTWNMZ7-?#@,"M)PYRW=Y.-?\\R9B1)RO3%W
M<QYG^UYPD[91^OLZ1U)[VI/<4!L\V<.SOZ>%#?MIV)#K["_;M1?S[T_$G5F#
M[VY\W$%[OUQ[OWV[L?D>#5Y0@ZMX]?&5X/E=2R4<?<HS\N"4+9*[WUY[NH]O
M9M%2FA>-?@BU7"K2F.ZG-DMV(G@29VX[.YO;W=E\4OTZO5_IR_GEY?FWQN6>
M.O=[.HT!+>:G!?N DG&BH#8!%>:E0D4]0//\7P>-$]&FK*%^T?C:;AZT:J)Y
M=K !EU!!'J#7+XGVLO'^SS66^O/M73GM^</J4D<YC]K])GHC_G"'CB=.Y2!V
MP&AC&'WF#&4!G*Y6B+;V&60VD<QM-_:68G-Y33L8N+(O&KI0\%J*<ZW?!/(B
MD@3:%49[[7.]U^-:%E5&=:8.:7SHS!8 76F@=W=WQ4G@7XEO R?LB\.0_'A-
M;&W' W'D!0%\N8F@\S-^<ZZE7Q,';2!L(,*;[W:WMH"L<<@B#K,)[;7/WY1B
MG*Y[CP/Q2I?63W;[Y*KJ]5G:KQ&FF<<#]'J;T.9C=P-/WK*( . U$-X=T1AV
MG+#K]&08B .](11(&XCT]B;R:(/A;3F^. H=O\L:8)1+U\7'MUM;6^MO-S??
M G # :_'L;\G6"UEX*JS.LF) V@#@6X,'=?;$U=#9\@8_]I5$=E&-QC>#W>Z
M 4P7VI9M?]6*7F-!LJ@F>FB+T)W=4*NHL7YP@]WVVY0J$YZXT^;RS^EQ +S;
MCFZB51LOG"MU"$S+_4&#_M0NFSN*([R3YGCLT- 1W_[OIS?NW5IM;#:S=;-9
M2?8E+;LMZ7'_CBT;Q>Z1>;?Q?@OM_8)[DG8VMC^@P7_"GJ0RQXW8D'2W3=2O
MTQL0ZH>GS;-FJWU9;S?_:(CZ<>.LO<1V)#"B6H6NJUK-L)@'5>GYY_7?VY>-
MACCZ>G8H\F[@_*S&0LAP E4#'_U\&:B7#>M_]C39HEN/GHJ>?[9=J>C[@3/B
MJ1YQZOC.52()=;)Q\8 *%/A;-?XVXWO*FDT@L"(L2YJ=RF%GR1T9X*N9QI:<
MQ @?#*?SLN%#J:=#'K6;=RZ?.N&M.'8\3UYYMR"T&81>?./R%*6K-9_#T0:X
M;!R7E]BW7.[ (A<='[JA[,9+5N>!LV8:6W(:(SXVG,YVQ\?_D%%$UHG#8-@)
M@WX?G#:#TY:&R*"SF70V.$IN29]/F/F#S]FX""6?8SLYCM!VWF*1U@Z; ;4U
M-AL$]0H$G,ILKK4HIW4*1V,^E#YW+"T?E75R<B!V=G:6VUE<9ONMA;VU(8Y#
MWD-43XY#V_Z0&AR-1W>_]I$;ZZZI:Y_CP:<W](VG3KT]\E#Q8AR)3H)(U/TK
MZ<E(;UW>W'R_G&14F>VU%F:]95F?&JK_G0X:?&YY%\MUQB&>[%U.8'84RK\Z
M7BS#7C <1P]O8@;H-I@-J"MM]JPF'+(ZXP!^JOH<69V1L".K XF0U0'FQ;*Z
M.CU0_#ZF6P)MT]!.,KKZ4.'[:Z#C@ZX.#Y#/F0<Y\CEKH$8^9SS K;'GN=<T
M//_B#$?[XB ,AC?2\UC?66QM[R*5,P[Q+V'@]$2+1VE43!F'+C_CWT'XO2;.
M_BVV-I<5^RVSL=9B?$^"%;KBRX;XXCEC]&GC\-8IED:ZPQ [OT8T;'=IK(;J
M+U1_^6>H_D+U=V7]HR2JO]O+ROX^*6@/8=1BE6B?.OX:[5VP\N]3AW*CP5>D
M_&OW61FEWLW[# G0D\;98>.RM83>+WA0N?VO.,#0N&SZ^:J_Z^V#P\N64(*_
MC>/F@3BX;!PVVTL*_X("53?;7K27C>U_]J39HOHD3X70/]NNE<K_@L+E,78)
M!>"R<UAS%N>.FD+5HL7-RLU?Q _F,WK9^*'4,R*/VEVL_B\X71YCE]$WFV)U
MM>9WBI0 !IW+8^Q2^F;ECC"*5@$&;8TUMN1,1JQL/J/MCI4+%4\%K<MCK+7A
M,AAM+*,-CIB+5P0VB[I8O07:0!MHEQGM%4@# ^@RFCV'.C!0-Q!U%@>KFI04
MN%1&LU>A)@6DRVAVNM^Y0&E@ %U&LV\&;BS7R92NW!N%4NT^VL\$IE:G&0PV
M5-ULH%UUM(M5F@+&930;M>M6@HZ<#UQ"S@>D%\GY"A(.!LAE-'O5VL% O>IF
M ^VJHXV\S@:,'Q,1!N & L[*T(7I" /D,II=N)0P8"ZCV5FF592",& NH]E9
MK@7]8.@'0S\X_0CZP= /AGYP:?5LH1_\LNT-_> B&QQ1<R6BY@7$0H_.+R\;
MK;8X_7K2;JXGHJ'_AEAH52F Y0K+]\5"+!04KCB%(18*JE:"JA! 0OQ@%J/M
M%D ZA;JBD9RV5/T(=#:3S@9+'T$LU%3:(E9&K&P6H^V.E2&M:"RM+0V7P6AC
M&6UPQ RQ4*S> FV@#;2KBS;$0JT!&F*A-J(.X1APJ2@N03C&%J0A%FH)T,F&
M1LB"6H4[<CR;T(9\C T8/U6ECO3.1-21WH%+2.^ ]"+I'71!C089NJ#VH8[$
MSB:TD=C9@#%T02T#'+J@%H ,75 K8(8NJ!4P0Q=TCM=8D"S0!84N*'1!H0L*
MV43H@E:YO:$+6F2#(VJN1-2\@"YH^\OII4CD0)L'XN"R<=ALBZ.O9X>__&7K
MW>;^ 21"J\H&K%Q8OAL6$J&@<,4I#(E04+425(7L$>('LQAMM^S1*305C>2T
MI9I'H+.9=#98\ @2H:;2%K$R8F6S&&UWK Q!16-I;6FX#$8;RVB#(V9(A&+U
M%F@#;:!=7;0A$6H-T) (M1%U:,B 2T5Q"1HRMB -B5!+@(9$J(VX(\>S"6TH
MR=B ,21";40=Z1VXA/0.2"^2WD$BU&B0(1%J'^I([&Q"&XF=#1A#(M0RP"$1
M:@'(D BU F9(A%H!,R1"YWB-!<D"B5!(A$(B%!*A4%"$1&B5VQL2H44V.*+F
M2D3-*Y (/8)$:%79@)4+RW?#0B(4%*XXA2$1"JI6@JJ0/4+\8!:C[98].H6F
MHI&<ME3S"'0VD\X&"QY!(M14VB)61JQL%J/MCI4AJ&@LK2T-E\%H8QEM<,0,
MB5"LW@)MH VTJXLV)$*M 1H2H3:B#@T9<*DH+D%#QA:D(1%J"="0"+41=^1X
M-J$-)1D;,(9$J(VH([T#EY#> >E%TCM(A!H-,B1"[4,=B9U-:".QLP%C2(1:
M!C@D0BT &1*A5L ,B5 K8(9$Z!ROL2!9(!$*B5!(A$(B% J*D BM<GM#(K3(
M!D?47(FH>042H<>0"*TJ&[!R8?EN6$B$@L(5IS D0D'52E 5LD>('\QBM-VR
M1Z?05#22TY9J'H'.9M+98,$C2(2:2EO$RHB5S6*TW;$R!!6-I;6EX3(8;2RC
M#8Z8(1&*U5N@#;2!=G71AD2H-4!#(M1&U*$A RX5Q25HR-B"-"1"+0$:$J$V
MXHX<SR:TH21C \:0"+41=:1WX!+2.R"]2'H'B5"C089$J'VH([&S"6TD=C9@
M#(E0RP"'1*@%($,BU J8(1%J!<R0")WC-18D"R1"(1%JA40H-$$AF0A-4'/:
M&YJ@138XPN1*A,F+:(*V&F+KW1U54"B!5I4#6*"P?-,KE$!!X8I3&$J@H&HE
MJ IU(\0/9C':;G6C4T@G&LEI2Z6-0&<SZ6RPKA&40$VE+6)EQ,IF,=KN6!FZ
MB<;2VM)P&8PVEM$&1\Q0 L7J+= &VD"[NFA#"=0:H*$$:B/JD(H!EXKB$J1B
M;$$:2J"6  TE4!MQ1XYG$]H0C+$!8RB!VH@ZTCMP">D=D%XDO8,2J-$@0PG4
M/M21V-F$-A([&S"&$JAE@$,)U *0H01J!<Q0 K4"9BB!SO$:"Y(%2J!0 K5"
M"72Q_@%A4.@F0ABT NT-8= B&QQ1<R6BYF<(@S;/+BY;=_1 Q6_G)X?-L^,6
MA$&KR@&L5UB^!Q;"H*!PQ2D,85!0M1)4A=@1X@>S&&VWV-$IE!2-Y+2E2D>@
MLYET-ECF",*@IM(6L3)B9;,8;7>L#!E%8VEM:;@,1AO+:(,C9@B#8O46: -M
MH%U=M"$,:@W0$ :U$74HQX!+17$)RC&V( UA4$N AC"HC;@CQ[,);>C'V( Q
MA$%M1!WI';B$] Y(+Y+>01C4:) A#&H?ZDCL;$(;B9T-&$,8U#+ (0QJ <@0
M!K4"9@B#6@$SA$'G>(T%R0)A4 B#0A@4PJ#0380P:)7;&\*@138XHN9*1,W/
M$ 8]K__>OFPT1.NB<="LG[3_+4X:9ZP)*@[.+R_.+^OMYOD9E$$K2 (L6%B^
M"=9T9=!D2PVA&H11HF ,\AI"7F,U09O^M8QB-<&@N MY4&-8"\DC!!%F,=IN
MR:-3Z"D:R6E+]8Y 9S/I;+#8$>1!3:4M8F7$RF8QVNY8&6**QM+:TG 9C#:6
MT09'S) 'Q1(NT ;:0+NZ:$,>U!J@(0]J(^K0CP&7BN(2]&-L01KRH)8 #7E0
M&W%'CF<3VE"1L0%CR(/:B#K2.W )Z1V07B2]@SRHT2!#'M0^U)'8V80V$CL;
M,(8\J&6 0Q[4 I A#VH%S) 'M0)FR(/.\1H+D@7RH) 'A3QHV>5!EU4'?=R_
M0SFQ6*G*=QOOM]#>+]?>;W<VMC^@P0MJ\.=$S&6.&TT.EQ?1!6U?UMN-X^:!
M.+AL'#;;XNCKV>'B>J _O0DL1?XG+$^88G,!(_?/SH07%29X:H#\V7:M2 D4
MS"V)L4O(@):=N@7+@(*R9AI;<AXC=C"<SLO&#M46-3HM3#$1A"Z)L<O(&4U1
MNFIR1N"R@5Q>0LBHW(%%T=*?X*R9QI:<QHB/#:>SW?%QH1*)X'1)C+4V1 :=
MS:2SP5%R\7*?!O$6*[1VV RHK;'9(*A7H/)99G.M17FU$I]EMMU:R*LH %/F
M%K662,6KOY397FMA+ES9L\SF6HORJF4]RVR]I: CG;,&ZF)U7\ILJ;4 KU;-
ML\RV6PLY,CD0"9D<8/XI(IYE-M5:A%>KX%EFVRV%'#F<-5 CAS,>X)4)=Y;9
M;&O1+E2UL\RF6HMPP9*=93;66HP+UNLLL['68@RQSCE>8S&RX*V>T;$@; IA
M4PB;EEW8='M99=,G-;NA_5BLV.;NQL<=M/?+M??;MQN;[]'@!34XC@.H1(:Q
M@+[I\<&%DC05AXV3^K?Z94/\=GYRV#P[;NF:CL6E3LWBP;+^W2ACGW2NU;$6
MC*XFHQ<7GB@W=R=5=L=>T'&\-#V]\,:1WD)U?)%Z9E#9$"HOK/):=BX?2U^&
M1.(+)XS])25>05ECC2TYCQ%/F,]HF^,)<1+W$$Z8PV2$$]91ME+35!AJ+7=0
M51EJYQY;']H1!\X:PUEC!]5"]*7!56.-+3F!$3&8S^AE(X9JJTR?%G9R!3A=
M'F.749F>8G755*9!9S/IO(3*=+DCC*+/8@%MC36VY$Q&K&P^H^V.E0L]P@*T
M+H^QUH;+8+2QC#8X8B[^7!:SJ(OU6J -M(%VF=%>P0$M +J,9J_ZC!:@7D:S
MJRGN"RZ5T>Q5Z/L"Z3*:O8+#6@!T&<U>_7DMP+WJ9@/MJJ-=K.(O,"ZCV:L^
MN 6HE]%LI'?@THK3.[@-$Z$N] @7@%Q&LU=]B@M0K[K90+OJ:".SLP'CE1WG
M L#+:';!)[H Y#*:7?BA+H"YC&87?JX+8"ZCV3C:9:[76) L.*X$QY7@N!(<
M5X+3''!<297;&\>5%-G@B)HK$34O<%S)8?./QF6K>=1L'(KFV<'Y:4.?7D(_
MXZ@2([9%0I$!:S)F,;HZ>J=+;ALB5(,P4AN&0%YCR&NL\&G3OY91K.90%'<A
M*&X,:Q%$((@PB]%VRSJ=0C/22$Y;JND$.IM)9X,%G2"!:BIM$2LC5C:+T7;'
MRA",-);6EH;+8+2QC#8X8H8$JD&E"H@H@3;0M@YM2*!: S0D4&U$'1HYX%)1
M7(($JBU(0P+5$J A@6HC[LCQ;$(;0CDV8 P)5!M11WH'+B&] ]*+I'=00#4:
M9"B@VH<Z$CN;T$9B9P/&4$"U#' HH%H ,A10K8 9"JA6P P%U#E>8T&R0 $5
M"JA00(4"*@0BH8!:Y?:& FJ1#8ZHN1)1\P(*J/7_$:WV9;W=.&X>B)/&V6'S
M[%AIH.HZ!HB@FK Q$IH,6)8QB]'FBZ"R8^8-0_+*[8H3RE=9+4?M)CJ^2'TS
MR&P(F8T513V6O@P=3UPX8>Q#$=48RB*B0$1A%J/-CRB2X$$TFW6(JIM%7<0/
MUE&V4A-3&%LM=U!5&5L7&$R1C!O&56,'TTQT^50..QA,C:$LDG$$#&8QVF[)
MY5.<YV DIRW56P:=S:2SP6++]7$\"$+ZH"=T#7$0@KFF,!?A,L)ELQAM=[B,
M\QR,I;6E$3,8;2RC$33;REPLV +MZJ&-(RNL 1I'5MB(.C1-P:6BN 1-4UN0
MQI$5E@"-(RMLQ!TYGDUH0]G4!HQQ9(6-J".] Y>0W@'I1=(['%EA-,@XLL(^
MU)'8V80V$CL;,,:1%98!CB,K+  91U98 3..K+ "9AQ9,<=K+$:6<KX5#M+
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M+3(P,C0Q,C,Q>&5X,3ED,2YH=&WM??M;VTB6]K]27\_L+'R?<("D;TE/[T.
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M9Q+0#VJQ@N7XH*$@L%HPM2@8M7?%K!\?T@3O#K$ 0_Q^?/UR5^G!?*".0>>
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M'*%#&WO?@SCNB)!XUX,X",1Q#JO$@W-1#64D23VC1C]R4OU?':7J!,[?!UV
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M4'^JD$&OK=80:T"3$O& 9!QG(*](GBLFUK$?>#:>:^401*?QE0D; \#*)"9
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MKQG22'MHPCJ29A/D>EAWIZ*\HE="7J7Y@G;55GGMKDS "C95K9T>S56W,QX
M@Q]^>W$6< .*B]'):W/2G=9RUK"QUK&-EW;$I?P+_=*@YJE6E0=R@";&^6-D
MZ9KF )\1GZ]8^F^^Z5..90<ZH!=>M1%>QQ6.&R-U5TL_5*U+-1TA#A[UYUFW
M#6Q0?:OZQ%X_??Y^(*LT+W8NJ/C&PN2QVVUZEF_(H5[;/K'Z7= XP;P! 5Z9
MB[^>@5GI.*B5OV2ACK);A@PTM@56;:/5[,$F],6FXV]K5["S);;7KU;)920L
M&=C@D]GHDU3AH%=8MWW07B7T \COI1*&GKB1%$<\0-@3V#6*X6$$[OO]/X'
M[3T#@8M6(_.^^?G ]7!X,O/3BVB3C4:UYKM#-VJCV+NZ5MQ<:9<&)"13BGB
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M:@9C); O#66X(57? P>9Y5EE=6 VE<%1'@AF@"^Y#D-A%C&$<S#?6G6^,(]
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M?>'XJ'=PO(QX2OG4S:']SX'TW:^)_ ]02P,$%     @ KX!\6FMV7!W("0
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M^!LEHOOFO5^^3[KO7D?]/U!+ P04    " "O@'Q:&C#P@[8%   #*P  &
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M7$+(,A\E+# +$$!T 3D%'V(/)&G9#70S9[]!:(;C>)5*];0Q^#.)Z0%M0I.
M#.\P]R684%%,S+),*X'_>F2 Z90@0$# =4"%3A6>1CYVA@!DAM&#HO04;T%\
MD(J%**=!TIG,9A3I5HDZ+14VJ]&2ADL#D>HT7I^S-%('&"+*=:'2HPEDQNB.
MPX+T?:5[=(!I5#2?J\=YD.4]$<O(UT3,T2!3<-_"177^SEGFXXXN '2E03T.
M%0A/2+2CX0O.:9J!6WVIR],>6(K2>1^=3Z%G+M<56NYR4:%;:B6"%BSQ%=QG
M0'VUT)]*#HPQ"W(H9QSD]4A-I7+IBAM?;D/G@0V=]B/I^H&YGYF_FRIX1&>L
MXDJ%6V9G_W45?N@TJPKOVGO/P+QTG2S3^G]=IR/+;#EO?:$TP90T'\XX1^)#
MPN::7^\Y5\*W&9.@]S:9YJ$5YMNE>\579/:RB]@'NT'5&JX2]SUIEXQG'[4*
MKJ=QG@FZFMJ_6[*I0[V9$TVU/WEUVB/5:]\Q#[8LN(G1M18LZ&Q9<&-8D"58
MF\8TYR\=D)3I<I 5U61%D91)Y,A40J;9L*&[*><$IZ%4K&>Q(T4.S!IED9O0
MQ-?MN&"0GVKD92N.FO&"3$6*-;3NR*JRL*R8S35AP'S/\);[HK6BVTIJ!;QP
MT6>X^7[;[+0?<_/:V5AM<8$+AES,JU"K?AMSW'FYG@3ZU9BC!9X\;[OOIUXF
M^$Q!5Q_[/52Q<*_R_=E4:W7^HZK9YM&CY+3!JJ%'VO8FZI;3X6N&XLL)[LF$
M4^.WGQ5EZXGZJ0!:3]1/QL8;P-ZZ_0:AWKK]3W;[=7'QI_<2I[@7<,D%E7Y$
MG$Y^E'VP9A[_M!(G"W?-_/UIS#_N\.4>PA-*B1A7UOL>K$E80-Y9^=\;:];,
MFN1W%N,^\@(B13<X.-8R ;P*[,V.B+?%7?/U!KF*S-/5PY"MRZ\C[*W+_SCN
M*PD9TS?I\P/"0<0@),,[\&=ZYTQ&8<A\D-LHV #8VRAXP0V3*\D2GZ7(_@^<
M?^]M#\1_\*&[^NE5=+]Y]ZC_=2K%+ GTP;60;E5GUAZ+7.XH0:W>O*DJTZ4'
M,LNFI><Q5Y_U3.D4C.*TCH8*I$MO!0M*7V@?FOOM^[*XO#&5G\45SY V\T=0
M_P)02P,$%     @ KX!\6A:HH@Z>!0  5R<  !@   !B=&%I+3(P,C0Q,C,Q
M>&5X,S)D,BYH=&WM6FU/XS@0_BL^T.V"U*1)2J&D7:12BA;=0A$MTMY')W$:
M:QT[Z[B4WJ^_<5ZZ:3E1#K;;HBWJ2VJ//3/VXV?&QIT_#*//(\Q]$J#/H^LO
M*!#^)"9<(5\2K*!T2E6$1B)),$?71$K*&#J7-!@3A&S+/#9MIV5:AG'6@;YZ
M12/!7=2H.ZVZ8SE-9)VXCNTV'71[C0[N1[U#+1VIF,$GP<%9)R8*(S_",B7J
MT][]Z-)H[9UU%%6,G'7JY7<NZXE@=M8)Z -*U8R13WLQEF/*#242MV$EJ@TM
MZU"])/-H3&F@(M>VK#_;"0X"RL<&(Z%R;=L\.?Y1)NDX^E$H4JHH>",)PXH^
M$-U[I5^?$2Q=3ZBHO:SBOUHF9;M0<&6$.*9LYGX<T9BDZ(9,T9V(,?]8RTO@
M.R62AA_;F71*_R'0-3C(*"=&1'([3?NTK<BC,C"C8]"F2]OYD+C%:'@+6J=Y
M0T^P "K[CQ'UJ/JP;Q];[89C.IVZ!^.7K,W61=.T=*GG@:9@"J-JYD8T" @'
M@0_[+<=JM#MU+?A;VE696Q^6)9'_8W)[_;O1U>55KSNZ&MR@V_N[X7WW9H1&
M V2WT+TY-'LF&O9[NC8'@-UH6K5U(^ M'G6'J'LQN!WU+ZKN;+/%"^-[:AVC
MP24:?>ZC8??NO'O3'QJ#KU_Z?Z-N;Z1K',OZM2LPMVNG[DW0H!Q80;F-XV2)
M>J\X\@7GQ->1((^D*B*HR_D$,W1'$B$5Q$IT*61<K$#+^ N)$)U3\=4G#(TB
M(G%")HKZ:2T7N>*^B0YT/YJ%'*O=$S$$YUGVRVX?HE#(3$U(4Q_4S"!$(0(F
M!NB"^"3VB$0-NP98<XYJ"*<@Q\HXKYL-B3^1$+M@8# /4/\1 C.': ]J8IJF
MVA-X:<D 8CT" PD87#4H=ZRTIY;)3L  F<(2 E6ZB3=#/I&*AJ"GAI*)3"<8
M.%>)*C?E U?A)FTN#D2B<XQJFP5)O<K HLP7+#W,26H,'AF9H:ZO=(U>9=HJ
MG+75<AY)LYJ(IN@;%U,8D#%Q-X%3G5QD5/-I3V<G.@W"'B.E$9Z0,(Z&+QC#
M24K<\J&J3\.P4*63$D"@ G@N)CU:[V+&HTLJ^8M6+.$=S,.@GBW 4T&$,81"
M1HH6S2Q9JKA4=%T2Y-O'T'DRAL[),S'[R7"_,(C75?",SY!B%@XWS-;1>AU^
M"IIEAP_LPQ?8O#!/EFG]7O-T:ID-9],3I0FFX/IPPA@0'Q VT_PZYUQ)OD^H
M)'KCE6H>6F*^ WR8/P*S%U7(;AX$96FX3-QSTBX8SSYMY%R/XRP2M#6U_QC)
MNE[J]8QHRLW3VFD/E>\CQVSN6/ ]KJZM8$%GQX+OA@4IA]PTQAE_Z06)J4X'
M:9Y-EA2)J02.3"1)-1O6=#5F#$$ST KY+%0DP(%IK4AR.>:^+H<.@^S()4M;
M06K"<C(5">30NB(MT\(B8S8WRX ;W0]M%<.66DO#<U2^ -E-6,N-YY!=.:NK
M="Z@PY"):;FZRM_&%#9;KB<)_F9,8016GO_-Z[&7"C91I*V/(9^Z^,L/K2HM
MH?*E?)+AOOA\(;<<F?:S,6!+)N!5KC7-UK.TN:V^962VSE7URR/DJH7PDP/F
M*E"_W?^5[E>H^J?A=0-FOP,HKF4J=@#ZN0#:%K"LSG,O($]UT366?H2<5G;,
MVMPR[*QVXGSFO@8Y1=;H":5$#-WJ[3V$+AJ@?2O[V[!;];2.[JC^1W. AHI0
M#D_J'6-M*YEI/6:OGYI6V[V#S@XZK[2[%U$2HLOY8<4@#*E/Y Y [\'L;0#0
MP:VD )T$L/,$18<;/\=ZS869ZK8UFN\0/.Q_&TLQX8$^?!+2+3.'RE6KQ8K"
MJ.4=99EK+%SR*HH6[G@MWQ]+\)@8^38=AXI(%S\(&A18.#DVCT[FB4YQGIQM
MPO-[:?7L6MN_4$L#!!0    ( *^ ?%IG,L9YD1    8_   7    8G1A:2TR
M,#(T,3(S,7AE>#1D,2YH=&WM6^ER&S<2?A5LLDF<*I(BY1RRJ+A*D15;5;Y*
MHG?S%YP!240S@PF (<5]^NT#F(.'+%^1G8JK+(DS.!I]?MT-GORKWS\O%K)(
M5"J>35X\%ZE)JEP57B1620]/5]HOQ,24I2S$"V6MSC+QJ]7I7 DQ&@Y^&HP.
MCP;#?O_Q":QU%B:9XE@\/#@\.C@<'OXHAC\?'XZ.#Q^)UR_$@S>3L^]Q],+G
M&?Q4,GU\DBLO1;*0UBG_RU=O)K_UC[YZ?.*US]3CDX/XF\=.3;I^?)+JI7!^
MG:E?OLJEG>NB[TUY_'!8^C',/(#7&V-N^BN=^L7Q:#C\9ES*--7%O)^IF3_^
M<7!TU#RR>KZHGQFGO8:S6)5)KY<*UVZMFF1*VN.I\8OQY@:[9I9QWLP4OC^3
MN<[6Q]]-=*Z<>*E6XM+DLOBNQT_@MU-6S[X;TVBG_Z=@:3B>5S>^+S,]A\61
MUC&?_QC>"?P_.N0_<,=I9\>5HK--39;"R_.;A9YJ+WX8C$X.IL"S\A-0F( F
M*=LB\6U4/3F_.KN\>#VY>/52O/I-3)Z=B\OSIQ=7D\O3EY-OOSXZ'/T\OA)7
MYV=O+B\F%^=7?R'I[\1=)OK\\OR)>//RR?DEDDR'&AW&<YW_?O;L].73<W%Z
M-OG(Q^CH=W,P7:1PJ.,^/7G/@SU5A;(R^Q1\#^0]_.E6ZG[5YO=$96*R #I*
M57F=N)ZX*)*!6$@'GD>))),._IH)IY+*@B$"+5;-M0.!@G.J8!\KKE2"%HH"
M@9%^H?!)''U^ ]ZH !=WFGA\/7KT\(>>@.4E^,84UGB $U ?#X?C]F!Z-!I_
M/Q"7:@:[@6-U BA5NA#>Q!DKU0L#XY/*;3XQE8U/9)&*UGYG)@=GO(YO+6Z$
MB]_"&5RA,!Y'P4P\D?9.N&KJ=*JEA2,/[D>:0*N8F2PS*]!7D2J76%V27(!&
M8(%(3)[#)^=-<DW'2)3U$KA96K/4#D:Z.#3*!D=9Y3Q%(ARN9SJ!#W3L(C&V
M-%;2'@]:$H59!\8V$V?6Y,+#.9%I^+M'FP098+ ";8KBICUW[C]=9W+E/F G
M7J#9R"J06YZ3T'A;>/)G!4YKIF$QU+.%TE8 \[55?@T4L(J@+M(.R/(*HCB*
MZ?UYAR/WSF2B>T+)9(%35PL-?RSD4HFI4B"\:IKI)%N+F<XBQM@P05ROMBQ0
M^5P[1S)K60(XU<;@_JO@S F0)&'"VE1X5H CMU#YH>>K#5.6)1Q'3C.UH9;X
M\@E @!4**;A..$RSRW.YZISHR=.SY[6L9Z EZ,EQ),S3!3S(:=['M-;W# 1G
M;)A7:)CW%PU Z,A:6?F%L;! BE('3:F4J$IR=_## _- &(?#86_(_X4#^U4D
MHK:#Z8E26K&4&4S_]W P'(Y$";Z5!@_$,SBXLFZW9[**+,YG3 *&H:7QBF1(
M5D"+0"C($!T+"?8'HO2X'KCA7'O/$R5/"WO0X@O>]W8"R+8*(P"]5PPY<2%T
MJH028?9OE05%LSVQN,,RI54J+VD9@T.*)<Q A>75\*'!U2B&U#X[;'4_JO"F
MQ*@!!\KTGY5.R4YZ(@5E,%G%(<6"IRD(&8%VW,Z(38&R^#1+#N"%\H@I<HA$
MR&,Y TF"\JPI=8+U<%2FY51GC3=#,V_1ACRN(0).X<",E)C*@Z,A2EN:RN,1
MP1") W%53?\ %(/DM=?R"^E!N<#S=SQ3C/UW6?O=>&-5HE!3(#72(*D4'+^F
M\Q!D"I2D"F"9W17N,$+A'E,C;8H;IA"X$F]P]ZJ)4,QSCB1(0:;FP.6UD$NI
M,SPA,@3>[:("AH-PB T@PD2Z14\PA@#[AA@)F@$?6TY!EAJ]!C/Z_J!16PJ%
MZON%9@ZA*@7S+LT*5"\PB3Q?&F)7(^?.<7H@+Q"WP_R&\ *PP+%U@"" )3>!
M8P6(U3EIUR@H< $.)%Z!;Y( -XRM<O)M2(FWLG RB;!M6CE=P$P!:H@:ERN%
ME [$Q:R9JYT(1,!F8%4\&PAHN[R.EK%?A*'!<>(2H-X0;_$8S).BRJ?,#1SM
M4-(>CSB32V,CX\)>ZB91*G6WSC-ES.0C<@J3JR*C$X*VS<CP/-.GT2N B5L"
M"0(B?X^F!;S('Z;K/L$' Y\)^@ CRF#(,F8OX%H58;Q=UDE<5S:O'0>LT/)R
MS2<@,34E0Q;>>\O(!N)U95TE"]J?C+U-K,I4+=G&,,,AD0-E!I +W-RZI9B1
MA6'3CDR#V+N:UU;)J(6H/S@[Z ]I]99"8!!2'Q<0?<+L^74MR'O&3:]V^UO,
MH$G+&4_Y-2LHNN$9PX>6I6Y*MK>)O4:[\-:&+I.5%80R<H.YC:H3&UAAIF]H
M&T@,];R@L G;D,O#WTW0PP_@]R$FX-^,U0,, D@'F; N)2H1I%8EP^D>F1B8
MG0;'&% -G'ZE*+[3KB&K2N*^F0:<%C^$#,[JQ+?1_I:I0E:15>2%8V *N_6V
M856OB]EZC8W#@H3'$-+@Z?;@B!Z'>$OXH\Z[0@2>4W$67;:D)+'&<DQY.\0/
MQ&X%:=2A)?C@A9&E":S,&L!G\YISHJ[(R>?Q2=M,Z#6H,E!&2 92.L#,,L51
M"N,].-S$;X= "GKMV>%<K1C:/>+K#;)XHZF*410XG%S#AIR=DB02F24(K]D!
MI:!BQ&TXX!)=&A6Q,5^EO0IO34:*+:\5@D7D$;X"6X8<E: BZ3S&$ WK^H$X
MK=.];,W^%XG!^OPNVT'!$F(G1\U\07$I+-X[9 WY3VFOE4<#2=0N/,<:A6O=
MQN1W9>\GR5#1O^++N"RFVH2QU\<+G8)QP0!,GX</QR<'.)#=*_<#^.?"QLE3
MF5S/K:F*M)^8S-CCKX?T;]RJZW=?+-B9@QL=9P!Q^N'S,%#8ARG>Y-R&"(]:
M+8;PI-UAV.Q=E* 7_2D([[I/*<6QS%9R[<;<6C@Z&AS^\,UX:BQP/+0;AAL]
MB;]1I^.#Q?Y)X,!@M T(Z-E[0H)30#3]"7@(P+%6G)/=D36=A4+GZZU"YQGC
M,S+)7[N5**P??5[-A+;<>&7\^QCS$9V,=[6 8KWLN5Q]?&F^>VUICH(I&@3=
MK?#%-@+HWET+?I (%6+.[WJ=!6!I:LH1K(XE4LBNL/Y8K]HN4E(NK8JYG*.+
MQNI$DWV!-YYJQDP<PC V8T\+4$N,("& 4Z$1T;@V(;VT2HDUV+P+I0T"8:%.
MNIGRP;:,,X@[#.FG*I&0V>_=LA<S*,I)=I'<R>[P8)@@)%9/%<:J K@'T7+/
M5()<H!:YLG-"BE0\$$YFJE6Z:IT!$QH' ;CFX@S6*@@:3D%0,^UC_M<Z ^R_
MEZ/:,4.1%ZN%06@\5[0KBP("?J:ECR5\YTQ"'P$#K8":!X8'4C6_E@56LU(<
M\+T8_?A-#9EK_%;KQ;=?/WPT=C%RAR#OFFI1[*%@"DR@$I+ "1U.4H;/2&@G
ML@#$0[ M)22"RS?XAV!"A$!89XD0J,8<V+?ZC%*U=_9-9YB;<Z/EUPB.GT1P
M?*_.ZE63M[.'2F,E$%G/Q()2<@Z"%D7ZC*I%]085H#UK$C_!-*@ O0,?I# 5
M0I&&0@F\@<#O"-U36HX5;BY<P$F6C#QA\3[J+:K5?$ZM5T+1@X9EA#I-D5%^
M0@@Y%@CW% 314R6R<KPMSV2WC"9%W9&EJDOH+6R*5:,_**7=5S_#E F>%_W=
M%=).#2VN$5JQVV6)X-Z!/&[([2ZCU/E>[1VP32@0N6=!#&28KA-U]J+^8)&]
MVDS1-E/MN"F&GQ?&>8VUX( W.(]EBW4;)ENQJZQL*U_YDFUWVV#%?V2"7EY]
M/J:+6AV;B[&GQ6J^QR"H2 *:N\2C^.;%0I>.@$9L(/8V"IW-$G5IES1F]S:A
MA(!1-!I=N^0X"XEFU\(@#N-V;;*^9 6Z:L7W4S+FL;@*!:07H4:)B+!5$OL<
M]2I$AR8X=*JS*&BZ*8(UBZ;6M[+8H23_@%5:K@_M6#Q6"3N;Q"I;*.36><S6
MQJ!A"3A-QMK;'GM7/8J\\$*KF3B_44E%[O\5EE,08X;^!.1+&!J*_>M\R6IY
MFBZI/O020@G\NN3*/'IK#I=MM85<$N*VS!AV1D<(4_. G>]?8W=I:4=1G%+7
M'#/%E !HG0-,U8SP,'8+BZ)J-([N@G4JU89N3!5\;M0Z"/<IX7%JV,=@+5W+
M!P9S>=O2>>5\0SZP)B.+"L4WOIR#60.W0-"PJ#DV,:C^/+Z'(*!9-,#YL BM
M3PW5#)3=,NB@U 3+?A[[=8'2$MB#A>\,@'ZT#4.V08N)K%L.3C+C5*>!9_C%
MHR$ PY0< UYFL)F^T[3189P'A###Z>Z1M@X;@P523^W%IG2>*$)=B!K#H;O<
M'D?&IMBA7D'605TJZ6N81778S6QU0V2 @REQHB,\'"*)C?+8UKN?PCO.@1UV
ME]MTXQ:D2GJ&=R8V=EE)Q]<] FG=X_6B.+<;*:39M>I$<3O3DCA*[X,$$<_2
M)CA>$KRK6O"XP.)'=]HB..11'-Q<_6.183(06_RA H)+F H<7+Q:T18N[=$2
M*^M6+E/B:[4//:,HL$*P'84H]R"W@BO&&SIW=BQX0%HBE^2CBL:QDF-Y1V?R
M18>EYDK6M/+B31&Z*E>44=U[F)%=\JI(WNZ+860;F]T7NG@6+Y^0>&>5KVRK
M97-;LZQNNH!M@VO.B!0NQ"WQ<B?#GEC4 16NX"_*TYN.8M@O&(K!FPB$K_!.
MCM28)#>W!T/^VFLM*1. "ER^9T"@\C(S:Z7JHE>9R5@;4C=X?SHTHAKN_=/F
M^:?-\[=H\^QW%QW_@&92%7A7Q6*MZJU.@DNI5M%W#KK=WDYUAFKE&&[RDN_A
M3*E"VZW'3/$RE2Q"08LOR> (Y3S>%: ]R OT0NF[+G:OP!M\1M'DMH;8\^:6
M!:*!Y^$6Y1J_RI"JO*AO9" 70JK7S6?XTT7A@+'@L.[OELTD=.0:?^G:97IR
MU'2I1%#2H4,VTO119'.+=+U5]^FL%!J >A//$)XM."U(92[G(<5![Y,L.-+5
MJX8O6 &,2BO(V'%*Q==7.WE0N!D?T_^ZW1(0'[85JJR,EU,"\MI;,@C3VQ@M
M('J6]KK7_M8"J#JL3]F31.Q(L9>_T1/[G[T[,9#N P;EV<NEV!W":DC!Q=FX
M0FL!MD[*!&9\;X\JX 'BX54YI'K_;&0'MZ3JVX9T=9*?M?M]AK[7H2R ;*=Z
M\9Y2(IT*4&(OER'G-]VD>A52R9K/W(H*U02\0 +L0^ZJFU(5V \(UP,W-"$P
ML=-@XG,G2I=\&[I@$7E&Q7P#F J$P:#!7>(UK77KOG!]C;(KW' SB0\%E($G
M=GA?I2Z65FP;TJ(H&\6&9+)#+C_1T4?P'6KCD7X29?N<O493VM] BFB)5<69
M7+6O?#-J:JZ,(1\:5<1U](8[:QF +CH6UI(C<J<5-&Y)7B3>/G45.!<Y!W*=
MWVBCL =H:A(=HU_OR9Q(C78T'T!0,#GD<9F^!F>V,-Q,!M+TDOLRR)EY^'I-
MH.DVA<)D7B""GB]JW\(625>[X1%>4 :O .$.(T@3ZFH 6S7N:O.[%'7U8..8
MJ>$L>-LODU:'FWF4R8;$&#M G=XV9K]*7<,Z1;_V*X"<L$S)!T$1_P%9;>O&
M;A*^X-2I9%"@;R35.)!0'D%1<7<*OZ&R);(5M@;P-#*+7?P][I"M;*92NK'0
M^N(D*M'@+X77'XJEET:G;X/2!_PU\@/Z%OK_ 5!+ P04    " "O@'Q:77\0
MG81'  "]^P$ %P   &)T86DM,C R-#$R,S%X97@T9#4N:'1M[7UY<]M(DN]7
MP>MY,TM&4+)D6;['\6B);FM&EK02W>Z.C?T#)(H4QB#  4#)G$__\JI"%0Z)
M<NN@96S,MD42J#,K*X]?9K[]/QL;@_C<C\<J\#X./QUZ03)>S%2<>^-4^3E\
M>QGFY]XPF<_]V/NDTC2,(N]]&@93Y7G;6YO/-[>?OMS<VMAX]Q;:VI.7DOBU
MM_/DZ<LG3[>>[GI;+UX_W7Z]L^6=?/(ZGX=[77SZ/)]%\%_E!^_>SE3N>^-S
M/\U4_O=?/@\_;+S\Y=W;/,PC]>[M$_TO/SM*@N6[MT%XX67Y,E)__V7FI],P
MWLB3.70QS]_ FT_@Y](SWS8NPR _?[V]M?77-W,_",)XNA&I2?YZ=_/ER^*K
M-)R>F^^2+,Q#F$NJ(C\/+Q2V?47/5@_PX%P_-DGB?&/BS\)H^?J_AN%,9=Z1
MNO1.DYD?_U>/OX%_,Y6&D_]Z0T]GX7\4- 1M<A^O96+XHV[V(LS"41B%^?+U
M>1@$*H8'_O:7ET^W=MZ\?8(/PCK,:]9B'"D_?3U*\O,WY66IF^_M3"-7W_(-
M/PJGT#BNL#4O#_]_^RG_@3V.G!XO%>W(*(D"^''P[1PFG7O/-G??/AGQ#&]]
MA&.@?Y5^[Q#?'QS_OC<X](8?!Z?]D\'GX<'>6<\[.-K;7-<1]S\-CO8'^U[_
M:-\['9P-^T/X\*5_>MH_&M[CF*\;YO#8._E\NO>Q?S;PSC[V8:3>\0=O[_C3
MI^,C[VQXO/?/6Q[LGSY[=/1R?Q0I_>(H20.5;HR3*/+GF7JM_["[?@[]G?/,
M\8".X1=8*AD-\RQ_D2?Z"^98](W#UW#8+E<K\RB/-@(X NT$<MQ4CU/ZW^:I
MYX&9N$KS<.Q'LH? ^J3%76C06B_I6*^=Q7ZLEA-H;1(EEWH-]>>-R]2?OQ[!
M7?)UXQ(6[%I&;'[W1UD2+7+U!GERE24S+Y3_YL$CGMB3/,7MO(49WL%1^N*G
MJ0^'Z2C9_-M?MI]OO?F?O_WEU?,7K][\+]]8M[(S=WYO02='B]E(I5XR\<Y
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M+:(IQ80W.;21* I$.A]UC>IW\4TN2)+0SNC>30,"*(\0104BKV\+2[I9OB]
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M@$LX.^.O7I#ZES%CBEQX*$)!0:0DDA+OGDM?N#EC.'XX-I2+,:,:[6>9>G"
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M'P6G3I'HW=S.A&F*EE"3Q7M&B9[Y@2*G("4[1^J3=*@2CFLHPJ<(;S296VG
M)$;Y"G.$IE:,+X'MSB:^R6?NPS<%C,&.(JN8]"N;A6$J9%JB_+AH*,!12;"-
M;7'KK&:>>+]8;AS$KO$HI\2Q5:@9FN'":VV1)?H4"Z3QK9=^QKRC:*," I<4
MIAS9CQYZKGTW!YI!GV#IW//^BPO"E+>IZ8$+"QDO!P>06W5<FK9_E"9?.3'
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MXV8.9.&0O-1AAI3P:,2"$<W$KD%B#ZYGCK,&JA9.34)_$@;% IRL5 / K'>
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M*;$Z/1 -+K.C8$V(/7+;SO96EV%_QOA><AQ*[@S$I932)6G&[IO(8XH[C)5
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M. ]=6TM.03DNSB8L4WW0(GDZZ5AN<504,@LD4542*:ESB?(=&718@B,HVU(
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M&P#J)OW"Z&VI"!<M]=IUM%W?L>;/X%?M*0WCA9A3<:GH0,IMYA45-7(,>]?
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MZO!%GUFCG2E<#5$$W!9$'$"E>VY2Y.!&LE2-[I2_KI[-\I/_+9PM9K@\:-4
MU=E)O:/!!24UZF952$M@Q5*2I()(=,I'/D]4]#2H+S7CY+*TV[Z.2+@"3TLG
MFDX,@JYAM7V=:/6J12>!WJ:#AAW>],KBM<OM&*U.2K76#PN2NY[.*HDN4\I)
M&M^X(5QBR0/%\D[GFU,NQ&SA#).NH#X+G/(#YG?;WMKX;R1C_>&?/9UW@>K:
M<L:PG@>D9Q.&)9M6 5LZ'UQGB;E>J,J+]%B79:9:;ZCSGZY%+X)?J3Z&9\+%
MW)="*MQ%;#KIQ=I:02G7A(Q4[T>3(!'3;F$B*"=W#-RPDQ#6-^0(!4%/PI0H
M?4R:Q+ H,XIY<+!T*TV@3,H,$27X-7*H&U.2I=L44 1*#.)>HX44<0''69#/
MMES0>/KLV!;W.+F,+PMC@71QJ5EJQPH#N=&T+NF$8-X3#!9YOS1;+/153JQ;
M.IB<RXML)0G_J_.;V.E-Z*WJ_:1A9P+6+[Y'*UXXP7+0*"$YTLWV*^)VQ1,N
M$+@ @K$<9*K7F&&1AJ0%+P,'6H (QHI3%G[+EQM ED#>G>?;;[/%O&IL?[&)
M@(@:/\8O[[+\[1-XYUV7$Y45J6-D0<F02*8R50Z9:>"J]XJFW=XF@5G@M#>1
MZAA;3J164'A[BU]]BS-7D=3>3']Z)BWLHH5=M+"+'Q)V\>JG\WJO-\6UL(M'
M3X M[**%7:S'3?4CP2YXFF[TJ)/HX$I74CWF@H1BK23[.AJ-/9*8"074V44N
M@B_H=4;PO5;!X.:-2.\.% T[[D";:DF@>H'1?&.,SHBB*ZI+5#45--T4O:2.
MEE^I<=#C;DS=UR1M[K?0(*XRSH%"*X7!R:WJF/BL@C;5P'76@QM;ME=6G!'&
MZ\OV%HZD2;2?V(E!NS:4OFE @1KEF&=$352*VG#&[Q%+Z)EZ*Y>ZUH>.Z@_C
M+$\7,X/D@!TKU6&AFPY)HRBU6]1LL2KOZH"=GFG\$C=6EB!K6 -39J=^XMT>
MCB@K OY\>][LM:XS#145<\0J8+U5J7%%:O,*ZK5.G#"I4[)_ @6[]:/>FA]U
M5/*C#A_ -F7EU4(NB FRTE!R":QX?_BN7X&#VM#J7#I*3AH%8_-EHYBI=E27
M=,2M=5)@4&JZ7;F:%6'>$BLM +SY($'VY3NRQ8[<&G;DZ8VP(T>)]R%EX@!2
M8><^1\3"+Y/BEPI,5E*@&VA:N4K053 &\J%$H5IHD<7J*-/U'GU=([VX4"UI
MK>QYN2H,S;A<2#V"+P(\ER:1WK=<0F&E-0VQ<#U0<]^Y$ 7S1%]A[AF)LI?\
MD1VGE,XJL%<-'UL=_MHUL?7$%BI+V!ZI6SM2.S<\4K@]<HKZF X!'1%\U> /
M-HN?S18QYD%C[%:JMQ\O@B+E?V>%9%(5XK"J%!BG:!U\DTN%40$5X\72"AN5
M5V'WK(;GF*(F>*F(C[I73I*2E*;F.JLN0E][;.&3VB#/K'%S[X).[IUL?MKL
MT4;^D:1?O3VJ-0=;2;A/WW;^]@J ")UD&[?-3K.['#6-)O"71H&@&'ZW^$S*
M-4L\PNFO,#O8S/+\9()VLVX%(CT_'!3GP$69@E5/UIU)',$T4=,8R)_A[C&2
M.4P*1 ]2&-,+*F]!+E%*D4$K.EID<%"SC.:IV9- <RZZK#4#Z\%*."2/S(W"
M*QFG2*-/9F7O92DE$]$A#1S>/D=ZU'UQZ1H_"("IZ:)<LO[%EQ-=>:9TIC2Y
M/T 4]?;62^)7!Y.2?_9^Q[)E#>5]F/P^5A$N:.K/U0)!WSVXC,?WBU.VA[2[
MN^L=8C'"+W!K3;S]%/;\P0:#[7[TB1#WAM[6\]WM[0<;2Q_A$V36\_[A7^ )
M/4V"-)PNU']ZH+'&R"]_P[-T D< TQOFO0<;Z]YYJ";>(2CND7<\ ?5'Q*@B
MM^,90C@PO]'#G<,!LHS7WK]2O8S_;Q0FW^ XY-9IV 3^\7!#_$*2,V=,E=*2
M!F=B91.+Y8[/DX=C)8<^7&@S[V_^;/X&I._\:PC<]O#PY,$&]'1KR]O#C)]Q
M0*IZJE3^<(PVR7(4,3[UO:VGV]O/'Y*+  ,Y0;N#=[0)S"T&XH^3[(WW3X7$
M=HC?16A'S/U[)OSMZMF<XS@WS_4@_U]TB>?QC?<5QPK?ZX'*#RVTI86VM-"6
M'Q+:LKWUTT$+UIOD6FS+HR? %MO28EO6XZKZ\; MA1''!*DDY L7$Q2YX!VC
ME!5X+<YVM/NR9764)%]UWE[,W%[)<?M08>/'*05=Z?+KY($8)>1BQ B0,28P
MU[&<;,-NGK_$.<$,PWE(X4D^UE XQYAT$W8QJD2*L$$:0UA]TPF_:5):FPK2
MU936QH@=2Z '&P4)"]!Z1&[-(_+L1AX1+5OT,8J,_2+#BH.-<N*0F1HMT12/
MI"$[''UF5>$R?D2.*+-3+0M,I!1W5!=91IEQY_,DQ!Z\&-;(Z8]]-[J2 /D#
M8BLA4*741J4!">[S9BJ=*E-[Q&Z0HY\IH@[CG_CGF'SFXO6_47_&M>/+@:GI
M\F8MZO@_PB$A Y =DB!0Y']%J84\760$K[*J%63:K9 5?@1KF' X,2"K*'O2
MN-7&\47NXD7*O&<LNT2'O*DQ\=^:,E148Z!(VTWU%?A504B4UB#AVFL4H=D!
M?L4Q7>/(A[G@USW,%$+Q9E2(*@RZY9S]>1V,B;S"%J_$"DVQOB#TK$\E5TO+
MNFZ-=>W>B'5]"C-$67)I^3:CQIUFU+BGPE/>*1=;0CP@0[J85W'AJ:%U6T@6
M-QT:ROY,<X#'_MP?H^^6&A)\9R6$O3%#!Q70 6:E05RZ2%7&*#*3^ZC CB:3
MJVL^F5H+#(Y$W+#.$&*2DQ0(T+"4*'ZDV,60+DSU$HS\-O#MFR^*C1^MYC$Q
M$!==^VI"E?B*0C>EV<GDZ&F]?CV2%KDF5'Y.Q8QP#L*V[;O/5 +J7)XKOCRP
M,96D4S\._R-("@(,D=0H$&)%;)YKU0G$6GYR+NH>7_*8Z IH>^KKJBX$T5UR
M^GX+&=SMF5TO[J&94B@*9+UZBI!:8',6'&C)7+AQSQ6$3=T ]RZJKR)@(>[%
M::^3'-:E[C<D$2R:4?VE4DHPSVOHSX@%!15B>L09:H"<7L>+0I^T2\))VE1)
M):KLVF@6H+)S=:5%9U^(R+(KZ1#+TC$!T7+90Z(:E%G&*/UJ0@7X9IPJ6)":
MFB;MI7)7\.)[N53ZNM978""4>)?H)&Q%44LJ4I.SD E'*9#@#^18@H19-NHK
MUDVRY#([8^%:U\##9HI3-Y"X;I7>1&)'<V?$(&=HQE(4*#-?FBRFY[6<TF0&
M0;8--(_<:"66Z!3V$WX+9\F/*DDM[%J-16% /6G_(@EI^3*EOA*WIR]PP9(1
M*AV:Z\Y52G6VI(:*=?'45I3EL"+RNF,T"*;!(TIUBM3BE$$NU\#K,;Q*@"E<
M>LF1P_D"J0<*LN G<_^K5'PTS^@JKGZF%<98H3*"D]6%XZ1$$G*Y%*X]0:H7
M%Z=6-$K9_MQ*N5,?C3C(47T$L2&+_F*3BP:3@=:C4C^RRNE9Q=6=<!]<) 0&
M<G8-*T>'4TD='RW=-VQ3LC#P<W])[D0*CT$YAIBVDROHBJQBIF^N9,-=:V0@
MIG,L+?8J:UW ]LOEG_!-*C@8,;0S0MB+3C4)NBG^C6J@B1##\Y%QT%!I':Z-
MC>.$;PP!1+65,F"F$EV <TYB:E=-<-,)]YQ@29?8FK+P)@;$85T[-9L;P*DP
MGZRP0$@2(2DHEL#*C)( S7:4G>9?<#RS(!Q+4 (',]4M)QKP8KVG1>Q9HL\C
M<:,$NII6BZS??U# 8[\5QP]Q*YYI@PRSP#[PS&DL5Z-5R [K@H,898I]6Y!W
MZSJ(_$NT/9=+6XU(Y()VRR%KJ,F5GA4EK/Q\P<Z8&>96@BJM39025$EM2 K*
M*\Q.JX?A6-6RW.S1A!]>Y G>EF,ZY$VY?@,)32O-TTC1(RF2FTB07RR55LG]
M0#%*>5G#*N66E(]AJF-S4?;/W#WEM<R<_:0+P 0WD&@#>UNH "L(_M **7:B
MQ(E.8E42O7+82V;)Y)+X]R)DH(I$@Z:H5!.S9SL@;I-=@M1582HDA.0SHU3.
ML+"L!6MP?3U1N8/3M>#"M&DA6TA3"VEJ(4T_)J3IYIB9'QU1LMXDUT*:'CT!
MMI"F%M*T'E?5ND*:?B8M-W@0VR_J Y1%!N7X+VC635WS;V:%L)NTLD4M@*J*
M,4L"1D>A34JK&Z:(-%(D&DS$^"*&9),MI4%UK5=(6A/+K1&?>A#B&R.)H>V$
M2>Y4(G"O3D'%&K<54.:;9MA@"_KH-%6<0!QU\"+G>V'1AM?9N6>7,V>J;JGJ
MUJAJ\A!4]2M'A\=3[]"_?./]P[+Y,IGU#P^]__X\.!L>'!^=>7O'1WN#TZ.#
MHU^]X<<!?CP;GG[>PQ][WF_]PX/]@^$?/6]P].'X=&_P:7 T]/I'^][!T7!P
M>G(Z&/;Q2>_X [Q]<.9]Z9^>]N&1LX_8R_N!]^OQ;]#Z8-][_P>])^W#%_A)
M6L7FO/[>WO'I?A]&XWTY&'ZDT1SVOYQQVP/O#+H:X(>CP1?OC^/3?])CQY^'
MWNG@U_[IOC<\IN=.3@^.]@Y.#@?T)O3WX?!@;T@?H#E\Y'1P_ $8?'_OHVY[
M[_C32?^(1XB?/QX?[@]./7P4QGUP>CKX[7BO__[P#^_L\_M/!]":=#;X?>_P
M\]G!;P/O'Y]/#\[V#_:*Y=!#QD8_#*"]_B%T]/D4WCX[& YQQ6':U#TLL3VS
MGO?^^/3X\Z\TOD_]HX_]X; /VP&+1<_W]__Q&;HR2X]#WS\X._D,O>&8/Q_A
MZ.%A:!\6X&C H\*?:&GA%_H7WQO"?IWU^0%X=CCX='((H][7DX=GH>F]SV=G
M\AVTV8$5/H01P RHG=/!V0GT81;%HA49G2R(W=G^\=YG?.2LVZ,EJEGL+WU8
MV3/^N?_KZ0"V].B8NNG#<$Z'1#9'N"D'0WA*UOX42.!X;S# \?7H][W#_L$G
M&$ ?WH#_<2LG@].SXR,@4]K4?UCC+V\E=P'40KOWO93#DS'=>C"!WP[VB*)I
MO&=GYH#@JN!@]/?O![C4^((<%3V@YHGC>?O4/SC$/_O0Z,D?FO*]WP[Z>&0.
MSN $0WOP&C" X<&' _B K^ W=&H/?OTX]/8'AS#NTS^\#FWUX+>#_<$1#UO_
MU,6QTGAX<AZL,Y/I_BD.'T8\^/ !%Q@)&-8>IDWS.QC:6TO[P].2I6$N0BSC
M8(C$_>OQ,3..L\\?/ASL'2"%-:PC=U,<=_C\$1<#:;Q_<%00LV%5^P,@66(C
MAP>?#@QQ?>G_0?^>TG+@3'$?3%_R%)S2(]AW6 !X=<C\#MC-38A%" 1'0WW1
M$O7AS!P M<#O0)9_M)?SK5W.TX>XG#\JR@*3%7#%<_G&)'5,R67/Z+,X5"36
MQ=&RI[-^VI(?0<4K\F*1*4B<9D4E1L(*D&92U"L3X;"BG+2T=FNT=OX@'EP%
M@B #W)9,;P<Q%RZB78\)8$,5B*H44"8I*R$5H2?PU46L8J#4,6=0#6.!&I&W
MD;$F]"CA23'KCWXXM-$I17K>0CFY=AQ2$(;\ON+7(W)F39LQ,HR^3=5H6=3=
M:W Z"EX($ROF):@0ZD^H3$FF))Z1.YW(6CB-Q2R"))HP'Q22P:=8PV9XG(R=
MD6X)M6/*@Q@TK$1,F!:*_DONV3LZPA53</G _L_I "0)ED+A6N[_.B"%X0CE
M%)*X#@<?AM[[P_[1/_^W=9JV3M/6:?IC.DV?_G0^J_4FN=9I^N@)L'6:MD[3
M];BJ?@2G:2D>%G-!'*'-\@A--U_8-N3BXC'# :$+ U?SX$CB8!%19NSQ0L*$
M*(M$$4"2Z/R))DB(LKMRU#&".L>4N9T@]'<#%_S.W;PS:7!C:W/KY8M7SW>V
MMY[]=14A\!J)3P]/NMWF&:_ _)^]VGQU)?.W2-EJ'+TIDRBYU*NG/V]<IO[\
M-3./2UBJ:P^U^=T?40P-J.]PON__>/]IEK[J;;M[C3C1KO?MKO>S9YLOKA0X
MVP6_P8)?+^W?@+6L"9/7E 2L/(/+[N^_//WE^E,,_/O%/<_M_<'Q[WN#0W+>
M]$\&GX<'>V<][^!H;_,FVEB[/VLWM\>\:7_V.KR+<R39ZF]X@XCD)^K5]OR;
M1RX%3^ME/\:6M+1VK],Y\F?JSU ;R@H/3&JGX?C<3P/O+%=A#'_E+3$]$#$-
M,6W)=U'3O0ZSMI #UTZ@F@H?PMB/J8RBU%5X4%O>BF2Q)L-HW6^M^VUM6>)Z
MN$JV=WXZ[\=ZDUSK?GOT!-BZWUKWVWI<5>OF?KL6%/9VY'0I(,E1$@7<#&<E
M2]+9Z\5\KE)$*J*,/3Y7P0*D)."FH]N44&]IZ+^\^W!\^@EA;H/?!Z=[!V<#
M@9X_X'#_9TC.2MM/V9!NL:%*MDZG8G)>W29*[T8Y[0_]()2RD;_"M",,:[OC
MNFD_43[ESG:EGKOBS9>$.&$Y$6Q9Q/$Z^+OD.;KRF,B;>"PD^U%7UW@&^FPN
M;MGS?&\?&-<E(N/M)(<K]RRN?;MG&#PGXR6O/4./R>>O4?B4_2VW8G\#-;&"
M)#&CFA( LTFO-%-^3%#^4AX_]0 YT1X[X3Z]AG 9^FT2;F4$U##IAPW_NQ<@
M_M_^LOU\Z\TZ_!?# ,II#&$M,-FPR?[5TNIMT^I.#:V:2O0YY8BF/)5S?SFS
M@OY-5?"3E$H[ZZ""F1]0@8T.2$:81SQ6W76X$>N6]RYWZTQ-$^5]/O#.EC-@
M]-^[.W_[RZL7SYZ]<7=HS\_.S?JW:WNK:RLW]I[.B:B76:YFD3W/%"?VV]XJ
M93U?@]UX)&SI68DMG3@705CL# A[F.>^+J&UE'DOY:DOW3 !%H:=Z;SQ_AB+
M9A490TO)G)6=P+&2<]<P0>E8F>3<DR2*DDL,)-O_TM_S^M +YB8^6LQ&*GTX
M_O@8"&6W1"CO&?8J6[ T07JU]&(+9:F:PR92QF(4L*543Z:WT.09QLL0X_!"
MREK,5<&*).S2B:+Z"N-"UBM']''P*R9+E? [+-&#]=&^C:6\&+X1$X%0^O)Z
M7;CC7T?!AE?M=(*N;O>LR'X[^,8ES( HZ7+??K7SK$>E"C@]4!?3*L\P\4\@
M,&,8*?Q=XH3;';];.B-V12A.0(N2 IEYU!VE(UTW?/'WN[MN%VCL.!^V=Q\0
MAREV6>JX LG\$:&8J[@6'G+!'Q?P=34*W]UJ*?P^P<8W8"]W,.5]C%JY&1X'
M3^3C !*N?B":YDN>C3E(%W'^@\QYW0GR3MW4N^L$2KP'LOTQYK/N)(D V**<
M3\LL6V:Y+I39,LN66:X92=XT,J5ED"V#7,.)M0RR99#K$D[5LLB61:[AQ%H6
MV;+(M0D2;'GD#\\C'W',Y#6!*YTS^,7/L13H;)%1(FBNQ<OU@@6(2M[TV+%%
M46EI^$W*TC D=>*/5<F;W&T#+]O RW7D:>L6)+?][*>+>UMODFL#+Q\] ;:!
MEUO.;?,GHBPODE!?,(U!ED]&2;"$?\[S6?3N_P-02P$"% ,4    " "O@'Q:
ML*SL?$07  #:$ $ $0              @ $     8G1A:2TR,#(T,3(S,2YX
M<V102P$"% ,4    " "O@'Q:B\&E84\3  "-*0$ %0              @ %S
M%P  8G1A:2TR,#(T,3(S,5]C86PN>&UL4$L! A0#%     @ KX!\6DZEENDD
M20  \.D$ !4              ( !]2H  &)T86DM,C R-#$R,S%?9&5F+GAM
M;%!+ 0(4 Q0    ( *^ ?%H9@Q'P(9@  $]7"@ 5              "  4QT
M  !B=&%I+3(P,C0Q,C,Q7VQA8BYX;6Q02P$"% ,4    " "O@'Q:H5*ZV6QH
M  !UX < %0              @ &@# $ 8G1A:2TR,#(T,3(S,5]P<F4N>&UL
M4$L! A0#%     @ KX!\6OEX^(A*508 U<P\ !4              ( !/W4!
M &)T86DM,C R-#$R,S%X,3!K+FAT;5!+ 0(4 Q0    ( *^ ?%I'E"L6O"(!
M (Q" 0 8              "  ;S*!P!B=&%I+3(P,C0Q,C,Q>#$P:S P,2YJ
M<&=02P$"% ,4    " "O@'Q:L8N&CC 1 0![9P$ &               @ &N
M[0@ 8G1A:2TR,#(T,3(S,7@Q,&LP,#(N:G!G4$L! A0#%     @ KX!\6CYI
MHC&TY   QB$! !@              ( !%/\) &)T86DM,C R-#$R,S%X,3!K
M,# S+FIP9U!+ 0(4 Q0    ( *^ ?%KAF>Y0LP$! '0E 0 8
M  "  ?[C"@!B=&%I+3(P,C0Q,C,Q>#$P:S P-"YJ<&=02P$"% ,4    " "O
M@'Q:HLJA8Q-+ 0 .A0$ &               @ 'GY0L 8G1A:2TR,#(T,3(S
M,7@Q,&LP,#4N:G!G4$L! A0#%     @ KX!\6G][6;>M"P$ KCT! !@
M         ( !,#$- &)T86DM,C R-#$R,S%X,3!K,# V+FIP9U!+ 0(4 Q0
M   ( *^ ?%JZIH3P#X ! #JS 0 8              "  1,]#@!B=&%I+3(P
M,C0Q,C,Q>#$P:S P-RYJ<&=02P$"% ,4    " "O@'Q: -XCMJXX 0#$;@$
M&               @ %8O0\ 8G1A:2TR,#(T,3(S,7@Q,&LP,#@N:G!G4$L!
M A0#%     @ KX!\6M!6MZFW,@  ]D<& !H              ( !//80 &)T
M86DM,C R-#$R,S%X97@Q,&0R,C8N:'1M4$L! A0#%     @ KX!\6H8/V0'
M0   !@ " !@              ( !*RD1 &)T86DM,C R-#$R,S%X97@Q.60Q
M+FAT;5!+ 0(4 Q0    ( *^ ?%KUCIZ$\0$  *@$   8              "
M 2%J$0!B=&%I+3(P,C0Q,C,Q>&5X,C%D,2YH=&U02P$"% ,4    " "O@'Q:
M FTI^8($   %$0  &               @ %(;!$ 8G1A:2TR,#(T,3(S,7AE
M>#(S9#$N:'1M4$L! A0#%     @ KX!\6CG0&$-D"0  SF0  !@
M     ( ! '$1 &)T86DM,C R-#$R,S%X97@S,60Q+FAT;5!+ 0(4 Q0    (
M *^ ?%IK=EP=R D   ][   8              "  9IZ$0!B=&%I+3(P,C0Q
M,C,Q>&5X,S%D,BYH=&U02P$"% ,4    " "O@'Q:&C#P@[8%   #*P  &
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L=&%I+3(P,C0Q,C,Q>&5X-&0U+FAT;5!+!08     &  8 'H&  #7Z!$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>btai-20241231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:btai="http://www.bioxceltherapeutics.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="btai-20241231.xsd" xlink:type="simple"/>
    <context id="Duration_11_21_2024_To_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_QAwpylSU5UyaB8Q_rrtbYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="Duration_12_5_2023_To_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_3RWlGpXOtESBeWP1E_X8Xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-05</startDate>
            <endDate>2023-12-05</endDate>
        </period>
    </context>
    <context id="Duration_3_3_2025_To_3_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_N0FLHzjjW0ebf_9f1FrfOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:PurchaseAgreementRegisteredSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-03</startDate>
            <endDate>2025-03-03</endDate>
        </period>
    </context>
    <context id="Duration_3_25_2024_To_3_25_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_p4L6ETPqFEWoA9lBndZOtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-25</startDate>
            <endDate>2024-03-25</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_mzi71qMtwUW4NC2oL1_1RQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_10_2025_To_2_10_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wNzSowqeUkChgrK7zHK_5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-10</startDate>
            <endDate>2025-02-10</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mVjyx3cGLEy1gJnnx6T0VA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JBhziCHFEUu1-FicgIwmyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6eSNIlZJN0KWpLFkIG2zfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gi1gHYnNBk66zzB63nP9Xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2OE8-Puy-k62aulMwMTDvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QQDsQgcnEkyWGJT2fjUW4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_tv06eTkorUuLZsqZJC7L6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="As_Of_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_GIUFHpY0_EqDv2ibJW6xSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xOcQ1mX8HUS3oomqLm_lMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_vq2yym5s9EyjbM2-H8oIkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_v9I1drvLSkCReDIKAPrJEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_StockPlan2017Member_L_iPsP7adEiG4elxGlZNHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:StockPlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-20</instant>
        </period>
    </context>
    <context id="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_vDwwtKHeaUKjbZq0pfe-PA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-20</instant>
        </period>
    </context>
    <context id="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_N0vp5VFCUkqtRrwPRBSFFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-20</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_tHUExHKUMUmrePF-CWMIfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_qoDjPOgKl02zcP5r7FAQuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_RvCrri81RU2aLpOi6LE4XQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_OpSGdiyFOEqI7cFehOL59A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BcKPgE027Eq07dZFNZcBVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dHuj7RaJ8EKL0Sny_5o-CQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xVBddGnbW0ybwujG6xab2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SRyiKYrKEE6xThkeoaB7WA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ida0xzaxyUGKvrdsH2Fr0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_S6eKsZBc2UGXa8jiNAbKrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_B1zotSn0RUq8Gi-caKB5-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_urjzmG69Fk6Da0LeQweFZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_p0pq-UOWxEu_wI0sw4gUPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_hTkGBWRuAUSz0YVpoWxPsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_A8ZHOdOBykqthS4c1Q8gUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_Sa7bc9y2BEeY9w4XybT9qQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_5_8_2024_To_5_8_2024_IhAulVfqfE-gUqz51YDtXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2024-05-08</startDate>
            <endDate>2024-05-08</endDate>
        </period>
    </context>
    <context id="Duration_8_8_2023_To_8_8_2023_1AQEFh0qkU22JOe-2n46Ww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2023-08-08</startDate>
            <endDate>2023-08-08</endDate>
        </period>
    </context>
    <context id="Duration_9_17_2024_To_9_17_2024_OiBFsSYoqEGoJgxld_C82A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2024-09-17</startDate>
            <endDate>2024-09-17</endDate>
        </period>
    </context>
    <context id="As_Of_9_17_2024_XxyLTPFqzUyn2yLJ69oiWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2024-09-17</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aq06NwagjEu8lcUy9jbLbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gdYMQB6xIEGwPzlcPnEPVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_4_30_2022_Zfgyqm8oPECQksmotjQKJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember__lhd_4aX8kyoPoUbqHBE0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_MsiOU9Br5ESWVEwY_A5X2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_awYc1AER0EGr0NZ0NV2hSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_bGkvra2V9Ue26IMBxqrCww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_MJeawgIMDEyPxu7dj7F8aQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_3NEbuF2yQ0q1F_2-3706qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_kXPimCUV7keG3q0uOSWbGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_zmvJP9XWKUylAuis6tmJsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_27_2024_To_3_27_2024_1d4XGKCHW0m2lIKs8HPE9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2024-03-27</startDate>
            <endDate>2024-03-27</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_g-3YkuAMa0WFmUst9waAug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_11_22_2024_To_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_qCNNy1whp0ivehAR5sAVYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-22</startDate>
            <endDate>2024-11-22</endDate>
        </period>
    </context>
    <context id="Duration_3_27_2024_To_3_27_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_RvjnXZnJAEar_nFyvWCG8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-27</startDate>
            <endDate>2024-03-27</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_AhSo6vKkHk2Ijnc-39vr0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_DmobgouGJEKpKx5umwnDTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_dCk4KHjYVECYOD1bNWMxhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_0Fa5GpoDykyuoxmj8TA-dQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_AF3B6HHa0kyLVVlQaBJT2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_CehH3SOYY0-qk9E4i9FXiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_vPHQPh73CEuoO2NrgO5-hQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_CDdL6odIhEyB7dtSsjWgHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_q1hbZmrNS0GGTI07xc-mMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_0gKxZS-bl0i0rf4ETalC4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_QcDNt3XBCU29K3TtzRineQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E9MLp3OJ8EufrFv1jvE6sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oXWwEn3ERUe7z06ZWkBHXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_11_2024_To_7_11_2024_srt_RangeAxis_srt_MinimumMember_l8F9i5yxlk2GrsHmZ41AHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-11</startDate>
            <endDate>2024-07-11</endDate>
        </period>
    </context>
    <context id="Duration_7_11_2024_To_7_11_2024_srt_RangeAxis_srt_MaximumMember_MahkWQ1D0kWY8CGoanrcrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-11</startDate>
            <endDate>2024-07-11</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_4_30_2022_AGdwF45rAUaEqJM-M8UB2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheDMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_KgqW-5X7r06gLp9NBzxFsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheCMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_KEur4f2KVkKKQYGXeBkN_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheBMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_6ZZ0nOytkkyfb35YWqDR_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_OgOR5W9P3kGRnS_l9vYR4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="Duration_11_25_2024_To_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_DqkDewrv3kmwfGEQUIsTbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-25</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_5eL_-_utPUCNyy4fj-GOyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_p63njE8R7Eu_9LSZHS_XWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_N-lEdCI780-JkLi3BNV9Ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_25_2024_To_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_355-JNdbG0a2GsWONO9ZWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-25</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="Duration_11_21_2024_To_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_KgwhcGdOLE6rb5LSOLdQQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="Duration_12_5_2023_To_12_5_2023_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_NN4G50mhQUiE2MWFIStQGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-05</startDate>
            <endDate>2023-12-05</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Lm8AZQPL40KMLw_EFZsryQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_Mb79eA35SUKhSf2JoRymdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_j0QU6pzy1kWBLf65tC1seA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_4epNlYQKv0iKvwBrZlbiTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_sog3pKgdW0eiohkZeERd4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_3fPI5jL5i0amKn6Rp0WTxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_ZZb5ojV8nECXF6PGT2Sv6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OZo6Dpf0wkeLIC74MDokcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_B-Y0cXQAQ0Sb_-x7Pz9oew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_S1WaCx3EFEyAR8UWU9J9zA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_mCar_ZgvpEWSra0NQcz42g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_7e_v0kd2N0eBHM_SA31z7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_387uYLHD2EqiYkh3ZygEsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_LcJiex4QpE2YqESAdf6fpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_2mozctssp0KbH0y09FoRew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_SeVI2KEJJkaPytkbFhDmdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_OG-f8LWXVEuAP6w4PvNKlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_6A5TfvgGDkyeNTAS_CDIyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_RYPqtdbPfUOCOJbUwsxRdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_vnbH2b6cvk6tsJ16seh7xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_fnIGASQkZ0KT8yEsdC0CCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_0MsOXlyLLki32Y4tNC1zZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_btai_MeasurementInputProbabilityOfExerciseMember_R6UHsXs59kO6T0pv-5n4Pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">btai:MeasurementInputProbabilityOfExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_btai_MeasurementInputEstimatedPremiumMember_Nx0QCxfhw0uGTxWALoXeBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">btai:MeasurementInputEstimatedPremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_V0NHkt3bfk2Ba2s21MfECQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrants2024StrikePriceNotAmendedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_OQu-LcOiKkqIepIPSq1fgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_qJT7c0kn9Eu2AFMTvKrocQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_nUBe9GYzxE-ZmBiqq4O37Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_k8T7cHsMIUGhoBLO_zrk7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_T8m7TXv_3kCCweETb2zyjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_u9-8OCpVJkG9nsYV-XtccA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-25</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_p6z9MJatyUSUOiTjIZSLJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-25</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_mLs5yiiHEkCXZbPPpDd3Ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-25</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_jgX2LEyonkeD7lRM74FyMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-25</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_cLng8ai8UkazAQbJGlFaNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-25</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_yGOW9iQj6UGPG-rEriM09Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_6kMEiu_1N06tYfLStTj0oQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_oLqCI4mI10aP6GWCCHFvVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_icjol4YP1kutdR0RMqnOew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_qc0Go_Cfk020vCx7lAeh0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_CGrKS2JtHkaQ1g9h6LmHqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_9G_zTSXx60uhtuDGxqBgBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_oWedOZ60s0mXTRW5Lcn6Tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_1xcAi6iP-EO-REO2QzswUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_c4v5KMKYk0ChF42pkKq26w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_hovoRwmQvEeyatpC8QBdeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Cs-w0dC4c0WGpoXT9tdaBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember__BmWodN8tEOta3SjGS5jbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_goRVwXyuWUydp4Kjx4bF3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_0FNSOQxNAE-0IkMjsa2iKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_TN6VQOKYb02WtCDp3elR3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_aidNv9HgNk2DhIo_TgvNhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_2DCibhs95kq8Jc8YpX7xJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vpbgA0Y3d02GV60wknoGug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ExafltryU0uKvGWyPhUsBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_WvQM_Cfj6UW7acmcXHo-pQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_iXjg5DQGe0ydE6a0tFygQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AtesnzW9Vk62r5o4Z5MLOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MeVvKC1qK0CFc5qbgrTI9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_HN9QZyHZZEqqvDSOhHwi6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_JBeXWTEcBki5v7foWKB49w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_XYejg84PY0-8-DI1vMLBvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_DdDbFFCDBE64P_O4BJl7kA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_nJRaa39oO02skohtFNO_CQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_HcAF3jq9Q06V5LIYvzVw4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AmN6FsQg1EitMV_BHxN7_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ecW8VPGztk2Gf79xQBkyNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_cPgf57S61Uyah5MXLI1evA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KTr0ds-yYES_mpozAK0KPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rgfcXxi9006PlNFx3qH35g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1mPU0Lx-nE-RmcrvYY9V3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5D28fXSYSUCIMdnKx2CzdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_vDidZuvwFUuTvGIhGHCssg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_qKlv5oEboUGlNN_gzIoC-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_7_8_2022_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_rBZ8Wee2aUaWKVAwuLAbJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-08</instant>
        </period>
    </context>
    <context id="As_Of_4_28_2022_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_na3LkfDiw0K2aagoP_bMuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-28</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_4QXVMUpriU-O3ONSCTxFLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_d7MaxUhhVECHSCm80cC1Ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_T8y78WMP4ECZ9sQKm-yKhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_xroiFJrnD0eA_jiPBHLdvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_07DuWNjS7E2tMACIgVlBjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_LmEJHhC5GEuhV4cvR-CyZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_I-pOhJgS20CdZAck10nsIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_2OCsk1QU00-KJSY3sMd-yQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_UmSoTOy6ZEqdvjDqQLaKEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_7_11_2024_M-RCVSP_HEGMyNg657_jKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2024-07-11</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_btai_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_W_hOEF0UGE6XdSlHUL5Rsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">btai:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_btai_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_5C4QWry9fk6gmoPexiMApw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">btai:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uVBBMguAlEqRZE6UprsHRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tk2nuQrdU0uVZYuijUkSUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WhUd_ZOlBUmqQn-nMAVDoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_nr25qN2kxkCVXTVDwzfXDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:PurchaseAgreementRegisteredSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_qU4qYdPWcke_ZGR8vt26Xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-25</instant>
        </period>
    </context>
    <context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_T6cTQVW5iEu7v6aQO3r8Lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_tnK7lRA_PkmprsVLffcXvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_G-NzlEzfREKwJKc_rBs35Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_3zrIDKZAEUqRigs4dt4KAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024PrefundedAccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_aWycUKhL-06MF4rymZ6neQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024PrefundedAccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_LGUU816Yp0m2LKivHXs1uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_0htohoQg0EW5M9buTb1qzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_PrefundedWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_yKIZRxNDvEu7Hv10JhQ-7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:PrefundedWarrantsMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:PurchaseAgreementRegisteredSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_c4ZQpDZ5ekCFoY0FzRG6JA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:PurchaseAgreementRegisteredSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_tkaY4qbmDUqjsdxXtER_7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:PurchaseAgreementRegisteredSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_P_XszpuZj0GQUjB1hTtEgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_IntraCoastalCapitalMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_b02B55BM6EG9d7CRINubvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:IntraCoastalCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_HudsonBayCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_McrVOhYGbEC_tS_1BvXkKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:HudsonBayCapitalManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_HeightsCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_gmwEIZ8DKkiPWDp5YfOhFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:HeightsCapitalManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_ArmisticeCapitalMasterFundMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_mhbEOSMN9E-6fQNPjBHEBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:ArmisticeCapitalMasterFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_FRRTD6E8_UWc7CqpvzLbPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantShares2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_lI6dv2jX_EWXRmyQX2VxXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_sWnPUgoZNUaV48uFc0AzEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_UVB3pFbO506ugN_GMsELIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_WWey9zxoakaXp0S1ZYs4vg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_kfeh-8yR4k-MMGH2ApsgLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrants2024StrikePriceNotAmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_P_lWwiR8M0e2d17J1qElcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_Olx3FwfBuUyeg4UcTjGZjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_-Q7xp87Es0iyjocCWGGiMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_ULyHbDGAWkiYKXfDf_TeDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OriginalWarrantsMember_NyepRdGwwE65aulGXbIqFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OriginalWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_JyNR98gl_k-4MeLePLJWaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_ao0h5xCb-0is227s68HQKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-25</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_IrTiliqP_U6VjgDahhs3oQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-25</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_oiu1ThMdnUOs-KiwIduWmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-25</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_zFzFVctYTUm5PGuvO5mZ0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantShares2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_5ri5JcF8t06zRgfNuESzxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_7Rf_XFQB_kmb6iMCoS8NYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_W5J6mPqvkkqYc6G6pFfyUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_uPbZgXmXZUiSsb-dyLE4HA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_jhStatqo5EaSoSvdA9RW0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_waelNlOubE2wBVFPlyHhnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_Lzrt-ozGkUiBpO-gtGyjpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_8wNKxgPGRUu5CFwHgwGsEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_a-yRAQ6nhkmrbi3aQ6cBLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_uVcJZBaEUU2RieeIBXowxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_btai_BioxcelWarrantsAggregateMember_D-VgH0D5EkWR5T5lmAPfSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_lFtYhgCxvUaKZc-Y-rTpsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_ufIYMMNpvEWk__kIwMRFvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_1Vg-MGOfMUG52-OKD_lr3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_btai_BioxcelWarrantsAggregateMember_yQW7FSPMyU-tXyPdIkz20Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_OQGpm4OmO0GvGOO9BwRRtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_vlhYBLGO70Kx9W7BpuYnNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_QvezY-cudU6QqyNRbmjCmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_oEnUYj2nH0S7nHVXLQ4q4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0DAGDztWUkKwXUglANCasg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_ecd_IndividualAxis_btai_VimalMehtaMember_I0XJDPHFNECy_x1rSOZJ9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:VimalMehtaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_ecd_IndividualAxis_btai_RichardSteinhartMember_4GcV7wKgb0qyo8g-DWuPiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:RichardSteinhartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_ecd_IndividualAxis_btai_JavierRodriguezMember_bkghpJl7jUGxwTp51yM2GA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:JavierRodriguezMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_ecd_IndividualAxis_btai_FrankYoccaMember_1VVE1uh3REuAmq0XmRLywQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:FrankYoccaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_VimalMehtaMember_fZwn5BB5AEyBJNs2qszV2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:VimalMehtaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_RichardSteinhartMember_6zb1jv50yke5UAZ2fdNlYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:RichardSteinhartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_JavierRodriguezMember_u3tdF-_eYkmI9WHxmSaiPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:JavierRodriguezMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_FrankYoccaMember_EjqW660Xi0ae7YJdz_f5pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:FrankYoccaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_12_31_2024_3PEv7wfJfUKxY2X6WXJQ_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ILN-_SN1KEyD2kZtjTgasA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_26_2025_l5KrQw1_MEy8y_GUvIg7oQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2025-03-26</instant>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_vxYm8GIUnUOKESLLX6fb8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_M-TubXQul02zZZfaAcmBuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="Duration_3_28_2025_To_3_28_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_PrefundedWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_zbIxHgjTxE2SCgROmOBKRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:PrefundedWarrantsMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:PurchaseAgreementRegisteredSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-28</startDate>
            <endDate>2025-03-28</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2025_To_2_28_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_KmnbJXUr7EyUFHylcIdSIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024PrefundedAccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_g6yAJhZGY0yVCcOg2tqiqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_Wv-fkHFxikOa4i1-EXoS9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_IRUWqt-XME6DBPhp1Szf3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-20</startDate>
            <endDate>2020-05-20</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mnMmxsdqv0CnwoCMs9Wk3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_CrXc_wq4WE6253aRHA7iZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_pyA1UGmh10OZkxGv9jCGdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2023_To_11_30_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_EVFuPSms4EKLkPgGiKPLIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="Duration_5_31_2021_To_5_31_2021_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_7HqDJsFg10yEnahziR0XDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-31</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_V2jj_eDlt0q_u0vXSYoyKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="Duration_3_20_2024_To_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_4EZhC-NYEUGDlhcjArlf5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantShares2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-03-20</endDate>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_Hql-Wv3mXkKp2hBGSh3usg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_cP_MaCBZ7UyPaY583or7dQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_w_gcoxE8C0GzioKd7L0Zdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="As_Of_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_m9UZs2c2l0S2PukXjZUImg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_hoC3FYJ7zkS3zSkEUQbGEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_WgBqcPiqCk2sU5U9HArJCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_HHsV3q--b0-Hi4NmC1wOxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterFundingOfTrancheBLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_M-8oLHEl10ODoYzrqVk1qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:FromAndAfterFundingOfTrancheBLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_tXi0TB25sk2fARG5mILYWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_G6VSgb21CUeRJAKu7-undQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_X9rWZSSabEakPXkM8Eutyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_xR9vxlNSTk2dU3JYtP5BmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_FD1LiU8FskaLMx-wupgQpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_jyI3cFSKl0a4pfcKd3ZJiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-03-20</endDate>
        </period>
    </context>
    <context id="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_8e8qqxErlUCxNND1J5ekRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-03-20</endDate>
        </period>
    </context>
    <context id="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_5ZybN_dt3E6T6rIGI2RnCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-03-20</endDate>
        </period>
    </context>
    <context id="Duration_2_12_2024_To_2_12_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_QkgOxhTM3EWQV2UEUZ202A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-12</startDate>
            <endDate>2024-02-12</endDate>
        </period>
    </context>
    <context id="As_Of_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_ots7YDarCkyspj_MFv5RgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_a4FuB-EA3US0t7LRQkJ_0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-13</instant>
        </period>
    </context>
    <context id="As_Of_11_12_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_1pH0cdjOhkqjWy9MM_KenA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-12</instant>
        </period>
    </context>
    <context id="Duration_12_5_2023_To_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_54xfhc08YEGFKmDToW_EHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-05</startDate>
            <endDate>2023-12-05</endDate>
        </period>
    </context>
    <context id="Duration_11_13_2023_To_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_9T8VX87-MkurojwuBrp51A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-13</startDate>
            <endDate>2023-11-13</endDate>
        </period>
    </context>
    <context id="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_jWcBt1FrAUy7Aw7aYKtEBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-20</startDate>
            <endDate>2020-05-20</endDate>
        </period>
    </context>
    <context id="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_hsgX06rVV0aG4JHyHT8zVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_WSKgB0WSZUCURjOJ6-sK0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_DBnAiitHfkaS-GOZJ2VMnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_V7ch7PHY70Gc6KcqC2X73Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_R53JeYIpIkKLogFP9f7n0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember__PljhQkwa0ehF3g8M7cQfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_t-V_k3tNdUCIUzhMpzNVHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_2_12_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_jnGiVGydjU-NmDn4wyec3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-12</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_r6Nt5rznFkuA80tgQ2K1yA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">btai:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">btai:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_SalesMilestonesMember_ivfM8IqGnEukjOEO4xau4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btai:SalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_DevelopmentMilestonesMember_jNVSm8QxO0KzJACAONNxDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btai:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_TfYSaq0lxkWKFNAMb3ByvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_c3NRP_HuykWiud2XxAIfdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IE4SFBMuyECxTHM_3bnLDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_30_2017_To_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__Rfp0WkOeUSwkyApqU9Aow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_eSrtMnrTnkmoVkWywMsDcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_WO_5QqewW0WCAmc5bwIHMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_Y_HWoZmdDBn0OhfgBS6ig-MA">
        <measure>btai:Y</measure>
    </unit>
    <unit id="Unit_Standard_segment_u3k5mJIKoECDA2MsRZB6Gg">
        <measure>btai:segment</measure>
    </unit>
    <unit id="Unit_Standard_employee_g1iuox2T4U2nGaIKFGYE2w">
        <measure>btai:employee</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      id="Hidden_La-EaG7Cp0W0ee4WZ-arqQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      id="Hidden_Ab0U0OpCdEqMgbG5X47l-Q"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tc_APWTfR0U6kedsQCr81AF0w_2_1">0001720893</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tc_qcvV8B_U40Oh2eivP8Vqow_4_1">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tc_5UvOUen8ZEi_MVruR7keLg_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tc_W7OMxTAtT0WBfpIeoX5x0g_6_1">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Hidden_hYGHwvMpfU6F1AX9KwsGtA"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Hidden_JUhYODu6bUCF--FUwX6LDw"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Hidden_VjkgfzRL90eELJLE8OO7cg">http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      id="Hidden_IIpe6ROVE0uzyVQI76hytw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      id="Hidden_QropzL8Q3USNg_pLCNbuTg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Hidden_7DatXox1g0qQEKSaGo77iw"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">1871000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Hidden__r-eL5w_Z0mc8eX5EelIrQ"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">3102000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_2_10_2025_To_2_10_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wNzSowqeUkChgrK7zHK_5A"
      decimals="4"
      id="Hidden_MAC978-QcU6PY1cLIWQ4hg"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.0625</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_vDidZuvwFUuTvGIhGHCssg"
      id="Hidden_q_7viYeZgU21L0rksnVcQQ">http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember</us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration>
    <us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
      contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_hsgX06rVV0aG4JHyHT8zVg"
      id="Hidden_kFih0nmoC0-H7vISN9YfvQ">http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember</us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mnMmxsdqv0CnwoCMs9Wk3Q"
      id="Hidden_O-R2_NsEcUirYc0hrciCHQ">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_A8ZHOdOBykqthS4c1Q8gUA"
      id="Hidden_ZV8mysUnJEKMO7_R1BXZ3w">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      id="Hidden_a6pX1JmlWkyKm9cKj1tV7w">http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      id="Hidden_pNs2n3-e20CuK4JoOz4cQA">http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <dei:DocumentType
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_CR6bYiZGZkejh6BYHUt_vw">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tc_4v9eKKTRJkWt15xV8lUm-g_2_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_Rsp6rTnSGUyygdFZFfWxbw">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_WEbOj44HhEOVsIof9-7ocA">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tc_mwQts6P_x0G44JMRohTffg_5_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_Hhe8aMgLsEmO9f-pprL07w">001-38410</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_SQVjzB8MlUWfWXJbdZjCBQ">BioXcel Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_5-Ta2br0DUS12kPc5bSh6g">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_EqfjrnE5JkuzYHK0WPprMg">82-1386754</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_3QprBY7kmUeUkTksH6bPUQ">555 Long Wharf Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_hE7boxFu90-0xMq1xvEsFQ">New Haven</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_WPDBBFxuhkyMMl6VOakFwg">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_BmiXigH__EmJkR1rP1JzOQ">06511</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_Lw0laxJT00-JlLDgGPa9MA">475</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_gyXRQY4OXE-PMEcUO_r8XQ">238-6837</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_VGf5o9U3RUiRowP9ToY-vg">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tc_r1Klw1ce9UGfRbz9A7Psgg_2_1">BTAI</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_z_QB4zzLvkuivsEtLSsbrA">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_FTU5wZcEKkmYVyPph2p74Q">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_z_dd8c-Jk0OUJ7O6QPpmNg">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_fB__nzwTHkG0QgGSLQ5Qkw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_w3vN2-B2PEezZOhQm40S3g">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_jr5pE5ZbY0yb0254UkvkmA">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_qCpelrbQQUuU3pPF-4YROg">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_0NyfAe4HiE2eltyiXRWVbg">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_pC_eA2VbcUW1-Fq8DLn_aw">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_-uNV0xlIO0mBQ9mRwC4i5g">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_J9RlO0ssaUekcgfx2bWQBQ">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2024_ILN-_SN1KEyD2kZtjTgasA"
      decimals="0"
      id="Narr_moAhNTvvyk-fS6_yU3wEqg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">41276960</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_26_2025_l5KrQw1_MEy8y_GUvIg7oQ"
      decimals="INF"
      id="Narr_qQaaRzXd6kK2MgB6SXAGFg"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">5486038</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_n2X5ZYsTDkqJ_gH8Ob196w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. Our cybersecurity risk management program includes a cybersecurity incident response plan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;We designed and assessed our program based on the National Institute of Standards and Technology Cybersecurity Framework. This does not imply that we meet any particular technical standards, specifications, or requirements, only &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;that we used the National Institute of Standards and Technology Cybersecurity Framework as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Our cybersecurity risk management program is integrated into our overall enterprise risk management program, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Our cybersecurity risk management program includes:&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;"&gt;&#x25cf;&lt;/span&gt;risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise information technology environment;&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;"&gt;&#x25cf;&lt;/span&gt;a management team responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents;&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;"&gt;&#x25cf;&lt;/span&gt;the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls;&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;"&gt;&#x25cf;&lt;/span&gt;cybersecurity awareness training of our employees, incident response personnel, and senior management; &lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;"&gt;&#x25cf;&lt;/span&gt;a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;"&gt;&#x25cf;&lt;/span&gt;a third-party risk management process for service providers, suppliers, and vendors.&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;There can be no assurance that our cybersecurity risk management program and processes, including our policies, controls or procedures, will be fully implemented, complied with or effective in protecting our systems and information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. For more information, see the section titled &#x201c;Risk Factors&#x2014; Business interruptions could adversely affect future operations, revenues, and financial conditions, and may increase our costs and expenses.&#x201d;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_7zodwI12e0S5nPgzwFA9mA">Our cybersecurity risk management program is integrated into our overall enterprise risk management program, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_TRtM47qSUE6wxI0uytHF9A">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_dPonRqmVE0Gz22iJ1-ZZUg">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_pVosgLZFLUuug5JsgPeZ5A">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_lbz4sC9AFE-d3-PHXchNsA">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_Bsq8NNhVuUiCRofGVV9C3g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the &#x201c;Committee&#x201d;) oversight of cybersecurity and other information technology risks. The Committee oversees management&#x2019;s implementation of our cybersecurity risk management program. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Committee receives periodic reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also receives briefings from management on our cyber risk management program. Board members receive presentations on cybersecurity topics from the internal Security Incident Management Team or external experts as part of the Board&#x2019;s continuing education on topics that impact public companies.&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_19re0ChUEUCJ3xwXcfaC_g">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the &#x201c;Committee&#x201d;) oversight of cybersecurity and other information technology risks</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_eqAkuSFejUWQxbjPZsjzAg">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_2pBcIpVUukephPE604ywuA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Committee receives periodic reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also receives briefings from management on our cyber risk management program. Board members receive presentations on cybersecurity topics from the internal Security Incident Management Team or external experts as part of the Board&#x2019;s continuing education on topics that impact public companies.&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_xGSNAbpM-kWm8LwGv5Ovzw">The Committee receives periodic reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_AR8RH3v9nk-Tvv3VHfrLog">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_OYG9G6OuekqxgIhv_Yb0zA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Our Security Incident Management Team, which includes our Chief Financial Officer, the Executive Director of Information Technology, Chief Legal Officer and the Quality Assurance Director, has approximately 30 combined years of risk management experience and is responsible for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. Our Security Incident Management Team&#x2019;s experience includes prior work experience in cybersecurity; financial management and controls, data quality assurance and liability and risk management.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Our management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the information technology environment.&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_CFKtzp4YekG2xU7LJPrRzg">Chief Financial Officer, the Executive Director of Information Technology, Chief Legal Officer and the Quality Assurance Director</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Group_VxUQm0PYXE6A4oyt0eD8WQ">30 combined years of risk management experience</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <dei:AuditorName
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_hQyi2u_3skOA9Gi47k-S2Q">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_FgyQBiyiUUufa0LyhEQ33Q">42</dei:AuditorFirmId>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_WIskErTylEiU0cW_IWL52g">Stamford, Connecticut</dei:AuditorLocation>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="Duration_10_1_2024_To_12_31_2024_3PEv7wfJfUKxY2X6WXJQ_g"
      id="Tb_RvJWPy3V1Eq9CZTMwhskMA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Insider Trading Arrangements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;(a)&lt;/span&gt;&lt;/span&gt;On December 14, 2024, Vimal Mehta, Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 2,184 shares of the Company&#x2019;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;(b)&lt;/span&gt;&lt;/span&gt;On December 14, 2024, Richard Steinhart, Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 1,563 shares of the Company&#x2019;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;(c)&lt;/span&gt;&lt;/span&gt;On December 14, 2024, Javier Rodriguez, Senior Vice President, Chief Legal Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 1,563 shares of the Company&#x2019;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;(d)&lt;/span&gt;&lt;/span&gt;On December 14, 2024, Frank Yocca, Chief Scientific Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 1,563 shares of the Company&#x2019;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Each of these plans were terminated effective March 17, 2025.&lt;/p&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_VimalMehtaMember_fZwn5BB5AEyBJNs2qszV2g"
      id="Narr_P5pdjdNi2UyJL_9mSu-I6A">December 14, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_VimalMehtaMember_fZwn5BB5AEyBJNs2qszV2g"
      id="Narr_n9_s9iJZFUCwUtiIu95OEA">Vimal Mehta</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_VimalMehtaMember_fZwn5BB5AEyBJNs2qszV2g"
      id="Narr_PpPCx8J0UU6TWo61dDgqvw">Chief Executive Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_VimalMehtaMember_fZwn5BB5AEyBJNs2qszV2g"
      id="Narr_21BMKKD10kiiSNgiIZibKw">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="As_Of_12_31_2024_ecd_IndividualAxis_btai_VimalMehtaMember_I0XJDPHFNECy_x1rSOZJ9g"
      decimals="0"
      id="Narr_d2sDwJu3oEOPdnz4_etApQ"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">2184</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_VimalMehtaMember_fZwn5BB5AEyBJNs2qszV2g"
      id="Narr_2h9F-8cdyUy0ir2nAl3a_w">December 31, 2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrAdoptionDate
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_RichardSteinhartMember_6zb1jv50yke5UAZ2fdNlYw"
      id="Narr_7gwnkEjyw0a_KMeLf5An0A">December 14, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_RichardSteinhartMember_6zb1jv50yke5UAZ2fdNlYw"
      id="Narr_dvg4QoNveEiRRCwh0-UUQw">Richard Steinhart</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_RichardSteinhartMember_6zb1jv50yke5UAZ2fdNlYw"
      id="Narr_BXgH1I7HxEq1-5h_Vk2yQw">Chief Executive Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_RichardSteinhartMember_6zb1jv50yke5UAZ2fdNlYw"
      id="Narr_QNbvNQ9XYUaegfm9OZNLUg">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="As_Of_12_31_2024_ecd_IndividualAxis_btai_RichardSteinhartMember_4GcV7wKgb0qyo8g-DWuPiQ"
      decimals="0"
      id="Narr_1e2i9xeB5UmFz9IleBv6hg"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">1563</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_RichardSteinhartMember_6zb1jv50yke5UAZ2fdNlYw"
      id="Narr_0Wg-TDQDIkqWfI7Py0dn_g">December 31, 2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrAdoptionDate
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_JavierRodriguezMember_u3tdF-_eYkmI9WHxmSaiPg"
      id="Narr_RKa72M52hUujnMvYdpXpMg">December 14, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_JavierRodriguezMember_u3tdF-_eYkmI9WHxmSaiPg"
      id="Narr_enqyZRIbyUW3NnHLwim0tQ">Javier Rodriguez</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_JavierRodriguezMember_u3tdF-_eYkmI9WHxmSaiPg"
      id="Narr_s_VEeybnW0u9KWVgu3P79w">Senior Vice President, Chief Legal Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_JavierRodriguezMember_u3tdF-_eYkmI9WHxmSaiPg"
      id="Narr_-NML_yPyEkOBeIjbf9syAg">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="As_Of_12_31_2024_ecd_IndividualAxis_btai_JavierRodriguezMember_bkghpJl7jUGxwTp51yM2GA"
      decimals="0"
      id="Narr_C1S9GiD3PkOHr1X6JP24XA"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">1563</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_JavierRodriguezMember_u3tdF-_eYkmI9WHxmSaiPg"
      id="Narr_YYNcOuBMUEe9QO9ng0Z-Tg">December 31, 2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrAdoptionDate
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_FrankYoccaMember_EjqW660Xi0ae7YJdz_f5pg"
      id="Narr_ttBbrXKlqUO3lO3E58u5LQ">December 14, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_FrankYoccaMember_EjqW660Xi0ae7YJdz_f5pg"
      id="Narr_ryD9M5mt-0Kl6h_1MYxq2g">Frank Yocca</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_FrankYoccaMember_EjqW660Xi0ae7YJdz_f5pg"
      id="Narr_Nsn6AT2EF0qKySuJdWWYlg">Chief Scientific Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_FrankYoccaMember_EjqW660Xi0ae7YJdz_f5pg"
      id="Narr_Cc3EVWYjbUmKmmFNkhg63g">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="As_Of_12_31_2024_ecd_IndividualAxis_btai_FrankYoccaMember_1VVE1uh3REuAmq0XmRLywQ"
      decimals="0"
      id="Narr_8FoSLpOFU06FwlMUShVvKw"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">1563</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_btai_FrankYoccaMember_EjqW660Xi0ae7YJdz_f5pg"
      id="Narr_afqH43djXU-JPof2BHL4iQ">December 31, 2025</ecd:TrdArrExpirationDate>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_q6FBZWrm-k-GQ9utRDyoFQ">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_wDn2n51etUCuJWcCE7bwKg_7_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">29854000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_FSmgQEacqke9UyNi1dAcuQ_7_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">65221000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_Wx9NwN8rF0OZip_LKgp_6Q_8_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">131000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_uyXKu9k-pkSevF-Ya5QSiA_8_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">71000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_LOcWeBrW8EqEozjr55xzcg_9_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">679000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_hVGxeXTqiUW7EsDMYXQTyw_9_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1991000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_rCulIDayAUWL_LZqP_L_Lw_10_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">5290000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_3kgTo6RGWk2srVHEl9bUFA_10_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2782000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_rlVnUiS360CV3c3UynfY9Q_11_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1440000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_90UrBx45n0G_dVOiyE130A_11_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2078000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_1qpoyPuONUyVuvs-IlVZKA_12_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">37394000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc__BPlloRcPUqXr_U9JMScgQ_12_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">72143000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_it7Gq6xR8EelYrC8YjtflA_13_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">475000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_7B5L_Z6zZ0evrlgk6ZafDA_13_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">784000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_3fqTos16AkShygwKGWbqeA_14_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">382000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_knExMRmLwEmOSvuiyuzexA_14_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">688000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_a4Nvjl0zwUmHzBegLOwR0g_15_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">87000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_66WfEgjV4U6HYPxxlTx-Qg_15_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">87000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_Ak8G1e7wF0OnwPMX5p2CKQ_16_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">38338000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_oN9dOpdZ9U-yKrMJ_KEJsQ_16_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">73702000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_M9EZhUGI7EGoEYh2RQ1rhw_20_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">15990000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_T7t-sPc5HUWEpwhP_wBy_A_20_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">13654000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_gW0MlG0dpku8PG7qj7Bm_Q_21_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">5762000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_B-jXinGCUUCtA7n5OdQSMQ_21_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">12424000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_CehH3SOYY0-qk9E4i9FXiA"
      decimals="-3"
      id="Tc_Y9KbOoBe4UKs18BF05kvsA_22_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">107000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_q1hbZmrNS0GGTI07xc-mMg"
      decimals="-3"
      id="Tc_nTM2_0iEMk6tkKJt5TK1aQ_22_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">107000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_WT6xCQEwkUm3adPP662_LQ_23_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">736000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_vPHQPh73CEuoO2NrgO5-hQ"
      decimals="-3"
      id="Tc_8jNHqh_QsEOMP2NMaiMn-A_24_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">374000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_0gKxZS-bl0i0rf4ETalC4w"
      decimals="-3"
      id="Tc__A_Wpg8Z6U-yQp0mKmwtHg_24_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">346000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_Bvs0e8AtU0aI4sAwDDcNaQ_25_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">22233000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_o8YeDKvTckqgXgrfyj4X0g_25_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">27267000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_QLFF2wejAEq9-fHWVB9_pA_26_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">65000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_QXrBmpsdkEy49sDM5A4Eiw_26_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">440000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_mtOjvaJIeEmRYYJZQp2Ugw_27_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">6633000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_zmhR0sY2RkW22ToMvgpTkA_27_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1905000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_7Fef2iOPaUCgr6cdHaW-QA_28_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">102508000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_TGihjN5oFkGwdE-CEiwY6g_28_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">100598000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_7-NCwgwh5UiehLH6RloZHQ_29_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">131439000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_W8yCHc-3402bRCmq8a49cA_29_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">130210000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="INF"
      id="Narr_OM4CuqL8ikCbAvhml4yNag"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="INF"
      id="Narr_5pjbbjdRr0q4R906uHT_ug"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Narr_ns6kTW8Np0SnRLs3uAGG8w"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Narr_ZDqiMS5orUWGHE-9bUXsIA"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Narr_1eDx_R2FqkyW760eg-hyhQ"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Narr_ta8J35HBvEas5ZRSIS3wGw"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="INF"
      id="Narr_L8SVXDQMiEu3Ljd3oPB1Ag"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="INF"
      id="Narr_cRvaO1GLjE24LkkIE3eaeA"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Narr_sKbPyXzogkyVd7gZzPPcBw"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Narr_ZtUwwVU34UGFWdaZWhcAAQ"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Narr_lncJZ73D80ORtzNo6R1_lA"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">3102000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Narr_blGOn7ldWkOh1D_bDn7RbQ"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">1871000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_9O3mcoILSEeWpfc2TPljhA_34_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">49000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_xNLfVhXcQUqUeEOD4nHJTg_34_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">30000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_6l12LPTL_Uip9dXQdiGK3A_35_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">557047000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_6MY8CRBKU0WefHN4siuY4w_35_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">534060000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_DRbft5OeD0alWbLcfGbohg_36_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-650197000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_FKEaSLwTiUKm7GWP8gMnFg_36_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-590598000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_uNAR3RTpuUS5ahbe2TeSJA_37_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-93101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_LSPYQF50eEqq9nl2o2l1lw_37_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-56508000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_VoT4_AnPRUy2PXAzWrT0lw_38_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">38338000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_JC7bpRUO3k6bjAa-0Gyd6g_38_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">73702000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc__DRUaMxmF0qCxoNrjEuEow_5_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2266000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_g-qtegWCjkujIkV7t31Uug_5_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1380000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_M5ui7YXppk2I2HJVnLa2eg_8_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2143000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_rDrDHP39nUeSKt0G8CYWbA_8_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1260000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_JtKz9xxJyU2JVfkHNUD8eQ_9_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">30435000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_Nj4jZWCSNk6pJBt9JDK4tA_9_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">84326000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_lqu6EJneiUe10lYz_cQMLQ_10_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">34492000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_CSIrpq8PF0mWmE3cXcNRZg_10_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">83413000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_gU1RFB8SykOfa7aId3p-3A_11_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2441000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_jEQdYyKJjUKS1CU4LeonIA_11_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">4163000</us-gaap:RestructuringCharges>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_MJPLFbs-zUCY9EVpKvNImA_12_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">69511000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_b1uyunSyp02RIr5o5gnNfg_12_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">173162000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_DXlUIO7vkEWDqfR_DHxjTg_13_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-67245000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_iKxQ6cNwdEi7fa4chuQMRw_13_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-171782000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_rWK2ejghzUW8mmc22w9VBw_15_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">15129000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_f5mdIHkUZkazeToOnsmceg_15_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">13314000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_nwkP-HbgWEWTyZDtKA7f5Q_16_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2602000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_3qsPkgMKBkekTZhKf9_VJw_16_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">5649000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_BhQetiGC6E2BG2NIHjUCLA_17_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">20173000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_PAkUN6XmUUKjVSRuRaHypw_17_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">394000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_x0K6UNZDp0mXuac0fJjcSg_18_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-59599000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_rygaUMPjlEy9C-gXEzH9UQ_18_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-179053000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="2"
      id="Tc_fQCBuA7EaUGiL5YVNxerxQ_19_3"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">-23.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="2"
      id="Tc_iLx_AVer9k-G-x-tZrQa6Q_19_6"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">-98.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_r_k5fA-XCEamT02Wqxl31Q_20_3"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">2535000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_H4GqXKkTd0qn3NqfhaMkcg_20_6"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">1821000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WhUd_ZOlBUmqQn-nMAVDoQ"
      decimals="-3"
      id="Tc_SD-K-vdmPkmqVpTYF5PDAg_4_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">1759000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WhUd_ZOlBUmqQn-nMAVDoQ"
      decimals="-3"
      id="Tc_YyjfrstR7E-lvf3zGH6FYQ_4_5"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QQDsQgcnEkyWGJT2fjUW4Q"
      decimals="-3"
      id="Tc_KjeYjhShJUyp2CUTw1hkWQ_4_8"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">488292000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2OE8-Puy-k62aulMwMTDvg"
      decimals="-3"
      id="Tc_4wnvvl432Ei94OWpXPV-_g_4_11"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-411545000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_jhStatqo5EaSoSvdA9RW0g"
      decimals="-3"
      id="Tc_9ke2M_kdck-bTdK7HYND4Q_4_14"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">76775000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gdYMQB6xIEGwPzlcPnEPVA"
      decimals="-3"
      id="Tc_9gkd_-q-h0eRVk0jhNzKGw_5_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">88000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gdYMQB6xIEGwPzlcPnEPVA"
      decimals="-3"
      id="Tc_8NIhAKk9OU2ESBPVdXI6sA_5_5"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0DAGDztWUkKwXUglANCasg"
      decimals="-3"
      id="Tc_Cbe200upiUqUgWeKKKG7iQ_5_8"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">26219000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_8LpAsR4m2ku5YPowz1CA1w_5_14"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">26221000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0DAGDztWUkKwXUglANCasg"
      decimals="-3"
      id="Tc_hMz3p6A0jUCucu-Loxbm4w_6_8"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">18614000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_P3bEk81xUkWrwrfKzJKGoQ_6_14"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">18614000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gdYMQB6xIEGwPzlcPnEPVA"
      decimals="-3"
      id="Tc_AnOf7Y5RmU-VqwZIwnMV6A_7_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">20000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0DAGDztWUkKwXUglANCasg"
      decimals="-3"
      id="Tc_9CrOyNzF_E-02MabGfWOiw_7_8"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">508000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_PYMyNEc6CUWWzyLq4ZKqEQ_7_14"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">508000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0DAGDztWUkKwXUglANCasg"
      decimals="-3"
      id="Tc_4BkgoPJ3CEurBwxkJMifYg_8_8"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">254000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_uWEfvFxM5068Ay1tH2x6GQ_8_14"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">254000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0DAGDztWUkKwXUglANCasg"
      decimals="-3"
      id="Tc_5cZ4gy4osEKPYU-3_b8EvQ_9_8"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_2qRyfMNrm0OIOFvw-N0sLA_9_14"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gdYMQB6xIEGwPzlcPnEPVA"
      decimals="-3"
      id="Tc_ctB_kWHU60KlbZNr43u0Sw_10_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">4000</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0DAGDztWUkKwXUglANCasg"
      decimals="-3"
      id="Tc_f9QM71w3O0yuWTn7SahtZQ_10_8"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-27000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_LWV88Pq7HEGF1D-oc_0NwQ_10_14"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-27000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oXWwEn3ERUe7z06ZWkBHXA"
      decimals="-3"
      id="Tc_LmaZVA23r0uKp6_oOyKIvA_11_11"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-179053000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_pGmrOQXZv0CaY7hPHoBXIw_11_14"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-179053000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tk2nuQrdU0uVZYuijUkSUA"
      decimals="-3"
      id="Tc__TqgxHUzfEGfBdkseFfYOw_12_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">1871000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tk2nuQrdU0uVZYuijUkSUA"
      decimals="-3"
      id="Tc_WjO2lUfeD06LFyVbzmRefw_12_5"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">30000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gi1gHYnNBk66zzB63nP9Xg"
      decimals="-3"
      id="Tc_cKtj3vhvOUGfRADRppRjTg_12_8"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">534060000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6eSNIlZJN0KWpLFkIG2zfw"
      decimals="-3"
      id="Tc_6kbeMNBQDEGGKgzEOBInhg_12_11"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-590598000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_ub53iDpYjE2gchvfBzIlJQ_12_14"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-56508000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aq06NwagjEu8lcUy9jbLbA"
      decimals="-3"
      id="Tc_fqp6NtAhE0SC6sTPqAW6Jw_13_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">1209000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aq06NwagjEu8lcUy9jbLbA"
      decimals="-3"
      id="Tc_h2V6iaOW0k2N3yzteQgfAQ_13_5"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">19000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IE4SFBMuyECxTHM_3bnLDw"
      decimals="-3"
      id="Tc_9BvmRlzVAEyZ__TQmkm5_Q_13_8"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">9907000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_INhPPGOvGU-vSbsxrzOHbg_13_14"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">9926000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IE4SFBMuyECxTHM_3bnLDw"
      decimals="-3"
      id="Tc_g5ohsxcbkU-TyO1rjC6nDw_14_8"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">6156000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_ELJ7UccM1EG4fjF_Wl1RsQ_14_14"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">6156000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IE4SFBMuyECxTHM_3bnLDw"
      decimals="-3"
      id="Tc_A6RsqA672kyw1xWVb_cqyg_15_8"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2540000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_scjv-xJ9mkC_mrksSABAWg_15_14"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2540000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IE4SFBMuyECxTHM_3bnLDw"
      decimals="-3"
      id="Tc_6vZQ6jiXPk2Bcqla4PEMKg_16_8"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">59000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_4AM_HelPxE6oUA5T9zOLnw_16_14"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">59000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <btai:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IE4SFBMuyECxTHM_3bnLDw"
      decimals="-3"
      id="Tc_tTglCQ5UAEiIQGHSyozCgg_17_8"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">4379000</btai:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued>
    <btai:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_6aCezCO2l06jOcLcfn4dDA_17_14"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">4379000</btai:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aq06NwagjEu8lcUy9jbLbA"
      decimals="-3"
      id="Tc_mP-yIj7fs066P6Xg8jqIcQ_18_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">22000</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IE4SFBMuyECxTHM_3bnLDw"
      decimals="-3"
      id="Tc_BdwnH8Wvrk6vNw0s01ahyA_18_8"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-54000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_jjKI6dwYA0u-hp4OK3zJ_Q_18_14"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-54000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E9MLp3OJ8EufrFv1jvE6sw"
      decimals="-3"
      id="Tc_FbbTJTUs-EuKN0TzLu4Vcg_19_11"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-59599000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_Yya2HamnQ06e1Sov7Azzfw_19_14"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-59599000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uVBBMguAlEqRZE6UprsHRw"
      decimals="-3"
      id="Tc_kASOo1R_AEGmekm9MawLQw_20_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">3102000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uVBBMguAlEqRZE6UprsHRw"
      decimals="-3"
      id="Tc_ZryX6dz2kkOAqCQyhNMtpQ_20_5"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JBhziCHFEUu1-FicgIwmyA"
      decimals="-3"
      id="Tc_RHNZUmAky0KNc9Fi52wWbA_20_8"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">557047000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mVjyx3cGLEy1gJnnx6T0VA"
      decimals="-3"
      id="Tc_GmizxBLxv0CBeG0NreA4IA_20_11"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-650197000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_FB0AIPkyL0CG2D4o7jBYXw_20_14"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-93101000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_NPXlII4cf0mzKjsDVPl1bQ_4_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-59599000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_PVP9Uf5FgEOEAt7lfkjS4Q_4_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-179053000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_YDIPajfnfkaSg65yC3hrHg_6_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">309000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_Ju8E22o_vECZq2KmmLw18g_6_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">318000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_0LB6Z04JTEGnRIfL3AI1og_7_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">467000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_vT3zvaBUx0280BW5SjbGNQ_7_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1373000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_z3V5OGt2jEi5vICNWXaLZA_8_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">20180000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_HmPu-ezXbkiK1njSwTkh0w_8_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">438000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_dVJkP8AGTkqVE0EvSiXo5w_9_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">6156000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_UCTEbD3Jjk6vWlGqB0Azgg_9_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">18614000</us-gaap:ShareBasedCompensation>
    <us-gaap:PaidInKindInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_j2m1o7VKi0Wt0YnE2G39cw_10_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">6543000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_dQ0vejjH80akm5HBfxXMFA_10_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1872000</us-gaap:PaidInKindInterest>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_wwS9kThs5kKediq3dyObtA_11_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-2000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_LelWDZsPIE6apsCUfCsj6w_12_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">306000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_rOtalHdbck-cNiKYL7T0Ow_12_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">288000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_piKo2GVdxU2V0iFv8wgX7g_14_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">60000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_cXtTQWimGEO5MxsuJbHRZQ_14_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-177000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_ygpe8_wScECCCfUE_eABVQ_15_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-1312000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_M9YSJ-Y9bEWa0PwvV3gU_A_15_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">6000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_jgXjyF7NM0GhE1As7eTrmw_16_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1872000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_LDZnTgWOxkG-z7SLC3HdWg_16_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-2888000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_LlhJY5316EWzlFx4FqlR1w_17_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-4327000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_K3RmUyF1_ECAs06KjNp9pQ_17_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-3219000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_TIVXgdEmmkyrQ-S3rlSbKQ_18_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-736000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_VePVpZte4U-pw1CmWkz6_g_18_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2497000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_fcF-k6o4PkyeSpnFsKv1ww_19_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-346000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_YkZxIviQl0SHy-pyuI882w_19_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-319000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_ORDREqeU_kS-uru2ObC4jA_20_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-72027000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_7auEB7nnBEuTjUqMfWXdlQ_20_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-155006000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_VBwODVTZmU-QsSelfLnLnw_23_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">20000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_a1THV5mJGkiG3-oZGUYCVA_24_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-20000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_MQ1buLidQkKeMB63lBKOdA_27_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">39688000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_E6F2UrHC5EeS1WDAwuehkA_27_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">27032000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_OxX-Q_9Z3EOtoWpbcIJwyA_28_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">180000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_n011BKLqAU6UYApAt_tk4A_29_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2500000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_2hKVRxhjEE-zZv1xfOrZvg_30_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">474000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_5SDu9yUVLEu7b5jUz4tsWw_30_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">811000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_gz8ujaGf4UepyHOQSNXO6Q_31_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">54000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_HjdrIcY9Z0yXmHUjMEj7lQ_31_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">27000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_22VykyxxMEu0P9RcabN-Vg_32_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">508000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_lGsdgsdBK0ib5V2X_4a4Tw_33_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">36660000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_k_N3Szc3MUqGMORULACs8Q_33_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">26522000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_-ul54TSijEGwLDFG2pCOcg_35_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-35367000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_vMv4Nq9pokmoOf7IUhnaNQ_35_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-128504000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_banP-UBuiUGYVVnVUhOBew_36_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">65221000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_jhStatqo5EaSoSvdA9RW0g"
      decimals="-3"
      id="Tc_sjcYvGd2f0yg71IhlR-VLA_36_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">193725000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_p8Sc7emTKEOqdci9B2CECQ_37_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">29854000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_eXVD-qyXGE2tp9Z15IOeMA_37_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">65221000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <btai:FairValueStockPurchaseWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_sdGz0KqF50qjMPkNrjPmSg_40_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2540000</btai:FairValueStockPurchaseWarrants>
    <btai:FairValueStockPurchaseWarrants
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_BzkXsToZAU2cUpAIERREcw_40_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">200000</btai:FairValueStockPurchaseWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_CiPqX7uSp0WWM-7ggb6-0w_41_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">59000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_moC3X-HKvUyGul9H1DGFVQ_41_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">254000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_8F7UCu-FIkWt-DnVe_4McA_42_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">7968000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_S7kh_Dm340miFn5MW18jsA_42_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">7551000</us-gaap:InterestPaidNet>
    <btai:ConversionOfAccruedInterestToLongTermDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_hU0Z7rNDzU-u4VVNG32NRw_43_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-767000</btai:ConversionOfAccruedInterestToLongTermDebt>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_b2EBZSxDbUatlKdXxP0iHA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;1. Nature of the Business&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BioXcel Therapeutics, Inc. (&#x201c;BTI&#x201d; or the &#x201c;Company&#x201d;) is a biopharmaceutical company utilizing artificial intelligence (&#x201c;AI&#x201d;) approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company is focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients&#x2019; lives. BTI employs a unique AI platform to reduce therapeutic development costs and potentially accelerate timelines. The Company&#x2019;s approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI management believes this differentiated approach has the potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As used in these consolidated financial statements, unless otherwise specified or the context otherwise requires, the terms &#x201c;BioXcel LLC&#x201d; refers to the Company&#x2019;s former parent and current significant stockholder, BioXcel LLC and, its predecessor, BioXcel Corporation. &#x201c;OnkosXcel&#x201d; refers to BTI&#x2019;s wholly owned subsidiary for its advanced immuno-oncology assets, OnkosXcel Therapeutics, LLC.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;On April 6, 2022, BTI announced that the United States (&#x201c;U.S.&#x201d;) Food and Drug Administration (&#x201c;FDA&#x201d;) approved IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (dexmedetomidine or &#x201c;Dex&#x201d;) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; is approved to be self-administrated by patients under the supervision of a health care provider. On July 6, 2022, BTI announced that IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;, was commercially available in doses of 120 and 180 micrograms.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s most advanced clinical development program is BXCL501. In indications other than those approved by the FDA as IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;, BXCL501 is an investigational proprietary, orally dissolving, film formulation of Dex for the treatment of agitation associated with psychiatric and neurological disorders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s advanced immuno-oncology asset, BXCL701, is an investigational, orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment na&#xef;ve to checkpoint inhibitors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI was incorporated under the laws of the State of Delaware on March 29, 2017. The Company&#x2019;s principal office is in New Haven, Connecticut.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_y1Zc7t9nykGULModqYlIYQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;2. Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The accompanying consolidated financial statements include those of the Company and its subsidiaries after elimination of all intercompany accounts and transactions and have been prepared in conformity with United States (&#x201c;U.S.&#x201d;) Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As of December 31, 2024, the Company had cash and cash equivalents of $29,854 and an accumulated deficit of $650,197. BTI has incurred substantial net losses and negative cash flows from operating activities in nearly every fiscal period since inception and expects this trend to continue for the foreseeable future. The Company recognized net losses of $59,599 and $179,053 for the years ended December 31, 2024 and 2023, respectively, and had net cash used in operating activities of $72,027 and $155,006 for the years ended December 31, 2024 and 2023, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Under ASC Topic 205-40, Presentation of Financial Statements - Going Concern, management is required at each reporting period to evaluate whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s history of significant losses, its negative cash flows from operations, potential near-term increased covenant-driven amortization payments under its Credit Agreement, its limited liquidity resources currently on hand, and its dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, have resulted in management&#x2019;s assessment that there is substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period of at least 12 months from the issuance date of the financial statements included in this Annual Report on Form 10-K. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;This going concern evaluation takes into consideration the potential mitigating effect of management&#x2019;s Reprioritization (as defined in Note 4, Restructuring). When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt about the Company&#x2019;s ability to continue as a going concern. The mitigating effect of management&#x2019;s plans, however, is only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered probable of being effectively implemented, the plans need to be approved by the Company&#x2019;s Board of Directors. The Company&#x2019;s Reprioritization was approved by the Board of Directors on August 8, 2023; however, such plans, including the additional restructuring actions taken in the second and third quarters of 2024,  will not mitigate the entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business and does not include any adjustments that may result from the outcome of this uncertainty. The going concern analysis does not consider possible future amendments to or restructuring of the Credit Agreement (as defined in Note 9, Debt and Credit Facilities) or other potential sources of debt or equity capital.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Successful completion of the Company&#x2019;s development programs and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to support the Company&#x2019;s cost structure and operating plan. Management&#x2019;s plans to improve the Company&#x2019;s liquidity and reduce its operating expenses and capital requirements include, among other things, pursuing one or more of the following steps to raise additional capital, none of which can be guaranteed or are entirely within the Company&#x2019;s control:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;raise funding through the sale of the Company&#x2019;s equity securities;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;raise funding through third-party investments in or other strategic options for OnkosXcel;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;raise funding through debt financing and/or restructuring of its existing OFA Facilities; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;establish collaborations with potential partners to advance the Company&#x2019;s product pipeline;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;establish collaborations with potential marketing partners;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;reduce overhead and headcount to focus on core priorities; and/or&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;any combination of the foregoing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;If the Company is unable to raise capital when needed or on acceptable terms, or if it is unable to procure collaboration arrangements to advance its programs, the Company would be forced to discontinue some of its operations or develop and implement a plan, beyond its Reprioritization initiatives, to further extend payables, reduce overhead, scale back or cease some or all of its revised operating plan until sufficient additional capital is raised to support further operations. &lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_8DWbtQZfJEKLZbqij2-2ww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The accompanying consolidated financial statements include those of the Company and its subsidiaries after elimination of all intercompany accounts and transactions and have been prepared in conformity with United States (&#x201c;U.S.&#x201d;) Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Narr_Fs4zfcqSDUalFhudCTd5CA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">29854000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Narr_cKHh4VSP8kqaVtsSJNHUwA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-650197000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Narr_L-q2_ays6kOnCGQGZw_9Fg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-59599000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Narr_ImI6IKc-cUKyf0QZoALZSQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-179053000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Narr_uo6BSIkqG0eneOy0Qv5vyw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-72027000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Narr_5jMGOEVSOUyO8PIVVNuJUQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-155006000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_Vxw582losEGMk5tlVjsqZg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;3. Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the consolidated financial statements and notes thereto. Estimates are used in the following areas, among others: revenue recognition, inventory valuation, derivative liabilities, stock-based compensation expense, accrued expenses and income taxes. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reverse Stock Split&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;On February 10, 2025, the Company completed a &lt;span style="-sec-ix-hidden:Hidden_MAC978-QcU6PY1cLIWQ4hg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1-for-16&lt;/span&gt;&lt;/span&gt; reverse stock split of its issued and outstanding common stock (the &#x201c;Reverse Stock Split&#x201d;). As a result of the Reverse Stock Split, each 16 shares of common stock issued and outstanding immediately prior to February 10, 2025 were automatically converted into one of a share of common stock. The Reverse Stock Split affected all common stockholders uniformly and did not alter any stockholder's percentage interest in the Company's equity, except to the extent that the Reverse Stock Split would result in a stockholder owning a fractional share. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise would be entitled to receive a fractional share instead were entitled to receive cash in lieu of such fractional share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Reverse Stock Split did not change the par value of the common stock or the authorized number of shares of common stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;All common share and per-share amounts in this Form 10-K have been retroactively restated to reflect the effect of the Reverse Stock Split.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of December 31, 2024 and 2023, cash equivalents were comprised primarily of money market funds. Cash and cash equivalents held at financial institutions may at times exceed federally insured amounts. BTI management believes it mitigates such risk by investing in or through major financial institutions.&lt;/p&gt;&lt;p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Accounts Receivable, Net&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Liberation Serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt;Accounts receivable arise from sales of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt;IGALMI&lt;/span&gt;&lt;sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt; and represent amounts due from distributors. Payment terms generally range from &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt;30&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt;75 days&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt; from the date of the sale transaction, and accordingly, do not involve a significant financing component. Receivables from product sales are recorded net of allowances which generally include distribution fees, prompt payment discounts, chargebacks, and credit losses. Allowances for distribution fees, prompt payment discounts and chargebacks are based on contractual terms. The Company estimated the current expected credit losses of its accounts receivable by assessing the risk of loss and available relevant information about collectability, existing contractual payment terms, actual payment patterns of its customers, individual customer circumstances, and reasonable and supportable forecast of economic conditions expected to exist throughout the contractual life of the receivable. Based on its assessment, as of December 31, 2024, the Company determined that an allowance for credit losses was not required.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Concentrations of Credit Risk&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Liberation Serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The Company sells IGALMI&lt;/span&gt;&lt;sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; through a drop-ship program under which orders from hospitals and similar health care institutions are processed through wholesalers, but shipments of the product are sent directly to the individual hospitals and similar health care institutions. BTI also contracts directly with intermediaries such as group purchasing organizations (&#x201c;GPOs&#x201d;). All trade accounts receivables are due from the distributor that fulfills orders on behalf of the Company.&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; For the years ended December 31, 2024 and 2023, one customer accounted for approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;32%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;39%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; of the Company&#x2019;s net product revenue, respectively. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Inventory&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory is stated at the lower of cost or net realizable value. Cost of inventory is determined on a first-in, first-out basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;BTI capitalizes inventory costs associated with the Company&#x2019;s products prior to regulatory approval, when, based on management&#x2019;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development expense in the Consolidated Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, will be recorded within Cost of goods sold in the Consolidated Statements of Operations. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected, write-downs of inventory may be required.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred Initial Public Offering Costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Deferred initial public offering costs of $2,570, consisted of legal, accounting, and other costs that were directly related to the Company&#x2019;s proposed initial public offering of OnkosXcel. These costs were charged to the Consolidated Statements of Operations during the year ended December 31, 2023 as the initial public offering was delayed for an extended period of time. The costs were recorded as Selling, general and administrative expenses. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Property and equipment are recorded at cost and depreciated over the shorter of their remaining lease term or their estimated useful life on a straight-line basis as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:2.15pt;"&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"&gt;3-5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"&gt;7 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.1pt;"&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"&gt;Lesser of life of improvement or lease term&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Expenditures for maintenance and repairs which do not improve or extend the useful lives of the respective assets are expensed as incurred. When assets are sold or retired, the related cost and accumulated depreciation are removed from their respective accounts and any resulting gain or loss is included within Other (income) expense, net in the Consolidated Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to undiscounted future net cash flows expected to be generated from its use and disposition. Impairment charges are recognized at the amount by which the carrying amount of an asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, other current liabilities, and the long-term portion of operating lease liabilities in the Consolidated Balance Sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;ROU assets represent BTI&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses the implicit rate when readily determinable. As BTI&#x2019;s leases do not provide an implicit rate, it used an incremental &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any prepaid lease payments made and is reduced by lease incentives. The Company&#x2019;s leases may include options to extend the lease; such options are included in determining the lease term when it is reasonably certain that BTI will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;Debt and Detachable Warrants&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Detachable warrants are evaluated for classification as either equity instruments, derivative liabilities, or liabilities depending on the specific terms of the warrant agreement. In circumstances in which debt is issued with equity-classified warrants, the proceeds from the issuance of debt are first allocated to the debt and then the warrants at their estimated fair values. The portion of the proceeds allocated to the warrants are accounted for as paid-in capital and a debt discount. The remaining proceeds, as further reduced by discounts created by the bifurcation of any embedded derivatives, are allocated to the debt. Detachable warrants classified as derivative liabilities are accounted for as indicated under &#x201c;&lt;i style="font-style:italic;"&gt;Derivative Assets and Liabilities&lt;/i&gt;&#x201d; section of this Note and as a debt discount. The Company accounts for debt as liabilities measured at amortized cost and amortizes the resulting debt discount from the allocation of proceeds to interest expense using the effective interest method over the expected term of the debt instrument. The Company considers whether there are any embedded features in debt instruments that require bifurcation and separately accounts for them as derivative financial instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company entered into financing arrangements, the terms of which involve significant assumptions and estimates, including future net product sales, in determining interest expense, amortization period of the debt discount, as well as the classification between current and long-term portions. In estimating future net product sales, the Company assesses prevailing market conditions using various external market data against the Company&#x2019;s anticipated sales and planned commercial activities. Consequently, the Company imputes interest on the carrying value of the debt and records interest expense using an imputed effective interest rate. The Company reassesses the expected payments during each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of the Company&#x2019;s current and long-term portions of the debt.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;Derivative Assets and Liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Derivative assets and liabilities are recorded on the Company`s Consolidated Balance Sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded as other income or expense within Other (income) expense, net in the Consolidated Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company does not use derivative instruments for speculative purposes or to hedge exposures to cash-flow or market risks. Certain financing facilities entered into by the Company include freestanding financial instruments and/or embedded features that require separate accounting as derivative assets and/or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s revenues consist of product sales of IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition, BTI management performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The exercise of a material right may be accounted for as a contract modification or as a continuation of the contract for accounting purposes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such goods and services are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the Company&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company allocates the transaction price (the amount of consideration it expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#x2019;s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI distributes IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in the U.S. through arrangements with a distributor, wholesalers, and GPOs. The distributor and wholesalers help process and fulfill orders from hospitals on the Company&#x2019;s behalf. The Company believes the hospitals are its customers.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company recognizes product revenues, net of consideration payable to customers, as well as variable consideration related to certain allowances and accruals that are determined using either the expected value or most likely amount method, depending on the type of the variable consideration, in its consolidated financial statements at the point in time when control transfers to the customer, which is typically when the product has been delivered to the customer&#x2019;s location. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company&#x2019;s only performance obligation identified for IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; is to deliver the quantity of product ordered to the location specified by the customer&#x2019;s order. The Company records shipping and handling costs associated with delivery of product to its customers within Selling, general and administrative expenses on its Consolidated Statements of Operations. Under the Company&#x2019;s current product sales arrangements, BTI does not have contract assets (unbilled receivables), as it generally invoices its customer at the time of revenue recognition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI sells IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; at wholesale acquisition cost, less any agreed upon discounts and calculates product revenue net of variable consideration and consideration payable to third parties associated with distribution of product. The Company records reserves, based on contractual terms, for the following components of consideration related to product sold during the reporting period. Calculating these amounts involves estimates and judgments, and the Company reviews these estimates quarterly and records any material adjustments in the period they are identified, which affects net product revenue and earnings in the period such variances occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Trade Discounts and Allowances&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company provides the distributor and wholesalers with discounts for prompt payment and pays fees to the distributor, wholesalers and GPOs related to distribution of the product. BTI expects the relevant third parties to earn these discounts and fees, and therefore it deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Government Rebates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; is eligible for purchase by, or qualifies for reimbursement from, Medicaid and other U.S. government programs that are eligible for rebates on the price they pay for the product. To determine the appropriate amount to reserve for these rebates, BTI applies the applicable government discount to these sales, and estimates the portion of total rebates that it anticipates will be claimed. The Company deducts certain government rebates from gross product &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;revenue and accounts receivable at the time it recognizes the related revenue; other government rebates are recognized as an accrued liability at the time BTI recognizes the related revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Chargebacks&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI provides product discounts to hospitals associated with certain GPOs. The Company estimates the chargebacks that it expects to be obligated to provide based upon the terms of the applicable arrangements. BTI deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Product Returns&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company provides contractual return rights to its customers including the right to return product within six months of product expiration and up to 12 months after product expiration, as well as for incorrect shipments, and damaged or defective product, which the Company expects to be rare. Management expects product returns to be minimal, thus BTI recognizes a nominal allowance for product returns at the time of each sale. In the future, if any of these factors and/or the history of product returns changes, the Company will adjust the allowance for product returns.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI classifies all fees paid to the distributor, other than those discussed above and those related to warehouse operations, as Selling, general and administrative expenses on its Consolidated Statements of Operations. Fees paid to the distributor for warehouse operations are classified as Cost of goods sold on BTI&#x2019;s Consolidated Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost of Goods Sold&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Cost of goods sold includes the cost of producing and distributing inventories that are related to product revenues during the respective period. Cost of goods sold also includes costs related to excess or obsolete inventory adjustment charges, as well as costs related to warehouse operations paid to distributors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company measures and recognizes stock-based compensation expense based on estimated fair value for all share-based awards made to employees, non-employee service providers, and directors, including stock options, BTI restricted stock units (&#x201c;BTI RSUs&#x201d;), OnkosXcel profit sharing units (&#x201c;PSUs&#x201d;), OnkosXcel restricted stock units (&#x201c;OnkosXcel RSUs&#x201d;) and BTI performance stock units (&#x201c;Performance Units&#x201d;). The Company&#x2019;s 2017 Equity Incentive Plan (the &#x201c;2017 Plan&#x201d;) became effective in August 2017. The Company&#x2019;s 2020 Incentive Award Plan (the &#x201c;2020 Plan&#x201d;) became effective in May 2020. Following the effective date of the 2020 Plan, the Company ceased granting awards under the 2017 Plan; however, the terms and conditions of the 2017 Plan continue to govern any outstanding awards granted thereunder.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s stock-based awards are valued at fair value on the date of grant and that fair value is recognized as an expense in the Consolidated Statements of Operations over the requisite service period using the accelerated attribution method. The estimated value of the BTI RSUs and Performance Units is based on the Company&#x2019;s closing stock price on the grant date. The estimated fair value of OnkosXcel RSUs are based on the OnkosXcel valuation on the grant date. The estimated fair value of stock-options and PSUs was determined using the Black-Scholes pricing model on the date of grant. For awards subject to performance-based vesting conditions, the Company recognizes stock-based compensation expense when the achievement of the performance condition becomes probable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Black-Scholes pricing model is affected by the Company&#x2019;s stock price, as well as assumptions regarding variables including, but not limited to, the strike price of the instrument, the risk-free rate, the expected stock price volatility over the term of the awards and expected term of the awards. The Company has elected to account for forfeitures as they occur, by reversing compensation cost when the award is forfeited.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Research and development expenses include wages, benefits, non-cash stock-based compensation, facilities, supplies, external services, clinical study, manufacturing costs related to clinical trials and other expenses that are directly related to the Company&#x2019;s research and development activities. At the end of the reporting period, the Company estimates the progress toward completion of the research or development objectives and, depending on the amount and timing of payments to the service providers may record net prepaid or accrued expense for associated research and development costs. Such estimates are subject to change as additional information becomes available. The Company expenses research and development costs as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Most of the Company&#x2019;s service providers invoice BTI monthly in arrears for services performed. The Company estimates its accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to management at that time. BTI management periodically confirms the accuracy of the Company&#x2019;s estimates with the service providers and makes adjustments if necessary.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Although management does not expect its estimates to be materially different from amounts actually incurred, management&#x2019;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in BTI reporting amounts that are too high or too low in any particular period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Patent Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Costs related to filing and pursuing patent applications are recorded in Selling, general and administrative expenses in the Consolidated Statements of Operations and are expensed as incurred since recoverability of such expenditures is uncertain.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company measures certain financial assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources, or observable inputs, and (2) an entity&#x2019;s own assumptions about market participant assumptions developed based on the best information available in the circumstances, or unobservable inputs. The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). Fair value measurements must be classified and disclosed in one of the following three categories:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Level 1&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Level 2&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Level 3&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management&#x2019;s estimates of market participant assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considering counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI uses an asset and liability approach for financial accounting and reporting of income taxes. Deferred tax assets and liabilities are determined based on temporary differences between financial reporting and tax basis assets and liabilities and are measured by applying enacted rates and laws to taxable years in which differences are expected to be recovered or settled. Further, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that the rate changes. A valuation allowance is required when it is &#x201c;more likely than not&#x201d; that all or a portion of deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;U.S. GAAP prescribes a comprehensive model for how a company should recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on a tax return, including a decision whether to file or not file a return in a particular jurisdiction. The Company&#x2019;s financial statements reflect expected future tax consequences of such positions presuming the taxing authorities&#x2019; full knowledge of the position and all relevant facts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company does not have any unrecognized tax benefits as of December 31, 2024 and 2023. BTI reviews all tax positions to ensure the tax treatment selected is sustainable based on its technical merits and that the position would be sustained if challenged.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Earnings (Loss) per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Earnings (loss) per share (&#x201c;EPS&#x201d;) is calculated by dividing net income or loss attributable to common stockholders by the weighted average number of shares of common stock that were outstanding, including pre-funded warrants. Shares of common stock into which the pre-funded warrant may be exercised are considered outstanding for the purposes of computing EPS because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date. Diluted EPS is calculated by adjusting the weighted average number of shares of common stock that were outstanding for the dilutive effect of common stock equivalents. In periods in which a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be antidilutive.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Segment Information&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company operates in a single segment. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. To date, the Company&#x2019;s chief operating decision maker has made such decisions and assessed performance at the Company level as one segment. See Note 19, &lt;i style="font-style:italic;"&gt;Segment Information&lt;/i&gt; for further information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment reporting, which requires disclosure of incremental segment information on an annual and interim basis. The standard is effective for years beginning after December 15, 2023, and interim periods beginning after December 15, 2024 and early adoption is permitted. The Company adopted the new standard in fiscal year 2024 for annual and retrospective reporting periods with all interim disclosures to begin in the first quarter of fiscal year 2025. For additional information, see Note 19, &lt;i style="font-style:italic;"&gt;Segment Information&lt;/i&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounting Pronouncements effective in future periods&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In December 2023, the FASB issued ASU 2023-09, Improvements to income tax disclosures, which requires disclosure of disaggregated income taxes paid by jurisdiction, enhances disclosures in the effective tax rate reconciliation and modifies other income tax-related disclosures. The amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the effect of adopting this guidance on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_5g1rXGgsz020SIKHUQ3klw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the consolidated financial statements and notes thereto. Estimates are used in the following areas, among others: revenue recognition, inventory valuation, derivative liabilities, stock-based compensation expense, accrued expenses and income taxes. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <btai:ReverseStockSplit
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_hESLlgQl5k-ThHhHerbhsQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reverse Stock Split&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;On February 10, 2025, the Company completed a &lt;span style="-sec-ix-hidden:Hidden_MAC978-QcU6PY1cLIWQ4hg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1-for-16&lt;/span&gt;&lt;/span&gt; reverse stock split of its issued and outstanding common stock (the &#x201c;Reverse Stock Split&#x201d;). As a result of the Reverse Stock Split, each 16 shares of common stock issued and outstanding immediately prior to February 10, 2025 were automatically converted into one of a share of common stock. The Reverse Stock Split affected all common stockholders uniformly and did not alter any stockholder's percentage interest in the Company's equity, except to the extent that the Reverse Stock Split would result in a stockholder owning a fractional share. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise would be entitled to receive a fractional share instead were entitled to receive cash in lieu of such fractional share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Reverse Stock Split did not change the par value of the common stock or the authorized number of shares of common stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;All common share and per-share amounts in this Form 10-K have been retroactively restated to reflect the effect of the Reverse Stock Split.&lt;/p&gt;</btai:ReverseStockSplit>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_G9o9t0Qh0k67SLrqA4M1Aw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of December 31, 2024 and 2023, cash equivalents were comprised primarily of money market funds. Cash and cash equivalents held at financial institutions may at times exceed federally insured amounts. BTI management believes it mitigates such risk by investing in or through major financial institutions.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_KHPbwTe2w0igfsywezL1yg">&lt;p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Accounts Receivable, Net&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Liberation Serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt;Accounts receivable arise from sales of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt;IGALMI&lt;/span&gt;&lt;sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt; and represent amounts due from distributors. Payment terms generally range from &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt;30&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt;75 days&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt; from the date of the sale transaction, and accordingly, do not involve a significant financing component. Receivables from product sales are recorded net of allowances which generally include distribution fees, prompt payment discounts, chargebacks, and credit losses. Allowances for distribution fees, prompt payment discounts and chargebacks are based on contractual terms. The Company estimated the current expected credit losses of its accounts receivable by assessing the risk of loss and available relevant information about collectability, existing contractual payment terms, actual payment patterns of its customers, individual customer circumstances, and reasonable and supportable forecast of economic conditions expected to exist throughout the contractual life of the receivable. Based on its assessment, as of December 31, 2024, the Company determined that an allowance for credit losses was not required.&lt;/span&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <btai:AccountsReceivablePaymentTerm
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_eSrtMnrTnkmoVkWywMsDcQ"
      id="Narr_gwH8SeDJWkCJPRD9dcAHuQ">P30D</btai:AccountsReceivablePaymentTerm>
    <btai:AccountsReceivablePaymentTerm
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_WO_5QqewW0WCAmc5bwIHMA"
      id="Narr_xjUbxg9zGU6IZAogykeSKQ">P75D</btai:AccountsReceivablePaymentTerm>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_WCRAb3QpE0yKTPnIi60dsQ">&lt;p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Concentrations of Credit Risk&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Liberation Serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;The Company sells IGALMI&lt;/span&gt;&lt;sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; through a drop-ship program under which orders from hospitals and similar health care institutions are processed through wholesalers, but shipments of the product are sent directly to the individual hospitals and similar health care institutions. BTI also contracts directly with intermediaries such as group purchasing organizations (&#x201c;GPOs&#x201d;). All trade accounts receivables are due from the distributor that fulfills orders on behalf of the Company.&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; For the years ended December 31, 2024 and 2023, one customer accounted for approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;32%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;39%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; of the Company&#x2019;s net product revenue, respectively. &lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_btai_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_W_hOEF0UGE6XdSlHUL5Rsw"
      decimals="2"
      id="Narr_ANW2_yuB9EaYNNx-h1SZ0w"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_btai_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_5C4QWry9fk6gmoPexiMApw"
      decimals="2"
      id="Narr_mJ5Bi097NEaVxDHrmmBH8w"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_2ntKSYA_ok6gwcA7muIQ0Q">&lt;p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Inventory&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory is stated at the lower of cost or net realizable value. Cost of inventory is determined on a first-in, first-out basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;BTI capitalizes inventory costs associated with the Company&#x2019;s products prior to regulatory approval, when, based on management&#x2019;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development expense in the Consolidated Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, will be recorded within Cost of goods sold in the Consolidated Statements of Operations. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected, write-downs of inventory may be required.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <btai:DeferredOfferingCostsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_Xb2ynxG2Z06UZjcc_ERtnQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred Initial Public Offering Costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Deferred initial public offering costs of $2,570, consisted of legal, accounting, and other costs that were directly related to the Company&#x2019;s proposed initial public offering of OnkosXcel. These costs were charged to the Consolidated Statements of Operations during the year ended December 31, 2023 as the initial public offering was delayed for an extended period of time. The costs were recorded as Selling, general and administrative expenses. &lt;/p&gt;</btai:DeferredOfferingCostsPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Narr_RqyGVl2LSES2zgoTt9Jkgg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2570000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_4YG4IP4P706I8QygkVDYKA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Property and equipment are recorded at cost and depreciated over the shorter of their remaining lease term or their estimated useful life on a straight-line basis as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:2.15pt;"&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"&gt;3-5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"&gt;7 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.1pt;"&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"&gt;Lesser of life of improvement or lease term&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Expenditures for maintenance and repairs which do not improve or extend the useful lives of the respective assets are expensed as incurred. When assets are sold or retired, the related cost and accumulated depreciation are removed from their respective accounts and any resulting gain or loss is included within Other (income) expense, net in the Consolidated Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to undiscounted future net cash flows expected to be generated from its use and disposition. Impairment charges are recognized at the amount by which the carrying amount of an asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <btai:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_za4Bqbh_CEytdwSYVhzBPg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:2.15pt;"&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"&gt;3-5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"&gt;7 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.1pt;"&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"&gt;Lesser of life of improvement or lease term&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</btai:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember__lhd_4aX8kyoPoUbqHBE0A"
      id="Narr_rshY3B3M6k-VFmAv9TtYYQ">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_MsiOU9Br5ESWVEwY_A5X2w"
      id="Narr_Eho9Tl-y3E-S3iMeZZ1WxQ">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_bGkvra2V9Ue26IMBxqrCww"
      id="Tc_WsiIVQj4bEmetxBd_UAGHw_2_1">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_e4g6Ns5NN0em99G-4SpDhQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, other current liabilities, and the long-term portion of operating lease liabilities in the Consolidated Balance Sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;ROU assets represent BTI&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses the implicit rate when readily determinable. As BTI&#x2019;s leases do not provide an implicit rate, it used an incremental &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any prepaid lease payments made and is reduced by lease incentives. The Company&#x2019;s leases may include options to extend the lease; such options are included in determining the lease term when it is reasonably certain that BTI will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_Ly9jnhFfOEKGH079vCR8GQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;Debt and Detachable Warrants&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Detachable warrants are evaluated for classification as either equity instruments, derivative liabilities, or liabilities depending on the specific terms of the warrant agreement. In circumstances in which debt is issued with equity-classified warrants, the proceeds from the issuance of debt are first allocated to the debt and then the warrants at their estimated fair values. The portion of the proceeds allocated to the warrants are accounted for as paid-in capital and a debt discount. The remaining proceeds, as further reduced by discounts created by the bifurcation of any embedded derivatives, are allocated to the debt. Detachable warrants classified as derivative liabilities are accounted for as indicated under &#x201c;&lt;i style="font-style:italic;"&gt;Derivative Assets and Liabilities&lt;/i&gt;&#x201d; section of this Note and as a debt discount. The Company accounts for debt as liabilities measured at amortized cost and amortizes the resulting debt discount from the allocation of proceeds to interest expense using the effective interest method over the expected term of the debt instrument. The Company considers whether there are any embedded features in debt instruments that require bifurcation and separately accounts for them as derivative financial instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company entered into financing arrangements, the terms of which involve significant assumptions and estimates, including future net product sales, in determining interest expense, amortization period of the debt discount, as well as the classification between current and long-term portions. In estimating future net product sales, the Company assesses prevailing market conditions using various external market data against the Company&#x2019;s anticipated sales and planned commercial activities. Consequently, the Company imputes interest on the carrying value of the debt and records interest expense using an imputed effective interest rate. The Company reassesses the expected payments during each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of the Company&#x2019;s current and long-term portions of the debt.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_QZhStKG2Pku-UYssk1qU0g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;Derivative Assets and Liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Derivative assets and liabilities are recorded on the Company`s Consolidated Balance Sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded as other income or expense within Other (income) expense, net in the Consolidated Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company does not use derivative instruments for speculative purposes or to hedge exposures to cash-flow or market risks. Certain financing facilities entered into by the Company include freestanding financial instruments and/or embedded features that require separate accounting as derivative assets and/or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_rr8SpmddcEKuvcOr0L3X6g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s revenues consist of product sales of IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition, BTI management performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The exercise of a material right may be accounted for as a contract modification or as a continuation of the contract for accounting purposes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such goods and services are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the Company&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company allocates the transaction price (the amount of consideration it expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#x2019;s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI distributes IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in the U.S. through arrangements with a distributor, wholesalers, and GPOs. The distributor and wholesalers help process and fulfill orders from hospitals on the Company&#x2019;s behalf. The Company believes the hospitals are its customers.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company recognizes product revenues, net of consideration payable to customers, as well as variable consideration related to certain allowances and accruals that are determined using either the expected value or most likely amount method, depending on the type of the variable consideration, in its consolidated financial statements at the point in time when control transfers to the customer, which is typically when the product has been delivered to the customer&#x2019;s location. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company&#x2019;s only performance obligation identified for IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; is to deliver the quantity of product ordered to the location specified by the customer&#x2019;s order. The Company records shipping and handling costs associated with delivery of product to its customers within Selling, general and administrative expenses on its Consolidated Statements of Operations. Under the Company&#x2019;s current product sales arrangements, BTI does not have contract assets (unbilled receivables), as it generally invoices its customer at the time of revenue recognition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI sells IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; at wholesale acquisition cost, less any agreed upon discounts and calculates product revenue net of variable consideration and consideration payable to third parties associated with distribution of product. The Company records reserves, based on contractual terms, for the following components of consideration related to product sold during the reporting period. Calculating these amounts involves estimates and judgments, and the Company reviews these estimates quarterly and records any material adjustments in the period they are identified, which affects net product revenue and earnings in the period such variances occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Trade Discounts and Allowances&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company provides the distributor and wholesalers with discounts for prompt payment and pays fees to the distributor, wholesalers and GPOs related to distribution of the product. BTI expects the relevant third parties to earn these discounts and fees, and therefore it deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Government Rebates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; is eligible for purchase by, or qualifies for reimbursement from, Medicaid and other U.S. government programs that are eligible for rebates on the price they pay for the product. To determine the appropriate amount to reserve for these rebates, BTI applies the applicable government discount to these sales, and estimates the portion of total rebates that it anticipates will be claimed. The Company deducts certain government rebates from gross product &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;revenue and accounts receivable at the time it recognizes the related revenue; other government rebates are recognized as an accrued liability at the time BTI recognizes the related revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Chargebacks&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI provides product discounts to hospitals associated with certain GPOs. The Company estimates the chargebacks that it expects to be obligated to provide based upon the terms of the applicable arrangements. BTI deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Product Returns&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company provides contractual return rights to its customers including the right to return product within six months of product expiration and up to 12 months after product expiration, as well as for incorrect shipments, and damaged or defective product, which the Company expects to be rare. Management expects product returns to be minimal, thus BTI recognizes a nominal allowance for product returns at the time of each sale. In the future, if any of these factors and/or the history of product returns changes, the Company will adjust the allowance for product returns.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI classifies all fees paid to the distributor, other than those discussed above and those related to warehouse operations, as Selling, general and administrative expenses on its Consolidated Statements of Operations. Fees paid to the distributor for warehouse operations are classified as Cost of goods sold on BTI&#x2019;s Consolidated Statements of Operations.&lt;/p&gt;</us-gaap:RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_WWXNblWIREKIonLG92-jdA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost of Goods Sold&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Cost of goods sold includes the cost of producing and distributing inventories that are related to product revenues during the respective period. Cost of goods sold also includes costs related to excess or obsolete inventory adjustment charges, as well as costs related to warehouse operations paid to distributors.&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_A38KZjV58UeOnOzV6MU8XA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company measures and recognizes stock-based compensation expense based on estimated fair value for all share-based awards made to employees, non-employee service providers, and directors, including stock options, BTI restricted stock units (&#x201c;BTI RSUs&#x201d;), OnkosXcel profit sharing units (&#x201c;PSUs&#x201d;), OnkosXcel restricted stock units (&#x201c;OnkosXcel RSUs&#x201d;) and BTI performance stock units (&#x201c;Performance Units&#x201d;). The Company&#x2019;s 2017 Equity Incentive Plan (the &#x201c;2017 Plan&#x201d;) became effective in August 2017. The Company&#x2019;s 2020 Incentive Award Plan (the &#x201c;2020 Plan&#x201d;) became effective in May 2020. Following the effective date of the 2020 Plan, the Company ceased granting awards under the 2017 Plan; however, the terms and conditions of the 2017 Plan continue to govern any outstanding awards granted thereunder.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s stock-based awards are valued at fair value on the date of grant and that fair value is recognized as an expense in the Consolidated Statements of Operations over the requisite service period using the accelerated attribution method. The estimated value of the BTI RSUs and Performance Units is based on the Company&#x2019;s closing stock price on the grant date. The estimated fair value of OnkosXcel RSUs are based on the OnkosXcel valuation on the grant date. The estimated fair value of stock-options and PSUs was determined using the Black-Scholes pricing model on the date of grant. For awards subject to performance-based vesting conditions, the Company recognizes stock-based compensation expense when the achievement of the performance condition becomes probable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Black-Scholes pricing model is affected by the Company&#x2019;s stock price, as well as assumptions regarding variables including, but not limited to, the strike price of the instrument, the risk-free rate, the expected stock price volatility over the term of the awards and expected term of the awards. The Company has elected to account for forfeitures as they occur, by reversing compensation cost when the award is forfeited.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_FPRDWzP4nEOa3EQqqd71CQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Research and development expenses include wages, benefits, non-cash stock-based compensation, facilities, supplies, external services, clinical study, manufacturing costs related to clinical trials and other expenses that are directly related to the Company&#x2019;s research and development activities. At the end of the reporting period, the Company estimates the progress toward completion of the research or development objectives and, depending on the amount and timing of payments to the service providers may record net prepaid or accrued expense for associated research and development costs. Such estimates are subject to change as additional information becomes available. The Company expenses research and development costs as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Most of the Company&#x2019;s service providers invoice BTI monthly in arrears for services performed. The Company estimates its accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to management at that time. BTI management periodically confirms the accuracy of the Company&#x2019;s estimates with the service providers and makes adjustments if necessary.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Although management does not expect its estimates to be materially different from amounts actually incurred, management&#x2019;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in BTI reporting amounts that are too high or too low in any particular period.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <btai:PatentCostsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_2sgDRV6JWEGVs5W2j2iOew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Patent Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Costs related to filing and pursuing patent applications are recorded in Selling, general and administrative expenses in the Consolidated Statements of Operations and are expensed as incurred since recoverability of such expenditures is uncertain.&lt;/p&gt;</btai:PatentCostsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb__BpBBHgDQUayy24T23mSNA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company measures certain financial assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources, or observable inputs, and (2) an entity&#x2019;s own assumptions about market participant assumptions developed based on the best information available in the circumstances, or unobservable inputs. The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). Fair value measurements must be classified and disclosed in one of the following three categories:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Level 1&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Level 2&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Level 3&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management&#x2019;s estimates of market participant assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considering counterparty credit risk in its assessment of fair value.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_Qf57rZ7aWU6i-F4yF6gUWQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI uses an asset and liability approach for financial accounting and reporting of income taxes. Deferred tax assets and liabilities are determined based on temporary differences between financial reporting and tax basis assets and liabilities and are measured by applying enacted rates and laws to taxable years in which differences are expected to be recovered or settled. Further, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that the rate changes. A valuation allowance is required when it is &#x201c;more likely than not&#x201d; that all or a portion of deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;U.S. GAAP prescribes a comprehensive model for how a company should recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on a tax return, including a decision whether to file or not file a return in a particular jurisdiction. The Company&#x2019;s financial statements reflect expected future tax consequences of such positions presuming the taxing authorities&#x2019; full knowledge of the position and all relevant facts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company does not have any unrecognized tax benefits as of December 31, 2024 and 2023. BTI reviews all tax positions to ensure the tax treatment selected is sustainable based on its technical merits and that the position would be sustained if challenged.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_B1dhGlLyz0uaVfPL-8HaGw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Earnings (Loss) per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Earnings (loss) per share (&#x201c;EPS&#x201d;) is calculated by dividing net income or loss attributable to common stockholders by the weighted average number of shares of common stock that were outstanding, including pre-funded warrants. Shares of common stock into which the pre-funded warrant may be exercised are considered outstanding for the purposes of computing EPS because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date. Diluted EPS is calculated by adjusting the weighted average number of shares of common stock that were outstanding for the dilutive effect of common stock equivalents. In periods in which a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be antidilutive.&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_J68cTCSbrUaHGlgbiNrObA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Segment Information&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company operates in a single segment. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. To date, the Company&#x2019;s chief operating decision maker has made such decisions and assessed performance at the Company level as one segment. See Note 19, &lt;i style="font-style:italic;"&gt;Segment Information&lt;/i&gt; for further information&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="INF"
      id="Narr_5SefTZ4e-USl2lG4ksXgPA"
      unitRef="Unit_Standard_segment_u3k5mJIKoECDA2MsRZB6Gg">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_nTdf79PS8UGpGhBW44h2Hg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment reporting, which requires disclosure of incremental segment information on an annual and interim basis. The standard is effective for years beginning after December 15, 2023, and interim periods beginning after December 15, 2024 and early adoption is permitted. The Company adopted the new standard in fiscal year 2024 for annual and retrospective reporting periods with all interim disclosures to begin in the first quarter of fiscal year 2025. For additional information, see Note 19, &lt;i style="font-style:italic;"&gt;Segment Information&lt;/i&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounting Pronouncements effective in future periods&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In December 2023, the FASB issued ASU 2023-09, Improvements to income tax disclosures, which requires disclosure of disaggregated income taxes paid by jurisdiction, enhances disclosures in the effective tax rate reconciliation and modifies other income tax-related disclosures. The amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the effect of adopting this guidance on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_C-8iiDJ4_kqu_k6VLMq9_A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;4. Restructuring&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On August 8, 2023, the Company&#x2019;s Board of Directors approved a broad-based strategic reprioritization (the &#x201c;Reprioritization&#x201d;). The Company took actions to reduce certain operational and workforce expenses that were no longer deemed core to ongoing operations in order to extend its cash runway and drive innovation and growth in high potential clinical development and value creating opportunities. These actions included a shift in commercial strategy for &lt;/span&gt;IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background:#ffffff;"&gt; in the institutional setting, a reduction of in-hospital commercialization expenses, a suspension of programs no longer determined to be core to ongoing operations, and a prioritization of at-home treatment setting opportunities for BXCL501.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;As part of this strategy, the Company&#x2019;s Board of Directors approved a reduction of approximately &lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;60%&lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt; of the Company&#x2019;s workforce. The Company notified impacted employees on August 14, 2023 and recorded total restructuring costs of &lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;$4,163&lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt; for the year ended December 31, 2023. These costs consisted of severance and benefit costs of &lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;$4,063&lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt; and contract termination costs of &lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;$100&lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;. The Company paid $&lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;3,998&lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt; of severance and benefit costs and &lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;$100&lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt; of contract termination costs in the year ended December 31, 2023. The Reprioritization is substantially complete as of December 31, 2023, and any remaining costs are expected to be paid during the first quarter of 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;background:#ffffff;"&gt; On May 8, 2024 the Company took additional actions as part of its continued efforts to preserve cash and prioritize investment in its core clinical programs.&lt;/span&gt; &lt;span style="background:#ffffff;"&gt;As part of these actions, the Company initiated a further reduction of approximately &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;15%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; of the Company&#x2019;s then current workforce. The Company notified impacted employees on May 8, 2024 and recorded total restructuring costs of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$856&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; for the three months ended June 30, 2024. These costs consisted of severance and benefit costs, all of which were paid during the three months ended June 30, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On September 17, 2024, the Company approved a plan for an additional reduction in its workforce of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;15&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; employees, or approximately &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;28%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; of the Company&#x2019;s headcount (the &#x201c;Clinical Prioritization&#x201d;), in order to extend its cash runway and prioritize investment on the clinical development of its lead neuroscience asset, BXCL501. The Company incurred aggregate charges in connection with the Clinical Prioritization of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1,586&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; which relate primarily to severance and benefits costs. Accordingly, the Company recorded a restructuring charge of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1,553&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; in the third quarter 2024, and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$33&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; in the fourth quarter. The Company completed the Clinical Prioritization in October 2024, and paid &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$983&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; of the related costs during the fourth quarter of 2024 and expects to pay the remaining &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$603&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; in the first quarter of 2025,&lt;/span&gt; &lt;span style="background:#ffffff;"&gt;which is included in Accrued Expenses on the Consolidated Balance at December 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="Duration_8_8_2023_To_8_8_2023_1AQEFh0qkU22JOe-2n46Ww"
      decimals="2"
      id="Narr_EMzvvq-4ZEupTQWo_ERqVg"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.60</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringCharges
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Narr_1gd8MEuARUyaZln0ugdqSw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">4163000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_dCk4KHjYVECYOD1bNWMxhA"
      decimals="-3"
      id="Narr_aghL1WJnWEO1oZd3eCmsFQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">4063000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_0Fa5GpoDykyuoxmj8TA-dQ"
      decimals="-3"
      id="Narr_2DJ2KY8Do02Ur9pcYcGK1w"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">100000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_dCk4KHjYVECYOD1bNWMxhA"
      decimals="-3"
      id="Narr_Fnd6m4WoDkC4UP_oeqGHeg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">3998000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_0Fa5GpoDykyuoxmj8TA-dQ"
      decimals="-3"
      id="Narr_YNeEMBUwX0aqwD3n7sdAVQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">100000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="Duration_5_8_2024_To_5_8_2024_IhAulVfqfE-gUqz51YDtXg"
      decimals="2"
      id="Narr_rrbhC145UUGnsWGrnK8SkQ"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.15</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringCharges
      contextRef="Duration_4_1_2024_To_6_30_2024_Sa7bc9y2BEeY9w4XybT9qQ"
      decimals="-3"
      id="Narr_QtGZu3MJP02Th6GPxFhGuQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">856000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="Duration_9_17_2024_To_9_17_2024_OiBFsSYoqEGoJgxld_C82A"
      decimals="INF"
      id="Narr_EXNdDpaD7kuXQTSMOVp8aA"
      unitRef="Unit_Standard_employee_g1iuox2T4U2nGaIKFGYE2w">15</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="Duration_9_17_2024_To_9_17_2024_OiBFsSYoqEGoJgxld_C82A"
      decimals="2"
      id="Narr_QzXFCoHu70Ox6fUpwhy2yA"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.28</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="As_Of_9_17_2024_XxyLTPFqzUyn2yLJ69oiWg"
      decimals="-3"
      id="Narr_qDPb1X8YgEClFJeaQBkw8A"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1586000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringCharges
      contextRef="Duration_7_1_2024_To_9_30_2024_UmSoTOy6ZEqdvjDqQLaKEw"
      decimals="-3"
      id="Narr_0rsOnjxVy0qM_zsihiwpHA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1553000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="Duration_10_1_2024_To_12_31_2024_3PEv7wfJfUKxY2X6WXJQ_g"
      decimals="-3"
      id="Narr_43pzq9w4C0qeKvp2Zu_9Zw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">33000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="Duration_10_1_2024_To_12_31_2024_3PEv7wfJfUKxY2X6WXJQ_g"
      decimals="-3"
      id="Narr_xsyDwB8gRUKtpA_TxSSSXA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">983000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveCurrent
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Narr_dJ8V48jLXkOre0BC_lqsIg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">603000</us-gaap:RestructuringReserveCurrent>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_m97jkR_Wxkqy4NToLw7Aww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;5. Inventory&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Inventory consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 935&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work-in-process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 651&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 173&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 405&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,991&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-weight:normal;"&gt;The Company recorded inventory write-downs due to excess inventory of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$1,980&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$1,191&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; for the years ended December 31, 2024 and 2023, respectively. &lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_rUk3n8q2ek-FXVBhAMrrMg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 935&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work-in-process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 651&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 173&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 405&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,991&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_N9_aUdvfz02lo9SGxKiOyQ_4_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">506000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_xAKez48BPEqQeADEoXNl6A_4_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">935000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_LWuw0Z4my0uEDpVinv0M1w_5_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">651000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_Qo8EP9n3q0Cq1bgnFKpD0w_6_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">173000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_s1WGbsxzJ0OCJJDLRMGleA_6_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">405000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_DFp61K_yO0G2zRtZ23-wlQ_7_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">679000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_YoUQv1wqFEq19fGB_Q9j-A_7_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1991000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Narr_i8Qe1GoG2UKZCerApkW_og"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1980000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Narr_rzpGtQdwbkeJufyBmYO7zQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1191000</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_RkDe0T9R8k-VG95x6i46Cg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;6. Property and Equipment, net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Property and equipment, net consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computers and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 202&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 202&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 575&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,977&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,977&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,502)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,193)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 475&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 784&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Depreciation expense was &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$309&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$318&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; for the years ended December 31, 2024 and 2023, respectively&lt;/span&gt;.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_dqyqXLST-0WPG5_RJwlYDQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computers and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 202&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 202&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 575&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,977&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,977&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,502)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,193)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 475&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 784&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_MJeawgIMDEyPxu7dj7F8aQ"
      decimals="-3"
      id="Tc_qVG17WtNXk2uiCK10g8svw_4_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">202000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_zmvJP9XWKUylAuis6tmJsw"
      decimals="-3"
      id="Tc_EwWv_oMfSEaH8NrkmWyBSw_4_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">202000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_bGkvra2V9Ue26IMBxqrCww"
      decimals="-3"
      id="Tc_beOGo0y9S0uQ0bozpotd_w_5_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">575000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_kXPimCUV7keG3q0uOSWbGQ"
      decimals="-3"
      id="Tc_128qP_96PUOo6DeEAl9xdw_5_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">575000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_awYc1AER0EGr0NZ0NV2hSg"
      decimals="-3"
      id="Tc_kJ1aE3zR00-GInc3qqyulA_6_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_3NEbuF2yQ0q1F_2-3706qw"
      decimals="-3"
      id="Tc_-yU0HZEuzkahsIDUMRB8lA_6_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_HCemepjXdUGQOLe0UU6UZw_7_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1977000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_xRILo3N2UkSECx5SU4XXYA_7_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1977000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_tWyIDfJR3UG3r-yi8vZz9Q_8_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1502000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_nBJhpiO-aEucXhTI7ycCSw_8_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1193000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_3WfFViRN6USXILpBdVpm2Q_9_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">475000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_szjT7xc5n06gSuRHn3kUCw_9_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">784000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Narr_dKpsQHHPUkaxWfMzrLvmJQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">309000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Narr_XJPwnO91m0entE9XWX4qtA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">318000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_iJQnt4jIik6OkffjhTQ8AA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;7. Accrued Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Accrued expenses consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,107&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,406&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued compensation and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 163&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,604&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,562&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 116&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 322&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 177&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued restructuring costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 603&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,424&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_MOcbDLYkY0K3LZRkhUnCjA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,107&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,406&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued compensation and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 163&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,604&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,562&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 116&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 322&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 177&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued restructuring costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 603&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,424&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <btai:AccruedResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_lhznq-vKX0SilfstPM4OBA_3_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">3107000</btai:AccruedResearchAndDevelopmentExpenses>
    <btai:AccruedResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_rPUlTrJK0Uq65RtnIujVTQ_3_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">6406000</btai:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_qLa2A5JLaUaNZ6MVaxXAgg_4_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">35000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_WZwqkPk-oku1NwtFMZQdmQ_4_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">163000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_jvP6LykweUuVOdDFhKv3-w_5_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1604000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc__TC84mtqX0mZ3oy2k6Ad6w_5_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">5562000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_tqTwPo0RdE-cqmBzyHQdIA_6_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">91000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_ups9l_ZtqkO9COAHJYVgfA_6_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">116000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_M_bDtcbPkES3zxYHnDqVuQ_7_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">322000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_rATNd_fAhEKyxGcbJiUNwQ_7_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">177000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:RestructuringReserveCurrent
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_LlsWX6JVEEqdaCFZ8PT2hg_8_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">603000</us-gaap:RestructuringReserveCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_fCRsPh05fkOCn7st9QjHDQ_9_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">5762000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_KPv-qz3ouUOb4Xg1V05ouQ_9_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">12424000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_ak-1n17HIkKMcgqnTBGG1g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;8. Transactions with BioXcel LLC&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company entered into a Separation and Shared Services Agreement with BioXcel LLC that took effect on June 30, 2017, as amended and restated thereafter (the &#x201c;Services Agreement&#x201d;), pursuant to which BioXcel LLC had agreed to provide the Company with certain intellectual property prosecution and management and research and development activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Under the Services Agreement, the Company had an option, exercisable until December 31, 2024, to enter into a separate collaborative services agreement with BioXcel LLC pursuant to which BioXcel LLC shall perform product identification and related services for us utilizing its EvolverAI. We agreed to pay BioXcel LLC $18 per month from March 13, 2023, to December 31, 2024 in exchange for this option. This option was not exercised. However, BioXcel LLC continues to perform certain administrative services under the terms of the expired contract. We agreed to negotiate any such collaborative services agreement in good faith and to incorporate reasonable market-based terms, including consideration for BioXcel LLC reflecting a low, single-digit royalty on net sales and reasonable development and commercialization milestone payments, provided that (i) development milestone payments shall not exceed $10,000 in the aggregate and not be payable prior to proof of concept in humans and (ii) commercialization milestone payments shall be based on reaching annual net sales levels, be limited to 3% of the applicable net sales level, and not exceed $30,000 in the aggregate. We did not exercise our option to renew the agreement for product identification and related services utilizing BioXcel LLC&#x2019;s EvolverAI. Subsequent to December 31, 2024 no development activity has been carried out by BioXcel LLC and none is contemplated.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Service charges recorded under the Services Agreement for the years December 31, 2024 and 2023 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#0563c1;font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 938&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,075&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 392&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 211&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,330&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,286&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;There were no service charges due as of December 31, 2024 and December 31, 2023.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <btai:AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement
      contextRef="Duration_6_30_2017_To_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__Rfp0WkOeUSwkyApqU9Aow"
      decimals="-3"
      id="Narr_vuOMByfm7UOIhMKncJFRng"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">18000</btai:AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement>
    <btai:CollaborativeArrangementMilestonePaymentsPotential
      contextRef="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_DevelopmentMilestonesMember_jNVSm8QxO0KzJACAONNxDQ"
      decimals="-3"
      id="Narr_kNp3h3hYG0Cp9bD_9yY3eg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">10000000</btai:CollaborativeArrangementMilestonePaymentsPotential>
    <btai:CollaborativeArrangementMilestonePotentialPercent
      contextRef="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_SalesMilestonesMember_ivfM8IqGnEukjOEO4xau4Q"
      decimals="2"
      id="Narr_ipZ0ZW4cykSlX_ytfxcrQw"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.03</btai:CollaborativeArrangementMilestonePotentialPercent>
    <btai:CollaborativeArrangementMilestonePaymentsPotential
      contextRef="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_SalesMilestonesMember_ivfM8IqGnEukjOEO4xau4Q"
      decimals="-3"
      id="Narr_e2yrzqpYxUahda9ob-pJVw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">30000000</btai:CollaborativeArrangementMilestonePaymentsPotential>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_jF5Lnz3RckqDrCgq8Q3Fuw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#0563c1;font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 938&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,075&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 392&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 211&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,330&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,286&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_I-pOhJgS20CdZAck10nsIQ"
      decimals="-3"
      id="Tc_qs9wWCHpAEq8vteFrJ5LuA_4_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">938000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_2OCsk1QU00-KJSY3sMd-yQ"
      decimals="-3"
      id="Tc_Zg8Mo6m2z02z4jeQom0RkQ_4_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1075000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_I-pOhJgS20CdZAck10nsIQ"
      decimals="-3"
      id="Tc_UetzDKmFTk6-PxyoCuvxOw_5_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">392000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_2OCsk1QU00-KJSY3sMd-yQ"
      decimals="-3"
      id="Tc_1mFaI-aVEU-BEESjiDYq1g_5_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">211000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_I-pOhJgS20CdZAck10nsIQ"
      decimals="-3"
      id="Tc_9LfEuHBScEeGBi296-kOKw_6_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1330000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_2OCsk1QU00-KJSY3sMd-yQ"
      decimals="-3"
      id="Tc_6nlYvwnR2EqCDe6EelIEew_6_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1286000</us-gaap:CostsAndExpenses>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_CDdL6odIhEyB7dtSsjWgHg"
      decimals="-3"
      id="Narr_iipxHS0P70eY42aaxk6DRQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_AF3B6HHa0kyLVVlQaBJT2A"
      decimals="-3"
      id="Narr_EfMgLa3-6EK4ICVIRj93Jw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_pnlowyoIIka0thGS0TAsIg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;9. Debt and Credit Facilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Debt, net of unamortized discounts and financing costs, consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Credit Agreement and Guaranty&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 102,319&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 102,319&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Payable-in-kind ("PIK") interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 361&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total long-term debt liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 106,722&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 102,680&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unamortized debt premiums, discounts and issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,214)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,082)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 102,508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 100,598&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;On April 19, 2022, the Company entered into two strategic financing agreements: (i) a Credit Agreement and Guaranty (the &#x201c;Credit Agreement&#x201d;) by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the &#x201c;Lenders&#x201d;), and Oaktree Fund Administration LLC (&#x201c;OFA&#x201d;) as administrative agent, and (ii) a Revenue Interest Financing Agreement (the &#x201c;RIFA&#x201d;; and together with the Credit Agreement, the &#x201c;OFA Facilities&#x201d;) by and among the Company, the purchasers party thereto (the &#x201c;RIFA Purchasers&#x201d;) and OFA as administrative agent. Under the OFA Facilities, the Lenders and the RIFA Purchasers agreed to, in the aggregate between the two OFA Facilities, provide up to $260,000 in gross funding to support the Company&#x2019;s commercial activities of IGALMI&lt;sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; sublingual film. In addition, the OFA Facilities are intended to support the expansion of clinical development efforts of BXCL501, which includes a Phase 3 program for the acute treatment of agitation in patients with Alzheimer&#x2019;s disease, and for general corporate purposes. The Lenders and RIFA Purchasers are comprised of affiliates of Oaktree Capital Management, L.P. and Qatar Investment Authority.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"&gt;&lt;b style="font-weight:bold;"&gt;Waiver and First Amendment to Credit Agreement and Guaranty&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On November 13, 2023, the Company, the lenders party to the Credit Agreement and OFA entered into a Waiver and First Amendment to Credit Agreement and Guaranty (the &#x201c;First Amendment&#x201d;) that provided for (i) a waiver and a modification to the covenant in the Credit Agreement regarding investments in OnkosXcel and (ii) an agreement among the parties to further revise key financial terms in the Credit Agreement and terminate the RIFA. Pursuant to the First Amendment, the Lenders agreed to permit the Company to invest up to a maximum of $30,000 at any time outstanding in OnkosXcel, increased from $25,000 at any time outstanding. The First Amendment also waived any defaults or events of default arising under the Credit Agreement due to a breach prior to the date of the First Amendment of the OnkosXcel investment covenant, or a breach of the Company&#x2019;s obligation to notify OFA of such default. In connection with the First Amendment, the Company paid the Lenders a fee of $180 (representing 0.25% of the loans outstanding under the Credit Agreement on the date of the First Amendment) and agreed to pay to the Lenders an exit fee equal to 0.25% of the loans under the Credit Agreement repaid upon maturity or prepayment of the loans. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"&gt;&lt;b style="font-weight:bold;"&gt;Second Amendment to Credit Agreement and Guaranty and Termination of the RIFA&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.25;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;On December 5, 2023, (the &#x201c;Second Amendment Effective Date&#x201d;), the Company entered into the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement (the &#x201c;Second Amendment&#x201d;), which further amended the Credit Agreement. On the Second Amendment Effective Date, the Credit Agreement was amended to provide up to $202,319 in senior secured term loans, including the initial Tranche A of $70,000, which was funded on April 28, 2022, and related capitalized interest on Tranche A through the Second Amendment Effective Date in the amount of $72,319. In addition, the $30,000 in financing previously provided to the Company under the RIFA on July 8, 2022 was converted to a term loan under the Credit Agreement (the &#x201c;Tranche A-2 Term Loan&#x201d;). The RIFA and all commitments for potential future funding thereunder were terminated. In addition, pursuant to the Second Amendment, the Lenders agreed to permit the Company to invest up to a maximum of $30,865 at any time outstanding in OnkosXcel, increased from $30,000. In connection with the Second Amendment, the Company agreed to pay to the Lenders an exit fee equal to 0.25% of the loans under the Credit Agreement repaid upon maturity or prepayment of the loans (which exit fee is in addition to, and not in lieu of, the exit fee provided for by the First Amendment). As of September 30, 2024, $100,000 in commitments under the Credit Agreement remains unfunded, and Oaktree has an Equity Investment Right (as defined below) to purchase up to $5,000 of Common Stock from the Company. The blended effective interest rate on the Tranches A-1 and A-2 as of December 31, 2023 was approximately 13.5%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The remaining tranches may be borrowed at the Company&#x2019;s option prior to December 31, 2024, subject to satisfaction of certain conditions, including regulatory and financial milestones. Tranche B of the Credit Agreement is $20,000 and is available upon satisfaction of certain conditions and financial milestones. Tranche C of the Credit Agreement is $30,000 and is available upon satisfaction of certain conditions, including receipt of certain regulatory and financial milestones. Tranche D of the Credit Agreement is $50,000 and is available upon satisfaction of the Tranche C Term Loans conditions precedent to, and the funding of Tranche C Loans, including specified minimum net sales of the Company attributable to sales of BXCL501 for a trailing twelve consecutive month period, on or before December 31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The loans under the Credit Agreement do not amortize and mature on April 19, 2027. The Company may, at its option, no earlier than September 21, 2026 and no later than October 21, 2026, request an extension of the maturity date to April, 19, 2028, provided that the Company satisfies certain conditions including receipt of certain regulatory and financial milestones. Borrowings under the Credit Agreement are issued at a &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;200&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;-basis point original issue discount and bear interest at a variable annual rate of TERM &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_q_7viYeZgU21L0rksnVcQQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;SOFR&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; (but not less than &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;2.5%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; or more than &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;5.5%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;) plus &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;7.5%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;, payable quarterly. The rate resets every three months based on the current Term SOFR rate. Of such interest, above &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;8%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per annum is, at the Company&#x2019;s option, payable in kind by capitalizing and adding such interest to the outstanding principal amount of loans from the first payment date on which such interest is owed through&lt;/span&gt; &lt;span style="font-size:10pt;"&gt;March 31, 2025, unless, with respect to any payment date, the Company elects to pay all or a portion of such interest in cash. The Company is required to pay a ticking fee equal to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;0.75%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per annum on the undrawn amount of the commitments, payable quarterly commencing 120 days after April 22, 2022 through the termination of the commitments, which is expensed as incurred and recognized as interest expense in the Consolidated Statements of Operations. The Company may voluntarily prepay the Credit Agreement at any time subject to a prepayment fee.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s obligations under the Credit Agreement are guaranteed by BTI&#x2019;s existing and subsequently acquired or organized subsidiaries, subject to certain exceptions. BTI&#x2019;s obligations under the Credit Agreement and the related guarantees thereunder are secured, subject to customary permitted liens and other agreed upon exceptions, by (i) a pledge of all of the equity interests of all of the Company&#x2019;s existing and any future direct subsidiaries, and (ii) a perfected security interest in all of its and the guarantors&#x2019; tangible and intangible assets (except that the guarantees provided by the BXCL701 Subsidiaries (as defined below) are unsecured).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness, and dividends and other distributions, subject to certain exceptions, including specific exceptions with respect to product commercialization and development activities. The Company must also comply with certain financial covenants, including (i) maintenance of cash or permitted cash equivalent investments in accounts controlled by OFA for the Lenders, of at least (a) initially, $15,000, (b) from and after the funding of the Tranche B &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;loans, $20,000, and (c) from and after the Company&#x2019;s satisfaction of the funding conditions for the Tranche C loans, $15,000, provided, that the liquidity covenant applicable at any time will be increased upon certain events related to a sale of OnkosXcel (up to a maximum amount equal to $37,500), provided that the minimum liquidity amount will in no event exceed 50% of the aggregate amount of loans outstanding under the Credit Agreement at any time; and (ii) a minimum revenue test, measured quarterly beginning with the Company&#x2019;s fiscal quarter ending on December 31, 2024 (such six-month period the &#x201c;Revenue Covenant Measurement Period&#x201d;), that requires it and its subsidiaries&#x2019; consolidated net revenue for the six consecutive month period ending on the last day of each such fiscal quarter to not be less than a minimum revenue amount specified in the Credit Agreement (such testing date, the &#x201c;Revenue Covenant Measurement Testing Date&#x201d; and the covenant described in this clause (ii) the &#x201c;Revenue Covenant&#x201d;). The Company&#x2019;s failure to comply with the financial covenants will result in an event of default, subject to certain cure rights with respect to the Revenue Covenant. If, as of a Revenue Covenant Measurement Testing Date, the Company&#x2019;s revenue for the applicable Revenue Covenant Measurement Period is less than the minimum revenue amount specified for the applicable period then required under the Revenue Covenant, the Company would have a right to cure such shortfall for a total of three fiscal periods by making a revenue cure payment (which would be treated as prepayments of the loans subject to a prepayment fee) to the Lenders in an amount equal to the difference between such minimum required revenue amount and the Company&#x2019;s actual revenues for such Revenue Covenant Measurement Period, such payment to not be less than $1,000. If paid, the Company will be deemed to have complied with the Revenue Covenant as of such Revenue Covenant Measurement Testing Date. Any such payment will be applied to the prepayment of the loans under the Credit Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Notwithstanding the foregoing, the Credit Agreement permits OnkosXcel (together with OnkosXcel Employee Holdings, LLC (&#x201c;Employee Holdings&#x201d;), a subsidiary of BTI, and their respective subsidiaries, the &#x201c;BXCL701 Subsidiaries&#x201d;) to receive third-party investment or transfer all or substantially all of their assets to an unaffiliated third party, in each case subject to terms and conditions set forth in the Credit Agreement, including the escrow of certain proceeds received by BTI and its subsidiaries (other than the BXCL701 Subsidiaries) in respect of these disposition events and, under circumstances set forth in the Credit Agreement, the mandatory prepayment of such escrowed amounts. The Company&#x2019;s equity interests in the BXCL701 Subsidiaries have been pledged in support of its obligations under the Credit Agreement, and the BXCL701 Subsidiaries have provided direct guarantees of BTI&#x2019;s obligations under the Credit Agreement on an unsecured basis. However, the pledge, guarantee and other obligations of the BXCL701 Subsidiaries under the Credit Agreement will be released upon certain agreed upon events, including an initial public offering by the BXCL701 Subsidiaries or the ownership by unaffiliated third parties of at least 20% of the equity interests in the BXCL701 Subsidiaries.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Credit Agreement contains events of default that are customary for financings of this type relating to, among other things, payment defaults, breach of covenants, breach of representations and warranties, cross default to material indebtedness, bankruptcy-related defaults, judgment defaults, breach of the financial covenants described above, and the occurrence of certain change of control events. In certain circumstances, events of default are subject to customary cure periods. The Credit Agreement also contains certain regulatory-related events of default, which do not have cure periods. Following an event of default and any applicable cure period, the Lenders will have the right upon notice to terminate any undrawn commitments and may accelerate all amounts outstanding under the Credit Agreement, in addition to other remedies available to them as the Company&#x2019;s secured creditors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"&gt;&lt;b style="font-weight:bold;"&gt;Waiver and Third and Fourth Amendments to Credit Agreement and Guaranty&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On February 12, 2024, the Company entered into the Third Amendment to Credit Agreement and Guaranty (the &#x201c;Third Amendment&#x201d;), which amended the Credit Agreement. Pursuant to the Third Amendment, the Lenders agreed to waive the covenant that the Company shall not receive a report and opinion from the Company&#x2019;s independent auditors that contains a &#x201c;going concern&#x201d; or like qualification or exception or emphasis of matter of going concern footnote with respect to the Company&#x2019;s financial statements for the fiscal year ended December 31, 2023 and, as a result, such event shall not be an event of default. As a condition to the effectiveness of the Third Amendment, among other things, the Company shall have received at least &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$40,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; in gross proceeds from a registered public sale of the Company&#x2019;s common stock, warrants and/or pre-funded warrants&lt;/span&gt; on or before February 20, 2024. The Company did not meet this condition and therefore the Third Amendment did not become effective.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On March 20, 2024 (the &#x201c;Effective Date&#x201d;), the Company entered into the Fourth Amendment to the Credit Agreement and Guaranty (the &#x201c;Fourth Amendment&#x201d;), which amended the Credit Agreement. Pursuant to the Fourth Amendment, the Lenders agreed to waive the covenant that the Company shall not receive a report and opinion from the Company&#x2019;s independent registered public accounting firm that contains a &#x201c;going concern&#x201d; or similar qualification with respect to the Company&#x2019;s financial statements for the year ended December 31, 2023. Accordingly, while the Company&#x2019;s independent registered public accounting firm&#x2019;s report contained in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 contains a &#x201c;going concern&#x201d; explanatory paragraph, it does not constitute an event of default under the Credit Agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Fourth Amendment includes a covenant that the Company will receive, (i) after the Effective Date and on or before April 15, 2024, at least $25,000 in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or in non-refundable cash consideration from partnering transactions entered into after the Effective Date (so long as such partnering transactions would not require the Company or any of its subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made) and (ii) after the Effective Date and on or before November 30, 2024, at least $50,000 (for the avoidance of doubt, inclusive of amounts previously counted toward the preceding clause (i)) in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent (as defined in the Credit Agreement) in its sole discretion ) from partnering transactions entered into after the Effective Date. Failure to perform this covenant would constitute (A) a default under the Credit Agreement and (B) an event of default under the Credit Agreement, subject to a cure period, solely in the case of clause (i) of the preceding sentence, until May 15, 2024. For the avoidance of doubt, failure to perform clause (ii) of the preceding sentence would constitute an immediate event of default under the Credit Agreement without any cure or grace period. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In addition, the Fourth Amendment provides that if the Company has not, after the Effective Date and on or before September 30, 2024, received at least $40,000 in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the Effective Date, the &#x201c;Minimum Liquidity Amount&#x201d; (as defined in the Credit Agreement) that the Company is required to maintain at all times will increase to $25,000 from $15,000, unless and until the Company has received, after the Effective Date and on or before November 30, 2024, at least $50,000&lt;span style="white-space:pre-wrap;"&gt; in gross proceeds from the issuance of the Company&#x2019;s common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the Effective Date.  On March 27, 2024, the Company received &lt;/span&gt;$25,000 in gross proceeds from the issuance of its common stock, warrants, and pre-funded warrants discussed in Note 11, &lt;i style="font-style:italic;"&gt;Common Stock Financing Activities&lt;/i&gt;, satisfying the April 15, 2024 covenant requirement of the Fourth Amendment. During the third quarter of 2024, the Company received $467&lt;span style="white-space:pre-wrap;"&gt; of gross proceeds from the issuance of the Company&#x2019;s common stock.  As of September 30, 2024, the Company had satisfied &lt;/span&gt;$30,943 of the $40,000 required to maintain the Minimum Liquidity Amount and the $50,000&lt;span style="white-space:pre-wrap;"&gt; gross proceeds requirement.  As a result, at September 30, 2024, the Minimum Liquidity Amount increased to &lt;/span&gt;$25,000. As of September 30, 2024, we were in compliance with all restrictive and financial covenants under the Credit Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0pt -0.25pt;"&gt;&lt;b style="font-weight:bold;"&gt;Waiver and Fifth Amendment to Credit Agreement and Guaranty&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On November 21, 2024, the Company entered into the Fifth Amendment to Credit Agreement and Guaranty and First Amendment to Fourth Amendment to Credit Agreement and Guaranty (the &#x201c;Fifth Amendment&#x201d;), which amended the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the &#x201c;Lenders&#x201d;), and Oaktree Fund Administration LLC (&#x201c;OFA&#x201d;) as administrative agent (as amended by the Waiver and First Amendment to Credit Agreement and Guaranty, dated as of November 13, 2023, the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement, dated as of December 5, 2023, the Third Amendment to Credit Agreement, dated as of February 12, 2024, and the Fourth Amendment to Credit Agreement and Guaranty, dated as of March 20, 2024 (the &#x201c;Fourth Amendment&#x201d;), the &#x201c;Existing Credit Agreement&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Pursuant to the Fifth Amendment, the Lenders agreed to, among other things, (i) waive the Credit Agreement&#x2019;s covenant that the report and opinion the Company will receive from its independent registered public accounting firm with respect to the financial statements for the year ending December 31, 2024 will not contain a &#x201c;going concern&#x201d; or similar qualification, (ii) permanently waive the Credit Agreement&#x2019;s minimum revenue covenant, and (iii) waive the Fourth Amendment&#x2019;s requirement that the Company raise, after the effective date of the Fourth Amendment and on or before November 30, 2024, at least $50,000 in gross cash proceeds from the issuance of its common stock, warrants, and/or pre-funded warrants, and/or in cash and/or non-cash consideration from newly entered-into partnering transactions. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Fifth Amendment includes a new capital raising covenant requiring that the Company receive (A) after the effective date of the Fifth Amendment and on or prior to November 27, 2024, at least $7,000 in gross cash proceeds from the issuance of the Company&#x2019;s common stock, warrants and/or pre-funded warrants(&#x201c;Raise 1&#x201d;), (B) after the effective date of the Fifth Amendment and on or before March 15, 2025 (provided that the Company was required to use its commercially reasonable efforts to satisfy the requirement by February 15, 2025), at least $18,000 in net cash proceeds (including the proceeds of Raise 1) from (i) the issuance of the Company&#x2019;s common stock, warrants and/or pre-funded warrants, (ii) non-refundable cash consideration from partnering transactions entered into after the effective date of the Fifth Amendment (so long as such partnering transactions would not require the Company or any of its subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made), (iii) the issuance of the Company&#x2019;s subordinated debt (subject to terms set forth in the Fifth Amendment), and/or (iv) asset sales permitted pursuant to the Credit Agreement or consented to by the Lenders (such capital raise, &#x201c;Raise 2&#x201d;), and (C) after the effective date of the Fifth Amendment and on or prior to the earlier of (x) August 15, 2025 and (y) the date that is 30 days after the final data readout of the SERENITY At-Home Phase 3 trial, at least $29,000 in net cash proceeds (including the proceeds from Raise 1 and Raise 2) from the same permitted capital raising activities listed in the preceding clause (B). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In connection with the Fifth Amendment and the required capital raises described in the preceding paragraph, the Lenders agreed to modify the Credit Agreement&#x2019;s minimum liquidity covenant to require minimum cash liquidity of $7,500 (instead of $25,000) from and after the closing of Raise 1until March 30, 2025. On March 31, 2025, the minimum liquidity amount will increase to $10,000 and on September 30, 2025, the minimum liquidity amount will further increase to $15,000. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In connection with the Fifth Amendment, the Company paid a one-time amortization payment of $2,500 principal amount, together with accrued and unpaid interest and a portion of the prepayment fee and other fees payable in December 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The Fifth Amendment also modifies the interest rate of the loans provided under the Credit Agreement from a floating rate of Term &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_kFih0nmoC0-H7vISN9YfvQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;SOFR&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; plus &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;7.50%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per annum, to a fixed rate of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;13%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per annum, retroactive to and effective as of September 30, 2024. For the quarterly payment dates ending December 31, 2024, March 31, 2025, and June 30, 2025, the Company will have the ability to make interest payments of up to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;10%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per annum &#x201c;in-kind&#x201d; by capitalizing and adding such interest to the outstanding principal amount of the loans under the Credit Agreement. In addition, pursuant to the Fifth Amendment, the Company will be required to make quarterly amortization payments equal to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;5.0%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; of the principal amount of funded loans, together with applicable prepayment fees, beginning on March 31, 2026. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;On the effective date of the Fifth Amendment and as a condition to effectiveness thereof, the Company&#x2019;s wholly owned subsidiaries OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC (collectively, &#x201c;OnkosXcel&#x201d;), which previously provided unsecured guarantees of the Company&#x2019;s obligations under the Credit Agreement, granted security interests in substantially all of their assets to support such obligations. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Fifth Amendment amends the negative covenants under the Credit Agreement to remove flexibility the Company and its subsidiaries previously had thereunder to undertake various transactions, including, without limitation, with respect to potential dispositions of OnkosXcel or out-licenses by OnkosXcel of its intellectual property. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Pursuant to the Fifth Amendment, the Company committed to appoint a new independent board director (subject to customary background checks, applicable law, confirmation of independence and Nasdaq rules), and to provide the independent director with various privileges and committee memberships on the board of directors of the Company &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;(including the appointment of such director on committee to be formed to focus on capital raising and evaluate strategic options). The Company also agreed to engage an investment banker reasonably acceptable to OFA and the Lenders to assist the Company and its board of directors with evaluating and exploring strategic options. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company also agreed to covenants requiring that the Company&#x2019;s cash expenditures be monitored by the Lenders according to a board-approved budget provided to the Lenders prior to the signing of the Fifth Amendment, which cash budget will be updated on a bi-weekly basis going forward. The Company will not be permitted to make disbursements for any two-week period in excess of 115% of the aggregate budgeted amount of disbursements for the applicable period. Finally, pursuant to the Fifth Amendment, the Company is restricted from paying cash bonuses for its employees or executives during the fiscal years 2024 and 2025 without OFA&#x2019;s consent or increasing the cash compensation for fiscal year 2025 for certain senior officers of the Company from their compensation for fiscal year 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue Interest Financing Agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As noted, the RIFA was terminated when the Company entered into the Second Amendment, which amended the Credit Agreement (as amended by the First Amendment). The $30,000 Tranche A previously provided to the Company under the RIFA was converted to the Tranche A-2 Term Loan. Prior to termination, the RIFA provided up to $120,000 in potential financing in exchange for a capped revenue interest on net sales of IGALMI&lt;sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;, and other future BXCL501 products, if any, that received regulatory approval for sale. The initial Tranche A of $30,000 was funded on July 8, 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Under the terms of the RIFA, the Purchasers were to receive tiered revenue interest payments on U.S. net sales of IGALMI&lt;sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;, and other future BXCL501 products, if any, that receive regulatory approval for sale, equal to a royalty ranging from 0.375% to 7.750% of net sales of IGALMI&lt;sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;, and other future BXCL501 products, if any, approved for sale in the U.S., subject to a hard cap equal to 1.75x the total amount funded. The Company would also have been required to make certain additional payments to the Purchasers from time to time to ensure that the aggregate amount of payments received by the Purchasers under the RIFA were at least equal to certain agreed upon minimum levels as of certain specified dates, subject to terms and conditions set forth in the RIFA. Revenue interest payments due under the RIFA were payable quarterly based on net sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants and Equity Investment Right&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In connection with the closing of the Second Amendment, on the Second Amendment Effective Date, the Company amended and restated the warrants granted to the Lenders on April 19, 2022 to purchase up to 17 shares of the Company&#x2019;s common stock at an exercise price of $320.6 per share (the &#x201c;Closing Date Warrants&#x201d;). Pursuant to the amendment and restatement of the Closing Date Warrants, dated December 5, 2023 (the &#x201c;Amended and Restated Closing Date Warrants&#x201d;), the exercise price of the Closing Date Warrants has been reduced to $58.3232 per share. In addition, the Company granted new warrants to the Lenders to purchase up to 4 shares of the Company&#x2019;s common stock (the &#x201c;2023 Warrant Shares&#x201d;) at an exercise price of $58.3232 per share (the &#x201c;2023 Warrants&#x201d;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;and together with the Amended and Restated Closing Date Warrants, the &#x201c;Warrants&#x201d;). The Amended and Restated Closing Date Warrants and the 2023 Warrants will expire on April 19, 2029 and may be net exercised at the holders election. In addition, pursuant to the Credit Agreement, the Lenders have the right to purchase shares of the Company&#x2019;s common stock after the Second Amendment Effective Date, so long as borrowings under the Credit Agreement are outstanding, for a purchase price of $5,000 at a price per share equal to a 10% premium to the volume-weighted average price of the common stock over the 30 trading days prior to the Lenders&#x2019; election to proceed with such equity investment (the &#x201c;Equity Investment Right&#x201d;). BTI entered into a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;) with the Lenders and filed a registration statement on Form S-3 to register the shares issuable upon exercise of the Warrants and, if issued, the shares related to the Equity Investment Right, for resale. The maximum shares of the Company&#x2019;s common stock issuable under the Warrants (including the Closing Date Warrants and the 2023 Warrants) and Lenders&#x2019; Equity Investment Right was 366 as of March 31, 2024.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;On the Second Amendment Effective Date, Company amended and restated its Registration Rights Agreement (the &#x201c;Amended and Restated Registration Rights Agreement&#x201d;) with the Lenders, dated April 19, 2022, pursuant to which the Company agreed to register the 2023 Warrant Shares for resale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As part of the Credit Agreement, OnkosXcel, a wholly owned subsidiary of BTI, granted warrants to the Lenders to purchase 175 individual limited liability company units (which number of units is not in thousands; referred to herein as &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;the &#x201c;OnkosXcel Warrants&#x201d;). The strike price of the OnkosXcel Warrants is formulaic based on the value of OnkosXcel at the time of exercise and can only be exercised upon occurrence of an equity related liquidity event for OnkosXcel of at least $20,000. The exercise price per unit of the OnkosXcel Warrants will be set upon the earlier of the closing of the next sale (or series of related sales) by OnkosXcel of equity securities of OnkosXcel with aggregate proceeds of not less than $20,000 to unrelated third parties (the &#x201c;Next Equity Financing&#x201d;) at an exercise price per unit equal to a 10% premium over the price per unit of the equity securities sold by OnkosXcel in such Next Equity Financing or, in the event of a sale of OnkosXcel prior to the Next Equity Financing or an initial public offering constituting the Next Equity Financing, the lesser of (x) 75% of the fair value of the consideration to be paid for a unit upon the consummation of such transaction and (y) 150% of the valuation applicable to the initial profits units issued by OnkosXcel after the closing of the Credit Agreement. The OnkosXcel Warrants are transferable with approval from BTI, which cannot be unreasonably withheld, expire on April 19, 2029, and may be net exercised at the holder&#x2019;s election.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In connection with the closing of the Fourth Amendment discussed below, the Company granted new warrants to the Lenders to purchase up to 6 shares of its common stock (the &#x201c;2024 Warrant Shares&#x201d;) at an exercise price of $49.1568 per share (the &#x201c;2024 Warrants&#x201d;), which represents a 10% premium over the arithmetic average of the volume-weighted average price of the Company&#x2019;s common stock on the Nasdaq Capital Market during the 30 trading days preceding the Effective Date. The 2024 Warrants will expire on April 19, 2029 and may be net exercised at the holder&#x2019;s election. On the Effective Date, the Company amended and restated its Amended and Restated Registration Rights Agreement (the &#x201c;Second Amended and Restated Registration Rights Agreement&#x201d;) with the Lenders, originally dated April 19, 2022. Pursuant to the Second Amended and Restated Registration Rights Agreement, the Company agreed to register the 2024 Warrant Shares for resale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fifth Amendment Warrants, Registration Rights Agreement and Equity Investment Right Termination&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Prior to the Fifth Amendment, pursuant to the Credit Agreement, the Lenders had the right to purchase shares of our common stock, so long as borrowings under the Credit Agreement are outstanding, for a purchase price of $5,000 at a price per share equal to a 10% premium to the volume-weighted average price of the common stock over the 30 trading days prior to the Lenders&#x2019; election to proceed with such equity investment (the &#x201c;Equity Investment Right&#x201d;). The Equity investment Right was terminated as part of the Fifth Amendment. We entered into a registration rights agreement with the Lenders (as amended and restated in connection with the Second Amendment, the &#x201c;Amended and Restated Registration Rights Agreement&#x201d;) and filed registration statements on Form S-3 to register the shares issuable upon exercise of the Closing Date Warrants, 2023 Warrants and the New Warrants for resale. The maximum shares of our common stock issuable under the Closing Date Warrants, the 2023 Warrants and the Lenders&#x2019; Equity Investment Right was 366. On the Effective Date, we further amended and restated the Amended and Restated Registration Rights Agreement (the &#x201c;Second Amended and Restated Registration Rights Agreement&#x201d;) with the Lenders. Pursuant to the Second Amended and Restated Registration Rights Agreement, we agreed to register the 2024 Warrant Shares for resale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In connection with the closing of the Fifth Amendment, the Company agreed to, substantially concurrently with the closing of Raise 1, grant new warrants to the Lenders to purchase an aggregate of 313 shares of common stock on the closing date of the Fifth Amendment, at an exercise price of $0.16 per share (the &#x201c;New Warrants&#x201d;). The New Warrants will expire on the seventh anniversary of their issuance. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In addition, the Company agreed to, substantially concurrently with the closing of Raise 1, amend and restate all warrants to purchase stock of the Company issued to the Lenders prior to the effective date of the Fifth Amendment, to revise the exercise price thereunder to an exercise price equal to the lower of (i) the price per share of the common stock of the Company issued in Raise 1 and (ii) arithmetic average of the volume-weighted average price of the Company&#x2019;s common stock on the Nasdaq Capital Market during the 30 trading days preceding Raise 1 (such existing warrants, as amended and restated, the &#x201c;Original Warrants&#x201d;). The Original Warrants provide the Lenders with the right to purchase a total of 28 shares of common stock of the Company, and the exercise prices of $58.3232 per share and $49.1568 per share were reduced to $7.68 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;On the date of issuance of the New Warrants, the Company agreed to amend and restate its Second Amended and Restated Registration Rights Agreement with the Lenders, dated March 20, 2024. Pursuant to such amendment and restatement (the &#x201c;Third Amended and Restated Registration Rights Agreement&#x201d;), the Company will agree to register the shares of common stock issuable under the New Warrants, in addition to all Original Warrants, for resale. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As part of entering into the Credit Agreement, OnkosXcel, a wholly owned subsidiary of BTI, granted the OnkosXcel Warrants to the Lenders to purchase 175 individual limited liability company units. The strike price of the OnkosXcel Warrants is formulaic based on the value of OnkosXcel at the time of exercise and can only be exercised upon occurrence of an equity related liquidity event for OnkosXcel of at least $20,000. The exercise price per unit of the OnkosXcel Warrants will be set upon the earlier of the closing of the next sale (or series of related sales) by OnkosXcel of equity securities of OnkosXcel with aggregate proceeds of not less than $20,000 to unrelated third parties (the &#x201c;Next Equity Financing&#x201d;) at an exercise price per unit equal to a 10% premium over the price per unit of the equity securities sold by OnkosXcel in such Next Equity Financing or, in the event of a sale of OnkosXcel prior to the Next Equity Financing or an initial public offering constituting the Next Equity Financing, the lesser of (x) 75% of the fair value of the consideration to be paid for a unit upon the consummation of such transaction and (y) 150% of the valuation applicable to the initial profits units issued by OnkosXcel after the closing of the Credit Agreement. The OnkosXcel Warrants are transferable with approval from BTI, which cannot be unreasonably withheld, expire on April 19, 2029, and may be net exercised at the holder&#x2019;s election.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Maturities of long-term debt are expected to be as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,291&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Interest expense was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 14,662&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11,941&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accretion of debt discount and amortization of financing costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 467&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,373&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 15,129&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 13,314&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_Kij1Ur66H0CBcFdcp3k-eg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Credit Agreement and Guaranty&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 102,319&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 102,319&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Payable-in-kind ("PIK") interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 361&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total long-term debt liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 106,722&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 102,680&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unamortized debt premiums, discounts and issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,214)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,082)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 102,508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 100,598&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_4QXVMUpriU-O3ONSCTxFLw"
      decimals="-3"
      id="Tc_bb5pZaglkEmYPd964WCr0w_3_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">102319000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_d7MaxUhhVECHSCm80cC1Ow"
      decimals="-3"
      id="Tc_ciBEmfGnck6LyAUYMujJsA_3_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">102319000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_vDidZuvwFUuTvGIhGHCssg"
      decimals="-3"
      id="Tc_AmTlVCa_lUumkCiBM4vfZg_4_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">4403000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_qKlv5oEboUGlNN_gzIoC-w"
      decimals="-3"
      id="Tc__EA0tJMPk0OVquvltP6JdA_4_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">361000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_nvkpEcHBU0ip7OGCG64NnA_5_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">106722000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_F_bX0hXkQECrgV30k33e2w_5_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">102680000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_aC3QB6UhzUKvjDxV2DGJmg_6_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">4214000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_g4T8dasIkUmp4EWdhvAH4w_6_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2082000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_R8mp4VT2SUyAzyzNeHdIMw_7_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">102508000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_o6Y5qxO1J02FuJqgsmh7sw_7_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">100598000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_r6Nt5rznFkuA80tgQ2K1yA"
      decimals="-3"
      id="Narr_z6ud9DbfMUuRDDjCtmLQaA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">260000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <btai:LineOfCreditFacilityInvestmentAllowed
      contextRef="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_a4FuB-EA3US0t7LRQkJ_0Q"
      decimals="-3"
      id="Narr_3QTP4VdmM0O8FhJf01N7gA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">30000000</btai:LineOfCreditFacilityInvestmentAllowed>
    <btai:LineOfCreditFacilityInvestmentAllowed
      contextRef="As_Of_11_12_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_1pH0cdjOhkqjWy9MM_KenA"
      decimals="-3"
      id="Narr_IIuGE9KDN02Nb0em-EEwTg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">25000000</btai:LineOfCreditFacilityInvestmentAllowed>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_a4FuB-EA3US0t7LRQkJ_0Q"
      decimals="-3"
      id="Narr_5N--k_YxFEOKVS44X9gtKw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">180000</us-gaap:DebtInstrumentFeeAmount>
    <btai:LineOfCreditFacilityAmendmentFeePercentage
      contextRef="Duration_11_13_2023_To_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_9T8VX87-MkurojwuBrp51A"
      decimals="4"
      id="Narr_qWxQHnFLuUCLTAUo9yN8HQ"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.0025</btai:LineOfCreditFacilityAmendmentFeePercentage>
    <btai:LineOfCreditFacilityExitFeePercentage
      contextRef="Duration_11_13_2023_To_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_9T8VX87-MkurojwuBrp51A"
      decimals="4"
      id="Narr_UMLkMNYZBkqZQFGmH7FGMQ"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.0025</btai:LineOfCreditFacilityExitFeePercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_ots7YDarCkyspj_MFv5RgQ"
      decimals="-3"
      id="Narr_4lQliM05dEiW8htnSDS98g"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">202319000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_4_28_2022_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_na3LkfDiw0K2aagoP_bMuA"
      decimals="-3"
      id="Narr_mzErjDzyT0SaOwyyHNWwmw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">70000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_xroiFJrnD0eA_jiPBHLdvA"
      decimals="-3"
      id="Narr_40e1QPjxK0eUttA4DF_ayw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">72319000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_T8y78WMP4ECZ9sQKm-yKhw"
      decimals="-3"
      id="Narr_1ZBZ42r0YESa8qMdtET-CQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">30000000</us-gaap:DebtInstrumentCarryingAmount>
    <btai:LineOfCreditFacilityInvestmentAllowed
      contextRef="As_Of_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_ots7YDarCkyspj_MFv5RgQ"
      decimals="-3"
      id="Narr_9vAbj-kYCk6J4bmov5yffQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">30865000</btai:LineOfCreditFacilityInvestmentAllowed>
    <btai:LineOfCreditFacilityInvestmentAllowed
      contextRef="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_a4FuB-EA3US0t7LRQkJ_0Q"
      decimals="-3"
      id="Narr_06rhDkjdxUGMZRaQ25h21A"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">30000000</btai:LineOfCreditFacilityInvestmentAllowed>
    <btai:LineOfCreditFacilityExitFeePercentage
      contextRef="Duration_12_5_2023_To_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_54xfhc08YEGFKmDToW_EHg"
      decimals="4"
      id="Narr_bzDLw6CtE0KJYp_x_iQF1w"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.0025</btai:LineOfCreditFacilityExitFeePercentage>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember__PljhQkwa0ehF3g8M7cQfA"
      decimals="-3"
      id="Narr_PzKEej3WL02HwzJh7vI1AQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">100000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <btai:EquityInvestmentRightAmountUnfunded
      contextRef="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember__PljhQkwa0ehF3g8M7cQfA"
      decimals="-3"
      id="Narr_og4AmSifw06MQrk3vpLseA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">5000000</btai:EquityInvestmentRightAmountUnfunded>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_d7MaxUhhVECHSCm80cC1Ow"
      decimals="3"
      id="Narr_B-2_ykkTRU2_IcjP2axH5A"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.135</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheBMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_6ZZ0nOytkkyfb35YWqDR_A"
      decimals="-3"
      id="Narr_A2BL2VRohUipEUJt7jNgrw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheCMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_KEur4f2KVkKKQYGXeBkN_w"
      decimals="-3"
      id="Narr_jt--ezaRrUyr4GEiZcq4eA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">30000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheDMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_KgqW-5X7r06gLp9NBzxFsg"
      decimals="-3"
      id="Narr_6_6Le6AvKkGP89Vkh5YjjA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <btai:DebtInstrumentInterestRateDiscountRatePercentage
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_WSKgB0WSZUCURjOJ6-sK0w"
      decimals="4"
      id="Narr_Tgjz261VhkukSTWZcEKdnw"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.0200</btai:DebtInstrumentInterestRateDiscountRatePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_07DuWNjS7E2tMACIgVlBjw"
      decimals="3"
      id="Narr_CGDPzmKqIE-DmHZO4Gz_cQ"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_LmEJHhC5GEuhV4cvR-CyZw"
      decimals="3"
      id="Narr_ptoeuyLDP0--QU4xerthbQ"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.055</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <btai:DebtInstrumentIncrementalOnVariableRatePercent
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_WSKgB0WSZUCURjOJ6-sK0w"
      decimals="3"
      id="Narr_T632fGPrPUy8w9bdHbDukA"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.075</btai:DebtInstrumentIncrementalOnVariableRatePercent>
    <btai:PaidInKindInterestPercentage
      contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_hoC3FYJ7zkS3zSkEUQbGEw"
      decimals="2"
      id="Narr_4FaxuBCRYUGTEx6o2soihA"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.08</btai:PaidInKindInterestPercentage>
    <btai:TickingFeesPercentage
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_WSKgB0WSZUCURjOJ6-sK0w"
      decimals="4"
      id="Narr_03lQWHfk6k-Zr2a6gRQjtw"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.0075</btai:TickingFeesPercentage>
    <btai:NetCashRequiredMinimum
      contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_r6Nt5rznFkuA80tgQ2K1yA"
      decimals="-3"
      id="Narr_F3QH9sDgu0mwF77K0Z0E7Q"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">15000000</btai:NetCashRequiredMinimum>
    <btai:NetCashRequiredMinimum
      contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterFundingOfTrancheBLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_M-8oLHEl10ODoYzrqVk1qg"
      decimals="-3"
      id="Narr_Sf_A1bfVpUKkRehezZ5baQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">20000000</btai:NetCashRequiredMinimum>
    <btai:NetCashRequiredMinimum
      contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_HHsV3q--b0-Hi4NmC1wOxA"
      decimals="-3"
      id="Narr_j0M99_lXVka0D1Td0I3-xA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">15000000</btai:NetCashRequiredMinimum>
    <btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement
      contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_r6Nt5rznFkuA80tgQ2K1yA"
      decimals="-3"
      id="Narr_Hvn3vYKTzkuTy9QdQPfTrg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">37500000</btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement>
    <btai:PercentageOfOutstandingLoan
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_cP_MaCBZ7UyPaY583or7dQ"
      decimals="2"
      id="Narr_5EYwhps1hk-2vUNDmk6mbg"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.50</btai:PercentageOfOutstandingLoan>
    <btai:SubsidiaryOwnershipPercentage
      contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_r6Nt5rznFkuA80tgQ2K1yA"
      decimals="2"
      id="Narr_ul7K1ZQy6U-Rv8sSfeLyrw"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.20</btai:SubsidiaryOwnershipPercentage>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_2_12_2024_To_2_12_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_QkgOxhTM3EWQV2UEUZ202A"
      decimals="-3"
      id="Narr_4iuZqeLCkEGHiG1ZRy3Bew"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">40000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_5ZybN_dt3E6T6rIGI2RnCw"
      decimals="-3"
      id="Narr_dvZx9-7y0EiuNxBzNOn0Qg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">25000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_8e8qqxErlUCxNND1J5ekRw"
      decimals="-3"
      id="Narr_eD_xyibvvk6NH58SqdT-ew"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">50000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_jyI3cFSKl0a4pfcKd3ZJiA"
      decimals="-3"
      id="Narr_momK8UdtTES6w60bp05hiQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">40000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement
      contextRef="As_Of_3_20_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_t-V_k3tNdUCIUzhMpzNVHA"
      decimals="-3"
      id="Narr_EUnNgCc1ukaLE7nwxCIr5Q"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">25000000</btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement>
    <btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement
      contextRef="As_Of_2_12_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_jnGiVGydjU-NmDn4wyec3A"
      decimals="-3"
      id="Narr_sldbe_iBAUCg_tVGwZN2qg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">15000000</btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_8e8qqxErlUCxNND1J5ekRw"
      decimals="-3"
      id="Narr_oW_wGVx-o06k8g8Dp7NYGQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">50000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_3_27_2024_To_3_27_2024_1d4XGKCHW0m2lIKs8HPE9g"
      decimals="-3"
      id="Narr_D-4UU8PkU0uThszFM_VxlA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">25000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_7_1_2024_To_9_30_2024_UmSoTOy6ZEqdvjDqQLaKEw"
      decimals="-3"
      id="Narr_72AmK-XXgEK8QlEFOtl6Ow"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">467000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_g-3YkuAMa0WFmUst9waAug"
      decimals="-3"
      id="Narr_x86QvB4eTEq7xJFg7BxLMQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">30943000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_7_1_2024_To_9_30_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_xR9vxlNSTk2dU3JYtP5BmA"
      decimals="-3"
      id="Narr_EW78NtWuNUOSyXL8UgI70w"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">40000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_7_1_2024_To_9_30_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_FD1LiU8FskaLMx-wupgQpw"
      decimals="-3"
      id="Narr_GCRR9U-NMUiWEswLG2D1Pg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">50000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement
      contextRef="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember__PljhQkwa0ehF3g8M7cQfA"
      decimals="-3"
      id="Narr_YSVWVKMU60WmcHsHef1scQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">25000000</btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_8e8qqxErlUCxNND1J5ekRw"
      decimals="-3"
      id="Narr_yeamzHZmE0uzJQfynRx0dg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">50000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_X9rWZSSabEakPXkM8Eutyw"
      decimals="-3"
      id="Narr_IbpJEfyPqEewv52wR5ZtVQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">7000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_tXi0TB25sk2fARG5mILYWg"
      decimals="-3"
      id="Narr_iwZP0WlSlky_zjhXSrbY-w"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">18000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_G6VSgb21CUeRJAKu7-undQ"
      decimals="-3"
      id="Narr_JvWchaReuESUpt5iCdT8TA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">29000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement
      contextRef="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_R53JeYIpIkKLogFP9f7n0w"
      decimals="-3"
      id="Narr_GqR9bBlgSUqjeWg3uvhqsA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">7500000</btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement>
    <btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement
      contextRef="As_Of_3_20_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_t-V_k3tNdUCIUzhMpzNVHA"
      decimals="-3"
      id="Narr_7S768G2XOk62usHK8NePaA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">25000000</btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement>
    <btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement
      contextRef="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_DBnAiitHfkaS-GOZJ2VMnw"
      decimals="-3"
      id="Narr_8vm0Fv417EuJDZrlOnqWRw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">10000000</btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement>
    <btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement
      contextRef="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_V7ch7PHY70Gc6KcqC2X73Q"
      decimals="-3"
      id="Narr_2TNBeIW5QU6oVry9kkwgdQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">15000000</btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_hsgX06rVV0aG4JHyHT8zVg"
      decimals="-3"
      id="Narr_W9NZ9qAb-0WHeISeqS9c1w"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2500000</us-gaap:RepaymentsOfLongTermDebt>
    <btai:DebtInstrumentIncrementalOnVariableRatePercent
      contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_hsgX06rVV0aG4JHyHT8zVg"
      decimals="4"
      id="Narr_H-cE9QD2OEqjJTXe4lG4ZQ"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.075</btai:DebtInstrumentIncrementalOnVariableRatePercent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_m9UZs2c2l0S2PukXjZUImg"
      decimals="2"
      id="Narr_Yvr1qV1v60SYkUQJh4eBUg"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.13</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <btai:PaidInKindInterestPercentage
      contextRef="As_Of_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_m9UZs2c2l0S2PukXjZUImg"
      decimals="2"
      id="Narr_1lHo102UjUOiPnfmolG8Lw"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.10</btai:PaidInKindInterestPercentage>
    <btai:DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded
      contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_hsgX06rVV0aG4JHyHT8zVg"
      decimals="3"
      id="Narr_5Ple9qk5MEm6Q437iM9XTA"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.05</btai:DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded>
    <btai:MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod
      contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_hsgX06rVV0aG4JHyHT8zVg"
      decimals="2"
      id="Narr_QLv4ydk7z0ykM8OQ4wuZpg"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">1.15</btai:MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="Duration_12_5_2023_To_12_5_2023_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_NN4G50mhQUiE2MWFIStQGA"
      decimals="-3"
      id="Narr_TgKCJ0oseU6iFU4q3-EPSw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">30000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_OgOR5W9P3kGRnS_l9vYR4A"
      decimals="-3"
      id="Narr_eT8rTzud_kysYJTKpkPpcw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">120000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_7_8_2022_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_rBZ8Wee2aUaWKVAwuLAbJQ"
      decimals="-3"
      id="Narr_xwEoZzBoBESKh6LNhpXUSg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">30000000</us-gaap:DebtInstrumentFaceAmount>
    <btai:BorrowingsBasedOnNetSalesPercent
      contextRef="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_TfYSaq0lxkWKFNAMb3ByvA"
      decimals="5"
      id="Narr_nfapiErS1ka0_FNzlCC0Rg"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.00375</btai:BorrowingsBasedOnNetSalesPercent>
    <btai:BorrowingsBasedOnNetSalesPercent
      contextRef="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_c3NRP_HuykWiud2XxAIfdw"
      decimals="5"
      id="Narr_mEagg9q8SE2ZNc8XyTTN0g"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.0775</btai:BorrowingsBasedOnNetSalesPercent>
    <btai:ThresholdRatioOfDebtToRevenueRatio
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_vxYm8GIUnUOKESLLX6fb8Q"
      decimals="4"
      id="Narr_moNtva-RlkyfpJf7Vsg8bQ"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.0175</btai:ThresholdRatioOfDebtToRevenueRatio>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_V2jj_eDlt0q_u0vXSYoyKQ"
      decimals="-3"
      id="Narr_wLRZp7cVa06Af5mnAofUgg"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">17000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_V2jj_eDlt0q_u0vXSYoyKQ"
      decimals="1"
      id="Narr_lvPt7qybgUeakS6Xg7mrYA"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">320.6</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_uPbZgXmXZUiSsb-dyLE4HA"
      decimals="INF"
      id="Narr_QARI2Y83iUSSM7IT-OB_ew"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">58.3232</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_W5J6mPqvkkqYc6G6pFfyUQ"
      decimals="-3"
      id="Narr_NPai5LrwL0ek0dCRMGgExA"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">4000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_W5J6mPqvkkqYc6G6pFfyUQ"
      decimals="INF"
      id="Narr_Zs8mLkC7-ka-3SWLlpM5ig"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">58.3232</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <btai:RightToPurchaseStockLenders
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_V2jj_eDlt0q_u0vXSYoyKQ"
      decimals="-3"
      id="Narr_Kl7T-hn3BEmsuz21Gbe-DQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">5000000</btai:RightToPurchaseStockLenders>
    <btai:PremiumSharePricePercent
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_Hql-Wv3mXkKp2hBGSh3usg"
      decimals="2"
      id="Narr_2gll38NJAUWYMkzJN2uz1Q"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.10</btai:PremiumSharePricePercent>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_3_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_0htohoQg0EW5M9buTb1qzQ"
      decimals="-3"
      id="Narr_YvdeUC90KUOAUfEFyXZzeA"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">366000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_M-TubXQul02zZZfaAcmBuA"
      decimals="-3"
      id="Narr_AGj20-0Ot0ygGGaBir5sOA"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">175000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <btai:ThresholdLiquidityEventAmountForExerciseOfWarrants
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_M-TubXQul02zZZfaAcmBuA"
      decimals="-3"
      id="Narr_e0giVGQs1kyBZb13Sr-tEQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">20000000</btai:ThresholdLiquidityEventAmountForExerciseOfWarrants>
    <btai:ThresholdLiquidityEventAmountForExerciseOfWarrants
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_M-TubXQul02zZZfaAcmBuA"
      decimals="-3"
      id="Narr_2ISEd3JlZEiLLP96IWMFPA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">20000000</btai:ThresholdLiquidityEventAmountForExerciseOfWarrants>
    <btai:PremiumSharePricePercent
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_w_gcoxE8C0GzioKd7L0Zdw"
      decimals="2"
      id="Narr_b6ICsD0Ruk2jh0_swMajiQ"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.10</btai:PremiumSharePricePercent>
    <btai:PercentageOfFairValueConsiderationToBePaid
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_w_gcoxE8C0GzioKd7L0Zdw"
      decimals="2"
      id="Narr_bR1_VrKJqkuEgxhswQlukQ"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.75</btai:PercentageOfFairValueConsiderationToBePaid>
    <btai:PercentageOfValuationApplicableToInitialProfits
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_w_gcoxE8C0GzioKd7L0Zdw"
      decimals="2"
      id="Narr_Mpjd835JBkiL_yW7R6nAzA"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">1.50</btai:PercentageOfValuationApplicableToInitialProfits>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_zFzFVctYTUm5PGuvO5mZ0w"
      decimals="-3"
      id="Narr_hTr5mMA63UakHECdGstXHQ"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">6000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_zFzFVctYTUm5PGuvO5mZ0w"
      decimals="INF"
      id="Narr_8eUuV0oBCUaVgLR0zAzUuw"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">49.1568</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <btai:PremiumSharePricePercent
      contextRef="Duration_3_20_2024_To_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_4EZhC-NYEUGDlhcjArlf5w"
      decimals="2"
      id="Narr_r2tTbYWFFkWJUgKHnYEU_w"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.10</btai:PremiumSharePricePercent>
    <btai:RightToPurchaseStockLenders
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_V2jj_eDlt0q_u0vXSYoyKQ"
      decimals="-3"
      id="Narr_G3xj6b5AR06NM0pz3Ym00Q"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">5000000</btai:RightToPurchaseStockLenders>
    <btai:PremiumSharePricePercent
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_Hql-Wv3mXkKp2hBGSh3usg"
      decimals="2"
      id="Narr_gV7eBlBvqEiM5Pju7l8rGg"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.10</btai:PremiumSharePricePercent>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_V2jj_eDlt0q_u0vXSYoyKQ"
      decimals="-3"
      id="Narr_FScMXLbuN0GhqPszg9m2CA"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">366000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_JyNR98gl_k-4MeLePLJWaw"
      decimals="-3"
      id="Narr_m5SC0sqHZUObDNgqkhRHXA"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">313000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_JyNR98gl_k-4MeLePLJWaw"
      decimals="INF"
      id="Narr_J9-3py89o0mTx8WguRp16Q"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">0.16</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OriginalWarrantsMember_NyepRdGwwE65aulGXbIqFQ"
      decimals="-3"
      id="Narr_potX2l4ni0aP0Q0ca4O7Ig"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">28000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_uPbZgXmXZUiSsb-dyLE4HA"
      decimals="INF"
      id="Narr_KCJIdAI6RkS2tqPO9PwESQ"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">58.3232</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_zFzFVctYTUm5PGuvO5mZ0w"
      decimals="INF"
      id="Narr__Li9Q2frYkePaIgyR9oaug"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">49.1568</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OriginalWarrantsMember_NyepRdGwwE65aulGXbIqFQ"
      decimals="INF"
      id="Narr_7tptBFElsEiHhgFz0Jotpw"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_M-TubXQul02zZZfaAcmBuA"
      decimals="-3"
      id="Narr_dZeUqWJAmkOKDtghKIG19w"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">175000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <btai:ThresholdLiquidityEventAmountForExerciseOfWarrants
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_M-TubXQul02zZZfaAcmBuA"
      decimals="-3"
      id="Narr_cJYXcv04WEyFg9akO4triQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">20000000</btai:ThresholdLiquidityEventAmountForExerciseOfWarrants>
    <btai:ThresholdLiquidityEventAmountForExerciseOfWarrants
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_M-TubXQul02zZZfaAcmBuA"
      decimals="-3"
      id="Narr_40EigtwIb0i5Xg9wixUzOQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">20000000</btai:ThresholdLiquidityEventAmountForExerciseOfWarrants>
    <btai:PremiumSharePricePercent
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_w_gcoxE8C0GzioKd7L0Zdw"
      decimals="2"
      id="Narr_2nXF3eVmx0qIoXJpLT08eA"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.10</btai:PremiumSharePricePercent>
    <btai:PercentageOfFairValueConsiderationToBePaid
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_w_gcoxE8C0GzioKd7L0Zdw"
      decimals="2"
      id="Narr_qKywLVGcIkaKGSTb-mBaQw"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.75</btai:PercentageOfFairValueConsiderationToBePaid>
    <btai:PercentageOfValuationApplicableToInitialProfits
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_w_gcoxE8C0GzioKd7L0Zdw"
      decimals="2"
      id="Narr_U9Gg0Kxz50CiHeq-qL0yUQ"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">1.50</btai:PercentageOfValuationApplicableToInitialProfits>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_aN85nPDAdkWcym4d6veUJw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,291&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_M7kJ0Tx4AUqeCmOFFibaSw_4_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">22431000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_yfAGY13orkW_f1f08UKrwg_5_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">84291000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <btai:ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_rC9m098uT0-fJNoymaqjmQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 14,662&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11,941&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accretion of debt discount and amortization of financing costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 467&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,373&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 15,129&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 13,314&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</btai:ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_bg2qDPwALUODXyL1aPFECQ_5_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">14662000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_fShetc6VFkmJnnD-qPSfbQ_5_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">11941000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_qpxQG-3zUUKR-mHRLTKz2g_6_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">467000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_YJBi5D-CRUKoQLiFPAzgcw_6_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1373000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_C4frGGlVMk6AE9NxcdtR_g_7_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">15129000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_hD2ueJJZqUGGgrsc-rNhNQ_7_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">13314000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_ZKGXBNc1h0e6WwdVzjebEg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;10. Derivative Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;BTI identified certain freestanding financial instruments and/or embedded features that require separate accounting from the borrowings under the OFA Facilities. This includes the OnkosXcel Warrants and Equity Investment Right held by the Lenders, along with certain put/call options.  The OnkosXcel Warrants and Equity Investment Right do not meet certain scope exceptions under U.S. GAAP, primarily because the exercise prices and number of shares of the Company&#x2019;s common stock issuable under the instruments are variable, and the instruments meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Consolidated Balance Sheets. The respective derivative liabilities are recorded at fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#x2019;s Consolidated Statements of Operations.&lt;/span&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;As discussed in Note 9, &lt;i style="font-style:italic;"&gt;Debt and Credit Facilities&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;, the Equity Investment Right was terminated on November 25, 2024 in connection with the Fifth Amendment to the Credit Agreement.  The Company recorded the termination gain of &lt;/span&gt;$1,263 within Other (income) expense, net in the Company&#x2019;s Consolidated Statements of Operations for the carrying value of the Equity Investment Right. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"&gt;With respect to the Securities Purchase Agreement discussed in Note 11, &lt;i style="font-style:italic;"&gt;Common Stock Financing Activities&lt;/i&gt;, BTI determined that the Accompanying Warrants fail the equity classification criteria and are therefore classified as liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity ("ASC 480") and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The Accompanying Warrants failed to meet the requirements to be indexed to equity and equity &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;classified, and meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Consolidated Balance Sheet as of December 31, 2024. The respective derivative liabilities were recorded at fair value on the date of issuance in the amount of $19,347 and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#x2019;s Consolidated Statements of Operations. We value the Accompanying Warrants using the Black-Scholes option pricing model as discussed in Note 14, &lt;i style="font-style:italic;"&gt;Fair measurements&lt;/i&gt;. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"&gt;On November 21, 2024, the exercise price of 534 of the Accompanying Warrants was reduced from $51.20 to $9.136 per share. As a result of the repricing, the Company recorded the increase in fair value of $1,000&lt;span style="white-space:pre-wrap;"&gt; as an increase to the carrying value of Derivative liabilities, recorded as an increase to their carrying value, and as a loss in Other (income) expense, net, in the Company&#x2019;s Consolidated Statements of Operations.  For the year ended December 31, 2024, the Company recorded total net gains of &lt;/span&gt;$17,027, including the $1,000 repricing loss, in Other (income) expense, net, in the Company&#x2019;s Consolidated Statements of Operations. As of December 31, 2024, the fair value of the Accompanying Warrants was $2,320.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"&gt;On November 25, 2024, as discussed below, the Company issued additional warrants (the &#x201c;November 2024 Accompanying Warrants&#x201d;). The November 2024 Accompanying Warrants failed to meet the requirements to be indexed to equity and equity classified, and meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Consolidated Balance Sheet as of December 31, 2024. The respective derivative liabilities were recorded at fair value on the date of issuance in the amount of $5,562 and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#x2019;s Consolidated Statements of Operations. For the year ended December 31, 2024, the Company recorded total net gains of $1,289 in Other (income) expense, net, in the Company&#x2019;s Consolidated Statements of Operations. As of December 31, 2024, the fair value of the November 2024 Accompanying Warrants was $4,273.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="Duration_11_25_2024_To_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_DqkDewrv3kmwfGEQUIsTbQ"
      decimals="-3"
      id="Narr_qXvgRJcmTESr0XESPDr5bQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-1263000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_oiu1ThMdnUOs-KiwIduWmQ"
      decimals="-3"
      id="Narr_d52i4YluhEaWqS_ROy451Q"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">19347000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_G-NzlEzfREKwJKc_rBs35Q"
      decimals="-3"
      id="Narr_XURSzU6e60mtXippLHiedQ"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">534000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_oiu1ThMdnUOs-KiwIduWmQ"
      decimals="INF"
      id="Narr_XUUNZMsoO0ijtbbCgfWZEg"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">51.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_-Q7xp87Es0iyjocCWGGiMg"
      decimals="INF"
      id="Narr_0AOhGgJS3Eeem6t8y_2Qfw"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">9.136</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_KgwhcGdOLE6rb5LSOLdQQw"
      decimals="-3"
      id="Narr_3id09s4HGU2oshUzJX9qTg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1000000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_5eL_-_utPUCNyy4fj-GOyA"
      decimals="-3"
      id="Narr_Kgn_JvCe9UifFyyHcImJFw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">17027000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_KgwhcGdOLE6rb5LSOLdQQw"
      decimals="-3"
      id="Narr_u-6wRRiz_Ee3bZugf2WbaQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1000000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_JBeXWTEcBki5v7foWKB49w"
      decimals="-3"
      id="Narr_j952oct2DEiHun8DobxGTQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2320000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_DdDbFFCDBE64P_O4BJl7kA"
      decimals="-3"
      id="Narr_-uPk3XgLnEK61NOKavGbNg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">5562000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_p63njE8R7Eu_9LSZHS_XWw"
      decimals="-3"
      id="Narr_gSUBK2h8PUazwFONTY_P9g"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1289000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_XYejg84PY0-8-DI1vMLBvw"
      decimals="-3"
      id="Narr_AwY-FMeQvE6JjnJkz-r21A"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">4273000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <btai:FinancingActivitiesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_Ech13adQ10-3jkW5KFGFww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;11. Common Stock Financing Activities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-weight:normal;"&gt;In May 2021, the Company entered into&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; an &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;Open Market Sale Agreement (as amended, supplemented and/or restated from time to time, the &#x201c;Sale Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;) pursuant to which the Company could offer and sell shares of its common stock, having an aggregate offering price of up to &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$100,000&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, from time to time, through an &#x201c;at the market offering&#x201d; program under which Jefferies will act as sale agent. In November 2023, the Company amended the Sale Agreement to increase the size of the &#x201c;at the market offering" program to &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$150,000&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;. For the year ended December 31, 2023, the Company sold &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;88&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; shares of its common stock for a gross amount of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$27,032&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, incurred issuance costs of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$811&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, and received net proceeds of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$26,221&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;. For the year ended December 31, 2024, the Company sold &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;240&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; shares of its common stock for a gross amount of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$7,682&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, incurred issuance costs of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$231&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, and received net proceeds of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$7,451&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On March 25, 2024, the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with the purchasers named therein (collectively, the &#x201c;Purchasers&#x201d;). Pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Purchasers in a registered direct offering (the &#x201c;Offering&#x201d;) under an effective shelf registration statement on Form S-3 (File No. 333-275261) and a related prospectus supplement filed with the Securities and Exchange Commission on March 25, 2024 (the &#x201c;Prospectus Supplement&#x201d;) an aggregate of 191 shares (the &#x201c;Shares&#x201d;) of common stock, par value $0.001 per share, and accompanying warrants (the &#x201c;Accompanying Warrants&#x201d;) to purchase up to 191 shares of common stock at a combined offering price of $4.416 per Share and Accompanying Warrant and pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase up to 348 shares of common stock and Accompanying Warrants to purchase up to 348 shares of common stock, at a combined offering price of $46.40 per share underlying each Pre-Funded Warrant and Accompanying Warrant, which equals the offering price per Share and Accompanying Warrant less the $0.016 exercise price per share of the Pre-Funded Warrants. The Pre-Funded Warrants and Accompanying Warrants are not listed on the Nasdaq Capital Market or any other securities exchange or trading system and the Company does not intend to list them. On March 27, 2024, The Company received $25,000 of gross proceeds from the Offering, incurred issuance costs of $248, and received net proceeds of $24,752. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Pre-Funded Warrants have an exercise price per share of common stock equal to $0.016 per share. The exercise price and the number of shares of common stock issuable upon exercise of the Pre-Funded Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The Pre-Funded Warrants are exercisable at any time after the date of issuance. For the year ended December 31, 2024, 348 Pre-Funded Warrants were exercised and the same number of shares of common stock were issued in exchange for $6 of proceeds received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Accompanying Warrants have an exercise price per share of common stock equal to $51.20 per share. The exercise price and the number of shares of common stock issuable upon exercise of the Accompanying Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The Accompanying Warrants will be exercisable at any time after the date of issuance and will expire on the fifth anniversary of the date of issuance. The Accompanying Warrants do not meet certain scope exceptions under U.S. GAAP, primarily because they did not meet the requirements to be indexed to equity and equity classified, and the instruments meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Consolidated Balance Sheet as of December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On November 22, 2024, the Company entered into an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;) with Canaccord Genuity LLC, as underwriter (the &#x201c;Underwriter&#x201d;), in connection with the issuance and sale by the Company in a public offering of (i) 350 shares of the Company&#x2019;s common stock, and accompanying warrants (the &#x201c;November 2024 Accompanying Warrants&#x201d;) to purchase 350 shares of Common Stock, at a combined public offering price of $7.68 per share, and, in lieu thereof to certain investors, (ii) pre-funded warrants to purchase 563 shares of Common Stock, and accompanying warrants (the &#x201c;November 2024 Accompanying Warrants&#x201d;) to purchase 563 shares of Common Stock, at a combined public offering price of $7.664 per pre-funded warrant, which equals the public offering price per share of Common Stock and accompanying warrant less the $0.016 exercise price per share of the pre-funded warrants, less underwriting discounts and commissions, pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-275261) and a related prospectus supplement filed with the Securities and Exchange Commission. For the year ended December 31, 2024, 80 pre-funded warrants were exercised and the same number of shares of common stock were issued in exchange for $1 of proceeds received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Each of the November 2024 Accompanying Warrants in the offering is subject to customary beneficial ownership limitations on exercisability, is exercisable at any time after the date of issuance of such warrant and, in the case of the accompanying warrants, will expire on the fifth anniversary of the date of issuance. Each of the November 2024 Accompanying Warrants will have an exercise price of $7.68 per underlying share of Common Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company received net proceeds from the offering of approximately $6,128, after deducting underwriting discounts and commissions and offering expenses of $871. The Company intends to use the net proceeds of the offering to fund the SERENITY At-Home trial, prepare for the initiation of the TRANQUILITY In-Care trial, working capital and general corporate purposes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</btai:FinancingActivitiesDisclosureTextBlock>
    <btai:SaleOfStockMaximumValueSharesToBeIssued
      contextRef="Duration_5_31_2021_To_5_31_2021_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_7HqDJsFg10yEnahziR0XDQ"
      decimals="-3"
      id="Narr_PApXZWbGFE2q4kmQ6AE2lg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">100000000</btai:SaleOfStockMaximumValueSharesToBeIssued>
    <btai:SaleOfStockMaximumValueSharesToBeIssued
      contextRef="Duration_11_1_2023_To_11_30_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_EVFuPSms4EKLkPgGiKPLIw"
      decimals="-3"
      id="Narr_b1wboK9GRUCmVMmoxgduqg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">150000000</btai:SaleOfStockMaximumValueSharesToBeIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_DmobgouGJEKpKx5umwnDTQ"
      decimals="-3"
      id="Narr_bHjMndFqpkmNFW4U_c8ypQ"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">88000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_DmobgouGJEKpKx5umwnDTQ"
      decimals="-3"
      id="Narr_P-l9s5EMTk-ft7ozvnf6rg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">27032000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_DmobgouGJEKpKx5umwnDTQ"
      decimals="-3"
      id="Narr_70xMgkDVXkmSspsmWkI5tw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">811000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_DmobgouGJEKpKx5umwnDTQ"
      decimals="-3"
      id="Narr_CX1_W8zOi0im1x3AS9-49Q"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">26221000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_AhSo6vKkHk2Ijnc-39vr0A"
      decimals="-3"
      id="Narr_32U-3Q6hmE-EghzoTJKTJQ"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">240000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_AhSo6vKkHk2Ijnc-39vr0A"
      decimals="-3"
      id="Narr_-R9hXF7Q0UKnkRevX12IMw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">7682000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_AhSo6vKkHk2Ijnc-39vr0A"
      decimals="-3"
      id="Narr_tQmE4RISRkGFrW0ALVoZ7g"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">231000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_AhSo6vKkHk2Ijnc-39vr0A"
      decimals="-3"
      id="Narr_M11C5RDGuk-hx0uG1wrpDA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">7451000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_25_2024_To_3_25_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_p4L6ETPqFEWoA9lBndZOtQ"
      decimals="-3"
      id="Narr_CCxOm-c5ZUCdHv6rvPXaTA"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">191000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_25_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_qU4qYdPWcke_ZGR8vt26Xg"
      decimals="INF"
      id="Narr_1OBjeUMWn0ucow-THWco9Q"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_IrTiliqP_U6VjgDahhs3oQ"
      decimals="-3"
      id="Narr_3xyzvmfCR0q2gf2QqzpBOw"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">191000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_25_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_qU4qYdPWcke_ZGR8vt26Xg"
      decimals="3"
      id="Narr_5GhdMbO1EkWsR7X-GwNvvA"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">4.416</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_ao0h5xCb-0is227s68HQKA"
      decimals="-3"
      id="Narr_NVU3ef06sUO-i99MsfNSMw"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">348000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_ao0h5xCb-0is227s68HQKA"
      decimals="-3"
      id="Narr_ub3bt0n000uWmPPpR8EW8A"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">348000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_IrTiliqP_U6VjgDahhs3oQ"
      decimals="2"
      id="Narr_sRipCJu6MkmvwBcoz2MMsw"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">46.4</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_ao0h5xCb-0is227s68HQKA"
      decimals="3"
      id="Narr_0OEUi39XXkWr3NUGAXZHHw"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">0.016</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_3_27_2024_To_3_27_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_RvjnXZnJAEar_nFyvWCG8g"
      decimals="-3"
      id="Narr_dL6qF8WIUEO02E-neGjLaA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">25000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_3_27_2024_To_3_27_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_RvjnXZnJAEar_nFyvWCG8g"
      decimals="-3"
      id="Narr_STMK8SmTrkqtsMpSBFUwoQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">248000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_3_27_2024_To_3_27_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_RvjnXZnJAEar_nFyvWCG8g"
      decimals="-3"
      id="Narr_lu8P-JzdeUmXJL_TGlz51Q"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">24752000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_ao0h5xCb-0is227s68HQKA"
      decimals="3"
      id="Narr_oCT9RSAFJEC6TSVO4IDzbA"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">0.016</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <btai:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_Wv-fkHFxikOa4i1-EXoS9A"
      decimals="-3"
      id="Narr_3rg3dzx140W_fE_ukqOFJQ"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">348000</btai:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_Wv-fkHFxikOa4i1-EXoS9A"
      decimals="-3"
      id="Narr_SNDKpqyv1EuaP-6ZRdNEeg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">6000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_IrTiliqP_U6VjgDahhs3oQ"
      decimals="2"
      id="Narr_GL940G2DW06TkkFK-md8tw"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">51.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_22_2024_To_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_qCNNy1whp0ivehAR5sAVYg"
      decimals="-3"
      id="Narr_xZD2Vw6OQk68t55MyDj7fA"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">350000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_LGUU816Yp0m2LKivHXs1uw"
      decimals="-3"
      id="Narr_PZbqZ0fFRkysqcMsxJWuZQ"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">350000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_GIUFHpY0_EqDv2ibJW6xSg"
      decimals="2"
      id="Narr_HSdSjDq7u0KnQ_y3Zw-T9Q"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">7.68</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_aWycUKhL-06MF4rymZ6neQ"
      decimals="-3"
      id="Narr_cc31xntSlEykzkaCATiyLw"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">563000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_aWycUKhL-06MF4rymZ6neQ"
      decimals="-3"
      id="Narr__UtSg8HGI0qDIQ9FUoiYfw"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">563000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_tv06eTkorUuLZsqZJC7L6Q"
      decimals="3"
      id="Narr_bMIUcLzcXEidjl7UTLWUUw"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">7.664</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_Olx3FwfBuUyeg4UcTjGZjg"
      decimals="3"
      id="Narr_9Z9f5jBVqkCzlJtPWy9s6g"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">0.016</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <btai:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_g6yAJhZGY0yVCcOg2tqiqA"
      decimals="-3"
      id="Narr_umca_E17mEyB2Dao3PLY9w"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">80000</btai:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_g6yAJhZGY0yVCcOg2tqiqA"
      decimals="-3"
      id="Narr_Z63IXbKN_0eHj68euqPx4A"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_GIUFHpY0_EqDv2ibJW6xSg"
      decimals="2"
      id="Narr_kKPJkEjKd0CdiuCjNmdA2A"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">7.68</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_11_22_2024_To_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_qCNNy1whp0ivehAR5sAVYg"
      decimals="-3"
      id="Narr_JVhplASQyEehCfB-wz6xbA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">6128000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_11_22_2024_To_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_qCNNy1whp0ivehAR5sAVYg"
      decimals="-3"
      id="Narr_w8fZ-LlxKkGRilm96WMZaQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">871000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_w4XCdc3kwEOCwQ113U_K1w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;12. Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;2017 Equity Incentive Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s 2017 Plan became effective in August 2017. Following the effective date of the Company's 2020 Plan, the Company ceased granting awards under the 2017 Plan, however, the terms and conditions of the 2017 Plan continue to govern any outstanding awards granted thereunder.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020 Incentive Award Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s 2020 Plan was approved and became effective at the Company&#x2019;s 2020 annual meeting of stockholders on May 20, 2020, and unless earlier terminated by the Board of Directors, will remain in effect until March 26, 2030. The 2020 Plan originally authorized for issuance the sum of (i) 57 shares of the Company&#x2019;s common stock and (ii) 15 shares of the Company&#x2019;s common stock, which represents the number of shares that remained available for &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;issuance under the 2017 Plan immediately prior to the approval of the 2020 Plan by the Company&#x2019;s stockholders. Any shares of common stock which, immediately prior to the approval of the 2020 Plan by the Company&#x2019;s stockholders, were subject to awards granted under the 2017 Plan that are forfeited or lapse unexercised and are not issued under the 2017 Plan will increase the number of shares of common stock available for grant under the 2020 Plan. In addition, the number of shares available for issuance under the 2020 Plan will increase on the first day of each calendar year, beginning January 1, 2021 and ending on and including January 1, 2030, by a number of shares equal to the lesser of (A) 4% of the aggregate number of shares of the Company&#x2019;s common stock outstanding on the final day of the immediately preceding calendar year and (B) such smaller number of shares of common stock as determined by the Board of Directors. The shares available for issuance under the 2020 Plan increased by 75 shares and 70 shares on January 1, 2024 and 2023, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Stock-based awards granted under the 2020 Plan have a term of ten years. The vesting schedule of all awards granted under the 2020 Plan is determined by the Board of Directors, which is generally four years. Stock-based awards granted under the 2020 Plan include stock options, BTI RSUs, and Performance Units.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As of December 31, 2024, there were 42 shares available to be granted under the 2020 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;BTI Restricted stock units&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The table below summarizes activity relating to BTI RSUs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In 2024, the Company granted 22 time-based BTI RSUs to certain employees, executives, and board members. The RSUs granted to employees and executives vest 100% at the &lt;span style="-sec-ix-hidden:Hidden_O-R2_NsEcUirYc0hrciCHQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-year anniversary of the grant date. The weighted average grant date fair value per share for the BTI RSUs granted to employees and executives in 2024 was $23.43. Unrecognized stock-based compensation expense related to these awards was $13 as of December 31, 2024. The RSUs granted to board members vest monthly over a &lt;span style="-sec-ix-hidden:Hidden_ZV8mysUnJEKMO7_R1BXZ3w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;12-month&lt;/span&gt;&lt;/span&gt; period, beginning in November 2024. The weighted average grant date fair value per share for the BTI RSUs granted to board members was $9.12. Unrecognized stock-based compensation expense related to these awards was $185 as of December 31, 2024. Unrecognized stock-based compensation expense related to awards issued prior to 2024 was $575 and $1,715 as of December 31, 2024 and 2023, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;BTI Performance stock units &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The table below summarizes activity relating to Performance Units related to BTI common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 33&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (27)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (23)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In July 2024, the Company granted 87 Performance Units to employees. The Performance Units vest on the one-year anniversary of the grant date, provided certain performance criteria are met. The weighted average value per share &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;of Performance Units granted in 2024 was $19.20. None of the Performance Units had vested as of December 31, 2024. Unrecognized stock-based compensation expense related to these Performance Units expected to vest was zero as of December 31, 2024 since it is uncertain whether any performance criteria will be met.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;OnkosXcel Profit sharing units&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The table below summarizes activity relating to the PSUs associated with OnkosXcel as described below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price per unit&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in whole dollars)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,626&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,176&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (89)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,506&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested units as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 941&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,570&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;During 2024, OnkosXcel Employee Holdings, LLC, a management holding company used to facilitate the grant of equity interests to service providers of OnkosXcel granted 15 individual (not in thousands) time-based PSUs related to OnkosXcel to certain employees of the Company in consideration for services provided to OnkosXcel. The PSUs represent indirect equity interests in OnkosXcel. These PSUs vest ratably over 48 months.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The fair values of the PSUs granted in 2024 was $8 per unit, and was estimated at the date of grant using a Black-Scholes option pricing model. The total fair value of the PSUs vested during the year ended December 31, 2024 was $1,165.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:22.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024 grant profit share unit valuation inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 97.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free rate of interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Unrecognized stock-based compensation expense related to the PSUs was $377 as of December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;OnkosXcel restricted stock units&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The table below summarizes activity relating to the OnkosXcel RSUs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 225&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (41)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 176&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As of December 31, 2024, the Company had 176 OnkosXcel Restricted Stock Units outstanding. Unrecognized stock-based compensation expense related to the awards expected to vest was approximately $210 as of December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;BTI Stock options&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;A summary of the Company&#x2019;s stock option activity for the year ended December 31, 2024, is presented below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price per share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 311&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 296.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 214.56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 339.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 311&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 265.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options vested and exercisable as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 249&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 291.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As of December 31, 2024, the intrinsic value of options outstanding was $0. The intrinsic value for stock options is calculated based on the difference between the exercise prices of the underlying awards and the quoted stock price of the Company&#x2019;s common stock as of the reporting date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The total intrinsic value of stock options exercised for the year ended December 31, 2024 was $0. The total intrinsic value of stock options exercisable as of December 31, 2024 was $0.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The weighted average grant date fair value of options granted during the year ended December 31, 2024 was $16.63.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The weighted average grant date fair value of options vested as of December 31, 2024 was $215.98.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The weighted average remaining contractual life is 4.9 years for options exercisable as of December 31, 2024. The weighted average remaining contractual life was 5.6 years for options outstanding as of December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Unrecognized compensation expense related to unvested stock option awards as of December 31, 2024, was $7,691 and will be recognized over the remaining vesting periods of the underlying awards. The weighted-average period over which such compensation is expected to be recognized is 0.9 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The fair value of options granted during the years ended December 31, 2024 and 2023 was estimated using the Black-Scholes pricing model with the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.15969849%;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;width:28.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;width:28.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;5.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;5.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected stock price volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;108.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;112.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;96.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;109.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free rate of interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;4.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;4.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;3.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;4.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In 2024, the Company continued using the historical volatility of its common stock to estimate volatility. Prior to 2023, volatility was estimated using a combination of the historical volatility of publicly traded peer companies and that of the Company&#x2019;s common stock. The expected term of the awards is estimated based on the simplified method, which calculates the expected term based upon the midpoint of the term of the award and the vesting period. The Company uses the simplified method because it does not have sufficient option exercise data to provide a reasonable basis upon which to estimate the expected term. The expected dividend yield is zero percent as the Company has no history of paying dividends nor does management expect to pay dividends over the contractual terms of these options. The risk-free interest rates are determined by reference to the U.S. Treasury yield curve in effect at the time of grant, with maturities approximating the expected term of the stock options. The fair value of the underlying common stock is generally determined as the closing price of the Company&#x2019;s common stock on The Nasdaq Capital Market on the grant date, with consideration of whether there is material nonpublic information that could impact that estimated fair value when it is released.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company recognized stock-based compensation expense related to awards issued under the 2017 Plan and the 2020 Plan, as well as the OnkosXcel PSUs and OnkosXcel RSU&#x2019;s, of $6,156 and $18,614 for the years ended December 31, 2024 and 2023, respectively, which were comprised as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,324&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,905&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,290&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,156&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,614&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020 Employee Stock Purchase Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s 2020 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) was also approved and became effective at the Company&#x2019;s 2020 annual meeting of stockholders on May 20, 2020. The ESPP is designed to assist eligible employees of the Company with the opportunity to purchase the Company&#x2019;s common stock at a discount through accumulated payroll deductions during successive offering periods. The aggregate number of shares that may be issued pursuant to rights granted under the ESPP is 6 shares of common stock. In addition, the number of shares available for issuance under the ESPP will increase on the first day of each calendar year, beginning on January 1, 2021 and ending on and including January 1, 2030, by a number of shares of common stock equal to the lesser of (a) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the Board of Directors. The number of shares that may be issued or transferred pursuant to rights granted under the component of the ESPP that is intended to qualify for favorable U.S. federal tax treatment under Section 423 of the Internal Revenue Code (the &#x201c;Section 423 Component&#x201d;) shall not exceed 31 shares. The purchase price will be determined by the administrator of the ESPP and, for purposes of the Section 423 Component, shall not be less than 85% of the fair value of a share on the first trading day or on the last trading day of the applicable offering period, whichever is lower. The shares available for issuance under the ESPP increased by 19 shares and 18 shares on January 1, 2024 and 2023, respectively. To date, no shares have been sold under the ESPP. There were 75 shares available for issuance as of December 31, 2024.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_vDwwtKHeaUKjbZq0pfe-PA"
      decimals="-3"
      id="Narr_DytSpWfXaUiWskDHTMyJjQ"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">57000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_StockPlan2017Member_L_iPsP7adEiG4elxGlZNHw"
      decimals="-3"
      id="Narr_buItFEJDjUSwe9V0eEMIsw"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant
      contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_IRUWqt-XME6DBPhp1Szf3w"
      decimals="2"
      id="Narr_FKEqmhJHFkaI4DCv6CKiOQ"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.04</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_tHUExHKUMUmrePF-CWMIfw"
      decimals="-3"
      id="Narr_9RzAfBMTvkW_dm6nOICUGQ"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_RvCrri81RU2aLpOi6LE4XQ"
      decimals="-3"
      id="Narr_QjXkTj2JtUOUWRDNHsX0lQ"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">70000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_IRUWqt-XME6DBPhp1Szf3w"
      id="Narr_RSWSoak-NUqH2Dhpqkjx2Q">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_IRUWqt-XME6DBPhp1Szf3w"
      id="Narr_AoyhVKjXAk-N-ByJLJx17A">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_vq2yym5s9EyjbM2-H8oIkw"
      decimals="-3"
      id="Narr_JmCyXVdwT0-gWAzrz5VseQ"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">42000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mnMmxsdqv0CnwoCMs9Wk3Q"
      id="Tb_3LVvkB_iPkeNgCVM3t5uAw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OZo6Dpf0wkeLIC74MDokcw"
      decimals="-3"
      id="Tc_JK5tCM_jiUag0cVgsZ2V1g_5_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mnMmxsdqv0CnwoCMs9Wk3Q"
      decimals="-3"
      id="Tc_ulPtLyxjekmgWfQD8UmKtA_6_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">22000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mnMmxsdqv0CnwoCMs9Wk3Q"
      decimals="-3"
      id="Tc_Rfq4QqSe8U-hBsKv4SsszQ_7_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">1000</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mnMmxsdqv0CnwoCMs9Wk3Q"
      decimals="-3"
      id="Tc_XPUQXN2oEEe4oc1jxT14PQ_8_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_4epNlYQKv0iKvwBrZlbiTQ"
      decimals="-3"
      id="Tc_8G_0-wOhy0O6-M9H2mYEZQ_9_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">27000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mnMmxsdqv0CnwoCMs9Wk3Q"
      decimals="-3"
      id="Narr_je2esAzPd0OEyXOIEk6zzQ"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">22000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_mnMmxsdqv0CnwoCMs9Wk3Q"
      decimals="2"
      id="Narr_Z4It-7WfJUq8PaPBXp6g9g"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_p0pq-UOWxEu_wI0sw4gUPQ"
      decimals="2"
      id="Narr_0Izr3jfUKUOz8iDb4Xt8aA"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">23.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_j0QU6pzy1kWBLf65tC1seA"
      decimals="-3"
      id="Narr_NNPbjO7Az0-dk1Mshe0uxA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">13000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_A8ZHOdOBykqthS4c1Q8gUA"
      decimals="2"
      id="Narr_OsIjeO4ke0qm-u9pMS4Lpg"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">9.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_Mb79eA35SUKhSf2JoRymdA"
      decimals="-3"
      id="Narr_5nprP3xroEOOtkoDZaCRlw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">185000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_4epNlYQKv0iKvwBrZlbiTQ"
      decimals="-3"
      id="Narr_rXsESn35p0eQ6OrG-6I3Nw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">575000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OZo6Dpf0wkeLIC74MDokcw"
      decimals="-3"
      id="Narr_2tjc0VoQNEy77Z8n4SxrBg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1715000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_CrXc_wq4WE6253aRHA7iZQ"
      id="Tb_v1_RaLknT0azb28FEA9rXg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 33&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (27)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (23)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_S6eKsZBc2UGXa8jiNAbKrA"
      decimals="-3"
      id="Tc_osd9tHcXlUaILwZ1zcDO8Q_4_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">33000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_CrXc_wq4WE6253aRHA7iZQ"
      decimals="-3"
      id="Tc_l21IQ64PAU6xXLPQsG8P1w_5_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">87000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_CrXc_wq4WE6253aRHA7iZQ"
      decimals="-3"
      id="Tc_KzHMgA06XE2HZ3mZEjYhZA_6_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">27000</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_CrXc_wq4WE6253aRHA7iZQ"
      decimals="-3"
      id="Tc_6g3fI_dZDkmnHD-N_Unfpw_7_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">23000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_sog3pKgdW0eiohkZeERd4Q"
      decimals="-3"
      id="Tc_BRfMkzegwE2fDT-KoBZzfw_8_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">70000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_hTkGBWRuAUSz0YVpoWxPsA"
      decimals="-3"
      id="Narr_5nvvrvf_-k-uX9h9Kmekgw"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">87000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_hTkGBWRuAUSz0YVpoWxPsA"
      id="Narr_VyVQ9G0kq0uLB1BBi642YA">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_hTkGBWRuAUSz0YVpoWxPsA"
      decimals="2"
      id="Narr_2EQopZo7d0KE77PQdcqi6Q"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">19.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_CrXc_wq4WE6253aRHA7iZQ"
      decimals="-3"
      id="Narr_zaHiYx7mZUK0FJlSuXn1PQ"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_sog3pKgdW0eiohkZeERd4Q"
      decimals="-3"
      id="Narr_RVdjYtFmqUONntd-WwYwnA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ"
      id="Tb_g7EWuwCyvUqhEukX91rBhA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price per unit&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in whole dollars)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,626&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,176&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (89)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,506&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested units as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 941&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,570&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_urjzmG69Fk6Da0LeQweFZA"
      decimals="0"
      id="Tc_SG8Nve11vkS4idfjMjScaQ_6_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">1240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_urjzmG69Fk6Da0LeQweFZA"
      decimals="0"
      id="Tc_lX04YYC9fEO2JrMNn3blqg_6_5"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">5626</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ"
      decimals="0"
      id="Tc_s0Effp49l0e3vEYGym69pw_7_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ"
      decimals="0"
      id="Tc_5E3jDf2MzESNdQfjRn-OoQ_7_5"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">10176</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ"
      decimals="0"
      id="Tc_seTg2e45ZkWOGf87DdGEMQ_8_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">89</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ"
      decimals="0"
      id="Tc_snrdCXe5rUq7o4oO5hM47A_8_5"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">5506</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_3fPI5jL5i0amKn6Rp0WTxA"
      decimals="0"
      id="Tc_EymraiM9ZUa-dWmDgH9BsA_10_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">1166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_3fPI5jL5i0amKn6Rp0WTxA"
      decimals="0"
      id="Tc_VTfd6dXSR0eeXz6vYtT7pg_12_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">941</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_3fPI5jL5i0amKn6Rp0WTxA"
      decimals="0"
      id="Tc_sigdsAeU7Eewp8dGvD-shQ_12_5"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">5570</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ"
      decimals="0"
      id="Narr_2AJ8iXFoCkGYFIe4Fy4QrQ"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ"
      id="Narr_OWMKyjoSQU62xaUA5jREvQ">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_urjzmG69Fk6Da0LeQweFZA"
      decimals="INF"
      id="Narr_Xq6NSpalFUuhdJW7VSI2xg"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ"
      decimals="-3"
      id="Narr_6zfZDEfPnk2cCogUmrasxg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1165000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ"
      id="Tb_D2x87gjqo0W4usCOGOupGA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:22.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024 grant profit share unit valuation inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 97.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free rate of interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ"
      decimals="3"
      id="Tc_PXsWhw_HnUmCJ3BRP8Hhpg_4_2"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.974</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ"
      decimals="3"
      id="Tc_9OROBP9JQEifVo4E8qqnQQ_5_2"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ"
      decimals="3"
      id="Tc_tsAjFBQedUqbtPh2K3ppEg_6_2"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ"
      id="Tc_vxRV85kK3EigZ1nm-fRL3g_7_2">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_3fPI5jL5i0amKn6Rp0WTxA"
      decimals="-3"
      id="Narr_TGboIdn2m06gV6t4IO2-EA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">377000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_pyA1UGmh10OZkxGv9jCGdQ"
      id="Tb_uwmcdaIEU0yASUtrONdT8Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 225&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (41)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 176&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_B1zotSn0RUq8Gi-caKB5-Q"
      decimals="-3"
      id="Tc_A7gYG0lKJUiu50OF4eAWtw_5_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">225000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_pyA1UGmh10OZkxGv9jCGdQ"
      decimals="-3"
      id="Tc_bNZIJ2_1rEitSHVoY4iA8g_7_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">41000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_pyA1UGmh10OZkxGv9jCGdQ"
      decimals="-3"
      id="Tc_nln9tHp7Kkq5T1sy-crcFA_8_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">8000</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_ZZb5ojV8nECXF6PGT2Sv6w"
      decimals="-3"
      id="Tc_tKALX5RNRkiI86m5CxWRfQ_9_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">176000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_ZZb5ojV8nECXF6PGT2Sv6w"
      decimals="-3"
      id="Narr_5CvY1EMHLU2mnIEkjNLMJg"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">176000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_ZZb5ojV8nECXF6PGT2Sv6w"
      decimals="-3"
      id="Narr_LjzgBVMw6UGvu_O0nulHVQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">210000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_3X_RCJ835UiX1GbPfXOhVA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price per share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 311&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 296.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 214.56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 339.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 311&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 265.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options vested and exercisable as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 249&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 291.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xOcQ1mX8HUS3oomqLm_lMg"
      decimals="-3"
      id="Tc_4LvNdyFbWUuK5bEQdJGl_Q_5_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">311000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xOcQ1mX8HUS3oomqLm_lMg"
      decimals="2"
      id="Tc_R3bBf9z81EuOneuuocEM2A_5_5"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">296.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA"
      decimals="-3"
      id="Tc_rnmmoEJdvE2k81kiX3WPBQ_6_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA"
      decimals="2"
      id="Tc__X6ztAOWnUa5I3n4w4o2lQ_6_5"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA"
      decimals="-3"
      id="Tc_824DSkS7AkK58_C9NxjFtA_7_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">24000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA"
      decimals="2"
      id="Tc_JGmnGmoj9UydPEsNdCzCWw_7_5"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">214.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA"
      decimals="-3"
      id="Tc_AUEHHyQWK0CHj7n1gs5rHQ_8_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">16000</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod>
    <btai:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA"
      decimals="2"
      id="Tc_c0gviB4hS0qv2O44ZgK4Dg_8_5"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">339.74</btai:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Lm8AZQPL40KMLw_EFZsryQ"
      decimals="-3"
      id="Tc_7S2_YR_Sbky2WNVjp3vuaA_10_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">311000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Lm8AZQPL40KMLw_EFZsryQ"
      decimals="2"
      id="Tc_mbHqjhq-B02VaAdV7Uacvg_10_5"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">265.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Lm8AZQPL40KMLw_EFZsryQ"
      decimals="-3"
      id="Tc_HXNXuUdfW0a7-CsEpMNhxA_12_2"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">249000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Lm8AZQPL40KMLw_EFZsryQ"
      decimals="2"
      id="Tc_oUrocvpDREm5_yEYOZyqRA_12_5"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">291.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Lm8AZQPL40KMLw_EFZsryQ"
      decimals="-3"
      id="Narr_1lKK3VgCZ0S67L-BK4rxpQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA"
      decimals="-3"
      id="Narr_a3eVEhAez0qsMCgeG3wBvg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Lm8AZQPL40KMLw_EFZsryQ"
      decimals="-3"
      id="Narr_lH7lPlJiHkmO-tj_0kUf2A"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA"
      decimals="2"
      id="Narr_eqmj8xg1okihiWZYDzzMzA"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">16.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA"
      decimals="2"
      id="Narr_Nyl365e6wkasUjfz12L7wQ"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">215.98</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA"
      id="Narr_A1WZc3bedkmN_lwW1wuiWQ">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA"
      id="Narr_Ov1qMAjAhEW4GsD55OVENw">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Lm8AZQPL40KMLw_EFZsryQ"
      decimals="-3"
      id="Narr_HJp3_lDbMkeJYAK5AOU9ww"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">7691000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA"
      id="Narr_Vl6HSpNAGkG8t52MUQRvMA">P0Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA"
      id="Tb_396TYDIOAEGdWkJH8-Bg-A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.15969849%;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;width:28.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;width:28.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;5.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;5.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected stock price volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;108.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;112.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;96.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;109.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free rate of interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;4.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;4.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;3.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;4.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dHuj7RaJ8EKL0Sny_5o-CQ"
      id="Tc_lcOv27roJkWQN-8LMidvGQ_5_3">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xVBddGnbW0ybwujG6xab2Q"
      id="Tc_B2IEgDXi1EKn1aktvvbS1A_5_6">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SRyiKYrKEE6xThkeoaB7WA"
      id="Tc_3RRA-ukr7Em26VxgR5P3Eg_5_9">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ida0xzaxyUGKvrdsH2Fr0g"
      id="Tc_sR6yqJv5-Eyh5xYcPMggZQ_5_12">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA"
      decimals="3"
      id="Tc_gxtGFMKEsECd92oQbpjfjA_6_3"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">1.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA"
      decimals="3"
      id="Tc_r3AWElxGbke67u2Ir2rv3w_6_6"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">1.125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BcKPgE027Eq07dZFNZcBVA"
      decimals="3"
      id="Tc_oiRIN87T7Uau_LFVukq3_A_6_9"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.969</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BcKPgE027Eq07dZFNZcBVA"
      decimals="3"
      id="Tc_lgCL_OFJ6UqR91LgvHmtaw_6_12"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">1.099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA"
      decimals="3"
      id="Tc_2OSGOcrtk0yKLrGMXzJ-mA_7_3"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA"
      decimals="3"
      id="Tc_vyLM5LagA0WeBsJaVF4mAQ_7_6"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BcKPgE027Eq07dZFNZcBVA"
      decimals="3"
      id="Tc_0rGLekzUp0C2zNUZgTHUDQ_7_9"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BcKPgE027Eq07dZFNZcBVA"
      decimals="3"
      id="Tc_4lIUTR7q30KBaiA1tPcAjg_7_12"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dHuj7RaJ8EKL0Sny_5o-CQ"
      decimals="3"
      id="Tc_YeEHIdN5OE6r4KKlsy4n7Q_8_3"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xVBddGnbW0ybwujG6xab2Q"
      decimals="3"
      id="Tc_cr5UmTG6R0ShStXEAQbB4g_8_6"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SRyiKYrKEE6xThkeoaB7WA"
      decimals="3"
      id="Tc_f-1MBhjsl0Cvcc6GD_Uuaw_8_9"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Ida0xzaxyUGKvrdsH2Fr0g"
      decimals="3"
      id="Tc_Yme81ypqi0WKWRS29BUspw_8_12"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_A5mli8qD-keGgtUPKhwzDA"
      decimals="2"
      id="Narr_Rfhv7J7za0aS8BToHCF-1w"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Narr_CRdbko3nTEmJ46mw5Du7qQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">6156000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Narr_JmdFsj47BU2T-DSwcGOSqw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">18614000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_a3Khwuo_xESyJKkMFwhR3A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,324&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,905&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,290&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,156&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,614&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_vlhYBLGO70Kx9W7BpuYnNQ"
      decimals="-3"
      id="Tc_uKRR59a5VUSrUpnLr66NOQ_4_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2251000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_oEnUYj2nH0S7nHVXLQ4q4A"
      decimals="-3"
      id="Tc_pAZTyWjVl0ORvW6PJ0AmAg_4_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">6324000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_OQGpm4OmO0GvGOO9BwRRtQ"
      decimals="-3"
      id="Tc_TGrzPJvJGEaH0QooPSwVOQ_5_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">3905000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_QvezY-cudU6QqyNRbmjCmg"
      decimals="-3"
      id="Tc_55KFj9_CcEinBbgsoB1jew_5_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">12290000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_S27lB7MvckmUmcbj3JSVQA_6_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">6156000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_8PU91MvRi0CA92DUKE1GzQ_6_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">18614000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_N0vp5VFCUkqtRrwPRBSFFQ"
      decimals="-3"
      id="Narr_vUEJ-1qj2EiGLDzLM97ArA"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant
      contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_jWcBt1FrAUy7Aw7aYKtEBA"
      decimals="2"
      id="Narr_liODfQ7RDUGj9flfoP1pBw"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.01</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant>
    <btai:EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred
      contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_jWcBt1FrAUy7Aw7aYKtEBA"
      decimals="-3"
      id="Narr_XoPS5sN1qkaN0vICFtVgcw"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">31000</btai:EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_jWcBt1FrAUy7Aw7aYKtEBA"
      decimals="2"
      id="Narr_eeuCXgkS3Uyc0qYLvSdnKw"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_qoDjPOgKl02zcP5r7FAQuQ"
      decimals="-3"
      id="Narr_dT9SgqSnjkqZ9Lh6adeBQg"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">19000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_OpSGdiyFOEqI7cFehOL59A"
      decimals="-3"
      id="Narr_YMHHaIxI40iEfWP4TZcz-A"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">18000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_mzi71qMtwUW4NC2oL1_1RQ"
      decimals="-3"
      id="Narr_JjiYAnzFmUuj26dozWVN9Q"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_v9I1drvLSkCReDIKAPrJEg"
      decimals="-3"
      id="Narr_Xo-Dg0rJ-k-wa8D6OPzmqQ"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_DnqbMHzgOkCGrUWsBlRTvA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;13. Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI leases office space for its corporate headquarters at 555 Long Wharf Drive, New Haven, Connecticut (the &#x201c;HQ Lease&#x201d;) under an operating lease that expires in February 2026. The Company has an option to renew the HQ Lease for one additional five-year term. Payments under the HQ Lease are fixed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company also leases equipment such as copiers and information technology equipment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The future minimum annual lease payments under operating leases, as of December 31, 2024, were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ending December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 456&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 439&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less current portion of lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (374)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Long-term portion of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The current portion of the Company&#x2019;s operating lease liability of $374, as of December 31, 2024, is included in &lt;span style="-sec-ix-hidden:Hidden_a6pX1JmlWkyKm9cKj1tV7w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt; on the Consolidated Balance Sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Lease expense was $394 and $392 for the years ended December 31, 2024 and 2023, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Lease renewal options are not included in the ROU asset or lease liability.&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Narr_JEYYfJ-iNkKM4ptopKBgvw">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      id="Narr__wqTJCnF_EerPbbI2hgpoQ">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_iGxtDmnr7ka2iT4aWc-1nA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ending December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 456&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 439&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less current portion of lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (374)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Long-term portion of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_hk1j1jNepkWOp0qlrEq32w_3_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">391000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_2Au4khYNp0qWWeHJ3U9xcg_4_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">65000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_3boxCoW3PUOm5l3Tezt5bg_6_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">456000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_dlZ1MzUWSUC61lyfnD6JPQ_7_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">17000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_v1VlaICbTES2BzOmextnDg_8_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">439000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_9RGRMJmjGEiMQmi-JoJT1Q_9_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">374000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_tJCKJBckRU6Siu-qwmQBEw_10_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">65000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Narr_EaMb015Ot0K3E85WxBmvFQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">374000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Narr_d0YYYFWSeE2bjzlxM07ryQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">394000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Narr_MVwLD-57AUemN4__MOiJbg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">392000</us-gaap:OperatingLeaseExpense>
    <us-gaap:DefinedBenefitPlanTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_Up-G7bDkO0OFuhijvK1a0A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 14. Employee Benefit Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company maintains a defined contribution retirement plan for its employees that complies with Section 401(k) of the Internal Revenue Code (the &#x201c;401(K) Plan&#x201d;). Employees are eligible to participate in the 401(K) Plan and can contribute a portion of their pay into the 401(K) Plan, subject to annual limits established by the U.S. Internal Revenue Service. Participating employees receive an employer matching contribution equal to 50% of eligible employee contributions on the first 5% of eligible compensation contributed. Employer contributions to the 401(K) Plan were $289 and $788&lt;span style="background:#ffffff;"&gt; for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:DefinedBenefitPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="2"
      id="Narr_UAl0p0HwF0mkaAl_1pfbnA"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="2"
      id="Narr_6NPBv2bSBEq3jePcSL1lUQ"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Narr_7ZTcEtNW9kmDQF1sUk8N9w"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">289000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Narr_BCXBAA7oeEqKkyi731cB7Q"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">788000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_P4AF5ciWSEmrb3tg5IdOXw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;15. Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company groups its assets and liabilities measured at fair value in three levels based on the nature of the inputs and assumptions used to determine fair value. Refer to Note 3, Summary of Significant Accounting Policies, for additional information on the accounting policies related to fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The carrying amounts of Cash and cash equivalents, Accounts receivable, net and Accounts payable approximate fair value due to the short-term nature of these instruments. As of December 31, 2024 and 2023, the Company had $29,036 and $64,860, respectively, primarily in money market funds that hold U.S. government cash equivalent instruments (included in Cash and cash equivalents) which were valued based on Level 1 inputs. There were no transfers between levels within the hierarchy during the years ended December 31, 2024 and 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Derivative liabilities measured at fair value on a recurring basis are summarized below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liability - BTI Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,593&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liability - OnkosXcel Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,633&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,633&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liability - BTI Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,193&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,193&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,193&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liability - OnkosXcel Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 712&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 712&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 712&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,905&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,905&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,905&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Derivative liabilities are comprised of the OnkosXcel Warrants and Equity Investment Right held by the Lenders. The fair value of the derivative liabilities was determined using Monte Carlo simulation models for the Equity Investment Right, and Binomial Option Pricing and Distribution models for the OnkosXcel Warrants.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;As discussed in Note 9, &lt;i style="font-style:italic;"&gt;Debt and Credit Facilities&lt;/i&gt;, the Equity Investment Right was terminated on November 25, 2024 in connection with the Fifth Amendment to the Credit Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following table presents changes in Level 3 liabilities measured at fair value for the year ended December 31, 2024. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liabilities, Balance - January 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,905&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,343&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Termination of Derivative liabilities - Equity Investment Right&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,263)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_pNs2n3-e20CuK4JoOz4cQA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"&gt;   Change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (602)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (438)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liabilities, Balance - December 31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,905&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The derivative liabilities were reported at their fair values in the Consolidated Balance Sheets. The changes in the fair value of the derivative liabilities were reported as gains in the Consolidated Statements of Operations as Other (income) expense, net, for the years ended December 31, 2024 and 2023, in the amounts of $20,181 and $438, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Inputs used to calculate the estimated fair value of the Equity Investment Right were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:22.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Equity Investment Right&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Strike price relative to volume weighted 30-day average&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 110.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility (annual)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 112.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Probability of exercise&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 91.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Time period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Estimated premium to 30-day average&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 24.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The changes in fair value of the Equity Investment Right up to its termination date were recorded&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;in the Consolidated Statements of Operations as Other (income) expense, net.  The final carrying value of the Equity Investment Right of &lt;/span&gt;$1,263 upon derecognition was recorded was recorded as a reduction of derivative liability with the offset recorded as a gain in Other (income) expense, net, in the Consolidated Statements of Operations. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In estimating the fair value of the derivative liability related to the OnkosXcel Warrants, inputs included third-party fair value estimates of OnkosXcel limited liability company units along with the volatility of those units (which was set at 100% based on the historical volatility of the Company&#x2019;s stock, along with a peer group of comparable publicly traded companies), and the timing and probability of the relevant capital transactions occurring.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The estimated fair value of the Credit Agreement as of December 31, 2024, was $94,204. Both observable and unobservable inputs were used to determine the fair value of long-term debt, which was classified within the Level 3 category.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The following table presents the BTI warrants issued by the Company and the corresponding balance sheet classification:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant Recipient&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant Type&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issue Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Lenders and RIFA Purchasers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Closing Date Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4/19/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Lenders and RIFA Purchasers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;2023 Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12/5/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Lenders and RIFA Purchasers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;2024 Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3/20/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Lenders and RIFA Purchasers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;New Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;11/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 313&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Armistice Capital Master Fund Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.136&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 534&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Armistice Capital Master Fund Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Armistice Capital Master Fund Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;November 2024 Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;11/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Heights Capital Management&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;November 2024 Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;11/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Hudson Bay Capital Management&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;November 2024 Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;11/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;IntraCoastal Capital, LLC&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;November 2024 Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;11/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total warrants issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,792&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The fair value of the Closing Date Warrants, which was a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of $3,245 was recorded as a component of stockholders&#x2019; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the OFA Facilities. This non-recurring measurement is classified as Level 2. The inputs used were a strike price of $320.64, the Company&#x2019;s stock price of $238.88, volatility of 95%, term of 7 years and risk-free rate of 2.95%. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As discussed in Note 9, Debt and Credit Facilities, in connection with the closing of the Second Amendment&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;of the&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;Credit Agreement, on the Second Amendment Effective Date, the Company amended and restated the Closing Date Warrants granted to the Lenders to have an exercise price of $58.3232 per share. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Using a Black-Scholes pricing model, the Company determined that the Closing Date Warrants&#x2019; fair values at the original strike price of $320.64 and the amended strike price of $58.3232 were $548 and $802, respectively, as of the Second Amendment Effective Date. The Closing Date Warrants&#x2019; incremental increase in fair value for the repricing of $254, was recorded as a component of stockholders&#x2019; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts refinanced under the Credit Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In connection with the Second Amendment, the Company issued 4 &#x201c;2023 Warrants&#x201d; at a strike price of $58.3232 per share. The fair value of the 2023 Warrants, which is a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of $200 was recorded as a component of stockholders&#x2019; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the Credit Agreement. This non-recurring measurement is classified as Level 2. The inputs used were a strike price of $58.3232, the Company&#x2019;s stock price of $59.36, volatility of 99%, term of 5.4 years and risk-free rate of 4.14%. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In connection with the Fourth Amendment, the Company issued 6 &#x201c;2024 Warrants&#x201d; at a strike price of $49.1568&lt;span style="white-space:pre-wrap;"&gt; per share.  The fair value of the &#x201c;2024 Warrants&#x201d;, which was a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of &lt;/span&gt;$224 was recorded as a component of stockholders&#x2019; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the OFA Facilities. This non-recurring measurement is classified as Level 2. The inputs used were a strike price of $49.1568, the Company&#x2019;s stock price of $44.48, volatility of 112.2%, term of 5 years and risk-free rate of 4.25%. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In addition, in connection with the Fifth Amendment of the Credit Agreement, on the Fifth Amendment Effective Date of November 25, 2024, the Company amended and restated the Closing Date Warrants, 2023 Warrants, and 2024 Warrants granted to the Lenders to have an exercise price of $7.68 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Using a Black-Scholes pricing model, the Company determined that the Closing Date Warrants, 2023 Warrants, and 2024 Warrants&#x2019; fair values at the previously amended strike price of $58.3232 and original strike price of $49.1568 the amended strike price of $7.68 were $105 and $164, respectively, as of the Fifth Amendment Effective Date. The Closing Date Warrants, 2023 Warrants, and 2024 Warrants&#x2019; incremental increase in fair value for the repricing of $59, was recorded as a component of stockholders&#x2019; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts refinanced under the Credit Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"&gt;The fair value of the Accompanying Warrants at issuance on March 25, 2024 was determined using a Black-Scholes pricing model and the fair value of $19,347 was recorded as a derivative liability with the offset recorded as a component of stockholders&#x2019; equity in Additional-paid-in-capital in the Consolidated Balance Sheets. This fair value measurement is classified as Level 2. The valuation inputs used were a strike price of $51.20, the Company&#x2019;s stock price of $44.96, volatility of 112.2%, a term of 5 years and a risk-free rate of 4.2%&lt;span style="white-space:pre-wrap;"&gt;.  On November 25, 2024, &lt;/span&gt;534 of the 539 Accompanying Warrants&#x2019; strike price were amended to $9.136&lt;span style="white-space:pre-wrap;"&gt;, as part of the consideration provided to one of the investors in the November 2024 Equity raise discussed in Note 11, Common Stock Financing Activities.  The increase in fair value due to the amended strike price of &lt;/span&gt;$1,000&lt;span style="white-space:pre-wrap;"&gt; was recorded as an increase in the carrying value of the Derivative liability, with the offset recorded as a loss in Other (income) expense, net, in the Company&#x2019;s Consolidated Statements of Operations.  We remeasured the Accompanying Warrants&#x2019; fair value at December 31, 2024 of &lt;/span&gt;$2,320 and recorded a net gain of $17,027, including the repricing loss of $1,000 for the year ended December 31, 2024, respectively within Other (income) expense, net in the Company&#x2019;s Consolidated Statements of Operations. The valuation inputs used as of December 31, 2024 were a strike prices of $9.136 and $51.20 for 534 and 5 Accompanying Warrants, respectively, the Company&#x2019;s stock price of $5.984, volatility of 112.3%, term of 4.2 years and risk-free rate of 4.4%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"&gt;The fair value of the November 2024 Accompanying Warrants at issuance on November 25, 2024 was determined using a Black-Scholes pricing model and the fair value of $5,562 was recorded as a derivative liability with the offset recorded as a component of stockholders&#x2019; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets. This fair value measurement is classified as Level 2. The valuation inputs used were a strike price of $7.68, the Company&#x2019;s stock price of $7.52, volatility of 112.5%, a term of 5 years and a risk-free rate of 4.2%&lt;span style="white-space:pre-wrap;"&gt;.  We remeasured the fair value at December 31, 2024 of &lt;/span&gt;$4,273 and recorded an unrealized gain of $1,289 for the year ended December 31, 2024, respectively within Other (income) expense, net in the Company&#x2019;s Consolidated Statements of Operations. The valuation inputs used as of December 31, 2024 were a strike price of $7.68, the Company&#x2019;s stock price of $5.984, volatility of 112.3%, term of 4.9 years and risk-free rate of 4.4%.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_waelNlOubE2wBVFPlyHhnA"
      decimals="-3"
      id="Narr_Yx-1T2erikKnn9WerkX1KQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">29036000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_Lzrt-ozGkUiBpO-gtGyjpg"
      decimals="-3"
      id="Narr_eEp335E7tEWmIpL9a05QQw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">64860000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_KfqBRRIJq0eWZoL8AjttPg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liability - BTI Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,593&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liability - OnkosXcel Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,633&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,633&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liability - BTI Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,193&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,193&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,193&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liability - OnkosXcel Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 712&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 712&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 712&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,905&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,905&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,905&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vpbgA0Y3d02GV60wknoGug"
      decimals="-3"
      id="Tc_72WUJbdxIE2vmLD87TYDQw_5_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">6593000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_2DCibhs95kq8Jc8YpX7xJw"
      decimals="-3"
      id="Tc_-vguBhTDoEmy7uoNVXkNEA_5_9"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">6593000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MeVvKC1qK0CFc5qbgrTI9A"
      decimals="-3"
      id="Tc_ZRXOB6F6nkyL52ZAN7m5oQ_5_15"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">6593000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_aidNv9HgNk2DhIo_TgvNhA"
      decimals="-3"
      id="Tc_Qbo5dHmdI0C1QS8MAVZ1ew_6_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">40000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_TN6VQOKYb02WtCDp3elR3w"
      decimals="-3"
      id="Tc_vth1vAP5G02VGzBOAMFbLQ_6_12"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">40000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AtesnzW9Vk62r5o4Z5MLOg"
      decimals="-3"
      id="Tc_arbe1Xi-YUW3VxKy5X76mw_6_15"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">40000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_iXjg5DQGe0ydE6a0tFygQg"
      decimals="-3"
      id="Tc_M_xOmUiy-EqfFVIeEBgLXA_7_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">6633000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_WvQM_Cfj6UW7acmcXHo-pQ"
      decimals="-3"
      id="Tc_Y7LE8H59bUumE0SYcmlxNQ_7_9"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">6593000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ExafltryU0uKvGWyPhUsBQ"
      decimals="-3"
      id="Tc_mEem8GzLdkCU9jNPUfm90w_7_12"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">40000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_HN9QZyHZZEqqvDSOhHwi6g"
      decimals="-3"
      id="Tc_s6wzWmLgyUOkOy5_3A9kfQ_7_15"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">6633000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ecW8VPGztk2Gf79xQBkyNA"
      decimals="-3"
      id="Tc_hWBZXzEGy0OkfhKlD1KrSg_6_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1193000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AmN6FsQg1EitMV_BHxN7_Q"
      decimals="-3"
      id="Tc_mnprdyph8E-Jyzn6gxTAHw_6_12"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1193000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1mPU0Lx-nE-RmcrvYY9V3A"
      decimals="-3"
      id="Tc_h2WLEXWhxkSP4cuRHk8thA_6_15"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1193000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_HcAF3jq9Q06V5LIYvzVw4w"
      decimals="-3"
      id="Tc_LS7N3c9KuEiCoCspeWGdjg_7_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">712000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_nJRaa39oO02skohtFNO_CQ"
      decimals="-3"
      id="Tc_hoqMhTRCvUOBY5W3Cf8w4g_7_12"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">712000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rgfcXxi9006PlNFx3qH35g"
      decimals="-3"
      id="Tc_ppN3WqIgxk-2McIFQABnVA_7_15"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">712000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KTr0ds-yYES_mpozAK0KPg"
      decimals="-3"
      id="Tc_a8FLKDQh0UewzumQApLAlg_8_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1905000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_cPgf57S61Uyah5MXLI1evA"
      decimals="-3"
      id="Tc_U1n3_lvFp0iftTj6eWnTUQ_8_12"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1905000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5D28fXSYSUCIMdnKx2CzdQ"
      decimals="-3"
      id="Tc_a2gl0i0VnkS9NkTcBX31ag_8_15"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1905000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_ymuULb7c8kii2Pc5Q1p2ug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liabilities, Balance - January 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,905&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,343&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Termination of Derivative liabilities - Equity Investment Right&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,263)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_pNs2n3-e20CuK4JoOz4cQA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"&gt;   Change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (602)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (438)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liabilities, Balance - December 31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,905&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_NgiXRCw8Pkum2He_H4qHmA_5_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1905000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2022_jhStatqo5EaSoSvdA9RW0g"
      decimals="-3"
      id="Tc_Lu6yb6haJEiYn2IQPW1eFw_5_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2343000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_N-lEdCI780-JkLi3BNV9Ig"
      decimals="-3"
      id="Tc_YRJ0-RgZ1EGQsQnsyNIcrw_6_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-1263000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_eg_j3K3JFU-Lx3M2haqIhg_7_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-602000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_lgJevMl-kUOTmRIpNW7pFA_7_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-438000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_lBJmMafRb0G-Ki46KGMbrw_8_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">40000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_rH23dbxBJECIAlyUX9A2XA_8_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1905000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Narr_CgPhfjGHZUWhhJwi2DYdJg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">20181000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Narr_nhC3PVzD3k2-SZ7EkwfGGw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">438000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_0ABcwZINVUe9wkzF0spJeg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:22.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Equity Investment Right&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Strike price relative to volume weighted 30-day average&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 110.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility (annual)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 112.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Probability of exercise&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 91.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Time period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Estimated premium to 30-day average&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 24.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_fnIGASQkZ0KT8yEsdC0CCQ"
      decimals="3"
      id="Tc_SG_Hzl5Ym0WN4qT_lxPcHA_3_2"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">1.10</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_RYPqtdbPfUOCOJbUwsxRdQ"
      decimals="3"
      id="Tc_TYyyQ2_0bEu8S9Gyo-8bIA_4_2"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">1.123</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_btai_MeasurementInputProbabilityOfExerciseMember_R6UHsXs59kO6T0pv-5n4Pg"
      decimals="3"
      id="Tc_vtNuzWlxj0-lgBgkUS7-5g_5_2"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.91</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_vnbH2b6cvk6tsJ16seh7xw"
      decimals="1"
      id="Tc_3FYmf9XQlEq_-4WfcgLNvw_6_2"
      unitRef="Unit_Standard_Y_HWoZmdDBn0OhfgBS6ig-MA">1.3</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_btai_MeasurementInputEstimatedPremiumMember_Nx0QCxfhw0uGTxWALoXeBQ"
      decimals="3"
      id="Tc_wZN6npRSn0OAzslaMXig6Q_7_2"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.24</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_0MsOXlyLLki32Y4tNC1zZQ"
      decimals="4"
      id="Tc_gUvG4McpVkix-okSVxeNoQ_8_2"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.0426</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_N-lEdCI780-JkLi3BNV9Ig"
      decimals="-3"
      id="Narr_-6osztAr3keOITjdCHrfew"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-1263000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_LcJiex4QpE2YqESAdf6fpQ"
      decimals="2"
      id="Narr_UO3ujvaWwkei-P-nFhsMpA"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">1</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DebtInstrumentFairValue
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Narr_IALmiBbQBkyfeqCfJQDmig"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">94204000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_vgoOoCX4P0yqgJsmS7iaPw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant Recipient&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant Type&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issue Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Lenders and RIFA Purchasers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Closing Date Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4/19/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Lenders and RIFA Purchasers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;2023 Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12/5/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Lenders and RIFA Purchasers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;2024 Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3/20/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Lenders and RIFA Purchasers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;New Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;11/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 313&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Armistice Capital Master Fund Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.136&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 534&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Armistice Capital Master Fund Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Armistice Capital Master Fund Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;November 2024 Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;11/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Heights Capital Management&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;November 2024 Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;11/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Hudson Bay Capital Management&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;November 2024 Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;11/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;IntraCoastal Capital, LLC&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;November 2024 Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;11/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total warrants issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,792&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_UVB3pFbO506ugN_GMsELIg"
      decimals="INF"
      id="Tc_gYGF2gKd20G4Jp2K6Zhw3w_3_7"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_UVB3pFbO506ugN_GMsELIg"
      decimals="-3"
      id="Tc_UqOxqJlfcUC8FRc-l_I8_g_3_9"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">17000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_sWnPUgoZNUaV48uFc0AzEg"
      decimals="INF"
      id="Tc_-0pEx3jb5UCr9Qa_sS9g2A_4_7"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_sWnPUgoZNUaV48uFc0AzEg"
      decimals="-3"
      id="Tc_71qBnk45uUioGYtmj4KCTQ_4_9"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">4000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_FRRTD6E8_UWc7CqpvzLbPA"
      decimals="INF"
      id="Tc_khacn_CpKkCj7LMpNv08RA_5_7"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_FRRTD6E8_UWc7CqpvzLbPA"
      decimals="-3"
      id="Tc_NktHRmJZWki2PnoYz3q1HA_5_9"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">6000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_WWey9zxoakaXp0S1ZYs4vg"
      decimals="INF"
      id="Tc_rLqlh3NOAU6cF_WUTjUMVg_6_7"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">0.16</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_WWey9zxoakaXp0S1ZYs4vg"
      decimals="-3"
      id="Tc_l5wyGU8N2kOGIlYV-iaMPA_6_9"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">313000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_lI6dv2jX_EWXRmyQX2VxXw"
      decimals="INF"
      id="Tc_oc7jeAJXOEihf6eR-VhtBA_7_7"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">9.136</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_lI6dv2jX_EWXRmyQX2VxXw"
      decimals="-3"
      id="Tc_3pOOow48sUa1dVM9Wx0OzA_7_9"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">534000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_kfeh-8yR4k-MMGH2ApsgLQ"
      decimals="INF"
      id="Tc_IaN1VnW04Eerr2shWvZWXw_8_7"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">51.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_kfeh-8yR4k-MMGH2ApsgLQ"
      decimals="-3"
      id="Tc_9M4tuiwPdEy96ct--tw8_Q_8_9"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">5000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_ArmisticeCapitalMasterFundMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_mhbEOSMN9E-6fQNPjBHEBg"
      decimals="INF"
      id="Tc_j6uEPsnAZ0qLVTD1cN3flQ_9_7"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_ArmisticeCapitalMasterFundMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_mhbEOSMN9E-6fQNPjBHEBg"
      decimals="-3"
      id="Tc_o__pnvJOmk25lX47AIgFFQ_9_9"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">846000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_HeightsCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_gmwEIZ8DKkiPWDp5YfOhFg"
      decimals="INF"
      id="Tc_PVQY4A9QmkqBjmYz2_2Qvw_10_7"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_HeightsCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_gmwEIZ8DKkiPWDp5YfOhFg"
      decimals="-3"
      id="Tc_8HiCHTa-4UKeP1qGVxnoHw_10_9"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">27000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_HudsonBayCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_McrVOhYGbEC_tS_1BvXkKg"
      decimals="INF"
      id="Tc_aQ5_UQJqcUyGWjrajM5WZQ_11_7"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_HudsonBayCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_McrVOhYGbEC_tS_1BvXkKg"
      decimals="-3"
      id="Tc_CMLxpyV3gUSYd5OjuS2JIg_11_9"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">27000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_IntraCoastalCapitalMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_b02B55BM6EG9d7CRINubvQ"
      decimals="INF"
      id="Tc_cbFh_RUsOUO2i6N0Oj2qbQ_12_7"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_btai_IntraCoastalCapitalMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_b02B55BM6EG9d7CRINubvQ"
      decimals="-3"
      id="Tc_xcAirjtQ6kibcgbGhUgQUQ_12_9"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">13000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_1LqgdJglcUGaBJlfQgrsyg_13_9"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">1792000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_V2jj_eDlt0q_u0vXSYoyKQ"
      decimals="-3"
      id="Narr_IfCNEcr2FU2hlNh1v4Z5rA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">3245000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_0FNSOQxNAE-0IkMjsa2iKA"
      decimals="2"
      id="Narr_zP7CztmVwkqsSwGcGdp30g"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">320.64</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_hovoRwmQvEeyatpC8QBdeQ"
      decimals="2"
      id="Narr_mlPb1kSkSE2a8sx_ViDzRQ"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">238.88</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember__BmWodN8tEOta3SjGS5jbg"
      decimals="2"
      id="Narr__mNGtxWtlkGV9jwprWfhxA"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.95</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_goRVwXyuWUydp4Kjx4bF3w"
      decimals="0"
      id="Narr_H_dSYWfo3UO5tUI1t18kXg"
      unitRef="Unit_Standard_Y_HWoZmdDBn0OhfgBS6ig-MA">7</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Cs-w0dC4c0WGpoXT9tdaBw"
      decimals="4"
      id="Narr_CB4BlM8pik2Ehkv01A6JWQ"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.0295</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_uPbZgXmXZUiSsb-dyLE4HA"
      decimals="4"
      id="Narr_EtwfBFxgZUa46iuthVrw5g"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">58.3232</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_V2jj_eDlt0q_u0vXSYoyKQ"
      decimals="2"
      id="Narr__cK1r9nU_0CeQxSGmsl_3A"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">320.64</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_uPbZgXmXZUiSsb-dyLE4HA"
      decimals="4"
      id="Narr_bPV52s73f0yqgKJ174viNg"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">58.3232</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_V2jj_eDlt0q_u0vXSYoyKQ"
      decimals="-3"
      id="Narr_fotGYMvTQESYtKKjO86hbA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">548000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_uPbZgXmXZUiSsb-dyLE4HA"
      decimals="-3"
      id="Narr_sRQkVBEN4UWb3-IdeYEqrw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">802000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="Duration_12_5_2023_To_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_3RWlGpXOtESBeWP1E_X8Xw"
      decimals="-3"
      id="Narr_CZh6qz6mSUy_uM5i5VDXwg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">254000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_W5J6mPqvkkqYc6G6pFfyUQ"
      decimals="-3"
      id="Narr_BnCCiLg7WU23yDMf3k7Plw"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">4000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_W5J6mPqvkkqYc6G6pFfyUQ"
      decimals="INF"
      id="Narr_m4HXoHg4wUiRO0p8LnBRDg"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">58.3232</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_W5J6mPqvkkqYc6G6pFfyUQ"
      decimals="-3"
      id="Narr__knjBFoulEaroamvQyRXJQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">200000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_c4v5KMKYk0ChF42pkKq26w"
      decimals="INF"
      id="Narr_G2sS02W_Wkuv_yEX0EelPg"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">58.3232</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_CGrKS2JtHkaQ1g9h6LmHqw"
      decimals="INF"
      id="Narr_SNj66793hUKMLXO3HZ2BSA"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">59.36</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_oWedOZ60s0mXTRW5Lcn6Tg"
      decimals="2"
      id="Narr_3bIZgG3ucE2EOP4vTElLsg"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.99</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_1xcAi6iP-EO-REO2QzswUQ"
      decimals="1"
      id="Narr_Xm0_YFWzJUKLRLv6045P2w"
      unitRef="Unit_Standard_Y_HWoZmdDBn0OhfgBS6ig-MA">5.4</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_9G_zTSXx60uhtuDGxqBgBg"
      decimals="4"
      id="Narr_yPrpa08X7Ue2IF2ZF7t7Eg"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.0414</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_5ri5JcF8t06zRgfNuESzxQ"
      decimals="-3"
      id="Narr_y8OT7YHwV02pE0AulyKW2A"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">6000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_5ri5JcF8t06zRgfNuESzxQ"
      decimals="INF"
      id="Narr_Y0G5jgXw2UeW2ytvEM2o1Q"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">49.1568</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_5ri5JcF8t06zRgfNuESzxQ"
      decimals="-3"
      id="Narr_Q53NZogRvECoQNorDdMBkg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">224000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_qc0Go_Cfk020vCx7lAeh0w"
      decimals="INF"
      id="Narr_z5n40YCbDkmubmm_oEcc7Q"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">49.1568</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_yGOW9iQj6UGPG-rEriM09Q"
      decimals="2"
      id="Narr_jqFvNXxG70Gn8c4DkirsEQ"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">44.48</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_oLqCI4mI10aP6GWCCHFvVQ"
      decimals="3"
      id="Narr_KSf0yEzTlkCbdS9KvssB9Q"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">1.122</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_icjol4YP1kutdR0RMqnOew"
      decimals="0"
      id="Narr_RosgqvyR90WzF3BUZ8YBYQ"
      unitRef="Unit_Standard_Y_HWoZmdDBn0OhfgBS6ig-MA">5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_6kMEiu_1N06tYfLStTj0oQ"
      decimals="4"
      id="Narr_Z0yO87uCmEiRhUgXSDyvHA"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.0425</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_ULyHbDGAWkiYKXfDf_TeDQ"
      decimals="2"
      id="Narr_gb-Ev_EijU-GSpege_ZXiA"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_uPbZgXmXZUiSsb-dyLE4HA"
      decimals="4"
      id="Narr_RBQP2KWXWUKE4iqYng4-IA"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">58.3232</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_7Rf_XFQB_kmb6iMCoS8NYQ"
      decimals="INF"
      id="Narr_Q9c3QrYBPkmRO-Cl77c_Eg"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">49.1568</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_ULyHbDGAWkiYKXfDf_TeDQ"
      decimals="2"
      id="Narr_7uw-9rLv0EGdMv9iMVCkgw"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_7Rf_XFQB_kmb6iMCoS8NYQ"
      decimals="-3"
      id="Narr_fcTNiuT6qkakYX6Ajxyo-A"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">105000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_ULyHbDGAWkiYKXfDf_TeDQ"
      decimals="-3"
      id="Narr_StLHP9la0kGKQXvnerGnrw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">164000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_QAwpylSU5UyaB8Q_rrtbYQ"
      decimals="-3"
      id="Narr_cBXuh5ugYk-wE6cZMdWPxA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">59000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_oiu1ThMdnUOs-KiwIduWmQ"
      decimals="-3"
      id="Narr_NnWQ-LhmyUW-an7iLxWVQg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">19347000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_cLng8ai8UkazAQbJGlFaNQ"
      decimals="2"
      id="Narr_ZpSP8ej5Fk6cwKk16ZBHNg"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">51.2</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_u9-8OCpVJkG9nsYV-XtccA"
      decimals="2"
      id="Narr_0UccDEgA9kCqb9S7ZzQg_w"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">44.96</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_mLs5yiiHEkCXZbPPpDd3Ow"
      decimals="3"
      id="Narr_DaFlzXFFUkK5PuN6j-8lig"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">1.122</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_jgX2LEyonkeD7lRM74FyMQ"
      decimals="0"
      id="Narr_BrSsBC3Dx0-asrBzmfF6_Q"
      unitRef="Unit_Standard_Y_HWoZmdDBn0OhfgBS6ig-MA">5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_p6z9MJatyUSUOiTjIZSLJA"
      decimals="4"
      id="Narr_ofZvfnDtcUKNIj9sQKOgiQ"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.042</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_T6cTQVW5iEu7v6aQO3r8Lg"
      decimals="-3"
      id="Narr__TXsu-IPaEimVO85SB3W4Q"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">534000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_tnK7lRA_PkmprsVLffcXvQ"
      decimals="-3"
      id="Narr_DqoV2NEFe02IFVz8hmPYYA"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">539000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_P_lWwiR8M0e2d17J1qElcg"
      decimals="3"
      id="Narr_qdIqWh38i0G1gHvtfPAfug"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">9.136</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_11_25_2024_To_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_355-JNdbG0a2GsWONO9ZWw"
      decimals="-3"
      id="Narr_k_5unHlIckqoTJ8hQdUKrw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1000000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_JBeXWTEcBki5v7foWKB49w"
      decimals="-3"
      id="Narr_zKMZsAAXi0Wy94W8AWjTAQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2320000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_5eL_-_utPUCNyy4fj-GOyA"
      decimals="-3"
      id="Narr_N5bS-PTwqkKntQs2kPSCJQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">17027000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_11_25_2024_To_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_355-JNdbG0a2GsWONO9ZWw"
      decimals="-3"
      id="Narr_XrFAt-RjR0CjUYEj3PtQIw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1000000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_B-Y0cXQAQ0Sb_-x7Pz9oew"
      decimals="3"
      id="Narr_XRXRxeKOpE2xKmXwmrjruQ"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">9.136</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_V0NHkt3bfk2Ba2s21MfECQ"
      decimals="2"
      id="Narr_WAlyBo_Yq0uVB1mmWsXGWw"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">51.2</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_lI6dv2jX_EWXRmyQX2VxXw"
      decimals="-3"
      id="Narr_sSslnN4dKkWcqeMPd3gZyA"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">534000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_kfeh-8yR4k-MMGH2ApsgLQ"
      decimals="-3"
      id="Narr_qowBgTDF4kWjnQGVAmWH6Q"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">5000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_387uYLHD2EqiYkh3ZygEsA"
      decimals="3"
      id="Narr_rMwtYr_WeUCDVJVcoS5X1g"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">5.984</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_mCar_ZgvpEWSra0NQcz42g"
      decimals="4"
      id="Narr_j5Il53NgZkWo78JNjsTElw"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">1.123</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_7e_v0kd2N0eBHM_SA31z7g"
      decimals="1"
      id="Narr_X-cR1tZ2hkGRC-l7uTXOig"
      unitRef="Unit_Standard_Y_HWoZmdDBn0OhfgBS6ig-MA">4.2</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_S1WaCx3EFEyAR8UWU9J9zA"
      decimals="4"
      id="Narr_4Ubumsl_4kuybKlJ_qLmwg"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.044</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_DdDbFFCDBE64P_O4BJl7kA"
      decimals="-3"
      id="Narr_5uyBc8Eadked2Nd13wRTUg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">5562000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_T8m7TXv_3kCCweETb2zyjw"
      decimals="2"
      id="Narr_efH-sfKzf02lYz5EQBKyDw"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">7.68</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_OQu-LcOiKkqIepIPSq1fgg"
      decimals="2"
      id="Narr__8YQ7lahJ0Gf0FSvTifIig"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">7.52</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_nUBe9GYzxE-ZmBiqq4O37Q"
      decimals="4"
      id="Narr_yC_qJaIBRkyPHw1RIeWXow"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">1.125</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_k8T7cHsMIUGhoBLO_zrk7Q"
      decimals="0"
      id="Narr_0RYn7FdBy0q7Io2TeWAmLA"
      unitRef="Unit_Standard_Y_HWoZmdDBn0OhfgBS6ig-MA">5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_qJT7c0kn9Eu2AFMTvKrocQ"
      decimals="4"
      id="Narr_DIrjVNwM5kC_VacEBjAuZg"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.042</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_XYejg84PY0-8-DI1vMLBvw"
      decimals="-3"
      id="Narr_WdwZDbTpP0qxET1IkNyr1w"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">4273000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_p63njE8R7Eu_9LSZHS_XWw"
      decimals="-3"
      id="Narr_N67ZcGyW306eJXZwcyOzGQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1289000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_P_XszpuZj0GQUjB1hTtEgw"
      decimals="2"
      id="Narr__diLg1yyhECOyd9ObjVFZg"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_2mozctssp0KbH0y09FoRew"
      decimals="3"
      id="Narr_khp_xIDqMUi1OxFRzUto7A"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">5.984</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_OG-f8LWXVEuAP6w4PvNKlQ"
      decimals="4"
      id="Narr_CIUwvQ8yM0a81OD8Zv0Kjg"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">1.123</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_6A5TfvgGDkyeNTAS_CDIyA"
      decimals="1"
      id="Narr_iTSQ1B0YaU2wj3w8wv_bJw"
      unitRef="Unit_Standard_Y_HWoZmdDBn0OhfgBS6ig-MA">4.9</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_SeVI2KEJJkaPytkbFhDmdg"
      decimals="4"
      id="Narr_etNGQiazv0G7UEfncxuYKw"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.044</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_48gd2FjgdU6bDWyknSslHQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;16. Income Taxes &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The significant components of the Company's net deferred tax assets at December 31, 2024 are shown below. In determining the realizability of the Company's net deferred tax assets, the Company considered numerous factors, including historical profitability, estimated future taxable income, and the industry in which it operates. Based on this &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;information the Company has provided a valuation allowance for the full amount of its net deferred tax asset because the Company has determined that it is more likely than not that they will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Federal net operating losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 90,853&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,770&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State net operating losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,152&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,255&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,915&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,188&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,048&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized research &amp;amp; development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,377&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 49,603&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 202&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 103&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Lease accounting - liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 212&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Disallowed charitable contributions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Deferred Costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 674&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cancellation of debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,483&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (192,149)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (173,679)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 197&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Debt amendment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (500)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Unrealized loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (100)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (185)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (600)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (197)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Net deferred tax asset (liability)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The income tax expense/(benefit) for the year ended December 31, 2024 differed from the amounts computed by applying the U.S. federal income tax rate of 21% to loss before tax benefit as a result of tax credits generated and changes in the Company&#x2019;s valuation allowance. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;A reconciliation between the Company&#x2019;s effective tax rate and the federal statutory rate are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,516)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37,601)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 381&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (573)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant mark-to-market&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,238)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal and state credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,870)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,082)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (343)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,261)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 116&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,210&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,470&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (31.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,307&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (30.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;At December 31, 2024 the Company had approximately $432,634 of gross federal and $443,454 of gross state net operating loss carry-forwards. If not utilized, the federal and state net operating loss carry-forwards will begin to expire in 2037. The federal net operating loss of $429,988&lt;span style="white-space:pre-wrap;"&gt; incurred after December 31, 2017 will carryforward indefinitely.  The utilization of such net operating loss carry-forwards and realization of tax benefits in future years depends predominantly upon having taxable income. The Company has approximately &lt;/span&gt;$15,965 of federal orphan drug credits and research and development credits which will begin to expire in 2037 if not utilized. The Company also has approximately $1,548 of state research and development credits which will begin to expire in 2040 if not utilized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Utilization of the NOL and research tax credit carryforwards may be subject to a substantial annual limitation due to ownership limitations that has occurred or that could occur in the future, as required by section 382 of the Code, as well as similar state and foreign provisions.  These ownership changes may limit the amount of the NOL and research credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively.  In general, an &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;"ownership change" as defined by Section 382 of the Code results from a transaction or series of transactions over a three year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a by certain stockholders or public groups.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax positions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of December&#160;31, 2024, there were no uncertain positions. The Company's U.S. federal and state NOLs have occurred since its inception in 2017 and as such, tax years subject to potential tax examination could apply from that date because the utilization of net operating losses from prior years opens the relevant year to audit by the U.S. Internal Revenue Service and/or state taxing authorities. The Company did not have any unrecognized tax benefits and has not accrued any interest or penalties for the years ended December 31, 2024 and 2023. &lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_IAzJQcoBHkWBEJx-exTqyA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Federal net operating losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 90,853&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,770&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State net operating losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,152&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,255&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,915&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,188&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,048&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized research &amp;amp; development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,377&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 49,603&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 202&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 103&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Lease accounting - liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 212&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Disallowed charitable contributions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Deferred Costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 674&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cancellation of debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,483&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (192,149)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (173,679)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 197&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Debt amendment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (500)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Unrealized loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (100)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (185)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (600)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (197)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Net deferred tax asset (liability)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_-aYLNdByDESEKKntkq4VSQ_4_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">90853000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_o5FxJw8PtEuCAylzvTQgQA_4_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">73770000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_00-IfM6KBUW4RvWETNYXzQ_5_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">23152000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_pCNFJQrtQkOtklShtHNGew_5_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">21255000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_--3eNQs0xkencSY8k5e5rQ_6_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">14601000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_0_PIlG-S-EOrjVHcliBIfA_6_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">13915000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_i6eGEyNDnUeQN1eyCNgjlQ_7_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">17188000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_u7RlniXCrkayKcdA94J0PA_7_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">15048000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_PBXkb5TehkaDHbQMpAsW8w_8_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">44377000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_ih9PBMTHlkSXa4HQfARhXQ_8_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">49603000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_NzRlTFkvt0CxU-GFTibREg_9_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">202000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_QesD3uUYWEWQlL_7D4dlaA_10_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">103000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_5WDGZY75ck-D0l5QC10Osw_10_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">73000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <btai:DeferredTaxAssetsLeaseAccountingLiability
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_-10ExVHU0EaMizVeZ3x8Fg_11_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">115000</btai:DeferredTaxAssetsLeaseAccountingLiability>
    <btai:DeferredTaxAssetsLeaseAccountingLiability
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_pXN4arWqF0iTXtfevTav8g_11_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">212000</btai:DeferredTaxAssetsLeaseAccountingLiability>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_2VwnwSArGk2CFADqugUW9g_12_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <btai:DeferredTaxAssetsCapitalizedIpoCosts
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_BEgPqcegfkiV3_cqWf1Ahg_13_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">674000</btai:DeferredTaxAssetsCapitalizedIpoCosts>
    <btai:DeferredTaxAssetsCancellationOfDebt
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_B8Uj-QWUBE-Xkh62U4If0w_14_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1483000</btai:DeferredTaxAssetsCancellationOfDebt>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_kyDdec1tSUub8ADb_aKOUQ_15_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">192149000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_CXeEg040HE6KkkmDiZwzuw_15_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">173679000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_cQSrmDx-eke8TpZPDlxiYg_16_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">600000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_tqc0A1U1t0iBdRMbd4mdWw_16_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">197000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_b4mc_RnCI0G37KYegAmgFg_18_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">500000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts>
    <us-gaap:DeferredTaxLiabilitiesDerivatives
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc__H1lXtpbfkeMeHMt1L5Czw_19_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">12000</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_OToRdRsRqEeqIZ7nadBEvg_20_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">100000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_2YbJse8YxEuMJkJD7jkYkg_20_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">185000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Tc_4gNZgQOg00iPq4IzxfVqug_21_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">600000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Tc_eZt5ZTLx0UCROKg2kldg8w_21_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">197000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="2"
      id="Narr_Hzh8sOLj0kG-5XtLulvqWg"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_VlyBtO7DsEmYhEA5gYk39A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,516)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37,601)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 381&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (573)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant mark-to-market&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,238)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal and state credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,870)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,082)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (343)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,261)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 116&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,210&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,470&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (31.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,307&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (30.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_b99KLTJSyE6QrIIzYi_u7g_2_2"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-12516000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="3"
      id="Tc_Qcm3z3HGjUCxTIq_jJqOWg_2_4"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_Z-eh5BYXPE62WdhgFsjRKg_2_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-37601000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="3"
      id="Tc_4y2Ngrkxg0iJJuI90OZzTA_2_9"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_IHmg61sfBkiEbDlu-jRk7A_3_2"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">381000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="3"
      id="Tc_EKfUfFBYi0SwqLjLajG34Q_3_4"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_797SceW4b0iWsGEIY1dHxw_3_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-573000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="3"
      id="Tc_x0ywU-OZwkWCM8j-wtE24A_3_9"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <btai:EffectiveIncomeTaxRateReconciliationWarrantValuationAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_zpP6vFXCJkCxYJCbz-QfJQ_4_2"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-4238000</btai:EffectiveIncomeTaxRateReconciliationWarrantValuationAmount>
    <btai:EffectiveIncomeTaxRateReconciliationWarrantValuationPercent
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="3"
      id="Tc_4C0CdyAoLE6iElYBi540hA_4_4"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.071</btai:EffectiveIncomeTaxRateReconciliationWarrantValuationPercent>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_DCzqP88Yf0SdauwaXdS79A_5_2"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1870000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="3"
      id="Tc_ZCtMq8JnUUy3QbTA3lOofg_5_4"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">-0.032</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_xuOGaCCNhEOgrtbtAHlTgg_5_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">4082000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="3"
      id="Tc_aW8LiEm9q0ySdCRHG_vD6w_5_9"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">-0.023</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_9cHFXIn5sUiP33Hia2UVXg_6_2"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-343000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="3"
      id="Tc_4K436LkfnU6Pnz8HK4LTMg_6_4"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_CqESKsHk60eRt9OJLJdeFw_6_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-14261000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="3"
      id="Tc_buSR0qjOQEy_2nSA0F9QfQ_6_9"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0.08</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_QdFnc5s-Fk61TzcD17G6-Q_7_2"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">116000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="3"
      id="Tc_ltJ_sxKTfkuChxpuZsT8ag_7_4"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_mOeyn9HLTU-TWrsCIQP7WA_7_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1210000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="3"
      id="Tc_HGyBbVa9Lk67u0DXhO7EFg_7_9"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_BMnS8KarjUOQ5eooSgnSdA_8_2"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">18470000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="3"
      id="Tc_I54ulXiMdUy6HL_u8tAlUQ_8_4"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">-0.31</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_bWtA4ZBfsEiJczC7V964Bw_8_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">55307000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="3"
      id="Tc_AsAzc_N_KEaCRxg5ektE3A_8_9"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">-0.309</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_XgcGESru60uMR_gvJHuMng_9_2"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="3"
      id="Tc__RKihOyc1Uy9Jyb4d-4ePQ_9_4"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_k2yXXbtZcUu4-eX1lnOc4Q_9_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="3"
      id="Tc_BvBayO8PxkimGxQqCV2g6Q_9_9"
      unitRef="Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_WgBqcPiqCk2sU5U9HArJCg"
      decimals="-3"
      id="Narr_xRKEydazU0-iG01pRCksCg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">432634000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_QcDNt3XBCU29K3TtzRineQ"
      decimals="-3"
      id="Narr_HIhJSAARY0aIRqHzuc47oA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">443454000</us-gaap:OperatingLossCarryforwards>
    <btai:OperatingLossCarryforwardsNoExpiration
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_WgBqcPiqCk2sU5U9HArJCg"
      decimals="-3"
      id="Narr_f4tWTzQBYUifGIvAvgi9fQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">429988000</btai:OperatingLossCarryforwardsNoExpiration>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_WgBqcPiqCk2sU5U9HArJCg"
      decimals="-3"
      id="Narr_4OW40Uiv2k23DEHqPwtzJw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">15965000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_QcDNt3XBCU29K3TtzRineQ"
      decimals="-3"
      id="Narr_uQG4vDnRQkGI97Xh5aVJ0Q"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1548000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Narr_54RjO3puV0Oo_-DzGrfn4g"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Narr_tuJToK8tV0-KR9wiMC8XLw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ"
      decimals="-3"
      id="Narr_i3kICxQCL0iUZHR4t0aNAQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ"
      decimals="-3"
      id="Narr_x0M-NhxW0kqMhivWmM8a4Q"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_aszjcJ4lUUK1qgQmIFp9mA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 17. Net Loss Per Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Basic and diluted net loss per share are as follows&lt;/span&gt;:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss (numerator)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (59,599)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (179,053)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average shares (denominator)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,535&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,821&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted net loss per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (23.51)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (98.33)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Potentially dilutive securities outstanding consists of stock options, RSUs and performance units, and BTI warrants. The Company had common stock equivalents outstanding are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 311&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 311&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Performance stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;BTI Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,792&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total common stock equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 376&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_AUYZG1VJ00e_EU0jy_pwOQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss (numerator)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (59,599)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (179,053)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average shares (denominator)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,535&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,821&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted net loss per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (23.51)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (98.33)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_GcNlUIjM6UqLUOFmdQMAlQ_5_3"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-59599000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc__62zOC11IkaZX3V4INfqxQ_5_6"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-179053000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_QsM5_28TeUGNpi1Wd23Z4A_6_3"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">2535000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_xBJe3XurZEuM6tdWrjqbiQ_6_6"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">1821000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="2"
      id="Tc_mu-6FZvUdEar2ChaXrevbw_7_3"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">-23.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="2"
      id="Tc_wIjEUQeVHEObyGQnEh3OHQ_7_6"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">-98.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_V2TmzLxX90GaVJhLgyqABA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 311&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 311&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Performance stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;BTI Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,792&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total common stock equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 376&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_uVcJZBaEUU2RieeIBXowxA"
      decimals="-3"
      id="Tc_PW61Q56hLkmicjq9lZ7zZg_5_3"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">311000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_1Vg-MGOfMUG52-OKD_lr3Q"
      decimals="-3"
      id="Tc_qSzpjeeEfkKFhy6WfcubSA_5_6"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">311000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_8wNKxgPGRUu5CFwHgwGsEw"
      decimals="-3"
      id="Tc_qe3u61zynEiEm9akqIwhJA_6_3"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">27000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_lFtYhgCxvUaKZc-Y-rTpsQ"
      decimals="-3"
      id="Tc_7MMisImvLEiaWmZK6V-w3A_6_6"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">12000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_a-yRAQ6nhkmrbi3aQ6cBLw"
      decimals="-3"
      id="Tc_sA-rgOrPdkqipnWtq_WO5A_7_3"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">70000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_ufIYMMNpvEWk__kIwMRFvA"
      decimals="-3"
      id="Tc_5ShsUn-BTUu8LlTJCXVnxw_7_6"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">31000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_btai_BioxcelWarrantsAggregateMember_D-VgH0D5EkWR5T5lmAPfSQ"
      decimals="-3"
      id="Tc_0Mhy_Lu7AE2UCTJHN3Qs8Q_8_3"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">1792000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_btai_BioxcelWarrantsAggregateMember_yQW7FSPMyU-tXyPdIkz20Q"
      decimals="-3"
      id="Tc_VMlHxkqiukuNs_jHXlnFDQ_8_6"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">22000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_Cmz-QKhW60em3tPfV7z50Q_9_3"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">2200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_Oi0BuD5DwEatsFn0jtvlJw_9_6"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">376000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_CHLjQEC-OkOmSORwZuLAwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 18. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;From time to time, in the ordinary course of business, the Company may be subject to litigation and regulatory examinations as well as information gathering requests, inquiries and/or investigations. Other than the below, the Company is not currently subject to any matters where it believes there is a reasonable possibility that a material loss may be incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On July 7, 2023, plaintiff Katelyn Martin filed a class action complaint against the Company and certain executives in the United States District Court for the District of Connecticut, captioned &lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Martin v. BioXcel Therapeutics, et al.&lt;/i&gt;&lt;span style="background:#ffffff;"&gt;, 3:23-cv-00915 (D. Conn). &lt;/span&gt;The case has since been renamed to &lt;i style="font-style:italic;"&gt;Hills et al v. BioXcel Therapeutics, Inc. et al&lt;/i&gt;. &lt;span style="background:#ffffff;"&gt;On October 4, 2023, pursuant to the Private Securities Litigation Reform Act, the court appointed two co-Lead Plaintiffs. The co-Lead Plaintiffs filed an amended complaint on December 5, 2023, alleging violations of Sections 10(b) and 20A of the Securities and Exchange Act of 1934 (the &#x201c;Exchange Act&#x201d;) and SEC Rule 10b-5 promulgated thereunder. On July 11, 2024, the Court dismissed the amended complaint without prejudice and, on August 1, 2024, co-Lead Plaintiffs filed a second amended complaint. The second amended complaint alleges that defendants made false or misleading statements regarding the TRANQUILITY II trial and the development of BXCL501 for an expanded indication related to the &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;background:#ffffff;"&gt;treatment of certain Alzheimer&#x2019;s-related agitation. The Company moved to dismiss the second amended complaint on September 6, 2024. On February 24, 2025, while the Company&#x2019;s motion to dismiss remained pending, Plaintiffs moved for leave to further amend their complaint. The Company filed an opposition to the motion on March 17, 2025. Plaintiffs&#x2019; reply is due April 7, 2025.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On November 28, 2023, Plaintiffs Pratheesan Panancherry and Jeffrey Bastress filed a stockholder derivative complaint in the United States District Court for the District of Connecticut purportedly on behalf of the Company and against Vimal Mehta, Richard I. Steinhart, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption &lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Panancherry et al v. Mehta et al&lt;/i&gt;&lt;span style="background:#ffffff;"&gt;, 3:23-cv-1554. Following the initial action, Plaintiffs Maria Vomvolakis (3:24-cv-3) and Kelly Fowler (3:24-cv-203) each filed separate stockholder derivative complaints in the District of Connecticut raising similar claims as Panancherry and Bastress, including business torts and violations of the Securities Exchange Act of 1934. The cases have been consolidated under the caption &lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;In re BioXcel Therapeutics, Inc. Stockholder Derivative Litigation&lt;/i&gt;&lt;span style="background:#ffffff;"&gt;, 3:23-cv-1554 (D. Conn.). The consolidated action is currently stayed.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On January 11, 2024, Plaintiff Jeremy Smith filed a stockholder derivative complaint in the United States District Court for the District of Delaware purportedly on behalf of the Company and against Vimal Mehta, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, Richard I. Steinhart, Robert Risinger, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption &lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Smith v. Mehta et al,&lt;/i&gt;&lt;span style="background:#ffffff;"&gt; 1:24-cv-00041. Following the initial action, Plaintiff Janice Korff filed a stockholder derivative complaint in the District of Delaware raising similar claims as Smith (1:24-cv-130), including business torts and violations of the Securities Exchange Act of 1934. The cases have been consolidated under the caption &lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;In re BioXcel Therapeutics, Inc. Derivative Litigation&lt;/i&gt;&lt;span style="background:#ffffff;"&gt;, 1:24-cv-00041 (D. Del.). The consolidated action is currently stayed.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;At this time, the Company does not believe the claims in the above-captioned matters have merit, and intends to vigorously defend against them; however, the potential costs and liabilities associated with this litigation are uncertain.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;In April 2022, the Company signed a commercial supply agreement that requires minimum annual payments for the first three years of the agreement that in aggregate total &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$10,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; for the &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;three-year&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; period, of which &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$5,000&lt;/span&gt;&lt;span style="white-space:pre-wrap;background:#ffffff;"&gt; was originally due in year ended 2024.  On July 11, 2024, the Company entered into an amendment to the commercial supply agreement (the &#x201c;Product Supply Agreement Amendment&#x201d;) that reduces the specified minimum annual payment over the next three years starting in the year ended 2024 and, thereafter, for a specified interval, provides for minimum annual payments to the extent that the Company receives approval of a supplemental new drug application (sNDA) or a new drug application (NDA) from the FDA for enumerated indications. The Company&#x2019;s renegotiated agreement reduced the minimum commitment for 2024 to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; and thereafter for the term of the agreement in annual amounts ranging from &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$2,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$5,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; subject, in certain instances, to the extent that the Company receives approval of an sNDA or NDA from the FDA for enumerated indications. In accordance with the Product Supply Agreement Amendment, the minimum commitments were reduced to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;, &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$2,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$2,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; in the years 2024, 2025, and 2026.&lt;/span&gt; &lt;span style="background:#ffffff;"&gt;In addition, the Company agreed to make a reconciliation payment of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1,200&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;, paid in the third quarter of 2024 for full settlement for amounts due prior to the July 11, 2024 amendment.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="Duration_4_1_2022_To_4_30_2022_AGdwF45rAUaEqJM-M8UB2g"
      decimals="-3"
      id="Narr_Nowc3FRmWEiVzRzRUcEJxg"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">10000000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:LongtermPurchaseCommitmentPeriod
      contextRef="Duration_4_1_2022_To_4_30_2022_AGdwF45rAUaEqJM-M8UB2g"
      id="Narr_6f-4VtPZMUu4v0HpIrfK4A">P3Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
      contextRef="As_Of_4_30_2022_Zfgyqm8oPECQksmotjQKJw"
      decimals="-3"
      id="Narr_OOhLULeKRkCCJ8Ifx29enQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">5000000</us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear>
    <us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
      contextRef="As_Of_7_11_2024_M-RCVSP_HEGMyNg657_jKg"
      decimals="-3"
      id="Narr_zxZ_xY9ZKUiP0v2FFGUvDQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1000000</us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="Duration_7_11_2024_To_7_11_2024_srt_RangeAxis_srt_MinimumMember_l8F9i5yxlk2GrsHmZ41AHQ"
      decimals="-3"
      id="Narr_jUkqeiYjk0mKaoOe20jN6Q"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2000000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="Duration_7_11_2024_To_7_11_2024_srt_RangeAxis_srt_MaximumMember_MahkWQ1D0kWY8CGoanrcrQ"
      decimals="-3"
      id="Narr_zlTDSjxSTkGU-6Nyq95_ew"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">5000000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
      contextRef="As_Of_7_11_2024_M-RCVSP_HEGMyNg657_jKg"
      decimals="-3"
      id="Narr_ErlXrWBmH0yzQ1DwA4Q0YA"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1000000</us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_7_11_2024_M-RCVSP_HEGMyNg657_jKg"
      decimals="-3"
      id="Narr_QtBhqDigdEO8ibV3NVteqw"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2000000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="As_Of_7_11_2024_M-RCVSP_HEGMyNg657_jKg"
      decimals="-3"
      id="Narr_jFARImbbYkKa7zNVq-SgCQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2000000</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract
      contextRef="Duration_7_1_2024_To_9_30_2024_UmSoTOy6ZEqdvjDqQLaKEw"
      decimals="-3"
      id="Narr_3zhFol5FQ0KFVi355dgNpQ"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1200000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_88ypPxPhg0OEUE-YNOneJg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 19. Segment Information&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company views its operations and manages its business as one operating and reportable segment, utilizing artificial intelligence (&#x201c;AI&#x201d;) to develop transformative medicines in neuroscience and immuno-oncology. We are focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients&#x2019; lives. We employ various AI platforms to reduce therapeutic development costs and potentially accelerate development timelines. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Consistent with the operational structure, the Chief Executive Officer, as the chief operating decision maker (&#x201c;CODM&#x201d;), reviews weekly cash usage and allocates resources based on consolidated net loss that also is reported on the consolidated statements of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets. The CODM utilizes consolidated net loss by comparing actual results against budgeted amounts on a quarterly basis. As part of this process, consolidated net loss is a critical performance measure used to evaluate the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Company&#x2019;s operating performance and guide strategic decisions and resource allocations, including additional investments in research and development and commercialization activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following table provides information about the Company&#x2019;s one reportable segment and includes the reconciliation to consolidated net loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Product revenue, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,266&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,380&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,143&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,260&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Personnel and related costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,351&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Non-cash stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,324&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,067&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,590&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Clinical trials expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,384&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,094&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Chemical, manufacturing and controls cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,927&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,687&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,010&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,280&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,435&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,326&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Personnel and related costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,516&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,331&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Non-cash stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (401)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,081&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 554&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 965&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Commercial and marketing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,389&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,485&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Travel related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 309&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,004&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,038&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Total commercial costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,273&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,904&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Selling, general and administrative costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Personnel and related costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,340&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,840&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Non-cash stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,306&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,209&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,583&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,345&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Commercial and marketing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Travel related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 446&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 982&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,544&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,133&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Total selling, general and administrative costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45,509&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restructuring costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,441&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,163&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69,511&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 173,162&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other (income) expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,129&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,314&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,602)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,649)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Other (income) expense, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20,173)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (394)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Segment net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (59,599)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (179,053)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Adjustments and reconciling items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Consolidated Net Loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (59,599)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (179,053)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="INF"
      id="Narr_mgr_hkifLES4Bpb8bNas7w"
      unitRef="Unit_Standard_segment_u3k5mJIKoECDA2MsRZB6Gg">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="INF"
      id="Narr_V89GXYh-RkS6Fb2pTYZuLw"
      unitRef="Unit_Standard_segment_u3k5mJIKoECDA2MsRZB6Gg">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_0O0Klvog0UqvgKunFBQGfQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Product revenue, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,266&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,380&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,143&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,260&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Personnel and related costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,351&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Non-cash stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,324&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,067&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,590&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Clinical trials expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,384&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,094&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Chemical, manufacturing and controls cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,927&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,687&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,010&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,280&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,435&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,326&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Personnel and related costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,516&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,331&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Non-cash stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (401)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,081&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 554&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 965&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Commercial and marketing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,389&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,485&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Travel related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 309&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,004&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,038&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Total commercial costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,273&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,904&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Selling, general and administrative costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Personnel and related costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,340&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,840&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Non-cash stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,306&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,209&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,583&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,345&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Commercial and marketing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Travel related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 446&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 982&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,544&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,133&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Total selling, general and administrative costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45,509&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restructuring costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,441&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,163&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69,511&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 173,162&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other (income) expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,129&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,314&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,602)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,649)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Other (income) expense, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20,173)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (394)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Segment net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (59,599)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (179,053)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Adjustments and reconciling items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Consolidated Net Loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (59,599)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (179,053)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_GuQvf4ivIEaez-H_oGkY9w_4_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2266000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_R-pypFpH5E6zn9aRGgGq5g_4_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1380000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_9Tf5q6M1BEeHyWeoisbnYQ_6_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2143000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_U4MDeMhkTk2huujaL1jW1w_6_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1260000</us-gaap:CostOfGoodsAndServicesSold>
    <btai:ResearchAndDevelopmentExpenseLaborAndRelatedExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_so_hNCyaqUSV8hd696KMVA_8_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">9796000</btai:ResearchAndDevelopmentExpenseLaborAndRelatedExpense>
    <btai:ResearchAndDevelopmentExpenseLaborAndRelatedExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_37M693IcZ0qUqX6wBFgm3A_8_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">16351000</btai:ResearchAndDevelopmentExpenseLaborAndRelatedExpense>
    <btai:ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_SJLbon_MG0SUAlePV7xZeA_9_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2251000</btai:ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense>
    <btai:ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_X-2dSv9IBEiU5I7d9Mwoug_9_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">6324000</btai:ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense>
    <btai:ResearchAndDevelopmentExpenseProfessionalFees
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_HVqMY44vxE-pyldN2JPykg_10_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">5067000</btai:ResearchAndDevelopmentExpenseProfessionalFees>
    <btai:ResearchAndDevelopmentExpenseProfessionalFees
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_lhh7YHBABUixMCJDCyYqrw_10_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">14590000</btai:ResearchAndDevelopmentExpenseProfessionalFees>
    <btai:ResearchAndDevelopmentExpenseClinicalTrialsExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_VUkdVeKlPkyOLc7-kHlxxA_11_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">9384000</btai:ResearchAndDevelopmentExpenseClinicalTrialsExpense>
    <btai:ResearchAndDevelopmentExpenseClinicalTrialsExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_VTa4TFIrQ0a9k2K4ElWb3Q_11_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">35094000</btai:ResearchAndDevelopmentExpenseClinicalTrialsExpense>
    <btai:ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_GdahhxyJfUukBKeqoyapiQ_12_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1927000</btai:ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense>
    <btai:ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_QXV9cx5V2kS1RJ4d9MEgrA_12_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">8687000</btai:ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense>
    <btai:ResearchAndDevelopmentExpenseTravelAndOtherExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_36rQcptcAEyhaUsHuwQCxg_13_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2010000</btai:ResearchAndDevelopmentExpenseTravelAndOtherExpenses>
    <btai:ResearchAndDevelopmentExpenseTravelAndOtherExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_rrh9RB63CU2MLyDB0cmJ4g_13_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">3280000</btai:ResearchAndDevelopmentExpenseTravelAndOtherExpenses>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_VP6VyV4aS0WxO1-9sAmjyw_14_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">30435000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_8FDKGXxkOEa-zmwVYli9Uw_14_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">84326000</us-gaap:ResearchAndDevelopmentExpense>
    <btai:CommercialCostsLaborAndRelatedExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_wlIqq0fes0aW1CcQ1E5adg_16_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2516000</btai:CommercialCostsLaborAndRelatedExpense>
    <btai:CommercialCostsLaborAndRelatedExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_2MtiVBnkZUCSEk4ahyWu9A_16_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">19331000</btai:CommercialCostsLaborAndRelatedExpense>
    <btai:CommercialCostsShareBasedPaymentArrangementExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_4zon9lBmUUevEGAJasA_TQ_17_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-401000</btai:CommercialCostsShareBasedPaymentArrangementExpense>
    <btai:CommercialCostsShareBasedPaymentArrangementExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_Nz4gtSgUhE2E6RhyY2vnzA_17_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1081000</btai:CommercialCostsShareBasedPaymentArrangementExpense>
    <btai:CommercialCostsProfessionalFees
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_zcw22piTV0-RlzMg0j0PSQ_18_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">554000</btai:CommercialCostsProfessionalFees>
    <btai:CommercialCostsProfessionalFees
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_INQPU3GUikWfRc2jUBLjvA_18_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">965000</btai:CommercialCostsProfessionalFees>
    <btai:CommercialCostsCommercialAndMarketing
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_mTQTLtQP_EKQxE_eYqc0Ng_19_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">1389000</btai:CommercialCostsCommercialAndMarketing>
    <btai:CommercialCostsCommercialAndMarketing
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_7yoIhSJI9E-tefvwX7E1Tw_19_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">12485000</btai:CommercialCostsCommercialAndMarketing>
    <btai:CommercialCostsTravelAndOtherExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_NpDqQKTN60qyd3u63PSXuQ_20_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">309000</btai:CommercialCostsTravelAndOtherExpenses>
    <btai:CommercialCostsTravelAndOtherExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_1MeQx3LtHUKWROLW8MMZHQ_20_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2004000</btai:CommercialCostsTravelAndOtherExpenses>
    <btai:CommercialCostsOtherExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_AXgZzPdjz0S64dQlK3aeRg_21_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">906000</btai:CommercialCostsOtherExpenses>
    <btai:CommercialCostsOtherExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_vlF4QWT0m0W09iaCwcm3sw_21_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2038000</btai:CommercialCostsOtherExpenses>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_ilMPDnV-Bk2ardNDySoywA_22_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">5273000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_omHITt1XZkyWlWHQTzauiA_22_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">37904000</us-gaap:OtherCostAndExpenseOperating>
    <btai:SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_c6uZ0r7vME267WXWWH8WUw_24_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">5340000</btai:SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense>
    <btai:SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_LZLvgRVXL0GscvDVozgBCA_24_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">7840000</btai:SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense>
    <btai:SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_RBER1YKJHU2eV8yEWelztA_25_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">4306000</btai:SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense>
    <btai:SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_xEnq1yu6wUOGaLpukPefkw_25_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">11209000</btai:SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense>
    <btai:SellingGeneralAndAdministrativeExpenseProfessionalFees
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_rA82zl4Og0yGfwWRLRNzuQ_26_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">15583000</btai:SellingGeneralAndAdministrativeExpenseProfessionalFees>
    <btai:SellingGeneralAndAdministrativeExpenseProfessionalFees
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_hRj-OBzwIUaic-yttb6JmQ_26_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">21345000</btai:SellingGeneralAndAdministrativeExpenseProfessionalFees>
    <btai:SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_GX2zMDjw4UaJoxkBmSfAYA_28_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">446000</btai:SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses>
    <btai:SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_Git4ZdgMBUCsJ4A2YkDYhg_28_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">982000</btai:SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses>
    <btai:SellingGeneralAndAdministrativeCostsOtherExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_RiWClZEE9kOZDhX2pW9iRQ_29_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">3544000</btai:SellingGeneralAndAdministrativeCostsOtherExpenses>
    <btai:SellingGeneralAndAdministrativeCostsOtherExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_uHAQ9-vvdEWGWpHINrFxhw_29_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">4133000</btai:SellingGeneralAndAdministrativeCostsOtherExpenses>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_3BVQSHsoSUudSjq4Bc8YyQ_30_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">29219000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_x9Soc_2VqkG32Gc6C4ujCw_30_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">45509000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_FPYlMipogkiOtacyFfgPkA_31_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2441000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_B_rx7Lcnb06tbXglApxGlg_31_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">4163000</us-gaap:RestructuringCharges>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_cSD8ViH2vUe-Fet8eb5ifA_32_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">69511000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_XaXON9XdHk6BbLdmQ8UMVg_32_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">173162000</us-gaap:CostsAndExpenses>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_c7wydqsIuEaH8o08aIlT_w_34_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">15129000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_DZUmBEPzX0-0aXwNkcBMkQ_34_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">13314000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_-c8gDhvZOUCRkYY-GDj0WA_35_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">2602000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_N9HMYFCWZkuzIuidm-clnQ_35_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">5649000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_rbLtvLz9MkeqgiRqQXI7dA_36_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">20173000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_hQGl6wcJWEG7KgAy2LGCJg_36_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">394000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_jhRzDEXQyEqQMD8cL4rMgA"
      decimals="-3"
      id="Tc_9UjKEocG0Eq6I7rfdodBSQ_37_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-59599000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_Mo07b3LrOkifY1rXeLdP4g"
      decimals="-3"
      id="Tc_mqut_NAbuU2_gogYOJJRTA_37_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-179053000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      decimals="-3"
      id="Tc_DybdfURVkE2pIPyGgkv-LQ_39_4"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-59599000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_7vYyZYIHjEWpBU4expHcqQ"
      decimals="-3"
      id="Tc_Dd9IuWWb0ESXCphqe4s_Hg_39_7"
      unitRef="Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g">-179053000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw"
      id="Tb_MhdA_xXsX0CA_ZhGYiqjJQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 20. Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As discussed in Note 11, &lt;i style="font-style:italic;"&gt;Common Stock Financing Activities&lt;/i&gt;, in connection with the November 2024 issuance and sale in a public offering of (i) 350 shares of the Company&#x2019;s common stock, and the November 2024 Accompanying Warrants to purchase 350 shares of Common Stock, and (ii) pre-funded warrants to purchase 563 shares of Common Stock, in February 2025, certain investors exercised the remaining 483 pre-funded warrants to purchase 483 shares of Common Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On March 3, 2025, the Company entered into the Purchase Agreement with the Purchaser named therein. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Purchaser and the Purchaser agreed to buy in a registered direct offering (i) an aggregate of 188 shares (the &#x201c;Shares&#x201d;) of common stock, par value $0.001 per share and accompanying warrants to purchase up to 188 shares of Common Stock at a combined offering price of $3.50 per Share and accompanying warrant, and (ii) the Pre-Funded Warrants to purchase up to 3,812 shares of Common Stock and accompanying warrants to purchase up to 3,812 shares of Common Stock, at a combined offering price of $3.499 per share underlying the Pre-Funded Warrants and accompanying warrant, which equals the offering price per Share and accompanying warrant less the $0.001exercise price per share of the Pre-Funded Warrants, pursuant to an effective registration statement on Form S-3 (File No. 333-275261), including the base prospectus included therein, and prospectus supplement filed with the SEC on March 4, 2025. As of March 28, 2025, 1,688 Pre-Funded Warrants were exercised. In the 2025 Offering, the Company also issued to the Purchaser warrants (the &#x201c;Option Warrants&#x201d;), to purchase up to 4,000 shares of Common Stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 4,000 shares of Common Stock to the Purchaser. The pre-funded warrants and accompanying warrants issuable upon exercise of the Option Warrants will have substantially identical terms as the Pre-Funded Warrants and the accompanying warrants. The exercise price of the Option Warrants is $3.50 per underlying share of Common Stock and accompanying warrant to purchase one share of Common Stock, or $3.499 per underlying pre-funded warrant to purchase one share of Common Stock and accompanying warrant to purchase one share of Common Stock. The Option Warrants expired on March 18, 2025 without being exercised.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On March 26, 2025, we and Jefferies terminated that certain Open Market Sales Agreement, dated May 10, 2021, as amended on November 1, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_22_2024_To_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_qCNNy1whp0ivehAR5sAVYg"
      decimals="-3"
      id="Narr_bhIrfx3tfkuTGXG8wGNU0A"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">350000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_LGUU816Yp0m2LKivHXs1uw"
      decimals="-3"
      id="Narr_UYVnWD0MsEir9JwdJVT-IQ"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">350000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_aWycUKhL-06MF4rymZ6neQ"
      decimals="-3"
      id="Narr_uL_YXyE87EqkptaVeQGEPg"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">563000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_28_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_3zrIDKZAEUqRigs4dt4KAw"
      decimals="-3"
      id="Narr_D-ZKB4YChEeE_oguBkHZUw"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">483000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <btai:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_2_1_2025_To_2_28_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_KmnbJXUr7EyUFHylcIdSIw"
      decimals="-3"
      id="Narr_brbmGn__mkiFD2YAbf2T_g"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">483000</btai:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_3_2025_To_3_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_N0FLHzjjW0ebf_9f1FrfOg"
      decimals="-3"
      id="Narr_PGWmJRgExE2dNNOG5LC09g"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">188000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_nr25qN2kxkCVXTVDwzfXDg"
      decimals="INF"
      id="Narr_xGdSCibeR0G4Jo5O--SDvQ"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_tkaY4qbmDUqjsdxXtER_7A"
      decimals="-3"
      id="Narr_qmaRdVkadkOh8Bt9Va2VVQ"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">188000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_nr25qN2kxkCVXTVDwzfXDg"
      decimals="INF"
      id="Narr_gSV0BvJ8XEexVzOxrGIZSA"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">3.5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_PrefundedWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_yKIZRxNDvEu7Hv10JhQ-7Q"
      decimals="-3"
      id="Narr_YPKn1pYWUEmwqO3NlbOdbA"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">3812000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_PrefundedWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_yKIZRxNDvEu7Hv10JhQ-7Q"
      decimals="-3"
      id="Narr_MBRHm-puxU-70-atvFP6Lw"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">3812000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_tkaY4qbmDUqjsdxXtER_7A"
      decimals="INF"
      id="Narr_4JtrnfixIEC9dOiBc31ajA"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">3.499</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_PrefundedWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_yKIZRxNDvEu7Hv10JhQ-7Q"
      decimals="INF"
      id="Narr_IIw4fOCurUWx3c4dFRaYmQ"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <btai:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_3_28_2025_To_3_28_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_PrefundedWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_zbIxHgjTxE2SCgROmOBKRw"
      decimals="-3"
      id="Narr_hUrTXzBiyUy1taK5pJjQgA"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">1688000</btai:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_c4ZQpDZ5ekCFoY0FzRG6JA"
      decimals="-3"
      id="Narr_Y5BTWT2_Z0i1xsb9SBscaQ"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">4000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_c4ZQpDZ5ekCFoY0FzRG6JA"
      decimals="-3"
      id="Narr_Ev3BgZEWu0m6I4MNG3GT3A"
      unitRef="Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw">4000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_c4ZQpDZ5ekCFoY0FzRG6JA"
      decimals="INF"
      id="Narr_jWn8o43H6kalsMEKsE-tZg"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">3.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_PurchaseAgreementRegisteredSecuritiesMember_tkaY4qbmDUqjsdxXtER_7A"
      decimals="INF"
      id="Narr_DOmjG037SEWIIcvSxMEDzg"
      unitRef="Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A">3.499</us-gaap:SharesIssuedPricePerShare>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 26, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-38410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BioXcel Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1386754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">555 Long Wharf Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Haven<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">238-6837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BTAI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,276,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,486,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Stamford, Connecticut<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001720893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 29,854<span></span>
</td>
<td class="nump">$ 65,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">679<span></span>
</td>
<td class="nump">1,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses</a></td>
<td class="nump">5,290<span></span>
</td>
<td class="nump">2,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,440<span></span>
</td>
<td class="nump">2,078<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">37,394<span></span>
</td>
<td class="nump">72,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">382<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">38,338<span></span>
</td>
<td class="nump">73,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">15,990<span></span>
</td>
<td class="nump">13,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">5,762<span></span>
</td>
<td class="nump">12,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">736<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,233<span></span>
</td>
<td class="nump">27,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities</a></td>
<td class="nump">6,633<span></span>
</td>
<td class="nump">1,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">102,508<span></span>
</td>
<td class="nump">100,598<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">131,439<span></span>
</td>
<td class="nump">130,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 18)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' (deficit) equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000 shares authorized; no shares issued and outstanding as of December 31, 2024 and December 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 200,000 and 100,000 shares authorized as of December 31, 2024 and December 31, 2023, respectively; 3,102 and 1,871 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="nump">557,047<span></span>
</td>
<td class="nump">534,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(650,197)<span></span>
</td>
<td class="num">(590,598)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' (deficit) equity</a></td>
<td class="num">(93,101)<span></span>
</td>
<td class="num">(56,508)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' (deficit) equity</a></td>
<td class="nump">38,338<span></span>
</td>
<td class="nump">73,702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 374<span></span>
</td>
<td class="nump">$ 346<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">3,102<span></span>
</td>
<td class="nump">1,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">3,102<span></span>
</td>
<td class="nump">1,871<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue, net</a></td>
<td class="nump">$ 2,266<span></span>
</td>
<td class="nump">$ 1,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">2,143<span></span>
</td>
<td class="nump">1,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">30,435<span></span>
</td>
<td class="nump">84,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">34,492<span></span>
</td>
<td class="nump">83,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">2,441<span></span>
</td>
<td class="nump">4,163<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">69,511<span></span>
</td>
<td class="nump">173,162<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(67,245)<span></span>
</td>
<td class="num">(171,782)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (income) expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">15,129<span></span>
</td>
<td class="nump">13,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(2,602)<span></span>
</td>
<td class="num">(5,649)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">(20,173)<span></span>
</td>
<td class="num">(394)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (59,599)<span></span>
</td>
<td class="num">$ (179,053)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share attributable to common stockholders (in dollars per share)</a></td>
<td class="num">$ (23.51)<span></span>
</td>
<td class="num">$ (98.33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share attributable to common stockholders (in dollars per share)</a></td>
<td class="num">$ (23.51)<span></span>
</td>
<td class="num">$ (98.33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic (in shares)</a></td>
<td class="nump">2,535<span></span>
</td>
<td class="nump">1,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted (in shares)</a></td>
<td class="nump">2,535<span></span>
</td>
<td class="nump">1,821<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 488,292<span></span>
</td>
<td class="num">$ (411,545)<span></span>
</td>
<td class="nump">$ 76,775<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">1,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">26,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1', window );">Repricing of stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings', window );">Vesting of restricted stock units, net of employee tax obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Vesting of restricted stock units, net of employee tax obligations (in shares)</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(179,053)<span></span>
</td>
<td class="num">(179,053)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">534,060<span></span>
</td>
<td class="num">(590,598)<span></span>
</td>
<td class="num">$ (56,508)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">1,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">9,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="nump">1,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1', window );">Repricing of stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued', window );">Issuance of pre-funded stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings', window );">Vesting of restricted stock units, net of employee tax obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Vesting of restricted stock units, net of employee tax obligations (in shares)</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59,599)<span></span>
</td>
<td class="num">(59,599)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 557,047<span></span>
</td>
<td class="num">$ (650,197)<span></span>
</td>
<td class="num">$ (93,101)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">3,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,102<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of pre-funded warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>OPERATING CASH FLOW ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (59,599)<span></span>
</td>
<td class="num">$ (179,053)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Reconciliation of net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Accretion of debt discount and amortization of financing costs</a></td>
<td class="nump">467<span></span>
</td>
<td class="nump">1,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(20,180)<span></span>
</td>
<td class="num">(438)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">6,156<span></span>
</td>
<td class="nump">18,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Payable-in-kind interest on Credit Agreement</a></td>
<td class="nump">6,543<span></span>
</td>
<td class="nump">1,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Operating lease right-of-use assets</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Accounts receivable</a></td>
<td class="num">(60)<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">1,312<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, other current assets and other assets</a></td>
<td class="num">(1,872)<span></span>
</td>
<td class="nump">2,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses, due to related parties, and other current liabilities</a></td>
<td class="num">(4,327)<span></span>
</td>
<td class="num">(3,219)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest</a></td>
<td class="num">(736)<span></span>
</td>
<td class="nump">2,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(346)<span></span>
</td>
<td class="num">(319)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(72,027)<span></span>
</td>
<td class="num">(155,006)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING CASH FLOW ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of equipment and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash from investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING CASH FLOW ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from issuance of common stock and warrants</a></td>
<td class="nump">39,688<span></span>
</td>
<td class="nump">27,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payment of principal of Long-term debt</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs for common stock and warrants issuance</a></td>
<td class="num">(474)<span></span>
</td>
<td class="num">(811)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of employee tax obligations related to vesting restricted stock units</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">36,660<span></span>
</td>
<td class="nump">26,522<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(35,367)<span></span>
</td>
<td class="num">(128,504)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">65,221<span></span>
</td>
<td class="nump">193,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">29,854<span></span>
</td>
<td class="nump">65,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_FairValueStockPurchaseWarrants', window );">Issuance of stock purchase warrants</a></td>
<td class="nump">2,540<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Repricing of stock purchase warrants</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 7,968<span></span>
</td>
<td class="nump">7,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ConversionOfAccruedInterestToLongTermDebt', window );">Conversion of accrued interest to long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 767<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ConversionOfAccruedInterestToLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of accrued interest that is converted into long erm debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ConversionOfAccruedInterestToLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_FairValueStockPurchaseWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of issues of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_FairValueStockPurchaseWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_OrganizationAndPrincipalActivitiesAbstract', window );"><strong>Nature of the Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of the Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;1. Nature of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BioXcel Therapeutics, Inc. (&#8220;BTI&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company utilizing artificial intelligence (&#8220;AI&#8221;) approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company is focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients&#8217; lives. BTI employs a unique AI platform to reduce therapeutic development costs and potentially accelerate timelines. The Company&#8217;s approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI management believes this differentiated approach has the potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As used in these consolidated financial statements, unless otherwise specified or the context otherwise requires, the terms &#8220;BioXcel LLC&#8221; refers to the Company&#8217;s former parent and current significant stockholder, BioXcel LLC and, its predecessor, BioXcel Corporation. &#8220;OnkosXcel&#8221; refers to BTI&#8217;s wholly owned subsidiary for its advanced immuno-oncology assets, OnkosXcel Therapeutics, LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April 6, 2022, BTI announced that the United States (&#8220;U.S.&#8221;) Food and Drug Administration (&#8220;FDA&#8221;) approved IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (dexmedetomidine or &#8220;Dex&#8221;) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is approved to be self-administrated by patients under the supervision of a health care provider. On July 6, 2022, BTI announced that IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, was commercially available in doses of 120 and 180 micrograms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s most advanced clinical development program is BXCL501. In indications other than those approved by the FDA as IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, BXCL501 is an investigational proprietary, orally dissolving, film formulation of Dex for the treatment of agitation associated with psychiatric and neurological disorders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s advanced immuno-oncology asset, BXCL701, is an investigational, orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment na&#239;ve to checkpoint inhibitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI was incorporated under the laws of the State of Delaware on March 29, 2017. The Company&#8217;s principal office is in New Haven, Connecticut.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_OrganizationAndPrincipalActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_OrganizationAndPrincipalActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;2. Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements include those of the Company and its subsidiaries after elimination of all intercompany accounts and transactions and have been prepared in conformity with United States (&#8220;U.S.&#8221;) Generally Accepted Accounting Principles (&#8220;GAAP&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2024, the Company had cash and cash equivalents of $29,854 and an accumulated deficit of $650,197. BTI has incurred substantial net losses and negative cash flows from operating activities in nearly every fiscal period since inception and expects this trend to continue for the foreseeable future. The Company recognized net losses of $59,599 and $179,053 for the years ended December 31, 2024 and 2023, respectively, and had net cash used in operating activities of $72,027 and $155,006 for the years ended December 31, 2024 and 2023, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under ASC Topic 205-40, Presentation of Financial Statements - Going Concern, management is required at each reporting period to evaluate whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s history of significant losses, its negative cash flows from operations, potential near-term increased covenant-driven amortization payments under its Credit Agreement, its limited liquidity resources currently on hand, and its dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, have resulted in management&#8217;s assessment that there is substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of at least 12 months from the issuance date of the financial statements included in this Annual Report on Form 10-K. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">This going concern evaluation takes into consideration the potential mitigating effect of management&#8217;s Reprioritization (as defined in Note 4, Restructuring). When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered probable of being effectively implemented, the plans need to be approved by the Company&#8217;s Board of Directors. The Company&#8217;s Reprioritization was approved by the Board of Directors on August 8, 2023; however, such plans, including the additional restructuring actions taken in the second and third quarters of 2024,  will not mitigate the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business and does not include any adjustments that may result from the outcome of this uncertainty. The going concern analysis does not consider possible future amendments to or restructuring of the Credit Agreement (as defined in Note 9, Debt and Credit Facilities) or other potential sources of debt or equity capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to support the Company&#8217;s cost structure and operating plan. Management&#8217;s plans to improve the Company&#8217;s liquidity and reduce its operating expenses and capital requirements include, among other things, pursuing one or more of the following steps to raise additional capital, none of which can be guaranteed or are entirely within the Company&#8217;s control:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>raise funding through the sale of the Company&#8217;s equity securities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>raise funding through third-party investments in or other strategic options for OnkosXcel;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>raise funding through debt financing and/or restructuring of its existing OFA Facilities; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>establish collaborations with potential partners to advance the Company&#8217;s product pipeline;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>establish collaborations with potential marketing partners;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>reduce overhead and headcount to focus on core priorities; and/or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>any combination of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If the Company is unable to raise capital when needed or on acceptable terms, or if it is unable to procure collaboration arrangements to advance its programs, the Company would be forced to discontinue some of its operations or develop and implement a plan, beyond its Reprioritization initiatives, to further extend payables, reduce overhead, scale back or cease some or all of its revised operating plan until sufficient additional capital is raised to support further operations. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;3. Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the consolidated financial statements and notes thereto. Estimates are used in the following areas, among others: revenue recognition, inventory valuation, derivative liabilities, stock-based compensation expense, accrued expenses and income taxes. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On February 10, 2025, the Company completed a <span style="-sec-ix-hidden:Hidden_MAC978-QcU6PY1cLIWQ4hg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1-for-16</span></span> reverse stock split of its issued and outstanding common stock (the &#8220;Reverse Stock Split&#8221;). As a result of the Reverse Stock Split, each 16 shares of common stock issued and outstanding immediately prior to February 10, 2025 were automatically converted into one of a share of common stock. The Reverse Stock Split affected all common stockholders uniformly and did not alter any stockholder's percentage interest in the Company's equity, except to the extent that the Reverse Stock Split would result in a stockholder owning a fractional share. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise would be entitled to receive a fractional share instead were entitled to receive cash in lieu of such fractional share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Reverse Stock Split did not change the par value of the common stock or the authorized number of shares of common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">All common share and per-share amounts in this Form 10-K have been retroactively restated to reflect the effect of the Reverse Stock Split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of December 31, 2024 and 2023, cash equivalents were comprised primarily of money market funds. Cash and cash equivalents held at financial institutions may at times exceed federally insured amounts. BTI management believes it mitigates such risk by investing in or through major financial institutions.</p><p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Accounts Receivable, Net</b></p><p style="font-family:'Liberation Serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Accounts receivable arise from sales of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">IGALMI</span><sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"> and represent amounts due from distributors. Payment terms generally range from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">30</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"> to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">75 days</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"> from the date of the sale transaction, and accordingly, do not involve a significant financing component. Receivables from product sales are recorded net of allowances which generally include distribution fees, prompt payment discounts, chargebacks, and credit losses. Allowances for distribution fees, prompt payment discounts and chargebacks are based on contractual terms. The Company estimated the current expected credit losses of its accounts receivable by assessing the risk of loss and available relevant information about collectability, existing contractual payment terms, actual payment patterns of its customers, individual customer circumstances, and reasonable and supportable forecast of economic conditions expected to exist throughout the contractual life of the receivable. Based on its assessment, as of December 31, 2024, the Company determined that an allowance for credit losses was not required.</span></p><p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Concentrations of Credit Risk</b></p><p style="font-family:'Liberation Serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Company sells IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';"> through a drop-ship program under which orders from hospitals and similar health care institutions are processed through wholesalers, but shipments of the product are sent directly to the individual hospitals and similar health care institutions. BTI also contracts directly with intermediaries such as group purchasing organizations (&#8220;GPOs&#8221;). All trade accounts receivables are due from the distributor that fulfills orders on behalf of the Company.</span><span style="font-family:'Times New Roman','Times','serif';"> For the years ended December 31, 2024 and 2023, one customer accounted for approximately </span><span style="font-family:'Times New Roman','Times','serif';">32%</span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">39%</span><span style="font-family:'Times New Roman','Times','serif';"> of the Company&#8217;s net product revenue, respectively. </span></p><p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Inventory</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or net realizable value. Cost of inventory is determined on a first-in, first-out basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">BTI capitalizes inventory costs associated with the Company&#8217;s products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development expense in the Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, will be recorded within Cost of goods sold in the Consolidated Statements of Operations. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected, write-downs of inventory may be required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Deferred Initial Public Offering Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Deferred initial public offering costs of $2,570, consisted of legal, accounting, and other costs that were directly related to the Company&#8217;s proposed initial public offering of OnkosXcel. These costs were charged to the Consolidated Statements of Operations during the year ended December 31, 2023 as the initial public offering was delayed for an extended period of time. The costs were recorded as Selling, general and administrative expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Property and equipment are recorded at cost and depreciated over the shorter of their remaining lease term or their estimated useful life on a straight-line basis as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:2.15pt;"><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Equipment</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">3-5 years</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Furniture</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">7 years</p></td></tr><tr style="height:13.1pt;"><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">Lesser of life of improvement or lease term</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Expenditures for maintenance and repairs which do not improve or extend the useful lives of the respective assets are expensed as incurred. When assets are sold or retired, the related cost and accumulated depreciation are removed from their respective accounts and any resulting gain or loss is included within Other (income) expense, net in the Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to undiscounted future net cash flows expected to be generated from its use and disposition. Impairment charges are recognized at the amount by which the carrying amount of an asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, other current liabilities, and the long-term portion of operating lease liabilities in the Consolidated Balance Sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">ROU assets represent BTI&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses the implicit rate when readily determinable. As BTI&#8217;s leases do not provide an implicit rate, it used an incremental </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any prepaid lease payments made and is reduced by lease incentives. The Company&#8217;s leases may include options to extend the lease; such options are included in determining the lease term when it is reasonably certain that BTI will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Debt and Detachable Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Detachable warrants are evaluated for classification as either equity instruments, derivative liabilities, or liabilities depending on the specific terms of the warrant agreement. In circumstances in which debt is issued with equity-classified warrants, the proceeds from the issuance of debt are first allocated to the debt and then the warrants at their estimated fair values. The portion of the proceeds allocated to the warrants are accounted for as paid-in capital and a debt discount. The remaining proceeds, as further reduced by discounts created by the bifurcation of any embedded derivatives, are allocated to the debt. Detachable warrants classified as derivative liabilities are accounted for as indicated under &#8220;<i style="font-style:italic;">Derivative Assets and Liabilities</i>&#8221; section of this Note and as a debt discount. The Company accounts for debt as liabilities measured at amortized cost and amortizes the resulting debt discount from the allocation of proceeds to interest expense using the effective interest method over the expected term of the debt instrument. The Company considers whether there are any embedded features in debt instruments that require bifurcation and separately accounts for them as derivative financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company entered into financing arrangements, the terms of which involve significant assumptions and estimates, including future net product sales, in determining interest expense, amortization period of the debt discount, as well as the classification between current and long-term portions. In estimating future net product sales, the Company assesses prevailing market conditions using various external market data against the Company&#8217;s anticipated sales and planned commercial activities. Consequently, the Company imputes interest on the carrying value of the debt and records interest expense using an imputed effective interest rate. The Company reassesses the expected payments during each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of the Company&#8217;s current and long-term portions of the debt.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Derivative Assets and Liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Derivative assets and liabilities are recorded on the Company`s Consolidated Balance Sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded as other income or expense within Other (income) expense, net in the Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company does not use derivative instruments for speculative purposes or to hedge exposures to cash-flow or market risks. Certain financing facilities entered into by the Company include freestanding financial instruments and/or embedded features that require separate accounting as derivative assets and/or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Revenue Recognition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s revenues consist of product sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition, BTI management performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The exercise of a material right may be accounted for as a contract modification or as a continuation of the contract for accounting purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such goods and services are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the Company&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company allocates the transaction price (the amount of consideration it expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#8217;s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI distributes IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the U.S. through arrangements with a distributor, wholesalers, and GPOs. The distributor and wholesalers help process and fulfill orders from hospitals on the Company&#8217;s behalf. The Company believes the hospitals are its customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company recognizes product revenues, net of consideration payable to customers, as well as variable consideration related to certain allowances and accruals that are determined using either the expected value or most likely amount method, depending on the type of the variable consideration, in its consolidated financial statements at the point in time when control transfers to the customer, which is typically when the product has been delivered to the customer&#8217;s location. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company&#8217;s only performance obligation identified for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is to deliver the quantity of product ordered to the location specified by the customer&#8217;s order. The Company records shipping and handling costs associated with delivery of product to its customers within Selling, general and administrative expenses on its Consolidated Statements of Operations. Under the Company&#8217;s current product sales arrangements, BTI does not have contract assets (unbilled receivables), as it generally invoices its customer at the time of revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI sells IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> at wholesale acquisition cost, less any agreed upon discounts and calculates product revenue net of variable consideration and consideration payable to third parties associated with distribution of product. The Company records reserves, based on contractual terms, for the following components of consideration related to product sold during the reporting period. Calculating these amounts involves estimates and judgments, and the Company reviews these estimates quarterly and records any material adjustments in the period they are identified, which affects net product revenue and earnings in the period such variances occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Trade Discounts and Allowances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company provides the distributor and wholesalers with discounts for prompt payment and pays fees to the distributor, wholesalers and GPOs related to distribution of the product. BTI expects the relevant third parties to earn these discounts and fees, and therefore it deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Government Rebates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is eligible for purchase by, or qualifies for reimbursement from, Medicaid and other U.S. government programs that are eligible for rebates on the price they pay for the product. To determine the appropriate amount to reserve for these rebates, BTI applies the applicable government discount to these sales, and estimates the portion of total rebates that it anticipates will be claimed. The Company deducts certain government rebates from gross product </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">revenue and accounts receivable at the time it recognizes the related revenue; other government rebates are recognized as an accrued liability at the time BTI recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Chargebacks</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI provides product discounts to hospitals associated with certain GPOs. The Company estimates the chargebacks that it expects to be obligated to provide based upon the terms of the applicable arrangements. BTI deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product Returns</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company provides contractual return rights to its customers including the right to return product within six months of product expiration and up to 12 months after product expiration, as well as for incorrect shipments, and damaged or defective product, which the Company expects to be rare. Management expects product returns to be minimal, thus BTI recognizes a nominal allowance for product returns at the time of each sale. In the future, if any of these factors and/or the history of product returns changes, the Company will adjust the allowance for product returns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI classifies all fees paid to the distributor, other than those discussed above and those related to warehouse operations, as Selling, general and administrative expenses on its Consolidated Statements of Operations. Fees paid to the distributor for warehouse operations are classified as Cost of goods sold on BTI&#8217;s Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Cost of Goods Sold</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold includes the cost of producing and distributing inventories that are related to product revenues during the respective period. Cost of goods sold also includes costs related to excess or obsolete inventory adjustment charges, as well as costs related to warehouse operations paid to distributors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company measures and recognizes stock-based compensation expense based on estimated fair value for all share-based awards made to employees, non-employee service providers, and directors, including stock options, BTI restricted stock units (&#8220;BTI RSUs&#8221;), OnkosXcel profit sharing units (&#8220;PSUs&#8221;), OnkosXcel restricted stock units (&#8220;OnkosXcel RSUs&#8221;) and BTI performance stock units (&#8220;Performance Units&#8221;). The Company&#8217;s 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;) became effective in August 2017. The Company&#8217;s 2020 Incentive Award Plan (the &#8220;2020 Plan&#8221;) became effective in May 2020. Following the effective date of the 2020 Plan, the Company ceased granting awards under the 2017 Plan; however, the terms and conditions of the 2017 Plan continue to govern any outstanding awards granted thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s stock-based awards are valued at fair value on the date of grant and that fair value is recognized as an expense in the Consolidated Statements of Operations over the requisite service period using the accelerated attribution method. The estimated value of the BTI RSUs and Performance Units is based on the Company&#8217;s closing stock price on the grant date. The estimated fair value of OnkosXcel RSUs are based on the OnkosXcel valuation on the grant date. The estimated fair value of stock-options and PSUs was determined using the Black-Scholes pricing model on the date of grant. For awards subject to performance-based vesting conditions, the Company recognizes stock-based compensation expense when the achievement of the performance condition becomes probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Black-Scholes pricing model is affected by the Company&#8217;s stock price, as well as assumptions regarding variables including, but not limited to, the strike price of the instrument, the risk-free rate, the expected stock price volatility over the term of the awards and expected term of the awards. The Company has elected to account for forfeitures as they occur, by reversing compensation cost when the award is forfeited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Research and development expenses include wages, benefits, non-cash stock-based compensation, facilities, supplies, external services, clinical study, manufacturing costs related to clinical trials and other expenses that are directly related to the Company&#8217;s research and development activities. At the end of the reporting period, the Company estimates the progress toward completion of the research or development objectives and, depending on the amount and timing of payments to the service providers may record net prepaid or accrued expense for associated research and development costs. Such estimates are subject to change as additional information becomes available. The Company expenses research and development costs as incurred.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Most of the Company&#8217;s service providers invoice BTI monthly in arrears for services performed. The Company estimates its accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to management at that time. BTI management periodically confirms the accuracy of the Company&#8217;s estimates with the service providers and makes adjustments if necessary.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Although management does not expect its estimates to be materially different from amounts actually incurred, management&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in BTI reporting amounts that are too high or too low in any particular period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Costs related to filing and pursuing patent applications are recorded in Selling, general and administrative expenses in the Consolidated Statements of Operations and are expensed as incurred since recoverability of such expenditures is uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company measures certain financial assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources, or observable inputs, and (2) an entity&#8217;s own assumptions about market participant assumptions developed based on the best information available in the circumstances, or unobservable inputs. The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). Fair value measurements must be classified and disclosed in one of the following three categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Level 1</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Level 2</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Level 3</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management&#8217;s estimates of market participant assumptions.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considering counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI uses an asset and liability approach for financial accounting and reporting of income taxes. Deferred tax assets and liabilities are determined based on temporary differences between financial reporting and tax basis assets and liabilities and are measured by applying enacted rates and laws to taxable years in which differences are expected to be recovered or settled. Further, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that the rate changes. A valuation allowance is required when it is &#8220;more likely than not&#8221; that all or a portion of deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">U.S. GAAP prescribes a comprehensive model for how a company should recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on a tax return, including a decision whether to file or not file a return in a particular jurisdiction. The Company&#8217;s financial statements reflect expected future tax consequences of such positions presuming the taxing authorities&#8217; full knowledge of the position and all relevant facts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company does not have any unrecognized tax benefits as of December 31, 2024 and 2023. BTI reviews all tax positions to ensure the tax treatment selected is sustainable based on its technical merits and that the position would be sustained if challenged.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Earnings (Loss) per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Earnings (loss) per share (&#8220;EPS&#8221;) is calculated by dividing net income or loss attributable to common stockholders by the weighted average number of shares of common stock that were outstanding, including pre-funded warrants. Shares of common stock into which the pre-funded warrant may be exercised are considered outstanding for the purposes of computing EPS because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date. Diluted EPS is calculated by adjusting the weighted average number of shares of common stock that were outstanding for the dilutive effect of common stock equivalents. In periods in which a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be antidilutive.&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Segment Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company operates in a single segment. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. To date, the Company&#8217;s chief operating decision maker has made such decisions and assessed performance at the Company level as one segment. See Note 19, <i style="font-style:italic;">Segment Information</i> for further information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently adopted accounting pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In November 2023, the FASB issued ASU 2023-07, Segment reporting, which requires disclosure of incremental segment information on an annual and interim basis. The standard is effective for years beginning after December 15, 2023, and interim periods beginning after December 15, 2024 and early adoption is permitted. The Company adopted the new standard in fiscal year 2024 for annual and retrospective reporting periods with all interim disclosures to begin in the first quarter of fiscal year 2025. For additional information, see Note 19, <i style="font-style:italic;">Segment Information</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting Pronouncements effective in future periods</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, Improvements to income tax disclosures, which requires disclosure of disaggregated income taxes paid by jurisdiction, enhances disclosures in the effective tax rate reconciliation and modifies other income tax-related disclosures. The amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the effect of adopting this guidance on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;4. Restructuring</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="background:#ffffff;">On August 8, 2023, the Company&#8217;s Board of Directors approved a broad-based strategic reprioritization (the &#8220;Reprioritization&#8221;). The Company took actions to reduce certain operational and workforce expenses that were no longer deemed core to ongoing operations in order to extend its cash runway and drive innovation and growth in high potential clinical development and value creating opportunities. These actions included a shift in commercial strategy for </span>IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="background:#ffffff;"> in the institutional setting, a reduction of in-hospital commercialization expenses, a suspension of programs no longer determined to be core to ongoing operations, and a prioritization of at-home treatment setting opportunities for BXCL501.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;background:#ffffff;">As part of this strategy, the Company&#8217;s Board of Directors approved a reduction of approximately </span><span style="font-weight:normal;background:#ffffff;">60%</span><span style="font-weight:normal;background:#ffffff;"> of the Company&#8217;s workforce. The Company notified impacted employees on August 14, 2023 and recorded total restructuring costs of </span><span style="font-weight:normal;background:#ffffff;">$4,163</span><span style="font-weight:normal;background:#ffffff;"> for the year ended December 31, 2023. These costs consisted of severance and benefit costs of </span><span style="font-weight:normal;background:#ffffff;">$4,063</span><span style="font-weight:normal;background:#ffffff;"> and contract termination costs of </span><span style="font-weight:normal;background:#ffffff;">$100</span><span style="font-weight:normal;background:#ffffff;">. The Company paid $</span><span style="font-weight:normal;background:#ffffff;">3,998</span><span style="font-weight:normal;background:#ffffff;"> of severance and benefit costs and </span><span style="font-weight:normal;background:#ffffff;">$100</span><span style="font-weight:normal;background:#ffffff;"> of contract termination costs in the year ended December 31, 2023. The Reprioritization is substantially complete as of December 31, 2023, and any remaining costs are expected to be paid during the first quarter of 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;background:#ffffff;"> On May 8, 2024 the Company took additional actions as part of its continued efforts to preserve cash and prioritize investment in its core clinical programs.</span> <span style="background:#ffffff;">As part of these actions, the Company initiated a further reduction of approximately </span><span style="background:#ffffff;">15%</span><span style="background:#ffffff;"> of the Company&#8217;s then current workforce. The Company notified impacted employees on May 8, 2024 and recorded total restructuring costs of </span><span style="background:#ffffff;">$856</span><span style="background:#ffffff;"> for the three months ended June 30, 2024. These costs consisted of severance and benefit costs, all of which were paid during the three months ended June 30, 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On September 17, 2024, the Company approved a plan for an additional reduction in its workforce of </span><span style="background:#ffffff;">15</span><span style="background:#ffffff;"> employees, or approximately </span><span style="background:#ffffff;">28%</span><span style="background:#ffffff;"> of the Company&#8217;s headcount (the &#8220;Clinical Prioritization&#8221;), in order to extend its cash runway and prioritize investment on the clinical development of its lead neuroscience asset, BXCL501. The Company incurred aggregate charges in connection with the Clinical Prioritization of </span><span style="background:#ffffff;">$1,586</span><span style="background:#ffffff;"> which relate primarily to severance and benefits costs. Accordingly, the Company recorded a restructuring charge of </span><span style="background:#ffffff;">$1,553</span><span style="background:#ffffff;"> in the third quarter 2024, and </span><span style="background:#ffffff;">$33</span><span style="background:#ffffff;"> in the fourth quarter. The Company completed the Clinical Prioritization in October 2024, and paid </span><span style="background:#ffffff;">$983</span><span style="background:#ffffff;"> of the related costs during the fourth quarter of 2024 and expects to pay the remaining </span><span style="background:#ffffff;">$603</span><span style="background:#ffffff;"> in the first quarter of 2025,</span> <span style="background:#ffffff;">which is included in Accrued Expenses on the Consolidated Balance at December 31, 2024.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;5. Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Inventory consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 935</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 651</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 405</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total inventory</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,991</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"><span style="font-weight:normal;">The Company recorded inventory write-downs due to excess inventory of </span><span style="font-weight:normal;">$1,980</span><span style="font-weight:normal;"> and </span><span style="font-weight:normal;">$1,191</span><span style="font-weight:normal;"> for the years ended December 31, 2024 and 2023, respectively. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;6. Property and Equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Property and equipment, net consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 202</p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 575</p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,200</p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total property and equipment</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,977</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,977</p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,502)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,193)</p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 784</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"><span style="font-weight:normal;">Depreciation expense was </span><span style="font-weight:normal;">$309</span><span style="font-weight:normal;"> and </span><span style="font-weight:normal;">$318</span><span style="font-weight:normal;"> for the years ended December 31, 2024 and 2023, respectively</span>.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;7. Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Accrued expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,406</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 163</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,562</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 116</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 322</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 177</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued restructuring costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 603</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total accrued expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,424</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with BioXcel LLC<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Transactions with BioXcel LLC</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Transactions with BioXcel LLC</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;8. Transactions with BioXcel LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company entered into a Separation and Shared Services Agreement with BioXcel LLC that took effect on June 30, 2017, as amended and restated thereafter (the &#8220;Services Agreement&#8221;), pursuant to which BioXcel LLC had agreed to provide the Company with certain intellectual property prosecution and management and research and development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the Services Agreement, the Company had an option, exercisable until December 31, 2024, to enter into a separate collaborative services agreement with BioXcel LLC pursuant to which BioXcel LLC shall perform product identification and related services for us utilizing its EvolverAI. We agreed to pay BioXcel LLC $18 per month from March 13, 2023, to December 31, 2024 in exchange for this option. This option was not exercised. However, BioXcel LLC continues to perform certain administrative services under the terms of the expired contract. We agreed to negotiate any such collaborative services agreement in good faith and to incorporate reasonable market-based terms, including consideration for BioXcel LLC reflecting a low, single-digit royalty on net sales and reasonable development and commercialization milestone payments, provided that (i) development milestone payments shall not exceed $10,000 in the aggregate and not be payable prior to proof of concept in humans and (ii) commercialization milestone payments shall be based on reaching annual net sales levels, be limited to 3% of the applicable net sales level, and not exceed $30,000 in the aggregate. We did not exercise our option to renew the agreement for product identification and related services utilizing BioXcel LLC&#8217;s EvolverAI. Subsequent to December 31, 2024 no development activity has been carried out by BioXcel LLC and none is contemplated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Service charges recorded under the Services Agreement for the years December 31, 2024 and 2023 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,075</p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 392</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 211</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,330</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,286</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">There were no service charges due as of December 31, 2024 and December 31, 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt and Credit Facilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt and Credit Facilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;9. Debt and Credit Facilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Debt, net of unamortized discounts and financing costs, consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Credit Agreement and Guaranty</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 102,319</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 102,319</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payable-in-kind ("PIK") interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 361</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total long-term debt liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 106,722</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 102,680</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unamortized debt premiums, discounts and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,214)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,082)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total long-term debt</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 102,508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 100,598</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April 19, 2022, the Company entered into two strategic financing agreements: (i) a Credit Agreement and Guaranty (the &#8220;Credit Agreement&#8221;) by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the &#8220;Lenders&#8221;), and Oaktree Fund Administration LLC (&#8220;OFA&#8221;) as administrative agent, and (ii) a Revenue Interest Financing Agreement (the &#8220;RIFA&#8221;; and together with the Credit Agreement, the &#8220;OFA Facilities&#8221;) by and among the Company, the purchasers party thereto (the &#8220;RIFA Purchasers&#8221;) and OFA as administrative agent. Under the OFA Facilities, the Lenders and the RIFA Purchasers agreed to, in the aggregate between the two OFA Facilities, provide up to $260,000 in gross funding to support the Company&#8217;s commercial activities of IGALMI<sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> sublingual film. In addition, the OFA Facilities are intended to support the expansion of clinical development efforts of BXCL501, which includes a Phase 3 program for the acute treatment of agitation in patients with Alzheimer&#8217;s disease, and for general corporate purposes. The Lenders and RIFA Purchasers are comprised of affiliates of Oaktree Capital Management, L.P. and Qatar Investment Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"><b style="font-weight:bold;">Waiver and First Amendment to Credit Agreement and Guaranty</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On November 13, 2023, the Company, the lenders party to the Credit Agreement and OFA entered into a Waiver and First Amendment to Credit Agreement and Guaranty (the &#8220;First Amendment&#8221;) that provided for (i) a waiver and a modification to the covenant in the Credit Agreement regarding investments in OnkosXcel and (ii) an agreement among the parties to further revise key financial terms in the Credit Agreement and terminate the RIFA. Pursuant to the First Amendment, the Lenders agreed to permit the Company to invest up to a maximum of $30,000 at any time outstanding in OnkosXcel, increased from $25,000 at any time outstanding. The First Amendment also waived any defaults or events of default arising under the Credit Agreement due to a breach prior to the date of the First Amendment of the OnkosXcel investment covenant, or a breach of the Company&#8217;s obligation to notify OFA of such default. In connection with the First Amendment, the Company paid the Lenders a fee of $180 (representing 0.25% of the loans outstanding under the Credit Agreement on the date of the First Amendment) and agreed to pay to the Lenders an exit fee equal to 0.25% of the loans under the Credit Agreement repaid upon maturity or prepayment of the loans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"><b style="font-weight:bold;">Second Amendment to Credit Agreement and Guaranty and Termination of the RIFA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.25;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On December 5, 2023, (the &#8220;Second Amendment Effective Date&#8221;), the Company entered into the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement (the &#8220;Second Amendment&#8221;), which further amended the Credit Agreement. On the Second Amendment Effective Date, the Credit Agreement was amended to provide up to $202,319 in senior secured term loans, including the initial Tranche A of $70,000, which was funded on April 28, 2022, and related capitalized interest on Tranche A through the Second Amendment Effective Date in the amount of $72,319. In addition, the $30,000 in financing previously provided to the Company under the RIFA on July 8, 2022 was converted to a term loan under the Credit Agreement (the &#8220;Tranche A-2 Term Loan&#8221;). The RIFA and all commitments for potential future funding thereunder were terminated. In addition, pursuant to the Second Amendment, the Lenders agreed to permit the Company to invest up to a maximum of $30,865 at any time outstanding in OnkosXcel, increased from $30,000. In connection with the Second Amendment, the Company agreed to pay to the Lenders an exit fee equal to 0.25% of the loans under the Credit Agreement repaid upon maturity or prepayment of the loans (which exit fee is in addition to, and not in lieu of, the exit fee provided for by the First Amendment). As of September 30, 2024, $100,000 in commitments under the Credit Agreement remains unfunded, and Oaktree has an Equity Investment Right (as defined below) to purchase up to $5,000 of Common Stock from the Company. The blended effective interest rate on the Tranches A-1 and A-2 as of December 31, 2023 was approximately 13.5%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The remaining tranches may be borrowed at the Company&#8217;s option prior to December 31, 2024, subject to satisfaction of certain conditions, including regulatory and financial milestones. Tranche B of the Credit Agreement is $20,000 and is available upon satisfaction of certain conditions and financial milestones. Tranche C of the Credit Agreement is $30,000 and is available upon satisfaction of certain conditions, including receipt of certain regulatory and financial milestones. Tranche D of the Credit Agreement is $50,000 and is available upon satisfaction of the Tranche C Term Loans conditions precedent to, and the funding of Tranche C Loans, including specified minimum net sales of the Company attributable to sales of BXCL501 for a trailing twelve consecutive month period, on or before December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;">The loans under the Credit Agreement do not amortize and mature on April 19, 2027. The Company may, at its option, no earlier than September 21, 2026 and no later than October 21, 2026, request an extension of the maturity date to April, 19, 2028, provided that the Company satisfies certain conditions including receipt of certain regulatory and financial milestones. Borrowings under the Credit Agreement are issued at a </span><span style="font-size:10pt;">200</span><span style="font-size:10pt;">-basis point original issue discount and bear interest at a variable annual rate of TERM </span><span style="-sec-ix-hidden:Hidden_q_7viYeZgU21L0rksnVcQQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">SOFR</span></span><span style="font-size:10pt;"> (but not less than </span><span style="font-size:10pt;">2.5%</span><span style="font-size:10pt;"> or more than </span><span style="font-size:10pt;">5.5%</span><span style="font-size:10pt;">) plus </span><span style="font-size:10pt;">7.5%</span><span style="font-size:10pt;">, payable quarterly. The rate resets every three months based on the current Term SOFR rate. Of such interest, above </span><span style="font-size:10pt;">8%</span><span style="font-size:10pt;"> per annum is, at the Company&#8217;s option, payable in kind by capitalizing and adding such interest to the outstanding principal amount of loans from the first payment date on which such interest is owed through</span> <span style="font-size:10pt;">March 31, 2025, unless, with respect to any payment date, the Company elects to pay all or a portion of such interest in cash. The Company is required to pay a ticking fee equal to </span><span style="font-size:10pt;">0.75%</span><span style="font-size:10pt;"> per annum on the undrawn amount of the commitments, payable quarterly commencing 120 days after April 22, 2022 through the termination of the commitments, which is expensed as incurred and recognized as interest expense in the Consolidated Statements of Operations. The Company may voluntarily prepay the Credit Agreement at any time subject to a prepayment fee.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s obligations under the Credit Agreement are guaranteed by BTI&#8217;s existing and subsequently acquired or organized subsidiaries, subject to certain exceptions. BTI&#8217;s obligations under the Credit Agreement and the related guarantees thereunder are secured, subject to customary permitted liens and other agreed upon exceptions, by (i) a pledge of all of the equity interests of all of the Company&#8217;s existing and any future direct subsidiaries, and (ii) a perfected security interest in all of its and the guarantors&#8217; tangible and intangible assets (except that the guarantees provided by the BXCL701 Subsidiaries (as defined below) are unsecured).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness, and dividends and other distributions, subject to certain exceptions, including specific exceptions with respect to product commercialization and development activities. The Company must also comply with certain financial covenants, including (i) maintenance of cash or permitted cash equivalent investments in accounts controlled by OFA for the Lenders, of at least (a) initially, $15,000, (b) from and after the funding of the Tranche B </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">loans, $20,000, and (c) from and after the Company&#8217;s satisfaction of the funding conditions for the Tranche C loans, $15,000, provided, that the liquidity covenant applicable at any time will be increased upon certain events related to a sale of OnkosXcel (up to a maximum amount equal to $37,500), provided that the minimum liquidity amount will in no event exceed 50% of the aggregate amount of loans outstanding under the Credit Agreement at any time; and (ii) a minimum revenue test, measured quarterly beginning with the Company&#8217;s fiscal quarter ending on December 31, 2024 (such six-month period the &#8220;Revenue Covenant Measurement Period&#8221;), that requires it and its subsidiaries&#8217; consolidated net revenue for the six consecutive month period ending on the last day of each such fiscal quarter to not be less than a minimum revenue amount specified in the Credit Agreement (such testing date, the &#8220;Revenue Covenant Measurement Testing Date&#8221; and the covenant described in this clause (ii) the &#8220;Revenue Covenant&#8221;). The Company&#8217;s failure to comply with the financial covenants will result in an event of default, subject to certain cure rights with respect to the Revenue Covenant. If, as of a Revenue Covenant Measurement Testing Date, the Company&#8217;s revenue for the applicable Revenue Covenant Measurement Period is less than the minimum revenue amount specified for the applicable period then required under the Revenue Covenant, the Company would have a right to cure such shortfall for a total of three fiscal periods by making a revenue cure payment (which would be treated as prepayments of the loans subject to a prepayment fee) to the Lenders in an amount equal to the difference between such minimum required revenue amount and the Company&#8217;s actual revenues for such Revenue Covenant Measurement Period, such payment to not be less than $1,000. If paid, the Company will be deemed to have complied with the Revenue Covenant as of such Revenue Covenant Measurement Testing Date. Any such payment will be applied to the prepayment of the loans under the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Notwithstanding the foregoing, the Credit Agreement permits OnkosXcel (together with OnkosXcel Employee Holdings, LLC (&#8220;Employee Holdings&#8221;), a subsidiary of BTI, and their respective subsidiaries, the &#8220;BXCL701 Subsidiaries&#8221;) to receive third-party investment or transfer all or substantially all of their assets to an unaffiliated third party, in each case subject to terms and conditions set forth in the Credit Agreement, including the escrow of certain proceeds received by BTI and its subsidiaries (other than the BXCL701 Subsidiaries) in respect of these disposition events and, under circumstances set forth in the Credit Agreement, the mandatory prepayment of such escrowed amounts. The Company&#8217;s equity interests in the BXCL701 Subsidiaries have been pledged in support of its obligations under the Credit Agreement, and the BXCL701 Subsidiaries have provided direct guarantees of BTI&#8217;s obligations under the Credit Agreement on an unsecured basis. However, the pledge, guarantee and other obligations of the BXCL701 Subsidiaries under the Credit Agreement will be released upon certain agreed upon events, including an initial public offering by the BXCL701 Subsidiaries or the ownership by unaffiliated third parties of at least 20% of the equity interests in the BXCL701 Subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Credit Agreement contains events of default that are customary for financings of this type relating to, among other things, payment defaults, breach of covenants, breach of representations and warranties, cross default to material indebtedness, bankruptcy-related defaults, judgment defaults, breach of the financial covenants described above, and the occurrence of certain change of control events. In certain circumstances, events of default are subject to customary cure periods. The Credit Agreement also contains certain regulatory-related events of default, which do not have cure periods. Following an event of default and any applicable cure period, the Lenders will have the right upon notice to terminate any undrawn commitments and may accelerate all amounts outstanding under the Credit Agreement, in addition to other remedies available to them as the Company&#8217;s secured creditors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"><b style="font-weight:bold;">Waiver and Third and Fourth Amendments to Credit Agreement and Guaranty</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">On February 12, 2024, the Company entered into the Third Amendment to Credit Agreement and Guaranty (the &#8220;Third Amendment&#8221;), which amended the Credit Agreement. Pursuant to the Third Amendment, the Lenders agreed to waive the covenant that the Company shall not receive a report and opinion from the Company&#8217;s independent auditors that contains a &#8220;going concern&#8221; or like qualification or exception or emphasis of matter of going concern footnote with respect to the Company&#8217;s financial statements for the fiscal year ended December 31, 2023 and, as a result, such event shall not be an event of default. As a condition to the effectiveness of the Third Amendment, among other things, the Company shall have received at least </span><span style="background:#ffffff;">$40,000</span><span style="background:#ffffff;"> in gross proceeds from a registered public sale of the Company&#8217;s common stock, warrants and/or pre-funded warrants</span> on or before February 20, 2024. The Company did not meet this condition and therefore the Third Amendment did not become effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 20, 2024 (the &#8220;Effective Date&#8221;), the Company entered into the Fourth Amendment to the Credit Agreement and Guaranty (the &#8220;Fourth Amendment&#8221;), which amended the Credit Agreement. Pursuant to the Fourth Amendment, the Lenders agreed to waive the covenant that the Company shall not receive a report and opinion from the Company&#8217;s independent registered public accounting firm that contains a &#8220;going concern&#8221; or similar qualification with respect to the Company&#8217;s financial statements for the year ended December 31, 2023. Accordingly, while the Company&#8217;s independent registered public accounting firm&#8217;s report contained in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 contains a &#8220;going concern&#8221; explanatory paragraph, it does not constitute an event of default under the Credit Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Fourth Amendment includes a covenant that the Company will receive, (i) after the Effective Date and on or before April 15, 2024, at least $25,000 in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or in non-refundable cash consideration from partnering transactions entered into after the Effective Date (so long as such partnering transactions would not require the Company or any of its subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made) and (ii) after the Effective Date and on or before November 30, 2024, at least $50,000 (for the avoidance of doubt, inclusive of amounts previously counted toward the preceding clause (i)) in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent (as defined in the Credit Agreement) in its sole discretion ) from partnering transactions entered into after the Effective Date. Failure to perform this covenant would constitute (A) a default under the Credit Agreement and (B) an event of default under the Credit Agreement, subject to a cure period, solely in the case of clause (i) of the preceding sentence, until May 15, 2024. For the avoidance of doubt, failure to perform clause (ii) of the preceding sentence would constitute an immediate event of default under the Credit Agreement without any cure or grace period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, the Fourth Amendment provides that if the Company has not, after the Effective Date and on or before September 30, 2024, received at least $40,000 in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the Effective Date, the &#8220;Minimum Liquidity Amount&#8221; (as defined in the Credit Agreement) that the Company is required to maintain at all times will increase to $25,000 from $15,000, unless and until the Company has received, after the Effective Date and on or before November 30, 2024, at least $50,000<span style="white-space:pre-wrap;"> in gross proceeds from the issuance of the Company&#8217;s common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the Effective Date.  On March 27, 2024, the Company received </span>$25,000 in gross proceeds from the issuance of its common stock, warrants, and pre-funded warrants discussed in Note 11, <i style="font-style:italic;">Common Stock Financing Activities</i>, satisfying the April 15, 2024 covenant requirement of the Fourth Amendment. During the third quarter of 2024, the Company received $467<span style="white-space:pre-wrap;"> of gross proceeds from the issuance of the Company&#8217;s common stock.  As of September 30, 2024, the Company had satisfied </span>$30,943 of the $40,000 required to maintain the Minimum Liquidity Amount and the $50,000<span style="white-space:pre-wrap;"> gross proceeds requirement.  As a result, at September 30, 2024, the Minimum Liquidity Amount increased to </span>$25,000. As of September 30, 2024, we were in compliance with all restrictive and financial covenants under the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0pt -0.25pt;"><b style="font-weight:bold;">Waiver and Fifth Amendment to Credit Agreement and Guaranty</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On November 21, 2024, the Company entered into the Fifth Amendment to Credit Agreement and Guaranty and First Amendment to Fourth Amendment to Credit Agreement and Guaranty (the &#8220;Fifth Amendment&#8221;), which amended the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the &#8220;Lenders&#8221;), and Oaktree Fund Administration LLC (&#8220;OFA&#8221;) as administrative agent (as amended by the Waiver and First Amendment to Credit Agreement and Guaranty, dated as of November 13, 2023, the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement, dated as of December 5, 2023, the Third Amendment to Credit Agreement, dated as of February 12, 2024, and the Fourth Amendment to Credit Agreement and Guaranty, dated as of March 20, 2024 (the &#8220;Fourth Amendment&#8221;), the &#8220;Existing Credit Agreement&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the Fifth Amendment, the Lenders agreed to, among other things, (i) waive the Credit Agreement&#8217;s covenant that the report and opinion the Company will receive from its independent registered public accounting firm with respect to the financial statements for the year ending December 31, 2024 will not contain a &#8220;going concern&#8221; or similar qualification, (ii) permanently waive the Credit Agreement&#8217;s minimum revenue covenant, and (iii) waive the Fourth Amendment&#8217;s requirement that the Company raise, after the effective date of the Fourth Amendment and on or before November 30, 2024, at least $50,000 in gross cash proceeds from the issuance of its common stock, warrants, and/or pre-funded warrants, and/or in cash and/or non-cash consideration from newly entered-into partnering transactions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Fifth Amendment includes a new capital raising covenant requiring that the Company receive (A) after the effective date of the Fifth Amendment and on or prior to November 27, 2024, at least $7,000 in gross cash proceeds from the issuance of the Company&#8217;s common stock, warrants and/or pre-funded warrants(&#8220;Raise 1&#8221;), (B) after the effective date of the Fifth Amendment and on or before March 15, 2025 (provided that the Company was required to use its commercially reasonable efforts to satisfy the requirement by February 15, 2025), at least $18,000 in net cash proceeds (including the proceeds of Raise 1) from (i) the issuance of the Company&#8217;s common stock, warrants and/or pre-funded warrants, (ii) non-refundable cash consideration from partnering transactions entered into after the effective date of the Fifth Amendment (so long as such partnering transactions would not require the Company or any of its subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made), (iii) the issuance of the Company&#8217;s subordinated debt (subject to terms set forth in the Fifth Amendment), and/or (iv) asset sales permitted pursuant to the Credit Agreement or consented to by the Lenders (such capital raise, &#8220;Raise 2&#8221;), and (C) after the effective date of the Fifth Amendment and on or prior to the earlier of (x) August 15, 2025 and (y) the date that is 30 days after the final data readout of the SERENITY At-Home Phase 3 trial, at least $29,000 in net cash proceeds (including the proceeds from Raise 1 and Raise 2) from the same permitted capital raising activities listed in the preceding clause (B). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the Fifth Amendment and the required capital raises described in the preceding paragraph, the Lenders agreed to modify the Credit Agreement&#8217;s minimum liquidity covenant to require minimum cash liquidity of $7,500 (instead of $25,000) from and after the closing of Raise 1until March 30, 2025. On March 31, 2025, the minimum liquidity amount will increase to $10,000 and on September 30, 2025, the minimum liquidity amount will further increase to $15,000. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the Fifth Amendment, the Company paid a one-time amortization payment of $2,500 principal amount, together with accrued and unpaid interest and a portion of the prepayment fee and other fees payable in December 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;">The Fifth Amendment also modifies the interest rate of the loans provided under the Credit Agreement from a floating rate of Term </span><span style="-sec-ix-hidden:Hidden_kFih0nmoC0-H7vISN9YfvQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">SOFR</span></span><span style="font-size:10pt;"> plus </span><span style="font-size:10pt;">7.50%</span><span style="font-size:10pt;"> per annum, to a fixed rate of </span><span style="font-size:10pt;">13%</span><span style="font-size:10pt;"> per annum, retroactive to and effective as of September 30, 2024. For the quarterly payment dates ending December 31, 2024, March 31, 2025, and June 30, 2025, the Company will have the ability to make interest payments of up to </span><span style="font-size:10pt;">10%</span><span style="font-size:10pt;"> per annum &#8220;in-kind&#8221; by capitalizing and adding such interest to the outstanding principal amount of the loans under the Credit Agreement. In addition, pursuant to the Fifth Amendment, the Company will be required to make quarterly amortization payments equal to </span><span style="font-size:10pt;">5.0%</span><span style="font-size:10pt;"> of the principal amount of funded loans, together with applicable prepayment fees, beginning on March 31, 2026. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On the effective date of the Fifth Amendment and as a condition to effectiveness thereof, the Company&#8217;s wholly owned subsidiaries OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC (collectively, &#8220;OnkosXcel&#8221;), which previously provided unsecured guarantees of the Company&#8217;s obligations under the Credit Agreement, granted security interests in substantially all of their assets to support such obligations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Fifth Amendment amends the negative covenants under the Credit Agreement to remove flexibility the Company and its subsidiaries previously had thereunder to undertake various transactions, including, without limitation, with respect to potential dispositions of OnkosXcel or out-licenses by OnkosXcel of its intellectual property. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Pursuant to the Fifth Amendment, the Company committed to appoint a new independent board director (subject to customary background checks, applicable law, confirmation of independence and Nasdaq rules), and to provide the independent director with various privileges and committee memberships on the board of directors of the Company </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">(including the appointment of such director on committee to be formed to focus on capital raising and evaluate strategic options). The Company also agreed to engage an investment banker reasonably acceptable to OFA and the Lenders to assist the Company and its board of directors with evaluating and exploring strategic options. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company also agreed to covenants requiring that the Company&#8217;s cash expenditures be monitored by the Lenders according to a board-approved budget provided to the Lenders prior to the signing of the Fifth Amendment, which cash budget will be updated on a bi-weekly basis going forward. The Company will not be permitted to make disbursements for any two-week period in excess of 115% of the aggregate budgeted amount of disbursements for the applicable period. Finally, pursuant to the Fifth Amendment, the Company is restricted from paying cash bonuses for its employees or executives during the fiscal years 2024 and 2025 without OFA&#8217;s consent or increasing the cash compensation for fiscal year 2025 for certain senior officers of the Company from their compensation for fiscal year 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Revenue Interest Financing Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As noted, the RIFA was terminated when the Company entered into the Second Amendment, which amended the Credit Agreement (as amended by the First Amendment). The $30,000 Tranche A previously provided to the Company under the RIFA was converted to the Tranche A-2 Term Loan. Prior to termination, the RIFA provided up to $120,000 in potential financing in exchange for a capped revenue interest on net sales of IGALMI<sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and other future BXCL501 products, if any, that received regulatory approval for sale. The initial Tranche A of $30,000 was funded on July 8, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the terms of the RIFA, the Purchasers were to receive tiered revenue interest payments on U.S. net sales of IGALMI<sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and other future BXCL501 products, if any, that receive regulatory approval for sale, equal to a royalty ranging from 0.375% to 7.750% of net sales of IGALMI<sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and other future BXCL501 products, if any, approved for sale in the U.S., subject to a hard cap equal to 1.75x the total amount funded. The Company would also have been required to make certain additional payments to the Purchasers from time to time to ensure that the aggregate amount of payments received by the Purchasers under the RIFA were at least equal to certain agreed upon minimum levels as of certain specified dates, subject to terms and conditions set forth in the RIFA. Revenue interest payments due under the RIFA were payable quarterly based on net sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Warrants and Equity Investment Right</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the closing of the Second Amendment, on the Second Amendment Effective Date, the Company amended and restated the warrants granted to the Lenders on April 19, 2022 to purchase up to 17 shares of the Company&#8217;s common stock at an exercise price of $320.6 per share (the &#8220;Closing Date Warrants&#8221;). Pursuant to the amendment and restatement of the Closing Date Warrants, dated December 5, 2023 (the &#8220;Amended and Restated Closing Date Warrants&#8221;), the exercise price of the Closing Date Warrants has been reduced to $58.3232 per share. In addition, the Company granted new warrants to the Lenders to purchase up to 4 shares of the Company&#8217;s common stock (the &#8220;2023 Warrant Shares&#8221;) at an exercise price of $58.3232 per share (the &#8220;2023 Warrants&#8221;<span style="font-size:12pt;"> </span>and together with the Amended and Restated Closing Date Warrants, the &#8220;Warrants&#8221;). The Amended and Restated Closing Date Warrants and the 2023 Warrants will expire on April 19, 2029 and may be net exercised at the holders election. In addition, pursuant to the Credit Agreement, the Lenders have the right to purchase shares of the Company&#8217;s common stock after the Second Amendment Effective Date, so long as borrowings under the Credit Agreement are outstanding, for a purchase price of $5,000 at a price per share equal to a 10% premium to the volume-weighted average price of the common stock over the 30 trading days prior to the Lenders&#8217; election to proceed with such equity investment (the &#8220;Equity Investment Right&#8221;). BTI entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the Lenders and filed a registration statement on Form S-3 to register the shares issuable upon exercise of the Warrants and, if issued, the shares related to the Equity Investment Right, for resale. The maximum shares of the Company&#8217;s common stock issuable under the Warrants (including the Closing Date Warrants and the 2023 Warrants) and Lenders&#8217; Equity Investment Right was 366 as of March 31, 2024.<span style="font-size:12pt;"> </span>On the Second Amendment Effective Date, Company amended and restated its Registration Rights Agreement (the &#8220;Amended and Restated Registration Rights Agreement&#8221;) with the Lenders, dated April 19, 2022, pursuant to which the Company agreed to register the 2023 Warrant Shares for resale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As part of the Credit Agreement, OnkosXcel, a wholly owned subsidiary of BTI, granted warrants to the Lenders to purchase 175 individual limited liability company units (which number of units is not in thousands; referred to herein as </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">the &#8220;OnkosXcel Warrants&#8221;). The strike price of the OnkosXcel Warrants is formulaic based on the value of OnkosXcel at the time of exercise and can only be exercised upon occurrence of an equity related liquidity event for OnkosXcel of at least $20,000. The exercise price per unit of the OnkosXcel Warrants will be set upon the earlier of the closing of the next sale (or series of related sales) by OnkosXcel of equity securities of OnkosXcel with aggregate proceeds of not less than $20,000 to unrelated third parties (the &#8220;Next Equity Financing&#8221;) at an exercise price per unit equal to a 10% premium over the price per unit of the equity securities sold by OnkosXcel in such Next Equity Financing or, in the event of a sale of OnkosXcel prior to the Next Equity Financing or an initial public offering constituting the Next Equity Financing, the lesser of (x) 75% of the fair value of the consideration to be paid for a unit upon the consummation of such transaction and (y) 150% of the valuation applicable to the initial profits units issued by OnkosXcel after the closing of the Credit Agreement. The OnkosXcel Warrants are transferable with approval from BTI, which cannot be unreasonably withheld, expire on April 19, 2029, and may be net exercised at the holder&#8217;s election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the closing of the Fourth Amendment discussed below, the Company granted new warrants to the Lenders to purchase up to 6 shares of its common stock (the &#8220;2024 Warrant Shares&#8221;) at an exercise price of $49.1568 per share (the &#8220;2024 Warrants&#8221;), which represents a 10% premium over the arithmetic average of the volume-weighted average price of the Company&#8217;s common stock on the Nasdaq Capital Market during the 30 trading days preceding the Effective Date. The 2024 Warrants will expire on April 19, 2029 and may be net exercised at the holder&#8217;s election. On the Effective Date, the Company amended and restated its Amended and Restated Registration Rights Agreement (the &#8220;Second Amended and Restated Registration Rights Agreement&#8221;) with the Lenders, originally dated April 19, 2022. Pursuant to the Second Amended and Restated Registration Rights Agreement, the Company agreed to register the 2024 Warrant Shares for resale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Fifth Amendment Warrants, Registration Rights Agreement and Equity Investment Right Termination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Prior to the Fifth Amendment, pursuant to the Credit Agreement, the Lenders had the right to purchase shares of our common stock, so long as borrowings under the Credit Agreement are outstanding, for a purchase price of $5,000 at a price per share equal to a 10% premium to the volume-weighted average price of the common stock over the 30 trading days prior to the Lenders&#8217; election to proceed with such equity investment (the &#8220;Equity Investment Right&#8221;). The Equity investment Right was terminated as part of the Fifth Amendment. We entered into a registration rights agreement with the Lenders (as amended and restated in connection with the Second Amendment, the &#8220;Amended and Restated Registration Rights Agreement&#8221;) and filed registration statements on Form S-3 to register the shares issuable upon exercise of the Closing Date Warrants, 2023 Warrants and the New Warrants for resale. The maximum shares of our common stock issuable under the Closing Date Warrants, the 2023 Warrants and the Lenders&#8217; Equity Investment Right was 366. On the Effective Date, we further amended and restated the Amended and Restated Registration Rights Agreement (the &#8220;Second Amended and Restated Registration Rights Agreement&#8221;) with the Lenders. Pursuant to the Second Amended and Restated Registration Rights Agreement, we agreed to register the 2024 Warrant Shares for resale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the closing of the Fifth Amendment, the Company agreed to, substantially concurrently with the closing of Raise 1, grant new warrants to the Lenders to purchase an aggregate of 313 shares of common stock on the closing date of the Fifth Amendment, at an exercise price of $0.16 per share (the &#8220;New Warrants&#8221;). The New Warrants will expire on the seventh anniversary of their issuance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, the Company agreed to, substantially concurrently with the closing of Raise 1, amend and restate all warrants to purchase stock of the Company issued to the Lenders prior to the effective date of the Fifth Amendment, to revise the exercise price thereunder to an exercise price equal to the lower of (i) the price per share of the common stock of the Company issued in Raise 1 and (ii) arithmetic average of the volume-weighted average price of the Company&#8217;s common stock on the Nasdaq Capital Market during the 30 trading days preceding Raise 1 (such existing warrants, as amended and restated, the &#8220;Original Warrants&#8221;). The Original Warrants provide the Lenders with the right to purchase a total of 28 shares of common stock of the Company, and the exercise prices of $58.3232 per share and $49.1568 per share were reduced to $7.68 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On the date of issuance of the New Warrants, the Company agreed to amend and restate its Second Amended and Restated Registration Rights Agreement with the Lenders, dated March 20, 2024. Pursuant to such amendment and restatement (the &#8220;Third Amended and Restated Registration Rights Agreement&#8221;), the Company will agree to register the shares of common stock issuable under the New Warrants, in addition to all Original Warrants, for resale. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As part of entering into the Credit Agreement, OnkosXcel, a wholly owned subsidiary of BTI, granted the OnkosXcel Warrants to the Lenders to purchase 175 individual limited liability company units. The strike price of the OnkosXcel Warrants is formulaic based on the value of OnkosXcel at the time of exercise and can only be exercised upon occurrence of an equity related liquidity event for OnkosXcel of at least $20,000. The exercise price per unit of the OnkosXcel Warrants will be set upon the earlier of the closing of the next sale (or series of related sales) by OnkosXcel of equity securities of OnkosXcel with aggregate proceeds of not less than $20,000 to unrelated third parties (the &#8220;Next Equity Financing&#8221;) at an exercise price per unit equal to a 10% premium over the price per unit of the equity securities sold by OnkosXcel in such Next Equity Financing or, in the event of a sale of OnkosXcel prior to the Next Equity Financing or an initial public offering constituting the Next Equity Financing, the lesser of (x) 75% of the fair value of the consideration to be paid for a unit upon the consummation of such transaction and (y) 150% of the valuation applicable to the initial profits units issued by OnkosXcel after the closing of the Credit Agreement. The OnkosXcel Warrants are transferable with approval from BTI, which cannot be unreasonably withheld, expire on April 19, 2029, and may be net exercised at the holder&#8217;s election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Maturities of long-term debt are expected to be as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,291</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Interest expense was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14,662</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,941</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion of debt discount and amortization of financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 467</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,373</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total interest expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,314</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;10. Derivative Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">BTI identified certain freestanding financial instruments and/or embedded features that require separate accounting from the borrowings under the OFA Facilities. This includes the OnkosXcel Warrants and Equity Investment Right held by the Lenders, along with certain put/call options.  The OnkosXcel Warrants and Equity Investment Right do not meet certain scope exceptions under U.S. GAAP, primarily because the exercise prices and number of shares of the Company&#8217;s common stock issuable under the instruments are variable, and the instruments meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Consolidated Balance Sheets. The respective derivative liabilities are recorded at fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#8217;s Consolidated Statements of Operations.</span><span style="font-size:12pt;"> </span>As discussed in Note 9, <i style="font-style:italic;">Debt and Credit Facilities</i><span style="white-space:pre-wrap;">, the Equity Investment Right was terminated on November 25, 2024 in connection with the Fifth Amendment to the Credit Agreement.  The Company recorded the termination gain of </span>$1,263 within Other (income) expense, net in the Company&#8217;s Consolidated Statements of Operations for the carrying value of the Equity Investment Right. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;">With respect to the Securities Purchase Agreement discussed in Note 11, <i style="font-style:italic;">Common Stock Financing Activities</i>, BTI determined that the Accompanying Warrants fail the equity classification criteria and are therefore classified as liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity ("ASC 480") and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The Accompanying Warrants failed to meet the requirements to be indexed to equity and equity </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">classified, and meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Consolidated Balance Sheet as of December 31, 2024. The respective derivative liabilities were recorded at fair value on the date of issuance in the amount of $19,347 and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#8217;s Consolidated Statements of Operations. We value the Accompanying Warrants using the Black-Scholes option pricing model as discussed in Note 14, <i style="font-style:italic;">Fair measurements</i>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;">On November 21, 2024, the exercise price of 534 of the Accompanying Warrants was reduced from $51.20 to $9.136 per share. As a result of the repricing, the Company recorded the increase in fair value of $1,000<span style="white-space:pre-wrap;"> as an increase to the carrying value of Derivative liabilities, recorded as an increase to their carrying value, and as a loss in Other (income) expense, net, in the Company&#8217;s Consolidated Statements of Operations.  For the year ended December 31, 2024, the Company recorded total net gains of </span>$17,027, including the $1,000 repricing loss, in Other (income) expense, net, in the Company&#8217;s Consolidated Statements of Operations. As of December 31, 2024, the fair value of the Accompanying Warrants was $2,320.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;">On November 25, 2024, as discussed below, the Company issued additional warrants (the &#8220;November 2024 Accompanying Warrants&#8221;). The November 2024 Accompanying Warrants failed to meet the requirements to be indexed to equity and equity classified, and meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Consolidated Balance Sheet as of December 31, 2024. The respective derivative liabilities were recorded at fair value on the date of issuance in the amount of $5,562 and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#8217;s Consolidated Statements of Operations. For the year ended December 31, 2024, the Company recorded total net gains of $1,289 in Other (income) expense, net, in the Company&#8217;s Consolidated Statements of Operations. As of December 31, 2024, the fair value of the November 2024 Accompanying Warrants was $4,273.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Financing Activities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_FinancingActivitiesAbstract', window );"><strong>Common Stock Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_FinancingActivitiesDisclosureTextBlock', window );">Common Stock Financing Activities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;11. Common Stock Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"><span style="font-weight:normal;">In May 2021, the Company entered into</span><span style="font-weight:normal;"> an </span><span style="font-weight:normal;">Open Market Sale Agreement (as amended, supplemented and/or restated from time to time, the &#8220;Sale Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) pursuant to which the Company could offer and sell shares of its common stock, having an aggregate offering price of up to </span><span style="font-weight:normal;">$100,000</span><span style="font-weight:normal;">, from time to time, through an &#8220;at the market offering&#8221; program under which Jefferies will act as sale agent. In November 2023, the Company amended the Sale Agreement to increase the size of the &#8220;at the market offering" program to </span><span style="font-weight:normal;">$150,000</span><span style="font-weight:normal;">. For the year ended December 31, 2023, the Company sold </span><span style="font-weight:normal;">88</span><span style="font-weight:normal;"> shares of its common stock for a gross amount of </span><span style="font-weight:normal;">$27,032</span><span style="font-weight:normal;">, incurred issuance costs of </span><span style="font-weight:normal;">$811</span><span style="font-weight:normal;">, and received net proceeds of </span><span style="font-weight:normal;">$26,221</span><span style="font-weight:normal;">. For the year ended December 31, 2024, the Company sold </span><span style="font-weight:normal;">240</span><span style="font-weight:normal;"> shares of its common stock for a gross amount of </span><span style="font-weight:normal;">$7,682</span><span style="font-weight:normal;">, incurred issuance costs of </span><span style="font-weight:normal;">$231</span><span style="font-weight:normal;">, and received net proceeds of </span><span style="font-weight:normal;">$7,451</span><span style="font-weight:normal;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 25, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with the purchasers named therein (collectively, the &#8220;Purchasers&#8221;). Pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Purchasers in a registered direct offering (the &#8220;Offering&#8221;) under an effective shelf registration statement on Form S-3 (File No. 333-275261) and a related prospectus supplement filed with the Securities and Exchange Commission on March 25, 2024 (the &#8220;Prospectus Supplement&#8221;) an aggregate of 191 shares (the &#8220;Shares&#8221;) of common stock, par value $0.001 per share, and accompanying warrants (the &#8220;Accompanying Warrants&#8221;) to purchase up to 191 shares of common stock at a combined offering price of $4.416 per Share and Accompanying Warrant and pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to 348 shares of common stock and Accompanying Warrants to purchase up to 348 shares of common stock, at a combined offering price of $46.40 per share underlying each Pre-Funded Warrant and Accompanying Warrant, which equals the offering price per Share and Accompanying Warrant less the $0.016 exercise price per share of the Pre-Funded Warrants. The Pre-Funded Warrants and Accompanying Warrants are not listed on the Nasdaq Capital Market or any other securities exchange or trading system and the Company does not intend to list them. On March 27, 2024, The Company received $25,000 of gross proceeds from the Offering, incurred issuance costs of $248, and received net proceeds of $24,752. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Pre-Funded Warrants have an exercise price per share of common stock equal to $0.016 per share. The exercise price and the number of shares of common stock issuable upon exercise of the Pre-Funded Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The Pre-Funded Warrants are exercisable at any time after the date of issuance. For the year ended December 31, 2024, 348 Pre-Funded Warrants were exercised and the same number of shares of common stock were issued in exchange for $6 of proceeds received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Accompanying Warrants have an exercise price per share of common stock equal to $51.20 per share. The exercise price and the number of shares of common stock issuable upon exercise of the Accompanying Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The Accompanying Warrants will be exercisable at any time after the date of issuance and will expire on the fifth anniversary of the date of issuance. The Accompanying Warrants do not meet certain scope exceptions under U.S. GAAP, primarily because they did not meet the requirements to be indexed to equity and equity classified, and the instruments meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Consolidated Balance Sheet as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On November 22, 2024, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Canaccord Genuity LLC, as underwriter (the &#8220;Underwriter&#8221;), in connection with the issuance and sale by the Company in a public offering of (i) 350 shares of the Company&#8217;s common stock, and accompanying warrants (the &#8220;November 2024 Accompanying Warrants&#8221;) to purchase 350 shares of Common Stock, at a combined public offering price of $7.68 per share, and, in lieu thereof to certain investors, (ii) pre-funded warrants to purchase 563 shares of Common Stock, and accompanying warrants (the &#8220;November 2024 Accompanying Warrants&#8221;) to purchase 563 shares of Common Stock, at a combined public offering price of $7.664 per pre-funded warrant, which equals the public offering price per share of Common Stock and accompanying warrant less the $0.016 exercise price per share of the pre-funded warrants, less underwriting discounts and commissions, pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-275261) and a related prospectus supplement filed with the Securities and Exchange Commission. For the year ended December 31, 2024, 80 pre-funded warrants were exercised and the same number of shares of common stock were issued in exchange for $1 of proceeds received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Each of the November 2024 Accompanying Warrants in the offering is subject to customary beneficial ownership limitations on exercisability, is exercisable at any time after the date of issuance of such warrant and, in the case of the accompanying warrants, will expire on the fifth anniversary of the date of issuance. Each of the November 2024 Accompanying Warrants will have an exercise price of $7.68 per underlying share of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company received net proceeds from the offering of approximately $6,128, after deducting underwriting discounts and commissions and offering expenses of $871. The Company intends to use the net proceeds of the offering to fund the SERENITY At-Home trial, prepare for the initiation of the TRANQUILITY In-Care trial, working capital and general corporate purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_FinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_FinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_FinancingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Financing Activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_FinancingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;12. Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">2017 Equity Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s 2017 Plan became effective in August 2017. Following the effective date of the Company's 2020 Plan, the Company ceased granting awards under the 2017 Plan, however, the terms and conditions of the 2017 Plan continue to govern any outstanding awards granted thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">2020 Incentive Award Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s 2020 Plan was approved and became effective at the Company&#8217;s 2020 annual meeting of stockholders on May 20, 2020, and unless earlier terminated by the Board of Directors, will remain in effect until March 26, 2030. The 2020 Plan originally authorized for issuance the sum of (i) 57 shares of the Company&#8217;s common stock and (ii) 15 shares of the Company&#8217;s common stock, which represents the number of shares that remained available for </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">issuance under the 2017 Plan immediately prior to the approval of the 2020 Plan by the Company&#8217;s stockholders. Any shares of common stock which, immediately prior to the approval of the 2020 Plan by the Company&#8217;s stockholders, were subject to awards granted under the 2017 Plan that are forfeited or lapse unexercised and are not issued under the 2017 Plan will increase the number of shares of common stock available for grant under the 2020 Plan. In addition, the number of shares available for issuance under the 2020 Plan will increase on the first day of each calendar year, beginning January 1, 2021 and ending on and including January 1, 2030, by a number of shares equal to the lesser of (A) 4% of the aggregate number of shares of the Company&#8217;s common stock outstanding on the final day of the immediately preceding calendar year and (B) such smaller number of shares of common stock as determined by the Board of Directors. The shares available for issuance under the 2020 Plan increased by 75 shares and 70 shares on January 1, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Stock-based awards granted under the 2020 Plan have a term of ten years. The vesting schedule of all awards granted under the 2020 Plan is determined by the Board of Directors, which is generally four years. Stock-based awards granted under the 2020 Plan include stock options, BTI RSUs, and Performance Units.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2024, there were 42 shares available to be granted under the 2020 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BTI Restricted stock units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The table below summarizes activity relating to BTI RSUs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares </b></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6)</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 27</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In 2024, the Company granted 22 time-based BTI RSUs to certain employees, executives, and board members. The RSUs granted to employees and executives vest 100% at the <span style="-sec-ix-hidden:Hidden_O-R2_NsEcUirYc0hrciCHQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-year anniversary of the grant date. The weighted average grant date fair value per share for the BTI RSUs granted to employees and executives in 2024 was $23.43. Unrecognized stock-based compensation expense related to these awards was $13 as of December 31, 2024. The RSUs granted to board members vest monthly over a <span style="-sec-ix-hidden:Hidden_ZV8mysUnJEKMO7_R1BXZ3w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12-month</span></span> period, beginning in November 2024. The weighted average grant date fair value per share for the BTI RSUs granted to board members was $9.12. Unrecognized stock-based compensation expense related to these awards was $185 as of December 31, 2024. Unrecognized stock-based compensation expense related to awards issued prior to 2024 was $575 and $1,715 as of December 31, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BTI Performance stock units </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The table below summarizes activity relating to Performance Units related to BTI common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares </b></p></td></tr><tr><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 33</p></td></tr><tr><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 87</p></td></tr><tr><td style="vertical-align:bottom;width:86.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27)</p></td></tr><tr><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23)</p></td></tr><tr><td style="vertical-align:bottom;width:86.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 70</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In July 2024, the Company granted 87 Performance Units to employees. The Performance Units vest on the one-year anniversary of the grant date, provided certain performance criteria are met. The weighted average value per share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">of Performance Units granted in 2024 was $19.20. None of the Performance Units had vested as of December 31, 2024. Unrecognized stock-based compensation expense related to these Performance Units expected to vest was zero as of December 31, 2024 since it is uncertain whether any performance criteria will be met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">OnkosXcel Profit sharing units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The table below summarizes activity relating to the PSUs associated with OnkosXcel as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price per unit</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in whole dollars)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,626</p></td></tr><tr><td style="vertical-align:bottom;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,176</p></td></tr><tr><td style="vertical-align:bottom;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (89)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,506</p></td></tr><tr><td style="vertical-align:bottom;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested units as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 941</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,570</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">During 2024, OnkosXcel Employee Holdings, LLC, a management holding company used to facilitate the grant of equity interests to service providers of OnkosXcel granted 15 individual (not in thousands) time-based PSUs related to OnkosXcel to certain employees of the Company in consideration for services provided to OnkosXcel. The PSUs represent indirect equity interests in OnkosXcel. These PSUs vest ratably over 48 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The fair values of the PSUs granted in 2024 was $8 per unit, and was estimated at the date of grant using a Black-Scholes option pricing model. The total fair value of the PSUs vested during the year ended December 31, 2024 was $1,165.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:22.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024 grant profit share unit valuation inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 97.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Unrecognized stock-based compensation expense related to the PSUs was $377 as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">OnkosXcel restricted stock units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The table below summarizes activity relating to the OnkosXcel RSUs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">units</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 225</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Granted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Vested</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (41)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Cancelled</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 176</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2024, the Company had 176 OnkosXcel Restricted Stock Units outstanding. Unrecognized stock-based compensation expense related to the awards expected to vest was approximately $210 as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BTI Stock options</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A summary of the Company&#8217;s stock option activity for the year ended December 31, 2024, is presented below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price per share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 311</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 296.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 214.56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 339.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 311</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 265.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options vested and exercisable as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 291.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2024, the intrinsic value of options outstanding was $0. The intrinsic value for stock options is calculated based on the difference between the exercise prices of the underlying awards and the quoted stock price of the Company&#8217;s common stock as of the reporting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The total intrinsic value of stock options exercised for the year ended December 31, 2024 was $0. The total intrinsic value of stock options exercisable as of December 31, 2024 was $0.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The weighted average grant date fair value of options granted during the year ended December 31, 2024 was $16.63.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The weighted average grant date fair value of options vested as of December 31, 2024 was $215.98.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The weighted average remaining contractual life is 4.9 years for options exercisable as of December 31, 2024. The weighted average remaining contractual life was 5.6 years for options outstanding as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Unrecognized compensation expense related to unvested stock option awards as of December 31, 2024, was $7,691 and will be recognized over the remaining vesting periods of the underlying awards. The weighted-average period over which such compensation is expected to be recognized is 0.9 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The fair value of options granted during the years ended December 31, 2024 and 2023 was estimated using the Black-Scholes pricing model with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.15969849%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;width:28.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;width:28.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">5.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">5.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected stock price volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">108.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">112.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">96.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">109.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">3.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">4.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In 2024, the Company continued using the historical volatility of its common stock to estimate volatility. Prior to 2023, volatility was estimated using a combination of the historical volatility of publicly traded peer companies and that of the Company&#8217;s common stock. The expected term of the awards is estimated based on the simplified method, which calculates the expected term based upon the midpoint of the term of the award and the vesting period. The Company uses the simplified method because it does not have sufficient option exercise data to provide a reasonable basis upon which to estimate the expected term. The expected dividend yield is zero percent as the Company has no history of paying dividends nor does management expect to pay dividends over the contractual terms of these options. The risk-free interest rates are determined by reference to the U.S. Treasury yield curve in effect at the time of grant, with maturities approximating the expected term of the stock options. The fair value of the underlying common stock is generally determined as the closing price of the Company&#8217;s common stock on The Nasdaq Capital Market on the grant date, with consideration of whether there is material nonpublic information that could impact that estimated fair value when it is released.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company recognized stock-based compensation expense related to awards issued under the 2017 Plan and the 2020 Plan, as well as the OnkosXcel PSUs and OnkosXcel RSU&#8217;s, of $6,156 and $18,614 for the years ended December 31, 2024 and 2023, respectively, which were comprised as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,324</p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,905</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,290</p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,156</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,614</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">2020 Employee Stock Purchase Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s 2020 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was also approved and became effective at the Company&#8217;s 2020 annual meeting of stockholders on May 20, 2020. The ESPP is designed to assist eligible employees of the Company with the opportunity to purchase the Company&#8217;s common stock at a discount through accumulated payroll deductions during successive offering periods. The aggregate number of shares that may be issued pursuant to rights granted under the ESPP is 6 shares of common stock. In addition, the number of shares available for issuance under the ESPP will increase on the first day of each calendar year, beginning on January 1, 2021 and ending on and including January 1, 2030, by a number of shares of common stock equal to the lesser of (a) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the Board of Directors. The number of shares that may be issued or transferred pursuant to rights granted under the component of the ESPP that is intended to qualify for favorable U.S. federal tax treatment under Section 423 of the Internal Revenue Code (the &#8220;Section 423 Component&#8221;) shall not exceed 31 shares. The purchase price will be determined by the administrator of the ESPP and, for purposes of the Section 423 Component, shall not be less than 85% of the fair value of a share on the first trading day or on the last trading day of the applicable offering period, whichever is lower. The shares available for issuance under the ESPP increased by 19 shares and 18 shares on January 1, 2024 and 2023, respectively. To date, no shares have been sold under the ESPP. There were 75 shares available for issuance as of December 31, 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;13. Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI leases office space for its corporate headquarters at 555 Long Wharf Drive, New Haven, Connecticut (the &#8220;HQ Lease&#8221;) under an operating lease that expires in February 2026. The Company has an option to renew the HQ Lease for one additional five-year term. Payments under the HQ Lease are fixed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company also leases equipment such as copiers and information technology equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The future minimum annual lease payments under operating leases, as of December 31, 2024, were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year ending December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 391</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total lease payments</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 456</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 439</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less current portion of lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (374)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Long-term portion of operating lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The current portion of the Company&#8217;s operating lease liability of $374, as of December 31, 2024, is included in <span style="-sec-ix-hidden:Hidden_a6pX1JmlWkyKm9cKj1tV7w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other current liabilities</span></span> on the Consolidated Balance Sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Lease expense was $394 and $392 for the years ended December 31, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Lease renewal options are not included in the ROU asset or lease liability.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAbstract', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 14. Employee Benefit Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company maintains a defined contribution retirement plan for its employees that complies with Section 401(k) of the Internal Revenue Code (the &#8220;401(K) Plan&#8221;). Employees are eligible to participate in the 401(K) Plan and can contribute a portion of their pay into the 401(K) Plan, subject to annual limits established by the U.S. Internal Revenue Service. Participating employees receive an employer matching contribution equal to 50% of eligible employee contributions on the first 5% of eligible compensation contributed. Employer contributions to the 401(K) Plan were $289 and $788<span style="background:#ffffff;"> for the years ended December 31, 2024 and 2023, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 715<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477317/912-715-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;15. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company groups its assets and liabilities measured at fair value in three levels based on the nature of the inputs and assumptions used to determine fair value. Refer to Note 3, Summary of Significant Accounting Policies, for additional information on the accounting policies related to fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The carrying amounts of Cash and cash equivalents, Accounts receivable, net and Accounts payable approximate fair value due to the short-term nature of these instruments. As of December 31, 2024 and 2023, the Company had $29,036 and $64,860, respectively, primarily in money market funds that hold U.S. government cash equivalent instruments (included in Cash and cash equivalents) which were valued based on Level 1 inputs. There were no transfers between levels within the hierarchy during the years ended December 31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Derivative liabilities measured at fair value on a recurring basis are summarized below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - BTI Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,593</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - OnkosXcel Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total derivative liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,633</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,633</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - BTI Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,193</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - OnkosXcel Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 712</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total derivative liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,905</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,905</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,905</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Derivative liabilities are comprised of the OnkosXcel Warrants and Equity Investment Right held by the Lenders. The fair value of the derivative liabilities was determined using Monte Carlo simulation models for the Equity Investment Right, and Binomial Option Pricing and Distribution models for the OnkosXcel Warrants.<span style="font-size:12pt;"> </span>As discussed in Note 9, <i style="font-style:italic;">Debt and Credit Facilities</i>, the Equity Investment Right was terminated on November 25, 2024 in connection with the Fifth Amendment to the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table presents changes in Level 3 liabilities measured at fair value for the year ended December 31, 2024. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liabilities, Balance - January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,905</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,343</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Termination of Derivative liabilities - Equity Investment Right</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,263)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_pNs2n3-e20CuK4JoOz4cQA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">   Change in fair value</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (602)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (438)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liabilities, Balance - December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,905</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The derivative liabilities were reported at their fair values in the Consolidated Balance Sheets. The changes in the fair value of the derivative liabilities were reported as gains in the Consolidated Statements of Operations as Other (income) expense, net, for the years ended December 31, 2024 and 2023, in the amounts of $20,181 and $438, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Inputs used to calculate the estimated fair value of the Equity Investment Right were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:22.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity Investment Right</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Strike price relative to volume weighted 30-day average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 110.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility (annual)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 112.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Probability of exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 91.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Time period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Estimated premium to 30-day average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 24.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The changes in fair value of the Equity Investment Right up to its termination date were recorded<span style="font-size:12pt;"> </span><span style="white-space:pre-wrap;">in the Consolidated Statements of Operations as Other (income) expense, net.  The final carrying value of the Equity Investment Right of </span>$1,263 upon derecognition was recorded was recorded as a reduction of derivative liability with the offset recorded as a gain in Other (income) expense, net, in the Consolidated Statements of Operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In estimating the fair value of the derivative liability related to the OnkosXcel Warrants, inputs included third-party fair value estimates of OnkosXcel limited liability company units along with the volatility of those units (which was set at 100% based on the historical volatility of the Company&#8217;s stock, along with a peer group of comparable publicly traded companies), and the timing and probability of the relevant capital transactions occurring.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The estimated fair value of the Credit Agreement as of December 31, 2024, was $94,204. Both observable and unobservable inputs were used to determine the fair value of long-term debt, which was classified within the Level 3 category.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following table presents the BTI warrants issued by the Company and the corresponding balance sheet classification:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Warrant Recipient</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issue Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Classification</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Closing Date Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4/19/2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">2023 Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/5/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">2024 Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3/20/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">New Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Armistice Capital Master Fund Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 534</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Armistice Capital Master Fund Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Armistice Capital Master Fund Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Heights Capital Management</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Hudson Bay Capital Management</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">IntraCoastal Capital, LLC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total warrants issued</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The fair value of the Closing Date Warrants, which was a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of $3,245 was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the OFA Facilities. This non-recurring measurement is classified as Level 2. The inputs used were a strike price of $320.64, the Company&#8217;s stock price of $238.88, volatility of 95%, term of 7 years and risk-free rate of 2.95%. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As discussed in Note 9, Debt and Credit Facilities, in connection with the closing of the Second Amendment<span style="font-size:12pt;"> </span>of the<span style="font-size:12pt;"> </span>Credit Agreement, on the Second Amendment Effective Date, the Company amended and restated the Closing Date Warrants granted to the Lenders to have an exercise price of $58.3232 per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Using a Black-Scholes pricing model, the Company determined that the Closing Date Warrants&#8217; fair values at the original strike price of $320.64 and the amended strike price of $58.3232 were $548 and $802, respectively, as of the Second Amendment Effective Date. The Closing Date Warrants&#8217; incremental increase in fair value for the repricing of $254, was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts refinanced under the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the Second Amendment, the Company issued 4 &#8220;2023 Warrants&#8221; at a strike price of $58.3232 per share. The fair value of the 2023 Warrants, which is a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of $200 was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the Credit Agreement. This non-recurring measurement is classified as Level 2. The inputs used were a strike price of $58.3232, the Company&#8217;s stock price of $59.36, volatility of 99%, term of 5.4 years and risk-free rate of 4.14%. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the Fourth Amendment, the Company issued 6 &#8220;2024 Warrants&#8221; at a strike price of $49.1568<span style="white-space:pre-wrap;"> per share.  The fair value of the &#8220;2024 Warrants&#8221;, which was a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of </span>$224 was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the OFA Facilities. This non-recurring measurement is classified as Level 2. The inputs used were a strike price of $49.1568, the Company&#8217;s stock price of $44.48, volatility of 112.2%, term of 5 years and risk-free rate of 4.25%. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, in connection with the Fifth Amendment of the Credit Agreement, on the Fifth Amendment Effective Date of November 25, 2024, the Company amended and restated the Closing Date Warrants, 2023 Warrants, and 2024 Warrants granted to the Lenders to have an exercise price of $7.68 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Using a Black-Scholes pricing model, the Company determined that the Closing Date Warrants, 2023 Warrants, and 2024 Warrants&#8217; fair values at the previously amended strike price of $58.3232 and original strike price of $49.1568 the amended strike price of $7.68 were $105 and $164, respectively, as of the Fifth Amendment Effective Date. The Closing Date Warrants, 2023 Warrants, and 2024 Warrants&#8217; incremental increase in fair value for the repricing of $59, was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts refinanced under the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;">The fair value of the Accompanying Warrants at issuance on March 25, 2024 was determined using a Black-Scholes pricing model and the fair value of $19,347 was recorded as a derivative liability with the offset recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Consolidated Balance Sheets. This fair value measurement is classified as Level 2. The valuation inputs used were a strike price of $51.20, the Company&#8217;s stock price of $44.96, volatility of 112.2%, a term of 5 years and a risk-free rate of 4.2%<span style="white-space:pre-wrap;">.  On November 25, 2024, </span>534 of the 539 Accompanying Warrants&#8217; strike price were amended to $9.136<span style="white-space:pre-wrap;">, as part of the consideration provided to one of the investors in the November 2024 Equity raise discussed in Note 11, Common Stock Financing Activities.  The increase in fair value due to the amended strike price of </span>$1,000<span style="white-space:pre-wrap;"> was recorded as an increase in the carrying value of the Derivative liability, with the offset recorded as a loss in Other (income) expense, net, in the Company&#8217;s Consolidated Statements of Operations.  We remeasured the Accompanying Warrants&#8217; fair value at December 31, 2024 of </span>$2,320 and recorded a net gain of $17,027, including the repricing loss of $1,000 for the year ended December 31, 2024, respectively within Other (income) expense, net in the Company&#8217;s Consolidated Statements of Operations. The valuation inputs used as of December 31, 2024 were a strike prices of $9.136 and $51.20 for 534 and 5 Accompanying Warrants, respectively, the Company&#8217;s stock price of $5.984, volatility of 112.3%, term of 4.2 years and risk-free rate of 4.4%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;">The fair value of the November 2024 Accompanying Warrants at issuance on November 25, 2024 was determined using a Black-Scholes pricing model and the fair value of $5,562 was recorded as a derivative liability with the offset recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets. This fair value measurement is classified as Level 2. The valuation inputs used were a strike price of $7.68, the Company&#8217;s stock price of $7.52, volatility of 112.5%, a term of 5 years and a risk-free rate of 4.2%<span style="white-space:pre-wrap;">.  We remeasured the fair value at December 31, 2024 of </span>$4,273 and recorded an unrealized gain of $1,289 for the year ended December 31, 2024, respectively within Other (income) expense, net in the Company&#8217;s Consolidated Statements of Operations. The valuation inputs used as of December 31, 2024 were a strike price of $7.68, the Company&#8217;s stock price of $5.984, volatility of 112.3%, term of 4.9 years and risk-free rate of 4.4%.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;16. Income Taxes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The significant components of the Company's net deferred tax assets at December 31, 2024 are shown below. In determining the realizability of the Company's net deferred tax assets, the Company considered numerous factors, including historical profitability, estimated future taxable income, and the industry in which it operates. Based on this </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">information the Company has provided a valuation allowance for the full amount of its net deferred tax asset because the Company has determined that it is more likely than not that they will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal net operating losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90,853</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,770</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State net operating losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,255</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,915</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,188</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,048</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research &amp; development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49,603</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 103</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease accounting - liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 212</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Disallowed charitable contributions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred Costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 674</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cancellation of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,483</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (192,149)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (173,679)</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 197</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Debt amendment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12)</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (100)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (185)</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (600)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (197)</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net deferred tax asset (liability)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The income tax expense/(benefit) for the year ended December 31, 2024 differed from the amounts computed by applying the U.S. federal income tax rate of 21% to loss before tax benefit as a result of tax credits generated and changes in the Company&#8217;s valuation allowance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A reconciliation between the Company&#8217;s effective tax rate and the federal statutory rate are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,516)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,601)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (573)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant mark-to-market</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,238)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal and state credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,870)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,082)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (343)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,470</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (30.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">At December 31, 2024 the Company had approximately $432,634 of gross federal and $443,454 of gross state net operating loss carry-forwards. If not utilized, the federal and state net operating loss carry-forwards will begin to expire in 2037. The federal net operating loss of $429,988<span style="white-space:pre-wrap;"> incurred after December 31, 2017 will carryforward indefinitely.  The utilization of such net operating loss carry-forwards and realization of tax benefits in future years depends predominantly upon having taxable income. The Company has approximately </span>$15,965 of federal orphan drug credits and research and development credits which will begin to expire in 2037 if not utilized. The Company also has approximately $1,548 of state research and development credits which will begin to expire in 2040 if not utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Utilization of the NOL and research tax credit carryforwards may be subject to a substantial annual limitation due to ownership limitations that has occurred or that could occur in the future, as required by section 382 of the Code, as well as similar state and foreign provisions.  These ownership changes may limit the amount of the NOL and research credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively.  In general, an </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">"ownership change" as defined by Section 382 of the Code results from a transaction or series of transactions over a three year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a by certain stockholders or public groups.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax positions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of December&#160;31, 2024, there were no uncertain positions. The Company's U.S. federal and state NOLs have occurred since its inception in 2017 and as such, tax years subject to potential tax examination could apply from that date because the utilization of net operating losses from prior years opens the relevant year to audit by the U.S. Internal Revenue Service and/or state taxing authorities. The Company did not have any unrecognized tax benefits and has not accrued any interest or penalties for the years ended December 31, 2024 and 2023. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 17. Net Loss Per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Basic and diluted net loss per share are as follows</span>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss (numerator)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (59,599)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (179,053)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares (denominator)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,535</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,821</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23.51)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (98.33)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Potentially dilutive securities outstanding consists of stock options, RSUs and performance units, and BTI warrants. The Company had common stock equivalents outstanding are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 311</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 311</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Performance stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 31</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">BTI Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22</p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total common stock equivalents</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 376</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 18. Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">From time to time, in the ordinary course of business, the Company may be subject to litigation and regulatory examinations as well as information gathering requests, inquiries and/or investigations. Other than the below, the Company is not currently subject to any matters where it believes there is a reasonable possibility that a material loss may be incurred.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">On July 7, 2023, plaintiff Katelyn Martin filed a class action complaint against the Company and certain executives in the United States District Court for the District of Connecticut, captioned </span><i style="font-style:italic;background:#ffffff;">Martin v. BioXcel Therapeutics, et al.</i><span style="background:#ffffff;">, 3:23-cv-00915 (D. Conn). </span>The case has since been renamed to <i style="font-style:italic;">Hills et al v. BioXcel Therapeutics, Inc. et al</i>. <span style="background:#ffffff;">On October 4, 2023, pursuant to the Private Securities Litigation Reform Act, the court appointed two co-Lead Plaintiffs. The co-Lead Plaintiffs filed an amended complaint on December 5, 2023, alleging violations of Sections 10(b) and 20A of the Securities and Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) and SEC Rule 10b-5 promulgated thereunder. On July 11, 2024, the Court dismissed the amended complaint without prejudice and, on August 1, 2024, co-Lead Plaintiffs filed a second amended complaint. The second amended complaint alleges that defendants made false or misleading statements regarding the TRANQUILITY II trial and the development of BXCL501 for an expanded indication related to the </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;background:#ffffff;">treatment of certain Alzheimer&#8217;s-related agitation. The Company moved to dismiss the second amended complaint on September 6, 2024. On February 24, 2025, while the Company&#8217;s motion to dismiss remained pending, Plaintiffs moved for leave to further amend their complaint. The Company filed an opposition to the motion on March 17, 2025. Plaintiffs&#8217; reply is due April 7, 2025.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">On November 28, 2023, Plaintiffs Pratheesan Panancherry and Jeffrey Bastress filed a stockholder derivative complaint in the United States District Court for the District of Connecticut purportedly on behalf of the Company and against Vimal Mehta, Richard I. Steinhart, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption </span><i style="font-style:italic;background:#ffffff;">Panancherry et al v. Mehta et al</i><span style="background:#ffffff;">, 3:23-cv-1554. Following the initial action, Plaintiffs Maria Vomvolakis (3:24-cv-3) and Kelly Fowler (3:24-cv-203) each filed separate stockholder derivative complaints in the District of Connecticut raising similar claims as Panancherry and Bastress, including business torts and violations of the Securities Exchange Act of 1934. The cases have been consolidated under the caption </span><i style="font-style:italic;background:#ffffff;">In re BioXcel Therapeutics, Inc. Stockholder Derivative Litigation</i><span style="background:#ffffff;">, 3:23-cv-1554 (D. Conn.). The consolidated action is currently stayed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">On January 11, 2024, Plaintiff Jeremy Smith filed a stockholder derivative complaint in the United States District Court for the District of Delaware purportedly on behalf of the Company and against Vimal Mehta, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, Richard I. Steinhart, Robert Risinger, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption </span><i style="font-style:italic;background:#ffffff;">Smith v. Mehta et al,</i><span style="background:#ffffff;"> 1:24-cv-00041. Following the initial action, Plaintiff Janice Korff filed a stockholder derivative complaint in the District of Delaware raising similar claims as Smith (1:24-cv-130), including business torts and violations of the Securities Exchange Act of 1934. The cases have been consolidated under the caption </span><i style="font-style:italic;background:#ffffff;">In re BioXcel Therapeutics, Inc. Derivative Litigation</i><span style="background:#ffffff;">, 1:24-cv-00041 (D. Del.). The consolidated action is currently stayed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">At this time, the Company does not believe the claims in the above-captioned matters have merit, and intends to vigorously defend against them; however, the potential costs and liabilities associated with this litigation are uncertain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">In April 2022, the Company signed a commercial supply agreement that requires minimum annual payments for the first three years of the agreement that in aggregate total </span><span style="background:#ffffff;">$10,000</span><span style="background:#ffffff;"> for the </span><span style="background:#ffffff;">three-year</span><span style="background:#ffffff;"> period, of which </span><span style="background:#ffffff;">$5,000</span><span style="white-space:pre-wrap;background:#ffffff;"> was originally due in year ended 2024.  On July 11, 2024, the Company entered into an amendment to the commercial supply agreement (the &#8220;Product Supply Agreement Amendment&#8221;) that reduces the specified minimum annual payment over the next three years starting in the year ended 2024 and, thereafter, for a specified interval, provides for minimum annual payments to the extent that the Company receives approval of a supplemental new drug application (sNDA) or a new drug application (NDA) from the FDA for enumerated indications. The Company&#8217;s renegotiated agreement reduced the minimum commitment for 2024 to </span><span style="background:#ffffff;">$1,000</span><span style="background:#ffffff;"> and thereafter for the term of the agreement in annual amounts ranging from </span><span style="background:#ffffff;">$2,000</span><span style="background:#ffffff;"> to </span><span style="background:#ffffff;">$5,000</span><span style="background:#ffffff;"> subject, in certain instances, to the extent that the Company receives approval of an sNDA or NDA from the FDA for enumerated indications. In accordance with the Product Supply Agreement Amendment, the minimum commitments were reduced to </span><span style="background:#ffffff;">$1,000</span><span style="background:#ffffff;">, </span><span style="background:#ffffff;">$2,000</span><span style="background:#ffffff;"> and </span><span style="background:#ffffff;">$2,000</span><span style="background:#ffffff;"> in the years 2024, 2025, and 2026.</span> <span style="background:#ffffff;">In addition, the Company agreed to make a reconciliation payment of </span><span style="background:#ffffff;">$1,200</span><span style="background:#ffffff;">, paid in the third quarter of 2024 for full settlement for amounts due prior to the July 11, 2024 amendment.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 19. Segment Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company views its operations and manages its business as one operating and reportable segment, utilizing artificial intelligence (&#8220;AI&#8221;) to develop transformative medicines in neuroscience and immuno-oncology. We are focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients&#8217; lives. We employ various AI platforms to reduce therapeutic development costs and potentially accelerate development timelines. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Consistent with the operational structure, the Chief Executive Officer, as the chief operating decision maker (&#8220;CODM&#8221;), reviews weekly cash usage and allocates resources based on consolidated net loss that also is reported on the consolidated statements of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets. The CODM utilizes consolidated net loss by comparing actual results against budgeted amounts on a quarterly basis. As part of this process, consolidated net loss is a critical performance measure used to evaluate the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company&#8217;s operating performance and guide strategic decisions and resource allocations, including additional investments in research and development and commercialization activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table provides information about the Company&#8217;s one reportable segment and includes the reconciliation to consolidated net loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Product revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,380</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Less:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,143</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,260</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,351</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,324</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,067</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,590</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Clinical trials expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,384</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,094</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Chemical, manufacturing and controls cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,927</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,687</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,280</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="white-space:pre-wrap;">     Total research and development costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,326</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,516</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,331</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (401)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,081</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 965</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Commercial and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,389</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,485</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Travel related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,004</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,038</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="white-space:pre-wrap;">    Total commercial costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,904</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,840</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,306</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,209</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,345</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Commercial and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Travel related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 446</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 982</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,133</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="white-space:pre-wrap;">    Total selling, general and administrative costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,509</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restructuring costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,163</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,511</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 173,162</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other (income) expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,314</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,602)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,649)</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other (income) expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20,173)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (394)</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Segment net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (59,599)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (179,053)</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments and reconciling items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consolidated Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (59,599)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (179,053)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 20. Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As discussed in Note 11, <i style="font-style:italic;">Common Stock Financing Activities</i>, in connection with the November 2024 issuance and sale in a public offering of (i) 350 shares of the Company&#8217;s common stock, and the November 2024 Accompanying Warrants to purchase 350 shares of Common Stock, and (ii) pre-funded warrants to purchase 563 shares of Common Stock, in February 2025, certain investors exercised the remaining 483 pre-funded warrants to purchase 483 shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 3, 2025, the Company entered into the Purchase Agreement with the Purchaser named therein. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Purchaser and the Purchaser agreed to buy in a registered direct offering (i) an aggregate of 188 shares (the &#8220;Shares&#8221;) of common stock, par value $0.001 per share and accompanying warrants to purchase up to 188 shares of Common Stock at a combined offering price of $3.50 per Share and accompanying warrant, and (ii) the Pre-Funded Warrants to purchase up to 3,812 shares of Common Stock and accompanying warrants to purchase up to 3,812 shares of Common Stock, at a combined offering price of $3.499 per share underlying the Pre-Funded Warrants and accompanying warrant, which equals the offering price per Share and accompanying warrant less the $0.001exercise price per share of the Pre-Funded Warrants, pursuant to an effective registration statement on Form S-3 (File No. 333-275261), including the base prospectus included therein, and prospectus supplement filed with the SEC on March 4, 2025. As of March 28, 2025, 1,688 Pre-Funded Warrants were exercised. In the 2025 Offering, the Company also issued to the Purchaser warrants (the &#8220;Option Warrants&#8221;), to purchase up to 4,000 shares of Common Stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 4,000 shares of Common Stock to the Purchaser. The pre-funded warrants and accompanying warrants issuable upon exercise of the Option Warrants will have substantially identical terms as the Pre-Funded Warrants and the accompanying warrants. The exercise price of the Option Warrants is $3.50 per underlying share of Common Stock and accompanying warrant to purchase one share of Common Stock, or $3.499 per underlying pre-funded warrant to purchase one share of Common Stock and accompanying warrant to purchase one share of Common Stock. The Option Warrants expired on March 18, 2025 without being exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 26, 2025, we and Jefferies terminated that certain Open Market Sales Agreement, dated May 10, 2021, as amended on November 1, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (59,599)<span></span>
</td>
<td class="num">$ (179,053)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Insider Trading Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>On December 14, 2024, Vimal Mehta, Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 2,184 shares of the Company&#8217;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>On December 14, 2024, Richard Steinhart, Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 1,563 shares of the Company&#8217;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>On December 14, 2024, Javier Rodriguez, Senior Vice President, Chief Legal Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 1,563 shares of the Company&#8217;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>On December 14, 2024, Frank Yocca, Chief Scientific Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 1,563 shares of the Company&#8217;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Each of these plans were terminated effective March 17, 2025.</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_IndividualAxis=btai_VimalMehtaMember', window );">Vimal Mehta</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Vimal Mehta<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Executive Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December 14, 2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">December 31, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">2,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_IndividualAxis=btai_RichardSteinhartMember', window );">Richard Steinhart</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Richard Steinhart<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Executive Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December 14, 2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">December 31, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">1,563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_IndividualAxis=btai_JavierRodriguezMember', window );">Javier Rodriguez</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Javier Rodriguez<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Senior Vice President, Chief Legal Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December 14, 2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">December 31, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">1,563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_IndividualAxis=btai_FrankYoccaMember', window );">Frank Yocca</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Frank Yocca<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Scientific Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December 14, 2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">December 31, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">1,563<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=btai_VimalMehtaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=btai_VimalMehtaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=btai_RichardSteinhartMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=btai_RichardSteinhartMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=btai_JavierRodriguezMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=btai_JavierRodriguezMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=btai_FrankYoccaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=btai_FrankYoccaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. Our cybersecurity risk management program includes a cybersecurity incident response plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We designed and assessed our program based on the National Institute of Standards and Technology Cybersecurity Framework. This does not imply that we meet any particular technical standards, specifications, or requirements, only </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">that we used the National Institute of Standards and Technology Cybersecurity Framework as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our cybersecurity risk management program is integrated into our overall enterprise risk management program, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our cybersecurity risk management program includes:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise information technology environment;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>a management team responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>cybersecurity awareness training of our employees, incident response personnel, and senior management; </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>a third-party risk management process for service providers, suppliers, and vendors.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There can be no assurance that our cybersecurity risk management program and processes, including our policies, controls or procedures, will be fully implemented, complied with or effective in protecting our systems and information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. For more information, see the section titled &#8220;Risk Factors&#8212; Business interruptions could adversely affect future operations, revenues, and financial conditions, and may increase our costs and expenses.&#8221;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Our cybersecurity risk management program is integrated into our overall enterprise risk management program, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the &#8220;Committee&#8221;) oversight of cybersecurity and other information technology risks. The Committee oversees management&#8217;s implementation of our cybersecurity risk management program. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Committee receives periodic reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also receives briefings from management on our cyber risk management program. Board members receive presentations on cybersecurity topics from the internal Security Incident Management Team or external experts as part of the Board&#8217;s continuing education on topics that impact public companies.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the &#8220;Committee&#8221;) oversight of cybersecurity and other information technology risks<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Committee receives periodic reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also receives briefings from management on our cyber risk management program. Board members receive presentations on cybersecurity topics from the internal Security Incident Management Team or external experts as part of the Board&#8217;s continuing education on topics that impact public companies.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our Security Incident Management Team, which includes our Chief Financial Officer, the Executive Director of Information Technology, Chief Legal Officer and the Quality Assurance Director, has approximately 30 combined years of risk management experience and is responsible for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. Our Security Incident Management Team&#8217;s experience includes prior work experience in cybersecurity; financial management and controls, data quality assurance and liability and risk management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the information technology environment.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Chief Financial Officer, the Executive Director of Information Technology, Chief Legal Officer and the Quality Assurance Director<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">30 combined years of risk management experience<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">The Committee receives periodic reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements include those of the Company and its subsidiaries after elimination of all intercompany accounts and transactions and have been prepared in conformity with United States (&#8220;U.S.&#8221;) Generally Accepted Accounting Principles (&#8220;GAAP&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the consolidated financial statements and notes thereto. Estimates are used in the following areas, among others: revenue recognition, inventory valuation, derivative liabilities, stock-based compensation expense, accrued expenses and income taxes. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ReverseStockSplit', window );">Reverse Stock Split</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On February 10, 2025, the Company completed a <span style="-sec-ix-hidden:Hidden_MAC978-QcU6PY1cLIWQ4hg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1-for-16</span></span> reverse stock split of its issued and outstanding common stock (the &#8220;Reverse Stock Split&#8221;). As a result of the Reverse Stock Split, each 16 shares of common stock issued and outstanding immediately prior to February 10, 2025 were automatically converted into one of a share of common stock. The Reverse Stock Split affected all common stockholders uniformly and did not alter any stockholder's percentage interest in the Company's equity, except to the extent that the Reverse Stock Split would result in a stockholder owning a fractional share. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise would be entitled to receive a fractional share instead were entitled to receive cash in lieu of such fractional share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Reverse Stock Split did not change the par value of the common stock or the authorized number of shares of common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">All common share and per-share amounts in this Form 10-K have been retroactively restated to reflect the effect of the Reverse Stock Split.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of December 31, 2024 and 2023, cash equivalents were comprised primarily of money market funds. Cash and cash equivalents held at financial institutions may at times exceed federally insured amounts. BTI management believes it mitigates such risk by investing in or through major financial institutions.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable, Net</a></td>
<td class="text"><p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Accounts Receivable, Net</b></p><p style="font-family:'Liberation Serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Accounts receivable arise from sales of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">IGALMI</span><sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"> and represent amounts due from distributors. Payment terms generally range from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">30</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"> to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">75 days</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"> from the date of the sale transaction, and accordingly, do not involve a significant financing component. Receivables from product sales are recorded net of allowances which generally include distribution fees, prompt payment discounts, chargebacks, and credit losses. Allowances for distribution fees, prompt payment discounts and chargebacks are based on contractual terms. The Company estimated the current expected credit losses of its accounts receivable by assessing the risk of loss and available relevant information about collectability, existing contractual payment terms, actual payment patterns of its customers, individual customer circumstances, and reasonable and supportable forecast of economic conditions expected to exist throughout the contractual life of the receivable. Based on its assessment, as of December 31, 2024, the Company determined that an allowance for credit losses was not required.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Concentrations of Credit Risk</b></p><p style="font-family:'Liberation Serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Company sells IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';"> through a drop-ship program under which orders from hospitals and similar health care institutions are processed through wholesalers, but shipments of the product are sent directly to the individual hospitals and similar health care institutions. BTI also contracts directly with intermediaries such as group purchasing organizations (&#8220;GPOs&#8221;). All trade accounts receivables are due from the distributor that fulfills orders on behalf of the Company.</span><span style="font-family:'Times New Roman','Times','serif';"> For the years ended December 31, 2024 and 2023, one customer accounted for approximately </span><span style="font-family:'Times New Roman','Times','serif';">32%</span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">39%</span><span style="font-family:'Times New Roman','Times','serif';"> of the Company&#8217;s net product revenue, respectively. </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Inventory</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or net realizable value. Cost of inventory is determined on a first-in, first-out basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">BTI capitalizes inventory costs associated with the Company&#8217;s products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development expense in the Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, will be recorded within Cost of goods sold in the Consolidated Statements of Operations. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected, write-downs of inventory may be required.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_DeferredOfferingCostsPolicyTextBlock', window );">Deferred Initial Public Offering Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Deferred Initial Public Offering Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Deferred initial public offering costs of $2,570, consisted of legal, accounting, and other costs that were directly related to the Company&#8217;s proposed initial public offering of OnkosXcel. These costs were charged to the Consolidated Statements of Operations during the year ended December 31, 2023 as the initial public offering was delayed for an extended period of time. The costs were recorded as Selling, general and administrative expenses. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Property and equipment are recorded at cost and depreciated over the shorter of their remaining lease term or their estimated useful life on a straight-line basis as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:2.15pt;"><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Equipment</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">3-5 years</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Furniture</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">7 years</p></td></tr><tr style="height:13.1pt;"><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">Lesser of life of improvement or lease term</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Expenditures for maintenance and repairs which do not improve or extend the useful lives of the respective assets are expensed as incurred. When assets are sold or retired, the related cost and accumulated depreciation are removed from their respective accounts and any resulting gain or loss is included within Other (income) expense, net in the Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to undiscounted future net cash flows expected to be generated from its use and disposition. Impairment charges are recognized at the amount by which the carrying amount of an asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, other current liabilities, and the long-term portion of operating lease liabilities in the Consolidated Balance Sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">ROU assets represent BTI&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses the implicit rate when readily determinable. As BTI&#8217;s leases do not provide an implicit rate, it used an incremental </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any prepaid lease payments made and is reduced by lease incentives. The Company&#8217;s leases may include options to extend the lease; such options are included in determining the lease term when it is reasonably certain that BTI will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt and Detachable Warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Debt and Detachable Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Detachable warrants are evaluated for classification as either equity instruments, derivative liabilities, or liabilities depending on the specific terms of the warrant agreement. In circumstances in which debt is issued with equity-classified warrants, the proceeds from the issuance of debt are first allocated to the debt and then the warrants at their estimated fair values. The portion of the proceeds allocated to the warrants are accounted for as paid-in capital and a debt discount. The remaining proceeds, as further reduced by discounts created by the bifurcation of any embedded derivatives, are allocated to the debt. Detachable warrants classified as derivative liabilities are accounted for as indicated under &#8220;<i style="font-style:italic;">Derivative Assets and Liabilities</i>&#8221; section of this Note and as a debt discount. The Company accounts for debt as liabilities measured at amortized cost and amortizes the resulting debt discount from the allocation of proceeds to interest expense using the effective interest method over the expected term of the debt instrument. The Company considers whether there are any embedded features in debt instruments that require bifurcation and separately accounts for them as derivative financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company entered into financing arrangements, the terms of which involve significant assumptions and estimates, including future net product sales, in determining interest expense, amortization period of the debt discount, as well as the classification between current and long-term portions. In estimating future net product sales, the Company assesses prevailing market conditions using various external market data against the Company&#8217;s anticipated sales and planned commercial activities. Consequently, the Company imputes interest on the carrying value of the debt and records interest expense using an imputed effective interest rate. The Company reassesses the expected payments during each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of the Company&#8217;s current and long-term portions of the debt.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Assets and Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Derivative Assets and Liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Derivative assets and liabilities are recorded on the Company`s Consolidated Balance Sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded as other income or expense within Other (income) expense, net in the Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company does not use derivative instruments for speculative purposes or to hedge exposures to cash-flow or market risks. Certain financing facilities entered into by the Company include freestanding financial instruments and/or embedded features that require separate accounting as derivative assets and/or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Revenue Recognition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s revenues consist of product sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition, BTI management performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The exercise of a material right may be accounted for as a contract modification or as a continuation of the contract for accounting purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such goods and services are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the Company&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company allocates the transaction price (the amount of consideration it expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#8217;s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI distributes IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the U.S. through arrangements with a distributor, wholesalers, and GPOs. The distributor and wholesalers help process and fulfill orders from hospitals on the Company&#8217;s behalf. The Company believes the hospitals are its customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company recognizes product revenues, net of consideration payable to customers, as well as variable consideration related to certain allowances and accruals that are determined using either the expected value or most likely amount method, depending on the type of the variable consideration, in its consolidated financial statements at the point in time when control transfers to the customer, which is typically when the product has been delivered to the customer&#8217;s location. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company&#8217;s only performance obligation identified for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is to deliver the quantity of product ordered to the location specified by the customer&#8217;s order. The Company records shipping and handling costs associated with delivery of product to its customers within Selling, general and administrative expenses on its Consolidated Statements of Operations. Under the Company&#8217;s current product sales arrangements, BTI does not have contract assets (unbilled receivables), as it generally invoices its customer at the time of revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI sells IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> at wholesale acquisition cost, less any agreed upon discounts and calculates product revenue net of variable consideration and consideration payable to third parties associated with distribution of product. The Company records reserves, based on contractual terms, for the following components of consideration related to product sold during the reporting period. Calculating these amounts involves estimates and judgments, and the Company reviews these estimates quarterly and records any material adjustments in the period they are identified, which affects net product revenue and earnings in the period such variances occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Trade Discounts and Allowances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company provides the distributor and wholesalers with discounts for prompt payment and pays fees to the distributor, wholesalers and GPOs related to distribution of the product. BTI expects the relevant third parties to earn these discounts and fees, and therefore it deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Government Rebates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is eligible for purchase by, or qualifies for reimbursement from, Medicaid and other U.S. government programs that are eligible for rebates on the price they pay for the product. To determine the appropriate amount to reserve for these rebates, BTI applies the applicable government discount to these sales, and estimates the portion of total rebates that it anticipates will be claimed. The Company deducts certain government rebates from gross product </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">revenue and accounts receivable at the time it recognizes the related revenue; other government rebates are recognized as an accrued liability at the time BTI recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Chargebacks</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI provides product discounts to hospitals associated with certain GPOs. The Company estimates the chargebacks that it expects to be obligated to provide based upon the terms of the applicable arrangements. BTI deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product Returns</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company provides contractual return rights to its customers including the right to return product within six months of product expiration and up to 12 months after product expiration, as well as for incorrect shipments, and damaged or defective product, which the Company expects to be rare. Management expects product returns to be minimal, thus BTI recognizes a nominal allowance for product returns at the time of each sale. In the future, if any of these factors and/or the history of product returns changes, the Company will adjust the allowance for product returns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI classifies all fees paid to the distributor, other than those discussed above and those related to warehouse operations, as Selling, general and administrative expenses on its Consolidated Statements of Operations. Fees paid to the distributor for warehouse operations are classified as Cost of goods sold on BTI&#8217;s Consolidated Statements of Operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods Sold</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Cost of Goods Sold</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold includes the cost of producing and distributing inventories that are related to product revenues during the respective period. Cost of goods sold also includes costs related to excess or obsolete inventory adjustment charges, as well as costs related to warehouse operations paid to distributors.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company measures and recognizes stock-based compensation expense based on estimated fair value for all share-based awards made to employees, non-employee service providers, and directors, including stock options, BTI restricted stock units (&#8220;BTI RSUs&#8221;), OnkosXcel profit sharing units (&#8220;PSUs&#8221;), OnkosXcel restricted stock units (&#8220;OnkosXcel RSUs&#8221;) and BTI performance stock units (&#8220;Performance Units&#8221;). The Company&#8217;s 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;) became effective in August 2017. The Company&#8217;s 2020 Incentive Award Plan (the &#8220;2020 Plan&#8221;) became effective in May 2020. Following the effective date of the 2020 Plan, the Company ceased granting awards under the 2017 Plan; however, the terms and conditions of the 2017 Plan continue to govern any outstanding awards granted thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s stock-based awards are valued at fair value on the date of grant and that fair value is recognized as an expense in the Consolidated Statements of Operations over the requisite service period using the accelerated attribution method. The estimated value of the BTI RSUs and Performance Units is based on the Company&#8217;s closing stock price on the grant date. The estimated fair value of OnkosXcel RSUs are based on the OnkosXcel valuation on the grant date. The estimated fair value of stock-options and PSUs was determined using the Black-Scholes pricing model on the date of grant. For awards subject to performance-based vesting conditions, the Company recognizes stock-based compensation expense when the achievement of the performance condition becomes probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Black-Scholes pricing model is affected by the Company&#8217;s stock price, as well as assumptions regarding variables including, but not limited to, the strike price of the instrument, the risk-free rate, the expected stock price volatility over the term of the awards and expected term of the awards. The Company has elected to account for forfeitures as they occur, by reversing compensation cost when the award is forfeited.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Research and development expenses include wages, benefits, non-cash stock-based compensation, facilities, supplies, external services, clinical study, manufacturing costs related to clinical trials and other expenses that are directly related to the Company&#8217;s research and development activities. At the end of the reporting period, the Company estimates the progress toward completion of the research or development objectives and, depending on the amount and timing of payments to the service providers may record net prepaid or accrued expense for associated research and development costs. Such estimates are subject to change as additional information becomes available. The Company expenses research and development costs as incurred.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Most of the Company&#8217;s service providers invoice BTI monthly in arrears for services performed. The Company estimates its accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to management at that time. BTI management periodically confirms the accuracy of the Company&#8217;s estimates with the service providers and makes adjustments if necessary.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Although management does not expect its estimates to be materially different from amounts actually incurred, management&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in BTI reporting amounts that are too high or too low in any particular period.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Costs related to filing and pursuing patent applications are recorded in Selling, general and administrative expenses in the Consolidated Statements of Operations and are expensed as incurred since recoverability of such expenditures is uncertain.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company measures certain financial assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources, or observable inputs, and (2) an entity&#8217;s own assumptions about market participant assumptions developed based on the best information available in the circumstances, or unobservable inputs. The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). Fair value measurements must be classified and disclosed in one of the following three categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Level 1</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Level 2</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Level 3</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management&#8217;s estimates of market participant assumptions.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considering counterparty credit risk in its assessment of fair value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI uses an asset and liability approach for financial accounting and reporting of income taxes. Deferred tax assets and liabilities are determined based on temporary differences between financial reporting and tax basis assets and liabilities and are measured by applying enacted rates and laws to taxable years in which differences are expected to be recovered or settled. Further, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that the rate changes. A valuation allowance is required when it is &#8220;more likely than not&#8221; that all or a portion of deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">U.S. GAAP prescribes a comprehensive model for how a company should recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on a tax return, including a decision whether to file or not file a return in a particular jurisdiction. The Company&#8217;s financial statements reflect expected future tax consequences of such positions presuming the taxing authorities&#8217; full knowledge of the position and all relevant facts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company does not have any unrecognized tax benefits as of December 31, 2024 and 2023. BTI reviews all tax positions to ensure the tax treatment selected is sustainable based on its technical merits and that the position would be sustained if challenged.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Earnings (Loss) per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Earnings (loss) per share (&#8220;EPS&#8221;) is calculated by dividing net income or loss attributable to common stockholders by the weighted average number of shares of common stock that were outstanding, including pre-funded warrants. Shares of common stock into which the pre-funded warrant may be exercised are considered outstanding for the purposes of computing EPS because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date. Diluted EPS is calculated by adjusting the weighted average number of shares of common stock that were outstanding for the dilutive effect of common stock equivalents. In periods in which a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be antidilutive.&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Segment Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company operates in a single segment. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. To date, the Company&#8217;s chief operating decision maker has made such decisions and assessed performance at the Company level as one segment. See Note 19, <i style="font-style:italic;">Segment Information</i> for further information</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently adopted accounting pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In November 2023, the FASB issued ASU 2023-07, Segment reporting, which requires disclosure of incremental segment information on an annual and interim basis. The standard is effective for years beginning after December 15, 2023, and interim periods beginning after December 15, 2024 and early adoption is permitted. The Company adopted the new standard in fiscal year 2024 for annual and retrospective reporting periods with all interim disclosures to begin in the first quarter of fiscal year 2025. For additional information, see Note 19, <i style="font-style:italic;">Segment Information</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting Pronouncements effective in future periods</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, Improvements to income tax disclosures, which requires disclosure of disaggregated income taxes paid by jurisdiction, enhances disclosures in the effective tax rate reconciliation and modifies other income tax-related disclosures. The amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the effect of adopting this guidance on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_DeferredOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_DeferredOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for patent costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy - Reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org/705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing revenue from a transaction on a gross or net basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock', window );">Schedule of property and equipment useful lives</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:2.15pt;"><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Equipment</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">3-5 years</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Furniture</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">7 years</p></td></tr><tr style="height:13.1pt;"><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">Lesser of life of improvement or lease term</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of Property Plant And Equipment Useful Lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 935</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 651</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 405</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total inventory</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,991</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 202</p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 575</p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,200</p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total property and equipment</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,977</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,977</p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,502)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,193)</p></td></tr><tr><td style="vertical-align:bottom;width:65.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 784</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,406</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 163</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,562</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 116</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 322</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 177</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued restructuring costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 603</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total accrued expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,424</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with BioXcel LLC (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Transactions with BioXcel LLC</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of service charges</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,075</p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 392</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 211</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,330</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,286</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt and Credit Facilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Credit Agreement and Guaranty</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 102,319</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 102,319</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payable-in-kind ("PIK") interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 361</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total long-term debt liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 106,722</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 102,680</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unamortized debt premiums, discounts and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,214)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,082)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total long-term debt</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 102,508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 100,598</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of maturities on long-term debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,291</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock', window );">Schedule of long-term debt interest expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14,662</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,941</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion of debt discount and amortization of financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 467</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,373</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total interest expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,314</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest expense associated with long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price per share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 311</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 296.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 214.56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 339.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 311</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 265.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options vested and exercisable as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 291.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation charges</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,324</p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,905</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,290</p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,156</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,614</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">BTI RSU</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of activity relating to RSUs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares </b></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6)</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 27</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">BTI PSU</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock', window );">Schedule of activity relating to PSUs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares </b></p></td></tr><tr><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 33</p></td></tr><tr><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 87</p></td></tr><tr><td style="vertical-align:bottom;width:86.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27)</p></td></tr><tr><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23)</p></td></tr><tr><td style="vertical-align:bottom;width:86.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 70</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember', window );">OnkosXcel PSU</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock', window );">Schedule of activity relating to PSUs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price per unit</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in whole dollars)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,626</p></td></tr><tr><td style="vertical-align:bottom;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,176</p></td></tr><tr><td style="vertical-align:bottom;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (89)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,506</p></td></tr><tr><td style="vertical-align:bottom;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested units as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 941</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,570</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:22.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024 grant profit share unit valuation inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 97.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btai_RestrictedStockUnitsOnkosxcelMember', window );">OnkosXcel RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of activity relating to RSUs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">units</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 225</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Granted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Vested</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (41)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Cancelled</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 176</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.15969849%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;width:28.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;width:28.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">5.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">5.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected stock price volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">108.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">112.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">96.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">109.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:40.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">3.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">4.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:40.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding performance-based awards that are fully vested and expected to vest. Includes, but is not limited to, unvested awards for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=btai_RestrictedStockUnitsOnkosxcelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=btai_RestrictedStockUnitsOnkosxcelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of maturities of the operating lease liability</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year ending December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 391</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total lease payments</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 456</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 439</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less current portion of lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (374)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Long-term portion of operating lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of fair value on a recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - BTI Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,593</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - OnkosXcel Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total derivative liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,633</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,633</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - BTI Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,193</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - OnkosXcel Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 712</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total derivative liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,905</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,905</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,905</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Schedule of changes in Level 3 liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liabilities, Balance - January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,905</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,343</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Termination of Derivative liabilities - Equity Investment Right</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,263)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_pNs2n3-e20CuK4JoOz4cQA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">   Change in fair value</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (602)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (438)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liabilities, Balance - December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,905</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of fair value unobservable inputs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:22.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity Investment Right</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Strike price relative to volume weighted 30-day average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 110.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility (annual)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 112.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Probability of exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 91.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Time period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Estimated premium to 30-day average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 24.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Warrant Recipient</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issue Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Classification</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Closing Date Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4/19/2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">2023 Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/5/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">2024 Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3/20/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">New Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Armistice Capital Master Fund Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 534</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Armistice Capital Master Fund Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Armistice Capital Master Fund Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Heights Capital Management</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Hudson Bay Capital Management</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">IntraCoastal Capital, LLC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total warrants issued</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of net deferred tax assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal net operating losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90,853</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,770</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State net operating losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,255</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,915</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,188</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,048</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research &amp; development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49,603</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 103</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease accounting - liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 212</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Disallowed charitable contributions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred Costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 674</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cancellation of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,483</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (192,149)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (173,679)</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 197</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Debt amendment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12)</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (100)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (185)</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (600)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (197)</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net deferred tax asset (liability)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective tax rate and statutory rate reconciliation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,516)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,601)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (573)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant mark-to-market</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,238)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal and state credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,870)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,082)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (343)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,470</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (30.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss (numerator)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (59,599)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (179,053)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares (denominator)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,535</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,821</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23.51)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (98.33)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 311</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 311</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Performance stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 31</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">BTI Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22</p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total common stock equivalents</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 376</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of reportable segment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Product revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,380</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Less:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,143</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,260</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,351</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,324</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,067</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,590</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Clinical trials expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,384</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,094</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Chemical, manufacturing and controls cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,927</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,687</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,280</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="white-space:pre-wrap;">     Total research and development costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,326</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,516</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,331</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (401)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,081</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 965</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Commercial and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,389</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,485</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Travel related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,004</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,038</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="white-space:pre-wrap;">    Total commercial costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,904</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,840</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,306</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,209</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,345</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Commercial and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Travel related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 446</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 982</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,133</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="white-space:pre-wrap;">    Total selling, general and administrative costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,509</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restructuring costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,163</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,511</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 173,162</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other (income) expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,314</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,602)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,649)</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other (income) expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20,173)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (394)</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Segment net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (59,599)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (179,053)</p></td></tr><tr><td style="vertical-align:bottom;width:58.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments and reconciling items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consolidated Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (59,599)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (179,053)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 29,854<span></span>
</td>
<td class="nump">$ 65,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">650,197<span></span>
</td>
<td class="nump">590,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net losses</a></td>
<td class="nump">59,599<span></span>
</td>
<td class="nump">179,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="nump">$ 72,027<span></span>
</td>
<td class="nump">$ 155,006<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 10, 2025</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split</a></td>
<td class="nump">0.0625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_AccountsReceivablePaymentTerm', window );">Accounts receivable payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_AccountsReceivablePaymentTerm', window );">Accounts receivable payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">75 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_AccountsReceivablePaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The credit period offered to customers or receivables by the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_AccountsReceivablePaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Concentrations (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember', window );">Revenue benchmark | Customer concentration | Customer one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=btai_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=btai_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 17, 2024 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th"><div>May 08, 2024</div></th>
<th class="th"><div>Aug. 08, 2023</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Employees eliminated (as a percent)</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 1,553<span></span>
</td>
<td class="nump">$ 856<span></span>
</td>
<td class="nump">$ 2,441<span></span>
</td>
<td class="nump">$ 4,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Employees eliminated | employee</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected total restructuring charges</a></td>
<td class="nump">$ 1,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Accrued restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance and benefit costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember', window );">Contract termination costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 506<span></span>
</td>
<td class="nump">$ 935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">679<span></span>
</td>
<td class="nump">1,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs</a></td>
<td class="nump">$ 1,980<span></span>
</td>
<td class="nump">$ 1,191<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 1,977<span></span>
</td>
<td class="nump">$ 1,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(1,502)<span></span>
</td>
<td class="num">(1,193)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">575<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 3,107<span></span>
</td>
<td class="nump">$ 6,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">1,604<span></span>
</td>
<td class="nump">5,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Accrued taxes</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Accrued restructuring costs</a></td>
<td class="nump">603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 5,762<span></span>
</td>
<td class="nump">$ 12,424<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with BioXcel LLC (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Transactions with BioXcel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,435<span></span>
</td>
<td class="nump">$ 84,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,492<span></span>
</td>
<td class="nump">83,413<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,511<span></span>
</td>
<td class="nump">173,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Transactions with BioXcel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other Liabilities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | BioXcel LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Transactions with BioXcel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement', window );">Monthly agreement option fees</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">938<span></span>
</td>
<td class="nump">1,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,330<span></span>
</td>
<td class="nump">1,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other Liabilities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | BioXcel LLC | Development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Transactions with BioXcel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_CollaborativeArrangementMilestonePaymentsPotential', window );">Potential milestone payments</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | BioXcel LLC | Sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Transactions with BioXcel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_CollaborativeArrangementMilestonePaymentsPotential', window );">Potential milestone payments</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_CollaborativeArrangementMilestonePotentialPercent', window );">Maximum milestone (as as percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fees per month to be paid to enter into collaborative service agreement option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_CollaborativeArrangementMilestonePaymentsPotential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of potential maximum payments that could be paid under the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_CollaborativeArrangementMilestonePaymentsPotential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_CollaborativeArrangementMilestonePotentialPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum percentage of net sales payable under a collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_CollaborativeArrangementMilestonePotentialPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=btai_BioxcelCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=btai_BioxcelCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=btai_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=btai_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=btai_SalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=btai_SalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities - Debt summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total long-term debt liability</a></td>
<td class="nump">$ 106,722<span></span>
</td>
<td class="nump">$ 102,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt premiums, discounts and issuance costs</a></td>
<td class="num">(4,214)<span></span>
</td>
<td class="num">(2,082)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">102,508<span></span>
</td>
<td class="nump">100,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">4,403<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total long-term debt liability</a></td>
<td class="nump">$ 102,319<span></span>
</td>
<td class="nump">$ 102,319<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities - Credit Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 21, 2024</div></th>
<th class="th"><div>Mar. 27, 2024</div></th>
<th class="th"><div>Mar. 20, 2024</div></th>
<th class="th"><div>Feb. 12, 2024</div></th>
<th class="th"><div>Dec. 05, 2023</div></th>
<th class="th"><div>Nov. 13, 2023</div></th>
<th class="th"><div>Apr. 19, 2022</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 12, 2023</div></th>
<th class="th"><div>Apr. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total long-term debt liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,722<span></span>
</td>
<td class="nump">$ 102,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of common stock and warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payment of principal of Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_OfaAdministrativeAgentMember', window );">OFA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_NetCashRequiredMinimum', window );">Cash maintenance in controlled accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement', window );">Minimum Liquidity Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_SubsidiaryOwnershipPercentage', window );">Subsidiary ownership (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_PercentageOfOutstandingLoan', window );">Outstanding loan (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_OfaAdministrativeAgentMember', window );">OFA | From and after the funding of Tranche B loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_NetCashRequiredMinimum', window );">Cash maintenance in controlled accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_OfaAdministrativeAgentMember', window );">OFA | From and after satisfaction of funding conditions for tranche C loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_NetCashRequiredMinimum', window );">Cash maintenance in controlled accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_LineOfCreditFacilityInvestmentAllowed', window );">Maximum investment allowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,865<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt instrument fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_LineOfCreditFacilityAmendmentFeePercentage', window );">Amendment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_LineOfCreditFacilityExitFeePercentage', window );">Exit fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total long-term debt liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,319<span></span>
</td>
<td class="nump">$ 102,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_EquityInvestmentRightAmountUnfunded', window );">Equity Investment Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_DebtInstrumentInterestRateDiscountRatePercentage', window );">Discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration', window );">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</a></td>
<td class="text">us-gaap:SecuredOvernightFinancingRateSofrMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:SecuredOvernightFinancingRateSofrMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_DebtInstrumentIncrementalOnVariableRatePercent', window );">Incremental interest rate (as a percent)</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_PaidInKindInterestPercentage', window );">Debt paid-in-kind interest (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_TickingFeesPercentage', window );">Ticking fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement', window );">Minimum Liquidity Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt', window );">Minimum revenue required from equity sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of common stock and warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payment of principal of Long-term debt</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed rate</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded', window );">Principal payment of loans (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod', window );">Maximum percentage of budgeted amount allowed for disbursement</a></td>
<td class="nump">115.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement | Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total long-term debt liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement | Tranche A-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total long-term debt liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement | Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement | Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement | Tranche D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement | Period one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement', window );">Minimum Liquidity Amount</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt', window );">Minimum revenue required from equity sale</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement | Period two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement', window );">Minimum Liquidity Amount</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt', window );">Minimum revenue required from equity sale</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement | Period three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement', window );">Minimum Liquidity Amount</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt', window );">Minimum revenue required from equity sale</a></td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum liquidity required per the financial covenant of debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_DebtInstrumentIncrementalOnVariableRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage points added to the reference rate and variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_DebtInstrumentIncrementalOnVariableRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_DebtInstrumentInterestRateDiscountRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of  basis point original issue discount at which the borrowings under the credit agreement are issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_DebtInstrumentInterestRateDiscountRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the quarterly amortization payments as percentage of principal amount of funded loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_EquityInvestmentRightAmountUnfunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of equity investment right in the OFA that is currently unfunded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_EquityInvestmentRightAmountUnfunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_LineOfCreditFacilityAmendmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The line of credit facility fee for credit agreement amendment based on a loans outstanding, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_LineOfCreditFacilityAmendmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_LineOfCreditFacilityExitFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The line of credit facility exit fee, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_LineOfCreditFacilityExitFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_LineOfCreditFacilityInvestmentAllowed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the Lenders agree to permit the entity to invest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_LineOfCreditFacilityInvestmentAllowed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of budgeted amount allowed for disbursement in applicable period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount of gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_NetCashRequiredMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum maintenance of cash or permitted cash equivalent investments in accounts controlled by lenders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_NetCashRequiredMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_PaidInKindInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Paid-in-kind interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_PaidInKindInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_PercentageOfOutstandingLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding Loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_PercentageOfOutstandingLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_SubsidiaryOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock of subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_SubsidiaryOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_TickingFeesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents ticking fees percentage relating to debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_TickingFeesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of variable interest rate on debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btai_OfaAdministrativeAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btai_OfaAdministrativeAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_FromAndAfterFundingOfTrancheBLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_FromAndAfterFundingOfTrancheBLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_TrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_TrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_TrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_TrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_TrancheCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_TrancheCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_TrancheDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_TrancheDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_PeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_PeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_PeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_PeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_PeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_PeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt and Credit Facilities - Revenue Interest Financing (Details) - Revenue interest financing - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 05, 2023</div></th>
<th class="th"><div>Apr. 19, 2022</div></th>
<th class="th"><div>Jul. 08, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Debt extinguishment</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ThresholdRatioOfDebtToRevenueRatio', window );">Debt to revenue multiplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_RevenueInterestFinancingAgreementMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_BorrowingsBasedOnNetSalesPercent', window );">Borrowing allowed per net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_RevenueInterestFinancingAgreementMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_BorrowingsBasedOnNetSalesPercent', window );">Borrowing allowed per net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_RevenueInterestFinancingAgreementMember', window );">Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_BorrowingsBasedOnNetSalesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum borrowings allowed based on a percentage of net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_BorrowingsBasedOnNetSalesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ThresholdRatioOfDebtToRevenueRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents threshold ratio for debt to revenue ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ThresholdRatioOfDebtToRevenueRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btai_RevenueInterestFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btai_RevenueInterestFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_TrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_TrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt and Credit Facilities - Warrants (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 20, 2024</div></th>
<th class="th"><div>Apr. 19, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 21, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 05, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember', window );">Closing Date Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 49.1568<span></span>
</td>
<td class="nump">$ 320.64<span></span>
</td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58.3232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_RightToPurchaseStockLenders', window );">Maximum equity investment allowed for lenders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_PremiumSharePricePercent', window );">Premium share price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Common stock issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_NewWarrantsMember', window );">New Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.16<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OriginalWarrantsMember', window );">Original Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantShares2024Member', window );">2024 Warrant Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 49.1568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_PremiumSharePricePercent', window );">Premium share price (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember', window );">OnkosXcel Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_PremiumSharePricePercent', window );">Premium share price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ThresholdLiquidityEventAmountForExerciseOfWarrants', window );">Threshold amount of liquidity event for exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_PercentageOfFairValueConsiderationToBePaid', window );">Percentage of fair value of consideration to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_PercentageOfValuationApplicableToInitialProfits', window );">Percentage of valuation applicable to initial profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_PercentageOfFairValueConsiderationToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair value of consideration to be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_PercentageOfFairValueConsiderationToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_PercentageOfValuationApplicableToInitialProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of valuation applicable to initial profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_PercentageOfValuationApplicableToInitialProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_PremiumSharePricePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents premium percentage for share price determined over a specified period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_PremiumSharePricePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_RightToPurchaseStockLenders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum equity investment allowed for lenders in entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_RightToPurchaseStockLenders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ThresholdLiquidityEventAmountForExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold amount of  liquidity event for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ThresholdLiquidityEventAmountForExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_NewWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_NewWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OriginalWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_OriginalWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantShares2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantShares2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt and Credit Facilities - Maturities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt and Credit Facilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2026</a></td>
<td class="nump">$ 22,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2027</a></td>
<td class="nump">$ 84,291<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities - Interest (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt and Credit Facilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">$ 14,662<span></span>
</td>
<td class="nump">$ 11,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Accretion of debt discount and amortization of financing costs</a></td>
<td class="nump">467<span></span>
</td>
<td class="nump">1,373<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Total interest expense</a></td>
<td class="nump">$ 15,129<span></span>
</td>
<td class="nump">$ 13,314<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 25, 2024</div></th>
<th class="th"><div>Nov. 21, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 25, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,633<span></span>
</td>
<td class="nump">$ 1,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (loss) on derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,181<span></span>
</td>
<td class="nump">$ 438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_EquityInvestmentMember', window );">Equity Investment Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Increase (decrease) carrying value</a></td>
<td class="num">$ (1,263)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,263)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember', window );">March 2024 Accompanying Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment warrants</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (loss) on derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember', window );">March 2024 Accompanying Warrants, Strike Price Amended</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">534<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember', window );">November 2024 Accompanying Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">$ 5,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (loss) on derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_EquityInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_EquityInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Financing Activities (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 22, 2024</div></th>
<th class="th"><div>Mar. 27, 2024</div></th>
<th class="th"><div>Mar. 25, 2024</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 21, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 474<span></span>
</td>
<td class="nump">$ 811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,688<span></span>
</td>
<td class="nump">$ 27,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of common stock and warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember', window );">March 2024 Accompanying Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_JefferiesMember', window );">Jefferies Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_SaleOfStockMaximumValueSharesToBeIssued', window );">Maximum value shares to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,682<span></span>
</td>
<td class="nump">$ 27,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,451<span></span>
</td>
<td class="nump">$ 26,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredDirectOfferingMember', window );">Registered direct offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredDirectOfferingMember', window );">Registered direct offering | March 2024 Accompanying Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredDirectOfferingMember', window );">Registered direct offering | March 2024 Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants, stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredOfferingMember', window );">Underwriting Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock offering costs</a></td>
<td class="nump">$ 871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds issuance of common stock</a></td>
<td class="nump">$ 6,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredOfferingMember', window );">Underwriting Agreement | March 2024 Accompanying Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="nump">7.664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredOfferingMember', window );">Underwriting Agreement | March 2024 Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants, stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredOfferingMember', window );">Underwriting Agreement | November 2024 Accompanying Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredOfferingMember', window );">Underwriting Agreement | November 2024 Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="nump">563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_SaleOfStockMaximumValueSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate net offering price of shares permitted to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_SaleOfStockMaximumValueSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=btai_JefferiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=btai_JefferiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024PrefundedAccompanyingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_November2024PrefundedAccompanyingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation - Description (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>May 20, 2020</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=btai_IncentiveAwardPlan2020Member', window );">2020 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant', window );">Annual increase in shares available for grant (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares available for issuance (in shares)</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Terms of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=btai_StockPlan2017Member', window );">2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of aggregate number of shares of common stock outstanding of the immediately preceding calendar year as a increase to common stock available for grant under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=btai_IncentiveAwardPlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=btai_IncentiveAwardPlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=btai_StockPlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=btai_StockPlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Non-options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">BTI RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod', window );">Cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
<td class="nump">$ 1,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">BTI RSU | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">BTI RSU | Nonemployee consultant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">BTI PSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">87,000<span></span>
</td>
<td class="nump">87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod', window );">Cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted average price (in dollars per share)</a></td>
<td class="nump">$ 19.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember', window );">OnkosXcel PSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod', window );">Cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested aggregate (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Weighted average price beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue', window );">Cancelled, Weighted average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested, Weighted average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value, non-option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btai_RestrictedStockUnitsOnkosxcelMember', window );">OnkosXcel RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod', window );">Cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a cancelled event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=btai_RestrictedStockUnitsOnkosxcelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=btai_RestrictedStockUnitsOnkosxcelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Options (Details) - Employee Stock Option<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares) | shares</a></td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod', window );">Options cancelled (in shares) | shares</a></td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options vested and exercisable (in shares) | shares</a></td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per shares)</a></td>
<td class="nump">$ 296.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited (in dollars per shares)</a></td>
<td class="nump">214.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice', window );">Options cancelled (in dollars per shares)</a></td>
<td class="nump">339.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end balance (in dollars per shares)</a></td>
<td class="nump">265.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable (in dollars per shares)</a></td>
<td class="nump">$ 291.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value, outstanding | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value, exercised | $</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value, exercisable | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 16.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options vested (in dollars per share)</a></td>
<td class="nump">$ 215.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, exercisable</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, outstanding</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense | $</a></td>
<td class="nump">$ 7,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining unamortized expense period</a></td>
<td class="text">10 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were cancelled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember', window );">OnkosXcel PSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility (as a percent)</a></td>
<td class="nump">97.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate of interest (as a percent)</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility, minimum (as a percent)</a></td>
<td class="nump">108.00%<span></span>
</td>
<td class="nump">96.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, maximum (as a percent)</a></td>
<td class="nump">112.50%<span></span>
</td>
<td class="nump">109.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free rate of interest, minimum (as a percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free rate of interest, maximum (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation costs</a></td>
<td class="nump">$ 6,156<span></span>
</td>
<td class="nump">$ 18,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation costs</a></td>
<td class="nump">2,251<span></span>
</td>
<td class="nump">6,324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation costs</a></td>
<td class="nump">$ 3,905<span></span>
</td>
<td class="nump">$ 12,290<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - ESPP (Details) - 2020 Employee Stock Purchase Plan - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>May 20, 2020</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Purchase Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant', window );">Annual increase in shares available for grant (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred', window );">Maximum number of shares issued or transferred under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price as a percent of fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares available for issuance (in shares)</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum number of shares issued or transferred under ESPP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of aggregate number of shares of common stock outstanding of the immediately preceding calendar year as a increase to common stock available for grant under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=btai_EmployeeStockPurchasePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=btai_EmployeeStockPurchasePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturities of the operating lease liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current portion of lease liability</a></td>
<td class="num">$ (374)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Liabilities, Current<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 440<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="nump">$ 394<span></span>
</td>
<td class="nump">$ 392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Option to renew the lease</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAbstract', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution, percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer contribution percent on eligible contribution</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contribution amount</a></td>
<td class="nump">$ 289<span></span>
</td>
<td class="nump">$ 788<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>186
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Hierarchy (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">$ 6,633<span></span>
</td>
<td class="nump">$ 1,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair value money market accounts</a></td>
<td class="nump">29,036<span></span>
</td>
<td class="nump">64,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">6,633<span></span>
</td>
<td class="nump">1,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | BTI Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">6,593<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | OnkosXcel Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">6,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | BTI Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">6,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">1,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | BTI Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | OnkosXcel Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">6,633<span></span>
</td>
<td class="nump">1,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | BTI Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">6,593<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | OnkosXcel Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 712<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_BioxcelWarrantsAggregateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_BioxcelWarrantsAggregateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Level 3 (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Level 3 liabilities reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 1,905<span></span>
</td>
<td class="nump">$ 2,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">$ (602)<span></span>
</td>
<td class="num">$ (438)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Other Nonoperating Income (Expense)<span></span>
</td>
<td class="text">Other Nonoperating Income (Expense)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 1,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_EquityInvestmentMember', window );">Equity Investment Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Level 3 liabilities reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Termination of Derivative liabilities - Equity Investment Right</a></td>
<td class="num">$ (1,263)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_EquityInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_EquityInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Inputs (Details)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 25, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>Y </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 21, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 05, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>Y </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>Y </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 25, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>Y</div>
</th>
<th class="th">
<div>Mar. 20, 2024 </div>
<div>USD ($) </div>
<div>Y </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 19, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>Y </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value debt | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,633<span></span>
</td>
<td class="nump">$ 1,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (loss) on derivatives | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,181<span></span>
</td>
<td class="nump">438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1', window );">Repricing of stock purchase warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_EquityInvestmentMember', window );">Equity Investment Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Increase (decrease) carrying value | $</a></td>
<td class="num">$ (1,263)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,263)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_EquityInvestmentMember', window );">Equity Investment Rights | Strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_EquityInvestmentMember', window );">Equity Investment Rights | Volatility (annual)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_EquityInvestmentMember', window );">Equity Investment Rights | Probability of exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_EquityInvestmentMember', window );">Equity Investment Rights | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_EquityInvestmentMember', window );">Equity Investment Rights | Estimated premium to 30-day average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_EquityInvestmentMember', window );">Equity Investment Rights | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember', window );">OnkosXcel Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember', window );">OnkosXcel Warrants | Volatility (annual)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember', window );">Closing Date Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value warrant classified as equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164<span></span>
</td>
<td class="nump">$ 802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">$ 548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="nump">$ 58.3232<span></span>
</td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.1568<span></span>
</td>
<td class="nump">$ 320.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1', window );">Repricing of stock purchase warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember', window );">Closing Date Warrants | Strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320.64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember', window );">Closing Date Warrants | Volatility (annual)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember', window );">Closing Date Warrants | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember', window );">Closing Date Warrants | Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember', window );">Closing Date Warrants | Share price input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member', window );">2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value warrant classified as equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58.3232<span></span>
</td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member', window );">2023 Warrants | Strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.3232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member', window );">2023 Warrants | Volatility (annual)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member', window );">2023 Warrants | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member', window );">2023 Warrants | Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member', window );">2023 Warrants | Share price input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024Member', window );">2024 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value warrant classified as equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.1568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024Member', window );">2024 Warrants | Strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.1568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024Member', window );">2024 Warrants | Volatility (annual)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024Member', window );">2024 Warrants | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024Member', window );">2024 Warrants | Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024Member', window );">2024 Warrants | Share price input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember', window );">March 2024 Accompanying Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value warrant classified as equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (loss) on derivatives | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment warrants | $</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="nump">539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember', window );">March 2024 Accompanying Warrants | Strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember', window );">March 2024 Accompanying Warrants | Volatility (annual)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember', window );">March 2024 Accompanying Warrants | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember', window );">March 2024 Accompanying Warrants | Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember', window );">March 2024 Accompanying Warrants | Share price input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember', window );">March 2024 Accompanying Warrants, Strike Price Amended</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="nump">534<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember', window );">March 2024 Accompanying Warrants, Strike Price Amended | Strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 9.136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrants2024StrikePriceNotAmendedMember', window );">March 2024 Accompanying Warrants, Strike Price Not Amended</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrants2024StrikePriceNotAmendedMember', window );">March 2024 Accompanying Warrants, Strike Price Not Amended | Strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember', window );">November 2024 Accompanying Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value warrant classified as equity | $</a></td>
<td class="nump">$ 5,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability | $</a></td>
<td class="nump">$ 5,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (loss) on derivatives | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember', window );">November 2024 Accompanying Warrants | Strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="nump">7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember', window );">November 2024 Accompanying Warrants | Volatility (annual)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="nump">1.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember', window );">November 2024 Accompanying Warrants | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input | Y</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember', window );">November 2024 Accompanying Warrants | Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="nump">0.042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember', window );">November 2024 Accompanying Warrants | Share price input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="nump">7.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_EquityInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_EquityInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=btai_MeasurementInputProbabilityOfExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=btai_MeasurementInputProbabilityOfExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=btai_MeasurementInputEstimatedPremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=btai_MeasurementInputEstimatedPremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrants2024StrikePriceNotAmendedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrants2024StrikePriceNotAmendedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>189
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Warrants outstanding (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 25, 2024</div></th>
<th class="th"><div>Nov. 21, 2024</div></th>
<th class="th"><div>Mar. 20, 2024</div></th>
<th class="th"><div>Dec. 05, 2023</div></th>
<th class="th"><div>Apr. 19, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">1,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember', window );">Closing Date Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="nump">$ 49.1568<span></span>
</td>
<td class="nump">$ 58.3232<span></span>
</td>
<td class="nump">$ 320.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member', window );">2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58.3232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantShares2024Member', window );">2024 Warrant Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.1568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_NewWarrantsMember', window );">New Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember', window );">March 2024 Accompanying Warrants, Strike Price Amended</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 9.136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">534<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrants2024StrikePriceNotAmendedMember', window );">March 2024 Accompanying Warrants, Strike Price Not Amended</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 51.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember', window );">November 2024 Accompanying Warrants | Armistice Capital Master Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember', window );">November 2024 Accompanying Warrants | Heights Capital Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember', window );">November 2024 Accompanying Warrants | Hudson Bay Capital Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember', window );">November 2024 Accompanying Warrants | IntraCoastal Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantShares2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantShares2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_NewWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_NewWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrants2024StrikePriceNotAmendedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrants2024StrikePriceNotAmendedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=btai_ArmisticeCapitalMasterFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=btai_ArmisticeCapitalMasterFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=btai_HeightsCapitalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=btai_HeightsCapitalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=btai_HudsonBayCapitalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=btai_HudsonBayCapitalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=btai_IntraCoastalCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=btai_IntraCoastalCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>190
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating losses</a></td>
<td class="nump">$ 90,853<span></span>
</td>
<td class="nump">$ 73,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating losses</a></td>
<td class="nump">23,152<span></span>
</td>
<td class="nump">21,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock options</a></td>
<td class="nump">14,601<span></span>
</td>
<td class="nump">13,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Tax credits</a></td>
<td class="nump">17,188<span></span>
</td>
<td class="nump">15,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research &amp; development</a></td>
<td class="nump">44,377<span></span>
</td>
<td class="nump">49,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expense</a></td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_DeferredTaxAssetsLeaseAccountingLiability', window );">Lease accounting - liability</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards', window );">Disallowed charitable contributions</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_DeferredTaxAssetsCapitalizedIpoCosts', window );">Deferred Costs</a></td>
<td class="nump">674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_DeferredTaxAssetsCancellationOfDebt', window );">Cancellation of Debt</a></td>
<td class="nump">1,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(192,149)<span></span>
</td>
<td class="num">(173,679)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts', window );">Debt Amendment</a></td>
<td class="num">(500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDerivatives', window );">Unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (600)<span></span>
</td>
<td class="num">$ (197)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_DeferredTaxAssetsCancellationOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from cancellation of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_DeferredTaxAssetsCancellationOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_DeferredTaxAssetsCapitalizedIpoCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized IPO costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_DeferredTaxAssetsCapitalizedIpoCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_DeferredTaxAssetsLeaseAccountingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease accounting, liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_DeferredTaxAssetsLeaseAccountingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from derivatives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>191
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Reconciliation between effective and statutory rate, Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="num">$ (12,516)<span></span>
</td>
<td class="num">$ (37,601)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">381<span></span>
</td>
<td class="num">(573)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_EffectiveIncomeTaxRateReconciliationWarrantValuationAmount', window );">Warrant mark-to-market</a></td>
<td class="num">(4,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Federal and state credits</a></td>
<td class="num">(1,870)<span></span>
</td>
<td class="num">(4,082)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="num">(343)<span></span>
</td>
<td class="num">(14,261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">1,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">18,470<span></span>
</td>
<td class="nump">55,307<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total effective tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between effective and statutory rate, Percent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate (as a percent)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation (as a percent)</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_EffectiveIncomeTaxRateReconciliationWarrantValuationPercent', window );">Warrant mark-to-market (as a percent)</a></td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Federal and state tax credits (as a percent)</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State Taxes (as a percent)</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other (as a percent)</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance (as a percent)</a></td>
<td class="num">(31.00%)<span></span>
</td>
<td class="num">(30.90%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Income tax related interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between effective and statutory rate, Percent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="nump">432,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_OperatingLossCarryforwardsNoExpiration', window );">Operating loss carryforward with no expiration</a></td>
<td class="nump">429,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry-forwards</a></td>
<td class="nump">15,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between effective and statutory rate, Percent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="nump">443,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry-forwards</a></td>
<td class="nump">$ 1,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_EffectiveIncomeTaxRateReconciliationWarrantValuationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to warrant valuation adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_EffectiveIncomeTaxRateReconciliationWarrantValuationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_EffectiveIncomeTaxRateReconciliationWarrantValuationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to warrant valuation adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_EffectiveIncomeTaxRateReconciliationWarrantValuationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_OperatingLossCarryforwardsNoExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward with no expiration, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_OperatingLossCarryforwardsNoExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>192
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss (numerator)</a></td>
<td class="num">$ (59,599)<span></span>
</td>
<td class="num">$ (179,053)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares (denominator) - basic (in shares)</a></td>
<td class="nump">2,535<span></span>
</td>
<td class="nump">1,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares (denominator) - diluted (in shares)</a></td>
<td class="nump">2,535<span></span>
</td>
<td class="nump">1,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="num">$ (23.51)<span></span>
</td>
<td class="num">$ (98.33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (23.51)<span></span>
</td>
<td class="num">$ (98.33)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>193
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Antidilutive (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Common stock equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Common stock equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">311<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">BTI RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Common stock equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">BTI PSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Common stock equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=btai_BioxcelWarrantsAggregateMember', window );">BTI Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Common stock equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">1,792<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=btai_BioxcelWarrantsAggregateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=btai_BioxcelWarrantsAggregateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>194
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 11, 2024</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Purchase agreement expected cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Purchase agreement expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear', window );">2024 purchase obligation, remainder of year</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2025 purchase obligation</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2026 purchase obligation</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract', window );">Reconciliation payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Purchase agreement expected cost</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Purchase agreement expected cost</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>195
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,266<span></span>
</td>
<td class="nump">$ 1,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,143<span></span>
</td>
<td class="nump">1,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,435<span></span>
</td>
<td class="nump">84,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>Selling, general and administrative costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Total selling, general and administrative costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,492<span></span>
</td>
<td class="nump">83,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 1,553<span></span>
</td>
<td class="nump">$ 856<span></span>
</td>
<td class="nump">2,441<span></span>
</td>
<td class="nump">4,163<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,511<span></span>
</td>
<td class="nump">173,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (income) expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,129<span></span>
</td>
<td class="nump">13,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,602)<span></span>
</td>
<td class="num">(5,649)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,173)<span></span>
</td>
<td class="num">(394)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (59,599)<span></span>
</td>
<td class="num">(179,053)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=btai_SingleReportableSegmentMember', window );">Single reportable segment | Operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,266<span></span>
</td>
<td class="nump">1,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,143<span></span>
</td>
<td class="nump">1,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense', window );">Personnel and related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,796<span></span>
</td>
<td class="nump">16,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense', window );">Non-cash stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,251<span></span>
</td>
<td class="nump">6,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ResearchAndDevelopmentExpenseProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,067<span></span>
</td>
<td class="nump">14,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense', window );">Clinical trials expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,384<span></span>
</td>
<td class="nump">35,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense', window );">Chemical, manufacturing and controls cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,927<span></span>
</td>
<td class="nump">8,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ResearchAndDevelopmentExpenseTravelAndOtherExpenses', window );">Travel related expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,010<span></span>
</td>
<td class="nump">3,280<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,435<span></span>
</td>
<td class="nump">84,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DirectOperatingCostsAbstract', window );"><strong>Commercial costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_CommercialCostsLaborAndRelatedExpense', window );">Personnel and related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,516<span></span>
</td>
<td class="nump">19,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_CommercialCostsShareBasedPaymentArrangementExpense', window );">Non-cash stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(401)<span></span>
</td>
<td class="nump">1,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_CommercialCostsProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">554<span></span>
</td>
<td class="nump">965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_CommercialCostsCommercialAndMarketing', window );">Commercial and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,389<span></span>
</td>
<td class="nump">12,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_CommercialCostsTravelAndOtherExpenses', window );">Travel related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">2,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_CommercialCostsOtherExpenses', window );">Other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">906<span></span>
</td>
<td class="nump">2,038<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Total commercial costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,273<span></span>
</td>
<td class="nump">37,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>Selling, general and administrative costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense', window );">Personnel and related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,340<span></span>
</td>
<td class="nump">7,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense', window );">Non-cash stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,306<span></span>
</td>
<td class="nump">11,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_SellingGeneralAndAdministrativeExpenseProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,583<span></span>
</td>
<td class="nump">21,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses', window );">Travel related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">446<span></span>
</td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_SellingGeneralAndAdministrativeCostsOtherExpenses', window );">Other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,544<span></span>
</td>
<td class="nump">4,133<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Total selling, general and administrative costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,219<span></span>
</td>
<td class="nump">45,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,441<span></span>
</td>
<td class="nump">4,163<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,511<span></span>
</td>
<td class="nump">173,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (income) expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,129<span></span>
</td>
<td class="nump">13,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,602)<span></span>
</td>
<td class="num">(5,649)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,173)<span></span>
</td>
<td class="num">(394)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (59,599)<span></span>
</td>
<td class="num">$ (179,053)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_CommercialCostsCommercialAndMarketing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The commercial costs recognized in the period for promotion, public relations, and brand or product advertising.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_CommercialCostsCommercialAndMarketing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_CommercialCostsLaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of commercial costs for salary, wage, profit sharing; incentive and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_CommercialCostsLaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_CommercialCostsOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other expenses related to commercial costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_CommercialCostsOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_CommercialCostsProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of commercial costs related to a fee charged for services from professionals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_CommercialCostsProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_CommercialCostsShareBasedPaymentArrangementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of commercial costs for award under share-based payment arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_CommercialCostsShareBasedPaymentArrangementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_CommercialCostsTravelAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of commercial costs related to travel expenses during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_CommercialCostsTravelAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense during the period related to chemical, manufacturing and control costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense during the period related to clinical trial expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense during the period related to salary, wage, profit sharing incentive and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ResearchAndDevelopmentExpenseProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense during the period related to a fee charged for services from professionals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ResearchAndDevelopmentExpenseProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense during the period related to expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ResearchAndDevelopmentExpenseTravelAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense during the period related to travel expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ResearchAndDevelopmentExpenseTravelAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_SellingGeneralAndAdministrativeCostsOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other expenses related to selling, general and administrative costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_SellingGeneralAndAdministrativeCostsOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expense for salary, wage, profit sharing; incentive and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_SellingGeneralAndAdministrativeExpenseProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expense related to a fee charged for services from professionals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_SellingGeneralAndAdministrativeExpenseProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expense for award under share-based payment arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expense related to travel expenses during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectOperatingCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DirectOperatingCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=btai_SingleReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=btai_SingleReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>196
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 28, 2025</div></th>
<th class="th"><div>Mar. 03, 2025</div></th>
<th class="th"><div>Nov. 22, 2024</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredOfferingMember', window );">Underwriting Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredOfferingMember', window );">Underwriting Agreement | November 2024 Accompanying Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredOfferingMember', window );">Underwriting Agreement | November 2024 Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Underwriting Agreement | November 2024 Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants, stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Purchase Agreement | March 2025 Accompanying Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Purchase Agreement | March 2025 Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants, stock issued (in shares)</a></td>
<td class="nump">1,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Purchase Agreement | March 2025 Option Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024PrefundedAccompanyingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_November2024PrefundedAccompanyingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=btai_PurchaseAgreementRegisteredSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=btai_PurchaseAgreementRegisteredSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrantsMarch2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrantsMarch2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_PrefundedWarrantsMarch2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_PrefundedWarrantsMarch2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OptionWarrantsMarch2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_OptionWarrantsMarch2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>197
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>299</ContextCount>
  <ElementCount>425</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>96</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995210101 - Disclosure - Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureRestructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureInventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995210801 - Disclosure - Transactions with BioXcel LLC</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc</Role>
      <ShortName>Transactions with BioXcel LLC</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995210901 - Disclosure - Debt and Credit Facilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities</Role>
      <ShortName>Debt and Credit Facilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995211001 - Disclosure - Derivative Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstruments</Role>
      <ShortName>Derivative Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995211101 - Disclosure - Common Stock Financing Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities</Role>
      <ShortName>Common Stock Financing Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995211201 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995211301 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995211401 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995211501 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995211601 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995211701 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995211801 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995211901 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995212001 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>99920302 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>99930303 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>99930503 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureInventory</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>99930603 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>99930703 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>99930803 - Disclosure - Transactions with BioXcel LLC (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables</Role>
      <ShortName>Transactions with BioXcel LLC (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>99930903 - Disclosure - Debt and Credit Facilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables</Role>
      <ShortName>Debt and Credit Facilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>99931203 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>99931303 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureLeases</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>99931503 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>99931603 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>99931703 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>99931903 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformation</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails</Role>
      <ShortName>Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>99940301 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>99940302 - Disclosure - Summary of Significant Accounting Policies - Concentrations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Concentrations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - Restructuring (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails</Role>
      <ShortName>Restructuring (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureRestructuring</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - Property and equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>99940801 - Disclosure - Transactions with BioXcel LLC (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails</Role>
      <ShortName>Transactions with BioXcel LLC (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>99940901 - Disclosure - Debt and Credit Facilities - Debt summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails</Role>
      <ShortName>Debt and Credit Facilities - Debt summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>99940902 - Disclosure - Debt and Credit Facilities - Credit Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails</Role>
      <ShortName>Debt and Credit Facilities - Credit Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>99940903 - Disclosure - Debt and Credit Facilities - Revenue Interest Financing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails</Role>
      <ShortName>Debt and Credit Facilities - Revenue Interest Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>99940904 - Disclosure - Debt and Credit Facilities - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails</Role>
      <ShortName>Debt and Credit Facilities - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>99940905 - Disclosure - Debt and Credit Facilities - Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails</Role>
      <ShortName>Debt and Credit Facilities - Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>99940906 - Disclosure - Debt and Credit Facilities - Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails</Role>
      <ShortName>Debt and Credit Facilities - Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>99941001 - Disclosure - Derivative Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails</Role>
      <ShortName>Derivative Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstruments</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>99941101 - Disclosure - Common Stock Financing Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails</Role>
      <ShortName>Common Stock Financing Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>99941201 - Disclosure - Stock-Based Compensation - Description (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails</Role>
      <ShortName>Stock-Based Compensation - Description (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>99941202 - Disclosure - Stock-Based Compensation - Non-options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Non-options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>99941203 - Disclosure - Stock-Based Compensation - Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>99941204 - Disclosure - Stock-Based Compensation - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>99941205 - Disclosure - Stock-Based Compensation - Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>99941206 - Disclosure - Stock-Based Compensation - ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails</Role>
      <ShortName>Stock-Based Compensation - ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>99941301 - Disclosure - Leases - Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails</Role>
      <ShortName>Leases - Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>99941302 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>99941401 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlan</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>99941501 - Disclosure - Fair Value Measurements - Hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails</Role>
      <ShortName>Fair Value Measurements - Hierarchy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>99941502 - Disclosure - Fair Value Measurements - Level 3 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details</Role>
      <ShortName>Fair Value Measurements - Level 3 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>99941503 - Disclosure - Fair Value Measurements - Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails</Role>
      <ShortName>Fair Value Measurements - Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>99941504 - Disclosure - Fair Value Measurements - Warrants outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails</Role>
      <ShortName>Fair Value Measurements - Warrants outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>99941601 - Disclosure - Income Taxes - Deferred Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails</Role>
      <ShortName>Income Taxes - Deferred Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>99941602 - Disclosure - Income Taxes - Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails</Role>
      <ShortName>Income Taxes - Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>99941701 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>99941702 - Disclosure - Net Loss Per Share - Antidilutive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails</Role>
      <ShortName>Net Loss Per Share - Antidilutive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>99941801 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>99941901 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="btai-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>99942001 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>79</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>btai-20241231.xsd</File>
    <File>btai-20241231_cal.xml</File>
    <File>btai-20241231_def.xml</File>
    <File>btai-20241231_lab.xml</File>
    <File>btai-20241231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="btai-20241231x10k.htm">btai-20241231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>btai-20241231x10k001.jpg</File>
    <File>btai-20241231x10k002.jpg</File>
    <File>btai-20241231x10k003.jpg</File>
    <File>btai-20241231x10k004.jpg</File>
    <File>btai-20241231x10k005.jpg</File>
    <File>btai-20241231x10k006.jpg</File>
    <File>btai-20241231x10k007.jpg</File>
    <File>btai-20241231x10k008.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="809">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>199
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "btai-20241231x10k.htm": {
   "nsprefix": "btai",
   "nsuri": "http://www.bioxceltherapeutics.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "btai-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "btai-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "btai-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "btai-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "btai-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "btai-20241231x10k.htm"
     ]
    }
   },
   "keyStandard": 358,
   "keyCustom": 67,
   "axisStandard": 28,
   "axisCustom": 0,
   "memberStandard": 37,
   "memberCustom": 55,
   "hidden": {
    "total": 20,
    "http://fasb.org/us-gaap/2024": 16,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 299,
   "entityCount": 1,
   "segmentCount": 96,
   "elementCount": 763,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 809,
    "http://xbrl.sec.gov/dei/2024": 37,
    "http://xbrl.sec.gov/ecd/2024": 26,
    "http://xbrl.sec.gov/cyd/2024": 15
   },
   "report": {
    "R1": {
     "role": "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets",
     "longName": "995200100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:ReceivablesNetCurrent",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations",
     "longName": "995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity",
     "longName": "995200300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WhUd_ZOlBUmqQn-nMAVDoQ",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WhUd_ZOlBUmqQn-nMAVDoQ",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureNatureOfBusiness",
     "longName": "995210101 - Disclosure - Nature of the Business",
     "shortName": "Nature of the Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation",
     "longName": "995210201 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995210301 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureRestructuring",
     "longName": "995210401 - Disclosure - Restructuring",
     "shortName": "Restructuring",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureInventory",
     "longName": "995210501 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet",
     "longName": "995210601 - Disclosure - Property and Equipment, net",
     "shortName": "Property and Equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses",
     "longName": "995210701 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc",
     "longName": "995210801 - Disclosure - Transactions with BioXcel LLC",
     "shortName": "Transactions with BioXcel LLC",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities",
     "longName": "995210901 - Disclosure - Debt and Credit Facilities",
     "shortName": "Debt and Credit Facilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstruments",
     "longName": "995211001 - Disclosure - Derivative Financial Instruments",
     "shortName": "Derivative Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities",
     "longName": "995211101 - Disclosure - Common Stock Financing Activities",
     "shortName": "Common Stock Financing Activities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "btai:FinancingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "btai:FinancingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation",
     "longName": "995211201 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureLeases",
     "longName": "995211301 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlan",
     "longName": "995211401 - Disclosure - Employee Benefit Plan",
     "shortName": "Employee Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:DefinedBenefitPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:DefinedBenefitPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements",
     "longName": "995211501 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxes",
     "longName": "995211601 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare",
     "longName": "995211701 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "995211801 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformation",
     "longName": "995211901 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents",
     "longName": "995212001 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R28": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2024_To_12_31_2024_3PEv7wfJfUKxY2X6WXJQ_g",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2024_To_12_31_2024_3PEv7wfJfUKxY2X6WXJQ_g",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "99920302 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "99930303 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "btai:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "btai:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables",
     "longName": "99930503 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables",
     "longName": "99930603 - Disclosure - Property and Equipment, net (Tables)",
     "shortName": "Property and Equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables",
     "longName": "99930703 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables",
     "longName": "99930803 - Disclosure - Transactions with BioXcel LLC (Tables)",
     "shortName": "Transactions with BioXcel LLC (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables",
     "longName": "99930903 - Disclosure - Debt and Credit Facilities (Tables)",
     "shortName": "Debt and Credit Facilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables",
     "longName": "99931203 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureLeasesTables",
     "longName": "99931303 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables",
     "longName": "99931503 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesTables",
     "longName": "99931603 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables",
     "longName": "99931703 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationTables",
     "longName": "99931903 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails",
     "longName": "99940201 - Disclosure - Basis of Presentation (Details)",
     "shortName": "Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "longName": "99940301 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:DeferredOfferingCosts",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "btai:DeferredOfferingCostsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:DeferredOfferingCosts",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "btai:DeferredOfferingCostsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsDetails",
     "longName": "99940302 - Disclosure - Summary of Significant Accounting Policies - Concentrations (Details)",
     "shortName": "Summary of Significant Accounting Policies - Concentrations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_btai_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_W_hOEF0UGE6XdSlHUL5Rsw",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_btai_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_W_hOEF0UGE6XdSlHUL5Rsw",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails",
     "longName": "99940401 - Disclosure - Restructuring (Details)",
     "shortName": "Restructuring (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "Duration_9_17_2024_To_9_17_2024_OiBFsSYoqEGoJgxld_C82A",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_9_17_2024_To_9_17_2024_OiBFsSYoqEGoJgxld_C82A",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails",
     "longName": "99940501 - Disclosure - Inventory (Details)",
     "shortName": "Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
     "longName": "99940601 - Disclosure - Property and equipment, net (Details)",
     "shortName": "Property and equipment, net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails",
     "longName": "99940701 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "btai:AccruedResearchAndDevelopmentExpenses",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "btai:AccruedResearchAndDevelopmentExpenses",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
     "longName": "99940801 - Disclosure - Transactions with BioXcel LLC (Details)",
     "shortName": "Transactions with BioXcel LLC (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_6_30_2017_To_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__Rfp0WkOeUSwkyApqU9Aow",
      "name": "btai:AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails",
     "longName": "99940901 - Disclosure - Debt and Credit Facilities - Debt summary (Details)",
     "shortName": "Debt and Credit Facilities - Debt summary (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
     "longName": "99940902 - Disclosure - Debt and Credit Facilities - Credit Agreement (Details)",
     "shortName": "Debt and Credit Facilities - Credit Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_r6Nt5rznFkuA80tgQ2K1yA",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails",
     "longName": "99940903 - Disclosure - Debt and Credit Facilities - Revenue Interest Financing (Details)",
     "shortName": "Debt and Credit Facilities - Revenue Interest Financing (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "Duration_12_5_2023_To_12_5_2023_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_NN4G50mhQUiE2MWFIStQGA",
      "name": "us-gaap:ExtinguishmentOfDebtAmount",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_12_5_2023_To_12_5_2023_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_NN4G50mhQUiE2MWFIStQGA",
      "name": "us-gaap:ExtinguishmentOfDebtAmount",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
     "longName": "99940904 - Disclosure - Debt and Credit Facilities - Warrants (Details)",
     "shortName": "Debt and Credit Facilities - Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_V2jj_eDlt0q_u0vXSYoyKQ",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_V2jj_eDlt0q_u0vXSYoyKQ",
      "name": "btai:RightToPurchaseStockLenders",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails",
     "longName": "99940905 - Disclosure - Debt and Credit Facilities - Maturities (Details)",
     "shortName": "Debt and Credit Facilities - Maturities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails",
     "longName": "99940906 - Disclosure - Debt and Credit Facilities - Interest (Details)",
     "shortName": "Debt and Credit Facilities - Interest (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "btai:ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "btai:ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
     "longName": "99941001 - Disclosure - Derivative Financial Instruments (Details)",
     "shortName": "Derivative Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R59": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
     "longName": "99941101 - Disclosure - Common Stock Financing Activities (Details)",
     "shortName": "Common Stock Financing Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_5_31_2021_To_5_31_2021_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_7HqDJsFg10yEnahziR0XDQ",
      "name": "btai:SaleOfStockMaximumValueSharesToBeIssued",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "btai:FinancingActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
     "longName": "99941201 - Disclosure - Stock-Based Compensation - Description (Details)",
     "shortName": "Stock-Based Compensation - Description (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_vDwwtKHeaUKjbZq0pfe-PA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_vDwwtKHeaUKjbZq0pfe-PA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
     "longName": "99941202 - Disclosure - Stock-Based Compensation - Non-options (Details)",
     "shortName": "Stock-Based Compensation - Non-options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OZo6Dpf0wkeLIC74MDokcw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OZo6Dpf0wkeLIC74MDokcw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails",
     "longName": "99941203 - Disclosure - Stock-Based Compensation - Options (Details)",
     "shortName": "Stock-Based Compensation - Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xOcQ1mX8HUS3oomqLm_lMg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xOcQ1mX8HUS3oomqLm_lMg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
     "longName": "99941204 - Disclosure - Stock-Based Compensation - Assumptions (Details)",
     "shortName": "Stock-Based Compensation - Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_iWV0CaPsVkiXqlcQ-zUTCQ",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails",
     "longName": "99941205 - Disclosure - Stock-Based Compensation - Expense (Details)",
     "shortName": "Stock-Based Compensation - Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails",
     "longName": "99941206 - Disclosure - Stock-Based Compensation - ESPP (Details)",
     "shortName": "Stock-Based Compensation - ESPP (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_N0vp5VFCUkqtRrwPRBSFFQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_N0vp5VFCUkqtRrwPRBSFFQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails",
     "longName": "99941301 - Disclosure - Leases - Maturities (Details)",
     "shortName": "Leases - Maturities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails",
     "longName": "99941302 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlanDetails",
     "longName": "99941401 - Disclosure - Employee Benefit Plan (Details)",
     "shortName": "Employee Benefit Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:DefinedBenefitPlanTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "Unit_Standard_pure_s_vrAmtAKUSwWE1ETDAP9g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:DefinedBenefitPlanTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails",
     "longName": "99941501 - Disclosure - Fair Value Measurements - Hierarchy (Details)",
     "shortName": "Fair Value Measurements - Hierarchy (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_waelNlOubE2wBVFPlyHhnA",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details",
     "longName": "99941502 - Disclosure - Fair Value Measurements - Level 3 (Details)",
     "shortName": "Fair Value Measurements - Level 3 (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_CSseJ01C6kSLLM5L6SoxCQ",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_jhStatqo5EaSoSvdA9RW0g",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
     "longName": "99941503 - Disclosure - Fair Value Measurements - Inputs (Details)",
     "shortName": "Fair Value Measurements - Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:DebtInstrumentFairValue",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:DebtInstrumentFairValue",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails",
     "longName": "99941504 - Disclosure - Fair Value Measurements - Warrants outstanding (Details)",
     "shortName": "Fair Value Measurements - Warrants outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_FRRTD6E8_UWc7CqpvzLbPA",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails",
     "longName": "99941601 - Disclosure - Income Taxes - Deferred Tax (Details)",
     "shortName": "Income Taxes - Deferred Tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails",
     "longName": "99941602 - Disclosure - Income Taxes - Reconciliation (Details)",
     "shortName": "Income Taxes - Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails",
     "longName": "99941701 - Disclosure - Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R76": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails",
     "longName": "99941702 - Disclosure - Net Loss Per Share - Antidilutive (Details)",
     "shortName": "Net Loss Per Share - Antidilutive (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "longName": "99941801 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2022_To_4_30_2022_AGdwF45rAUaEqJM-M8UB2g",
      "name": "us-gaap:LongTermPurchaseCommitmentAmount",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2022_To_4_30_2022_AGdwF45rAUaEqJM-M8UB2g",
      "name": "us-gaap:LongTermPurchaseCommitmentAmount",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
     "longName": "99941901 - Disclosure - Segment Information (Details)",
     "shortName": "Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_hghDGiCtOkSIwyjC2JIT0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_ofujOrYRzUG-0fB_SKRtNw",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Unit_Standard_segment_u3k5mJIKoECDA2MsRZB6Gg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails",
     "longName": "99942001 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wTixNk4RcEqWuVaOUoYpcQ",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_bpWi2hQgHEO9u9Kw-FVA6A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_2_28_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_3zrIDKZAEUqRigs4dt4KAw",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Unit_Standard_shares_qow8Yx0ukUi-kLyYpGszHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20241231x10k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "btai_AccompanyingWarrants2024StrikePriceNotAmendedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "AccompanyingWarrants2024StrikePriceNotAmendedMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertains to 2024 accompanying warrants strike price not amended.",
        "label": "Accompanying Warrants 2024 Strike Price Not Amended [Member]",
        "terseLabel": "March 2024 Accompanying Warrants, Strike Price Not Amended"
       }
      }
     },
     "auth_ref": []
    },
    "btai_AccompanyingWarrantsMarch2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "AccompanyingWarrantsMarch2025Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertains to March 2025 Accompanying Warrants.",
        "label": "Accompanying Warrants, March 2025 [Member]",
        "terseLabel": "March 2025 Accompanying Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r55",
      "r60",
      "r912"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r703"
     ]
    },
    "btai_AccountsReceivablePaymentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "AccountsReceivablePaymentTerm",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The credit period offered to customers or receivables by the company.",
        "label": "Accounts Receivable, Payment Term",
        "terseLabel": "Accounts receivable payment term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "btai_AccruedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r142",
      "r537"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fees per month to be paid to enter into collaborative service agreement option.",
        "label": "Additional Fees Per Month to Enter into Collaborative Service Agreement",
        "terseLabel": "Monthly agreement option fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in-capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r703",
      "r977"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r854",
      "r855",
      "r856",
      "r858",
      "r921",
      "r978"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of pre-funded warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments To Additional Paid In Capital, Pre Funded Warrant Issued",
        "terseLabel": "Issuance of pre-funded stock purchase warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r357"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of stock purchase warrants",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r31",
      "r97"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Reconciliation of net loss to net cash used in operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r739",
      "r750",
      "r760",
      "r793"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r742",
      "r753",
      "r763",
      "r796"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r754",
      "r764",
      "r788",
      "r797",
      "r801",
      "r809"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation costs",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r391"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails": {
       "parentTag": "us-gaap_InterestExpenseNonoperating",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Accretion of debt discount and amortization of financing costs",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r679",
      "r680",
      "r847",
      "r931"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Potentially dilutive securities (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Common stock equivalents",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "btai_ArmisticeCapitalMasterFundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "ArmisticeCapitalMasterFundMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Armistice Capital Master Fund Ltd.",
        "label": "Armistice Capital Master Fund [Member]",
        "terseLabel": "Armistice Capital Master Fund"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r117",
      "r144",
      "r168",
      "r204",
      "r210",
      "r235",
      "r239",
      "r248",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r304",
      "r438",
      "r442",
      "r479",
      "r528",
      "r603",
      "r664",
      "r665",
      "r703",
      "r718",
      "r881",
      "r882",
      "r937"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r149",
      "r168",
      "r248",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r304",
      "r438",
      "r442",
      "r479",
      "r703",
      "r881",
      "r882",
      "r937"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r723",
      "r746"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r723",
      "r746"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r723",
      "r746"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "btai_BioxcelCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "BioxcelCorporationMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents BioXcel LLC.",
        "label": "BioXcel Corporation [Member]",
        "terseLabel": "BioXcel LLC"
       }
      }
     },
     "auth_ref": []
    },
    "btai_BioxcelWarrantsAggregateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "BioxcelWarrantsAggregateMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertains to the aggregate of BioXcel equity Warrants.",
        "label": "BioXcel Warrants, Aggregate [Member]",
        "terseLabel": "BTI Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_BorrowingsBasedOnNetSalesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "BorrowingsBasedOnNetSalesPercent",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum borrowings allowed based on a percentage of net sales.",
        "label": "Borrowings Based on Net Sales, Percent",
        "terseLabel": "Borrowing allowed per net sales (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r140",
      "r650"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair value money market accounts",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r922",
      "r923"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of the period",
        "periodStartLabel": "Cash and cash equivalents, beginning of the period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r85",
      "r165"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r85"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Derivative Financial Instruments",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Common stock issuable (in shares)",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase common stock (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding (in shares)",
        "verboseLabel": "Number of Warrants (in shares)",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement [Member]",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "btai_CollaborativeArrangementMilestonePaymentsPotential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "CollaborativeArrangementMilestonePaymentsPotential",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of potential maximum payments that could be paid under the collaborative agreement.",
        "label": "Collaborative Arrangement, Milestone Payments Potential",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "btai_CollaborativeArrangementMilestonePotentialPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "CollaborativeArrangementMilestonePotentialPercent",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum percentage of net sales payable under a collaborative agreement.",
        "label": "Collaborative Arrangement Milestone Potential Percent",
        "terseLabel": "Maximum milestone (as as percent)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_CommercialCostsCommercialAndMarketing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "CommercialCostsCommercialAndMarketing",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_OtherCostAndExpenseOperating",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The commercial costs recognized in the period for promotion, public relations, and brand or product advertising.",
        "label": "Commercial Costs, Commercial and Marketing",
        "terseLabel": "Commercial and marketing"
       }
      }
     },
     "auth_ref": []
    },
    "btai_CommercialCostsLaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "CommercialCostsLaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_OtherCostAndExpenseOperating",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commercial costs for salary, wage, profit sharing; incentive and other employee benefit.",
        "label": "Commercial Costs, Labor and Related Expense",
        "terseLabel": "Personnel and related costs"
       }
      }
     },
     "auth_ref": []
    },
    "btai_CommercialCostsOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "CommercialCostsOtherExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_OtherCostAndExpenseOperating",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other expenses related to commercial costs.",
        "label": "Commercial Costs, Other Expenses",
        "terseLabel": "Other expenses"
       }
      }
     },
     "auth_ref": []
    },
    "btai_CommercialCostsProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "CommercialCostsProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_OtherCostAndExpenseOperating",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commercial costs related to a fee charged for services from professionals.",
        "label": "Commercial Costs, Professional Fees",
        "terseLabel": "Professional fees"
       }
      }
     },
     "auth_ref": []
    },
    "btai_CommercialCostsShareBasedPaymentArrangementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "CommercialCostsShareBasedPaymentArrangementExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_OtherCostAndExpenseOperating",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commercial costs for award under share-based payment arrangement",
        "label": "Commercial Costs, Share-Based Payment Arrangement, Expense",
        "terseLabel": "Non-cash stock-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "btai_CommercialCostsTravelAndOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "CommercialCostsTravelAndOtherExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_OtherCostAndExpenseOperating",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commercial costs related to travel expenses during the period.",
        "label": "Commercial Costs, Travel Expenses",
        "terseLabel": "Travel related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 18)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r111",
      "r530",
      "r590"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r286",
      "r287",
      "r646",
      "r871",
      "r879"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r708",
      "r709",
      "r710",
      "r712",
      "r713",
      "r714",
      "r715",
      "r854",
      "r855",
      "r858",
      "r921",
      "r976",
      "r978"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r591"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r66",
      "r591",
      "r609",
      "r978",
      "r979"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, 200,000 and 100,000 shares authorized as of December 31, 2024 and December 31, 2023, respectively; 3,102 and 1,871 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r532",
      "r703"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r101"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computers and equipment",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r45",
      "r46",
      "r246",
      "r645"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r45",
      "r46",
      "r246",
      "r566",
      "r645"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r45",
      "r46",
      "r246",
      "r645",
      "r834"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r126"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentrations of Risk",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk (as a percent)",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r45",
      "r46",
      "r246"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r23",
      "r45",
      "r106",
      "r645"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r45",
      "r46",
      "r246",
      "r645"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r115",
      "r175",
      "r204",
      "r212",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r664",
      "r665",
      "r881",
      "r882"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r115",
      "r175",
      "r204",
      "r212",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r664",
      "r665",
      "r881",
      "r882"
     ]
    },
    "us-gaap_ContractTerminationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractTerminationMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Termination [Member]",
        "terseLabel": "Contract termination costs",
        "documentation": "Termination of a contract associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r674",
      "r675"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract",
        "terseLabel": "Reconciliation payment",
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation, to be Paid, Year One",
        "terseLabel": "2025 purchase obligation",
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationDueInSecondYear",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation, to be Paid, Year Two",
        "terseLabel": "2026 purchase obligation",
        "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "btai_ConversionOfAccruedInterestToLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "ConversionOfAccruedInterestToLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of accrued interest that is converted into long erm debt.",
        "label": "Conversion Of Accrued Interest To Long-Term Debt",
        "negatedLabel": "Conversion of accrued interest to long-term debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r521"
     ]
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Goods Sold",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r309",
      "r337",
      "r507",
      "r517",
      "r527",
      "r652",
      "r654"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "btai_CreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "CreditFacilityMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to a Credit Agreement and Guaranty (the \"Credit Agreement\").",
        "label": "Credit Facility [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer concentration",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r246"
     ]
    },
    "btai_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer classified as one.",
        "label": "Customer One [Member]",
        "terseLabel": "Customer one"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r820"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r820"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r822"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r822"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r735",
      "r824"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r822"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r726",
      "r815"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r727",
      "r816"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r727",
      "r816"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r725",
      "r814"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r725",
      "r814"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r725",
      "r814"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r817"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r730",
      "r819"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r730",
      "r819"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r820"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r734",
      "r823"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r732",
      "r821"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r729",
      "r818"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt and Credit Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt and Credit Facilities",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r167",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r292",
      "r293",
      "r305",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r321",
      "r328",
      "r329",
      "r331",
      "r488"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r54",
      "r55",
      "r108",
      "r110",
      "r175",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r702",
      "r848",
      "r872",
      "r873",
      "r874",
      "r930",
      "r932"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate (as a percent)",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Total long-term debt liability",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r110",
      "r332"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount borrowed",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r488",
      "r489",
      "r677",
      "r678",
      "r702"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value debt",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r478",
      "r677",
      "r678",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Debt instrument fee",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "DebtInstrumentFinancialCovenantMinimumLiquidityRequirement",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum liquidity required per the financial covenant of debt agreement.",
        "label": "Debt Instrument, Financial Covenant, Minimum Liquidity Requirement",
        "terseLabel": "Minimum Liquidity Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Increase, Accrued Interest",
        "terseLabel": "Accrued interest",
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "btai_DebtInstrumentIncrementalOnVariableRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "DebtInstrumentIncrementalOnVariableRatePercent",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental percentage points added to the reference rate and variable rate on the debt instrument.",
        "label": "Debt Instrument, Incremental on Variable Rate, Percent",
        "terseLabel": "Incremental interest rate (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_DebtInstrumentInterestRateDiscountRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "DebtInstrumentInterestRateDiscountRatePercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of  basis point original issue discount at which the borrowings under the credit agreement are issued.",
        "label": "Debt Instrument Interest Rate, Discount Rate Percentage",
        "terseLabel": "Discount rate (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate (as a percent)",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r334",
      "r488",
      "r489",
      "r702"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Fixed rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r307"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r330",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r702",
      "r848",
      "r930",
      "r932"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r175",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r702",
      "r848",
      "r872",
      "r873",
      "r874",
      "r930",
      "r932"
     ]
    },
    "btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the quarterly amortization payments as percentage of principal amount of funded loans.",
        "label": "Debt Instrument, Quarterly Amortization Payments as Percentage of Principal Amount Funded",
        "terseLabel": "Principal payment of loans (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r32",
      "r33",
      "r49",
      "r95",
      "r96",
      "r175",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r330",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r702",
      "r848",
      "r930",
      "r932"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized debt premiums, discounts and issuance costs",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r333",
      "r487",
      "r488",
      "r489",
      "r677",
      "r678",
      "r702"
     ]
    },
    "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]",
        "documentation": "Indicates type of variable interest rate on debt instrument."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt and Detachable Warrants",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r109",
      "r414"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "btai_DeferredOfferingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferred offering costs.",
        "label": "Deferred Offering Costs [Policy Text Block]",
        "terseLabel": "Deferred Initial Public Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "btai_DeferredTaxAssetsCancellationOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "DeferredTaxAssetsCancellationOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from cancellation of debt.",
        "label": "Deferred Tax Assets, Cancellation of Debt",
        "terseLabel": "Cancellation of Debt"
       }
      }
     },
     "auth_ref": []
    },
    "btai_DeferredTaxAssetsCapitalizedIpoCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "DeferredTaxAssetsCapitalizedIpoCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized IPO costs.",
        "label": "Deferred Tax Assets, Capitalized IPO Costs",
        "terseLabel": "Deferred Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsCharitableContributionCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Charitable Contribution Carryforwards",
        "terseLabel": "Disallowed charitable contributions",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "terseLabel": "Capitalized research &amp; development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "btai_DeferredTaxAssetsLeaseAccountingLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "DeferredTaxAssetsLeaseAccountingLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease accounting, liability.",
        "label": "Deferred Tax Assets, Lease Accounting, Liability",
        "terseLabel": "Lease accounting - liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset (liability)",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Federal net operating losses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "State net operating losses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Depreciation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Tax credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock options",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expense",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs",
        "negatedLabel": "Debt Amendment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Derivatives",
        "negatedLabel": "Unrealized loss",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from derivatives."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Right-of-use assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_DefinedBenefitPlanAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Text Block]",
        "terseLabel": "Employee Benefit Plan",
        "documentation": "The entire disclosure for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r520",
      "r686"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer contribution amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer contribution percent on eligible contribution",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer matching contribution, percent",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r29"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "Change in fair value of derivative liabilities",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Financial Instruments",
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r444",
      "r451"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Derivative liabilities",
        "verboseLabel": "Warrant derivative liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Derivative liability input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r460"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Assets and Liabilities",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r40",
      "r41",
      "r42",
      "r44",
      "r174",
      "r189"
     ]
    },
    "btai_DevelopmentMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "DevelopmentMilestonesMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestones defined by the collaboration agreement.",
        "label": "Development Milestones [Member]",
        "terseLabel": "Development milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DirectOperatingCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DirectOperatingCostsAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Direct Operating Costs [Abstract]",
        "terseLabel": "Commercial costs:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r359",
      "r387",
      "r388",
      "r390",
      "r688"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r722",
      "r723",
      "r746"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r722",
      "r723",
      "r746",
      "r789"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per share attributable to common stockholders (in dollars per share)",
        "verboseLabel": "Basic net loss per share (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r192",
      "r194",
      "r196",
      "r197",
      "r198",
      "r203",
      "r432",
      "r435",
      "r453",
      "r454",
      "r523",
      "r542",
      "r656"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share attributable to common stockholders (in dollars per share)",
        "verboseLabel": "Diluted net loss per share (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r194",
      "r196",
      "r197",
      "r198",
      "r203",
      "r432",
      "r435",
      "r453",
      "r454",
      "r523",
      "r542",
      "r656"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings (Loss) Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r200"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r199",
      "r201",
      "r202"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax (as a percent)",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r692"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Reconciliation between effective and statutory rate, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory rate (as a percent)",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r400",
      "r423",
      "r692"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Valuation allowance (as a percent)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r692",
      "r850",
      "r913"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "verboseLabel": "Stock based compensation (as a percent)",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r850",
      "r913",
      "r915"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other (as a percent)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r850",
      "r913",
      "r914"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State Taxes (as a percent)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r692",
      "r850",
      "r913"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Federal and state tax credits (as a percent)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r406",
      "r850",
      "r913"
     ]
    },
    "btai_EffectiveIncomeTaxRateReconciliationWarrantValuationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationWarrantValuationAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to warrant valuation adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Warrant Valuation, Amount",
        "terseLabel": "Warrant mark-to-market"
       }
      }
     },
     "auth_ref": []
    },
    "btai_EffectiveIncomeTaxRateReconciliationWarrantValuationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationWarrantValuationPercent",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to warrant valuation adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Warrant Valuation, Percent",
        "terseLabel": "Warrant mark-to-market (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation and benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Remaining unamortized expense period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Severance [Member]",
        "terseLabel": "Severance and benefit costs",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOwnershipPlanESOPDisclosuresLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]",
        "terseLabel": "Employee Stock Purchase Plan",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "btai_EmployeeStockPurchasePlan2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "EmployeeStockPurchasePlan2020Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the 2020 Employee Stock Purchase Plan.",
        "label": "Employee Stock Purchase Plan 2020 [Member]",
        "terseLabel": "2020 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum number of shares issued or transferred under ESPP.",
        "label": "Employee Stock Purchase Plan, Maximum Number Of Shares Issued Or Transferred",
        "terseLabel": "Maximum number of shares issued or transferred under ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "terseLabel": "Equipment",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r134",
      "r154",
      "r155",
      "r156",
      "r176",
      "r177",
      "r178",
      "r180",
      "r185",
      "r187",
      "r189",
      "r205",
      "r249",
      "r250",
      "r265",
      "r341",
      "r421",
      "r422",
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r452",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r490",
      "r492",
      "r500",
      "r541",
      "r560",
      "r561",
      "r562",
      "r579",
      "r633"
     ]
    },
    "btai_EquityInvestmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "EquityInvestmentMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the Equity Investment agreement.",
        "label": "Equity Investment [Member]",
        "terseLabel": "Equity Investment Rights"
       }
      }
     },
     "auth_ref": []
    },
    "btai_EquityInvestmentRightAmountUnfunded": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "EquityInvestmentRightAmountUnfunded",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of equity investment right in the OFA that is currently unfunded.",
        "label": "Equity Investment Right, Amount Unfunded",
        "terseLabel": "Equity Investment Right"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r739",
      "r750",
      "r760",
      "r793"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r747",
      "r757",
      "r790"
     ]
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value",
        "documentation": "Measured as an estimate of fair value."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r478",
      "r677",
      "r678"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ExtinguishmentOfDebtAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Debt extinguishment",
        "documentation": "Gross amount of debt extinguished."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Repricing of stock purchase warrants",
        "verboseLabel": "Fair value adjustment warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r4"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value assets and liabilities",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r470",
      "r695"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r470",
      "r695"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair value inputs",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r698"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r698"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of fair value unobservable inputs",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r698"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Level 3 reconciliation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r471",
      "r696"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument asset measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r471",
      "r696"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r455",
      "r457",
      "r458",
      "r459",
      "r460",
      "r469",
      "r470",
      "r472",
      "r512",
      "r513",
      "r514",
      "r677",
      "r678",
      "r684",
      "r685",
      "r686",
      "r695",
      "r698"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Basis [Axis]",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r677",
      "r678"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r458",
      "r460",
      "r695",
      "r925",
      "r928"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r467",
      "r468",
      "r469",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r522",
      "r695",
      "r699"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r346",
      "r351",
      "r457",
      "r470",
      "r512",
      "r684",
      "r685",
      "r686",
      "r695"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r346",
      "r351",
      "r457",
      "r458",
      "r470",
      "r513",
      "r677",
      "r678",
      "r684",
      "r685",
      "r686",
      "r695"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r457",
      "r458",
      "r459",
      "r460",
      "r470",
      "r514",
      "r677",
      "r678",
      "r684",
      "r685",
      "r686",
      "r695",
      "r698"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Level 3 liabilities reconciliation",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r458",
      "r460",
      "r695",
      "r925",
      "r928"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r471"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "terseLabel": "Termination of Derivative liabilities - Equity Investment Right",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r471"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r471"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r455",
      "r457",
      "r458",
      "r459",
      "r460",
      "r469",
      "r470",
      "r472",
      "r512",
      "r513",
      "r514",
      "r677",
      "r678",
      "r684",
      "r685",
      "r686",
      "r695",
      "r698"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r928"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of changes in Level 3 liabilities",
        "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r466",
      "r471"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r471"
     ]
    },
    "btai_FairValueStockPurchaseWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "FairValueStockPurchaseWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of issues of warrants.",
        "label": "Fair Value, Stock Purchase Warrants",
        "terseLabel": "Issuance of stock purchase warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_FinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "FinancingActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Common Stock Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "btai_FinancingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "FinancingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for Financing Activities.",
        "label": "Financing Activities Disclosure [Text Block]",
        "terseLabel": "Common Stock Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r754",
      "r764",
      "r797"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r754",
      "r764",
      "r797"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r754",
      "r764",
      "r797"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r754",
      "r764",
      "r797"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r754",
      "r764",
      "r797"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "btai_FrankYoccaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "FrankYoccaMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Frank Yocca.",
        "label": "Frank Yocca"
       }
      }
     },
     "auth_ref": []
    },
    "btai_FromAndAfterFundingOfTrancheBLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "FromAndAfterFundingOfTrancheBLoansMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the statement scenario, from and after the funding of Tranche B loans.",
        "label": "From and After Funding of Tranche B Loans [Member]",
        "terseLabel": "From and after the funding of Tranche B loans"
       }
      }
     },
     "auth_ref": []
    },
    "btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the statement scenario, from and after satisfaction of the funding conditions for the Tranche C loans.",
        "label": "From and After Satisfaction of Funding Conditions for Tranche C Loans [Member]",
        "terseLabel": "From and after satisfaction of funding conditions for tranche C loans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "terseLabel": "Gain (loss) on derivatives",
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ]
    },
    "btai_HeightsCapitalManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "HeightsCapitalManagementMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Heights Capital Management.",
        "label": "Heights Capital Management [Member]",
        "terseLabel": "Heights Capital Management"
       }
      }
     },
     "auth_ref": []
    },
    "btai_HudsonBayCapitalManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "HudsonBayCapitalManagementMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Hudson Bay Capital Management.",
        "label": "Hudson Bay Capital Management [Member]",
        "terseLabel": "Hudson Bay Capital Management"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r723",
      "r746"
     ]
    },
    "btai_IncentiveAwardPlan2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "IncentiveAwardPlan2020Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2020 Incentive Award Plan.",
        "label": "2020 Incentive Award Plan",
        "terseLabel": "2020 Incentive Award Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r273",
      "r278",
      "r462",
      "r466",
      "r471",
      "r557",
      "r559",
      "r618",
      "r649",
      "r697",
      "r947"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r278",
      "r462",
      "r466",
      "r471",
      "r557",
      "r559",
      "r618",
      "r649",
      "r697",
      "r947"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r400",
      "r401",
      "r410",
      "r418",
      "r692",
      "r918"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r400",
      "r401",
      "r410",
      "r418",
      "r692",
      "r918"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r395",
      "r400",
      "r407",
      "r408",
      "r409",
      "r412",
      "r417",
      "r424",
      "r426",
      "r427",
      "r428",
      "r574",
      "r692"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Income tax related interest and penalties",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Total effective tax",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r132",
      "r188",
      "r189",
      "r204",
      "r218",
      "r239",
      "r399",
      "r400",
      "r425",
      "r544",
      "r692"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Reconciliation between effective and statutory rate, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r397",
      "r398",
      "r412",
      "r413",
      "r416",
      "r420",
      "r570"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r692",
      "r913"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Federal statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r692"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Stock based compensation",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r913",
      "r915"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r913",
      "r914"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State taxes",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r692",
      "r913"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "negatedLabel": "Federal and state credits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r406",
      "r913"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "negatedLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Derivative Liabilities",
        "terseLabel": "Increase (decrease) carrying value",
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer)."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Interest Payable, Net",
        "terseLabel": "Accrued interest",
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r835",
      "r846"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued expenses, due to related parties, and other current liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses, other current assets and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r754",
      "r764",
      "r788",
      "r797",
      "r801",
      "r809"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r813"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r813"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r813"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails": {
       "parentTag": "us-gaap_InterestExpenseNonoperating",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r325",
      "r335",
      "r679",
      "r680"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Nonoperating",
        "terseLabel": "Interest expense",
        "totalLabel": "Total interest expense",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r844"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r162",
      "r163"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "btai_IntraCoastalCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "IntraCoastalCapitalMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to IntraCoastal Capital, LLC.",
        "label": "Intra Coastal Capital [Member]",
        "terseLabel": "IntraCoastal Capital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureInventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r651",
      "r703"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r139",
      "r146",
      "r251",
      "r252",
      "r254",
      "r519",
      "r655"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work-in-process",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-downs",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r213",
      "r239",
      "r664",
      "r843"
     ]
    },
    "btai_JavierRodriguezMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "JavierRodriguezMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Javier Rodriguez.",
        "label": "Javier Rodriguez"
       }
      }
     },
     "auth_ref": []
    },
    "btai_JefferiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "JefferiesMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Jefferies LLC.",
        "label": "Jefferies [Member]",
        "terseLabel": "Jefferies Sale Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r499"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Option to renew the lease",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Summary of maturities of the operating lease liability",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "verboseLabel": "Renewal term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r54",
      "r55",
      "r56",
      "r59",
      "r60",
      "r61",
      "r64",
      "r168",
      "r248",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r304",
      "r439",
      "r442",
      "r443",
      "r479",
      "r589",
      "r657",
      "r718",
      "r881",
      "r937",
      "r938"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' (deficit) equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r112",
      "r534",
      "r703",
      "r849",
      "r869",
      "r929"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r138",
      "r168",
      "r248",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r304",
      "r439",
      "r442",
      "r443",
      "r479",
      "r703",
      "r881",
      "r937",
      "r938"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "btai_LineOfCreditFacilityAmendmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "LineOfCreditFacilityAmendmentFeePercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The line of credit facility fee for credit agreement amendment based on a loans outstanding, expressed as a percentage.",
        "label": "Line of Credit Facility, Amendment Fee Percentage",
        "terseLabel": "Amendment fee (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_LineOfCreditFacilityExitFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "LineOfCreditFacilityExitFeePercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The line of credit facility exit fee, expressed as a percentage.",
        "label": "Line of Credit Facility, Exit Fee Percentage",
        "terseLabel": "Exit fee (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_LineOfCreditFacilityInvestmentAllowed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "LineOfCreditFacilityInvestmentAllowed",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount the Lenders agree to permit the entity to invest in subsidiary.",
        "label": "Line of Credit Facility, Investment Allowed",
        "terseLabel": "Maximum investment allowed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Debt",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r848",
      "r880"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r58"
     ]
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining borrowing capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r58",
      "r293"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Table]",
        "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r58",
      "r293",
      "r848",
      "r880"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r175",
      "r323"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r175",
      "r323"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total long-term debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment, Amount",
        "terseLabel": "Purchase agreement expected cost",
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermPurchaseCommitmentPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment, Period",
        "terseLabel": "Purchase agreement expected term",
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r246",
      "r683",
      "r704",
      "r707",
      "r884",
      "r946",
      "r948",
      "r949",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r353",
      "r392",
      "r460",
      "r518",
      "r556",
      "r558",
      "r565",
      "r581",
      "r582",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r647",
      "r648",
      "r670",
      "r681",
      "r687",
      "r698",
      "r699",
      "r700",
      "r701",
      "r705",
      "r883",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944"
     ]
    },
    "btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of budgeted amount allowed for disbursement in applicable period.",
        "label": "Maximum Percentage Of Budgeted Amount For Disbursements in Applicable Period",
        "terseLabel": "Maximum percentage of budgeted amount allowed for disbursement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r924",
      "r925",
      "r926"
     ]
    },
    "btai_MeasurementInputEstimatedPremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "MeasurementInputEstimatedPremiumMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using estimated premium.",
        "label": "Estimated premium to 30-day average",
        "terseLabel": "Estimated premium to 30-day average"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "terseLabel": "Strike price",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r924",
      "r925",
      "r926"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Term",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r924",
      "r925",
      "r926"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Volatility (annual)",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r924",
      "r925",
      "r926"
     ]
    },
    "btai_MeasurementInputProbabilityOfExerciseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "MeasurementInputProbabilityOfExerciseMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which there is a probability of exercise.",
        "label": "Probability of exercise",
        "terseLabel": "Probability of exercise"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free rate",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r924",
      "r925",
      "r926"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Share price input",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r924",
      "r925",
      "r926"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r698"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r698"
     ]
    },
    "btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount of gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants for debt.",
        "label": "Minimum Gross Proceeds From The Issuance of Common Stock, Warrants And (Or) Pre-funded Warrants For Debt",
        "terseLabel": "Minimum revenue required from equity sale"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r353",
      "r392",
      "r460",
      "r518",
      "r556",
      "r558",
      "r565",
      "r581",
      "r582",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r647",
      "r648",
      "r670",
      "r681",
      "r687",
      "r698",
      "r699",
      "r700",
      "r705",
      "r883",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r246",
      "r683",
      "r704",
      "r707",
      "r884",
      "r946",
      "r948",
      "r949",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of the Business",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r133"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "FINANCING CASH FLOW ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash from investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "INVESTING CASH FLOW ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "OPERATING CASH FLOW ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "btai_NetCashRequiredMinimum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "NetCashRequiredMinimum",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum maintenance of cash or permitted cash equivalent investments in accounts controlled by lenders.",
        "label": "Net Cash Required, Minimum",
        "terseLabel": "Cash maintenance in controlled accounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net losses",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss (numerator)",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r87",
      "r113",
      "r136",
      "r151",
      "r152",
      "r156",
      "r168",
      "r179",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r188",
      "r189",
      "r195",
      "r248",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r304",
      "r432",
      "r435",
      "r454",
      "r479",
      "r540",
      "r611",
      "r631",
      "r632",
      "r716",
      "r881"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "btai_NewWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "NewWarrantsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to the warrants issued per the credit agreement.",
        "label": "New Warrants [Member]",
        "terseLabel": "New Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r754",
      "r764",
      "r788",
      "r797"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (income) expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrelated Party [Member]",
        "terseLabel": "Nonrelated Party",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r851",
      "r852"
     ]
    },
    "btai_November2024AccompanyingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "November2024AccompanyingWarrantsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertains to November 2024 Accompanying warrants.",
        "label": "November 2024 Accompanying Warrants [Member]",
        "terseLabel": "November 2024 Accompanying Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_November2024PrefundedAccompanyingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "November2024PrefundedAccompanyingWarrantsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertains to November 2024 Pre-Funded Warrants.",
        "label": "November 2024 Prefunded Accompanying Warrants [Member]",
        "terseLabel": "November 2024 Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r861"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r669",
      "r861"
     ]
    },
    "btai_OfaAdministrativeAgentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "OfaAdministrativeAgentMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents OFA as debt administrative agent.",
        "label": "OFA Administrative Agent [Member]",
        "terseLabel": "OFA"
       }
      }
     },
     "auth_ref": []
    },
    "btai_OnkosxcelWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "OnkosxcelWarrantMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to OnkosXcel warrants.",
        "label": "OnkosXcel Warrant [Member]",
        "terseLabel": "OnkosXcel Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r658",
      "r860",
      "r862",
      "r863",
      "r864",
      "r865"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Maturities of the operating lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less current portion of lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry-forwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Income tax",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "btai_OperatingLossCarryforwardsNoExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "OperatingLossCarryforwardsNoExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward with no expiration, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards, No Expiration",
        "terseLabel": "Operating loss carryforward with no expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating segments",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r664",
      "r665"
     ]
    },
    "btai_OptionWarrantsMarch2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "OptionWarrantsMarch2025Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertains to March 2025 Option Warrants.",
        "label": "Option Warrants, March 2025 [Member]",
        "terseLabel": "March 2025 Option Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_OrganizationAndPrincipalActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "OrganizationAndPrincipalActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Nature of the Business"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r104",
      "r567",
      "r568"
     ]
    },
    "btai_OriginalWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "OriginalWarrantsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to the Original Warrants issued per the credit agreement.",
        "label": "Original Warrants [Member]",
        "terseLabel": "Original Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other accrued expenses",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r703"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCostAndExpenseOperating",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Cost and Expense, Operating",
        "totalLabel": "Total commercial costs",
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r543",
      "r664"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r703"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income) expense, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r741",
      "r752",
      "r762",
      "r795"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r755",
      "r765",
      "r798"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r755",
      "r765",
      "r798"
     ]
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Payable-in-kind interest on Credit Agreement",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "btai_PaidInKindInterestPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "PaidInKindInterestPercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paid-in-kind interest rate for funds borrowed, under the debt agreement.",
        "label": "Paid-in-Kind Interest, Percentage",
        "terseLabel": "Debt paid-in-kind interest (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_PatentCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "PatentCostsPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for patent costs.",
        "label": "Patent Costs [Policy Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Restructuring",
        "terseLabel": "Payments for restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r845"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Offering costs for common stock and warrants issuance",
        "verboseLabel": "Stock offering costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Payment of employee tax obligations related to vesting restricted stock units",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of equipment and leasehold improvements",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "btai_PercentageOfFairValueConsiderationToBePaid": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "PercentageOfFairValueConsiderationToBePaid",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair value of consideration to be paid.",
        "label": "Percentage of Fair Value Consideration to Be Paid",
        "terseLabel": "Percentage of fair value of consideration to be paid"
       }
      }
     },
     "auth_ref": []
    },
    "btai_PercentageOfOutstandingLoan": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "PercentageOfOutstandingLoan",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of outstanding Loan.",
        "label": "Percentage of Outstanding Loan",
        "terseLabel": "Outstanding loan (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_PercentageOfValuationApplicableToInitialProfits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "PercentageOfValuationApplicableToInitialProfits",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of valuation applicable to initial profits.",
        "label": "Percentage of Valuation Applicable to Initial Profits",
        "terseLabel": "Percentage of valuation applicable to initial profits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "terseLabel": "BTI PSU",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "btai_PeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "PeriodOneMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for the first period.",
        "label": "Period One [Member]",
        "terseLabel": "Period one"
       }
      }
     },
     "auth_ref": []
    },
    "btai_PeriodThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "PeriodThreeMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for the third period.",
        "label": "Period Three [Member]",
        "terseLabel": "Period three"
       }
      }
     },
     "auth_ref": []
    },
    "btai_PeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "PeriodTwoMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for the second period.",
        "label": "Period Two [Member]",
        "terseLabel": "Period two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Portion at Fair Value Measurement [Member]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r336"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r591"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r336"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r591",
      "r609",
      "r978",
      "r979"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000 shares authorized; no shares issued and outstanding as of December 31, 2024 and December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r531",
      "r703"
     ]
    },
    "btai_PrefundedWarrantsMarch2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "PrefundedWarrantsMarch2025Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertains to March 2025 Pre-Funded Warrants.",
        "label": "Prefunded Warrants, March 2025 [Member]",
        "terseLabel": "March 2025 Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_PremiumSharePricePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "PremiumSharePricePercent",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents premium percentage for share price determined over a specified period of time.",
        "label": "Premium Share Price, Percent",
        "terseLabel": "Premium share price (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Gross proceeds issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from issuance of common stock and warrant",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r571"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r11"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r151",
      "r152",
      "r160",
      "r168",
      "r179",
      "r185",
      "r188",
      "r189",
      "r248",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r304",
      "r432",
      "r435",
      "r437",
      "r440",
      "r441",
      "r454",
      "r479",
      "r524",
      "r539",
      "r578",
      "r611",
      "r631",
      "r632",
      "r693",
      "r694",
      "r717",
      "r842",
      "r881"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r499"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r127",
      "r130",
      "r131"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "verboseLabel": "Total property and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r141",
      "r538"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "verboseLabel": "Property and equipment, net",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r499",
      "r525",
      "r538",
      "r703"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r127",
      "r130",
      "r536"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and equipment, net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r499"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "btai_PurchaseAgreementRegisteredSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "PurchaseAgreementRegisteredSecuritiesMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the Purchase Agreement. A registered security offering March 2025.",
        "label": "Purchase Agreement, Registered Securities [Member]",
        "terseLabel": "Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Obligation, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2024 purchase obligation, remainder of year",
        "documentation": "Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r345",
      "r353",
      "r382",
      "r383",
      "r384",
      "r392",
      "r460",
      "r515",
      "r516",
      "r518",
      "r556",
      "r558",
      "r565",
      "r581",
      "r582",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r647",
      "r648",
      "r670",
      "r681",
      "r687",
      "r698",
      "r699",
      "r700",
      "r701",
      "r705",
      "r710",
      "r875",
      "r883",
      "r925",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r345",
      "r353",
      "r382",
      "r383",
      "r384",
      "r392",
      "r460",
      "r515",
      "r516",
      "r518",
      "r556",
      "r558",
      "r565",
      "r581",
      "r582",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r647",
      "r648",
      "r670",
      "r681",
      "r687",
      "r698",
      "r699",
      "r700",
      "r701",
      "r705",
      "r710",
      "r875",
      "r883",
      "r925",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944"
     ]
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables, Net, Current",
        "terseLabel": "Accounts receivable, net",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of reportable segment",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r747",
      "r757",
      "r790"
     ]
    },
    "btai_RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "RegisteredDirectOfferingMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to registered direct offering.",
        "label": "Registered Direct Offering [Member]",
        "terseLabel": "Registered direct offering"
       }
      }
     },
     "auth_ref": []
    },
    "btai_RegisteredOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "RegisteredOfferingMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the registered offering.",
        "label": "Registered Offering [Member]",
        "terseLabel": "Underwriting Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r352",
      "r504",
      "r505",
      "r529",
      "r535",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r608",
      "r610",
      "r638"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "terseLabel": "Related Party",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r504",
      "r505",
      "r506",
      "r507",
      "r529",
      "r535",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r608",
      "r610",
      "r638"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Transactions with BioXcel",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r614",
      "r615",
      "r618"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions with BioXcel LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r352",
      "r504",
      "r505",
      "r529",
      "r535",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r608",
      "r610",
      "r638",
      "r936"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Transactions with BioXcel LLC",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r502",
      "r503",
      "r505",
      "r508",
      "r575",
      "r576",
      "r577",
      "r616",
      "r617",
      "r618",
      "r636",
      "r637"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Payment of principal of Long-term debt",
        "terseLabel": "Payment of principal of Long-term debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r572"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r309",
      "r337",
      "r507",
      "r517",
      "r527",
      "r653",
      "r654"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Total research and development costs",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r649",
      "r664",
      "r945"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Abstract]",
        "terseLabel": "Research and development costs:"
       }
      }
     },
     "auth_ref": []
    },
    "btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense during the period related to chemical, manufacturing and control costs.",
        "label": "Research and Development Expense, Chemical, manufacturing and controls Expense",
        "terseLabel": "Chemical, manufacturing and controls cost"
       }
      }
     },
     "auth_ref": []
    },
    "btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentExpenseClinicalTrialsExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense during the period related to clinical trial expenses.",
        "label": "Research and Development Expense, Clinical Trials Expense",
        "terseLabel": "Clinical trials expense"
       }
      }
     },
     "auth_ref": []
    },
    "btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentExpenseLaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense during the period related to salary, wage, profit sharing incentive and other employee benefit.",
        "label": "Research and Development Expense, Labor And Related Expense",
        "terseLabel": "Personnel and related costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "btai_ResearchAndDevelopmentExpenseProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentExpenseProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense during the period related to a fee charged for services from professionals.",
        "label": "Research and Development Expense, Professional Fees",
        "terseLabel": "Professional fees"
       }
      }
     },
     "auth_ref": []
    },
    "btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense during the period related to expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Research and Development Expense, Share-Based Payment Arrangement, Expense",
        "terseLabel": "Non-cash stock-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "btai_ResearchAndDevelopmentExpenseTravelAndOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentExpenseTravelAndOtherExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense during the period related to travel expenses.",
        "label": "Research and Development Expense, Travel Expenses",
        "terseLabel": "Travel related expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r737",
      "r748",
      "r758",
      "r791"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r749",
      "r759",
      "r792"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r745",
      "r756",
      "r766",
      "r799"
     ]
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings",
        "terseLabel": "Vesting of restricted stock units, net of employee tax obligations (in shares)",
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": []
    },
    "btai_RestrictedStockUnitsOnkosxcelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "RestrictedStockUnitsOnkosxcelMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument associated with OnkosXcel, which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units Onkosxcel [Member]",
        "terseLabel": "OnkosXcel RSUs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "BTI RSU",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings",
        "terseLabel": "Vesting of restricted stock units, net of employee tax obligations",
        "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuring"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r277",
      "r280",
      "r285"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Expected total restructuring charges",
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r279",
      "r282",
      "r284"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Employees eliminated",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Employees eliminated (as a percent)",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring costs",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r281",
      "r282",
      "r876"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r282",
      "r283"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r284"
     ]
    },
    "us-gaap_RestructuringReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Reserve, Current",
        "terseLabel": "Accrued restructuring costs",
        "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset."
       }
      }
     },
     "auth_ref": [
      "r837",
      "r877",
      "r878"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r97",
      "r533",
      "r563",
      "r564",
      "r573",
      "r592",
      "r703"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r176",
      "r177",
      "r178",
      "r180",
      "r185",
      "r187",
      "r189",
      "r249",
      "r250",
      "r265",
      "r421",
      "r422",
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r445",
      "r447",
      "r448",
      "r450",
      "r452",
      "r490",
      "r492",
      "r560",
      "r562",
      "r579",
      "r978"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Product revenue, net",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r204",
      "r211",
      "r212",
      "r233",
      "r239",
      "r243",
      "r245",
      "r246",
      "r342",
      "r343",
      "r521"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerProductAndServiceBenchmarkMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Product and Service Benchmark [Member]",
        "terseLabel": "Revenue benchmark",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer for specified product or service, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "btai_RevenueInterestFinancingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "RevenueInterestFinancingAgreementMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the Revenue Interest Financing agreement",
        "label": "Revenue Interest Financing Agreement [Member]",
        "terseLabel": "Revenue interest financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition Accounting Policy, Gross and Net Revenue Disclosure [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for recognizing revenue from a transaction on a gross or net basis."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "btai_ReverseStockSplit": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "ReverseStockSplit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy - Reverse stock split.",
        "label": "Reverse Stock Split",
        "terseLabel": "Reverse Stock Split"
       }
      }
     },
     "auth_ref": []
    },
    "btai_RichardSteinhartMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "RichardSteinhartMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Richard Steinhart.",
        "label": "Richard Steinhart"
       }
      }
     },
     "auth_ref": []
    },
    "btai_RightToPurchaseStockLenders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "RightToPurchaseStockLenders",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum equity investment allowed for lenders in entity's common stock.",
        "label": "Right to Purchase Stock, Lenders",
        "terseLabel": "Maximum equity investment allowed for lenders"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds issuance of common stock",
        "verboseLabel": "Proceeds from issuance of common stock and warrants",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "btai_SaleOfStockMaximumValueSharesToBeIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "SaleOfStockMaximumValueSharesToBeIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate net offering price of shares permitted to be issued.",
        "label": "Sale of Stock, Maximum Value Shares to be Issued",
        "terseLabel": "Maximum value shares to be issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "btai_SalesMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "SalesMilestonesMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestones are payable when annual sales reach certain levels.",
        "label": "Sales Milestones [Member]",
        "terseLabel": "Sales milestones"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r190",
      "r354",
      "r831",
      "r857"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potentially dilutive securities",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of debt",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r32",
      "r33",
      "r49",
      "r95",
      "r96",
      "r677",
      "r679",
      "r853",
      "r930"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of net deferred tax assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of net loss per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of effective tax rate and statutory rate reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r692",
      "r913"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation charges",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Ownership Plan (ESOP) [Table]",
        "documentation": "Disclosure of information about employee stock ownership plan (ESOP) by plan."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value on a recurring basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r922",
      "r923"
     ]
    },
    "btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest expense associated with long-term debt.",
        "label": "Schedule of Interest Expense Associated with Long Term Debt [Table Text Block]",
        "terseLabel": "Schedule of long-term debt interest expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r72",
      "r73",
      "r74"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of maturities on long-term debt",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r499"
     ]
    },
    "btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of Property Plant And Equipment Useful Lives.",
        "label": "Schedule of Property Plant And Equipment Useful Lives [Table Text Block]",
        "terseLabel": "Schedule of property and equipment useful lives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r614",
      "r615",
      "r618"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of service charges",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r284"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Performance-Based Units, Vested and Expected to Vest [Table Text Block]",
        "terseLabel": "Schedule of activity relating to PSUs",
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding performance-based awards that are fully vested and expected to vest. Includes, but is not limited to, unvested awards for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of activity relating to RSUs",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r100"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of warrants outstanding",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117",
      "r204",
      "r207",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r246",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r279",
      "r284",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r661",
      "r664",
      "r665",
      "r671",
      "r706",
      "r946",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r204",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r222",
      "r224",
      "r225",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r246",
      "r659",
      "r662",
      "r663",
      "r664",
      "r666",
      "r668",
      "r669"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r242",
      "r245",
      "r660",
      "r661",
      "r667"
     ]
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "btai_SellingGeneralAndAdministrativeCostsOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "SellingGeneralAndAdministrativeCostsOtherExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other expenses related to selling, general and administrative costs.",
        "label": "Selling, General and Administrative Costs, Other Expenses",
        "terseLabel": "Other expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "totalLabel": "Total selling, general and administrative costs",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense [Abstract]",
        "terseLabel": "Selling, general and administrative costs:"
       }
      }
     },
     "auth_ref": []
    },
    "btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expense for salary, wage, profit sharing; incentive and other employee benefit.",
        "label": "Selling, General and Administrative Expense, Labor and Related Expense",
        "terseLabel": "Personnel and related costs"
       }
      }
     },
     "auth_ref": []
    },
    "btai_SellingGeneralAndAdministrativeExpenseProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "SellingGeneralAndAdministrativeExpenseProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expense related to a fee charged for services from professionals.",
        "label": "Selling, General and Administrative Expense, Professional Fees",
        "terseLabel": "Professional fees"
       }
      }
     },
     "auth_ref": []
    },
    "btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expense for award under share-based payment arrangement",
        "label": "Selling, General and Administrative Expense, Share-Based Payment Arrangement, Expense",
        "terseLabel": "Non-cash stock-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expense related to travel expenses during the period.",
        "label": "Selling, General and Administrative Expense, Travel Expenses",
        "terseLabel": "Travel related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Cancelled in Period",
        "negatedLabel": "Cancelled (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a cancelled event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Cancelled, Weighted Average Grant Date Fair Value",
        "terseLabel": "Cancelled, Weighted average price (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted, Weighted average price (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value",
        "terseLabel": "Fair value (in dollars per share)",
        "documentation": "Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "terseLabel": "Non-options outstanding (in shares)",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, Weighted average price ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, Weighted average price beginning balance (in dollars per share)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value, non-option",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield (as a percent)",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility (as a percent)",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected stock price volatility, maximum (as a percent)",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected stock price volatility, minimum (as a percent)",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate of interest (as a percent)",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free rate of interest, maximum (as a percent)",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free rate of interest, minimum (as a percent)",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "verboseLabel": "Stock-Based Compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase in shares available for issuance (in shares)",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Authorized shares",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Available for grant (in shares)",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Options"
       }
      }
     },
     "auth_ref": []
    },
    "btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Cancelled in Period",
        "negatedLabel": "Options cancelled (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options vested and exercisable (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options vested and exercisable (in dollars per shares)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value, exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options forfeited (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted-average grant-date fair value of options granted (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Intrinsic value, outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Number of Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, end balance (in dollars per shares)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per shares)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested aggregate (in shares)",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested, Weighted average price (in dollars per share)",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of aggregate number of shares of common stock outstanding of the immediately preceding calendar year as a increase to common stock available for grant under the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage Of Increase In Common Stock Available For Grant",
        "terseLabel": "Annual increase in shares available for grant (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ]
    },
    "btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were cancelled.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Cancelled in Period, Weighted Average Exercise Price",
        "terseLabel": "Options cancelled (in dollars per shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited (in dollars per shares)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "terseLabel": "Employee",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "terseLabel": "Nonemployee consultant",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting (as a percent)",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Terms of award",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Intrinsic value, exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life, exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted average remaining contractual life, outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of options vested (in dollars per share)",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price as a percent of fair market value",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Offering price (in dollars per share)",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r166"
     ]
    },
    "btai_SingleReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "SingleReportableSegmentMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertains to single reportable segment.",
        "label": "Single Reportable Segment [Member]",
        "terseLabel": "Single reportable segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117",
      "r135",
      "r204",
      "r207",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r246",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r267",
      "r279",
      "r284",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r661",
      "r664",
      "r665",
      "r671",
      "r706",
      "r946",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r66",
      "r69",
      "r70",
      "r134",
      "r154",
      "r155",
      "r156",
      "r176",
      "r177",
      "r178",
      "r180",
      "r185",
      "r187",
      "r189",
      "r205",
      "r249",
      "r250",
      "r265",
      "r341",
      "r421",
      "r422",
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r452",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r490",
      "r492",
      "r500",
      "r541",
      "r560",
      "r561",
      "r562",
      "r579",
      "r633"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "verboseLabel": "Disclosure",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r205",
      "r492",
      "r521",
      "r569",
      "r580",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r591",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r610",
      "r612",
      "r613",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r633",
      "r711"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r190",
      "r354",
      "r831",
      "r832",
      "r857"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r205",
      "r247",
      "r492",
      "r521",
      "r569",
      "r580",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r591",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r610",
      "r612",
      "r613",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r633",
      "r711"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r740",
      "r751",
      "r761",
      "r794"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued under ESPP",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r65",
      "r66",
      "r97"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued (in shares)",
        "verboseLabel": "Issuance of common stock, net of offering costs (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r65",
      "r66",
      "r97",
      "r571",
      "r633",
      "r644"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)",
        "verboseLabel": "Exercise of stock options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r65",
      "r66",
      "r97",
      "r368"
     ]
    },
    "btai_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period Shares Warrants Exercised",
        "terseLabel": "Exercise of warrants, stock issued (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r65",
      "r66",
      "r97",
      "r579",
      "r633",
      "r644",
      "r717"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r66",
      "r69",
      "r70",
      "r97"
     ]
    },
    "btai_StockPlan2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "StockPlan2017Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the 2017 Stock Plan.",
        "label": "2017 Equity Incentive Plan",
        "terseLabel": "2017 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' (deficit) equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r69",
      "r70",
      "r90",
      "r593",
      "r609",
      "r634",
      "r635",
      "r703",
      "r718",
      "r849",
      "r869",
      "r929",
      "r978"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' (deficit) equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Events",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r510"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r510"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r510"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r510"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r510"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r511"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "btai_SubsidiaryOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "SubsidiaryOwnershipPercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock of subsidiary.",
        "label": "Subsidiary Ownership, Percentage",
        "terseLabel": "Subsidiary ownership (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Shares issued",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carry-forwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes Payable, Current",
        "terseLabel": "Accrued taxes",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55"
     ]
    },
    "btai_ThresholdLiquidityEventAmountForExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "ThresholdLiquidityEventAmountForExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold amount of  liquidity event for exercise of warrants.",
        "label": "Threshold Liquidity Event Amount for Exercise of Warrants",
        "terseLabel": "Threshold amount of liquidity event for exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_ThresholdRatioOfDebtToRevenueRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "ThresholdRatioOfDebtToRevenueRatio",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents threshold ratio for debt to revenue ratio.",
        "label": "Threshold Ratio of Debt to Revenue Ratio",
        "terseLabel": "Debt to revenue multiplier"
       }
      }
     },
     "auth_ref": []
    },
    "btai_TickingFeesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "TickingFeesPercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents ticking fees percentage relating to debt instrument.",
        "label": "Ticking Fees Percentage",
        "terseLabel": "Ticking fee (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_TimeBasedProfitSharingUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "TimeBasedProfitSharingUnitsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to OnkosXcel time based profit-sharing units",
        "label": "Time Based Profit Sharing Units [Member]",
        "terseLabel": "OnkosXcel PSU"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable, Net",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r866",
      "r867",
      "r868"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "btai_TrancheBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "TrancheBMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Tranche B.",
        "label": "Tranche B"
       }
      }
     },
     "auth_ref": []
    },
    "btai_TrancheCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "TrancheCMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Tranche C.",
        "label": "Tranche C"
       }
      }
     },
     "auth_ref": []
    },
    "btai_TrancheDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "TrancheDMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Tranche D.",
        "label": "Tranche D [Member]",
        "terseLabel": "Tranche D"
       }
      }
     },
     "auth_ref": []
    },
    "btai_TrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "TrancheMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Tranche A.",
        "label": "Tranche A"
       }
      }
     },
     "auth_ref": []
    },
    "btai_TrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "TrancheTwoMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Tranche A2.",
        "label": "Tranche A Two [Member]",
        "terseLabel": "Tranche A-2"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r282",
      "r283"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r411",
      "r691"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r124",
      "r125",
      "r128",
      "r129"
     ]
    },
    "btai_VimalMehtaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "VimalMehtaMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Vimal Mehta.",
        "label": "Vimal Mehta"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount",
        "terseLabel": "Repricing of stock purchase warrants",
        "documentation": "Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r340"
     ]
    },
    "btai_WarrantOaktreeAndQiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "WarrantOaktreeAndQiaMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the Oaktree (OFA) issued April 2022.",
        "label": "Warrant Oaktree and Qia [Member]",
        "terseLabel": "Closing Date Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_WarrantShares2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "WarrantShares2024Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to the warrant shares issued in 2024.",
        "label": "Warrant Shares 2024 [Member]",
        "terseLabel": "2024 Warrant Shares"
       }
      }
     },
     "auth_ref": []
    },
    "btai_Warrants2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "Warrants2023Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to the warrants issued in 2023.",
        "label": "Warrants 2023 [Member]",
        "terseLabel": "2023 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_Warrants2024AccompanyingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "Warrants2024AccompanyingWarrantsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2024 Accompanying Warrants.",
        "label": "Warrants 2024, Accompanying Warrants [Member]",
        "verboseLabel": "March 2024 Accompanying Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "Warrants2024AccompanyingWarrantsStrikePriceAmendedMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertains to 2024 accompanying warrants Strike price amended.",
        "label": "Warrants 2024 Accompanying Warrants Strike Price Amended [Member]",
        "terseLabel": "March 2024 Accompanying Warrants, Strike Price Amended"
       }
      }
     },
     "auth_ref": []
    },
    "btai_Warrants2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "Warrants2024Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to the warrants issued in 2024.",
        "label": "Warrants 2024 [Member]",
        "terseLabel": "2024 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_Warrants2024PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20241231",
     "localname": "Warrants2024PreFundedWarrantsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2024 Pre-Funded Warrants.",
        "label": "Warrants 2024, Pre Funded Warrants [Member]",
        "terseLabel": "March 2024 Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants outstanding value",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r924",
      "r925",
      "r926"
     ]
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Not Settleable in Cash, Fair Value Disclosure",
        "terseLabel": "Fair value warrant classified as equity",
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity."
       }
      }
     },
     "auth_ref": [
      "r922",
      "r923",
      "r927"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding - diluted (in shares)",
        "verboseLabel": "Weighted average shares (denominator) - diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r198"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares (denominator) - basic (in shares)",
        "verboseLabel": "Weighted average shares outstanding - basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r198"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3A"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715-20/tableOfContent"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "715",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477317/912-715-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
